APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

APPROVED DRUG PRODUCTS

WITH

THERAPEUTIC EQUIVALENCE EVALUATIONS

37th EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2017

FDA data supplied by DrugPatentWatch.com

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2016.

37th EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2017

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

CONTENTS

PAGE

PREFACE TO THIRTY SEVENTH EDITION…….....iv

1 INTRODUCTION..... vi
1.1 Content and Exclusion vi
1.2 Therapeutic Equivalence-Related Terms vi
1.3 Further Guidance on Bioequivalence ix
1.4 Reference Listed Drug and Reference Standard..... ix
1.5 General Policies and Legal Status x
1.6 Practitioner/User Responsibilities x
1.7 Therapeutic Equivalence Evaluations Codes xii
1.8 Description of Certain Special Situations xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product..... xxiii
1.11 Discontinued Section xxiv
1.12 Changes to the Orange Book.....xxiv
1.13 Availability of the Edition xxv

2 HOW TO USE THE DRUG PRODUCTS LISTS 2-1
2.1 Key Sections for Using the Drug Product Lists …….....2-1
2.2 Drug Product Illustration ……..……..2-3
2.3 Therapeutic Equivalence Evaluations Illustration ……..……2-4

DRUG PRODUCT LISTS
Prescription Drug Product List ……...3-1
OTC Drug Product List ……..……4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered
by the Center for Biologics Evaluation and Research List ..……..5-1
Discontinued Drug Product List ……..……....6-1
Orphan Products Designations and Approvals List ……..……..7-1
Drug Products Which Must Demonstrate in vivo Bioavailability
Only if Product Fails to Achieve Adequate Dissolution ……..……..8-1

APPENDICES
A. Product Name Index ……..……..……A-1
B. Product Name Index Listed by Applicant ……..……..B-1
C. Uniform Terms ……..……..……...C-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM ……..…….....AD1
A. Patent and Exclusivity Lists ……..……..……ADA1
B. Patent and Exclusivity Terms ..……..……ADB1

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

PREFACE TO THIRTY SEVENTH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the list, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products in the Orange Book is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January l979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

FDA data supplied by DrugPatentWatch.com

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the Orange Book incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the FD&C Act for periods of exclusivity and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy, Office of Generic Drugs, Center for Drug Evaluation and Research, 7620 Standish Place, Rockville, MD 20855-2773. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1. INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.[1] This publication also includes indices of prescription and OTC drug products by trade name (proprietary name) or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as described in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided in Appendix C.

An *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book. Tentative approval lists are available on FDA's website at Drug Approval Reports. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list.

Distributors or repackagers of products listed in the Orange Book are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

[1] Newly approved products are added to parts 1, 2, or 3, of the Orange Book, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are formulated to contain the same amount of active ingredient, and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity). They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the Orange Book, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain)*. Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant’s drug product even if the applicant’s drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an applicant’s drug product are considered to have the same code as the applicant.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (*e.g.*, weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (*e.g.*, weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (*e.g.*, certain drug-device combination products for which the amount of drug substance is emitted per use or unit time). Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

The strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, but is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of “EQ” next to their expression of strength. This “EQ” designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., “EQ 200MG BASE”), rather than in terms of the strength of the active ingredient.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(8)(B) of the FD&C Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.[2]

1.4 Reference Listed Drug and Reference Standard

A reference listed drug (21 CFR 314.3(b)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA. Generally, a reference listed drug is a drug product approved in a new drug application under section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval. FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances (e.g., where the reference listed drug has been withdrawn from sale and an ANDA is selected as the reference standard), the reference listed drug and the reference standard may be different.

FDA has identified reference listed drugs in the Prescription Drug Product and OTC Drug Product Lists. Forthcoming, FDA will identify reference listed drugs in the Discontinued Drug Product List. These identified reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

FDA also has identified in the Prescription Drug Product and OTC Drug Product Lists reference standards to which the *in vivo* bioequivalence is compared. These identified reference standards represent the FDA's best judgment at this time as to the appropriate comparator for purposes of in vivo bioequivalence testing.

In some instances when a listed drug is not designated as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may ask FDA to

---

[2] We note that prior editions of the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See FDA Drugs guidance Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm; FDA Drugs guidance (Product-Specific Recommendations for Generic Drug Development) Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm; see generally 21 CFR part 320.

designate a reference listed drug for that drug product. Potential applicants should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting such a request. If the request is granted, the listed drug will be designated as a reference listed drug, in which case an ANDA citing the designated reference listed drug may be submitted. Section 1.7, *Therapeutic Equivalence Evaluations Codes* (*products meeting necessary bioequivalence requirements*) explains the character coding system (e.g., ***AB, AB1, AB2, AB3...***) for multisource drug products listed under the same heading with two reference listed drugs.

A potential applicant should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that potential applicants have adequate information required for *in vivo* bioequivalence studies, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale for other than safety and efficacy reasons. Historically, there were two situations in which two listed drugs that had been shown to be bioequivalent to each other had both been identified by the symbol "+" in the Orange Book. The first situation was when the in vivo determination of bioequivalence is self-evident and a waiver of any *in vivo* bioequivalence may be granted. The second situation was when the bioequivalence of two listed products may be determined through *in vitro* methodology.

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is either in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based

on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. For example, there may also be allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by other than the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant’s drug product even if the applicant’s drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the Orange Book, distributors or repackagers of an applicant’s drug product are considered to have the same code as the applicant. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In many instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products in the Orange Book are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms,

that the applicant designations in the Orange Book are, in most cases, correct.

To relate firm name information on a product label to that in the Orange Book, the following should be noted: the applicant's name always appears in the Orange Book. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears in the Orange Book and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears in the Orange Book and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears in the Orange Book; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the Orange Book, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that in the Orange Book, the following should be noted: if the applicant is the marketer, its name appears in the Orange Book and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established name of the active ingredient, if no trade name exists) appears in the Orange Book. If a corporate relationship exists between an applicant and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the applicant to appear in the Orange Book. If there is no known corporate relationship between the applicant and the marketer, the established drug name (i.e., non-proprietary name) appears in the Orange Book.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an application that has been approved and that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other

pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX,** or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"**A**" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "**A**" code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for

post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency may use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical

alternatives and thus not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength)* generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference listed drug products that are not identified as bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or

repackagers are not included in the Orange Book, they are considered therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection

5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms,* the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.[3] In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as xmg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as xmg/vial.

With the finalization of the Hatch-Waxman Amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end, the Orange Book now displays the strength of all new approvals of parenteral solutions. Previously, we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/mL. If this drug product had a 20 mL and 60 mL container approved, we would now display two product strengths for this product, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1Gm / 20mL (50mg/mL) and 3Gm / 60mL (50mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

3 The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

Drug products that FDA, at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products.

"**B**" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "**B**" code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the "**B**" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of “enteric” coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients*

sodium bicarbonate and alginic acid. A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium. Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.[4]

The chart outlines TE codes for all 0.025 mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001

[4] Lloyd’s Levothroid tablets (NDA 021116) is currently listed in the Discontinued Drug Product List section of the Orange Book and Mylan’s levothyroxine product (ANDA 076187) has been selected as the reference standard for ANDA applicants to use to establish bioequivalence to Levothroid. If an ANDA that uses Mylan’s levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHROID	LLOYD	0.025MG	N/A[5]	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

Patent Certification(s) and Reference Standard based upon a suitability petition. An ANDA that utilizes as a reference standard a product approved pursuant to a suitability petition must demonstrate that the proposed product can be expected to have the same therapeutic effect as the reference listed drug. It must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition. (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, i.e., such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will not accept for review and/or will not approve a 505(b)(2) application or an ANDA under section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for the ANDA or 505(b)(2) application will be determined by analysis of the applicant’s patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all ANDAs and 505(b)(2) applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its right to the exclusivity protection, qualified ANDAs or 505(b)(2) applications may be accepted for review and/or approved, as applicable, pursuant to the NDA holder's exclusivity being waived. An NDA for which the holder has waived its exclusivity as to all ANDAs and 505(b)(2) applications will be coded with a “W” in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

[5] Levothroid is in the Discontinued Drug Product List and therefore no longer is assigned a TE code.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

FDA data supplied by DrugPatentWatch.com

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has already been made that the products were not withdrawn for safety or effectiveness reasons have "**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**" following the product strength. The determinations listed in Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions for the same drug product. The Orange Book FR Safety or Effectiveness Determinations List, available on FDA's website, lists products that have notices. The list is updated quarterly. Notices issued during the year routinely are added to the Electronic Orange Book on FDA's website.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports indicate the product is no longer marketed or as a result of other Agency administrative actions. Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book staff of any changes or corrections, including any change in a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that 21 CFR 314.81(b)(3)(iv) requires an applicant to submit a notice to the Agency within fifteen working days of the withdrawal from sale of a drug product. In addition, a request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1, 2 or 3 of the Orange Book (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already included in the Orange Book, but rather intends to apply the change prospectively to drug products added to the Orange Book.

We can be contacted by email at orangebook@fda.hhs.gov. Send Changes by mail to:

FDA/CDER Orange Book Staff
Office of Generic Drug Policy
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

FDA data supplied by DrugPatentWatch.com

1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, Electronic Orange Book, by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, 866-512-1800.

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by “N” is a New Drug Application (NDA or commonly the innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "**A**" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

FDA data supplied by DrugPatentWatch.com

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant *(Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

FDA data supplied by DrugPatentWatch.com

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT → MEPERIDINE HYDROCHLORIDE

DOSAGE FORM; ROUTE OF ADMINISTRATION → INJECTABLE;INJECTION

TRADE OR GENERIC NAMES → **HEXANON**

REFERENCE LISTED DRUG* (+)
REFERENCE STANDARD * (!)

AP	**+!**	PAGE PHARMA	**25MG/ML**	**N013111**	**001**	AUG 22, 1983
AP	**+!**		**50MG/ML**	**N013111**	**002**	AUG 22, 1983
AP	**+!**		**75MG/ML**	**N013111**	**003**	AUG 22, 1983
AP	**+!**		**100MG/ML**	**N013111**	**004**	JAN 04, 1989

MEPERIDINE HCL

THERAPEUTIC EQUIVALENCE (TE)
CODE FOR MULTISOURCE PRODUCT →

AP		GREENBERG PHARM	**25MG/ML**	**A064890**	001	FEB 29, 1987
AP			**50MG/ML**	**A064890**	002	FEB 29, 1987
AP			**75MG/ML**	**A064890**	003	FEB 29, 1987
AP			**100MG/ML**	**A064890**	004	MAR 08, 1992

SINGLE SOURCE PRODUCT (NO TE CODE)

	!	TIMOKIM LLC	10MG/ML	A099225	001	DEC 12, 1995
AP		JOHNSON MED	**25MG/ML**	**A099226**	**001**	NOV 27, 1993
	!	KENDRA PHARM	150MG/ML	A079444	001	OCT 31, 1999

APPLICANT

AVAILABLE STRENGTH(S) OF A PRODUCT

APPLICATION NUMBER AND PRODUCT NUMBER
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY

APPROVAL DATE

*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY
ACTIVE INGREDIENT → HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

PRODUCT INFORMATION →

TABLET;ORAL
HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL
REINWALD LABS 25MG;15MG;0.1MG A069808 001 JAN 18, 1982

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **A")** AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION.*

PRODUCTS CONSIDERED THERAPEUTICALLY EQUIVALENT TO EACH OTHER

	SULFASALAZINE				
	TABLET; ORAL				
	FAZINE				
AB	PARKLAND	**500MG**	**A042999**	**001**
	SULAZINE			
AB	URSA	**500MG**	**A042222**	**001**

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCTS LISTED

	SULFASALAZINE			
BP	BROWN	500MG	A041297	001

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY EQUIVALENT TO EACH OTHER

	SULFASALAZINE			
	TABLET; ORAL			
	FAZINE			
AB	PARKLAND	**500MG**	**A042999**	**001**
	SULFASALAZINE			
BP	BROWN	500MG	A041297	001
	SOUTH	500MG	A067627	001

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION DRUG PRODUCT LIST

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA		HETERO LABS LTD III	**EQ 20MG BASE/ML**	**A201107**	**001** Sep 26, 2016

ZIAGEN

AA	+	VIIV HLTHCARE	**EQ 20MG BASE/ML**	**N020978**	**001** Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATE

AB		APOTEX INC	**EQ 300MG BASE**	**A201570**	**001** Dec 17, 2012
AB		AUROBINDO PHARMA LTD	**EQ 300MG BASE**	**A077844**	**001** Dec 17, 2012
AB		HETERO LABS LTD III	**EQ 300MG BASE**	**A091560**	**001** Sep 13, 2013
AB		MYLAN PHARMS INC	**EQ 300MG BASE**	**A091294**	**001** Jun 18, 2012
AB		STRIDES PHARMA	**EQ 300MG BASE**	**A091050**	**001** Oct 28, 2016

ZIAGEN

AB	+	VIIV HLTHCARE	**EQ 300MG BASE**	**N020977**	**001** Dec 17, 1998

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

	+	VIIV HLTHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551	001 Aug 22, 2014

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		TEVA PHARMS USA	**EQ 600MG BASE;300MG**	**A079246**	**001** Sep 29, 2016

EPZICOM

AB	+	VIIV HLTHCARE	**EQ 600MG BASE;300MG**	**N021652**	**001** Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

AB		LUPIN LTD	**EQ 300MG BASE;150MG;300MG**	**A202912**	**001** Dec 05, 2013

TRIZIVIR

AB	+	VIIV HLTHCARE	**EQ 300MG BASE;150MG;300MG**	**N021205**	**001** Nov 14, 2000

ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

	+	JANSSEN BIOTECH	250MG	N202379	001 Apr 28, 2011

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB		BARR LABS DIV TEVA	**333MG**	**A200143**	**001** Nov 18, 2013
AB	+	GLENMARK GENERICS	**333MG**	**A202229**	**001** Jul 16, 2013
AB		MYLAN PHARMS INC	**333MG**	**A200142**	**001** Mar 11, 2014

ACARBOSE

TABLET;ORAL

ACARBOSE

AB		EMCURE PHARMS LTD	**25MG**	**A202271**	**001** Feb 07, 2012
AB			**50MG**	**A202271**	**002** Feb 07, 2012
AB			**100MG**	**A202271**	**003** Feb 07, 2012
AB		IMPAX LABS	**25MG**	**A078441**	**001** May 14, 2009
AB			**50MG**	**A078441**	**002** May 14, 2009
AB			**100MG**	**A078441**	**003** May 14, 2009
AB		MYLAN	**25MG**	**A091053**	**001** Jan 06, 2011
AB			**50MG**	**A091053**	**002** Jan 06, 2011
AB			**100MG**	**A091053**	**003** Jan 06, 2011
AB		STRIDES PHARMA	**25MG**	**A090912**	**001** Jul 27, 2011
AB			**50MG**	**A090912**	**002** Jul 27, 2011
AB			**100MG**	**A090912**	**003** Jul 27, 2011
AB		VIRTUS PHARM	**25MG**	**A091343**	**001** Oct 17, 2013
AB			**50MG**	**A091343**	**002** Oct 17, 2013
AB			**100MG**	**A091343**	**003** Oct 17, 2013
AB		WATSON LABS	**25MG**	**A077532**	**001** May 07, 2008
AB			**50MG**	**A077532**	**002** May 07, 2008
AB			**100MG**	**A077532**	**003** May 07, 2008
AB		WEST-WARD PHARMS INT	**25MG**	**A078470**	**001** May 07, 2008
AB			**50MG**	**A078470**	**002** May 07, 2008
AB			**100MG**	**A078470**	**003** May 07, 2008

PRECOSE

AB	+	BAYER HLTHCARE	**25MG**	**N020482**	**004** May 29, 1997
AB			**50MG**	**N020482**	**001** Sep 06, 1995
AB			**100MG**	**N020482**	**002** Sep 06, 1995

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION DRUG PRODUCT LIST

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

AB		AMNEAL PHARM	**EQ 200MG BASE**	**A075047**	**001** Dec 30, 1999
AB			**EQ 400MG BASE**	**A075047**	**002** Dec 30, 1999
AB		MYLAN	**EQ 200MG BASE**	**A074288**	**001** Apr 24, 1995
AB			**EQ 400MG BASE**	**A074288**	**002** Apr 24, 1995

SECTRAL

AB		PROMIUS PHARMA	**EQ 200MG BASE**	**N018917**	**001** Dec 28, 1984
AB	+		**EQ 400MG BASE**	**N018917**	**003** Dec 28, 1984

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

ACETAMINOPHEN

AP		PADDOCK LLC	**1GM/100ML (10MG/ML)**	**A202605**	**001** Jun 13, 2016
AP		SANDOZ INC	**1GM/100ML (10MG/ML)**	**A204052**	**001** Mar 22, 2016

OFIRMEV

AP	+	MALLINCKRODT IP	**1GM/100ML (10MG/ML)**	**N022450**	**001** Nov 02, 2010

ACETAMINOPHEN

		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001 Oct 28, 2015

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		CNTY LINE PHARMS	**325MG;50MG**	**A205120**	**001** Oct 30, 2015
AA		LARKEN LABS INC	**325MG;50MG**	**A203484**	**002** Dec 04, 2015
AA		MIKART INC	**300MG;50MG**	**A207386**	**001** Nov 15, 2016
AA	+	NEXGEN PHARMA	**300MG;50MG**	**A090956**	**001** Aug 23, 2011

BUTAPAP

AA	+	MIKART	**325MG;50MG**	**A089987**	**001** Oct 26, 1992

ALLZITAL

		LARKEN LABS INC	325MG;25MG	A203484	001 Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB	+	NEXGEN PHARMA	**300MG;50MG;40MG**	**A040885**	**001** Nov 16, 2009
AB		NUVO PHARM INC	**300MG;50MG;40MG**	**A207118**	**001** Oct 28, 2016
	+	MAYNE PHARMA INC	325MG;50MG;40MG	A089007	001 Mar 17, 1986

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	+	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001 Jan 31, 2003

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		CNTY LINE PHARMS	**325MG;50MG;40MG**	**A204984**	**001** Jan 10, 2017
AA		HIKMA PHARMS LLC	**325MG;50MG;40MG**	**A089718**	**001** Jun 12, 1995
AA		LANNETT HOLDINGS INC	**325MG;50MG;40MG**	**A200243**	**001** Sep 13, 2012
AA		MALLINCKRODT	**325MG;50MG;40MG**	**A087804**	**001** Jan 24, 1985
AA		MIKART	**325MG;50MG;40MG**	**A089175**	**001** Jan 21, 1987
AA	+	VINTAGE PHARMS	**325MG;50MG;40MG**	**A040511**	**001** Aug 27, 2003

FIORICET

AA		ACTAVIS LABS UT INC	**325MG;50MG;40MG**	**A088616**	**001** Nov 09, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		HIKMA INTL PHARMS	**325MG;50MG;40MG;30MG**	**A075618**	**001** Mar 23, 2001
AB		NEXGEN PHARMA INC	**325MG;50MG;40MG;30MG**	**A076560**	**001** Jun 10, 2004
AB		VINTAGE PHARMS	**325MG;50MG;40MG;30MG**	**A075929**	**001** Apr 22, 2002

FIORICET W/ CODEINE

AB	+	ACTAVIS LABS UT INC	**325MG;50MG;40MG;30MG**	**N020232**	**001** Jul 30, 1992

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

		NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560	002 Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

		WRASER PHARMS LLC	320.5MG;30MG;16MG	A204785	001 Nov 26, 2014

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

		LARKEN LABS INC	325MG;30MG;16MG	A204209	001 Sep 30, 2016

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		HI TECH PHARMA	120MG/5ML;12MG/5ML	A040119 001	Apr 26, 1996
AA		MIKART	120MG/5ML;12MG/5ML	A089450 001	Oct 27, 1992
AA	+	PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001	
AA		VINTAGE PHARMS	120MG/5ML;12MG/5ML	A091238 001	Nov 10, 2011
AA		WOCKHARDT	120MG/5ML;12MG/5ML	A087006 001	

SUSPENSION;ORAL

CAPITAL AND CODEINE

	+	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS NY	300MG;30MG	A040779 001	May 29, 2008
AA		AUROLIFE PHARMA LLC	300MG;15MG	A202800 001	Apr 15, 2013
AA			300MG;30MG	A202800 002	Apr 15, 2013
AA			300MG;60MG	A202800 003	Apr 15, 2013
AA	+	MALLINCKRODT INC	300MG;15MG	A040419 001	May 31, 2001
AA			300MG;30MG	A040419 002	May 31, 2001
AA			300MG;60MG	A040419 003	May 31, 2001
AA		SUN PHARM INDS LTD	300MG;30MG	A085868 001	
AA			300MG;60MG	A087083 001	
AA		TEVA	300MG;15MG	A088627 001	Mar 06, 1985
AA			300MG;30MG	A088628 001	Mar 06, 1985
AA	+		300MG;60MG	A088629 001	Mar 06, 1985
AA		VINTAGE	300MG;15MG	A089990 001	Sep 30, 1988
AA			300MG;30MG	A089805 001	Sep 30, 1988
AA		VINTAGE PHARMS	300MG;60MG	A089828 001	Sep 30, 1988

TYLENOL W/ CODEINE NO. 3

AA	+	JANSSEN PHARMS	300MG;30MG	A085055 003	

TYLENOL W/ CODEINE NO. 4

AA		JANSSEN PHARMS	300MG;60MG	A085055 004	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+	MIKART	325MG/15ML;7.5MG/15ML	A040482 001	Sep 25, 2003
AA		PHARM ASSOC	325MG/15ML;7.5MG/15ML	A040838 001	May 10, 2013
AA		VINTAGE PHARMS	325MG/15ML;7.5MG/15ML	A040894 001	Jul 19, 2011
AA		VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012

ZYFREL

AA		CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468 001	Apr 14, 2016

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	+	MIKART	300MG/15ML;10MG/15ML	A040881 001	Feb 25, 2010
	+	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834 001	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

AA		MALLINCKRODT	325MG;5MG	A040409 001	Oct 20, 2000

ANEXSIA 7.5/325

AA		MALLINCKRODT	325MG;7.5MG	A040405 001	Sep 08, 2000

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ACTAVIS LABS FL INC	300MG;5MG	A206470 001	Jun 02, 2016
AA			300MG;7.5MG	A206470 002	Jun 02, 2016
AA			300MG;10MG	A206470 003	Jun 02, 2016
AA		AMNEAL PHARMS	300MG;10MG	A207137 001	Nov 29, 2016
AA		AMNEAL PHARMS NY	325MG;5MG	A040736 001	Aug 25, 2006
AA			325MG;7.5MG	A040746 002	May 10, 2016
AA			325MG;10MG	A040746 001	Aug 25, 2006
AA		AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012
AA			325MG;7.5MG	A201013 002	Apr 11, 2012
AA			325MG;10MG	A201013 003	Apr 11, 2012
AA		LARKEN LABS INC	325MG;5MG	A202935 002	Jun 15, 2016
AA			325MG;7.5MG	A202935 003	Jun 15, 2016
AA			325MG;10MG	A202935 004	Jun 15, 2016
AA		MALLINCKRODT	325MG;10MG	A040400 001	Jul 26, 2000
AA	+	MIKART	300MG;5MG	A040658 001	Jan 19, 2006
AA	+		300MG;7.5MG	A040556 002	Mar 24, 2006
AA	+		300MG;10MG	A040556 001	Jun 23, 2004
AA	+		325MG;2.5MG	A040846 001	Jun 09, 2010
AA			325MG;7.5MG	A040432 001	Jan 22, 2003
AA		NOVEL LABS INC	300MG;5MG	A206142 001	Nov 14, 2016
AA			300MG;7.5MG	A206142 002	Nov 14, 2016
AA			300MG;10MG	A206142 003	Nov 14, 2016

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		325MG;5MG	A206245	001	Dec 01, 2016
AA		325MG;7.5MG	A206245	002	Dec 01, 2016
AA		325MG;10MG	A206245	003	Dec 01, 2016
AA	PAR PHARM	300MG;5MG	A205001	001	Jul 05, 2016
AA		300MG;7.5MG	A205001	002	Jul 05, 2016
AA		300MG;10MG	A205001	003	Jul 05, 2016
AA	RHODES PHARMS	325MG;5MG	A202991	001	Apr 12, 2016
AA		325MG;7.5MG	A202991	002	Apr 12, 2016
AA		325MG;10MG	A202991	003	Apr 12, 2016
AA	SUN PHARM INDS INC	325MG;5MG	A090118	001	Dec 23, 2008
AA		325MG;7.5MG	A090118	002	Dec 23, 2008
AA		325MG;10MG	A090118	003	Dec 23, 2008
AA	TRIS PHARMA INC	300MG;5MG	A202214	004	Mar 15, 2016
AA		300MG;7.5MG	A202214	005	Mar 15, 2016
AA		300MG;10MG	A202214	006	Mar 15, 2016
AA		325MG;5MG	A202214	001	Mar 27, 2013
AA		325MG;7.5MG	A202214	002	Mar 27, 2013
AA		325MG;10MG	A202214	003	Mar 27, 2013
AA	VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011
AA		300MG;7.5MG	A090415	002	Jan 24, 2011
AA		300MG;10MG	A090415	003	Jan 24, 2011
AA		325MG;5MG	A040655	001	Jan 19, 2006
AA		325MG;7.5MG	A040656	001	Jan 19, 2006
AA		325MG;10MG	A040355	001	May 31, 2000

NORCO

AA	APIL	325MG;2.5MG	A040148	004	Jul 07, 2014
AA +		325MG;5MG	A040099	001	Jun 25, 1997
AA		325MG;5MG	A040148	005	Jul 07, 2014
AA +		325MG;7.5MG	A040148	003	Sep 12, 2000
AA +		325MG;10MG	A040148	001	Feb 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

AA +	MALLINCKRODT INC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

AA	VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014

TABLET;ORAL

OXYCET

AA	MALLINCKRODT	325MG;5MG	A087463	001	Dec 07, 1983

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS ELIZABETH	325MG;2.5MG	A201447	001	Apr 12, 2013
AA		325MG;5MG	A201447	002	Apr 12, 2013
AA		325MG;7.5MG	A201447	003	Apr 12, 2013
AA		325MG;10MG	A201447	004	Apr 12, 2013
AA	ALVOGEN MALTA	325MG;5MG	A202677	003	Mar 08, 2016
AA		325MG;7.5MG	A202677	001	Jul 26, 2012
AA		325MG;10MG	A202677	002	Jul 26, 2012
AA	AMNEAL PHARMS NY	325MG;5MG	A040777	001	Nov 27, 2007
AA		325MG;7.5MG	A040778	002	Jun 27, 2014
AA		325MG;10MG	A040778	001	Nov 27, 2007
AA	AUROLIFE PHARMA LLC	325MG;2.5MG	A201972	001	Jul 15, 2013
AA		325MG;5MG	A201972	002	Jul 15, 2013
AA		325MG;7.5MG	A201972	003	Jul 15, 2013
AA		325MG;10MG	A201972	004	Jul 15, 2013
AA	CEROVENE INC	325MG;5MG	A207574	001	Dec 13, 2016
AA	MALLINCKRODT	325MG;7.5MG	A040545	001	Jun 30, 2004
AA		325MG;10MG	A040545	002	Jun 30, 2004
AA	MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20, 2008
AA		325MG;5MG	A090177	002	Oct 20, 2008
AA		325MG;7.5MG	A090177	003	Oct 20, 2008
AA		325MG;10MG	A090177	004	Oct 20, 2008
AA	RHODES PHARMS	325MG;5MG	A201278	001	Aug 28, 2014
AA		325MG;7.5MG	A201278	002	Aug 28, 2014
AA		325MG;10MG	A201278	003	Aug 28, 2014
AA	SUN PHARM INDS INC	325MG;2.5MG	A090535	001	Dec 26, 2013
AA		325MG;5MG	A090535	002	Dec 26, 2013
AA		325MG;7.5MG	A090535	003	Dec 26, 2013
AA		325MG;10MG	A090535	004	Dec 26, 2013
AA	VINTAGE PHARMS	325MG;2.5MG	A090733	001	Jul 11, 2013

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA			**325MG;5MG**	**A040105**	**001** Jul 30, 1996
AA			**325MG;7.5MG**	**A090734**	**001** Jul 11, 2013
AA			**325MG;10MG**	**A090734**	**002** Jul 11, 2013
AA		WATSON LABS	**325MG;5MG**	**A040171**	**001** Oct 30, 1997
AA			**325MG;7.5MG**	**A040535**	**001** Sep 05, 2003
AA			**325MG;10MG**	**A040535**	**002** Sep 05, 2003

PERCOCET

AA	+	VINTAGE PHARMS LLC	**325MG;2.5MG**	**A040330**	**001** Jun 25, 1999
AA	+		**325MG;5MG**	**A040330**	**002** Jun 25, 1999
AA	+		**325MG;7.5MG**	**A040434**	**001** Nov 23, 2001
AA	+		**325MG;10MG**	**A040434**	**002** Nov 23, 2001

ROXICET

AA		WEST-WARD PHARMS INT	**325MG;5MG**	**A087003**	**001**

OXYCODONE AND ACETAMINOPHEN

	+	MIKART	300MG;2.5MG	A040608	001 Dec 30, 2005
	+		300MG;5MG	A040608	002 Dec 30, 2005
	+		300MG;7.5MG	A040608	003 Dec 30, 2005
	+		300MG;10MG	A040608	004 Dec 30, 2005

TABLET, EXTENDED RELEASE;ORAL

XARTEMIS XR

	+	MALLINCKRODT INC	325MG;7.5MG	N204031	001 Mar 11, 2014

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		AMNEAL PHARMS	**325MG;37.5MG**	**A090485**	**001** Dec 09, 2009
AB		APOTEX INC	**325MG;37.5MG**	**A078778**	**001** Apr 07, 2014
AB		ATLAS PHARMS LLC	**325MG;37.5MG**	**A202076**	**001** Mar 30, 2012
AB		MICRO LABS LTD INDIA	**325MG;37.5MG**	**A201952**	**001** Dec 14, 2012
AB		MYLAN	**325MG;37.5MG**	**A077858**	**001** Sep 26, 2008
AB		PAR PHARM	**325MG;37.5MG**	**A076475**	**001** Apr 21, 2005
AB		SUN PHARM INDS INC	**325MG;37.5MG**	**A077184**	**001** Dec 16, 2005
AB		ZYDUS PHARMS USA INC	**325MG;37.5MG**	**A090460**	**001** Sep 06, 2012

ULTRACET

AB	+	JANSSEN PHARMS	**325MG;37.5MG**	**N021123**	**001** Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		HERITAGE PHARMS INC	**500MG**	**A090779**	**001** Jul 14, 2011
AB		NOSTRUM LABS INC	**500MG**	**A204691**	**001** Mar 29, 2016
AB		NOVAST LABS LTD	**500MG**	**A203434**	**001** Sep 30, 2016
AB		ZYDUS PHARMS USA INC	**500MG**	**A040904**	**001** Dec 10, 2008

DIAMOX

AB	+	TEVA BRANDED PHARM	**500MG**	**N012945**	**001**

TABLET;ORAL

ACETAZOLAMIDE

AB		HERITAGE PHARMA	**125MG**	**A205530**	**001** Oct 27, 2016
AB			**250MG**	**A205530**	**002** Oct 27, 2016
AB		LANNETT	**250MG**	**A084840**	**001**
AB		MUTUAL PHARM	**125MG**	**A089752**	**001** Jun 22, 1988
AB		TARO	**125MG**	**A040195**	**001** May 28, 1997
AB	+		**250MG**	**A040195**	**002** May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		SAGENT AGILA	**EQ 500MG BASE/VIAL**	**A200880**	**001** May 09, 2012
AP		WEST-WARD PHARMS INT	**EQ 500MG BASE/VIAL**	**A040089**	**001** Feb 28, 1995
AP	+	X GEN PHARMS	**EQ 500MG BASE/VIAL**	**A040784**	**001** Dec 10, 2008

ACETAZOLAMIDE SODIUM

AP		EMCURE PHARMS LTD	**EQ 500MG BASE/VIAL**	**A202693**	**001** Dec 19, 2014

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		B BRAUN	**250MG/100ML**	**N018161**	**001**
AT		BAXTER HLTHCARE	**250MG/100ML**	**N018523**	**001** Feb 19, 1982
AT		HOSPIRA	**250MG/100ML**	**N017656**	**001**

FDA data supplied by DrugPatentWatch.com

ACETIC ACID, GLACIAL
SOLUTION/DROPS;OTIC
ACETIC ACID

AT		TARO	**2%**	**A088638**	**001** Sep 06, 1984
AT		VINTAGE	**2%**	**A040607**	**001** Feb 24, 2005
AT	+	WOCKHARDT	**2%**	**A040166**	**001** Jul 26, 1996

VOSOL

AT		HI TECH PHARMA	**2%**	**N012179**	**001**

ACETIC ACID, GLACIAL; ALUMINUM ACETATE
SOLUTION/DROPS;OTIC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

	+	BAUSCH AND LOMB	2%;0.79%	A040063	001 Feb 25, 1994

ACETIC ACID, GLACIAL; HYDROCORTISONE
SOLUTION/DROPS;OTIC
ACETASOL HC

AT		ACTAVIS MID ATLANTIC	**2%;1%**	**A087143**	**001** Jan 13, 1982

HYDROCORTISONE AND ACETIC ACID

AT		TARO	**2%;1%**	**A088759**	**001** Mar 04, 1985
AT		VINTAGE	**2%;1%**	**A040609**	**001** Feb 06, 2006

VOSOL HC

AT	+	HI TECH PHARMA	**2%;1%**	**N012770**	**001**

ACETOHYDROXAMIC ACID
TABLET;ORAL
LITHOSTAT

	+	MISSION PHARMA	250MG	N018749	001 May 31, 1983

ACETYLCHOLINE CHLORIDE
FOR SOLUTION;OPHTHALMIC
MIOCHOL-E

	+	BAUSCH AND LOMB	20MG/VIAL	N020213	001 Sep 22, 1993

ACETYLCYSTEINE
INJECTABLE;INTRAVENOUS
ACETADOTE

AP	+	CUMBERLAND PHARMS	**6GM/30ML (200MG/ML)**	**N021539**	**001** Jan 23, 2004

ACETYLCYSTEINE

AP		AKORN INC	**6GM/30ML (200MG/ML)**	**A203173**	**001** Mar 24, 2015
AP		AUROBINDO PHARMA LTD	**6GM/30ML (200MG/ML)**	**A207358**	**001** Feb 29, 2016
AP		FRESENIUS KABI USA	**6GM/30ML (200MG/ML)**	**A200644**	**001** Nov 07, 2012
AP		MYLAN INSTITUTIONAL	**6GM/30ML (200MG/ML)**	**A203624**	**001** Jun 19, 2015

SOLUTION;INHALATION, ORAL
ACETYLCYSTEINE

AN		ALVOGEN INC	**10%**	**A204674**	**001** Feb 11, 2014
AN			**20%**	**A203853**	**001** Jun 21, 2012
AN		HOSPIRA	**10%**	**A073664**	**001** Aug 30, 1994
AN			**20%**	**A074037**	**001** Aug 30, 1994
AN	+	LUITPOLD	**10%**	**A072489**	**001** Jul 28, 1995
AN	+		**20%**	**A072547**	**001** Jul 28, 1995

TABLET, EFFERVESCENT;ORAL
CETYLEV

		ARBOR PHARMS LLC	500MG	N207916	001 Jan 29, 2016
	+		2.5GM	N207916	002 Jan 29, 2016

ACITRETIN
CAPSULE;ORAL
ACITRETIN

AB		BARR LABS INC	**10MG**	**A091455**	**001** Apr 04, 2013
AB			**25MG**	**A091455**	**002** Apr 04, 2013
AB		IMPAX LABS INC	**10MG**	**A202552**	**001** Dec 23, 2015
AB			**17.5MG**	**A202552**	**002** Dec 23, 2015
AB			**22.5MG**	**A202552**	**003** Dec 23, 2015
AB			**25MG**	**A202552**	**004** Dec 23, 2015
AB		MYLAN PHARMS INC	**10MG**	**A202148**	**001** Sep 10, 2015
AB			**17.5MG**	**A203707**	**001** Sep 10, 2015
AB			**22.5MG**	**A203707**	**002** Sep 10, 2015
AB			**25MG**	**A202148**	**002** Sep 10, 2015
AB		SIGMAPHARM LABS LLC	**10MG**	**A204633**	**001** May 22, 2015
AB			**17.5MG**	**A204633**	**002** May 22, 2015
AB			**22.5MG**	**A204633**	**003** May 22, 2015
AB			**25MG**	**A204633**	**004** May 22, 2015
AB		TEVA PHARMS USA	**17.5MG**	**A202897**	**001** Apr 04, 2013
AB			**22.5MG**	**A202897**	**002** Apr 04, 2013

FDA data supplied by DrugPatentWatch.com

ACITRETIN
CAPSULE;ORAL
SORIATANE

AB	STIEFEL LABS INC	**10MG**	**N019821**	**001**	Oct 28, 1996
AB		**17.5MG**	**N019821**	**003**	Aug 06, 2009
AB		**22.5MG**	**N019821**	**004**	Aug 06, 2009
AB +		**25MG**	**N019821**	**002**	Oct 28, 1996

ACLIDINIUM BROMIDE
POWDER, METERED;INHALATION
TUDORZA PRESSAIR

+	ASTRAZENECA PHARMS	0.4MG/INH	N202450	001	Jul 23, 2012

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE
CAPSULE;ORAL
SEMPREX-D

+	AUXILIUM PHARMS INC	8MG;60MG	N019806	001	Mar 25, 1994

ACYCLOVIR
CAPSULE;ORAL
ACYCLOVIR

AB	APOTEX INC	**200MG**	**A075677**	**001**	Sep 28, 2005
AB	CADILA PHARMS LTD	**200MG**	**A201445**	**001**	Mar 06, 2014
AB	DAVA PHARMS INC	**200MG**	**A074833**	**001**	Apr 22, 1997
AB	MYLAN	**200MG**	**A074727**	**001**	Apr 22, 1997
AB	STASON	**200MG**	**A075090**	**001**	Jan 26, 1999
AB	TEVA	**200MG**	**A074578**	**001**	Apr 22, 1997
AB	ZYDUS PHARMS USA INC	**200MG**	**A204313**	**001**	Mar 25, 2016

ZOVIRAX

AB +	DELCOR ASSET CORP	**200MG**	**N018828**	**001**	Jan 25, 1985

CREAM;TOPICAL
ZOVIRAX

+	VIB	5%	N021478	001	Dec 30, 2002

OINTMENT;TOPICAL
ACYCLOVIR

AB	AMNEAL PHARMS	**5%**	**A204605**	**001**	Jun 18, 2014
AB	FOUGERA PHARMS INC	**5%**	**A206633**	**001**	May 11, 2016
AB	MYLAN PHARMS INC	**5%**	**A202459**	**001**	Apr 03, 2013
AB	TARO	**5%**	**A205469**	**001**	Dec 21, 2016

ZOVIRAX

AB +	VALEANT BERMUDA	**5%**	**N018604**	**001**	Mar 29, 1982

SUSPENSION;ORAL
ACYCLOVIR

AB	ACTAVIS MID ATLANTIC	**200MG/5ML**	**A074738**	**001**	Apr 28, 1997
AB	HI TECH PHARMA	**200MG/5ML**	**A077026**	**001**	Jun 07, 2005

ZOVIRAX

AB +	DELCOR ASSET	**200MG/5ML**	**N019909**	**001**	Dec 22, 1989

TABLET;BUCCAL
SITAVIG

+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013

TABLET;ORAL
ACYCLOVIR

AB	APOTEX INC	**400MG**	**A077309**	**001**	Sep 29, 2005
AB		**800MG**	**A077309**	**002**	Sep 29, 2005
AB	CADILA PHARMS LTD	**400MG**	**A202168**	**001**	Nov 15, 2013
AB		**800MG**	**A202168**	**002**	Nov 15, 2013
AB	CARLSBAD	**400MG**	**A075382**	**001**	Apr 30, 1999
AB		**800MG**	**A075382**	**002**	Apr 30, 1999
AB	DAVA PHARMS INC	**400MG**	**A074946**	**001**	Nov 19, 1997
AB		**800MG**	**A074946**	**002**	Nov 19, 1997
AB	HETERO LABS LTD V	**400MG**	**A203834**	**001**	Oct 29, 2013
AB		**800MG**	**A203834**	**002**	Oct 29, 2013
AB	MYLAN	**400MG**	**A075211**	**001**	Sep 28, 1998
AB		**800MG**	**A075211**	**002**	Sep 28, 1998
AB	TEVA	**400MG**	**A074556**	**002**	Apr 22, 1997
AB		**800MG**	**A074556**	**003**	Apr 22, 1997
AB	ZYDUS PHARMS USA INC	**400MG**	**A204314**	**001**	Aug 19, 2014
AB		**800MG**	**A204314**	**002**	Aug 19, 2014

ZOVIRAX

AB	DELCOR ASSET CORP	**400MG**	**N020089**	**001**	Apr 30, 1991
AB +		**800MG**	**N020089**	**002**	Apr 30, 1991

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR SODIUM
INJECTABLE;INJECTION
ACYCLOVIR SODIUM

AP		AUROBINDO PHARMA LTD	**EQ 50MG BASE/ML**	**A203701**	**001**	Oct 11, 2013
AP	+	FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A074930**	**001**	May 13, 1998
AP	+		**EQ 500MG BASE/VIAL**	**A075015**	**001**	Apr 30, 1998
AP		HIKMA PHARMS LLC	**EQ 500MG BASE/VIAL**	**A205771**	**001**	Feb 29, 2016
	+		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016

ACYCLOVIR; HYDROCORTISONE
CREAM;TOPICAL
XERESE

	+	VALEANT BERMUDA	5%;1%	N022436	001	Jul 31, 2009

ADAPALENE
CREAM;TOPICAL
ADAPALENE

AB		FOUGERA PHARMS	**0.1%**	**A090824**	**001**	Jun 30, 2010

DIFFERIN

AB	+	GALDERMA LABS LP	**0.1%**	**N020748**	**001**	May 26, 2000

GEL;TOPICAL
ADAPALENE

AB		ACTAVIS MID ATLANTIC	**0.3%**	**A201000**	**001**	Oct 27, 2014
AB		GLENMARK GENERICS	**0.1%**	**A091314**	**001**	Jul 01, 2010
AB		PLIVA HRVATSKA DOO	**0.1%**	**A090962**	**001**	Jun 02, 2010
AB		TARO	**0.3%**	**A208322**	**001**	Jun 23, 2016
AB		TOLMAR	**0.3%**	**A200298**	**001**	Jun 14, 2012

DIFFERIN

AB	+	GALDERMA LABS LP	**0.3%**	**N021753**	**001**	Jun 19, 2007

LOTION;TOPICAL
DIFFERIN

	+	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010

SOLUTION;TOPICAL
ADAPALENE

AB		CALL INC	**0.1%**	**A203981**	**001**	Sep 23, 2016
AB	+		**0.1%**	**A204593**	**001**	Jan 05, 2016

ADAPALENE; BENZOYL PEROXIDE
GEL;TOPICAL
ADAPALENE AND BENZOYL PEROXIDE

AB		ACTAVIS MID ATLANTIC	**0.1%;2.5%**	**A203790**	**001**	Sep 30, 2015

EPIDUO

AB	+	GALDERMA LABS LP	**0.1%;2.5%**	**N022320**	**001**	Dec 08, 2008

EPIDUO FORTE

	+	GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015

ADEFOVIR DIPIVOXIL
TABLET;ORAL
ADEFOVIR DIPIVOXIL

AB		SIGMAPHARM LABS LLC	**10MG**	**A202051**	**001**	Aug 29, 2013

HEPSERA

AB	+	GILEAD	**10MG**	**N021449**	**001**	Sep 20, 2002

ADENOSINE
INJECTABLE;INJECTION
ADENOCARD

AP	+	ASTELLAS	**3MG/ML**	**N019937**	**002**	Oct 30, 1989

ADENOSINE

AP		AKORN	**3MG/ML**	**A078076**	**001**	Oct 31, 2008
AP		EUROHLTH INTL SARL	**3MG/ML**	**A076404**	**001**	Jun 16, 2004
AP			**3MG/ML**	**A076500**	**001**	Jun 16, 2004
AP		FRESENIUS KABI USA	**3MG/ML**	**A077133**	**001**	Apr 27, 2005
AP		GLAND PHARMA LTD	**3MG/ML**	**A077283**	**001**	Jun 14, 2007
AP		LUITPOLD	**3MG/ML**	**A090010**	**001**	Apr 28, 2009
AP		MYLAN LABS LTD	**3MG/ML**	**A078640**	**001**	Mar 21, 2014
AP			**3MG/ML**	**A078686**	**001**	May 13, 2009

SOLUTION;IV (INFUSION)
ADENOSINE

AP		AKORN	**60MG/20ML (3MG/ML)**	**A090450**	**001**	Oct 02, 2014
AP			**90MG/30ML (3MG/ML)**	**A090450**	**002**	Oct 02, 2014
AP		EMCURE PHARMS LTD	**60MG/20ML (3MG/ML)**	**A202313**	**001**	Sep 15, 2014
AP			**90MG/30ML (3MG/ML)**	**A202313**	**002**	Sep 15, 2014
AP		HOSPIRA INC	**60MG/20ML (3MG/ML)**	**A203883**	**001**	Mar 24, 2014
AP			**90MG/30ML (3MG/ML)**	**A203883**	**002**	Mar 24, 2014
AP		SAGENT STRIDES	**60MG/20ML (3MG/ML)**	**A090212**	**001**	Mar 28, 2014

ADENOSINE
SOLUTION;IV (INFUSION)
ADENOSINE

AP			**90MG/30ML (3MG/ML)**	**A090212**	**002**	Mar 28, 2014
AP	**+**	TEVA PHARMS USA	**60MG/20ML (3MG/ML)**	**A077425**	**001**	Aug 29, 2013
AP	**+**		**90MG/30ML (3MG/ML)**	**A077425**	**002**	Aug 29, 2013

AFATINIB DIMALEATE
TABLET;ORAL
GILOTRIF

		BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013
			EQ 30MG BASE	N201292	002	Jul 12, 2013
	+		EQ 40MG BASE	N201292	003	Jul 12, 2013

ALBENDAZOLE
TABLET;ORAL
ALBENZA

	+	AMEDRA PHARMS LLC	200MG	N020666	001	Jun 11, 1996

ALBUMIN HUMAN
INJECTABLE;INJECTION
OPTISON

	+	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997

ALBUMIN IODINATED I-125 SERUM
INJECTABLE;INJECTION
JEANATOPE

		ISO TEX	100uCi/10ML (10uCi/ML)	N017836	003	Jun 08, 2004
			500uCi/0.5ML	N017836	001	
	+		1,000uCi/ML	N017836	002	

ALBUMIN IODINATED I-131 SERUM
INJECTABLE;INJECTION
MEGATOPE

	+	ISO TEX	0.5mCi/VIAL	N017837	001	
	+		1mCi/VIAL	N017837	002	

ALBUTEROL SULFATE
AEROSOL, METERED;INHALATION
PROAIR HFA

BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004

PROVENTIL-HFA

BX	+	3M	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996

VENTOLIN HFA

BX	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001

POWDER, METERED;INHALATION
PROAIR RESPICLICK

	+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015

SOLUTION;INHALATION
ACCUNEB

AN	**+**	MYLAN SPECLT	**EQ 0.021% BASE**	**N020949**	**002**	Apr 30, 2001
AN	**+**		**EQ 0.042% BASE**	**N020949**	**001**	Apr 30, 2001

ALBUTEROL SULFATE

AN	**+**	BAUSCH AND LOMB	**EQ 0.5% BASE**	**A075050**	**001**	Jun 18, 1998
AN		HI TECH PHARMA	**EQ 0.5% BASE**	**A074543**	**001**	Jan 15, 1998
AN		NEPHRON	**EQ 0.021% BASE**	**A076355**	**002**	Mar 31, 2010
AN			**EQ 0.042% BASE**	**A076355**	**001**	Jun 28, 2004
AN	**+**		**EQ 0.083% BASE**	**A074880**	**001**	Sep 17, 1997
AN			**EQ 0.5% BASE**	**A075664**	**001**	Jun 26, 2001
AN		RITEDOSE CORP	**EQ 0.083% BASE**	**A077839**	**001**	Dec 16, 2008
AN		WATSON LABS	**EQ 0.021% BASE**	**A077772**	**001**	Sep 25, 2007
AN			**EQ 0.042% BASE**	**A077772**	**002**	Sep 25, 2007

SYRUP;ORAL
ALBUTEROL SULFATE

AA		AMNEAL PHARMS	**EQ 2MG BASE/5ML**	**A079241**	**001**	May 12, 2010
AA		G AND W LABS INC	**EQ 2MG BASE/5ML**	**A074454**	**001**	Sep 25, 1995
AA		HI TECH PHARMA	**EQ 2MG BASE/5ML**	**A074749**	**001**	Jan 30, 1998
AA	**+**	TEVA	**EQ 2MG BASE/5ML**	**A073419**	**001**	Mar 30, 1992
AA		VINTAGE	**EQ 2MG BASE/5ML**	**A078105**	**001**	Dec 27, 2006
AA		VISTAPHARM	**EQ 2MG BASE/5ML**	**A077788**	**001**	Jun 26, 2007

TABLET;ORAL
ALBUTEROL SULFATE

AB		MYLAN	**EQ 2MG BASE**	**A072894**	**002**	Jan 17, 1991
AB	**+**		**EQ 4MG BASE**	**A072894**	**001**	Jan 17, 1991
AB		SUN PHARM INDS	**EQ 2MG BASE**	**A072637**	**002**	Dec 05, 1989

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE
TABLET;ORAL
ALBUTEROL SULFATE

AB		**EQ 4MG BASE**	**A072637**	**001**	Dec 05, 1989

TABLET, EXTENDED RELEASE;ORAL
ALBUTEROL SULFATE

AB	MYLAN	**EQ 4MG BASE**	**A078092**	**002**	Jan 29, 2007
AB		**EQ 8MG BASE**	**A078092**	**001**	Jan 29, 2007

VOSPIRE ER

AB	DAVA PHARMS INC	**EQ 4MG BASE**	**A076130**	**002**	Sep 26, 2002
AB +		**EQ 8MG BASE**	**A076130**	**003**	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
SOLUTION;INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN	CIPLA LTD	**EQ 0.083% BASE;0.017%**	**A077559**	**001**	Dec 31, 2007
AN	NEPHRON	**EQ 0.083% BASE;0.017%**	**A076749**	**001**	Dec 31, 2007
AN	RITEDOSE CORP	**EQ 0.083% BASE;0.017%**	**A202496**	**001**	Oct 01, 2012
AN	TEVA PHARMS	**EQ 0.083% BASE;0.017%**	**A076724**	**001**	Dec 31, 2007
AN	WATSON LABS	**EQ 0.083% BASE;0.017%**	**A077063**	**001**	Dec 31, 2007

SPRAY, METERED;INHALATION
COMBIVENT RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011

ALCAFTADINE
SOLUTION/DROPS;OPHTHALMIC
LASTACAFT

+	ALLERGAN	0.25%	N022134	001	Jul 28, 2010

ALCLOMETASONE DIPROPIONATE
CREAM;TOPICAL
ALCLOMETASONE DIPROPIONATE

AB +	FOUGERA PHARMS	**0.05%**	**A076973**	**001**	Jul 12, 2005
AB	GLENMARK GENERICS	**0.05%**	**A079061**	**001**	Jun 23, 2009
AB	TARO	**0.05%**	**A076587**	**001**	Sep 15, 2005

OINTMENT;TOPICAL
ALCLOMETASONE DIPROPIONATE

AB +	FOUGERA PHARMS	**0.05%**	**A076884**	**001**	Jul 18, 2005
AB	GLENMARK GENERICS	**0.05%**	**A079227**	**001**	Jul 30, 2009
AB	TARO	**0.05%**	**A076730**	**001**	Jul 29, 2004

ALECTINIB HYDROCHLORIDE
CAPSULE;ORAL
ALECENSA

+	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434	001	Dec 11, 2015

ALENDRONATE SODIUM
SOLUTION;ORAL
ALENDRONATE SODIUM

+	WEST-WARD PHARMS INT	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013

TABLET;ORAL
ALENDRONATE SODIUM

AB	APOTEX	**EQ 5MG BASE**	**A077982**	**001**	Aug 04, 2008
AB		**EQ 10MG BASE**	**A077982**	**002**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A077982**	**003**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A077982**	**004**	Aug 04, 2008
AB	AUROBINDO PHARMA	**EQ 10MG BASE**	**A090124**	**001**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A090124**	**002**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A090124**	**003**	Aug 04, 2008
AB	AUSTARPHARMA LLC	**EQ 5MG BASE**	**A090258**	**001**	Sep 24, 2009
AB		**EQ 10MG BASE**	**A090258**	**002**	Sep 24, 2009
AB		**EQ 35MG BASE**	**A090258**	**003**	Sep 24, 2009
AB		**EQ 70MG BASE**	**A090258**	**004**	Sep 24, 2009
AB	CIPLA LTD	**EQ 5MG BASE**	**A076768**	**001**	Aug 04, 2008
AB		**EQ 10MG BASE**	**A076768**	**002**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A076768**	**003**	Aug 04, 2008
AB		**EQ 40MG BASE**	**A076768**	**004**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A076768**	**005**	Aug 04, 2008
AB	DR REDDYS LABS LTD	**EQ 5MG BASE**	**A079049**	**003**	Aug 04, 2008
AB		**EQ 10MG BASE**	**A079049**	**004**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A079049**	**001**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A079049**	**002**	Aug 04, 2008
AB	IMPAX LABS INC	**EQ 5MG BASE**	**A075710**	**001**	Feb 06, 2008
AB		**EQ 10MG BASE**	**A075710**	**002**	Feb 06, 2008
AB		**EQ 35MG BASE**	**A075710**	**003**	Feb 06, 2008

FDA data supplied by DrugPatentWatch.com

ALENDRONATE SODIUM
TABLET;ORAL
ALENDRONATE SODIUM

AB		**EQ 40MG BASE**	**A075710**	**004**	Feb 06, 2008
AB		**EQ 70MG BASE**	**A075710**	**005**	Feb 06, 2008
AB	JUBILANT CADISTA	**EQ 5MG BASE**	**A090557**	**001**	Feb 18, 2010
AB		**EQ 10MG BASE**	**A090557**	**002**	Feb 18, 2010
AB		**EQ 35MG BASE**	**A090557**	**003**	Feb 18, 2010
AB		**EQ 70MG BASE**	**A090557**	**004**	Feb 18, 2010
AB	MYLAN	**EQ 5MG BASE**	**A076584**	**001**	Aug 04, 2008
AB		**EQ 10MG BASE**	**A076584**	**002**	Aug 04, 2008
AB		**EQ 35MG BASE**	**A076584**	**003**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A076584**	**004**	Aug 04, 2008
AB	SUN PHARMA GLOBAL	**EQ 5MG BASE**	**A090022**	**001**	Sep 10, 2008
AB		**EQ 10MG BASE**	**A090022**	**002**	Sep 10, 2008
AB		**EQ 35MG BASE**	**A090022**	**003**	Sep 10, 2008
AB		**EQ 70MG BASE**	**A090022**	**004**	Sep 10, 2008
AB	WATSON LABS	**EQ 35MG BASE**	**A076984**	**001**	Aug 04, 2008
AB		**EQ 40MG BASE**	**A076984**	**002**	Aug 04, 2008
AB		**EQ 70MG BASE**	**A076984**	**003**	Aug 04, 2008

FOSAMAX

AB	**+** MERCK AND CO INC	**EQ 70MG BASE**	**N020560**	**005**	Oct 20, 2000

TABLET, EFFERVESCENT;ORAL
BINOSTO

	+ MISSION PHARMA	EQ 70MG BASE	N202344	001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL
TABLET;ORAL
FOSAMAX PLUS D

	MERCK	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005
	+	EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007

ALFENTANIL HYDROCHLORIDE
INJECTABLE;INJECTION
ALFENTA

AP	**+** AKORN	**EQ 0.5MG BASE/ML**	**N019353**	**001**	Dec 29, 1986

ALFENTANIL

AP	HOSPIRA	**EQ 0.5MG BASE/ML**	**A075221**	**001**	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
ALFUZOSIN HYDROCHLORIDE

AB	APOTEX INC	**10MG**	**A079013**	**001**	Jul 18, 2011
AB	AUROBINDO PHARMA LTD	**10MG**	**A079060**	**001**	Aug 30, 2012
AB	INVAGEN PHARMS	**10MG**	**A090284**	**001**	Jan 17, 2012
AB	MYLAN	**10MG**	**A079014**	**001**	Jul 18, 2011
AB	SUN PHARMA GLOBAL	**10MG**	**A079057**	**001**	Jul 18, 2011
AB	TEVA PHARMS	**10MG**	**A079056**	**001**	Jul 18, 2011
AB	TORRENT PHARMS	**10MG**	**A079054**	**001**	Jul 18, 2011
AB	UNICHEM LABS LTD	**10MG**	**A203192**	**001**	Jan 28, 2016

UROXATRAL

AB	**+** CONCORDIA PHARMS INC	**10MG**	**N021287**	**001**	Jun 12, 2003

ALISKIREN HEMIFUMARATE
TABLET;ORAL
TEKTURNA

	NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007
	+	EQ 300MG BASE	N021985	002	Mar 05, 2007

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
TEKTURNA HCT

	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008
		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008
	+	EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008
	+	EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008

ALITRETINOIN
GEL;TOPICAL
PANRETIN

	+ EISAI INC	EQ 0.1% BASE	N020886	001	Feb 02, 1999

FDA data supplied by DrugPatentWatch.com

ALLOPURINOL

TABLET;ORAL

	ALLOPURINOL				
AB	ACCORD HLTHCARE	**100MG**	**A203154**	**001**	May 06, 2013
AB		**300MG**	**A203154**	**002**	May 06, 2013
AB	APOTEX INC	**100MG**	**A077353**	**001**	Sep 08, 2005
AB		**300MG**	**A077353**	**002**	Sep 08, 2005
AB	INDOCO REMEDIES	**100MG**	**A204467**	**001**	Jul 28, 2016
AB		**300MG**	**A204467**	**002**	Jul 28, 2016
AB	IPCA LABS LTD	**100MG**	**A090637**	**001**	Mar 16, 2011
AB		**300MG**	**A090637**	**002**	Mar 16, 2011
AB	MUTUAL PHARM	**100MG**	**A071449**	**001**	Jan 09, 1987
AB	MYLAN	**100MG**	**A018659**	**001**	Oct 24, 1986
AB		**300MG**	**A018659**	**002**	Oct 24, 1986
AB	NORTHSTAR HLTHCARE	**100MG**	**A078253**	**001**	Sep 11, 2007
AB		**300MG**	**A078253**	**002**	Sep 11, 2007
AB	SUN PHARM INDS	**300MG**	**A071450**	**001**	Jan 09, 1987
AB	SUN PHARM INDS INC	**100MG**	**A078390**	**001**	Aug 30, 2007
AB		**300MG**	**A078390**	**002**	Aug 30, 2007
AB	VINTAGE PHARMS	**100MG**	**A075798**	**001**	Jun 27, 2003
AB		**300MG**	**A075798**	**002**	Jun 27, 2003
AB	WATSON LABS	**100MG**	**N018832**	**002**	Sep 28, 1984
AB		**300MG**	**N018877**	**001**	Sep 28, 1984
	LOPURIN				
AB	DR REDDYS LA	**100MG**	**A071586**	**001**	Apr 02, 1987
AB		**300MG**	**A071587**	**001**	Apr 02, 1987
	ZYLOPRIM				
AB	SEBELA IRELAND LTD	**100MG**	**N016084**	**001**	
AB +		**300MG**	**N016084**	**002**	

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

	ALLOPURINOL SODIUM				
AP	WEST-WARD PHARMS INT	**EQ 500MG BASE/VIAL**	**A076870**	**001**	Aug 26, 2004
	ALOPRIM				
AP +	MYLAN INSTITUTIONAL	**EQ 500MG BASE/VIAL**	**N020298**	**001**	May 17, 1996

ALMOTRIPTAN MALATE

TABLET;ORAL

	ALMOTRIPTAN MALATE				
AB	AJANTA PHARMA LTD	**EQ 6.25MG BASE**	**A205523**	**001**	Mar 03, 2016
AB		**EQ 12.5MG BASE**	**A205523**	**002**	Mar 03, 2016
AB	MYLAN PHARMS INC	**EQ 6.25MG BASE**	**A205171**	**001**	Nov 09, 2015
AB		**EQ 12.5MG BASE**	**A205171**	**002**	Nov 09, 2015
AB	TEVA PHARMS USA	**EQ 6.25MG BASE**	**A078027**	**001**	Jul 07, 2015
AB		**EQ 12.5MG BASE**	**A078027**	**002**	Jul 07, 2015
	AXERT				
AB	JANSSEN PHARMS	**EQ 6.25MG BASE**	**N021001**	**001**	May 07, 2001
AB +		**EQ 12.5MG BASE**	**N021001**	**002**	May 07, 2001

ALOGLIPTIN BENZOATE

TABLET;ORAL

	NESINA				
	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013
		EQ 12.5MG BASE	N022271	002	Jan 25, 2013
+		EQ 25MG BASE	N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

	KAZANO				
	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013
+		EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

	OSENI				
	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013
		EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013
		EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013
		EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013
		EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013
+		EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013

FDA data supplied by DrugPatentWatch.com

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB	AMNEAL PHARMS	**EQ 0.5MG BASE**	**A206647**	**001**	Dec 22, 2016
AB		**EQ 1MG BASE**	**A206647**	**002**	Dec 22, 2016
AB	WEST-WARD PHARMS INT	**EQ 0.5MG BASE**	**A200652**	**001**	May 04, 2015
AB		**EQ 1MG BASE**	**A200652**	**002**	May 04, 2015

LOTRONEX

AB	SEBELA IRELAND LTD	**EQ 0.5MG BASE**	**N021107**	**002**	Dec 23, 2003
AB +		**EQ 1MG BASE**	**N021107**	**001**	Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE;INJECTION

INFUVITE ADULT

+	SANDOZ	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N021163	001	May 18, 2000

INJECTABLE;IV (INFUSION)

INFUVITE ADULT

+	SANDOZ	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	N021559	001	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE;ORAL

ALPRAZOLAM

+	WEST-WARD PHARMS INT	1MG/ML	A074312	001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	**0.25MG**	**A074342**	**001**	Oct 31, 1993
AB		**0.5MG**	**A074342**	**002**	Oct 31, 1993
AB		**1MG**	**A074342**	**003**	Oct 31, 1993
AB		**2MG**	**A074342**	**004**	Oct 31, 1993
AB	APOTEX INC	**0.25MG**	**A077741**	**001**	Jan 19, 2007
AB		**0.5MG**	**A077741**	**002**	Jan 19, 2007
AB		**1MG**	**A077741**	**003**	Jan 19, 2007
AB		**2MG**	**A077741**	**004**	Jan 19, 2007
AB	AUROBINDO PHARMA LTD	**0.25MG**	**A203346**	**001**	Jul 31, 2015
AB		**0.5MG**	**A203346**	**002**	Jul 31, 2015
AB		**1MG**	**A203346**	**003**	Jul 31, 2015
AB		**2MG**	**A203346**	**004**	Jul 31, 2015
AB	DAVA INTL INC	**0.25MG**	**A074174**	**001**	Oct 19, 1993
AB		**0.5MG**	**A074174**	**002**	Oct 19, 1993
AB		**1MG**	**A074174**	**003**	Oct 19, 1993
AB		**2MG**	**A074174**	**004**	Oct 19, 1993
AB	MYLAN	**0.25MG**	**A074215**	**001**	Jan 27, 1994
AB		**0.5MG**	**A074215**	**002**	Jan 27, 1994
AB		**1MG**	**A074215**	**003**	Jan 27, 1994
AB		**2MG**	**A074215**	**004**	Jan 27, 1994
AB	MYLAN PHARMS INC	**0.25MG**	**A074046**	**001**	Oct 19, 1993
AB		**0.5MG**	**A074046**	**002**	Oct 19, 1993
AB		**1MG**	**A074046**	**003**	Oct 19, 1993
AB		**2MG**	**A074046**	**004**	May 07, 1997
AB	NATCO PHARMA LTD	**0.25MG**	**A200739**	**001**	Apr 15, 2015
AB		**0.5MG**	**A200739**	**002**	Apr 15, 2015
AB		**1MG**	**A200739**	**003**	Apr 15, 2015
AB		**2MG**	**A200739**	**004**	Apr 15, 2015
AB	SANDOZ	**0.25MG**	**A074112**	**001**	Dec 29, 1995
AB		**0.5MG**	**A074112**	**002**	Dec 29, 1995
AB		**1MG**	**A074112**	**003**	Dec 29, 1995
AB		**2MG**	**A074909**	**001**	Mar 25, 1998
AB	SUN PHARMA GLOBAL	**0.25MG**	**A090082**	**001**	Jun 17, 2010
AB		**0.5MG**	**A090082**	**002**	Jun 17, 2010
AB		**1MG**	**A090082**	**003**	Jun 17, 2010
AB		**2MG**	**A090082**	**004**	Jun 17, 2010
AB	VINTAGE	**0.25MG**	**A078491**	**001**	Sep 25, 2008
AB		**0.5MG**	**A078491**	**002**	Sep 25, 2008
AB		**1MG**	**A078491**	**003**	Sep 25, 2008
AB		**2MG**	**A078491**	**004**	Dec 12, 2008
AB	VINTAGE PHARMS	**0.25MG**	**A090248**	**001**	Sep 17, 2010

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM					
AB		0.5MG	A090248	002	Sep 17, 2010
AB		1MG	A090248	003	Sep 17, 2010
AB		2MG	A090248	004	Sep 17, 2010
XANAX					
AB	PHARMACIA AND UPJOHN	0.25MG	N018276	001	
AB		0.5MG	N018276	002	
AB +		1MG	N018276	003	
AB		2MG	N018276	004	Nov 27, 1985

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM					
AB	ACTAVIS ELIZABETH	0.5MG	A078056	001	Feb 13, 2007
AB		1MG	A078056	002	Feb 13, 2007
AB		2MG	A078056	003	Feb 13, 2007
AB		3MG	A078056	004	Feb 13, 2007
AB	AMNEAL PHARMS NY	0.5MG	A078387	001	May 30, 2008
AB		1MG	A078387	002	May 30, 2008
AB		2MG	A078387	003	May 30, 2008
AB		3MG	A078387	004	May 30, 2008
AB	ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011
AB		1MG	A078469	002	Sep 29, 2011
AB		2MG	A078469	003	Sep 29, 2011
AB		3MG	A078469	004	Sep 29, 2011
AB	ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006
AB		1MG	A077725	002	Jul 31, 2006
AB		2MG	A077725	004	Jul 31, 2006
AB		3MG	A077725	003	Jul 31, 2006
AB	APOTEX INC	0.5MG	A078449	001	Nov 12, 2008
AB		1MG	A078449	004	Dec 23, 2015
AB		2MG	A078449	002	Nov 12, 2008
AB		3MG	A078449	003	Nov 12, 2008
AB	AUROBINDO PHARMA USA	0.5MG	A090871	001	Jun 07, 2011
AB		1MG	A090871	002	Jun 07, 2011
AB		2MG	A090871	003	Jun 07, 2011
AB		3MG	A090871	004	Jun 07, 2011
AB	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008
AB		1MG	A078489	002	Oct 17, 2008
AB		2MG	A078489	003	Oct 17, 2008
AB		3MG	A078489	004	Oct 17, 2008
AB	MYLAN	0.5MG	A077391	002	Jan 26, 2006
AB		1MG	A077391	003	Jan 26, 2006
AB		2MG	A077391	004	Jan 26, 2006
AB		3MG	A077391	001	Jan 26, 2006
XANAX XR					
AB	PHARMACIA AND UPJOHN	0.5MG	N021434	001	Jan 17, 2003
AB		1MG	N021434	002	Jan 17, 2003
AB		2MG	N021434	003	Jan 17, 2003
AB +		3MG	N021434	004	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM					
AB	ACTAVIS ELIZABETH	0.25MG	A078561	001	Mar 16, 2010
AB		0.5MG	A078561	002	Mar 16, 2010
AB		1MG	A078561	003	Mar 16, 2010
AB		2MG	A078561	004	Mar 16, 2010
AB	PAR PHARM	0.25MG	A078088	001	Jan 09, 2009
AB		0.5MG	A078088	002	Jan 09, 2009
AB +		1MG	A078088	003	Jan 09, 2009
AB		2MG	A078088	004	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL					
AP	TEVA PHARMS USA	0.5MG/ML	A075196	001	Apr 30, 1999
AP	WEST-WARD PHARMS INT	0.5MG/ML	A074815	001	Jan 20, 1998
CAVERJECT					
AP	PHARMACIA AND UPJOHN	0.01MG/VIAL	N020379	001	Jul 06, 1995
AP +		0.02MG/VIAL	N020379	002	Jul 06, 1995
AP +		0.04MG/VIAL	N020379	004	May 19, 1997
EDEX					
AP	AUXILIUM PHARMS INC	0.01MG/VIAL	N020649	002	Jun 12, 1997
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997

FDA data supplied by DrugPatentWatch.com

ALPROSTADIL
INJECTABLE;INJECTION

		EDEX				
AP	**+**		**0.04MG/VIAL**	**N020649**	**004**	Jun 12, 1997
		PROSTIN VR PEDIATRIC				
AP	**+**	PHARMACIA AND UPJOHN	**0.5MG/ML**	**N018484**	**001**	
		CAVERJECT				
		PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996
		CAVERJECT IMPULSE				
		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001	Jun 11, 2002
			0.02MG/VIAL	N021212	002	Jun 11, 2002
		EDEX				
	+	AUXILIUM PHARMS INC	0.01MG/VIAL	N020649	005	Jul 30, 1998
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY;URETHRAL

		MUSE				
	+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996
	+		0.25MG	N020700	002	Nov 19, 1996
	+		0.5MG	N020700	003	Nov 19, 1996
	+		1MG	N020700	004	Nov 19, 1996

ALTRETAMINE
CAPSULE;ORAL

		HEXALEN				
	+	EISAI INC	50MG	N019926	001	Dec 26, 1990

ALVIMOPAN
CAPSULE;ORAL

		ENTEREG				
	+	CUBIST PHARMS	12MG	N021775	001	May 20, 2008

AMANTADINE HYDROCHLORIDE
CAPSULE;ORAL

		AMANTADINE HYDROCHLORIDE				
AB		BIONPHARMA INC	**100MG**	**A078720**	**001**	May 29, 2008
AB		NEWGEN PHARMS LLC	**100MG**	**A207570**	**001**	Sep 30, 2016
AB	**+**	SANDOZ	**100MG**	**A071293**	**001**	Feb 18, 1987
AB		USL PHARMA	**100MG**	**A070589**	**001**	Aug 05, 1986
AB		WATSON LABS INC	**100MG**	**A208107**	**001**	Dec 06, 2016
AB		ZYDUS PHARMS USA INC	**100MG**	**A208278**	**001**	May 31, 2016

SYRUP;ORAL

		AMANTADINE HYDROCHLORIDE				
AA	**+**	CAROLINA MEDCL	**50MG/5ML**	**A075819**	**001**	Sep 11, 2002
AA	**+**	HI TECH PHARMA	**50MG/5ML**	**A074170**	**001**	Oct 28, 1994
AA	**+**	MIKART	**50MG/5ML**	**A074028**	**001**	Jun 28, 1993
AA	**+**	PHARM ASSOC	**50MG/5ML**	**A074509**	**001**	Jul 17, 1995
AA	**+**	WOCKHARDT	**50MG/5ML**	**A075060**	**001**	Dec 24, 1998

TABLET;ORAL

		AMANTADINE HYDROCHLORIDE				
AB	**+**	USL PHARMA	**100MG**	**A076186**	**001**	Dec 16, 2002
AB		WATSON LABS INC	**100MG**	**A208096**	**001**	Dec 15, 2016

AMBRISENTAN
TABLET;ORAL

		LETAIRIS				
		GILEAD	5MG	N022081	001	Jun 15, 2007
	+		10MG	N022081	002	Jun 15, 2007

AMCINONIDE
CREAM;TOPICAL

		AMCINONIDE				
AB	**+**	FOUGERA PHARMS	**0.1%**	**A076065**	**001**	May 15, 2003
AB		TARO PHARM INDS	**0.1%**	**A076229**	**001**	May 31, 2002

LOTION;TOPICAL

		AMCINONIDE				
	+	FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002

OINTMENT;TOPICAL

		AMCINONIDE				
AB	**+**	FOUGERA PHARMS	**0.1%**	**A076096**	**001**	Nov 19, 2002
AB		TARO PHARM INDS	**0.1%**	**A076367**	**001**	Mar 19, 2003

AMIFOSTINE
INJECTABLE;INJECTION

		AMIFOSTINE			
AP		SUN PHARMA GLOBAL	**500MG/VIAL**	**A077126 001**	Mar 14, 2008
		ETHYOL			
AP	+	CLINIGEN HLTHCARE	**500MG/VIAL**	**N020221 001**	Dec 08, 1995

AMIKACIN SULFATE
INJECTABLE;INJECTION

		AMIKACIN SULFATE			
AP	+	EMCURE PHARMS LTD	**EQ 250MG BASE/ML**	**A204040 001**	Dec 12, 2013
AP		FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A205605 001**	Dec 09, 2015
AP			**EQ 250MG BASE/ML**	**A205604 001**	Dec 09, 2015
AP		SAGENT PHARMS	**EQ 250MG BASE/ML**	**A203323 001**	May 12, 2016
AP		TEVA PHARMS USA	**EQ 250MG BASE/ML**	**A064045 002**	Sep 28, 1993
AP	+	WEST-WARD PHARMS INT	**EQ 50MG BASE/ML**	**A063313 001**	Apr 11, 1994
AP			**EQ 250MG BASE/ML**	**A063315 001**	Apr 11, 1994

AMILORIDE HYDROCHLORIDE
TABLET;ORAL

		AMILORIDE HYDROCHLORIDE			
AB	+	PAR PHARM	**5MG**	**A070346 001**	Jan 22, 1986
AB		SIGMAPHARM LABS LLC	**5MG**	**A079133 001**	Jan 30, 2009
AB		ZYDUS PHARMS USA INC	**5MG**	**A204180 001**	Aug 07, 2015
		MIDAMOR			
AB		PADDOCK LLC	**5MG**	**N018200 001**	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
TABLET;ORAL

		AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE			
AB		BARR	**EQ 5MG ANHYDROUS;50MG**	**A071111 001**	May 10, 1988
AB	+	MYLAN	**EQ 5MG ANHYDROUS;50MG**	**A073209 001**	Oct 31, 1991

AMINO ACIDS
INJECTABLE;INJECTION

		AMINO ACIDS			
		B BRAUN	15%(150GM/1000ML)	A091112 001	Apr 13, 2012
			15%(300GM/2000ML)	A091112 002	Apr 13, 2012
		AMINOSYN 10%			
		HOSPIRA	10% (10GM/100ML)	N017673 003	
		AMINOSYN 10% (PH6)			
		HOSPIRA	10% (10GM/100ML)	N017673 008	Nov 18, 1985
		AMINOSYN 3.5%			
		HOSPIRA	3.5% (3.5GM/100ML)	N017789 004	
		AMINOSYN 5%			
		HOSPIRA	5% (5GM/100ML)	N017673 001	
		AMINOSYN 7%			
		HOSPIRA	7% (7GM/100ML)	N017673 002	
		AMINOSYN 7% (PH6)			
		HOSPIRA	7% (7GM/100ML)	N017673 006	Nov 18, 1985
		AMINOSYN 8.5%			
		HOSPIRA	8.5% (8.5GM/100ML)	N017673 004	
		AMINOSYN 8.5% (PH6)			
		HOSPIRA	8.5% (8.5GM/100ML)	N017673 007	Nov 18, 1985
		AMINOSYN II 10%			
		HOSPIRA	10% (10GM/100ML)	N019438 005	Apr 03, 1986
		AMINOSYN II 10% IN PLASTIC CONTAINER			
		HOSPIRA	10% (10GM/100ML)	N020015 001	Dec 19, 1991
		AMINOSYN II 15% IN PLASTIC CONTAINER			
		HOSPIRA	15% (15GM/100ML)	N020041 001	Dec 19, 1991
		AMINOSYN II 7%			
		HOSPIRA	7% (7GM/100ML)	N019438 003	Apr 03, 1986
		AMINOSYN II 8.5%			
		HOSPIRA	8.5% (8.5GM/100ML)	N019438 004	Apr 03, 1986
		AMINOSYN-HBC 7%			
		HOSPIRA	7% (7GM/100ML)	N019374 001	Jul 12, 1985
		AMINOSYN-HF 8%			
		HOSPIRA	8% (8GM/100ML)	A020345 001	Apr 04, 1996
		AMINOSYN-PF 10%			
		HOSPIRA	10% (10GM/100ML)	N019492 002	Oct 17, 1986
		AMINOSYN-PF 7%			
		HOSPIRA	7% (7GM/100ML)	N019398 001	Sep 06, 1985
		AMINOSYN-RF 5.2%			
		HOSPIRA	5.2% (5.2GM/100ML)	N018429 001	

AMINO ACIDS

INJECTABLE;INJECTION

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996
FREAMINE HBC 6.9%				
	B BRAUN	6.9% (6.9GM/100ML)	N016822 006	May 17, 1983
FREAMINE III 10%				
	B BRAUN	10% (10GM/100ML)	N016822 005	
FREAMINE III 8.5%				
	B BRAUN	8.5% (8.5GM/100ML)	N016822 004	
HEPATAMINE 8%				
	B BRAUN	8% (8GM/100ML)	N018676 001	Aug 03, 1982
NEPHRAMINE 5.4%				
	B BRAUN	5.4% (5.4GM/100ML)	N017766 001	
PREMASOL 10% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	10% (10GM/100ML)	A075880 002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	6% (6GM/100ML)	A075880 001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	20% (20GM/100ML)	N020849 001	Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	10% (10MG/100ML)	N018931 003	Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931 001	Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931 002	Aug 23, 1984
TROPHAMINE				
+	B BRAUN	6% (6GM/100ML)	N019018 001	Jul 20, 1984
TROPHAMINE 10%				
+	B BRAUN	10% (10GM/100ML)	N019018 003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PROCALAMINE				
	B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582 001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 002	Mar 26, 1997
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 005	Mar 26, 1997
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678 001	Mar 26, 1997
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678 008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678 019	Mar 26, 1997

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678 021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;IV (INFUSION)

KABIVEN IN PLASTIC CONTAINER

	FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML ;147MG/100ML;3.9GM/100ML (1026ML)	N200656 004	Aug 25, 2014
		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (1540ML)	N200656 005	Aug 25, 2014
		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2053ML)	N200656 006	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2566ML)	N200656 007	Aug 25, 2014

PERIKABIVEN IN PLASTIC CONTAINER

	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1440ML)	N200656 001	Aug 25, 2014
		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1920ML)	N200656 002	Aug 25, 2014
		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML)	N200656 003	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N020734 002	Sep 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N020734 005	Sep 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N020734 001	Sep 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N020734 008	Sep 29, 1997

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N020734 010	Sep 29, 1997

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N020734 011	Sep 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N020734 007	Sep 29, 1997

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;10GM/100ML	N020734 014	Sep 29, 1997

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;15GM/100ML	N020734 015	Sep 29, 1997

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;20GM/100ML	N020734 016	Sep 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;25GM/100ML	N020734 017	Sep 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5%;35GM/100ML	N020734 018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML ;440MG/100ML;690MG/100ML	N016822 007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N017789 003	

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

FREAMINE III 3% W/ ELECTROLYTES

	B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822 003	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

	HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437 004	Apr 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES

	HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437 005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 7% W/ ELECTROLYTES

	HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789 002	

AMINOSYN 8.5% W/ ELECTROLYTES

	HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673 005	

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

AP	LUITPOLD	**250MG/ML**	**A071192 001**	Dec 01, 1987

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	+ HOSPIRA	**250MG/ML**	**A070010 001**	Mar 09, 1987

SYRUP;ORAL

AMICAR

AA	+ CLOVER PHARMS	**1.25GM/5ML**	**N015230 002**	

AMINOCAPROIC ACID

AA	AKORN	**1.25GM/5ML**	**A074759 001**	Sep 02, 1998

TABLET;ORAL

AMICAR

AB	CLOVER PHARMS	**500MG**	**N015197 001**	

AMINOCAPROIC

AB	AKORN	**500MG**	**A075602 001**	May 24, 2001

AMICAR

	+ CLOVER PHARMS	1GM	N015197 002	Jun 24, 2004

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL;TOPICAL

AMELUZ

	+ BIOFRONTERA	10%	N208081 001	May 10, 2016

SOLUTION;TOPICAL

LEVULAN

	+ DUSA	20%	N020965 001	Dec 03, 1999

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

AP	+ HOSPIRA	**25MG/ML**	**A087242 001**	Oct 26, 1983
AP	LUITPOLD	**25MG/ML**	**A087600 001**	

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE;ORAL

PASER

	+ JACOBUS	4GM/PACKET	A074346 001	Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

AP	+ AKORN	**50MG/ML**	**A076232 001**	Jul 05, 2006
AP	+ FRESENIUS KABI USA	**50MG/ML**	**A075761 001**	Oct 15, 2002
AP	+ GLAND PHARMA LTD	**50MG/ML**	**A077161 001**	Apr 20, 2005
AP	HIKMA FARMACEUTICA	**50MG/ML**	**A077234 001**	Feb 25, 2008
AP	+ HOSPIRA	**50MG/ML**	**A075955 001**	Oct 18, 2002
AP	HOSPIRA INC	**50MG/ML**	**A203884 001**	Nov 25, 2013
AP		**50MG/ML**	**A203885 001**	Nov 25, 2013
AP	+ MYLAN INSTITUTIONAL	**50MG/ML**	**A076217 001**	Oct 15, 2002
AP	WOCKHARDT	**50MG/ML**	**A077610 001**	Oct 30, 2008
AP		**50MG/ML**	**A077834 001**	Oct 30, 2008

FDA data supplied by DrugPatentWatch.com

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

NEXTERONE

AP	BAXTER HLTHCARE	**50MG/ML**	**N022325**	**001**	Dec 24, 2008
+		150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010
+		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB	APOTEX INC	**200MG**	**A078578**	**001**	Nov 06, 2008
AB	AUROBINDO PHARMA LTD	**200MG**	**A204742**	**001**	Jun 03, 2016
AB	MURTY PHARMS	**100MG**	**A077069**	**003**	Oct 04, 2016
AB		**200MG**	**A077069**	**001**	Apr 08, 2005
AB		**400MG**	**A077069**	**002**	Apr 08, 2005
AB	MYLAN	**200MG**	**A075188**	**001**	Feb 24, 1999
AB	SANDOZ	**200MG**	**A075315**	**001**	Dec 23, 1998
AB		**400MG**	**A075315**	**002**	Jun 30, 2000
AB	SWAN PHARMS LLC	**200MG**	**A075389**	**001**	Jan 25, 2001
AB	TARO	**100MG**	**A075424**	**002**	Dec 18, 2002
AB		**200MG**	**A075424**	**001**	Mar 30, 2001
AB		**400MG**	**A076362**	**001**	Nov 29, 2002
AB	TEVA PHARMS	**200MG**	**A074739**	**001**	Nov 30, 1998
AB	ZYDUS PHARMS USA INC	**200MG**	**A079029**	**001**	Sep 16, 2008

CORDARONE

AB	+ WYETH PHARMS INC	**200MG**	**N018972**	**001**	Dec 24, 1985

PACERONE

AB	UPSHER SMITH	**100MG**	**A075135**	**002**	Apr 12, 2005
AB		**200MG**	**A075135**	**001**	Apr 30, 1998

AMIODARONE HYDROCHLORIDE

	TARO	300MG	A076362	002	Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	**10MG**	**A202446**	**001**	Jun 04, 2014
AB		**25MG**	**A202446**	**002**	Jun 04, 2014
AB		**50MG**	**A202446**	**003**	Jun 04, 2014
AB		**75MG**	**A202446**	**004**	Jun 04, 2014
AB		**100MG**	**A202446**	**005**	Jun 04, 2014
AB		**150MG**	**A202446**	**006**	Jun 04, 2014
AB	MYLAN	**10MG**	**A086009**	**002**	
AB		**25MG**	**A086009**	**003**	
AB		**50MG**	**A086009**	**001**	
AB		**75MG**	**A086009**	**004**	
AB		**100MG**	**A086009**	**005**	
AB		**150MG**	**A086009**	**006**	
AB	SANDOZ	**10MG**	**A085969**	**001**	
AB	+	**25MG**	**A085966**	**001**	
AB		**50MG**	**A085968**	**001**	
AB		**75MG**	**A085971**	**001**	
AB		**100MG**	**A085967**	**001**	
AB		**150MG**	**A085970**	**001**	
AB	VINTAGE PHARMS	**10MG**	**A040218**	**001**	Sep 11, 1997
AB		**25MG**	**A040218**	**002**	Sep 11, 1997
AB		**50MG**	**A040218**	**003**	Sep 11, 1997
AB		**75MG**	**A040218**	**004**	Sep 11, 1997
AB		**100MG**	**A040218**	**005**	Sep 11, 1997
AB		**150MG**	**A040218**	**006**	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
+		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
+		25MG;2MG	A071443	004	Nov 10, 1988
+		25MG;4MG	A071443	005	Nov 10, 1988
+		50MG;4MG	A071443	001	Nov 10, 1988

FDA data supplied by DrugPatentWatch.com

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553	001	Apr 29, 2013
AB		EQ 5MG BASE	A202553	002	Apr 29, 2013
AB		EQ 10MG BASE	A202553	003	Apr 29, 2013
AB	ALKEM	EQ 2.5MG BASE	A078925	001	May 04, 2009
AB		EQ 5MG BASE	A078925	002	May 04, 2009
AB		EQ 10MG BASE	A078925	003	May 04, 2009
AB	AMNEAL PHARMS NY	EQ 2.5MG BASE	A078477	001	Jan 16, 2008
AB		EQ 5MG BASE	A078477	002	Jan 16, 2008
AB		EQ 10MG BASE	A078477	003	Jan 16, 2008
AB	APOTEX	EQ 2.5MG BASE	A076719	001	May 23, 2007
AB		EQ 5MG BASE	A076719	002	May 23, 2007
AB		EQ 10MG BASE	A076719	003	May 23, 2007
AB	AUROBINDO PHARMA	EQ 2.5MG BASE	A078021	001	Jul 17, 2007
AB		EQ 5MG BASE	A078021	002	Jul 17, 2007
AB		EQ 10MG BASE	A078021	003	Jul 17, 2007
AB	CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016
AB		EQ 5MG BASE	A090752	001	Apr 15, 2011
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011
AB	CIPLA LTD	EQ 2.5MG BASE	A077073	001	Sep 26, 2007
AB		EQ 5MG BASE	A077073	002	Sep 26, 2007
AB		EQ 10MG BASE	A077073	003	Sep 26, 2007
AB	DR REDDYS LABS LTD	EQ 2.5MG BASE	A076692	001	Jul 20, 2007
AB		EQ 5MG BASE	A076692	002	Jul 20, 2007
AB		EQ 10MG BASE	A076692	003	Jul 20, 2007
AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552	001	Apr 08, 2009
AB		EQ 5MG BASE	A078552	002	Apr 08, 2009
AB		EQ 10MG BASE	A078552	003	Apr 08, 2009
AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011
AB		EQ 5MG BASE	A077771	002	Apr 12, 2011
AB		EQ 10MG BASE	A077771	003	Apr 12, 2011
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A077955	001	Aug 28, 2007
AB		EQ 2.5MG BASE	A206367	001	Dec 10, 2015
AB		EQ 5MG BASE	A077955	002	Aug 28, 2007
AB		EQ 5MG BASE	A206367	002	Dec 10, 2015
AB		EQ 10MG BASE	A077955	003	Aug 28, 2007
AB		EQ 10MG BASE	A206367	003	Dec 10, 2015
AB	LUPIN	EQ 2.5MG BASE	A078043	001	Jul 12, 2007
AB		EQ 5MG BASE	A078043	002	Jul 12, 2007
AB		EQ 10MG BASE	A078043	003	Jul 12, 2007
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012
AB		EQ 10MG BASE	A201380	002	Apr 13, 2012
AB	MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005
AB		EQ 5MG BASE	A076418	002	Oct 03, 2005
AB		EQ 10MG BASE	A076418	003	Oct 03, 2005
AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A078224	001	Feb 27, 2008
AB		EQ 5MG BASE	A078224	002	Feb 27, 2008
AB		EQ 10MG BASE	A078224	003	Feb 27, 2008
AB	ORCHID HLTHCARE	EQ 2.5MG BASE	A078453	001	Jul 02, 2009
AB		EQ 5MG BASE	A078453	002	Jul 02, 2009
AB		EQ 10MG BASE	A078453	003	Jul 02, 2009
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016
AB		EQ 5MG BASE	A207821	002	Jul 11, 2016
AB		EQ 10MG BASE	A207821	003	Jul 11, 2016
AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015
AB		EQ 5MG BASE	A204900	002	Jul 23, 2015
AB		EQ 10MG BASE	A204900	003	Jul 23, 2015
AB	SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007
AB		EQ 5MG BASE	A078231	002	Nov 30, 2007
AB		EQ 10MG BASE	A078231	003	Nov 30, 2007
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007
AB	TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007
AB		EQ 5MG BASE	A076846	002	Jun 28, 2007
AB		EQ 10MG BASE	A076846	003	Jun 28, 2007
AB	TORRENT PHARMS	EQ 2.5MG BASE	A078573	001	Sep 22, 2008
AB		EQ 5MG BASE	A078573	002	Sep 22, 2008
AB		EQ 10MG BASE	A078573	003	Sep 22, 2008
AB	UNICHEM LABS LTD	EQ 2.5MG BASE	A203245	001	Oct 21, 2013

FDA data supplied by DrugPatentWatch.com

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB		EQ 5MG BASE	A203245	002	Oct 21, 2013
AB		EQ 10MG BASE	A203245	003	Oct 21, 2013
AB	UPSHER SMITH	EQ 2.5MG BASE	A077759	001	Jul 09, 2007
AB		EQ 5MG BASE	A077759	002	Jul 09, 2007
AB		EQ 10MG BASE	A077759	003	Jul 09, 2007
AB	VINTAGE	EQ 2.5MG BASE	A078414	001	Apr 07, 2010
AB		EQ 5MG BASE	A078414	002	Apr 07, 2010
AB		EQ 10MG BASE	A078414	003	Apr 07, 2010
AB	VIVIMED LABS	EQ 2.5MG BASE	A077516	001	Jul 11, 2007
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007
AB	WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007
AB		EQ 5MG BASE	A077671	002	Jul 19, 2007
AB		EQ 10MG BASE	A077671	003	Jul 19, 2007
AB	WEST-WARD PHARMS INT	EQ 2.5MG BASE	A077262	001	Jul 09, 2007
AB		EQ 5MG BASE	A077262	002	Jul 09, 2007
AB		EQ 10MG BASE	A077262	003	Jul 09, 2007
AB	WOCKHARDT	EQ 2.5MG BASE	A078500	001	Sep 06, 2007
AB		EQ 5MG BASE	A078500	002	Sep 06, 2007
AB		EQ 10MG BASE	A078500	003	Sep 06, 2007
AB	ZYDUS PHARMS USA	EQ 2.5MG BASE	A078226	001	Jul 09, 2007
AB		EQ 5MG BASE	A078226	002	Jul 09, 2007
AB		EQ 10MG BASE	A078226	003	Jul 09, 2007

NORVASC

AB	PFIZER	EQ 2.5MG BASE	N019787	001	Jul 31, 1992
AB		EQ 5MG BASE	N019787	002	Jul 31, 1992
AB +		EQ 10MG BASE	N019787	003	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014
AB		EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014
AB		EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014
AB		EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014
AB		EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014
AB		EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014
AB		EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014
AB		EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014
AB		EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014
AB		EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014
AB		EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014
AB	MYLAN PHARMS INC	EQ 2.5MG BASE;EQ 10MG BASE	A200465	001	Nov 29, 2013
AB		EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013
AB		EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013
AB		EQ 5MG BASE;EQ 10MG BASE	A200465	004	Nov 29, 2013
AB		EQ 5MG BASE;EQ 20MG BASE	A200465	005	Nov 29, 2013
AB		EQ 5MG BASE;EQ 40MG BASE	A200465	006	Nov 29, 2013
AB		EQ 5MG BASE;EQ 80MG BASE	A200465	007	Nov 29, 2013
AB		EQ 10MG BASE;EQ 10MG BASE	A200465	008	Nov 29, 2013
AB		EQ 10MG BASE;EQ 20MG BASE	A200465	009	Nov 29, 2013
AB		EQ 10MG BASE;EQ 40MG BASE	A200465	010	Nov 29, 2013
AB		EQ 10MG BASE;EQ 80MG BASE	A200465	011	Nov 29, 2013

CADUET

AB	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004
AB		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004
AB		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004
AB		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004
AB		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004
AB		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004
AB		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004
AB		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004
AB		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004
AB		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004
AB +		EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004

FDA data supplied by DrugPatentWatch.com

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013
AB		EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013
AB		EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013
AB		EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013
AB		EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013
AB		EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013
AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239	001	Sep 05, 2012
AB		EQ 5MG BASE;10MG	A202239	002	Sep 05, 2012
AB		EQ 5MG BASE;20MG	A202239	003	Sep 05, 2012
AB		EQ 5MG BASE;40MG	A202239	004	Sep 05, 2012
AB		EQ 10MG BASE;20MG	A202239	005	Sep 05, 2012
AB		EQ 10MG BASE;40MG	A202239	006	Sep 05, 2012
AB	DR REDDYS LABS INC	EQ 2.5MG BASE;10MG	A077183	001	Apr 15, 2010
AB		EQ 5MG BASE;10MG	A077183	002	Apr 15, 2010
AB		EQ 5MG BASE;20MG	A077183	003	Apr 15, 2010
AB		EQ 5MG BASE;40MG	A090149	001	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A077183	004	Apr 15, 2010
AB		EQ 10MG BASE;40MG	A090149	002	Jul 05, 2011
AB	LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466	001	Feb 05, 2010
AB		EQ 5MG BASE;10MG	A078466	002	Feb 05, 2010
AB		EQ 5MG BASE;20MG	A078466	003	Feb 05, 2010
AB		EQ 5MG BASE;40MG	A078466	005	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A078466	004	Feb 05, 2010
AB		EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011
AB	MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010
AB		EQ 5MG BASE;10MG	A077375	002	May 21, 2010
AB		EQ 5MG BASE;20MG	A077375	003	May 21, 2010
AB		EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A077375	004	May 21, 2010
AB		EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011
AB	PAR PHARM	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010
AB		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010
AB		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010
AB		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010
AB		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010
AB		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010
AB	TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007
AB		EQ 5MG BASE;10MG	A077179	002	May 18, 2007
AB		EQ 5MG BASE;20MG	A077179	003	May 18, 2007
AB		EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A077179	004	May 18, 2007
AB		EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011
AB	WATSON LABS	EQ 2.5MG BASE;10MG	A077890	001	Oct 14, 2010
AB		EQ 5MG BASE;10MG	A077890	002	Oct 14, 2010
AB		EQ 5MG BASE;20MG	A077890	003	Oct 14, 2010
AB		EQ 10MG BASE;20MG	A077890	004	Oct 14, 2010
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364	001	Jul 05, 2011
AB		EQ 10MG BASE;40MG	A090364	002	Jul 05, 2011

LOTREL

AB	NOVARTIS	EQ 2.5MG BASE;10MG	N020364	002	Mar 03, 1995
AB		EQ 5MG BASE;10MG	N020364	003	Mar 03, 1995
AB		EQ 5MG BASE;20MG	N020364	004	Mar 03, 1995
AB		EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006
AB		EQ 10MG BASE;20MG	N020364	005	Jun 20, 2002
AB +		EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	PAR PHARM INC	EQ 5MG BASE;12.5MG;20MG	A206137	001	Oct 26, 2016
AB		EQ 5MG BASE;12.5MG;40MG	A206137	002	Oct 26, 2016
AB		EQ 5MG BASE;25MG;40MG	A206137	003	Oct 26, 2016
AB		EQ 10MG BASE;12.5MG;40MG	A206137	004	Oct 26, 2016
AB		EQ 10MG BASE;25MG;40MG	A206137	005	Oct 26, 2016
AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016
AB		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016
AB		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016
AB		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016
AB		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016
AB	TORRENT PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016

FDA data supplied by DrugPatentWatch.com

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB		EQ 5MG BASE;12.5MG;40MG	A203580	002	Oct 26, 2016
AB		EQ 5MG BASE;25MG;40MG	A203580	003	Oct 26, 2016
AB		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016
AB		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016
	TRIBENZOR				
AB	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010
AB		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010
AB		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010
AB		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010
AB +		EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015
AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015
AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015
AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015
AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015
AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015
AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015
AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015
AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015
AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015
AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012
AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012
AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012
AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012
AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 03, 2015
AB		5MG;25MG;160MG	A201593	002	Jun 03, 2015
AB		10MG;12.5MG;160MG	A201593	003	Jun 03, 2015
AB		10MG;25MG;160MG	A201593	004	Jun 03, 2015
AB		10MG;25MG;320MG	A201593	005	Jun 03, 2015
	EXFORGE HCT				
AB	NOVARTIS	5MG;12.5MG;160MG	N022314	001	Apr 30, 2009
AB		5MG;25MG;160MG	N022314	002	Apr 30, 2009
AB		10MG;12.5MG;160MG	N022314	003	Apr 30, 2009
AB		10MG;25MG;160MG	N022314	004	Apr 30, 2009
AB +		10MG;25MG;320MG	N022314	005	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	AJANTA PHARMA LTD	EQ 5MG BASE;20MG	A207216	001	Oct 28, 2016
AB		EQ 5MG BASE;40MG	A207216	002	Oct 28, 2016
AB		EQ 10MG BASE;20MG	A207216	003	Oct 28, 2016
AB		EQ 10MG BASE;40MG	A207216	004	Oct 28, 2016
AB	MACLEODS PHARMS LTD	EQ 5MG BASE;20MG	A206884	001	Oct 26, 2016
AB		EQ 5MG BASE;40MG	A206884	003	Oct 26, 2016
AB		EQ 10MG BASE;20MG	A206884	002	Oct 26, 2016
AB		EQ 10MG BASE;40MG	A206884	004	Oct 26, 2016
AB	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016
AB		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016
AB		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016
AB		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016
AB	TORRENT PHARMS LLC	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016
AB		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016
AB		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016
AB		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016
	AZOR				
AB	DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007
AB		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007
AB		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007
AB +		EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007

FDA data supplied by DrugPatentWatch.com

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

AB	ALEMBIC PHARMS LTD	**EQ 5MG BASE;40MG**	**A205234**	**001**	Nov 17, 2016
AB		**EQ 5MG BASE;80MG**	**A205234**	**003**	Nov 17, 2016
AB		**EQ 10MG BASE;40MG**	**A205234**	**002**	Nov 17, 2016
AB		**EQ 10MG BASE;80MG**	**A205234**	**004**	Nov 17, 2016
AB	LUPIN LTD	**EQ 5MG BASE;40MG**	**A201586**	**001**	Jan 08, 2014
AB		**EQ 5MG BASE;80MG**	**A201586**	**003**	Jan 08, 2014
AB		**EQ 10MG BASE;40MG**	**A201586**	**002**	Jan 08, 2014
AB		**EQ 10MG BASE;80MG**	**A201586**	**004**	Jan 08, 2014
AB	MYLAN PHARMS INC	**EQ 5MG BASE;40MG**	**A202516**	**001**	Aug 26, 2014
AB		**EQ 5MG BASE;80MG**	**A202516**	**003**	Aug 26, 2014
AB		**EQ 10MG BASE;40MG**	**A202516**	**002**	Aug 26, 2014
AB		**EQ 10MG BASE;80MG**	**A202516**	**004**	Aug 26, 2014
AB	TORRENT PHARMS LTD	**EQ 5MG BASE;40MG**	**A202517**	**001**	Jan 08, 2014
AB		**EQ 5MG BASE;80MG**	**A202517**	**003**	Jan 08, 2014
AB		**EQ 10MG BASE;40MG**	**A202517**	**002**	Jan 08, 2014
AB		**EQ 10MG BASE;80MG**	**A202517**	**004**	Jan 08, 2014

TWYNSTA

AB	BOEHRINGER INGELHEIM	**EQ 5MG BASE;40MG**	**N022401**	**001**	Oct 16, 2009
AB		**EQ 5MG BASE;80MG**	**N022401**	**003**	Oct 16, 2009
AB		**EQ 10MG BASE;40MG**	**N022401**	**002**	Oct 16, 2009
AB	**+**	**EQ 10MG BASE;80MG**	**N022401**	**004**	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	**EQ 5MG BASE;160MG**	**A202713**	**001**	Apr 03, 2015
AB		**EQ 5MG BASE;320MG**	**A202713**	**003**	Apr 03, 2015
AB		**EQ 10MG BASE;160MG**	**A202713**	**002**	Apr 03, 2015
AB		**EQ 10MG BASE;320MG**	**A202713**	**004**	Apr 03, 2015
AB	AUROBINDO PHARMA LTD	**EQ 5MG BASE;160MG**	**A206512**	**001**	Apr 22, 2016
AB		**EQ 5MG BASE;320MG**	**A206512**	**002**	Apr 22, 2016
AB		**EQ 10MG BASE;160MG**	**A206512**	**003**	Apr 22, 2016
AB		**EQ 10MG BASE;320MG**	**A206512**	**004**	Apr 22, 2016
AB	INVAGEN PHARMS	**EQ 5MG BASE;160MG**	**A205137**	**001**	Sep 16, 2016
AB		**EQ 5MG BASE;320MG**	**A205137**	**003**	Sep 16, 2016
AB		**EQ 10MG BASE;160MG**	**A205137**	**002**	Sep 16, 2016
AB		**EQ 10MG BASE;320MG**	**A205137**	**004**	Sep 16, 2016
AB	LUPIN	**EQ 5MG BASE;160MG**	**A090245**	**001**	Mar 30, 2015
AB		**EQ 5MG BASE;320MG**	**A090245**	**003**	Mar 30, 2015
AB		**EQ 10MG BASE;160MG**	**A090245**	**002**	Mar 30, 2015
AB		**EQ 10MG BASE;320MG**	**A090245**	**004**	Mar 30, 2015
AB	MYLAN PHARMS INC	**EQ 5MG BASE;160MG**	**A090483**	**001**	Mar 30, 2015
AB		**EQ 5MG BASE;320MG**	**A090483**	**003**	Mar 30, 2015
AB		**EQ 10MG BASE;160MG**	**A090483**	**002**	Mar 30, 2015
AB		**EQ 10MG BASE;320MG**	**A090483**	**004**	Mar 30, 2015
AB	NOVEL LABS INC	**EQ 5MG BASE;160MG**	**A202829**	**001**	Mar 30, 2015
AB		**EQ 5MG BASE;320MG**	**A202829**	**003**	Mar 30, 2015
AB		**EQ 10MG BASE;160MG**	**A202829**	**002**	Mar 30, 2015
AB		**EQ 10MG BASE;320MG**	**A202829**	**004**	Mar 30, 2015
AB	PAR PHARM INC	**EQ 5MG BASE;160MG**	**A090011**	**001**	Mar 28, 2013
AB		**EQ 5MG BASE;320MG**	**A090011**	**003**	Mar 28, 2013
AB		**EQ 10MG BASE;160MG**	**A090011**	**002**	Mar 28, 2013
AB		**EQ 10MG BASE;320MG**	**A090011**	**004**	Mar 28, 2013
AB	TEVA PHARMS USA	**EQ 5MG BASE;160MG**	**A091235**	**001**	Mar 30, 2015
AB		**EQ 5MG BASE;320MG**	**A091235**	**003**	Mar 30, 2015
AB		**EQ 10MG BASE;160MG**	**A091235**	**002**	Mar 30, 2015
AB		**EQ 10MG BASE;320MG**	**A091235**	**004**	Mar 30, 2015
AB	TORRENT PHARMS LTD	**EQ 5MG BASE;160MG**	**A202377**	**001**	Mar 30, 2015
AB		**EQ 5MG BASE;320MG**	**A202377**	**002**	Mar 30, 2015
AB		**EQ 10MG BASE;160MG**	**A202377**	**003**	Mar 30, 2015
AB		**EQ 10MG BASE;320MG**	**A202377**	**004**	Mar 30, 2015

EXFORGE

AB	NOVARTIS	**EQ 5MG BASE;160MG**	**N021990**	**002**	Jun 20, 2007

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

EXFORGE

AB			**EQ 5MG BASE;320MG**	**N021990**	**004**	Jun 20, 2007
AB	+		**EQ 10MG BASE;160MG**	**N021990**	**003**	Jun 20, 2007
AB	+		**EQ 10MG BASE;320MG**	**N021990**	**005**	Jun 20, 2007

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		3D IMAGING DRUG	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203779**	**001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)**	**A204352**	**001**	May 01, 2015
AP		BRIGHAM WOMENS HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203783**	**001**	Oct 30, 2014
AP		CARDINAL HEALTH 414	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203700**	**001**	Feb 25, 2013
AP	+	FEINSTEIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**N022119**	**001**	Aug 23, 2007
AP		GLOBAL ISOTOPES LLC	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204465**	**001**	Oct 23, 2014
AP		IBA MOLECULAR N AM	**18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)**	**A204667**	**001**	Apr 22, 2015
AP		JOHNS HOPKINS UNIV	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204514**	**001**	Aug 19, 2014
AP		KREITCHMAN PET CTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203938**	**001**	Dec 09, 2013
AP		MA GENERAL HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A207025**	**001**	Feb 03, 2016
AP		MCPRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203321**	**001**	Feb 25, 2013
AP		MIDWEST MEDCL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204457**	**001**	Nov 18, 2015
AP		MIPS CRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204535**	**001**	Nov 20, 2014
AP		PETNET	**30mCi-300mCi (3.75-37.5mCi/ML)**	**A204510**	**001**	Nov 02, 2015
AP		SPECTRON MRC LLC	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204455**	**001**	Apr 23, 2015
AP		UCLA BIOMEDICAL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203812**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204496**	**001**	Mar 28, 2014
AP		UNIV TX MD ANDERSON	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203933**	**001**	Jun 27, 2014
AP		WA UNIV SCH MED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204506**	**001**	Feb 07, 2014
		ESSENTIAL ISOTOPES	3.75-260mCi/ML	A205687	001	Dec 17, 2015
		HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543	001	Dec 14, 2012
		NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015
		PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015
		SHERTECH LABS LLC	3.75-260mCi/ML	A204366	001	Sep 19, 2014
		WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356	001	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	**EQ 12% BASE**	**A075774**	**001**	May 01, 2002
AB		TARO	**EQ 12% BASE**	**A075883**	**001**	Apr 10, 2003
AB		WATSON LABS INC	**EQ 12% BASE**	**A076829**	**001**	Feb 07, 2006

LOTION;TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	**EQ 12% BASE**	**A075570**	**001**	Jun 23, 2004
AB		TARO	**EQ 12% BASE**	**A076216**	**001**	May 28, 2004
AB		WATSON LABS INC	**EQ 12% BASE**	**A075575**	**001**	Jun 11, 2002

AMOXAPINE

TABLET;ORAL

AMOXAPINE

		WATSON LABS	25MG	A072688	001	Aug 28, 1992
			50MG	A072689	001	Aug 28, 1992
			100MG	A072690	001	Aug 28, 1992
	+		150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB		AM ANTIBIOTICS	**250MG**	**A062058**	**001**	
AB			**500MG**	**A062058**	**002**	
AB		AUROBINDO	**250MG**	**A065271**	**001**	Nov 09, 2005
AB			**500MG**	**A065271**	**002**	Nov 09, 2005
AB		DAVA PHARMS INC	**250MG**	**A062884**	**001**	Feb 25, 1988
AB			**500MG**	**A062881**	**001**	Feb 25, 1988
AB		HIKMA PHARMS	**250MG**	**A065291**	**001**	Feb 05, 2007
AB			**500MG**	**A065291**	**002**	Feb 05, 2007
AB		SANDOZ	**250MG**	**A064076**	**001**	Sep 30, 1994
AB			**500MG**	**A064076**	**002**	Sep 30, 1994

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

CAPSULE;ORAL

	AMOXICILLIN				
AB	TEVA	**250MG**	**A061926**	**001**	
AB	+	**500MG**	**A061926**	**003**	
	AMOXIL				
AB	DR REDDYS LABS INC	**250MG**	**A062216**	**001**	
AB		**500MG**	**A062216**	**004**	

FOR SUSPENSION;ORAL

	AMOXICILLIN				
AB	AUROBINDO	**200MG/5ML**	**A065334**	**001**	Dec 28, 2006
AB		**400MG/5ML**	**A065334**	**002**	Dec 28, 2006
AB	AUROBINDO PHARMA LTD	**125MG/5ML**	**A204030**	**001**	Sep 15, 2014
AB		**250MG/5ML**	**A204030**	**002**	Sep 15, 2014
AB	DAVA PHARMS INC	**125MG/5ML**	**A062927**	**001**	Nov 25, 1988
AB		**250MG/5ML**	**A062927**	**002**	Nov 25, 1988
AB	HIKMA	**125MG/5ML**	**A065322**	**002**	Jun 19, 2006
AB		**200MG/5ML**	**A065325**	**002**	Jun 19, 2006
AB		**250MG/5ML**	**A065322**	**001**	Jun 19, 2006
AB		**400MG/5ML**	**A065325**	**001**	Jun 19, 2006
AB	SANDOZ	**125MG/5ML**	**A065387**	**001**	Mar 26, 2007
AB		**200MG/5ML**	**A065378**	**001**	Mar 26, 2007
AB		**250MG/5ML**	**A065387**	**002**	Mar 26, 2007
AB		**400MG/5ML**	**A065378**	**002**	Mar 26, 2007
AB	TEVA	**125MG/5ML**	**A061931**	**001**	
AB		**200MG/5ML**	**A065119**	**001**	Dec 04, 2002
AB	+	**250MG/5ML**	**A061931**	**002**	
AB	+	**400MG/5ML**	**A065119**	**002**	Dec 04, 2002
AB	WOCKHARDT	**400MG/5ML**	**A065319**	**002**	Jun 18, 2007
	AMOXICILLIN PEDIATRIC				
AB	TEVA	**50MG/ML**	**A061931**	**003**	Dec 01, 1982
	AMOXIL				
AB	DR REDDYS LABS INC	**50MG/ML**	**A062226**	**005**	
AB		**125MG/5ML**	**A062226**	**001**	
AB		**200MG/5ML**	**N050760**	**001**	Apr 15, 1999
AB		**250MG/5ML**	**A062226**	**002**	
AB		**400MG/5ML**	**N050760**	**002**	Apr 15, 1999
	LAROTID				
AB	DR REDDYS LABS INC	**125MG/5ML**	**A062226**	**003**	
AB		**250MG/5ML**	**A062226**	**004**	

TABLET;ORAL

	AMOXICILLIN				
AB	AUROBINDO	**500MG**	**A065256**	**001**	Nov 09, 2005
AB		**875MG**	**A065256**	**002**	Nov 09, 2005
AB	HIKMA	**875MG**	**A065255**	**001**	Mar 29, 2006
AB	SANDOZ	**500MG**	**A065228**	**001**	Jul 13, 2005
AB		**875MG**	**A065228**	**002**	Jul 13, 2005
AB	TEVA	**500MG**	**A065056**	**001**	Sep 18, 2000
AB	+	**875MG**	**A065056**	**002**	Sep 18, 2000
	AMOXIL				
AB	DR REDDYS LABS INC	**500MG**	**N050754**	**002**	Jul 10, 1998
AB		**875MG**	**N050754**	**001**	Jul 10, 1998

TABLET, CHEWABLE;ORAL

	AMOXICILLIN				
AB	TEVA	**125MG**	**A064013**	**002**	Sep 11, 1995
AB	+	**250MG**	**A064013**	**001**	Dec 22, 1992
	AMOXIL				
AB	DR REDDYS LABS INC	**125MG**	**N050542**	**002**	
AB		**250MG**	**N050542**	**001**	

TABLET, EXTENDED RELEASE;ORAL

	MOXATAG				
	+ VERNALIS R AND D LTD	775MG	N050813	001	Jan 23, 2008

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

	LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN				
AB	RISING PHARMS INC	**500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG**	**A206006**	**001**	Oct 07, 2016
AB	SANDOZ INC	**500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG**	**A202588**	**001**	Mar 04, 2014
AB	TEVA PHARMS USA	**500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG**	**A200218**	**001**	Aug 30, 2013

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL
PREVPAC

AB	+	TAKEDA PHARMS USA	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE
CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

	+	GASTROENTERO	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM
FOR SUSPENSION;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011
AB			400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011
AB			600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011
AB		HIKMA PHARMS	200MG/5ML;EQ 28.5MG BASE/5ML	A065191	002	Jan 25, 2005
AB			400MG/5ML;EQ 57MG BASE/5ML	A065191	001	Jan 25, 2005
AB			600MG/5ML;EQ 42.9MG BASE/5ML	A065373	001	Nov 09, 2007
AB		SANDOZ	200MG/5ML;EQ 28.5MG BASE/5ML	A065066	001	Jun 05, 2002
AB			400MG/5ML;EQ 57MG BASE/5ML	A065066	002	Jun 05, 2002
AB		SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098	001	Dec 16, 2002
AB			400MG/5ML;EQ 57MG BASE/5ML	A065098	002	Dec 16, 2002
AB			600MG/5ML;EQ 42.9MG BASE/5ML	A065358	001	Aug 13, 2007
AB		TEVA	200MG/5ML;EQ 28.5MG BASE/5ML	A065089	001	May 25, 2004
AB	+		400MG/5ML;EQ 57MG BASE/5ML	A065089	002	May 25, 2004
AB	+		600MG/5ML;EQ 42.9MG BASE/5ML	A065162	001	Mar 12, 2004
AB		WOCKHARDT	250MG/5ML;EQ 62.5MG BASE/5ML	A065431	001	Nov 25, 2008
AB		WOCKHARDT EU OPERATN	600MG/5ML;EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013
		AUGMENTIN '125'				
AB		DR REDDYS LABS INC	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984
		AUGMENTIN '200'				
AB		DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996
		AUGMENTIN '250'				
AB	+	DR REDDYS LABS INC	250MG/5ML;EQ 62.5MG BASE/5ML	N050575	002	Aug 06, 1984
		AUGMENTIN '400'				
AB		DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996
		AUGMENTIN ES-600				
AB		DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001

TABLET;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569	001	Jan 20, 2012
AB			500MG;EQ 125MG BASE	A091569	002	Jan 20, 2012
AB			875MG;EQ 125MG BASE	A091568	001	Jan 20, 2012
AB		HIKMA PHARMS	875MG;EQ 125MG BASE	A203824	001	Aug 23, 2016
AB		MICRO LABS LTD INDIA	250MG;EQ 125MG BASE	A205707	001	Dec 30, 2016
AB			500MG;EQ 125MG BASE	A205707	002	Dec 30, 2016
AB			875MG;EQ 125MG BASE	A204755	003	Dec 30, 2016
AB		SANDOZ	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005
AB			500MG;EQ 125MG BASE	A065064	001	Mar 15, 2002
AB			875MG;EQ 125MG BASE	A065063	001	Mar 14, 2002
AB		SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002
AB			875MG;EQ 125MG BASE	A065093	001	Nov 21, 2002
AB		TEVA	500MG;EQ 125MG BASE	A065101	001	Oct 30, 2002
AB		TEVA PHARMS USA	875MG;EQ 125MG BASE	A065096	001	Oct 29, 2002
		AUGMENTIN '250'				
AB	+	DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984
		AUGMENTIN '500'				
AB	+	DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984
		AUGMENTIN '875'				
AB	+	DR REDDYS LABS INC	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996

TABLET, CHEWABLE;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005
AB	+		400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005
		AUGMENTIN '200'				
AB		DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996
		AUGMENTIN '400'				
AB		DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE;ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM				
AB	SANDOZ	**1GM;EQ 62.5MG BASE**	**A090227**	**001**	Apr 21, 2010
	AUGMENTIN XR				
AB	+ DR REDDYS LABS INC	**1GM;EQ 62.5MG BASE**	**N050785**	**001**	Sep 25, 2002

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

	DYANAVEL XR				
	+ TRIS PHARMA INC	EQ 2.5MG BASE/ML	N208147	001	Oct 19, 2015

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

	ADZENYS XR-ODT				
	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016
		EQ 6.3MG BASE	N204326	002	Jan 27, 2016
		EQ 9.4MG BASE	N204326	003	Jan 27, 2016
		EQ 12.5MG BASE	N204326	004	Jan 27, 2016
		EQ 15.7MG BASE	N204326	005	Jan 27, 2016
	+	EQ 18.8MG BASE	N204326	006	Jan 27, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

	ADDERALL XR 10				
AB	SHIRE	**2.5MG;2.5MG;2.5MG;2.5MG**	**N021303**	**001**	Oct 11, 2001
	ADDERALL XR 15				
AB	SHIRE	**3.75MG;3.75MG;3.75MG;3.75MG**	**N021303**	**006**	May 22, 2002
	ADDERALL XR 20				
AB	SHIRE	**5MG;5MG;5MG;5MG**	**N021303**	**002**	Oct 11, 2001
	ADDERALL XR 25				
AB	SHIRE	**6.25MG;6.25MG;6.25MG;6.25MG**	**N021303**	**004**	May 22, 2002
	ADDERALL XR 30				
AB	+ SHIRE	**7.5MG;7.5MG;7.5MG;7.5MG**	**N021303**	**003**	Oct 11, 2001
	ADDERALL XR 5				
AB	SHIRE	**1.25MG;1.25MG;1.25MG;1.25MG**	**N021303**	**005**	May 22, 2002
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
AB	ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A077302**	**001**	Jun 22, 2012
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A077302**	**002**	Jun 22, 2012
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A077302**	**003**	Jun 22, 2012
AB		**5MG;5MG;5MG;5MG**	**A077302**	**004**	Jun 22, 2012
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A077302**	**005**	Jun 22, 2012
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A077302**	**006**	Jun 22, 2012
AB	IMPAX LABS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A076852**	**001**	Feb 16, 2016
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A076852**	**002**	Feb 16, 2016
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A076852**	**003**	Feb 16, 2016
AB		**5MG;5MG;5MG;5MG**	**A076852**	**004**	Feb 16, 2016
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A076852**	**005**	Feb 16, 2016
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A076852**	**006**	Feb 16, 2016
AB	TEVA	**1.25MG;1.25MG;1.25MG;1.25MG**	**A077488**	**001**	Apr 29, 2013
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A077488**	**002**	Apr 29, 2013
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A077488**	**003**	Apr 29, 2013
AB		**5MG;5MG;5MG;5MG**	**A077488**	**004**	Apr 29, 2013
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A077488**	**005**	Apr 29, 2013
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A077488**	**006**	Apr 29, 2013
	DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE				
AB	BARR LABS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A076536**	**001**	Feb 12, 2013
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A076536**	**002**	Feb 12, 2013
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A076536**	**003**	Feb 12, 2013
AB		**5MG;5MG;5MG;5MG**	**A076536**	**004**	Feb 12, 2013
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A076536**	**005**	Feb 12, 2013
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A076536**	**006**	Feb 12, 2013

TABLET;ORAL

	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
AB	ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040456**	**001**	May 06, 2003
AB		**1.25MG;1.25MG;1.25MG;1.25MG**	**A206340**	**001**	Feb 05, 2016
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A206340**	**002**	Feb 05, 2016
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A040456**	**002**	May 06, 2003
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A206340**	**003**	Feb 05, 2016
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A206340**	**004**	Feb 05, 2016
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A206340**	**005**	Feb 05, 2016
AB		**5MG;5MG;5MG;5MG**	**A040456**	**003**	May 06, 2003
AB		**5MG;5MG;5MG;5MG**	**A206340**	**006**	Feb 05, 2016
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A040456**	**004**	May 06, 2003
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A206340**	**007**	Feb 05, 2016

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		AUROLIFE PHARMA LLC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A202424**	**001** Nov 27, 2013
AB			**1.875MG;1.875MG;1.875MG;1.875MG**	**A202424**	**002** Nov 27, 2013
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A202424**	**003** Nov 27, 2013
AB			**3.125MG;3.125MG;3.125MG;3.125MG**	**A202424**	**004** Nov 27, 2013
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A202424**	**005** Nov 27, 2013
AB			**5MG;5MG;5MG;5MG**	**A202424**	**006** Nov 27, 2013
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A202424**	**007** Nov 27, 2013
AB		BARR	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040422**	**001** Feb 11, 2002
AB			**1.875MG;1.875MG;1.875MG;1.875MG**	**A040422**	**005** Mar 19, 2003
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A040422**	**002** Feb 11, 2002
AB			**3.125MG;3.125MG;3.125MG;3.125MG**	**A040422**	**006** Mar 19, 2003
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A040422**	**007** Mar 19, 2003
AB			**5MG;5MG;5MG;5MG**	**A040422**	**003** Feb 11, 2002
AB	**+**		**7.5MG;7.5MG;7.5MG;7.5MG**	**A040422**	**004** Feb 11, 2002
AB		COREPHARMA	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040444**	**001** Jun 19, 2002
AB			**1.875MG;1.875MG;1.875MG;1.875MG**	**A040444**	**005** Nov 03, 2014
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A040444**	**002** Jun 19, 2002
AB			**3.125MG;3.125MG;3.125MG;3.125MG**	**A040444**	**006** Nov 03, 2014
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A040444**	**007** Nov 03, 2014
AB			**5MG;5MG;5MG;5MG**	**A040444**	**003** Jun 19, 2002
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A040444**	**004** Jun 19, 2002
AB		MALLINCKRODT INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040440**	**001** Oct 07, 2003
AB			**1.875MG;1.875MG;1.875MG;1.875MG**	**A040440**	**002** Oct 07, 2003
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A040440**	**003** Oct 07, 2003
AB			**3.125MG;3.125MG;3.125MG;3.125MG**	**A040440**	**004** Oct 07, 2003
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A040440**	**005** Oct 07, 2003
AB			**5MG;5MG;5MG;5MG**	**A040440**	**006** Oct 07, 2003
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A040440**	**007** Oct 07, 2003
AB		MYLAN PHARMS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A206721**	**001** Nov 10, 2015
AB			**1.875MG;1.875MG;1.875MG;1.875MG**	**A206721**	**002** Nov 10, 2015
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A206721**	**003** Nov 10, 2015
AB			**3.125MG;3.125MG;3.125MG;3.125MG**	**A206721**	**004** Nov 10, 2015
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A206721**	**005** Nov 10, 2015
AB			**5MG;5MG;5MG;5MG**	**A206721**	**006** Nov 10, 2015
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A206721**	**007** Nov 10, 2015
AB		SANDOZ	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040439**	**004** Sep 27, 2002
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A040439**	**001** Jun 14, 2002
AB			**5MG;5MG;5MG;5MG**	**A040439**	**002** Jun 14, 2002
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A040439**	**003** Jun 14, 2002
AB		SUN PHARM INDS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A040480**	**001** Sep 09, 2003
AB			**1.875MG;1.875MG;1.875MG;1.875MG**	**A040480**	**002** Sep 09, 2003
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A040480**	**003** Sep 09, 2003
AB			**3.125MG;3.125MG;3.125MG;3.125MG**	**A040480**	**004** Sep 09, 2003
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A040480**	**005** Sep 09, 2003
AB			**5MG;5MG;5MG;5MG**	**A040480**	**006** Sep 09, 2003
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A040480**	**007** Sep 09, 2003

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001 Aug 09, 2012
+		10MG	A200166	002 Aug 09, 2012

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

+	X GEN PHARMS	50MG/VIAL	A063206	001 Apr 29, 1992

INJECTABLE, LIPID COMPLEX;INJECTION

ABELCET

+	SIGMA TAU	5MG/ML	N050724	001 Nov 20, 1995

INJECTABLE, LIPOSOMAL;INJECTION

AMBISOME

+	ASTELLAS	50MG/VIAL	N050740	001 Aug 11, 1997

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP		ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884 001	Apr 03, 2013
AP			EQ 1GM BASE/VIAL	A090884 002	Apr 03, 2013
AP			EQ 2GM BASE/VIAL	A090884 003	Apr 03, 2013
AP			EQ 10GM BASE/VIAL	A090889 001	Apr 03, 2013
AP		ANTIBIOTICE	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009
AP			EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009
AP			EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009
AP			EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009
AP		AUROBINDO PHARMA	EQ 125MG BASE/VIAL	A065499 001	Aug 17, 2010
AP			EQ 250MG BASE/VIAL	A065499 002	Aug 17, 2010
AP			EQ 500MG BASE/VIAL	A065499 003	Aug 17, 2010
AP			EQ 1GM BASE/VIAL	A065499 004	Aug 17, 2010
AP			EQ 2GM BASE/VIAL	A065499 005	Aug 17, 2010
AP			EQ 10GM BASE/VIAL	A065493 001	Aug 17, 2010
AP		HANFORD GC	EQ 250MG BASE/VIAL	A063145 001	Apr 15, 1993
AP			EQ 500MG BASE/VIAL	A063146 001	Apr 15, 1993
AP			EQ 1GM BASE/VIAL	A062772 001	Apr 15, 1993
AP			EQ 2GM BASE/VIAL	A063140 001	Apr 15, 1993
AP			EQ 10GM BASE/VIAL	A063142 001	Apr 15, 1993
AP		HOSPIRA INC	EQ 250MG BASE/VIAL	A202864 001	Sep 04, 2015
AP			EQ 500MG BASE/VIAL	A202864 002	Sep 04, 2015
AP			EQ 1GM BASE/VIAL	A202864 003	Sep 04, 2015
AP			EQ 2GM BASE/VIAL	A202864 004	Sep 04, 2015
AP			EQ 10GM BASE/VIAL	A202865 001	Sep 04, 2015
AP		ISTITUTO BIO ITA SPA	EQ 10GM BASE/VIAL	A201404 001	Dec 20, 2013
AP			EQ 125MG BASE/VIAL	A062797 001	Jul 12, 1993
AP			EQ 250MG BASE/VIAL	A062719 001	May 12, 1987
AP			EQ 500MG BASE/VIAL	A062719 003	May 12, 1987
AP			EQ 1GM BASE/VIAL	A062719 002	May 12, 1987
AP			EQ 2GM BASE/VIAL	A062797 002	Jul 12, 1993
AP		MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025 001	Apr 09, 2014
AP			EQ 500MG BASE/VIAL	A201025 002	Apr 09, 2014
AP			EQ 1GM BASE/VIAL	A201025 003	Apr 09, 2014
AP			EQ 2GM BASE/VIAL	A201025 004	Apr 09, 2014
AP			EQ 10GM BASE/VIAL	A202198 001	Apr 07, 2014
AP		SAGENT PHARMS	EQ 125MG BASE/VIAL	A090583 001	Nov 27, 2015
AP			EQ 250MG BASE/VIAL	A090583 002	Nov 27, 2015
AP			EQ 500MG BASE/VIAL	A090583 003	Nov 27, 2015
AP			EQ 1GM BASE/VIAL	A090583 004	Nov 27, 2015
AP			EQ 2GM BASE/VIAL	A090583 005	Nov 27, 2015
AP			EQ 10GM BASE/VIAL	A090581 001	Oct 20, 2015
AP	+	SANDOZ	EQ 125MG BASE/VIAL	A061395 001	
AP	+		EQ 250MG BASE/VIAL	A061395 002	
AP	+		EQ 500MG BASE/VIAL	A061395 003	
AP	+		EQ 1GM BASE/VIAL	A061395 004	
AP	+		EQ 2GM BASE/VIAL	A061395 005	
AP	+		EQ 10GM BASE/VIAL	A061395 006	

POWDER;INTRAVENOUS

AMPICILLIN SODIUM

AP	+	SANDOZ	EQ 1GM BASE/VIAL	A062738 001	Feb 19, 1987
AP	+		EQ 2GM BASE/VIAL	A062738 002	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP		ACS DOBFAR	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065406 001	Dec 22, 2009
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065406 002	Dec 22, 2009
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065403 001	Dec 23, 2009
AP		ANTIBIOTICS SA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201406 001	Dec 07, 2015
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201406 002	Dec 07, 2015
AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340 001	Sep 20, 2010
AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349 001	Sep 20, 2010
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340 002	Sep 20, 2010
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349 002	Sep 20, 2010
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339 001	Sep 20, 2010
AP		EUROHLTH INTL SARL	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074 001	Mar 19, 2002
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074 002	Mar 19, 2002
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076 001	Mar 19, 2002
AP		HANFORD GC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065176 001	Nov 30, 2005
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065176 002	Nov 30, 2005

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005
AP	HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011
AP		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007
AP	MYLAN LABS LTD	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014
AP	SAGENT PHARMS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090579	001	Jan 08, 2016
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090579	002	Jan 08, 2016
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090578	001	Jan 11, 2016
AP	SANDOZ	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065241	001	Jul 25, 2006
AP		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065310	001	Jul 25, 2006
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065241	002	Jul 25, 2006
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065310	002	Jul 25, 2006
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065240	001	Jul 25, 2006

UNASYN

AP	+ PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A062901	002	Feb 27, 1992
AP	+	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A062901	001	Nov 23, 1988
AP	+	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N050608	002	Dec 31, 1986
AP	+	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N050608	001	Dec 31, 1986
AP	+	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N050608	005	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

AB	DAVA PHARMS INC	EQ 250MG BASE	A062883	001	Feb 25, 1988
AB	+	EQ 500MG BASE	A062882	001	Feb 25, 1988
AB	SANDOZ	EQ 250MG BASE	A064082	001	Aug 29, 1995
AB		EQ 500MG BASE	A064082	002	Aug 29, 1995

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE

	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989
+		EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333	001	Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

AB	BARR	EQ 0.5MG BASE	A076530	001	Apr 18, 2005
AB		EQ 1MG BASE	A076530	002	Apr 18, 2005
AB	IMPAX LABS	EQ 0.5MG BASE	A076910	001	Apr 18, 2005
AB		EQ 1MG BASE	A076910	002	Apr 18, 2005
AB	IVAX SUB TEVA PHARMS	EQ 0.5MG BASE	A076468	001	Apr 18, 2005
AB	+	EQ 1MG BASE	A076468	002	Apr 18, 2005
AB	MYLAN	EQ 0.5MG BASE	A076811	001	Apr 18, 2005
AB		EQ 1MG BASE	A076811	002	Apr 18, 2005
AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A077613	001	Jun 27, 2006
AB		EQ 1MG BASE	A077613	002	Jun 27, 2006

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A090568	001	Jun 28, 2010
AB	APOTEX INC	1MG	A200654	001	May 11, 2012
AB	CIPLA LTD	1MG	A091164	001	Jun 28, 2010
AB	DR REDDYS LABS LTD	1MG	A090732	001	Jun 28, 2010
AB	FRESENIUS KABI ONCOL	1MG	A090088	001	Jun 28, 2010
AB	MYLAN	1MG	A091051	001	Jun 28, 2010
AB	NATCO PHARMA LTD	1MG	A079220	001	Jun 28, 2010
AB	SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010
AB	SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011
AB	TEVA PHARMS	1MG	A078058	001	Jun 28, 2010
AB	WEST-WARD PHARMS INT	1MG	A078485	001	Jun 28, 2010

ANASTROZOLE
TABLET;ORAL
ANASTROZOLE

AB		ZYDUS PHARMS USA INC	**1MG**	**A078921**	**001** Jun 28, 2010
ARIMIDEX					
AB	**+**	ASTRAZENECA	**1MG**	**N020541**	**001** Dec 27, 1995

ANIDULAFUNGIN
INJECTABLE;IV (INFUSION)
ERAXIS

	+	VICURON	50MG/VIAL	N021632	001 Feb 17, 2006
	+		100MG/VIAL	N021632	002 Nov 14, 2006

APIXABAN
TABLET;ORAL
ELIQUIS

		BRISTOL MYERS SQUIBB	2.5MG	N202155	001 Dec 28, 2012
	+		5MG	N202155	002 Dec 28, 2012

APOMORPHINE HYDROCHLORIDE
INJECTABLE;SUBCUTANEOUS
APOKYN

	+	US WORLDMEDS	30MG/3ML (10MG/ML)	N021264	002 Apr 20, 2004

APRACLONIDINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
APRACLONIDINE HYDROCHLORIDE

AT		AKORN INC	**EQ 0.5% BASE**	**A077764**	**001** Mar 12, 2009
IOPIDINE					
AT	**+**	NOVARTIS PHARMS CORP	**EQ 0.5% BASE**	**N020258**	**001** Jul 30, 1993
	+		EQ 1% BASE	N019779	001 Dec 31, 1987

APREMILAST
TABLET;ORAL
OTEZLA

		CELGENE CORP	10MG	N205437	001 Mar 21, 2014
			20MG	N205437	002 Mar 21, 2014
	+		30MG	N205437	003 Mar 21, 2014

APREPITANT
CAPSULE;ORAL
APREPITANT

AB		SANDOZ	**40MG**	**A090999**	**001** Sep 24, 2012
AB			**80MG**	**A090999**	**002** Sep 24, 2012
AB			**125MG**	**A090999**	**003** Sep 24, 2012
EMEND					
AB		MERCK	**40MG**	**N021549**	**003** Jun 30, 2006
AB			**80MG**	**N021549**	**001** Mar 26, 2003
AB	**+**		**125MG**	**N021549**	**002** Mar 26, 2003

FOR SUSPENSION;ORAL
EMEND

	+	MSD MERCK CO	125MG/KIT	N207865	001 Dec 17, 2015

ARFORMOTEROL TARTRATE
SOLUTION;INHALATION
BROVANA

	+	SUNOVION	EQ 0.015MG BASE/2ML	N021912	001 Oct 06, 2006

ARGATROBAN
INJECTABLE;INJECTION
ARGATROBAN

AP		FRESENIUS KABI USA	**250MG/2.5ML (100MG/ML)**	**N201811**	**001** Mar 23, 2015
AP		HIKMA PHARM CO LTD	**250MG/2.5ML (100MG/ML)**	**N203049**	**001** Jan 05, 2012
AP		HOSPIRA INC	**250MG/2.5ML (100MG/ML)**	**A204120**	**001** Sep 21, 2016
AP		MYLAN INSTITUTIONAL	**250MG/2.5ML (100MG/ML)**	**A202626**	**001** Jun 30, 2014
AP		PAR STERILE PRODUCTS	**250MG/2.5ML (100MG/ML)**	**A091665**	**001** Jun 30, 2014
AP	**+**	PFIZER	**250MG/2.5ML (100MG/ML)**	**N020883**	**001** Jun 30, 2000

INJECTABLE;IV (INFUSION)
ARGATROBAN IN 0.9% SODIUM CHLORIDE

		TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001 Dec 15, 2014

ARGATROBAN IN SODIUM CHLORIDE

	+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001 Jun 29, 2011
	+	SANDOZ	125MG/125ML (1MG/ML)	N022485	001 May 09, 2011

FDA data supplied by DrugPatentWatch.com

ARGININE HYDROCHLORIDE
INJECTABLE;INJECTION
R-GENE 10

	+	PHARMACIA AND UPJOHN	10GM/100ML	N016931	001

ARIPIPRAZOLE
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT

		OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001 Feb 28, 2013
			300MG	N202971	003 Sep 29, 2014
	+		400MG/VIAL	N202971	002 Feb 28, 2013
			400MG	N202971	004 Sep 29, 2014

SOLUTION;ORAL
ARIPIPRAZOLE

AA	+	AMNEAL PHARMS	**1MG/ML**	**A203906**	**001** Aug 14, 2015
AA		APOTEX INC	**1MG/ML**	**A204094**	**001** Sep 30, 2015
AA		SILARX PHARMS INC	**1MG/ML**	**A204171**	**001** Aug 14, 2015

TABLET;ORAL
ABILIFY

AB		OTSUKA	**2MG**	**N021436**	**006** Nov 15, 2002
AB	+		**5MG**	**N021436**	**005** Nov 15, 2002
AB	+		**10MG**	**N021436**	**001** Nov 15, 2002
AB			**15MG**	**N021436**	**002** Nov 15, 2002
AB			**20MG**	**N021436**	**003** Nov 15, 2002
AB			**30MG**	**N021436**	**004** Nov 15, 2002

ARIPIPRAZOLE

AB		ACCORD HLTHCARE	**2MG**	**A206251**	**001** Dec 07, 2016
AB			**5MG**	**A206251**	**002** Dec 07, 2016
AB			**10MG**	**A206251**	**003** Dec 07, 2016
AB			**15MG**	**A206251**	**004** Dec 07, 2016
AB			**20MG**	**A206251**	**005** Dec 07, 2016
AB			**30MG**	**A206251**	**006** Dec 07, 2016
AB		AJANTA PHARMA LTD	**2MG**	**A206174**	**001** Sep 12, 2016
AB			**5MG**	**A206174**	**002** Sep 12, 2016
AB			**10MG**	**A206174**	**003** Sep 12, 2016
AB			**15MG**	**A206174**	**004** Sep 12, 2016
AB			**20MG**	**A206174**	**005** Sep 12, 2016
AB			**30MG**	**A206174**	**006** Sep 12, 2016
AB		ALEMBIC PHARMS LTD	**2MG**	**A202101**	**001** Apr 28, 2015
AB			**5MG**	**A202101**	**002** Apr 28, 2015
AB			**10MG**	**A202101**	**003** Apr 28, 2015
AB			**15MG**	**A202101**	**004** Apr 28, 2015
AB			**20MG**	**A202101**	**005** Apr 28, 2015
AB			**30MG**	**A202101**	**006** Apr 28, 2015
AB		AMNEAL PHARMS	**2MG**	**A204838**	**001** Jun 17, 2016
AB			**5MG**	**A204838**	**002** Jun 17, 2016
AB			**10MG**	**A204838**	**003** Jun 17, 2016
AB			**15MG**	**A204838**	**004** Jun 17, 2016
AB			**20MG**	**A204838**	**005** Jun 17, 2016
AB			**30MG**	**A204838**	**006** Jun 17, 2016
AB		APOTEX INC	**2MG**	**A078583**	**001** Jul 24, 2015
AB			**5MG**	**A078583**	**002** Jul 24, 2015
AB			**10MG**	**A078583**	**003** Jul 24, 2015
AB			**15MG**	**A078583**	**004** Jul 24, 2015
AB			**20MG**	**A078583**	**005** Jul 24, 2015
AB			**30MG**	**A078583**	**006** Jul 24, 2015
AB		AUROBINDO PHARMA LTD	**2MG**	**A203908**	**001** Oct 08, 2015
AB			**5MG**	**A203908**	**002** Oct 08, 2015
AB			**10MG**	**A203908**	**003** Oct 08, 2015
AB			**15MG**	**A203908**	**004** Oct 08, 2015
AB			**20MG**	**A203908**	**005** Oct 08, 2015
AB			**30MG**	**A203908**	**006** Oct 08, 2015
AB		HETERO LABS LTD V	**2MG**	**A205064**	**001** Apr 28, 2015
AB			**5MG**	**A205064**	**002** Apr 28, 2015
AB			**10MG**	**A205064**	**003** Apr 28, 2015
AB			**15MG**	**A205064**	**004** Apr 28, 2015
AB			**20MG**	**A205064**	**005** Apr 28, 2015
AB			**30MG**	**A205064**	**006** Apr 28, 2015
AB		MACLEODS PHARMS LTD	**2MG**	**A204111**	**001** Oct 07, 2016
AB			**5MG**	**A204111**	**002** Oct 07, 2016
AB			**10MG**	**A204111**	**003** Oct 07, 2016
AB			**15MG**	**A204111**	**004** Oct 07, 2016
AB			**20MG**	**A204111**	**005** Oct 07, 2016

FDA data supplied by DrugPatentWatch.com

ARIPIPRAZOLE
TABLET;ORAL
ARIPIPRAZOLE

AB		**30MG**	**A204111**	**006**	Oct 07, 2016
AB	SCIEGEN PHARMS INC	**2MG**	**A206383**	**001**	Sep 29, 2016
AB		**5MG**	**A206383**	**002**	Sep 29, 2016
AB		**10MG**	**A206383**	**003**	Sep 29, 2016
AB		**15MG**	**A206383**	**004**	Sep 29, 2016
AB		**20MG**	**A206383**	**005**	Sep 29, 2016
AB		**30MG**	**A206383**	**006**	Sep 29, 2016
AB	STASON PHARMS	**2MG**	**A091279**	**001**	Jan 09, 2017
AB		**5MG**	**A091279**	**002**	Jan 09, 2017
AB		**10MG**	**A091279**	**003**	Jan 09, 2017
AB		**15MG**	**A091279**	**004**	Jan 09, 2017
AB		**20MG**	**A091279**	**005**	Jan 09, 2017
AB		**30MG**	**A091279**	**006**	Jan 09, 2017
AB	TEVA PHARMS USA	**2MG**	**A078607**	**001**	Apr 28, 2015
AB		**5MG**	**A078607**	**002**	Apr 28, 2015
AB		**10MG**	**A078608**	**001**	Apr 28, 2015
AB		**15MG**	**A078708**	**001**	Apr 28, 2015
AB		**20MG**	**A078708**	**002**	Apr 28, 2015
AB		**30MG**	**A078708**	**003**	Apr 28, 2015
AB	TORRENT PHARMS LTD	**2MG**	**A201519**	**001**	Apr 28, 2015
AB		**10MG**	**A201519**	**003**	Apr 28, 2015
AB		**5MG**	**A201519**	**002**	Apr 28, 2015
AB		**15MG**	**A201519**	**004**	Apr 28, 2015
AB		**20MG**	**A201519**	**005**	Apr 28, 2015
AB		**30MG**	**A201519**	**006**	Apr 28, 2015

TABLET, ORALLY DISINTEGRATING;ORAL
ARIPIPRAZOLE

+	ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015
		15MG	A202102	002	Apr 28, 2015

ARIPIPRAZOLE LAUROXIL
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA

	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
+		882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015

ARMODAFINIL
TABLET;ORAL
ARMODAFINIL

AB	LUPIN LTD	**50MG**	**A200751**	**001**	Nov 28, 2016
AB		**150MG**	**A200751**	**003**	Nov 28, 2016
AB		**200MG**	**A200751**	**004**	Nov 28, 2016
AB		**250MG**	**A200751**	**005**	Nov 28, 2016
AB	MYLAN PHARMS INC	**50MG**	**A200043**	**001**	Jun 01, 2012
AB		**150MG**	**A200043**	**002**	Jun 01, 2012
AB		**250MG**	**A200043**	**003**	Jun 01, 2012
AB	NATCO PHARMA LTD	**50MG**	**A202768**	**001**	Nov 28, 2016
AB		**150MG**	**A202768**	**002**	Nov 28, 2016
AB		**250MG**	**A202768**	**003**	Nov 28, 2016

NUVIGIL

AB	CEPHALON	**50MG**	**N021875**	**001**	Jun 15, 2007
AB		**150MG**	**N021875**	**003**	Jun 15, 2007
AB		**200MG**	**N021875**	**005**	Mar 26, 2009
AB	**+**	**250MG**	**N021875**	**004**	Jun 15, 2007

ARSENIC TRIOXIDE
INJECTABLE;INJECTION
TRISENOX

+	CEPHALON	1MG/ML	N021248	001	Sep 25, 2000

ARTEMETHER; LUMEFANTRINE
TABLET;ORAL
COARTEM

+	NOVARTIS	20MG;120MG	N022268	001	Apr 07, 2009

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE				
AP	HOSPIRA	**4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)**	**A079138**	**001**	Jun 18, 2010
	SEPTOCAINE				
AP	**+** DEPROCO	**4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)**	**N020971**	**001**	Apr 03, 2000
	ORABLOC				
	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010
	+	4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010
	SEPTOCAINE				
	+ DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;IV (INFUSION)

INFUVITE PEDIATRIC				
+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)				
+ SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646	001	Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;IV (INFUSION)

M.V.I. PEDIATRIC				
+ HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001	Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)				
+ HOSPIRA	20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809	006	Sep 09, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;IV (INFUSION)

M.V.I. ADULT				
+ HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001	Jan 30, 2004
M.V.I. ADULT (PHARMACY BULK PACKAGE)				
+ HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

MOVIPREP				
+ SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	N021881	001	Aug 02, 2006

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS				
FOREST LABS LLC	EQ 2.5 BASE	N022117	003	Mar 12, 2015
	EQ 5MG BASE	N022117	001	Aug 13, 2009
+	EQ 10MG BASE	N022117	002	Aug 13, 2009

ASPIRIN
CAPSULE, EXTENDED RELEASE;ORAL
DURLAZA

	+	NEW HAVEN PHARMS	162.5MG	N200671	001 Sep 04, 2015

ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE;ORAL
FIORINAL

AA	**+**	ALLERGAN SALES LLC	**325MG;50MG;40MG**	**N017534**	**005** Apr 16, 1986

LANORINAL

AA		LANNETT	**325MG;50MG;40MG**	**A086996**	**002** Oct 11, 1985

TABLET;ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

AA	**+**	HIKMA INTL PHARMS	**325MG;50MG;40MG**	**A086162**	**002** Feb 16, 1984
AA		PHARMACEUTICS INTL	**325MG;50MG;40MG**	**A204195**	**001** Sep 22, 2016

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
CAPSULE;ORAL
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE

AB		MAYNE PHARMA INC	**325MG;50MG;40MG;30MG**	**A203335**	**001** Oct 30, 2015

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB		NEXGEN PHARMA INC	**325MG;50MG;40MG;30MG**	**A075231**	**001** Nov 30, 2001
AB		STEVENS J	**325MG;50MG;40MG;30MG**	**A074951**	**001** Aug 31, 1998

FIORINAL W/CODEINE

AB	**+**	ALLERGAN SALES LLC	**325MG;50MG;40MG;30MG**	**N019429**	**003** Oct 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
CAPSULE;ORAL
SYNALGOS-DC

	+	SUN PHARM INDS	356.4MG;30MG;16MG	N011483	004 Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
TABLET;ORAL
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

		SANDOZ	385MG;30MG;25MG	A074654	001 Dec 31, 1996
	+		770MG;60MG;50MG	A074654	002 Dec 31, 1996

ASPIRIN; CARISOPRODOL
TABLET;ORAL
CARISOPRODOL AND ASPIRIN

AB	**+**	HERITAGE PHARMS INC	**325MG;200MG**	**A089594**	**001** Mar 31, 1989
AB		INGENUS PHARMS NJ	**325MG;200MG**	**A040832**	**001** Jan 07, 2010
AB		OXFORD PHARMS	**325MG;200MG**	**A040252**	**001** Dec 10, 1997
AB		SANDOZ	**325MG;200MG**	**A040116**	**001** Apr 25, 1996

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
TABLET;ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		INGENUS PHARMS NJ	**325MG;200MG;16MG**	**A040860**	**001** Jan 07, 2010
AB	**+**	SANDOZ	**325MG;200MG;16MG**	**A040118**	**001** Apr 16, 1996

ASPIRIN; DIPYRIDAMOLE
CAPSULE, EXTENDED RELEASE;ORAL
AGGRENOX

AB	**+**	BOEHRINGER INGELHEIM	**25MG;200MG**	**N020884**	**001** Nov 22, 1999

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	**25MG;200MG**	**A206392**	**001** Mar 08, 2016
AB		BARR	**25MG;200MG**	**A078804**	**001** Aug 14, 2009

ASPIRIN; METHOCARBAMOL
TABLET;ORAL
METHOCARBAMOL AND ASPIRIN

	+	STEVENS J	325MG;400MG	A081145	001 Jan 31, 1995

ASPIRIN; OMEPRAZOLE
TABLET, DELAYED RELEASE;ORAL
YOSPRALA

		ARALEZ PHARMS	81MG;40MG	N205103	001 Sep 14, 2016
	+		325MG;40MG	N205103	002 Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE
TABLET;ORAL
OXYCODONE AND ASPIRIN

AA		ACTAVIS LABS FL INC	**325MG;4.8355MG**	**A090084**	**001** Mar 22, 2011
AA		MAYNE PHARMA INC	**325MG;4.8355MG**	**A091670**	**001** Mar 16, 2011

PERCODAN

AA	**+**	ENDO PHARMS	**325MG;4.8355MG**	**N007337**	**007** Aug 05, 2005

FDA data supplied by DrugPatentWatch.com

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB	TEVA PHARMS USA	**EQ 150MG BASE**	**A091673**	**002**	Apr 22, 2014
AB		**EQ 200MG BASE**	**A091673**	**003**	Apr 22, 2014
AB		**EQ 300MG BASE**	**A091673**	**004**	Apr 22, 2014

REYATAZ

AB	BRISTOL MYERS SQUIBB	**EQ 150MG BASE**	**N021567**	**002**	Jun 20, 2003
AB		**EQ 200MG BASE**	**N021567**	**003**	Jun 20, 2003
AB +		**EQ 300MG BASE**	**N021567**	**004**	Oct 16, 2006

ATAZANAVIR SULFATE

	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014

POWDER;ORAL

REYATAZ

+	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

+	BRISTOL-MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN MALTA	**25MG**	**A073646**	**001**	Jul 31, 1992
AB		**50MG**	**A072303**	**001**	Jul 15, 1988
AB		**100MG**	**A072304**	**001**	Jul 15, 1988
AB	AUROBINDO PHARMA	**25MG**	**A078512**	**001**	Oct 31, 2007
AB		**50MG**	**A078512**	**002**	Oct 31, 2007
AB		**100MG**	**A078512**	**003**	Oct 31, 2007
AB	DAVA PHARMS INC	**50MG**	**A073542**	**001**	Dec 19, 1991
AB		**100MG**	**A073543**	**001**	Dec 19, 1991
AB	IPCA LABS LTD	**25MG**	**A077877**	**001**	Dec 27, 2006
AB		**50MG**	**A077877**	**002**	Dec 27, 2006
AB		**100MG**	**A077877**	**003**	Dec 27, 2006
AB	MYLAN	**25MG**	**A073457**	**002**	Apr 26, 1999
AB		**50MG**	**A073457**	**003**	Jan 24, 1992
AB		**100MG**	**A073457**	**001**	Jan 24, 1992
AB	SANDOZ	**25MG**	**A074052**	**001**	May 01, 1992
AB		**50MG**	**A073025**	**001**	Sep 17, 1991
AB		**100MG**	**A073026**	**001**	Sep 17, 1991
AB	SUN PHARM INDS	**25MG**	**A074499**	**001**	Jul 30, 1997
AB		**50MG**	**A073475**	**001**	Mar 30, 1993
AB		**100MG**	**A073476**	**001**	Mar 30, 1993
AB	SUN PHARM INDS INC	**25MG**	**A078210**	**001**	Jul 10, 2007
AB		**50MG**	**A078210**	**002**	Jul 10, 2007
AB		**100MG**	**A078210**	**003**	Jul 10, 2007
AB	TEVA	**25MG**	**A074056**	**003**	Jul 19, 2004
AB		**50MG**	**A074056**	**001**	Jan 18, 1995
AB		**100MG**	**A074056**	**002**	Jan 18, 1995
AB	UNIQUE PHARM LABS	**25MG**	**A077443**	**001**	Sep 13, 2006
AB		**50MG**	**A077443**	**002**	Sep 13, 2006
AB		**100MG**	**A077443**	**003**	Sep 13, 2006
AB	ZYDUS PHARMS USA	**25MG**	**A076900**	**001**	Jan 28, 2005
AB		**50MG**	**A076900**	**002**	Jan 28, 2005
AB		**100MG**	**A076900**	**003**	Jan 28, 2005

TENORMIN

AB	ALVOGEN MALTA	**25MG**	**N018240**	**004**	Apr 09, 1990
AB		**50MG**	**N018240**	**001**	
AB +		**100MG**	**N018240**	**002**	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	**50MG;25MG**	**A072301**	**001**	May 31, 1990
AB		**100MG;25MG**	**A072302**	**001**	May 31, 1990
AB	MUTUAL PHARM	**50MG;25MG**	**A073581**	**001**	Apr 29, 1993
AB	MYLAN	**50MG;25MG**	**A074203**	**001**	Oct 31, 1993
AB		**100MG;25MG**	**A074203**	**002**	Oct 31, 1993
AB	SUN PHARM INDS	**100MG;25MG**	**A073582**	**001**	Apr 29, 1993
AB	WATSON LABS	**50MG;25MG**	**A073665**	**001**	Jul 02, 1992
AB		**100MG;25MG**	**A073665**	**002**	Jul 02, 1992

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION DRUG PRODUCT LIST

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

TENORETIC 100

AB	+	ALVOGEN MALTA	**100MG;25MG**	**N018760**	**001** Jun 08, 1984

TENORETIC 50

AB		ALVOGEN MALTA	**50MG;25MG**	**N018760**	**002** Jun 08, 1984

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

STRATTERA

		LILLY	10MG	N021411	002 Nov 26, 2002
			18MG	N021411	003 Nov 26, 2002
			25MG	N021411	004 Nov 26, 2002
			40MG	N021411	005 Nov 26, 2002
	+		60MG	N021411	006 Nov 26, 2002
			80MG	N021411	007 Feb 14, 2005
			100MG	N021411	008 Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		APOTEX INC	**EQ 10MG BASE**	**A090548**	**001** May 29, 2012
AB			**EQ 20MG BASE**	**A090548**	**002** May 29, 2012
AB			**EQ 40MG BASE**	**A090548**	**003** May 29, 2012
AB			**EQ 80MG BASE**	**A090548**	**004** May 29, 2012
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A091650**	**001** Jul 17, 2012
AB			**EQ 20MG BASE**	**A091650**	**002** Jul 17, 2012
AB			**EQ 40MG BASE**	**A091650**	**003** Jul 17, 2012
AB			**EQ 80MG BASE**	**A202357**	**001** Jul 17, 2012
AB		INVAGEN PHARMS	**EQ 10MG BASE**	**A204846**	**001** Jan 09, 2017
AB			**EQ 20MG BASE**	**A204846**	**002** Jan 09, 2017
AB			**EQ 40MG BASE**	**A204846**	**003** Jan 09, 2017
AB			**EQ 80MG BASE**	**A204846**	**004** Jan 09, 2017
AB		KREMERS URBAN PHARMS	**EQ 10MG BASE**	**A091624**	**001** Apr 05, 2013
AB			**EQ 20MG BASE**	**A091624**	**002** Apr 05, 2013
AB			**EQ 40MG BASE**	**A091624**	**003** Apr 05, 2013
AB			**EQ 80MG BASE**	**A091624**	**004** Apr 05, 2013
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A091226**	**001** May 29, 2012
AB			**EQ 20MG BASE**	**A091226**	**002** May 29, 2012
AB			**EQ 40MG BASE**	**A091226**	**003** May 29, 2012
AB			**EQ 80MG BASE**	**A091226**	**004** May 29, 2012
AB		SANDOZ INC	**EQ 10MG BASE**	**A077575**	**001** May 29, 2012
AB			**EQ 20MG BASE**	**A077575**	**002** May 29, 2012
AB			**EQ 40MG BASE**	**A077575**	**003** May 29, 2012
AB			**EQ 80MG BASE**	**A077575**	**004** May 29, 2012
AB		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A205519**	**001** May 19, 2016
AB			**EQ 20MG BASE**	**A205519**	**002** May 19, 2016
AB			**EQ 40MG BASE**	**A205519**	**003** May 19, 2016
AB			**EQ 80MG BASE**	**A205519**	**004** May 19, 2016
AB		SUN PHARM INDS LTD	**EQ 10MG BASE**	**A076477**	**001** Nov 30, 2011
AB			**EQ 20MG BASE**	**A076477**	**002** Nov 30, 2011
AB			**EQ 40MG BASE**	**A076477**	**003** Nov 30, 2011
AB			**EQ 80MG BASE**	**A076477**	**004** Nov 30, 2011

LIPITOR

AB		PFIZER	**EQ 10MG BASE**	**N020702**	**001** Dec 17, 1996
AB			**EQ 20MG BASE**	**N020702**	**002** Dec 17, 1996
AB			**EQ 40MG BASE**	**N020702**	**003** Dec 17, 1996
AB	+		**EQ 80MG BASE**	**N020702**	**004** Apr 07, 2000

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB		AMNEAL PHARMS	**750MG/5ML**	**A202960**	**001** Mar 18, 2014

MEPRON

AB	+	GLAXOSMITHKLINE LLC	**750MG/5ML**	**N020500**	**001** Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	**62.5MG;25MG**	**A091211**	**002** Apr 06, 2015
AB			**250MG;100MG**	**A091211**	**001** Jan 12, 2011
AB		MYLAN PHARMS INC	**62.5MG;25MG**	**A202362**	**001** May 27, 2014
AB			**250MG;100MG**	**A202362**	**002** May 27, 2014

FDA data supplied by DrugPatentWatch.com

ATOVAQUONE; PROGUANIL HYDROCHLORIDE
TABLET;ORAL
MALARONE

AB	**+**	GLAXOSMITHKLINE	**250MG;100MG**	**N021078** **001**	Jul 14, 2000

MALARONE PEDIATRIC

AB		GLAXOSMITHKLINE	**62.5MG;25MG**	**N021078** **002**	Jul 14, 2000

ATRACURIUM BESYLATE
INJECTABLE;INJECTION
ATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A206011** **001**	Apr 08, 2015
AP		HOSPIRA INC	**10MG/ML**	**A090761** **001**	Oct 18, 2012
AP		NANJING KING-FRIEND	**10MG/ML**	**A091489** **001**	Feb 17, 2012
AP	**+**	WEST-WARD PHARMS INT	**10MG/ML**	**A074901** **001**	Jul 18, 1997

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	**10MG/ML**	**A206010** **001**	Apr 08, 2015
AP		HOSPIRA INC	**10MG/ML**	**A090782** **001**	Oct 18, 2012
AP		NANJING KING-FRIEND	**10MG/ML**	**A091488** **001**	Feb 17, 2012
AP	**+**	WEST-WARD PHARMS INT	**10MG/ML**	**A074900** **001**	Jul 18, 1997

ATROPINE
INJECTABLE;INJECTION
ATROPEN

	+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106 004	Sep 17, 2004
	+		EQ 0.5MG SULFATE/0.7ML	N017106 003	Jun 19, 2003
	+		EQ 1MG SULFATE/0.7ML	N017106 002	Jun 19, 2003
	+		EQ 2MG SULFATE/0.7ML	N017106 001	

ATROPINE SULFATE
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ATROPINE SULFATE ANSYR PLASTIC SYRINGE

	+	HOSPIRA	0.05MG/ML	N021146 002	Jul 09, 2001
	+		0.1MG/ML	N021146 001	Jul 09, 2001

SOLUTION/DROPS;OPHTHALMIC
ATROPINE SULFATE

	+	AKORN	1%	N206289 001	Jul 18, 2014

ISOPTO ATROPINE

		NOVARTIS PHARMS CORP	1%	N208151 001	Dec 01, 2016

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE
TABLET;ORAL
MOTOFEN

	+	SEBELA IRELAND LTD	0.025MG;1MG	N017744 002	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
SOLUTION;ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	**+**	WEST-WARD PHARMS INT	**0.025MG/5ML;2.5MG/5ML**	**A087708** **001**	May 03, 1982

TABLET;ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		LANNETT	**0.025MG;2.5MG**	**A085372** **001**	
AA		MYLAN	**0.025MG;2.5MG**	**A085762** **001**	
AA		PAR PHARM	**0.025MG;2.5MG**	**A040357** **001**	May 02, 2000

LOMOTIL

AA	**+**	GD SEARLE LLC	**0.025MG;2.5MG**	**N012462** **001**	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE
INJECTABLE;INJECTION
ENLON-PLUS

	+	MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019678 001	Nov 06, 1991

ATROPINE; PRALIDOXIME CHLORIDE
INJECTABLE;INTRAMUSCULAR
DUODOTE

	+	MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML	N021983 001	Sep 28, 2006

AURANOFIN
CAPSULE;ORAL
RIDAURA

	+	SEBELA IRELAND LTD	3MG	N018689 001	May 24, 1985

AVANAFIL
TABLET;ORAL
STENDRA

	METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012
		100MG	N202276	002	Apr 27, 2012
+		200MG	N202276	003	Apr 27, 2012

AVIBACTAM SODIUM; CEFTAZIDIME
POWDER;IV (INFUSION)
AVYCAZ

+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015

AXITINIB
TABLET;ORAL
INLYTA

	PF PRISM CV	1MG	N202324	001	Jan 27, 2012
+		5MG	N202324	002	Jan 27, 2012

AZACITIDINE
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP	DR REDDYS LABS LTD	**100MG/VIAL**	**A201537**	**001**	Sep 16, 2013
AP	MYLAN INSTITUTIONAL	**100MG/VIAL**	**A204949**	**001**	Apr 28, 2016
AP	SHILPA MEDICARE	**100MG/VIAL**	**A207518**	**001**	Sep 29, 2016

VIDAZA

AP	**+** CELGENE	**100MG/VIAL**	**N050794**	**001**	May 19, 2004

POWDER;IV (INFUSION), SUBCUTANEOUS
AZACITIDINE

	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016

AZATHIOPRINE
TABLET;ORAL
AZASAN

AB	AAIPHARMA LLC	**25MG**	**A075252**	**002**	Feb 03, 2003
AB		**50MG**	**A075252**	**001**	Jun 07, 1999
AB		**75MG**	**A075252**	**003**	Feb 03, 2003
AB		**100MG**	**A075252**	**004**	Feb 03, 2003

AZATHIOPRINE

AB	AMNEAL PHARMS LLC	**50MG**	**A074069**	**001**	Feb 16, 1996
AB	MYLAN	**50MG**	**A075568**	**001**	Dec 13, 1999
AB	ZYDUS PHARMS USA	**25MG**	**A077621**	**002**	Sep 05, 2008
AB		**50MG**	**A077621**	**001**	Mar 15, 2007
AB		**75MG**	**A077621**	**003**	Sep 05, 2008
AB		**100MG**	**A077621**	**004**	Sep 05, 2008

IMURAN

AB	**+** SEBELA IRELAND LTD	**50MG**	**N016324**	**001**	

AZATHIOPRINE SODIUM
INJECTABLE;INJECTION
AZATHIOPRINE SODIUM

+	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995

AZELAIC ACID
AEROSOL, FOAM;TOPICAL
FINACEA

+	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015

CREAM;TOPICAL
AZELEX

+	ALLERGAN	20%	N020428	001	Sep 13, 1995

GEL;TOPICAL
FINACEA

+	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002

AZELASTINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
AZELASTINE HYDROCHLORIDE

AT	AKORN	**0.05%**	**A203660**	**001**	Nov 08, 2016
AT	ALCON PHARMA	**0.05%**	**A202305**	**001**	May 31, 2012
AT	APOTEX INC	**0.05%**	**A078621**	**001**	Aug 03, 2009
AT	SUN PHARMA GLOBAL	**0.05%**	**A078738**	**001**	Jun 21, 2010

OPTIVAR

AT	**+** MEDA PHARMS	**0.05%**	**N021127**	**001**	May 22, 2000

SPRAY, METERED;NASAL
ASTELIN

AB	**+** MEDA PHARMS	**EQ 0.125MG BASE/SPRAY**	**N020114**	**001**	Nov 01, 1996

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

	ASTEPRO				
AB	**+** MEDA PHARMS	**EQ 0.1876MG BASE/SPRAY**	**N022203**	**002**	Aug 31, 2009
	AZELASTINE HYDROCHLORIDE				
AB	APOTEX INC	**EQ 0.125MG BASE/SPRAY**	**A077954**	**001**	Apr 30, 2009
AB		**EQ 0.1876MG BASE/SPRAY**	**A201846**	**001**	Aug 31, 2012
AB	BRECKENRIDGE PHARMS	**EQ 0.125MG BASE/SPRAY**	**A090176**	**001**	Jul 28, 2015
AB	PERRIGO ISRAEL	**EQ 0.1876MG BASE/SPRAY**	**A202743**	**001**	May 08, 2014
AB	SUN PHARMA GLOBAL	**EQ 0.125MG BASE/SPRAY**	**A090423**	**001**	May 23, 2012
AB	WEST-WARD PHARMS INT	**EQ 0.125MG BASE/SPRAY**	**A091444**	**001**	Oct 24, 2014

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

	DYMISTA				
	+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

	EDARBI				
	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011
	+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

	EDARBYCLOR				
	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011
	+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

	AZITHROMYCIN				
AB	PLIVA	**EQ 100MG BASE/5ML**	**A065246**	**002**	Jul 05, 2006
AB		**EQ 200MG BASE/5ML**	**A065246**	**001**	Jul 05, 2006
AB	TEVA PHARMS	**EQ 100MG BASE/5ML**	**A065419**	**001**	Jun 24, 2008
AB		**EQ 200MG BASE/5ML**	**A065419**	**002**	Jun 24, 2008
	ZITHROMAX				
AB	PFIZER	**EQ 100MG BASE/5ML**	**N050710**	**001**	Oct 19, 1995
AB	**+**	**EQ 200MG BASE/5ML**	**N050710**	**002**	Oct 19, 1995
	AZITHROMYCIN				
BX	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015
BX		EQ 200MG BASE/5ML	A065488	002	May 15, 2015
	ZITHROMAX				
	+ PFIZER	EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE;ORAL

	ZMAX				
	+ PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005

INJECTABLE;INJECTION

	AZITHROMYCIN				
AP	AUROBINDO PHARMA LTD	**EQ 500MG BASE/VIAL**	**A203294**	**001**	Jun 19, 2015
AP	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A065179**	**001**	Dec 13, 2005
AP	GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A065501**	**001**	Nov 09, 2009
AP	HOSPIRA	**EQ 500MG BASE/VIAL**	**A065500**	**001**	Jun 26, 2009
AP		**EQ 500MG BASE/VIAL**	**A065511**	**001**	Jun 26, 2009
AP	SAGENT STRIDES	**EQ 500MG BASE/VIAL**	**A065506**	**001**	Mar 24, 2009
AP	SUN PHARM INDS LTD	**EQ 500MG BASE/VIAL**	**A090923**	**001**	Apr 02, 2013
	ZITHROMAX				
AP	**+** PFIZER	**EQ 500MG BASE/VIAL**	**N050733**	**001**	Jan 30, 1997

SOLUTION/DROPS;OPHTHALMIC

	AZASITE				
	+ OAK PHARMS INC	1%	N050810	001	Apr 27, 2007

TABLET;ORAL

	AZITHROMYCIN				
AB	APOTEX CORP	**EQ 250MG BASE**	**A065507**	**001**	Jul 13, 2011
AB		**EQ 500MG BASE**	**A065509**	**001**	Jul 13, 2011
AB		**EQ 600MG BASE**	**A065508**	**001**	Jul 13, 2011
AB	LUPIN LTD	**EQ 250MG BASE**	**A065398**	**001**	May 15, 2015
AB		**EQ 500MG BASE**	**A065399**	**001**	May 15, 2015
AB		**EQ 600MG BASE**	**A065400**	**001**	May 15, 2015
AB	MYLAN	**EQ 250MG BASE**	**A065365**	**001**	May 30, 2007
AB		**EQ 500MG BASE**	**A065366**	**001**	May 30, 2007
AB		**EQ 600MG BASE**	**A065360**	**001**	Jan 08, 2007
AB	PLIVA	**EQ 250MG BASE**	**A065225**	**001**	Nov 14, 2005
AB		**EQ 500MG BASE**	**A065223**	**001**	Nov 14, 2005

FDA data supplied by DrugPatentWatch.com

AZITHROMYCIN
TABLET;ORAL

	AZITHROMYCIN				
AB		**EQ 600MG BASE**	**A065218**	**001**	Nov 14, 2005
AB	SANDOZ	**EQ 250MG BASE**	**A065211**	**001**	Nov 14, 2005
AB		**EQ 500MG BASE**	**A065212**	**001**	Nov 14, 2005
AB		**EQ 600MG BASE**	**A065209**	**001**	Nov 14, 2005
AB	TEVA	**EQ 250MG BASE**	**A065153**	**001**	Nov 14, 2005
AB		**EQ 500MG BASE**	**A065193**	**001**	Nov 14, 2005
AB		**EQ 600MG BASE**	**A065150**	**001**	Nov 14, 2005
AB	WOCKHARDT	**EQ 250MG BASE**	**A065404**	**001**	Feb 11, 2008
AB		**EQ 500MG BASE**	**A065405**	**001**	Feb 11, 2008
AB		**EQ 600MG BASE**	**A065302**	**003**	Feb 11, 2008
	ZITHROMAX				
AB	PFIZER	**EQ 250MG BASE**	**N050711**	**001**	Jul 18, 1996
AB		**EQ 500MG BASE**	**N050784**	**001**	May 24, 2002
AB +		**EQ 600MG BASE**	**N050730**	**001**	Jun 12, 1996

AZTREONAM
FOR SOLUTION;INHALATION

	CAYSTON				
+	GILEAD	75MG/VIAL	N050814	001	Feb 22, 2010

INJECTABLE;INJECTION

	AZACTAM				
AP +	BRISTOL MYERS SQUIBB	**1GM/VIAL**	**N050580**	**002**	Dec 31, 1986
AP +		**2GM/VIAL**	**N050580**	**003**	Dec 31, 1986
	AZTREONAM				
AP	FRESENIUS KABI USA	**1GM/VIAL**	**A065439**	**002**	Jun 18, 2010
AP		**2GM/VIAL**	**A065439**	**003**	Jun 18, 2010
	AZACTAM IN PLASTIC CONTAINER				
+	BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989
+		40MG/ML	N050632	001	May 24, 1989
	AZTREONAM				
	FRESENIUS KABI USA	500MG/VIAL	A065439	001	Jun 18, 2010

BACITRACIN
INJECTABLE;INJECTION

	BACIIM				
AP	X GEN PHARMS	**50,000 UNITS/VIAL**	**A064153**	**001**	May 09, 1997
	BACITRACIN				
AP	FRESENIUS KABI USA	**50,000 UNITS/VIAL**	**A065116**	**001**	Dec 03, 2002
AP +	PHARMACIA AND UPJOHN	**50,000 UNITS/VIAL**	**A060733**	**002**	
AP	SAGENT STRIDES	**50,000 UNITS/VIAL**	**A090211**	**001**	May 11, 2010
AP	XELLIA PHARMS APS	**50,000 UNITS/VIAL**	**A203177**	**001**	Aug 25, 2014
	PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001	

OINTMENT;OPHTHALMIC

	BACITRACIN				
+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT;OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE				
AT	AKORN	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A065213**	**001**	Jul 25, 2012
AT +	BAUSCH AND LOMB	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064068**	**001**	Oct 30, 1995

OINTMENT;TOPICAL

	CORTISPORIN				
+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT;OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC				
AT	AKORN	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A065088**	**001**	Feb 06, 2004
AT +	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064064**	**001**	Oct 30, 1995
AT	PERRIGO CO TENNESSEE	**400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM**	**A060764**	**002**	

FDA data supplied by DrugPatentWatch.com

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	**500 UNITS/GM;10,000 UNITS/GM**	**A064028**	**001**	Jan 30, 1995
AT	+	BAUSCH AND LOMB	**500 UNITS/GM;10,000 UNITS/GM**	**A064046**	**001**	Jan 26, 1995
AT		PERRIGO CO TENNESSEE	**500 UNITS/GM;10,000 UNITS/GM**	**A065022**	**001**	Feb 27, 2002

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+	PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP		SINTETICA SA	**0.05MG/ML**	**A091193**	**001**	May 03, 2016
AP			**0.5MG/ML**	**A091193**	**002**	May 03, 2016
AP			**2MG/ML**	**A091193**	**003**	May 03, 2016

GABLOFEN

AP		MALLINCKRODT INC	**0.05MG/ML**	**N022462**	**001**	Nov 19, 2010
AP			**0.5MG/ML**	**N022462**	**002**	Nov 19, 2010
AP			**2MG/ML**	**N022462**	**003**	Nov 19, 2010

LIORESAL

AP	+	SAOL THERAPS RES LTD	**0.05MG/ML**	**N020075**	**003**	Nov 07, 1996
AP	+		**0.5MG/ML**	**N020075**	**001**	Jun 17, 1992
AP	+		**2MG/ML**	**N020075**	**002**	Jun 17, 1992

GABLOFEN

		MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012

TABLET;ORAL

BACLOFEN

AB		CARACO	**10MG**	**A077984**	**001**	Aug 14, 2006
AB		IMPAX LABS	**10MG**	**A077971**	**001**	Oct 26, 2007
AB			**20MG**	**A077971**	**002**	Oct 26, 2007
AB		IVAX SUB TEVA PHARMS	**10MG**	**A072234**	**001**	Jul 21, 1988
AB	+		**20MG**	**A072235**	**001**	Jul 21, 1988
AB		LANNETT	**10MG**	**A077241**	**002**	Jul 06, 2007
AB			**20MG**	**A077241**	**001**	Dec 20, 2005
AB		MYLAN	**10MG**	**A077181**	**001**	Jul 29, 2005
AB			**20MG**	**A077121**	**002**	Jul 29, 2005
AB		MYLAN PHARMS INC	**10MG**	**A090334**	**001**	Feb 18, 2010
AB			**20MG**	**A090334**	**002**	Feb 18, 2010
AB		NORTHSTAR HLTHCARE	**10MG**	**A078401**	**002**	Sep 18, 2009
AB			**20MG**	**A078401**	**001**	Sep 18, 2009
AB		OXFORD PHARMS	**10MG**	**A077089**	**001**	Oct 31, 2007
AB			**20MG**	**A077088**	**001**	Oct 31, 2007
AB		SUN PHARM INDS INC	**20MG**	**A077862**	**002**	Aug 14, 2006
AB		USL PHARMA	**10MG**	**A074584**	**001**	Aug 19, 1996
AB			**20MG**	**A074584**	**002**	Aug 19, 1996
AB		VINTAGE PHARMS	**10MG**	**A077156**	**001**	Aug 30, 2005
AB			**20MG**	**A077068**	**001**	Aug 30, 2005

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		APOTEX INC	**750MG**	**A077883**	**001**	Dec 28, 2007
AB		MYLAN	**750MG**	**A077807**	**001**	Dec 28, 2007
AB		WEST-WARD PHARMS INT	**750MG**	**A077806**	**001**	Dec 28, 2007

COLAZAL

AB	+	VALEANT PHARMS INTL	**750MG**	**N020610**	**001**	Jul 18, 2000

TABLET;ORAL

BALSALAZIDE DISODIUM

AB		PAR PHARM INC	**1.1GM**	**A206336**	**001**	Sep 08, 2015

GIAZO

AB	+	VALEANT PHARMS INTL	**1.1GM**	**N022205**	**001**	Feb 03, 2012

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

	+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016

PASTE;ORAL

VARIBAR

	+	BRACCO	40% (92GM/230ML)	N208844	001	Oct 14, 2016

BARIUM SULFATE
SUSPENSION;ORAL
READI-CAT 2
+ BRACCO 2% (9GM/450ML) N208143 001 Jan 15, 2016
READI-CAT 2 SMOOTHIES
BRACCO 2% (9GM/450ML) N208143 002 Jan 15, 2016

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
TABLET;ORAL
DUAVEE
+ WYETH PHARMS PFIZER EQ 20MG BASE;0.45MG N022247 001 Oct 03, 2013

BECLOMETHASONE DIPROPIONATE
AEROSOL, METERED;INHALATION
QVAR 40
+ TEVA BRANDED PHARM 0.04MG/INH N020911 002 Sep 15, 2000
QVAR 80
+ TEVA BRANDED PHARM 0.08MG/INH N020911 001 Sep 15, 2000
AEROSOL, METERED;NASAL
QNASL
TEVA BRANDED PHARM 0.04MG/ACTUATION N202813 002 Dec 17, 2014
+ 0.08MG/ACTUATION N202813 001 Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE
SPRAY, METERED;NASAL
BECONASE AQ
+ GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY N019389 001 Jul 27, 1987

BEDAQUILINE FUMARATE
TABLET;ORAL
SIRTURO
+ JANSSEN THERAP EQ 100MG BASE N204384 001 Dec 28, 2012

BELINOSTAT
POWDER;IV (INFUSION)
BELEODAQ
+ SPECTRUM PHARMS 500MG/VIAL N206256 001 Jul 03, 2014

BENAZEPRIL HYDROCHLORIDE
TABLET;ORAL
BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	**5MG**	**A076820**	**001**	Feb 03, 2006
AB		**10MG**	**A076820**	**002**	Feb 03, 2006
AB		**20MG**	**A076820**	**003**	Feb 03, 2006
AB		**40MG**	**A076820**	**004**	Feb 03, 2006
AB	APOTEX INC	**5MG**	**A077128**	**001**	Mar 08, 2006
AB		**10MG**	**A077128**	**002**	Mar 08, 2006
AB		**20MG**	**A077128**	**003**	Mar 08, 2006
AB		**40MG**	**A077128**	**004**	Mar 08, 2006
AB	AUROBINDO PHARMA	**10MG**	**A078212**	**001**	May 22, 2008
AB		**20MG**	**A078212**	**002**	May 22, 2008
AB		**40MG**	**A078212**	**003**	May 22, 2008
AB	IVAX SUB TEVA PHARMS	**5MG**	**A076333**	**001**	Feb 11, 2004
AB		**10MG**	**A076333**	**002**	Feb 11, 2004
AB		**20MG**	**A076333**	**003**	Feb 11, 2004
AB		**40MG**	**A076333**	**004**	Feb 11, 2004
AB	MYLAN	**5MG**	**A076430**	**001**	Feb 11, 2004
AB		**10MG**	**A076430**	**002**	Feb 11, 2004
AB		**20MG**	**A076430**	**003**	Feb 11, 2004
AB		**40MG**	**A076430**	**004**	Feb 11, 2004
AB	PRINSTON INC	**5MG**	**A076118**	**001**	Feb 11, 2004
AB		**10MG**	**A076118**	**002**	Feb 11, 2004
AB		**20MG**	**A076118**	**003**	Feb 11, 2004
AB		**40MG**	**A076118**	**004**	Feb 11, 2004
AB	SANDOZ	**5MG**	**A076402**	**001**	Feb 11, 2004
AB		**10MG**	**A076402**	**002**	Feb 11, 2004
AB		**20MG**	**A076402**	**003**	Feb 11, 2004
AB		**40MG**	**A076402**	**004**	Feb 11, 2004
AB	SUN PHARM INDS LTD	**5MG**	**A076344**	**001**	Feb 11, 2004
AB		**10MG**	**A076344**	**002**	Feb 11, 2004
AB		**20MG**	**A076344**	**003**	Feb 11, 2004
AB		**40MG**	**A076344**	**004**	Feb 11, 2004
AB	TEVA	**5MG**	**A076211**	**001**	Feb 11, 2004
AB		**10MG**	**A076211**	**002**	Feb 11, 2004
AB		**20MG**	**A076211**	**003**	Feb 11, 2004

FDA data supplied by DrugPatentWatch.com

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

	BENAZEPRIL HYDROCHLORIDE				
AB		**40MG**	**A076211**	**004**	Feb 11, 2004
AB	ZYDUS PHARMS USA	**5MG**	**A078848**	**001**	May 23, 2008
AB		**10MG**	**A078848**	**002**	May 23, 2008
AB		**20MG**	**A078848**	**003**	May 23, 2008
AB		**40MG**	**A078848**	**004**	May 23, 2008
	LOTENSIN				
AB	US PHARMS HOLDINGS I	**5MG**	**N019851**	**001**	Jun 25, 1991
AB		**10MG**	**N019851**	**002**	Jun 25, 1991
AB		**20MG**	**N019851**	**003**	Jun 25, 1991
AB	**+**	**40MG**	**N019851**	**004**	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

	BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
AB	APOTEX INC	**5MG;6.25MG**	**A078794**	**001**	Aug 21, 2014
AB		**10MG;12.5MG**	**A078794**	**002**	Aug 21, 2014
AB		**20MG;12.5MG**	**A078794**	**003**	Aug 21, 2014
AB		**20MG;25MG**	**A078794**	**004**	Aug 21, 2014
AB	MYLAN	**5MG;6.25MG**	**A076688**	**001**	Feb 11, 2004
AB		**10MG;12.5MG**	**A076688**	**002**	Feb 11, 2004
AB		**20MG;12.5MG**	**A076688**	**003**	Feb 11, 2004
AB		**20MG;25MG**	**A076688**	**004**	Feb 11, 2004
AB	SANDOZ	**5MG;6.25MG**	**A076631**	**001**	Feb 11, 2004
AB		**10MG;12.5MG**	**A076631**	**002**	Feb 11, 2004
AB		**20MG;12.5MG**	**A076631**	**003**	Feb 11, 2004
AB		**20MG;25MG**	**A076631**	**004**	Feb 11, 2004
	LOTENSIN HCT				
AB	US PHARMS HOLDINGS I	**5MG;6.25MG**	**N020033**	**001**	May 19, 1992
AB		**10MG;12.5MG**	**N020033**	**002**	May 19, 1992
AB		**20MG;12.5MG**	**N020033**	**004**	May 19, 1992
AB	**+**	**20MG;25MG**	**N020033**	**003**	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

	BENDAMUSTINE HYDROCHLORIDE				
AP	ACCORD HLTHCARE	**25MG/VIAL**	**A205574**	**001**	May 19, 2016
AP		**100MG/VIAL**	**A205574**	**002**	May 19, 2016
AP	BRECKENRIDGE PHARM	**25MG/VIAL**	**A205447**	**001**	Dec 29, 2016
AP		**100MG/VIAL**	**A205447**	**002**	Dec 29, 2016
AP	GLENMARK PHARMS LTD	**25MG/VIAL**	**A204771**	**001**	Mar 24, 2016
AP		**100MG/VIAL**	**A204771**	**002**	Mar 24, 2016
AP	HOSPIRA INC	**25MG/VIAL**	**A204086**	**001**	May 20, 2016
AP		**100MG/VIAL**	**A204086**	**002**	May 20, 2016
AP	INNOPHARMA LICENSING	**25MG/VIAL**	**A205476**	**001**	Mar 24, 2016
AP		**100MG/VIAL**	**A205476**	**002**	Mar 24, 2016
	TREANDA				
AP	**+** CEPHALON	**25MG/VIAL**	**N022249**	**002**	May 01, 2009
AP	**+**	**100MG/VIAL**	**N022249**	**001**	Mar 20, 2008

SOLUTION;IV (INFUSION)

	BENDEKA				
	+ EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015
	TREANDA				
	+ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013
	+	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

	CORZIDE				
AB	KING PHARMS	**5MG;40MG**	**N018647**	**001**	May 25, 1983
AB	**+**	**5MG;80MG**	**N018647**	**002**	May 25, 1983
	NADOLOL AND BENDROFLUMETHIAZIDE				
AB	IMPAX LABS	**5MG;40MG**	**A077833**	**001**	Mar 30, 2007
AB		**5MG;80MG**	**A077833**	**002**	Mar 30, 2007
AB	MYLAN	**5MG;40MG**	**A078688**	**001**	Feb 15, 2008
AB		**5MG;80MG**	**A078688**	**002**	Feb 15, 2008

FDA data supplied by DrugPatentWatch.com

BENZONATATE
CAPSULE;ORAL

		BENZONATATE				
AA		APOTEX INC	**100MG**	**A091310**	**001**	Jan 16, 2015
AA			**200MG**	**A091310**	**002**	Jan 16, 2015
AA		BIONPHARMA INC	**100MG**	**A081297**	**001**	Jan 29, 1993
AA			**200MG**	**A081297**	**002**	Oct 30, 2007
AA		CSPC NBP PHARM CO	**200MG**	**A202765**	**001**	Jul 31, 2015
AA		MIKART	**100MG**	**A040851**	**001**	Nov 09, 2009
AA			**150MG**	**A040851**	**002**	Nov 09, 2009
AA			**200MG**	**A040851**	**003**	Nov 09, 2009
AA		ORIT LABS LLC	**100MG**	**A040682**	**001**	Jul 30, 2007
AA			**200MG**	**A040682**	**002**	Jul 30, 2007
AA		STRIDES PHARMA	**100MG**	**A091133**	**001**	Jul 30, 2015
AA			**200MG**	**A091133**	**002**	Jul 30, 2015
AA		SUN PHARM INDS INC	**100MG**	**A040587**	**001**	Mar 19, 2008
AA			**200MG**	**A040587**	**002**	Mar 19, 2008
AA	+	THE PHARMA NETWORK	**100MG**	**A040627**	**001**	Mar 30, 2007
AA	+		**200MG**	**A040749**	**001**	Jul 25, 2007
AA	+	THEPHARMANETWORK LLC	**150MG**	**A201209**	**001**	Sep 24, 2014
AA		ZYDUS PHARMS USA	**100MG**	**A040597**	**001**	Jun 08, 2007
AA			**200MG**	**A040597**	**002**	Jun 08, 2007
		TESSALON				
AA		PFIZER	**100MG**	**N011210**	**001**	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE
GEL;TOPICAL

		ACANYA				
AB	+	DOW PHARM	**2.5%;EQ 1.2% BASE**	**N050819**	**001**	Oct 23, 2008
		BENZACLIN				
AB	+	VALEANT BERMUDA	**5%;EQ 1% BASE**	**N050756**	**001**	Dec 21, 2000
		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE				
AB		ACTAVIS LABS UT INC	**2.5%;EQ 1.2% BASE**	**A205128**	**001**	Jun 19, 2015
AB		MYLAN PHARMS INC	**5%;EQ 1% BASE**	**A065443**	**001**	Aug 11, 2009
AB		PERRIGO ISRAEL	**5%;EQ 1% BASE**	**A202440**	**001**	Sep 21, 2015
AB			**5%;1.2%**	**A090979**	**001**	Jun 26, 2012
AB		TOLMAR	**5%;1.2%**	**A203688**	**001**	Aug 25, 2016
		DUAC				
AB	+	STIEFEL	**5%;1.2%**	**N050741**	**001**	Aug 26, 2002
		ONEXTON				
	+	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN
GEL;TOPICAL

		BENZAMYCIN				
AB	+	VALEANT INTL	**5%;3%**	**N050557**	**001**	Oct 26, 1984
		ERYTHROMYCIN AND BENZOYL PEROXIDE				
AB		LYNE	**5%;3%**	**A065385**	**001**	Sep 18, 2015
AB		TOLMAR	**5%;3%**	**A065112**	**001**	Mar 29, 2004
		AKTIPAK				
	+	CUTANEA	5%;3%	N050769	001	Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE
TABLET;ORAL

		BENZPHETAMINE HYDROCHLORIDE				
AA		EMCURE PHARMS LTD	**50MG**	**A202061**	**001**	Jan 27, 2012
AA		EPIC PHARMA LLC	**50MG**	**A090346**	**001**	Dec 15, 2015
AA	+	KVK TECH	**50MG**	**A090968**	**001**	Jul 20, 2010
AA		MALLINCKRODT INC	**50MG**	**A040773**	**001**	Apr 25, 2007
AA		MIKART	**25MG**	**A090473**	**001**	Sep 15, 2010
AA			**50MG**	**A090473**	**002**	Sep 15, 2010
AA		PADDOCK	**50MG**	**A040578**	**001**	Apr 17, 2006
AA		TEDOR PHARM	**25MG**	**A040747**	**002**	Nov 20, 2015
AA			**50MG**	**A040747**	**001**	Mar 30, 2007

BENZTROPINE MESYLATE
INJECTABLE;INJECTION

		BENZTROPINE MESYLATE				
AP		FRESENIUS KABI USA	**1MG/ML**	**A090233**	**001**	Jul 28, 2009
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A090287**	**001**	Aug 31, 2009
AP		LUITPOLD	**1MG/ML**	**A091152**	**001**	Mar 29, 2010
AP		NAVINTA LLC	**1MG/ML**	**A091525**	**001**	Feb 05, 2013
		COGENTIN				
AP	+	OAK PHARMS AKORN	**1MG/ML**	**N012015**	**001**	

BENZTROPINE MESYLATE
TABLET;ORAL
BENZTROPINE MESYLATE

AA		ASPEN GLOBAL INC	**0.5MG**	**A204713**	**001**	Apr 14, 2015
AA			**1MG**	**A204713**	**002**	Apr 14, 2015
AA			**2MG**	**A204713**	**003**	Apr 14, 2015
AA		COREPHARMA	**0.5MG**	**A072264**	**001**	Feb 27, 1989
AA			**1MG**	**A072265**	**001**	Feb 27, 1989
AA			**2MG**	**A072266**	**001**	Feb 27, 1989
AA		INVAGEN PHARMS	**0.5MG**	**A090294**	**001**	Mar 29, 2010
AA			**1MG**	**A090294**	**002**	Mar 29, 2010
AA			**2MG**	**A090294**	**003**	Mar 29, 2010
AA		LEADING PHARMA LLC	**0.5MG**	**A090168**	**001**	Nov 28, 2012
AA			**1MG**	**A090168**	**002**	Nov 28, 2012
AA			**2MG**	**A090168**	**003**	Nov 28, 2012
AA		PLIVA	**0.5MG**	**A089058**	**001**	Aug 10, 1988
AA			**1MG**	**A089059**	**001**	Aug 10, 1988
AA			**2MG**	**A089060**	**001**	Aug 10, 1988
AA	+	USL PHARMA	**0.5MG**	**A040103**	**001**	Dec 12, 1996
AA	+		**1MG**	**A040103**	**002**	Dec 12, 1996
AA	+		**2MG**	**A040103**	**003**	Dec 12, 1996
AA		VINTAGE	**0.5MG**	**A040715**	**001**	Aug 27, 2007
AA			**1MG**	**A040715**	**002**	Aug 27, 2007
AA			**2MG**	**A040715**	**003**	Aug 27, 2007

BENZYL ALCOHOL
LOTION;TOPICAL
ULESFIA

+	SHIONOGI INC	5%	N022129	001	Apr 09, 2009

BENZYLPENICILLOYL POLYLYSINE
INJECTABLE;INJECTION
PRE-PEN

+	ALLERQUEST	60UMOLAR	N050114	001

BEPOTASTINE BESILATE
SOLUTION/DROPS;OPHTHALMIC
BEPREVE

+	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009

BERACTANT
SUSPENSION;INTRATRACHEAL
SURVANTA

+	ABBVIE	25MG/ML	N020032	001	Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE
SUSPENSION/DROPS;OPHTHALMIC
BESIVANCE

+	BAUSCH AND LOMB	EQ 0.6% BASE	N022308	001	May 28, 2009

BETAINE HYDROCHLORIDE
FOR SOLUTION;ORAL
CYSTADANE

+	RARE DIS THERAP	1GM/SCOOPFUL	N020576	001	Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
INJECTABLE;INJECTION
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB		LUITPOLD	**3MG/ML;EQ 3MG BASE/ML**	**A090747**	**001**	Jul 31, 2009

CELESTONE SOLUSPAN

AB	+	MERCK SHARP DOHME	**3MG/ML;EQ 3MG BASE/ML**	**N014602**	**001**	

BETAMETHASONE DIPROPIONATE
CREAM;TOPICAL
BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A070885**	**001**	Feb 03, 1987
AB	+	FOUGERA PHARMS	**EQ 0.05% BASE**	**N019137**	**001**	Jun 26, 1984
AB		TARO	**EQ 0.05% BASE**	**A073552**	**001**	Apr 30, 1992

CREAM, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A076215**	**001**	Dec 09, 2003
AB		GLENMARK GENERICS	**EQ 0.05% BASE**	**A078930**	**001**	Sep 23, 2008
AB		PERRIGO NEW YORK	**EQ 0.05% BASE**	**A076592**	**001**	Dec 09, 2003
AB		TARO	**EQ 0.05% BASE**	**A076543**	**001**	Dec 09, 2003
AB		TOLMAR	**EQ 0.05% BASE**	**A076603**	**001**	Jan 23, 2004

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

DIPROLENE AF

AB	+	MERCK SHARP DOHME	**EQ 0.05% BASE**	**N019555**	**001**	Apr 27, 1987

GEL, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	**EQ 0.05% BASE**	**A075276**	**001**	May 13, 2003
AB		TARO	**EQ 0.05% BASE**	**A076508**	**001**	Dec 02, 2003

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A070281**	**001**	Jul 31, 1985
AB	+	FOUGERA	**EQ 0.05% BASE**	**A070275**	**001**	Aug 12, 1985
AB		G AND W LABS INC	**EQ 0.05% BASE**	**A071467**	**001**	Aug 10, 1987
AB		PERRIGO NEW YORK	**EQ 0.05% BASE**	**A072538**	**001**	Jan 31, 1990

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A077111**	**001**	May 21, 2007
AB		TARO	**EQ 0.05% BASE**	**A077477**	**001**	May 21, 2007

DIPROLENE

AB	+	MERCK SHARP DOHME	**EQ 0.05% BASE**	**N019716**	**001**	Aug 01, 1988

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A071012**	**001**	Feb 03, 1987
AB	+	FOUGERA	**EQ 0.05% BASE**	**N019141**	**001**	Sep 04, 1984
AB		TARO	**EQ 0.05% BASE**	**A074271**	**001**	Sep 15, 1994

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A074304**	**001**	Aug 31, 1995
AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A075373**	**001**	Jun 22, 1999
AB		TARO	**EQ 0.05% BASE**	**A076753**	**001**	Oct 12, 2004

DIPROLENE

AB	+	MERCK SHARP DOHME	**EQ 0.05% BASE**	**N018741**	**001**	Jul 27, 1983

SPRAY;TOPICAL

SERNIVO

	+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

ENSTILAR

	+	LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		PERRIGO ISRAEL	**0.064%;0.005%**	**A200174**	**001**	Dec 12, 2014
AB		TOLMAR	**0.064%;0.005%**	**A201615**	**001**	Jan 14, 2013

TACLONEX

AB	+	LEO PHARMA AS	**0.064%;0.005%**	**N021852**	**001**	Jan 09, 2006

SUSPENSION;TOPICAL

TACLONEX

	+	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE;1%**	**A076002**	**001**	Aug 02, 2002
AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A075502**	**001**	Jun 05, 2001
AB		GLENMARK PHARMS	**EQ 0.05% BASE;1%**	**A202894**	**001**	Oct 30, 2015
AB		TARO	**EQ 0.05% BASE;1%**	**A075673**	**001**	May 29, 2001

LOTRISONE

AB	+	MERCK SHARP DOHME	**EQ 0.05% BASE;1%**	**N018827**	**001**	Jul 10, 1984

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A076516**	**001**	Jun 16, 2005
AB		TARO	**EQ 0.05% BASE;1%**	**A076493**	**001**	Jul 28, 2004

LOTRISONE

AB	+	MERCK SHARP DOHME	**EQ 0.05% BASE;1%**	**N020010**	**001**	Dec 08, 2000

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

	BETAMETHASONE VALERATE				
AB	PERRIGO	**0.12%**	**A078337**	**001**	Nov 26, 2012
	LUXIQ				
AB	+ DELCOR ASSET CORP	**0.12%**	**N020934**	**001**	Feb 28, 1999

CREAM;TOPICAL

	BETA-VAL				
AB	G AND W LABS INC	**EQ 0.1% BASE**	**N018642**	**001**	Mar 24, 1983
	BETAMETHASONE VALERATE				
AB	+ FOUGERA	**EQ 0.1% BASE**	**N018861**	**001**	Aug 31, 1983
	DERMABET				
AB	TARO	**EQ 0.1% BASE**	**A072041**	**001**	Jan 06, 1988
	VALNAC				
AB	ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070050**	**001**	Oct 10, 1984

LOTION;TOPICAL

	BETA-VAL				
AB	G AND W LABS INC	**EQ 0.1% BASE**	**A070072**	**001**	Jun 27, 1985
	BETAMETHASONE VALERATE				
AB	+ FOUGERA	**EQ 0.1% BASE**	**N018866**	**001**	Aug 31, 1983
AB	STI PHARMA LLC	**EQ 0.1% BASE**	**A070052**	**001**	Jul 31, 1985

OINTMENT;TOPICAL

	BETA-VAL				
AB	G AND W LABS INC	**EQ 0.1% BASE**	**A070069**	**001**	Dec 19, 1985
	BETAMETHASONE VALERATE				
AB	ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070051**	**001**	Oct 10, 1984
AB	+ FOUGERA	**EQ 0.1% BASE**	**N018865**	**001**	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

	BETAXOLOL HYDROCHLORIDE				
AT	AKORN	**EQ 0.5% BASE**	**A075386**	**001**	Jun 30, 2000
AT	TELIGENT PHARMA INC	**EQ 0.5% BASE**	**A075630**	**001**	Apr 12, 2001
AT	WOCKHARDT	**EQ 0.5% BASE**	**A078694**	**001**	Nov 16, 2009
	BETOPTIC				
AT	+ ALCON	**EQ 0.5% BASE**	**N019270**	**001**	Aug 30, 1985

SUSPENSION/DROPS;OPHTHALMIC

	BETOPTIC S				
	+ NOVARTIS PHARMS CORP	EQ 0.25% BASE	N019845	001	Dec 29, 1989

TABLET;ORAL

	BETAXOLOL HYDROCHLORIDE				
AB	EPIC PHARMA	**10MG**	**A075541**	**001**	Oct 22, 1999
AB	+	**20MG**	**A075541**	**002**	Oct 22, 1999
AB	KVK TECH	**10MG**	**A078962**	**001**	Jun 27, 2008
AB		**20MG**	**A078962**	**002**	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET;ORAL

	BETHANECHOL CHLORIDE				
AA	AMNEAL PHARM	**5MG**	**A040855**	**001**	Nov 21, 2007
AA		**10MG**	**A040855**	**002**	Nov 21, 2007
AA		**25MG**	**A040855**	**003**	Nov 21, 2007
AA		**50MG**	**A040855**	**004**	Nov 21, 2007
AA	HERITAGE PHARMA	**5MG**	**A091256**	**001**	May 04, 2010
AA		**10MG**	**A091256**	**002**	May 04, 2010
AA		**25MG**	**A091256**	**003**	May 04, 2010
AA		**50MG**	**A091256**	**004**	May 04, 2010
AA	LANNETT	**10MG**	**A040704**	**001**	Mar 27, 2008
AA		**25MG**	**A040678**	**003**	Mar 27, 2008
AA	LANNETT HOLDINGS INC	**5MG**	**A040703**	**001**	Mar 27, 2008
AA		**50MG**	**A040677**	**001**	Mar 27, 2008
AA	PHARMAX	**5MG**	**A040725**	**001**	Oct 26, 2007
AA		**10MG**	**A040726**	**001**	Oct 26, 2007
AA		**25MG**	**A040727**	**001**	Oct 26, 2007
AA		**50MG**	**A040728**	**001**	Oct 26, 2007
AA	UPSHER SMITH	**5MG**	**A040633**	**001**	Jun 01, 2005
AA		**10MG**	**A040634**	**001**	Jun 01, 2005
AA		**25MG**	**A040635**	**001**	Jun 01, 2005
AA		**50MG**	**A040636**	**001**	Jun 01, 2005
AA	WOCKHARDT	**5MG**	**A040532**	**001**	Sep 29, 2003
AA		**10MG**	**A040533**	**001**	Sep 29, 2003
AA		**25MG**	**A040534**	**001**	Sep 29, 2003
AA		**50MG**	**A040518**	**001**	Sep 29, 2003

FDA data supplied by DrugPatentWatch.com

BETHANECHOL CHLORIDE
TABLET;ORAL

	DUVOID					
AA		BI-COASTAL PHARMA	**10MG**	**A086262**	**001**	
AA			**25MG**	**A086263**	**001**	
AA			**50MG**	**A085882**	**003**	
	URECHOLINE					
AA	+	ODYSSEY PHARMS	**5MG**	**A089095**	**001**	Dec 19, 1985
AA	+		**10MG**	**A088440**	**001**	May 29, 1984
AA	+		**25MG**	**A088441**	**001**	May 29, 1984
AA	+		**50MG**	**A089096**	**001**	Dec 19, 1985

BEXAROTENE
CAPSULE;ORAL

	BEXAROTENE					
AB		BIONPHARMA INC	**75MG**	**A203174**	**001**	Aug 12, 2014
	TARGRETIN					
AB	+	VALEANT LUXEMBOURG	**75MG**	**N021055**	**001**	Dec 29, 1999
GEL;TOPICAL						
	TARGRETIN					
	+	VALEANT LUXEMBOURG	1%	N021056	001	Jun 28, 2000

BICALUTAMIDE
TABLET;ORAL

	BICALUTAMIDE					
AB		ACCORD HLTHCARE	**50MG**	**A078917**	**001**	Jul 06, 2009
AB		ACTAVIS TOTOWA	**50MG**	**A078634**	**001**	Aug 28, 2009
AB		APOTEX INC	**50MG**	**A200274**	**001**	May 21, 2015
AB		FRESENIUS KABI ONCOL	**50MG**	**A079045**	**001**	May 13, 2010
AB		MYLAN	**50MG**	**A079185**	**001**	Jul 06, 2009
AB		SANDOZ	**50MG**	**A078575**	**001**	Jul 06, 2009
AB		STASON PHARMS	**50MG**	**A091011**	**001**	Jun 10, 2015
AB		SUN PHARMA GLOBAL	**50MG**	**A079110**	**001**	Jul 06, 2009
AB		TEVA	**50MG**	**A076932**	**001**	Jul 06, 2009
AB		ZYDUS PHARMS USA INC	**50MG**	**A079089**	**001**	Jul 06, 2009
	CASODEX					
AB	+	ASTRAZENECA	**50MG**	**N020498**	**001**	Oct 04, 1995

BIMATOPROST
SOLUTION/DROPS;OPHTHALMIC

	BIMATOPROST					
AT		ALCON RES LTD	**0.03%**	**A202565**	**001**	May 05, 2015
AT		APOTEX INC	**0.03%**	**A090449**	**001**	Jul 20, 2015
AT	+	LUPIN LTD	**0.03%**	**A203991**	**001**	Feb 20, 2015
	LUMIGAN					
	+	ALLERGAN	0.01%	N022184	001	Aug 31, 2010
SOLUTION/DROPS;TOPICAL						
	BIMATOPROST					
AT		APOTEX INC	**0.03%**	**A201894**	**001**	Dec 01, 2014
AT		SANDOZ INC	**0.03%**	**A202719**	**001**	Apr 19, 2016
	LATISSE					
AT	+	ALLERGAN	**0.03%**	**N022369**	**001**	Dec 24, 2008

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

	PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL					
	+	NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM	A202217	001	Aug 20, 2014

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE
CAPSULE;ORAL

	PYLERA					
	+	FOREST LABS LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006

BISOPROLOL FUMARATE
TABLET;ORAL

	BISOPROLOL FUMARATE					
AB		AUROBINDO PHARMA	**5MG**	**A077910**	**001**	Dec 27, 2006
AB			**10MG**	**A077910**	**002**	Dec 27, 2006
AB		MYLAN	**5MG**	**A075831**	**001**	Dec 14, 2005
AB	+		**10MG**	**A075831**	**002**	Dec 14, 2005
AB		SANDOZ	**5MG**	**A075643**	**001**	Nov 16, 2000
AB			**10MG**	**A075643**	**002**	Nov 16, 2000
AB		TEVA PHARMS	**5MG**	**A075644**	**001**	Jun 26, 2001
AB			**10MG**	**A075644**	**002**	Jun 26, 2001
AB		UNICHEM PHARMS (USA)	**5MG**	**A078635**	**001**	Aug 18, 2009

FDA data supplied by DrugPatentWatch.com

BISOPROLOL FUMARATE
TABLET;ORAL
BISOPROLOL FUMARATE

AB		**10MG**	**A078635**	**002**	Aug 18, 2009

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	**2.5MG;6.25MG**	**A075768**	**001**	Sep 25, 2000
AB		**5MG;6.25MG**	**A075768**	**002**	Sep 25, 2000
AB		**10MG;6.25MG**	**A075768**	**003**	Sep 25, 2000
AB	SANDOZ	**2.5MG;6.25MG**	**A075579**	**001**	Sep 25, 2000
AB		**5MG;6.25MG**	**A075579**	**002**	Sep 25, 2000
AB		**10MG;6.25MG**	**A075579**	**003**	Sep 25, 2000
AB	UNICHEM	**2.5MG;6.25MG**	**A079106**	**001**	Jul 28, 2010
AB		**5MG;6.25MG**	**A079106**	**002**	Jul 28, 2010
AB		**10MG;6.25MG**	**A079106**	**003**	Jul 28, 2010

ZIAC

AB	TEVA WOMENS	**2.5MG;6.25MG**	**N020186**	**003**	Mar 26, 1993
AB		**5MG;6.25MG**	**N020186**	**001**	Mar 26, 1993
AB +		**10MG;6.25MG**	**N020186**	**002**	Mar 26, 1993

BIVALIRUDIN
INJECTABLE;INTRAVENOUS
ANGIOMAX

AP +	THE MEDICINES CO	**250MG/VIAL**	**N020873**	**001**	Dec 15, 2000

BIVALIRUDIN

AP	FRESENIUS KABI USA	**250MG/VIAL**	**A090189**	**001**	Oct 28, 2016
AP	HOSPIRA INC	**250MG/VIAL**	**A090811**	**001**	Jul 14, 2015
AP		**250MG/VIAL**	**A090816**	**001**	Jul 14, 2015

BLEOMYCIN SULFATE
INJECTABLE;INJECTION
BLEOMYCIN SULFATE

AP +	FRESENIUS KABI USA	**EQ 15 UNITS BASE/VIAL**	**A065185**	**001**	Jan 28, 2008
AP +		**EQ 30 UNITS BASE/VIAL**	**A065185**	**002**	Jan 28, 2008
AP	HOSPIRA	**EQ 15 UNITS BASE/VIAL**	**A065031**	**001**	Mar 10, 2000
AP		**EQ 30 UNITS BASE/VIAL**	**A065031**	**002**	Mar 10, 2000
AP	TEVA PHARMS USA	**EQ 15 UNITS BASE/VIAL**	**A065033**	**001**	Jun 27, 2000
AP		**EQ 30 UNITS BASE/VIAL**	**A065033**	**002**	Jun 27, 2000
AP	WEST-WARD PHARMS INT	**EQ 15 UNITS BASE/VIAL**	**A065042**	**002**	Oct 17, 2001
AP		**EQ 30 UNITS BASE/VIAL**	**A065042**	**001**	Oct 17, 2001

BORTEZOMIB
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
VELCADE

+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003

BOSENTAN
TABLET;ORAL
TRACLEER

	ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001
+		125MG	N021290	002	Nov 20, 2001

BOSUTINIB MONOHYDRATE
TABLET;ORAL
BOSULIF

+	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012
		EQ 500MG BASE	N203341	002	Sep 04, 2012

BREXPIPRAZOLE
TABLET;ORAL
REXULTI

	OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015
		0.5MG	N205422	002	Jul 10, 2015
		1MG	N205422	003	Jul 10, 2015
		2MG	N205422	004	Jul 10, 2015
		3MG	N205422	005	Jul 10, 2015
+		4MG	N205422	006	Jul 10, 2015

BRIMONIDINE TARTRATE
GEL;TOPICAL
MIRVASO
+ GALDERMA LABS LP EQ 0.33% BASE N204708 001 Aug 23, 2013
SOLUTION/DROPS;OPHTHALMIC
ALPHAGAN P
AT + ALLERGAN 0.15% N021262 001 Mar 16, 2001
BRIMONIDINE TARTRATE
AT AKORN **0.2% A076439 001** Mar 14, 2006
AT ALCON PHARMS LTD **0.2% A076254 001** Sep 16, 2003
AT + BAUSCH AND LOMB 0.2% A076260 001 May 28, 2003
AT INDOCO REMEDIES **0.2% A091691 001** Nov 18, 2014
AT SANDOZ **0.2% A078075 001** Jan 30, 2008
QOLIANA
AT ALCON PHARMS LTD **0.15% N021764 001** May 22, 2006
ALPHAGAN P
+ ALLERGAN 0.1% N021770 001 Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE
SUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA
+ NOVARTIS PHARMS CORP 0.2%;1% N204251 001 Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
COMBIGAN
+ ALLERGAN 0.2%;EQ 0.5% BASE N021398 001 Oct 30, 2007

BRINZOLAMIDE
SUSPENSION/DROPS;OPHTHALMIC
AZOPT
+ NOVARTIS PHARMS CORP 1% N020816 001 Apr 01, 1998

BRIVARACETAM
SOLUTION;INTRAVENOUS
BRIVIACT
+ UCB INC 50MG/5ML (10MG/ML) N205837 001 May 12, 2016
SOLUTION;ORAL
BRIVIACT
+ UCB INC 10MG/ML N205838 001 May 12, 2016
TABLET;ORAL
BRIVIACT
UCB INC 10MG N205836 001 May 12, 2016
25MG N205836 002 May 12, 2016
50MG N205836 003 May 12, 2016
75MG N205836 004 May 12, 2016
+ 100MG N205836 005 May 12, 2016

BROMFENAC SODIUM
SOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM
AT1 APOTEX INC **EQ 0.09% ACID A202435 001** Jun 19, 2014
AT1 + COASTAL PHARMS EQ 0.09% ACID A201211 001 May 11, 2011
AT1 LUITPOLD **EQ 0.09% ACID A202030 001** Jan 09, 2013
AT1 PADDOCK LLC **EQ 0.09% ACID A201941 001** Feb 10, 2015
AT2 APOTEX INC **EQ 0.09% ACID A202620 001** Jun 23, 2014
AT2 HI-TECH PHARMACAL **EQ 0.09% ACID A203395 001** Jan 22, 2014
BROMSITE
+ SUN PHARMA GLOBAL EQ 0.075% ACID N206911 001 Apr 08, 2016
PROLENSA
+ BAUSCH AND LOMB EQ 0.07% ACID N203168 001 Apr 05, 2013

BROMOCRIPTINE MESYLATE
CAPSULE;ORAL
BROMOCRIPTINE MESYLATE
AB + MYLAN EQ 5MG BASE A077226 001 Apr 04, 2005
AB ZYDUS PHARMS USA INC **EQ 5MG BASE A078899 001** Jul 30, 2008
PARLODEL
AB US PHARMS HOLDINGS I **EQ 5MG BASE N017962 002** Mar 01, 1982
TABLET;ORAL
BROMOCRIPTINE MESYLATE
AB MYLAN **EQ 2.5MG BASE A076962 001** Sep 24, 2004
AB + PADDOCK LLC EQ 2.5MG BASE A077646 001 Oct 01, 2008
AB SANDOZ INC **EQ 2.5MG BASE A074631 001** Jan 13, 1998

FDA data supplied by DrugPatentWatch.com

BROMOCRIPTINE MESYLATE

TABLET;ORAL

	PARLODEL				
AB		US PHARMS HOLDINGS I	**EQ 2.5MG BASE**	**N017962**	**001**
	CYCLOSET				
	+	VEROSCIENCE	EQ 0.8MG BASE	N020866	001 May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

	BROMFED-DM				
AA	+	WOCKHARDT	**2MG/5ML;10MG/5ML;30MG/5ML**	**A088811**	**001** Jun 07, 1985
	BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE				
AA		ACELLA PHARMS LLC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A203375**	**001** Sep 20, 2016
AA		PADDOCK LLC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205292**	**001** Jul 15, 2014
AA		VINTAGE PHARMS	**2MG/5ML;10MG/5ML;30MG/5ML**	**A202940**	**001** Jul 21, 2014

BUDESONIDE

AEROSOL, FOAM;RECTAL

	UCERIS				
	+	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001 Oct 07, 2014

CAPSULE;ORAL

	BUDESONIDE				
AB		ALVOGEN MALTA	**3MG**	**A206724**	**001** Nov 23, 2016
AB		BARR LABS DIV TEVA	**3MG**	**A090379**	**001** Apr 02, 2014
AB		MAYNE PHARMA	**3MG**	**A206623**	**001** Apr 08, 2016
AB		MYLAN	**3MG**	**A090410**	**001** May 16, 2011
	ENTOCORT EC				
AB	+	PERRIGO PHARMA INTL	**3MG**	**N021324**	**001** Oct 02, 2001

POWDER, METERED;INHALATION

	PULMICORT FLEXHALER				
		ASTRAZENECA	0.08MG/INH	N021949	001 Jul 12, 2006
	+		0.16MG/INH	N021949	002 Jul 12, 2006

SUSPENSION;INHALATION

	BUDESONIDE				
AN		APOTEX INC	**0.25MG/2ML**	**A078202**	**001** Mar 30, 2009
AN			**0.5MG/2ML**	**A078202**	**002** Mar 30, 2009
AN		IMPAX LABS INC	**0.25MG/2ML**	**A078404**	**001** Jul 31, 2012
AN			**0.5MG/2ML**	**A078404**	**002** Jul 31, 2012
AN		SANDOZ INC	**0.25MG/2ML**	**A201966**	**003** Sep 27, 2013
AN			**0.5MG/2ML**	**A201966**	**002** Sep 27, 2013
AN			**1MG/2ML**	**A201966**	**001** Sep 27, 2013
AN		TEVA PHARMS	**0.25MG/2ML**	**A077519**	**001** Nov 18, 2008
AN			**0.5MG/2ML**	**A077519**	**002** Nov 18, 2008
AN		TEVA PHARMS USA	**1MG/2ML**	**A204548**	**001** Mar 08, 2016
	PULMICORT RESPULES				
AN		ASTRAZENECA PHARMS	**0.25MG/2ML**	**N020929**	**001** Aug 08, 2000
AN			**0.5MG/2ML**	**N020929**	**002** Aug 08, 2000
AN	+		**1MG/2ML**	**N020929**	**003** Aug 08, 2000

TABLET, EXTENDED RELEASE;ORAL

	UCERIS				
	+	VALEANT PHARMS INTL	9MG	N203634	001 Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

	SYMBICORT				
	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001 Jul 21, 2006
	+		0.16MG/INH;0.0045MG/INH	N021929	002 Jul 21, 2006

BUMETANIDE

INJECTABLE;INJECTION

	BUMETANIDE				
AP	+	AMPHASTAR PHARMS INC	**0.25MG/ML**	**A074441**	**001** Jan 27, 1995
AP		EUROHLTH INTL SARL	**0.25MG/ML**	**A079196**	**001** Apr 30, 2008
AP		HOSPIRA	**0.25MG/ML**	**A074332**	**001** Oct 31, 1994

TABLET;ORAL

	BUMETANIDE				
AB		IVAX SUB TEVA PHARMS	**0.5MG**	**A074225**	**001** Apr 24, 1995
AB			**1MG**	**A074225**	**002** Apr 24, 1995
AB			**2MG**	**A074225**	**003** Apr 24, 1995
AB		SANDOZ	**0.5MG**	**A074700**	**001** Nov 21, 1996
AB			**1MG**	**A074700**	**002** Nov 21, 1996
AB	+		**2MG**	**A074700**	**003** Nov 21, 1996
	BUMEX				
AB		VALIDUS PHARMS INC	**0.5MG**	**N018225**	**002** Feb 28, 1983

FDA data supplied by DrugPatentWatch.com

BUMETANIDE
TABLET;ORAL
BUMEX

AB		**1MG**	**N018225**	**001**	Feb 28, 1983
AB		**2MG**	**N018225**	**003**	Jun 14, 1985

BUPIVACAINE
INJECTABLE, LIPOSOMAL;INJECTION
EXPAREL

+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011
+		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	**0.25%**	**A207183**	**001**	May 13, 2016
AP		**0.5%**	**A207183**	**002**	May 13, 2016
AP	HOSPIRA	**0.25%**	**A070583**	**001**	Feb 17, 1987
AP		**0.25%**	**A070586**	**001**	Mar 03, 1987
AP		**0.25%**	**A070590**	**001**	Feb 17, 1987
AP		**0.25%**	**N018053**	**002**	
AP		**0.5%**	**A070584**	**001**	Feb 17, 1986
AP		**0.5%**	**A070597**	**001**	Mar 03, 1987
AP		**0.5%**	**A070609**	**001**	Mar 03, 1987
AP		**0.5%**	**N018053**	**001**	
AP		**0.75%**	**A070585**	**001**	Mar 03, 1987
AP		**0.75%**	**N018053**	**003**	
AP	SAGENT AGILA	**0.25%**	**A091503**	**001**	Oct 18, 2011
AP		**0.5%**	**A091503**	**002**	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	AUROBINDO PHARMA LTD	**0.25%**	**A203895**	**001**	Nov 05, 2013
AP		**0.5%**	**A203895**	**002**	Nov 05, 2013
AP		**0.75%**	**A203895**	**003**	Nov 05, 2013
AP	SAGENT AGILA	**0.25%**	**A091487**	**002**	Oct 18, 2011
AP		**0.5%**	**A091487**	**001**	Oct 18, 2011
AP		**0.75%**	**A091487**	**003**	Oct 18, 2011

MARCAINE HYDROCHLORIDE

AP	+ HOSPIRA	**0.25%**	**N016964**	**001**	
AP	+	**0.5%**	**N016964**	**006**	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	+ HOSPIRA	**0.25%**	**N016964**	**012**	
AP	+	**0.5%**	**N016964**	**005**	
AP	+	**0.75%**	**N016964**	**009**	

SENSORCAINE

AP	FRESENIUS KABI USA	**0.25%**	**A070552**	**001**	May 21, 1986
AP		**0.25%**	**N018304**	**001**	
AP		**0.5%**	**A070553**	**001**	May 21, 1986
AP		**0.5%**	**N018304**	**002**	
AP		**0.75%**	**A070554**	**001**	May 21, 1986
AP		**0.75%**	**N018304**	**003**	

INJECTABLE;SPINAL
BUPIVACAINE HYDROCHLORIDE

AP	CLARIS	**0.75%**	**A207266**	**001**	Jul 25, 2016
AP	HOSPIRA	**0.75%**	**A071810**	**001**	Dec 11, 1987

MARCAINE

AP	+ HOSPIRA	**0.75%**	**N018692**	**001**	May 04, 1984

SENSORCAINE

AP	FRESENIUS KABI USA	**0.75%**	**A071202**	**001**	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE
INJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	+ HOSPIRA	**0.5%;0.005MG/ML**	**A071168**	**001**	Jun 16, 1988
AP		**0.5%;0.005MG/ML**	**A071170**	**001**	Jun 16, 1988
+		0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
		0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE
INJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	SEPTODONT	**0.5%;0.0091MG/ML**	**A077250**	**001**	Sep 27, 2006

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

AP	+ HOSPIRA	**0.5%;0.0091MG/ML**	**N022046**	**001**	Jul 13, 1983

FDA data supplied by DrugPatentWatch.com

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE
INJECTABLE;INJECTION

		MARCAINE HYDROCHLORIDE W/ EPINEPHRINE			
AP	+ HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**004**	
AP	+	**0.5%;0.0091MG/ML**	**N016964**	**008**	
		MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE			
AP	+ HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**013**	
AP	+	**0.5%;0.0091MG/ML**	**N016964**	**007**	
AP	+	**0.75%;0.0091MG/ML**	**N016964**	**010**	
		SENSORCAINE			
AP	FRESENIUS KABI USA	**0.25%;0.0091MG/ML**	**A070966**	**001**	Oct 13, 1987
AP		**0.25%;0.0091MG/ML**	**A070967**	**001**	Oct 13, 1987
AP		**0.5%;0.0091MG/ML**	**A070968**	**001**	Oct 13, 1987
AP		**0.5%;0.0091MG/ML**	**N018304**	**004**	Sep 02, 1983
AP		**0.75%;0.0091MG/ML**	**N018304**	**005**	Sep 02, 1983

BUPRENORPHINE
FILM, EXTENDED RELEASE;TRANSDERMAL

	BUTRANS			
	PURDUE PHARMA LP	5MCG/HR	N021306	001 Jun 30, 2010
		7.5MCG/HR	N021306	005 Jun 30, 2014
		10MCG/HR	N021306	002 Jun 30, 2010
		15MCG/HR	N021306	004 Jul 25, 2013
	+	20MCG/HR	N021306	003 Jun 30, 2010

BUPRENORPHINE HYDROCHLORIDE
FILM;BUCCAL

	BELBUCA			
	ENDO PHARMS INC	EQ 0.075MG BASE	N207932	001 Oct 23, 2015
		EQ 0.15MG BASE	N207932	002 Oct 23, 2015
		EQ 0.3MG BASE	N207932	003 Oct 23, 2015
		EQ 0.45MG BASE	N207932	004 Oct 23, 2015
		EQ 0.6MG BASE	N207932	005 Oct 23, 2015
		EQ 0.75MG BASE	N207932	006 Oct 23, 2015
	+	EQ 0.9MG BASE	N207932	007 Oct 23, 2015

IMPLANT;IMPLANTATION

	PROBUPHINE			
	+ BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001 May 26, 2016

INJECTABLE;INJECTION

		BUPRENEX			
AP	+ INDIVIOR INC	**EQ 0.3MG BASE/ML**	**N018401**	**001**	
		BUPRENORPHINE HYDROCHLORIDE			
AP	HOSPIRA	**EQ 0.3MG BASE/ML**	**A074137**	**001**	Jun 03, 1996
AP	LUITPOLD	**EQ 0.3MG BASE/ML**	**A078331**	**001**	Mar 27, 2007
AP	PAR STERILE PRODUCTS	**EQ 0.3MG BASE/ML**	**A206586**	**001**	Jul 28, 2015
AP	WEST-WARD PHARMS INT	**EQ 0.3MG BASE/ML**	**A076931**	**001**	Mar 02, 2005

TABLET;SUBLINGUAL

		BUPRENORPHINE HYDROCHLORIDE			
AB	ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090819**	**001**	Feb 19, 2015
AB		**EQ 8MG BASE**	**A090819**	**002**	Feb 19, 2015
AB	BARR	**EQ 2MG BASE**	**A090360**	**001**	May 07, 2010
AB		**EQ 8MG BASE**	**A090360**	**002**	May 07, 2010
AB	ETHYPHARM	**EQ 2MG BASE**	**A090622**	**001**	Sep 24, 2010
AB		**EQ 8MG BASE**	**A090622**	**002**	Sep 24, 2010
AB	MYLAN PHARMS INC	**EQ 2MG BASE**	**A201066**	**001**	Mar 06, 2015
AB		**EQ 8MG BASE**	**A201066**	**002**	Mar 06, 2015
AB	SANDOZ INC	**EQ 2MG BASE**	**A090279**	**001**	Jun 10, 2015
AB		**EQ 8MG BASE**	**A090279**	**002**	Jun 10, 2015
AB	SUN PHARM INDS LTD	**EQ 2MG BASE**	**A201760**	**001**	Jan 29, 2016
AB		**EQ 8MG BASE**	**A201760**	**002**	Jan 29, 2016
AB	WEST-WARD PHARMS INT	**EQ 2MG BASE**	**A078633**	**001**	Oct 08, 2009
AB	+	**EQ 8MG BASE**	**A078633**	**002**	Oct 08, 2009

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
FILM;BUCCAL

	BUNAVAIL			
	BIODELIVERY SCI INTL	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001 Jun 06, 2014
		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002 Jun 06, 2014
	+	EQ 6.3MG BASE;EQ 1MG BASE	N205637	003 Jun 06, 2014

FILM;BUCCAL, SUBLINGUAL

	SUBOXONE			
	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001 Aug 30, 2010
		EQ 4MG BASE;EQ 1MG BASE	N022410	003 Aug 10, 2012
		EQ 8MG BASE;EQ 2MG BASE	N022410	002 Aug 30, 2010

FDA data supplied by DrugPatentWatch.com

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

SUBOXONE

	+		EQ 12MG BASE;EQ 3MG BASE	N022410	004 Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE;EQ 0.5MG BASE**	**A091422**	**001** Feb 22, 2013
AB	**+**		**EQ 8MG BASE;EQ 2MG BASE**	**A091422**	**002** Feb 22, 2013
AB		AMNEAL PHARMS	**EQ 8MG BASE;EQ 2MG BASE**	**A203136**	**002** Feb 22, 2013
AB		ETHYPHARM USA CORP	**EQ 2MG BASE;EQ 0.5MG BASE**	**A204431**	**001** Oct 16, 2015
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A204431**	**002** Oct 16, 2015
AB		KREMERS URBAN PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205022**	**001** Sep 19, 2016
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205022**	**002** Sep 19, 2016
AB		SUN PHARM INDS LTD	**EQ 8MG BASE;EQ 2MG BASE**	**A201633**	**002** Aug 05, 2016
AB		TEVA PHARMS USA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A091149**	**001** Sep 08, 2014
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A091149**	**002** Sep 08, 2014
AB		WEST-WARD PHARMS INT	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203326**	**001** Jun 27, 2014
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A203326**	**002** Jun 27, 2014

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		AMNEAL PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203136**	**001** Feb 22, 2013
AB		SUN PHARM INDS LTD	**EQ 2MG BASE;EQ 0.5MG BASE**	**A201633**	**001** Aug 05, 2016

ZUBSOLV

		OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006 Oct 04, 2016
			EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001 Jul 03, 2013
			EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005 Jun 04, 2015
	+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002 Jul 03, 2013
			EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003 Dec 11, 2014
			EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004 Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

		VALEANT PHARMS NORTH	174MG	N022108	001 Apr 23, 2008
			348MG	N022108	002 Apr 23, 2008
	+		522MG	N022108	003 Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB		APOTEX INC	**75MG**	**A076143**	**001** Jan 17, 2006
AB	**+**		**100MG**	**A076143**	**002** Jan 17, 2006
AB		HERITAGE PHARMA	**75MG**	**A206975**	**001** Aug 19, 2016
AB			**100MG**	**A206975**	**002** Aug 19, 2016
AB		MYLAN	**75MG**	**A075491**	**001** Apr 17, 2000
AB			**100MG**	**A075491**	**002** Apr 17, 2000
AB		SANDOZ	**75MG**	**A075584**	**001** Feb 07, 2000
AB			**100MG**	**A075584**	**002** Feb 07, 2000

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1		ACTAVIS LABS FL INC	**100MG**	**A079095**	**001** Mar 24, 2009
AB1			**150MG**	**A079095**	**002** Mar 24, 2009
AB1			**200MG**	**A079095**	**003** Mar 24, 2009
AB1		ANCHEN PHARMS	**100MG**	**A091459**	**001** Jun 09, 2011
AB1			**150MG**	**A091459**	**002** Jun 09, 2011
AB1			**200MG**	**A091459**	**003** Jun 09, 2011
AB1		IMPAX LABS	**100MG**	**A075913**	**001** Jan 28, 2004
AB1			**150MG**	**A075913**	**002** Mar 22, 2004
AB1			**200MG**	**A076711**	**001** Dec 03, 2004
AB1		INVAGEN PHARMS	**100MG**	**A206674**	**001** Feb 09, 2016
AB1			**150MG**	**A206674**	**002** Feb 09, 2016
AB1			**200MG**	**A206674**	**003** Feb 09, 2016
AB1		JUBILANT GENERICS	**100MG**	**A202774**	**001** Oct 11, 2013
AB1			**150MG**	**A202774**	**002** Oct 11, 2013
AB1			**200MG**	**A202774**	**003** Oct 11, 2013
AB1		MYLAN	**100MG**	**A090325**	**001** Apr 08, 2010
AB1			**150MG**	**A090325**	**002** Apr 08, 2010
AB1			**200MG**	**A090325**	**003** Apr 08, 2010
AB1		PRINSTON INC	**100MG**	**A202304**	**001** May 26, 2015
AB1			**150MG**	**A202304**	**002** May 26, 2015
AB1			**200MG**	**A202304**	**003** May 26, 2015
AB1		SANDOZ	**100MG**	**A075932**	**001** Nov 25, 2003
AB1			**150MG**	**A075932**	**002** Mar 22, 2004
AB1			**200MG**	**A075932**	**003** Jun 22, 2005

FDA data supplied by DrugPatentWatch.com

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

	BUPROPION HYDROCHLORIDE				
AB1	SCIEGEN PHARMS INC	**100MG**	**A205794**	**001**	Mar 01, 2016
AB1		**150MG**	**A205794**	**002**	Mar 01, 2016
AB1		**200MG**	**A205794**	**003**	Mar 01, 2016
AB1	SUN PHARMA GLOBAL	**100MG**	**A078866**	**001**	Apr 06, 2010
AB1		**150MG**	**A078866**	**002**	Apr 06, 2010
AB1		**200MG**	**A078866**	**003**	Apr 06, 2010
AB1	TORRENT PHARMS LTD	**100MG**	**A203969**	**001**	Oct 31, 2014
AB1		**150MG**	**A203969**	**002**	Oct 31, 2014
AB1		**200MG**	**A203969**	**003**	Oct 31, 2014
AB1	WATSON LABS INC	**100MG**	**A077455**	**001**	Jul 19, 2010
AB1		**150MG**	**A077455**	**002**	Mar 12, 2008
AB1		**200MG**	**A077455**	**003**	Jul 19, 2010
	WELLBUTRIN SR				
AB1	GLAXOSMITHKLINE	**100MG**	**N020358**	**002**	Oct 04, 1996
AB1		**150MG**	**N020358**	**003**	Oct 04, 1996
AB1 +		**200MG**	**N020358**	**004**	Jun 14, 2002
	BUPROPION HYDROCHLORIDE				
AB2	ACTAVIS LABS FL INC	**150MG**	**A079094**	**001**	Mar 24, 2009
AB2	ANCHEN PHARMS	**150MG**	**A091520**	**001**	Jun 09, 2011
AB2	IMPAX LABS	**150MG**	**A075914**	**001**	May 27, 2004
AB2	JUBILANT GENERICS	**150MG**	**A202775**	**001**	Oct 11, 2013
AB2	MYLAN	**150MG**	**A090941**	**001**	May 03, 2010
AB2	SANDOZ INC	**150MG**	**A077475**	**001**	Mar 12, 2008
AB2	SCIEGEN PHARMS INC	**150MG**	**A206122**	**001**	Aug 17, 2016
	ZYBAN				
AB2 +	GLAXOSMITHKLINE	**150MG**	**N020711**	**003**	May 14, 1997
	BUPROPION HYDROCHLORIDE				
AB3	ACTAVIS LABS FL INC	**150MG**	**A077715**	**001**	Nov 26, 2008
AB3	ANCHEN PHARMS	**150MG**	**A077284**	**001**	Dec 14, 2006
AB3		**300MG**	**A077284**	**002**	Dec 14, 2006
AB3	IMPAX LABS	**150MG**	**A077415**	**001**	Nov 26, 2008
AB3	INVAGEN PHARMS	**150MG**	**A206556**	**001**	Aug 26, 2016
AB3		**300MG**	**A206556**	**002**	Aug 26, 2016
AB3	MYLAN	**150MG**	**A090942**	**001**	Jul 14, 2010
AB3		**300MG**	**A090942**	**002**	Jul 14, 2010
AB3	SUN PHARMA GLOBAL	**150MG**	**A200695**	**001**	Dec 18, 2014
AB3	WATSON LABS INC	**150MG**	**A077285**	**001**	Nov 26, 2008
AB3		**300MG**	**A077285**	**002**	Aug 15, 2008
AB3	WOCKHARDT LTD	**150MG**	**A202189**	**001**	Nov 21, 2012
AB3	ZYDUS PHARMS USA INC	**300MG**	**A201567**	**001**	Jan 17, 2014
	WELLBUTRIN XL				
AB3	VALEANT INTL	**150MG**	**N021515**	**001**	Aug 28, 2003
AB3 +		**300MG**	**N021515**	**002**	Aug 28, 2003
	FORFIVO XL				
+	EDGEMONT PHARMS LLC	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

	CONTRAVE				
+	OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

	BUSPIRONE HYDROCHLORIDE				
AB	ACCORD HLTHCARE	**5MG**	**A202557**	**001**	Dec 30, 2014
AB		**7.5MG**	**A202557**	**002**	Dec 30, 2014
AB		**10MG**	**A202557**	**003**	Dec 30, 2014
AB		**15MG**	**A202557**	**004**	Dec 30, 2014
AB		**30MG**	**A202557**	**005**	Dec 30, 2014
AB	DR REDDYS LABS LTD	**5MG**	**A078246**	**001**	Feb 27, 2009
AB		**10MG**	**A078246**	**002**	Feb 27, 2009
AB		**15MG**	**A078246**	**003**	Feb 27, 2009
AB		**30MG**	**A078246**	**004**	Feb 27, 2009
AB	HERITAGE PHARMA	**5MG**	**A204582**	**001**	Sep 18, 2015
AB		**10MG**	**A204582**	**002**	Sep 18, 2015
AB		**15MG**	**A204582**	**003**	Sep 18, 2015
AB		**30MG**	**A204582**	**004**	Sep 18, 2015
AB	IMPAX LABS INC	**5MG**	**A074253**	**001**	Mar 28, 2001
AB		**10MG**	**A074253**	**002**	Mar 28, 2001
AB		**15MG**	**A074253**	**003**	Mar 13, 2002

FDA data supplied by DrugPatentWatch.com

BUSPIRONE HYDROCHLORIDE
TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB		MYLAN	**5MG**	**A075467**	**001** Feb 28, 2002
AB			**5MG**	**A076008**	**003** Mar 01, 2002
AB			**7.5MG**	**A075467**	**002** Mar 28, 2001
AB			**7.5MG**	**A076008**	**002** Jul 08, 2013
AB			**10MG**	**A075467**	**003** Feb 28, 2002
AB			**10MG**	**A076008**	**004** Mar 01, 2002
AB			**15MG**	**A075467**	**004** Feb 28, 2002
AB			**15MG**	**A076008**	**005** Mar 28, 2001
AB			**30MG**	**A076008**	**001** Jun 28, 2001
AB		ORION CORP ORION	**5MG**	**A202087**	**001** Dec 16, 2015
AB			**10MG**	**A202087**	**002** Dec 16, 2015
AB			**15MG**	**A202087**	**003** Dec 16, 2015
AB			**30MG**	**A202087**	**004** Dec 16, 2015
AB		OXFORD PHARMS	**30MG**	**A078302**	**001** Dec 17, 2007
AB		STRIDES ARCOLAB LTD	**5MG**	**A202330**	**001** Aug 25, 2014
AB			**10MG**	**A202330**	**002** Aug 25, 2014
AB			**15MG**	**A202330**	**003** Aug 25, 2014
AB			**30MG**	**A202330**	**004** Aug 25, 2014
AB		TEVA	**5MG**	**A075022**	**001** Feb 28, 2002
AB			**10MG**	**A075022**	**002** Feb 28, 2002
AB	**+**		**15MG**	**A075022**	**003** Feb 28, 2002
AB			**30MG**	**A075022**	**004** Mar 25, 2004
AB		ZYDUS PHARMS USA INC	**5MG**	**A078888**	**001** Feb 07, 2014
AB			**10MG**	**A078888**	**002** Feb 07, 2014
AB			**15MG**	**A078888**	**003** Feb 07, 2014
AB			**30MG**	**A078888**	**004** Feb 07, 2014

BUSULFAN
INJECTABLE;INJECTION
BUSULFAN

AP		LUITPOLD PHARMS INC	**6MG/ML**	**A202259**	**001** Dec 22, 2015

BUSULFEX

AP	**+**	OTSUKA PHARM	**6MG/ML**	**N020954**	**001** Feb 04, 1999

TABLET;ORAL
MYLERAN

	+	ASPEN GLOBAL	2MG	N009386	001

BUTABARBITAL SODIUM
TABLET;ORAL
BUTISOL SODIUM

	+	MEDA PHARMS	30MG	N000793	004

BUTENAFINE HYDROCHLORIDE
CREAM;TOPICAL
MENTAX

	+	MYLAN	1%	N020524	001 Oct 18, 1996

BUTOCONAZOLE NITRATE
CREAM;VAGINAL
GYNAZOLE-1

	+	PERRIGO ISRAEL	2%	A200923	001 May 18, 2012

BUTORPHANOL TARTRATE
INJECTABLE;INJECTION
BUTORPHANOL TARTRATE

AP		EUROHLTH INTL SARL	**2MG/ML**	**A075046**	**001** Aug 12, 1998
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078400**	**001** May 01, 2009
AP			**2MG/ML**	**A078400**	**002** May 01, 2009

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		EUROHLTH INTL SARL	**1MG/ML**	**A075045**	**001** Aug 12, 1998
AP			**2MG/ML**	**A075045**	**002** Aug 12, 1998
AP		HOSPIRA	**1MG/ML**	**A074626**	**001** Jan 23, 1997
AP			**2MG/ML**	**A074626**	**002** Jan 23, 1997

SPRAY, METERED;NASAL
BUTORPHANOL TARTRATE

AB		APOTEX INC	**1MG/SPRAY**	**A075499**	**001** Dec 04, 2002
AB	**+**	MYLAN	**1MG/SPRAY**	**A075759**	**001** Aug 08, 2001
AB		WEST-WARD PHARMS INT	**1MG/SPRAY**	**A075824**	**001** Mar 12, 2002

FDA data supplied by DrugPatentWatch.com

CABAZITAXEL
SOLUTION;IV (INFUSION)
JEVTANA KIT

	+	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023 001	Jun 17, 2010

CABERGOLINE
TABLET;ORAL

		CABERGOLINE			
AB		ACTAVIS LABS FL INC	**0.5MG**	**A078035 001**	Apr 21, 2008
AB		APOTEX CORP	**0.5MG**	**A201503 001**	Mar 08, 2013
AB		IVAX SUB TEVA PHARMS	**0.5MG**	**A077750 001**	Mar 07, 2007
AB		MYLAN PHARMS INC	**0.5MG**	**A202947 001**	Dec 02, 2013
AB	+	PAR PHARM	**0.5MG**	**A076310 001**	Dec 29, 2005

CABOZANTINIB S-MALATE
CAPSULE;ORAL
COMETRIQ

		EXELIXIS	EQ 20MG BASE	N203756 001	Nov 29, 2012
	+		EQ 80MG BASE	N203756 002	Nov 29, 2012

TABLET;ORAL
CABOMETYX

		EXELIXIS INC	EQ 20MG BASE	N208692 001	Apr 25, 2016
			EQ 40MG BASE	N208692 002	Apr 25, 2016
	+		EQ 60MG BASE	N208692 003	Apr 25, 2016

CAFFEINE CITRATE
SOLUTION;INTRAVENOUS

		CAFCIT			
AP	+	WEST-WARD PHARMS INT	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793 001**	Sep 21, 1999
		CAFFEINE CITRATE			
AP		AUROBINDO PHARMA LTD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A205013 001**	Sep 22, 2015
AP		EXELA PHARMA SCIENCE	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077233 001**	Sep 21, 2006
AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077997 001**	Jul 20, 2007
AP		LUITPOLD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077906 001**	May 15, 2007
AP		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090827 001**	Aug 29, 2012
AP		SUN PHARMA GLOBAL	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090077 001**	Sep 30, 2009

SOLUTION;ORAL

		CAFCIT			
AA	+	WEST-WARD PHARMS INT	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793 002**	Apr 12, 2000
		CAFFEINE CITRATE			
AA		EXELA PHARMA SCS LLC	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077304 001**	Sep 21, 2006
AA		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A078002 001**	Jan 31, 2008
AA		LUITPOLD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090064 001**	Nov 20, 2009
AA		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A091102 001**	Aug 29, 2012
AA		SUN PHARMA GLOBAL	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090357 001**	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE
SUPPOSITORY;RECTAL
MIGERGOT

	+	HORIZON PHARMA	100MG;2MG	A086557 001	Oct 04, 1983

TABLET;ORAL

		CAFERGOT			
AA	+	SANDOZ	**100MG;1MG**	**A084294 001**	
		ERGOTAMINE TARTRATE AND CAFFEINE			
AA		HIKMA INTL PHARMS	**100MG;1MG**	**A040510 001**	Sep 17, 2004
AA		MIKART	**100MG;1MG**	**A040590 001**	Sep 16, 2005

CALCIFEDIOL
CAPSULE, EXTENDED RELEASE;ORAL
RAYALDEE

	+	OPKO IRELAND GLOBAL	0.03MG	N208010 001	Jun 17, 2016

CALCIPOTRIENE
AEROSOL, FOAM;TOPICAL
SORILUX

	+	STIEFEL LABS INC	0.005%	N022563 001	Oct 06, 2010

CREAM;TOPICAL

		CALCIPOTRIENE			
AB		GLENMARK PHARMS	**0.005%**	**A205772 001**	Jun 09, 2015
AB		TOLMAR	**0.005%**	**A200935 001**	May 30, 2012
		DOVONEX			
AB	+	LEO PHARMA AS	**0.005%**	**N020554 001**	Jul 22, 1996

OINTMENT;TOPICAL
CALCIPOTRIENE

	+	GLENMARK GENERICS	0.005%	A090633 001	Mar 24, 2010

FDA data supplied by DrugPatentWatch.com

CALCIPOTRIENE

SOLUTION;TOPICAL

CALCIPOTRIENE

AT		FOUGERA PHARMS	**0.005%**	**A078305**	**001** May 06, 2008
AT		G AND W LABS INC	**0.005%**	**A078468**	**001** Mar 24, 2011
AT		HI TECH PHARMA	**0.005%**	**A077579**	**001** Nov 19, 2009
AT	+	TOLMAR	**0.005%**	**A077029**	**001** Nov 20, 2009

CALCITONIN SALMON

INJECTABLE;INJECTION

MIACALCIN

	+	MYLAN IRELAND LTD	200 IU/ML	N017808	002 Mar 29, 1991

SPRAY, METERED;NASAL

CALCITONIN-SALMON

AB		APOTEX INC	**200 IU/SPRAY**	**A076396**	**001** Nov 17, 2008
AB		PAR PHARM	**200 IU/SPRAY**	**A076979**	**001** Jun 08, 2009

MIACALCIN

AB	+	MYLAN IRELAND LTD	**200 IU/SPRAY**	**N020313**	**002** Aug 17, 1995

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		BIONPHARMA INC	**0.25MCG**	**A091174**	**001** May 24, 2013
AB			**0.5MCG**	**A091174**	**002** May 24, 2013
AB		STRIDES PHARMA	**0.25MCG**	**A091356**	**001** Dec 12, 2014
AB			**0.5MCG**	**A091356**	**002** Dec 12, 2014
AB		TEVA	**0.25MCG**	**A075765**	**001** Oct 12, 2001
AB			**0.5MCG**	**A075765**	**002** Oct 12, 2001
AB		WEST-WARD PHARMS INT	**0.25MCG**	**A076917**	**001** Mar 27, 2006

ROCALTROL

AB		VALIDUS PHARMS	**0.25MCG**	**N018044**	**001**
AB	+		**0.5MCG**	**N018044**	**002**

INJECTABLE;INJECTION

CALCITRIOL

		AKORN	0.001MG/ML	A078066	001 Jan 29, 2008

OINTMENT;TOPICAL

VECTICAL

	+	GALDERMA LABS LP	3MCG/GM	N022087	001 Jan 23, 2009

SOLUTION;ORAL

CALCITRIOL

AA		WEST-WARD PHARMS INT	**1MCG/ML**	**A076242**	**001** Jul 18, 2003

ROCALTROL

AA	+	VALIDUS PHARMS	**1MCG/ML**	**N021068**	**001** Nov 20, 1998

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB		AMNEAL PHARMS	**667MG**	**A201658**	**001** Oct 06, 2014
AB		ECI PHARMS LLC	**667MG**	**A203298**	**001** Jul 26, 2016
AB		HERITAGE PHARMS INC	**667MG**	**A202315**	**001** Jun 29, 2015
AB		INVAGEN PHARMS	**667MG**	**A203135**	**001** Feb 07, 2013
AB		LUPIN LTD	**667MG**	**A202127**	**001** Jul 09, 2015
AB		NOSTRUM LABS INC	**667MG**	**A203179**	**001** Oct 26, 2015
AB		PADDOCK LLC	**667MG**	**A091312**	**001** Jun 01, 2012
AB		WEST-WARD PHARMS INT	**667MG**	**A077728**	**001** Feb 26, 2008

PHOSLO GELCAPS

AB	+	FRESENIUS MEDCL	**667MG**	**N021160**	**003** Apr 02, 2001

SOLUTION;ORAL

PHOSLYRA

	+	FRESENIUS MEDCL	667MG/5ML	N022581	001 Apr 18, 2011

TABLET;ORAL

CALCIUM ACETATE

AB		HERITAGE PHARMS INC	**667MG**	**A202885**	**001** Jan 22, 2015
AB		INVAGEN PHARMS	**667MG**	**A202420**	**001** Feb 05, 2013
AB		PADDOCK LLC	**667MG**	**A091561**	**001** Apr 13, 2011

ELIPHOS

AB	+	CYPRESS PHARM	**667MG**	**A078502**	**001** Nov 25, 2008

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE
INJECTABLE;INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+	HOSPIRA	100MG/ML	N021117	001	Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SOLUTION;IRRIGATION

		BSS PLUS				
AT	**+**	ALCON	**0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML**	**N018469**	**001**	
		ENDOSOL EXTRA				
AT	**+**	AKORN	**0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML**	**N020079**	**001**	Nov 27, 1991

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
INJECTABLE;INJECTION

		PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER			
	+	BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008
		PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008
		PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008
		PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006
		PRISMASOL BGK 2/0 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006
		PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006
		PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008
		PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006
		PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008
		PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SOLUTION;INTRAPERITONEAL

		DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
AT		FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**001**	Nov 30, 1984
		DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER				
AT		FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**004**	Nov 30, 1984
		DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER				
AT		FRESENIUS MEDCL	**18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**001**	Aug 19, 1992
		DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
AT		FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**002**	Nov 30, 1984
		DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER				
AT		FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**005**	Nov 30, 1984

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

	DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER				
AT	FRESENIUS MEDCL	**18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**002**	Aug 19, 1992
	DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
AT	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**003**	Nov 30, 1984
	DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER				
AT	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**006**	Nov 30, 1984
	DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER				
AT	FRESENIUS MEDCL	**18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**003**	Aug 19, 1992
	DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N017512**	**001**	
	DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N017512**	**003**	
	DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N017512**	**002**	
	DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**001**	Dec 04, 1992
	DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N017512**	**007**	Jul 09, 1984
	DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N017512**	**008**	Jul 09, 1984
	DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N017512**	**009**	Jul 09, 1984
	DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**004**	
AT		**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**001**	Dec 04, 1992
	DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**005**	
AT		**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**002**	Dec 04, 1992
	DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
AT	BAXTER HLTHCARE	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**006**	
AT		**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**003**	Dec 04, 1992
	DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	002	Dec 04, 1992
	DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992
	DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	004	Dec 04, 1992
	DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985
	DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

	ELLIOTTS B SOLUTION				
+	LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	**33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML**	**N018254**	**001**	
	DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER				
AP	B BRAUN	**33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML**	**N020000**	**001**	Apr 17, 1992

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017608**	**001**	
	DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER				
AP	B BRAUN	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019634**	**003**	Feb 24, 1988
	LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016679**	**001**	
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**006**	Apr 05, 1985
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**004**	Apr 05, 1985
AP		**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**005**	Apr 05, 1985
AP	HOSPIRA	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019685**	**002**	Oct 17, 1988
AP		**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019685**	**008**	Oct 17, 1988
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**007**	Apr 05, 1985
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**008**	Apr 05, 1985
AP	HOSPIRA	**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019685**	**004**	Oct 17, 1988
	DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER				
	B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG/100ML;160MG/100ML	N019634	001	Feb 24, 1988
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	002	Apr 05, 1985
		20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367	003	Apr 05, 1985
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	001	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

+	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N018895	001	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

BALANCED SALT

AT	AKORN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A075503**	**001**	Sep 27, 2006
AT	B BRAUN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A091387**	**001**	Feb 03, 2010
	BSS				
AT	**+** ALCON	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**N020742**	**001**	Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314	N207026	001	Jan 13, 2015

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

		GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/10			

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**A075323**	**001**	Apr 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	+	HOSPIRA	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**N018608**	**001**	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N020002**	**001**	Apr 17, 1992
AP		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N016693**	**001**	
AP		HOSPIRA	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018251**	**001**	

SOLUTION;IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018156**	**001**	
AT		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018495**	**001**	Feb 19, 1982
AT		HOSPIRA	**33MG/100ML;30MG/100ML;860MG/100ML**	**N017635**	**001**	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019632**	**001**	Feb 29, 1988
AP	+	BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016682**	**001**	
AP		HOSPIRA	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017641**	**001**	

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018681**	**001**	Dec 27, 1982
AT		BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018494**	**001**	Feb 19, 1982
AT	+		**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018921**	**001**	Apr 03, 1984
AT	+	HOSPIRA	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019416**	**001**	Jan 17, 1986

CALFACTANT

SUSPENSION;INTRATRACHEAL

INFASURF PRESERVATIVE FREE

	+	ONY	35MG/ML	N020521	001	Jul 01, 1998

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

		JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
	+		300MG	N204042	002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

INVOKAMET

		JANSSEN PHARMS	50MG;500MG	N204353	001	Aug 08, 2014
			50MG;1GM	N204353	002	Aug 08, 2014
			150MG;500MG	N204353	003	Aug 08, 2014
	+		150MG;1GM	N204353	004	Aug 08, 2014

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

		JANSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016
			50MG;1GM	N205879	002	Sep 20, 2016
			150MG;500MG	N205879	003	Sep 20, 2016
	+		150MG;1GM	N205879	004	Sep 20, 2016

FDA data supplied by DrugPatentWatch.com

CANDESARTAN CILEXETIL
TABLET;ORAL

	ATACAND				
AB	ASTRAZENECA	**4MG**	**N020838**	**001**	Jun 04, 1998
AB		**8MG**	**N020838**	**002**	Jun 04, 1998
AB		**16MG**	**N020838**	**003**	Jun 04, 1998
AB	+	**32MG**	**N020838**	**004**	Jun 04, 1998
	CANDESARTAN CILEXETIL				
AB	APOTEX INC	**4MG**	**A202079**	**001**	Jan 10, 2014
AB		**8MG**	**A202079**	**002**	Jan 10, 2014
AB		**16MG**	**A202079**	**003**	Jan 10, 2014
AB		**32MG**	**A202079**	**004**	Jan 10, 2014
AB	MACLEODS PHARMS LTD	**4MG**	**A203813**	**001**	Dec 05, 2016
AB		**8MG**	**A203813**	**002**	Dec 05, 2016
AB		**16MG**	**A203813**	**003**	Dec 05, 2016
AB		**32MG**	**A203813**	**004**	Dec 05, 2016
AB	SANDOZ	**4MG**	**A078702**	**001**	May 03, 2013
AB		**8MG**	**A078702**	**002**	May 03, 2013
AB		**16MG**	**A078702**	**003**	May 03, 2013
AB		**32MG**	**A078702**	**004**	May 03, 2013

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE
TABLET;ORAL

	ATACAND HCT				
AB	ASTRAZENECA	**16MG;12.5MG**	**N021093**	**001**	Sep 05, 2000
AB		**32MG;12.5MG**	**N021093**	**002**	Sep 05, 2000
AB	+	**32MG;25MG**	**N021093**	**003**	May 16, 2008
	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE				
AB	APOTEX INC	**16MG;12.5MG**	**A202884**	**001**	Dec 04, 2012
AB		**32MG;12.5MG**	**A202884**	**002**	Dec 04, 2012
AB		**32MG;25MG**	**A202884**	**003**	Jun 03, 2013
AB	DR REDDYS LABS LTD	**16MG;12.5MG**	**A202965**	**001**	Jun 03, 2013
AB		**32MG;12.5MG**	**A202965**	**002**	Jun 03, 2013
AB		**32MG;25MG**	**A202965**	**003**	Jun 03, 2013
AB	MACLEODS PHARMS LTD	**16MG;12.5MG**	**A204100**	**001**	Feb 27, 2015
AB		**32MG;12.5MG**	**A204100**	**002**	Feb 27, 2015
AB		**32MG;25MG**	**A204100**	**003**	Feb 27, 2015
AB	MYLAN LABS	**16MG;12.5MG**	**A090704**	**001**	Dec 04, 2012
AB		**32MG;12.5MG**	**A090704**	**002**	Dec 04, 2012
AB		**32MG;25MG**	**A090704**	**003**	Dec 04, 2012

CANGRELOR
POWDER;IV (INFUSION)

	KENGREAL				
+	CHIESI USA INC	50MG/VIAL	N204958	001	Jun 22, 2015

CAPECITABINE
TABLET;ORAL

	CAPECITABINE				
AB	ACCORD HLTHCARE	**150MG**	**A202593**	**001**	Apr 23, 2015
AB		**500MG**	**A202593**	**002**	Apr 23, 2015
AB	MYLAN PHARMS INC	**150MG**	**A090943**	**001**	Aug 08, 2014
AB		**500MG**	**A090943**	**002**	Aug 08, 2014
AB	SHILPA MEDICARE LTD	**150MG**	**A207456**	**001**	Dec 12, 2016
AB		**500MG**	**A207456**	**002**	Dec 12, 2016
AB	TEVA PHARMS USA	**150MG**	**A091649**	**001**	Sep 16, 2013
AB		**500MG**	**A091649**	**002**	Sep 16, 2013
AB	WEST-WARD PHARMS INT	**150MG**	**A200483**	**001**	Jul 14, 2016
AB		**500MG**	**A200483**	**002**	Jul 14, 2016
	XELODA				
AB	HOFFMANN LA ROCHE	**150MG**	**N020896**	**001**	Apr 30, 1998
AB	+	**500MG**	**N020896**	**002**	Apr 30, 1998

CAPREOMYCIN SULFATE
INJECTABLE;INJECTION

	CAPASTAT SULFATE				
+	AKORN	EQ 1GM BASE/VIAL	N050095	001	

CAPSAICIN
PATCH;TOPICAL

	QUTENZA				
+	ACORDA	8%	N022395	001	Nov 16, 2009

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL
TABLET;ORAL
CAPTOPRIL

AB		HIKMA INTL PHARMS	**12.5MG**	**A074505**	**001**	Feb 13, 1996
AB			**25MG**	**A074505**	**002**	Feb 13, 1996
AB			**50MG**	**A074505**	**003**	Feb 13, 1996
AB			**100MG**	**A074505**	**004**	Feb 13, 1996
AB		MYLAN	**12.5MG**	**A074434**	**001**	Feb 13, 1996
AB			**25MG**	**A074434**	**002**	Feb 13, 1996
AB			**50MG**	**A074434**	**003**	Feb 13, 1996
AB	**+**		**100MG**	**A074434**	**004**	Feb 13, 1996
AB		PRINSTON INC	**12.5MG**	**A074477**	**001**	Feb 13, 1996
AB			**25MG**	**A074477**	**002**	Feb 13, 1996
AB			**50MG**	**A074477**	**003**	Feb 13, 1996
AB			**100MG**	**A074477**	**004**	Feb 13, 1996
AB		TEVA	**12.5MG**	**A074322**	**001**	Feb 13, 1996
AB			**25MG**	**A074322**	**002**	Feb 13, 1996
AB			**50MG**	**A074322**	**003**	Feb 13, 1996
AB			**100MG**	**A074322**	**004**	Feb 13, 1996
AB		WATSON LABS	**12.5MG**	**A074386**	**001**	May 23, 1996
AB			**25MG**	**A074386**	**002**	May 23, 1996
AB			**50MG**	**A074386**	**003**	May 23, 1996
AB			**100MG**	**A074386**	**004**	May 23, 1996
AB		WOCKHARDT	**12.5MG**	**A074532**	**001**	Mar 28, 1997
AB			**25MG**	**A074532**	**002**	Mar 28, 1997
AB			**50MG**	**A074532**	**003**	Mar 28, 1997
AB			**100MG**	**A074532**	**004**	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE
TABLET;ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB		G AND W LABS INC	**25MG;15MG**	**A074827**	**001**	Dec 29, 1997
AB			**25MG;25MG**	**A074827**	**002**	Dec 29, 1997
AB			**50MG;15MG**	**A074827**	**004**	Dec 29, 1997
AB			**50MG;25MG**	**A074827**	**003**	Dec 29, 1997
AB		MYLAN	**25MG;15MG**	**A074896**	**001**	Dec 29, 1997
AB	**+**		**25MG;25MG**	**A074896**	**002**	Dec 29, 1997
AB	**+**		**50MG;15MG**	**A074896**	**004**	Dec 29, 1997
AB			**50MG;25MG**	**A074896**	**003**	Dec 29, 1997

CARBACHOL
SOLUTION;INTRAOCULAR
MIOSTAT

	+	ALCON	0.01%	N016968	001	

CARBAMAZEPINE
CAPSULE, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

AB		APOTEX INC	**100MG**	**A078986**	**001**	Nov 25, 2011
AB			**200MG**	**A078986**	**002**	Nov 25, 2011
AB			**300MG**	**A078986**	**003**	Nov 25, 2011
AB		MYLAN IRELAND LTD	**100MG**	**A076697**	**001**	May 20, 2011
AB			**200MG**	**A076697**	**002**	May 20, 2011
AB			**300MG**	**A076697**	**003**	May 20, 2011
AB		TARO	**100MG**	**A201106**	**001**	Jun 21, 2013
AB			**200MG**	**A201106**	**002**	Jun 21, 2013
AB			**300MG**	**A201106**	**003**	Jun 21, 2013
AB		TEVA PHARMS	**100MG**	**A078592**	**001**	Sep 20, 2012
AB			**200MG**	**A078592**	**002**	Sep 20, 2012
AB			**300MG**	**A078592**	**003**	Sep 20, 2012

CARBATROL

AB		SHIRE	**100MG**	**N020712**	**003**	Sep 30, 1997
AB			**200MG**	**N020712**	**001**	Sep 30, 1997
AB	**+**		**300MG**	**N020712**	**002**	Sep 30, 1997

EQUETRO

		VALIDUS PHARMS INC	100MG	N021710	001	Dec 10, 2004
			200MG	N021710	002	Dec 10, 2004
	+		300MG	N021710	003	Dec 10, 2004

SOLUTION;IV (INFUSION)
CARNEXIV

	+	LUNDBECK LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016

FDA data supplied by DrugPatentWatch.com

CARBAMAZEPINE

SUSPENSION;ORAL

	CARBAMAZEPINE				
AB	WOCKHARDT	**100MG/5ML**	**A075714**	**001**	Jun 05, 2002
	TEGRETOL				
AB	+ NOVARTIS	**100MG/5ML**	**N018927**	**001**	Dec 18, 1987
	TERIL				
AB	TARO	**100MG/5ML**	**A076729**	**001**	Sep 20, 2004

TABLET;ORAL

	CARBAMAZEPINE				
AB	APOTEX INC	**200MG**	**A075948**	**001**	Feb 27, 2002
AB	TARO	**200MG**	**A074649**	**001**	Oct 03, 1996
AB	TORRENT PHARMS	**200MG**	**A077272**	**002**	Dec 07, 2005
	EPITOL				
AB	TEVA	**200MG**	**A070541**	**001**	Sep 17, 1986
	TEGRETOL				
AB	+ NOVARTIS	**200MG**	**N016608**	**001**	
	CARBAMAZEPINE				
	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005
		300MG	A077272	003	Dec 07, 2005
		400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE;ORAL

	CARBAMAZEPINE				
AB	TARO PHARM INDS	**100MG**	**A075687**	**001**	Oct 24, 2000
AB	TORRENT PHARMS	**100MG**	**A075712**	**001**	Jul 05, 2001
	EPITOL				
AB	TEVA	**100MG**	**A073524**	**001**	Jul 29, 1992
	TEGRETOL				
AB	+ NOVARTIS	**100MG**	**N018281**	**001**	
	CARBAMAZEPINE				
	+ TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

TABLET, EXTENDED RELEASE;ORAL

	CARBAMAZEPINE				
AB	TARO	**100MG**	**A078115**	**001**	Mar 31, 2009
AB		**200MG**	**A078115**	**002**	Mar 31, 2009
AB		**400MG**	**A078115**	**003**	Mar 31, 2009
	TEGRETOL-XR				
AB	NOVARTIS	**100MG**	**N020234**	**001**	Mar 25, 1996
AB		**200MG**	**N020234**	**002**	Mar 25, 1996
AB	+	**400MG**	**N020234**	**003**	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

	CARBIDOPA				
AB	ALVOGEN MALTA	**25MG**	**A204291**	**001**	Jan 08, 2016
AB	AMERIGEN PHARMS LTD	**25MG**	**A203261**	**001**	Mar 10, 2014
AB	EDENBRIDGE PHARMS	**25MG**	**A205304**	**001**	Feb 17, 2016
	LODOSYN				
AB	+ ATON	**25MG**	**N017830**	**001**	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

	CARBIDOPA, LEVODOPA AND ENTACAPONE				
AB	SUN PHARMA GLOBAL	**25MG;200MG;100MG**	**A079085**	**001**	May 10, 2012
AB		**37.5MG;200MG;150MG**	**A079085**	**002**	May 10, 2012
AB	WOCKHARDT LTD	**12.5MG;200MG;50MG**	**A090786**	**001**	Nov 20, 2012
AB		**18.75MG;200MG;75MG**	**A090833**	**001**	Nov 20, 2012
AB		**25MG;200MG;100MG**	**A090833**	**002**	Nov 20, 2012
AB		**31.25MG;200MG;125MG**	**A090833**	**003**	Nov 20, 2012
AB		**37.5MG;200MG;150MG**	**A090833**	**004**	Nov 20, 2012
AB		**50MG;200MG;200MG**	**A090833**	**005**	Nov 20, 2012
	STALEVO 100				
AB	ORION PHARMA	**25MG;200MG;100MG**	**N021485**	**002**	Jun 11, 2003
	STALEVO 125				
AB	ORION PHARMA	**31.25MG;200MG;125MG**	**N021485**	**006**	Aug 29, 2008
	STALEVO 150				
AB	ORION PHARMA	**37.5MG;200MG;150MG**	**N021485**	**003**	Jun 11, 2003
	STALEVO 200				
AB	+ ORION PHARMA	**50MG;200MG;200MG**	**N021485**	**004**	Aug 02, 2007
	STALEVO 50				
AB	+ ORION PHARMA	**12.5MG;200MG;50MG**	**N021485**	**001**	Jun 11, 2003
	STALEVO 75				
AB	ORION PHARMA	**18.75MG;200MG;75MG**	**N021485**	**005**	Aug 29, 2008

FDA data supplied by DrugPatentWatch.com

CARBIDOPA; LEVODOPA

	CAPSULE, EXTENDED RELEASE;ORAL					
	RYTARY					
		IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015
			36.25MG;145MG	N203312	002	Jan 07, 2015
			48.75MG;195MG	N203312	003	Jan 07, 2015
	+		61.25MG;245MG	N203312	004	Jan 07, 2015
	SUSPENSION;ENTERAL					
	DUOPA					
	+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015
	TABLET;ORAL					
	CARBIDOPA AND LEVODOPA					
AB		ACTAVIS ELIZABETH	**10MG;100MG**	**A074260**	**001**	Sep 03, 1993
AB			**25MG;100MG**	**A074260**	**002**	Sep 03, 1993
AB			**25MG;250MG**	**A074260**	**003**	Sep 03, 1993
AB		APOTEX INC	**10MG;100MG**	**A077120**	**001**	Jun 02, 2008
AB			**25MG;100MG**	**A077120**	**002**	Jun 02, 2008
AB			**25MG;250MG**	**A077120**	**003**	Jun 02, 2008
AB		MAYNE PHARMA	**10MG;100MG**	**A073618**	**001**	Aug 28, 1992
AB			**25MG;100MG**	**A073589**	**001**	Aug 28, 1992
AB			**25MG;250MG**	**A073607**	**001**	Aug 28, 1992
AB		MYLAN	**10MG;100MG**	**A090324**	**001**	Sep 28, 2009
AB			**25MG;100MG**	**A090324**	**002**	Sep 28, 2009
AB			**25MG;250MG**	**A090324**	**003**	Sep 28, 2009
AB		SUN PHARM INDS	**10MG;100MG**	**A078536**	**001**	Oct 28, 2008
AB			**25MG;100MG**	**A078536**	**002**	Oct 28, 2008
AB			**25MG;250MG**	**A078536**	**003**	Oct 28, 2008
	SINEMET					
AB		MERCK SHARP DOHME	**10MG;100MG**	**N017555**	**001**	
AB			**25MG;100MG**	**N017555**	**003**	
AB	**+**		**25MG;250MG**	**N017555**	**002**	
	TABLET, EXTENDED RELEASE;ORAL					
	CARBIDOPA AND LEVODOPA					
AB		ACCORD HLTHCARE	**25MG;100MG**	**A202323**	**001**	Feb 08, 2013
AB			**50MG;200MG**	**A202323**	**002**	Feb 08, 2013
AB		APOTEX	**25MG;100MG**	**A076212**	**001**	Jun 16, 2004
AB			**50MG;200MG**	**A076212**	**002**	Jun 16, 2004
AB		IMPAX LABS	**25MG;100MG**	**A076521**	**001**	May 14, 2004
AB			**50MG;200MG**	**A076521**	**002**	May 14, 2004
AB		MYLAN	**25MG;100MG**	**A075091**	**002**	Apr 21, 2000
AB			**50MG;200MG**	**A075091**	**001**	Sep 30, 1999
AB		SUN PHARM INDS	**25MG;100MG**	**A077828**	**001**	Aug 23, 2007
AB			**50MG;200MG**	**A077828**	**002**	Aug 23, 2007
	SINEMET CR					
AB		MERCK SHARP DOHME	**25MG;100MG**	**N019856**	**002**	Dec 24, 1992
AB	**+**		**50MG;200MG**	**N019856**	**001**	May 30, 1991
	TABLET, ORALLY DISINTEGRATING;ORAL					
	CARBIDOPA AND LEVODOPA					
AB		MYLAN	**10MG;100MG**	**A078893**	**001**	Sep 18, 2008
AB			**25MG;100MG**	**A078893**	**002**	Sep 18, 2008
AB	**+**		**25MG;250MG**	**A078893**	**003**	Sep 18, 2008
AB		SUN PHARMA GLOBAL	**10MG;100MG**	**A078690**	**001**	Jul 31, 2009
AB			**25MG;100MG**	**A078690**	**002**	Jul 31, 2009
AB			**25MG;250MG**	**A078690**	**003**	Jul 31, 2009

CARBINOXAMINE MALEATE

	SOLUTION;ORAL					
	CARBINOXAMINE MALEATE					
AA		CYPRESS PHARM	**4MG/5ML**	**A090418**	**001**	May 04, 2010
AA	**+**	MIKART	**4MG/5ML**	**A040458**	**001**	Apr 25, 2003
AA		VINTAGE PHARMS	**4MG/5ML**	**A040814**	**001**	Feb 26, 2008
	SUSPENSION, EXTENDED RELEASE;ORAL					
	KARBINAL ER					
	+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013
	TABLET;ORAL					
	CARBINOXAMINE MALEATE					
AA		CYPRESS PHARM	**4MG**	**A090417**	**001**	Aug 23, 2010
AA		INVAGEN PHARMS	**4MG**	**A090435**	**001**	Apr 15, 2010
AA	**+**	MIKART	**4MG**	**A040442**	**001**	Mar 19, 2003
AA		MISSION PHARMACAL CO	**4MG**	**A090756**	**001**	May 27, 2011
AA		VINTAGE PHARMS	**4MG**	**A040639**	**002**	May 30, 2008
		MIKART INC	6MG	A207484	001	May 31, 2016

FDA data supplied by DrugPatentWatch.com

CARBOPLATIN
INJECTABLE;IV (INFUSION)
CARBOPLATIN

AP		AKORN	50MG/5ML (10MG/ML)	A090475	001	Jul 29, 2009
AP			150MG/15ML (10MG/ML)	A090475	002	Jul 29, 2009
AP			450MG/45ML (10MG/ML)	A090475	003	Jul 29, 2009
AP			600MG/60ML (10MG/ML)	A091268	002	Jul 28, 2010
AP		CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007
AP			150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007
AP			450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007
AP			600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007
AP		FRESENIUS KABI ONCOL	50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006
AP			150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006
AP			450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006
AP		FRESENIUS KABI USA	450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004
AP			450MG/45ML (10MG/ML)	A077266	003	Feb 15, 2006
AP			600MG/60ML (10MG/ML)	A077266	004	Feb 15, 2006
AP		HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004
AP			150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004
AP			450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004
AP			600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004
AP		MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007
AP			150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007
AP			450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007
AP		MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011
AP			150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011
AP			450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011
AP			600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011
AP		NANJING KING-FRIEND	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005
AP			150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005
AP			450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005
AP			600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013
AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004
AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004
AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004
AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007
AP		PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008
AP			150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008
AP			450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008
AP			600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008
AP		SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008
AP			150MG/15ML (10MG/ML)	A078280	002	May 08, 2008
AP			450MG/45ML (10MG/ML)	A078280	003	May 08, 2008
AP		SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016
AP			150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016
AP			450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016
AP		SUN PHARMA GLOBAL	50MG/5ML (10MG/ML)	A077926	001	Sep 19, 2008
AP			150MG/15ML (10MG/ML)	A077926	002	Sep 19, 2008
AP			450MG/45ML (10MG/ML)	A077926	003	Sep 19, 2008
AP	+	TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005
AP	+		150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005
AP	+		450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005
AP	+		600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005
AP		WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004
AP			150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004
AP			450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004
AP			600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006
	+	MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011

CARBOPROST TROMETHAMINE
INJECTABLE;INJECTION
HEMABATE

+	PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001	

CARFILZOMIB
POWDER;INTRAVENOUS
KYPROLIS

	ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016
+		60MG/VIAL	N202714	001	Jul 20, 2012

FDA data supplied by DrugPatentWatch.com

CARGLUMIC ACID
TABLET;ORAL
CARBAGLU

+	ORPHAN EUROPE	200MG	N022562	001	Mar 18, 2010

CARIPRAZINE HYDROCHLORIDE
CAPSULE;ORAL
VRAYLAR

	FOREST RES INST INC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015
		EQ 3MG BASE	N204370	002	Sep 17, 2015
		EQ 4.5MG BASE	N204370	003	Sep 17, 2015
+		EQ 6MG BASE	N204370	004	Sep 17, 2015

CARISOPRODOL
TABLET;ORAL

	CARISOPRODOL				
AA	ACCELRX LABS	**350MG**	**A040576**	**001**	Jun 07, 2005
AA	AUROBINDO PHARMA	**350MG**	**A040792**	**001**	Aug 06, 2009
AA	INGENUS PHARMS NJ	**350MG**	**A040823**	**001**	Oct 22, 2008
AA	NATCO PHARMA LTD	**350MG**	**A090988**	**001**	Oct 28, 2014
AA	ORIENT PHARMA CO LTD	**350MG**	**A205085**	**001**	Oct 28, 2014
AA	SCIEGEN PHARMS INC	**350MG**	**A203374**	**001**	Jan 27, 2014
AA	STRIDES PHARMA	**350MG**	**A205513**	**002**	Nov 12, 2015
AA	SUN PHARM INDS	**350MG**	**A089346**	**001**	Oct 17, 1991
AA	SUN PHARM INDS LTD	**350MG**	**A040755**	**001**	Feb 27, 2007
AA	VINTAGE PHARMS	**350MG**	**A040245**	**001**	Sep 08, 1997
AA	WATSON LABS	**350MG**	**A087499**	**001**	Apr 20, 1982
AA	WILSHIRE PHARMS INC	**350MG**	**A205126**	**002**	Jul 08, 2015
	SOMA				
AA	MEDA PHARMS	**350MG**	**N011792**	**001**	
	CARISOPRODOL				
AB	AUROBINDO PHARMA	**250MG**	**A040792**	**002**	Nov 08, 2016
AB	STRIDES PHARMA	**250MG**	**A205513**	**001**	Nov 12, 2015
AB	WILSHIRE PHARMS INC	**250MG**	**A205126**	**001**	Jul 08, 2015
	SOMA				
AB +	MEDA PHARMS	**250MG**	**N011792**	**004**	Sep 13, 2007

CARMUSTINE
IMPLANT;INTRACRANIAL
GLIADEL

+	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996

INJECTABLE;INJECTION
BICNU

+	EMCURE PHARMS LTD	100MG/VIAL	N017422	001	

CARTEOLOL HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

	CARTEOLOL HYDROCHLORIDE				
AT	ALCON	**1%**	**A075476**	**001**	Jan 03, 2000
AT	BAUSCH AND LOMB	**1%**	**A075546**	**001**	Jan 20, 2000
	OCUPRESS				
AT +	NOVARTIS	**1%**	**N019972**	**001**	May 23, 1990

CARVEDILOL
TABLET;ORAL

	CARVEDILOL				
AB	APOTEX INC	**3.125MG**	**A078165**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078165**	**002**	Sep 05, 2007
AB		**12.5MG**	**A078165**	**003**	Sep 05, 2007
AB		**25MG**	**A078165**	**004**	Sep 05, 2007
AB	AUROBINDO PHARMA	**3.125MG**	**A078332**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078332**	**002**	Sep 05, 2007
AB		**12.5MG**	**A078332**	**003**	Sep 05, 2007
AB		**25MG**	**A078332**	**004**	Sep 05, 2007
AB	BEXIMCO USA	**3.125MG**	**A078384**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078384**	**002**	Sep 05, 2007
AB		**12.5MG**	**A078384**	**003**	Sep 05, 2007
AB		**25MG**	**A078384**	**004**	Sep 05, 2007
AB	CIPLA LTD	**3.125MG**	**A077474**	**001**	Sep 05, 2007
AB		**6.25MG**	**A077474**	**002**	Sep 05, 2007
AB		**12.5MG**	**A077474**	**003**	Sep 05, 2007
AB		**25MG**	**A077474**	**004**	Sep 05, 2007
AB	DR REDDYS LABS LTD	**3.125MG**	**A076649**	**001**	Sep 05, 2007
AB		**6.25MG**	**A076649**	**002**	Sep 05, 2007
AB		**12.5MG**	**A076649**	**003**	Sep 05, 2007

FDA data supplied by DrugPatentWatch.com

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB		**25MG**	**A076649**	**004**	Sep 05, 2007
AB	GLENMARK GENERICS	**3.125MG**	**A078251**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078251**	**002**	Sep 05, 2007
AB		**12.5MG**	**A078251**	**003**	Sep 05, 2007
AB		**25MG**	**A078251**	**004**	Sep 05, 2007
AB	LUPIN	**3.125MG**	**A078217**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078217**	**002**	Sep 05, 2007
AB		**12.5MG**	**A078217**	**003**	Sep 05, 2007
AB		**25MG**	**A078217**	**004**	Sep 05, 2007
AB	MYLAN	**3.125MG**	**A077316**	**001**	Sep 05, 2007
AB		**6.25MG**	**A077316**	**002**	Sep 05, 2007
AB		**12.5MG**	**A077316**	**003**	Sep 05, 2007
AB		**25MG**	**A077316**	**004**	Sep 05, 2007
AB	PLIVA HRVATSKA DOO	**3.125MG**	**A078240**	**001**	Oct 30, 2007
AB		**6.25MG**	**A078240**	**002**	Oct 30, 2007
AB		**12.5MG**	**A078240**	**003**	Oct 30, 2007
AB		**25MG**	**A078240**	**004**	Oct 30, 2007
AB	SANDOZ	**3.125MG**	**A078227**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078227**	**002**	Sep 05, 2007
AB		**12.5MG**	**A078227**	**003**	Sep 05, 2007
AB		**25MG**	**A078227**	**004**	Sep 05, 2007
AB	SUN PHARM INDS INC	**3.125MG**	**A077346**	**004**	Sep 05, 2007
AB		**6.25MG**	**A077346**	**001**	Sep 05, 2007
AB		**12.5MG**	**A077346**	**002**	Sep 05, 2007
AB		**25MG**	**A077346**	**003**	Sep 05, 2007
AB	SUN PHARM INDS LTD	**3.125MG**	**A076989**	**001**	Sep 05, 2007
AB		**6.25MG**	**A076989**	**002**	Sep 05, 2007
AB		**12.5MG**	**A076989**	**003**	Sep 05, 2007
AB		**25MG**	**A076989**	**004**	Sep 05, 2007
AB	TARO	**3.125MG**	**A077780**	**001**	Sep 05, 2007
AB		**6.25MG**	**A077780**	**002**	Sep 05, 2007
AB		**12.5MG**	**A077780**	**003**	Sep 05, 2007
AB		**25MG**	**A077780**	**004**	Sep 05, 2007
AB	TEVA	**3.125MG**	**A076373**	**001**	Sep 05, 2007
AB		**6.25MG**	**A076373**	**002**	Sep 05, 2007
AB		**12.5MG**	**A076373**	**003**	Sep 05, 2007
AB		**25MG**	**A076373**	**004**	Sep 05, 2007
AB	ZYDUS PHARMS USA INC	**3.125MG**	**A077614**	**004**	Sep 05, 2007
AB		**6.25MG**	**A077614**	**001**	Sep 05, 2007
AB		**12.5MG**	**A077614**	**002**	Sep 05, 2007
AB		**25MG**	**A077614**	**003**	Sep 05, 2007

COREG

AB	SMITHKLINE BEECHAM	**3.125MG**	**N020297**	**004**	May 29, 1997
AB		**6.25MG**	**N020297**	**003**	Sep 14, 1995
AB	**+**	**12.5MG**	**N020297**	**002**	Sep 14, 1995
AB		**25MG**	**N020297**	**001**	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

COREG CR

	SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006
		20MG	N022012	002	Oct 20, 2006
+		40MG	N022012	003	Oct 20, 2006
		80MG	N022012	004	Oct 20, 2006

CASPOFUNGIN ACETATE

INJECTABLE;IV (INFUSION)

CANCIDAS

+	MERCK	50MG/VIAL	N021227	001	Jan 26, 2001
+		70MG/VIAL	N021227	002	Jan 26, 2001

POWDER;IV (INFUSION)

CASPOFUNGIN ACETATE

AP	FRESENIUS KABI USA	**50MG/VIAL**	**N206110**	**001**	Dec 30, 2016
AP		**70MG/VIAL**	**N206110**	**002**	Dec 30, 2016

CEFACLOR

CAPSULE;ORAL

CEFACLOR

AB		HIKMA	**EQ 250MG BASE**	**A065350**	**001** Apr 03, 2007
AB	**+**		**EQ 500MG BASE**	**A065350**	**002** Apr 03, 2007
AB		YUNG SHIN PHARM	**EQ 250MG BASE**	**A065146**	**001** Jan 22, 2004
AB			**EQ 500MG BASE**	**A065146**	**002** Jan 22, 2004

FOR SUSPENSION;ORAL

CEFACLOR

AB		YUNG SHIN PHARM	**EQ 125MG BASE/5ML**	**A065412**	**001** Feb 17, 2012
AB			**EQ 187MG BASE/5ML**	**A065412**	**002** Feb 17, 2012
AB			**EQ 250MG BASE/5ML**	**A065412**	**003** Feb 17, 2012
AB	**+**		**EQ 375MG BASE/5ML**	**A065412**	**004** Feb 17, 2012

TABLET, EXTENDED RELEASE;ORAL

CEFACLOR

		TEVA	EQ 375MG BASE	A065058	001 Sep 04, 2002
	+		EQ 500MG BASE	A065058	002 Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A065352**	**001** Jan 25, 2007
AB		HIKMA	**EQ 500MG BASE**	**A065311**	**001** Feb 07, 2006
AB		LUPIN	**EQ 500MG BASE**	**A065392**	**001** May 29, 2007
AB		ORCHID HLTHCARE	**EQ 500MG BASE**	**A065309**	**001** Sep 18, 2006
AB		SANDOZ	**EQ 500MG BASE**	**A062291**	**001**
AB	**+**	TEVA PHARMS	**EQ 500MG BASE**	**A065282**	**001** Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXIL

AB		AUROBINDO	**EQ 250MG BASE/5ML**	**A065349**	**001** Apr 25, 2013
AB			**EQ 500MG BASE/5ML**	**A065349**	**002** Apr 25, 2013
AB		HIKMA PHARMS	**EQ 250MG BASE/5ML**	**A091036**	**001** Nov 28, 2012
AB			**EQ 500MG BASE/5ML**	**A091036**	**002** Nov 28, 2012
AB		LUPIN	**EQ 250MG BASE/5ML**	**A065396**	**001** Feb 21, 2008
AB	**+**		**EQ 500MG BASE/5ML**	**A065396**	**002** Feb 21, 2008
AB		ORCHID HLTHCARE	**EQ 250MG BASE/5ML**	**A065307**	**002** Oct 16, 2006
AB			**EQ 500MG BASE/5ML**	**A065307**	**003** Oct 16, 2006

TABLET;ORAL

CEFADROXIL

AB		HIKMA	**EQ 1GM BASE**	**A065260**	**001** Mar 30, 2006
AB		ORCHID HLTHCARE	**EQ 1GM BASE**	**A065301**	**001** Sep 18, 2006
	+	TEVA PHARMS	EQ 1GM BASE	A062774	001 Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065303**	**001** Oct 22, 2008
AP			**EQ 1GM BASE/VIAL**	**A065303**	**002** Oct 22, 2008
AP			**EQ 10GM BASE/VIAL**	**A065306**	**001** Oct 22, 2008
AP			**EQ 20GM BASE/VIAL**	**A065306**	**002** Aug 18, 2014
AP		FACTA FARMA	**EQ 500MG BASE/VIAL**	**A063214**	**001** Dec 27, 1991
AP			**EQ 1GM BASE/VIAL**	**A063207**	**001** Dec 27, 1991
AP			**EQ 10GM BASE/VIAL**	**A063209**	**001** Dec 27, 1991
AP	**+**		**EQ 20GM BASE/VIAL**	**A063209**	**002** Apr 30, 1999
AP		HIKMA FARMACEUTICA	**EQ 500MG BASE/VIAL**	**A065047**	**001** Sep 18, 2001
AP			**EQ 1GM BASE/VIAL**	**A065047**	**002** Sep 18, 2001
AP			**EQ 10GM BASE/VIAL**	**A065143**	**001** Oct 18, 2004
AP	**+**	HOSPIRA INC	**EQ 500MG BASE/VIAL**	**A065226**	**001** Apr 21, 2005
AP	**+**		**EQ 1GM BASE/VIAL**	**A065226**	**002** Apr 21, 2005
AP	**+**		**EQ 1GM BASE/VIAL**	**A065244**	**001** Aug 12, 2005
AP			**EQ 1GM BASE/VIAL**	**A201654**	**001** Feb 03, 2016
AP	**+**		**EQ 10GM BASE/VIAL**	**A065247**	**001** Aug 12, 2005
AP		QILU PHARM CO LTD	**EQ 1GM BASE/VIAL**	**A203661**	**001** Dec 28, 2015
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A062831**	**001** Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A062831**	**002** Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A065345**	**001** May 09, 2007
AP			**EQ 10GM BASE/VIAL**	**A062831**	**003** Sep 25, 1992

KEFZOL

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A061773**	**002**
AP			**EQ 1GM BASE/VIAL**	**A061773**	**003**
AP			**EQ 10GM BASE/VIAL**	**A061773**	**004**

ANCEF IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001 Mar 28, 1991

FDA data supplied by DrugPatentWatch.com

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

ANCEF IN PLASTIC CONTAINER

+		EQ 20MG BASE/ML	A063002	002	Mar 28, 1991

CEFAZOLIN AND DEXTROSE

+	B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012

CEFAZOLIN SODIUM

+	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
+		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

	BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015

CEFDINIR

CAPSULE;ORAL

CEFDINIR

AB		AUROBINDO PHARMA	**300MG**	**A065434**	**001**	Jan 07, 2008
AB		LUPIN	**300MG**	**A065264**	**001**	May 19, 2006
AB		ORCHID HLTHCARE	**300MG**	**A065418**	**001**	Jul 18, 2007
AB	**+**	SANDOZ	**300MG**	**A065330**	**001**	Apr 06, 2007
AB		TEVA PHARMS	**300MG**	**A065368**	**001**	May 09, 2007

FOR SUSPENSION;ORAL

CEFDINIR

AB		AUROBINDO PHARMA	**125MG/5ML**	**A065473**	**001**	Dec 14, 2007
AB			**250MG/5ML**	**A065473**	**002**	Dec 14, 2007
AB		LUPIN	**125MG/5ML**	**A065259**	**001**	May 31, 2006
AB			**250MG/5ML**	**A065259**	**002**	May 07, 2007
AB		ORCHID HLTHCARE	**125MG/5ML**	**A065429**	**001**	Jul 18, 2007
AB			**250MG/5ML**	**A065429**	**002**	Jul 18, 2007
AB		SANDOZ	**125MG/5ML**	**A065337**	**001**	Apr 06, 2007
AB	**+**		**250MG/5ML**	**A065337**	**002**	Apr 06, 2007
AB		TEVA PHARMS	**125MG/5ML**	**A065332**	**001**	May 04, 2007
AB			**250MG/5ML**	**A065332**	**002**	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065441**	**001**	Mar 20, 2008
AP			**EQ 2GM BASE/VIAL**	**A065441**	**002**	Mar 20, 2008
AP		HOSPIRA INC	**EQ 500MG BASE/VIAL**	**A065369**	**001**	Jun 18, 2007
AP			**EQ 1GM BASE/VIAL**	**A065369**	**002**	Jun 18, 2007
AP			**EQ 1GM BASE/VIAL**	**A202268**	**001**	Jul 30, 2012
AP			**EQ 2GM BASE/VIAL**	**A065369**	**003**	Jun 18, 2007
AP			**EQ 2GM BASE/VIAL**	**A202268**	**002**	Jul 30, 2012
AP		QILU PHARM CO LTD	**EQ 500MG BASE/VIAL**	**A203704**	**001**	Feb 01, 2016
AP			**EQ 1GM BASE/VIAL**	**A203704**	**002**	Feb 01, 2016
AP			**EQ 2GM BASE/VIAL**	**A203704**	**003**	Feb 01, 2016
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A091048**	**001**	Jan 04, 2017
AP			**EQ 2GM BASE/VIAL**	**A091048**	**002**	Jan 04, 2017

MAXIPIME

AP	**+**	HOSPIRA INC	**EQ 500MG BASE/VIAL**	**N050679**	**001**	Jan 18, 1996
AP	**+**		**EQ 1GM BASE/VIAL**	**N050679**	**002**	Jan 18, 1996
AP	**+**		**EQ 2GM BASE/VIAL**	**N050679**	**003**	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
+		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008

CEFIXIME

CAPSULE;ORAL

SUPRAX

+	LUPIN LTD	400MG	N203195	001	Jun 01, 2012

FOR SUSPENSION;ORAL

CEFIXIME

AB		AUROBINDO PHARMA LTD	**100MG/5ML**	**A204835**	**001**	Apr 14, 2015
AB			**200MG/5ML**	**A204835**	**002**	Apr 14, 2015

SUPRAX

AB		LUPIN PHARMS	**100MG/5ML**	**A065129**	**001**	Feb 23, 2004
AB			**200MG/5ML**	**A065355**	**001**	Apr 10, 2007
	+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013

FDA data supplied by DrugPatentWatch.com

CEFIXIME

TABLET;ORAL

SUPRAX

+	LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004

TABLET, CHEWABLE;ORAL

SUPRAX

	LUPIN LTD	100MG	A065380	001	Oct 25, 2010
		150MG	A065380	002	Oct 25, 2010
+		200MG	A065380	003	Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME

AP	HIKMA	**EQ 500MG BASE/VIAL**	**A065072**	**001**	Nov 20, 2002
AP		**EQ 1GM BASE/VIAL**	**A065072**	**002**	Nov 20, 2002
AP		**EQ 2GM BASE/VIAL**	**A065072**	**003**	Nov 20, 2002
AP		**EQ 10GM BASE/VIAL**	**A065071**	**001**	Nov 20, 2002
AP	WOCKHARDT	**EQ 1GM BASE/VIAL**	**A065197**	**001**	Aug 29, 2006

CEFOTAXIME SODIUM

AP	HOSPIRA INC	**EQ 500MG BASE/VIAL**	**A065290**	**001**	Aug 11, 2006
AP		**EQ 1GM BASE/VIAL**	**A065290**	**002**	Aug 11, 2006
AP		**EQ 1GM BASE/VIAL**	**A065293**	**001**	Aug 10, 2006
AP		**EQ 1GM BASE/VIAL**	**A203132**	**001**	Feb 19, 2016
AP		**EQ 2GM BASE/VIAL**	**A065290**	**003**	Aug 11, 2006
AP		**EQ 2GM BASE/VIAL**	**A065293**	**002**	Aug 10, 2006
AP		**EQ 2GM BASE/VIAL**	**A203132**	**002**	Feb 19, 2016
AP		**EQ 10GM BASE/VIAL**	**A065292**	**001**	Aug 10, 2006
AP	LUPIN	**EQ 500MG BASE/VIAL**	**A065124**	**001**	Sep 24, 2003
AP		**EQ 1GM BASE/VIAL**	**A065124**	**002**	Sep 24, 2003
AP		**EQ 2GM BASE/VIAL**	**A065124**	**003**	Sep 24, 2003
AP	WOCKHARDT	**EQ 500MG BASE/VIAL**	**A065197**	**002**	Jun 20, 2008
AP		**EQ 2GM BASE/VIAL**	**A065197**	**003**	Jun 20, 2008

CLAFORAN

AP	+ SANOFI AVENTIS US	**EQ 1GM BASE/VIAL**	**A062659**	**001**	Jan 13, 1987
AP	+	**EQ 2GM BASE/VIAL**	**A062659**	**002**	Jan 13, 1987
AP	+ US PHARM HOLDINGS	**EQ 500MG BASE/VIAL**	**N050547**	**001**	
AP	+	**EQ 1GM BASE/VIAL**	**N050547**	**002**	
AP	+	**EQ 2GM BASE/VIAL**	**N050547**	**003**	
AP	+	**EQ 10GM BASE/VIAL**	**N050547**	**004**	Dec 29, 1983

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

AP	TELIGENT PHARMA INC	**EQ 1GM BASE/VIAL**	**N050588**	**001**	Dec 27, 1985
AP		**EQ 2GM BASE/VIAL**	**N050588**	**002**	Dec 27, 1985

CEFOTETAN

AP	+ FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A065374**	**001**	Aug 09, 2007
AP	+	**EQ 2GM BASE/VIAL**	**A065374**	**002**	Aug 09, 2007
AP	+	**EQ 10GM BASE/VIAL**	**A065375**	**001**	Aug 09, 2007
AP	HIKMA FARMACEUTICA	**EQ 1GM BASE/VIAL**	**A091031**	**001**	Oct 26, 2011
AP		**EQ 2GM BASE/VIAL**	**A091031**	**002**	Oct 26, 2011
AP	WEST-WARD PHARM CORP	**EQ 10GM BASE/VIAL**	**A091030**	**001**	Oct 26, 2011

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

+	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007
+		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE;INJECTION

CEFOXITIN

AP	+ ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065414**	**001**	Jun 12, 2009
AP	+	**EQ 2GM BASE/VIAL**	**A065414**	**002**	Jun 12, 2009
AP	+	**EQ 10GM BASE/VIAL**	**A065415**	**001**	May 19, 2010
AP	ACS DOBFAR SPA	**EQ 1GM BASE/VIAL**	**A065467**	**001**	Aug 31, 2011
AP		**EQ 2GM BASE/VIAL**	**A065467**	**002**	Aug 31, 2011
AP		**EQ 10GM BASE/VIAL**	**A065464**	**001**	Aug 31, 2011
AP	EUROHLTH INTL SARL	**EQ 1GM BASE/VIAL**	**A065051**	**001**	Sep 11, 2000
AP		**EQ 2GM BASE/VIAL**	**A065051**	**002**	Sep 11, 2000
AP		**EQ 10GM BASE/VIAL**	**A065050**	**001**	Sep 11, 2000
AP	HIKMA FARMACEUTICA	**EQ 1GM BASE/VIAL**	**A065238**	**001**	Mar 12, 2010
AP		**EQ 2GM BASE/VIAL**	**A065238**	**002**	Mar 12, 2010
AP		**EQ 10GM BASE/VIAL**	**A065239**	**001**	Mar 02, 2010
AP	HOSPIRA INC	**EQ 1GM BASE/VIAL**	**A065313**	**001**	Jan 23, 2006
AP		**EQ 2GM BASE/VIAL**	**A065313**	**002**	Jan 23, 2006
AP		**EQ 10GM BASE/VIAL**	**A065312**	**001**	Feb 13, 2006

CEFOXITIN SODIUM
INJECTABLE;INJECTION
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP	**+**	B BRAUN	**EQ 1GM BASE/VIAL**	**N065214 001**	Mar 10, 2006
AP	**+**		**EQ 2GM BASE/VIAL**	**N065214 002**	Mar 10, 2006

MEFOXIN IN PLASTIC CONTAINER

	+	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182 001	Jan 25, 1993
	+		EQ 40MG BASE/ML	A063182 002	Jan 25, 1993

POWDER;IV (INFUSION)
CEFOXITIN IN PLASTIC CONTAINER

		SAMSON MEDCL	EQ 100GM BASE	A200938 001	Nov 16, 2015

CEFPODOXIME PROXETIL
FOR SUSPENSION;ORAL
CEFPODOXIME PROXETIL

AB		AUROBINDO PHARMA LTD	**EQ 50MG BASE/5ML**	**A065409 001**	Jun 08, 2007
AB			**EQ 100MG BASE/5ML**	**A065409 002**	Jun 08, 2007
AB		SANDOZ	**EQ 50MG BASE/5ML**	**A090031 001**	Jan 14, 2009
AB	**+**		**EQ 100MG BASE/5ML**	**A090031 002**	Jan 14, 2009

TABLET;ORAL
CEFPODOXIME PROXETIL

AB		AUROBINDO PHARMA	**EQ 100MG BASE**	**A065370 001**	Jun 11, 2007
AB			**EQ 200MG BASE**	**A065370 002**	Jun 11, 2007
AB		ORCHID HLTHCARE	**EQ 100MG BASE**	**A065388 001**	Nov 14, 2007
AB			**EQ 200MG BASE**	**A065388 002**	Nov 14, 2007
AB		SANDOZ	**EQ 100MG BASE**	**A065462 001**	May 28, 2008
AB	**+**		**EQ 200MG BASE**	**A065462 002**	May 28, 2008

CEFPROZIL
FOR SUSPENSION;ORAL
CEFPROZIL

AB		APOTEX INC	**125MG/5ML**	**A065351 001**	Feb 29, 2012
AB			**250MG/5ML**	**A065351 002**	Feb 29, 2012
AB		AUROBINDO PHARMA	**125MG/5ML**	**A065381 001**	Jan 30, 2007
AB			**250MG/5ML**	**A065381 002**	Jan 30, 2007
AB		LUPIN	**125MG/5ML**	**A065261 001**	Dec 19, 2005
AB	**+**		**250MG/5ML**	**A065261 002**	Dec 19, 2005
AB		ORCHID HLTHCARE	**125MG/5ML**	**A065284 002**	Dec 30, 2005
AB			**250MG/5ML**	**A065284 001**	Dec 30, 2005
AB		SANDOZ	**125MG/5ML**	**A065257 001**	Dec 08, 2005
AB			**250MG/5ML**	**A065257 002**	Dec 08, 2005
AB		TEVA PHARMS	**125MG/5ML**	**A065236 001**	Dec 08, 2005
AB			**250MG/5ML**	**A065236 002**	Dec 08, 2005

TABLET;ORAL
CEFPROZIL

AB		APOTEX INC	**250MG**	**A065327 001**	Mar 26, 2008
AB			**500MG**	**A065327 002**	Mar 26, 2008
AB		AUROBINDO PHARMA LTD	**250MG**	**A065340 001**	May 24, 2007
AB			**500MG**	**A065340 002**	May 24, 2007
AB		LUPIN	**250MG**	**A065276 001**	Dec 08, 2005
AB	**+**		**500MG**	**A065276 002**	Dec 08, 2005
AB		ORCHID HLTHCARE	**250MG**	**A065267 001**	Dec 19, 2005
AB			**500MG**	**A065267 002**	Dec 19, 2005
AB		SANDOZ	**250MG**	**A065235 001**	Nov 14, 2005
AB			**500MG**	**A065235 002**	Nov 14, 2005
AB		TEVA	**250MG**	**A065208 001**	Dec 06, 2005
AB			**500MG**	**A065208 002**	Dec 06, 2005
AB		WOCKHARDT	**250MG**	**A065428 001**	Jun 14, 2007
AB			**500MG**	**A065428 002**	Jun 14, 2007

CEFTAROLINE FOSAMIL
POWDER;IV (INFUSION)
TEFLARO

		CEREXA	400MG/VIAL	N200327 001	Oct 29, 2010
	+		600MG/VIAL	N200327 002	Oct 29, 2010

CEFTAZIDIME
INJECTABLE;INJECTION
CEFTAZIDIME

AP		ACS DOBFAR	**500MG/VIAL**	**A062640 001**	Nov 20, 1985
AP			**1GM/VIAL**	**A062640 002**	Nov 20, 1985
AP			**2GM/VIAL**	**A062640 003**	Nov 20, 1985
AP			**6GM/VIAL**	**A062640 004**	Feb 03, 1992
AP		WOCKHARDT	**1GM/VIAL**	**A065196 001**	Oct 15, 2008

FDA data supplied by DrugPatentWatch.com

CEFTAZIDIME
INJECTABLE;INJECTION

		FORTAZ				
AP	**+**	IGI LABS INC	**500MG/VIAL**	**N050578**	**001**	Jul 19, 1985
AP	**+**		**1GM/VIAL**	**N050578**	**002**	Jul 19, 1985
AP	**+**		**2GM/VIAL**	**N050578**	**003**	Jul 19, 1985
AP	**+**		**6GM/VIAL**	**N050578**	**004**	Jul 19, 1985
		TAZICEF				
AP		HOSPIRA	**500MG/VIAL**	**A062662**	**001**	Mar 06, 1986
AP			**1GM/VIAL**	**A062662**	**002**	Mar 06, 1986
AP			**1GM/VIAL**	**A064032**	**001**	Oct 31, 1993
AP			**2GM/VIAL**	**A062662**	**003**	Mar 06, 1986
AP			**2GM/VIAL**	**A064032**	**002**	Oct 31, 1993
AP			**6GM/VIAL**	**A062662**	**004**	Mar 06, 1986
		CEFTAZIDIME IN DEXTROSE CONTAINER				
		B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011
	+		EQ 2GM BASE	N050823	002	Jun 13, 2011

CEFTAZIDIME SODIUM
INJECTABLE;INJECTION

		FORTAZ IN PLASTIC CONTAINER				
	+	IGI LABS INC	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM
POWDER;IV (INFUSION)

		ZERBAXA				
	+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014

CEFTRIAXONE SODIUM
INJECTABLE;INJECTION

		CEFTRIAXONE				
AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065329**	**001**	Jul 24, 2008
AP			**EQ 1GM BASE/VIAL**	**A065329**	**002**	Jul 24, 2008
AP			**EQ 2GM BASE/VIAL**	**A065329**	**003**	Jul 24, 2008
AP			**EQ 10GM BASE/VIAL**	**A065328**	**001**	Jul 24, 2008
AP		BEDFORD	**EQ 10GM BASE/VIAL**	**A065475**	**001**	Aug 18, 2008
AP		FACTA FARMA	**EQ 10GM BASE/VIAL**	**A065269**	**001**	Feb 28, 2007
AP		HOSPIRA INC	**EQ 10GM BASE/VIAL**	**A065232**	**001**	Aug 02, 2005
AP		LUPIN	**EQ 10GM BASE/VIAL**	**A065263**	**001**	Sep 12, 2006
AP	**+**	SANDOZ	**EQ 10GM BASE/VIAL**	**A065168**	**001**	May 17, 2005
AP	**+**	SANDOZ INC	**EQ 1GM BASE/VIAL**	**A065204**	**001**	May 03, 2005
AP	**+**		**EQ 2GM BASE/VIAL**	**A065204**	**002**	May 03, 2005
AP		WOCKHARDT	**EQ 1GM BASE/VIAL**	**A065180**	**001**	May 12, 2006
		CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER				
AP	**+**	B BRAUN	**EQ 1GM BASE/VIAL**	**N050796**	**001**	Apr 20, 2005
AP	**+**		**EQ 2GM BASE/VIAL**	**N050796**	**002**	Apr 20, 2005
		CEFTRIAXONE				
		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014
		CEFTRIAXONE IN PLASTIC CONTAINER				
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
	+		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

		CEFTRIAXONE				
AP		AKORN INC	**EQ 250MG BASE/VIAL**	**A065305**	**001**	Jan 11, 2008
AP			**EQ 500MG BASE/VIAL**	**A065305**	**002**	Jan 11, 2008
AP			**EQ 1GM BASE/VIAL**	**A065305**	**003**	Jan 11, 2008
AP			**EQ 2GM BASE/VIAL**	**A065305**	**004**	Jan 11, 2008
AP		HIKMA FARMACEUTICA	**EQ 250MG BASE/VIAL**	**A065342**	**001**	Jan 10, 2008
AP			**EQ 500MG BASE/VIAL**	**A065342**	**002**	Jan 10, 2008
AP			**EQ 1GM BASE/VIAL**	**A065342**	**003**	Jan 10, 2008
AP			**EQ 2GM BASE/VIAL**	**A065342**	**004**	Jan 10, 2008
AP		HOSPIRA INC	**EQ 250MG BASE/VIAL**	**A065230**	**001**	Aug 02, 2005
AP			**EQ 500MG BASE/VIAL**	**A065230**	**002**	Aug 02, 2005
AP			**EQ 1GM BASE/VIAL**	**A065230**	**003**	Aug 02, 2005
AP			**EQ 2GM BASE/VIAL**	**A065230**	**004**	Aug 02, 2005
AP		LUPIN	**EQ 250MG BASE/VIAL**	**A065125**	**001**	Sep 30, 2003
AP			**EQ 500MG BASE/VIAL**	**A065125**	**002**	Sep 30, 2003
AP			**EQ 1GM BASE/VIAL**	**A065125**	**003**	Sep 30, 2003
AP			**EQ 2GM BASE/VIAL**	**A065125**	**004**	Sep 30, 2003
AP		QILU PHARM CO LTD	**EQ 250MG BASE/VIAL**	**A203702**	**001**	Jun 29, 2016
AP			**EQ 500MG BASE/VIAL**	**A203702**	**002**	Jun 29, 2016
AP			**EQ 1GM BASE/VIAL**	**A203702**	**003**	Jun 29, 2016
AP			**EQ 2GM BASE/VIAL**	**A203702**	**004**	Jun 29, 2016

CEFTRIAXONE SODIUM
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

		CEFTRIAXONE				
AP	+	SANDOZ	**EQ 250MG BASE/VIAL**	**A065169**	**001**	May 09, 2005
AP	+		**EQ 500MG BASE/VIAL**	**A065169**	**002**	May 09, 2005
AP	+		**EQ 1GM BASE/VIAL**	**A065169**	**003**	May 09, 2005
AP	+		**EQ 2GM BASE/VIAL**	**A065169**	**004**	May 09, 2005
AP		WOCKHARDT	**EQ 250MG BASE/VIAL**	**A065391**	**001**	Apr 12, 2007
AP			**EQ 500MG BASE/VIAL**	**A065391**	**002**	Apr 12, 2007
AP			**EQ 2GM BASE/VIAL**	**A065391**	**003**	Apr 12, 2007

CEFUROXIME AXETIL
FOR SUSPENSION;ORAL

		CEFTIN				
		GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994
	+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997

TABLET;ORAL

		CEFTIN				
AB		GLAXOSMITHKLINE	**EQ 125MG BASE**	**N050605**	**001**	Dec 28, 1987
AB			**EQ 250MG BASE**	**N050605**	**002**	Dec 28, 1987
AB	+		**EQ 500MG BASE**	**N050605**	**003**	Dec 28, 1987
		CEFUROXIME AXETIL				
AB		ALKEM LABS LTD	**EQ 250MG BASE**	**A065496**	**001**	Jun 07, 2010
AB			**EQ 500MG BASE**	**A065496**	**002**	Jun 07, 2010
AB		ANI PHARMS INC	**EQ 250MG BASE**	**A065190**	**001**	Oct 18, 2004
AB			**EQ 500MG BASE**	**A065190**	**002**	Oct 18, 2004
AB		APOTEX	**EQ 250MG BASE**	**A065069**	**001**	Oct 02, 2002
AB			**EQ 500MG BASE**	**A065069**	**002**	Oct 02, 2002
AB		AUROBINDO PHARMA LTD	**EQ 125MG BASE**	**A065308**	**001**	Mar 29, 2006
AB			**EQ 250MG BASE**	**A065308**	**002**	Mar 29, 2006
AB			**EQ 500MG BASE**	**A065308**	**003**	Mar 29, 2006
AB		LUPIN	**EQ 250MG BASE**	**A065135**	**001**	Jul 25, 2003
AB			**EQ 500MG BASE**	**A065135**	**002**	Jul 25, 2003
AB		ORCHID HLTHCARE	**EQ 125MG BASE**	**A065359**	**001**	Feb 15, 2008
AB			**EQ 250MG BASE**	**A065359**	**002**	Feb 15, 2008
AB			**EQ 500MG BASE**	**A065359**	**003**	Feb 15, 2008
AB		WOCKHARDT	**EQ 125MG BASE**	**A065166**	**001**	Jul 29, 2005
AB			**EQ 250MG BASE**	**A065166**	**002**	Jul 29, 2005
AB			**EQ 500MG BASE**	**A065166**	**003**	Jul 29, 2005

CEFUROXIME SODIUM
INJECTABLE;INJECTION

		CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER				
AP	+	B BRAUN	**EQ 750MG BASE/VIAL**	**N050780**	**001**	Feb 21, 2001
AP	+		**EQ 1.5GM BASE/VIAL**	**N050780**	**002**	Feb 21, 2001
		CEFUROXIME SODIUM				
AP		FACTA FARMA	**EQ 1.5GM BASE/VIAL**	**A064125**	**002**	May 30, 1997
AP			**EQ 7.5GM BASE/VIAL**	**A064124**	**001**	May 30, 1997
AP		HIKMA FARMACEUTICA	**EQ 1.5GM BASE/VIAL**	**A065048**	**002**	Jan 09, 2004
AP			**EQ 7.5GM BASE/VIAL**	**A065046**	**001**	Jan 09, 2004
AP		HOSPIRA INC	**EQ 1.5GM BASE/VIAL**	**A065483**	**002**	Oct 15, 2008
AP			**EQ 1.5GM BASE/VIAL**	**A065503**	**001**	Oct 15, 2008
AP			**EQ 7.5GM BASE/VIAL**	**A065484**	**001**	Oct 15, 2008
		ZINACEF				
AP	+	IGI LABS INC	**EQ 1.5GM BASE/VIAL**	**N050558**	**003**	Oct 19, 1983
AP	+		**EQ 7.5GM BASE/VIAL**	**N050558**	**004**	Oct 23, 1986
		ZINACEF IN PLASTIC CONTAINER				
	+	IGI LABS INC	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

		CEFUROXIME SODIUM				
AB		FACTA FARMA	**EQ 750MG BASE/VIAL**	**A064125**	**001**	May 30, 1997
AB		HIKMA FARMACEUTICA	**EQ 750MG BASE/VIAL**	**A065048**	**001**	Jan 09, 2004
		ZINACEF				
AB	+	IGI LABS INC	**EQ 750MG BASE/VIAL**	**N050558**	**002**	Oct 19, 1983
		CEFUROXIME SODIUM				
AP		HOSPIRA INC	**EQ 750MG BASE/VIAL**	**A065483**	**001**	Oct 15, 2008

CELECOXIB
CAPSULE;ORAL

		CELEBREX				
AB		GD SEARLE	**50MG**	**N020998**	**004**	Dec 15, 2006
AB			**100MG**	**N020998**	**001**	Dec 31, 1998
AB			**200MG**	**N020998**	**002**	Dec 31, 1998
AB	+		**400MG**	**N020998**	**003**	Aug 29, 2002

CELECOXIB
CAPSULE;ORAL
CELECOXIB

AB	ALEMBIC PHARMS LTD	**50MG**	**A204519**	**001**	Aug 21, 2015
AB		**100MG**	**A204519**	**002**	Aug 21, 2015
AB		**200MG**	**A204519**	**003**	Aug 21, 2015
AB		**400MG**	**A204519**	**004**	Aug 21, 2015
AB	APOTEX INC	**50MG**	**A204197**	**001**	Jun 02, 2015
AB		**100MG**	**A204197**	**002**	Jun 02, 2015
AB		**200MG**	**A204197**	**003**	Jun 02, 2015
AB	AUROBINDO PHARMA LTD	**50MG**	**A206827**	**001**	Feb 01, 2016
AB		**100MG**	**A206827**	**002**	Feb 01, 2016
AB		**200MG**	**A206827**	**003**	Feb 01, 2016
AB		**400MG**	**A206827**	**004**	Feb 01, 2016
AB	CIPLA LTD	**50MG**	**A207446**	**001**	Sep 23, 2015
AB		**100MG**	**A207446**	**002**	Sep 23, 2015
AB		**200MG**	**A207446**	**003**	Sep 23, 2015
AB		**400MG**	**A207446**	**004**	Sep 23, 2015
AB	LUPIN LTD	**50MG**	**A202240**	**001**	Oct 29, 2014
AB		**100MG**	**A202240**	**002**	Jun 09, 2015
AB		**200MG**	**A202240**	**003**	Jun 09, 2015
AB		**400MG**	**A202240**	**004**	Jun 09, 2015
AB	MACLEODS PHARMS LTD	**50MG**	**A204590**	**001**	Mar 16, 2016
AB		**100MG**	**A204590**	**002**	Mar 16, 2016
AB		**200MG**	**A204590**	**003**	Mar 16, 2016
AB		**400MG**	**A204590**	**004**	Mar 16, 2016
AB	MYLAN PHARMS INC	**50MG**	**A078857**	**001**	May 30, 2014
AB		**100MG**	**A078857**	**002**	Feb 11, 2015
AB		**200MG**	**A078857**	**003**	Feb 11, 2015
AB		**400MG**	**A078857**	**004**	Feb 11, 2015
AB	TEVA	**50MG**	**A076898**	**001**	May 30, 2014
AB		**100MG**	**A076898**	**002**	May 30, 2014
AB		**200MG**	**A076898**	**003**	May 30, 2014
AB		**400MG**	**A076898**	**004**	May 30, 2014
AB	TORRENT PHARMS LTD	**50MG**	**A207677**	**001**	Dec 23, 2015
AB		**100MG**	**A207677**	**002**	Dec 23, 2015
AB		**200MG**	**A207677**	**003**	Dec 23, 2015
AB		**400MG**	**A207677**	**004**	Dec 23, 2015
AB	WATSON LABS INC	**50MG**	**A200562**	**001**	Feb 11, 2015
AB		**100MG**	**A200562**	**002**	Feb 11, 2015
AB		**200MG**	**A200562**	**003**	Feb 11, 2015
AB		**400MG**	**A200562**	**004**	Feb 11, 2015

CEPHALEXIN
CAPSULE;ORAL
CEPHALEXIN

AB	ALKEM LABS LTD	**EQ 250MG BASE**	**A090836**	**001**	Dec 20, 2010
AB		**EQ 500MG BASE**	**A090836**	**002**	Dec 20, 2010
AB		**EQ 750MG BASE**	**A090836**	**004**	Mar 29, 2013
AB	AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A065253**	**001**	Nov 16, 2005
AB		**EQ 500MG BASE**	**A065253**	**002**	Nov 16, 2005
AB	BELCHER PHARMS	**EQ 250MG BASE**	**A062713**	**001**	Jul 15, 1988
AB		**EQ 500MG BASE**	**A062713**	**002**	Jul 15, 1988
AB	HIKMA	**EQ 250MG BASE**	**A065215**	**001**	Jan 24, 2006
AB		**EQ 500MG BASE**	**A065215**	**002**	Jan 24, 2006
AB	LUPIN	**EQ 250MG BASE**	**A065229**	**001**	Nov 25, 2005
AB		**EQ 500MG BASE**	**A065229**	**002**	Nov 25, 2005
AB	ORCHID HLTHCARE	**EQ 250MG BASE**	**A065248**	**001**	Jun 28, 2005
AB		**EQ 500MG BASE**	**A065248**	**002**	Jun 28, 2005
AB	SUN PHARM INDS (IN)	**EQ 250MG BASE**	**A062791**	**001**	Jun 11, 1987
AB		**EQ 500MG BASE**	**A062791**	**002**	Jun 11, 1987
AB	TEVA	**EQ 250MG BASE**	**A062702**	**001**	Feb 13, 1987
AB		**EQ 500MG BASE**	**A062702**	**002**	Feb 13, 1987
AB	YUNG SHIN PHARM	**EQ 250MG BASE**	**A065152**	**001**	Feb 24, 2005
AB		**EQ 500MG BASE**	**A065152**	**002**	Feb 24, 2005
	KEFLEX				
AB	PRAGMA PHARMS LLC	**EQ 250MG BASE**	**N050405**	**002**	
AB		**EQ 500MG BASE**	**N050405**	**003**	
AB	**+**	**EQ 750MG BASE**	**N050405**	**005**	May 12, 2006
	CEPHALEXIN				
	ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013

CEPHALEXIN
FOR SUSPENSION;ORAL
CEPHALEXIN

AB		LUPIN	**EQ 125MG BASE/5ML**	**A065234 001**	Aug 17, 2005
AB			**EQ 250MG BASE/5ML**	**A065234 002**	Aug 17, 2005
AB		ORCHID HLTHCARE	**EQ 125MG BASE/5ML**	**A065326 001**	Jul 10, 2006
AB			**EQ 250MG BASE/5ML**	**A065326 002**	Jul 10, 2006
AB		TEVA	**EQ 125MG BASE/5ML**	**A062703 001**	Feb 13, 1987
AB	**+**		**EQ 250MG BASE/5ML**	**A062703 002**	Feb 13, 1987

TABLET;ORAL
CEPHALEXIN

		TEVA	EQ 250MG BASE	A063023 001	Jan 12, 1989
	+		EQ 500MG BASE	A063024 001	Jan 12, 1989

CERITINIB
CAPSULE;ORAL
ZYKADIA

	+	NOVARTIS PHARMS CORP	150MG	N205755 001	Apr 29, 2014

CETIRIZINE HYDROCHLORIDE
SYRUP;ORAL
CETIRIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**5MG/5ML**	**A090766 001**	Oct 07, 2009
AA		BIO PHARM INC	**5MG/5ML**	**A078870 001**	Apr 27, 2009
AA		BRECKENRIDGE PHARM	**5MG/5ML**	**A078488 001**	Oct 06, 2008
AA		NOSTRUM LABS INC	**5MG/5ML**	**A090191 001**	Nov 12, 2009
AA	**+**	PERRIGO R AND D	**5MG/5ML**	**A078398 001**	Jun 17, 2008
AA		SILARX	**5MG/5ML**	**A078876 001**	May 11, 2012
AA		TARO	**5MG/5ML**	**A076601 001**	Jun 20, 2008
AA		TEVA PHARMS	**5MG/5ML**	**A077279 001**	May 27, 2008
AA		VINTAGE	**5MG/5ML**	**A078496 001**	Sep 25, 2009

CETRORELIX
INJECTABLE;INJECTION
CETROTIDE

	+	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197 001	Aug 11, 2000

CEVIMELINE HYDROCHLORIDE
CAPSULE;ORAL
CEVIMELINE HYDROCHLORIDE

AB		APOTEX INC	**30MG**	**A091260 001**	Aug 25, 2011
AB		NOVEL LABS INC	**30MG**	**A204746 001**	Dec 30, 2016
AB		PACK PHARMS LLC	**30MG**	**A203775 001**	Jun 04, 2014
AB		WEST-WARD PHARMS INT	**30MG**	**A091591 001**	Jul 08, 2013

EVOXAC

AB	**+**	DAIICHI SANKYO INC	**30MG**	**N020989 002**	Jan 11, 2000

CHENODIOL
TABLET;ORAL
CHENODIOL

	+	NEXGEN PHARMA	250MG	A091019 001	Oct 22, 2009

CHLORAMBUCIL
TABLET;ORAL
LEUKERAN

	+	ASPEN GLOBAL INC	2MG	N010669 002	

CHLORAMPHENICOL SODIUM SUCCINATE
INJECTABLE;INJECTION
CHLORAMPHENICOL SODIUM SUCCINATE

	+	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365 001	Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE
CAPSULE;ORAL
CHLORDIAZEPOXIDE HYDROCHLORIDE

AB		BARR	**5MG**	**A084768 001**	
AB			**10MG**	**A083116 001**	
AB			**25MG**	**A084769 001**	
AB		USL PHARMA	**10MG**	**A084623 001**	

LIBRIUM

AB		VALEANT PHARM INTL	**5MG**	**A085461 001**	
AB			**10MG**	**A085472 001**	
AB	**+**		**25MG**	**A085475 001**	

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL					
LIBRAX					
	+	VALEANT PHARMS	5MG;2.5MG	N012750 001	

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL					
CHLORHEXIDINE GLUCONATE					
AT		HI TECH PHARMA	**0.12%**	**A074356 001**	May 07, 1996
AT		LYNE	**0.12%**	**A074291 001**	Dec 28, 1995
AT		TEVA	**0.12%**	**A074522 001**	Dec 15, 1995
AT		WOCKHARDT	**0.12%**	**A075006 001**	Mar 03, 2004
AT		XTTRIUM	**0.12%**	**A077789 001**	Jun 18, 2009
PAROEX					
AT		SUNSTAR AMERICAS	**0.12%**	**A076434 001**	Nov 29, 2005
PERIDEX					
AT	**+**	3M	**0.12%**	**N019028 001**	Aug 13, 1986
PERIOGARD					
AT		COLGATE	**0.12%**	**A073695 001**	Jan 14, 1994
AT		COLGATE-PALMOLIVE CO	**0.12%**	**A203212 001**	Jan 28, 2016
TABLET;DENTAL					
PERIOCHIP					
	+	DEXCEL PHARMA	2.5MG	N020774 001	May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
CHLOROPROCAINE HYDROCHLORIDE					
AP		HOSPIRA	**2%**	**A087447 001**	Apr 16, 1982
AP			**3%**	**A087446 001**	Apr 16, 1982
AP		WEST-WARD PHARMS INT	**2%**	**A040273 001**	Sep 09, 1998
AP			**3%**	**A040273 002**	Sep 09, 1998
NESACAINE					
AP		FRESENIUS KABI USA	**2%**	**N009435 002**	
NESACAINE-MPF					
AP	**+**	FRESENIUS KABI USA	**2%**	**N009435 006**	May 02, 1996
AP	**+**		**3%**	**N009435 007**	May 02, 1996
NESACAINE					
	+	FRESENIUS KABI USA	1%	N009435 001	

CHLOROQUINE PHOSPHATE

TABLET;ORAL					
ARALEN					
AA	**+**	SANOFI AVENTIS US	**EQ 300MG BASE**	**N006002 001**	
CHLOROQUINE PHOSPHATE					
AA	**+**	HIKMA PHARMS LLC	**EQ 150MG BASE**	**A083082 001**	
AA			**EQ 300MG BASE**	**A083082 002**	Sep 17, 1999
AA		IPCA LABS LTD	**EQ 150MG BASE**	**A090610 001**	Dec 03, 2009
AA			**EQ 300MG BASE**	**A090249 001**	Dec 03, 2009
AA		NATCO PHARMA LTD	**EQ 150MG BASE**	**A091621 001**	Jan 21, 2011
AA			**EQ 300MG BASE**	**A090612 001**	Jan 21, 2011

CHLOROTHIAZIDE

SUSPENSION;ORAL					
DIURIL					
	+	SALIX PHARMS	250MG/5ML	N011870 001	
TABLET;ORAL					
CHLOROTHIAZIDE					
	+	MYLAN	250MG	A084388 001	
			500MG	A084217 001	

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION					
CHLOROTHIAZIDE SODIUM					
AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090896 001**	Oct 16, 2009
AP		LUITPOLD	**EQ 500MG BASE/VIAL**	**A202561 001**	Apr 22, 2013
AP		MYLAN INSTITUTIONAL	**EQ 500MG BASE/VIAL**	**A202493 001**	Jun 18, 2014
AP		SAGENT PHARMS	**EQ 500MG BASE/VIAL**	**A202462 001**	May 29, 2015
AP		SUN PHARMA GLOBAL	**EQ 500MG BASE/VIAL**	**A091546 001**	Jul 26, 2011
DIURIL					
AP	**+**	OAK PHARMS AKORN	**EQ 500MG BASE/VIAL**	**N011145 005**	

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

	HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE				
AA		TRIS PHARMA INC	**4MG/5ML;5MG/5ML**	**A206438 001**	Jan 27, 2015
	VITUZ				
AA	**+**	CYPRESS PHARM	**4MG/5ML;5MG/5ML**	**N204307 001**	Feb 20, 2013

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
AA		TRIS PHARMA INC	**4MG/5ML;5MG/5ML;60MG/5ML**	**A203838 001**	Nov 26, 2014
	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
AA		PADDOCK LLC	**4MG/5ML;5MG/5ML;60MG/5ML**	**A204627 001**	Apr 29, 2014
	HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
AA		MAYNE PHARMA INC	**4MG/5ML;5MG/5ML;60MG/5ML**	**A205657 001**	Aug 03, 2015
	ZUTRIPRO				
AA	**+**	CYPRESS PHARM	**4MG/5ML;5MG/5ML;60MG/5ML**	**N022439 001**	Jun 08, 2011

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

	TUZISTRA XR				
	+	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768 001	Apr 30, 2015

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

	TUSSICAPS				
		ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273 002	Sep 24, 2007
	+		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273 001	Sep 24, 2007

SUSPENSION, EXTENDED RELEASE;ORAL

	HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX				
AB		TRIS PHARMA INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**A091632 001**	Oct 01, 2010
	HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX				
AB		NEOS THERAP INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**A091671 001**	Jun 29, 2012
	TUSSIONEX PENNKINETIC				
AB	**+**	UCB INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**N019111 001**	Dec 31, 1987

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

	CHLORPROMAZINE HYDROCHLORIDE				
	+	EUROHLTH INTL SARL	25MG/ML	A083329 001	

TABLET;ORAL

	CHLORPROMAZINE HYDROCHLORIDE				
BP		USL PHARMA	10MG	A083386 001	
BP			25MG	A084112 001	
BP			50MG	A084113 001	
BP			100MG	A084114 001	
BP			200MG	A084115 001	

CHLORPROPAMIDE

TABLET;ORAL

	CHLORPROPAMIDE				
AB		ANI PHARMS INC	**100MG**	**A088921 001**	Apr 12, 1985
AB			**250MG**	**A088922 001**	Apr 12, 1985
AB		MYLAN	**100MG**	**A088549 002**	Jun 01, 1984
AB			**250MG**	**A088549 001**	Jun 01, 1984
	DIABINESE				
AB		PFIZER	**100MG**	**N011641 003**	
AB	**+**		**250MG**	**N011641 006**	

CHLORTHALIDONE

TABLET;ORAL

	CHLORTHALIDONE				
AB		MYLAN	**25MG**	**A086831 002**	
AB	**+**		**50MG**	**A086831 001**	
AB		SUN PHARM INDS	**25MG**	**A089286 002**	Jul 21, 1986
AB			**50MG**	**A089286 001**	Jul 21, 1986

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
TABLET;ORAL
CLORPRES

		MYLAN	15MG;0.1MG	A071325 003	Feb 09, 1987
			15MG;0.2MG	A071325 002	Feb 09, 1987
	+		15MG;0.3MG	A071325 001	Feb 09, 1987

CHLORZOXAZONE
TABLET;ORAL
CHLORZOXAZONE

AA		BARR	**500MG**	**A089895 001**	May 04, 1988
AA	**+**	WATSON LABS	**500MG**	**A089859 001**	May 04, 1988
		MIKART	375MG	A040861 001	Jun 01, 2010
	+		750MG	A040861 002	Jun 01, 2010
	+	MIKART INC	250MG	A207483 001	Jun 24, 2016

CHOLESTYRAMINE
POWDER;ORAL
CHOLESTYRAMINE

AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077204 001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077204 002**	Aug 26, 2005
AB	**+**	SANDOZ	**EQ 4GM RESIN/PACKET**	**A074557 001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074557 002**	Aug 15, 1996

CHOLESTYRAMINE LIGHT

AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077203 001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077203 002**	Aug 26, 2005
AB	**+**	SANDOZ	**EQ 4GM RESIN/PACKET**	**A074558 001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074558 002**	Aug 15, 1996

PREVALITE

AB		UPSHER SMITH	**EQ 4GM RESIN/PACKET**	**A073263 001**	Feb 22, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A073263 002**	Oct 30, 1997

CHOLIC ACID
CAPSULE;ORAL
CHOLBAM

		RTRX	50MG	N205750 001	Mar 17, 2015
	+		250MG	N205750 002	Mar 17, 2015

CHOLINE C-11
INJECTABLE;INTRAVENOUS
CHOLINE C-11

AP		GLOBAL ISOTOPES LLC	**4-33.1mCi/ML**	**A206319 001**	Nov 13, 2015
AP	**+**	MCPRF	**4-33.1mCi/ML**	**N203155 001**	Sep 12, 2012
AP		UNIV TX MD ANDERSON	**4-33.1mCi/ML**	**A205690 001**	Oct 29, 2015
AP		WA UNIV SCH MED	**4-33.1mCi/ML**	**A208413 001**	Jan 10, 2017

CHOLINE FENOFIBRATE
CAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

AB		ACTAVIS ELIZABETH	**EQ 45MG FENOFIBRIC ACID**	**A200920 001**	Oct 07, 2015
AB			**EQ 135MG FENOFIBRIC ACID**	**A200920 002**	Oct 07, 2015
AB		ANCHEN PHARMS	**EQ 45MG FENOFIBRIC ACID**	**A201573 002**	Jul 18, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A201573 001**	Jul 18, 2013
AB		IMPAX LABS INC	**EQ 45MG FENOFIBRIC ACID**	**A200264 001**	Sep 07, 2016
AB			**EQ 135MG FENOFIBRIC ACID**	**A200264 002**	Sep 07, 2016
AB		LUPIN LTD	**EQ 45MG FENOFIBRIC ACID**	**A200750 001**	Dec 04, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A200750 002**	Dec 04, 2013
AB		MYLAN PHARMS INC	**EQ 45MG FENOFIBRIC ACID**	**A200913 001**	Mar 25, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A200913 002**	Mar 25, 2013

TRILIPIX

AB		ABBVIE	**EQ 45MG FENOFIBRIC ACID**	**N022224 001**	Dec 15, 2008
AB	**+**		**EQ 135MG FENOFIBRIC ACID**	**N022224 002**	Dec 15, 2008

CHORIOGONADOTROPIN ALFA
INJECTABLE;SUBCUTANEOUS
OVIDREL

	+	EMD SERONO	EQ 0.25MG /0.5ML	N021149 002	Oct 06, 2003

CHROMIC CHLORIDE
INJECTABLE;INJECTION
CHROMIC CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961 001	Jun 26, 1986

FDA data supplied by DrugPatentWatch.com

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

	+	TAKEDA GMBH	0.08MG/INH	N021658	002 Jan 10, 2008
	+		0.16MG/INH	N021658	003 Jan 10, 2008

AEROSOL, METERED;NASAL

ZETONNA

	+	TAKEDA GMBH	0.037MG/INH	N202129	001 Jan 20, 2012

SPRAY, METERED;NASAL

OMNARIS

	+	TAKEDA GMBH	0.05MG/INH	N022004	001 Oct 20, 2006

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A076435**	**001** Dec 29, 2004
AB		G AND W LABS INC	**0.77%**	**A078463**	**001** Dec 20, 2010
AB		GLENMARK PHARMS	**0.77%**	**A090273**	**001** Nov 10, 2009
AB		PERRIGO	**0.77%**	**A077364**	**001** Mar 03, 2006
AB		TARO	**0.77%**	**A076790**	**001** Apr 12, 2005

LOPROX

AB	+	MEDIMETRIKS PHARMS	**0.77%**	**N018748**	**001** Dec 30, 1982

GEL;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A077896**	**001** Jun 10, 2008
AB		GLENMARK GENERICS	**0.77%**	**A091595**	**001** Feb 29, 2012
AB		PADDOCK LLC	**0.77%**	**A078266**	**001** Jan 07, 2009

LOPROX

AB	+	CNTY LINE PHARMS	**0.77%**	**N020519**	**001** Jul 21, 1997

SHAMPOO;TOPICAL

CICLOPIROX

AT		ACTAVIS MID ATLANTIC	**1%**	**A090490**	**001** Nov 24, 2009
AT		FOUGERA PHARMS	**1%**	**A090146**	**001** May 25, 2010
AT		PERRIGO	**1%**	**A078594**	**001** Feb 16, 2010
AT		TARO	**1%**	**A090269**	**001** Feb 23, 2011

LOPROX

AT	+	MEDICIS	**1%**	**N021159**	**001** Feb 28, 2003

SOLUTION;TOPICAL

CICLOPIROX

AT		ACTAVIS MID ATLANTIC	**8%**	**A078046**	**001** Sep 18, 2007
AT		AKORN	**8%**	**A078975**	**001** Feb 17, 2010
AT		APOTEX INC	**8%**	**A078172**	**001** Sep 18, 2007
AT		CIPLA LTD	**8%**	**A078124**	**001** Sep 18, 2007
AT		G AND W LABS	**8%**	**A078233**	**001** Sep 18, 2007
AT		HI TECH PHARMA	**8%**	**A078270**	**001** Sep 18, 2007
AT		PERRIGO NEW YORK	**8%**	**A077623**	**001** Sep 18, 2007
AT		TARO PHARM INDS	**8%**	**A078144**	**001** Sep 18, 2007
AT		TOLMAR	**8%**	**A077687**	**001** Sep 18, 2007

PENLAC

AT	+	VALEANT BERMUDA	**8%**	**N021022**	**001** Dec 17, 1999

SUSPENSION;TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	**0.77%**	**A076422**	**001** Aug 06, 2004
AB		PERRIGO NEW YORK	**0.77%**	**A077676**	**001** Dec 15, 2006
AB		TARO	**0.77%**	**A077092**	**001** Aug 10, 2005

LOPROX

AB	+	MEDIMETRIKS PHARMS	**0.77%**	**N019824**	**001** Dec 30, 1988

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP		EMCURE PHARMS LTD	**EQ 75MG BASE/ML**	**A202501**	**001** Jul 26, 2012
AP	+	MYLAN INSTITUTIONAL	**EQ 75MG BASE/ML**	**A201276**	**001** Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

IMIPENEM AND CILASTATIN

AP		ACS DOBFAR	**EQ 250MG BASE/VIAL;250MG/VIAL**	**A090577**	**001** Dec 21, 2011
AP			**EQ 500MG BASE/VIAL;500MG/VIAL**	**A090577**	**002** Dec 21, 2011
AP		HOSPIRA INC	**EQ 250MG BASE/VIAL;250MG/VIAL**	**A090825**	**001** Nov 16, 2011
AP			**EQ 500MG BASE/VIAL;500MG/VIAL**	**A090825**	**002** Nov 16, 2011
AP			**EQ 500MG BASE/VIAL;500MG/VIAL**	**A091007**	**001** Nov 16, 2011

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

PRIMAXIN

AP	+	MERCK	**EQ 250MG BASE/VIAL;250MG/VIAL**	**N050587**	**001**	Nov 26, 1985
AP	+		**EQ 500MG BASE/VIAL;500MG/VIAL**	**N050587**	**002**	Nov 26, 1985

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

AB		APOTEX INC	**50MG**	**A077030**	**001**	Dec 10, 2004
AB			**100MG**	**A077030**	**002**	Dec 10, 2004
AB		BIOKEY	**50MG**	**A077722**	**001**	Sep 24, 2012
AB			**100MG**	**A077831**	**001**	Sep 24, 2012
AB		BRECKENRIDGE PHARM	**50MG**	**A077708**	**001**	Sep 28, 2009
AB			**100MG**	**A077708**	**002**	Sep 28, 2009
AB		MYLAN	**50MG**	**A077323**	**002**	Apr 20, 2006
AB			**100MG**	**A077323**	**001**	Apr 20, 2006
AB		MYLAN PHARMS INC	**50MG**	**A077019**	**001**	Nov 23, 2004
AB			**100MG**	**A077019**	**002**	Nov 23, 2004
AB		PLIVA HRVATSKA DOO	**50MG**	**A077898**	**001**	Oct 29, 2007
AB			**100MG**	**A077898**	**002**	Oct 29, 2007
AB		SANDOZ	**50MG**	**A077310**	**001**	Nov 08, 2005
AB			**100MG**	**A077021**	**001**	Nov 23, 2004
AB	+	TEVA	**50MG**	**A077027**	**001**	Nov 24, 2004
AB	+		**100MG**	**A077027**	**002**	Nov 24, 2004
AB		WEST-WARD PHARMS INT	**50MG**	**A077024**	**001**	May 17, 2005
AB			**100MG**	**A077024**	**002**	May 17, 2005

CIMETIDINE

TABLET;ORAL

CIMETIDINE

AB		APOTEX	**200MG**	**A074890**	**001**	Dec 18, 1998
AB			**300MG**	**A074890**	**002**	Dec 18, 1998
AB			**400MG**	**A074890**	**003**	Dec 18, 1998
AB			**800MG**	**A074890**	**004**	Dec 18, 1998
AB		MYLAN	**200MG**	**A074246**	**001**	May 17, 1994
AB			**300MG**	**A074246**	**002**	May 17, 1994
AB			**400MG**	**A074246**	**003**	May 17, 1994
AB	+		**800MG**	**A074246**	**004**	May 17, 1994
AB		PLIVA	**800MG**	**A074566**	**001**	Feb 27, 1997
AB		TEVA	**200MG**	**A074151**	**001**	May 17, 1994
AB			**300MG**	**A074151**	**002**	May 17, 1994
AB			**400MG**	**A074151**	**003**	May 17, 1994
AB			**800MG**	**A074463**	**001**	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

AP		DAVA PHARMS INC	**EQ 300MG BASE/2ML**	**A074428**	**001**	Apr 25, 1996

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA		ANI PHARMS INC	**EQ 300MG BASE/5ML**	**A074610**	**001**	Sep 26, 1996
AA	+	HI TECH PHARMA	**EQ 300MG BASE/5ML**	**A074664**	**001**	Oct 28, 1997
AA		PHARM ASSOC	**EQ 300MG BASE/5ML**	**A074553**	**001**	Jan 27, 1997
AA		WOCKHARDT	**EQ 300MG BASE/5ML**	**A074757**	**001**	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET;ORAL

SENSIPAR

		AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004
			EQ 60MG BASE	N021688	002	Mar 08, 2004
	+		EQ 90MG BASE	N021688	003	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

AB		BAYER HLTHCARE	**250MG/5ML**	**N020780**	**001**	Sep 26, 1997
AB	+		**500MG/5ML**	**N020780**	**002**	Sep 26, 1997

CIPROFLOXACIN

AB		LUPIN LTD	**250MG/5ML**	**A200563**	**001**	Mar 05, 2014
AB			**500MG/5ML**	**A200563**	**002**	Mar 05, 2014

INJECTABLE;INJECTION

CIPRO

AP	+	BAYER HLTHCARE	**400MG/40ML (10MG/ML)**	**N019847**	**001**	Dec 26, 1990
AP	+		**200MG/20ML (10MG/ML)**	**N019847**	**002**	Dec 26, 1990

CIPROFLOXACIN

INJECTABLE;INJECTION

		CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ BAYER HLTHCARE	**200MG/100ML**	**N019857**	**001**	Dec 26, 1990
AP	+	**400MG/200ML**	**N019857**	**002**	Dec 26, 1990
		CIPROFLOXACIN			
AP	CLARIS	**200MG/20ML (10MG/ML)**	**A078062**	**001**	Apr 29, 2008
AP		**400MG/40ML (10MG/ML)**	**A078062**	**002**	Apr 29, 2008
AP	HIKMA FARMACEUTICA	**200MG/20ML (10MG/ML)**	**A076717**	**001**	Dec 22, 2009
AP		**400MG/40ML (10MG/ML)**	**A076717**	**002**	Dec 22, 2009
AP	HOSPIRA	**200MG/20ML (10MG/ML)**	**A077245**	**001**	Aug 28, 2006
AP		**400MG/40ML (10MG/ML)**	**A077245**	**002**	Aug 28, 2006
		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ACS DOBFAR INFO SA	**200MG/100ML**	**A078252**	**001**	Mar 18, 2008
AP		**400MG/200ML**	**A078252**	**002**	Mar 18, 2008
AP	CLARIS	**200MG/100ML**	**A078024**	**001**	Mar 18, 2008
AP		**400MG/200ML**	**A078024**	**002**	Mar 18, 2008
AP	HIKMA FARMACEUTICA	**400MG/200ML**	**A078431**	**001**	Nov 18, 2009
AP	HOSPIRA	**200MG/100ML**	**A077753**	**001**	Mar 18, 2008
AP		**400MG/200ML**	**A077753**	**002**	Mar 18, 2008

INJECTABLE, SUSPENSION;OTIC

		OTIPRIO			
	+ OTONOMY INC	6% (60MG/ML)	N207986	001	Dec 10, 2015

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC

		CILOXAN			
	+ NOVARTIS PHARMS CORP	EQ 0.3% BASE	N020369	001	Mar 30, 1998

SOLUTION/DROPS;OPHTHALMIC

		CILOXAN			
AT	+ NOVARTIS PHARMS CORP	**EQ 0.3% BASE**	**N019992**	**001**	Dec 31, 1990
		CIPROFLOXACIN HYDROCHLORIDE			
AT	AKORN INC	**EQ 0.3% BASE**	**A076555**	**001**	Dec 11, 2008
AT	FDC LTD	**EQ 0.3% BASE**	**A077568**	**001**	Jun 30, 2008
AT	PHARMAFORCE	**EQ 0.3% BASE**	**A078598**	**001**	Jan 16, 2008
AT	RISING PHARMS INC	**EQ 0.3% BASE**	**A077689**	**001**	Dec 13, 2006
AT	TELIGENT PHARMA INC	**EQ 0.3% BASE**	**A076754**	**001**	Jun 09, 2004
AT	WATSON LABS INC	**EQ 0.3% BASE**	**A076673**	**001**	Jan 21, 2005

SOLUTION/DROPS;OTIC

		CETRAXAL			
	+ WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009

TABLET;ORAL

		CIPRO			
AB	BAYER HLTHCARE	**EQ 100MG BASE**	**N019537**	**001**	Apr 08, 1996
AB		**EQ 250MG BASE**	**N019537**	**002**	Oct 22, 1987
AB	+	**EQ 500MG BASE**	**N019537**	**003**	Oct 22, 1987
AB		**EQ 750MG BASE**	**N019537**	**004**	Oct 22, 1987
		CIPROFLOXACIN HYDROCHLORIDE			
AB	APOTEX	**EQ 250MG BASE**	**A076896**	**001**	Nov 04, 2004
AB		**EQ 500MG BASE**	**A076896**	**002**	Nov 04, 2004
AB		**EQ 750MG BASE**	**A076896**	**003**	Nov 04, 2004
AB	AUROBINDO PHARMA	**EQ 250MG BASE**	**A077859**	**001**	Apr 26, 2007
AB		**EQ 500MG BASE**	**A077859**	**002**	Apr 26, 2007
AB		**EQ 750MG BASE**	**A077859**	**003**	Apr 26, 2007
AB	CARLSBAD	**EQ 250MG BASE**	**A076126**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076126**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076126**	**004**	Jun 09, 2004
AB	DR REDDYS LABS LTD	**EQ 100MG BASE**	**A075593**	**002**	Jun 09, 2004
AB		**EQ 250MG BASE**	**A075593**	**003**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A075593**	**004**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A075593**	**001**	Jun 09, 2004
AB	HIKMA	**EQ 250MG BASE**	**A076558**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076558**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076558**	**004**	Jun 09, 2004
AB	IVAX SUB TEVA PHARMS	**EQ 250MG BASE**	**A076089**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076089**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076089**	**004**	Jun 09, 2004
AB	MYLAN	**EQ 100MG BASE**	**A075817**	**001**	Jun 25, 2007
AB		**EQ 250MG BASE**	**A075685**	**002**	Jun 09, 2004
AB		**EQ 250MG BASE**	**A075817**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A075685**	**003**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A075817**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A075685**	**001**	Jun 09, 2004

CIPROFLOXACIN HYDROCHLORIDE
TABLET;ORAL
CIPROFLOXACIN HYDROCHLORIDE

AB		**EQ 750MG BASE**	**A075817**	**004**	Jun 09, 2004
AB	SUN PHARM INDS LTD	**EQ 250MG BASE**	**A075747**	**001**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A075747**	**002**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A075747**	**003**	Jun 09, 2004
AB	TARO	**EQ 100MG BASE**	**A076912**	**001**	Feb 18, 2005
AB		**EQ 250MG BASE**	**A076912**	**002**	Oct 06, 2004
AB		**EQ 500MG BASE**	**A076912**	**003**	Oct 06, 2004
AB		**EQ 750MG BASE**	**A076912**	**004**	Oct 06, 2004
AB	UNIQUE PHARM LABS	**EQ 250MG BASE**	**A076639**	**001**	Sep 10, 2004
AB		**EQ 500MG BASE**	**A076639**	**002**	Sep 10, 2004
AB		**EQ 750MG BASE**	**A076639**	**003**	Sep 10, 2004
AB	WATSON LABS	**EQ 100MG BASE**	**A076794**	**001**	Feb 10, 2005
AB		**EQ 250MG BASE**	**A076794**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076794**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076794**	**004**	Jun 09, 2004

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE
SOLUTION/DROPS;OTIC
OTOVEL

+	LABORATORIOS SALVAT	EQ 0.3% BASE;0.025%	N208251	001	Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE
SUSPENSION/DROPS;OTIC
CIPRO HC

+	NOVARTIS PHARMS CORP	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
CIPROFLOXACIN EXTENDED RELEASE

AB	ANCHEN PHARMS	**212.6MG;EQ 287.5MG BASE**	**A078166**	**002**	Nov 27, 2007
AB		**425.2MG;EQ 574.9MG BASE**	**A078166**	**001**	Nov 27, 2007
AB	DR REDDYS LABS LTD	**425.2MG;EQ 574.9MG BASE**	**A077701**	**001**	Mar 26, 2007
AB	**+** MYLAN PHARMS INC	**212.6MG;EQ 287.5MG BASE**	**A078183**	**001**	Mar 22, 2007
AB	**+**	**425.2MG;EQ 574.9MG BASE**	**A078183**	**002**	Mar 22, 2007

CIPROFLOXACIN; DEXAMETHASONE
SUSPENSION/DROPS;OTIC
CIPRODEX

+	NOVARTIS PHARMS CORP	0.3%;0.1%	N021537	001	Jul 18, 2003

CISATRACURIUM BESYLATE
INJECTABLE;INJECTION
CISATRACURIUM BESYLATE

AP	FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203183**	**001**	Feb 26, 2015
AP	SANDOZ INC	**EQ 2MG BASE/ML**	**A200159**	**001**	Feb 03, 2012

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203182**	**001**	Feb 26, 2015
AP		**EQ 10MG BASE/ML**	**A203182**	**002**	Feb 26, 2015
AP	SANDOZ INC	**EQ 2MG BASE/ML**	**A200154**	**001**	Feb 03, 2012
AP		**EQ 10MG BASE/ML**	**A200154**	**002**	Feb 03, 2012

NIMBEX

AP	**+** ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**001**	Dec 15, 1995

NIMBEX PRESERVATIVE FREE

AP	**+** ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**003**	Dec 15, 1995
AP	**+**	**EQ 10MG BASE/ML**	**N020551**	**002**	Dec 15, 1995

CISPLATIN
INJECTABLE;INJECTION
CISPLATIN

AP	ACCORD HLTHCARE	**1MG/ML**	**A206774**	**001**	Aug 18, 2015
AP	**+** FRESENIUS KABI USA	**1MG/ML**	**A074735**	**001**	Jul 16, 1999
AP	HQ SPCLT PHARMA	**1MG/ML**	**N018057**	**004**	Nov 08, 1988
AP	MYLAN LABS LTD	**1MG/ML**	**A091062**	**001**	Apr 18, 2012
AP	PHARMACHEMIE BV	**1MG/ML**	**A074656**	**001**	May 16, 2000
AP	WEST-WARD PHARMS INT	**1MG/ML**	**A075036**	**001**	Nov 07, 2000

CITALOPRAM HYDROBROMIDE
CAPSULE;ORAL
CITALOPRAM HYDROBROMIDE

	MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007
		EQ 20MG BASE	A077668	002	Feb 28, 2007
+		EQ 40MG BASE	A077668	003	Feb 28, 2007

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006
AA	HETERO LABS LTD III	EQ 10MG BASE/5ML	A201450	001	Dec 15, 2015
AA	SILARX	EQ 10MG BASE/5ML	A077629	001	Jun 15, 2006
AA +	WEST-WARD PHARMS INT	EQ 10MG BASE/5ML	A077043	001	Dec 13, 2004

TABLET;ORAL

CELEXA

AB	FOREST LABS	EQ 10MG BASE	N020822	001	Apr 27, 2000
AB		EQ 20MG BASE	N020822	002	Jul 17, 1998
AB +		EQ 40MG BASE	N020822	003	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

AB	AMNEAL PHARMS NY	EQ 10MG BASE	A077289	001	Nov 30, 2006
AB		EQ 20MG BASE	A077289	002	Nov 30, 2006
AB		EQ 40MG BASE	A077289	003	Nov 30, 2006
AB	APOTEX INC	EQ 10MG BASE	A077046	001	Nov 24, 2004
AB	AUROBINDO	EQ 10MG BASE	A077031	001	Oct 28, 2004
AB		EQ 20MG BASE	A077031	002	Oct 28, 2004
AB		EQ 40MG BASE	A077031	003	Oct 28, 2004
AB	CIPLA LTD	EQ 10MG BASE	A077044	001	Nov 05, 2004
AB		EQ 20MG BASE	A077044	002	Nov 05, 2004
AB		EQ 40MG BASE	A077044	003	Nov 05, 2004
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A077038	001	Oct 28, 2004
AB		EQ 20MG BASE	A077038	002	Oct 28, 2004
AB		EQ 40MG BASE	A077038	003	Oct 28, 2004
AB	EPIC PHARMA	EQ 10MG BASE	A077045	003	Apr 29, 2005
AB		EQ 20MG BASE	A077045	002	Apr 29, 2005
AB		EQ 40MG BASE	A077045	001	Apr 29, 2005
AB	G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004
AB		EQ 20MG BASE	A077048	002	Nov 16, 2004
AB		EQ 40MG BASE	A077048	003	Nov 16, 2004
AB	GLENMARK GENERICS	EQ 10MG BASE	A077654	001	Feb 27, 2009
AB		EQ 20MG BASE	A077654	002	Feb 27, 2009
AB		EQ 40MG BASE	A077654	003	Feb 27, 2009
AB	INVAGEN PHARMS	EQ 10MG BASE	A077534	001	Oct 03, 2006
AB		EQ 20MG BASE	A077534	002	Oct 03, 2006
AB		EQ 40MG BASE	A077534	003	Oct 03, 2006
AB	JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015
AB		EQ 20MG BASE	A205407	002	Dec 23, 2015
AB		EQ 40MG BASE	A205407	003	Dec 23, 2015
AB	MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005
AB		EQ 10MG BASE	A077042	001	Nov 05, 2004
AB		EQ 20MG BASE	A077039	002	Feb 03, 2005
AB		EQ 20MG BASE	A077042	002	Nov 05, 2004
AB		EQ 40MG BASE	A077039	003	Feb 03, 2005
AB		EQ 40MG BASE	A077042	003	Nov 05, 2004
AB	MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004
AB		EQ 20MG BASE	A077037	002	Nov 05, 2004
AB		EQ 40MG BASE	A077037	003	Nov 05, 2004
AB	PLIVA	EQ 10MG BASE	A077232	001	Oct 31, 2005
AB		EQ 20MG BASE	A077232	002	Oct 31, 2005
AB		EQ 40MG BASE	A077232	003	Oct 31, 2005
AB	SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004
AB		EQ 20MG BASE	A077032	002	Nov 12, 2004
AB		EQ 40MG BASE	A077032	003	Nov 12, 2004
AB	TORPHARM	EQ 20MG BASE	A077046	002	Nov 24, 2004
AB		EQ 40MG BASE	A077046	003	Nov 24, 2004
AB	TORRENT PHARMS	EQ 10MG BASE	A078216	001	Mar 27, 2007
AB		EQ 20MG BASE	A078216	002	Mar 27, 2007
AB		EQ 40MG BASE	A078216	003	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML;3.177GM/100ML	N019481	001	Oct 02, 1990

FDA data supplied by DrugPatentWatch.com

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE
FOR SOLUTION;ORAL
PREPOPIK

	+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	N202535 001	Jul 16, 2012

CITRIC ACID; UREA C-13
FOR SOLUTION, TABLET, FOR SOLUTION;ORAL
IDKIT:HP

	+	EXALENZ BIOSCIENCE	N/A,4GM;75MG,N/A	N021314 001	Dec 17, 2002

CLADRIBINE
INJECTABLE;INJECTION
CLADRIBINE

AP	+	FRESENIUS KABI USA	**1MG/ML**	**A076571 001**	Apr 22, 2004
AP		MYLAN LABS LTD	**1MG/ML**	**A200510 001**	Oct 06, 2011
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A075405 001**	Feb 28, 2000

CLARITHROMYCIN
FOR SUSPENSION;ORAL
BIAXIN

AB		ABBVIE	**125MG/5ML**	**N050698 001**	Dec 23, 1993
AB	+		**250MG/5ML**	**N050698 002**	Dec 23, 1993

CLARITHROMYCIN

AB		SANDOZ	**125MG/5ML**	**A065283 002**	Sep 04, 2007
AB			**250MG/5ML**	**A065283 003**	Sep 04, 2007
AB		SUN PHARM INDS LTD	**125MG/5ML**	**A065382 001**	Aug 30, 2007
AB			**250MG/5ML**	**A065382 002**	Aug 30, 2007

TABLET;ORAL
BIAXIN

AB	+	ABBVIE	**250MG**	**N050662 001**	Oct 31, 1991
AB	+		**500MG**	**N050662 002**	Oct 31, 1991

CLARITHROMYCIN

AB		ALLIED PHARMA INC	**250MG**	**A202710 001**	Jun 10, 2013
AB			**500MG**	**A202710 002**	Jun 10, 2013
AB		APOTEX CORP	**250MG**	**A065384 001**	Aug 20, 2007
AB			**500MG**	**A065384 002**	Aug 20, 2007
AB		AUROBINDO	**250MG**	**A065489 001**	Jul 25, 2012
AB			**500MG**	**A065489 002**	Jul 25, 2012
AB		HEC PHARM USA INC	**250MG**	**A203584 001**	Sep 28, 2015
AB			**500MG**	**A203584 002**	Sep 28, 2015
AB		MYLAN	**250MG**	**A065195 001**	Mar 11, 2005
AB			**500MG**	**A065195 002**	Mar 11, 2005
AB		SANDOZ	**250MG**	**A065144 001**	Oct 18, 2005
AB			**500MG**	**A065136 001**	Aug 25, 2005
AB		SUN PHARM INDS LTD	**250MG**	**A065174 001**	Sep 24, 2004
AB			**500MG**	**A065174 002**	Sep 24, 2004
AB		TEVA	**250MG**	**A065155 001**	May 31, 2005
AB			**500MG**	**A065155 002**	May 31, 2005
AB		WEST-WARD PHARMS INT	**250MG**	**A065178 002**	May 25, 2004
AB			**500MG**	**A065178 001**	May 25, 2004
AB		WOCKHARDT	**250MG**	**A065266 001**	May 31, 2006
AB			**500MG**	**A065266 002**	May 31, 2006

TABLET, EXTENDED RELEASE;ORAL
CLARITHROMYCIN

AB		ACTAVIS LABS FL INC	**500MG**	**A065145 001**	Jun 24, 2004
AB		ALLIED PHARMA INC	**500MG**	**A203243 001**	Feb 29, 2016
AB		LUPIN LTD	**500MG**	**A202532 001**	Sep 15, 2015
AB	+	MAYNE PHARMA	**500MG**	**A065154 001**	May 18, 2005

CLEMASTINE FUMARATE
SYRUP;ORAL
CLEMASTINE FUMARATE

AA	+	TEVA	**EQ 0.5MG BASE/5ML**	**A073399 001**	Jun 30, 1994
AA		WOCKHARDT	**EQ 0.5MG BASE/5ML**	**A074863 001**	Mar 13, 1998

TABLET;ORAL
CLEMASTINE FUMARATE

AB		SANDOZ	**2.68MG**	**A073459 001**	Oct 31, 1993
AB	+	TEVA	**2.68MG**	**A073283 001**	Jan 31, 1992

CLEVIDIPINE
EMULSION;INTRAVENOUS
CLEVIPREX

+	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008
+		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013

CLINDAMYCIN HYDROCHLORIDE
CAPSULE;ORAL

	CLEOCIN HYDROCHLORIDE				
AB	PHARMACIA AND UPJOHN	**EQ 75MG BASE**	**N050162**	**001**	
AB		**EQ 150MG BASE**	**N050162**	**002**	
AB	**+**	**EQ 300MG BASE**	**N050162**	**003**	Apr 14, 1988
	CLINDAMYCIN HYDROCHLORIDE				
AB	AUROBINDO PHARMA	**EQ 150MG BASE**	**A065442**	**001**	Aug 26, 2009
AB		**EQ 300MG BASE**	**A065442**	**002**	Aug 26, 2009
AB	COREPHARMA	**EQ 150MG BASE**	**A065194**	**001**	Mar 22, 2004
AB		**EQ 300MG BASE**	**A065194**	**002**	Mar 22, 2004
AB	G AND W LABS INC	**EQ 150MG BASE**	**A063029**	**001**	Sep 20, 1989
AB		**EQ 300MG BASE**	**A063029**	**002**	Aug 05, 2005
AB	LANNETT	**EQ 75MG BASE**	**A065242**	**001**	Aug 12, 2005
AB		**EQ 150MG BASE**	**A065242**	**002**	Aug 12, 2005
AB		**EQ 300MG BASE**	**A065243**	**001**	Aug 12, 2005
AB	MYLAN PHARMS INC	**EQ 75MG BASE**	**A091225**	**001**	May 31, 2011
AB		**EQ 150MG BASE**	**A091225**	**002**	May 31, 2011
AB		**EQ 300MG BASE**	**A091225**	**003**	May 31, 2011
AB	SUN PHARM INDS LTD	**EQ 150MG BASE**	**A065061**	**001**	Feb 02, 2001
AB		**EQ 300MG BASE**	**A065061**	**002**	Feb 02, 2001
AB	WATSON LABS	**EQ 150MG BASE**	**A063083**	**001**	Jul 31, 1991
AB		**EQ 300MG BASE**	**A063083**	**002**	Mar 18, 2003
AB	ZYDUS PHARMS USA	**EQ 75MG BASE**	**A065217**	**001**	Jan 31, 2005
AB		**EQ 150MG BASE**	**A065217**	**002**	Jan 31, 2005
AB		**EQ 300MG BASE**	**A065217**	**003**	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE
FOR SOLUTION;ORAL

	CLEOCIN				
AA	**+** PHARMACIA AND UPJOHN	**EQ 75MG BASE/5ML**	**A062644**	**001**	Apr 07, 1986
	CLINDAMYCIN PALMITATE HYDROCHLORIDE				
AA	AMNEAL PHARMS	**EQ 75MG BASE/5ML**	**A203513**	**001**	Mar 13, 2014
AA	AUROBINDO PHARMA LTD	**EQ 75MG BASE/5ML**	**A202409**	**001**	Apr 30, 2013
AA	LYNE	**EQ 75MG BASE/5ML**	**A201821**	**001**	Aug 28, 2012
AA	MYLAN PHARMS INC	**EQ 75MG BASE/5ML**	**A203063**	**001**	May 25, 2016
AA	PADDOCK LABS	**EQ 75MG BASE/5ML**	**A090902**	**001**	Jul 07, 2010

CLINDAMYCIN PHOSPHATE
AEROSOL, FOAM;TOPICAL

	CLINDAMYCIN PHOSPHATE				
AT	PERRIGO UK FINCO	**1%**	**A090785**	**001**	Mar 31, 2010
	EVOCLIN				
AT	**+** DELCOR ASSET CORP	**1%**	**N050801**	**001**	Oct 22, 2004

CREAM;VAGINAL

	CLEOCIN				
AB	**+** PHARMACIA AND UPJOHN	**EQ 2% BASE**	**N050680**	**002**	Mar 02, 1998
	CLINDAMYCIN PHOSPHATE				
AB	FOUGERA PHARMS	**EQ 2% BASE**	**A065139**	**001**	Dec 27, 2004
	CLINDESSE				
	+ PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004

GEL;TOPICAL

	CLEOCIN T				
AB	**+** PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050615**	**001**	Jan 07, 1987
	CLINDAMYCIN PHOSPHATE				
AB	FOUGERA PHARMS	**EQ 1% BASE**	**A064160**	**001**	Jan 28, 2000
	CLINDAGEL				
BT	+ PRECISION DERMAT	EQ 1% BASE	N050782	001	Nov 27, 2000

INJECTABLE;INJECTION

	CLEOCIN PHOSPHATE				
AP	PHARMACIA AND UPJOHN	**EQ 150MG BASE/ML**	**A062803**	**001**	Oct 16, 1987
AP	**+**	**EQ 150MG BASE/ML**	**N050441**	**001**	
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	**+** PHARMACIA AND UPJOHN	**EQ 6MG BASE/ML**	**N050639**	**001**	Aug 30, 1989
AP	**+**	**EQ 12MG BASE/ML**	**N050639**	**002**	Aug 30, 1989
AP	**+**	**EQ 18MG BASE/ML**	**N050639**	**003**	Apr 10, 1991

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

	CLINDAMYCIN PHOSPHATE				
AP	ALVOGEN INC	**EQ 150MG BASE/ML**	**A062800**	**001**	Jul 24, 1987
AP		**EQ 150MG BASE/ML**	**A062801**	**001**	Jul 24, 1987
AP		**EQ 150MG BASE/ML**	**A062943**	**001**	Sep 29, 1988
AP	EUROHLTH INTL SARL	**EQ 150MG BASE/ML**	**A065206**	**001**	Sep 24, 2004
AP	FRESENIUS KABI USA	**EQ 150MG BASE/ML**	**A065346**	**001**	Mar 29, 2007
AP		**EQ 150MG BASE/ML**	**A065347**	**001**	May 09, 2007
AP	SAGENT PHARMS	**EQ 150MG BASE/ML**	**A090108**	**001**	Sep 30, 2011
AP	SAGENT STRIDES	**EQ 150MG BASE/ML**	**A090109**	**001**	Sep 30, 2011
AP	WEST-WARD PHARMS INT	**EQ 150MG BASE/ML**	**A062889**	**001**	Apr 25, 1988
	CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER				
AP	AKORN INC	**EQ 6MG BASE/ML**	**A203048**	**001**	Apr 04, 2013
AP		**EQ 12MG BASE/ML**	**A203048**	**002**	Apr 04, 2013
AP		**EQ 18MG BASE/ML**	**A203048**	**003**	Apr 04, 2013
AP	SANDOZ INC	**EQ 6MG BASE/ML**	**A201692**	**001**	May 31, 2012
AP		**EQ 12MG BASE/ML**	**A201692**	**002**	May 31, 2012
AP		**EQ 18MG BASE/ML**	**A201692**	**003**	May 31, 2012
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
	+ ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989

LOTION;TOPICAL

	CLEOCIN T				
AB	**+** PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050600**	**001**	May 31, 1989
	CLINDAMYCIN PHOSPHATE				
AB	FOUGERA PHARMS	**EQ 1% BASE**	**A065067**	**001**	Jan 31, 2002

SOLUTION;TOPICAL

	CLEOCIN T				
AT	**+** PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050537**	**001**	
	CLINDA-DERM				
AT	PADDOCK LLC	**EQ 1% BASE**	**A063329**	**001**	Sep 30, 1992
	CLINDAMYCIN PHOSPHATE				
AT	FOUGERA	**EQ 1% BASE**	**A064159**	**001**	Jun 05, 1997
AT	FOUGERA PHARMS	**EQ 1% BASE**	**A065254**	**001**	Feb 14, 2006
AT	G AND W LABS INC	**EQ 1% BASE**	**A062811**	**001**	Sep 01, 1988
AT	PERRIGO NEW YORK	**EQ 1% BASE**	**A064050**	**001**	Nov 30, 1995
AT	TARO PHARM INDS	**EQ 1% BASE**	**A065184**	**001**	Mar 31, 2004
AT	TELIGENT PHARMA INC	**EQ 1% BASE**	**A206945**	**001**	Dec 30, 2016
AT	VINTAGE PHARMS	**EQ 1% BASE**	**A203343**	**001**	May 29, 2015
AT	WOCKHARDT	**EQ 1% BASE**	**A063304**	**001**	Jul 15, 1997

SUPPOSITORY;VAGINAL

	CLEOCIN				
	+ PHARMACIA AND UPJOHN	100MG	N050767	001	Aug 13, 1999

SWAB;TOPICAL

	CLEOCIN				
AT	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N050537**	**002**	Feb 22, 1994
	CLINDAMYCIN PHOSPHATE				
AT	AKORN	**EQ 1% BASE**	**A065513**	**001**	Jun 17, 2010
AT	PERRIGO NEW YORK	**EQ 1% BASE**	**A065049**	**001**	May 25, 2000
	CLINDETS				
AT	PERRIGO	**EQ 1% BASE**	**A064136**	**001**	Sep 30, 1996

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

	CLINDAMYCIN PHOSPHATE AND TRETINOIN				
AB	ACTAVIS MID ATLANTIC	**1.2%;0.025%**	**A202564**	**001**	Jun 12, 2015
	ZIANA				
AB	**+** MEDICIS	**1.2%;0.025%**	**N050802**	**001**	Nov 07, 2006
	VELTIN				
BX	+ AQUA PHARMS LLC	1.2%;0.025%	N050803	001	Jul 16, 2010

CLOBAZAM

SUSPENSION;ORAL

	ONFI				
	+ LUNDBECK LLC	2.5MG/ML	N203993	001	Dec 14, 2012

TABLET;ORAL

	ONFI				
	LUNDBECK LLC	10MG	N202067	002	Oct 21, 2011
	+	20MG	N202067	003	Oct 21, 2011

FDA data supplied by DrugPatentWatch.com

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

	CLOBETASOL PROPIONATE					
AB1		PERRIGO ISRAEL	**0.05%**	**A077763**	**001**	Mar 10, 2008
	OLUX					
AB1	**+**	DELCOR ASSET CORP	**0.05%**	**N021142**	**001**	May 26, 2000
	CLOBETASOL PROPIONATE					
AB2		PERRIGO ISRAEL	**0.05%**	**A201402**	**001**	Aug 14, 2012
	OLUX E					
AB2	**+**	DELCOR ASSET	**0.05%**	**N022013**	**001**	Jan 12, 2007

CREAM;TOPICAL

	CLOBETASOL PROPIONATE					
AB1		FOUGERA	**0.05%**	**A074392**	**001**	Sep 30, 1996
AB1		G AND W LABS INC	**0.05%**	**A074139**	**001**	Aug 03, 1994
AB1		TARO	**0.05%**	**A074249**	**001**	Jul 08, 1996
	CORMAX					
AB1	**+**	HI TECH PHARMA	**0.05%**	**A074220**	**001**	May 16, 1997
	CLOBETASOL PROPIONATE (EMOLLIENT)					
AB2	**+**	FOUGERA PHARMS	**0.05%**	**A075430**	**001**	May 26, 1999
AB2		TARO	**0.05%**	**A075633**	**001**	May 17, 2000
	EMBELINE E					
AB2		HI TECH PHARMA	**0.05%**	**A075325**	**001**	Dec 24, 1998

GEL;TOPICAL

	CLOBETASOL PROPIONATE					
AB	**+**	FOUGERA PHARMS	**0.05%**	**A075368**	**001**	Feb 15, 2000
AB		PERRIGO	**0.05%**	**A075027**	**001**	Oct 31, 1997
AB		TARO	**0.05%**	**A075279**	**001**	May 28, 1999
	EMBELINE					
AB		HI TECH PHARMA	**0.05%**	**A076141**	**001**	Apr 12, 2002

LOTION;TOPICAL

	CLOBETASOL PROPIONATE					
AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078223**	**001**	Dec 04, 2008
AB		TARO	**0.05%**	**A200302**	**001**	Jul 02, 2012
AB		TELIGENT PHARMA INC	**0.05%**	**A208667**	**001**	Nov 29, 2016
	CLOBEX					
AB	**+**	GALDERMA LABS LP	**0.05%**	**N021535**	**001**	Jul 24, 2003

OINTMENT;TOPICAL

	CLOBETASOL PROPIONATE					
AB	**+**	FOUGERA PHARMS	**0.05%**	**A074407**	**001**	Feb 23, 1996
AB		G AND W LABS INC	**0.05%**	**A074089**	**001**	Feb 16, 1994
AB		TARO	**0.05%**	**A074248**	**001**	Jul 12, 1996
	EMBELINE					
AB		HI TECH PHARMA	**0.05%**	**A074221**	**001**	Mar 31, 1995

SHAMPOO;TOPICAL

	CLOBETASOL PROPIONATE					
AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078854**	**001**	Jun 07, 2011
AB		PERRIGO ISRAEL	**0.05%**	**A090974**	**001**	Aug 09, 2012
	CLOBEX					
AB	**+**	GALDERMA LABS	**0.05%**	**N021644**	**001**	Feb 05, 2004

SOLUTION;TOPICAL

	CLOBETASOL PROPIONATE					
AT		FOUGERA PHARMS	**0.05%**	**A075391**	**001**	Feb 08, 1999
AT		G AND W LABS INC	**0.05%**	**A074331**	**001**	Dec 15, 1995
AT		NOVEL LABS INC	**0.05%**	**A206075**	**001**	Nov 23, 2015
AT		TARO	**0.05%**	**A075224**	**001**	Nov 16, 1998
AT			**0.05%**	**A075363**	**001**	Dec 29, 2000
AT		TOLMAR	**0.05%**	**A076977**	**001**	Aug 05, 2005
AT		WOCKHARDT	**0.05%**	**A075205**	**001**	Nov 13, 1998
	EMBELINE					
AT	**+**	HI TECH PHARMA	**0.05%**	**A074222**	**001**	Dec 06, 1995

SPRAY;TOPICAL

	CLOBETASOL PROPIONATE					
AT		PADDOCK LLC	**0.05%**	**A090898**	**001**	Jun 16, 2011
	CLOBEX					
AT	**+**	GALDERMA LABS LP	**0.05%**	**N021835**	**001**	Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

	CLODERM					
	+	PROMIUS PHARMA LLC	0.1%	N017765	001	

CLOFARABINE
INJECTABLE;IV (INFUSION)
CLOLAR

	+	GENZYME	20MG/20ML (1MG/ML)	N021673	001 Dec 28, 2004

CLOFAZIMINE
CAPSULE;ORAL
LAMPRENE

	+	NOVARTIS	50MG	N019500	002 Dec 15, 1986

CLOMIPHENE CITRATE
TABLET;ORAL

		CLOMID			
AB	**+**	SANOFI AVENTIS US	**50MG**	**N016131**	**002**
		CLOMIPHENE CITRATE			
AB		PAR PHARM	**50MG**	**A075528**	**001** Aug 30, 1999

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE;ORAL

		ANAFRANIL			
AB	**+**	MALLINCKRODT LLC	**25MG**	**N019906**	**001** Dec 29, 1989
AB			**50MG**	**N019906**	**002** Dec 29, 1989
AB			**75MG**	**N019906**	**003** Dec 29, 1989
		CLOMIPRAMINE HYDROCHLORIDE			
AB		MYLAN	**25MG**	**A074947**	**001** Apr 30, 1998
AB			**50MG**	**A074947**	**002** Apr 30, 1998
AB			**75MG**	**A074947**	**003** Apr 30, 1998
AB		SANDOZ	**25MG**	**A074364**	**001** Mar 29, 1996
AB			**50MG**	**A074364**	**002** Mar 29, 1996
AB			**75MG**	**A074364**	**003** Mar 29, 1996
AB		TARO	**25MG**	**A074694**	**001** Dec 31, 1996
AB			**50MG**	**A074694**	**002** Dec 31, 1996
AB			**75MG**	**A074694**	**003** Dec 31, 1996
AB		TEVA	**25MG**	**A074958**	**001** Aug 26, 1997
AB			**50MG**	**A074958**	**002** Aug 26, 1997
AB			**75MG**	**A074958**	**003** Aug 26, 1997

CLONAZEPAM
TABLET;ORAL

		CLONAZEPAM			
AB		ACCORD HLTHCARE	**0.5MG**	**A077147**	**001** May 02, 2005
AB			**1MG**	**A077147**	**002** May 02, 2005
AB			**2MG**	**A077147**	**003** May 02, 2005
AB		ACTAVIS ELIZABETH	**0.5MG**	**A074869**	**001** Oct 31, 1996
AB			**1MG**	**A074869**	**002** Oct 31, 1996
AB			**2MG**	**A074869**	**003** Oct 31, 1996
AB		MYLAN	**0.5MG**	**A075150**	**001** Oct 05, 1998
AB			**1MG**	**A075150**	**002** Oct 05, 1998
AB			**2MG**	**A075150**	**003** Oct 05, 1998
AB		MYLAN PHARMS INC	**0.5MG**	**A074940**	**001** Oct 30, 1997
AB			**1MG**	**A074940**	**002** Oct 30, 1997
AB			**2MG**	**A074940**	**003** Oct 30, 1997
AB		SANDOZ	**0.5MG**	**A074979**	**001** Aug 29, 1997
AB			**1MG**	**A074979**	**002** Aug 29, 1997
AB			**2MG**	**A074979**	**003** Aug 29, 1997
AB		SUN PHARM INDS INC	**0.5MG**	**A075423**	**001** Apr 27, 2001
AB			**1MG**	**A075423**	**002** Apr 27, 2001
AB			**2MG**	**A075423**	**003** Apr 27, 2001
AB		TEVA	**0.5MG**	**A074569**	**001** Sep 10, 1996
AB			**1MG**	**A074569**	**002** Sep 10, 1996
AB			**2MG**	**A074569**	**003** Sep 10, 1996
AB		VINTAGE PHARMS	**0.5MG**	**A077856**	**001** Jun 28, 2006
AB			**1MG**	**A077856**	**002** Jun 28, 2006
AB			**2MG**	**A077856**	**003** Jun 28, 2006
AB		WATSON LABS	**0.5MG**	**A074964**	**001** Dec 30, 1997
AB			**1MG**	**A074964**	**002** Dec 30, 1997
AB			**2MG**	**A074964**	**003** Dec 30, 1997
		KLONOPIN			
AB		ROCHE	**0.5MG**	**N017533**	**001**
AB	**+**		**1MG**	**N017533**	**002**
AB			**2MG**	**N017533**	**003**

TABLET, ORALLY DISINTEGRATING;ORAL

		CLONAZEPAM			
AB		BARR	**0.125MG**	**A077194**	**001** Aug 10, 2005

FDA data supplied by DrugPatentWatch.com

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

AB		0.25MG	A077194	002	Aug 10, 2005
AB		0.5MG	A077194	003	Aug 10, 2005
AB		1MG	A077194	004	Aug 10, 2005
AB		2MG	A077194	005	Aug 10, 2005
AB	PAR PHARM	0.125MG	A077171	001	Aug 03, 2005
AB		0.25MG	A077171	002	Aug 03, 2005
AB		0.5MG	A077171	003	Aug 03, 2005
AB	+	1MG	A077171	004	Aug 03, 2005
AB		2MG	A077171	005	Aug 03, 2005
AB	SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014
AB		0.25MG	A078654	002	Aug 27, 2014
AB		0.5MG	A078654	003	Aug 27, 2014
AB		1MG	A078654	004	Aug 27, 2014
AB		2MG	A078654	005	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CATAPRES-TTS-1

AB	BOEHRINGER INGELHEIM	0.1MG/24HR	N018891	001	Oct 10, 1984

CATAPRES-TTS-2

AB	BOEHRINGER INGELHEIM	0.2MG/24HR	N018891	002	Oct 10, 1984

CATAPRES-TTS-3

AB	+ BOEHRINGER INGELHEIM	0.3MG/24HR	N018891	003	Oct 10, 1984

CLONIDINE

AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014
AB		0.2MG/24HR	A090873	002	May 06, 2014
AB		0.3MG/24HR	A090873	003	May 06, 2014
AB	AVEVA	0.1MG/24HR	A076157	001	Aug 18, 2009
AB		0.2MG/24HR	A076157	002	Aug 18, 2009
AB		0.3MG/24HR	A076157	003	Aug 18, 2009
AB	MAYNE PHARMA	0.1MG/24HR	A079090	001	Aug 20, 2010
AB		0.2MG/24HR	A079090	002	Aug 20, 2010
AB		0.3MG/24HR	A079090	003	Aug 20, 2010
AB	MYLAN TECHNOLOGIES	0.1MG/24HR	A076166	001	Jul 16, 2010
AB		0.2MG/24HR	A076166	002	Jul 16, 2010
AB		0.3MG/24HR	A076166	003	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP	EXELA PHARMA SCS LLC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013
AP	FRESENIUS KABI USA	1MG/10ML (0.1MG/ML)	A200673	001	Jul 08, 2011
AP		5MG/10ML (0.5MG/ML)	A200673	002	Jul 08, 2011
AP	HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011
AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011
AP	LUITPOLD	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009
AP		5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009
AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014
AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014

DURACLON

AP	MYLAN INSTITUTIONAL	1MG/10ML (0.1MG/ML)	N020615	001	Oct 02, 1996
AP	+	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999

TABLET;ORAL

CATAPRES

AB	BOEHRINGER INGELHEIM	0.1MG	N017407	001	
AB		0.2MG	N017407	002	
AB	+	0.3MG	N017407	003	

CLONIDINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	0.1MG	A070974	001	Dec 16, 1986
AB		0.2MG	A070975	001	Dec 16, 1986
AB		0.3MG	A070976	001	Dec 16, 1986
AB	ALEMBIC PHARMS LTD	0.1MG	A091368	001	Dec 06, 2011
AB		0.2MG	A091368	002	Dec 06, 2011
AB		0.3MG	A091368	003	Dec 06, 2011
AB	FRONTIDA BIOPHARM	0.1MG	A070925	001	Sep 04, 1987
AB		0.2MG	A070924	001	Sep 04, 1987
AB		0.3MG	A070923	001	Sep 04, 1987
AB	IMPAX LABS	0.1MG	A078099	001	Aug 27, 2009
AB		0.2MG	A078099	002	Aug 27, 2009

FDA data supplied by DrugPatentWatch.com

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

	CLONIDINE HYDROCHLORIDE				
AB		**0.3MG**	**A078099**	**003**	Aug 27, 2009
AB	MYLAN	**0.1MG**	**A070317**	**002**	Jul 09, 1987
AB		**0.2MG**	**A070317**	**003**	Jun 09, 1987
AB		**0.3MG**	**A070317**	**001**	Jun 09, 1987
AB	SUN PHARM INDS INC	**0.1MG**	**A090329**	**001**	Jul 03, 2014
AB		**0.2MG**	**A090329**	**002**	Jul 03, 2014
AB		**0.3MG**	**A090329**	**003**	Jul 03, 2014
AB	UNICHEM	**0.1MG**	**A078895**	**001**	Aug 26, 2009
AB		**0.2MG**	**A078895**	**002**	Aug 26, 2009
AB		**0.3MG**	**A078895**	**003**	Aug 26, 2009
AB	VINTAGE	**0.1MG**	**A077901**	**001**	Mar 09, 2007
AB		**0.2MG**	**A077901**	**002**	Mar 09, 2007
AB		**0.3MG**	**A077901**	**003**	Mar 09, 2007
AB	YUNG SHIN PHARM	**0.1MG**	**A202297**	**001**	Jun 13, 2013
AB		**0.2MG**	**A202297**	**002**	Jun 13, 2013
AB		**0.3MG**	**A202297**	**003**	Jun 13, 2013

TABLET, EXTENDED RELEASE;ORAL

	CLONIDINE HYDROCHLORIDE				
AB1	ACTAVIS ELIZABETH	**0.1MG**	**A203320**	**001**	May 15, 2015
	CLONIDINE HYDROCHLORIDE				
AB1	ANCHEN PHARMS	**0.1MG**	**A202984**	**001**	Sep 30, 2013
	KAPVAY				
AB1	+ CONCORDIA PHARMS INC	**0.1MG**	**N022331**	**003**	Sep 28, 2010
	CLONIDINE HYDROCHLORIDE				
AB2	ACTAVIS ELIZABETH	**0.1MG**	**A202792**	**001**	May 15, 2015

CLOPIDOGREL BISULFATE

TABLET;ORAL

	CLOPIDOGREL BISULFATE				
AB	ACCORD HLTHCARE	**EQ 75MG BASE**	**A202925**	**001**	Mar 27, 2013
AB		**EQ 300MG BASE**	**A202925**	**002**	Mar 27, 2013
AB	AMNEAL PHARMS	**EQ 75MG BASE**	**A203751**	**001**	Apr 11, 2014
AB	APOTEX INC	**EQ 75MG BASE**	**A076274**	**001**	May 17, 2012
AB		**EQ 300MG BASE**	**A076274**	**002**	Mar 04, 2014
AB	AUROBINDO PHARMA LTD	**EQ 75MG BASE**	**A090540**	**001**	May 17, 2012
AB	DR REDDYS LABS INC	**EQ 75MG BASE**	**A076273**	**001**	Jan 14, 2008
AB	DR REDDYS LABS LTD	**EQ 300MG BASE**	**A091023**	**001**	May 17, 2012
AB	GATE PHARMS	**EQ 300MG BASE**	**A091216**	**001**	May 17, 2012
AB	MACLEODS PHARMS LTD	**EQ 75MG BASE**	**A202928**	**001**	Feb 10, 2014
AB	MYLAN PHARMS INC	**EQ 75MG BASE**	**A077665**	**001**	May 17, 2012
AB		**EQ 300MG BASE**	**A077665**	**002**	May 17, 2012
AB	ROXANE	**EQ 75MG BASE**	**A078004**	**001**	May 17, 2012
AB	SCIEGEN PHARMS INC	**EQ 75MG BASE**	**A204165**	**001**	Sep 15, 2014
AB		**EQ 300MG BASE**	**A204165**	**002**	Sep 15, 2014
AB	SUN PHARM INDS	**EQ 75MG BASE**	**A078133**	**001**	Jun 10, 2013
AB	SUN PHARMA GLOBAL	**EQ 75MG BASE**	**A090494**	**001**	May 17, 2012
AB	TEVA	**EQ 75MG BASE**	**A076999**	**001**	May 17, 2012
AB	TEVA PHARMS	**EQ 300MG BASE**	**A090625**	**001**	May 17, 2012
AB	TORRENT PHARMS LTD	**EQ 75MG BASE**	**A090844**	**001**	May 17, 2012
AB	WOCKHARDT LTD	**EQ 75MG BASE**	**A202266**	**001**	Aug 14, 2012
AB		**EQ 300MG BASE**	**A202266**	**002**	Nov 20, 2012
AB	ZYDUS PHARMS USA INC	**EQ 75MG BASE**	**A201686**	**001**	Oct 10, 2012
	PLAVIX				
AB	SANOFI AVENTIS US	**EQ 75MG BASE**	**N020839**	**001**	Nov 17, 1997
AB	+	**EQ 300MG BASE**	**N020839**	**002**	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

	CLORAZEPATE DIPOTASSIUM				
AB	MYLAN	**3.75MG**	**A071858**	**002**	Jul 17, 1987
AB		**7.5MG**	**A071858**	**003**	Jul 17, 1987
AB		**15MG**	**A071858**	**001**	Jul 17, 1987
AB	SUN PHARM INDS LTD	**3.75MG**	**A076911**	**001**	Sep 29, 2004
AB		**7.5MG**	**A076911**	**002**	Sep 29, 2004
AB		**15MG**	**A076911**	**003**	Sep 29, 2004
AB	TARO	**3.75MG**	**A075731**	**003**	Apr 27, 2000
AB		**7.5MG**	**A075731**	**002**	Apr 27, 2000
AB		**15MG**	**A075731**	**001**	Apr 27, 2000
	GEN-XENE				
AB	ALRA	**3.75MG**	**A071787**	**001**	Apr 26, 1988

FDA data supplied by DrugPatentWatch.com

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

	GEN-XENE					
AB			**7.5MG**	**A071788**	**001**	Apr 26, 1988
AB			**15MG**	**A071789**	**001**	Apr 26, 1988
	TRANXENE					
AB		RECORDATI RARE	**7.5MG**	**N017105**	**007**	
AB	+		**15MG**	**N017105**	**008**	

CLOTRIMAZOLE

CREAM;TOPICAL

	CLOTRIMAZOLE					
AB		FOUGERA PHARMS	**1%**	**A078338**	**001**	Sep 02, 2008
AB		GLENMARK PHARMS	**1%**	**A090219**	**001**	Aug 03, 2010
AB	+	TARO	**1%**	**A072640**	**001**	Aug 31, 1993

SOLUTION;TOPICAL

	CLOTRIMAZOLE					
AT	+	TARO	**1%**	**A074580**	**001**	Jul 29, 1996
AT		TEVA	**1%**	**A073306**	**001**	Feb 28, 1995

TROCHE/LOZENGE;ORAL

	CLOTRIMAZOLE					
AB		PADDOCK LLC	**10MG**	**A076763**	**001**	Oct 28, 2005
AB	+	WEST-WARD PHARMS INT	**10MG**	**A076387**	**001**	Jul 29, 2004

CLOZAPINE

SUSPENSION;ORAL

	VERSACLOZ					
	+	JAZZ PHARMS III	50MG/ML	N203479	001	Feb 06, 2013

TABLET;ORAL

	CLOZAPINE					
AB		ACCORD HLTHCARE	**25MG**	**A202873**	**001**	Nov 25, 2015
AB			**100MG**	**A202873**	**002**	Nov 25, 2015
AB		AUROBINDO PHARMA LTD	**25MG**	**A206433**	**001**	Nov 29, 2016
AB			**50MG**	**A206433**	**002**	Nov 29, 2016
AB			**100MG**	**A206433**	**003**	Nov 29, 2016
AB			**200MG**	**A206433**	**004**	Nov 29, 2016
AB		IVAX SUB TEVA PHARMS	**12.5MG**	**A074949**	**003**	Jul 31, 2003
AB			**25MG**	**A074949**	**001**	Nov 26, 1997
AB			**50MG**	**A074949**	**004**	Apr 25, 2005
AB			**50MG**	**A076809**	**003**	Dec 16, 2005
AB			**100MG**	**A074949**	**002**	Nov 26, 1997
AB			**100MG**	**A076809**	**002**	Dec 16, 2005
AB			**200MG**	**A076809**	**001**	Dec 16, 2005
AB		MAYNE PHARMA	**25MG**	**A203807**	**001**	Sep 17, 2015
AB			**100MG**	**A203807**	**002**	Sep 17, 2015
AB		MYLAN	**12.5MG**	**A075417**	**003**	Apr 15, 2010
AB			**25MG**	**A075417**	**001**	May 27, 1999
AB			**50MG**	**A075417**	**004**	Apr 15, 2010
AB			**100MG**	**A075417**	**002**	May 27, 1999
AB			**200MG**	**A075417**	**005**	Apr 15, 2010
AB		SUN PHARM INDS INC	**25MG**	**A075713**	**001**	Nov 15, 2002
AB			**50MG**	**A075713**	**003**	Aug 19, 2005
AB			**100MG**	**A075713**	**002**	Nov 15, 2002
	CLOZARIL					
AB		HERITAGE LIFE	**25MG**	**N019758**	**001**	Sep 26, 1989
AB	+		**100MG**	**N019758**	**002**	Sep 26, 1989

TABLET, ORALLY DISINTEGRATING;ORAL

	CLOZAPINE					
AB		BARR LABS INC	**25MG**	**A090308**	**001**	Nov 25, 2015
AB			**100MG**	**A090308**	**002**	Nov 25, 2015
AB		MYLAN PHARMS INC	**25MG**	**A201824**	**002**	Sep 15, 2015
AB			**100MG**	**A201824**	**003**	Sep 15, 2015
AB		TEVA PHARMS USA	**150MG**	**A203039**	**001**	Nov 25, 2015
AB			**200MG**	**A203039**	**002**	Nov 25, 2015
	FAZACLO ODT					
AB		JAZZ PHARMS III	**25MG**	**N021590**	**001**	Feb 10, 2004
AB	+		**100MG**	**N021590**	**002**	Feb 10, 2004
AB			**150MG**	**N021590**	**005**	Jul 09, 2010
AB			**200MG**	**N021590**	**006**	Jul 09, 2010
			12.5MG	N021590	004	May 30, 2007

COBICISTAT
TABLET;ORAL
TYBOST
+ GILEAD SCIENCES INC 150MG N203094 001 Sep 24, 2014

COBICISTAT; DARUNAVIR ETHANOLATE
TABLET;ORAL
PREZCOBIX
+ JANSSEN PRODS 150MG;EQ 800MG BASE N205395 001 Jan 29, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
GENVOYA
+ GILEAD SCIENCES INC 150MG;150MG;200MG;EQ 10MG BASE N207561 001 Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
STRIBILD
+ GILEAD SCIENCES INC 150MG;150MG;200MG;300MG N203100 001 Aug 27, 2012

COBIMETINIB FUMARATE
TABLET;ORAL
COTELLIC
+ GENENTECH INC EQ 20MG BASE N206192 001 Nov 10, 2015

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SYRUP;ORAL
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE
AA VINTAGE **10MG/5ML;5MG/5ML;6.25MG/5ML** **A040660 001** Dec 07, 2006
PROMETH VC W/ CODEINE
AA + ACTAVIS MID ATLANTIC **10MG/5ML;5MG/5ML;6.25MG/5ML** **A088764 001** Oct 31, 1984
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE
AA HI-TECH PHARMA CO **10MG/5ML;5MG/5ML;6.25MG/5ML** **A040674 001** Dec 23, 2014
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE
AA AMNEAL PHARMS **10MG/5ML;5MG/5ML;6.25MG/5ML** **A200963 001** Aug 26, 2015

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE
AA + ACTAVIS MID ATLANTIC **10MG/5ML;6.25MG/5ML** **A088763 001** Oct 31, 1984
AA AMNEAL PHARMS **10MG/5ML;6.25MG/5ML** **A200894 001** Apr 24, 2013
AA HI TECH PHARMA **10MG/5ML;6.25MG/5ML** **A040151 001** Aug 26, 1997
AA NOSTRUM LABS INC **10MG/5ML;6.25MG/5ML** **A090180 001** Mar 17, 2010
AA TRIS PHARMA INC **10MG/5ML;6.25MG/5ML** **A200386 001** Jun 29, 2012
AA WOCKHARDT **10MG/5ML;6.25MG/5ML** **A088875 001** Dec 17, 1984
PROMETHAZINE WITH CODEINE
AA VINTAGE **10MG/5ML;6.25MG/5ML** **A040650 001** Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SYRUP;ORAL
TRIACIN-C
+ STI PHARMA LLC 10MG/5ML;30MG/5ML;1.25MG/5ML A088704 001 Mar 22, 1985

CODEINE SULFATE
TABLET;ORAL
CODEINE SULFATE
AB LANNETT HOLDINGS INC **15MG** **A203046 001** Jun 13, 2014
AB **30MG** **A203046 002** Jun 13, 2014
AB **60MG** **A203046 003** Jun 13, 2014
AB ROXANE **15MG** **N022402 001** Jul 16, 2009
AB **30MG** **N022402 002** Jul 16, 2009
AB + **60MG** **N022402 003** Jul 16, 2009

COLCHICINE
CAPSULE;ORAL
MITIGARE
+ HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014
TABLET;ORAL
COLCRYS
+ TAKEDA PHARMS USA 0.6MG N022352 001 Jul 29, 2009

COLCHICINE; PROBENECID
TABLET;ORAL
COL-PROBENECID

AB	**+**	WATSON LABS	**0.5MG;500MG**	**A084279**	**001**

PROBENECID AND COLCHICINE

AB		INGENUS PHARMS NJ	**0.5MG;500MG**	**A040618**	**001** May 13, 2008

COLESEVELAM HYDROCHLORIDE
FOR SUSPENSION;ORAL
WELCHOL

		DAIICHI SANKYO	1.875GM/PACKET	N022362	001 Oct 02, 2009
	+		3.75GM/PACKET	N022362	002 Oct 02, 2009

TABLET;ORAL
WELCHOL

	+	DAIICHI SANKYO	625MG	N021176	001 May 26, 2000

COLESTIPOL HYDROCHLORIDE
GRANULE;ORAL
COLESTID

AB		PHARMACIA AND UPJOHN	**5GM/SCOOPFUL**	**N017563**	**003** Sep 22, 1995
AB	**+**		**5GM/PACKET**	**N017563**	**004** Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	**5GM/SCOOPFUL**	**A077277**	**001** May 02, 2006
AB			**5GM/PACKET**	**A077277**	**002** May 02, 2006

FLAVORED COLESTID

		PHARMACIA AND UPJOHN	5GM/PACKET	N017563	001
			5GM/SCOOPFUL	N017563	002

TABLET;ORAL
COLESTID

AB	**+**	PHARMACIA AND UPJOHN	**1GM**	**N020222**	**001** Jul 19, 1994

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	**1GM**	**A077510**	**001** Oct 24, 2006

COLISTIMETHATE SODIUM
INJECTABLE;INJECTION
COLISTIMETHATE SODIUM

AP		EMCURE PHARMS LTD	**EQ 150MG BASE/VIAL**	**A202359**	**001** Sep 28, 2012
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A065364**	**001** Apr 17, 2008
AP		PADDOCK LLC	**EQ 150MG BASE/VIAL**	**A065177**	**001** Mar 19, 2004
AP		SAGENT PHARMS	**EQ 150MG BASE/VIAL**	**A201365**	**001** Feb 19, 2014
AP		X GEN PHARMS	**EQ 150MG BASE/VIAL**	**A064216**	**001** Feb 26, 1999
AP		XELLIA PHARMS APS	**EQ 150MG BASE/VIAL**	**A205356**	**001** May 29, 2015

COLY-MYCIN M

AP	**+**	PAR STERILE PRODUCTS	**EQ 150MG BASE/VIAL**	**N050108**	**002**

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
SUSPENSION/DROPS;OTIC
COLY-MYCIN S

	+	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001

CONIVAPTAN HYDROCHLORIDE
INJECTABLE;IV (INFUSION)
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

	+	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002 Oct 08, 2008

COPPER
INTRAUTERINE DEVICE;INTRAUTERINE
PARAGARD T 380A

	+	TEVA WOMENS	309MG/COPPER	N018680	001 Nov 15, 1984

CORTICORELIN OVINE TRIFLUTATE
INJECTABLE;INJECTION
ACTHREL

	+	FERRING	EQ 0.1MG BASE/VIAL	N020162	001 May 23, 1996

CORTICOTROPIN
INJECTABLE;INJECTION
H.P. ACTHAR GEL

	+	MALLINCKRODT ARD	80 UNITS/ML	N008372	008

CORTISONE ACETATE
TABLET;ORAL
CORTISONE ACETATE
+ HIKMA INTL PHARMS 25MG A080776 002

COSYNTROPIN
INJECTABLE;INJECTION
CORTROSYN
AP + AMPHASTAR PHARMS INC 0.25MG/VIAL N016750 001
COSYNTROPIN
AP MYLAN INSTITUTIONAL **0.25MG/VIAL A090574 001** Dec 17, 2009
AP SANDOZ **0.25MG/VIAL A202147 001** Jun 29, 2012

CRISABOROLE
OINTMENT;TOPICAL
EUCRISA
+ ANACOR PHARMS INC 2% N207695 001 Dec 14, 2016

CRIZOTINIB
CAPSULE;ORAL
XALKORI
PF PRISM CV 200MG N202570 001 Aug 26, 2011
+ 250MG N202570 002 Aug 26, 2011

CROFELEMER
TABLET, DELAYED RELEASE;ORAL
FULYZAQ
+ NAPO PHARMS INC 125MG N202292 001 Dec 31, 2012

CROMOLYN SODIUM
CONCENTRATE;ORAL
CROMOLYN SODIUM
AA MICRO LABS LTD INDIA **100MG/5ML A202745 001** Apr 04, 2013
AA PACK PHARMS LLC **100MG/5ML A202583 001** Oct 27, 2011
GASTROCROM
AA + MEDA PHARMS 100MG/5ML N020479 001 Feb 29, 1996
SOLUTION;INHALATION
CROMOLYN SODIUM
AN BAUSCH AND LOMB **10MG/ML A075585 001** Dec 21, 2000
AN MYLAN SPECLT **10MG/ML A074209 001** Apr 26, 1994
AN + TEVA PHARMS 10MG/ML A075271 001 Jan 18, 2000
AN WOCKHARDT **10MG/ML A075346 001** Oct 25, 1999
SOLUTION/DROPS;OPHTHALMIC
CROLOM
AT BAUSCH AND LOMB **4% A074443 001** Jan 30, 1995
CROMOLYN SODIUM
AT + AKORN 4% A074706 001 Apr 29, 1998
AT ALCON **4% A075282 001** Jun 16, 1999

CROTAMITON
CREAM;TOPICAL
EURAX
+ RANBAXY 10% N006927 001
LOTION;TOPICAL
CROTAN
AT MARNEL PHARMS **10% A087204 001**
EURAX
AT + RANBAXY 10% N009112 003

CUPRIC CHLORIDE
INJECTABLE;INJECTION
CUPRIC CHLORIDE IN PLASTIC CONTAINER
+ HOSPIRA EQ 0.4MG COPPER/ML N018960 001 Jun 26, 1986

CYANOCOBALAMIN
INJECTABLE;INJECTION
CYANOCOBALAMIN
AP + LUITPOLD 1MG/ML A080737 001
AP SOMERSET THERAPS LLC **1MG/ML A206503 001** Dec 11, 2015
AP WEST-WARD PHARMS INT **1MG/ML A080515 002**
VIBISONE
AP + FRESENIUS KABI USA 1MG/ML A080557 003
SPRAY, METERED;NASAL
NASCOBAL
+ ENDO PHARMS INC 0.5MG/SPRAY N021642 001 Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

AMRIX

		TEVA PHARMS INTL	15MG	N021777	001 Feb 01, 2007
	+		30MG	N021777	002 Feb 01, 2007

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**5MG**	**A071611**	**002** Feb 03, 2006
AB			**7.5MG**	**A071611**	**003** Feb 03, 2006
AB			**10MG**	**A071611**	**001** May 03, 1989
AB		AUROBINDO PHARMA	**5MG**	**A078643**	**001** Sep 26, 2008
AB			**10MG**	**A078643**	**002** Sep 26, 2008
AB		FRONTIDA BIOPHARM	**5MG**	**A073541**	**002** Apr 06, 2006
AB			**10MG**	**A073541**	**001** May 23, 1995
AB		INVAGEN PHARMS	**5MG**	**A090478**	**001** Jul 23, 2010
AB			**10MG**	**A090478**	**002** Jul 23, 2010
AB		JUBILANT CADISTA	**5MG**	**A077563**	**001** Apr 19, 2006
AB			**10MG**	**A077563**	**002** Apr 19, 2006
AB		KVK TECH	**5MG**	**A078048**	**001** Feb 28, 2011
AB			**10MG**	**A078048**	**002** Feb 28, 2011
AB		MYLAN PHARMS INC	**5MG**	**A073144**	**002** Feb 03, 2006
AB			**7.5MG**	**A073144**	**003** Mar 25, 2013
AB	**+**		**10MG**	**A073144**	**001** May 30, 1991
AB		ORIT LABS LLC	**5MG**	**A078218**	**002** Jun 19, 2015
AB			**10MG**	**A078218**	**001** Apr 18, 2008
AB		OXFORD PHARMS	**10MG**	**A077209**	**001** Oct 04, 2005
AB		PLIVA	**10MG**	**A074421**	**001** Sep 29, 1995
AB		SUN PHARM INDS LTD	**5MG**	**A078722**	**001** May 12, 2008
AB			**7.5MG**	**A078722**	**002** May 12, 2008
AB			**10MG**	**A078722**	**003** May 12, 2008
AB		VINTAGE PHARMS	**5MG**	**A077797**	**001** Feb 28, 2007
AB			**10MG**	**A077797**	**002** Feb 28, 2007

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPENTOLATE

AT		AKORN	**1%**	**A040164**	**001** Jan 13, 1997

CYCLOGYL

AT	**+**	NOVARTIS PHARMS CORP	**0.5%**	**A084109**	**001**
AT	**+**		**1%**	**A084110**	**001**

CYCLOPENTOLATE HYDROCHLORIDE

AT		AKORN INC	**0.5%**	**A205937**	**001** Dec 09, 2015

PENTOLAIR

AT		BAUSCH AND LOMB	**1%**	**A040075**	**001** Apr 29, 1994

CYCLOGYL

	+	NOVARTIS PHARMS CORP	2%	A084108	001

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOMYDRIL

	+	NOVARTIS PHARMS CORP	0.2%;1%	A084300	001

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

		ROXANE	25MG	N203856	001 Sep 16, 2013
	+		50MG	N203856	002 Sep 16, 2013

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

AP	**+**	BAXTER HLTHCARE	**500MG/VIAL**	**A040745**	**001** May 21, 2008
AP	**+**		**1GM/VIAL**	**A040745**	**002** May 21, 2008
AP	**+**		**2GM/VIAL**	**A040745**	**003** May 21, 2008
AP		JIANGSU HENGRUI MED	**500MG/VIAL**	**A204555**	**001** Oct 31, 2014
AP			**1GM/VIAL**	**A204555**	**002** Oct 31, 2014
AP			**2GM/VIAL**	**A204555**	**003** Oct 31, 2014

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

	+	PURDUE GMP	250MG	A060593	001

CYCLOSPORINE

CAPSULE;ORAL

	CYCLOSPORINE				
AB1	IVAX SUB TEVA PHARMS	**25MG**	**A065110**	**003**	Mar 29, 2005
AB1		**50MG**	**A065110**	**001**	Mar 29, 2005
AB1		**100MG**	**A065110**	**002**	Mar 29, 2005
AB1	MAYNE PHARMA	**25MG**	**A065044**	**002**	Dec 20, 2000
AB1		**100MG**	**A065044**	**001**	Dec 20, 2000
AB1	SANDOZ	**25MG**	**A065017**	**002**	Jan 13, 2000
AB1		**100MG**	**A065017**	**001**	Jan 13, 2000
	GENGRAF				
AB1	ABBVIE	**25MG**	**A065003**	**001**	May 12, 2000
AB1		**50MG**	**A065003**	**002**	May 12, 2000
AB1		**100MG**	**A065003**	**003**	May 12, 2000
	NEORAL				
AB1	NOVARTIS	**25MG**	**N050715**	**001**	Jul 14, 1995
AB1 +		**100MG**	**N050715**	**002**	Jul 14, 1995
	CYCLOSPORINE				
AB2	APOTEX	**25MG**	**A065040**	**001**	May 09, 2002
AB2		**100MG**	**A065040**	**002**	May 09, 2002
	SANDIMMUNE				
AB2	NOVARTIS	**25MG**	**N050625**	**001**	Mar 02, 1990
AB2 +		**100MG**	**N050625**	**002**	Mar 02, 1990
BX		50MG	N050625	003	Nov 23, 1992

EMULSION;OPHTHALMIC

	RESTASIS				
+	ALLERGAN	0.05%	N050790	001	Dec 23, 2002
	RESTASIS MULTIDOSE				
+	ALLERGAN	0.05%	N050790	002	Oct 27, 2016

INJECTABLE;INJECTION

	CYCLOSPORINE				
AP	LUITPOLD	**50MG/ML**	**A065151**	**001**	Oct 07, 2003
AP	WEST-WARD PHARMS INT	**50MG/ML**	**A065004**	**001**	Oct 29, 1999
	SANDIMMUNE				
AP +	NOVARTIS	**50MG/ML**	**N050573**	**001**	Nov 14, 1983

SOLUTION;ORAL

	CYCLOSPORINE				
AB1	ABBVIE	**100MG/ML**	**A065025**	**001**	Mar 03, 2000
AB1	IVAX SUB TEVA PHARMS	**100MG/ML**	**A065078**	**001**	Mar 25, 2005
AB1	MAYNE PHARMA	**100MG/ML**	**A065054**	**001**	Dec 18, 2001
	NEORAL				
AB1 +	NOVARTIS	**100MG/ML**	**N050716**	**001**	Jul 14, 1995
	CYCLOSPORINE				
AB2	WOCKHARDT	**100MG/ML**	**A065133**	**001**	Sep 17, 2004
	SANDIMMUNE				
AB2 +	NOVARTIS	**100MG/ML**	**N050574**	**001**	Nov 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

	CYPROHEPTADINE HYDROCHLORIDE				
AA +	LYNE	**2MG/5ML**	**A040668**	**001**	Jun 28, 2006
AA	PATRIN PHARMA INC	**2MG/5ML**	**A204823**	**001**	Dec 27, 2016
AA	PHARM ASSOC	**2MG/5ML**	**A091295**	**001**	Mar 28, 2013

TABLET;ORAL

	CYPROHEPTADINE HYDROCHLORIDE				
AA	APEX PHARMS INC	**4MG**	**A207783**	**001**	Dec 29, 2016
AA	APPCO PHARMA LLC	**4MG**	**A206553**	**001**	Nov 29, 2016
AA	COREPHARMA	**4MG**	**A040537**	**001**	Sep 30, 2003
AA	INGENUS PHARMS NJ	**4MG**	**A205087**	**001**	Sep 23, 2015
AA +	IVAX SUB TEVA PHARMS	**4MG**	**A087056**	**001**	
AA	PAR PHARM	**4MG**	**A087129**	**001**	
AA	STASON PHARMS	**4MG**	**A040644**	**001**	May 30, 2006

CYSTEAMINE BITARTRATE

CAPSULE;ORAL

	CYSTAGON				
	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+		EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE;ORAL

	PROCYSBI				
	RAPTOR INC	EQ 25MG BASE	N203389	001	Apr 30, 2013
+		EQ 75MG BASE	N203389	002	Apr 30, 2013

FDA data supplied by DrugPatentWatch.com

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTARAN

	+	SIGMA TAU	EQ 0.44% BASE	N200740	001	Oct 02, 2012

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP	+	FRESENIUS KABI USA	**100MG/ML**	**A076512**	**001**	Jan 15, 2004
AP	+	HOSPIRA	**20MG/ML**	**A071868**	**001**	Jun 04, 1990
AP	+		**20MG/ML**	**A072168**	**001**	Aug 31, 1990
AP	+		**20MG/ML**	**A072945**	**001**	Feb 28, 1994
AP			**100MG/ML**	**A075383**	**001**	Nov 22, 1999
AP		MYLAN LABS LTD	**20MG/ML**	**A200914**	**001**	Dec 13, 2011
AP			**100MG/ML**	**A201784**	**001**	Jan 30, 2012
AP		MYLAN PHARMS INC	**20MG/ML**	**A200915**	**001**	Dec 13, 2011
AP			**20MG/ML**	**A200916**	**001**	Dec 13, 2011
AP		WEST-WARD PHARMS INT	**100MG/VIAL**	**A071471**	**001**	Aug 02, 1989
AP			**500MG/VIAL**	**A071472**	**001**	Aug 02, 1989
AP			**1GM/VIAL**	**A074245**	**001**	Aug 31, 1994
AP			**2GM/VIAL**	**A074245**	**002**	Aug 31, 1994

CYTOSAR-U

AP		TEVA PHARMS USA	**100MG/VIAL**	**A075206**	**001**	Dec 30, 1998
AP	+		**500MG/VIAL**	**A075206**	**002**	Dec 30, 1998
AP	+		**1GM/VIAL**	**A075206**	**004**	Dec 30, 1998
AP	+		**2GM/VIAL**	**A075206**	**003**	Dec 30, 1998

INJECTABLE, LIPOSOMAL;INJECTION

DEPOCYT

	+	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

PRADAXA

		BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010
			EQ 110MG BASE	N022512	003	Nov 20, 2015
	+		EQ 150MG BASE	N022512	002	Oct 19, 2010

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

		NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013
	+		EQ 75MG BASE	N202806	002	May 29, 2013

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

AP		FRESENIUS KABI USA	**100MG/VIAL**	**A075371**	**001**	Aug 27, 1999
AP			**200MG/VIAL**	**A075371**	**002**	Aug 27, 1999
AP		HOSPIRA	**200MG/VIAL**	**A075940**	**001**	Oct 18, 2001
AP		TEVA PHARMS USA	**200MG/VIAL**	**A075259**	**002**	Aug 27, 1998
AP	+		**500MG/VIAL**	**A075259**	**001**	Sep 22, 2000
AP		WEST-WARD PHARMS INT	**200MG/VIAL**	**A075812**	**001**	Jun 15, 2001
AP			**500MG/VIAL**	**A075812**	**002**	Oct 31, 2002

DTIC-DOME

AP	+	BAYER HLTHCARE	**100MG/VIAL**	**N017575**	**001**
AP	+		**200MG/VIAL**	**N017575**	**002**

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL

DAKLINZA

		BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015
	+		EQ 60MG BASE	N206843	002	Jul 24, 2015
			EQ 90MG BASE	N206843	003	Apr 13, 2016

DACTINOMYCIN

INJECTABLE;INJECTION

COSMEGEN

AP	+	RECORDATI RARE	**0.5MG/VIAL**	**N050682**	**001**

DACTINOMYCIN

AP		LUITPOLD PHARMS INC	**0.5MG/VIAL**	**A202562**	**001**	Aug 23, 2013

DALBAVANCIN HYDROCHLORIDE
POWDER;IV (INFUSION)
DALVANCE

+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014

DALFAMPRIDINE
TABLET, EXTENDED RELEASE;ORAL
AMPYRA

+	ACORDA	10MG	N022250	001	Jan 22, 2010

DALFOPRISTIN; QUINUPRISTIN
INJECTABLE;IV (INFUSION)
SYNERCID

+	KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999

DALTEPARIN SODIUM
INJECTABLE;SUBCUTANEOUS
FRAGMIN

	PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007
+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002

DANAZOL
CAPSULE;ORAL
DANAZOL

AB	BARR	**50MG**	**A074582**	**003**	May 29, 1998
AB		**100MG**	**A074582**	**002**	May 29, 1998
AB	**+**	**200MG**	**A074582**	**001**	Aug 09, 1996
AB	LANNETT	**50MG**	**A077246**	**002**	Apr 19, 2007
AB		**100MG**	**A077246**	**003**	Apr 19, 2007
AB		**200MG**	**A077246**	**001**	Sep 28, 2005

DANTROLENE SODIUM
CAPSULE;ORAL
DANTRIUM

AB	PAR STERILE PRODUCTS	**25MG**	**N017443**	**001**	
AB		**50MG**	**N017443**	**003**	
AB	**+**	**100MG**	**N017443**	**002**	

DANTROLENE SODIUM

AB	ELITE LABS INC	**25MG**	**A076686**	**001**	Oct 24, 2005
AB		**50MG**	**A076686**	**002**	Oct 24, 2005
AB		**100MG**	**A076686**	**003**	Oct 24, 2005
AB	IMPAX LABS	**25MG**	**A076856**	**001**	Mar 01, 2005
AB		**50MG**	**A076856**	**002**	Mar 01, 2005
AB		**100MG**	**A076856**	**003**	Mar 01, 2005

FOR SUSPENSION;INTRAVENOUS
RYANODEX

+	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014

INJECTABLE;INJECTION
DANTRIUM

AP	**+** PAR STERILE PRODUCTS	**20MG/VIAL**	**N018264**	**001**	

DANTROLENE SODIUM

AP	MYLAN INSTITUTIONAL	**20MG/VIAL**	**A205239**	**001**	Feb 18, 2016

REVONTO

AP	US WORLDMEDS	**20MG/VIAL**	**A078378**	**001**	Jul 24, 2007

DAPAGLIFLOZIN PROPANEDIOL
TABLET;ORAL
FARXIGA

	ASTRAZENECA AB	EQ 5MG BASE	N202293	001	Jan 08, 2014
+		EQ 10MG BASE	N202293	002	Jan 08, 2014

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
XIGDUO XR

	ASTRAZENECA AB	EQ 5MG BASE;500MG	N205649	001	Oct 29, 2014
		EQ 5MG BASE;1GM	N205649	002	Oct 29, 2014
		EQ 10MG BASE;500MG	N205649	003	Oct 29, 2014
+		EQ 10MG BASE;1GM	N205649	004	Oct 29, 2014

DAPSONE
GEL;TOPICAL
ACZONE

	+	ALLERGAN	5%	N021794 001	Jul 07, 2005
	+	ALLERGAN INC	7.5%	N207154 001	Feb 24, 2016

TABLET;ORAL
DAPSONE

AB		ALVOGEN	**25MG**	**A205429 001**	Jan 07, 2016
AB			**100MG**	**A205429 002**	Jan 07, 2016
AB		JACOBUS	**25MG**	**A086841 001**	
AB	**+**		**100MG**	**A086842 001**	
AB		NORTH CREEK PHARMS	**25MG**	**A204074 001**	May 10, 2016
AB			**100MG**	**A204074 002**	May 10, 2016
AB		NOSTRUM LABS INC	**25MG**	**A203887 001**	May 06, 2016
AB			**100MG**	**A203887 002**	May 06, 2016
AB		PAR PHARM INC	**25MG**	**A206505 001**	Dec 01, 2016
AB			**100MG**	**A206505 002**	Dec 01, 2016

DAPTOMYCIN
POWDER;INTRAVENOUS
CUBICIN

AP	**+**	CUBIST PHARMS LLC	**500MG/VIAL**	**N021572 002**	Sep 12, 2003

DAPTOMYCIN

AP		CRANE PHARMS LLC	**500MG/VIAL**	**A206005 001**	Jun 15, 2016
AP		HOSPIRA INC	**500MG/VIAL**	**A202857 001**	Sep 12, 2014
AP		TEVA PARENTERAL	**500MG/VIAL**	**A091039 001**	Mar 25, 2016

CUBICIN RF

	+	CUBIST PHARMS LLC	500MG/VIAL	N021572 003	Jul 06, 2016

DARIFENACIN HYDROBROMIDE
TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

AB		ANCHEN PHARMS	**EQ 7.5MG BASE**	**A091190 001**	Mar 13, 2015
AB			**EQ 15MG BASE**	**A091190 002**	Mar 13, 2015
AB		AUROBINDO PHARMA LTD	**EQ 7.5MG BASE**	**A206743 001**	Sep 19, 2016
AB			**EQ 15MG BASE**	**A206743 002**	Sep 19, 2016
AB		CIPLA LTD	**EQ 7.5MG BASE**	**A207664 001**	Sep 01, 2016
AB			**EQ 15MG BASE**	**A207664 002**	Sep 01, 2016
AB		JUBILANT GENERICS	**EQ 7.5MG BASE**	**A205550 001**	Oct 12, 2016
AB			**EQ 15MG BASE**	**A205550 002**	Oct 12, 2016
AB		TORRENT PHARMS LTD	**EQ 7.5MG BASE**	**A205209 001**	Nov 17, 2016
AB			**EQ 15MG BASE**	**A205209 002**	Nov 17, 2016

ENABLEX

AB		APIL	**EQ 7.5MG BASE**	**N021513 001**	Dec 22, 2004
AB	**+**		**EQ 15MG BASE**	**N021513 002**	Dec 22, 2004

DARUNAVIR ETHANOLATE
SUSPENSION;ORAL
PREZISTA

	+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895 001	Dec 16, 2011

TABLET;ORAL
PREZISTA

		JANSSEN PRODS	EQ 75MG BASE	N021976 004	Dec 18, 2008
			EQ 150MG BASE	N021976 005	Dec 18, 2008
			EQ 600MG BASE	N021976 002	Feb 25, 2008
	+		EQ 800MG BASE	N021976 006	Nov 09, 2012

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR
TABLET, TABLET;ORAL
VIEKIRA PAK (COPACKAGED)

	+	ABBVIE INC	EQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG	N206619 001	Dec 19, 2014

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR

	+	ABBVIE INC	EQ 200MG BASE;8.33MG;50MG;33.33MG	N208624 001	Jul 22, 2016

DASATINIB
TABLET;ORAL
DASATINIB

AB		APOTEX INC	**20MG**	**A202103 001**	Jun 10, 2016
AB			**50MG**	**A202103 002**	Jun 10, 2016
AB			**70MG**	**A202103 003**	Jun 10, 2016
AB			**100MG**	**A202103 004**	Jun 10, 2016

FDA data supplied by DrugPatentWatch.com

DASATINIB
TABLET;ORAL

	SPRYCEL				
AB	BRISTOL MYERS SQUIBB	**20MG**	**N021986**	**001**	Jun 28, 2006
AB		**50MG**	**N021986**	**002**	Jun 28, 2006
AB		**70MG**	**N021986**	**003**	Jun 28, 2006
AB +		**100MG**	**N021986**	**004**	May 30, 2008
		80MG	N021986	005	Oct 28, 2010
		140MG	N021986	006	Oct 28, 2010

DAUNORUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION

	CERUBIDINE				
AP +	WEST-WARD PHARMS INT	**EQ 20MG BASE/VIAL**	**A064103**	**001**	Feb 03, 1995
	DAUNORUBICIN HYDROCHLORIDE				
AP	FRESENIUS KABI USA	**EQ 20MG BASE/VIAL**	**A065000**	**001**	May 25, 1999
AP	TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A065035**	**001**	Jan 24, 2000
AP +	WEST-WARD PHARMS INT	**EQ 5MG BASE/ML**	**N050731**	**001**	Jan 30, 1998
	FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001

DECITABINE
INJECTABLE;INTRAVENOUS

	DACOGEN				
AP +	OTSUKA PHARM CO LTD	**50MG/VIAL**	**N021790**	**001**	May 02, 2006
	DECITABINE				
AP	DR REDDYS LABS LTD	**50MG/VIAL**	**A203131**	**001**	Jul 11, 2013
AP	SANDOZ INC	**50MG/VIAL**	**A202969**	**001**	Aug 28, 2014

POWDER;INTRAVENOUS

	DECITABINE				
+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014

DEFERASIROX
TABLET;ORAL

	JADENU				
	NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015
		180MG	N206910	002	Mar 30, 2015
+		360MG	N206910	003	Mar 30, 2015

TABLET, FOR SUSPENSION;ORAL

	DEFERASIROX				
AB	ACTAVIS ELIZABETH	**125MG**	**A203560**	**001**	Jan 26, 2016
AB		**250MG**	**A203560**	**002**	Jan 26, 2016
AB		**500MG**	**A203560**	**003**	Jan 26, 2016
	EXJADE				
AB	NOVARTIS	**125MG**	**N021882**	**001**	Nov 02, 2005
AB		**250MG**	**N021882**	**002**	Nov 02, 2005
AB +		**500MG**	**N021882**	**003**	Nov 02, 2005

DEFERIPRONE
SOLUTION;ORAL

	FERRIPROX				
+	APOPHARMA INC	100MG/ML	N208030	001	Sep 09, 2015

TABLET;ORAL

	FERRIPROX				
+	APOPHARMA INC	500MG	N021825	001	Oct 14, 2011

DEFEROXAMINE MESYLATE
INJECTABLE;INJECTION

	DEFEROXAMINE MESYLATE				
AP	FRESENIUS KABI USA	**500MG/VIAL**	**A078718**	**001**	Sep 15, 2009
AP		**2GM/VIAL**	**A078718**	**002**	Sep 15, 2009
AP	HOSPIRA	**500MG/VIAL**	**A076019**	**001**	Mar 17, 2004
AP		**2GM/VIAL**	**A076019**	**002**	Mar 17, 2004
AP	WEST-WARD PHARMS INT	**500MG/VIAL**	**A078086**	**001**	May 30, 2007
AP		**2GM/VIAL**	**A078086**	**002**	May 30, 2007
	DESFERAL				
AP +	NOVARTIS	**500MG/VIAL**	**N016267**	**001**	
AP +		**2GM/VIAL**	**N016267**	**002**	May 25, 2000

DEFIBROTIDE SODIUM
SOLUTION;IV (INFUSION)

	DEFITELIO				
+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016

FDA data supplied by DrugPatentWatch.com

DEGARELIX ACETATE
POWDER;SUBCUTANEOUS
FIRMAGON

		FERRING	EQ 80MG BASE/VIAL	N022201	001 Dec 24, 2008
	+		EQ 120MG BASE/VIAL	N022201	002 Dec 24, 2008

DELAVIRDINE MESYLATE
TABLET;ORAL
RESCRIPTOR

		VIIV HLTHCARE	100MG	N020705	001 Apr 04, 1997
	+		200MG	N020705	002 Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE
TABLET;ORAL
DEMECLOCYCLINE HYDROCHLORIDE

AB		AKORN	**150MG**	**A065389**	**001** Dec 01, 2008
AB			**300MG**	**A065389**	**002** Dec 01, 2008
AB		AMNEAL PHARM	**150MG**	**A065425**	**001** Feb 27, 2008
AB	**+**		**300MG**	**A065425**	**002** Feb 27, 2008
AB		BARR	**150MG**	**A065171**	**001** Dec 13, 2004
AB			**300MG**	**A065171**	**002** Dec 13, 2004
AB		EPIC PHARMA LLC	**150MG**	**A065447**	**001** Aug 18, 2015
AB			**300MG**	**A065447**	**002** Aug 18, 2015

DEOXYCHOLIC ACID
SOLUTION;SUBCUTANEOUS
KYBELLA

	+	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001 Apr 29, 2015

DESFLURANE
LIQUID;INHALATION
SUPRANE

	+	BAXTER HLTHCARE	99.9%	N020118	001 Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE
TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

AB		ACTAVIS TOTOWA	**10MG**	**A074430**	**001** Feb 09, 1996
AB			**25MG**	**A071601**	**001** Jun 05, 1987
AB			**50MG**	**A071588**	**001** Jun 05, 1987
AB			**75MG**	**A071602**	**001** Oct 05, 1987
AB			**100MG**	**A071766**	**001** Oct 05, 1987
AB			**150MG**	**A074430**	**002** Feb 09, 1996
AB		AMNEAL PHARMS CO	**10MG**	**A208105**	**001** Mar 17, 2016
AB			**25MG**	**A208105**	**002** Mar 17, 2016
AB			**50MG**	**A208105**	**003** Mar 17, 2016
AB			**75MG**	**A208105**	**004** Mar 17, 2016
AB			**100MG**	**A208105**	**005** Mar 17, 2016
AB			**150MG**	**A208105**	**006** Mar 17, 2016
AB		COREPHARMA	**10MG**	**A205153**	**001** Oct 28, 2016
AB			**25MG**	**A205153**	**002** Oct 28, 2016
AB			**50MG**	**A205153**	**003** Oct 28, 2016
AB			**75MG**	**A205153**	**004** Oct 28, 2016
AB			**100MG**	**A205153**	**005** Oct 28, 2016
AB			**150MG**	**A205153**	**006** Oct 28, 2016
AB		HERITAGE PHARMS INC	**10MG**	**A207433**	**001** May 05, 2016
AB			**25MG**	**A207433**	**002** May 05, 2016
AB			**50MG**	**A207433**	**003** May 05, 2016
AB			**75MG**	**A207433**	**004** May 05, 2016
AB			**100MG**	**A207433**	**005** May 05, 2016
AB			**150MG**	**A207433**	**006** May 05, 2016
AB		SANDOZ	**10MG**	**A072099**	**001** May 24, 1988
AB			**25MG**	**A072100**	**001** May 24, 1988
AB			**50MG**	**A072101**	**001** May 24, 1988
AB			**75MG**	**A072102**	**001** Jun 20, 1988
AB			**100MG**	**A072103**	**001** Jun 20, 1988
AB			**150MG**	**A072104**	**001** Jun 20, 1988

NORPRAMIN

AB		US PHARM HOLDINGS	**10MG**	**N014399**	**007** Feb 11, 1982
AB			**25MG**	**N014399**	**001**
AB			**50MG**	**N014399**	**003**
AB			**75MG**	**N014399**	**004**
AB	**+**		**100MG**	**N014399**	**005**
AB			**150MG**	**N014399**	**006**

FDA data supplied by DrugPatentWatch.com

DESIPRAMINE HYDROCHLORIDE
TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

	ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987
		50MG	A071803	003	Dec 08, 1987
		75MG	A071803	004	Dec 08, 1987
		150MG	A071803	005	May 29, 1997

DESIRUDIN RECOMBINANT
INJECTABLE;SUBCUTANEOUS
IPRIVASK

	+ VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003

DESLORATADINE
SOLUTION;ORAL

	CLARINEX				
AA	**+ MERCK SHARP DOHME**	**0.5MG/ML**	**N021300**	**001**	Sep 01, 2004
	DESLORATADINE				
AA	TARO	**0.5MG/ML**	**A202936**	**001**	May 26, 2016
AA	TARO PHARM INDS	**0.5MG/ML**	**A202592**	**001**	Jun 30, 2015

TABLET;ORAL

	CLARINEX				
AB	**+ MERCK SHARP DOHME**	**5MG**	**N021165**	**001**	Dec 21, 2001
	DESLORATADINE				
AB	BELCHER PHARMS	**5MG**	**A078355**	**001**	Apr 19, 2012
AB	DR REDDYS LABS LTD	**5MG**	**A078365**	**001**	Mar 08, 2011
AB	LUPIN PHARMS	**5MG**	**A078352**	**001**	Oct 25, 2010
AB	MYLAN PHARMS INC	**5MG**	**A078351**	**001**	Feb 10, 2012
AB	ORCHID HLTHCARE	**5MG**	**A078357**	**001**	Feb 19, 2010
AB	PERRIGO R AND D	**5MG**	**A078361**	**001**	Dec 22, 2011
AB	SANDOZ	**5MG**	**A078364**	**001**	Dec 03, 2010
AB	SUN PHARM INDS	**5MG**	**A078359**	**001**	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

	CLARINEX				
AB	MERCK SHARP DOHME	**2.5MG**	**N021312**	**002**	Jul 14, 2005
AB	**+**	**5MG**	**N021312**	**001**	Jun 26, 2002
	DESLORATADINE				
AB	REDDYS	**2.5MG**	**A078367**	**001**	Jul 12, 2010
AB		**5MG**	**A078367**	**002**	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE
TABLET, EXTENDED RELEASE;ORAL

	CLARINEX D 24 HOUR				
AB	**+ MERCK SHARP DOHME**	**5MG;240MG**	**N021605**	**001**	Mar 03, 2005
	DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR				
AB	DR REDDYS LABS LTD	**5MG;240MG**	**A078366**	**001**	Apr 26, 2011
	CLARINEX-D 12 HOUR				
	+ MERCK SHARP DOHME	2.5MG;120MG	N021313	001	Feb 01, 2006

DESMOPRESSIN ACETATE
INJECTABLE;INJECTION

	DDAVP				
AP	**+ FERRING PHARMS INC**	**0.004MG/ML**	**N018938**	**001**	Mar 30, 1984
	DESMOPRESSIN ACETATE				
AP	HOSPIRA	**0.004MG/ML**	**A075220**	**001**	Aug 28, 2000
AP	SUN PHARM INDS LTD	**0.004MG/ML**	**A091280**	**001**	Jan 25, 2013
AP	TEVA PHARMS USA	**0.004MG/ML**	**A074888**	**001**	Oct 15, 1997

SOLUTION;NASAL

	DDAVP				
AB	**+ FERRING PHARMS INC**	**0.01%**	**N017922**	**001**	
	DESMOPRESSIN ACETATE				
AB	SUN PHARM INDS	**0.01%**	**A077212**	**001**	Apr 12, 2012

SPRAY, METERED;NASAL

	DDAVP (NEEDS NO REFRIGERATION)				
AB	**+ FERRING PHARMS INC**	**0.01MG/SPRAY**	**N017922**	**003**	Aug 07, 1996
	DESMOPRESSIN ACETATE				
AB	**+ BAUSCH AND LOMB**	**0.01MG/SPRAY**	**A074830**	**001**	Jan 25, 1999
	DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)				
AB	APOTEX INC	**0.01MG/SPRAY**	**A076703**	**001**	Jan 27, 2005
AB	SUN PHARMA GLOBAL	**0.01MG/SPRAY**	**A078271**	**001**	Dec 23, 2013
	MINIRIN				
AB	**+ FERRING**	**0.01MG/SPRAY**	**N021333**	**001**	Sep 16, 2002
	STIMATE (NEEDS NO REFRIGERATION)				
	+ CSL BEHRING	0.15MG/SPRAY	N020355	002	Oct 24, 2007

DESMOPRESSIN ACETATE
TABLET;ORAL

	DDAVP				
AB	FERRING PHARMS INC	**0.1MG**	**N019955**	**001**	Sep 06, 1995
AB	+	**0.2MG**	**N019955**	**002**	Sep 06, 1995
	DESMOPRESSIN ACETATE				
AB	ACTAVIS LABS FL INC	**0.1MG**	**A076470**	**001**	Jul 01, 2005
AB		**0.2MG**	**A076470**	**002**	Jul 01, 2005
AB	APOTEX INC	**0.1MG**	**A077414**	**001**	Mar 07, 2006
AB		**0.2MG**	**A077414**	**002**	Mar 07, 2006
AB	GLENMARK PHARMS LTD	**0.1MG**	**A201831**	**001**	May 28, 2015
AB		**0.2MG**	**A201831**	**002**	May 28, 2015
AB	IMPAX LABS INC	**0.1MG**	**A077122**	**001**	Jan 25, 2006
AB		**0.2MG**	**A077122**	**002**	Jan 25, 2006
AB	MYLAN PHARMS INC	**0.1MG**	**A200653**	**001**	Jun 27, 2014
AB		**0.2MG**	**A200653**	**002**	Jun 27, 2014

DESOGESTREL; ETHINYL ESTRADIOL
TABLET;ORAL-28

	BEKYREE				
AB	LUPIN LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202226**	**001**	Aug 12, 2015
	CYCLESSA				
AB	+ ASPEN GLOBAL INC	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**N021090**	**001**	Dec 20, 2000
	DESOGEN				
AB	ORGANON USA INC	**0.15MG;0.03MG**	**N020071**	**002**	Dec 10, 1992
	DESOGESTREL AND ETHINYL ESTRADIOL				
AB	+ DURAMED PHARMS BARR	**0.15MG;0.03MG**	**A075256**	**002**	Aug 12, 1999
AB	JAI PHARMA LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202296**	**001**	Aug 30, 2013
AB		**0.15MG;0.03MG**	**A202085**	**001**	May 20, 2015
AB	MAYNE PHARMA	**0.15MG,N/A;0.02MG,0.01MG**	**A076916**	**001**	Dec 29, 2008
AB		**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A077182**	**001**	Jan 24, 2006
AB	NOVAST LABS LTD	**0.15MG;0.03MG**	**A091234**	**001**	Jul 12, 2013
AB	WATSON LABS	**0.15MG;0.03MG**	**A076915**	**001**	Jul 29, 2005
	EMOQUETTE				
AB	VINTAGE PHARMS LLC	**0.15MG;0.03MG**	**A076675**	**001**	Feb 25, 2011
	ENSKYCE				
AB	LUPIN LTD	**0.15MG;0.03MG**	**A201887**	**001**	Mar 07, 2013
	ISIBLOOM				
AB	SANDOZ INC	**0.15MG;0.03MG**	**A202789**	**001**	Aug 12, 2015
	KARIVA				
AB	+ BARR	**0.15MG,N/A;0.02MG,0.01MG**	**A075863**	**001**	Apr 05, 2002
	KIMIDESS				
AB	VINTAGE PHARMS	**0.15MG,N/A;0.02MG,0.01MG**	**A076681**	**001**	Apr 30, 2015
	PIMTREA				
AB	NOVAST LABS LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A091247**	**001**	Aug 01, 2013
	VELIVET				
AB	DURAMED PHARMS BARR	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A076455**	**001**	Feb 24, 2004
	VIORELE				
AB	GLENMARK GENERICS	**0.15MG,N/A;0.02MG,0.01MG**	**A091346**	**001**	Apr 02, 2012
	VOLNEA				
AB	SANDOZ INC	**0.15MG,N/A;0.02MG,0.01MG**	**A202689**	**001**	Sep 09, 2016

DESONIDE
AEROSOL, FOAM;TOPICAL

	VERDESO				
	+ AQUA PHARMS	0.05%	N021978	001	Sep 19, 2006

CREAM;TOPICAL

	DESONIDE				
AB	G AND W LABS INC	**0.05%**	**A074027**	**001**	Sep 28, 1992
AB	+ PERRIGO NEW YORK	**0.05%**	**N017010**	**001**	
AB	TARO	**0.05%**	**A073548**	**001**	Jun 30, 1992
	DESOWEN				
AB	GALDERMA LABS LP	**0.05%**	**N019048**	**001**	Dec 14, 1984

GEL;TOPICAL

	DESONATE				
	+ BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006

LOTION;TOPICAL

	DESONIDE				
AB	FOUGERA PHARMS	**0.05%**	**A075860**	**001**	Mar 19, 2002
AB	TARO	**0.05%**	**A202161**	**001**	Oct 31, 2014

DESONIDE
LOTION;TOPICAL
DESOWEN

AB	+	GALDERMA LABS LP	**0.05%**	**A072354**	**001**	Jan 24, 1992

OINTMENT;TOPICAL
DESONIDE

AB		FOUGERA PHARMS	**0.05%**	**A075751**	**001**	Mar 12, 2001
AB	+	PERRIGO NEW YORK	**0.05%**	**N017426**	**001**	
AB		TARO	**0.05%**	**A074254**	**001**	Aug 03, 1994

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**A071425**	**001**	Jun 15, 1988

DESOXIMETASONE
CREAM;TOPICAL
DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A205082**	**001**	Sep 04, 2015
AB		AKORN	**0.05%**	**A203787**	**001**	Jan 06, 2017
AB			**0.25%**	**A203234**	**001**	Jun 12, 2015
AB		FOUGERA PHARMS	**0.25%**	**A078369**	**001**	Jun 29, 2010
AB		LUPIN ATLANTIS	**0.05%**	**A208163**	**001**	Jan 10, 2017
AB			**0.25%**	**A208164**	**001**	Jan 09, 2017
AB		PERRIGO NEW YORK	**0.25%**	**A076510**	**001**	Jul 01, 2003

TOPICORT

AB	+	TARO	**0.05%**	**A073210**	**001**	Nov 30, 1990
AB	+		**0.25%**	**A073193**	**001**	Nov 30, 1990

GEL;TOPICAL
DESOXIMETASONE

AB		AKORN	**0.05%**	**A090727**	**001**	Mar 10, 2011
AB		GROUPE PARIMA INC	**0.05%**	**A204675**	**001**	Aug 12, 2016
AB		PERRIGO NEW YORK	**0.05%**	**A077552**	**001**	Jan 09, 2006

TOPICORT

AB	+	TARO	**0.05%**	**A074904**	**001**	Jul 14, 1998

OINTMENT;TOPICAL
DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A204965**	**001**	Nov 07, 2016
AB		AKORN	**0.25%**	**A201005**	**001**	Apr 24, 2014
AB		FOUGERA PHARMS	**0.25%**	**A078657**	**001**	Sep 28, 2012
AB		G AND W LABS INC	**0.25%**	**A206740**	**001**	Dec 23, 2016
AB		GLENMARK GENERICS	**0.25%**	**A202838**	**001**	Sep 20, 2013
AB		GROUPE PARIMA INC	**0.25%**	**A204272**	**001**	Nov 30, 2016
AB		LUPIN ATLANTIS	**0.05%**	**A208044**	**001**	Dec 12, 2016
AB			**0.25%**	**A208104**	**001**	Dec 01, 2016
AB		NOVEL LABS INC	**0.25%**	**A206792**	**001**	May 10, 2016
AB		PERRIGO ISRAEL	**0.25%**	**A077770**	**001**	Apr 20, 2015
AB		TELIGENT PHARMA INC	**0.25%**	**A208101**	**001**	Feb 25, 2016

TOPICORT

AB	+	TARO	**0.25%**	**A074286**	**001**	Jun 07, 1996
AB	+	TARO PHARMS NORTH	**0.05%**	**N018594**	**001**	Jan 17, 1985

SPRAY;TOPICAL
TOPICORT

	+	TARO	0.25%	N204141	001	Apr 11, 2013

DESVENLAFAXINE
TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE

BC	+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
BC	+		100MG	N204150	002	Mar 04, 2013

KHEDEZLA

BC		OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
BC			100MG	N204683	002	Jul 10, 2013

DESVENLAFAXINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE

	+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014
	+		EQ 100MG BASE	N205583	002	Jan 28, 2014

DESVENLAFAXINE SUCCINATE
TABLET, EXTENDED RELEASE;ORAL
DESVENLAFAXINE SUCCINATE

AB		ACTAVIS LABS FL INC	**EQ 25MG BASE**	**A204065**	**001**	Jul 29, 2016
AB			**EQ 50MG BASE**	**A204065**	**002**	Jul 29, 2016
AB			**EQ 100MG BASE**	**A204065**	**003**	Jul 29, 2016
AB		ALEMBIC PHARMS LTD	**EQ 50MG BASE**	**A204003**	**001**	Jun 29, 2015

FDA data supplied by DrugPatentWatch.com

DESVENLAFAXINE SUCCINATE
TABLET, EXTENDED RELEASE;ORAL

		DESVENLAFAXINE SUCCINATE				
AB			**EQ 100MG BASE**	**A204003**	**002**	Jun 29, 2015
AB		LUPIN LTD	**EQ 50MG BASE**	**A204172**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204172**	**002**	Jun 29, 2015
AB		MYLAN PHARMS INC	**EQ 50MG BASE**	**A204095**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204095**	**002**	Jun 29, 2015
AB		SANDOZ INC	**EQ 50MG BASE**	**A204028**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204028**	**002**	Jun 29, 2015
AB		WEST-WARD PHARMS INT	**EQ 50MG BASE**	**A204082**	**001**	Feb 16, 2016
AB			**EQ 100MG BASE**	**A204083**	**001**	Feb 16, 2016
		PRISTIQ				
AB		WYETH PHARMS INC	**EQ 25MG BASE**	**N021992**	**003**	Aug 20, 2014
AB	+		**EQ 50MG BASE**	**N021992**	**001**	Feb 29, 2008
AB	+		**EQ 100MG BASE**	**N021992**	**002**	Feb 29, 2008

DEXAMETHASONE
CONCENTRATE;ORAL

		DEXAMETHASONE INTENSOL				
	+	WEST-WARD PHARMS INT	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR;ORAL

		DEXAMETHASONE				
AA		LYNE	**0.5MG/5ML**	**A090891**	**001**	Jul 12, 2011
AA	+	STI PHARMA LLC	**0.5MG/5ML**	**A084754**	**001**	
AA		VINTAGE PHARMS	**0.5MG/5ML**	**A091188**	**001**	May 11, 2011
AA		WOCKHARDT EU OPERATN	**0.5MG/5ML**	**A088254**	**001**	Jul 27, 1983

IMPLANT;INTRAVITREAL

		OZURDEX				
	+	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009

SOLUTION;ORAL

		DEXAMETHASONE				
	+	WEST-WARD PHARMS INT	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION/DROPS;OPHTHALMIC

		MAXIDEX				
	+	NOVARTIS PHARMS CORP	0.1%	N013422	001	

TABLET;ORAL

		DEXAMETHASONE				
AB		ECR	**1.5MG**	**A040700**	**001**	Aug 15, 2008
AB		WEST-WARD PHARMS INT	**1.5MG**	**A084610**	**001**	
BP		PAR PHARM	0.5MG	A088148	001	Apr 28, 1983
BP			0.75MG	A088160	001	Apr 28, 1983
BP			1.5MG	A088237	001	Apr 28, 1983
BP			4MG	A088238	001	Apr 28, 1983
BP	+		6MG	A088481	001	Nov 28, 1983
BP		WEST-WARD PHARMS INT	0.5MG	A084611	001	
BP			0.75MG	A084613	001	
BP			1MG	A088306	001	Sep 15, 1983
BP			2MG	A087916	001	Aug 26, 1982
BP			4MG	A084612	001	
BP	+		6MG	A088316	001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE
INJECTABLE;INJECTION

		DEXAMETHASONE SODIUM PHOSPHATE				
AP		AUROBINDO PHARMA LTD	**EQ 4MG PHOSPHATE/ML**	**A206781**	**001**	Dec 01, 2015
AP	+	EUROHLTH INTL SARL	**EQ 10MG PHOSPHATE/ML**	**A087702**	**001**	Sep 07, 1982
AP		FRESENIUS KABI USA	**EQ 4MG PHOSPHATE/ML**	**A084916**	**001**	
AP			**EQ 4MG PHOSPHATE/ML**	**A203129**	**001**	Sep 30, 2015
AP	+		**EQ 10MG PHOSPHATE/ML**	**A040572**	**001**	Apr 22, 2005
AP	+	LUITPOLD	**EQ 4MG PHOSPHATE/ML**	**A087440**	**001**	Jul 21, 1982
AP		MYLAN LABS LTD	**EQ 4MG PHOSPHATE/ML**	**A040803**	**001**	Aug 29, 2008
AP			**EQ 10MG PHOSPHATE/ML**	**A040802**	**001**	Aug 29, 2008
		DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE				
AP	+	FRESENIUS KABI USA	**EQ 10MG PHOSPHATE/ML**	**A040491**	**001**	Apr 11, 2003

SOLUTION/DROPS;OPHTHALMIC, OTIC

		DEXAMETHASONE SODIUM PHOSPHATE				
AT	+	ALCON PHARMS LTD	**EQ 0.1% PHOSPHATE**	**A088771**	**001**	Jan 16, 1985
AT		BAUSCH AND LOMB	**EQ 0.1% PHOSPHATE**	**A040069**	**001**	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	**+**	NOVARTIS PHARMS CORP	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**N050065**	**002**

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064063**	**001** Jul 25, 1994
AT		PERRIGO CO TENNESSEE	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A062938**	**001** Jul 31, 1989

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064135**	**001** Sep 13, 1995

MAXITROL

AT		ALCON	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062341**	**001** May 22, 1984
AT	**+**	NOVARTIS PHARMS CORP	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N050023**	**002**

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

	+	NOVARTIS PHARMS CORP	0.1%;0.3%	N050616	001 Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	**+**	NOVARTIS PHARMS CORP	**0.1%;0.3%**	**N050592**	**001** Aug 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

AB		BAUSCH AND LOMB	**0.1%;0.3%**	**A064134**	**001** Oct 27, 1999

TOBRADEX ST

	+	NOVARTIS PHARMS CORP	0.05%;0.3%	N050818	001 Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

	+	WOCKHARDT	2MG/5ML	A088251	001 Mar 23, 1984

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

		TAKEDA PHARMS USA	30MG	N022287	001 Jan 30, 2009
	+		60MG	N022287	002 Jan 30, 2009

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

	+	TAKEDA PHARMS USA	30MG	N208056	001 Jan 26, 2016

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204023**	**001** Feb 09, 2016
AP		ACTAVIS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204686**	**001** Oct 17, 2016
AP		AKORN INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202585**	**001** Nov 24, 2014
AP		AUROBINDO PHARMA LTD	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205867**	**001** Mar 17, 2016
AP		FRESENIUS KABI USA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A201072**	**001** Sep 18, 2015
AP		MYLAN INSTITUTIONAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202881**	**001** Aug 18, 2014
AP		PAR STERILE PRODUCTS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A203972**	**001** Aug 18, 2014
AP		SANDOZ INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A091465**	**001** Jun 14, 2016
AP		SUN PHARM INDS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202126**	**001** Aug 20, 2015

PRECEDEX

AP	**+**	HOSPIRA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**N021038**	**001** Dec 17, 1999
	+		EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004 Nov 14, 2014
	+		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002 Mar 13, 2013
	+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003 Mar 13, 2013

SOLUTION;IV (INFUSION)

DEXMEDETOMIDINE HYDROCHLORIDE

	+	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002 Oct 21, 2015
			EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001 Oct 21, 2015

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		IMPAX LABS INC	**5MG**	**A079108**	**001** Aug 05, 2015
AB			**10MG**	**A079108**	**002** Aug 05, 2015
AB			**15MG**	**A079108**	**003** May 19, 2014
AB			**20MG**	**A079108**	**004** Dec 21, 2015
AB			**30MG**	**A079108**	**005** Nov 21, 2013
AB		INTELLIPHARMACEUTICS	**15MG**	**A078992**	**003** Nov 18, 2013
AB			**30MG**	**A078992**	**004** Nov 18, 2013
AB		MYLAN PHARMS INC	**5MG**	**A204266**	**001** Aug 25, 2015
AB			**10MG**	**A204266**	**002** Aug 25, 2015
AB			**15MG**	**A204266**	**003** Aug 25, 2015

FDA data supplied by DrugPatentWatch.com

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

	DEXMETHYLPHENIDATE HYDROCHLORIDE				
AB		**20MG**	**A204266**	**004**	Dec 21, 2015
AB		**30MG**	**A202580**	**001**	Aug 28, 2013
AB		**40MG**	**A204266**	**007**	Aug 25, 2015
AB	PAR PHARM INC	**5MG**	**A202842**	**001**	Nov 30, 2016
AB		**10MG**	**A202842**	**002**	Nov 30, 2016
AB		**15MG**	**A202842**	**003**	Nov 30, 2016
AB		**20MG**	**A202842**	**004**	Nov 30, 2016
AB		**25MG**	**A202842**	**005**	Nov 30, 2016
AB		**30MG**	**A202842**	**006**	Nov 30, 2016
AB		**35MG**	**A202842**	**007**	Nov 30, 2016
AB		**40MG**	**A202842**	**008**	Nov 30, 2016
AB	TEVA PHARMS USA	**5MG**	**A078908**	**001**	Nov 19, 2013
AB		**10MG**	**A078908**	**002**	Nov 19, 2013
AB		**15MG**	**A078908**	**004**	May 19, 2014
AB		**20MG**	**A078908**	**003**	Nov 19, 2013
AB		**30MG**	**A202731**	**003**	May 19, 2014
AB		**40MG**	**A202731**	**002**	Nov 19, 2013
	FOCALIN XR				
AB	NOVARTIS	**5MG**	**N021802**	**001**	May 26, 2005
AB		**10MG**	**N021802**	**002**	May 26, 2005
AB		**15MG**	**N021802**	**004**	Aug 01, 2006
AB		**20MG**	**N021802**	**003**	May 26, 2005
AB		**25MG**	**N021802**	**008**	Apr 21, 2011
AB		**30MG**	**N021802**	**005**	Oct 23, 2009
AB		**35MG**	**N021802**	**007**	Apr 21, 2011
AB	**+**	**40MG**	**N021802**	**006**	Aug 11, 2010

TABLET;ORAL

	DEXMETHYLPHENIDATE HYDROCHLORIDE				
AB	ABHAI INC	**2.5MG**	**A206931**	**001**	Dec 04, 2015
AB		**5MG**	**A206931**	**002**	Dec 04, 2015
AB		**10MG**	**A206931**	**003**	Dec 04, 2015
AB	NOVEL LABS INC	**2.5MG**	**A204534**	**001**	Dec 04, 2015
AB		**5MG**	**A204534**	**002**	Dec 04, 2015
AB		**10MG**	**A204534**	**003**	Dec 04, 2015
AB	SUN PHARM INDS	**2.5MG**	**A201231**	**001**	Sep 24, 2015
AB		**5MG**	**A201231**	**002**	Sep 24, 2015
AB		**10MG**	**A201231**	**003**	Sep 24, 2015
AB	TEVA PHARMS	**2.5MG**	**A077107**	**003**	Jan 29, 2007
AB		**5MG**	**A077107**	**001**	Jan 29, 2007
AB		**10MG**	**A077107**	**002**	Jan 29, 2007
AB	TRIS PHARMA INC	**2.5MG**	**A207901**	**001**	Aug 26, 2016
AB		**5MG**	**A207901**	**002**	Aug 26, 2016
AB		**10MG**	**A207901**	**003**	Aug 26, 2016
	FOCALIN				
AB	NOVARTIS	**2.5MG**	**N021278**	**001**	Nov 13, 2001
AB		**5MG**	**N021278**	**002**	Nov 13, 2001
AB	**+**	**10MG**	**N021278**	**003**	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

	DEXRAZOXANE HYDROCHLORIDE				
AP	GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A207321**	**001**	Nov 28, 2016
AP	MYLAN INSTITUTIONAL	**EQ 250MG BASE/VIAL**	**A200752**	**001**	Oct 19, 2011
AP		**EQ 500MG BASE/VIAL**	**A200752**	**002**	Oct 19, 2011
AP	WEST-WARD PHARMS INT	**EQ 250MG BASE/VIAL**	**A076068**	**001**	Sep 28, 2004
AP		**EQ 500MG BASE/VIAL**	**A076068**	**002**	Sep 28, 2004
	ZINECARD				
AP	**+** PHARMACIA AND UPJOHN	**EQ 250MG BASE/VIAL**	**N020212**	**001**	May 26, 1995
AP	**+**	**EQ 500MG BASE/VIAL**	**N020212**	**002**	May 26, 1995
	TOTECT				
	+ CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

	DEXEDRINE				
AB	AMEDRA PHARMS	**5MG**	**N017078**	**001**	
AB		**10MG**	**N017078**	**002**	
AB	**+**	**15MG**	**N017078**	**003**	
	DEXTROAMPHETAMINE SULFATE				
AB	ACTAVIS ELIZABETH	**5MG**	**A203901**	**001**	Nov 30, 2012

FDA data supplied by DrugPatentWatch.com

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

AB			10MG	A203901	002	Nov 30, 2012
AB			15MG	A203901	003	Nov 30, 2012
AB		MALLINCKRODT	5MG	A076353	001	May 06, 2003
AB			10MG	A076353	002	May 06, 2003
AB			15MG	A076353	003	May 06, 2003
AB		MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002
AB			10MG	A076137	002	Jan 18, 2002
AB			15MG	A076137	003	Jan 18, 2002
AB		MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016
AB			10MG	A206735	002	Jan 27, 2016
AB			15MG	A206735	003	Jan 27, 2016

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008
AA		TRIS PHARMA INC	5MG/5ML	A203644	001	May 29, 2013

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		AUROLIFE PHARMA LLC	5MG	A202893	001	Jul 31, 2013
AA			10MG	A202893	002	Jul 31, 2013
AA		AVANTHI INC	5MG	A203548	001	Nov 23, 2015
AA			10MG	A203548	002	Nov 23, 2015
AA		BARR	5MG	A040361	001	Jan 31, 2001
AA	+		10MG	A040361	002	Jan 31, 2001
AA		MALLINCKRODT	5MG	A040436	001	Jan 29, 2002
AA			10MG	A040436	002	Jan 29, 2002
AA		MIKART	5MG	A090533	002	Oct 25, 2011
AA			10MG	A090533	004	Oct 25, 2011
AA		NESHER PHARMS	5MG	A206588	001	Mar 28, 2016
AA			10MG	A206588	002	Mar 28, 2016
AA		NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016
AA			10MG	A204330	002	Mar 16, 2016
		MIKART	2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH W/ DEXTROMETHORPHAN

AA		G AND W LABS INC	15MG/5ML;6.25MG/5ML	A088762	001	Oct 31, 1984

PROMETHAZINE DM

AA	+	VINTAGE	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		HI TECH PHARMA	15MG/5ML;6.25MG/5ML	A040027	001	Jul 31, 1996

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		WOCKHARDT	15MG/5ML;6.25MG/5ML	A088864	001	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

NUEDEXTA

	+	AVANIR PHARMS	20MG;10MG	N021879	001	Oct 29, 2010

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	+	B BRAUN	10GM/100ML	N019626	004	Feb 02, 1988
AP	+	BAXTER HLTHCARE	10GM/100ML	N016694	001	
AP	+	HOSPIRA	10GM/100ML	N018080	001	

DEXTROSE 20% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	20GM/100ML	N017521	004	
AP	+	HOSPIRA	20GM/100ML	N018564	001	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	30GM/100ML	N017521	003	
AP	+	HOSPIRA	30GM/100ML	N019345	001	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	40GM/100ML	N017521	002	
AP	+	HOSPIRA	40GM/100ML	N018562	001	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	50MG/ML	N016730	002	
AP	+		5GM/100ML	N016730	001	

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+**		**5GM/100ML**	**N019626**	**002**	Feb 02, 1988
AP	**+**	BAXTER HLTHCARE	**50MG/ML**	**N016673**	**003**	Oct 30, 1985
AP	**+**		**50MG/ML**	**N020179**	**002**	Dec 07, 1992
AP	**+**		**5GM/100ML**	**N016673**	**001**	
AP	**+**		**5GM/100ML**	**N020179**	**001**	Dec 07, 1992
AP		FRESENIUS KABI USA	**50MG/ML**	**A207449**	**001**	Oct 21, 2016
AP	**+**	HOSPIRA	**50MG/ML**	**N016367**	**002**	
AP	**+**		**50MG/ML**	**N019222**	**001**	Jul 13, 1984
AP	**+**		**5GM/100ML**	**N019466**	**001**	Jul 15, 1985
AP	**+**		**5GM/100ML**	**N019479**	**001**	Sep 17, 1985

DEXTROSE 50% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**50GM/100ML**	**N017521**	**001**	
AP	**+**		**50GM/100ML**	**N020047**	**001**	Jul 02, 1991
AP	**+**	HOSPIRA	**50GM/100ML**	**N018563**	**001**	Mar 23, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**60GM/100ML**	**N017521**	**005**	Mar 26, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**70GM/100ML**	**N017521**	**006**	Mar 26, 1982
AP	**+**		**70GM/100ML**	**N020047**	**003**	Jul 02, 1991
AP	**+**	HOSPIRA	**70GM/100ML**	**N018561**	**001**	Mar 23, 1982
AP	**+**		**70GM/100ML**	**N019893**	**001**	Dec 26, 1989

DEXTROSE 25%

+	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998

DEXTROSE 50%

	HOSPIRA	500MG/ML	N019445	003	Sep 03, 2014

DEXTROSE 50% IN PLASTIC CONTAINER

	HOSPIRA	500MG/ML	N019445	001	Jun 03, 1986

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML	N017385	001

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019873	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N019844	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017609	001

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML**	**N017634**	**001**	
	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML**	**N017634**	**003**	
	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML**	**N017634**	**002**	
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	B BRAUN	**5GM/100ML;150MG/100ML**	**N019699**	**004**	Sep 29, 1989
	POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	B BRAUN	**5GM/100ML;300MG/100ML**	**N019699**	**006**	Sep 29, 1989
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	HOSPIRA	**5GM/100ML;224MG/100ML**	**N018371**	**003**	
	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634	004	
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;149MG/100ML	N018371	001	
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;298MG/100ML	N018371	002	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML	N019870	001	Jun 10, 1993

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ				
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**006**	Apr 13, 1982
AP		**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**007**	Apr 13, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)				
AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**004**	
	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ				
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**008**	Apr 13, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)				
AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**001**	
	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ				
AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**005**	Apr 13, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ				
AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;200MG/100ML**	**N018037**	**009**	Apr 13, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ				
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**002**	
	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)				
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**003**	
	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;330MG/100ML**	**N018629**	**005**	Mar 23, 1982
AP		**5GM/100ML;150MG/100ML;330MG/100ML**	**N018629**	**002**	Mar 23, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;330MG/100ML**	**N018629**	**003**	Mar 23, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML;330MG/100ML**	**N018629**	**004**	Mar 23, 1982
AP		**5GM/100ML;300MG/100ML;330MG/100ML**	**N018629**	**006**	Mar 23, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;330MG/100ML**	**N018629**	**007**	Mar 23, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;330MG/100ML**	**N018629**	**008**	Mar 23, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;330MG/100ML**	**N018629**	**001**	Mar 23, 1982
	DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML;450MG/100ML**	**N018008**	**010**	
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
AP	B BRAUN	**5GM/100ML;75MG/100ML;200MG/100ML**	**N019630**	**008**	Feb 17, 1988
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
AP	B BRAUN	**5GM/100ML;75MG/100ML;330MG/100ML**	**N019630**	**014**	Feb 17, 1988
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	B BRAUN	**5GM/100ML;75MG/100ML;450MG/100ML**	**N019630**	**020**	Feb 17, 1988
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	B BRAUN	**5GM/100ML;75MG/100ML;900MG/100ML**	**N019630**	**026**	Feb 17, 1988
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
AP	B BRAUN	**5GM/100ML;150MG/100ML;200MG/100ML**	**N019630**	**010**	Feb 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
INJECTABLE;INJECTION

	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630 016	Feb 17, 1988
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630 022	Feb 17, 1988
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630 028	Feb 17, 1988
	POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630 012	Feb 17, 1988
	POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630 018	Feb 17, 1988
	POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630 024	Feb 17, 1988
	POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	B BRAUN	5GM/100ML;300MG/100ML;900MG/100ML	N019630 030	Feb 17, 1988
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 005	Apr 28, 1982
AP		5GM/100ML;150MG/100ML;450MG/100ML	N018008 006	Apr 28, 1982
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 005	Mar 28, 1988
AP		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 009	Jul 05, 1983
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308 004	Apr 05, 1985
AP		5GM/100ML;150MG/100ML;900MG/100ML	N019308 002	Apr 05, 1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 002	Mar 24, 1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 004	Mar 24, 1988
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 006	Mar 28, 1988
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 006	Mar 24, 1988
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 007	Apr 28, 1982
AP	HOSPIRA	5GM/100ML;149MG/100ML;450MG/100ML	N018362 010	Jul 05, 1983
AP		5GM/100ML;298MG/100ML;450MG/100ML	N018362 007	Mar 28, 1988
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 005	Apr 05, 1985
AP		5GM/100ML;300MG/100ML;900MG/100ML	N019308 003	Apr 05, 1985
AP	HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N019691 005	Mar 24, 1988
AP		5GM/100ML;298MG/100ML;900MG/100ML	N019691 008	Mar 24, 1988
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 008	Apr 28, 1982
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 002	
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308 006	Apr 05, 1985
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 007	Mar 24, 1988
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 009	Apr 28, 1982
AP	HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N018362 003	
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308 007	Apr 05, 1985
AP	HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N019691 009	Mar 24, 1988
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 004	
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 008	Mar 28, 1988
AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362 004	Mar 28, 1988
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 001	Apr 05, 1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 001	Mar 24, 1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 003	Mar 24, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER			
	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER			
	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007	Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013	Feb 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;450MG/100ML N019630 019 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;900MG/100ML N019630 025 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;200MG/100ML N019630 032 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;450MG/100ML N019630 038 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;900MG/100ML N019630 044 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;75MG/100ML;300MG/100ML N019630 049 May 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;75MG/100ML;110MG/100ML N019630 002 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;200MG/100ML N019630 033 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;450MG/100ML N019630 039 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;900MG/100ML N019630 045 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;110MG/100ML;300MG/100ML N019630 050 May 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;110MG/100ML N019630 003 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;200MG/100ML N019630 009 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;330MG/100ML N019630 015 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;450MG/100ML N019630 021 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;900MG/100ML N019630 027 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;200MG/100ML N019630 034 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;450MG/100ML N019630 040 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;900MG/100ML N019630 046 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;150MG/100ML;300MG/100ML N019630 051 May 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;110MG/100ML N019630 004 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;200MG/100ML N019630 035 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;450MG/100ML N019630 041 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;900MG/100ML N019630 047 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;220MG/100ML;300MG/100ML N019630 052 May 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;110MG/100ML N019630 005 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;200MG/100ML N019630 011 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;330MG/100ML N019630 017 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;450MG/100ML N019630 023 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;900MG/100ML N019630 029 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;200MG/100ML N019630 036 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;450MG/100ML N019630 042 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;900MG/100ML N019630 048 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;300MG/100ML;300MG/100ML N019630 053 May 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;300MG/100ML;110MG/100ML N019630 006 Feb 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100ML N018365 002 Jul 05, 1983
5GM/100ML;149MG/100ML;225MG/100ML N018365 006 Mar 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100ML N018876 001 Jan 17, 1986
5GM/100ML;149MG/100ML;300MG/100ML N018876 006 Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N018365 008 Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N018876 007 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;149MG/100ML;225MG/100ML N018365 001
5GM/100ML;298MG/100ML;225MG/100ML N018365 009 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N018876 008 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;149MG/100ML;300MG/100ML N018876 002 Jan 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N018365 003 Jul 05, 1983

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N018876 003 Jan 17, 1986

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;298MG/100ML;225MG/100ML N018365 004 Jul 05, 1983

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N018876 004 Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100ML N018365 005 Mar 28, 1988
5GM/100ML;149MG/100ML;225MG/100ML N018365 007 Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100ML N018876 005 Mar 28, 1988
5GM/100ML;149MG/100ML;300MG/100ML N018876 009 Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **10GM/100ML;900MG/100ML** **N019631 015** Feb 24, 1988
AP BAXTER HLTHCARE **10GM/100ML;900MG/100ML** **N016696 001**

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **2.5GM/100ML;450MG/100ML** **N019631 004** Feb 24, 1988
AP + BAXTER HLTHCARE **2.5GM/100ML;450MG/100ML** **N016697 001**

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;200MG/100ML** **N019631 007** Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;330MG/100ML** **N019631 008** Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;450MG/100ML** **N019631 009** Feb 24, 1988
AP HOSPIRA **5GM/100ML;450MG/100ML** **N017607 001**

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;900MG/100ML** **N019631 010** Feb 24, 1988
AP HOSPIRA **5GM/100ML;900MG/100ML** **N017585 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;200MG/100ML** **N016689 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;330MG/100ML** **N016687 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;450MG/100ML** **N016683 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;900MG/100ML** **N016678 001**

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML N019631 011 Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;200MG/100ML N019631 012 Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;330MG/100ML N019631 013 Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;450MG/100ML N019631 014 Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML;110MG/100ML N019631 001 Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML;200MG/100ML N019631 002 Feb 24, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;330MG/100ML	N019631	003	Feb 24, 1988
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;900MG/100ML	N019631	005	Feb 24, 1988
	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML;300MG/100ML	N019631	016	Jan 19, 1990
	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML	N019631	006	Feb 24, 1988
	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
+	HOSPIRA	5GM/100ML;225MG/100ML	N017606	001	
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
+	HOSPIRA	5GM/100ML;300MG/100ML	N017799	001	

DIATRIZOATE MEGLUMINE

SOLUTION;URETHRAL

	CYSTOGRAFIN				
	BRACCO	30%	N010040	018	
	CYSTOGRAFIN DILUTE				
	BRACCO	18%	N010040	022	Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION

		MD-76R				
AP	**+**	LIEBEL-FLARSHEIM	**66%;10%**	**N019292**	**001**	Sep 29, 1989
		RENOGRAFIN-76				
AP	**+**	BRACCO	**66%;10%**	**N010040**	**001**	

SOLUTION;ORAL, RECTAL

		GASTROGRAFIN				
AA	**+**	BRACCO	**66%;10%**	**N011245**	**003**	
		MD-GASTROVIEW				
AA		LIEBEL-FLARSHEIM	**66%;10%**	**A087388**	**001**	

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION;INTRAUTERINE

		SINOGRAFIN				
	+	BRACCO	52.7%;26.8%	N011324	002	

DIAZEPAM

CONCENTRATE;ORAL

		DIAZEPAM				
AA		LANNETT HOLDINGS INC	**5MG/ML**	**A204433**	**001**	Apr 14, 2014
		DIAZEPAM INTENSOL				
AA	**+**	WEST-WARD PHARMS INT	**5MG/ML**	**A071415**	**001**	Apr 03, 1987

GEL;RECTAL

		DIASTAT				
		VALEANT PHARMS NORTH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997
		DIASTAT ACUDIAL				
		VALEANT PHARMS NORTH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005
	+		20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005

INJECTABLE;INJECTION

		DIAZEPAM				
	+	HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988
	+		50MG/10ML (5MG/ML)	A071583	001	Oct 13, 1987

SOLUTION;ORAL

		DIAZEPAM				
AA		LANNETT HOLDINGS INC	**5MG/5ML**	**A206477**	**001**	Jun 24, 2016
AA	**+**	WEST-WARD PHARMS INT	**5MG/5ML**	**A070928**	**001**	Apr 03, 1987

TABLET;ORAL

		DIAZEPAM				
AB		BARR	**2MG**	**A070152**	**001**	Nov 01, 1985
AB			**10MG**	**A070154**	**001**	Nov 01, 1985
AB		IVAX SUB TEVA PHARMS	**2MG**	**A071307**	**001**	Dec 10, 1986
AB			**5MG**	**A071321**	**001**	Dec 10, 1986
AB			**10MG**	**A071322**	**001**	Dec 10, 1986
AB		MAYNE PHARMA	**2MG**	**A071134**	**001**	Feb 03, 1987
AB			**5MG**	**A071135**	**001**	Feb 03, 1987
AB			**10MG**	**A071136**	**001**	Feb 03, 1987
AB		MYLAN	**2MG**	**A070325**	**002**	Sep 04, 1985
AB			**5MG**	**A070325**	**003**	Sep 04, 1985
AB			**10MG**	**A070325**	**001**	Sep 04, 1985
AB		VINTAGE PHARMS	**2MG**	**A077749**	**001**	Mar 31, 2006
AB			**5MG**	**A077749**	**002**	Mar 31, 2006

FDA data supplied by DrugPatentWatch.com

DIAZEPAM
TABLET;ORAL
DIAZEPAM

AB		**10MG**	**A077749**	**003**	Mar 31, 2006

VALIUM

AB	ROCHE	**2MG**	**N013263**	**002**	
AB		**5MG**	**N013263**	**004**	
AB	+	**10MG**	**N013263**	**006**	

DIAZEPAM

	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985
		5MG	A070228	003	Sep 26, 1985

DIAZOXIDE
SUSPENSION;ORAL
PROGLYCEM

+	TEVA BRANDED PHARM	50MG/ML	N017453	001	

DICHLORPHENAMIDE
TABLET;ORAL
KEVEYIS

	STRONGBRIDGE US	50MG	N011366	002	Aug 07, 2015

DICLOFENAC
CAPSULE;ORAL
ZORVOLEX

	IROKO PHARMS LLC	18MG	N204592	001	Oct 18, 2013
+		35MG	N204592	002	Oct 18, 2013

DICLOFENAC EPOLAMINE
PATCH;TOPICAL
FLECTOR

+	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007

DICLOFENAC POTASSIUM
CAPSULE;ORAL
DICLOFENAC POTASSIUM

AB	BIONPHARMA INC	**25MG**	**A204648**	**001**	Feb 23, 2016

ZIPSOR

AB	+ DEPOMED INC	**25MG**	**N022202**	**001**	Jun 16, 2009

FOR SOLUTION;ORAL
CAMBIA

AB	+ DEPOMED INC	**50MG**	**N022165**	**001**	Jun 17, 2009

DICLOFENAC POTASSIUM

AB	PAR FORM	**50MG**	**A202964**	**001**	May 02, 2016

TABLET;ORAL
DICLOFENAC POTASSIUM

AB	APOTEX	**50MG**	**A076561**	**001**	Mar 18, 2004
AB	+ MYLAN	**50MG**	**A075463**	**001**	Jul 26, 1999
AB	SANDOZ	**50MG**	**A075229**	**001**	Nov 20, 1998
AB	TEVA	**50MG**	**A075219**	**001**	Aug 06, 1998

DICLOFENAC SODIUM
GEL;TOPICAL
DICLOFENAC SODIUM

AB	ACTAVIS MID ATLANTIC	**3%**	**A206493**	**001**	Dec 02, 2015
AB	AMNEAL PHARMS	**1%**	**A208077**	**001**	Mar 18, 2016
AB	GLENMARK PHARMS LTD	**3%**	**A208301**	**001**	Sep 13, 2016
AB	TARO	**3%**	**A206298**	**001**	Apr 28, 2016

DICLOFENAC SODIUM

AB	TOLMAR	**3%**	**A200936**	**001**	Oct 28, 2013

SOLARAZE

AB	+ FOUGERA PHARMS	**3%**	**N021005**	**001**	Oct 16, 2000

VOLTAREN

AB	+ GLAXOSMITHKLINE CONS	**1%**	**N022122**	**001**	Oct 17, 2007

SOLUTION;INTRAVENOUS
DYLOJECT

+	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014

SOLUTION;TOPICAL
DICLOFENAC SODIUM

AT	AMNEAL PHARMS	**1.5%**	**A206116**	**001**	Sep 02, 2016
AT	APOTEX INC	**1.5%**	**A202027**	**001**	May 27, 2014
AT	LUPIN LTD	**1.5%**	**A204132**	**001**	Aug 20, 2015
AT	NOVEL LABS INC	**1.5%**	**A205878**	**001**	Dec 09, 2015
AT	PADDOCK LLC	**1.5%**	**A202393**	**001**	Nov 24, 2014
AT	TARO	**1.5%**	**A203818**	**001**	Nov 26, 2014

DICLOFENAC SODIUM

SOLUTION;TOPICAL

		DICLOFENAC SODIUM				
AT		TELIGENT PHARMA INC	**1.5%**	**A202769**	**001**	Jul 08, 2015
AT		WATSON LABS INC	**1.5%**	**A202852**	**001**	Nov 24, 2014
		PENNSAID				
AT	+	NUVO RES INC	**1.5%**	**N020947**	**001**	Nov 04, 2009
	+	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014

SOLUTION/DROPS;OPHTHALMIC

		DICLOFENAC SODIUM				
AT		AKORN	**0.1%**	**A077845**	**001**	Apr 17, 2008
AT		ALCON PHARMS LTD	**0.1%**	**A078031**	**001**	Feb 06, 2008
AT		ALTAIRE PHARMS INC	**0.1%**	**A203383**	**001**	Nov 16, 2015
AT		BAUSCH AND LOMB	**0.1%**	**A078792**	**001**	Dec 28, 2007
AT		RISING PHARMS INC	**0.1%**	**A078553**	**001**	Dec 28, 2007
		VOLTAREN				
AT	+	NOVARTIS	**0.1%**	**N020037**	**001**	Mar 28, 1991

TABLET, DELAYED RELEASE;ORAL

		DICLOFENAC SODIUM				
AB		ACTAVIS ELIZABETH	**50MG**	**A074514**	**001**	Mar 26, 1996
AB			**75MG**	**A074514**	**002**	Mar 26, 1996
AB		CARLSBAD	**25MG**	**A075185**	**002**	Nov 13, 1998
AB			**50MG**	**A075185**	**003**	Nov 13, 1998
AB			**75MG**	**A075185**	**001**	Nov 13, 1998
AB		MYLAN PHARMS INC	**50MG**	**A075281**	**002**	Feb 12, 2002
AB			**75MG**	**A075281**	**003**	Feb 12, 2002
AB	+	SANDOZ	**25MG**	**A074376**	**001**	Sep 28, 1995
AB	+		**50MG**	**A074376**	**002**	Sep 28, 1995
AB	+		**75MG**	**A074394**	**001**	Nov 30, 1995
AB		UNIQUE PHARM LABS	**25MG**	**A090066**	**001**	Dec 01, 2010
AB			**50MG**	**A090066**	**002**	Dec 01, 2010
AB			**75MG**	**A077863**	**003**	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

		DICLOFENAC SODIUM				
AB	+	ACTAVIS ELIZABETH	**100MG**	**A075910**	**001**	Jan 07, 2002
AB		DEXCEL LTD	**100MG**	**A076201**	**001**	Nov 06, 2002
AB		MYLAN	**100MG**	**A076152**	**001**	Dec 13, 2001
AB		VPNA	**100MG**	**A075492**	**001**	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

		ARTHROTEC				
AB		GD SEARLE LLC	**50MG;0.2MG**	**N020607**	**001**	Dec 24, 1997
AB	+		**75MG;0.2MG**	**N020607**	**002**	Dec 24, 1997
		DICLOFENAC SODIUM AND MISOPROSTOL				
AB		ACTAVIS LABS FL INC	**50MG;0.2MG**	**A201089**	**001**	Jul 09, 2012
AB			**75MG;0.2MG**	**A201089**	**002**	Jul 09, 2012
AB		AMNEAL PHARMS	**50MG;0.2MG**	**A203995**	**001**	Nov 25, 2016
AB			**75MG;0.2MG**	**A203995**	**002**	Nov 25, 2016
AB		EXELA PHARMA SCS LLC	**50MG;0.2MG**	**A200540**	**001**	Mar 14, 2014
AB			**75MG;0.2MG**	**A200540**	**002**	Mar 14, 2014
AB		SANDOZ	**50MG;0.2MG**	**A200158**	**001**	May 09, 2013
AB			**75MG;0.2MG**	**A200158**	**002**	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE;ORAL

		DICLOXACILLIN SODIUM				
AB		SANDOZ	**EQ 250MG BASE**	**A061454**	**001**	
AB	+		**EQ 500MG BASE**	**A061454**	**003**	
AB		TEVA	**EQ 250MG BASE**	**A062286**	**001**	Jun 03, 1982
AB			**EQ 500MG BASE**	**A062286**	**002**	Jun 03, 1982
		SANDOZ	EQ 125MG BASE	A061454	002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

		BENTYL				
AB	+	FOREST LABS INC	**10MG**	**N007409**	**003**	Oct 15, 1984
		DICYCLOMINE HYDROCHLORIDE				
AB		LANNETT	**10MG**	**A084285**	**001**	
AB		MYLAN	**10MG**	**A040319**	**001**	Sep 07, 1999
AB		WATSON LABS	**10MG**	**A085082**	**001**	Jun 19, 1986

FDA data supplied by DrugPatentWatch.com

DICYCLOMINE HYDROCHLORIDE
INJECTABLE;INJECTION

	BENTYL				
AP	+ FOREST LABS INC	**10MG/ML**	**N008370**	**001**	Oct 15, 1984
	BENTYL PRESERVATIVE FREE				
AP	+ FOREST LABS INC	**10MG/ML**	**N008370**	**002**	Oct 15, 1984
	DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)				
AP	WEST-WARD PHARMS INT	**10MG/ML**	**A040465**	**001**	Jun 30, 2003
SYRUP;ORAL					
	DICYCLOMINE HYDROCHLORIDE				
	+ MIKART	10MG/5ML	A040169	001	Mar 24, 2005
TABLET;ORAL					
	BENTYL				
AB	+ FOREST LABS INC	**20MG**	**N007409**	**001**	Oct 15, 1984
	DICYCLOMINE HYDROCHLORIDE				
AB	LANNETT	**20MG**	**A040230**	**001**	Feb 26, 1999
AB	MYLAN	**20MG**	**A040317**	**001**	Sep 07, 1999
AB	WATSON LABS	**20MG**	**A085223**	**001**	Jul 30, 1986

DIDANOSINE
CAPSULE, DELAYED REL PELLETS;ORAL

	DIDANOSINE				
AB	AUROBINDO PHARMA	**125MG**	**A090094**	**001**	Sep 24, 2008
AB		**200MG**	**A090094**	**002**	Sep 24, 2008
AB		**250MG**	**A090094**	**003**	Sep 24, 2008
AB		**400MG**	**A090094**	**004**	Sep 24, 2008
AB	BARR	**200MG**	**A077167**	**001**	Dec 03, 2004
AB		**250MG**	**A077167**	**002**	Dec 03, 2004
AB		**400MG**	**A077167**	**003**	Dec 03, 2004
AB	MYLAN PHARMS INC	**125MG**	**A090788**	**001**	Apr 08, 2010
AB		**200MG**	**A090788**	**002**	Apr 08, 2010
AB		**250MG**	**A090788**	**003**	Apr 08, 2010
AB		**400MG**	**A090788**	**004**	Apr 08, 2010
	VIDEX EC				
AB	BRISTOL MYERS SQUIBB	**125MG**	**N021183**	**001**	Oct 31, 2000
AB		**200MG**	**N021183**	**002**	Oct 31, 2000
AB		**250MG**	**N021183**	**003**	Oct 31, 2000
AB	+	**400MG**	**N021183**	**004**	Oct 31, 2000
FOR SOLUTION;ORAL					
	DIDANOSINE				
AA	AUROBINDO PHARMA	**10MG/ML**	**A078112**	**001**	Mar 08, 2007
	VIDEX				
AA	+ BRISTOL MYERS SQUIBB	**10MG/ML**	**N020156**	**001**	Oct 09, 1991
TABLET, FOR SUSPENSION;ORAL					
	DIDANOSINE				
	AUROBINDO	100MG	A077275	001	Aug 14, 2012
		150MG	A077275	002	Aug 14, 2012
	+	200MG	A077275	003	Aug 14, 2012

DIENOGEST; ESTRADIOL VALERATE
TABLET;ORAL

	ESTRADIOL VALERATE AND DIENOGEST				
AB	WATSON LABS INC	**N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A**	**A202349**	**001**	May 06, 2016
	NATAZIA				
AB	+ BAYER HLTHCARE	**N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A**	**N022252**	**001**	May 06, 2010

DIETHYLPROPION HYDROCHLORIDE
TABLET;ORAL

	DIETHYLPROPION HYDROCHLORIDE				
AA	AVANTHI INC	**25MG**	**A201212**	**001**	Dec 22, 2010
AA	LANNETT HOLDINGS INC	**25MG**	**A200177**	**001**	Jul 18, 2011
	TENUATE				
AA	+ ACTAVIS LABS UT INC	**25MG**	**N011722**	**002**	
TABLET, EXTENDED RELEASE;ORAL					
	DIETHYLPROPION HYDROCHLORIDE				
AB	LANNETT HOLDINGS INC	**75MG**	**A091680**	**001**	Oct 24, 2011
	TENUATE DOSPAN				
AB	+ ACTAVIS LABS UT INC	**75MG**	**N012546**	**001**	

FDA data supplied by DrugPatentWatch.com

DIFLORASONE DIACETATE
CREAM;TOPICAL
DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002
BX	+	TARO	0.05%	A075508	001	Apr 24, 2000

OINTMENT;TOPICAL
DIFLORASONE DIACETATE

AB		AKORN	**0.05%**	**A206572**	**001**	Jul 24, 2015
AB		FOUGERA PHARMS	**0.05%**	**A075374**	**001**	Apr 27, 1999
AB	**+**	TARO	**0.05%**	**A075331**	**001**	May 14, 1999

DIFLUNISAL
TABLET;ORAL
DIFLUNISAL

AB		HERITAGE PHARMA	**500MG**	**A202845**	**001**	Mar 08, 2012
AB	**+**	TEVA	**500MG**	**A073673**	**001**	Jul 31, 1992

DIFLUPREDNATE
EMULSION;OPHTHALMIC
DUREZOL

	+	NOVARTIS PHARMS CORP	0.05%	N022212	001	Jun 23, 2008

DIGOXIN
ELIXIR;ORAL
DIGOXIN

	+	ROXANE	0.05MG/ML	N021648	001	Aug 26, 2004

INJECTABLE;INJECTION
DIGOXIN

AP		EUROHLTH INTL SARL	**0.25MG/ML**	**A083391**	**001**	
AP		SANDOZ	**0.25MG/ML**	**A040481**	**001**	Aug 21, 2003

LANOXIN

AP	**+**	COVIS PHARMA SARL	**0.25MG/ML**	**N009330**	**002**	

LANOXIN PEDIATRIC

	+	COVIS PHARMA SARL	0.1MG/ML	N009330	004	

TABLET;ORAL
DIGOXIN

AB		HIKMA INTL PHARMS	**0.125MG**	**A077002**	**002**	Oct 30, 2007
AB			**0.25MG**	**A077002**	**001**	Oct 30, 2007
AB		IMPAX LABS	**0.125MG**	**A078556**	**001**	Jul 20, 2009
AB			**0.25MG**	**A078556**	**002**	Jul 20, 2009
AB		MYLAN PHARMS INC	**0.125MG**	**A040282**	**001**	Dec 23, 1999
AB			**0.25MG**	**A040282**	**002**	Dec 23, 1999
AB		STEVENS J	**0.125MG**	**A076268**	**001**	Jul 26, 2002
AB			**0.25MG**	**A076268**	**002**	Jul 26, 2002
AB		SUN PHARM INDS INC	**0.125MG**	**A076363**	**001**	Jan 31, 2003
AB			**0.25MG**	**A076363**	**002**	Jan 31, 2003

LANOXIN

AB		CONCORDIA PHARMS INC	**0.125MG**	**N020405**	**002**	Sep 30, 1997
AB	**+**		**0.25MG**	**N020405**	**004**	Sep 30, 1997
			0.0625MG	N020405	001	Sep 30, 1997
			0.1875MG	N020405	003	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE
INJECTABLE;INJECTION
D.H.E. 45

AP	**+**	VALEANT	**1MG/ML**	**N005929**	**001**	

DIHYDROERGOTAMINE MESYLATE

AP		EUROHLTH INTL SARL	**1MG/ML**	**A040453**	**001**	Jun 09, 2003
AP		PADDOCK LLC	**1MG/ML**	**A040475**	**001**	Apr 28, 2003

SPRAY, METERED;NASAL
MIGRANAL

	+	VALEANT	0.5MG/INH	N020148	001	Dec 08, 1997

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2		APOTEX	**120MG**	**A074943**	**003**	Dec 19, 2000
AB2			**180MG**	**A074943**	**002**	Dec 19, 2000
AB2			**240MG**	**A074943**	**001**	Aug 06, 1998
AB2		MYLAN	**120MG**	**A075124**	**002**	Mar 18, 1998
AB2			**180MG**	**A075124**	**003**	Mar 18, 1998
AB2	**+**		**240MG**	**A075124**	**001**	Mar 18, 1998

CARDIZEM CD

AB3		VALEANT INTL	**120MG**	**N020062**	**001**	Aug 10, 1992
AB3			**180MG**	**N020062**	**002**	Dec 27, 1991

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

		CARDIZEM CD				
AB3			**240MG**	**N020062**	**003**	Dec 27, 1991
AB3			**300MG**	**N020062**	**004**	Dec 27, 1991
AB3	**+**		**360MG**	**N020062**	**005**	Aug 24, 1999
		CARTIA XT				
AB3		ACTAVIS LABS FL INC	**120MG**	**A074752**	**002**	Jul 09, 1998
AB3			**180MG**	**A074752**	**001**	Jul 09, 1998
AB3			**240MG**	**A074752**	**003**	Jul 09, 1998
AB3			**300MG**	**A074752**	**004**	Jul 09, 1998
		DILTIAZEM HYDROCHLORIDE				
AB3		ACTAVIS ELIZABETH	**360MG**	**A202463**	**001**	Dec 07, 2012
AB3		PAR PHARM	**120MG**	**A074984**	**001**	Dec 20, 1999
AB3			**180MG**	**A074984**	**002**	Dec 20, 1999
AB3			**240MG**	**A074984**	**003**	Dec 20, 1999
AB3			**300MG**	**A074984**	**004**	Dec 20, 1999
AB3		SUN PHARMA GLOBAL	**120MG**	**A090492**	**001**	Oct 28, 2011
AB3			**180MG**	**A090492**	**002**	Oct 28, 2011
AB3			**240MG**	**A090492**	**003**	Oct 28, 2011
AB3			**300MG**	**A090492**	**004**	Oct 28, 2011
AB3			**360MG**	**A090492**	**005**	Oct 28, 2011
AB3		VALEANT PHARMS NORTH	**120MG**	**A075116**	**001**	Dec 23, 1999
AB3			**180MG**	**A075116**	**002**	Dec 23, 1999
AB3			**240MG**	**A075116**	**003**	Dec 23, 1999
AB3			**300MG**	**A075116**	**004**	Dec 23, 1999
AB4		SANDOZ	**120MG**	**A091022**	**001**	Sep 28, 2012
AB4			**180MG**	**A091022**	**002**	Sep 28, 2012
AB4			**240MG**	**A091022**	**003**	Sep 28, 2012
AB4			**300MG**	**A091022**	**004**	Sep 28, 2012
AB4			**360MG**	**A091022**	**005**	Sep 28, 2012
AB4			**420MG**	**A091022**	**006**	Sep 28, 2012
AB4		SUN PHARMA GLOBAL	**120MG**	**A090421**	**001**	Nov 15, 2010
AB4			**180MG**	**A090421**	**002**	Nov 15, 2010
AB4			**240MG**	**A090421**	**003**	Nov 15, 2010
AB4			**300MG**	**A090421**	**004**	Nov 15, 2010
AB4			**360MG**	**A090421**	**005**	Nov 15, 2010
		DILTZAC				
AB4		APOTEX INC	**120MG**	**A076395**	**001**	Feb 01, 2006
AB4			**180MG**	**A076395**	**002**	Feb 01, 2006
AB4			**240MG**	**A076395**	**003**	Feb 01, 2006
AB4			**300MG**	**A076395**	**004**	Feb 01, 2006
AB4			**360MG**	**A076395**	**005**	Feb 01, 2006
		TAZTIA XT				
AB4		ACTAVIS LABS FL INC	**120MG**	**A075401**	**001**	Apr 10, 2003
AB4			**180MG**	**A075401**	**002**	Apr 10, 2003
AB4			**240MG**	**A075401**	**003**	Apr 10, 2003
AB4			**300MG**	**A075401**	**004**	Apr 10, 2003
AB4			**360MG**	**A075401**	**005**	Apr 10, 2003
		TIAZAC				
AB4		VALEANT PHARMS NORTH	**120MG**	**N020401**	**001**	Sep 11, 1995
AB4			**180MG**	**N020401**	**002**	Sep 11, 1995
AB4			**240MG**	**N020401**	**003**	Sep 11, 1995
AB4			**300MG**	**N020401**	**004**	Sep 11, 1995
AB4			**360MG**	**N020401**	**005**	Sep 11, 1995
AB4	**+**		**420MG**	**N020401**	**006**	Oct 16, 1998
		DILTIAZEM HYDROCHLORIDE				
BC	+	MYLAN	120MG	A074910	003	May 02, 1997
			60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

INJECTABLE;INJECTION

		DILTIAZEM HYDROCHLORIDE				
AP		AKORN INC	**5MG/ML**	**A075086**	**001**	Apr 09, 1998
AP	**+**	AMPHASTAR PHARMS INC	**5MG/ML**	**A074617**	**001**	Feb 28, 1996
AP		EUROHLTH INTL SARL	**5MG/ML**	**A078538**	**001**	Dec 17, 2008
AP		HIKMA FARMACEUTICA	**5MG/ML**	**A202651**	**001**	Aug 09, 2012
AP		HOSPIRA	**5MG/ML**	**A074941**	**001**	Apr 15, 1998
AP		INTL MEDICATION	**5MG/ML**	**A075749**	**001**	Nov 21, 2001
	+	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002

TABLET;ORAL

		CARDIZEM				
AB		VALEANT INTL	**30MG**	**N018602**	**001**	Nov 05, 1982

DILTIAZEM HYDROCHLORIDE
TABLET;ORAL
CARDIZEM

AB			**60MG**	**N018602** **002**	Nov 05, 1982
AB			**90MG**	**N018602** **003**	Dec 08, 1986
AB	**+**		**120MG**	**N018602** **004**	Dec 08, 1986
	DILTIAZEM HYDROCHLORIDE				
AB		MYLAN	**30MG**	**A072838** **004**	Nov 05, 1992
AB			**60MG**	**A072838** **003**	Nov 05, 1992
AB			**90MG**	**A072838** **002**	Nov 05, 1992
AB			**120MG**	**A072838** **001**	Nov 05, 1992
AB		TEVA	**30MG**	**A074185** **001**	May 31, 1995
AB			**60MG**	**A074185** **002**	May 31, 1995
AB			**90MG**	**A074185** **003**	May 31, 1995
AB			**120MG**	**A074185** **004**	May 31, 1995

TABLET, EXTENDED RELEASE;ORAL
CARDIZEM LA

AB		VALEANT INTL	**120MG**	**N021392** **001**	Feb 06, 2003
AB			**180MG**	**N021392** **002**	Feb 06, 2003
AB			**240MG**	**N021392** **003**	Feb 06, 2003
AB			**300MG**	**N021392** **004**	Feb 06, 2003
AB			**360MG**	**N021392** **005**	Feb 06, 2003
AB	**+**		**420MG**	**N021392** **006**	Feb 06, 2003
	DILTIAZEM HYDROCHLORIDE				
AB		ACTAVIS LABS FL INC	**120MG**	**A077686** **006**	Mar 15, 2010
AB			**180MG**	**A077686** **005**	Mar 15, 2010
AB			**240MG**	**A077686** **004**	Mar 15, 2010
AB			**300MG**	**A077686** **003**	Mar 15, 2010
AB			**360MG**	**A077686** **002**	Mar 15, 2010
AB			**420MG**	**A077686** **001**	Mar 15, 2010

DIMENHYDRINATE
INJECTABLE;INJECTION
DIMENHYDRINATE

	+	FRESENIUS KABI USA	50MG/ML	A040519 001	Jun 23, 2004

DIMERCAPROL
INJECTABLE;INJECTION
BAL

	+	AKORN	10%	N005939 001	

DIMETHYL FUMARATE
CAPSULE, DELAYED RELEASE;ORAL
TECFIDERA

		BIOGEN IDEC INC	120MG	N204063 001	Mar 27, 2013
	+		240MG	N204063 002	Mar 27, 2013

DIMETHYL SULFOXIDE
SOLUTION;INTRAVESICAL
DIMETHYL SULFOXIDE

AT		MYLAN INSTITUTIONAL	**50%**	**A076185** **001**	Nov 29, 2002
	RIMSO-50				
AT	**+**	MYLAN INSTITUTIONAL	**50%**	**N017788** **001**	

DINOPROSTONE
GEL;ENDOCERVICAL
PREPIDIL

	+	PHARMACIA AND UPJOHN	0.5MG/3GM	N019617 001	Dec 09, 1992

INSERT, EXTENDED RELEASE;VAGINAL
CERVIDIL

	+	FERRING PHARMS INC	10MG	N020411 001	Mar 30, 1995

SUPPOSITORY;VAGINAL
PROSTIN E2

	+	PHARMACIA AND UPJOHN	20MG	N017810 001	

DIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

	+	BARR	50MG	A080738 001	

ELIXIR;ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

	+	PHARM ASSOC	12.5MG/5ML	A087513 001	Feb 10, 1982

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP		APP PHARMS	**50MG/ML**	**A040466** **001**	May 28, 2002

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002	
AP		HOSPIRA	50MG/ML	A040140	001	Nov 20, 1998
AP		MYLAN INSTITUTIONAL	50MG/ML	A040498	001	Jul 12, 2005

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	50MG/ML	A091526	001	Mar 26, 2013

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074939	001	Apr 13, 1998
AP		FRESENIUS KABI USA	5MG/ML	A074956	001	Sep 30, 1998
AP		WEST-WARD PHARMS INT	5MG/ML	A074521	001	Oct 18, 1996

TABLET;ORAL

DIPYRIDAMOLE

AB		BARR	25MG	A087184	001	Oct 03, 1990
AB			50MG	A087716	001	Oct 03, 1990
AB			75MG	A087717	001	Oct 03, 1990
AB		IMPAX LABS	25MG	A040782	001	Jul 18, 2007
AB			50MG	A040782	002	Jul 18, 2007
AB			75MG	A040782	003	Jul 18, 2007
AB		MURTY PHARMS	25MG	A040733	001	Feb 13, 2007
AB			50MG	A040733	002	Feb 13, 2007
AB			75MG	A040733	003	Feb 13, 2007
AB		ZYDUS PHARMS USA INC	25MG	A040874	001	Jan 28, 2008
AB			50MG	A040874	002	Jan 28, 2008
AB			75MG	A040874	003	Jan 28, 2008

PERSANTINE

AB		BOEHRINGER INGELHEIM	25MG	N012836	003	Dec 22, 1986
AB			50MG	N012836	004	Feb 06, 1987
AB	+		75MG	N012836	005	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

AB		MAYNE PHARMA	EQ 100MG BASE	A070173	001	May 31, 1985
AB			EQ 150MG BASE	A070174	001	May 31, 1985
AB		TEVA	EQ 100MG BASE	A070101	001	Feb 22, 1985
AB			EQ 150MG BASE	A070102	001	Feb 22, 1985

NORPACE

AB		GD SEARLE LLC	EQ 100MG BASE	N017447	001	
AB	+		EQ 150MG BASE	N017447	002	

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

AB	+	GD SEARLE LLC	EQ 150MG BASE	N018655	002	Jul 20, 1982
			EQ 100MG BASE	N018655	001	Jul 20, 1982

DISULFIRAM

TABLET;ORAL

ANTABUSE

AB		ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983
AB	+		500MG	A088483	001	Dec 08, 1983

DISULFIRAM

AB		MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015
AB			500MG	A203916	002	Mar 04, 2015
AB		SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011
AB			500MG	A091619	002	Mar 28, 2011
AB		VINTAGE PHARMS	250MG	A091563	001	Dec 31, 2012
AB			500MG	A091563	002	Dec 31, 2012
AB		WEST-WARD PHARMS INT	250MG	A202652	001	Feb 05, 2014
AB			500MG	A202652	002	Feb 05, 2014

DISULFIRAM

AB		ALVOGEN MALTA	250MG	A091681	001	Aug 08, 2013

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DEPAKOTE

AB	+	ABBVIE	EQ 125MG VALPROIC ACID	N019680	001	Sep 12, 1989

DIVALPROEX SODIUM

AB		DR REDDYS LABS LTD	EQ 125MG VALPROIC ACID	A078979	001	Jan 23, 2009
AB		MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011
AB		ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	A078919	001	Jan 27, 2009

FDA data supplied by DrugPatentWatch.com

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

AB	ABBVIE	EQ 125MG VALPROIC ACID	N018723	003	Oct 26, 1984
AB		EQ 250MG VALPROIC ACID	N018723	001	Mar 10, 1983
AB +		EQ 500MG VALPROIC ACID	N018723	002	Mar 10, 1983

DIVALPROEX SODIUM

AB	ACTAVIS LABS FL INC	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011
AB	ANCHEN PHARMS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008
AB	AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554	001	Apr 21, 2011
AB		EQ 250MG VALPROIC ACID	A090554	002	Apr 21, 2011
AB		EQ 500MG VALPROIC ACID	A090554	003	Apr 21, 2011
AB	DR REDDYS LABS LTD	EQ 125MG VALPROIC ACID	A078755	001	Jul 29, 2008
AB		EQ 250MG VALPROIC ACID	A078755	002	Jul 29, 2008
AB		EQ 500MG VALPROIC ACID	A078755	003	Jul 29, 2008
AB	LUPIN	EQ 125MG VALPROIC ACID	A078790	001	Jul 29, 2008
AB		EQ 250MG VALPROIC ACID	A078790	002	Jul 29, 2008
AB		EQ 500MG VALPROIC ACID	A078790	003	Jul 29, 2008
AB	MYLAN	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009
AB		EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009
AB		EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009
AB	NU PHARM	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008
AB		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008
AB		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008
AB	ORCHID HLTHCARE	EQ 125MG VALPROIC ACID	A078853	001	Nov 25, 2008
AB		EQ 250MG VALPROIC ACID	A078853	002	Nov 25, 2008
AB		EQ 500MG VALPROIC ACID	A078853	003	Nov 25, 2008
AB	SANDOZ	EQ 125MG VALPROIC ACID	A078290	003	Jul 29, 2008
AB		EQ 250MG VALPROIC ACID	A078290	002	Jul 29, 2008
AB		EQ 500MG VALPROIC ACID	A078290	001	Jul 29, 2008
AB	SUN PHARM INDS	EQ 125MG VALPROIC ACID	A078597	001	Jul 29, 2008
AB		EQ 250MG VALPROIC ACID	A078597	002	Jul 29, 2008
AB		EQ 500MG VALPROIC ACID	A078597	003	Jul 29, 2008
AB	TEVA	EQ 125MG VALPROIC ACID	A076941	001	Jul 29, 2008
AB		EQ 250MG VALPROIC ACID	A076941	002	Jul 29, 2008
AB		EQ 500MG VALPROIC ACID	A076941	003	Jul 29, 2008
AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011
AB		EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011
AB		EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011
AB	UPSHER SMITH	EQ 125MG VALPROIC ACID	A078182	001	Jul 29, 2008
AB		EQ 250MG VALPROIC ACID	A078182	002	Jul 29, 2008
AB		EQ 500MG VALPROIC ACID	A078182	003	Jul 29, 2008
AB	VINTAGE	EQ 125MG VALPROIC ACID	A090210	001	Nov 30, 2009
AB		EQ 250MG VALPROIC ACID	A090210	002	Nov 30, 2009
AB		EQ 500MG VALPROIC ACID	A090210	003	Nov 30, 2009
AB	WOCKHARDT	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008
AB		EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008
AB		EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008
AB	ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	A077100	001	Mar 05, 2009
AB		EQ 250MG VALPROIC ACID	A077100	002	Mar 05, 2009
AB		EQ 500MG VALPROIC ACID	A077100	003	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

AB	ABBVIE	EQ 250MG VALPROIC ACID	N021168	002	May 31, 2002
AB +		EQ 500MG VALPROIC ACID	N021168	001	Aug 04, 2000

DIVALPROEX SODIUM

AB	AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015
AB		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015
AB	ANCHEN PHARMS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009
AB		EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009
AB	AUROBINDO PHARMA LTD	EQ 250MG VALPROIC ACID	A202419	001	Jun 02, 2014
AB		EQ 500MG VALPROIC ACID	A202419	002	Jun 02, 2014
AB	DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161	001	Mar 15, 2012
AB	IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009
AB		EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009
AB	MYLAN	EQ 250MG VALPROIC ACID	A077567	001	Jan 29, 2009
AB		EQ 500MG VALPROIC ACID	A077567	002	Jan 29, 2009
AB	REDDYS	EQ 500MG VALPROIC ACID	A090070	001	Mar 12, 2012
AB	WOCKHARDT	EQ 250MG VALPROIC ACID	A078705	002	Feb 10, 2009
AB		EQ 500MG VALPROIC ACID	A078705	001	Aug 04, 2009
AB	ZYDUS PHARMS USA INC	EQ 250MG VALPROIC ACID	A078239	001	Feb 27, 2009
AB		EQ 500MG VALPROIC ACID	A078239	002	Aug 04, 2009

FDA data supplied by DrugPatentWatch.com

DOBUTAMINE HYDROCHLORIDE
INJECTABLE;INJECTION

		DOBUTAMINE HYDROCHLORIDE				
AP		HOSPIRA	**EQ 12.5MG BASE/ML**	**A074086**	**001**	Nov 29, 1993
AP	+		**EQ 12.5MG BASE/ML**	**A074292**	**001**	Feb 16, 1995
AP		WEST-WARD PHARMS INT	**EQ 12.5MG BASE/ML**	**A074277**	**001**	Oct 31, 1994
		DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	+	BAXTER HLTHCARE	**EQ 50MG BASE/100ML**	**N020255**	**001**	Oct 19, 1993
AP	+		**EQ 100MG BASE/100ML**	**N020255**	**003**	Oct 19, 1993
AP	+		**EQ 200MG BASE/100ML**	**N020255**	**004**	Oct 19, 1993
AP	+		**EQ 400MG BASE/100ML**	**N020255**	**005**	Oct 19, 1993
AP	+	HOSPIRA	**EQ 50MG BASE/100ML**	**N020201**	**003**	Oct 19, 1993
AP	+		**EQ 100MG BASE/100ML**	**N020201**	**002**	Oct 19, 1993
AP	+		**EQ 200MG BASE/100ML**	**N020201**	**001**	Oct 19, 1993
AP	+		**EQ 400MG BASE/100ML**	**N020201**	**006**	Jul 07, 1994

DOCETAXEL
INJECTABLE;INJECTION

		DOCETAXEL				
AP		ACCORD HLTHCARE	**20MG/ML (20MG/ML)**	**N201195**	**003**	Apr 20, 2012
AP			**80MG/4ML (20MG/ML)**	**N201195**	**004**	Apr 20, 2012
AP	+		**160MG/8ML (20MG/ML)**	**N201195**	**005**	Apr 20, 2012
AP		ACTAVIS INC	**20MG/ML (20MG/ML)**	**N203551**	**001**	Apr 12, 2013
AP			**80MG/4ML (20MG/ML)**	**N203551**	**002**	Apr 12, 2013
AP		DR REDDYS LABS LTD	**20MG/ML (20MG/ML)**	**A204193**	**001**	Nov 05, 2014
AP			**80MG/4ML (20MG/ML)**	**A204193**	**002**	Nov 05, 2014
AP	+	HOSPIRA INC	**20MG/2ML (10MG/ML)**	**N022234**	**001**	Mar 08, 2011
AP	+		**80MG/8ML (10MG/ML)**	**N022234**	**002**	Mar 08, 2011
AP	+		**160MG/16ML (10MG/ML)**	**N022234**	**003**	Mar 08, 2011
AP		SANDOZ	**20MG/2ML (10MG/ML)**	**N201525**	**001**	Jun 29, 2011
AP			**80MG/8ML (10MG/ML)**	**N201525**	**002**	Jun 29, 2011
AP			**160MG/16ML (10MG/ML)**	**N201525**	**003**	Jun 29, 2011
AP		TEVA PHARMS USA	**20MG/ML (20MG/ML)**	**A203877**	**001**	Sep 16, 2015
AP			**80MG/4ML (20MG/ML)**	**A203877**	**002**	Sep 16, 2015
		TAXOTERE				
AP	+	SANOFI AVENTIS US	**20MG/ML (20MG/ML)**	**N020449**	**003**	Aug 03, 2010
AP	+		**80MG/4ML (20MG/ML)**	**N020449**	**004**	Aug 02, 2010
AP	+		**160MG/8ML (20MG/ML)**	**N020449**	**005**	Apr 13, 2012
		DOCEFREZ				
	+	SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011
	+		80MG/VIAL	N022534	002	May 03, 2011
		DOCETAXEL				
		ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011
			80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011
		ACTAVIS INC	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013
		HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016
			80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016
			120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016
		PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014
			80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014
			130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014
			200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014

SOLUTION;IV (INFUSION)

		DOCETAXEL				
		EAGLE PHARMS	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015
			80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015
			160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015

DOFETILIDE
CAPSULE;ORAL

		DOFETILIDE				
AB		TIGER PHARMS LLC	**0.125MG**	**A207058**	**001**	Jun 06, 2016
AB			**0.25MG**	**A207058**	**002**	Jun 06, 2016
AB			**0.5MG**	**A207058**	**003**	Jun 06, 2016
		TIKOSYN				
AB		PFIZER	**0.125MG**	**N020931**	**001**	Oct 01, 1999
AB			**0.25MG**	**N020931**	**002**	Oct 01, 1999
AB	+		**0.5MG**	**N020931**	**003**	Oct 01, 1999

FDA data supplied by DrugPatentWatch.com

DOLASETRON MESYLATE
INJECTABLE;INJECTION
ANZEMET

+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997

TABLET;ORAL
ANZEMET

	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997
+		100MG	N020623	002	Sep 11, 1997

DOLUTEGRAVIR SODIUM
TABLET;ORAL
TIVICAY

	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016
		EQ 25MG BASE	N204790	003	Jun 09, 2016
+		EQ 50MG BASE	N204790	001	Aug 12, 2013

DONEPEZIL HYDROCHLORIDE
TABLET;ORAL

	ARICEPT				
AB	EISAI INC	**5MG**	**N020690**	**002**	Nov 25, 1996
AB	**+**	**10MG**	**N020690**	**001**	Nov 25, 1996
AB	**+**	**23MG**	**N022568**	**001**	Jul 23, 2010
	DONEPEZIL HYDROCHLORIDE				
AB	ACTAVIS ELIZABETH	**23MG**	**A202415**	**001**	Dec 17, 2015
AB	ALEMBIC PHARMS LTD	**5MG**	**A201724**	**001**	Feb 25, 2013
AB		**10MG**	**A201724**	**002**	Feb 25, 2013
AB	APOTEX	**5MG**	**A078841**	**001**	Jun 02, 2011
AB		**10MG**	**A078841**	**002**	Jun 02, 2011
AB	AUROBINDO	**5MG**	**A090056**	**001**	May 31, 2011
AB		**10MG**	**A090056**	**002**	May 31, 2011
AB	CIPLA LTD	**5MG**	**A077518**	**001**	May 31, 2011
AB		**10MG**	**A077518**	**002**	May 31, 2011
AB	CSPC OUYI PHARM CO	**5MG**	**A202114**	**001**	Jul 05, 2013
AB		**10MG**	**A202114**	**002**	Jul 05, 2013
AB	DEXCEL PHARMA	**23MG**	**A203713**	**001**	Feb 19, 2016
AB	DR REDDYS LABS LTD	**5MG**	**A201001**	**001**	May 31, 2011
AB		**10MG**	**A201001**	**002**	May 31, 2011
AB		**23MG**	**A202723**	**001**	Jul 24, 2013
AB	HETERO LABS LTD V	**5MG**	**A203034**	**001**	Jan 30, 2015
AB		**10MG**	**A203034**	**002**	Jan 30, 2015
AB	INDICUS PHARMA	**5MG**	**A201634**	**001**	Jun 13, 2012
AB		**10MG**	**A201634**	**002**	Jun 13, 2012
AB		**23MG**	**A203419**	**001**	Apr 12, 2016
AB	JUBILANT GENERICS	**5MG**	**A090768**	**001**	May 31, 2011
AB		**10MG**	**A090768**	**002**	May 31, 2011
AB	LUPIN LTD	**23MG**	**A202782**	**001**	Oct 30, 2015
AB	MACLEODS PHARMS LTD	**5MG**	**A201146**	**001**	Aug 17, 2012
AB		**10MG**	**A201146**	**002**	Aug 17, 2012
AB		**23MG**	**A202631**	**001**	Jan 22, 2014
AB	MYLAN PHARMS INC	**5MG**	**A090521**	**001**	May 31, 2011
AB		**10MG**	**A090521**	**002**	May 31, 2011
AB		**23MG**	**A202656**	**001**	Oct 22, 2015
AB	OSMOTICA PHARM US	**23MG**	**A203114**	**001**	Jan 26, 2016
AB	PAR PHARM	**23MG**	**A202542**	**001**	Jul 24, 2013
AB	PLIVA HRVATSKA DOO	**5MG**	**A090425**	**001**	May 31, 2011
AB		**10MG**	**A090425**	**002**	May 31, 2011
AB	PRINSTON INC	**5MG**	**A200292**	**001**	May 31, 2011
AB		**10MG**	**A200292**	**002**	May 31, 2011
AB	ROXANE	**5MG**	**A078662**	**001**	May 31, 2011
AB		**10MG**	**A078662**	**002**	May 31, 2011
AB	SANDOZ	**5MG**	**A090290**	**001**	May 31, 2011
AB		**10MG**	**A090290**	**002**	May 31, 2011
AB	SCIEGEN PHARMS INC	**5MG**	**A203907**	**001**	Oct 29, 2014
AB		**10MG**	**A203907**	**002**	Oct 29, 2014
AB	SUN PHARM INDS	**5MG**	**A090493**	**001**	May 31, 2011
AB		**10MG**	**A090493**	**002**	May 31, 2011
AB	SUN PHARM INDS LTD	**5MG**	**A076786**	**001**	Nov 26, 2010
AB		**10MG**	**A076786**	**002**	Nov 26, 2010
AB		**23MG**	**A204293**	**001**	Jun 05, 2015
AB	TEVA	**5MG**	**A077344**	**001**	May 31, 2011
AB		**10MG**	**A077344**	**002**	May 31, 2011
AB	TORRENT PHARMS	**5MG**	**A090686**	**001**	May 31, 2011

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB			**10MG**	**A090686**	**002** May 31, 2011
AB		TWI PHARMS INC	**23MG**	**A203104**	**001** Oct 29, 2014
AB		UNICHEM LABS LTD	**5MG**	**A203656**	**001** Jun 23, 2016
AB			**10MG**	**A203656**	**002** Jun 23, 2016
AB		VIVIMED LABS	**5MG**	**A090551**	**001** May 31, 2011
AB			**10MG**	**A090551**	**002** May 31, 2011
AB		WOCKHARDT	**5MG**	**A091267**	**001** May 31, 2011
AB			**10MG**	**A091267**	**002** May 31, 2011
AB		ZYDUS PHARMS USA INC	**5MG**	**A090100**	**001** Oct 24, 2012
AB			**10MG**	**A090100**	**002** Oct 24, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

ARICEPT ODT

AB		EISAI INC	**5MG**	**N021720**	**001** Oct 18, 2004
AB	**+**		**10MG**	**N021720**	**002** Oct 18, 2004

DONEPEZIL HYDROCHLORIDE

AB		BARR	**5MG**	**A078388**	**002** Nov 26, 2010
AB			**10MG**	**A078388**	**001** Nov 26, 2010
AB		MACLEODS PHARMS LTD	**5MG**	**A201787**	**001** Dec 14, 2012
AB			**10MG**	**A201787**	**002** Dec 14, 2012
AB		SANDOZ	**5MG**	**A091198**	**001** May 10, 2011
AB			**10MG**	**A091198**	**002** May 10, 2011
AB		UNICHEM LABS LTD	**5MG**	**A204831**	**001** Nov 10, 2016
AB			**10MG**	**A204831**	**002** Nov 10, 2016
AB		ZYDUS PHARMS USA INC	**5MG**	**A090175**	**001** May 10, 2011
AB			**10MG**	**A090175**	**002** May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

		FOREST LABS LLC	10MG;7MG	N206439	003 Jul 18, 2016
			10MG;14MG	N206439	001 Dec 23, 2014
			10MG;21MG	N206439	004 Jul 18, 2016
	+		10MG;28MG	N206439	002 Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

AP	**+**	HOSPIRA	**40MG/ML**	**N018132**	**001**
AP	**+**		**80MG/100ML**	**N018132**	**002** Feb 04, 1982
AP	**+**		**80MG/ML**	**N018132**	**004** Jul 09, 1982
AP	**+**		**160MG/100ML**	**N018132**	**003** Feb 04, 1982
AP	**+**	LUITPOLD	**40MG/ML**	**A070799**	**001** Feb 11, 1987
AP	**+**		**80MG/ML**	**A070820**	**001** Feb 11, 1987
AP	**+**		**160MG/ML**	**A070826**	**001** Feb 11, 1987

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

AP	**+**	B BRAUN	**80MG/100ML**	**N019099**	**002** Oct 15, 1986
AP	**+**		**320MG/100ML**	**N019099**	**004** Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+**	B BRAUN	**160MG/100ML**	**N019099**	**003** Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**80MG/100ML**	**N019615**	**001** Mar 27, 1987
AP	**+**		**160MG/100ML**	**N019615**	**002** Mar 27, 1987
AP	**+**		**320MG/100ML**	**N019615**	**003** Mar 27, 1987
AP	**+**	HOSPIRA	**80MG/100ML**	**N018826**	**001** Sep 30, 1983
AP	**+**		**160MG/100ML**	**N018826**	**002** Sep 30, 1983
AP	**+**		**320MG/100ML**	**N018826**	**003** Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

	+	B BRAUN	40MG/100ML	N019099	001 Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	640MG/100ML	N019615	004 Mar 27, 1987

DORIPENEM

INJECTABLE;IV (INFUSION)

DORIBAX

		SHIONOGI INC	250MG/VIAL	N022106	002 Oct 05, 2010
	+		500MG/VIAL	N022106	001 Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

	DORZOLAMIDE HYDROCHLORIDE				
AT	ALCON PHARMS LTD	**EQ 2% BASE**	**A078981**	**001**	Apr 13, 2009
AT	BAUSCH AND LOMB	**EQ 2% BASE**	**A090143**	**001**	Jun 25, 2009
AT	HI TECH PHARMA	**EQ 2% BASE**	**A077846**	**001**	Oct 28, 2008
AT	LUITPOLD	**EQ 2% BASE**	**A079186**	**001**	Nov 18, 2009
AT	SANDOZ	**EQ 2% BASE**	**A078748**	**001**	Nov 06, 2008
AT	TEVA PHARMS	**EQ 2% BASE**	**A078756**	**001**	Dec 04, 2008
AT	WATSON LABS INC	**EQ 2% BASE**	**A202053**	**001**	Sep 11, 2014
AT	ZACH SYSTEMS	**EQ 2% BASE**	**A091034**	**001**	Dec 04, 2013
	TRUSOPT				
AT	**+** MERCK	**EQ 2% BASE**	**N020408**	**001**	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC

	COSOPT				
AT	**+** OAK PHARMS INC	**EQ 2% BASE;EQ 0.5% BASE**	**N020869**	**001**	Apr 07, 1998
	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE				
AT	AKORN INC	**EQ 2% BASE;EQ 0.5% BASE**	**A203058**	**001**	Sep 22, 2014
AT	ALCON RES	**EQ 2% BASE;EQ 0.5% BASE**	**A090604**	**001**	Nov 18, 2009
AT	BAUSCH AND LOMB	**EQ 2% BASE;EQ 0.5% BASE**	**A090037**	**001**	Jul 14, 2009
AT	HI TECH PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**A077847**	**001**	Oct 28, 2008
AT	SANDOZ	**EQ 2% BASE;EQ 0.5% BASE**	**A078749**	**001**	Nov 06, 2008
AT	TEVA PHARMS	**EQ 2% BASE;EQ 0.5% BASE**	**A078704**	**001**	Sep 28, 2009
AT	WATSON LABS INC	**EQ 2% BASE;EQ 0.5% BASE**	**A202054**	**001**	Sep 03, 2014
AT	ZACH SYSTEMS	**EQ 2% BASE;EQ 0.5% BASE**	**A091180**	**001**	Dec 04, 2013
	COSOPT PF				
	+ OAK PHARMS INC	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012

DOXAPRAM HYDROCHLORIDE
INJECTABLE;INJECTION

	DOPRAM				
AP	**+** WEST-WARD PHARMS INT	**20MG/ML**	**N014879**	**001**	
	DOXAPRAM HYDROCHLORIDE				
AP	AMPHASTAR PHARMS INC	**20MG/ML**	**A076266**	**001**	Jan 10, 2003

DOXAZOSIN MESYLATE
TABLET;ORAL

	CARDURA				
AB	**+** PFIZER	**EQ 1MG BASE**	**N019668**	**001**	Nov 02, 1990
AB		**EQ 2MG BASE**	**N019668**	**002**	Nov 02, 1990
AB		**EQ 4MG BASE**	**N019668**	**003**	Nov 02, 1990
AB		**EQ 8MG BASE**	**N019668**	**004**	Nov 02, 1990
	DOXAZOSIN MESYLATE				
AB	ACCORD HLTHCARE	**EQ 1MG BASE**	**A202824**	**001**	Jun 11, 2014
AB		**EQ 2MG BASE**	**A202824**	**002**	Jun 11, 2014
AB		**EQ 4MG BASE**	**A202824**	**003**	Jun 11, 2014
AB		**EQ 8MG BASE**	**A202824**	**004**	Jun 11, 2014
AB	APOTEX	**EQ 1MG BASE**	**A075580**	**001**	Oct 18, 2000
AB		**EQ 2MG BASE**	**A075580**	**002**	Oct 18, 2000
AB		**EQ 4MG BASE**	**A075580**	**003**	Oct 18, 2000
AB		**EQ 8MG BASE**	**A075580**	**004**	Oct 18, 2000
AB	DAVA PHARMS INC	**EQ 1MG BASE**	**A076161**	**001**	Jun 10, 2004
AB		**EQ 2MG BASE**	**A076161**	**002**	Jun 10, 2004
AB		**EQ 4MG BASE**	**A076161**	**003**	Jun 10, 2004
AB		**EQ 8MG BASE**	**A076161**	**004**	Jun 10, 2004
AB	MYLAN	**EQ 1MG BASE**	**A075509**	**001**	Oct 19, 2000
AB		**EQ 2MG BASE**	**A075509**	**002**	Oct 19, 2000
AB		**EQ 4MG BASE**	**A075509**	**003**	Oct 19, 2000
AB		**EQ 8MG BASE**	**A075509**	**004**	Oct 19, 2000
AB	PLIVA	**EQ 1MG BASE**	**A075750**	**001**	Jun 08, 2001
AB		**EQ 2MG BASE**	**A075750**	**002**	Jun 08, 2001
AB		**EQ 4MG BASE**	**A075750**	**003**	Jun 08, 2001
AB		**EQ 8MG BASE**	**A075750**	**004**	Jun 08, 2001
AB	TEVA	**EQ 1MG BASE**	**A075536**	**001**	Oct 18, 2000
AB		**EQ 2MG BASE**	**A075536**	**002**	Oct 18, 2000
AB		**EQ 4MG BASE**	**A075536**	**003**	Oct 18, 2000
AB		**EQ 8MG BASE**	**A075536**	**004**	Oct 18, 2000

TABLET, EXTENDED RELEASE;ORAL

	CARDURA XL				
	PFIZER	EQ 4MG BASE	N021269	001	Feb 22, 2005
	+	EQ 8MG BASE	N021269	002	Feb 22, 2005

FDA data supplied by DrugPatentWatch.com

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 10MG BASE	A070791	002	May 13, 1986
AB	+		EQ 25MG BASE	A070791	003	May 13, 1986
AB			EQ 50MG BASE	A070791	001	May 13, 1986
AB			EQ 75MG BASE	A070791	004	May 13, 1986
AB	+		EQ 100MG BASE	A070791	005	May 13, 1986
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

AA		SILARX	EQ 10MG BASE/ML	A074721	001	Dec 29, 1998
AA	+	TEVA PHARMS	EQ 10MG BASE/ML	A071609	001	Nov 09, 1987
AA		WOCKHARDT	EQ 10MG BASE/ML	A071918	001	Jul 20, 1988

CREAM;TOPICAL

ZONALON

+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013
AB			EQ 6MG BASE	A201951	002	Jul 26, 2013
AB		MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016
AB			EQ 6MG BASE	A202337	002	Jan 20, 2016

SILENOR

AB		PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010
AB	+		EQ 6MG BASE	N022036	002	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB		RISING PHARMS INC	0.5MCG	A201518	001	Sep 09, 2016
AB			1MCG	A201518	002	Sep 09, 2016
AB			2.5MCG	A201518	003	Sep 09, 2016
AB		WEST-WARD PHARMS INT	0.5MCG	A091433	001	Sep 23, 2011
AB			1MCG	A091433	002	Jan 14, 2014
AB			2.5MCG	A091433	003	Jan 14, 2014

HECTOROL

AB		GENZYME CORP	0.5MCG	N020862	002	Apr 23, 2004
AB			1MCG	N020862	003	Jul 13, 2009
AB	+		2.5MCG	N020862	001	Jun 09, 1999

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016
AP			4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015
AP		HIKMA PHARMS LLC	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013
AP		SANDOZ INC	4MCG/2ML (2MCG/ML)	A091333	001	May 05, 2014
AP			4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014

HECTOROL

AP		GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000
AP	+		4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014
AP			200MG/100ML	A203622	002	Jun 27, 2014
AP		ALVOGEN INC	2MG/ML	A065515	001	Nov 08, 2012
AP		FRESENIUS KABI USA	2MG/ML	A063277	001	Oct 26, 1995
AP		MYLAN LABS LTD	2MG/ML	A200901	001	Feb 14, 2012
AP			10MG/VIAL	A200170	001	Oct 28, 2011
AP			50MG/VIAL	A200170	002	Oct 28, 2011
AP		PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995
AP			10MG/VIAL	A063097	001	May 21, 1990
AP			20MG/VIAL	A063097	002	May 21, 1990
AP			50MG/VIAL	A063097	003	May 21, 1990
AP			200MG/100ML	A063336	004	Feb 28, 1995
AP	+	PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987
AP	+		200MG/100ML	N050629	002	May 03, 1988
AP		SAGENT PHARMS	2MG/ML	A091495	001	Mar 18, 2013
AP		SUN PHARM INDS	2MG/ML	A091418	001	Feb 15, 2012
AP		TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995
AP			200MG/100ML	A064140	002	Jul 28, 1995
AP		WEST-WARD PHARMS INT	2MG/ML	A062975	001	Mar 17, 1989

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	+		**10MG/VIAL**	**A062921**	**001**	Mar 17, 1989
AP	+		**20MG/VIAL**	**A062921**	**002**	Mar 17, 1989
AP	+		**50MG/VIAL**	**A062921**	**003**	Mar 17, 1989
AP			**200MG/100ML**	**A064097**	**001**	Sep 13, 1994
		PHARMACIA AND UPJOHN	150MG/75ML	N050629	003	Mar 28, 2011

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL (LIPOSOMAL)

AB		JANSSEN RES AND DEV	**20MG/10ML (2MG/ML)**	**N050718**	**001**	Nov 17, 1995
AB			**50MG/25ML (2MG/ML)**	**N050718**	**002**	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	+	SUN PHARMA GLOBAL	**20MG/10ML (2MG/ML)**	**A203263**	**001**	Feb 04, 2013
AB	+		**50MG/25ML (2MG/ML)**	**A203263**	**002**	Feb 04, 2013

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		G AND W LABS INC	**EQ 50MG BASE**	**A204446**	**001**	May 28, 2015
AB			**EQ 75MG BASE**	**A204446**	**002**	May 28, 2015
AB			**EQ 100MG BASE**	**A204446**	**003**	May 28, 2015
AB		IMPAX LABS INC	**EQ 150MG BASE**	**A200065**	**001**	Feb 17, 2011
AB		LUPIN LTD	**EQ 50MG BASE**	**A204234**	**001**	Mar 05, 2014
AB			**EQ 75MG BASE**	**A204234**	**002**	Mar 05, 2014
AB			**EQ 100MG BASE**	**A204234**	**003**	Mar 05, 2014
AB		MYLAN PHARMS INC	**EQ 150MG BASE**	**A202778**	**001**	Jun 08, 2012
AB		PAR PHARM	**EQ 50MG BASE**	**A065055**	**001**	Dec 01, 2000
AB			**EQ 100MG BASE**	**A065055**	**002**	Dec 01, 2000
AB	+		**EQ 150MG BASE**	**A065055**	**003**	Jul 15, 2005
AB		SUN PHARM INDS LTD	**EQ 50MG BASE**	**A065053**	**001**	Nov 22, 2000
AB			**EQ 75MG BASE**	**A065053**	**003**	Sep 10, 2003
AB			**EQ 100MG BASE**	**A065053**	**002**	Nov 22, 2000
AB		ZYDUS PHARMS USA INC	**EQ 50MG BASE**	**A205115**	**001**	Feb 18, 2016
AB			**EQ 75MG BASE**	**A205115**	**002**	Feb 18, 2016
AB			**EQ 100MG BASE**	**A205115**	**003**	Feb 18, 2016

MONODOX

AB		AQUA PHARMS	**EQ 50MG BASE**	**N050641**	**002**	Feb 10, 1992
AB			**EQ 75MG BASE**	**N050641**	**003**	Oct 18, 2006
AB	+		**EQ 100MG BASE**	**N050641**	**001**	Dec 29, 1989

ORACEA

	+	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB		CHARTWELL LIFE SCI	**EQ 25MG BASE/5ML**	**A065454**	**001**	Jul 16, 2008
AB		LUPIN LTD	**EQ 25MG BASE/5ML**	**A201678**	**001**	Mar 18, 2013

VIBRAMYCIN

AB	+	PFIZER	**EQ 25MG BASE/5ML**	**N050006**	**001**	

TABLET;ORAL

DOXYCYCLINE

AB		HERITAGE PHARMS INC	**EQ 50MG BASE**	**A091605**	**001**	Dec 20, 2011
AB			**EQ 75MG BASE**	**A091605**	**002**	Dec 20, 2011
AB			**EQ 100MG BASE**	**A091605**	**003**	Dec 20, 2011
AB			**EQ 150MG BASE**	**A091605**	**004**	Dec 20, 2011
AB		LANNETT	**EQ 50MG BASE**	**A065285**	**001**	Dec 08, 2005
AB			**EQ 75MG BASE**	**A065285**	**003**	Jul 30, 2008
AB			**EQ 100MG BASE**	**A065285**	**002**	Dec 08, 2005
AB			**EQ 150MG BASE**	**A065285**	**004**	Jul 30, 2008
AB		MYLAN	**EQ 50MG BASE**	**A065377**	**001**	Nov 07, 2006
AB			**EQ 75MG BASE**	**A065377**	**002**	Nov 07, 2006
AB			**EQ 100MG BASE**	**A065377**	**003**	Nov 07, 2006
AB			**EQ 150MG BASE**	**A065427**	**001**	Jun 07, 2007
AB		PAR PHARM	**EQ 50MG BASE**	**A065070**	**001**	Dec 15, 2000
AB			**EQ 75MG BASE**	**A065070**	**003**	Dec 30, 2002
AB			**EQ 100MG BASE**	**A065070**	**002**	Dec 15, 2000
AB	+		**EQ 150MG BASE**	**A065070**	**004**	Jul 14, 2005
AB		SUN PHARM INDS LTD	**EQ 50MG BASE**	**A065356**	**001**	May 31, 2006
AB			**EQ 75MG BASE**	**A065356**	**002**	May 31, 2006
AB			**EQ 100MG BASE**	**A065356**	**003**	May 31, 2006

DOXYCYCLINE CALCIUM
SUSPENSION;ORAL
VIBRAMYCIN

	+	PFIZER	EQ 50MG BASE/5ML	N050480	001

DOXYCYCLINE HYCLATE
CAPSULE;ORAL

		DOXYCYCLINE HYCLATE				
AB		ACTAVIS LABS FL INC	**EQ 50MG BASE**	**A062031**	**002**	Oct 13, 1982
AB			**EQ 100MG BASE**	**A062031**	**001**	
AB		AMNEAL PHARMS	**EQ 100MG BASE**	**A207289**	**001**	Jun 27, 2016
AB		CHARTWELL LIFE SCI	**EQ 50MG BASE**	**A062500**	**001**	Sep 11, 1984
AB			**EQ 100MG BASE**	**A062500**	**002**	Sep 11, 1984
AB		HIKMA INTL PHARMS	**EQ 50MG BASE**	**A062396**	**002**	Nov 07, 1984
AB			**EQ 100MG BASE**	**A062396**	**001**	May 07, 1984
AB		MUTUAL PHARM	**EQ 50MG BASE**	**A062675**	**001**	Jul 10, 1986
AB		MYLAN	**EQ 50MG BASE**	**A062337**	**001**	Mar 29, 1982
AB			**EQ 100MG BASE**	**A062337**	**002**	Mar 29, 1982
AB		SUN PHARM INDS	**EQ 100MG BASE**	**A062676**	**001**	Jul 10, 1986
		VIBRAMYCIN				
AB	**+**	PFIZER	**EQ 100MG BASE**	**N050007**	**002**	
		ACTICLATE CAP				
	+	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016
		DOXYCYCLINE HYCLATE				
	+	HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005

CAPSULE, DELAYED RELEASE;ORAL

		DOXYCYCLINE HYCLATE				
		MEDICIS	EQ 75MG BASE	A065281	001	Dec 21, 2005
	+		EQ 100MG BASE	A065281	002	Dec 21, 2005

INJECTABLE;INJECTION

		DOXY 100				
AP	**+**	FRESENIUS KABI USA	**EQ 100MG BASE/VIAL**	**A062475**	**001**	Dec 09, 1983
		DOXYCYCLINE				
AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A091406**	**001**	Aug 21, 2012
AP	**+**	WEST-WARD PHARMS INT	**EQ 100MG BASE/VIAL**	**A062569**	**001**	Mar 09, 1988
		DOXY 200				
	+	FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A062475	002	Dec 09, 1983

SYSTEM, EXTENDED RELEASE;PERIODONTAL

		ATRIDOX				
	+	TOLMAR	50MG	N050751	001	Sep 03, 1998

TABLET;ORAL

		DOXYCYCLINE HYCLATE				
AB		ACTAVIS LABS FL INC	**EQ 100MG BASE**	**A062421**	**001**	Feb 02, 1983
AB		BLU CARIBE INC	**EQ 100MG BASE**	**A062269**	**002**	Nov 08, 1982
AB		CHARTWELL LIFE SCI	**EQ 100MG BASE**	**A062505**	**001**	Sep 11, 1984
AB	**+**	HIKMA INTL PHARMS	**EQ 100MG BASE**	**A065095**	**001**	Jul 02, 2003
AB		IVAX SUB TEVA PHARMS	**EQ 20MG BASE**	**A065163**	**001**	May 13, 2005
AB	**+**	LANNETT	**EQ 20MG BASE**	**A065277**	**001**	Nov 10, 2005
AB		LARKEN LABS	**EQ 20MG BASE**	**A065287**	**001**	Feb 28, 2006
AB		MYLAN	**EQ 100MG BASE**	**A062432**	**001**	Feb 15, 1983
AB		SUN PHARM INDS	**EQ 20MG BASE**	**A065134**	**001**	May 13, 2005
AB			**EQ 100MG BASE**	**A062677**	**001**	Jul 10, 1986
		ACTICLATE				
		AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014
	+		EQ 150MG BASE	N205931	002	Jul 25, 2014

TABLET, DELAYED RELEASE;ORAL

		DORYX				
AB		MAYNE PHARMA	**EQ 50MG BASE**	**N050795**	**006**	Dec 19, 2014
AB			**EQ 75MG BASE**	**N050795**	**001**	May 06, 2005
AB			**EQ 80MG BASE**	**N050795**	**004**	Apr 11, 2013
AB			**EQ 100MG BASE**	**N050795**	**002**	May 06, 2005
AB			**EQ 150MG BASE**	**N050795**	**003**	Jun 20, 2008
AB	**+**		**EQ 200MG BASE**	**N050795**	**005**	Apr 11, 2013
		DOXYCYCLINE HYCLATE				
AB		ACTAVIS ELIZABETH	**EQ 75MG BASE**	**A090134**	**001**	Dec 14, 2011
AB			**EQ 100MG BASE**	**A090134**	**002**	Dec 14, 2011
AB		HERITAGE PHARMS INC	**EQ 75MG BASE**	**A200856**	**001**	Apr 30, 2013
AB			**EQ 100MG BASE**	**A200856**	**002**	Apr 30, 2013
AB			**EQ 150MG BASE**	**A200856**	**003**	Apr 30, 2013
AB		MYLAN	**EQ 50MG BASE**	**A090431**	**003**	May 23, 2016
AB			**EQ 75MG BASE**	**A090431**	**001**	Dec 28, 2010
AB			**EQ 80MG BASE**	**A090431**	**004**	Apr 29, 2016
AB			**EQ 100MG BASE**	**A090431**	**002**	Dec 28, 2010

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE HYCLATE
TABLET, DELAYED RELEASE;ORAL

	DOXYCYCLINE HYCLATE				
AB		**EQ 200MG BASE**	**A090431**	**005**	May 19, 2016
AB	MYLAN PHARMS INC	**EQ 150MG BASE**	**A091052**	**001**	Feb 08, 2012
AB	PRINSTON INC	**EQ 150MG BASE**	**A207494**	**001**	Nov 15, 2016
AB		**EQ 200MG BASE**	**A207494**	**002**	Nov 15, 2016
	DORYX MPC				
	MAYNE PHARMA	EQ 60MG BASE	N050795	007	May 20, 2016
+		EQ 120MG BASE	N050795	008	May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE
TABLET, DELAYED RELEASE;ORAL

	DICLEGIS				
AB	+ DUCHESNAY	**10MG;10MG**	**N021876**	**001**	Apr 08, 2013
	DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE				
AB	ACTAVIS LABS FL INC	**10MG;10MG**	**A205811**	**001**	Aug 19, 2016

TABLET, EXTENDED RELEASE;ORAL

	BONJESTA				
+	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016

DRONABINOL
CAPSULE;ORAL

	DRONABINOL				
AB	AKORN INC	**2.5MG**	**A079217**	**001**	Jun 20, 2014
AB		**5MG**	**A079217**	**002**	Jun 20, 2014
AB		**10MG**	**A079217**	**003**	Jun 20, 2014
AB	SVC PHARMA	**2.5MG**	**A078292**	**001**	Jun 27, 2008
AB		**5MG**	**A078292**	**002**	Jun 27, 2008
AB		**10MG**	**A078292**	**003**	Jun 27, 2008
	MARINOL				
AB	ABBVIE	**2.5MG**	**N018651**	**001**	May 31, 1985
AB +		**5MG**	**N018651**	**002**	May 31, 1985
AB		**10MG**	**N018651**	**003**	May 31, 1985

DRONEDARONE HYDROCHLORIDE
TABLET;ORAL

	MULTAQ				
+	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009

DROPERIDOL
INJECTABLE;INJECTION

	DROPERIDOL				
AP	HOSPIRA	**2.5MG/ML**	**A071981**	**001**	Feb 29, 1988
AP	LUITPOLD	**2.5MG/ML**	**A072123**	**001**	Oct 24, 1988
	INAPSINE				
AP +	AKORN INC	**2.5MG/ML**	**N016796**	**001**	

DROSPIRENONE; ESTRADIOL
TABLET;ORAL

	ANGELIQ				
	BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012
+		0.5MG;1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL
TABLET;ORAL

	DROSPIRENONE AND ETHINYL ESTRADIOL				
AB	BARR	**3MG;0.02MG**	**A078515**	**001**	Mar 30, 2009
AB	GLENMARK PHARMS LTD	**3MG;0.02MG**	**A204296**	**001**	Aug 17, 2015
AB	JAI PHARMA LTD	**3MG;0.02MG**	**A202594**	**001**	Oct 22, 2015
AB	WATSON LABS	**3MG;0.02MG**	**A078833**	**001**	Nov 28, 2011
	LORYNA				
AB	SANDOZ	**3MG;0.02MG**	**A079221**	**001**	Mar 28, 2011
	MELAMISA				
AB	NOVAST LABS LTD	**3MG;0.02MG**	**A202016**	**001**	Jan 26, 2016
	NIKKI				
AB	LUPIN LTD	**3MG;0.02MG**	**A201661**	**001**	May 27, 2014
	YAZ				
AB +	BAYER HLTHCARE	**3MG;0.02MG**	**N021676**	**001**	Mar 16, 2006

TABLET;ORAL-28

	DROSPIRENONE AND ETHINYL ESTRADIOL				
AB	ACCORD HLTHCARE	**3MG;0.03MG**	**A207245**	**001**	Nov 22, 2016
AB	APOTEX INC	**3MG;0.03MG**	**A205876**	**001**	Sep 21, 2016
AB	BARR	**3MG;0.03MG**	**A077527**	**001**	May 09, 2008
AB	GLENMARK PHARMS LTD	**3MG;0.03MG**	**A204848**	**001**	Mar 25, 2016

DROSPIRENONE; ETHINYL ESTRADIOL
TABLET;ORAL-28

	DROSPIRENONE AND ETHINYL ESTRADIOL				
AB	JAI PHARMA LTD	**3MG;0.03MG**	**A202131**	**001**	May 04, 2015
AB	LUPIN LTD	**3MG;0.03MG**	**A201663**	**001**	Dec 18, 2012
AB	MAYNE PHARMA	**3MG;0.03MG**	**A090081**	**001**	Sep 07, 2010
	SYEDA				
AB	SANDOZ	**3MG;0.03MG**	**A090114**	**001**	Mar 28, 2011
	YAELA				
AB	NOVAST LABS LTD	**3MG;0.03MG**	**A202015**	**001**	Nov 19, 2014
	YASMIN				
AB +	BAYER HLTHCARE	**3MG;0.03MG**	**N021098**	**001**	May 11, 2001

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM
TABLET;ORAL

	BEYAZ				
AB	BAYER HLTHCARE	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**N022532**	**001**	Sep 24, 2010
	DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM				
AB	WATSON LABS INC	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A203593**	**001**	Oct 11, 2016
AB		**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A203594**	**001**	Oct 11, 2016
	SAFYRAL				
AB +	BAYER HLTHCARE	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**N022574**	**001**	Dec 16, 2010

DROXIDOPA
CAPSULE;ORAL

	NORTHERA				
	LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014
		200MG	N203202	002	Feb 18, 2014
+		300MG	N203202	003	Feb 18, 2014

DULOXETINE HYDROCHLORIDE
CAPSULE, DELAYED REL PELLETS;ORAL

	CYMBALTA				
AB	LILLY	**EQ 20MG BASE**	**N021427**	**001**	Aug 03, 2004
AB		**EQ 30MG BASE**	**N021427**	**002**	Aug 03, 2004
AB +		**EQ 60MG BASE**	**N021427**	**004**	Aug 03, 2004
	DULOXETINE HYDROCHLORIDE				
AB	ACTAVIS ELIZABETH	**EQ 20MG BASE**	**A090776**	**001**	Dec 17, 2013
AB		**EQ 30MG BASE**	**A090776**	**002**	Dec 17, 2013
AB		**EQ 60MG BASE**	**A090776**	**003**	Dec 17, 2013
AB	AJANTA PHARMA LTD	**EQ 20MG BASE**	**A208706**	**001**	Jan 06, 2017
AB		**EQ 30MG BASE**	**A208706**	**002**	Jan 06, 2017
AB		**EQ 60MG BASE**	**A208706**	**003**	Jan 06, 2017
AB	ALEMBIC PHARMS LTD	**EQ 20MG BASE**	**A202949**	**001**	Jun 09, 2014
AB		**EQ 30MG BASE**	**A202949**	**002**	Jun 09, 2014
AB		**EQ 60MG BASE**	**A202949**	**003**	Jun 09, 2014
AB	ALKEM LABS LTD	**EQ 20MG BASE**	**A203197**	**001**	Aug 26, 2015
AB		**EQ 30MG BASE**	**A203197**	**002**	Aug 26, 2015
AB		**EQ 60MG BASE**	**A203197**	**003**	Aug 26, 2015
AB	ANCHEN PHARMS	**EQ 20MG BASE**	**A090780**	**001**	Oct 28, 2015
AB		**EQ 30MG BASE**	**A090780**	**002**	Oct 28, 2015
AB		**EQ 60MG BASE**	**A090780**	**003**	Oct 28, 2015
AB	APOTEX INC	**EQ 20MG BASE**	**A202045**	**001**	Jun 11, 2014
AB		**EQ 30MG BASE**	**A202045**	**002**	Jun 11, 2014
AB		**EQ 60MG BASE**	**A202045**	**003**	Jun 11, 2014
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A090778**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090778**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090778**	**003**	Dec 11, 2013
AB	BRECKENRIDGE PHARM	**EQ 20MG BASE**	**A203088**	**001**	Jun 11, 2014
AB		**EQ 30MG BASE**	**A203088**	**002**	Jun 11, 2014
AB		**EQ 60MG BASE**	**A203088**	**003**	Jun 11, 2014
AB	DR REDDYS LABS LTD	**EQ 20MG BASE**	**A090723**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090723**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090723**	**003**	Dec 11, 2013
AB	HETERO LABS LTD III	**EQ 20MG BASE**	**A204343**	**001**	Aug 03, 2016
AB		**EQ 30MG BASE**	**A204343**	**002**	Aug 03, 2016
AB		**EQ 60MG BASE**	**A204343**	**003**	Aug 03, 2016
AB	INVENTIA HLTHCARE	**EQ 20MG BASE**	**A202336**	**001**	Oct 28, 2015
AB		**EQ 30MG BASE**	**A202336**	**002**	Oct 28, 2015
AB		**EQ 60MG BASE**	**A202336**	**003**	Oct 28, 2015
AB	LUPIN LTD	**EQ 20MG BASE**	**A090694**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090694**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090694**	**004**	Dec 11, 2013
AB	SUN PHARMA GLOBAL	**EQ 20MG BASE**	**A090745**	**001**	Dec 11, 2013

DULOXETINE HYDROCHLORIDE
CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB		**EQ 30MG BASE**	**A090745**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090745**	**003**	Dec 11, 2013
AB	TEVA PHARMS USA	**EQ 20MG BASE**	**A090783**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090783**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090783**	**003**	Dec 11, 2013
AB	TORRENT PHARMS LTD	**EQ 20MG BASE**	**A090774**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090774**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090774**	**003**	Dec 11, 2013
AB	ZYDUS PHARMS USA INC	**EQ 20MG BASE**	**A090728**	**001**	Jan 08, 2014
AB		**EQ 20MG BASE**	**A090739**	**001**	Jan 08, 2014
AB		**EQ 30MG BASE**	**A090728**	**002**	Jan 08, 2014
AB		**EQ 30MG BASE**	**A090739**	**002**	Jan 08, 2014
AB		**EQ 60MG BASE**	**A090728**	**003**	Jan 08, 2014
AB		**EQ 60MG BASE**	**A090739**	**003**	Jan 08, 2014
	LUPIN LTD	EQ 40MG BASE	A090694	003	Dec 11, 2013

DUTASTERIDE
CAPSULE;ORAL
AVODART

AB	**+** GLAXOSMITHKLINE	**0.5MG**	**N021319**	**001**	Nov 20, 2001

DUTASTERIDE

AB	ACTAVIS LABS FL INC	**0.5MG**	**A202808**	**001**	Nov 20, 2015
AB	AMNEAL PHARMS	**0.5MG**	**A203118**	**001**	Nov 20, 2015
AB	APOTEX INC	**0.5MG**	**A204292**	**001**	Nov 24, 2015
AB	ASCENT PHARMS INC	**0.5MG**	**A206574**	**001**	Oct 21, 2016
AB	AUROLIFE PHARMA LLC	**0.5MG**	**A202660**	**001**	Nov 20, 2015
AB	BARR	**0.5MG**	**A090095**	**001**	Dec 21, 2010
AB	BIONPHARMA INC	**0.5MG**	**A200899**	**001**	Nov 20, 2015
AB	BRECKENRIDGE PHARM	**0.5MG**	**A204705**	**001**	Nov 20, 2015
AB	INTERGEL PHARMS INC	**0.5MG**	**A206373**	**001**	Mar 17, 2016
AB	MYLAN PHARMS INC	**0.5MG**	**A203241**	**001**	Jun 14, 2016
AB	RISING PHARMS INC	**0.5MG**	**A202530**	**001**	Nov 20, 2015
AB	STRIDES PHARMA	**0.5MG**	**A204262**	**001**	Nov 20, 2015
AB	VINTAGE PHARMS LLC	**0.5MG**	**A202421**	**001**	Nov 20, 2015
AB	WEST-WARD PHARMS INT	**0.5MG**	**A202204**	**001**	Nov 23, 2015

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE
CAPSULE;ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	**0.5MG;0.4MG**	**A202975**	**001**	Nov 20, 2015
AB	ANCHEN PHARMS	**0.5MG;0.4MG**	**A202509**	**001**	Feb 26, 2014

JALYN

AB	**+** GLAXOSMITHKLINE	**0.5MG;0.4MG**	**N022460**	**001**	Jun 14, 2010

ECHOTHIOPHATE IODIDE
FOR SOLUTION;OPHTHALMIC
PHOSPHOLINE IODIDE

	+ WYETH PHARMS INC	0.125%	N011963	001	

ECONAZOLE NITRATE
AEROSOL, FOAM;TOPICAL
ECOZA

	+ EXELTIS SUISSE	1%	N205175	001	Oct 24, 2013

CREAM;TOPICAL
ECONAZOLE NITRATE

AB	FOUGERA PHARMS	**1%**	**A076075**	**001**	Nov 26, 2002
AB	**+** PERRIGO NEW YORK	**1%**	**A076479**	**001**	Jun 23, 2004
AB	TARO	**1%**	**A076005**	**001**	Nov 26, 2002
AB	TELIGENT PHARMA INC	**1%**	**A076574**	**001**	Dec 17, 2004

EDETATE CALCIUM DISODIUM
INJECTABLE;INJECTION
CALCIUM DISODIUM VERSENATE

	+ MEDICIS	200MG/ML	N008922	001	

EDOXABAN TOSYLATE
TABLET;ORAL
SAVAYSA

	DAIICHI SANKYO INC	EQ 15MG BASE	N206316	001	Jan 08, 2015
		EQ 30MG BASE	N206316	002	Jan 08, 2015
	+	EQ 60MG BASE	N206316	003	Jan 08, 2015

EDROPHONIUM CHLORIDE
INJECTABLE;INJECTION
ENLON

+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985

EFAVIRENZ
CAPSULE;ORAL
SUSTIVA

	BRISTOL MYERS SQUIBB	50MG	N020972	001	Sep 17, 1998
+		200MG	N020972	003	Sep 17, 1998

TABLET;ORAL
EFAVIRENZ

AB	MYLAN PHARMS INC	**600MG**	**A091471**	**001**	Feb 17, 2016

SUSTIVA

AB	**+** BRISTOL MYERS SQUIBB	**600MG**	**N021360**	**002**	Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
ATRIPLA

+	GILEAD	600MG;200MG;300MG	N021937	001	Jul 12, 2006

EFINACONAZOLE
SOLUTION;TOPICAL
JUBLIA

+	DOW PHARM	10%	N203567	001	Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE
CREAM;TOPICAL
VANIQA

+	SKINMEDICA	13.9%	N021145	001	Jul 27, 2000

ELBASVIR; GRAZOPREVIR
TABLET;ORAL
ZEPATIER

+	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016

ELETRIPTAN HYDROBROMIDE
TABLET;ORAL
RELPAX

	PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002
+		EQ 40MG BASE	N021016	002	Dec 26, 2002

ELIGLUSTAT TARTRATE
CAPSULE;ORAL
CERDELGA

+	GENZYME CORP	EQ 84MG BASE	N205494	001	Aug 19, 2014

ELTROMBOPAG OLAMINE
FOR SUSPENSION;ORAL
PROMACTA

+	NOVARTIS PHARMS CORP	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015

TABLET;ORAL
PROMACTA

	NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011
		EQ 25MG ACID	N022291	001	Nov 20, 2008
		EQ 50MG ACID	N022291	002	Nov 20, 2008
+		EQ 75MG ACID	N022291	003	Sep 08, 2009
+		EQ 100MG ACID	N022291	005	Nov 16, 2012

ELUXADOLINE
TABLET;ORAL
VIBERZI

	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015
+		100MG	N206940	002	May 27, 2015

ELVITEGRAVIR
TABLET;ORAL
VITEKTA

	GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014
+		150MG	N203093	002	Sep 24, 2014

EMEDASTINE DIFUMARATE
SOLUTION/DROPS;OPHTHALMIC
EMADINE

+	NOVARTIS PHARMS CORP	0.05%	N020706	001	Dec 29, 1997

FDA data supplied by DrugPatentWatch.com

EMPAGLIFLOZIN
TABLET;ORAL
JARDIANCE

	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014
+		25MG	N204629	002	Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN
TABLET;ORAL
GLYXAMBI

	BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015
+		25MG;5MG	N206073	002	Jan 30, 2015

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
TABLET;ORAL
SYNJARDY

	BOEHRINGER INGELHEIM	5MG;500MG	N206111	001	Aug 26, 2015
		5MG;1GM	N206111	002	Aug 26, 2015
		12.5MG;500MG	N206111	003	Aug 26, 2015
+		12.5MG;1GM	N206111	004	Aug 26, 2015

TABLET, EXTENDED RELEASE;ORAL
SYNJARDY XR

	BOEHRINGER INGELHEIM	5MG;1GM	N208658	001	Dec 09, 2016
		10MG;1GM	N208658	002	Dec 09, 2016
		12.5MG;1GM	N208658	003	Dec 09, 2016
+		25MG;1GM	N208658	004	Dec 09, 2016

EMTRICITABINE
CAPSULE;ORAL
EMTRIVA

+	GILEAD	200MG	N021500	001	Jul 02, 2003

SOLUTION;ORAL
EMTRIVA

+	GILEAD	10MG/ML	N021896	001	Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
ODEFSEY

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
COMPLERA

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
DESCOVY

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
TRUVADA

	GILEAD	100MG;150MG	N021752	002	Mar 10, 2016
		133MG;200MG	N021752	003	Mar 10, 2016
		167MG;250MG	N021752	004	Mar 10, 2016
+		200MG;300MG	N021752	001	Aug 02, 2004

ENALAPRIL MALEATE
FOR SOLUTION;ORAL
EPANED KIT

+	SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013

SOLUTION;ORAL
EPANED

	SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016

TABLET;ORAL
ENALAPRIL MALEATE

AB	APOTEX	**2.5MG**	**A075178**	**002**	Mar 23, 2001
AB		**5MG**	**A075178**	**001**	Mar 23, 2001
AB		**10MG**	**A075178**	**003**	Mar 23, 2001
AB		**20MG**	**A075178**	**004**	Mar 23, 2001
AB	MYLAN	**2.5MG**	**A075480**	**001**	Aug 22, 2000
AB		**5MG**	**A075480**	**002**	Aug 22, 2000
AB		**10MG**	**A075480**	**003**	Aug 22, 2000
AB		**20MG**	**A075480**	**004**	Aug 22, 2000
AB	SANDOZ INC	**2.5MG**	**A075496**	**001**	Aug 22, 2000
AB		**5MG**	**A075496**	**002**	Aug 22, 2000

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE
TABLET;ORAL
ENALAPRIL MALEATE

AB		10MG	A075459	001	Aug 22, 2000
AB		20MG	A075459	002	Aug 22, 2000
AB	TARO	2.5MG	A075657	001	Jan 23, 2001
AB		5MG	A075657	002	Jan 23, 2001
AB		10MG	A075657	003	Jan 23, 2001
AB		20MG	A075657	004	Jan 23, 2001
AB	TEVA	2.5MG	A075479	001	Aug 22, 2000
AB		5MG	A075479	002	Aug 22, 2000
AB		10MG	A075479	003	Aug 22, 2000
AB		20MG	A075479	004	Aug 22, 2000
AB	WOCKHARDT USA	2.5MG	A075483	001	Aug 22, 2000
AB		5MG	A075483	002	Aug 22, 2000
AB		10MG	A075483	003	Aug 22, 2000
AB		20MG	A075483	004	Aug 22, 2000

VASOTEC

AB	VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988
AB		5MG	N018998	001	Dec 24, 1985
AB		10MG	N018998	002	Dec 24, 1985
AB +		20MG	N018998	003	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	5MG;12.5MG	A076486	001	Oct 27, 2004
AB		10MG;25MG	A076486	002	Oct 27, 2004
AB	DR REDDYS LABS LTD	5MG;12.5MG	A075909	001	Oct 15, 2001
AB		10MG;25MG	A075909	002	Oct 15, 2001
AB	G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001
AB		10MG;25MG	A075727	002	Sep 18, 2001
AB	MYLAN	5MG;12.5MG	A075624	001	Sep 18, 2001
AB		10MG;25MG	A075624	002	Sep 18, 2001
AB	TARO PHARM INDS	5MG;12.5MG	A075788	001	Sep 18, 2001
AB		10MG;25MG	A075788	002	Sep 18, 2001

VASERETIC

AB	VALEANT INTL	5MG;12.5MG	N019221	003	Jul 12, 1995
AB +		10MG;25MG	N019221	001	Oct 31, 1986

ENALAPRILAT
INJECTABLE;INJECTION
ENALAPRILAT

AP +	AMPHASTAR PHARMS INC	1.25MG/ML	A075634	001	Aug 22, 2000
AP	HIKMA FARMACEUTICA	1.25MG/ML	A078687	001	Dec 23, 2008
AP +	HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000
AP	TEVA PHARMS USA	1.25MG/ML	A075578	001	Aug 22, 2000

ENFUVIRTIDE
INJECTABLE;SUBCUTANEOUS
FUZEON

+	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003

ENOXAPARIN SODIUM
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
ENOXAPARIN SODIUM

AB	SANDOZ INC	300MG/3ML (100MG/ML)	A078660	001	Nov 28, 2011

LOVENOX

AB	SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003

INJECTABLE;SUBCUTANEOUS
ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	AMPHASTAR PHARM	30MG/0.3ML (100MG/ML)	A076684	001	Sep 19, 2011
AP		40MG/0.4ML (100MG/ML)	A076684	002	Sep 19, 2011
AP		60MG/0.6ML (100MG/ML)	A076684	003	Sep 19, 2011
AP		80MG/0.8ML (100MG/ML)	A076684	004	Sep 19, 2011
AP		100MG/ML (100MG/ML)	A076684	005	Sep 19, 2011
AP		120MG/0.8ML (150MG/ML)	A076684	006	Sep 19, 2011
AP		150MG/ML (150MG/ML)	A076684	007	Sep 19, 2011
AP	SANDOZ	30MG/0.3ML (100MG/ML)	A077857	002	Jul 23, 2010
AP		40MG/0.4ML (100MG/ML)	A077857	003	Jul 23, 2010
AP		60MG/0.6ML (100MG/ML)	A077857	004	Jul 23, 2010
AP		80MG/0.8ML (100MG/ML)	A077857	005	Jul 23, 2010
AP		100MG/ML (100MG/ML)	A077857	001	Jul 23, 2010
AP		120MG/0.8ML (150MG/ML)	A077857	006	Jul 23, 2010

ENOXAPARIN SODIUM
INJECTABLE;SUBCUTANEOUS

	ENOXAPARIN SODIUM (PRESERVATIVE FREE)				
AP		**150MG/ML (150MG/ML)**	**A077857**	**007**	Jul 23, 2010
AP	TEVA	**30MG/0.3ML (100MG/ML)**	**A076726**	**001**	Jun 23, 2014
AP		**40MG/0.4ML (100MG/ML)**	**A076726**	**002**	Jun 23, 2014
AP		**60MG/0.6ML (100MG/ML)**	**A076726**	**003**	Jun 23, 2014
AP		**80MG/0.8ML (100MG/ML)**	**A076726**	**004**	Jun 23, 2014
AP		**100MG/ML (100MG/ML)**	**A076726**	**005**	Jun 23, 2014
AP		**120MG/0.8ML (150MG/ML)**	**A076726**	**006**	Jun 23, 2014
AP		**150MG/ML (150MG/ML)**	**A076726**	**007**	Jun 23, 2014
	LOVENOX (PRESERVATIVE FREE)				
AP	SANOFI AVENTIS US	**30MG/0.3ML (100MG/ML)**	**N020164**	**001**	Mar 29, 1993
AP		**40MG/0.4ML (100MG/ML)**	**N020164**	**002**	Jan 30, 1998
AP		**60MG/0.6ML (100MG/ML)**	**N020164**	**003**	Mar 27, 1998
AP		**80MG/0.8ML (100MG/ML)**	**N020164**	**004**	Mar 27, 1998
AP	**+**	**100MG/ML (100MG/ML)**	**N020164**	**005**	Mar 27, 1998
AP		**120MG/0.8ML (150MG/ML)**	**N020164**	**007**	Jun 02, 2000
AP		**150MG/ML (150MG/ML)**	**N020164**	**008**	Jun 02, 2000

ENTACAPONE
TABLET;ORAL

	COMTAN				
AB	**+** ORION PHARMA	**200MG**	**N020796**	**001**	Oct 19, 1999
	ENTACAPONE				
AB	AUROBINDO PHARMA LTD	**200MG**	**A203437**	**001**	Jun 19, 2015
AB	MYLAN PHARMS INC	**200MG**	**A202394**	**001**	May 13, 2013
AB	SUN PHARMA GLOBAL	**200MG**	**A090690**	**001**	Jul 16, 2012
AB	WOCKHARDT LTD	**200MG**	**A078941**	**001**	Aug 16, 2012

ENTECAVIR
SOLUTION;ORAL

	BARACLUDE				
	+ BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005

TABLET;ORAL

	BARACLUDE				
AB	BRISTOL MYERS SQUIBB	**0.5MG**	**N021797**	**001**	Mar 29, 2005
AB	**+**	**1MG**	**N021797**	**002**	Mar 29, 2005
	ENTECAVIR				
AB	AMNEAL PHARMS	**0.5MG**	**A206652**	**001**	Nov 12, 2015
AB		**1MG**	**A206652**	**002**	Nov 12, 2015
AB	AUROBINDO PHARMA LTD	**0.5MG**	**A206217**	**001**	Aug 26, 2015
AB		**1MG**	**A206217**	**002**	Aug 26, 2015
AB	CIPLA LTD	**0.5MG**	**A206872**	**001**	Dec 06, 2016
AB		**1MG**	**A206872**	**002**	Dec 06, 2016
AB	HETERO LABS LTD V	**0.5MG**	**A205740**	**001**	Aug 21, 2015
AB		**1MG**	**A205740**	**002**	Aug 21, 2015
AB	PAR PHARM INC	**0.5MG**	**A206294**	**001**	Nov 23, 2016
AB		**1MG**	**A206294**	**002**	Nov 23, 2016
AB	TEVA PHARMS USA	**0.5MG**	**A202122**	**001**	Aug 26, 2014
AB		**1MG**	**A202122**	**002**	Aug 26, 2014

ENZALUTAMIDE
CAPSULE;ORAL

	XTANDI				
	+ ASTELLAS	40MG	N203415	001	Aug 31, 2012

EPHEDRINE SULFATE
SOLUTION;INTRAVENOUS

	AKOVAZ				
	+ FLAMEL IRELAND LTD	50MG/ML	N208289	001	Apr 29, 2016

EPINASTINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

	ELESTAT				
AT	**+** ALLERGAN	**0.05%**	**N021565**	**001**	Oct 16, 2003
	EPINASTINE HYDROCHLORIDE				
AT	ALCON RES LTD	**0.05%**	**A203384**	**001**	Dec 07, 2016
AT	APOTEX	**0.05%**	**A090919**	**001**	Oct 31, 2011
AT	BRECKENRIDGE PHARM	**0.05%**	**A090870**	**001**	Mar 14, 2011
AT	SOMERSET THERAPS LLC	**0.05%**	**A090951**	**001**	Oct 31, 2011
AT	SUN PHARM INDS	**0.05%**	**A091626**	**001**	Oct 31, 2011

EPINEPHRINE
INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN
+ PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML) N204200 001 Dec 07, 2012
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENACLICK
BX + AMEDRA PHARMS EQ 0.15MG/DELIVERY N020800 003 Nov 25, 2009
BX + EQ 0.3MG/DELIVERY N020800 004 Nov 25, 2009
AUVI-Q
BX + KALEO INC EQ 0.15MG/DELIVERY N201739 002 Aug 10, 2012
BX EQ 0.3MG/DELIVERY N201739 001 Aug 10, 2012
EPIPEN
BX + MYLAN SPECLT 0.3MG/DELIVERY N019430 001 Dec 22, 1987
EPIPEN JR.
BX + MYLAN SPECLT 0.15MG/DELIVERY N019430 002 Dec 22, 1987
ADRENALIN
+ PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML) N204640 001 Dec 18, 2013
SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE
BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N205029 001 Jul 29, 2014

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
LIGNOSPAN FORTE
+ DEPROCO EQ 0.02MG BASE/ML;2% A088389 001 Jan 22, 1985
LIGNOSPAN STANDARD
+ DEPROCO EQ 0.01MG BASE/ML;2% A088390 001 Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CITANEST FORTE DENTAL
AP + DENTSPLY PHARM 0.005MG/ML;4% N021383 001
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE
AP SEPTODONT INC 0.005MG/ML;4% A078959 001 Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE
AP EASTMAN KODAK 0.01MG/ML;2% A040057 002 Feb 26, 1993
AP 0.02MG/ML;2% A040057 001 Feb 26, 1993
AP HOSPIRA 0.005MG/ML;0.5% A089635 001 Jun 21, 1988
AP 0.005MG/ML;1.5% A088571 001 Sep 13, 1985
AP 0.005MG/ML;1.5% A089645 001 Jun 21, 1988
AP 0.005MG/ML;2% A089651 001 Jun 21, 1988
AP 0.01MG/ML;1% A089644 001 Jun 21, 1988
AP 0.01MG/ML;2% A078772 001 May 12, 2008
AP 0.01MG/ML;2% A089646 001 Jun 21, 1988
AP 0.02MG/ML;2% A078772 002 May 12, 2008
OCTOCAINE
AP + SEPTODONT 0.01MG/ML;2% A084048 001
AP + 0.02MG/ML;2% A084048 002
XYLOCAINE W/ EPINEPHRINE
AP + FRESENIUS KABI USA 0.005MG/ML;0.5% N006488 012
AP + 0.005MG/ML;1% N006488 018 Nov 13, 1986
AP + 0.005MG/ML;1.5% N006488 017
AP + 0.005MG/ML;2% N006488 019 Nov 13, 1986
AP + 0.01MG/ML;1% N006488 004
AP + 0.02MG/ML;2% N006488 005

EPIRUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
ELLENCE
AP + PFIZER INC 200MG/100ML (2MG/ML) N050778 001 Sep 15, 1999
AP 50MG/25ML (2MG/ML) N050778 002 Sep 15, 1999
EPIRUBICIN HYDROCHLORIDE
AP ACTAVIS TOTOWA 10MG/5ML (2MG/ML) A065445 001 Sep 18, 2008
AP 50MG/25ML (2MG/ML) A065445 002 Sep 18, 2008
AP 200MG/100ML (2MG/ML) A065445 003 Sep 18, 2008
AP AKORN INC 50MG/25ML (2MG/ML) A090163 001 Jun 24, 2009
AP CIPLA LTD 50MG/25ML (2MG/ML) A065361 001 Oct 22, 2007
AP 200MG/100ML (2MG/ML) A065361 002 Oct 22, 2007
AP FRESENIUS KABI ONCOL 200MG/100ML (2MG/ML) A065411 001 Aug 20, 2007
AP 50MG/25ML (2MG/ML) A065411 002 Aug 20, 2007
AP FRESENIUS KABI USA 10MG/5ML (2MG/ML) A065408 001 Oct 15, 2007

EPIRUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION

	EPIRUBICIN HYDROCHLORIDE				
AP		**50MG/25ML (2MG/ML)**	**A065408**	**002**	Oct 15, 2007
AP		**150MG/75ML (2MG/ML)**	**A065408**	**003**	Oct 15, 2007
AP		**200MG/100ML (2MG/ML)**	**A065408**	**004**	Oct 15, 2007
AP	HISUN PHARM HANGZHOU	**50MG/25ML (2MG/ML)**	**A090075**	**001**	Mar 25, 2010
AP		**200MG/100ML (2MG/ML)**	**A090075**	**002**	Mar 25, 2010
AP	HOSPIRA	**10MG/5ML (2MG/ML)**	**A065343**	**001**	Apr 19, 2007
AP		**150MG/75ML (2MG/ML)**	**A065343**	**003**	Apr 19, 2007
AP		**200MG/100ML (2MG/ML)**	**A065343**	**004**	Apr 19, 2007
AP	IMPAX LABS INC	**50MG/25ML (2MG/ML)**	**A065331**	**001**	Aug 09, 2007
AP		**200MG/100ML (2MG/ML)**	**A065331**	**002**	Aug 09, 2007
AP	MYLAN LABS LTD	**50MG/25ML (2MG/ML)**	**A091599**	**001**	Mar 12, 2012
AP		**200MG/100ML (2MG/ML)**	**A091599**	**002**	Mar 12, 2012
AP	WEST-WARD PHARMS INT	**50MG/25ML (2MG/ML)**	**A065289**	**001**	Jun 27, 2007
AP		**200MG/100ML (2MG/ML)**	**A065289**	**002**	Jun 27, 2007

EPLERENONE
TABLET;ORAL

	EPLERENONE				
AB	APOTEX	**25MG**	**A078482**	**001**	Jul 30, 2008
AB		**50MG**	**A078482**	**002**	Jul 30, 2008
AB	SANDOZ	**25MG**	**A078510**	**001**	Aug 01, 2008
AB		**50MG**	**A078510**	**002**	Aug 01, 2008
	INSPRA				
AB	GD SEARLE LLC	**25MG**	**N021437**	**001**	Sep 27, 2002
AB +		**50MG**	**N021437**	**002**	Sep 27, 2002

EPOPROSTENOL SODIUM
INJECTABLE;INJECTION

	EPOPROSTENOL SODIUM				
AP	TEVA PHARMS USA	**EQ 0.5MG BASE/VIAL**	**A078396**	**001**	Apr 23, 2008
AP		**EQ 1.5MG BASE/VIAL**	**A078396**	**002**	Apr 23, 2008
	FLOLAN				
AP +	GLAXOSMITHKLINE LLC	**EQ 0.5MG BASE/VIAL**	**N020444**	**001**	Sep 20, 1995
AP +		**EQ 1.5MG BASE/VIAL**	**N020444**	**002**	Sep 20, 1995
	VELETRI				
	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012
+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008

EPROSARTAN MESYLATE
TABLET;ORAL

	EPROSARTAN MESYLATE				
AB	MYLAN PHARMS INC	**EQ 400MG BASE**	**A202012**	**001**	Nov 16, 2011
AB		**EQ 600MG BASE**	**A202012**	**002**	Nov 16, 2011
	TEVETEN				
AB	ABBVIE	**EQ 400MG BASE**	**N020738**	**005**	Dec 22, 1997
AB +		**EQ 600MG BASE**	**N020738**	**006**	May 27, 1999

EPTIFIBATIDE
INJECTABLE;INJECTION

	EPTIFIBATIDE				
AP	AMNEAL PHARMS	**2MG/ML**	**A205581**	**001**	Dec 08, 2016
AP		**75MG/100ML**	**A205581**	**002**	Dec 08, 2016
AP	AUROBINDO PHARMA LTD	**2MG/ML**	**A206127**	**001**	Dec 08, 2015
AP		**75MG/100ML**	**A206127**	**002**	Dec 08, 2015
AP	TEVA PHARMS USA	**2MG/ML**	**A090854**	**001**	Jun 12, 2015
	INTEGRILIN				
AP +	SCHERING	**2MG/ML**	**N020718**	**001**	May 18, 1998
AP +		**75MG/100ML**	**N020718**	**002**	May 18, 1998

ERGOCALCIFEROL
CAPSULE;ORAL

	DRISDOL				
AA +	US PHARM HOLDINGS	**50,000 IU**	**N003444**	**001**	
	ERGOCALCIFEROL				
AA	ORIT LABS LLC	**50,000 IU**	**A040833**	**001**	May 20, 2009
AA	SIGMAPHARM LABS LLC	**50,000 IU**	**A091004**	**001**	Jul 14, 2010
AA	STRIDES PHARMA	**50,000 IU**	**A090455**	**001**	Aug 03, 2010
AA	SUN PHARM INDS INC	**50,000 IU**	**A040865**	**001**	Dec 29, 2009
	VITAMIN D				
AA	BIONPHARMA INC	**50,000 IU**	**A080704**	**001**	

FDA data supplied by DrugPatentWatch.com

ERGOLOID MESYLATES
TABLET;ORAL
ERGOLOID MESYLATES

AB		SUN PHARM INDS	**1MG**	**A081113**	**001** Oct 31, 1991

HYDERGINE

AB	**+**	NOVARTIS	**1MG**	**N017993**	**001**

ERGOTAMINE TARTRATE
TABLET;SUBLINGUAL
ERGOMAR

	+	TERSERA THERAP	2MG	A087693	001 Feb 24, 1983

ERIBULIN MESYLATE
SOLUTION;INTRAVENOUS
HALAVEN

	+	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE
TABLET;ORAL
TARCEVA

		OSI PHARMS	EQ 25MG BASE	N021743	001 Nov 18, 2004
			EQ 100MG BASE	N021743	002 Nov 18, 2004
	+		EQ 150MG BASE	N021743	003 Nov 18, 2004

ERTAPENEM SODIUM
INJECTABLE;INTRAMUSCULAR, IV (INFUSION)
INVANZ

	+	MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001 Nov 21, 2001

ERYTHROMYCIN
CAPSULE, DELAYED REL PELLETS;ORAL
ERYC

AB	**+**	MAYNE PHARMA	**250MG**	**N050536**	**001**

ERYTHROMYCIN

AB		ARBOR PHARMS LLC	**250MG**	**A062746**	**001** Dec 22, 1986

GEL;TOPICAL
ERYGEL

AT	**+**	DELCOR ASSET CORP	**2%**	**N050617**	**001** Oct 21, 1987

ERYTHROMYCIN

AT		FOUGERA PHARMS	**2%**	**A064184**	**001** Sep 30, 1997
AT		PERRIGO	**2%**	**A063211**	**001** Jan 29, 1993

OINTMENT;OPHTHALMIC
ERYTHROMYCIN

AT		AKORN	**0.5%**	**A064030**	**001** Jul 18, 1996
AT		BAUSCH AND LOMB	**0.5%**	**A064067**	**001** Jul 29, 1994
AT	**+**	PERRIGO CO TENNESSEE	**0.5%**	**A062447**	**001** Sep 26, 1983

OINTMENT;TOPICAL
AKNE-MYCIN

	+	DOW PHARM	2%	N050584	001 Jan 10, 1985

SOLUTION;TOPICAL
ERYTHROMYCIN

AT	**+**	FOUGERA PHARMS	**2%**	**A064187**	**001** Sep 30, 1997
AT		PERRIGO NEW YORK	**2%**	**A063038**	**001** Jan 11, 1991
AT		WOCKHARDT	**2%**	**A062825**	**001** Oct 23, 1987

SWAB;TOPICAL
ERYTHROMYCIN

AT		AKORN	**2%**	**A090215**	**001** May 12, 2010
AT	**+**	PERRIGO	**2%**	**A064126**	**001** Jul 03, 1996

TABLET;ORAL
ERYTHROMYCIN

		ARBOR PHARMS LLC	250MG	A061621	001
	+		500MG	A061621	002

TABLET, COATED PARTICLES;ORAL
PCE

		ARBOR PHARMS LLC	333MG	N050611	001 Sep 09, 1986
	+		500MG	N050611	002 Aug 22, 1990

TABLET, DELAYED RELEASE;ORAL
ERY-TAB

		ARBOR PHARMS LLC	250MG	A062298	001
			333MG	A062298	003 Mar 29, 1982
	+		500MG	A062298	002

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN ETHYLSUCCINATE
GRANULE;ORAL
E.E.S.

AB	ARBOR PHARMS LLC	**EQ 200MG BASE/5ML**	**N050207 001**	
	ERYPED			
AB	ARBOR PHARMS LLC	**EQ 200MG BASE/5ML**	**N050207 003**	Mar 30, 1987
+		EQ 400MG BASE/5ML	N050207 002	

TABLET;ORAL
E.E.S. 400

BX	+ ARBOR PHARMS LLC	EQ 400MG BASE	A061905 002	Aug 12, 1982
	ERYTHROMYCIN ETHYLSUCCINATE			
BX	+ ARBOR PHARMS LLC	EQ 400MG BASE	A061904 001	

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL
GRANULE;ORAL
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+	BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062759 001	May 20, 1988

ERYTHROMYCIN LACTOBIONATE
INJECTABLE;INJECTION
ERYTHROCIN

AP	HOSPIRA	**EQ 500MG BASE/VIAL**	**A062638 001**	Oct 31, 1986
AP	**+**	**EQ 500MG BASE/VIAL**	**N050609 001**	Sep 24, 1986
+		EQ 1GM BASE/VIAL	A062638 002	Oct 31, 1986

ERYTHROMYCIN STEARATE
TABLET;ORAL
ERYTHROCIN STEARATE

+	ARBOR PHARMS LLC	EQ 250MG BASE	A060359 001	

ESCITALOPRAM OXALATE
SOLUTION;ORAL
ESCITALOPRAM OXALATE

AA	AMNEAL PHARMS	**EQ 5MG BASE/5ML**	**A202227 001**	Mar 14, 2012
AA	ANTRIM PHARMS LLC	**EQ 5MG BASE/5ML**	**A203967 001**	May 26, 2015
AA	AUROBINDO PHARMA LTD	**EQ 5MG BASE/5ML**	**A079062 001**	Apr 02, 2012
AA	HETERO LABS LTD III	**EQ 5MG BASE/5ML**	**A202221 001**	Jun 12, 2012
AA	MACLEODS PHARMS LTD	**EQ 5MG BASE/5ML**	**A202754 001**	Mar 31, 2016
AA	SILARX PHARMS INC	**EQ 5MG BASE/5ML**	**A090477 001**	Jun 12, 2013
AA	TARO	**EQ 5MG BASE/5ML**	**A079121 001**	May 03, 2012
	LEXAPRO			
AA	**+** FOREST LABS	**EQ 5MG BASE/5ML**	**N021365 001**	Nov 27, 2002

TABLET;ORAL
ESCITALOPRAM OXALATE

AB	ACCORD HLTHCARE	**EQ 5MG BASE**	**A202389 001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A202389 002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A202389 003**	Sep 11, 2012
AB	APOTEX INC	**EQ 5MG BASE**	**A078777 001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A078777 002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A078777 003**	Sep 11, 2012
AB	AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A090432 001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A090432 002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A090432 003**	Sep 11, 2012
AB	HIKMA PHARMS	**EQ 5MG BASE**	**A078766 001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A078766 002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A078766 003**	Sep 11, 2012
AB	INVAGEN PHARMS	**EQ 5MG BASE**	**A078604 001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A078604 002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A078604 003**	Sep 11, 2012
AB	JUBILANT GENERICS	**EQ 5MG BASE**	**A202280 001**	Sep 12, 2012
AB		**EQ 10MG BASE**	**A202280 002**	Sep 12, 2012
AB		**EQ 20MG BASE**	**A202280 003**	Sep 12, 2012
AB	LUPIN LTD	**EQ 5MG BASE**	**A078169 001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A078169 002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A078169 003**	Sep 11, 2012
AB	MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A202210 001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A202210 002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A202210 003**	Sep 11, 2012
AB	MYLAN PHARMS INC	**EQ 5MG BASE**	**A077550 001**	May 14, 2015
AB		**EQ 10MG BASE**	**A077550 002**	May 14, 2015
AB		**EQ 20MG BASE**	**A077550 003**	May 14, 2015
AB	PRINSTON INC	**EQ 5MG BASE**	**A078032 001**	Aug 28, 2015
AB		**EQ 10MG BASE**	**A078032 002**	Aug 28, 2015
AB		**EQ 20MG BASE**	**A078032 003**	Aug 28, 2015

FDA data supplied by DrugPatentWatch.com

ESCITALOPRAM OXALATE
TABLET;ORAL

	ESCITALOPRAM OXALATE				
AB	STI PHARMA LLC	**EQ 5MG BASE**	**A077512**	**001**	Sep 12, 2012
AB		**EQ 10MG BASE**	**A077512**	**002**	Sep 12, 2012
AB		**EQ 20MG BASE**	**A077512**	**003**	Sep 12, 2012
AB	TEVA PHARMS USA	**EQ 5MG BASE**	**A076765**	**001**	Mar 14, 2012
AB		**EQ 10MG BASE**	**A076765**	**002**	Mar 14, 2012
AB		**EQ 20MG BASE**	**A076765**	**003**	Mar 14, 2012
AB	TORRENT PHARMS LTD	**EQ 5MG BASE**	**A090939**	**001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A090939**	**002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A090939**	**003**	Sep 11, 2012
AB	ZYDUS PHARMS USA INC	**EQ 5MG BASE**	**A077734**	**001**	Sep 11, 2012
AB		**EQ 10MG BASE**	**A077734**	**002**	Sep 11, 2012
AB		**EQ 20MG BASE**	**A077734**	**003**	Sep 11, 2012
	LEXAPRO				
AB	FOREST LABS	**EQ 5MG BASE**	**N021323**	**001**	Aug 14, 2002
AB		**EQ 10MG BASE**	**N021323**	**002**	Aug 14, 2002
AB	**+**	**EQ 20MG BASE**	**N021323**	**003**	Aug 14, 2002

ESLICARBAZEPINE ACETATE
TABLET;ORAL

	APTIOM				
	SUNOVION PHARMS INC	200MG	N022416	001	Nov 08, 2013
		400MG	N022416	002	Nov 08, 2013
		600MG	N022416	003	Nov 08, 2013
	+	800MG	N022416	004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE
INJECTABLE;INJECTION

	BREVIBLOC				
AP	**+** BAXTER HLTHCARE	**10MG/ML**	**N019386**	**006**	Feb 25, 2003
	ESMOLOL HYDROCHLORIDE				
AP	AUROBINDO PHARMA LTD	**10MG/ML**	**A205520**	**001**	Jul 23, 2015
AP	FRESENIUS KABI USA	**10MG/ML**	**A076573**	**001**	May 02, 2005
AP	LUITPOLD PHARMS INC	**10MG/ML**	**A201126**	**001**	Feb 20, 2015
AP	MYLAN INSTITUTIONAL	**10MG/ML**	**A076474**	**001**	May 02, 2005
AP	WEST-WARD PHARMS INT	**10MG/ML**	**A076323**	**001**	Aug 10, 2004
	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003
	BREVIBLOC IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001
SOLUTION;INTRAVENOUS					
	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER				
	+ HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016
	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER				
	+ HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016

ESOMEPRAZOLE MAGNESIUM
CAPSULE, DELAYED REL PELLETS;ORAL

	ESOMEPRAZOLE MAGNESIUM				
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A205606**	**001**	Apr 21, 2016
AB		**EQ 40MG BASE**	**A205606**	**002**	Apr 21, 2016
AB	DR REDDYS LABS LTD	**EQ 20MG BASE**	**A078279**	**001**	Sep 25, 2015
AB		**EQ 40MG BASE**	**A078279**	**002**	Sep 25, 2015
AB	IVAX SUB TEVA PHARMS	**EQ 20MG BASE**	**A078003**	**001**	Jan 26, 2015
AB		**EQ 40MG BASE**	**A078003**	**002**	Jan 26, 2015
AB	MYLAN PHARMS INC	**EQ 20MG BASE**	**A078936**	**001**	Aug 02, 2015
AB		**EQ 40MG BASE**	**A078936**	**002**	Aug 03, 2015
AB	TORRENT PHARMS LTD	**EQ 20MG BASE**	**A203636**	**001**	Oct 19, 2015
AB		**EQ 40MG BASE**	**A203636**	**002**	Oct 19, 2015
	NEXIUM				
AB	ASTRAZENECA PHARMS	**EQ 20MG BASE**	**N021153**	**001**	Feb 20, 2001
AB	**+**	**EQ 40MG BASE**	**N021153**	**002**	Feb 20, 2001
	ESOMEPRAZOLE MAGNESIUM				
BX	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015
BX		EQ 40MG BASE	A202784	002	Sep 21, 2015
FOR SUSPENSION, DELAYED RELEASE;ORAL					
	NEXIUM				
	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011
		EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011
		EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008
		EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006
	+	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006

FDA data supplied by DrugPatentWatch.com

ESOMEPRAZOLE MAGNESIUM; NAPROXEN
TABLET, DELAYED RELEASE;ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	**EQ 20MG BASE;375MG**	**A202461**	**001**	Sep 27, 2013
AB		**EQ 20MG BASE;500MG**	**A202461**	**002**	Sep 27, 2013
VIMOVO					
AB	HORIZON PHARMA USA	**EQ 20MG BASE;375MG**	**N022511**	**002**	Apr 30, 2010
AB +		**EQ 20MG BASE;500MG**	**N022511**	**001**	Apr 30, 2010

ESOMEPRAZOLE SODIUM
INJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	ACCORD HLTHCARE	**EQ 40MG BASE/VIAL**	**A205379**	**001**	Sep 25, 2015
AP	AUROBINDO PHARMA LTD	**EQ 20MG BASE/VIAL**	**A204657**	**001**	Aug 10, 2016
AP		**EQ 40MG BASE/VIAL**	**A204657**	**002**	Aug 10, 2016
AP	SUN PHARMA GLOBAL	**EQ 20MG BASE/VIAL**	**A200882**	**001**	Mar 18, 2013
AP		**EQ 40MG BASE/VIAL**	**A200882**	**002**	Mar 18, 2013
NEXIUM IV					
AP +	ASTRAZENECA PHARMS	**EQ 20MG BASE/VIAL**	**N021689**	**001**	Mar 31, 2005
AP +		**EQ 40MG BASE/VIAL**	**N021689**	**002**	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM
CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

	R2 PHARMA LLC	24.65MG	N202342	001	Aug 06, 2013
+		49.3MG	N202342	002	Aug 06, 2013

ESTAZOLAM
TABLET;ORAL
ESTAZOLAM

AB	MAYNE PHARMA	**1MG**	**A074921**	**001**	Jul 10, 1997
AB +		**2MG**	**A074921**	**002**	Jul 10, 1997
AB	PAR PHARM	**1MG**	**A074826**	**001**	Jul 03, 1997
AB		**2MG**	**A074826**	**002**	Jul 03, 1997
AB	WATSON LABS	**1MG**	**A074818**	**001**	Aug 19, 1997
AB		**2MG**	**A074818**	**002**	Aug 19, 1997

ESTRADIOL
CREAM;VAGINAL
ESTRACE

+	ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984

FILM, EXTENDED RELEASE;TRANSDERMAL
CLIMARA

AB	BAYER HLTHCARE	**0.0375MG/24HR**	**N020375**	**005**	May 27, 2003
AB		**0.06MG/24HR**	**N020375**	**006**	May 27, 2003
ESTRADIOL					
AB	MYLAN TECHNOLOGIES	**0.0375MG/24HR**	**A075182**	**004**	Jul 20, 2006
AB		**0.06MG/24HR**	**A075182**	**005**	Jul 20, 2006
AB1		**0.025MG/24HR**	**A201675**	**001**	Dec 19, 2014
AB1		**0.0375MG/24HR**	**A201675**	**002**	Dec 19, 2014
AB1		**0.05MG/24HR**	**A201675**	**003**	Dec 19, 2014
AB1		**0.075MG/24HR**	**A201675**	**004**	Dec 19, 2014
AB1		**0.1MG/24HR**	**A201675**	**005**	Dec 19, 2014
VIVELLE					
AB1	NOVARTIS	**0.05MG/24HR**	**N020323**	**002**	Oct 28, 1994
AB1		**0.1MG/24HR**	**N020323**	**004**	Oct 28, 1994
VIVELLE-DOT					
AB1	NOVARTIS	**0.025MG/24HR**	**N020538**	**009**	May 03, 2002
AB1		**0.0375MG/24HR**	**N020538**	**005**	Jan 08, 1999
AB1		**0.05MG/24HR**	**N020538**	**006**	Jan 08, 1999
AB1		**0.075MG/24HR**	**N020538**	**007**	Jan 08, 1999
AB1 +		**0.1MG/24HR**	**N020538**	**008**	Jan 08, 1999
CLIMARA					
AB2	BAYER HLTHCARE	**0.025MG/24HR**	**N020375**	**004**	Mar 05, 1999
AB2		**0.05MG/24HR**	**N020375**	**001**	Dec 22, 1994
AB2		**0.075MG/24HR**	**N020375**	**003**	Mar 23, 1998
AB2 +		**0.1MG/24HR**	**N020375**	**002**	Dec 22, 1994
ESTRADIOL					
AB2	MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A075182**	**003**	Jan 26, 2005
AB2		**0.05MG/24HR**	**A075182**	**006**	Feb 24, 2000
AB2		**0.075MG/24HR**	**A075182**	**002**	Jan 26, 2005
AB2		**0.1MG/24HR**	**A075182**	**001**	Feb 24, 2000
ALORA					
BX	ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002

FDA data supplied by DrugPatentWatch.com

ESTRADIOL

	FILM, EXTENDED RELEASE;TRANSDERMAL				
	ALORA				
BX		0.05MG/24HR	N020655	001	Dec 20, 1996
BX		0.075MG/24HR	N020655	002	Dec 20, 1996
BX		0.1MG/24HR	N020655	003	Dec 20, 1996
	ESTRADERM				
BX	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
BX +		0.1MG/24HR	N019081	003	Sep 10, 1986
	MENOSTAR				
+	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004
	MINIVELLE				
	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014
		0.0375MG/24HR	N203752	001	Oct 29, 2012
		0.05MG/24HR	N203752	003	Oct 29, 2012
		0.075MG/24HR	N203752	002	Oct 29, 2012
+		0.1MG/24HR	N203752	004	Oct 29, 2012
	GEL;TRANSDERMAL				
	DIVIGEL				
	VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007
		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007
+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007
	GEL, METERED;TRANSDERMAL				
	ELESTRIN				
+	MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006
	ESTROGEL				
+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004
	INSERT, EXTENDED RELEASE;VAGINAL				
	ESTRING				
+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472	001	Apr 26, 1996
	SPRAY;TRANSDERMAL				
	EVAMIST				
+	ELAN PHARMA INTL LTD	1.53MG/SPRAY	N022014	001	Jul 27, 2007
	TABLET;ORAL				
	ESTRADIOL				
AB	BARR LABS INC	**0.5MG**	**A040197**	**001**	Oct 22, 1997
AB		**1MG**	**A040197**	**002**	Oct 22, 1997
AB +		**2MG**	**A040197**	**003**	Oct 22, 1997
AB	EPIC PHARMA INC	**0.5MG**	**A040275**	**001**	Dec 29, 1998
AB		**1MG**	**A040275**	**002**	Dec 29, 1998
AB		**2MG**	**A040275**	**003**	Dec 29, 1998
AB	MAYNE PHARMA	**0.5MG**	**A040114**	**003**	Mar 14, 1996
AB		**1MG**	**A040114**	**001**	Mar 14, 1996
AB		**2MG**	**A040114**	**002**	Mar 14, 1996
AB	MYLAN	**0.5MG**	**A040326**	**001**	Apr 21, 1999
AB		**1MG**	**A040326**	**002**	Apr 21, 1999
AB		**2MG**	**A040326**	**003**	Apr 21, 1999
	TABLET;VAGINAL				
	ESTRADIOL				
AB	AMNEAL PHARMS	**10MCG**	**A205256**	**001**	May 29, 2015
	VAGIFEM				
AB +	NOVO NORDISK INC	**10MCG**	**N020908**	**002**	Nov 25, 2009

ESTRADIOL ACETATE

	INSERT, EXTENDED RELEASE;VAGINAL				
	FEMRING				
	APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003
	TABLET;ORAL				
	FEMTRACE				
	APIL	0.45MG	N021633	001	Aug 20, 2004
		0.9MG	N021633	002	Aug 20, 2004
+		1.8MG	N021633	003	Aug 20, 2004

ESTRADIOL CYPIONATE

	INJECTABLE;INJECTION				
	DEPO-ESTRADIOL				
+	PHARMACIA AND UPJOHN	5MG/ML	A085470	003	

ESTRADIOL HEMIHYDRATE
EMULSION;TOPICAL
ESTRASORB

	+	EXELTIS USA INC	0.25%	N021371 001	Oct 09, 2003

ESTRADIOL VALERATE
INJECTABLE;INJECTION

		DELESTROGEN			
AO	**+**	PAR STERILE PRODUCTS	**20MG/ML**	**N009402 004**	
AO	**+**		**40MG/ML**	**N009402 003**	
		ESTRADIOL VALERATE			
AO		LUITPOLD	**20MG/ML**	**A090920 001**	Jan 19, 2010
AO			**40MG/ML**	**A090920 002**	Jan 19, 2010
		DELESTROGEN			
	+	PAR STERILE PRODUCTS	10MG/ML	N009402 002	

ESTRADIOL; LEVONORGESTREL
FILM, EXTENDED RELEASE;TRANSDERMAL
CLIMARA PRO

	+	BAYER HLTHCARE	0.045MG/24HR;0.015MG/24HR	N021258 001	Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE
FILM, EXTENDED RELEASE;TRANSDERMAL
COMBIPATCH

		NOVEN PHARMS INC	0.05MG/24HR;0.14MG/24HR	N020870 001	Aug 07, 1998
	+		0.05MG/24HR;0.25MG/24HR	N020870 002	Aug 07, 1998

TABLET;ORAL

		ACTIVELLA			
AB		AMNEAL PHARMS LLC	**0.5MG;0.1MG**	**N020907 002**	Dec 28, 2006
AB	**+**		**1MG;0.5MG**	**N020907 001**	Nov 18, 1998
		AMABELZ			
AB		LUPIN LTD	**0.5MG;0.1MG**	**A203339 001**	Jun 20, 2016
AB			**1MG;0.5MG**	**A203339 002**	Jun 20, 2016
		ESTRADIOL AND NORETHINDRONE ACETATE			
AB		BARR	**1MG;0.5MG**	**A079193 001**	May 11, 2010
AB		BRECKENRIDGE PHARM	**0.5MG;0.1MG**	**A078324 002**	Jun 09, 2011
AB			**1MG;0.5MG**	**A078324 001**	Apr 17, 2008
AB		TEVA PHARMS USA	**0.5MG;0.1MG**	**A200747 001**	Mar 08, 2012

ESTRADIOL; NORGESTIMATE
TABLET;ORAL
ESTRADIOL AND NORGESTIMATE

	+	BARR	1MG,1MG;N/A,0.09MG	A076812 001	Apr 29, 2005

ESTRAMUSTINE PHOSPHATE SODIUM
CAPSULE;ORAL
EMCYT

	+	PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045 001	

ESTROGENS, CONJUGATED
CREAM;TOPICAL, VAGINAL
PREMARIN

	+	WYETH PHARMS INC	0.625MG/GM	N020216 001	

INJECTABLE;INJECTION
PREMARIN

	+	WYETH PHARMS INC	25MG/VIAL	N010402 001	

TABLET;ORAL
PREMARIN

		WYETH PHARMS INC	0.3MG	N004782 003	
			0.45MG	N004782 006	Jul 16, 2003
	+		0.625MG	N004782 004	
	+		0.9MG	N004782 005	Jan 26, 1984
	+		1.25MG	N004782 001	

ESTROGENS, CONJUGATED SYNTHETIC B
TABLET;ORAL
ENJUVIA

		TEVA WOMENS	0.3MG	N021443 001	Dec 20, 2004
			0.45MG	N021443 002	Dec 20, 2004
			0.9MG	N021443 005	Apr 27, 2007

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

	PREMPHASE 14/14				
+	WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995
	PREMPRO				
+	WYETH PHARMS INC	0.3MG;1.5MG	N020527	005	Jun 04, 2003
+		0.45MG;1.5MG	N020527	004	Mar 12, 2003
+		0.625MG;2.5MG	N020527	001	Nov 17, 1995
+		0.625MG;5MG	N020527	003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET;ORAL

	MENEST				
	MONARCH PHARMS	0.3MG	A084951	001	
		0.625MG	A084948	001	
		1.25MG	A084950	001	
+		2.5MG	A084949	001	

ESTROPIPATE

TABLET;ORAL

	ESTROPIPATE				
AB	BARR	**0.75MG**	**A040135**	**001**	Nov 27, 1996
AB		**1.5MG**	**A040135**	**002**	Nov 27, 1996
AB		**3MG**	**A040135**	**003**	Nov 27, 1996
AB	MYLAN	**0.75MG**	**A040359**	**001**	Aug 26, 1999
AB		**1.5MG**	**A040359**	**002**	Aug 26, 1999
AB	WATSON LABS	**0.75MG**	**A081213**	**001**	Sep 23, 1993
AB		**1.5MG**	**A081214**	**001**	Sep 23, 1993
AB		**3MG**	**A081215**	**001**	Sep 23, 1993
	OGEN .625				
AB	PHARMACIA AND UPJOHN	**0.75MG**	**A083220**	**001**	
	OGEN 1.25				
AB	PHARMACIA AND UPJOHN	**1.5MG**	**A083220**	**002**	
	OGEN 2.5				
AB +	PHARMACIA AND UPJOHN	**3MG**	**A083220**	**003**	
	OGEN 5				
	PHARMACIA AND UPJOHN	6MG	A083220	004	

ESZOPICLONE

TABLET;ORAL

	ESZOPICLONE				
AB	AUROBINDO PHARMA LTD	**1MG**	**A208451**	**001**	Sep 15, 2016
AB		**2MG**	**A208451**	**002**	Sep 15, 2016
AB		**3MG**	**A208451**	**003**	Sep 15, 2016
AB	DR REDDYS LABS LTD	**1MG**	**A091024**	**001**	Apr 15, 2014
AB		**2MG**	**A091024**	**002**	Apr 15, 2014
AB		**3MG**	**A091024**	**003**	Apr 15, 2014
AB	GLENMARK GENERICS	**1MG**	**A091166**	**001**	Apr 15, 2014
AB		**2MG**	**A091166**	**002**	Apr 15, 2014
AB		**3MG**	**A091166**	**003**	Apr 15, 2014
AB	LUPIN LTD	**1MG**	**A091124**	**001**	Sep 13, 2011
AB		**2MG**	**A091124**	**002**	Sep 13, 2011
AB		**3MG**	**A091124**	**003**	Sep 13, 2011
AB	MACLEODS PHARMS LTD	**1MG**	**A202929**	**001**	Jan 30, 2015
AB		**2MG**	**A202929**	**002**	Jan 30, 2015
AB		**3MG**	**A202929**	**003**	Jan 30, 2015
AB	MYLAN PHARMS INC	**1MG**	**A091151**	**001**	Mar 26, 2013
AB		**2MG**	**A091151**	**002**	Mar 26, 2013
AB		**3MG**	**A091151**	**003**	Mar 26, 2013
AB	ORCHID HLTHCARE	**1MG**	**A091113**	**001**	Jun 10, 2014
AB		**2MG**	**A091113**	**002**	Jun 10, 2014
AB		**3MG**	**A091113**	**003**	Jun 10, 2014
AB	SUN PHARMA GLOBAL	**1MG**	**A091103**	**001**	Apr 03, 2013
AB		**2MG**	**A091103**	**002**	Apr 03, 2013
AB		**3MG**	**A091103**	**003**	Apr 03, 2013
AB	TEVA	**1MG**	**A091169**	**001**	May 23, 2011
AB		**2MG**	**A091169**	**002**	May 23, 2011
AB		**3MG**	**A091169**	**003**	May 23, 2011
AB	WEST-WARD PHARMS INT	**1MG**	**A091153**	**001**	Apr 15, 2014
AB		**2MG**	**A091153**	**002**	Apr 15, 2014
AB		**3MG**	**A091153**	**003**	Apr 15, 2014
	LUNESTA				
AB	SUNOVION PHARMS INC	**1MG**	**N021476**	**001**	Dec 15, 2004
AB		**2MG**	**N021476**	**002**	Dec 15, 2004

FDA data supplied by DrugPatentWatch.com

ESZOPICLONE
TABLET;ORAL

	LUNESTA				
AB	**+**		**3MG**	**N021476**	**003** Dec 15, 2004

ETEPLIRSEN
SOLUTION;IV (INFUSION)

	EXONDYS 51				
	+	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001 Sep 19, 2016
	+		500MG/10ML (50MG/ML)	N206488	002 Sep 19, 2016

ETHACRYNATE SODIUM
INJECTABLE;INJECTION

	EDECRIN				
AP	**+**	ATON	**EQ 50MG BASE/VIAL**	**N016093**	**001**
	ETHACRYNATE SODIUM				
AP		MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A204634**	**001** Aug 23, 2016
AP		PAR STERILE PRODUCTS	**EQ 50MG BASE/VIAL**	**A205473**	**001** Jul 29, 2015

ETHACRYNIC ACID
TABLET;ORAL

	EDECRIN				
AB	**+**	ATON	**25MG**	**N016092**	**001**
	ETHACRYNIC ACID				
AB		EDENBRIDGE PHARMS	**25MG**	**A205609**	**001** Jun 30, 2016

ETHAMBUTOL HYDROCHLORIDE
TABLET;ORAL

	ETHAMBUTOL HYDROCHLORIDE				
AB		AKORN	**100MG**	**A075095**	**001** Nov 30, 1999
AB			**400MG**	**A075095**	**002** Nov 30, 1999
AB		BARR	**400MG**	**A076057**	**001** Nov 26, 2001
AB		LUPIN	**100MG**	**A078939**	**001** Jun 17, 2009
AB			**400MG**	**A078939**	**002** Jun 17, 2009
	MYAMBUTOL				
AB		STI PHARMA LLC	**100MG**	**N016320**	**001**
AB	**+**		**400MG**	**N016320**	**003**

ETHANOLAMINE OLEATE
INJECTABLE;INJECTION

	ETHAMOLIN				
	+	QOL MEDCL	50MG/ML	N019357	001 Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE
TABLET;ORAL-28

	ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL				
AB		JAI PHARMA LTD	**0.05MG;1MG**	**A204704**	**001** Feb 09, 2016
	KELNOR				
AB		BARR	**0.035MG;1MG**	**A076785**	**001** May 23, 2005
	ZOVIA 1/35E-28				
AB		MAYNE PHARMA	**0.035MG;1MG**	**A072721**	**001** Dec 30, 1991
	ZOVIA 1/50E-28				
AB	**+**	WATSON LABS	**0.05MG;1MG**	**A072723**	**001** Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL
RING;VAGINAL

	NUVARING				
	+	ORGANON USA INC	0.015MG/24HR;0.12MG/24HR	N021187	001 Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL
TABLET;ORAL

	ASHLYNA				
AB		GLENMARK GENERICS	**0.03MG,0.01MG;0.15MG,N/A**	**A203163**	**001** Feb 23, 2015
	DAYSEE				
AB		LUPIN LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A091467**	**001** Apr 10, 2013
	FAYOSIM				
AB		LUPIN LTD	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**A205943**	**001** Mar 29, 2016
	INTROVALE				
AB		SANDOZ	**0.03MG;0.15MG**	**A079064**	**001** Sep 27, 2010
	LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB		AMNEAL PHARMS	**0.03MG;0.15MG**	**A203871**	**001** Nov 13, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A203872**	**001** Dec 22, 2015
AB		GLENMARK GENERICS	**0.02MG;0.09MG**	**A202791**	**001** Apr 09, 2015
AB		GLENMARK PHARMS LTD	**0.03MG;0.15MG**	**A203164**	**001** Jun 12, 2015
AB		JAI PHARMA LTD	**0.03MG;0.15MG**	**A200490**	**001** Apr 21, 2015
AB		LUPIN LTD	**0.02MG,0.01MG;0.1MG,N/A**	**A091674**	**001** Oct 26, 2011

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

	LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB		**0.03MG;0.15MG**	**A091440**	**001**	Oct 23, 2012
AB	MAYNE PHARMA	**0.02MG,0.01MG;0.1MG,N/A**	**A200407**	**001**	Oct 25, 2011
AB	+ WATSON LABS	**0.02MG;0.09MG**	**A079218**	**001**	Jun 06, 2011
	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL				
AB	JAI PHARMA LTD	**0.02MG,0.01MG;0.1MG,N/A**	**A200493**	**001**	Jun 17, 2015
AB		**0.03MG,0.01MG;0.15MG,N/A**	**A200492**	**001**	May 27, 2015
AB	MAYNE PHARMA	**0.03MG,0.01MG;0.15MG,N/A**	**A078834**	**001**	May 31, 2011
	LOSEASONIQUE				
AB	TEVA BRANDED PHARM	**0.02MG,0.01MG;0.1MG,N/A**	**N022262**	**001**	Oct 24, 2008
	QUARTETTE				
AB	+ TEVA BRANDED PHARM	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**N204061**	**001**	Mar 28, 2013
	QUASENSE				
AB	WATSON LABS	**0.03MG;0.15MG**	**A077101**	**001**	Sep 06, 2006
	SEASONALE				
AB	+ TEVA BRANDED PHARM	**0.03MG;0.15MG**	**N021544**	**001**	Sep 05, 2003
	SEASONIQUE				
AB	+ TEVA BRANDED PHARM	**0.03MG,0.01MG;0.15MG,N/A**	**N021840**	**001**	May 25, 2006
	SETLAKIN				
AB	NOVAST LABS LTD	**0.03MG;0.15MG**	**A090716**	**001**	Sep 15, 2014

TABLET;ORAL-28

	ALTAVERA				
AB	SANDOZ	**0.03MG;0.15MG**	**A079102**	**001**	Aug 03, 2010
	AYUNA				
AB	AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206866**	**001**	Sep 23, 2016
	ELIFEMME				
AB	SANDOZ INC	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A202507**	**001**	Dec 04, 2015
	ENPRESSE-28				
AB	DURAMED PHARMS BARR	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A075809**	**002**	Jul 16, 2001
	KURVELO				
AB	LUPIN LTD	**0.03MG;0.15MG**	**A091408**	**001**	Oct 17, 2012
	LEVONEST				
AB	NOVAST LABS LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A090719**	**001**	Dec 29, 2010
	LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB	AMNEAL PHARMS	**0.03MG;0.15MG**	**A201095**	**001**	Dec 08, 2014
AB	JAI PHARMA LTD	**0.03MG;0.15MG**	**A091663**	**001**	Dec 21, 2012
AB	LUPIN LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A200248**	**001**	Nov 19, 2015
	LEVORA 0.15/30-28				
AB	+ MAYNE PHARMA	**0.03MG;0.15MG**	**A073594**	**001**	Dec 13, 1993
	MARLISSA				
AB	GLENMARK GENERICS	**0.03MG;0.15MG**	**A091452**	**001**	Feb 29, 2012
	MYZILRA				
AB	VINTAGE PHARMS LLC	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A077502**	**001**	Nov 23, 2011
	PORTIA-28				
AB	BARR	**0.03MG;0.15MG**	**A075866**	**002**	May 23, 2002
	TRIVORA-28				
AB	+ MAYNE PHARMA	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A074538**	**002**	Dec 18, 1997
	AFIRMELLE				
AB1	AUROBINDO PHARMA LTD	**0.02MG;0.1MG**	**A206886**	**001**	Nov 14, 2016
	AVIANE-28				
AB1	DURAMED PHARMS BARR	**0.02MG;0.1MG**	**A075796**	**001**	Apr 30, 2001
	FALMINA				
AB1	NOVAST LABS LTD	**0.02MG;0.1MG**	**A090721**	**001**	Mar 28, 2012
	LEVONORGESTREL AND ETHINYL ESTRADIOL				
AB1	AMNEAL PHARMS	**0.02MG;0.1MG**	**A201108**	**001**	Feb 05, 2014
AB1	JAI PHARMA LTD	**0.02MG;0.1MG**	**A200245**	**001**	Oct 09, 2013
AB1	LUPIN LTD	**0.02MG;0.1MG**	**A091425**	**001**	Jan 18, 2013
AB1	+ MAYNE PHARMA	**0.02MG;0.1MG**	**A076625**	**001**	Nov 18, 2004
	ORSYTHIA				
AB1	VINTAGE PHARMS LLC	**0.02MG;0.1MG**	**A077099**	**001**	May 11, 2011
	VIENVA				
AB1	SANDOZ INC	**0.02MG;0.1MG**	**A201088**	**001**	May 21, 2015
	LESSINA-28				
AB2	BARR	**0.02MG;0.1MG**	**A075803**	**002**	Mar 20, 2002

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2		JAI PHARMA LTD	0.02MG;0.1MG	A202247 001	Dec 08, 2014
AB2	+	MAYNE PHARMA	0.02MG;0.1MG	A077681 001	May 31, 2006

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

XULANE

AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910 001	Apr 16, 2014

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

		NORINYL 1+35 21-DAY			
AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565 001	
		NORTREL 1/35-21			
AB		BARR	0.035MG;1MG	A072693 001	Feb 28, 1992
		NORTREL 7/7/7			
		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478 001	Aug 30, 2002

TABLET;ORAL-28

		ALYACEN 1/35			
AB		GLENMARK GENERICS	0.035MG;1MG	A091634 001	Jan 19, 2012
		ALYACEN 7/7/7			
AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636 001	Jan 19, 2012
		ARANELLE			
AB		BARR	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	A076783 001	Sep 29, 2004
		BALZIVA-28			
AB		BARR	0.035MG;0.4MG	A076238 001	Apr 22, 2004
		BREVICON 28-DAY			
AB		ALLERGAN SALES LLC	0.035MG;0.5MG	N017743 001	
		BRIELLYN			
AB		GLENMARK GENERICS	0.035MG;0.4MG	A090538 001	Mar 22, 2011
		CYCLAFEM 0.5/35			
AB		VINTAGE PHARMS	0.035MG;0.5MG	A203413 001	Dec 16, 2015
		CYCLAFEM 1/35			
AB		VINTAGE PHARMS LLC	0.035MG;1MG	A076337 001	Nov 12, 2010
		CYCLAFEM 7/7/7			
AB		VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338 001	Nov 16, 2010
		CYONANZ			
AB		AUROBINDO PHARMA LTD	0.035MG;0.5MG	A207055 001	Oct 21, 2016
		DASETTA 1/35			
AB		NOVAST LABS LTD	0.035MG;1MG	A090948 001	Dec 22, 2011
		DASETTA 7/7/7			
AB		NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A090946 001	Dec 22, 2011
		GILDAGIA			
AB		VINTAGE PHARMS	0.035MG;0.4MG	A078376 001	Nov 06, 2012
		MODICON 28			
AB	+	JANSSEN PHARMS	0.035MG;0.5MG	N017735 001	
		NORETHINDRONE AND ETHINYL ESTRADIOL			
AB	+	JAI PHARMA LTD	0.035MG;0.4MG	A200897 001	May 11, 2015
AB			0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A200486 001	Dec 28, 2015
AB			0.035MG;0.5MG	A200488 001	Oct 21, 2015
AB			0.035MG;1MG	A200489 001	Oct 21, 2015
AB		MAYNE PHARMA	0.035MG;0.5MG	A070686 001	Jan 29, 1987
AB		WATSON LABS	0.035MG;0.4MG	A078323 001	Feb 04, 2010
AB			0.035MG;1MG	A070687 001	Jan 29, 1987
		NORINYL 1+35 28-DAY			
AB		ALLERGAN SALES LLC	0.035MG;1MG	N017565 002	
		NORTREL 0.5/35-28			
AB		BARR	0.035MG;0.5MG	A072695 001	Feb 28, 1992
		NORTREL 1/35-28			
AB		BARR	0.035MG;1MG	A072696 001	Feb 28, 1992
		NORTREL 7/7/7			
AB		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478 002	Aug 30, 2002
		NYLIA 1/35			
AB		AUROBINDO PHARMA LTD	0.035MG;1MG	A207056 001	Oct 21, 2016
		NYLIA 7/7/7			
AB		AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A207054 001	Oct 21, 2016

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

		ORTHO-NOVUM 1/35-28				
AB	+	JANSSEN PHARMS	**0.035MG;1MG**	**N017919**	**002**	
		ORTHO-NOVUM 7/7/7-28				
AB	+	JANSSEN PHARMS	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**N018985**	**002**	Apr 04, 1984
		PHILITH				
AB		NOVAST LABS LTD	**0.035MG;0.4MG**	**A090947**	**001**	Dec 22, 2011
		PIRMELLA 1/35				
AB		LUPIN LTD	**0.035MG;1MG**	**A201512**	**001**	Apr 24, 2013
		PIRMELLA 7/7/7				
AB		LUPIN LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A201510**	**001**	Apr 24, 2013
		TRI-NORINYL 28-DAY				
AB	+	MAYNE PHARMA	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**N018977**	**002**	Apr 13, 1984
		VYFEMLA				
AB		LUPIN LTD	**0.035MG;0.4MG**	**A201886**	**001**	Sep 26, 2013
		WERA				
AB		NOVAST LABS LTD	**0.035MG;0.5MG**	**A091204**	**001**	Mar 27, 2012
		NORETHINDRONE AND ETHINYL ESTRADIOL				
	+	JAI PHARMA LTD	0.05MG;1MG	A203006	001	Aug 05, 2013
		NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)				
		WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988

TABLET, CHEWABLE;ORAL

		FEMCON FE				
AB	+	APIL	**0.035MG;0.4MG**	**N021490**	**001**	Nov 14, 2003
		KAITLIB FE				
AB		LUPIN LTD	**0.025MG;0.8MG**	**A203448**	**001**	Dec 17, 2015
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
AB		AMNEAL PHARMS	**0.035MG;0.4MG**	**A078892**	**001**	Sep 26, 2011
AB	+	APIL	**0.025MG;0.8MG**	**N022573**	**001**	Dec 22, 2010
AB		BARR	**0.035MG;0.4MG**	**A078965**	**001**	Aug 05, 2010
AB		JAI PHARMA LTD	**0.025MG;0.8MG**	**A203371**	**001**	Apr 23, 2014
AB			**0.035MG;0.4MG**	**A202086**	**001**	Apr 01, 2015
AB		LUPIN LTD	**0.035MG;0.4MG**	**A091332**	**001**	Mar 23, 2016

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

		TAYTULLA				
	+	APIL	0.02MG;1MG	N204426	001	Apr 19, 2013

TABLET;ORAL

		BLISOVI 24 FE				
AB		LUPIN LTD	**0.02MG;1MG**	**A091398**	**001**	Oct 28, 2015
		FEMHRT				
AB		APIL	**0.0025MG;0.5MG**	**N021065**	**001**	Jan 14, 2005
		FYAVOLV				
AB		LUPIN LTD	**0.005MG;1MG**	**A204213**	**002**	Dec 10, 2015
AB			**0.0025MG;0.5MG**	**A204213**	**001**	Dec 10, 2015
		GILDESS 24 FE				
AB		VINTAGE PHARMS	**0.02MG;1MG**	**A090293**	**001**	Dec 01, 2014
		LARIN 24 FE				
AB		NOVAST LABS LTD	**0.02MG;1MG**	**A202994**	**001**	Feb 18, 2015
		LERIBANE				
AB		NOVAST LABS LTD	**0.0025MG;0.5MG**	**A203435**	**002**	Jun 03, 2016
AB			**0.005MG;1MG**	**A203435**	**001**	Jun 03, 2016
		LO LOESTRIN FE				
AB	+	APIL	**0.01MG,0.01MG;1MG,N/A**	**N022501**	**001**	Oct 21, 2010
		LOESTRIN 24 FE				
AB		APIL	**0.02MG;1MG**	**N021871**	**001**	Feb 17, 2006
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL				
AB	+	BARR LABS INC	**0.005MG;1MG**	**A076221**	**001**	Nov 06, 2009
AB		GLENMARK GENERICS	**0.0025MG;0.5MG**	**A203038**	**001**	Apr 02, 2015
AB			**0.005MG;1MG**	**A203038**	**002**	Apr 02, 2015
AB		JAI PHARMA LTD	**0.005MG;1MG**	**A207259**	**001**	Dec 27, 2016
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
AB		JAI PHARMA LTD	**0.01MG,0.01MG;1MG,N/A**	**A205049**	**001**	May 31, 2016
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE				
AB	+	AMNEAL PHARMS	**0.02MG;1MG**	**A078267**	**001**	Sep 01, 2009
AB		BARR LABS INC	**0.02MG;1MG**	**A090938**	**001**	Dec 01, 2014
AB		JAI PHARMA LTD	**0.02MG;1MG**	**A202742**	**001**	Oct 30, 2014

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21

	GILDESS 1.5/30				
AB	VINTAGE PHARMS LLC	**0.03MG;1.5MG**	**A077075**	**002**	Jul 24, 2012
	GILDESS 1/20				
AB	VINTAGE PHARMS LLC	**0.02MG;1MG**	**A077077**	**002**	Jul 24, 2012
	JUNEL 1.5/30				
AB	BARR	**0.03MG;1.5MG**	**A076381**	**001**	May 30, 2003
	JUNEL 1/20				
AB	BARR	**0.02MG;1MG**	**A076380**	**001**	May 30, 2003
	LARIN 1.5/30				
AB	NOVAST LABS LTD	**0.03MG;1.5MG**	**A202996**	**001**	Mar 20, 2014
	LARIN 1/20				
AB	NOVAST LABS LTD	**0.02MG;1MG**	**A202995**	**001**	Dec 04, 2013
	LOESTRIN 21 1.5/30				
AB	APIL	**0.03MG;1.5MG**	**N017875**	**001**	
	LOESTRIN 21 1/20				
AB	APIL	**0.02MG;1MG**	**N017876**	**001**	
	MICROGESTIN 1.5/30				
AB	MAYNE PHARMA	**0.03MG;1.5MG**	**A075548**	**002**	Jul 30, 2003
	MICROGESTIN 1/20				
AB	MAYNE PHARMA	**0.02MG;1MG**	**A075647**	**002**	Jul 30, 2003
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL				
AB	GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206969**	**001**	Jan 20, 2016
AB	JAI PHARMA LTD	**0.02MG;1MG**	**A202771**	**001**	Nov 06, 2013
AB		**0.03MG;1.5MG**	**A202770**	**001**	Feb 19, 2015
	TRI-LEGEST 21				
	BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076405	001	Oct 26, 2007

TABLET;ORAL-28

	BLISOVI FE 1.5/30				
AB	LUPIN LTD	**0.03MG;1.5MG**	**A201585**	**001**	Nov 18, 2015
	BLISOVI FE 1/20				
AB	LUPIN LTD	**0.02MG;1MG**	**A201584**	**001**	Nov 18, 2015
	ESTROSTEP FE				
AB	**+** APIL	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**N020130**	**002**	Oct 09, 1996
	GILDESS FE 1.5/30				
AB	VINTAGE PHARMS LLC	**0.03MG;1.5MG**	**A077075**	**001**	Apr 28, 2005
	GILDESS FE 1/20				
AB	VINTAGE PHARMS LLC	**0.02MG;1MG**	**A077077**	**001**	May 20, 2005
	JUNEL FE 1.5/30				
AB	BARR	**0.03MG;1.5MG**	**A076064**	**001**	Sep 18, 2003
	JUNEL FE 1/20				
AB	BARR	**0.02MG;1MG**	**A076081**	**001**	Sep 18, 2003
	LARIN FE 1.5/30				
AB	NOVAST LABS LTD	**0.03MG;1.5MG**	**A091453**	**001**	Aug 23, 2013
	LARIN FE 1/20				
AB	NOVAST LABS LTD	**0.02MG;1MG**	**A091454**	**001**	Aug 26, 2013
	LOESTRIN FE 1.5/30				
AB	**+** APIL	**0.03MG;1.5MG**	**N017355**	**001**	
	LOESTRIN FE 1/20				
AB	APIL	**0.02MG;1MG**	**N017354**	**001**	
	MICROGESTIN FE 1.5/30				
AB	MAYNE PHARMA	**0.03MG;1.5MG**	**A075548**	**001**	Feb 05, 2001
	MICROGESTIN FE 1/20				
AB	MAYNE PHARMA	**0.02MG;1MG**	**A075647**	**001**	Feb 05, 2001
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL				
AB	JAI PHARMA LTD	**0.02MG;1MG**	**A202772**	**001**	Nov 14, 2013
AB		**0.03MG;1.5MG**	**A202741**	**001**	Feb 20, 2015
AB	MAYNE PHARMA	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076629**	**001**	Mar 18, 2010
	TRI-LEGEST FE				
AB	BARR	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076105**	**001**	Oct 26, 2007

TABLET, CHEWABLE;ORAL

	MIBELAS 24 FE				
AB	LUPIN ATLANTIS	**0.02MG;1MG**	**A206287**	**001**	May 24, 2016
	MINASTRIN 24 FE				
AB	**+** APIL	**0.02MG;1MG**	**N203667**	**001**	May 08, 2013

TABLET, CHEWABLE, TABLET;ORAL

	LO MINASTRIN FE				
	+ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL

	NORGESTIMATE AND ETHINYL ESTRADIOL				
AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A200494	001	Jun 17, 2011

TABLET;ORAL-28

	ESTARYLLA				
AB	SANDOZ	0.035MG;0.25MG	A090794	001	Jan 30, 2013
	MILI				
AB	AUROBINDO PHARMA LTD	0.035MG;0.25MG	A205449	001	Jul 07, 2016
	MONO-LINYAH				
AB	NOVAST LABS LTD	0.035MG;0.25MG	A090523	001	May 23, 2012
	NORGESTIMATE AND ETHINYL ESTRADIOL				
AB	AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A203870	001	Nov 12, 2015
AB		0.035MG;0.25MG	A203865	001	Oct 27, 2015
AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538	001	Apr 05, 2012
AB	GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A204057	001	Feb 23, 2016
AB	HAUPT PHARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A203873	001	May 12, 2016
AB	JAI PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A202132	001	Sep 09, 2015
AB		0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG	A201897	001	Jan 27, 2016
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A205588	001	Apr 26, 2016
AB		0.035MG;0.25MG	A205630	001	Oct 27, 2016
AB	LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A200541	001	Jun 25, 2012
AB	OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG; 0.25MG	A200383	001	Apr 07, 2015
AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015
	ORTHO CYCLEN-28				
AB	+ JANSSEN PHARMS	0.035MG;0.25MG	N019653	002	Dec 29, 1989
	ORTHO TRI-CYCLEN				
AB	+ JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	N019697	001	Jul 03, 1992
	ORTHO TRI-CYCLEN LO				
AB	+ JANSSEN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	N021241	001	Aug 22, 2002
	PREVIFEM				
AB	VINTAGE PHARMS LLC	0.035MG;0.25MG	A076334	001	Jan 09, 2004
	SPRINTEC				
AB	BARR	0.035MG;0.25MG	A075804	001	Sep 25, 2002
	TRI LO SPRINTEC				
AB	BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A076784	001	Jun 29, 2009
	TRI-ESTARYLLA				
AB	SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A090793	001	Jan 30, 2013
	TRI-LINYAH				
AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A090524	001	May 30, 2012
	TRI-LO-ESTARYLLA				
AB	SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A091232	001	Jun 29, 2015
	TRI-LO-MILI				
AB	AUROBINDO PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A205762	001	Nov 04, 2016
	TRI-MILI				
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A205441	001	Jul 06, 2016
	TRI-PREVIFEM				
AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A076335	001	Mar 26, 2004
	TRI-SPRINTEC				
AB	BARR	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A075808	001	Dec 29, 2003

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORGESTREL
TABLET;ORAL-21
CRYSELLE

AB	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**001**	Nov 30, 2001

TABLET;ORAL-28
CRYSELLE

AB	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**002**	Nov 30, 2001

ELINEST

AB	NOVAST LABS LTD	**0.03MG;0.3MG**	**A091105**	**001**	Mar 28, 2012

LOW-OGESTREL-28

AB	MAYNE PHARMA	**0.03MG;0.3MG**	**A075288**	**002**	Jul 28, 1999

NORGESTREL AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	**0.03MG;0.3MG**	**A201828**	**001**	Jun 21, 2016

OGESTREL 0.5/50-28

+	WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999

ETHIODIZED OIL
OIL;INTRALYMPHATIC, INTRAUTERINE
LIPIODOL

+	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001	

ETHIONAMIDE
TABLET;ORAL
TRECATOR

+	WYETH PHARMS INC	250MG	N013026	002	

ETHOSUXIMIDE
CAPSULE;ORAL
ETHOSUXIMIDE

AB	AKORN	**250MG**	**A040686**	**001**	May 28, 2008
AB	BIONPHARMA INC	**250MG**	**A040430**	**001**	Oct 28, 2002
AB	HERITAGE PHARMS INC	**250MG**	**A200892**	**001**	Sep 25, 2012

ZARONTIN

AB	**+** PARKE DAVIS	**250MG**	**N012380**	**001**	

SYRUP;ORAL
ETHOSUXIMIDE

AA	MIKART	**250MG/5ML**	**A040506**	**001**	Dec 22, 2003
AA	PHARM ASSOC	**250MG/5ML**	**A040253**	**001**	Nov 22, 2000
AA	TEVA PHARMS	**250MG/5ML**	**A081306**	**001**	Jul 30, 1993

ZARONTIN

AA	**+** PARKE DAVIS	**250MG/5ML**	**A080258**	**001**	

ETHOTOIN
TABLET;ORAL
PEGANONE

+	RECORDATI RARE	250MG	N010841	001	

ETIDRONATE DISODIUM
TABLET;ORAL
DIDRONEL

AB	APIL	**200MG**	**N017831**	**001**	
AB	**+**	**400MG**	**N017831**	**002**	

ETIDRONATE DISODIUM

AB	MYLAN	**200MG**	**A075800**	**001**	Jan 24, 2003
AB		**400MG**	**A075800**	**002**	Jan 24, 2003

ETODOLAC
CAPSULE;ORAL
ETODOLAC

AB	ANI PHARMS INC	**200MG**	**A075126**	**001**	Sep 16, 1999
AB		**300MG**	**A075126**	**002**	Sep 16, 1999
AB	APOTEX	**200MG**	**A075419**	**001**	Jul 28, 2000
AB		**300MG**	**A075419**	**002**	Jul 28, 2000
AB	TARO	**200MG**	**A075078**	**001**	Apr 30, 1998
AB	**+**	**300MG**	**A075078**	**002**	Apr 30, 1998

TABLET;ORAL
ETODOLAC

AB	APOTEX INC	**400MG**	**A076004**	**001**	Dec 03, 2002
AB		**500MG**	**A076004**	**002**	Dec 03, 2002
AB	MYLAN	**400MG**	**A075104**	**001**	Feb 06, 1998
AB		**500MG**	**A075104**	**002**	Nov 20, 1998
AB	SANDOZ	**400MG**	**A074903**	**001**	Apr 11, 1997
AB		**500MG**	**A074903**	**002**	Apr 19, 1999
AB	TARO PHARM INDS	**400MG**	**A075074**	**001**	Mar 11, 1998
AB	**+**	**500MG**	**A075074**	**002**	Apr 25, 2000

FDA data supplied by DrugPatentWatch.com

ETODOLAC
TABLET;ORAL
ETODOLAC

AB		TEVA	**400MG**	**A075009**	**001**	Nov 26, 1997
AB			**500MG**	**A075009**	**002**	Dec 28, 1999

TABLET, EXTENDED RELEASE;ORAL
ETODOLAC

AB		TARO	**400MG**	**A076174**	**001**	Mar 13, 2003
AB			**500MG**	**A076174**	**002**	Mar 13, 2003
AB			**600MG**	**A076174**	**003**	Mar 13, 2003
AB		TEVA	**400MG**	**A075665**	**003**	Feb 05, 2001
AB			**500MG**	**A075665**	**002**	Jul 31, 2000
AB	**+**		**600MG**	**A075665**	**001**	Jul 31, 2000
AB		ZYDUS PHARMS USA INC	**400MG**	**A091134**	**001**	Jan 23, 2014
AB			**500MG**	**A091134**	**002**	Jan 23, 2014
AB			**600MG**	**A091134**	**003**	Jan 23, 2014

ETOMIDATE
INJECTABLE;INJECTION
AMIDATE

AP	**+**	HOSPIRA	**2MG/ML**	**N018227**	**001**	Sep 07, 1982

ETOMIDATE

AP		EMCURE PHARMS LTD	**2MG/ML**	**A204618**	**001**	Aug 13, 2014
AP		EUROHLTH INTL SARL	**2MG/ML**	**A074593**	**001**	Nov 04, 1996
AP		HIKMA FARMACEUTICA	**2MG/ML**	**A202354**	**001**	Feb 25, 2016
AP		LUITPOLD	**2MG/ML**	**A078867**	**001**	Dec 22, 2009
AP		MYLAN LABS LTD	**2MG/ML**	**A078289**	**001**	Jan 02, 2009
AP		PAR STERILE PRODUCTS	**2MG/ML**	**A091297**	**001**	Jun 20, 2012
AP		ZYDUS PHARMS USA INC	**2MG/ML**	**A202360**	**001**	Jul 18, 2014

ETONOGESTREL
IMPLANT;IMPLANTATION
NEXPLANON

	+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011

ETOPOSIDE
CAPSULE;ORAL
ETOPOSIDE

	+	MYLAN	50MG	A075635	001	Sep 19, 2001

INJECTABLE;INJECTION
ETOPOSIDE

AP		ACCORD HLTHCARE	**20MG/ML**	**A074513**	**001**	Mar 14, 1996
AP	**+**	FRESENIUS KABI USA	**20MG/ML**	**A074983**	**001**	Sep 30, 1998
AP		TEVA PHARMS USA	**20MG/ML**	**A074529**	**001**	Jul 24, 1996
AP		WEST-WARD PHARMS INT	**20MG/ML**	**A074290**	**001**	Jul 17, 1995

ETOPOSIDE PHOSPHATE
INJECTABLE;INJECTION
ETOPOPHOS PRESERVATIVE FREE

	+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996

ETRAVIRINE
TABLET;ORAL
INTELENCE

		JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012
			100MG	N022187	001	Jan 18, 2008
	+		200MG	N022187	002	Dec 22, 2010

EVEROLIMUS
TABLET;ORAL
AFINITOR

		NOVARTIS	2.5MG	N022334	003	Jul 09, 2010
			5MG	N022334	001	Mar 30, 2009
			7.5MG	N022334	004	Mar 30, 2012
	+		10MG	N022334	002	Mar 30, 2009

ZORTRESS

		NOVARTIS	0.25MG	N021560	001	Apr 20, 2010
			0.5MG	N021560	002	Apr 20, 2010
	+		0.75MG	N021560	003	Apr 20, 2010

TABLET, FOR SUSPENSION;ORAL
AFINITOR DISPERZ

		NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012
			3MG	N203985	002	Aug 29, 2012
	+		5MG	N203985	003	Aug 29, 2012

FDA data supplied by DrugPatentWatch.com

EXEMESTANE
TABLET;ORAL

	AROMASIN					
AB	+ PHARMACIA AND UPJOHN	**25MG**	**N020753**	**001**	Oct 21, 1999
	EXEMESTANE				
AB	ALVOGEN MALTA	**25MG**	**A200898**	**001**	Jul 28, 2014
AB	WEST-WARD PHARMS INT	**25MG**	**A077431**	**001**	Apr 01, 2011

EXENATIDE SYNTHETIC
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

	BYDUREON				
	+ ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012
	BYDUREON PEN				
	+ ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014

INJECTABLE;SUBCUTANEOUS

	BYETTA				
	+ ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
	+	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005

EZETIMIBE
TABLET;ORAL

	EZETIMIBE				
AB	GLENMARK PHARMS LTD	**10MG**	**A078560**	**001**	Jun 26, 2015
	ZETIA				
AB	+ MSD INTL GMBH	**10MG**	**N021445**	**001**	Oct 25, 2002

EZETIMIBE; SIMVASTATIN
TABLET;ORAL

	VYTORIN				
	MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004
		10MG;20MG	N021687	002	Jul 23, 2004
		10MG;40MG	N021687	003	Jul 23, 2004
	+	10MG;80MG	N021687	004	Jul 23, 2004

EZOGABINE
TABLET;ORAL

	POTIGA				
	GLAXOSMITHKLINE	50MG	N022345	001	Jun 10, 2011
		200MG	N022345	002	Jun 10, 2011
		300MG	N022345	003	Jun 10, 2011
	+	400MG	N022345	004	Jun 10, 2011

FAMCICLOVIR
TABLET;ORAL

	FAMCICLOVIR				
AB	APOTEX	**125MG**	**A091480**	**001**	Jul 22, 2011
AB		**250MG**	**A091480**	**002**	Jul 22, 2011
AB		**500MG**	**A091480**	**003**	Jul 22, 2011
AB	AUROBINDO PHARMA LTD	**125MG**	**A091114**	**001**	Mar 21, 2011
AB		**250MG**	**A091114**	**002**	Mar 21, 2011
AB		**500MG**	**A091114**	**003**	Mar 21, 2011
AB	CIPLA LTD	**125MG**	**A078278**	**001**	Mar 21, 2011
AB		**250MG**	**A078278**	**002**	Mar 21, 2011
AB		**500MG**	**A078278**	**003**	Mar 21, 2011
AB	HETERO LABS LTD V	**125MG**	**A202438**	**001**	Sep 10, 2014
AB		**250MG**	**A202438**	**002**	Sep 10, 2014
AB		**500MG**	**A202438**	**003**	Sep 10, 2014
AB	MACLEODS PHARMS LTD	**125MG**	**A201022**	**001**	Jan 12, 2012
AB		**250MG**	**A201022**	**002**	Jan 12, 2012
AB		**500MG**	**A201022**	**003**	Jan 12, 2012
AB	MYLAN	**125MG**	**A201333**	**001**	Mar 24, 2011
AB		**250MG**	**A201333**	**002**	Mar 24, 2011
AB		**500MG**	**A201333**	**003**	Mar 24, 2011
AB	TEVA PHARMS	**125MG**	**A077487**	**001**	Aug 24, 2007
AB		**250MG**	**A077487**	**002**	Aug 24, 2007
AB		**500MG**	**A077487**	**003**	Aug 24, 2007
AB	WEST-WARD PHARMS INT	**125MG**	**A090128**	**001**	Mar 21, 2011
AB		**250MG**	**A090128**	**002**	Mar 21, 2011
AB		**500MG**	**A090128**	**003**	Mar 21, 2011
	FAMVIR				
AB	NOVARTIS	**125MG**	**N020363**	**003**	Dec 11, 1995
AB		**250MG**	**N020363**	**001**	Apr 26, 1996
AB	+	**500MG**	**N020363**	**002**	Jun 29, 1994

FDA data supplied by DrugPatentWatch.com

FAMOTIDINE
FOR SUSPENSION;ORAL

		FAMOTIDINE				
AB		HI-TECH PHARMA CO	**40MG/5ML**	**A201995**	**001**	May 30, 2014
AB		LUPIN LTD	**40MG/5ML**	**A090440**	**001**	Jun 29, 2010
AB		NAVINTA LLC	**40MG/5ML**	**A091020**	**001**	May 27, 2010
		PEPCID				
AB	+	SALIX PHARMS	**40MG/5ML**	**N019527**	**001**	Feb 02, 1987

INJECTABLE;INJECTION

		FAMOTIDINE				
AP		AMPHASTAR PHARMS INC	**10MG/ML**	**A075651**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075684**	**001**	Apr 16, 2001
AP	+	EUROHLTH INTL SARL	**10MG/ML**	**A075488**	**001**	Apr 16, 2001
AP		FRESENIUS KABI USA	**10MG/ML**	**A075709**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078641**	**001**	Jun 25, 2008
		FAMOTIDINE PRESERVATIVE FREE				
AP		AMPHASTAR PHARMS INC	**10MG/ML**	**A075622**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075825**	**001**	Apr 17, 2001
AP	+	EUROHLTH INTL SARL	**10MG/ML**	**A075486**	**001**	Apr 16, 2001
AP		FRESENIUS KABI USA	**10MG/ML**	**A075813**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078642**	**001**	Jun 25, 2008
		FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER				
AP	+	BAXTER HLTHCARE	**0.4MG/ML**	**A075591**	**001**	May 10, 2001

SUSPENSION;ORAL

		FAMOTIDINE				
AB		NOVEL LABS INC	**40MG/5ML**	**A201695**	**001**	Dec 17, 2012

TABLET;ORAL

		FAMOTIDINE				
AB		ALEMBIC PHARMS LTD	**20MG**	**A078916**	**001**	May 22, 2009
AB			**40MG**	**A078916**	**002**	May 22, 2009
AB		APOTEX	**20MG**	**A075611**	**001**	Jul 23, 2001
AB			**40MG**	**A075611**	**002**	Jul 23, 2001
AB		AUROBINDO PHARMA LTD	**20MG**	**A206530**	**001**	Dec 22, 2015
AB			**40MG**	**A206530**	**002**	Dec 22, 2015
AB		CARLSBAD	**20MG**	**A075805**	**001**	Apr 16, 2001
AB			**40MG**	**A075805**	**002**	Apr 16, 2001
AB		DR REDDYS LABS LTD	**20MG**	**A075718**	**001**	Apr 16, 2001
AB			**40MG**	**A075718**	**002**	Apr 16, 2001
AB		IVAX SUB TEVA PHARMS	**20MG**	**A075511**	**001**	Apr 16, 2001
AB			**40MG**	**A075511**	**002**	Apr 16, 2001
AB		MYLAN	**20MG**	**A075704**	**001**	Apr 16, 2001
AB			**40MG**	**A075704**	**002**	Apr 16, 2001
AB		PERRIGO	**20MG**	**A077352**	**002**	Jul 27, 2005
AB			**40MG**	**A077352**	**001**	Jul 27, 2005
AB		TEVA	**20MG**	**A075311**	**001**	Apr 16, 2001
AB			**40MG**	**A075311**	**002**	Apr 16, 2001
AB		WOCKHARDT	**20MG**	**A075786**	**001**	Apr 16, 2001
AB			**40MG**	**A075786**	**002**	Apr 16, 2001
		PEPCID				
AB		VALEANT PHARMS NORTH	**20MG**	**N019462**	**001**	Oct 15, 1986
AB	+		**40MG**	**N019462**	**002**	Oct 15, 1986

FAMOTIDINE; IBUPROFEN
TABLET;ORAL

		DUEXIS				
	+	HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011

FEBUXOSTAT
TABLET;ORAL

		ULORIC				
		TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009
	+		80MG	N021856	002	Feb 13, 2009

FELBAMATE
SUSPENSION;ORAL

		FELBAMATE				
AB		AMNEAL PHARMS	**600MG/5ML**	**A202385**	**001**	Dec 16, 2011
		FELBATOL				
AB	+	MEDA PHARMS	**600MG/5ML**	**N020189**	**003**	Jul 29, 1993

TABLET;ORAL

		FELBAMATE				
AB		ALVOGEN MALTA	**400MG**	**A204595**	**001**	Jan 11, 2016
AB			**600MG**	**A204595**	**002**	Jan 11, 2016
AB		AMNEAL PHARMS	**400MG**	**A201680**	**001**	Sep 13, 2011

FDA data supplied by DrugPatentWatch.com

FELBAMATE
TABLET;ORAL

	FELBAMATE				
AB		**600MG**	**A201680**	**002**	Sep 13, 2011
AB	COREPHARMA	**400MG**	**A202284**	**001**	Nov 04, 2015
AB		**600MG**	**A202284**	**002**	Nov 04, 2015
	FELBATOL				
AB	MEDA PHARMS	**400MG**	**N020189**	**001**	Jul 29, 1993
AB	+	**600MG**	**N020189**	**002**	Jul 29, 1993

FELODIPINE
TABLET, EXTENDED RELEASE;ORAL

	FELODIPINE				
AB	AUROBINDO PHARMA LTD	**2.5MG**	**A203417**	**001**	Jan 17, 2013
AB		**5MG**	**A203417**	**002**	Jan 17, 2013
AB		**10MG**	**A203417**	**003**	Jan 17, 2013
AB	GLENMARK GENERICS	**2.5MG**	**A090365**	**001**	Dec 17, 2010
AB		**5MG**	**A090365**	**002**	Dec 17, 2010
AB		**10MG**	**A090365**	**003**	Dec 17, 2010
AB	HERITAGE PHARMS INC	**2.5MG**	**A201964**	**001**	Nov 08, 2013
AB		**5MG**	**A201964**	**002**	Nov 08, 2013
AB		**10MG**	**A201964**	**003**	Nov 08, 2013
AB	JUBILANT GENERICS	**2.5MG**	**A203983**	**001**	Aug 19, 2016
AB		**5MG**	**A203983**	**002**	Aug 19, 2016
AB		**10MG**	**A203983**	**003**	Aug 19, 2016
AB	MYLAN	**2.5MG**	**A078855**	**001**	Apr 17, 2008
AB		**5MG**	**A078855**	**002**	Apr 17, 2008
AB	+	**10MG**	**A078855**	**003**	Apr 17, 2008
AB	ORCHID HLTHCARE	**2.5MG**	**A203032**	**001**	May 21, 2015
AB		**5MG**	**A203032**	**002**	May 21, 2015
AB		**10MG**	**A203032**	**003**	May 21, 2015
AB	SUN PHARM INDS	**2.5MG**	**A075896**	**001**	Nov 02, 2004
AB		**5MG**	**A075896**	**002**	Nov 02, 2004
AB		**10MG**	**A075896**	**003**	Nov 02, 2004
AB	SUN PHARM INDS LTD	**2.5MG**	**A091200**	**001**	Dec 13, 2013
AB		**5MG**	**A091200**	**002**	Dec 13, 2013
AB		**10MG**	**A091200**	**003**	Dec 13, 2013
AB	TORRENT PHARMS LTD	**2.5MG**	**A202170**	**001**	Nov 28, 2011
AB		**5MG**	**A202170**	**002**	Nov 28, 2011
AB		**10MG**	**A202170**	**003**	Nov 28, 2011
AB	VINTAGE PHARMS LLC	**2.5MG**	**A200815**	**001**	Oct 28, 2011
AB		**5MG**	**A200815**	**002**	Oct 28, 2011
AB		**10MG**	**A200815**	**003**	Oct 28, 2011

FENOFIBRATE
CAPSULE;ORAL

	ANTARA (MICRONIZED)				
AB	LUPIN ATLANTIS	**43MG**	**N021695**	**001**	Nov 30, 2004
AB	+	**130MG**	**N021695**	**003**	Nov 30, 2004
	FENOFIBRATE				
AB	SUN PHARM INDS LTD	**43MG**	**A201748**	**001**	Oct 31, 2014
AB		**130MG**	**A201748**	**002**	Oct 31, 2014
	FENOFIBRATE (MICRONIZED)				
AB	APOTEX INC	**43MG**	**A202252**	**001**	Jul 26, 2013
AB		**130MG**	**A202252**	**002**	Jul 26, 2013
AB	DR REDDYS LABS SA	**43MG**	**A090859**	**001**	Mar 01, 2012
AB		**130MG**	**A090859**	**002**	Mar 01, 2012
AB	IMPAX LABS	**67MG**	**A075868**	**001**	Oct 27, 2003
AB		**134MG**	**A075868**	**002**	Oct 27, 2003
AB		**200MG**	**A075868**	**003**	Oct 27, 2003
AB	MYLAN PHARMS INC	**43MG**	**A202579**	**001**	Jan 10, 2013
AB		**67MG**	**A202676**	**001**	Oct 23, 2012
AB		**130MG**	**A202579**	**002**	Jan 10, 2013
AB		**134MG**	**A202676**	**002**	Oct 23, 2012
AB		**200MG**	**A202676**	**003**	Oct 23, 2012
AB	RHODES PHARMS	**67MG**	**A075753**	**001**	Sep 03, 2002
AB		**134MG**	**A075753**	**002**	Apr 09, 2002
AB	+	**200MG**	**A075753**	**003**	Apr 09, 2002
	ANTARA (MICRONIZED)				
	LUPIN ATLANTIS	30MG	N021695	004	Oct 18, 2013
		90MG	N021695	005	Oct 18, 2013
	LIPOFEN				
	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006

FENOFIBRATE
CAPSULE;ORAL
LIPOFEN

+		150MG	N021612	003	Jan 11, 2006

TABLET;ORAL
FENOFIBRATE

AB	AUROBINDO PHARMA LTD	**48MG**	**A205118**	**001**	May 05, 2016
AB		**145MG**	**A205118**	**002**	May 05, 2016
AB	CIPLA LTD	**48MG**	**A208709**	**001**	Dec 15, 2016
AB		**145MG**	**A208709**	**002**	Dec 15, 2016
AB	HETERO LABS LTD III	**48MG**	**A204598**	**001**	Jul 12, 2016
AB		**145MG**	**A204598**	**002**	Jul 12, 2016
AB	IMPAX LABS	**54MG**	**A076509**	**001**	Mar 26, 2008
AB		**160MG**	**A076509**	**002**	Mar 26, 2008
AB	LUPIN LTD	**48MG**	**A090856**	**001**	Dec 23, 2011
AB		**54MG**	**A204019**	**001**	Aug 17, 2015
AB		**145MG**	**A090856**	**002**	Dec 23, 2011
AB		**160MG**	**A204019**	**002**	Aug 17, 2015
AB	MYLAN	**40MG**	**A204475**	**001**	Jun 23, 2016
AB		**54MG**	**A076520**	**001**	Oct 25, 2007
AB		**120MG**	**A204475**	**002**	Jun 23, 2016
AB		**160MG**	**A076520**	**003**	Oct 25, 2007
AB	MYLAN PHARMS INC	**48MG**	**A202856**	**001**	Dec 07, 2012
AB		**145MG**	**A202856**	**002**	Dec 07, 2012
AB	RHODES PHARMS	**54MG**	**A076433**	**001**	May 13, 2005
AB +		**160MG**	**A076433**	**002**	May 13, 2005
AB	SUN PHARM INDS LTD	**54MG**	**A076635**	**001**	Oct 31, 2005
AB		**160MG**	**A076635**	**003**	Oct 31, 2005
AB	VALEANT PHARMS NORTH	**48MG**	**A090715**	**001**	Apr 05, 2012
AB		**145MG**	**A090715**	**002**	Apr 05, 2012

FENOGLIDE

AB	SANTARUS INC	**40MG**	**N022118**	**001**	Aug 10, 2007
AB +		**120MG**	**N022118**	**002**	Aug 10, 2007

TRICOR

AB	ABBVIE	**48MG**	**N021656**	**001**	Nov 05, 2004
AB +		**145MG**	**N021656**	**002**	Nov 05, 2004

TRIGLIDE

BX +	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005

FENOFIBRATE

	SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005

FENOFIBRIC ACID
TABLET;ORAL
FIBRICOR

	ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009
+		105MG	N022418	002	Aug 14, 2009

FENOLDOPAM MESYLATE
INJECTABLE;INJECTION
CORLOPAM

AP +	HOSPIRA	**EQ 10MG BASE/ML**	**N019922**	**001**	Sep 23, 1997

FENOLDOPAM MESYLATE

AP	SANDOZ	**EQ 10MG BASE/ML**	**A077155**	**001**	Feb 15, 2005
AP	WEST-WARD PHARMS INT	**EQ 10MG BASE/ML**	**A076582**	**001**	Oct 12, 2004

FENOPROFEN CALCIUM
CAPSULE;ORAL
NALFON

+	XSPIRE	EQ 200MG BASE	N017604	003	
		EQ 400MG BASE	N017604	004	Jul 21, 2009

TABLET;ORAL
FENOPROFEN CALCIUM

+	MYLAN PHARMS INC	EQ 600MG BASE	A072267	001	Aug 17, 1988

FENTANYL
FILM, EXTENDED RELEASE;TRANSDERMAL
DURAGESIC-100

AB	JANSSEN PHARMS	**100MCG/HR**	**N019813**	**001**	Aug 07, 1990

DURAGESIC-12

AB	JANSSEN PHARMS	**12.5MCG/HR**	**N019813**	**005**	Feb 04, 2005

DURAGESIC-25

AB +	JANSSEN PHARMS	**25MCG/HR**	**N019813**	**004**	Aug 07, 1990

DURAGESIC-50

AB	JANSSEN PHARMS	**50MCG/HR**	**N019813**	**003**	Aug 07, 1990

FDA data supplied by DrugPatentWatch.com

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

	DURAGESIC-75				
AB	JANSSEN PHARMS	**75MCG/HR**	**N019813**	**002**	Aug 07, 1990
	FENTANYL-100				
AB	3M DRUG DELIVERY	**100MCG/HR**	**A202097**	**005**	Nov 04, 2016
AB	ACTAVIS LABS UT INC	**100MCG/HR**	**A076709**	**004**	Aug 20, 2007
AB	AVEVA	**100MCG/HR**	**A077449**	**004**	Oct 20, 2008
AB	LAVIPHARM LABS	**100MCG/HR**	**A077051**	**004**	Aug 04, 2006
AB	MALLINCKRODT INC	**100MCG/HR**	**A077154**	**004**	Feb 09, 2011
AB	MYLAN TECHNOLOGIES	**100MCG/HR**	**A076258**	**004**	Jan 28, 2005
AB	PAR PHARM INC	**100MCG/HR**	**A077062**	**004**	Aug 20, 2007
	FENTANYL-12				
AB	3M DRUG DELIVERY	**12.5MCG/HR**	**A202097**	**001**	Nov 04, 2016
AB	AVEVA	**12.5MCG/HR**	**A077449**	**005**	Sep 11, 2015
AB	MALLINCKRODT INC	**12.5MCG/HR**	**A077154**	**005**	Jun 11, 2015
AB	MYLAN TECHNOLOGIES	**12.5MCG/HR**	**A076258**	**005**	Jan 23, 2007
	FENTANYL-25				
AB	3M DRUG DELIVERY	**25MCG/HR**	**A202097**	**002**	Nov 04, 2016
AB	ACTAVIS LABS UT INC	**25MCG/HR**	**A076709**	**001**	Aug 20, 2007
AB	AVEVA	**25MCG/HR**	**A077449**	**001**	Oct 20, 2008
AB	LAVIPHARM LABS	**25MCG/HR**	**A077051**	**001**	Aug 04, 2006
AB	MALLINCKRODT INC	**25MCG/HR**	**A077154**	**001**	Feb 09, 2011
AB	MYLAN TECHNOLOGIES	**25MCG/HR**	**A076258**	**001**	Jan 28, 2005
AB	PAR PHARM INC	**25MCG/HR**	**A077062**	**001**	Aug 20, 2007
	FENTANYL-50				
AB	3M DRUG DELIVERY	**50MCG/HR**	**A202097**	**003**	Nov 04, 2016
AB	ACTAVIS LABS UT INC	**50MCG/HR**	**A076709**	**002**	Aug 20, 2007
AB	AVEVA	**50MCG/HR**	**A077449**	**002**	Oct 20, 2008
AB	LAVIPHARM LABS	**50MCG/HR**	**A077051**	**002**	Aug 04, 2006
AB	MALLINCKRODT INC	**50MCG/HR**	**A077154**	**002**	Feb 09, 2011
AB	MYLAN TECHNOLOGIES	**50MCG/HR**	**A076258**	**002**	Jan 28, 2005
AB	PAR PHARM INC	**50MCG/HR**	**A077062**	**002**	Aug 20, 2007
	FENTANYL-75				
AB	3M DRUG DELIVERY	**75MCG/HR**	**A202097**	**004**	Nov 04, 2016
AB	ACTAVIS LABS UT INC	**75MCG/HR**	**A076709**	**003**	Aug 20, 2007
AB	AVEVA	**75MCG/HR**	**A077449**	**003**	Oct 20, 2008
AB	LAVIPHARM LABS	**75MCG/HR**	**A077051**	**003**	Aug 04, 2006
AB	MALLINCKRODT INC	**75MCG/HR**	**A077154**	**003**	Feb 09, 2011
AB	MYLAN TECHNOLOGIES	**75MCG/HR**	**A076258**	**003**	Jan 28, 2005
AB	PAR PHARM INC	**75MCG/HR**	**A077062**	**003**	Aug 20, 2007
	FENTANYL-37				
	MYLAN TECHNOLOGIES	37.5MCG/HR	A076258	006	Dec 29, 2014
	FENTANYL-62				
	MYLAN TECHNOLOGIES	62.5MCG/HR	A076258	007	Dec 29, 2014
	FENTANYL-87				
	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014

SPRAY;SUBLINGUAL

	SUBSYS				
	INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012
		0.2MG	N202788	002	Jan 04, 2012
+		0.4MG	N202788	003	Jan 04, 2012
		0.6MG	N202788	004	Jan 04, 2012
		0.8MG	N202788	005	Jan 04, 2012
		1.2MG	N202788	006	Aug 30, 2012
		1.6MG	N202788	007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE;INJECTION

	FENTANYL CITRATE				
AP	HOSPIRA	**EQ 0.05MG BASE/ML**	**N019115**	**001**	Jan 12, 1985
	FENTANYL CITRATE PRESERVATIVE FREE				
AP	HOSPIRA	**EQ 0.05MG BASE/ML**	**A072786**	**001**	Sep 24, 1991
AP +	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**N019101**	**001**	Jul 11, 1984
	SUBLIMAZE PRESERVATIVE FREE				
AP +	AKORN	**EQ 0.05MG BASE/ML**	**N016619**	**001**	

SPRAY, METERED;NASAL

	LAZANDA				
	DEPOMED INC	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
		EQ 0.3MG BASE	N022569	003	Dec 21, 2015
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011

FENTANYL CITRATE
TABLET;BUCCAL, SUBLINGUAL
FENTORA

	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
		EQ 0.2MG BASE	N021947	002	Sep 25, 2006
+		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
		EQ 0.6MG BASE	N021947	004	Sep 25, 2006
		EQ 0.8MG BASE	N021947	005	Sep 25, 2006

TABLET;SUBLINGUAL
ABSTRAL

	SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011
+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011
		EQ 0.6MG BASE	N022510	005	Jan 07, 2011
		EQ 0.8MG BASE	N022510	006	Jan 07, 2011

TROCHE/LOZENGE;TRANSMUCOSAL
ACTIQ

AB	CEPHALON	**EQ 0.2MG BASE**	**N020747**	**001**	Nov 04, 1998
AB	**+**	**EQ 0.4MG BASE**	**N020747**	**002**	Nov 04, 1998
AB		**EQ 0.6MG BASE**	**N020747**	**003**	Nov 04, 1998
AB		**EQ 0.8MG BASE**	**N020747**	**004**	Nov 04, 1998
AB		**EQ 1.2MG BASE**	**N020747**	**005**	Nov 04, 1998
AB		**EQ 1.6MG BASE**	**N020747**	**006**	Nov 04, 1998

FENTANYL CITRATE

AB	MALLINCKRODT	**EQ 0.2MG BASE**	**A078907**	**001**	Oct 30, 2009
AB		**EQ 0.4MG BASE**	**A078907**	**002**	Oct 30, 2009
AB		**EQ 0.6MG BASE**	**A078907**	**003**	Oct 30, 2009
AB		**EQ 0.8MG BASE**	**A078907**	**004**	Oct 30, 2009
AB		**EQ 1.2MG BASE**	**A078907**	**005**	Oct 30, 2009
AB		**EQ 1.6MG BASE**	**A078907**	**006**	Oct 30, 2009
AB	PAR PHARM	**EQ 0.2MG BASE**	**A077312**	**001**	Oct 30, 2009
AB		**EQ 0.4MG BASE**	**A077312**	**002**	Oct 30, 2009
AB		**EQ 0.6MG BASE**	**A077312**	**003**	Oct 30, 2009
AB		**EQ 0.8MG BASE**	**A077312**	**004**	Oct 30, 2009
AB		**EQ 1.2MG BASE**	**A077312**	**005**	Oct 30, 2009
AB		**EQ 1.6MG BASE**	**A077312**	**006**	Oct 30, 2009

FENTANYL HYDROCHLORIDE
SYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

+	THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006

FERRIC CARBOXYMALTOSE
INJECTABLE;INTRAVENOUS
INJECTAFER

+	LUITPOLD PHARMS INC	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013

FERRIC CITRATE
TABLET;ORAL
AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014

FERRIC HEXACYANOFERRATE(II)
CAPSULE;ORAL
RADIOGARDASE (PRUSSIAN BLUE)

+	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003

FERRIC PYROPHOSPHATE CITRATE
FOR SOLUTION;INTRAVENOUS
TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016

SOLUTION;IV (INFUSION)
TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015
		272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015

FERUMOXYTOL
SOLUTION;INTRAVENOUS
FERAHEME

+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009

FDA data supplied by DrugPatentWatch.com

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
TOVIAZ

AB		PFIZER	**4MG**	**N022030**	**001**	Oct 31, 2008
AB	**+**		**8MG**	**N022030**	**002**	Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE
SUSPENSION;ORAL
ALLEGRA

AB	**+**	SANOFI AVENTIS US	**30MG/5ML**	**N021963**	**001**	Oct 16, 2006

FEXOFENADINE HYDROCHLORIDE

AB		ACTAVIS MID ATLANTIC	**30MG/5ML**	**A201311**	**001**	Jul 25, 2012

TABLET;ORAL
FEXOFENADINE HYDROCHLORIDE

AB		BARR	**30MG**	**A076191**	**001**	Aug 31, 2005
AB			**60MG**	**A076191**	**002**	Aug 31, 2005
AB			**180MG**	**A076191**	**003**	Aug 31, 2005
AB		DR REDDYS LABS LTD	**30MG**	**A076502**	**001**	Apr 11, 2006
AB			**60MG**	**A076502**	**002**	Apr 11, 2006
AB			**180MG**	**A076502**	**003**	Apr 11, 2006
AB		MYLAN	**30MG**	**A077081**	**002**	Apr 11, 2008
AB			**60MG**	**A077081**	**003**	Apr 11, 2008
AB			**180MG**	**A077081**	**001**	Apr 16, 2007
AB		TEVA	**30MG**	**A076447**	**001**	Sep 01, 2005
AB			**60MG**	**A076447**	**002**	Sep 01, 2005
AB			**180MG**	**A076447**	**003**	Sep 01, 2005

FIDAXOMICIN
TABLET;ORAL
DIFICID

	+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011

FINAFLOXACIN
SUSPENSION/DROPS;OTIC
XTORO

	+	NOVARTIS PHARMS CORP	0.3%	N206307	001	Dec 17, 2014

FINASTERIDE
TABLET;ORAL
FINASTERIDE

AB		ACCORD HLTHCARE	**5MG**	**A090121**	**001**	Feb 23, 2010
AB		ACCORD HLTHCARE INC	**1MG**	**A091643**	**001**	Nov 05, 2013
AB		ACTAVIS TOTOWA	**1MG**	**A078371**	**001**	Nov 05, 2013
AB			**5MG**	**A077914**	**001**	Mar 28, 2007
AB		ALKEM LABS LTD	**1MG**	**A207750**	**001**	Jan 06, 2017
AB			**5MG**	**A204304**	**001**	Jan 05, 2017
AB		AUROBINDO PHARMA	**5MG**	**A078341**	**001**	Oct 30, 2007
AB		AUROBINDO PHARMA LTD	**1MG**	**A203687**	**001**	Nov 05, 2013
AB		CIPLA LTD	**1MG**	**A077335**	**001**	Nov 20, 2014
AB		DR REDDYS LABS INC	**1MG**	**A076436**	**001**	Jul 28, 2006
AB		DR REDDYS LABS LTD	**5MG**	**A076437**	**001**	Feb 28, 2007
AB		GEDEON RICHTER USA	**5MG**	**A077251**	**001**	Dec 22, 2006
AB		HETERO LABS LTD III	**1MG**	**A090060**	**001**	Jul 01, 2013
AB			**5MG**	**A090061**	**001**	Jun 07, 2010
AB		MYLAN	**5MG**	**A077578**	**001**	Dec 18, 2006
AB		MYLAN PHARMS INC	**1MG**	**A078161**	**001**	Nov 05, 2013
AB		SUN PHARMA GLOBAL	**1MG**	**A090508**	**001**	Jul 01, 2013
AB			**5MG**	**A090507**	**001**	Aug 16, 2011
AB		TEVA	**1MG**	**A076905**	**001**	Nov 05, 2013
AB			**5MG**	**A076511**	**001**	Dec 15, 2006
AB		ZYDUS PHARMS USA INC	**5MG**	**A078900**	**001**	Dec 28, 2009

PROPECIA

AB	**+**	MERCK	**1MG**	**N020788**	**001**	Dec 19, 1997

PROSCAR

AB	**+**	MERCK	**5MG**	**N020180**	**001**	Jun 19, 1992

FINGOLIMOD
CAPSULE;ORAL
GILENYA

	+	NOVARTIS	0.5MG	N022527	001	Sep 21, 2010

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL
EMULSION;INTRAVENOUS
SMOFLIPID 20%

	+	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648 001	Jul 13, 2016
	+		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648 002	Jul 13, 2016
	+		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648 003	Jul 13, 2016

FLAVOXATE HYDROCHLORIDE
TABLET;ORAL
FLAVOXATE HYDROCHLORIDE

AB		EPIC PHARMA	**100MG**	**A076835 001**	Nov 30, 2005
AB	**+**	PADDOCK LLC	**100MG**	**A076831 001**	Dec 16, 2004

FLECAINIDE ACETATE
TABLET;ORAL
FLECAINIDE ACETATE

AB		AMNEAL PHARM	**50MG**	**A075442 001**	Jul 31, 2001
AB			**100MG**	**A075442 002**	Jul 31, 2001
AB			**150MG**	**A075442 003**	Jul 31, 2001
AB		ANI PHARMS INC	**50MG**	**A075882 001**	Oct 28, 2002
AB			**100MG**	**A075882 002**	Oct 28, 2002
AB			**150MG**	**A075882 003**	Oct 28, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A202821 001**	Jul 08, 2015
AB			**100MG**	**A202821 002**	Jul 08, 2015
AB			**150MG**	**A202821 003**	Jul 08, 2015
AB		SUN PHARM INDS LTD	**50MG**	**A076421 001**	Mar 28, 2003
AB			**100MG**	**A076421 002**	Mar 28, 2003
AB			**150MG**	**A076421 003**	Mar 28, 2003
AB		WEST-WARD PHARMS INT	**50MG**	**A076278 001**	Jan 14, 2003
AB			**100MG**	**A076278 002**	Jan 14, 2003
AB	**+**		**150MG**	**A076278 003**	Jan 14, 2003

TAMBOCOR

AB		CNTY LINE PHARMS	**50MG**	**N018830 004**	Aug 23, 1988
AB			**100MG**	**N018830 001**	Oct 31, 1985
AB			**150MG**	**N018830 003**	Jun 03, 1988

FLIBANSERIN
TABLET;ORAL
ADDYI

	+	SPROUT PHARMS	100MG	N022526 001	Aug 18, 2015

FLORBETABEN F-18
SOLUTION;INTRAVENOUS
NEURACEQ

	+	PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677 001	Mar 19, 2014

FLORBETAPIR F-18
SOLUTION;INTRAVENOUS
AMYVID

	+	AVID RADIOPHARMS INC	10-30ML (13.5-51mCi/ML)	N202008 002	Apr 06, 2012
	+		10-50ML (13.5-51mCi/ML)	N202008 003	Apr 06, 2012

FLOXURIDINE
INJECTABLE;INJECTION
FLOXURIDINE

AP		FRESENIUS KABI USA	**500MG/VIAL**	**A075837 001**	Feb 22, 2001
AP	**+**	WEST-WARD PHARMS INT	**500MG/VIAL**	**A075387 001**	Apr 16, 2000

FLUCICLOVINE F-18
SOLUTION;INTRAVENOUS
AXUMIN

	+	BLUE EARTH	9-221mCi/ML	N208054 001	May 27, 2016

FLUCONAZOLE
FOR SUSPENSION;ORAL
DIFLUCAN

AB		PFIZER	**50MG/5ML**	**N020090 001**	Dec 23, 1993
AB	**+**		**200MG/5ML**	**N020090 002**	Dec 23, 1993

FLUCONAZOLE

AB		AUROBINDO PHARM	**50MG/5ML**	**A079150 001**	Sep 18, 2009
AB			**200MG/5ML**	**A079150 002**	Sep 18, 2009
AB		IVAX SUB TEVA PHARMS	**50MG/5ML**	**A077523 001**	Sep 12, 2007
AB			**200MG/5ML**	**A077523 002**	Sep 12, 2007
AB		WEST-WARD PHARMS INT	**50MG/5ML**	**A076246 001**	Jul 29, 2004

FLUCONAZOLE
FOR SUSPENSION;ORAL
FLUCONAZOLE

AB			**200MG/5ML**	**A076246**	**002** Jul 29, 2004

INJECTABLE;INJECTION
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PFIZER	**200MG/100ML (2MG/ML)**	**N019950**	**003** Sep 29, 1992
AP	+		**400MG/200ML (2MG/ML)**	**N019950**	**005** Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

AP	+	PFIZER	**200MG/100ML (2MG/ML)**	**N019950**	**001** Jan 29, 1990
AP	+		**400MG/200ML (2MG/ML)**	**N019950**	**006** Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	PFIZER	**200MG/100ML (2MG/ML)**	**N019950**	**002** Jan 29, 1990
AP	+		**400MG/200ML (2MG/ML)**	**N019950**	**004** Jan 29, 1990

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		CLARIS	**200MG/100ML (2MG/ML)**	**A077988**	**001** May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077988**	**002** May 26, 2010
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078764**	**001** Jan 30, 2012
AP			**400MG/200ML (2MG/ML)**	**A078764**	**002** Jan 30, 2012
AP		HOSPIRA	**200MG/100ML (2MG/ML)**	**A076304**	**001** Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076304**	**002** Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		CLARIS	**200MG/100ML (2MG/ML)**	**A077947**	**001** May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077947**	**002** May 26, 2010
AP		EUROHLTH INTL SARL	**200MG/100ML (2MG/ML)**	**A076087**	**001** Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076087**	**003** Jul 29, 2004
AP		FRESENIUS KABI USA	**200MG/100ML (2MG/ML)**	**A076145**	**001** Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076145**	**002** Jul 29, 2004
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A076736**	**001** Aug 23, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ACS DOBFAR INFO SA	**200MG/100ML (2MG/ML)**	**A079104**	**001** Jul 30, 2009
AP			**400MG/200ML (2MG/ML)**	**A079104**	**002** Jul 30, 2009
AP		BAXTER HLTHCARE	**200MG/100ML (2MG/ML)**	**A076766**	**001** Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076766**	**002** Jul 29, 2004
AP		CLARIS	**200MG/100ML (2MG/ML)**	**A077909**	**001** May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077909**	**002** May 26, 2010
AP		EUROHLTH INTL SARL	**200MG/100ML (2MG/ML)**	**A078107**	**001** Jul 30, 2008
AP			**400MG/200ML (2MG/ML)**	**A078107**	**002** Jul 30, 2008
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078698**	**001** Jan 30, 2012
AP			**400MG/200ML (2MG/ML)**	**A078698**	**002** Jan 30, 2012
AP		HOSPIRA	**200MG/100ML (2MG/ML)**	**A076303**	**001** Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076303**	**002** Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002 Sep 26, 2008

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		CLARIS	100MG/50ML (2MG/ML)	A077909	003 Apr 20, 2015

TABLET;ORAL
DIFLUCAN

AB		PFIZER	**50MG**	**N019949**	**001** Jan 29, 1990
AB			**100MG**	**N019949**	**002** Jan 29, 1990
AB			**150MG**	**N019949**	**004** Jun 30, 1994
AB	+		**200MG**	**N019949**	**003** Jan 29, 1990

FLUCONAZOLE

AB		APOTEX	**50MG**	**A076665**	**001** Jul 29, 2004
AB			**100MG**	**A076665**	**002** Jul 29, 2004
AB			**150MG**	**A076665**	**003** Jul 29, 2004
AB			**200MG**	**A076665**	**004** Jul 29, 2004
AB		AUROBINDO PHARMA	**50MG**	**A077731**	**001** Oct 07, 2008
AB			**100MG**	**A077731**	**002** Oct 07, 2008
AB			**150MG**	**A077731**	**003** Oct 07, 2008
AB			**200MG**	**A077731**	**004** Oct 07, 2008
AB		DR REDDYS LABS INC	**50MG**	**A076658**	**001** Jul 29, 2004
AB			**100MG**	**A076658**	**002** Jul 29, 2004
AB			**150MG**	**A076658**	**003** Jul 29, 2004
AB			**200MG**	**A076658**	**004** Jul 29, 2004
AB		GLENMARK GENERICS	**50MG**	**A077253**	**001** Jan 25, 2006
AB			**100MG**	**A077253**	**002** Jan 25, 2006
AB			**150MG**	**A077253**	**003** Jan 25, 2006
AB			**200MG**	**A077253**	**004** Jan 25, 2006
AB		HARRIS PHARM	**50MG**	**A078423**	**001** Mar 07, 2011
AB			**100MG**	**A078423**	**002** Mar 07, 2011
AB			**150MG**	**A078423**	**003** Mar 07, 2011

FDA data supplied by DrugPatentWatch.com

FLUCONAZOLE
TABLET;ORAL
FLUCONAZOLE

AB			200MG	A078423	004	Mar 07, 2011
AB		IVAX SUB TEVA PHARMS	50MG	A076077	001	Jul 29, 2004
AB			100MG	A076077	002	Jul 29, 2004
AB			150MG	A076077	003	Jul 29, 2004
AB			200MG	A076077	004	Jul 29, 2004
AB		MYLAN	50MG	A076351	001	Jul 29, 2004
AB			100MG	A076351	002	Jul 29, 2004
AB			150MG	A076351	003	Jul 29, 2004
AB			200MG	A076351	004	Jul 29, 2004
AB		TARO	50MG	A076507	001	Jul 29, 2004
AB			100MG	A076507	002	Jul 29, 2004
AB			150MG	A076507	003	Jul 29, 2004
AB			200MG	A076507	004	Jul 29, 2004
AB		TEVA	50MG	A074681	001	Jul 29, 2004
AB			100MG	A074681	002	Jul 29, 2004
AB			150MG	A074681	003	Jul 29, 2004
AB			200MG	A074681	004	Jul 29, 2004
AB		UNIQUE PHARM LABS	50MG	A076957	001	Sep 28, 2005
AB			100MG	A076957	002	Sep 28, 2005
AB			200MG	A076957	003	Sep 28, 2005

FLUCYTOSINE
CAPSULE;ORAL
ANCOBON

AB		VALEANT	250MG	N017001	001	
AB	+		500MG	N017001	002	

FLUCYTOSINE

AB		SIGMAPHARM LABS LLC	250MG	A201566	001	Jun 28, 2011
AB			500MG	A201566	002	Jun 28, 2011

FLUDARABINE PHOSPHATE
INJECTABLE;INJECTION
FLUDARABINE PHOSPHATE

AP		ACTAVIS TOTOWA	50MG/VIAL	A078610	001	Feb 11, 2009
AP	+	FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007
AP			50MG/VIAL	A078544	001	Oct 15, 2007
AP	+	HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007
AP		MUSTAFA NEVZAT ILAC	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010
AP		MYLAN LABS LTD	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011
AP			50MG/VIAL	A200648	001	Oct 16, 2012
AP		SAGENT PHARMS	50MG/VIAL	A076349	001	Aug 28, 2003
AP			50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004
AP	+	SANDOZ	50MG/2ML (25MG/ML)	N022137	001	Sep 21, 2007

FLUDEOXYGLUCOSE F-18
INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP		3D IMAGING DRUG	20-300mCi/ML	A203778	001	Oct 30, 2015
AP		BIOMEDCL RES FDN	20-300mCi/ML	A203710	001	May 01, 2015
AP			20-300mCi/ML	A203837	001	May 01, 2015
AP		BRIGHAM WOMENS	20-300mCi/ML	A203816	001	Oct 30, 2014
AP		CARDINAL HEALTH 414	20-300mCi/ML	A203603	001	Nov 13, 2015
AP		CHILDRENS HOSP MI	20-300mCi/ML	A204385	001	Oct 29, 2014
AP		CPDC	20-300mCi/ML	A204525	001	Oct 29, 2014
AP		ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014
AP	+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005
AP	+		20-400mCi/ML	N021870	002	Nov 21, 2008
AP		GLOBAL ISOTOPES LLC	20-300mCi/ML	A204463	001	Oct 21, 2014
AP	+	HOUSTON CYCLOTRON	20-500mCi/ML	A203665	001	Feb 14, 2013
AP		KETTERING MEDCTR	4-40mCi/ML	A204759	001	Oct 27, 2015
AP		KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016
AP		LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014
AP		MA GENERAL HOSP	20-300mCi/ML	A204333	001	Sep 25, 2014
AP		MCPRF	20-240mCi/ML	A203612	001	Aug 05, 2013
AP		MEM SLOAN-KETTERING	20-300mCi/ML	A208679	001	Dec 08, 2016
AP		METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015
AP		MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015
AP		MIPS CRF	20-300mCi/ML	A204472	001	Sep 11, 2015
AP		NCM USA BRONX LLC	20-300mCi/ML	A204512	001	Jan 07, 2015
AP		PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011
AP	+	QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015

FDA data supplied by DrugPatentWatch.com

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		SHERTECH LABS LLC	**20-300mCi/ML**	**A204264**	**001**	Dec 18, 2014
AP		TRIAD ISOTOPES INC	**20-300mCi/ML**	**A203920**	**001**	Jun 23, 2015
AP		TRUSTEES UNIV PA	**20-200mCi/ML**	**A203801**	**001**	Oct 29, 2014
AP	+	UCLA BIOMEDICAL	**4-40mCi/ML**	**A203811**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**20-300mCi/ML**	**A203902**	**001**	May 09, 2014
AP		UIHC PET IMAGING	**20-300mCi/ML**	**A203990**	**001**	Aug 06, 2014
AP		UNIV MICHIGAN	**20-300mCi/ML**	**A204531**	**001**	Jul 17, 2015
AP		UNIV TX MD ANDERSON	**20-300mCi/ML**	**A203246**	**002**	Jan 13, 2014
AP		UNIV UTAH CYCLOTRON	**20-300mCi/ML**	**A204498**	**001**	Jun 23, 2015
AP		WI MEDCL CYCLOTRON	**20-500mCi/ML**	**A203709**	**001**	Oct 23, 2013
AP		WUSM CYCLOTRON	**20-300mCi/ML**	**A203935**	**001**	Feb 05, 2014
AP		ZEVACOR PHARMA INC	**20-300mCi/ML**	**A203591**	**001**	Aug 31, 2015
		HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015
		SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015
		UNIV NORTH DAKOTA	4-500mCi/ML	A203994	001	Feb 04, 2015
		UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB		BARR	**0.1MG**	**A040425**	**001**	Jan 21, 2003
AB		HIKMA PHARMS	**0.1MG**	**A091302**	**001**	Jul 22, 2011
AB	+	IMPAX LABS	**0.1MG**	**A040431**	**001**	Mar 18, 2002

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		EUROHLTH INTL SARL	**0.5MG/5ML (0.1MG/ML)**	**A076256**	**002**	Oct 12, 2004
AP			**0.5MG/5ML (0.1MG/ML)**	**A076787**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076256**	**001**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076787**	**001**	Oct 12, 2004
AP		FRESENIUS KABI USA	**0.5MG/5ML (0.1MG/ML)**	**A076955**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076955**	**001**	Oct 12, 2004
AP		HIKMA FARMACEUTICA	**0.5MG/5ML (0.1MG/ML)**	**A078527**	**001**	Mar 23, 2009
AP			**1MG/10ML (0.1MG/ML)**	**A078527**	**002**	Mar 23, 2009
AP		MYLAN LABS LTD	**0.5MG/5ML (0.1MG/ML)**	**A078595**	**001**	May 13, 2008
AP	+		**1MG/10ML (0.1MG/ML)**	**A078595**	**002**	May 13, 2008
AP		SAGENT PHARMS	**0.5MG/5ML (0.1MG/ML)**	**A090584**	**001**	Aug 28, 2012
AP			**1MG/10ML (0.1MG/ML)**	**A090584**	**002**	Aug 28, 2012
AP		SANDOZ	**0.5MG/5ML (0.1MG/ML)**	**A077071**	**001**	May 03, 2005
AP			**1MG/10ML (0.1MG/ML)**	**A077071**	**002**	May 03, 2005

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROSPAN HFA

	+	MEDA PHARMS	0.078MG/INH	N021247	001	Jan 27, 2006

SPRAY, METERED;NASAL

FLUNISOLIDE

AB	+	BAUSCH AND LOMB	**0.025MG/SPRAY**	**A074805**	**001**	Feb 20, 2002
AB		HI TECH PHARMA CO	**0.025MG/SPRAY**	**A077704**	**001**	Aug 03, 2006
	+	APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA	**0.01%**	**A088170**	**001**	Dec 16, 1982
AT			**0.025%**	**A088169**	**001**	Dec 16, 1982
AT		G AND W LABS	**0.01%**	**A089526**	**001**	Jul 26, 1988
AT			**0.025%**	**A089525**	**001**	Jul 26, 1988
AT		TARO	**0.025%**	**A087104**	**001**	Apr 27, 1982

SYNALAR

AT	+	MEDIMETRIKS PHARMS	**0.01%**	**N012787**	**004**	
AT	+		**0.025%**	**N012787**	**002**	
AT	+		**0.025%**	**N012787**	**005**	

IMPLANT;INTRAVITREAL

ILUVIEN

	+	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014

RETISERT

	+	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005

FDA data supplied by DrugPatentWatch.com

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

DERMA-SMOOTHE/FS

AT	+	HILL DERMAC	**0.01%**	**N019452**	**001**	Feb 03, 1988
AT	+		**0.01%**	**N019452**	**002**	Nov 09, 2005

FLUOCINOLONE ACETONIDE

AT		AKORN	**0.01%**	**A091514**	**001**	Jun 25, 2015
AT		IDENTI PHARMS INC	**0.01%**	**A201759**	**001**	Oct 17, 2011
AT			**0.01%**	**A201764**	**001**	Oct 17, 2011
AT		LYNE	**0.01%**	**A090982**	**001**	Apr 25, 2016
AT			**0.01%**	**A203377**	**001**	Apr 25, 2016
AT		PERRIGO ISRAEL	**0.01%**	**A202847**	**001**	Aug 09, 2013
AT			**0.01%**	**A202848**	**001**	Aug 09, 2013
AT		TARO	**0.01%**	**A202368**	**001**	May 19, 2016
AT			**0.01%**	**A209336**	**001**	May 19, 2016

OIL/DROPS;OTIC

DERMOTIC

AT	+	HILL DERMAC	**0.01%**	**N019452**	**003**	Nov 09, 2005

FLUOCINOLONE ACETONIDE

AT		AKORN	**0.01%**	**A202705**	**001**	Sep 09, 2016
AT		IDENTI PHARMS INC	**0.01%**	**A091306**	**001**	Oct 17, 2011
AT		LYNE	**0.01%**	**A203378**	**001**	Apr 25, 2016

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT		FOUGERA	**0.025%**	**A088168**	**001**	Dec 16, 1982
AT		G AND W LABS	**0.025%**	**A089524**	**001**	Jul 26, 1988
AT		TARO	**0.025%**	**A040041**	**001**	Sep 15, 1994

SYNALAR

AT	+	MEDIMETRIKS PHARMS	**0.025%**	**N013960**	**001**	

SHAMPOO;TOPICAL

CAPEX

	+	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		ACTAVIS LABS UT INC	**0.01%**	**A208386**	**001**	Oct 21, 2016
AT		FOUGERA	**0.01%**	**A088167**	**001**	Dec 16, 1982
AT		G AND W LABS INC	**0.01%**	**A207441**	**001**	Sep 28, 2016
AT		GAVIS PHARMS LLC	**0.01%**	**A206422**	**001**	Sep 02, 2015
AT		TARO	**0.01%**	**A089124**	**001**	Sep 11, 1985

SYNALAR

AT	+	MEDIMETRIKS PHARMS	**0.01%**	**N015296**	**001**	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM;TOPICAL

TRI-LUMA

	+	GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

	+	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001	

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB		FOUGERA PHARMS INC	**0.1%**	**A200735**	**001**	Jul 14, 2014
AB		GLENMARK GENERICS	**0.1%**	**A091282**	**001**	Jul 14, 2014
AB		PERRIGO ISRAEL	**0.1%**	**A090256**	**001**	Jan 14, 2014
AB		TARO	**0.1%**	**A200734**	**001**	Jul 14, 2014

VANOS

AB	+	MEDICIS	**0.1%**	**N021758**	**001**	Feb 11, 2005

FLUOCINONIDE

AB1		FOUGERA	**0.05%**	**A073030**	**001**	Oct 17, 1994
AB1		G AND W LABS INC	**0.05%**	**A073085**	**001**	Feb 14, 1992
AB1	+	TARO	**0.05%**	**N019117**	**001**	Jun 26, 1984
AB1		TEVA	**0.05%**	**A072488**	**001**	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

AB2		FOUGERA PHARMS	**0.05%**	**A076586**	**001**	Jun 23, 2004
AB2	+	TARO	**0.05%**	**A072494**	**001**	Jan 19, 1989
AB2		TEVA	**0.05%**	**A072490**	**001**	Feb 07, 1989

GEL;TOPICAL

FLUOCINONIDE

AB		FOUGERA	**0.05%**	**A072933**	**001**	Dec 30, 1994
AB		G AND W LABS INC	**0.05%**	**A072537**	**001**	Feb 07, 1989

FLUOCINONIDE
GEL;TOPICAL
FLUOCINONIDE

AB	+	TARO	**0.05%**	**A074935**	**001**	Jul 29, 1997

OINTMENT;TOPICAL
FLUOCINONIDE

AB		FOUGERA PHARMS	**0.05%**	**A074905**	**001**	Aug 26, 1997
AB	+	TARO	**0.05%**	**A075008**	**001**	Jun 30, 1999
AB		TEVA	**0.05%**	**A073481**	**001**	Dec 27, 1991

LIDEX

AB		CNTY LINE PHARMS	**0.05%**	**N016909**	**002**	

SOLUTION;TOPICAL
FLUOCINONIDE

AT		FOUGERA	**0.05%**	**A072934**	**001**	Feb 27, 1995
AT		G AND W LABS INC	**0.05%**	**A071535**	**001**	Dec 02, 1988
AT	+	TARO	**0.05%**	**A074799**	**001**	Dec 31, 1996
AT		TEVA	**0.05%**	**A072511**	**001**	Feb 07, 1989

LIDEX

AT		CNTY LINE PHARMS	**0.05%**	**N018849**	**001**	Apr 06, 1984

FLUORESCEIN SODIUM
INJECTABLE;INTRAVENOUS
AK-FLUOR 10%

AP		AKORN	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N022186**	**001**	Aug 08, 2008

FLUORESCITE

AP	+	NOVARTIS PHARMS CORP	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N021980**	**001**	Mar 28, 2006

AK-FLUOR 25%

	+	AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008

FLUOROMETHOLONE
OINTMENT;OPHTHALMIC
FML

	+	ALLERGAN	0.1%	N017760	001	Sep 04, 1985

SUSPENSION/DROPS;OPHTHALMIC
FML

	+	ALLERGAN	0.1%	N016851	002	Jul 28, 1982

FML FORTE

		ALLERGAN	0.25%	N019216	001	Apr 23, 1986

FLUOROMETHOLONE ACETATE
SUSPENSION/DROPS;OPHTHALMIC
FLAREX

	+	NOVARTIS PHARMS CORP	0.1%	N019079	001	Feb 11, 1986

FLUOROURACIL
CREAM;TOPICAL
CARAC

AB	+	VALEANT PHARMS NORTH	**0.5%**	**N020985**	**001**	Oct 27, 2000

EFUDEX

AB	+	VALEANT PHARM INTL	**5%**	**N016831**	**003**	

FLUOROURACIL

AB		SPEAR PHARMS	**5%**	**A077524**	**001**	Apr 11, 2008
AB		SPEAR PHARMS INC	**0.5%**	**A203122**	**001**	Apr 20, 2015
AB		TARO	**5%**	**A090368**	**001**	Mar 05, 2010

FLUOROPLEX

	+	AQUA PHARMS	1%	N016988	001	

TOLAK

	+	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015

INJECTABLE;INJECTION
FLUOROURACIL

AP	+	ACCORD HLTHCARE	**500MG/10ML (50MG/ML)**	**A040743**	**002**	Apr 26, 2007
AP	+		**1GM/20ML (50MG/ML)**	**A040743**	**001**	Apr 26, 2007
AP	+		**2.5GM/50ML (50MG/ML)**	**A040798**	**002**	Apr 26, 2007
AP	+		**5GM/100ML (50MG/ML)**	**A040798**	**001**	Apr 26, 2007
AP	+	FRESENIUS KABI USA	**500MG/10ML (50MG/ML)**	**A040279**	**002**	Sep 30, 1998
AP	+		**1GM/20ML (50MG/ML)**	**A040279**	**001**	Sep 30, 1998
AP	+		**2.5GM/50ML (50MG/ML)**	**A040278**	**001**	Sep 30, 1998
AP	+		**5GM/100ML (50MG/ML)**	**A040278**	**002**	Sep 30, 1998
AP		MYLAN LABS LTD	**500MG/10ML (50MG/ML)**	**A202668**	**001**	Jul 17, 2012
AP			**1GM/20ML (50MG/ML)**	**A202668**	**002**	Jul 17, 2012
AP			**2.5GM/50ML (50MG/ML)**	**A202669**	**001**	Jul 17, 2012
AP			**5GM/100ML (50MG/ML)**	**A202669**	**002**	Jul 17, 2012
AP		SAGENT PHARMS	**2.5GM/50ML (50MG/ML)**	**A203609**	**001**	Feb 17, 2016
AP			**5GM/100ML (50MG/ML)**	**A203609**	**002**	Feb 17, 2016

FDA data supplied by DrugPatentWatch.com

FLUOROURACIL
INJECTABLE;INJECTION

		FLUOROURACIL				
AP		SANDOZ	**2.5GM/50ML (50MG/ML)**	**A091299**	**001**	May 02, 2011
AP			**5GM/100ML (50MG/ML)**	**A091299**	**002**	May 02, 2011
AP	+	TEVA PHARMS USA	**500MG/10ML (50MG/ML)**	**A040333**	**001**	Jan 27, 2000
AP	+		**2.5GM/50ML (50MG/ML)**	**A040334**	**001**	Feb 25, 2000
AP	+		**5GM/100ML (50MG/ML)**	**A040334**	**002**	Feb 25, 2000
	+	SPECTRUM PHARMS	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016

SOLUTION;TOPICAL

		EFUDEX				
AT	+	VALEANT PHARM INTL	**2%**	**N016831**	**001**	
AT	+		**5%**	**N016831**	**002**	
		FLUOROURACIL				
AT		TARO	**2%**	**A076526**	**001**	Nov 05, 2003
AT			**5%**	**A076526**	**002**	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE
CAPSULE;ORAL

		FLUOXETINE HYDROCHLORIDE				
AB		ALEMBIC PHARMS LTD	**EQ 40MG BASE**	**A090223**	**003**	Mar 19, 2009
AB		AUROBINDO PHARMA	**EQ 40MG BASE**	**A078619**	**003**	Jan 31, 2008
AB		DR REDDYS LABS LTD	**EQ 40MG BASE**	**A075465**	**003**	Aug 02, 2001
AB		HERITAGE PHARMS INC	**EQ 40MG BASE**	**A201336**	**003**	Oct 01, 2012
AB		IVAX SUB TEVA PHARMS	**EQ 40MG BASE**	**A075245**	**003**	Sep 28, 2004
AB		MYLAN	**EQ 40MG BASE**	**A075207**	**003**	May 25, 2007
AB		PAR PHARM	**EQ 40MG BASE**	**A076922**	**003**	Dec 16, 2004
AB		SANDOZ	**EQ 40MG BASE**	**A075049**	**003**	Jan 29, 2002
AB		SCIEGEN PHARMS INC	**EQ 40MG BASE**	**A204597**	**003**	Mar 16, 2015
AB		SUN PHARM INDS LTD	**EQ 40MG BASE**	**A076990**	**001**	Dec 13, 2004
AB		TEVA	**EQ 40MG BASE**	**A075452**	**003**	Jan 29, 2002
		PROZAC				
AB	+	ELI LILLY AND CO	**EQ 40MG BASE**	**N018936**	**003**	Jun 15, 1999
		FLUOXETINE HYDROCHLORIDE				
AB1		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A090223**	**001**	Mar 19, 2009
AB1			**EQ 20MG BASE**	**A090223**	**002**	Mar 19, 2009
AB1		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078619**	**001**	Jan 31, 2008
AB1			**EQ 20MG BASE**	**A078619**	**002**	Jan 31, 2008
AB1		BARR	**EQ 10MG BASE**	**A074803**	**002**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A074803**	**001**	Aug 02, 2001
AB1		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A075465**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075465**	**002**	Jan 29, 2002
AB1		HERITAGE PHARMS INC	**EQ 10MG BASE**	**A201336**	**001**	Oct 01, 2012
AB1			**EQ 20MG BASE**	**A201336**	**002**	Oct 01, 2012
AB1		IVAX SUB TEVA PHARMS	**EQ 10MG BASE**	**A075245**	**002**	Jan 31, 2002
AB1			**EQ 20MG BASE**	**A075245**	**001**	Jan 31, 2002
AB1		LANDELA PHARM	**EQ 10MG BASE**	**A075464**	**001**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A075464**	**002**	Jan 30, 2002
AB1		MALLINCKRODT	**EQ 10MG BASE**	**A075658**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075658**	**002**	Jan 29, 2002
AB1		MYLAN	**EQ 10MG BASE**	**A075207**	**001**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A075207**	**002**	Jan 30, 2002
AB1		MYLAN PHARMS INC	**EQ 10MG BASE**	**A075577**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075577**	**002**	Jan 29, 2002
AB1		SANDOZ	**EQ 10MG BASE**	**A075049**	**001**	Aug 02, 2001
AB1			**EQ 20MG BASE**	**A075049**	**002**	Jan 29, 2002
AB1		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A204597**	**001**	Mar 16, 2015
AB1			**EQ 20MG BASE**	**A204597**	**002**	Mar 16, 2015
AB1		TEVA	**EQ 10MG BASE**	**A075452**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075452**	**002**	Jan 29, 2002
AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A076001**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A076001**	**002**	Jan 29, 2002
		PROZAC				
AB1		ELI LILLY AND CO	**EQ 10MG BASE**	**N018936**	**006**	Dec 23, 1992
AB1			**EQ 20MG BASE**	**N018936**	**001**	Dec 29, 1987
		FLUOXETINE HYDROCHLORIDE				
		MYLAN	EQ 10MG BASE	A078045	001	Nov 17, 2008
	+		EQ 20MG BASE	A078045	002	Nov 17, 2008

CAPSULE, DELAYED REL PELLETS;ORAL

		FLUOXETINE HYDROCHLORIDE				
AB		BARR	**EQ 90MG BASE**	**A076237**	**001**	Mar 24, 2010
AB		DR REDDYS LABS LTD	**EQ 90MG BASE**	**A078572**	**001**	Mar 22, 2010

FLUOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

PROZAC WEEKLY

AB	+	LILLY	**EQ 90MG BASE**	**N021235**	**001**	Feb 26, 2001

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA		AUROBINDO PHARM	**EQ 20MG BASE/5ML**	**A079209**	**001**	Mar 20, 2009
AA		MALLINCKRODT	**EQ 20MG BASE/5ML**	**A075920**	**001**	Jan 29, 2002
AA	+	PHARM ASSOC	**EQ 20MG BASE/5ML**	**A076015**	**001**	Jan 30, 2002
AA		SILARX	**EQ 20MG BASE/5ML**	**A077849**	**001**	Feb 09, 2007
AA		TEVA	**EQ 20MG BASE/5ML**	**A075506**	**001**	Aug 02, 2001
AA		WOCKHARDT	**EQ 20MG BASE/5ML**	**A075514**	**001**	Aug 29, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		DR REDDYS LABS INC	**EQ 10MG BASE**	**A076006**	**001**	Jan 30, 2002
AB		MYLAN	**EQ 10MG BASE**	**A075755**	**001**	Aug 02, 2001
AB	+		**EQ 20MG BASE**	**A075755**	**002**	Aug 02, 2001
AB		PAR FORM	**EQ 10MG BASE**	**A203836**	**001**	Aug 19, 2016
AB			**EQ 20MG BASE**	**A203836**	**002**	Aug 19, 2016
AB		TEVA	**EQ 10MG BASE**	**A075872**	**001**	Jan 29, 2002
AB1		TORRENT PHARMS LTD	**EQ 10MG BASE**	**A206937**	**001**	Oct 21, 2016
AB1			**EQ 20MG BASE**	**A206937**	**002**	Oct 21, 2016

SARAFEM

AB1		APIL	**EQ 10MG BASE**	**N021860**	**001**	May 19, 2006
AB1			**EQ 15MG BASE**	**N021860**	**002**	May 19, 2006
AB1	+		**EQ 20MG BASE**	**N021860**	**003**	May 19, 2006

SELFEMRA

AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A200151**	**001**	Feb 03, 2014
AB1			**EQ 15MG BASE**	**A200151**	**002**	Feb 03, 2014
AB1			**EQ 20MG BASE**	**A200151**	**003**	Feb 03, 2014

FLUOXETINE HYDROCHLORIDE

	+	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		PAR PHARM	**EQ 25MG BASE;EQ 3MG BASE**	**A077742**	**001**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077742**	**002**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077742**	**003**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077742**	**004**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077742**	**005**	Nov 02, 2012
AB		SANDOZ	**EQ 25MG BASE;EQ 3MG BASE**	**A078901**	**005**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A078901**	**001**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A078901**	**003**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A078901**	**002**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A078901**	**004**	Nov 16, 2012
AB		TEVA PHARMS	**EQ 25MG BASE;EQ 3MG BASE**	**A202074**	**001**	Mar 25, 2013
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077528**	**001**	Jun 19, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077528**	**002**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077528**	**003**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077528**	**004**	Jun 19, 2012

SYMBYAX

AB		LILLY	**EQ 25MG BASE;EQ 3MG BASE**	**N021520**	**001**	Apr 09, 2007
AB			**EQ 25MG BASE;EQ 6MG BASE**	**N021520**	**002**	Dec 24, 2003
AB			**EQ 25MG BASE;EQ 12MG BASE**	**N021520**	**004**	Dec 24, 2003
AB	+		**EQ 50MG BASE;EQ 6MG BASE**	**N021520**	**003**	Dec 24, 2003
AB			**EQ 50MG BASE;EQ 12MG BASE**	**N021520**	**005**	Dec 24, 2003

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

	+	USL PHARMA	10MG	A088342	001	Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO	+	FRESENIUS KABI USA	**25MG/ML**	**A071413**	**001**	Jul 14, 1987
AO		PAR STERILE PRODUCTS	**25MG/ML**	**A203732**	**001**	Jul 03, 2014
AO		WEST-WARD PHARMS INT	**25MG/ML**	**A074531**	**001**	Aug 30, 1996

FDA data supplied by DrugPatentWatch.com

FLUPHENAZINE HYDROCHLORIDE

	CONCENTRATE;ORAL				
	FLUPHENAZINE HYDROCHLORIDE				
	+ PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996
	ELIXIR;ORAL				
	FLUPHENAZINE HYDROCHLORIDE				
	+ PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996
	INJECTABLE;INJECTION				
	FLUPHENAZINE HYDROCHLORIDE				
	+ FRESENIUS KABI USA	2.5MG/ML	A089556	001	Apr 16, 1987
	TABLET;ORAL				
	FLUPHENAZINE HYDROCHLORIDE				
AB	LANNETT	**1MG**	**A089743**	**002**	Aug 25, 1988
AB		**2.5MG**	**A089743**	**003**	Aug 25, 1988
AB		**5MG**	**A089743**	**004**	Aug 25, 1988
AB		**10MG**	**A089743**	**001**	Aug 25, 1988
AB	MYLAN	**1MG**	**A089804**	**002**	Aug 12, 1988
AB		**2.5MG**	**A089804**	**003**	Aug 12, 1988
AB		**5MG**	**A089804**	**004**	Aug 12, 1988
AB	**+**	**10MG**	**A089804**	**001**	Aug 12, 1988
AB	SANDOZ	**1MG**	**A089586**	**002**	Oct 16, 1987
AB		**2.5MG**	**A089586**	**003**	Oct 16, 1987
AB		**5MG**	**A089586**	**004**	Oct 16, 1987
AB		**10MG**	**A089586**	**001**	Oct 16, 1987

FLURANDRENOLIDE

	CREAM;TOPICAL				
	CORDRAN SP				
AT	**+** AQUA PHARMS	**0.05%**	**N012806**	**002**	
	FLURANDRENOLIDE				
AT	TELIGENT PHARMA INC	**0.05%**	**A205342**	**001**	Apr 13, 2016
	CORDRAN SP				
	+ AQUA PHARMS	0.025%	N012806	003	
	LOTION;TOPICAL				
	CORDRAN				
AT	**+** AQUA PHARMS	**0.05%**	**N013790**	**001**	
	FLURANDRENOLIDE				
AT	PERRIGO UK FINCO	**0.05%**	**A207133**	**001**	Aug 30, 2016
AT	TELIGENT PHARMA INC	**0.05%**	**A205343**	**001**	Dec 22, 2016
	OINTMENT;TOPICAL				
	CORDRAN				
AT	**+** AQUA PHARMS	**0.05%**	**N012806**	**001**	
	FLURANDRENOLIDE				
AT	TELIGENT PHARMA INC	**0.05%**	**A207851**	**001**	Dec 30, 2016
	TAPE;TOPICAL				
	CORDRAN				
	+ ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001	

FLURAZEPAM HYDROCHLORIDE

	CAPSULE;ORAL				
	FLURAZEPAM HYDROCHLORIDE				
	MYLAN PHARMS INC	15MG	A070345	002	Nov 27, 1985
	+	30MG	A070345	001	Nov 27, 1985

FLURBIPROFEN

	TABLET;ORAL				
	FLURBIPROFEN				
AB	MYLAN	**50MG**	**A074358**	**001**	Jun 20, 1994
AB	**+**	**100MG**	**A074358**	**002**	Jun 20, 1994
AB	SUN PHARM INDS INC	**50MG**	**A075058**	**001**	Apr 27, 2001
AB		**100MG**	**A075058**	**002**	Apr 27, 2001
AB	TEVA	**100MG**	**A074431**	**001**	May 31, 1995

FLURBIPROFEN SODIUM

	SOLUTION/DROPS;OPHTHALMIC				
	FLURBIPROFEN SODIUM				
AT	BAUSCH AND LOMB	**0.03%**	**A074447**	**001**	Jan 04, 1995
	OCUFEN				
AT	**+** ALLERGAN	**0.03%**	**N019404**	**001**	Dec 31, 1986

FDA data supplied by DrugPatentWatch.com

FLUTAMIDE
CAPSULE;ORAL
FLUTAMIDE

AB		ACTAVIS LABS FL INC	**125MG**	**A075820**	**001**	Sep 18, 2001
AB	+	CIPLA LTD	**125MG**	**A075780**	**001**	Sep 19, 2001
AB		MYLAN	**125MG**	**A076224**	**001**	May 09, 2003
AB		PAR PHARM	**125MG**	**A075298**	**001**	Sep 18, 2001

FLUTEMETAMOL F-18
INJECTABLE;INTRAVENOUS
VIZAMYL

+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013
+		121.5mCi/30ML (4.05mCi/ML)	N203137	002	Oct 25, 2013

FLUTICASONE FUROATE
POWDER;INHALATION
ARNUITY ELLIPTA

+	GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014
+		0.2MG/INH	N205625	002	Aug 20, 2014

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE
POWDER;INHALATION
BREO ELLIPTA

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013
+		0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015

FLUTICASONE PROPIONATE
AEROSOL, METERED;INHALATION
FLOVENT HFA

+	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
+		0.11MG/INH	N021433	002	May 14, 2004
+		0.22MG/INH	N021433	001	May 14, 2004

CREAM;TOPICAL
FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	**0.05%**	**A076451**	**001**	May 14, 2004
AB		G AND W LABS	**0.05%**	**A077055**	**001**	Jun 30, 2006
AB	+	PERRIGO NEW YORK	**0.05%**	**A076793**	**001**	May 14, 2004
AB		TOLMAR	**0.05%**	**A076633**	**001**	May 14, 2004

LOTION;TOPICAL
CUTIVATE

AB	+	FOUGERA PHARMS	**0.05%**	**N021152**	**001**	Mar 31, 2005

FLUTICASONE PROPIONATE

AB		GLENMARK GENERICS	**0.05%**	**A090759**	**001**	May 02, 2011
AB		PERRIGO ISRAEL	**0.05%**	**A091553**	**001**	Jul 30, 2013

OINTMENT;TOPICAL
CUTIVATE

AB	+	FOUGERA PHARMS	**0.005%**	**N019957**	**001**	Dec 14, 1990

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	**0.005%**	**A076300**	**001**	May 14, 2004
AB		G AND W LABS	**0.005%**	**A077168**	**001**	Mar 03, 2006
AB		PERRIGO NEW YORK	**0.005%**	**A076668**	**001**	May 14, 2004

POWDER;INHALATION
FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000

FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000

FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000

SPRAY, METERED;NASAL
FLUTICASONE PROPIONATE

AB		APOTEX INC	**0.05MG/SPRAY**	**A077538**	**001**	Sep 12, 2007
AB		HI TECH PHARMA	**0.05MG/SPRAY**	**A077570**	**001**	Jan 16, 2008
AB		WEST-WARD PHARMS INT	**0.05MG/SPRAY**	**A076504**	**001**	Feb 22, 2006
AB		WOCKHARDT	**0.05MG/SPRAY**	**A078492**	**001**	Jan 09, 2012

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE
AEROSOL, METERED;INHALATION
ADVAIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER;INHALATION
ADVAIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

ADVAIR DISKUS 250/50

	+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077 002	Aug 24, 2000

ADVAIR DISKUS 500/50

	+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077 003	Aug 24, 2000

FLUVASTATIN SODIUM

CAPSULE;ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090595 001**	Apr 11, 2012
AB			**EQ 40MG BASE**	**A090595 002**	Apr 11, 2012
AB		TEVA PHARMS	**EQ 20MG BASE**	**A078407 001**	Jun 12, 2012
AB			**EQ 40MG BASE**	**A078407 002**	Jun 12, 2012

LESCOL

AB		NOVARTIS	**EQ 20MG BASE**	**N020261 001**	Dec 31, 1993
AB	+		**EQ 40MG BASE**	**N020261 002**	Dec 31, 1993

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	**EQ 80MG BASE**	**A202458 001**	Sep 11, 2015
AB		TEVA PHARMS USA	**EQ 80MG BASE**	**A079011 001**	Jan 27, 2016

LESCOL XL

AB	+	NOVARTIS	**EQ 80MG BASE**	**N021192 001**	Oct 06, 2000

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB		ACTAVIS ELIZABETH	**100MG**	**A091482 001**	Apr 23, 2013
AB			**150MG**	**A091482 002**	Nov 18, 2013
AB		ANCHEN PHARMS	**100MG**	**A091476 001**	Mar 13, 2013
AB			**150MG**	**A091476 002**	Mar 13, 2013
AB		TORRENT PHARMS LTD	**100MG**	**A203240 001**	Oct 31, 2014
AB			**150MG**	**A203240 002**	Oct 31, 2014

LUVOX CR

AB		JAZZ PHARMS	**100MG**	**N022033 001**	Feb 28, 2008
AB	+		**150MG**	**N022033 002**	Feb 28, 2008

TABLET;ORAL

FLUVOXAMINE MALEATE

AB		ANI PHARMS INC	**25MG**	**A075897 001**	Jan 25, 2001
AB			**50MG**	**A075897 002**	Jan 25, 2001
AB			**100MG**	**A075897 003**	Jan 25, 2001
AB		APOTEX	**25MG**	**A075902 001**	May 07, 2001
AB			**50MG**	**A075902 002**	May 07, 2001
AB			**100MG**	**A075902 003**	May 07, 2001
AB		MYLAN	**25MG**	**A075889 001**	Nov 29, 2000
AB			**50MG**	**A075889 002**	Nov 29, 2000
AB			**100MG**	**A075889 003**	Nov 29, 2000
AB		TEVA	**25MG**	**A075893 001**	Sep 10, 2002
AB			**50MG**	**A075893 002**	Sep 10, 2002
AB			**100MG**	**A075893 003**	Sep 10, 2002
AB		UPSHER-SMITH LABS	**25MG**	**A075888 001**	Nov 29, 2000
AB			**50MG**	**A075888 002**	Nov 29, 2000
AB	+		**100MG**	**A075888 003**	Nov 29, 2000

LUVOX

AB		ANI PHARMS	**25MG**	**N021519 001**	Dec 20, 2007
AB			**50MG**	**N021519 002**	Dec 20, 2007
AB			**100MG**	**N021519 003**	Dec 20, 2007

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

	+	FRESENIUS KABI USA	5MG/ML	A089202 001	Feb 18, 1986

TABLET;ORAL

FOLIC ACID

AA		AIPING PHARM INC	**1MG**	**A091145 001**	Jul 12, 2013
AA	+	AMNEAL PHARM	**1MG**	**A040625 001**	Jul 21, 2005
AA		CADILA PHARMS LTD	**1MG**	**A202437 001**	Jan 27, 2014
AA		CONTRACT PHARMACAL	**1MG**	**A085061 001**	
AA		HIKMA PHARMS LLC	**1MG**	**A080600 001**	
AA		INVAGEN PHARMS	**1MG**	**A090035 001**	Jun 09, 2009
AA		LEADING PHARMA LLC	**1MG**	**A040796 001**	Jan 12, 2009
AA		NUVO PHARM INC	**1MG**	**A204418 001**	Jul 28, 2015
AA		VINTAGE	**1MG**	**A040756 001**	Jun 04, 2010
AA	+	WATSON LABS	**1MG**	**A080680 001**	

FDA data supplied by DrugPatentWatch.com

FOLLITROPIN ALFA/BETA
INJECTABLE;SUBCUTANEOUS

	FOLLISTIM AQ				
+	ORGANON USA INC	300 IU/0.36ML	N021211	001	Mar 23, 2004
+		600 IU/0.72ML	N021211	002	Mar 23, 2004
+		900 IU/1.08ML	N021211	004	Feb 11, 2005
	GONAL-F				
+	EMD SERONO	450 IU/VIAL	N020378	005	Mar 26, 2004
		1,050 IU/VIAL	N020378	004	Feb 28, 2001
	GONAL-F RFF				
+	EMD SERONO	75 IU/VIAL	N021765	002	Mar 25, 2004
	GONAL-F RFF REDI-JECT				
+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004
+		450 IU/0.75ML	N021684	002	May 25, 2004
+		900 IU/1.5ML	N021684	003	May 25, 2004

FOMEPIZOLE
INJECTABLE;INJECTION

		ANTIZOL				
AP	**+**	PAR PHARM INC	**1.5GM/1.5ML (1GM/ML)**	**N020696**	**001**	Dec 04, 1997
		FOMEPIZOLE				
AP		LUITPOLD	**1.5GM/1.5ML (1GM/ML)**	**A078368**	**001**	Dec 14, 2007
AP		MYLAN INSTITUTIONAL	**1.5GM/1.5ML (1GM/ML)**	**A078639**	**001**	Mar 03, 2008
AP		NAVINTA LLC	**1.5GM/1.5ML (1GM/ML)**	**A078537**	**001**	Mar 06, 2008

FONDAPARINUX SODIUM
INJECTABLE;SUBCUTANEOUS

		ARIXTRA				
AP	**+**	MYLAN IRELAND LTD	**2.5MG/0.5ML**	**N021345**	**001**	Dec 07, 2001
AP	**+**		**5MG/0.4ML**	**N021345**	**002**	May 28, 2004
AP	**+**		**7.5MG/0.6ML**	**N021345**	**003**	May 28, 2004
AP	**+**		**10MG/0.8ML**	**N021345**	**004**	May 28, 2004
		FONDAPARINUX SODIUM				
AP		DR REDDYS LABS LTD	**2.5MG/0.5ML**	**A091316**	**001**	Jul 11, 2011
AP			**5MG/0.4ML**	**A091316**	**002**	Jul 11, 2011
AP			**7.5MG/0.6ML**	**A091316**	**003**	Jul 11, 2011
AP			**10MG/0.8ML**	**A091316**	**004**	Jul 11, 2011

FORMOTEROL FUMARATE
POWDER;INHALATION

	FORADIL				
+	NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001

SOLUTION;INHALATION

	PERFOROMIST				
+	MYLAN SPECLT	0.02MG/2ML	N022007	001	May 11, 2007

FORMOTEROL FUMARATE; GLYCOPYRROLATE
AEROSOL, METERED;INHALATION

	BEVESPI AEROSPHERE				
+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016

FORMOTEROL FUMARATE; MOMETASONE FUROATE
AEROSOL, METERED;INHALATION

	DULERA				
+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010
+		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM
SUSPENSION;ORAL

	LEXIVA				
+	VIIV HLTHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007

TABLET;ORAL

		FOSAMPRENAVIR CALCIUM				
AB		MYLAN PHARMS INC	**EQ 700MG BASE**	**A204060**	**001**	Apr 15, 2016
		LEXIVA				
AB	**+**	VIIV HLTHCARE	**EQ 700MG BASE**	**N021548**	**001**	Oct 20, 2003

FOSAPREPITANT DIMEGLUMINE
POWDER;INTRAVENOUS

		EMEND				
AP	**+**	MERCK AND CO INC	**EQ 150MG BASE/VIAL**	**N022023**	**002**	Nov 12, 2010
		FOSAPREPITANT DIMEGLUMINE				
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A206197**	**001**	Jun 09, 2016

FOSCARNET SODIUM
INJECTABLE;INJECTION

		FOSCARNET SODIUM				
AP		HOSPIRA	**2.4GM/100ML**	**A077174**	**001**	May 31, 2005
		FOSCAVIR				
AP	+	CLINIGEN HLTHCARE	**2.4GM/100ML**	**N020068**	**001**	Sep 27, 1991

FOSFOMYCIN TROMETHAMINE
FOR SUSPENSION;ORAL

		MONUROL				
	+	ZAMBON SPA	EQ 3GM BASE/PACKET	N050717	001	Dec 19, 1996

FOSINOPRIL SODIUM
TABLET;ORAL

		FOSINOPRIL SODIUM				
AB		APOTEX INC	**10MG**	**A076906**	**001**	May 17, 2005
AB			**20MG**	**A076906**	**002**	May 17, 2005
AB			**40MG**	**A076906**	**003**	May 17, 2005
AB		AUROBINDO PHARMA LTD	**10MG**	**A091163**	**001**	Mar 30, 2011
AB			**20MG**	**A091163**	**002**	Mar 30, 2011
AB			**40MG**	**A091163**	**003**	Mar 30, 2011
AB		INVAGEN PHARMS	**10MG**	**A077222**	**001**	Apr 20, 2005
AB			**20MG**	**A077222**	**002**	Apr 20, 2005
AB			**40MG**	**A077222**	**003**	Apr 20, 2005
AB		PRINSTON INC	**10MG**	**A205670**	**001**	Aug 29, 2016
AB			**20MG**	**A205670**	**002**	Aug 29, 2016
AB			**40MG**	**A205670**	**003**	Aug 29, 2016
AB		TEVA	**10MG**	**A076139**	**001**	Nov 25, 2003
AB			**20MG**	**A076139**	**002**	Nov 25, 2003
AB	+		**40MG**	**A076139**	**003**	Nov 25, 2003
AB		UPSHER-SMITH LABS	**10MG**	**A076483**	**001**	Apr 23, 2004
AB			**20MG**	**A076483**	**002**	Apr 23, 2004
AB			**40MG**	**A076483**	**003**	Apr 23, 2004

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
TABLET;ORAL

		FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE				
AB		AUROBINDO PHARMA	**10MG;12.5MG**	**A079245**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A079245**	**002**	Jul 09, 2009
AB		EMCURE PHARMS INDIA	**10MG;12.5MG**	**A079025**	**001**	Sep 17, 2010
AB	+		**20MG;12.5MG**	**A079025**	**002**	Sep 17, 2010
AB		INVAGEN PHARMS	**10MG;12.5MG**	**A090228**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A090228**	**002**	Jul 09, 2009
AB		SANDOZ	**10MG;12.5MG**	**A076961**	**001**	Sep 28, 2005
AB			**20MG;12.5MG**	**A076961**	**002**	Sep 28, 2005

FOSPHENYTOIN SODIUM
INJECTABLE;INJECTION

		CEREBYX				
AP	+	PARKE DAVIS	**EQ 50MG PHENYTOIN NA/ML**	**N020450**	**001**	Aug 05, 1996
		FOSPHENYTOIN SODIUM				
AP		AMNEAL PHARMS CO	**EQ 50MG PHENYTOIN NA/ML**	**A078476**	**001**	Mar 18, 2008
AP		EUROHLTH INTL SARL	**EQ 50MG PHENYTOIN NA/ML**	**A077481**	**001**	Aug 06, 2007
AP			**EQ 50MG PHENYTOIN NA/ML**	**A077989**	**001**	Aug 06, 2007
AP		HIKMA FARMACEUTICA	**EQ 50MG PHENYTOIN NA/ML**	**A078765**	**001**	Dec 02, 2009
AP		HOSPIRA	**EQ 50MG PHENYTOIN NA/ML**	**A078158**	**001**	Aug 06, 2007
AP		LUITPOLD	**EQ 50MG PHENYTOIN NA/ML**	**A078277**	**001**	Aug 06, 2007
AP			**EQ 50MG PHENYTOIN NA/ML**	**A090099**	**001**	May 13, 2010
AP		MYLAN LABS LTD	**EQ 50MG PHENYTOIN NA/ML**	**A078736**	**001**	Jun 08, 2010
AP		SUN PHARMA GLOBAL	**EQ 50MG PHENYTOIN NA/ML**	**A078417**	**001**	Mar 18, 2008
AP		WOCKHARDT	**EQ 50MG PHENYTOIN NA/ML**	**A078137**	**001**	Aug 06, 2007

FROVATRIPTAN SUCCINATE
TABLET;ORAL

		FROVA				
AB	+	ENDO PHARMS	**EQ 2.5MG BASE**	**N021006**	**001**	Nov 08, 2001
		FROVATRIPTAN SUCCINATE				
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**	**A204730**	**001**	Mar 11, 2016
AB		MYLAN PHARMS INC	**EQ 2.5MG BASE**	**A202931**	**001**	Aug 28, 2014

FULVESTRANT
INJECTABLE;INTRAMUSCULAR
FASLODEX

+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002

FUROSEMIDE
INJECTABLE;INJECTION
FUROSEMIDE

AP		AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016
AP		CLARIS	10MG/ML	A202747	001	Jan 27, 2014
AP		EMCURE PHARMS LTD	10MG/ML	A203428	001	Aug 26, 2014
AP		FRESENIUS KABI USA	10MG/ML	N018902	001	May 22, 1984
AP		HOSPIRA	10MG/ML	A075241	001	May 28, 1999
AP			10MG/ML	N018667	001	May 28, 1982
AP		WOCKHARDT	10MG/ML	A077941	001	Mar 22, 2007

SOLUTION;ORAL
FUROSEMIDE

AA	+	WEST-WARD PHARMS INT	10MG/ML	A070434	001	Apr 22, 1987
AA		WOCKHARDT	10MG/ML	A070655	001	Oct 02, 1987
		WEST-WARD PHARMS INT	40MG/5ML	A070433	001	Apr 22, 1987

TABLET;ORAL
FUROSEMIDE

AB		IPCA LABS LTD	20MG	A078010	001	Sep 18, 2006
AB			40MG	A078010	002	Sep 18, 2006
AB			80MG	A078010	003	Sep 18, 2006
AB		IVAX SUB TEVA PHARMS	20MG	N018413	001	Nov 30, 1983
AB			40MG	N018413	002	Nov 30, 1983
AB		LEADING PHARMA LLC	20MG	A077293	001	Nov 09, 2005
AB			40MG	A077293	002	Nov 09, 2005
AB			80MG	A077293	003	Nov 09, 2005
AB		MYLAN	20MG	N018487	001	
AB			40MG	N018487	002	
AB			80MG	A070082	001	Oct 29, 1986
AB		ROXANE	20MG	N018823	001	Nov 10, 1983
AB			40MG	N018823	002	Nov 10, 1983
AB		SANDOZ	20MG	N018569	002	
AB			40MG	N018569	001	
AB			80MG	N018569	005	Aug 14, 1984
AB		SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014
AB			40MG	A091258	002	Apr 01, 2014
AB			80MG	A091258	003	Apr 01, 2014
AB		VINTAGE PHARMS	20MG	A076796	001	Mar 26, 2004
AB			40MG	A076796	002	Mar 26, 2004
AB			80MG	A076796	003	Mar 26, 2004
AB		WEST-WARD PHARMS INT	80MG	A070086	001	Jan 24, 1986

LASIX

AB		US PHARM HOLDINGS	20MG	N016273	002
AB			40MG	N016273	001
AB	+		80MG	N016273	003

GABAPENTIN
CAPSULE;ORAL
GABAPENTIN

AB		ACTAVIS ELIZABETH	100MG	A075350	001	Sep 12, 2003
AB			300MG	A075350	002	Sep 12, 2003
AB			400MG	A075350	003	Sep 12, 2003
AB		ALKEM	100MG	A090858	001	Dec 17, 2010
AB			300MG	A090858	002	Dec 17, 2010
AB			400MG	A090858	003	Dec 17, 2010
AB		AMNEAL PHARMS NY	100MG	A078428	001	Jul 25, 2007
AB			300MG	A078428	002	Jul 25, 2007
AB			400MG	A078428	003	Jul 25, 2007
AB		APOTEX INC	100MG	A075360	001	Apr 06, 2005
AB			300MG	A075360	002	Apr 06, 2005
AB			400MG	A075360	003	Apr 06, 2005
AB		AUROBINDO PHARM	100MG	A078787	001	Jan 31, 2008
AB			300MG	A078787	002	Jan 31, 2008
AB			400MG	A078787	003	Jan 31, 2008
AB		INVAGEN PHARMS	100MG	A090705	001	Dec 30, 2009
AB			300MG	A090705	002	Dec 30, 2009
AB			400MG	A090705	003	Dec 30, 2009
AB		MARKSANS PHARMA	100MG	A090007	001	Jul 21, 2011
AB			300MG	A090007	002	Jul 21, 2011

FDA data supplied by DrugPatentWatch.com

GABAPENTIN

CAPSULE;ORAL

	GABAPENTIN				
AB		**400MG**	**A090007**	**003**	Jul 21, 2011
AB	MYLAN	**100MG**	**A090158**	**001**	Feb 14, 2011
AB		**300MG**	**A090158**	**002**	Feb 14, 2011
AB		**400MG**	**A090158**	**003**	Feb 14, 2011
AB	SCIEGEN PHARMS INC	**100MG**	**A204989**	**001**	Feb 18, 2016
AB		**300MG**	**A204989**	**002**	Feb 18, 2016
AB		**400MG**	**A204989**	**003**	Feb 18, 2016
AB	SUN PHARM INDS LTD	**100MG**	**A077242**	**001**	Aug 24, 2006
AB		**300MG**	**A077242**	**002**	Aug 24, 2006
AB		**400MG**	**A077242**	**003**	Aug 24, 2006
AB	TARO	**100MG**	**A077261**	**001**	Aug 02, 2013
AB		**300MG**	**A077261**	**002**	Aug 02, 2013
AB		**400MG**	**A077261**	**003**	Aug 02, 2013
AB	TEVA PHARMS	**100MG**	**A075435**	**001**	Oct 08, 2004
AB		**300MG**	**A075435**	**002**	Oct 08, 2004
AB		**400MG**	**A075435**	**003**	Oct 08, 2004
	NEURONTIN				
AB	PFIZER PHARMS	**100MG**	**N020235**	**001**	Dec 30, 1993
AB		**300MG**	**N020235**	**002**	Dec 30, 1993
AB	**+**	**400MG**	**N020235**	**003**	Dec 30, 1993

SOLUTION;ORAL

	GABAPENTIN				
AA	ACELLA PHARMS LLC	**250MG/5ML**	**A076403**	**001**	May 01, 2012
AA	AMNEAL PHARMS	**250MG/5ML**	**A202024**	**001**	Mar 23, 2012
AA	HI TECH PHARMA	**250MG/5ML**	**A078974**	**001**	Feb 18, 2011
AA	TARO	**250MG/5ML**	**A076672**	**001**	Jul 03, 2013
AA	TRIS PHARMA INC	**250MG/5ML**	**A091286**	**001**	Mar 14, 2016
	NEURONTIN				
AA	**+** PARKE DAVIS	**250MG/5ML**	**N021129**	**001**	Mar 02, 2000

TABLET;ORAL

	GABAPENTIN				
AB	ACI HEALTHCARE LTD	**600MG**	**A203244**	**002**	Jul 12, 2013
AB		**800MG**	**A203244**	**001**	Jul 12, 2013
AB	ACTAVIS ELIZABETH	**600MG**	**A075694**	**001**	Oct 21, 2004
AB		**800MG**	**A075694**	**002**	Oct 21, 2004
AB	ALKEM LABS LTD	**600MG**	**A206402**	**001**	Dec 23, 2015
AB		**800MG**	**A206402**	**002**	Dec 23, 2015
AB	APOTEX INC	**100MG**	**A077894**	**001**	Oct 10, 2006
AB		**300MG**	**A077894**	**002**	Oct 10, 2006
AB		**400MG**	**A077894**	**003**	Oct 10, 2006
AB		**600MG**	**A077661**	**004**	Sep 13, 2006
AB		**800MG**	**A077661**	**005**	Sep 13, 2006
AB	AUROBINDO PHARMA LTD	**600MG**	**A200651**	**001**	Oct 06, 2011
AB		**800MG**	**A200651**	**002**	Oct 06, 2011
AB	GLENMARK GENERICS	**600MG**	**A077662**	**001**	Aug 18, 2006
AB		**800MG**	**A077662**	**002**	Aug 18, 2006
AB	INVAGEN PHARMS	**600MG**	**A202764**	**001**	Oct 16, 2012
AB		**800MG**	**A202764**	**002**	Oct 16, 2012
AB	IVAX SUB TEVA PHARMS	**100MG**	**A076017**	**001**	Apr 28, 2004
AB		**300MG**	**A076017**	**002**	Apr 28, 2004
AB		**400MG**	**A076017**	**003**	Apr 28, 2004
AB		**600MG**	**A076017**	**004**	Apr 29, 2005
AB		**800MG**	**A076017**	**005**	Apr 29, 2005
AB	MYLAN PHARMS INC	**600MG**	**A090335**	**001**	Jun 01, 2010
AB		**800MG**	**A090335**	**002**	Jun 01, 2010
AB	SCIEGEN PHARMS INC	**600MG**	**A205101**	**001**	Feb 04, 2016
AB		**800MG**	**A205101**	**002**	Feb 04, 2016
AB	SUN PHARM INDS LTD	**600MG**	**A077525**	**001**	Aug 24, 2006
AB		**800MG**	**A077525**	**002**	Aug 24, 2006
AB	ZYDUS PHARMS USA INC	**600MG**	**A078926**	**001**	Feb 11, 2011
AB		**800MG**	**A078926**	**002**	Feb 11, 2011
	NEURONTIN				
AB	PFIZER PHARMS	**600MG**	**N020882**	**001**	Oct 09, 1998
AB	**+**	**800MG**	**N020882**	**002**	Oct 09, 1998
	GRALISE				
BX	+ DEPOMED INC	300MG	N022544	001	Jan 28, 2011
BX	+	600MG	N022544	002	Jan 28, 2011

FDA data supplied by DrugPatentWatch.com

GABAPENTIN ENACARBIL
TABLET, EXTENDED RELEASE;ORAL
HORIZANT

	ARBOR PHARMS LLC	300MG	N022399	002 Dec 13, 2011
+		600MG	N022399	001 Apr 06, 2011

GADOBENATE DIMEGLUMINE
INJECTABLE;INTRAVENOUS
MULTIHANCE

+	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001 Nov 23, 2004
+		5.29GM/10ML (529MG/ML)	N021357	002 Nov 23, 2004
+		7.935GM/15ML (529MG/ML)	N021357	003 Nov 23, 2004
+		10.58GM/20ML (529MG/ML)	N021357	004 Nov 23, 2004

MULTIHANCE MULTIPACK

+	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001 Nov 23, 2004
+		52.9GM/100ML (529MG/ML)	N021358	002 Nov 23, 2004

GADOBUTROL
SOLUTION;INTRAVENOUS
GADAVIST

+	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006 Dec 18, 2013
+		4.5354GM/7.5ML (604.72MG/ML)	N201277	001 Mar 14, 2011
+		6.0472GM/10ML (604.72MG/ML)	N201277	002 Mar 14, 2011
+		9.0708GM/15ML (604.72MG/ML)	N201277	003 Mar 14, 2011
+		18.1416GM/30ML (604.72MG/ML)	N201277	004 Mar 14, 2011
+		39.3068GM/65ML (604.72MG/ML)	N201277	005 Mar 14, 2011

GADODIAMIDE
INJECTABLE;INJECTION
OMNISCAN

+	GE HEALTHCARE	287MG/ML	N020123	001 Jan 08, 1993
+		28.7GM/100ML (287MG/ML)	N022066	002 Sep 05, 2007

GADOPENTETATE DIMEGLUMINE
INJECTABLE;INJECTION
MAGNEVIST

+	BAYER HLTHCARE	469.01MG/ML	N019596	001 Jun 02, 1988
+		469.01MG/ML	N021037	001 Mar 10, 2000

GADOTERATE MEGLUMINE
SOLUTION;INTRAVENOUS
DOTAREM

+	GUERBET	37.69GM/100ML (376.9MG/ML)	N204781	001 Mar 20, 2013
+		3.769GM/10ML (376.9MG/ML)	N204781	002 Mar 20, 2013
+		5.6535GM/15ML (376.9MG/ML)	N204781	003 Mar 20, 2013
+		7.538GM/20ML (376.9MG/ML)	N204781	004 Mar 20, 2013

GADOTERIDOL
INJECTABLE;INJECTION
PROHANCE

+	BRACCO	279.3MG/ML	N020131	001 Nov 16, 1992

PROHANCE MULTIPACK

+	BRACCO	279.3MG/ML	N021489	001 Oct 09, 2003

GADOVERSETAMIDE
INJECTABLE;INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001 Dec 08, 1999
+		3309MG/10ML (330.9MG/ML)	N020937	002 Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020937	003 Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020937	004 Dec 08, 1999
+		16.545GM/50ML (330.9MG/ML)	N020975	001 Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002 Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020976	003 Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020976	004 Dec 08, 1999
+		9927MG/30ML (330.9MG/ML)	N020976	001 Dec 08, 1999

GADOXETATE DISODIUM
SOLUTION;INTRAVENOUS
EOVIST

+	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001 Jul 03, 2008
		2.72145GM/15ML (181.43MG/ML)	N022090	002 Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	**EQ 8MG BASE**	**A204895**	**001**	Aug 05, 2016
AB		**EQ 16MG BASE**	**A204895**	**002**	Aug 05, 2016
AB		**EQ 24MG BASE**	**A204895**	**003**	Aug 05, 2016
AB	BARR	**EQ 8MG BASE**	**A078189**	**001**	Sep 15, 2008
AB		**EQ 16MG BASE**	**A078189**	**002**	Sep 15, 2008
AB		**EQ 24MG BASE**	**A078189**	**003**	Sep 15, 2008
AB	MYLAN	**EQ 8MG BASE**	**A090900**	**001**	Jan 24, 2011
AB		**EQ 16MG BASE**	**A090900**	**002**	Jan 24, 2011
AB		**EQ 24MG BASE**	**A090900**	**003**	Jan 24, 2011
AB	SUN PHARMA GLOBAL	**EQ 8MG BASE**	**A090178**	**001**	Feb 02, 2011
AB		**EQ 16MG BASE**	**A090178**	**002**	Feb 02, 2011
AB		**EQ 24MG BASE**	**A090178**	**003**	Feb 02, 2011
AB	WATSON LABS	**EQ 8MG BASE**	**A079028**	**001**	Dec 15, 2008
AB		**EQ 16MG BASE**	**A079028**	**002**	Dec 15, 2008
AB		**EQ 24MG BASE**	**A079028**	**003**	Dec 15, 2008

RAZADYNE ER

AB	**+** JANSSEN PHARMS	**EQ 8MG BASE**	**N021615**	**001**	Apr 01, 2005
AB		**EQ 16MG BASE**	**N021615**	**002**	Apr 01, 2005
AB		**EQ 24MG BASE**	**N021615**	**003**	Apr 01, 2005

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

	+ WEST-WARD PHARMS INT	4MG/ML	A078185	001	Jan 30, 2009

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB	APOTEX INC	**EQ 4MG BASE**	**A077781**	**001**	Sep 27, 2011
AB		**EQ 8MG BASE**	**A077781**	**002**	Sep 27, 2011
AB		**EQ 12MG BASE**	**A077781**	**003**	Sep 27, 2011
AB	AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A090957**	**001**	Mar 29, 2011
AB		**EQ 8MG BASE**	**A090957**	**002**	Mar 29, 2011
AB		**EQ 12MG BASE**	**A090957**	**003**	Mar 29, 2011
AB	BARR	**EQ 4MG BASE**	**A077605**	**001**	Aug 28, 2008
AB		**EQ 8MG BASE**	**A077605**	**002**	Aug 28, 2008
AB		**EQ 12MG BASE**	**A077605**	**003**	Aug 28, 2008
AB	DR REDDYS LABS LTD	**EQ 4MG BASE**	**A077593**	**001**	Sep 11, 2008
AB		**EQ 8MG BASE**	**A077593**	**002**	Sep 11, 2008
AB		**EQ 12MG BASE**	**A077593**	**003**	Sep 11, 2008
AB	MYLAN	**EQ 4MG BASE**	**A077590**	**001**	May 29, 2009
AB		**EQ 4MG BASE**	**A077603**	**001**	Aug 28, 2008
AB		**EQ 8MG BASE**	**A077590**	**002**	May 29, 2009
AB		**EQ 8MG BASE**	**A077603**	**002**	Aug 28, 2008
AB		**EQ 12MG BASE**	**A077590**	**003**	May 29, 2009
AB		**EQ 12MG BASE**	**A077603**	**003**	Aug 28, 2008
AB	SANDOZ	**EQ 4MG BASE**	**A077589**	**001**	Jun 22, 2009
AB		**EQ 8MG BASE**	**A077589**	**002**	Jun 22, 2009
AB		**EQ 12MG BASE**	**A077589**	**003**	Jun 22, 2009
AB	TEVA PHARMS	**EQ 4MG BASE**	**A077587**	**001**	Jul 09, 2009
AB		**EQ 8MG BASE**	**A077587**	**002**	Jul 09, 2009
AB		**EQ 12MG BASE**	**A077587**	**003**	Jul 09, 2009
AB	WEST-WARD PHARMS INT	**EQ 4MG BASE**	**A077608**	**001**	Feb 11, 2009
AB		**EQ 8MG BASE**	**A077608**	**002**	Feb 11, 2009
AB		**EQ 12MG BASE**	**A077608**	**003**	Feb 11, 2009
AB	ZYDUS PHARMS USA INC	**EQ 4MG BASE**	**A078898**	**001**	Feb 17, 2011
AB		**EQ 8MG BASE**	**A078898**	**002**	Feb 17, 2011
AB		**EQ 12MG BASE**	**A078898**	**003**	Feb 17, 2011

RAZADYNE

AB	**+** JANSSEN PHARMS	**EQ 4MG BASE**	**N021169**	**001**	Feb 28, 2001
AB		**EQ 8MG BASE**	**N021169**	**002**	Feb 28, 2001
AB		**EQ 12MG BASE**	**N021169**	**003**	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS	LANTHEUS MEDCL	2mCi/ML	N017478	001
BS	MALLINKRODT NUCLEAR	2mCi/ML	N018058	001

FDA data supplied by DrugPatentWatch.com

GALLIUM DOTATATE GA-68
POWDER;INTRAVENOUS
NETSPOT

	+	AAA USA INC	2.1-5.5mCi/ML	N208547	001 Jun 01, 2016

GANCICLOVIR
GEL;OPHTHALMIC
ZIRGAN

	+	BAUSCH AND LOMB	0.15%	N022211	001 Sep 15, 2009

GANCICLOVIR SODIUM
INJECTABLE;INJECTION

		CYTOVENE			
AP	**+**	ROCHE PALO	**EQ 500MG BASE/VIAL**	**N019661**	**001** Jun 23, 1989
		GANCICLOVIR			
AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090658**	**001** Jun 21, 2010
AP		LUITPOLD PHARMS INC	**EQ 500MG BASE/VIAL**	**A202624**	**001** Sep 18, 2013
AP		PAR STERILE PRODUCTS	**EQ 500MG BASE/VIAL**	**A204950**	**001** Dec 06, 2016

GANIRELIX ACETATE
INJECTABLE;INJECTION
GANIRELIX ACETATE

	+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057	001 Jul 29, 1999

GATIFLOXACIN
SOLUTION/DROPS;OPHTHALMIC

		GATIFLOXACIN			
AT		ALCON RES LTD	**0.5%**	**A204227**	**001** Jul 11, 2016
AT		HI-TECH PHARMA CO	**0.5%**	**A203189**	**001** Sep 03, 2014
AT		LUPIN LTD	**0.5%**	**A202653**	**001** Aug 28, 2013
		ZYMAXID			
AT	**+**	ALLERGAN	**0.5%**	**N022548**	**001** May 18, 2010
		ZYMAR			
	+	ALLERGAN	0.3%	N021493	001 Mar 28, 2003

GEFITINIB
TABLET;ORAL
IRESSA

	+	ASTRAZENECA PHARMS	250MG	N206995	001 Jul 13, 2015

GEMCITABINE HYDROCHLORIDE
INJECTABLE;INJECTION

		GEMCITABINE HYDROCHLORIDE			
AP		ACCORD HLTHCARE	**EQ 200MG BASE/VIAL**	**A091594**	**001** Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091594**	**002** Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A091594**	**003** Jul 25, 2011
AP		ACTAVIS INC	**200MG/5.26ML (38MG/ML)**	**A204549**	**001** Apr 11, 2016
AP			**1GM/26.3ML (38MG/ML)**	**A204549**	**002** Apr 11, 2016
AP			**2GM/52.6ML (38MG/ML)**	**A204549**	**003** Apr 11, 2016
AP		ACTAVIS TOTOWA	**EQ 200MG BASE/VIAL**	**A079160**	**001** Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A079160**	**002** Jul 25, 2011
AP		CIPLA LTD	**EQ 200MG BASE/VIAL**	**A078759**	**001** Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078759**	**002** Jul 25, 2011
AP		DR REDDYS LABS LTD	**EQ 200MG BASE/VIAL**	**A091365**	**001** Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091365**	**002** Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A202997**	**001** May 07, 2013
AP		EMCURE PHARMS LTD	**EQ 200MG BASE/VIAL**	**A202063**	**001** Sep 11, 2012
AP			**EQ 1GM BASE/VIAL**	**A202063**	**002** Sep 11, 2012
AP		FRESENIUS KABI ONCOL	**EQ 200MG BASE/VIAL**	**A090799**	**001** Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A090799**	**002** Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A090799**	**003** May 16, 2011
AP		FRESENIUS KABI USA	**EQ 2GM BASE/VIAL**	**A090242**	**003** May 16, 2011
AP		GLAND PHARMA LTD	**EQ 200MG BASE/VIAL**	**A204520**	**001** Jan 05, 2016
AP			**EQ 1GM BASE/VIAL**	**A204520**	**002** Jan 05, 2016
AP		HAMELN RDS GMBH	**EQ 200MG BASE/VIAL**	**A090663**	**001** Sep 10, 2012
AP			**EQ 1GM BASE/VIAL**	**A090663**	**002** Sep 10, 2012
AP		HOSPIRA	**EQ 200MG BASE/VIAL**	**A078339**	**001** Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078339**	**002** Jul 25, 2011
AP	**+**	HOSPIRA INC	**200MG/5.26ML (38MG/ML)**	**N200795**	**001** Aug 04, 2011
AP	**+**		**1GM/26.3ML (38MG/ML)**	**N200795**	**002** Aug 04, 2011
AP	**+**		**EQ 2GM BASE/VIAL**	**A079183**	**001** Nov 15, 2010
AP	**+**		**2GM/52.6ML (38MG/ML)**	**N200795**	**003** Aug 04, 2011
AP		JIANGSU HANSOH PHARM	**EQ 200MG BASE/VIAL**	**A202485**	**001** May 07, 2013
AP			**EQ 1GM BASE/VIAL**	**A202485**	**002** May 07, 2013
AP		LUITPOLD PHARMS INC	**EQ 200MG BASE/VIAL**	**A202031**	**001** May 07, 2013

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP			EQ 1GM BASE/VIAL	A202031	002	May 07, 2013
AP		MYLAN LABS LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011
AP			EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011
AP			EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011
AP		SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013
AP			EQ 1GM BASE/VIAL	A091597	002	May 07, 2013
AP		SUN PHARMA GLOBAL	EQ 200MG BASE/VIAL	A078433	001	Jul 25, 2011
AP			EQ 1GM BASE/VIAL	A078433	002	Jul 25, 2011
AP		TEVA PHARMS	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011

GEMZAR

AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB		APOTEX	600MG	A075034	001	Jul 20, 1998
AB		AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015
AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007
AB		CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016
AB		CHARTWELL MOLECULES	600MG	A074270	001	Sep 27, 1993
AB		HIKMA PHARMS	600MG	A078599	001	Aug 16, 2010
AB		IMPAX PHARMS	600MG	A078207	001	Jun 01, 2007
AB		INVAGEN PHARMS	600MG	A077836	001	Jul 27, 2006
AB		NORTHSTAR HLTHCARE	600MG	A079072	001	Sep 13, 2010
AB		SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008
AB		TEVA	600MG	A074256	001	Oct 31, 1993

LOPID

AB	+	PFIZER PHARMS	600MG	N018422	003	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB	+	LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003

GEMIFLOXACIN MESYLATE

AB		ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT	+	FOUGERA	EQ 0.1% BASE	A062531	001	Jul 05, 1984
AT		G AND W LABS INC	EQ 0.1% BASE	A064056	001	Apr 29, 1994
AT		PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001	
AT		TARO	EQ 0.1% BASE	A062427	001	May 26, 1983

INJECTABLE;INJECTION

GENTAMICIN SULFATE

AP		FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986
AP	+		EQ 40MG BASE/ML	A062366	001	Aug 04, 1983
AP		HOSPIRA	EQ 10MG BASE/ML	A062420	001	Aug 15, 1983
AP			EQ 10MG BASE/ML	A062612	004	Feb 20, 1986
AP			EQ 40MG BASE/ML	A062420	002	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	EQ 1.2MG BASE/ML	A062373	007	Sep 07, 1982
AP			EQ 1.6MG BASE/ML	A062373	008	Sep 07, 1982
AP			EQ 80MG BASE/100ML	A062373	002	Sep 07, 1982
AP			EQ 100MG BASE/100ML	A062373	005	Sep 07, 1982
AP		HOSPIRA	EQ 1.2MG BASE/ML	A062414	001	Aug 15, 1983
AP			EQ 1.6MG BASE/ML	A062414	003	Aug 15, 1983
AP			EQ 80MG BASE/100ML	A062414	008	Aug 15, 1983
AP			EQ 100MG BASE/100ML	A062414	010	Aug 15, 1983
	+	BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373	009	Sep 07, 1982
	+		EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

AT	+	AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995
AT		PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065024	001	Jul 30, 2004

OINTMENT;TOPICAL

GENTAMICIN SULFATE

AT		FOUGERA	EQ 0.1% BASE	A062533	001	Oct 05, 1984
AT	+	PERRIGO NEW YORK	EQ 0.1% BASE	A062351	001	Feb 18, 1982

GENTAMICIN SULFATE
OINTMENT;TOPICAL

	GENTAMICIN SULFATE				
AT	TARO	**EQ 0.1% BASE**	**A062477**	**001**	Dec 23, 1983
SOLUTION/DROPS;OPHTHALMIC					
	GENOPTIC				
AT	ALLERGAN	**EQ 0.3% BASE**	**A062452**	**001**	Oct 10, 1984
	GENTAK				
AT	AKORN	**EQ 0.3% BASE**	**A064163**	**001**	Oct 12, 2001
	GENTAMICIN SULFATE				
AT	AKORN	**EQ 0.3% BASE**	**A062635**	**001**	Jan 08, 1987
AT	ALCON RES LTD	**EQ 0.3% BASE**	**A062196**	**001**	
AT	**+** BAUSCH AND LOMB	**EQ 0.3% BASE**	**A064048**	**001**	May 11, 1994
AT	PERRIGO CO TENNESSEE	**EQ 0.3% BASE**	**A065121**	**001**	Jan 30, 2004

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC					
	PRED-G				
	+ ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989
SUSPENSION/DROPS;OPHTHALMIC					
	PRED-G				
	+ ALLERGAN	EQ 0.3% BASE;1%	N050586	001	Jun 10, 1988

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS					
	COPAXONE				
AP	**+** TEVA PHARMS USA	**20MG/ML**	**N020622**	**002**	Feb 12, 2002
	GLATOPA				
AP	SANDOZ INC	**20MG/ML**	**A090218**	**001**	Apr 16, 2015
	COPAXONE				
	+ TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014

GLIMEPIRIDE

TABLET;ORAL					
	AMARYL				
AB	**+** SANOFI AVENTIS US	**1MG**	**N020496**	**001**	Nov 30, 1995
AB		**2MG**	**N020496**	**002**	Nov 30, 1995
AB		**4MG**	**N020496**	**003**	Nov 30, 1995
	GLIMEPIRIDE				
AB	ACCORD HLTHCARE	**1MG**	**A078181**	**001**	Aug 23, 2007
AB		**2MG**	**A078181**	**002**	Aug 23, 2007
AB		**4MG**	**A078181**	**003**	Aug 23, 2007
AB	AUROBINDO PHARMA LTD	**1MG**	**A202759**	**001**	Jun 29, 2012
AB		**2MG**	**A202759**	**002**	Jun 29, 2012
AB		**4MG**	**A202759**	**003**	Jun 29, 2012
AB	CARLSBAD	**1MG**	**A077911**	**001**	Sep 22, 2009
AB		**2MG**	**A077911**	**002**	Sep 22, 2009
AB		**4MG**	**A077911**	**003**	Sep 22, 2009
AB	DR REDDYS LABS LTD	**1MG**	**A077091**	**001**	Oct 06, 2005
AB		**2MG**	**A077091**	**002**	Oct 06, 2005
AB		**4MG**	**A077091**	**003**	Oct 06, 2005
AB	INDOCO REMEDIES	**1MG**	**A202112**	**001**	Apr 17, 2013
AB		**2MG**	**A202112**	**002**	Apr 17, 2013
AB		**4MG**	**A202112**	**003**	Apr 17, 2013
AB	INVAGEN PHARMS	**1MG**	**A077295**	**001**	Oct 06, 2005
AB		**2MG**	**A077295**	**002**	Oct 06, 2005
AB		**4MG**	**A077295**	**003**	Oct 06, 2005
AB	MICRO LABS LTD INDIA	**1MG**	**A091220**	**001**	Jun 29, 2012
AB		**2MG**	**A091220**	**002**	Jun 29, 2012
AB		**4MG**	**A091220**	**004**	Jun 29, 2012
AB		**8MG**	**A091220**	**006**	Jun 29, 2012
AB	MYLAN	**1MG**	**A077624**	**001**	Nov 28, 2005
AB		**2MG**	**A077624**	**002**	Nov 28, 2005
AB		**4MG**	**A077624**	**003**	Nov 28, 2005
AB	TEVA	**1MG**	**A076802**	**001**	Oct 06, 2005
AB		**2MG**	**A076802**	**002**	Oct 06, 2005
AB		**4MG**	**A076802**	**003**	Oct 06, 2005
AB	VINTAGE	**1MG**	**A077370**	**001**	Dec 23, 2005
AB		**2MG**	**A077370**	**002**	Dec 23, 2005
AB		**4MG**	**A077370**	**003**	Dec 23, 2005
AB		**8MG**	**A077370**	**004**	Dec 23, 2005
	MICRO LABS LTD INDIA	3MG	A091220	003	Jun 29, 2012
		6MG	A091220	005	Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

DUETACT

AB	+	TAKEDA PHARMS USA	**2MG;30MG**	**N021925**	**001**	Jul 28, 2006
AB			**4MG;30MG**	**N021925**	**002**	Jul 28, 2006

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

AB		SANDOZ	**2MG;30MG**	**A201049**	**001**	Jan 04, 2013
AB			**4MG;30MG**	**A201049**	**002**	Jan 04, 2013

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

	+	TEVA PHARMS USA	1MG;4MG	A078709	001	Apr 01, 2016
			2MG;4MG	A078709	002	Apr 01, 2016
			2MG;8MG	A078709	004	Apr 01, 2016
			4MG;4MG	A078709	003	Apr 01, 2016
			4MG;8MG	A078709	005	Apr 01, 2016

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB		ACCORD HLTHCARE	**5MG**	**A074550**	**001**	Sep 11, 1997
AB			**10MG**	**A074550**	**002**	Sep 11, 1997
AB		ANI PHARMS INC	**5MG**	**A074497**	**001**	Aug 31, 1995
AB			**10MG**	**A074497**	**002**	Aug 31, 1995
AB		APOTEX	**5MG**	**A075795**	**001**	Jun 13, 2001
AB			**10MG**	**A075795**	**002**	Jun 13, 2001
AB		MYLAN	**5MG**	**A074226**	**001**	May 10, 1994
AB			**5MG**	**A074438**	**001**	Jun 20, 1995
AB			**10MG**	**A074226**	**002**	May 10, 1994
AB			**10MG**	**A074438**	**002**	Jun 20, 1995
AB		SANDOZ	**5MG**	**A074305**	**001**	Apr 07, 1995
AB			**10MG**	**A074305**	**002**	Apr 07, 1995
AB		SUN PHARM INDS INC	**5MG**	**A077820**	**001**	Jul 11, 2006
AB			**10MG**	**A077820**	**002**	Jul 11, 2006
AB		WATSON LABS	**5MG**	**A074223**	**001**	Feb 27, 1995
AB			**10MG**	**A074223**	**002**	Feb 27, 1995

GLUCOTROL

AB		PFIZER	**5MG**	**N017783**	**001**	May 08, 1984
AB	+		**10MG**	**N017783**	**002**	May 08, 1984

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB		MYLAN PHARMS INC	**2.5MG**	**A202298**	**001**	May 19, 2015
AB			**5MG**	**A202298**	**002**	May 19, 2015
AB			**10MG**	**A202298**	**003**	May 19, 2015
AB		PAR PHARM	**5MG**	**A076159**	**002**	Sep 20, 2013
AB			**10MG**	**A076159**	**001**	Sep 20, 2013
AB		UNIQUE PHARM LABS	**2.5MG**	**A204720**	**001**	Dec 29, 2016
AB			**5MG**	**A204720**	**002**	Dec 29, 2016
AB			**10MG**	**A204720**	**003**	Dec 29, 2016
AB		WATSON LABS	**2.5MG**	**A076467**	**003**	Mar 27, 2006
AB			**5MG**	**A076467**	**001**	Sep 08, 2003
AB			**10MG**	**A076467**	**002**	Nov 07, 2003

GLUCOTROL XL

AB		PFIZER	**2.5MG**	**N020329**	**003**	Aug 10, 1999
AB			**5MG**	**N020329**	**001**	Apr 26, 1994
AB	+		**10MG**	**N020329**	**002**	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		COREPHARMA	**2.5MG;250MG**	**A077507**	**001**	Oct 27, 2005
AB			**2.5MG;500MG**	**A077507**	**002**	Oct 27, 2005
AB			**5MG;500MG**	**A077507**	**003**	Oct 27, 2005
AB		HERITAGE PHARMS INC	**2.5MG;250MG**	**A078728**	**001**	Jun 23, 2010
AB			**2.5MG;500MG**	**A078728**	**002**	Jun 23, 2010
AB			**5MG;500MG**	**A078728**	**003**	Jun 23, 2010
AB		MYLAN	**2.5MG;250MG**	**A078083**	**001**	Apr 12, 2007
AB			**2.5MG;500MG**	**A078083**	**002**	Apr 12, 2007
AB			**5MG;500MG**	**A078083**	**003**	Apr 12, 2007
AB		SUN PHARM INDS INC	**2.5MG;250MG**	**A077620**	**001**	Jan 11, 2008
AB			**2.5MG;500MG**	**A077620**	**002**	Jan 11, 2008
AB			**5MG;500MG**	**A077620**	**003**	Jan 11, 2008
AB		TEVA PHARMS	**2.5MG;250MG**	**A077270**	**001**	Oct 28, 2005

FDA data supplied by DrugPatentWatch.com

GLIPIZIDE; METFORMIN HYDROCHLORIDE
TABLET;ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		**2.5MG;500MG**	**A077270**	**002**	Oct 28, 2005
AB	+	**5MG;500MG**	**A077270**	**003**	Oct 28, 2005
AB	ZYDUS PHARMS USA INC	**2.5MG;250MG**	**A078905**	**001**	Jan 31, 2011
AB		**2.5MG;500MG**	**A078905**	**002**	Jan 31, 2011
AB		**5MG;500MG**	**A078905**	**003**	Jan 31, 2011

GLUCAGON HYDROCHLORIDE
POWDER;INTRAMUSCULAR, INTRAVENOUS
GLUCAGON

	+ FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015

GLUCAGON HYDROCHLORIDE RECOMBINANT
INJECTABLE;INJECTION
GLUCAGEN

	+ NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998

GLUCAGON RECOMBINANT
INJECTABLE;INJECTION
GLUCAGON

	+ LILLY	1MG/VIAL	N020928	001	Sep 11, 1998

GLUTAMINE
FOR SOLUTION;ORAL
NUTRESTORE

	+ EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004

GLYBURIDE
TABLET;ORAL
GLYBURIDE (MICRONIZED)

AB	DAVA PHARMS INC	**1.5MG**	**A074591**	**001**	Dec 22, 1997
AB		**3MG**	**A074591**	**002**	Dec 22, 1997
AB		**4.5MG**	**A074591**	**003**	Dec 22, 1997
AB		**6MG**	**A074591**	**004**	Dec 22, 1997
AB	HIKMA	**1.5MG**	**A075890**	**001**	Jul 31, 2003
AB		**3MG**	**A075890**	**002**	Jul 31, 2003
AB		**6MG**	**A075890**	**003**	Jul 31, 2003
AB	MYLAN	**1.5MG**	**A074792**	**001**	Jun 26, 1998
AB		**3MG**	**A074792**	**002**	Jun 26, 1998
AB		**6MG**	**A074792**	**003**	Aug 17, 1999
AB	TEVA	**1.5MG**	**A074686**	**001**	Apr 20, 1999
AB		**3MG**	**A074686**	**002**	Apr 20, 1999
AB		**4.5MG**	**A074686**	**003**	Apr 20, 1999
AB		**6MG**	**A074686**	**004**	Apr 20, 1999

GLYNASE

AB	PHARMACIA AND UPJOHN	**1.5MG**	**N020051**	**001**	Mar 04, 1992
AB		**3MG**	**N020051**	**002**	Mar 04, 1992
AB	+	**6MG**	**N020051**	**004**	Sep 24, 1993

GLYBURIDE

AB1	AUROBINDO PHARMA	**1.25MG**	**A077537**	**001**	Oct 18, 2007
AB1		**2.5MG**	**A077537**	**002**	Oct 18, 2007
AB1		**5MG**	**A077537**	**003**	Oct 18, 2007
AB1	COREPHARMA	**1.25MG**	**A076257**	**001**	Jun 27, 2002
AB1		**2.5MG**	**A076257**	**002**	Jun 27, 2002
AB1		**5MG**	**A076257**	**003**	Jun 27, 2002
AB1	HERITAGE PHARMS INC	**1.25MG**	**A090937**	**001**	Feb 28, 2011
AB1		**2.5MG**	**A090937**	**002**	Feb 28, 2011
AB1		**5MG**	**A090937**	**003**	Feb 28, 2011
AB1	PHARMADAX INC	**1.25MG**	**A203581**	**001**	Apr 14, 2016
AB1		**2.5MG**	**A203581**	**002**	Apr 14, 2016
AB1		**5MG**	**A203581**	**003**	Apr 14, 2016
AB1	TEVA	**1.25MG**	**A074388**	**001**	Aug 29, 1995
AB1		**2.5MG**	**A074388**	**002**	Aug 29, 1995
AB1	+	**5MG**	**A074388**	**003**	Aug 29, 1995
AB1	ZYDUS PHARMS USA INC	**1.25mg**	**A206749**	**001**	May 10, 2016
AB1		**2.5mg**	**A206749**	**002**	May 10, 2016
AB1		**5MG**	**A206749**	**003**	May 10, 2016

DIABETA

AB2	SANOFI AVENTIS US	**1.25MG**	**N017532**	**001**	May 01, 1984
AB2		**2.5MG**	**N017532**	**002**	May 01, 1984
AB2	+	**5MG**	**N017532**	**003**	May 01, 1984

FDA data supplied by DrugPatentWatch.com

GLYBURIDE
TABLET;ORAL
GLYBURIDE

AB2		COREPHARMA	**1.25MG**	**A206079**	**001** Sep 30, 2015
AB2			**2.5MG**	**A206079**	**002** Sep 30, 2015
AB2			**5MG**	**A206079**	**003** Sep 30, 2015

GLYBURIDE; METFORMIN HYDROCHLORIDE
TABLET;ORAL
GLUCOVANCE

AB	+	BRISTOL MYERS SQUIBB	**2.5MG;500MG**	**N021178**	**002** Jul 31, 2000
AB			**5MG;500MG**	**N021178**	**003** Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**1.25MG;250MG**	**A076716**	**001** Jun 28, 2005
AB			**2.5MG;500MG**	**A076716**	**002** Jun 28, 2005
AB			**5MG;500MG**	**A076716**	**003** Jun 28, 2005
AB		AUROBINDO PHARMA	**1.25MG;250MG**	**A077870**	**001** Nov 14, 2007
AB			**2.5MG;500MG**	**A077870**	**002** Nov 14, 2007
AB			**5MG;500MG**	**A077870**	**003** Nov 14, 2007
AB		HERITAGE PHARMS INC	**1.25MG;250MG**	**A079009**	**001** Jun 03, 2009
AB			**2.5MG;500MG**	**A079009**	**002** Jun 03, 2009
AB			**5MG;500MG**	**A079009**	**003** Jun 03, 2009
AB		IMPAX LABS INC	**1.25MG;250MG**	**A076345**	**001** Feb 18, 2004
AB			**2.5MG;500MG**	**A076345**	**002** Feb 18, 2004
AB			**5MG;500MG**	**A076345**	**003** Feb 18, 2004
AB		ZYDUS PHARMS USA INC	**1.25MG;250MG**	**A206748**	**001** Feb 29, 2016
AB			**2.5MG;500MG**	**A206748**	**002** Feb 29, 2016
AB			**5MG;500MG**	**A206748**	**003** Feb 29, 2016

GLYCEROL PHENYLBUTYRATE
LIQUID;ORAL
RAVICTI

	+	HORIZON THERAPS INC	1.1GM/ML	N203284	001 Feb 01, 2013

GLYCINE
SOLUTION;IRRIGATION
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**1.5GM/100ML**	**N017865**	**001**

GLYCINE 1.5% IN PLASTIC CONTAINER

AT		B BRAUN	**1.5GM/100ML**	**N016784**	**001**
AT		HOSPIRA	**1.5GM/100ML**	**N018315**	**001**

GLYCOPYRROLATE
INJECTABLE;INJECTION
GLYCOPYRROLATE

AP	+	HIKMA FARMACEUTICA	**0.2MG/ML**	**A090963**	**001** Sep 21, 2011
AP		LUITPOLD	**0.2MG/ML**	**A089335**	**001** Jul 23, 1986

POWDER;INHALATION
SEEBRI

	+	NOVARTIS PHARMS CORP	15.6MCG/INH	N207923	001 Oct 29, 2015

SOLUTION;ORAL
CUVPOSA

	+	MERZ PHARMS	1MG/5ML	N022571	001 Jul 28, 2010

TABLET;ORAL
GLYCOPYRROLATE

AA		APPCO PHARMA LLC	**1MG**	**A207201**	**001** Jan 03, 2017
AA			**2MG**	**A207201**	**002** Jan 03, 2017
AA		AUROLIFE PHARMA LLC	**1MG**	**A202675**	**001** Apr 15, 2013
AA		DR REDDYS LABS LTD	**1MG**	**A040847**	**001** Mar 21, 2008
AA			**2MG**	**A040847**	**002** Mar 21, 2008
AA		LEADING PHARMA LLC	**1MG**	**A090195**	**001** Sep 21, 2012
AA			**2MG**	**A090195**	**002** Sep 21, 2012
AA		NATCO PHARMA LTD	**1MG**	**A091413**	**001** Jun 20, 2016
AA			**2MG**	**A091413**	**002** Jun 20, 2016
AA		NEXGEN PHARMA	**1.5MG**	**A091522**	**001** Mar 12, 2012
AA		PAR PHARM	**1MG**	**A040653**	**001** Aug 31, 2006
AA			**2MG**	**A040653**	**002** Aug 31, 2006
AA		RISING PHARMS INC	**1MG**	**A040821**	**001** Dec 29, 2008
AA			**2MG**	**A040821**	**002** Dec 29, 2008
AA		STASON PHARMS	**1MG**	**A091182**	**001** Feb 03, 2014
AA			**2MG**	**A091182**	**002** Feb 03, 2014
AA		SUN PHARM INDS LTD	**1MG**	**A040844**	**001** Aug 18, 2009
AA			**2MG**	**A040844**	**002** Aug 18, 2009
AA		VINTAGE PHARMS	**1MG**	**A090020**	**001** Oct 19, 2011

GLYCOPYRROLATE
TABLET;ORAL

	GLYCOPYRROLATE				
AA		**2MG**	**A090020**	**002**	Oct 19, 2011
	ROBINUL				
AA	+ CASPER PHARMA LLC	**1MG**	**N012827**	**001**	
	ROBINUL FORTE				
AA	+ CASPER PHARMA LLC	**2MG**	**N012827**	**002**	

GLYCOPYRROLATE ; INDACATEROL MALEATE
POWDER;INHALATION

	UTIBRON				
	+ NOVARTIS PHARMS CORP	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015

GONADOTROPIN, CHORIONIC
INJECTABLE;INJECTION

	CHORIONIC GONADOTROPIN				
AP	+ FERRING	**10,000 UNITS/VIAL**	**N017016**	**007**	
AP	+ FRESENIUS KABI USA	**10,000 UNITS/VIAL**	**N017067**	**002**	
	PREGNYL				
AP	+ ORGANON USA INC	**10,000 UNITS/VIAL**	**N017692**	**001**	

GOSERELIN ACETATE
IMPLANT;IMPLANTATION

	ZOLADEX				
	+ ASTRAZENECA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
	+	EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS;OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN				
AT	+ BAUSCH AND LOMB	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A064047**	**001**	Jan 31, 1996
AT	LUITPOLD	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A065187**	**001**	Oct 28, 2005
	NEOSPORIN				
AT	+ MONARCH PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A060582**	**001**	

GRANISETRON
FILM, EXTENDED RELEASE;TRANSDERMAL

	SANCUSO				
	+ KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008

INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

	SUSTOL				
	+ HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016

GRANISETRON HYDROCHLORIDE
INJECTABLE;INJECTION

	GRANISETRON HYDROCHLORIDE				
AP	AKORN INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A079119**	**001**	Sep 10, 2009
AP		**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A079078**	**001**	Sep 14, 2009
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A079078**	**002**	Sep 14, 2009
AP	AUROBINDO PHARMA LTD	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A204238**	**001**	Jul 06, 2016
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204238**	**002**	Jul 06, 2016
AP	BIONPHARMA INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078863**	**001**	Jun 30, 2008
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078880**	**001**	Jun 30, 2008
AP	CIPLA LTD	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078262**	**001**	Dec 31, 2007
AP		**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078258**	**001**	Jun 30, 2008
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078258**	**002**	Jun 30, 2008
AP	EUROHLTH INTL SARL	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A077913**	**001**	Jun 26, 2008
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077186**	**001**	Jun 30, 2008
AP		**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A077187**	**001**	Jun 30, 2008
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077177**	**001**	Dec 31, 2007
AP	FRESENIUS KABI USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078522**	**001**	Dec 31, 2007
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078090**	**001**	Jun 30, 2008
AP	HIKMA FARMACEUTICA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078629**	**001**	Dec 23, 2009
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078629**	**002**	Dec 23, 2009
AP	LUITPOLD	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A091274**	**001**	Sep 22, 2010
AP	SAGENT AGILA	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A091137**	**002**	Apr 09, 2010
AP	SAGENT STRIDES	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A091136**	**001**	Apr 09, 2010
AP		**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A091136**	**002**	Apr 09, 2010
AP	SANDOZ	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078534**	**001**	Apr 30, 2009
AP		**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078531**	**001**	Apr 30, 2009
AP		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078531**	**002**	Apr 30, 2009
AP	SANDOZ INC	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078835**	**001**	Jun 30, 2008

GRANISETRON HYDROCHLORIDE
INJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078835**	**002** Jun 30, 2008
AP	+	TEVA PHARMS USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078392**	**001** Dec 31, 2007
AP	+		**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A077963**	**001** Jan 03, 2008
AP	+		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077297**	**001** Jun 30, 2008
AP		WOCKHARDT USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078566**	**001** Feb 29, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078564**	**001** Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078565**	**001** Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		BIONPHARMA INC	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078863**	**002** Jun 30, 2008
AP	+	FRESENIUS KABI USA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078096**	**001** Jun 30, 2008

TABLET;ORAL
GRANISETRON HYDROCHLORIDE

AB		APOTEX INC	**EQ 1MG BASE**	**A078843**	**001** Feb 27, 2008
AB		CIPLA LTD	**EQ 1MG BASE**	**A078037**	**001** Feb 27, 2008
AB		DR REDDYS LABS LTD	**EQ 1MG BASE**	**A078846**	**001** Feb 27, 2009
AB		MYLAN	**EQ 1MG BASE**	**A078725**	**001** Jan 30, 2008
AB		NATCO PHARMA	**EQ 1MG BASE**	**A078969**	**001** Jun 22, 2009
AB		ORCHID HLTHCARE	**EQ 1MG BASE**	**A078678**	**001** Feb 13, 2008
AB		TARO	**EQ 1MG BASE**	**A090817**	**001** May 28, 2010
AB	+	TEVA PHARMS	**EQ 1MG BASE**	**A078080**	**001** Dec 31, 2007
AB		WEST-WARD PHARMS INT	**EQ 1MG BASE**	**A077842**	**001** Dec 31, 2007

GRISEOFULVIN, MICROSIZE
SUSPENSION;ORAL
GRISEOFULVIN

AB	+	ACTAVIS MID ATLANTIC	**125MG/5ML**	**A065394**	**001** Jul 06, 2007
AB		CIPLA LTD	**125MG/5ML**	**A065354**	**001** Sep 10, 2007
AB		PERRIGO CO TENNESSEE	**125MG/5ML**	**A065200**	**001** Mar 02, 2005
AB		VINTAGE PHARMS	**125MG/5ML**	**A065438**	**001** Oct 08, 2010

TABLET;ORAL
GRISEOFULVIN

AB	+	SANDOZ INC	**500MG**	**A091592**	**002** Aug 07, 2013
AB		SIGMAPHARM LABS LLC	**500MG**	**A202482**	**001** Oct 22, 2012
		SANDOZ INC	250MG	A091592	001 Aug 07, 2013

GRISEOFULVIN, ULTRAMICROSIZE
TABLET;ORAL
GRIS-PEG

AB		VALEANT PHARMS INC	**125MG**	**N050475**	**001**
AB	+		**250MG**	**N050475**	**002**

GRISEOFULVIN, ULTRAMICROSIZE

AB		RICONPHARMA LLC	**125MG**	**A204371**	**001** Jan 09, 2014
AB			**250MG**	**A204371**	**002** Jan 09, 2014

GRISEOFULVIN,ULTRAMICROSIZE

AB		SIGMAPHARM LABS LLC	**125MG**	**A202545**	**001** Oct 22, 2012
AB			**250MG**	**A202545**	**002** Oct 22, 2012

GUAIFENESIN; HYDROCODONE BITARTRATE
SOLUTION;ORAL
FLOWTUSS

		MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML	N022424	001 May 14, 2015

OBREDON

	+	SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001 Nov 14, 2014

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SOLUTION;ORAL
HYCOFENIX

	+	MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001 May 14, 2015

GUANABENZ ACETATE
TABLET;ORAL
GUANABENZ ACETATE

		ANI PHARMS INC	EQ 4MG BASE	A074149	001 Apr 07, 1995
	+		EQ 8MG BASE	A074149	002 Apr 07, 1995

GUANFACINE HYDROCHLORIDE
TABLET;ORAL
GUANFACINE HYDROCHLORIDE

AB		AMNEAL PHARM	**EQ 1MG BASE**	**A075109**	**001** Nov 25, 1998
AB			**EQ 2MG BASE**	**A075109**	**002** Nov 25, 1998
AB		EPIC PHARMA LLC	**EQ 1MG BASE**	**A074673**	**001** Feb 28, 1997
AB			**EQ 2MG BASE**	**A074673**	**002** Feb 28, 1997

FDA data supplied by DrugPatentWatch.com

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

	GUANFACINE HYDROCHLORIDE				
AB	MYLAN	**EQ 1MG BASE**	**A074796**	**001**	Jan 27, 1997
AB		**EQ 2MG BASE**	**A074796**	**002**	Jan 27, 1997
AB	WATSON LABS	**EQ 1MG BASE**	**A074145**	**001**	Oct 17, 1995
AB		**EQ 2MG BASE**	**A074145**	**002**	Oct 17, 1995
	TENEX				
AB	PROMIUS PHARMA	**EQ 1MG BASE**	**N019032**	**001**	Oct 27, 1986
AB	**+**	**EQ 2MG BASE**	**N019032**	**002**	Nov 07, 1988

TABLET, EXTENDED RELEASE;ORAL

	GUANFACINE HYDROCHLORIDE				
AB	ACTAVIS ELIZABETH	**EQ 1MG BASE**	**A200881**	**001**	Oct 05, 2012
AB		**EQ 2MG BASE**	**A200881**	**002**	Oct 05, 2012
AB		**EQ 3MG BASE**	**A200881**	**003**	Oct 05, 2012
AB		**EQ 4MG BASE**	**A200881**	**004**	Oct 05, 2012
AB	MYLAN PHARMS INC	**EQ 1MG BASE**	**A202578**	**001**	Jun 02, 2015
AB		**EQ 2MG BASE**	**A202578**	**002**	Jun 02, 2015
AB		**EQ 3MG BASE**	**A202578**	**003**	Jun 02, 2015
AB		**EQ 4MG BASE**	**A202578**	**004**	Jun 02, 2015
AB	SANDOZ INC	**EQ 1MG BASE**	**A202568**	**001**	Jun 03, 2015
AB		**EQ 2MG BASE**	**A202568**	**002**	Jun 03, 2015
AB		**EQ 3MG BASE**	**A202568**	**003**	Jun 03, 2015
AB		**EQ 4MG BASE**	**A202568**	**004**	Jun 03, 2015
AB	TEVA PHARMS USA	**EQ 1MG BASE**	**A201382**	**001**	Jun 02, 2015
AB		**EQ 2MG BASE**	**A201382**	**002**	Jun 02, 2015
AB		**EQ 3MG BASE**	**A201382**	**003**	Jun 02, 2015
AB		**EQ 4MG BASE**	**A201382**	**004**	Jun 02, 2015
AB	TWI PHARMS INC	**EQ 1MG BASE**	**A201408**	**001**	Jun 02, 2015
AB		**EQ 2MG BASE**	**A201408**	**002**	Jun 02, 2015
AB		**EQ 3MG BASE**	**A201408**	**003**	Jun 02, 2015
AB		**EQ 4MG BASE**	**A201408**	**004**	Jun 02, 2015
	INTUNIV				
AB	SHIRE	**EQ 1MG BASE**	**N022037**	**001**	Sep 02, 2009
AB		**EQ 2MG BASE**	**N022037**	**002**	Sep 02, 2009
AB		**EQ 3MG BASE**	**N022037**	**003**	Sep 02, 2009
AB	**+**	**EQ 4MG BASE**	**N022037**	**004**	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET;ORAL

	GUANIDINE HYDROCHLORIDE				
	MERCK SHARP DOHME	125MG	N001546	001	

HALCINONIDE

CREAM;TOPICAL

	HALOG				
	+ RANBAXY	0.1%	N017556	001	

OINTMENT;TOPICAL

	HALOG				
	+ RANBAXY	0.1%	N017824	001	

HALOBETASOL PROPIONATE

CREAM;TOPICAL

	HALOBETASOL PROPIONATE				
AB	FOUGERA PHARMS	**0.05%**	**A077001**	**001**	Dec 16, 2004
AB	G AND W LABS	**0.05%**	**A078162**	**001**	Apr 24, 2007
AB	PERRIGO ISRAEL	**0.05%**	**A077123**	**001**	Dec 16, 2004
AB	TARO	**0.05%**	**A077227**	**001**	Aug 04, 2005
	ULTRAVATE				
AB	**+** RANBAXY	**0.05%**	**N019967**	**001**	Dec 27, 1990

LOTION;TOPICAL

	ULTRAVATE				
	+ SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015

OINTMENT;TOPICAL

	HALOBETASOL PROPIONATE				
AB	G AND W LABS	**0.05%**	**A077721**	**001**	Sep 07, 2006
AB	PERRIGO	**0.05%**	**A076872**	**001**	Dec 16, 2004
AB	TARO	**0.05%**	**A076994**	**001**	Dec 16, 2004
	ULTRAVATE				
AB	**+** RANBAXY	**0.05%**	**N019968**	**001**	Dec 17, 1990

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB		MYLAN	0.5MG	A070278	006	Jun 10, 1986
AB			1MG	A070278	004	Jun 10, 1986
AB			2MG	A070278	001	Jun 10, 1986
AB			5MG	A070278	005	Jun 10, 1986
AB			10MG	A070278	002	Jul 16, 2009
AB			20MG	A070278	003	Jul 16, 2009
AB		SANDOZ	0.5MG	A071206	001	Nov 17, 1986
AB			1MG	A071207	001	Nov 17, 1986
AB	+		2MG	A071208	001	Nov 17, 1986
AB			5MG	A071209	001	Nov 17, 1986
AB			10MG	A071210	001	Mar 11, 1988
AB			20MG	A071211	001	Mar 11, 1988
AB		ZYDUS PHARMS USA	5MG	A077580	003	Nov 29, 2007
AB			10MG	A077580	004	Nov 29, 2007
AB			20MG	A077580	005	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALDOL

AO	+	JANSSEN PHARMS	EQ 50MG BASE/ML	N018701	001	Jan 14, 1986
AO	+		EQ 100MG BASE/ML	N018701	002	Jan 31, 1997

HALOPERIDOL DECANOATE

AO		FRESENIUS KABI USA	EQ 50MG BASE/ML	A074893	001	Dec 19, 1997
AO			EQ 100MG BASE/ML	A074893	002	Dec 19, 1997
AO		MYLAN LABS LTD	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000
AO			EQ 100MG BASE/ML	A075440	002	Feb 28, 2000
AO		TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999
AO			EQ 100MG BASE/ML	A075393	002	May 11, 1999
AO		WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998
AO			EQ 100MG BASE/ML	A075305	001	Sep 28, 1998

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL

AA		PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993
AA		SILARX	EQ 2MG BASE/ML	A073364	001	Sep 28, 1993
AA	+	TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988

INJECTABLE;INJECTION

HALDOL

AP	+	JANSSEN PHARMS	EQ 5MG BASE/ML	N015923	001	

HALOPERIDOL

AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A075689	001	Mar 09, 2001
AP		GLAND PHARMA LTD	EQ 5MG BASE/ML	A076774	001	Aug 25, 2004
AP		MYLAN LABS LTD	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009
AP		SAGENT PHARMS	EQ 5MG BASE/ML	A091637	001	Sep 02, 2011
AP			EQ 5MG BASE/ML	A200742	001	Sep 02, 2011
AP		TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001
AP		WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP	+	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	001	
AP			5,000 UNITS/ML	A206552	001	Jun 10, 2016
AP	+		5,000 UNITS/ML	N017651	006	
AP	+		10,000 UNITS/ML	N017029	003	
AP	+		20,000 UNITS/ML	N017029	004	
AP		HOSPIRA INC	1,000 UNITS/ML	A090571	001	Aug 31, 2009
AP			5,000 UNITS/ML	A090571	002	Aug 31, 2009
AP			10,000 UNITS/ML	A090571	003	Aug 31, 2009
AP		SAGENT PHARMS	1,000 UNITS/ML	A090808	001	Jun 30, 2010
AP			5,000 UNITS/ML	A090808	002	Jun 30, 2010
AP			10,000 UNITS/ML	A090808	003	Jun 30, 2010
AP			20,000 UNITS/ML	A090809	001	Jun 30, 2010
AP		SANDOZ	1,000 UNITS/ML	A091682	001	Jun 08, 2011
AP			5,000 UNITS/ML	A091659	001	Jun 08, 2011
AP			5,000 UNITS/ML	A091682	002	Jun 08, 2011
AP			10,000 UNITS/ML	A201002	001	Jun 08, 2011
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A202957	001	Jun 12, 2014
AP			5,000 UNITS/ML	A202733	001	Jun 12, 2014
AP			5,000 UNITS/ML	A202957	002	Jun 12, 2014

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM
INJECTABLE;INJECTION

		HEPARIN SODIUM				
AP			**10,000 UNITS/ML**	**A203198**	**001**	Jun 12, 2014
AP			**20,000 UNITS/ML**	**A203198**	**002**	Jun 12, 2014
AP	+	WEST-WARD PHARMS INT	**1,000 UNITS/ML**	**N017037**	**001**	
AP	+		**5,000 UNITS/ML**	**N017037**	**002**	
AP	+		**10,000 UNITS/ML**	**N017037**	**003**	
		HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**001**	Apr 28, 1982
		HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	+	B BRAUN	**200 UNITS/100ML**	**N019953**	**001**	Jul 20, 1992
AP		HOSPIRA	**200 UNITS/100ML**	**N018916**	**010**	Jun 23, 1989
		HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP		HOSPIRA	**10,000 UNITS/100ML**	**N019339**	**003**	Mar 27, 1985
		HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**002**	Apr 28, 1982
		HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		HOSPIRA	**200 UNITS/100ML**	**N018916**	**011**	Jun 23, 1989
		HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	+	B BRAUN	**4,000 UNITS/100ML**	**N019952**	**001**	Jul 20, 1992
AP		HOSPIRA	**4,000 UNITS/100ML**	**N019805**	**001**	Jan 25, 1989
		HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	+	B BRAUN	**5,000 UNITS/100ML**	**N019952**	**004**	Jul 20, 1992
AP	+		**10,000 UNITS/100ML**	**N019952**	**005**	Jul 20, 1992
AP		HOSPIRA	**5,000 UNITS/100ML**	**N019339**	**004**	Mar 27, 1985
AP			**5,000 UNITS/100ML**	**N019805**	**002**	Jan 25, 1989
AP			**10,000 UNITS/100ML**	**N019339**	**002**	Mar 27, 1985
		HEPARIN SODIUM IN PLASTIC CONTAINER				
AP	+	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**013**	Dec 05, 1985
AP	+		**5,000 UNITS/ML**	**N017029**	**014**	Dec 05, 1985
AP	+		**10,000 UNITS/ML**	**N017029**	**015**	Dec 05, 1985
AP	+		**20,000 UNITS/ML**	**N017029**	**016**	Dec 05, 1985
		HEPARIN SODIUM PRESERVATIVE FREE				
AP	+	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**010**	Apr 28, 1986
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090810**	**001**	Jun 30, 2010
AP		SHENZHEN TECHDOW	**1,000 UNITS/ML**	**A202732**	**001**	Jun 12, 2014
		HEPARIN SODIUM				
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
	+	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983
	+	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
	+		5,000 UNITS/ML	N201370	002	Jul 21, 2011
	+		10,000 UNITS/ML	N201370	003	Jul 21, 2011
		HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985
		HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
		HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
			10,000 UNITS/100ML	N018916	008	Jan 31, 1984
		HEPARIN SODIUM PRESERVATIVE FREE				
	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010
	+	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987
	+	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENE
SPONGE;TOPICAL

		PRE-OP				
AT	+	DAVIS AND GECK	**480MG**	**N017433**	**001**	
		PRE-OP II				
AT		DAVIS AND GECK	**480MG**	**N017433**	**002**	

HEXAMINOLEVULINATE HYDROCHLORIDE
FOR SOLUTION;INTRAVESICAL

		CYSVIEW KIT				
	+	PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010

HISTRELIN ACETATE
IMPLANT;SUBCUTANEOUS

		SUPPRELIN LA				
	+	ENDO PHARM	50MG	N022058	001	May 03, 2007
		VANTAS				
	+	ENDO PHARM	50MG	N021732	001	Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ACTAVIS MID ATLANTIC	1.5MG/5ML;5MG/5ML	A088017	001	Jul 05, 1983
AA	+	HI TECH PHARMA	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008
AA		WOCKHARDT	1.5MG/5ML;5MG/5ML	A088008	001	Mar 03, 1983

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA		NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011

TUSSIGON

AA	+	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985

HYALURONIDASE

INJECTABLE;INJECTION

AMPHADASE

	+	AMPHASTAR PHARM	150 UNITS/ML	N021665	001	Oct 26, 2004

VITRASE

	+	BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE;INJECTION

HYLENEX RECOMBINANT

	+	HALOZYME THERAP	150 UNITS/ML	N021859	001	Dec 02, 2005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009
AP		FRESENIUS KABI USA	20MG/ML	A040388	001	Mar 13, 2001
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997
AP		MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016
AP		NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013
AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012
AA			25MG	A200737	002	Dec 07, 2012
AA			50MG	A200737	003	Dec 07, 2012
AA			100MG	A200737	004	Dec 07, 2012
AA		CADILA PHARMS LTD	25MG	A203845	001	Sep 18, 2014
AA			50MG	A203845	002	Sep 18, 2014
AA			100MG	A203845	003	Sep 18, 2014
AA		GLENMARK PHARMS LTD	10MG	A090527	001	May 27, 2009
AA			25MG	A090527	002	May 27, 2009
AA			50MG	A090527	003	May 27, 2009
AA			100MG	A090527	004	May 27, 2009
AA		HERITAGE PHARMS INC	10MG	A086242	001	Feb 04, 2010
AA			25MG	A086242	003	
AA			50MG	A086242	002	
AA			100MG	A086242	004	Feb 04, 2010
AA		HETERO LABS LTD III	10MG	A040901	001	Sep 12, 2008
AA			25MG	A040901	002	Sep 12, 2008
AA			50MG	A040901	003	Sep 12, 2008
AA			100MG	A040901	004	Sep 12, 2008
AA		INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008
AA			25MG	A090255	002	Dec 15, 2008
AA			50MG	A090255	003	Dec 15, 2008
AA			100MG	A090255	004	Dec 15, 2008
AA		MYLAN	10MG	A090413	001	Dec 08, 2010
AA			25MG	A090413	002	Dec 08, 2010
AA			50MG	A090413	003	Dec 08, 2010
AA			100MG	A090413	004	Dec 08, 2010
AA		PAR PHARM	10MG	A087836	001	Oct 05, 1982
AA			25MG	A086961	002	
AA			50MG	A086962	001	
AA			100MG	A088391	001	Sep 27, 1983
AA	+	PLIVA	10MG	A089097	001	Dec 18, 1985
AA	+		25MG	A088467	001	May 01, 1984
AA	+		50MG	A088468	001	May 01, 1984
AA	+		100MG	A089098	001	Dec 18, 1985
AA		STRIDES PHARMA	25MG	A200770	001	May 03, 2013
AA			50MG	A200770	002	May 03, 2013
AA			100MG	A200770	003	May 03, 2013

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

	PAR PHARM	25MG;25MG	A088957	001	Oct 21, 1985
+		50MG;50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

BIDIL

+	ARBOR PHARMS LLC	37.5MG;20MG	N020727	001	Jun 23, 2005

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG	A200645	001	Nov 30, 2010
AB	APOTEX	12.5MG	A078389	001	May 16, 2008
AB	AUROBINDO PHARMA	12.5MG	A078164	001	Sep 18, 2007
AB	IPCA LABS LTD	12.5MG	A079237	001	Apr 02, 2009
AB	IVAX SUB TEVA PHARMS	12.5MG	A077005	001	Jul 13, 2005
AB	JUBILANT CADISTA	12.5MG	A078391	001	Feb 11, 2008
AB	MYLAN	12.5MG	A075640	001	Jan 28, 2000
AB	SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014
AB	UNICHEM	12.5MG	A090510	001	Jan 19, 2010
AB	VINTAGE PHARMS	12.5MG	A075907	001	Sep 17, 2002

MICROZIDE

AB +	ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB	ACCORD HLTHCARE	12.5MG	A202556	001	Sep 24, 2012
AB		25MG	A202556	002	Sep 24, 2012
AB		50MG	A202556	003	Sep 24, 2012
AB	ACTAVIS ELIZABETH	12.5MG	A040707	001	Feb 27, 2007
AB	APOTEX	25MG	A040774	001	Oct 03, 2007
AB		50MG	A040774	002	Oct 03, 2007
AB	AUROBINDO PHARMA	25MG	A040780	001	Jul 20, 2007
AB		50MG	A040780	002	Jul 20, 2007
AB	DAVA PHARMS INC	25MG	A087059	001	
AB		50MG	A087068	001	
AB	HERITAGE PHARMS INC	25MG	A085182	002	
AB		50MG	A085182	001	
AB	HIKMA INTL PHARMS	50MG	A084878	001	
AB	IPCA LABS LTD	12.5MG	A040807	001	Jul 20, 2007
AB		25MG	A040807	002	Jul 20, 2007
AB		50MG	A040807	003	Jul 20, 2007
AB	IVAX SUB TEVA PHARMS	25MG	A083177	001	
AB +		50MG	A083177	002	
AB	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
AB		50MG	A040809	002	Sep 04, 2007
AB	LEADING PHARMA LLC	25MG	A040702	001	Mar 16, 2007
AB		50MG	A040702	002	Mar 16, 2007
AB	MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
AB		25MG	A040735	002	Jan 23, 2007
AB		50MG	A040735	003	Jan 23, 2007
AB	SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014
AB		50MG	A203018	002	Jul 23, 2014
AB	SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008
AB		25MG	A040810	001	Mar 27, 2007
AB		50MG	A040810	002	Mar 27, 2007
AB	UNICHEM	25MG	A040907	001	Aug 15, 2008
AB		50MG	A040907	002	Aug 15, 2008
AB	VINTAGE PHARMS	25MG	A040412	001	Mar 29, 2002
AB		50MG	A040412	002	Mar 29, 2002

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

AB +	SANOFI AVENTIS US	12.5MG;150MG	N020758	002	Sep 30, 1997
AB +		12.5MG;300MG	N020758	003	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;150MG	A091370	001	Oct 15, 2012
AB		12.5MG;300MG	A091370	002	Oct 15, 2012
AB		25MG;300MG	A091370	003	Oct 12, 2016
AB	APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012
AB		12.5MG;300MG	A201505	002	Oct 15, 2012

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013
AB		12.5MG;300MG	A203630	002	Feb 22, 2013
AB		25MG;300MG	A203630	003	Mar 31, 2016
AB	DR REDDYS LABS LTD	12.5MG;150MG	A203500	001	Sep 27, 2012
AB		12.5MG;300MG	A203500	002	Sep 27, 2012
AB	HISUN PHARM HANGZHOU	12.5MG;150MG	A207896	001	Oct 14, 2016
AB		12.5MG;300MG	A207896	002	Oct 14, 2016
AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016
AB		12.5MG;300MG	A203036	002	Jan 15, 2016
AB		25MG;300MG	A203036	003	Jan 15, 2016
AB	LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013
AB		12.5MG;300MG	A201524	002	Feb 27, 2013
AB	MACLEODS PHARMS LTD	12.5MG;150MG	A202414	001	Sep 27, 2012
AB		12.5MG;300MG	A202414	002	Sep 27, 2012
AB	MYLAN PHARMS INC	12.5MG;150MG	A077969	001	Sep 27, 2012
AB		12.5MG;300MG	A077969	002	Sep 27, 2012
AB		25MG;300MG	A077969	003	Jul 20, 2016
AB	PRINSTON INC	12.5MG;150MG	A203072	001	May 09, 2014
AB		12.5MG;300MG	A203072	002	May 09, 2014
AB	SANDOZ	12.5MG;150MG	A077446	001	Sep 27, 2012
AB		12.5MG;300MG	A077446	002	Sep 27, 2012
AB	TEVA	12.5MG;150MG	A077369	001	Mar 30, 2012
AB		12.5MG;300MG	A077369	002	Mar 30, 2012
AB	WEST-WARD PHARMS INT	12.5MG;150MG	A090351	001	Oct 15, 2012
AB		12.5MG;300MG	A090351	002	Oct 15, 2012

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	12.5MG;10MG	A076674	001	Oct 05, 2004
AB		12.5MG;20MG	A076674	002	Oct 05, 2004
AB		25MG;20MG	A076674	003	Oct 05, 2004
AB	AUROBINDO	12.5MG;10MG	A077606	001	Mar 14, 2006
AB		12.5MG;20MG	A077606	002	Mar 14, 2006
AB		25MG;20MG	A077606	003	Mar 14, 2006
AB	HIKMA INTL PHARMS	12.5MG;10MG	A076265	001	Jul 08, 2002
AB		12.5MG;20MG	A076265	002	Jul 08, 2002
AB		25MG;20MG	A076265	003	Jul 08, 2002
AB	IVAX SUB TEVA PHARMS	12.5MG;10MG	A075776	001	Jul 01, 2002
AB		12.5MG;20MG	A075776	002	Jul 01, 2002
AB		25MG;20MG	A075776	003	Jul 01, 2002
AB	LUPIN	12.5MG;10MG	A077912	001	Sep 27, 2006
AB		12.5MG;20MG	A077912	002	Sep 27, 2006
AB		25MG;20MG	A077912	003	Sep 27, 2006
AB	MYLAN	12.5MG;10MG	A076113	001	Jul 01, 2002
AB		12.5MG;20MG	A076113	002	Jul 01, 2002
AB		25MG;20MG	A076113	003	Jul 01, 2002
AB	PRINSTON INC	12.5MG;10MG	A076230	001	Jul 01, 2002
AB		12.5MG;20MG	A076230	002	Jul 01, 2002
AB		25MG;20MG	A076230	003	Jul 01, 2002
AB	SANDOZ	12.5MG;10MG	A076262	001	Jul 01, 2002
AB		12.5MG;20MG	A076262	002	Jul 01, 2002
AB		25MG;20MG	A076262	003	Jul 01, 2002
AB	SUN PHARM INDS LTD	12.5MG;10MG	A076007	001	Jul 01, 2002
AB		12.5MG;20MG	A076007	002	Jul 01, 2002
AB		25MG;20MG	A076007	003	Jul 01, 2002
AB	WATSON LABS	12.5MG;10MG	A076194	003	Jul 01, 2002
AB		12.5MG;20MG	A076194	001	Jul 01, 2002
AB		25MG;20MG	A076194	002	Jul 01, 2002

ZESTORETIC

AB	ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993
AB +		12.5MG;20MG	N019888	001	Sep 20, 1990
AB +		25MG;20MG	N019888	002	Jul 20, 1989

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR

AB	MERCK SHARP DOHME	**12.5MG;50MG**	**N020387**	**001**	Apr 28, 1995
AB		**12.5MG;100MG**	**N020387**	**003**	Oct 20, 2005
AB +		**25MG;100MG**	**N020387**	**002**	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	**12.5MG;50MG**	**A091617**	**001**	Feb 17, 2012
AB		**12.5MG;100MG**	**A091617**	**002**	Feb 17, 2012
AB		**25MG;100MG**	**A091617**	**003**	Feb 17, 2012
AB	APOTEX	**12.5MG;50MG**	**A090150**	**001**	Oct 06, 2010
AB		**12.5MG;100MG**	**A090150**	**002**	Aug 11, 2010
AB		**25MG;100MG**	**A090150**	**003**	Oct 06, 2010
AB	AUROBINDO PHARMA	**12.5MG;50MG**	**A091629**	**001**	Oct 06, 2010
AB		**12.5MG;100MG**	**A091629**	**002**	Oct 06, 2010
AB		**25MG;100MG**	**A091629**	**003**	Jan 06, 2010
AB	CADISTA PHARMS	**12.5MG;50MG**	**A201845**	**001**	Sep 18, 2012
AB		**12.5MG;100MG**	**A201845**	**002**	Sep 18, 2012
AB		**25MG;100MG**	**A201845**	**003**	Sep 18, 2012
AB	IPCA LABS LTD	**12.5MG;50MG**	**A201682**	**001**	Mar 01, 2013
AB		**12.5MG;100MG**	**A201682**	**002**	Mar 01, 2013
AB		**25MG;100MG**	**A201682**	**003**	Mar 01, 2013
AB	LUPIN LTD	**12.5MG;50MG**	**A078245**	**001**	Oct 06, 2010
AB		**12.5MG;100MG**	**A078245**	**002**	May 21, 2010
AB		**25MG;100MG**	**A078245**	**003**	Oct 06, 2010
AB	MACLEODS PHARMS LTD	**12.5MG;50MG**	**A202289**	**001**	Aug 09, 2012
AB		**12.5MG;100MG**	**A202289**	**002**	Aug 09, 2012
AB		**25MG;100MG**	**A202289**	**003**	Aug 09, 2012
AB	MYLAN	**12.5MG;50MG**	**A091652**	**001**	Oct 06, 2010
AB		**12.5MG;100MG**	**A091652**	**002**	Apr 06, 2010
AB		**25MG;100MG**	**A091652**	**003**	Oct 06, 2010
AB	SANDOZ	**12.5MG;50MG**	**A077948**	**001**	Oct 06, 2010
AB		**12.5MG;100MG**	**A077948**	**003**	Aug 19, 2010
AB		**25MG;100MG**	**A077948**	**002**	Oct 06, 2010
AB	TEVA PHARMS	**12.5MG;50MG**	**A077157**	**001**	Apr 06, 2010
AB		**12.5MG;100MG**	**A077157**	**002**	Apr 06, 2010
AB		**25MG;100MG**	**A077157**	**003**	Apr 06, 2010
AB	TORRENT PHARMS	**12.5MG;50MG**	**A090528**	**001**	Oct 06, 2010
AB		**12.5MG;100MG**	**A090528**	**003**	Apr 06, 2010
AB		**25MG;100MG**	**A090528**	**002**	Oct 06, 2010
AB	WEST-WARD PHARMS INT	**12.5MG;50MG**	**A077732**	**002**	Oct 06, 2010
AB		**12.5MG;100MG**	**A077732**	**001**	Apr 06, 2010
AB		**25MG;100MG**	**A077732**	**003**	Oct 06, 2010
AB	ZYDUS PHARMS USA INC	**12.5MG;50MG**	**A078385**	**001**	Oct 06, 2010
AB		**25MG;100MG**	**A078385**	**002**	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG;250MG	A070265	002	Jan 23, 1986
+		25MG;250MG	A070265	001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

	CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

AB	US PHARMS HOLDINGS I	**25MG;50MG**	**N018303**	**001**	Dec 31, 1984
AB +		**25MG;100MG**	**N018303**	**002**	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	**25MG;50MG**	**A202870**	**001**	Nov 06, 2013
AB		**25MG;100MG**	**A202870**	**002**	Nov 06, 2013
AB		**50MG;100MG**	**A202870**	**003**	Nov 06, 2013
AB	MYLAN	**25MG;50MG**	**A076792**	**001**	Aug 20, 2004
AB		**25MG;100MG**	**A076792**	**002**	Aug 20, 2004
AB		**50MG;100MG**	**A076792**	**003**	Aug 20, 2004
AB	SUN PHARM INDS	**25MG;50MG**	**A090654**	**001**	Jan 19, 2012
AB		**25MG;100MG**	**A090654**	**002**	Jan 19, 2012
AB		**50MG;100MG**	**A090654**	**003**	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

	MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
AB		GLENMARK PHARMS	**12.5MG;7.5MG**	**A090718**	**001**	Mar 17, 2010
AB			**12.5MG;15MG**	**A090718**	**002**	Mar 17, 2010
AB			**25MG;15MG**	**A090718**	**003**	Mar 17, 2010
AB		TEVA	**12.5MG;7.5MG**	**A076980**	**001**	Mar 07, 2007
AB			**12.5MG;15MG**	**A076980**	**003**	Mar 07, 2007
AB	+		**25MG;15MG**	**A076980**	**002**	Mar 07, 2007
	MOEXIPRIL HYDROCHLORIDE AND HYDROCHOLROTHIAZIDE					
AB		HERITAGE PHARMS INC	**12.5MG;7.5MG**	**A202150**	**001**	Mar 07, 2014
AB			**12.5MG;15MG**	**A202150**	**002**	Mar 07, 2014
AB			**25MG;15MG**	**A202150**	**003**	Mar 07, 2014

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

	BENICAR HCT					
AB		DAIICHI SANKYO	**12.5MG;20MG**	**N021532**	**002**	Jun 05, 2003
AB			**12.5MG;40MG**	**N021532**	**003**	Jun 05, 2003
AB	+		**25MG;40MG**	**N021532**	**005**	Jun 05, 2003
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE					
AB		MYLAN PHARMS INC	**12.5MG;20MG**	**A078827**	**001**	Oct 26, 2016
AB			**12.5MG;40MG**	**A078827**	**002**	Oct 26, 2016
AB			**25MG;40MG**	**A078827**	**003**	Oct 26, 2016

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
AB		ANI PHARMS INC	**25MG;40MG**	**A072042**	**001**	Mar 14, 1988
AB			**25MG;80MG**	**A072043**	**001**	Mar 14, 1988
AB	+	MYLAN	**25MG;40MG**	**A070947**	**002**	Mar 04, 1987
AB	+		**25MG;80MG**	**A070947**	**001**	Apr 01, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

	ACCURETIC					
AB		PFIZER PHARMS	**12.5MG;EQ 10MG BASE**	**N020125**	**001**	Dec 28, 1999
AB			**12.5MG;EQ 20MG BASE**	**N020125**	**002**	Dec 28, 1999
AB	+		**25MG;EQ 20MG BASE**	**N020125**	**003**	Dec 28, 1999
	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
AB		APOTEX CORP	**12.5MG;EQ 10MG BASE**	**A091524**	**001**	Mar 12, 2013
AB			**12.5MG;EQ 20MG BASE**	**A091524**	**002**	Mar 12, 2013
AB			**25MG;EQ 20MG BASE**	**A091524**	**003**	Mar 12, 2013
AB		AUROBINDO PHARMA	**12.5MG;EQ 10MG BASE**	**A078450**	**001**	Aug 24, 2007
AB			**12.5MG;EQ 20MG BASE**	**A078450**	**002**	Aug 24, 2007
AB			**25MG;EQ 20MG BASE**	**A078450**	**003**	Aug 24, 2007
AB		INVAGEN PHARMS	**12.5MG;10MG**	**A201356**	**001**	Apr 20, 2011
AB			**12.5MG;20MG**	**A201356**	**002**	Apr 20, 2011
AB			**25MG;20MG**	**A201356**	**003**	Apr 20, 2011
AB		MYLAN	**12.5MG;EQ 10MG BASE**	**A077093**	**001**	Mar 28, 2005
AB			**12.5MG;EQ 20MG BASE**	**A077093**	**002**	Mar 28, 2005
AB			**25MG;EQ 20MG BASE**	**A077093**	**003**	Mar 28, 2005
AB		SUN PHARM INDS LTD	**12.5MG;EQ 10MG BASE**	**A078211**	**001**	Mar 04, 2009
AB			**12.5MG;EQ 20MG BASE**	**A078211**	**002**	Mar 04, 2009
AB			**25MG;EQ 20MG BASE**	**A078211**	**003**	Mar 04, 2009
	QUINARETIC					
AB		GAVIS PHARMS	**12.5MG;EQ 10MG BASE**	**A076374**	**001**	Mar 31, 2004
AB			**12.5MG;EQ 20MG BASE**	**A076374**	**002**	Mar 31, 2004
AB			**25MG;EQ 20MG BASE**	**A076374**	**003**	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

	ALDACTAZIDE					
AB		GD SEARLE LLC	**25MG;25MG**	**N012616**	**004**	Dec 30, 1982
	SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE					
AB		MYLAN	**25MG;25MG**	**A086513**	**001**	
AB		SUN PHARM INDS	**25MG;25MG**	**A089534**	**001**	Jul 02, 1987
	ALDACTAZIDE					
	+	GD SEARLE LLC	50MG;50MG	N012616	005	Dec 30, 1982

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT

AB		BOEHRINGER INGELHEIM	12.5MG;40MG	N021162	001	Nov 17, 2000
AB			12.5MG;80MG	N021162	002	Nov 17, 2000
AB	+		25MG;80MG	N021162	003	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG;40MG	A203010	001	Feb 25, 2014
AB			12.5MG;80MG	A203010	002	Feb 25, 2014
AB			25MG;80MG	A203010	003	Feb 25, 2014
AB		AUROBINDO PHARMA LTD	12.5MG;40MG	A208727	001	Dec 15, 2016
AB			12.5MG;80MG	A208727	002	Dec 15, 2016
AB			25MG;80MG	A208727	003	Dec 15, 2016
AB		LUPIN LTD	12.5MG;40MG	A091351	001	Aug 07, 2014
AB			12.5MG;80MG	A091351	002	Aug 07, 2014
AB			25MG;80MG	A091351	003	Aug 07, 2014
AB		MACLEODS PHARMS LTD	12.5MG;40MG	A204169	001	Nov 02, 2015
AB			12.5MG;80MG	A204169	002	Nov 02, 2015
AB			25MG;80MG	A204169	003	Nov 02, 2015
AB		MYLAN PHARMS INC	12.5MG;40MG	A091648	001	Feb 25, 2014
AB			12.5MG;80MG	A091648	002	Feb 25, 2014
AB			25MG;80MG	A091648	003	Feb 25, 2014
AB		TORRENT PHARMS LTD	12.5MG;40MG	A201192	001	Feb 25, 2014
AB			12.5MG;80MG	A201192	002	Feb 25, 2014
AB			25MG;80MG	A201192	003	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

DYAZIDE

AB	+	GLAXOSMITHKLINE LLC	25MG;37.5MG	N016042	003	Mar 03, 1994

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		DURAMED PHARMS BARR	25MG;37.5MG	A075052	001	Jun 18, 1999
AB		IVAX SUB TEVA PHARMS	25MG;50MG	A074259	001	Mar 30, 1995
AB		LANNETT HOLDINGS INC	25MG;37.5MG	A201407	001	Dec 09, 2011
AB		MYLAN	25MG;37.5MG	A074701	001	Jun 07, 1996
AB		SANDOZ	25MG;37.5MG	A074821	001	Jun 05, 1997
AB	+		25MG;50MG	A073191	001	Jul 31, 1991

TABLET;ORAL

MAXZIDE

AB	+	MYLAN PHARMS INC	50MG;75MG	N019129	001	Oct 22, 1984

MAXZIDE-25

AB		MYLAN PHARMS INC	25MG;37.5MG	N019129	003	May 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		ANI PHARMS INC	50MG;75MG	A073467	001	Jan 31, 1996
AB		APOTEX INC	25MG;37.5MG	A071251	002	May 05, 1998
AB			50MG;75MG	A071251	001	Apr 17, 1988
AB		PLIVA	25MG;37.5MG	A074026	001	Apr 26, 1996
AB		SANDOZ	25MG;37.5MG	A073281	001	Apr 30, 1992
AB			50MG;75MG	A072011	001	Jun 17, 1988
AB		WATSON LABS	25MG;37.5MG	A073449	001	Sep 23, 1993
AB			50MG;75MG	A071851	001	Nov 30, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

DIOVAN HCT

AB		NOVARTIS	12.5MG;80MG	N020818	001	Mar 06, 1998
AB			12.5MG;160MG	N020818	002	Mar 06, 1998
AB			12.5MG;320MG	N020818	004	Apr 28, 2006
AB			25MG;160MG	N020818	003	Jan 17, 2002
AB	+		25MG;320MG	N020818	005	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013
AB			12.5MG;160MG	A201662	002	Mar 21, 2013
AB			12.5MG;320MG	A201662	003	Mar 21, 2013
AB			25MG;160MG	A201662	004	Mar 21, 2013
AB			25MG;320MG	A201662	005	Mar 21, 2013
AB		APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013
AB			12.5MG;160MG	A203026	002	Mar 21, 2013
AB			12.5MG;320MG	A203026	003	Mar 21, 2013
AB			25MG;160MG	A203026	004	Mar 21, 2013
AB			25MG;320MG	A203026	005	Mar 21, 2013
AB		AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013
AB			12.5MG;160MG	A202519	002	Mar 21, 2013

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		**12.5MG;320MG**	**A202519**	**003**	Mar 21, 2013
AB		**25MG;160MG**	**A202519**	**004**	Mar 21, 2013
AB		**25MG;320MG**	**A202519**	**005**	Mar 21, 2013
AB	LUPIN LTD	**12.5MG;80MG**	**A078946**	**003**	Mar 21, 2013
AB		**12.5MG;160MG**	**A078946**	**004**	Mar 21, 2013
AB		**12.5MG;320MG**	**A078946**	**001**	Mar 21, 2013
AB		**25MG;160MG**	**A078946**	**005**	Mar 21, 2013
AB		**25MG;320MG**	**A078946**	**002**	Mar 21, 2013
AB	MACLEODS PHARMS LTD	**12.5MG;80MG**	**A203145**	**001**	Apr 19, 2013
AB		**12.5MG;160MG**	**A203145**	**002**	Apr 19, 2013
AB		**12.5MG;320MG**	**A203145**	**003**	Apr 19, 2013
AB		**25MG;160MG**	**A203145**	**004**	Apr 19, 2013
AB		**25MG;320MG**	**A203145**	**005**	Apr 19, 2013
AB	MYLAN PHARMS INC	**12.5MG;80MG**	**A078020**	**001**	Sep 21, 2012
AB		**12.5MG;160MG**	**A078020**	**002**	Sep 21, 2012
AB		**12.5MG;320MG**	**A078020**	**004**	Sep 21, 2012
AB		**25MG;160MG**	**A078020**	**003**	Sep 21, 2012
AB		**25MG;320MG**	**A078020**	**005**	Sep 21, 2012
AB	PRINSTON INC	**12.5MG;80MG**	**A206083**	**001**	Feb 08, 2016
AB		**12.5MG;160MG**	**A206083**	**002**	Feb 08, 2016
AB		**12.5MG;320MG**	**A206083**	**003**	Feb 08, 2016
AB		**25MG;160MG**	**A206083**	**004**	Feb 08, 2016
AB		**25MG;320MG**	**A206083**	**005**	Feb 08, 2016
AB	WATSON LABS INC	**12.5MG;80MG**	**A091519**	**001**	Mar 21, 2013
AB		**12.5MG;160MG**	**A091519**	**002**	Mar 21, 2013
AB		**12.5MG;320MG**	**A091519**	**003**	Mar 21, 2013
AB		**25MG;160MG**	**A091519**	**004**	Mar 21, 2013
AB		**25MG;320MG**	**A091519**	**005**	Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013
		15MG	N202880	002	Oct 25, 2013
		20MG	N202880	003	Oct 25, 2013
		30MG	N202880	004	Oct 25, 2013
		40MG	N202880	005	Oct 25, 2013
		50MG	N202880	006	Oct 25, 2013

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014
		30MG	N206627	002	Nov 20, 2014
		40MG	N206627	003	Nov 20, 2014
		60MG	N206627	004	Nov 20, 2014
		80MG	N206627	005	Nov 20, 2014
		100MG	N206627	006	Nov 20, 2014
		120MG	N206627	007	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	ACTAVIS LABS FL INC	**7.5MG;200MG**	**A076604**	**001**	Dec 31, 2003
AB	AMNEAL PHARMS NY	**5MG;200MG**	**A076642**	**002**	Mar 18, 2004
AB		**7.5MG;200MG**	**A076642**	**001**	Oct 12, 2004
AB	AUROLIFE PHARMA LLC	**7.5MG;200MG**	**A204575**	**001**	Jun 02, 2016
AB	SUN PHARM INDS INC	**2.5MG;200MG**	**A091633**	**001**	May 28, 2013
AB		**5MG;200MG**	**A091633**	**002**	May 28, 2013
AB		**7.5MG;200MG**	**A091633**	**003**	May 28, 2013
AB		**10MG;200MG**	**A091633**	**004**	May 28, 2013
AB	TEVA	**7.5MG;200MG**	**A076023**	**001**	Apr 11, 2003
AB	VINTAGE PHARMS	**5MG;200MG**	**A077727**	**001**	Nov 06, 2006
AB		**7.5MG;200MG**	**A077723**	**001**	Nov 06, 2006
AB		**10MG;200MG**	**A077723**	**002**	Nov 06, 2006

REPREXAIN

AB	AMNEAL PHARMS NY	**2.5MG;200MG**	**A076642**	**003**	Oct 19, 2007
AB		**10MG;200MG**	**A076642**	**004**	Oct 19, 2007

VICOPROFEN

AB	**+** ABBVIE	**7.5MG;200MG**	**N020716**	**001**	Sep 23, 1997

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA		COASTAL PHARMS	5MG/5ML;60MG/5ML	A205658 001	Nov 17, 2015
AA		PADDOCK LLC	5MG/5ML;60MG/5ML	A204658 001	Apr 29, 2014
AA		TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839 001	Oct 28, 2014
		REZIRA			
AA	+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442 001	Jun 08, 2011

HYDROCORTISONE

CREAM;TOPICAL

		ALA-CORT			
AT		CROWN LABS	2.5%	A080706 007	Jan 05, 2016
AT			1%	A080706 006	
		ANUSOL HC			
AT		SALIX PHARMS	2.5%	A088250 001	Jun 06, 1984
		HYDROCORTISONE			
AT		ACTAVIS MID ATLANTIC	1%	A087795 001	May 03, 1983
AT			2.5%	A089682 001	Mar 10, 1988
AT	+	FOUGERA	1%	A080693 003	
AT	+		2.5%	A089414 001	Dec 16, 1986
AT		PERRIGO NEW YORK	2.5%	A085025 001	
AT		RISING PHARMS INC	2.5%	A040879 001	Aug 20, 2010
AT		TARO	2.5%	A088799 001	Nov 09, 1984
AT		VINTAGE PHARMS	2.5%	A040503 001	Mar 12, 2004
		SYNACORT			
AT		MEDICIS	1%	A087458 001	
AT			2.5%	A087457 001	

ENEMA;RECTAL

		COLOCORT			
AB		PADDOCK LLC	100MG/60ML	A075172 001	Dec 03, 1999
		CORTENEMA			
AB	+	ANI PHARMS	100MG/60ML	N016199 001	
		HYDROCORTISONE			
AB		TEVA PHARMS	100MG/60ML	A074171 001	May 27, 1994

LOTION;TOPICAL

		HYDROCORTISONE			
AT	+	FOUGERA PHARMS	2.5%	A040351 001	Jul 25, 2000
AT		TARO	2.5%	A040247 001	Jul 23, 1999
AT		VINTAGE PHARMS	2.5%	A040417 001	Jul 30, 2003
		STIE-CORT			
AT		PERRIGO	2.5%	A089074 001	Nov 26, 1985
		ALA-SCALP			
		CROWN LABS	2%	A083231 001	

OINTMENT;TOPICAL

		HYDROCORTISONE			
AT		ACTAVIS MID ATLANTIC	1%	A087796 001	Oct 13, 1982
AT	+	FOUGERA	2.5%	A081203 001	May 28, 1993
AT	+	FOUGERA PHARMS	1%	A080692 001	
AT		PERRIGO NEW YORK	2.5%	A085027 001	
AT		TARO	1%	A086257 001	
		HYDROCORTISONE IN ABSORBASE			
AT		CAROLINA MEDCL	1%	A088138 001	Sep 06, 1985

SOLUTION;TOPICAL

		TEXACORT			
	+	MISSION PHARMA	2.5%	A081271 001	Apr 17, 1992

TABLET;ORAL

		CORTEF			
AB		PHARMACIA AND UPJOHN	5MG	N008697 003	
AB			10MG	N008697 001	
AB	+		20MG	N008697 002	
		HYDROCORTISONE			
AB		HIKMA INTL PHARMS	5MG	A083365 002	Feb 23, 2015
AB			10MG	A083365 003	Feb 23, 2015
AB			20MG	A083365 001	
AB		IMPAX LABS INC	5MG	A040646 001	Mar 30, 2007
AB			10MG	A040646 002	Mar 30, 2007
AB			20MG	A040646 003	Mar 30, 2007
AB		PHARMACEUTICS INTL	5MG	A207029 001	Apr 26, 2016
AB			10MG	A207029 002	Apr 26, 2016
AB			20MG	A207029 003	Apr 26, 2016
AB		VINTAGE	5MG	A040761 001	Jul 16, 2007
AB			10MG	A040761 002	Jul 16, 2007

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE
TABLET;ORAL
HYDROCORTISONE
AB **20MG** **A040761 003** Jul 16, 2007

HYDROCORTISONE ACETATE
AEROSOL, METERED;RECTAL
CORTIFOAM
+ MEDA PHARMS 10% N017351 001 Feb 10, 1982
CREAM;TOPICAL
HYDROCORTISONE ACETATE
+ FERNDALE LABS 2.5% A040259 001 Jul 29, 1999
MICORT-HC
+ SEBELA IRELAND LTD 2% A040398 001 Mar 29, 2002
2.5% A040396 001 Feb 27, 2001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
CREAM;TOPICAL
CORTISPORIN
+ MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE
AEROSOL, METERED;TOPICAL
EPIFOAM
BX MEDA PHARMS 1%;1% A086457 001
PROCTOFOAM HC
BX MEDA PHARMS 1%;1% A086195 001
CREAM;TOPICAL
PRAMOSONE
SEBELA IRELAND LTD 0.5%;1% A083778 001
1%;1% A085368 001
LOTION;TOPICAL
PRAMOSONE
SEBELA IRELAND LTD 1%;1% A085980 001
2.5%;1% A085979 001

HYDROCORTISONE ACETATE; UREA
CREAM;TOPICAL
U-CORT
TARO 1%;10% A089472 001 Jun 13, 1988

HYDROCORTISONE BUTYRATE
CREAM;TOPICAL
HYDROCORTISONE BUTYRATE
AB1 TARO PHARM INDS **0.1%** **A076654 001** Aug 03, 2005
LOCOID
AB1 **+** PRECISION DERMAT **0.1%** **N018514 001** Mar 31, 1982
HYDROCORTISONE BUTYRATE
AB2 GLENMARK GENERICS **0.1%** **A202145 001** Sep 27, 2013
LOCOID LIPOCREAM
AB2 **+** PRECISION DERMAT **0.1%** **N020769 001** Sep 08, 1997
LOTION;TOPICAL
LOCOID
+ PRECISION DERMAT 0.1% N022076 001 May 18, 2007
OINTMENT;TOPICAL
HYDROCORTISONE BUTYRATE
AB TARO **0.1%** **A076842 001** Dec 27, 2004
LOCOID
AB **+** PRECISION DERMAT **0.1%** **N018652 001** Oct 29, 1982
SOLUTION;TOPICAL
HYDROCORTISONE BUTYRATE
AT TARO PHARM INDS **0.1%** **A076364 001** Jan 14, 2004
LOCOID
AT **+** PRECISION DERMAT **0.1%** **N019116 001** Feb 25, 1987

HYDROCORTISONE PROBUTATE
CREAM;TOPICAL
PANDEL
+ FOUGERA PHARMS 0.1% N020453 001 Feb 28, 1997

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE SODIUM SUCCINATE
INJECTABLE;INJECTION

	A-HYDROCORT				
AP		HOSPIRA	**EQ 100MG BASE/VIAL**	**A040666**	**001** Apr 06, 2006
	SOLU-CORTEF				
AP	+	PHARMACIA AND UPJOHN	**EQ 100MG BASE/VIAL**	**N009866**	**001**
AP	+		**EQ 250MG BASE/VIAL**	**N009866**	**002**
AP	+		**EQ 500MG BASE/VIAL**	**N009866**	**003**
AP	+		**EQ 1GM BASE/VIAL**	**N009866**	**004**

HYDROCORTISONE VALERATE
CREAM;TOPICAL

	HYDROCORTISONE VALERATE				
AB		PERRIGO NEW YORK	**0.2%**	**A075666**	**001** May 24, 2000
AB	+	TARO	**0.2%**	**A075042**	**001** Aug 25, 1998

OINTMENT;TOPICAL

	HYDROCORTISONE VALERATE				
	+	TARO	0.2%	A075043	001 Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS;OTIC

	CORTISPORIN				
AT	+	MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N050479**	**001**
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
AT		ALCON PHARMS LTD	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062423**	**001** Aug 25, 1983
AT		BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064053**	**001** Dec 29, 1995
AT		LUITPOLD	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A065216**	**001** Oct 31, 2005

SUSPENSION/DROPS;OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
	+	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001 May 11, 1988

SUSPENSION/DROPS;OTIC

	CORTISPORIN				
AT	+	CASPER PHARMA LLC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N060613**	**001**
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
AT		ALCON PHARMS LTD	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062488**	**001** Nov 06, 1985
AT		LUITPOLD	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A065219**	**001** May 01, 2006
	OTICAIR				
AT		BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064065**	**001** Aug 28, 1996

HYDROFLUMETHIAZIDE
TABLET;ORAL

	SALURON				
AB	+	SHIRE LLC	**50MG**	**N011949**	**001**

HYDROMORPHONE HYDROCHLORIDE
INJECTABLE;INJECTION

	DILAUDID				
AP	+	PURDUE PHARM PRODS	**1MG/ML**	**N019034**	**003** Apr 30, 2009
AP	+		**2MG/ML**	**N019034**	**004** Apr 30, 2009
AP	+		**4MG/ML**	**N019034**	**005** Apr 30, 2009
	DILAUDID-HP				
AP	+	PURDUE PHARM PRODS	**10MG/ML**	**N019034**	**001** Jan 11, 1984
	HYDROMORPHONE HYDROCHLORIDE				
AP		AKORN	**10MG/ML**	**A078228**	**001** Apr 14, 2010
AP			**10MG/ML**	**A078261**	**001** Apr 14, 2010
AP		BARR	**10MG/ML**	**A076444**	**001** Apr 25, 2003
AP		HOSPIRA	**10MG/ML**	**A074598**	**001** Jun 19, 1997
AP		HOSPIRA INC	**1MG/ML**	**N200403**	**001** Dec 01, 2011
AP			**2MG/ML**	**N200403**	**002** Dec 01, 2011
AP			**4MG/ML**	**N200403**	**003** Dec 01, 2011
AP			**10MG/ML**	**A078591**	**001** Jun 17, 2008

SOLUTION;ORAL

	DILAUDID				
AA	+	PURDUE PHARM PRODS	**5MG/5ML**	**N019891**	**001** Dec 07, 1992
	HYDROMORPHONE HYDROCHLORIDE				
AA		WEST-WARD PHARMS INT	**5MG/5ML**	**A074653**	**001** Jul 29, 1998

TABLET;ORAL

	DILAUDID				
AB		PURDUE PHARM PRODS	**2MG**	**N019892**	**003** Nov 09, 2007
AB			**4MG**	**N019892**	**002** Nov 09, 2007
AB	+		**8MG**	**N019892**	**001** Dec 07, 1992
	HYDROMORPHONE HYDROCHLORIDE				
AB		AUROLIFE PHARMA LLC	**2MG**	**A205814**	**001** May 13, 2016
AB			**4MG**	**A205814**	**002** May 13, 2016

FDA data supplied by DrugPatentWatch.com

HYDROMORPHONE HYDROCHLORIDE

TABLET;ORAL

	HYDROMORPHONE HYDROCHLORIDE				
AB		**8MG**	**A205814**	**003**	May 13, 2016
AB	ELITE LABS	**8MG**	**A076723**	**001**	Oct 18, 2005
AB	LANNETT	**2MG**	**A077471**	**002**	Dec 09, 2009
AB		**2MG**	**A078439**	**001**	Dec 09, 2009
AB		**4MG**	**A077471**	**003**	Dec 09, 2009
AB		**4MG**	**A078439**	**002**	Dec 09, 2009
AB		**8MG**	**A077471**	**001**	Dec 09, 2009
AB	MALLINCKRODT	**2MG**	**A076855**	**002**	Sep 19, 2007
AB		**4MG**	**A076855**	**003**	Sep 19, 2007
AB		**8MG**	**A076855**	**001**	Dec 23, 2004
AB	WEST-WARD PHARMS INT	**4MG**	**A074597**	**003**	May 29, 2009
AB		**8MG**	**A074597**	**001**	Jul 29, 1998

TABLET, EXTENDED RELEASE;ORAL

	EXALGO				
AB	MALLINCKRODT INC	**8MG**	**N021217**	**001**	Mar 01, 2010
AB		**12MG**	**N021217**	**002**	Mar 01, 2010
AB		**16MG**	**N021217**	**003**	Mar 01, 2010
AB	**+**	**32MG**	**N021217**	**004**	Aug 24, 2012
	HYDROMORPHONE HYDROCHLORIDE				
AB	ACTAVIS LABS FL INC	**8MG**	**A202144**	**001**	May 12, 2014
AB		**12MG**	**A202144**	**002**	May 12, 2014
AB		**16MG**	**A202144**	**003**	May 12, 2014
AB		**32MG**	**A202144**	**004**	Jun 30, 2016
AB	OSMOTICA	**8MG**	**A205629**	**001**	Jul 07, 2016
AB		**12MG**	**A205629**	**002**	Jul 07, 2016
AB		**16MG**	**A205629**	**003**	Jul 07, 2016
AB		**32MG**	**A205629**	**004**	Jul 07, 2016
AB	PADDOCK LLC	**8MG**	**A204278**	**001**	Apr 06, 2015
AB		**12MG**	**A204278**	**002**	Apr 06, 2015
AB		**16MG**	**A204278**	**003**	Apr 06, 2015

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

	CYANOKIT				
+	SERB SA	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011
	HYDROXOCOBALAMIN				
+	WATSON LABS	1MG/ML	A085998	001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

	PAREMYD				
+	AKORN	1%;0.25%	N019261	001	Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

	HYDROXYCHLOROQUINE SULFATE				
AB	HIKMA PHARMS LLC	**200MG**	**A040760**	**001**	Aug 15, 2007
AB	IPCA LABS LTD	**200MG**	**A040766**	**001**	Jun 14, 2007
AB	MYLAN	**200MG**	**A040274**	**001**	May 29, 1998
AB	SANDOZ	**200MG**	**A040104**	**001**	Nov 30, 1995
AB	TEVA PHARMS	**200MG**	**A040081**	**001**	Sep 30, 1994
AB	WATSON LABS	**200MG**	**A040133**	**001**	Nov 30, 1995
AB	ZYDUS PHARMS USA INC	**200MG**	**A040657**	**001**	Sep 21, 2007
	PLAQUENIL				
AB	**+** CONCORDIA PHARMS INC	**200MG**	**N009768**	**001**	

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION

	HYDROXYPROGESTERONE CAPROATE				
+	ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015

SOLUTION;INTRAMUSCULAR

	MAKENA				
+	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011
	MAKENA PRESERVATIVE FREE				
+	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016

FDA data supplied by DrugPatentWatch.com

HYDROXYPROPYL CELLULOSE
INSERT;OPHTHALMIC
LACRISERT

	+	ATON	5MG	N018771	001

HYDROXYUREA
CAPSULE;ORAL
HYDREA

AB	+	BRISTOL MYERS SQUIBB	**500MG**	**N016295**	**001**	

HYDROXYUREA

AB		BARR	**500MG**	**A075143**	**001**	Oct 16, 1998
AB		PAR PHARM	**500MG**	**A075340**	**001**	Feb 24, 1999

DROXIA

		BRISTOL MYERS SQUIBB	200MG	N016295	002	Feb 25, 1998
			300MG	N016295	003	Feb 25, 1998
			400MG	N016295	004	Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE
INJECTABLE;INJECTION
HYDROXYZINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	**25MG/ML**	**A087329**	**001**	
AP	+		**50MG/ML**	**A087329**	**002**	
AP		LUITPOLD	**25MG/ML**	**A087408**	**001**	
AP			**50MG/ML**	**A087408**	**002**	

SYRUP;ORAL
HYDROXYZINE HYDROCHLORIDE

AA	+	HI TECH PHARMA	**10MG/5ML**	**A040010**	**001**	Oct 28, 1994
AA		SILARX PHARMS INC	**10MG/5ML**	**A201674**	**001**	Aug 21, 2013
AA	+	VINTAGE PHARMS	**10MG/5ML**	**A040391**	**001**	Apr 10, 2002
AA	+	WOCKHARDT	**10MG/5ML**	**A087294**	**001**	Apr 12, 1982

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

AB		AMNEAL PHARM	**10MG**	**A040808**	**001**	Sep 24, 2008
AB			**25MG**	**A040808**	**002**	Sep 24, 2008
AB			**50MG**	**A040808**	**003**	Sep 24, 2008
AB		ECI PHARMS LLC	**10MG**	**A040804**	**001**	Jun 30, 2008
AB			**25MG**	**A040804**	**002**	Jun 30, 2008
AB			**50MG**	**A040804**	**003**	Jun 30, 2008
AB		ELITE LABS INC	**10MG**	**A040604**	**002**	Dec 28, 2004
AB			**25MG**	**A040604**	**003**	Dec 28, 2004
AB			**50MG**	**A040604**	**001**	Dec 28, 2004
AB		HERITAGE PHARMA	**10MG**	**A204279**	**001**	Aug 20, 2014
AB			**25MG**	**A204279**	**002**	Aug 20, 2014
AB			**50MG**	**A204279**	**003**	Aug 20, 2014
AB		HETERO LABS LTD III	**10MG**	**A040805**	**001**	May 29, 2008
AB			**25MG**	**A040805**	**002**	May 29, 2008
AB			**50MG**	**A040805**	**003**	May 29, 2008
AB		INVAGEN PHARMS	**10MG**	**A040812**	**001**	Mar 12, 2008
AB			**25MG**	**A040812**	**002**	Mar 12, 2008
AB			**50MG**	**A040812**	**003**	Mar 12, 2008
AB		KVK TECH	**10MG**	**A040786**	**001**	Mar 20, 2007
AB			**25MG**	**A040787**	**001**	Mar 20, 2007
AB			**50MG**	**A040788**	**001**	Mar 20, 2007
AB		MYLAN	**10MG**	**A091176**	**001**	Jun 07, 2010
AB			**25MG**	**A091176**	**002**	Jun 07, 2010
AB			**50MG**	**A091176**	**003**	Jun 07, 2010
AB		NORTHSTAR HLTHCARE	**10MG**	**A040840**	**002**	Mar 31, 2008
AB			**25MG**	**A040840**	**003**	Mar 31, 2008
AB			**50MG**	**A040840**	**001**	Mar 31, 2008
AB	+	PLIVA	**10MG**	**A088617**	**001**	Jan 10, 1986
AB	+		**25MG**	**A088618**	**001**	Jan 10, 1986
AB	+		**50MG**	**A088619**	**001**	Jan 10, 1986
AB		SUN PHARM INDS INC	**10MG**	**A040899**	**001**	Jun 10, 2008
AB			**25MG**	**A040899**	**002**	Jun 10, 2008
AB			**50MG**	**A040899**	**003**	Jun 10, 2008
AB		VINTAGE PHARMS	**10MG**	**A040579**	**001**	May 27, 2005
AB			**25MG**	**A040574**	**001**	May 27, 2005
AB			**50MG**	**A040580**	**001**	May 27, 2005

HYDROXYZINE PAMOATE
CAPSULE;ORAL

	HYDROXYZINE PAMOATE				
AB	BARR	**EQ 25MG HCL**	**A088496**	**001**	Jun 15, 1984
AB		**EQ 50MG HCL**	**A088487**	**001**	Jun 15, 1984
AB	HERITAGE PHARMA	**EQ 25MG HYDROCHLORIDE**	**A201507**	**001**	Jun 03, 2013
AB		**EQ 50MG HYDROCHLORIDE**	**A201507**	**002**	Jun 03, 2013
AB	IMPAX LABS INC	**EQ 25MG HCL**	**A040156**	**001**	Jul 15, 1996
AB		**EQ 50MG HCL**	**A040156**	**002**	Jul 15, 1996
AB	SANDOZ	**EQ 25MG HCL**	**A087479**	**001**	
AB		**EQ 50MG HCL**	**A086183**	**001**	
	VISTARIL				
AB	PFIZER	**EQ 25MG HCL**	**N011459**	**002**	
AB	**+**	**EQ 50MG HCL**	**N011459**	**004**	
	HYDROXYZINE PAMOATE				
	BARR	EQ 100MG HCL	A088488	001	Jun 15, 1984

IBANDRONATE SODIUM
INJECTABLE;INTRAVENOUS

	BONIVA				
AP	**+** ROCHE	**EQ 3MG BASE/3ML**	**N021858**	**001**	Jan 06, 2006
	IBANDRONATE SODIUM				
AP	ACCORD HLTHCARE	**EQ 3MG BASE/3ML**	**A206058**	**001**	Feb 05, 2016
AP	APOTEX INC	**EQ 3MG BASE/3ML**	**A204222**	**001**	Oct 16, 2015
AP	AUROBINDO PHARMA LTD	**EQ 3MG BASE/3ML**	**A205332**	**001**	Aug 19, 2015
AP	EMCURE PHARMS LTD	**EQ 3MG BASE/3ML**	**A203987**	**001**	Sep 02, 2014
AP	MYLAN LABS LTD	**EQ 3MG BASE/3ML**	**A202671**	**001**	Sep 02, 2014
AP	SAGENT PHARMS	**EQ 3MG BASE/3ML**	**A202235**	**001**	Sep 02, 2014
AP	SUN PHARM INDS LTD	**EQ 3MG BASE/3ML**	**A090853**	**001**	Feb 14, 2014

TABLET;ORAL

	BONIVA				
AB	**+** HOFFMANN LA ROCHE	**EQ 150MG BASE**	**N021455**	**002**	Mar 24, 2005
	IBANDRONATE SODIUM				
AB	APOTEX INC	**EQ 150MG BASE**	**A078948**	**001**	Mar 19, 2012
AB	AUROBINDO PHARMA LTD	**EQ 150MG BASE**	**A204502**	**001**	Mar 11, 2016
AB	DR REDDYS LABS LTD	**EQ 150MG BASE**	**A078997**	**001**	Apr 30, 2012
AB	MYLAN PHARMS INC	**EQ 150MG BASE**	**A078995**	**001**	Mar 19, 2012
AB	ORCHID HLTHCARE	**EQ 150MG BASE**	**A078998**	**001**	Mar 19, 2012
AB	SUN PHARM INDS	**EQ 150MG BASE**	**A078996**	**001**	Aug 15, 2012
AB	WATSON LABS INC	**EQ 150MG BASE**	**A079003**	**001**	Mar 20, 2012

IBRUTINIB
CAPSULE;ORAL

	IMBRUVICA				
	+ PHARMACYCLICS INC	140MG	N205552	001	Nov 13, 2013

IBUPROFEN
SOLUTION;INTRAVENOUS

	CALDOLOR				
	+ CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009

SUSPENSION;ORAL

	IBUPROFEN				
AB	**+** ACTAVIS MID ATLANTIC	**100MG/5ML**	**A074978**	**001**	Mar 25, 1998
AB	HI-TECH PHARMACAL	**100MG/5ML**	**A205647**	**001**	Nov 03, 2016
AB	PERRIGO R AND D	**100MG/5ML**	**A076925**	**001**	Sep 23, 2004

TABLET;ORAL

	IBU-TAB				
AB	ALRA	**400MG**	**A071058**	**001**	Aug 11, 1988
AB		**600MG**	**A071059**	**001**	Aug 11, 1988
	IBUPROFEN				
AB	AIPING PHARM INC	**400MG**	**A202413**	**001**	Nov 23, 2016
AB		**600MG**	**A202413**	**002**	Nov 23, 2016
AB		**800MG**	**A202413**	**003**	Nov 23, 2016
AB	AMNEAL PHARMS NY	**400MG**	**A071334**	**001**	Nov 25, 1986
AB		**400MG**	**A078558**	**001**	Jun 18, 2007
AB		**600MG**	**A071335**	**001**	Nov 25, 1986
AB		**600MG**	**A078558**	**002**	Jun 18, 2007
AB		**800MG**	**A071935**	**001**	Oct 13, 1987
AB		**800MG**	**A078558**	**003**	Jun 18, 2007
AB	CONTRACT PHARMACAL	**400MG**	**A071268**	**002**	Oct 15, 1986
AB		**600MG**	**A071268**	**001**	Oct 15, 1986
AB		**800MG**	**A071268**	**003**	Jul 01, 1988
AB	DR REDDYS LA	**400MG**	**A075682**	**001**	Nov 14, 2001
AB		**600MG**	**A075682**	**002**	Nov 14, 2001

FDA data supplied by DrugPatentWatch.com

IBUPROFEN
TABLET;ORAL
IBUPROFEN

AB	+		**800MG**	**A075682** **003**	Nov 14, 2001
AB		DR REDDYS LABS INC	**400MG**	**A076112** **001**	Oct 31, 2001
AB			**600MG**	**A076112** **002**	Oct 31, 2001
AB			**800MG**	**A076112** **003**	Oct 31, 2001
AB		GRANULES INDIA LTD	**400MG**	**A091625** **001**	Sep 15, 2015
AB			**600MG**	**A091625** **002**	Sep 15, 2015
AB			**800MG**	**A091625** **003**	Sep 15, 2015
AB		MARKSANS PHARMA	**400MG**	**A090796** **001**	Dec 21, 2010
AB			**600MG**	**A090796** **002**	Dec 21, 2010
AB			**800MG**	**A090796** **003**	Dec 21, 2010
AB		PERRIGO R AND D	**400MG**	**A077114** **001**	Jul 18, 2005
AB			**600MG**	**A077114** **002**	Jul 18, 2005
AB			**800MG**	**A077114** **003**	Jul 18, 2005
AB		STRIDES PHARMA	**400MG**	**A078329** **001**	Feb 05, 2009
AB			**600MG**	**A078329** **002**	Feb 05, 2009
AB			**800MG**	**A078329** **003**	Feb 05, 2009
AB		VINTAGE PHARMS	**400MG**	**A071644** **001**	Feb 01, 1988

IBUPROFEN LYSINE
INJECTABLE;INTRAVENOUS
IBUPROFEN LYSINE

AP		EXELA PHARMA SCIENCE	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**A202402** **001**	Mar 30, 2016

NEOPROFEN

AP	+	RECORDATI RARE	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**N021903** **001**	Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE
TABLET;ORAL
OXYCODONE HYDROCHLORIDE AND IBUPROFEN

AB		ACTAVIS ELIZABETH	**400MG;5MG**	**A078769** **001**	Jan 04, 2008
AB	+	BARR LABS INC	**400MG;5MG**	**A078316** **001**	Nov 29, 2007
AB		WATSON LABS	**400MG;5MG**	**A078394** **001**	Nov 26, 2007

IBUTILIDE FUMARATE
INJECTABLE;INJECTION
CORVERT

AP	+	PHARMACIA AND UPJOHN	**0.1MG/ML**	**N020491** **001**	Dec 28, 1995

IBUTILIDE FUMARATE

AP		LUITPOLD	**0.1MG/ML**	**A090240** **001**	Jan 11, 2010
AP		MYLAN INSTITUTIONAL	**0.1MG/ML**	**A090643** **001**	Jan 11, 2010
AP			**0.1MG/ML**	**A090924** **001**	Jan 11, 2010

ICATIBANT ACETATE
INJECTABLE;SUBCUTANEOUS
FIRAZYR

	+	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150 001	Aug 25, 2011

ICODEXTRIN
SOLUTION;INTRAPERITONEAL
EXTRANEAL

	+	BAXTER HLTHCARE	7.5GM/100ML	N021321 001	Dec 20, 2002

ICOSAPENT ETHYL
CAPSULE;ORAL
VASCEPA

	+	AMARIN PHARMS	1GM	N202057 001	Jul 26, 2012

IDARUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
IDAMYCIN PFS

AP	+	PHARMACIA AND UPJOHN	**1MG/ML**	**N050734** **001**	Feb 17, 1997

IDARUBICIN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/ML**	**A065440** **001**	Aug 04, 2009
AP		MYLAN LABS LTD	**1MG/ML**	**A200144** **001**	Oct 11, 2012
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A065275** **001**	Dec 14, 2006
AP			**1MG/ML**	**A065288** **001**	May 15, 2007

IDARUBICIN HYDROCHLORIDE PFS

AP		TEVA PHARMS USA	**1MG/ML**	**A065036** **001**	May 01, 2002

FDA data supplied by DrugPatentWatch.com

IDELALISIB
TABLET;ORAL
ZYDELIG

		GILEAD SCIENCES INC	100MG	N205858	001 Jul 23, 2014
	+		150MG	N205858	002 Jul 23, 2014

IDOXURIDINE
SOLUTION/DROPS;OPHTHALMIC
DENDRID

	+	ALCON	0.1%	N014169	001

IFOSFAMIDE
INJECTABLE;INJECTION

		IFEX			
AP		BAXTER HLTHCARE	**1GM/VIAL**	**N019763**	**001** Dec 30, 1988
AP			**3GM/VIAL**	**N019763**	**002** Dec 30, 1988
		IFOSFAMIDE			
AP	+	FRESENIUS KABI USA	**1GM/VIAL**	**A076078**	**001** May 28, 2002
AP			**1GM/20ML (50MG/ML)**	**A090181**	**001** Sep 22, 2009
AP	+		**3GM/VIAL**	**A076078**	**002** May 28, 2002
AP			**3GM/60ML (50MG/ML)**	**A090181**	**002** Sep 22, 2009
AP		MYLAN LABS LTD	**1GM/20ML (50MG/ML)**	**A201689**	**001** Nov 26, 2012
AP			**3GM/60ML (50MG/ML)**	**A201689**	**002** Nov 26, 2012
AP	+	TEVA PHARMS USA	**1GM/20ML (50MG/ML)**	**A076657**	**001** Apr 04, 2007
AP	+		**3GM/60ML (50MG/ML)**	**A076657**	**002** Apr 04, 2007
AP		WEST-WARD PHARMS INT	**1GM/20ML(50MG/ML)**	**A076619**	**001** Jun 29, 2011
AP			**3GM/60ML(50MG/ML)**	**A076619**	**002** Jun 29, 2011

IFOSFAMIDE; MESNA
INJECTABLE;INTRAVENOUS
IFOSFAMIDE/MESNA KIT

	+	TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001 Feb 26, 2002
	+		3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002 Feb 26, 2002

ILOPERIDONE
TABLET;ORAL

		FANAPT			
AB	+	VANDA PHARMS INC	**1MG**	**N022192**	**001** May 06, 2009
AB			**2MG**	**N022192**	**002** May 06, 2009
AB			**4MG**	**N022192**	**003** May 06, 2009
AB			**6MG**	**N022192**	**004** May 06, 2009
AB			**8MG**	**N022192**	**005** May 06, 2009
AB			**10MG**	**N022192**	**006** May 06, 2009
AB			**12MG**	**N022192**	**007** May 06, 2009
		ILOPERIDONE			
AB		INVENTIA HLTHCARE	**1MG**	**A207231**	**001** Nov 28, 2016
AB			**2MG**	**A207231**	**002** Nov 28, 2016
AB			**4MG**	**A207231**	**003** Nov 28, 2016
AB			**6MG**	**A207231**	**004** Nov 28, 2016
AB			**8MG**	**A207231**	**005** Nov 28, 2016
AB			**10MG**	**A207231**	**006** Nov 28, 2016
AB			**12MG**	**A207231**	**007** Nov 28, 2016

ILOPROST
SOLUTION;INHALATION
VENTAVIS

	+	ACTELION PHARMS LTD	10MCG/ML (10MCG/ML)	N021779	002 Dec 08, 2005
	+		20MCG/ML (20MCG/ML)	N021779	003 Aug 07, 2009

IMATINIB MESYLATE
TABLET;ORAL

		GLEEVEC			
AB		NOVARTIS	**EQ 100MG BASE**	**N021588**	**001** Apr 18, 2003
AB	+		**EQ 400MG BASE**	**N021588**	**002** Apr 18, 2003
		IMATINIB MESYLATE			
AB		APOTEX INC	**EQ 100MG BASE**	**A079179**	**001** Aug 05, 2016
AB			**EQ 400MG BASE**	**A079179**	**002** Aug 05, 2016
AB		SUN PHARMA GLOBAL	**EQ 100MG BASE**	**A078340**	**001** Dec 03, 2015
AB			**EQ 400MG BASE**	**A078340**	**002** Dec 03, 2015
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A204285**	**001** Aug 04, 2016
AB			**EQ 400MG BASE**	**A204285**	**002** Aug 04, 2016

FDA data supplied by DrugPatentWatch.com

IMIGLUCERASE
INJECTABLE;INJECTION
CEREZYME

	GENZYME	200 UNITS/VIAL	N020367	001	May 23, 1994
+		400 UNITS/VIAL	N020367	002	Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE
TABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

AB	LEADING PHARMA LLC	**10MG**	**A040903**	**001**	Oct 24, 2012
AB		**25MG**	**A040903**	**002**	Oct 24, 2012
AB		**50MG**	**A040903**	**003**	Oct 24, 2012
AB	LUPIN LTD	**10MG**	**A090441**	**002**	Mar 11, 2010
AB		**25MG**	**A090441**	**003**	Mar 11, 2010
AB		**50MG**	**A090441**	**001**	Mar 11, 2010
AB	PAR PHARM	**10MG**	**A088292**	**001**	Oct 21, 1983
AB		**10MG**	**A089422**	**001**	Jul 14, 1987
AB		**25MG**	**A088262**	**001**	Oct 21, 1983
AB		**50MG**	**A088276**	**001**	Oct 21, 1983
AB	SANDOZ	**10MG**	**A084936**	**002**	
AB		**25MG**	**A083745**	**001**	
AB		**50MG**	**A084937**	**001**	
AB	SUN PHARM INDS	**10MG**	**A081048**	**001**	Jun 05, 1990
AB		**25MG**	**A081049**	**001**	Jun 05, 1990
AB		**50MG**	**A081050**	**001**	Jun 05, 1990

TOFRANIL

AB	MALLINCKRODT INC	**10MG**	**A087844**	**001**	May 22, 1984
AB		**25MG**	**A087845**	**001**	May 22, 1984
AB +		**50MG**	**A087846**	**001**	May 22, 1984

IMIPRAMINE PAMOATE
CAPSULE;ORAL
IMIPRAMINE PAMOATE

AB	LUPIN LTD	**EQ 75MG HCL**	**A090444**	**001**	Apr 16, 2010
AB		**EQ 100MG HCL**	**A090444**	**002**	Apr 16, 2010
AB		**EQ 125MG HCL**	**A090444**	**003**	Apr 16, 2010
AB		**EQ 150MG HCL**	**A090444**	**004**	Apr 16, 2010
AB	MYLAN PHARMS INC	**EQ 75MG HCL**	**A202338**	**001**	Jun 28, 2013
AB		**EQ 100MG HCL**	**A202338**	**002**	Jun 28, 2013
AB		**EQ 125MG HCL**	**A202338**	**003**	Jun 28, 2013
AB		**EQ 150MG HCL**	**A202338**	**004**	Jun 28, 2013
AB +	WEST-WARD PHARMS INT	**EQ 75MG HCL**	**A091099**	**001**	Apr 16, 2010
AB		**EQ 100MG HCL**	**A091099**	**002**	Apr 16, 2010
AB		**EQ 125MG HCL**	**A091099**	**003**	Apr 16, 2010
AB		**EQ 150MG HCL**	**A091099**	**004**	Apr 16, 2010

IMIQUIMOD
CREAM;TOPICAL
ALDARA

AB +	MEDICIS	**5%**	**N020723**	**001**	Feb 27, 1997

IMIQUIMOD

AB	APOTEX INC	**5%**	**A091308**	**001**	Apr 06, 2012
AB	FOUGERA PHARMS	**5%**	**A078548**	**001**	Feb 25, 2010
AB	G AND W LABS INC	**5%**	**A200481**	**001**	Apr 18, 2011
AB	GLENMARK GENERICS	**5%**	**A201994**	**001**	Mar 06, 2012
AB	PERRIGO ISRAEL	**5%**	**A078837**	**001**	Sep 07, 2010
AB	STRIDES PHARMA	**5%**	**A202002**	**001**	Jun 24, 2014
AB	TARO	**5%**	**A200173**	**001**	Apr 15, 2011
AB	TOLMAR	**5%**	**A091044**	**001**	Feb 28, 2011

ZYCLARA

+	MEDICIS	2.5%	N022483	002	Jul 15, 2011
+		3.75%	N022483	001	Mar 25, 2010

INAMRINONE LACTATE
INJECTABLE;INJECTION
AMRINONE LACTATE

+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075513	001	May 09, 2000

INDACATEROL MALEATE
POWDER;INHALATION
ARCAPTA NEOHALER

+	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011

FDA data supplied by DrugPatentWatch.com

INDAPAMIDE
TABLET;ORAL
INDAPAMIDE

AB	ACTAVIS ELIZABETH	**1.25MG**	**A074722**	**001**	Jun 17, 1996
AB		**2.5MG**	**A074722**	**002**	Jun 17, 1996
AB	AMERIGEN PHARMS LTD	**1.25MG**	**A075201**	**001**	Dec 04, 1998
AB		**2.5MG**	**A075201**	**002**	Dec 04, 1998
AB	ANI PHARMS INC	**1.25MG**	**A074299**	**002**	Apr 29, 1996
AB		**2.5MG**	**A074299**	**001**	Jul 27, 1995
AB	MYLAN	**1.25MG**	**A074461**	**002**	Mar 26, 1997
AB +		**2.5MG**	**A074461**	**001**	Mar 27, 1996
AB	MYLAN PHARMS INC	**1.25MG**	**A075105**	**001**	Jul 23, 1998
AB		**2.5MG**	**A075105**	**002**	Jul 23, 1998

INDINAVIR SULFATE
CAPSULE;ORAL
CRIXIVAN

	MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996
+		EQ 400MG BASE	N020685	001	Mar 13, 1996

INDIUM IN-111 CHLORIDE
INJECTABLE;INJECTION
INDICLOR

+	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992

INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE
INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985

INDIUM IN-111 PENTETATE DISODIUM
INJECTABLE;INTRATHECAL
MPI INDIUM DTPA IN 111

+	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT
INJECTABLE;INJECTION
OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994

INDOCYANINE GREEN
INJECTABLE;INJECTION
IC-GREEN

AP +	AKORN	**25MG/VIAL**	**N011525**	**001**	

INDOCYANINE GREEN

AP	DIAGNOSTIC GREEN	**25MG/VIAL**	**A040811**	**001**	Nov 21, 2007

INDOMETHACIN
CAPSULE;ORAL
INDOMETHACIN

AB	GLENMARK GENERICS	**25MG**	**A091276**	**001**	Dec 22, 2010
AB		**50MG**	**A091276**	**002**	Dec 22, 2010
AB	HERITAGE PHARMS INC	**25MG**	**N018851**	**001**	May 18, 1984
AB		**50MG**	**N018851**	**002**	May 18, 1984
AB	HETERO LABS LTD III	**25MG**	**A091240**	**001**	Apr 12, 2011
AB		**50MG**	**A091240**	**002**	Apr 12, 2011
AB	IVAX SUB TEVA PHARMS	**25MG**	**A070719**	**001**	Feb 12, 1986
AB		**50MG**	**A070756**	**001**	Feb 12, 1986
AB	MYLAN	**25MG**	**N018858**	**001**	Apr 20, 1984
AB +		**50MG**	**A070624**	**001**	Sep 04, 1985
AB	SANDOZ	**25MG**	**A070673**	**001**	Apr 29, 1987
AB		**50MG**	**A070674**	**001**	Apr 29, 1987
AB	SUN PHARM INDS INC	**25MG**	**A091401**	**001**	Mar 28, 2013
AB		**50MG**	**A091401**	**002**	Mar 28, 2013
AB	ZYDUS PHARMS USA INC	**25MG**	**A090403**	**001**	Nov 15, 2010
AB		**50MG**	**A090403**	**002**	Nov 15, 2010

TIVORBEX

	IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014
+		40MG	N204768	002	Feb 24, 2014

CAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN

AB	AMNEAL PHARMS	**75MG**	**A091549**	**001**	Dec 01, 2010
AB	AUROBINDO PHARMA LTD	**75MG**	**A204243**	**001**	Dec 27, 2016
AB	AVANTHI INC	**75MG**	**A079175**	**001**	Mar 06, 2009

FDA data supplied by DrugPatentWatch.com

INDOMETHACIN

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

AB		HETERO LABS LTD III	**75MG**	**A201807**	**001**	Sep 28, 2012
AB		JUBILANT GENERICS	**75MG**	**A202706**	**001**	Oct 05, 2015
AB		MYLAN PHARMS INC	**75MG**	**A202139**	**001**	Mar 20, 2014
AB		PADDOCK LLC	**75MG**	**A200529**	**001**	Nov 30, 2010
AB	**+**	SANDOZ	**75MG**	**A074464**	**001**	May 28, 1998
AB		WATSON LABS INC	**75MG**	**A202572**	**001**	Dec 09, 2013

INJECTABLE;INJECTION

INDOMETHACIN

	+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N022536	001	Mar 17, 2010

SUPPOSITORY;RECTAL

INDOMETHACIN

	+	G AND W LABS	50MG	A073314	001	Aug 31, 1992

SUSPENSION;ORAL

INDOCIN

	+	IROKO PHARMS	25MG/5ML	N018332	001	Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE;INJECTION

INDOCIN

AP	**+**	RECORDATI RARE	**EQ 1MG BASE/VIAL**	**N018878**	**001**	Jan 30, 1985

INDOMETHACIN SODIUM

AP		HOSPIRA INC	**EQ 1MG BASE/VIAL**	**A204118**	**001**	Apr 19, 2016
AP		WEST-WARD PHARMS INT	**EQ 1MG BASE/VIAL**	**A078713**	**001**	Jul 16, 2008

INGENOL MEBUTATE

GEL;TOPICAL

PICATO

	+	LEO LABS	0.015%	N202833	001	Jan 23, 2012
	+		0.05%	N202833	002	Jan 23, 2012

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG MIX 70/30

	+	NOVO NORDISK INC	700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)	N021172	001	Nov 01, 2001

NOVOLOG MIX 70/30 FLEXPEN

	+	NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	004	May 03, 2002

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG

	+	NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N020986	001	Jun 07, 2000

NOVOLOG FLEXPEN

	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	003	Jan 19, 2001

NOVOLOG FLEXTOUCH

	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013

NOVOLOG PENFILL

	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	002	Jun 07, 2000

INSULIN ASPART; INSULIN DEGLUDEC

SOLUTION;SUBCUTANEOUS

RYZODEG 70/30

	+	NOVO NORDISK INC	90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)	N203313	001	Sep 25, 2015

INSULIN DEGLUDEC

SOLUTION;SUBCUTANEOUS

TRESIBA

		NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N203314	001	Sep 25, 2015
	+		600 UNITS/3ML (200 UNITS/ML)	N203314	002	Sep 25, 2015

INSULIN DEGLUDEC; LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS

XULTOPHY 100/3.6

	+	NOVO NORDISK INC	300 UNITS/3ML;10.8MG/3ML (100 UNITS/ML;3.6MG/ML)	N208583	001	Nov 21, 2016

FDA data supplied by DrugPatentWatch.com

INSULIN DETEMIR RECOMBINANT
INJECTABLE;SUBCUTANEOUS
LEVEMIR
+ NOVO NORDISK INC 1000 UNITS/10ML (100 UNITS/ML) N021536 001 Jun 16, 2005
LEVEMIR FLEXTOUCH
+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 005 Oct 31, 2013

INSULIN GLARGINE
SOLUTION;SUBCUTANEOUS
BASAGLAR
ELI LILLY AND CO 300 UNITS/3ML (100 UNITS/ML) N205692 001 Dec 16, 2015

INSULIN GLARGINE RECOMBINANT
INJECTABLE;INJECTION
LANTUS
+ SANOFI AVENTIS US 100 UNITS/ML N021081 001 Apr 20, 2000
LANTUS SOLOSTAR
+ SANOFI AVENTIS US 300 UNITS/3ML (100 UNITS/ML) N021081 002 Apr 27, 2007
SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR
+ SANOFI US SERVICES 300 UNITS/ML (300 UNITS/ML) N206538 001 Feb 25, 2015

INSULIN GLARGINE; LIXISENATIDE
SOLUTION;SUBCUTANEOUS
SOLIQUA 100/33
+ SANOFI-AVENTIS US 300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML) N208673 001 Nov 21, 2016

INSULIN GLULISINE RECOMBINANT
INJECTABLE;IV (INFUSION), SUBCUTANEOUS
APIDRA
+ SANOFI AVENTIS US 1000 UNITS/10ML (100 UNITS/ML) N021629 001 Apr 16, 2004
+ 300 UNITS/3ML (100 UNITS/ML) N021629 002 Dec 20, 2005
INJECTABLE;SUBCUTANEOUS
APIDRA SOLOSTAR
SANOFI AVENTIS US 300 UNITS/3ML N021629 003 Feb 24, 2009

INSULIN HUMAN
SOLUTION;SUBCUTANEOUS
HUMULIN R
+ LILLY 10000 UNITS/20ML (500 UNITS/ML) N018780 004 Mar 31, 1994
HUMULIN R KWIKPEN
+ LILLY 1500 UNITS/3ML (500 UNITS/ML) N018780 002 Dec 29, 2015

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
INJECTABLE;INJECTION
HUMALOG MIX 50/50
+ LILLY 50 UNITS/ML;50 UNITS/ML N021018 001 Dec 22, 1999
HUMALOG MIX 50/50 KWIKPEN
+ LILLY 50 UNITS/ML;50 UNITS/ML N021018 002 Sep 06, 2007
HUMALOG MIX 75/25
+ LILLY 75 UNITS/ML;25 UNITS/ML N021017 001 Dec 22, 1999
HUMALOG MIX 75/25 KWIKPEN
+ LILLY 75 UNITS/ML;25 UNITS/ML N021017 002 Sep 06, 2007

INSULIN LISPRO RECOMBINANT
INJECTABLE;INJECTION
HUMALOG
+ LILLY 100 UNITS/ML N020563 001 Jun 14, 1996
HUMALOG KWIKPEN
+ LILLY 100 UNITS/ML N020563 003 Sep 06, 2007
SOLUTION;SUBCUTANEOUS
HUMALOG KWIKPEN
+ ELI LILLY AND CO 200 UNITS/ML N205747 001 May 26, 2015

INSULIN RECOMBINANT HUMAN
POWDER;INHALATION
AFREZZA
MANNKIND 4 UNITS/INH N022472 001 Jun 27, 2014
+ 8 UNITS/INH N022472 002 Jun 27, 2014
12 UNITS/INH N022472 003 Apr 17, 2015

FDA data supplied by DrugPatentWatch.com

IOBENGUANE SULFATE I-123
SOLUTION;INTRAVENOUS
ADREVIEW
+ GE HEALTHCARE 10mCi/5ML (2mCi/ML) N022290 001 Sep 19, 2008

IODIPAMIDE MEGLUMINE
INJECTABLE;INJECTION
CHOLOGRAFIN MEGLUMINE
+ BRACCO 52% N009321 003

IODIXANOL
INJECTABLE;INJECTION
VISIPAQUE 270
+ GE HEALTHCARE 55% N020351 001 Mar 22, 1996
55% N020808 001 Aug 29, 1997
VISIPAQUE 320
+ GE HEALTHCARE 65.2% N020351 002 Mar 22, 1996
65.2% N020808 002 Aug 29, 1997

IOFLUPANE I-123
SOLUTION;INTRAVENOUS
DATSCAN
+ GE HLTHCARE INC 5mCi/2.5ML (2mCi/ML) N022454 001 Jan 14, 2011

IOHEXOL
FOR SOLUTION;ORAL
ORALTAG
INTERPHARMA PRAHA AS 9.7GM/BOT N205383 001 Mar 26, 2015
INJECTABLE;INJECTION
OMNIPAQUE 140
+ GE HEALTHCARE 30.2% N018956 005 Nov 30, 1988
SOLUTION;INJECTION, ORAL
OMNIPAQUE 350
+ GE HEALTHCARE 75.5% N018956 004 Dec 26, 1985
75.5% N020608 003 Oct 24, 1995
SOLUTION;INJECTION, ORAL, RECTAL
OMNIPAQUE 180
+ GE HEALTHCARE 38.8% N018956 001 Dec 26, 1985
OMNIPAQUE 240
+ GE HEALTHCARE 51.8% N018956 002 Dec 26, 1985
51.8% N020608 001 Oct 24, 1995
OMNIPAQUE 300
+ GE HEALTHCARE 64.7% N018956 003 Dec 26, 1985
64.7% N020608 002 Oct 24, 1995

IOPAMIDOL
INJECTABLE;INJECTION
ISOVUE-300
AP **+** BRACCO **61%** **N018735 002** Dec 31, 1985
ISOVUE-370
AP **+** BRACCO **76%** **N018735 003** Dec 31, 1985
SCANLUX-300
AP MYLAN INSTITUTIONAL **61%** **A090394 001** Jun 18, 2010
SCANLUX-370
AP MYLAN INSTITUTIONAL **76%** **A090394 002** Jun 18, 2010
ISOVUE-200
+ BRACCO 41% N018735 006 Jul 07, 1987
ISOVUE-250
+ BRACCO 51% N018735 007 Jul 06, 1992
+ 51% N020327 002 Oct 12, 1994
ISOVUE-300
+ BRACCO 61% N020327 003 Oct 12, 1994
ISOVUE-370
+ BRACCO 76% N020327 004 Oct 12, 1994
ISOVUE-M 200
+ BRACCO 41% N018735 001 Dec 31, 1985
ISOVUE-M 300
+ BRACCO 61% N018735 004 Dec 31, 1985

IOPROMIDE
INJECTABLE;INJECTION
ULTRAVIST (PHARMACY BULK)

+	BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004
+		62.3%	N021425	001	Sep 20, 2002
+		76.9%	N021425	002	Sep 20, 2002

ULTRAVIST 150

+	BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995

ULTRAVIST 240

+	BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995

ULTRAVIST 300

+	BAYER HLTHCARE	62.3%	N020220	002	May 10, 1995

ULTRAVIST 300 IN PLASTIC CONTAINER

+	BAYER HLTHCARE	62.3%	N020220	005	Nov 18, 2008

ULTRAVIST 370

+	BAYER HLTHCARE	76.9%	N020220	001	May 10, 1995

IOTHALAMATE MEGLUMINE
INJECTABLE;INJECTION
CONRAY

+	LIEBEL-FLARSHEIM	60%	N013295	001	

CONRAY 30

+	LIEBEL-FLARSHEIM	30%	N016983	001	

CONRAY 43

+	LIEBEL-FLARSHEIM	43%	N013295	002	

SOLUTION;INTRAVESICAL
CYSTO-CONRAY II

	LIEBEL-FLARSHEIM	17.2%	N017057	002	

IOTHALAMATE SODIUM I-125
INJECTABLE;INJECTION
GLOFIL-125

	ISOTEX	250-300uCi/ML	N017279	001	

IOVERSOL
INJECTABLE;INJECTION
OPTIRAY 240

+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988

OPTIRAY 300

+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992
+		64%	N020923	004	May 13, 1999

OPTIRAY 320

+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988
+		68%	N020923	002	May 29, 1998

OPTIRAY 350

+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992
+		74%	N020923	003	May 28, 1998

IPRATROPIUM BROMIDE
AEROSOL, METERED;INHALATION
ATROVENT HFA

+	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004

SOLUTION;INHALATION
IPRATROPIUM BROMIDE

AN		AUROBINDO PHARMA LTD	**0.02%**	**A206543**	**001**	Oct 27, 2016
AN		BAUSCH AND LOMB INC	**0.02%**	**A075835**	**001**	Oct 15, 2001
AN		LANDELA PHARM	**0.02%**	**A077072**	**001**	Jul 19, 2005
AN		NEPHRON	**0.02%**	**A075562**	**001**	Sep 27, 2001
AN	**+**	RITEDOSE CORP	**0.02%**	**A075693**	**001**	Jan 26, 2001
AN		SUN PHARMA GLOBAL	**0.02%**	**A207903**	**001**	Jan 03, 2017
AN		WATSON LABS	**0.02%**	**A076291**	**001**	May 09, 2005

SPRAY, METERED;NASAL
ATROVENT

AB	**+**	BOEHRINGER INGELHEIM	**0.021MG/SPRAY**	**N020393**	**001**	Oct 20, 1995
AB	**+**		**0.042MG/SPRAY**	**N020394**	**001**	Oct 20, 1995

IPRATROPIUM BROMIDE

AB		BAUSCH AND LOMB	**0.021MG/SPRAY**	**A076025**	**001**	Mar 31, 2003
AB			**0.042MG/SPRAY**	**A076103**	**001**	Mar 31, 2003
AB		MYLAN SPECLT	**0.021MG/SPRAY**	**A075552**	**001**	Mar 31, 2003
AB			**0.042MG/SPRAY**	**A075553**	**001**	Mar 31, 2003
AB		WEST-WARD PHARMS INT	**0.021MG/SPRAY**	**A076664**	**001**	Nov 05, 2003
AB			**0.042MG/SPRAY**	**A076598**	**001**	Nov 05, 2003

FDA data supplied by DrugPatentWatch.com

IRBESARTAN
TABLET;ORAL
AVAPRO

AB		SANOFI AVENTIS US	75MG	N020757	001	Sep 30, 1997
AB			150MG	N020757	002	Sep 30, 1997
AB	+		300MG	N020757	003	Sep 30, 1997

IRBESARTAN

AB		AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015
AB			150MG	A203685	002	Dec 10, 2015
AB			300MG	A203685	003	Dec 10, 2015
AB		ALEMBIC PHARMS LTD	75MG	A091236	001	Oct 15, 2012
AB			150MG	A091236	002	Oct 15, 2012
AB			300MG	A091236	003	Oct 15, 2012
AB		APOTEX INC	75MG	A200832	001	Oct 15, 2012
AB			150MG	A200832	002	Oct 15, 2012
AB			300MG	A200832	003	Oct 15, 2012
AB		AUROBINDO PHARMA LTD	75MG	A203081	001	Sep 27, 2012
AB			150MG	A203081	002	Sep 27, 2012
AB			300MG	A203081	003	Sep 27, 2012
AB		CIPLA LTD	75MG	A077205	001	Nov 14, 2012
AB			150MG	A077205	002	Nov 14, 2012
AB			300MG	A077205	003	Nov 14, 2012
AB		DR REDDYS LABS LTD	75MG	A203161	001	Sep 27, 2012
AB			150MG	A203161	002	Sep 27, 2012
AB			300MG	A203161	003	Sep 27, 2012
AB		HETERO LABS LTD V	75MG	A202910	001	Sep 27, 2012
AB			150MG	A202910	002	Sep 27, 2012
AB			300MG	A202910	003	Sep 27, 2012
AB		HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016
AB			150MG	A206194	002	Jun 14, 2016
AB			300MG	A206194	003	Jun 14, 2016
AB		JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015
AB			150MG	A203534	002	Feb 23, 2015
AB			300MG	A203534	003	Feb 23, 2015
AB		LUPIN LTD	75MG	A201531	001	Oct 15, 2012
AB			150MG	A201531	002	Oct 15, 2012
AB			300MG	A201531	003	Oct 15, 2012
AB		MACLEODS PHARMS LTD	75MG	A202254	001	Oct 03, 2012
AB			150MG	A202254	002	Oct 03, 2012
AB			300MG	A202254	003	Oct 03, 2012
AB		MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012
AB			150MG	A200461	002	Sep 27, 2012
AB			300MG	A200461	003	Sep 27, 2012
AB		PRINSTON INC	75MG	A203071	001	Sep 27, 2012
AB			150MG	A203071	002	Sep 27, 2012
AB			300MG	A203071	003	Sep 27, 2012
AB		SANDOZ	75MG	A077466	001	Sep 27, 2012
AB			150MG	A077466	002	Sep 27, 2012
AB			300MG	A077466	003	Sep 27, 2012
AB		SCIEGEN PHARMS INC	75MG	A204774	001	Dec 07, 2015
AB			150MG	A204774	002	Dec 07, 2015
AB			300MG	A204774	003	Dec 07, 2015
AB		TEVA PHARMS	75MG	A077159	001	Mar 30, 2012
AB			150MG	A077159	002	Mar 30, 2012
AB			300MG	A077159	003	Mar 30, 2012
AB		UNICHEM LABS LTD	75MG	A203020	001	Dec 07, 2015
AB			150MG	A203020	002	Dec 07, 2015
AB			300MG	A203020	003	Dec 07, 2015
AB		WEST-WARD PHARMS INT	75MG	A090201	001	Oct 15, 2012
AB			150MG	A090201	002	Oct 15, 2012
AB			300MG	A090201	003	Oct 15, 2012
AB		ZYDUS PHARMS USA INC	75MG	A079213	001	Sep 27, 2012
AB			150MG	A079213	002	Sep 27, 2012
AB			300MG	A079213	003	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE
INJECTABLE;INJECTION
CAMPTOSAR

AP	+	PFIZER INC	40MG/2ML (20MG/ML)	N020571	001	Jun 14, 1996
AP	+		100MG/5ML (20MG/ML)	N020571	002	Jun 14, 1996
AP	+		300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010

FDA data supplied by DrugPatentWatch.com

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	**40MG/2ML (20MG/ML)**	**A079068**	**001**	Nov 21, 2008
AP		**100MG/5ML (20MG/ML)**	**A079068**	**002**	Nov 21, 2008
AP	ACTAVIS TOTOWA	**40MG/2ML (20MG/ML)**	**A078589**	**001**	Feb 27, 2008
AP		**100MG/5ML (20MG/ML)**	**A078589**	**002**	Feb 27, 2008
AP		**500MG/25ML (20MG/ML)**	**A078589**	**003**	Nov 18, 2015
AP	AKORN	**40MG/2ML (20MG/ML)**	**A090726**	**001**	Sep 16, 2009
AP		**100MG/5ML (20MG/ML)**	**A090726**	**002**	Sep 16, 2009
AP	CIPLA LTD	**40MG/2ML (20MG/ML)**	**A077219**	**001**	Feb 20, 2008
AP		**100MG/5ML (20MG/ML)**	**A077219**	**002**	Feb 20, 2008
AP	DR REDDYS LABS LTD	**40MG/2ML (20MG/ML)**	**A078953**	**001**	Apr 15, 2010
AP		**100MG/5ML (20MG/ML)**	**A078953**	**002**	Apr 15, 2010
AP	EMCURE PHARMS LTD	**40MG/2ML (20MG/ML)**	**A200771**	**001**	Feb 14, 2012
AP		**100MG/5ML (20MG/ML)**	**A200771**	**002**	Feb 14, 2012
AP	EUROHLTH INTL SARL	**40MG/2ML (20MG/ML)**	**A078753**	**001**	Dec 24, 2008
AP		**100MG/5ML (20MG/ML)**	**A078753**	**002**	Dec 24, 2008
AP	FRESENIUS KABI ONCOL	**40MG/2ML (20MG/ML)**	**A078188**	**001**	Feb 27, 2008
AP		**100MG/5ML (20MG/ML)**	**A078188**	**002**	Feb 27, 2008
AP	FRESENIUS KABI USA	**40MG/2ML (20MG/ML)**	**A077776**	**001**	Feb 27, 2008
AP		**100MG/5ML (20MG/ML)**	**A077776**	**002**	Feb 27, 2008
AP	HIKMA FARMACEUTICA	**40MG/2ML (20MG/ML)**	**A091032**	**001**	Dec 20, 2010
AP		**100MG/5ML (20MG/ML)**	**A091032**	**002**	Dec 20, 2010
AP	HISUN PHARM HANGZHOU	**40MG/2ML (20MG/ML)**	**A090016**	**001**	Jan 28, 2009
AP		**100MG/5ML (20MG/ML)**	**A090016**	**002**	Jan 28, 2009
AP	HOSPIRA	**40MG/2ML (20MG/ML)**	**A077915**	**001**	Feb 27, 2008
AP		**100MG/5ML (20MG/ML)**	**A077915**	**002**	Feb 27, 2008
AP +		**500MG/25ML (20MG/ML)**	**A078796**	**001**	Feb 27, 2008
AP	JIANGSU HENGRUI MED	**40MG/2ML (20MG/ML)**	**A090675**	**002**	Dec 16, 2011
AP		**100MG/5ML (20MG/ML)**	**A090675**	**001**	Dec 16, 2011
AP	MUSTAFA NEVZAT ILAC	**40MG/2ML (20MG/ML)**	**A090393**	**002**	May 13, 2011
AP		**100MG/5ML (20MG/ML)**	**A090393**	**003**	May 13, 2011
AP	PLIVA LACHEMA	**40MG/2ML (20MG/ML)**	**A078122**	**001**	Oct 31, 2008
AP		**100MG/5ML (20MG/ML)**	**A078122**	**002**	Oct 31, 2008
AP	QILU PHARM CO LTD	**40MG/2ML (20MG/ML)**	**A203380**	**001**	May 03, 2016
AP		**100MG/5ML (20MG/ML)**	**A203380**	**002**	May 03, 2016
AP		**300MG/15ML (20MG/ML)**	**A203380**	**003**	May 03, 2016
AP	SANDOZ INC	**40MG/2ML (20MG/ML)**	**A090137**	**001**	Nov 12, 2009
AP		**100MG/5ML (20MG/ML)**	**A090137**	**002**	Nov 12, 2009
AP	SUN PHARMA GLOBAL	**40MG/2ML (20MG/ML)**	**A078805**	**001**	Apr 21, 2008
AP		**100MG/5ML (20MG/ML)**	**A078805**	**002**	Apr 21, 2008
AP	TEVA PHARMS USA	**40MG/2ML (20MG/ML)**	**A090101**	**002**	Feb 27, 2008
AP		**100MG/5ML (20MG/ML)**	**A090101**	**003**	Feb 27, 2008
AP		**500MG/25ML (20MG/ML)**	**A090101**	**001**	Nov 26, 2008

INJECTABLE, LIPOSOMAL;IV (INFUSION)

ONIVYDE

+	MERRIMACK PHARMS	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015

IRON DEXTRAN

INJECTABLE;INJECTION

DEXFERRUM

BP	LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996

INFED

BP +	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001	

PROFERDEX

BP	NEW RIVER	EQ 50MG IRON/ML	N017807	001	

IRON SUCROSE

INJECTABLE;INTRAVENOUS

VENOFER

	LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005
+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000
		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007

ISAVUCONAZONIUM SULFATE

CAPSULE;ORAL

CRESEMBA

+	ASTELLAS	186MG	N207500	001	Mar 06, 2015

POWDER;IV (INFUSION)

CRESEMBA

+	ASTELLAS	372MG	N207501	001	Mar 06, 2015

FDA data supplied by DrugPatentWatch.com

ISOCARBOXAZID
TABLET;ORAL
MARPLAN
+ VALIDUS PHARMS INC 10MG N011961 001

ISOFLURANE
LIQUID;INHALATION
FORANE
AN + BAXTER HLTHCARE 99.9% N017624 001
ISOFLURANE
AN HALOCARBON PRODS **99.9% A075225 001** Oct 20, 1999
AN HOSPIRA **99.9% A074097 001** Jan 25, 1993
AN PIRAMAL CRITICAL **99.9% A074416 001** Sep 30, 1994
AN PIRAMAL ENT **99.9% A074502 001** Jun 27, 1995

ISONIAZID
INJECTABLE;INJECTION
ISONIAZID
+ SANDOZ 100MG/ML A040648 001 Jul 05, 2005
SYRUP;ORAL
ISONIAZID
+ CAROLINA MEDCL 50MG/5ML A088235 001 Nov 10, 1983
TABLET;ORAL
ISONIAZID
AA BARR **100MG A080936 001**
AA **300MG A080937 002**
AA MIKART **100MG A040090 001** Jun 26, 1997
AA **300MG A040090 002** Jun 26, 1997
AA + SANDOZ 100MG N008678 002
AA + **300MG N008678 003**
AA THEPHARMANETWORK LLC **100MG A202610 001** Oct 29, 2014
AA **300MG A202610 002** Oct 29, 2014
LANIAZID
AA LANNETT **300MG A089776 001** Jun 13, 1988

ISONIAZID; PYRAZINAMIDE; RIFAMPIN
TABLET;ORAL
RIFATER
+ SANOFI AVENTIS US 50MG;300MG;120MG N050705 001 May 31, 1994

ISONIAZID; RIFAMPIN
CAPSULE;ORAL
RIFAMATE
+ SANOFI AVENTIS US 150MG;300MG A061884 001

ISOPROTERENOL HYDROCHLORIDE
INJECTABLE;INJECTION
ISUPREL
+ HOSPIRA 0.2MG/ML N010515 001

ISOSORBIDE DINITRATE
CAPSULE, EXTENDED RELEASE;ORAL
DILATRATE-SR
+ AUXILIUM PHARMS LLC 40MG N019790 001 Sep 02, 1988
TABLET;ORAL
ISORDIL
AB VALEANT PHARMS NORTH **5MG N012093 007** Jul 29, 1988
ISOSORBIDE DINITRATE
AB HIKMA INTL PHARMS **5MG A086067 001** Oct 29, 1987
AB **10MG A086066 001** Oct 29, 1987
AB **20MG A088088 001** Nov 02, 1987
AB **30MG A040591 001** Jan 10, 2007
AB PAR PHARM **5MG A086923 001** Mar 12, 1987
AB **10MG A086925 001** Mar 12, 1987
AB **20MG A087537 001** Oct 02, 1987
AB + **30MG A087946 001** Jan 12, 1988
AB SANDOZ **5MG A086221 001** Jan 07, 1988
AB **10MG A086223 001** Jan 07, 1988
AB **20MG A089367 001** Apr 07, 1988
ISORDIL
+ VALEANT PHARMS NORTH 40MG N012093 001 Jul 29, 1988
TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE DINITRATE
+ SUN PHARM INDS INC 40MG A040009 001 Dec 30, 1998

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE MONONITRATE

TABLET;ORAL

	ISOSORBIDE MONONITRATE					
AB	ACTAVIS ELIZABETH	**10MG**	**A075037**	**002**	Oct 30, 1998
AB		**20MG**	**A075037**	**001**	Oct 30, 1998
AB	ANI PHARMS INC	**20MG**	**A075147**	**001**	Nov 27, 1998
AB	HIKMA PHARMS LLC	**20MG**	**A075361**	**001**	Oct 05, 2000
	MONOKET				
AB	KREMERS URBAN PHARMS	**10MG**	**N020215**	**002**	Jun 30, 1993
AB +		**20MG**	**N020215**	**001**	Jun 30, 1993

TABLET, EXTENDED RELEASE;ORAL

	ISOSORBIDE MONONITRATE				
AB	DEXCEL LTD	**30MG**	**A075522**	**002**	Sep 20, 2016
AB		**60MG**	**A075522**	**001**	Apr 17, 2000
AB	HIKMA PHARMS	**30MG**	**A076813**	**002**	Mar 30, 2006
AB		**60MG**	**A076813**	**001**	Jan 07, 2005
AB	KREMERS URBAN PHARMS	**30MG**	**A075155**	**002**	Jan 13, 2000
AB		**60MG**	**A075155**	**001**	Oct 30, 1998
AB +		**120MG**	**A075155**	**003**	Aug 04, 2000
AB	NESHER PHARMS	**30MG**	**A075395**	**001**	Mar 16, 2000
AB		**60MG**	**A075395**	**002**	Mar 16, 2000
AB		**120MG**	**A075395**	**003**	Mar 16, 2000
AB	TORRENT PHARMS	**30MG**	**A200270**	**001**	Jun 03, 2011
AB		**60MG**	**A200495**	**001**	Jun 03, 2011
AB		**120MG**	**A200495**	**002**	Jun 03, 2011
AB	VINTAGE PHARMS	**30MG**	**A090598**	**001**	Aug 11, 2010
AB		**60MG**	**A090598**	**002**	Aug 11, 2010
AB		**120MG**	**A090598**	**003**	Aug 11, 2010

ISOSULFAN BLUE

INJECTABLE;INJECTION

	ISOSULFAN BLUE				
AP	AUROBINDO PHARMA LTD	**1%**	**A206831**	**001**	Feb 02, 2016
AP +	MYLAN INSTITUTIONAL	**1%**	**A090874**	**001**	Jul 20, 2010

ISOTRETINOIN

CAPSULE;ORAL

	AMNESTEEM				
AB	MYLAN PHARMS INC	**10MG**	**A075945**	**001**	Nov 08, 2002
AB		**20MG**	**A075945**	**002**	Nov 08, 2002
AB		**40MG**	**A075945**	**003**	Nov 08, 2002
	CLARAVIS				
AB	TEVA PHARMS USA	**10MG**	**A076356**	**001**	Apr 11, 2003
AB		**20MG**	**A076135**	**002**	Apr 11, 2003
AB		**30MG**	**A076135**	**003**	May 11, 2006
AB +		**40MG**	**A076135**	**001**	Apr 11, 2003
	MYORISAN				
AB	DOUGLAS PHARMS	**10MG**	**A076485**	**001**	Jan 19, 2012
AB		**20MG**	**A076485**	**002**	Jan 19, 2012
AB		**30MG**	**A076485**	**004**	Aug 25, 2015
AB		**40MG**	**A076485**	**003**	Jan 19, 2012
	ZENATANE				
AB	DR REDDYS LABS LTD	**10MG**	**A202099**	**001**	Mar 25, 2013
AB		**20MG**	**A202099**	**002**	Mar 25, 2013
AB		**30MG**	**A202099**	**004**	Feb 23, 2015
AB		**40MG**	**A202099**	**003**	Mar 25, 2013
	ABSORICA				
BX	RANBAXY	10MG	N021951	001	May 25, 2012
BX		20MG	N021951	002	May 25, 2012
BX		30MG	N021951	003	May 25, 2012
BX +		40MG	N021951	004	May 25, 2012
		25MG	N021951	005	Aug 15, 2014
		35MG	N021951	006	Aug 15, 2014

ISRADIPINE

CAPSULE;ORAL

	ISRADIPINE				
AB	ELITE LABS INC	**2.5MG**	**A077169**	**001**	Apr 24, 2006
AB		**5MG**	**A077169**	**002**	Apr 24, 2006
AB	WATSON LABS	**2.5MG**	**A077317**	**001**	Jan 05, 2006
AB +		**5MG**	**A077317**	**002**	Jan 05, 2006

ISRADIPINE
TABLET, EXTENDED RELEASE;ORAL
ISRADIPINE

	MYLAN PHARMS INC	5MG	A201067	001	Nov 27, 2015
		10MG	A201067	002	Nov 27, 2015

ITRACONAZOLE
CAPSULE;ORAL
ITRACONAZOLE

AB	ACCORD HLTHCARE	**100MG**	**A205991**	**001**	May 26, 2016
AB	ALEMBIC PHARMS LTD	**100MG**	**A206741**	**001**	Dec 13, 2016
AB	AMNEAL PHARMS	**100MG**	**A205080**	**001**	Sep 26, 2016
AB	MYLAN PHARMS INC	**100MG**	**A200463**	**001**	Jul 20, 2012
AB	PAR PHARM INC	**100MG**	**A205724**	**001**	Dec 13, 2016
AB	SANDOZ	**100MG**	**A076104**	**001**	May 28, 2004

SPORANOX

AB	**+** JANSSEN PHARMS	**100MG**	**N020083**	**001**	Sep 11, 1992

SOLUTION;ORAL
SPORANOX

	+ JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997

TABLET;ORAL
ONMEL

	+ SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010

IVABRADINE HYDROCHLORIDE
TABLET;ORAL
CORLANOR

	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015
	+	EQ 7.5MG BASE	N206143	002	Apr 15, 2015

IVACAFTOR
GRANULE;ORAL
KALYDECO

	VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015
	+	75MG/PACKET	N207925	002	Mar 17, 2015

TABLET;ORAL
KALYDECO

	+ VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012

IVACAFTOR; LUMACAFTOR
TABLET;ORAL
ORKAMBI

	VERTEX PHARMS INC	125MG;100MG	N206038	002	Sep 28, 2016
	+	125MG;200MG	N206038	001	Jul 02, 2015

IVERMECTIN
CREAM;TOPICAL
SOOLANTRA

	+ GALDERMA LABS LP	1%	N206255	001	Dec 19, 2014

LOTION;TOPICAL
SKLICE

	+ ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012

TABLET;ORAL
IVERMECTIN

AB	EDENBRIDGE PHARMS	**3MG**	**A204154**	**001**	Oct 24, 2014

STROMECTOL

AB	**+** MERCK SHARP DOHME	**3MG**	**N050742**	**002**	Oct 08, 1998

IXABEPILONE
INJECTABLE;IV (INFUSION)
IXEMPRA KIT

	+ R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007
	+	45MG/VIAL	N022065	002	Oct 16, 2007

IXAZOMIB CITRATE
CAPSULE;ORAL
NINLARO

	MILLENNIUM PHARMS	EQ 2.3MG BASE	N208462	001	Nov 20, 2015
		EQ 3MG BASE	N208462	002	Nov 20, 2015
	+	EQ 4MG BASE	N208462	003	Nov 20, 2015

FDA data supplied by DrugPatentWatch.com

KANAMYCIN SULFATE
INJECTABLE;INJECTION
KANAMYCIN SULFATE

		FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001 Dec 17, 2002
	+		EQ 1GM BASE/3ML	A065111	002 Dec 17, 2002

KETAMINE HYDROCHLORIDE
INJECTABLE;INJECTION

		KETALAR			
AP	+	PAR STERILE PRODUCTS	**EQ 10MG BASE/ML**	**N016812**	**001**
AP	+		**EQ 50MG BASE/ML**	**N016812**	**002**
AP	+		**EQ 100MG BASE/ML**	**N016812**	**003**
		KETAMINE HYDROCHLORIDE			
AP		HOSPIRA	**EQ 50MG BASE/ML**	**A074549**	**001** Jun 27, 1996
AP			**EQ 100MG BASE/ML**	**A074549**	**002** Jun 27, 1996
AP		MYLAN INSTITUTIONAL	**EQ 10MG BASE/ML**	**A076092**	**001** Sep 30, 2008
AP			**EQ 50MG BASE/ML**	**A076092**	**002** Dec 28, 2001
AP			**EQ 100MG BASE/ML**	**A076092**	**003** Oct 25, 2002
AP		WEST-WARD PHARMS INT	**EQ 50MG BASE/ML**	**A074524**	**001** Mar 22, 1996
AP			**EQ 100MG BASE/ML**	**A074524**	**002** Mar 22, 1996

KETOCONAZOLE
AEROSOL, FOAM;TOPICAL

		EXTINA			
AT	+	DELCOR ASSET CORP	**2%**	**N021738**	**001** Jun 12, 2007
		KETOCONAZOLE			
AT		PERRIGO ISRAEL	**2%**	**A091550**	**001** Aug 25, 2011

CREAM;TOPICAL

		KETOCONAZOLE			
AB		FOUGERA PHARMS	**2%**	**A076294**	**001** Apr 28, 2004
AB	+	TEVA	**2%**	**A075581**	**001** Apr 25, 2000
		KETOZOLE			
AB		TARO	**2%**	**A075638**	**001** Dec 18, 2002

GEL;TOPICAL

		XOLEGEL			
	+	AQUA PHARMS	2%	N021946	001 Jul 28, 2006

SHAMPOO;TOPICAL

		KETOCONAZOLE			
AB		PERRIGO NEW YORK	**2%**	**A076419**	**001** Jan 07, 2004
AB		TOLMAR	**2%**	**A076942**	**001** Apr 11, 2005
		NIZORAL			
AB	+	JANSSEN PHARMS	**2%**	**N019927**	**001** Aug 31, 1990

TABLET;ORAL

		KETOCONAZOLE			
AB		MYLAN	**200MG**	**A075597**	**001** Dec 23, 1999
AB		TARO	**200MG**	**A075319**	**001** Jun 15, 1999
AB	+	TEVA	**200MG**	**A075273**	**001** Jun 15, 1999

KETOPROFEN
CAPSULE;ORAL

		KETOPROFEN			
AB		DORADO PHARMA	**50MG**	**A074014**	**002** Jan 29, 1993
AB			**75MG**	**A074014**	**003** Jan 29, 1993
AB		MYLAN	**50MG**	**A074035**	**002** Dec 31, 1996
AB			**75MG**	**A074035**	**003** Dec 31, 1996
AB		TEVA	**50MG**	**A073516**	**001** Dec 22, 1992
AB	+		**75MG**	**A073517**	**001** Dec 22, 1992
		DORADO PHARMA	25MG	A074014	001 Jan 29, 1993

CAPSULE, EXTENDED RELEASE;ORAL

		KETOPROFEN			
AB		ACTAVIS LABS FL INC	**100MG**	**A075270**	**002** Mar 24, 1999
AB			**150MG**	**A075270**	**003** Mar 24, 1999
AB			**200MG**	**A075270**	**001** Mar 24, 1999
AB		MYLAN	**100MG**	**A075679**	**003** Feb 20, 2002
AB			**150MG**	**A075679**	**002** Feb 20, 2002
AB	+		**200MG**	**A075679**	**001** Feb 20, 2002

KETOROLAC TROMETHAMINE
INJECTABLE;INJECTION

		KETOROLAC TROMETHAMINE			
AP		AMPHASTAR PHARM	**15MG/ML**	**A076209**	**001** Jul 21, 2004
AP			**30MG/ML**	**A076209**	**002** Jul 21, 2004
AP		FRESENIUS KABI USA	**15MG/ML**	**A075784**	**001** Jan 11, 2002
AP			**15MG/ML**	**A203242**	**001** Oct 07, 2015

FDA data supplied by DrugPatentWatch.com

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

		KETOROLAC TROMETHAMINE				
AP			**30MG/ML**	**A075784**	**002**	Jan 11, 2002
AP			**30MG/ML**	**A203242**	**002**	Oct 07, 2015
AP		GLAND PHARMA LTD	**15MG/ML**	**A204216**	**001**	Nov 01, 2016
AP			**30MG/ML**	**A204216**	**002**	Nov 01, 2016
AP	+	HOSPIRA	**15MG/ML**	**A074802**	**001**	Jun 05, 1997
AP			**15MG/ML**	**A074993**	**001**	Jan 27, 1999
AP	+		**30MG/ML**	**A074802**	**002**	Jun 05, 1997
AP			**30MG/ML**	**A074993**	**002**	Jan 27, 1999
AP		MYLAN LABS LTD	**15MG/ML**	**A078299**	**001**	Jul 16, 2007
AP			**15MG/ML**	**A201155**	**001**	Aug 04, 2014
AP			**30MG/ML**	**A078299**	**002**	Jul 16, 2007
AP			**30MG/ML**	**A201155**	**002**	Aug 04, 2014
AP		SAGENT PHARMS	**15MG/ML**	**A091065**	**001**	Nov 27, 2013
AP			**30MG/ML**	**A091065**	**002**	Nov 27, 2013
AP		SANDOZ	**30MG/ML**	**A076271**	**002**	Oct 06, 2004
AP		WOCKHARDT	**15MG/ML**	**A077942**	**001**	Mar 27, 2007
AP			**30MG/ML**	**A077942**	**002**	Mar 27, 2007
SOLUTION/DROPS;OPHTHALMIC						
		ACULAR				
AT	+	ALLERGAN	**0.5%**	**N019700**	**001**	Nov 09, 1992
		ACULAR LS				
AT	+	ALLERGAN	**0.4%**	**N021528**	**001**	May 30, 2003
		ACUVAIL				
AT	+	ALLERGAN	**0.45%**	**N022427**	**001**	Jul 22, 2009
		KETOROLAC TROMETHAMINE				
AT		AKORN	**0.4%**	**A078399**	**001**	Nov 05, 2009
AT			**0.5%**	**A078434**	**001**	Nov 05, 2009
AT		ALCON PHARMS LTD	**0.4%**	**A078721**	**001**	Nov 05, 2009
AT			**0.5%**	**A076583**	**001**	Nov 05, 2009
AT		APOTEX INC	**0.4%**	**A077308**	**001**	Nov 05, 2009
AT			**0.5%**	**A076109**	**001**	Nov 05, 2009
AT		SUN PHARMA GLOBAL	**0.5%**	**A090017**	**001**	Nov 05, 2009
SPRAY, METERED;NASAL						
		SPRIX				
	+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010
TABLET;ORAL						
		KETOROLAC TROMETHAMINE				
AB	+	MYLAN	**10MG**	**A074761**	**001**	May 16, 1997
AB		PLIVA	**10MG**	**A075284**	**001**	Jun 23, 1999
AB		TEVA	**10MG**	**A074754**	**001**	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION						
		OMIDRIA				
	+	OMEROS	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION						
		LABETALOL HYDROCHLORIDE				
AP		AKORN INC	**5MG/ML**	**A075431**	**001**	Nov 29, 1999
AP			**5MG/ML**	**A075524**	**001**	Nov 29, 1999
AP		GLAND PHARMA LTD	**5MG/ML**	**A090699**	**001**	Apr 03, 2012
AP	+	HOSPIRA	**5MG/ML**	**A075239**	**001**	Nov 29, 1999
AP	+		**5MG/ML**	**A075240**	**001**	Nov 29, 1999
AP		SAGENT STRIDES	**5MG/ML**	**A079134**	**001**	Feb 03, 2010
AP		WEST-WARD PHARMS INT	**5MG/ML**	**A075303**	**001**	May 28, 1999
TABLET;ORAL						
		LABETALOL HYDROCHLORIDE				
AB		ALLIED PHARMA INC	**100MG**	**A075215**	**001**	Jul 29, 1999
AB			**200MG**	**A075215**	**002**	Jul 29, 1999
AB			**300MG**	**A075215**	**003**	Jul 29, 1999
AB		IVAX SUB TEVA PHARMS	**100MG**	**A074787**	**001**	Aug 03, 1998
AB			**200MG**	**A074787**	**002**	Aug 03, 1998
AB			**300MG**	**A074787**	**003**	Aug 03, 1998
AB		PAR FORM	**100MG**	**A200908**	**001**	Jul 10, 2012
AB			**200MG**	**A200908**	**002**	Jul 10, 2012
AB			**300MG**	**A200908**	**003**	Jul 10, 2012
AB		SANDOZ	**100MG**	**A075113**	**001**	Aug 04, 1998
AB	+		**200MG**	**A075113**	**002**	Aug 04, 1998
AB			**300MG**	**A075113**	**003**	Aug 04, 1998

FDA data supplied by DrugPatentWatch.com

LABETALOL HYDROCHLORIDE
TABLET;ORAL

	LABETALOL HYDROCHLORIDE				
AB	WATSON LABS	**100MG**	**A075133**	**001**	Aug 03, 1998
AB		**200MG**	**A075133**	**002**	Aug 03, 1998
AB		**300MG**	**A075133**	**003**	Aug 03, 1998
	TRANDATE				
AB	CNTY LINE PHARMS	**100MG**	**N018716**	**001**	May 24, 1985
AB		**200MG**	**N018716**	**002**	Aug 01, 1984
AB		**300MG**	**N018716**	**003**	Aug 01, 1984

LACOSAMIDE
SOLUTION;INTRAVENOUS

	VIMPAT				
+	UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008

SOLUTION;ORAL

	LACOSAMIDE				
AA	AMNEAL PHARMS	**10MG/ML**	**A204839**	**001**	Apr 28, 2016
	VIMPAT				
AA +	UCB INC	**10MG/ML**	**N022255**	**001**	Apr 20, 2010

TABLET;ORAL

	LACOSAMIDE				
AB	ACTAVIS LABS FL INC	**50MG**	**A204855**	**001**	Apr 28, 2016
AB		**100MG**	**A204855**	**002**	Apr 28, 2016
AB		**150MG**	**A204855**	**003**	Apr 28, 2016
AB		**200MG**	**A204855**	**004**	Apr 28, 2016
AB	ALEMBIC PHARMS LTD	**50MG**	**A204974**	**001**	Apr 28, 2016
AB		**100MG**	**A204974**	**002**	Apr 28, 2016
AB		**150MG**	**A204974**	**003**	Apr 28, 2016
AB		**200MG**	**A204974**	**004**	Apr 28, 2016
AB	AMNEAL PHARMS	**50MG**	**A204857**	**001**	Sep 09, 2016
AB		**100MG**	**A204857**	**002**	Sep 09, 2016
AB		**150MG**	**A204857**	**003**	Sep 09, 2016
AB		**200MG**	**A204857**	**004**	Sep 09, 2016
AB	AUROBINDO PHARMA LTD	**50MG**	**A204994**	**001**	Apr 28, 2016
AB		**100MG**	**A204994**	**002**	Apr 28, 2016
AB		**150MG**	**A204994**	**003**	Apr 28, 2016
AB		**200MG**	**A204994**	**004**	Apr 28, 2016
AB	MSN LABS PVT LTD	**50MG**	**A204921**	**001**	Apr 28, 2016
AB		**100MG**	**A204921**	**002**	Apr 28, 2016
AB		**150MG**	**A204921**	**003**	Apr 28, 2016
AB		**200MG**	**A204921**	**004**	Apr 28, 2016
AB	MYLAN PHARMS INC	**50MG**	**A205026**	**001**	Apr 28, 2016
AB		**100MG**	**A205026**	**002**	Apr 28, 2016
AB		**150MG**	**A205026**	**003**	Apr 28, 2016
AB		**200MG**	**A205026**	**004**	Apr 28, 2016
AB	SUN PHARMA GLOBAL	**50MG**	**A205031**	**001**	Apr 28, 2016
AB		**100MG**	**A205031**	**002**	Apr 28, 2016
AB		**150MG**	**A205031**	**003**	Apr 28, 2016
AB		**200MG**	**A205031**	**004**	Apr 28, 2016
	VIMPAT				
AB	UCB INC	**50MG**	**N022253**	**001**	Oct 28, 2008
AB		**100MG**	**N022253**	**002**	Oct 28, 2008
AB		**150MG**	**N022253**	**003**	Oct 28, 2008
AB +		**200MG**	**N022253**	**004**	Oct 28, 2008

LACTULOSE
FOR SOLUTION;ORAL

	LACTULOSE				
+	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997
+		20GM/PACKET	A074712	002	Dec 10, 1997

SOLUTION;ORAL

	CONSTILAC				
AA	ALRA	**10GM/15ML**	**A071054**	**001**	Jul 26, 1988
	LACTULOSE				
AA	ANI PHARMS	**10GM/15ML**	**A078430**	**001**	Nov 28, 2007
AA	FRESENIUS KABI	**10GM/15ML**	**A090503**	**001**	Jan 25, 2012
AA +	HI TECH PHARMA	**10GM/15ML**	**A074076**	**001**	Jul 03, 1995
AA	MORTON GROVE	**10GM/15ML**	**A074602**	**001**	Nov 14, 1996
AA	PHARM ASSOC	**10GM/15ML**	**A074623**	**001**	Jul 30, 1996
AA	VINTAGE PHARMS	**10GM/15ML**	**A075993**	**001**	Jul 26, 2001
AA	VISTAPHARM	**10GM/15ML**	**A074138**	**001**	Sep 30, 1992
AA	WEST-WARD PHARMS INT	**10GM/15ML**	**A073591**	**001**	May 29, 1992

FDA data supplied by DrugPatentWatch.com

LACTULOSE
SOLUTION;ORAL, RECTAL

	CHOLAC					
AA		ALRA	**10GM/15ML**	**A071331**	**001**	Jul 26, 1988
	ENULOSE					
AA	+	ACTAVIS MID ATLANTIC	**10GM/15ML**	**A071548**	**001**	Aug 15, 1988
	GENERLAC					
AA		MORTON GROVE PHARMS	**10GM/15ML**	**A074603**	**001**	Oct 31, 1996
	LACTULOSE					
AA		ANI PHARMS	**10GM/15ML**	**A090426**	**001**	Nov 21, 2008
AA		BIO-PHARM INC	**10GM/15ML**	**A203762**	**001**	Mar 27, 2015
AA		FRESENIUS KABI	**10GM/15ML**	**A090502**	**001**	Jan 25, 2012
AA		HI TECH PHARMA	**10GM/15ML**	**A074077**	**001**	Jul 03, 1995

LAMIVUDINE
SOLUTION;ORAL

	EPIVIR					
AA	+	VIIV HLTHCARE	**10MG/ML**	**N020596**	**001**	Nov 17, 1995
	LAMIVUDINE					
AA		AUROBINDO PHARMA LTD	**10MG/ML**	**A077695**	**001**	Nov 21, 2016
AA		SILARX PHARMS INC	**10MG/ML**	**A203564**	**001**	Oct 31, 2014
	EPIVIR-HBV					
	+	GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998

TABLET;ORAL

	EPIVIR					
AB		VIIV HLTHCARE	**150MG**	**N020564**	**001**	Nov 17, 1995
AB	+		**300MG**	**N020564**	**003**	Jun 24, 2002
	EPIVIR-HBV					
AB	+	GLAXOSMITHKLINE	**100MG**	**N021003**	**001**	Dec 08, 1998
	LAMIVUDINE					
AB		APOTEX	**150MG**	**A091606**	**001**	Dec 02, 2011
AB			**300MG**	**A091606**	**002**	Dec 02, 2011
AB		APOTEX INC	**100MG**	**A202941**	**001**	Jan 02, 2014
AB		APPCO PHARMA LLC	**150MG**	**A206974**	**001**	Nov 21, 2016
AB			**300MG**	**A206974**	**002**	Nov 21, 2016
AB		AUROBINDO PHARMA LTD	**150MG**	**A077464**	**001**	Nov 21, 2016
AB			**150MG**	**A202032**	**001**	Nov 17, 2011
AB			**300MG**	**A077464**	**002**	Nov 21, 2016
AB			**300MG**	**A202032**	**002**	Nov 17, 2011
AB		CENTAUR PHARMS PVT	**150MG**	**A203586**	**001**	Nov 21, 2016
AB		HETERO LABS LTD V	**100MG**	**A203260**	**001**	Jan 02, 2014
AB			**150MG**	**A203277**	**001**	Jan 06, 2014
AB			**300MG**	**A203277**	**002**	Jan 06, 2014
AB		LUPIN LTD	**150MG**	**A205217**	**001**	Dec 18, 2014
AB			**300MG**	**A205217**	**002**	Dec 18, 2014
AB		MYLAN PHARMS INC	**100MG**	**A204002**	**001**	Dec 31, 2014
AB			**150MG**	**A204528**	**001**	Mar 04, 2016
AB			**300MG**	**A204528**	**002**	Mar 04, 2016

LAMIVUDINE; ZIDOVUDINE
TABLET;ORAL

	COMBIVIR					
AB	+	VIIV HLTHCARE	**150MG;300MG**	**N020857**	**001**	Sep 26, 1997
	LAMIVUDINE AND ZIDOVUDINE					
AB		AUROBINDO PHARMA LTD	**150MG;300MG**	**A202418**	**001**	May 15, 2012
AB		HETERO LABS LTD III	**150MG;300MG**	**A079124**	**001**	Sep 17, 2015
AB		HETERO LABS LTD V	**150MG;300MG**	**A203259**	**001**	Feb 03, 2014
AB		LUPIN LTD	**150MG;300MG**	**A090246**	**001**	May 15, 2012
AB		MYLAN PHARMS INC	**150MG;300MG**	**A204005**	**001**	Aug 28, 2014
AB		STRIDES PHARMA	**150MG;300MG**	**A079128**	**001**	May 13, 2015
AB		TEVA PHARMS	**150MG;300MG**	**A079081**	**001**	May 25, 2011

LAMOTRIGINE
TABLET;ORAL

	LAMICTAL					
AB	+	GLAXOSMITHKLINE LLC	**25MG**	**N020241**	**005**	Dec 27, 1994
AB			**100MG**	**N020241**	**001**	Dec 27, 1994
AB			**150MG**	**N020241**	**002**	Dec 27, 1994
AB			**200MG**	**N020241**	**003**	Dec 27, 1994
	LAMOTRIGINE					
AB		ALEMBIC PHARMS LTD	**25MG**	**A090607**	**001**	Jan 13, 2011
AB			**100MG**	**A090607**	**002**	Jan 13, 2011
AB			**150MG**	**A090607**	**003**	Jan 13, 2011
AB			**200MG**	**A090607**	**004**	Jan 13, 2011

FDA data supplied by DrugPatentWatch.com

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

AB	ALKEM LABS LTD	25MG	A200694	001	Jun 14, 2013
AB		100MG	A200694	002	Jun 14, 2013
AB		150MG	A200694	003	Jun 14, 2013
AB		200MG	A200694	004	Jun 14, 2013
AB	APOTEX INC	25MG	A078625	001	Jan 27, 2009
AB		100MG	A078625	002	Jan 27, 2009
AB		150MG	A078625	003	Jan 27, 2009
AB		200MG	A078625	004	Jan 27, 2009
AB	AUROBINDO PHARMA	25MG	A078956	001	Jan 27, 2009
AB		100MG	A078956	002	Jan 27, 2009
AB		150MG	A078956	003	Jan 27, 2009
AB		200MG	A078956	004	Jan 27, 2009
AB	CIPLA LTD	25MG	A077783	001	Nov 01, 2010
AB		100MG	A077783	002	Nov 01, 2010
AB		150MG	A077783	003	Nov 01, 2010
AB		200MG	A077783	004	Nov 01, 2010
AB	DR REDDYS LABS LTD	25MG	A076708	001	Jan 27, 2009
AB		100MG	A076708	002	Jan 27, 2009
AB		150MG	A076708	003	Jan 27, 2009
AB		200MG	A076708	004	Jan 27, 2009
AB	GLENMARK GENERICS	25MG	A090169	001	May 12, 2012
AB		100MG	A090169	002	May 12, 2012
AB		150MG	A090169	003	May 12, 2012
AB		200MG	A090169	004	May 12, 2012
AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009
AB		100MG	A079132	002	Jan 27, 2009
AB		150MG	A079132	003	Jan 27, 2009
AB		200MG	A079132	004	Jan 27, 2009
AB	LUPIN LTD	25MG	A078691	001	Jun 01, 2010
AB		100MG	A078691	002	Jun 01, 2010
AB		150MG	A078691	003	Jun 01, 2010
AB		200MG	A078691	004	Jun 01, 2010
AB	MYLAN	25MG	A077420	001	Jan 27, 2009
AB		100MG	A077420	002	Jan 27, 2009
AB		150MG	A077420	003	Jan 27, 2009
AB		200MG	A077420	004	Jan 27, 2009
AB	TARO PHARM INDS	25MG	A078525	001	Jan 27, 2009
AB		100MG	A078525	002	Jan 27, 2009
AB		150MG	A078525	003	Jan 27, 2009
AB		200MG	A078525	004	Jan 27, 2009
AB	TEVA	25MG	A076388	001	Aug 30, 2006
AB		100MG	A076388	002	Aug 30, 2006
AB		150MG	A076388	003	Aug 30, 2006
AB		200MG	A076388	004	Aug 30, 2006
AB	TORRENT PHARMS	25MG	A078947	001	Jan 27, 2009
AB		100MG	A078947	002	Jan 27, 2009
AB		150MG	A078947	003	Jan 27, 2009
AB		200MG	A078947	004	Jan 27, 2009
AB	UNICHEM LABS LTD	25MG	A090170	001	Oct 06, 2011
AB		100MG	A090170	002	Oct 06, 2011
AB		150MG	A090170	003	Oct 06, 2011
AB		200MG	A090170	004	Oct 06, 2011
AB	ZYDUS PHARMS USA	25MG	A077633	001	Jan 27, 2009
AB		100MG	A077633	003	Jan 27, 2009
AB		150MG	A077633	004	Jan 27, 2009
AB		200MG	A077633	005	Jan 27, 2009
		50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE;ORAL

LAMICTAL CD

AB	GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000
AB		5MG	N020764	001	Aug 24, 1998
AB +		25MG	N020764	002	Aug 24, 1998

LAMOTRIGINE

AB	ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014
AB		25MG	A201168	002	Jun 12, 2014
AB	AUROBINDO PHARMA	5MG	A090401	002	Nov 04, 2009
AB		25MG	A090401	003	Nov 04, 2009
AB	DR REDDYS LABS LTD	5MG	A076701	001	Jan 22, 2009

FDA data supplied by DrugPatentWatch.com

LAMOTRIGINE

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

AB		25MG	A076701	002	Jan 22, 2009
AB	GLENMARK GENERICS	5MG	A079099	001	Feb 19, 2009
AB		25MG	A079099	002	Feb 19, 2009
AB	JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011
AB		25MG	A200220	002	Feb 28, 2011
AB	MYLAN	5MG	A076630	001	Jan 22, 2009
AB		25MG	A076630	002	Jan 22, 2009
AB	TARO	5MG	A079204	001	Feb 04, 2009
AB		25MG	A079204	002	Feb 04, 2009
AB	TEVA	5MG	A076420	001	Jun 21, 2006
AB		25MG	A076420	002	Jun 21, 2006
AB	WATSON LABS	2MG	A076928	001	Jan 22, 2009
AB		5MG	A076928	002	Jan 22, 2009
AB		25MG	A076928	003	Jan 22, 2009
AB	ZYDUS PHARMS USA INC	5MG	A078009	002	Jan 22, 2009
AB		25MG	A078009	003	Jan 22, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	GLAXOSMITHKLINE LLC	25MG	N022115	001	May 29, 2009
AB +		50MG	N022115	002	May 29, 2009
AB		100MG	N022115	003	May 29, 2009
AB +		200MG	N022115	004	May 29, 2009
AB		250MG	N022115	006	Jun 21, 2011
AB		300MG	N022115	005	Apr 14, 2010

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	100MG	A200672	003	Oct 17, 2013
AB		200MG	A200672	004	Oct 17, 2013
AB		25MG	A200672	001	Oct 17, 2013
AB		50MG	A200672	002	Oct 17, 2013
AB		250MG	A203733	001	Nov 13, 2013
AB		300MG	A200672	005	Oct 17, 2013
AB	ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012
AB		50MG	A201374	002	Dec 26, 2012
AB		100MG	A201374	003	Dec 26, 2012
AB		200MG	A201374	004	Dec 26, 2012
AB		250MG	A201374	005	Dec 26, 2012
AB		300MG	A201374	006	Dec 26, 2012
AB	DR REDDYS LABS LTD	25MG	A202383	001	Jun 19, 2013
AB		50MG	A202383	002	Jun 19, 2013
AB		100MG	A202383	003	Jun 19, 2013
AB		200MG	A202383	004	Jun 19, 2013
AB		300MG	A202383	005	Jun 19, 2013
AB	PAR PHARM	25MG	A201791	001	Jan 18, 2013
AB		50MG	A201791	002	Jan 18, 2013
AB		100MG	A201791	003	Jan 18, 2013
AB		200MG	A201791	004	Jan 18, 2013
AB		250MG	A201791	005	Jan 18, 2013
AB		300MG	A201791	006	Jan 18, 2013
AB	TORRENT PHARMS LTD	25MG	A203370	001	Dec 23, 2013
AB		50MG	A203370	002	Dec 23, 2013
AB		100MG	A203370	003	Dec 23, 2013
AB		200MG	A203370	004	Dec 23, 2013
AB	WILSHIRE PHARMS INC	25MG	A202887	001	Jun 17, 2013
AB		50MG	A202887	002	Jun 17, 2013
AB		100MG	A202887	003	Jun 17, 2013
AB		200MG	A202887	004	Jun 17, 2013
AB	WOCKHARDT LTD	25MG	A202498	001	Jan 04, 2013
AB		50MG	A202498	002	Jan 04, 2013
AB		100MG	A202498	003	Jan 04, 2013
AB		200MG	A202498	004	Jan 04, 2013
AB		300MG	A202498	005	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

AB	GLAXOSMITHKLINE LLC	25MG	N022251	001	May 08, 2009
AB +		50MG	N022251	002	May 08, 2009
AB		100MG	N022251	003	May 08, 2009
AB		200MG	N022251	004	May 08, 2009

LAMOTRIGINE

AB	IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013

FDA data supplied by DrugPatentWatch.com

LAMOTRIGINE
TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB		**50MG**	**A200828**	**002**	Jul 15, 2013
AB		**100MG**	**A200828**	**003**	Jul 15, 2013
AB		**200MG**	**A200828**	**004**	Jul 15, 2013
AB	PAR PHARM	**25MG**	**A204158**	**001**	Oct 27, 2015
AB		**50MG**	**A204158**	**002**	Oct 27, 2015
AB		**100MG**	**A204158**	**003**	Oct 27, 2015
AB		**200MG**	**A204158**	**004**	Oct 27, 2015
AB	SCIEGEN PHARMS INC	**25MG**	**A206382**	**001**	Jun 17, 2016
AB		**50MG**	**A206382**	**002**	Jun 17, 2016
AB		**100MG**	**A206382**	**003**	Jun 17, 2016
AB		**200MG**	**A206382**	**004**	Jun 17, 2016

LANREOTIDE ACETATE
SOLUTION;SUBCUTANEOUS
SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007
+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007
+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007

LANSOPRAZOLE
CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	AJANTA PHARMA LTD	**15MG**	**A203957**	**001**	Oct 14, 2016
AB		**30MG**	**A203957**	**002**	Oct 14, 2016
AB	DR REDDYS LABS LTD	**15MG**	**A091269**	**001**	Oct 15, 2010
AB		**30MG**	**A091269**	**002**	Oct 15, 2010
AB	LABS LICONSA	**15MG**	**A203203**	**001**	Jul 25, 2016
AB		**30MG**	**A203203**	**002**	Jul 25, 2016
AB	MYLAN PHARMS INC	**15MG**	**A090763**	**001**	Nov 10, 2009
AB		**30MG**	**A090763**	**002**	Nov 10, 2009
AB	NATCO PHARMA LTD	**15MG**	**A201921**	**001**	Dec 18, 2012
AB		**30MG**	**A201921**	**002**	Dec 18, 2012
AB	SANDOZ	**15MG**	**A090331**	**001**	Apr 23, 2010
AB		**30MG**	**A090331**	**002**	Apr 23, 2010
AB	SUN PHARM INDS LTD	**15MG**	**A202637**	**001**	Sep 13, 2013
AB		**30MG**	**A091509**	**001**	Sep 13, 2013
AB	TEVA PHARMS	**15MG**	**A077255**	**001**	Nov 10, 2009
AB		**30MG**	**A077255**	**002**	Nov 10, 2009
AB	WOCKHARDT USA	**15MG**	**A202176**	**001**	Sep 14, 2012
AB		**30MG**	**A202176**	**002**	Sep 14, 2012
AB	ZYDUS HLTHCARE	**15MG**	**A202366**	**001**	Aug 19, 2013
AB		**30MG**	**A202366**	**002**	Aug 19, 2013

LANSOPRAZOLE

AB	KRKA TOVARNA ZDRAVIL	**15MG**	**A091212**	**001**	Sep 16, 2013
AB		**30MG**	**A091212**	**002**	Sep 16, 2013

PREVACID

AB	TAKEDA PHARMS USA	**15MG**	**N020406**	**001**	May 10, 1995
AB +		**30MG**	**N020406**	**002**	May 10, 1995

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL
PREVACID

	TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002
+		30MG	N021428	002	Aug 30, 2002

LANTHANUM CARBONATE
POWDER;ORAL
FOSRENOL

	SHIRE DEV LLC	EQ 750MG BASE	N204734	001	Sep 24, 2014
+		EQ 1GM BASE	N204734	002	Sep 24, 2014

TABLET, CHEWABLE;ORAL
FOSRENOL

	SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004
		EQ 750MG BASE	N021468	003	Nov 23, 2005
+		EQ 1GM BASE	N021468	004	Nov 23, 2005

LAPATINIB DITOSYLATE
TABLET;ORAL
TYKERB

+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007

FDA data supplied by DrugPatentWatch.com

LATANOPROST
SOLUTION/DROPS;OPHTHALMIC

	LATANOPROST					
AT		AKORN	**0.005%**	**A090887**	**001**	Jul 19, 2011
AT		ALCON RES	**0.005%**	**A091449**	**001**	Mar 22, 2011
AT		BAUSCH AND LOMB	**0.005%**	**A201006**	**001**	Mar 22, 2011
AT		DR REDDYS LABS LTD	**0.005%**	**A202077**	**001**	Feb 11, 2013
AT		FDC LTD	**0.005%**	**A202442**	**001**	Apr 22, 2016
AT		LUITPOLD	**0.005%**	**A200925**	**001**	Mar 22, 2011
AT		MYLAN	**0.005%**	**A201786**	**001**	Mar 22, 2011
	XALATAN					
AT	**+**	PHARMACIA AND UPJOHN	**0.005%**	**N020597**	**001**	Jun 05, 1996

LEDIPASVIR; SOFOSBUVIR
TABLET;ORAL

	HARVONI					
	+	GILEAD SCIENCES INC	90MG;400MG	N205834	001	Oct 10, 2014

LEFLUNOMIDE
TABLET;ORAL

	ARAVA					
AB		SANOFI AVENTIS US	**10MG**	**N020905**	**001**	Sep 10, 1998
AB	**+**		**20MG**	**N020905**	**002**	Sep 10, 1998
	LEFLUNOMIDE					
AB		ALEMBIC PHARMS LTD	**10MG**	**A091369**	**001**	Nov 21, 2011
AB			**20MG**	**A091369**	**002**	Nov 21, 2011
AB		APOTEX INC	**10MG**	**A077090**	**001**	Sep 13, 2005
AB			**20MG**	**A077090**	**002**	Sep 13, 2005
AB		BARR	**10MG**	**A077083**	**001**	Sep 13, 2005
AB			**20MG**	**A077083**	**002**	Sep 13, 2005
AB		HERITAGE PHARMS INC	**10MG**	**A077086**	**001**	Sep 13, 2005
AB			**20MG**	**A077086**	**002**	Sep 13, 2005
AB		TEVA PHARMS	**10MG**	**A077084**	**001**	Sep 13, 2005
AB			**20MG**	**A077084**	**002**	Sep 13, 2005
	ARAVA					
	+	SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998

LENALIDOMIDE
CAPSULE;ORAL

	REVLIMID					
		CELGENE	2.5MG	N021880	005	Dec 21, 2011
			5MG	N021880	001	Dec 27, 2005
			10MG	N021880	002	Dec 27, 2005
			15MG	N021880	003	Jun 29, 2006
			20MG	N021880	006	Jun 05, 2013
	+		25MG	N021880	004	Jun 29, 2006

LENVATINIB MESYLATE
CAPSULE;ORAL

	LENVIMA					
		EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015
	+		EQ 10MG BASE	N206947	002	Feb 13, 2015

LESINURAD
TABLET;ORAL

	ZURAMPIC					
	+	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015

LETROZOLE
TABLET;ORAL

	FEMARA					
AB	**+**	NOVARTIS PHARMS	**2.5MG**	**N020726**	**001**	Jul 25, 1997
	LETROZOLE					
AB		ACCORD HLTHCARE	**2.5MG**	**A090934**	**001**	Jun 03, 2011
AB		APOTEX INC	**2.5MG**	**A091303**	**001**	Apr 19, 2012
AB		DR REDDYS LABS LTD	**2.5MG**	**A091191**	**001**	Jun 03, 2011
AB		FRESENIUS KABI ONCOL	**2.5MG**	**A090491**	**001**	Jun 03, 2011
AB		HIKMA PHARMS	**2.5MG**	**A203796**	**001**	Jun 03, 2016
AB		INDICUS PHARMA	**2.5MG**	**A201804**	**001**	Jun 03, 2011
AB		JIANGSU HENGRUI MED	**2.5MG**	**A202716**	**001**	May 16, 2013
AB		KREMERS URBAN PHARMS	**2.5MG**	**A091098**	**001**	Jun 03, 2011
AB		LANNETT HOLDINGS INC	**2.5MG**	**A202048**	**001**	Oct 29, 2014
AB		MYLAN	**2.5MG**	**A078190**	**001**	Dec 24, 2008
AB		NATCO PHARMA LTD	**2.5MG**	**A200161**	**001**	Jun 03, 2011
AB		SUN PHARM INDS LTD	**2.5MG**	**A091466**	**001**	Jun 03, 2011

LETROZOLE
TABLET;ORAL
LETROZOLE

AB		TEVA PHARMS	**2.5MG**	**A090289**	**001** Jun 03, 2011
AB		VINTAGE PHARMS LLC	**2.5MG**	**A090789**	**001** Jun 03, 2011
AB		WEST-WARD PHARMS INT	**2.5MG**	**A090838**	**001** Jun 03, 2011

LEUCOVORIN CALCIUM
INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

AP		TEVA PHARMS USA	**EQ 100MG BASE/VIAL**	**A081277**	**001** Sep 28, 1993
AP			**EQ 350MG BASE/VIAL**	**A040174**	**001** Jun 12, 1997
AP	**+**	WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A089384**	**001** Sep 14, 1987
AP	**+**		**EQ 100MG BASE/VIAL**	**A089717**	**001** Mar 28, 1988

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A040258**	**001** Feb 26, 1999
AP		SAGENT PHARMS	**EQ 50MG BASE/VIAL**	**A200753**	**001** Sep 06, 2012
AP			**EQ 100MG BASE/VIAL**	**A200753**	**002** Sep 06, 2012
AP			**EQ 200MG BASE/VIAL**	**A200753**	**003** Sep 06, 2012
AP			**EQ 350MG BASE/VIAL**	**A200855**	**001** Sep 06, 2012
AP	**+**	WEST-WARD PHARMS INT	**EQ 200MG BASE/VIAL**	**A040056**	**001** May 23, 1995
AP	**+**		**EQ 350MG BASE/VIAL**	**A040335**	**001** Apr 20, 2000
	+	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286	001 Feb 26, 1999
	+	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A040347	001 Apr 25, 2000

TABLET;ORAL
LEUCOVORIN CALCIUM

AB		BARR	**EQ 5MG BASE**	**A071198**	**001** Sep 24, 1987
AB			**EQ 25MG BASE**	**A071199**	**001** Sep 24, 1987
AB		WEST-WARD PHARMS INT	**EQ 5MG BASE**	**A072733**	**001** Feb 22, 1993
AB	**+**		**EQ 25MG BASE**	**A072736**	**001** Feb 22, 1993
			EQ 10MG BASE	A072734	001 Feb 22, 1993
			EQ 15MG BASE	A072735	001 Feb 22, 1993

LEUPROLIDE ACETATE
INJECTABLE;INJECTION
LEUPROLIDE ACETATE

AP	**+**	SANDOZ	**1MG/0.2ML**	**A074728**	**001** Aug 04, 1998
AP		SUN PHARMA GLOBAL	**1MG/0.2ML**	**A078885**	**001** Mar 09, 2009
AP		TEVA PHARMS USA	**1MG/0.2ML**	**A075471**	**001** Oct 25, 2000

LUPRON DEPOT

	+	ABBVIE ENDOCRINE INC	3.75MG	N020011	002 Oct 26, 1995
	+		7.5MG/VIAL	N019732	001 Jan 26, 1989
	+		11.25MG/VIAL	N020708	001 Mar 07, 1997
	+		22.5MG/VIAL	N020517	001 Dec 22, 1995
	+		30MG/VIAL	N020517	002 May 30, 1997
			45MG/VIAL	N020517	003 Jun 17, 2011

LUPRON DEPOT-PED

	+	ABBVIE ENDOCRINE INC	7.5MG/VIAL	N020263	002 Apr 16, 1993
	+		11.25MG/VIAL	N020263	005 Jan 21, 1994
	+		11.25MG/VIAL	N020263	007 Aug 15, 2011
	+		15MG/VIAL	N020263	006 Jan 21, 1994
	+		30MG/VIAL	N020263	008 Aug 15, 2011

INJECTABLE;SUBCUTANEOUS
ELIGARD

	+	TOLMAR THERAP	7.5MG/VIAL	N021343	001 Jan 23, 2002
	+		22.5MG/VIAL	N021379	001 Jul 24, 2002
	+		30MG/VIAL	N021488	001 Feb 13, 2003
	+		45MG/VIAL	N021731	001 Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE
INJECTABLE, TABLET;INTRAMUSCULAR, ORAL
LUPANETA PACK

		ABBVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N203696	001 Dec 14, 2012
	+		11.25MG/VIAL,N/A;N/A,5MG	N203696	002 Dec 14, 2012

LEVALBUTEROL HYDROCHLORIDE
SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN		AUROBINDO PHARMA LTD	**EQ 0.0103% BASE**	**A207625**	**001** Dec 30, 2016
AN			**EQ 0.021% BASE**	**A207625**	**002** Dec 30, 2016
AN			**EQ 0.042% BASE**	**A207625**	**003** Dec 30, 2016
AN		CIPLA LTD	**EQ 0.021% BASE**	**A078171**	**002** Dec 13, 2013
AN			**EQ 0.042% BASE**	**A078171**	**003** Dec 13, 2013
AN			**EQ 0.0103% BASE**	**A078171**	**001** Dec 13, 2013

LEVALBUTEROL HYDROCHLORIDE
SOLUTION;INHALATION

	LEVALBUTEROL HYDROCHLORIDE				
AN	IMPAX LABS INC	**EQ 0.0103% BASE**	**A077756**	**003**	Apr 09, 2008
AN		**EQ 0.021% BASE**	**A077756**	**001**	Apr 09, 2008
AN		**EQ 0.042% BASE**	**A077756**	**002**	Apr 09, 2008
AN	MYLAN SPECLT	**EQ 0.0103% BASE**	**A077800**	**001**	Mar 15, 2013
AN		**EQ 0.021% BASE**	**A077800**	**002**	Mar 15, 2013
AN		**EQ 0.042% BASE**	**A077800**	**003**	Mar 15, 2013
AN		**EQ 0.25% BASE**	**A078309**	**001**	Mar 20, 2009
AN	RITEDOSE CORP	**EQ 0.0103% BASE**	**A203653**	**001**	Mar 22, 2016
AN		**EQ 0.021% BASE**	**A203653**	**002**	Mar 22, 2016
AN		**EQ 0.042% BASE**	**A203653**	**003**	Mar 22, 2016
AN	TEVA PARENTERAL	**EQ 0.25% BASE**	**A200875**	**001**	Sep 11, 2014
AN	TEVA PHARMS USA	**EQ 0.0103% BASE**	**A090297**	**001**	Apr 26, 2013
AN		**EQ 0.021% BASE**	**A090297**	**002**	Apr 26, 2013
AN		**EQ 0.042% BASE**	**A090297**	**003**	Apr 26, 2013
	XOPENEX				
AN	+ OAK PHARMS INC	**EQ 0.0103% BASE**	**N020837**	**003**	Jan 30, 2002
AN	+	**EQ 0.021% BASE**	**N020837**	**001**	Mar 25, 1999
AN	+	**EQ 0.042% BASE**	**N020837**	**002**	Mar 25, 1999
AN	+	**EQ 0.25% BASE**	**N020837**	**004**	Jul 18, 2003

LEVALBUTEROL TARTRATE
AEROSOL, METERED;INHALATION

	XOPENEX HFA				
	+ SUNOVION	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005

LEVETIRACETAM
INJECTABLE;IV (INFUSION)

	KEPPRA				
AP	+ UCB INC	**500MG/5ML (100MG/ML)**	**N021872**	**001**	Jul 31, 2006
	LEVETIRACETAM				
AP	AUROBINDO PHARMA LTD	**500MG/5ML (100MG/ML)**	**A204312**	**001**	Feb 01, 2016
AP	FRESENIUS KABI USA	**500MG/5ML (100MG/ML)**	**A090813**	**001**	May 26, 2010
AP		**500MG/5ML (100MG/ML)**	**A090876**	**001**	Aug 13, 2015
AP	HIKMA FARMACEUTICA	**500MG/5ML (100MG/ML)**	**A090981**	**001**	Oct 13, 2011
AP	HOSPIRA INC	**500MG/5ML (100MG/ML)**	**A202869**	**001**	Apr 06, 2012
AP	JUBILANT LIFE	**500MG/5ML (100MG/ML)**	**A206838**	**001**	Jun 02, 2016
AP	LUITPOLD	**500MG/5ML (100MG/ML)**	**A202143**	**001**	Jan 31, 2012
AP	MYLAN LABS LTD	**500MG/5ML (100MG/ML)**	**A203308**	**001**	Sep 16, 2016
AP	SAGENT PHARMS	**500MG/5ML (100MG/ML)**	**A091627**	**001**	Jun 26, 2013
AP	SUN PHARM INDS LTD	**500MG/5ML (100MG/ML)**	**A090754**	**001**	Jun 16, 2010
AP	X GEN PHARMS	**500MG/5ML (100MG/ML)**	**A091485**	**001**	Aug 05, 2011
	LEVETIRACETAM IN SODIUM CHLORIDE				
AP	AUROBINDO PHARMA LTD	**500MG/100ML (5MG/ML)**	**A207160**	**001**	Jan 04, 2017
AP		**1000MG/100ML (10MG/ML)**	**A207160**	**002**	Jan 04, 2017
AP		**1500MG/100ML (15MG/ML)**	**A207160**	**003**	Jan 04, 2017
AP	+ HQ SPECIALITY PHARMA	**500MG/100ML (5MG/ML)**	**N202543**	**001**	Nov 09, 2011
AP	+	**1000MG/100ML (10MG/ML)**	**N202543**	**002**	Nov 09, 2011
AP	+	**1500MG/100ML (15MG/ML)**	**N202543**	**003**	Nov 09, 2011

SOLUTION;ORAL

	KEPPRA				
AA	+ UCB INC	**100MG/ML**	**N021505**	**001**	Jul 15, 2003
	LEVETIRACETAM				
AA	ACTAVIS MID ATLANTIC	**100MG/ML**	**A078976**	**001**	Jan 15, 2009
AA	AMNEAL PHARMS	**100MG/ML**	**A090992**	**001**	Oct 27, 2009
AA	AUROBINDO PHARM	**100MG/ML**	**A079063**	**001**	Jan 15, 2009
AA	BRECKENRIDGE PHARM	**100MG/ML**	**A079120**	**001**	Jan 16, 2009
AA	HETERO LABS LTD III	**100MG/ML**	**A203052**	**001**	Feb 28, 2013
AA	HI-TECH PHARMACAL	**100MG/ML**	**A090601**	**001**	Feb 28, 2012
AA	LUPIN LTD	**100MG/ML**	**A090893**	**001**	Oct 17, 2011
AA	ORIT LABS LLC	**100MG/ML**	**A203067**	**001**	May 09, 2013
AA	PHARM ASSOC	**100MG/ML**	**A201157**	**001**	Jun 04, 2015
AA	ROXANE	**100MG/ML**	**A078582**	**001**	Jan 15, 2009
AA	SILARX	**100MG/ML**	**A090263**	**001**	Apr 03, 2009
AA	TARO	**100MG/ML**	**A078774**	**001**	Feb 10, 2009
AA	TOLMAR	**100MG/ML**	**A079107**	**001**	Jan 15, 2009
AA	TRIS PHARMA INC	**100MG/ML**	**A090461**	**001**	Sep 30, 2010
AA	VINTAGE PHARMS	**100MG/ML**	**A090079**	**001**	Apr 11, 2012
AA	WOCKHARDT	**100MG/ML**	**A090028**	**001**	Mar 03, 2010

FDA data supplied by DrugPatentWatch.com

LEVETIRACETAM
TABLET;ORAL

KEPPRA					
AB	UCB INC	**250MG**	**N021035**	**001**	Nov 30, 1999
AB		**500MG**	**N021035**	**002**	Nov 30, 1999
AB		**750MG**	**N021035**	**003**	Nov 30, 1999
AB +		**1GM**	**N021035**	**004**	Jan 06, 2006
LEVETIRACETAM					
AB	ACCORD HLTHCARE	**250MG**	**A090843**	**001**	Feb 14, 2011
AB		**500MG**	**A090843**	**002**	Feb 14, 2011
AB		**750MG**	**A090843**	**003**	Feb 14, 2011
AB		**1GM**	**A090843**	**004**	Feb 14, 2011
AB	AJANTA PHARMA	**250MG**	**A201293**	**001**	Jun 14, 2011
AB		**500MG**	**A201293**	**002**	Jun 14, 2011
AB		**750MG**	**A201293**	**003**	Jun 14, 2011
AB		**1GM**	**A201293**	**004**	Jun 14, 2011
AB	APOTEX INC	**250MG**	**A078869**	**001**	Mar 13, 2009
AB		**500MG**	**A078869**	**002**	Mar 13, 2009
AB		**750MG**	**A078869**	**003**	Mar 13, 2009
AB		**1GM**	**A078869**	**004**	Mar 13, 2009
AB	AUROBINDO PHARMA	**250MG**	**A078993**	**001**	Jan 15, 2009
AB		**500MG**	**A078993**	**002**	Jan 15, 2009
AB		**750MG**	**A078993**	**003**	Jan 15, 2009
AB		**1GM**	**A078993**	**004**	Jan 15, 2009
AB	BRECKENRIDGE PHARM	**250MG**	**A090511**	**001**	Aug 18, 2011
AB		**500MG**	**A090511**	**002**	Aug 18, 2011
AB		**750MG**	**A090511**	**003**	Aug 18, 2011
AB		**1GM**	**A090511**	**004**	Aug 18, 2011
AB	DR REDDYS LABS LTD	**250MG**	**A076920**	**001**	Jan 15, 2009
AB		**500MG**	**A076920**	**002**	Jan 15, 2009
AB		**750MG**	**A076920**	**003**	Jan 15, 2009
AB		**1GM**	**A078904**	**001**	Jan 15, 2009
AB	HETERO LABS LTD III	**250MG**	**A090515**	**001**	Oct 08, 2010
AB		**500MG**	**A090515**	**002**	Oct 08, 2010
AB		**750MG**	**A090515**	**003**	Oct 08, 2010
AB		**1GM**	**A090515**	**004**	Oct 08, 2010
AB	INVAGEN PHARMS	**250MG**	**A078234**	**001**	Jan 15, 2009
AB		**500MG**	**A078234**	**002**	Jan 15, 2009
AB		**750MG**	**A078234**	**003**	Jan 15, 2009
AB	LOTUS PHARM CO LTD	**500MG**	**A090906**	**001**	Nov 05, 2010
AB	LUPIN	**250MG**	**A078154**	**001**	Jan 15, 2009
AB		**500MG**	**A078154**	**002**	Jan 15, 2009
AB		**750MG**	**A078154**	**003**	Jan 15, 2009
AB		**1GM**	**A090025**	**001**	Jan 15, 2009
AB	METHAPHARM	**250MG**	**A090767**	**001**	Jul 28, 2010
AB		**500MG**	**A090767**	**002**	Jul 28, 2010
AB		**750MG**	**A090767**	**003**	Jul 28, 2010
AB		**1GM**	**A090767**	**004**	Jul 28, 2010
AB	MYLAN	**250MG**	**A076919**	**001**	Nov 04, 2008
AB		**500MG**	**A076919**	**002**	Nov 04, 2008
AB		**750MG**	**A076919**	**003**	Nov 04, 2008
AB		**1GM**	**A090261**	**001**	Dec 08, 2009
AB	ORCHID HLTHCARE	**250MG**	**A078526**	**001**	Jan 15, 2009
AB		**500MG**	**A078526**	**002**	Jan 15, 2009
AB		**750MG**	**A078526**	**003**	Jan 15, 2009
AB		**1GM**	**A090484**	**001**	Aug 05, 2010
AB	PRINSTON INC	**250MG**	**A078106**	**001**	Feb 10, 2009
AB		**500MG**	**A078106**	**002**	Feb 10, 2009
AB		**750MG**	**A078106**	**003**	Feb 10, 2009
AB		**1GM**	**A078106**	**004**	Feb 10, 2009
AB	ROXANE	**250MG**	**A078042**	**001**	Jan 15, 2009
AB		**500MG**	**A078042**	**002**	Jan 15, 2009
AB		**750MG**	**A078042**	**003**	Jan 15, 2009
AB		**1GM**	**A078042**	**004**	Jan 15, 2009
AB	SECAN PHARMS	**500MG**	**A205102**	**004**	Dec 16, 2015
AB		**1GM**	**A205102**	**003**	Dec 16, 2015
AB	TARO	**250MG**	**A078960**	**004**	Feb 01, 2010
AB		**500MG**	**A078960**	**003**	Feb 01, 2010
AB		**750MG**	**A078960**	**002**	Feb 01, 2010
AB		**1GM**	**A078960**	**001**	Feb 01, 2010
AB	TEVA PHARMS	**250MG**	**A078101**	**001**	Jan 15, 2009
AB		**500MG**	**A078101**	**002**	Jan 15, 2009

FDA data supplied by DrugPatentWatch.com

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

AB		**750MG**	**A078101**	**003**	Jan 15, 2009
AB		**1GM**	**A078101**	**004**	Jan 15, 2009
AB	TORRENT PHARMS	**250MG**	**A078858**	**001**	Jan 15, 2009
AB		**500MG**	**A078858**	**002**	Jan 15, 2009
AB		**750MG**	**A078858**	**003**	Jan 15, 2009
AB		**1GM**	**A078858**	**004**	Jan 15, 2009
AB	VINTAGE PHARMS	**250MG**	**A077319**	**001**	Mar 20, 2009
AB		**250MG**	**A091491**	**001**	Dec 14, 2010
AB		**500MG**	**A077319**	**002**	Mar 20, 2009
AB		**500MG**	**A091491**	**002**	Dec 14, 2010
AB		**750MG**	**A077319**	**003**	Mar 20, 2009
AB		**750MG**	**A091491**	**003**	Dec 14, 2010
AB		**1GM**	**A091491**	**004**	Dec 14, 2010
AB	WOCKHARDT	**250MG**	**A079042**	**001**	Jan 15, 2009
AB		**500MG**	**A079042**	**002**	Jan 15, 2009
AB		**750MG**	**A079042**	**003**	Jan 15, 2009
AB		**1GM**	**A079042**	**004**	Jan 15, 2009
AB	ZYDUS PHARMS USA INC	**250MG**	**A078918**	**001**	Apr 29, 2009
AB		**1GM**	**A078918**	**002**	Apr 29, 2009

TABLET, EXTENDED RELEASE;ORAL

KEPPRA XR

AB	UCB INC	**500MG**	**N022285**	**001**	Sep 12, 2008
AB	**+**	**750MG**	**N022285**	**002**	Feb 12, 2009

LEVETIRACETAM

AB	ACTAVIS ELIZABETH	**500MG**	**A091557**	**001**	Sep 12, 2011
AB		**750MG**	**A091557**	**002**	Sep 12, 2011
AB	ACTAVIS LABS FL INC	**500MG**	**A091093**	**001**	Sep 12, 2011
AB		**750MG**	**A091093**	**002**	Sep 12, 2011
AB	ANCHEN PHARMS	**500MG**	**A091360**	**001**	Oct 04, 2011
AB		**750MG**	**A091360**	**002**	Oct 04, 2011
AB	APOTEX INC	**500MG**	**A091261**	**001**	Sep 12, 2011
AB		**750MG**	**A091261**	**002**	Sep 12, 2011
AB	DEXCEL PHARMA	**500MG**	**A202167**	**001**	Sep 04, 2015
AB		**750MG**	**A202167**	**002**	Sep 04, 2015
AB	INTELLIPHARMACEUTICS	**500MG**	**A204511**	**001**	Feb 23, 2016
AB		**750MG**	**A204511**	**002**	Feb 23, 2016
AB	LOTUS PHARM CO LTD	**500MG**	**A202095**	**002**	Jun 06, 2016
AB		**750MG**	**A202095**	**001**	Jun 06, 2016
AB	LUPIN LTD	**500MG**	**A091399**	**001**	Sep 12, 2011
AB		**750MG**	**A091399**	**002**	Sep 12, 2011
AB	MYLAN PHARMS INC	**500MG**	**A200475**	**001**	Dec 19, 2011
AB		**750MG**	**A200475**	**002**	Dec 19, 2011
AB	NOSTRUM LABS INC	**500MG**	**A204754**	**001**	Aug 26, 2016
AB		**750MG**	**A204754**	**002**	Aug 26, 2016
AB	PAR PHARM	**500MG**	**A091291**	**001**	Sep 12, 2011
AB		**750MG**	**A091291**	**002**	Sep 12, 2011
AB	PHARMADAX INC	**500MG**	**A201464**	**001**	May 25, 2012
AB		**750MG**	**A201464**	**002**	May 25, 2012
AB	PRINSTON INC	**500MG**	**A203468**	**001**	May 21, 2015
AB		**750MG**	**A203468**	**002**	May 21, 2015
AB	ROUSES POINT PHARMS	**500MG**	**A202524**	**001**	Aug 27, 2012
AB		**750MG**	**A202524**	**002**	Aug 27, 2012
AB	SUN PHARM INDS	**500MG**	**A091285**	**001**	Sep 12, 2011
AB		**750MG**	**A091285**	**002**	Sep 12, 2011
AB	SUN PHARMA GLOBAL	**500MG**	**A203059**	**001**	Sep 09, 2013
AB		**750MG**	**A203059**	**002**	Sep 09, 2013
AB	TEVA PHARMS	**500MG**	**A091430**	**001**	Sep 12, 2011
AB		**750MG**	**A091430**	**002**	Sep 12, 2011
AB	TORRENT PHARMS LTD	**500MG**	**A091338**	**001**	May 29, 2012
AB		**750MG**	**A091338**	**002**	May 29, 2012
AB	VINTAGE PHARMS LLC	**500MG**	**A202533**	**001**	Jul 20, 2012
AB		**750MG**	**A202533**	**002**	Jul 20, 2012
	APOTEX INC	1GM	A202958	001	Feb 25, 2015
	MYLAN PHARMS INC	1GM	A200475	003	Dec 07, 2015

TABLET, FOR SUSPENSION;ORAL

SPRITAM

APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015
	500MG	N207958	002	Jul 31, 2015
	750MG	N207958	003	Jul 31, 2015

LEVETIRACETAM
TABLET, FOR SUSPENSION;ORAL
SPRITAM

	+	1GM	N207958	004	Jul 31, 2015

LEVOBUNOLOL HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

	AKBETA				
AT	AKORN	**0.25%**	**A074779**	**001**	Oct 29, 1996
AT		**0.5%**	**A074780**	**001**	Oct 29, 1996
	BETAGAN				
AT	+ ALLERGAN	**0.25%**	**N019814**	**001**	Jun 28, 1989
AT	+	**0.5%**	**N019219**	**002**	Dec 19, 1985
	LEVOBUNOLOL HYDROCHLORIDE				
AT	ALCON LABS INC	**0.25%**	**A074851**	**001**	Oct 28, 1996
AT	ALCON RES LTD	**0.5%**	**A074850**	**001**	Oct 28, 1996
AT	BAUSCH AND LOMB	**0.25%**	**A074307**	**001**	Mar 04, 1994
AT		**0.5%**	**A074326**	**001**	Mar 04, 1994

LEVOCARNITINE
INJECTABLE;INJECTION

	CARNITOR				
AP	+ SIGMA TAU	**200MG/ML**	**N020182**	**001**	Dec 16, 1992
	LEVOCARNITINE				
AP	LUITPOLD	**200MG/ML**	**A075861**	**001**	Jun 22, 2001
AP	WEST-WARD PHARMS INT	**200MG/ML**	**A075567**	**001**	Mar 29, 2001

SOLUTION;ORAL

	CARNITOR				
AA	+ SIGMA TAU	**1GM/10ML**	**N019257**	**001**	Apr 10, 1986
	CARNITOR SF				
AA	SIGMA TAU	**1GM/10ML**	**N019257**	**002**	Mar 28, 2007
	LEVOCARNITINE				
AA	HI TECH PHARMA	**1GM/10ML**	**A077399**	**001**	Oct 25, 2007
AA	LYNE	**1GM/10ML**	**A076851**	**001**	Aug 10, 2004

TABLET;ORAL

	CARNITOR				
AB	+ SIGMA TAU	**330MG**	**N018948**	**001**	Dec 27, 1985
	LEVOCARNITINE				
AB	COREPHARMA	**330MG**	**A076858**	**001**	Sep 20, 2004

LEVOCETIRIZINE DIHYDROCHLORIDE
SOLUTION;ORAL

	LEVOCETIRIZINE DIHYDROCHLORIDE				
AA	APOTEX INC	**2.5MG/5ML**	**A202915**	**001**	Aug 21, 2014
AA	L PERRIGO CO	**2.5MG/5ML**	**A091263**	**001**	Nov 07, 2011
AA	TARO PHARM INDS	**2.5MG/5ML**	**A202673**	**001**	Jul 26, 2013
	XYZAL				
AA	+ UCB INC	**2.5MG/5ML**	**N022157**	**001**	Jan 28, 2008

TABLET;ORAL

	LEVOCETIRIZINE DIHYDROCHLORIDE				
AB	APOTEX INC	**5MG**	**A203027**	**001**	Feb 13, 2015
AB	DR REDDYS LABS LTD	**5MG**	**A090392**	**001**	Feb 24, 2011
AB	GLENMARK GENERICS	**5MG**	**A090385**	**001**	Feb 24, 2011
AB	HETERO LABS LTD III	**5MG**	**A091264**	**001**	Jun 29, 2012
AB	MACLEODS PHARMS LTD	**5MG**	**A205564**	**001**	Jan 11, 2016
AB	MICRO LABS LTD INDIA	**5MG**	**A202046**	**001**	Sep 17, 2013
AB	NOSTRUM LABS INC	**5MG**	**A204323**	**001**	Dec 20, 2016
AB	SCIEGEN PHARMS INC	**5MG**	**A203646**	**001**	Sep 09, 2014
AB	SUN PHARM INDS LTD	**5MG**	**A201653**	**001**	Jun 26, 2015
AB	SUN PHARMA GLOBAL	**5MG**	**A090362**	**001**	Jan 31, 2013
AB	SYNTHON PHARMS	**5MG**	**A090229**	**001**	Nov 26, 2010
AB	TEVA PHARMS	**5MG**	**A090199**	**001**	Aug 22, 2011
	XYZAL				
AB	+ UCB INC	**5MG**	**N022064**	**001**	May 25, 2007

LEVOFLOXACIN
INJECTABLE;INJECTION

	LEVAQUIN				
AP	+ JANSSEN PHARMS	**EQ 500MG/20ML (EQ 25MG/ML)**	**N020635**	**001**	Dec 20, 1996
AP	+	**EQ 750MG/30ML (EQ 25MG/ML)**	**N020635**	**004**	Dec 20, 1996
	LEVOFLOXACIN				
AP	AUROBINDO PHARMA LTD	**EQ 500MG/20ML (EQ 25MG/ML)**	**A202328**	**001**	Jan 24, 2013
AP		**EQ 750MG/30ML (EQ 25MG/ML)**	**A202328**	**002**	Jan 24, 2013
AP	CLARIS	**EQ 500MG/20ML (EQ 25MG/ML)**	**A091436**	**001**	Jun 05, 2013

FDA data supplied by DrugPatentWatch.com

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP		EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013
AP			EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013
AP		SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011
AP			EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011
AP	+		EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011
AP	+		EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011
AP		AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016
AP			EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016
AP			EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016
AP		CLARIS	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013
AP			EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013
AP			EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013
AP		FRESENIUS KABI USA	EQ 250MG/50ML (EQ 5MG/ML)	A200674	001	Jun 19, 2013
AP			EQ 500MG/100ML (EQ 5MG/ML)	A200674	002	Jun 19, 2013
AP			EQ 750MG/150ML (EQ 5MG/ML)	A200674	003	Jun 19, 2013
AP		HIKMA FARMACEUTICA	EQ 250MG/50ML (EQ 5MG/ML)	A091375	001	Sep 16, 2011
AP			EQ 500MG/100ML (EQ5MG/ML)	A091375	002	Sep 16, 2011
AP			EQ 750MG/150ML (EQ 5MG/ML)	A091375	003	Sep 16, 2011
AP		HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015
AP			EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015
AP			EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015

SOLUTION;ORAL

LEVAQUIN

AA	+	JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004

LEVOFLOXACIN

AA		HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT		AKORN	0.5%	A090268	001	Dec 20, 2010
AT	+	RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010
AT		WATSON LABS INC	0.5%	A076826	001	Feb 10, 2011

TABLET;ORAL

LEVAQUIN

AB		JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996
AB			500MG	N020634	002	Dec 20, 1996
AB	+		750MG	N020634	003	Sep 08, 2000

LEVOFLOXACIN

AB		APOTEX INC	250MG	A090787	001	Sep 29, 2011
AB			500MG	A090787	002	Sep 29, 2011
AB			750MG	A090787	003	Sep 29, 2011
AB		AUROBINDO PHARMA LTD	250MG	A201043	001	Jun 20, 2011
AB			500MG	A201043	002	Jun 20, 2011
AB			750MG	A201043	003	Jun 20, 2011
AB		CIPLA LTD	250MG	A076890	001	Mar 30, 2012
AB			500MG	A076890	002	Mar 30, 2012
AB			750MG	A076890	003	Mar 30, 2012
AB		DR REDDYS LABS INC	250MG	A076710	001	Jun 20, 2011
AB			500MG	A076710	002	Jun 20, 2011
AB			750MG	A076710	003	Jun 20, 2011
AB		GLENMARK GENERICS	250MG	A200250	001	Jun 20, 2011
AB			500MG	A200250	002	Jun 20, 2011
AB			750MG	A200250	003	Jun 20, 2011
AB		HETERO LABS LTD V	250MG	A202801	001	Jan 08, 2015
AB			500MG	A202801	002	Jan 08, 2015
AB			750MG	A202801	003	Jan 08, 2015
AB		JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015
AB			500MG	A203613	002	Jun 19, 2015
AB		LUPIN	250MG	A078424	001	Jun 20, 2011
AB			500MG	A078424	002	Jun 20, 2011
AB			750MG	A078424	003	Jun 20, 2011
AB		MACLEODS PHARMS LTD	250MG	A200839	001	Mar 22, 2012
AB			500MG	A200839	002	Mar 22, 2012
AB			750MG	A200839	003	Mar 22, 2012
AB		MYLAN	250MG	A076276	001	Jun 20, 2011
AB			500MG	A076276	002	Jun 20, 2011
AB			750MG	A077097	001	Jun 20, 2011
AB		ORCHID HLTHCARE	250MG	A202200	001	Jan 30, 2012

LEVOFLOXACIN
TABLET;ORAL
LEVOFLOXACIN

AB		**500MG**	**A202200**	**002**	Jan 30, 2012
AB		**750MG**	**A202200**	**003**	Jan 30, 2012
AB	SANDOZ	**250MG**	**A077438**	**001**	Jun 20, 2011
AB		**500MG**	**A077438**	**002**	Jun 20, 2011
AB		**750MG**	**A077438**	**003**	Jun 20, 2011
AB	TEVA	**250MG**	**A076361**	**001**	Jun 20, 2011
AB		**500MG**	**A076361**	**002**	Jun 20, 2011
AB		**750MG**	**A076361**	**003**	Jun 20, 2011
AB	TORRENT PHARMS	**250MG**	**A090722**	**001**	Jun 20, 2011
AB		**500MG**	**A090722**	**002**	Jun 20, 2011
AB		**750MG**	**A090722**	**003**	Jun 20, 2011
AB	WOCKHARDT	**250MG**	**A090367**	**001**	Jun 20, 2011
AB		**500MG**	**A090367**	**002**	Jun 20, 2011
AB		**750MG**	**A090367**	**003**	Jun 20, 2011
AB	ZYDUS PHARMS USA INC	**250MG**	**A077652**	**001**	Sep 07, 2012
AB		**500MG**	**A077652**	**002**	Sep 07, 2012
AB		**750MG**	**A077652**	**003**	Sep 07, 2012

LEVOLEUCOVORIN CALCIUM
POWDER;IV (INFUSION)
FUSILEV

AP	**+** SPECTRUM PHARMS	**EQ 50MG BASE/VIAL**	**N020140**	**001**	Mar 07, 2008

LEVOLEUCOVORIN CALCIUM

AP	WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A206263**	**001**	Jun 16, 2016
	ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016

SOLUTION;IV (INFUSION)
LEVOLEUCOVORIN CALCIUM

AP	MYLAN TEORANTA	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A203576**	**001**	Oct 20, 2015
AP		**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A203576**	**002**	Oct 20, 2015
AP	SANDOZ INC	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A203563**	**001**	Mar 09, 2015
AP	**+**	**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A203563**	**002**	Mar 09, 2015

LEVOMILNACIPRAN HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
FETZIMA

	FOREST LABS INC	EQ 20MG BASE	N204168	001	Jul 25, 2013
		EQ 40MG BASE	N204168	002	Jul 25, 2013
		EQ 80MG BASE	N204168	003	Jul 25, 2013
+		EQ 120MG BASE	N204168	004	Jul 25, 2013

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
SCANDONEST L

+	DEPROCO	0.05MG/ML;2%	A088388	001	Oct 10, 1984

LEVONORGESTREL
INTRAUTERINE DEVICE;INTRAUTERINE

KYLEENA					
+	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016
LILETTA					
	MEDICINES360	52MG	N206229	001	Feb 26, 2015
MIRENA					
+	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000
SKYLA					
+	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013

TABLET;ORAL
LEVONORGESTREL

AB	JAI PHARMA LTD	**0.75MG**	**A202740**	**001**	Sep 02, 2016
AB	LOTUS PHARM CO LTD	**0.75MG**	**A202684**	**001**	Sep 02, 2016
AB	**+** PERRIGO R AND D	**0.75MG**	**A090740**	**001**	Dec 30, 2010

LEVORPHANOL TARTRATE
TABLET;ORAL
LEVORPHANOL TARTRATE

+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000

FDA data supplied by DrugPatentWatch.com

LEVOTHYROXINE SODIUM
CAPSULE;ORAL
TIROSINT

	INST BIOCHIMIQUE	0.013MG	N022121	001	Aug 01, 2007
	INSTITUT BIOCHIMIQUE	0.025MG	N021924	002	Oct 13, 2006
		0.05MG	N021924	003	Oct 13, 2006
		0.075MG	N021924	004	Oct 13, 2006
		0.088MG	N021924	010	Oct 02, 2009
		0.1MG	N021924	005	Oct 13, 2006
		0.112MG	N021924	008	Oct 02, 2009
		0.125MG	N021924	006	Oct 13, 2006
		0.137MG	N021924	009	Oct 02, 2009
+		0.15MG	N021924	007	Oct 13, 2006

POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

AP		FERA PHARMS LLC	**100MCG/VIAL**	**A206163**	**001**	Jun 29, 2016
AP			**500MCG/VIAL**	**A206163**	**002**	Jun 29, 2016
AP	+	FRESENIUS KABI USA	**100MCG/VIAL**	**N202231**	**001**	Jun 24, 2011
AP	+		**200MCG/VIAL**	**N202231**	**002**	Jun 24, 2011
AP	+		**500MCG/VIAL**	**N202231**	**003**	Jun 24, 2011
AP		PAR STERILE PRODUCTS	**200MCG/VIAL**	**A205366**	**001**	Dec 07, 2015

SOLUTION;ORAL
TIROSINT-SOL

	IBSA INST BIO	13MCG/ML	N206977	001	Dec 15, 2016
		25MCG/ML	N206977	002	Dec 15, 2016
		50MCG/ML	N206977	003	Dec 15, 2016
		75MCG/ML	N206977	004	Dec 15, 2016
		88MCG/ML	N206977	005	Dec 15, 2016
		100MCG/ML	N206977	006	Dec 15, 2016
		112MCG/ML	N206977	007	Dec 15, 2016
		125MCG/ML	N206977	008	Dec 15, 2016
		137MCG/ML	N206977	009	Dec 15, 2016
		150MCG/ML	N206977	010	Dec 15, 2016
		175MCG/ML	N206977	011	Dec 15, 2016
+		200MCG/ML	N206977	012	Dec 15, 2016

LEVOTHYROXINE SODIUM **
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL
SYNTHROID

-->		ABBVIE	**--> AB1,AB2**	**0.025MG**	N021402	001 Jul 24, 2002
-->			**--> AB1,AB2**	**0.05MG**	N021402	002 Jul 24, 2002
-->			**--> AB1,AB2**	**0.075MG**	N021402	003 Jul 24, 2002
-->			**--> AB1,AB2**	**0.088MG**	N021402	004 Jul 24, 2002
-->			**--> AB1,AB2**	**0.1MG**	N021402	005 Jul 24, 2002
-->			**--> AB1,AB2**	**0.112MG**	N021402	006 Jul 24, 2002
-->			**--> AB1,AB2**	**0.125MG**	N021402	007 Jul 24, 2002
-->			**--> AB1,AB2**	**0.137MG**	N021402	008 Jul 24, 2002
-->			**--> AB1,AB2**	**0.15MG**	N021402	009 Jul 24, 2002
-->			**--> AB1,AB2**	**0.175MG**	N021402	010 Jul 24, 2002
-->			**--> AB1,AB2**	**0.2MG**	N021402	012 Jul 24, 2002
-->	+		**--> AB1,AB2**	**0.3MG**	N021402	011 Jul 24, 2002

LEVO-T

-->		ALARA PHARM	**--> AB1,AB2,AB3**	**0.025MG**	N021342	001 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.05MG**	N021342	002 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.075MG**	N021342	003 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.088MG**	N021342	004 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.1MG**	N021342	005 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.112MG**	N021342	006 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.125MG**	N021342	007 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.137MG**	N021342	012 Dec 08, 2003
-->			**--> AB1,AB2,AB3**	**0.15MG**	N021342	008 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.175MG**	N021342	009 Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.2MG**	N021342	010 Mar 01, 2002

FDA data supplied by DrugPatentWatch.com

LEVOTHYROXINE SODIUM **
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL

	LEVO-T						
-->	+		--> AB1,AB2,AB3	0.3MG	N021342	011	Mar 01, 2002
	UNITHROID						
-->		STEVENS J	--> AB1,AB2,AB3	0.025MG	N021210	001	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.05MG	N021210	002	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.075MG	N021210	003	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.088MG	N021210	004	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.1MG	N021210	005	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.112MG	N021210	006	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.125MG	N021210	007	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.137MG	N021210	012	Feb 08, 2008
-->			--> AB1,AB2,AB3	0.15MG	N021210	008	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.175MG	N021210	009	Aug 21, 2000
-->			--> AB1,AB2,AB3	0.2MG	N021210	010	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.3MG	N021210	011	Aug 21, 2000
	LEVOTHYROXINE SODIUM						
-->		MYLAN	--> AB1,AB2,AB3,AB4	0.025MG	A076187	001	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.05MG	A076187	002	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.075MG	A076187	003	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.088MG	A076187	004	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.1MG	A076187	005	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.112MG	A076187	006	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.125MG	A076187	007	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.137MG	A076187	012	Dec 13, 2006
-->			--> AB1,AB2,AB3,AB4	0.15MG	A076187	008	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.175MG	A076187	009	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.2MG	A076187	010	Jun 05, 2002
-->	+		--> AB1,AB2,AB3,AB4	0.3MG	A076187	011	Jun 05, 2002
	LEVOXYL						
-->		KING PHARMS R AND D	--> AB1,AB3	0.025MG	N021301	001	May 25, 2001
-->			--> AB1,AB3	0.05MG	N021301	002	May 25, 2001
-->			--> AB1,AB3	0.075MG	N021301	003	May 25, 2001
-->			--> AB1,AB3	0.088MG	N021301	004	May 25, 2001
-->			--> AB1,AB3	0.1MG	N021301	005	May 25, 2001
-->			--> AB1,AB3	0.112MG	N021301	006	May 25, 2001
-->			--> AB1,AB3	0.125MG	N021301	007	May 25, 2001
-->			--> AB1,AB3	0.137MG	N021301	008	May 25, 2001
-->			--> AB1,AB3	0.15MG	N021301	009	May 25, 2001
-->			--> AB1,AB3	0.175MG	N021301	010	May 25, 2001
-->	+		--> AB1,AB3	0.2MG	N021301	011	May 25, 2001

LIDOCAINE
OINTMENT;TOPICAL

	LIDOCAINE					
AT		AMNEAL PHARMS	5%	A206297	001	Aug 07, 2015
AT	+	FOUGERA	5%	A080198	001	
AT		GLENMARK PHARMS LTD	5%	A206498	001	Sep 09, 2016
AT		SEPTODONT INC	5%	A040911	001	May 23, 2011
AT		TARO	5%	A086724	001	
AT		TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016

FDA data supplied by DrugPatentWatch.com

LIDOCAINE
PATCH;TOPICAL

	LIDOCAINE				
AB	ACTAVIS LABS UT INC	**5%**	**A200675**	**001**	Aug 23, 2012
AB	MYLAN TECHNOLOGIES	**5%**	**A202346**	**001**	Aug 07, 2015
	LIDODERM				
AB	+ TEIKOKU PHARMA USA	**5%**	**N020612**	**001**	Mar 19, 1999

LIDOCAINE HYDROCHLORIDE
GEL;OPHTHALMIC

	AKTEN				
	+ AKORN	3.5%	N022221	001	Oct 07, 2008

INJECTABLE;INJECTION

	LIDOCAINE HYDROCHLORIDE				
AP	HOSPIRA	**0.5%**	**A088328**	**001**	May 17, 1984
AP		**1%**	**A083158**	**001**	
AP		**1%**	**A088329**	**001**	May 17, 1984
AP		**2%**	**A040078**	**001**	Jun 23, 1995
AP		**2%**	**A083158**	**002**	
AP		**2%**	**A088294**	**001**	May 17, 1984
AP		**20%**	**A083158**	**003**	
AP	INTL MEDICATION	**1%**	**A083173**	**001**	
AP		**2%**	**A083173**	**002**	
AP	LUITPOLD	**1%**	**A080850**	**001**	
AP	LUITPOLD PHARMS INC	**1%**	**A091564**	**001**	Aug 14, 2015
AP	MYLAN LABS LTD	**0.5%**	**A091056**	**001**	Dec 08, 2010
AP		**0.5%**	**A091058**	**001**	Sep 30, 2010
AP		**1%**	**A091056**	**002**	Dec 08, 2010
AP		**1%**	**A091058**	**002**	Sep 30, 2010
AP		**2%**	**A202242**	**001**	Apr 11, 2014
	LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
AP	B BRAUN	**200MG/100ML**	**N019830**	**002**	Apr 08, 1992
AP	BAXTER HLTHCARE	**200MG/100ML**	**N018461**	**002**	
	LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
AP	B BRAUN	**400MG/100ML**	**N019830**	**003**	Apr 08, 1992
AP	BAXTER HLTHCARE	**400MG/100ML**	**N018461**	**003**	
	LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER				
AP	B BRAUN	**800MG/100ML**	**N019830**	**004**	Apr 08, 1992
AP	BAXTER HLTHCARE	**800MG/100ML**	**N018461**	**004**	Feb 22, 1982
	LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER				
AP	FRESENIUS KABI USA	**1%**	**A088586**	**001**	Jul 24, 1985
AP	HOSPIRA	**0.5%**	**A088325**	**001**	Jul 31, 1984
AP		**1%**	**A088299**	**001**	Jul 31, 1984
AP		**2%**	**A088327**	**001**	Jul 31, 1984
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE				
AP	AUROBINDO PHARMA LTD	**1%**	**A203040**	**001**	Mar 14, 2013
AP		**1%**	**A203082**	**001**	Mar 14, 2013
AP		**2%**	**A203040**	**002**	Mar 14, 2013
AP		**2%**	**A203082**	**002**	Mar 14, 2013
AP	FRESENIUS KABI USA	**1%**	**A080404**	**002**	
AP		**2%**	**A080404**	**003**	
AP		**2%**	**N017584**	**001**	
AP		**4%**	**N017584**	**002**	
AP	HOSPIRA	**1%**	**A080408**	**001**	
AP		**1.5%**	**A080408**	**002**	
AP		**4%**	**A088295**	**001**	May 17, 1984
AP	INTL MEDICATION	**20%**	**N017702**	**001**	
AP	MYLAN LABS LTD	**2%**	**A090665**	**001**	Sep 27, 2010
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER				
AP	HOSPIRA	**1%**	**A040302**	**001**	Sep 28, 1998
AP		**2%**	**A040302**	**002**	Sep 28, 1998
	XYLOCAINE				
AP	+ FRESENIUS KABI USA	**0.5%**	**N006488**	**008**	
AP	+	**1%**	**N006488**	**007**	
AP	+	**1.5%**	**N006488**	**010**	
AP	+	**2%**	**N006488**	**002**	
	XYLOCAINE 4% PRESERVATIVE FREE				
AP	+ FRESENIUS KABI USA	**4%**	**N010417**	**001**	
	XYLOCAINE PRESERVATIVE FREE				
AP	+ FRESENIUS KABI USA	**1%**	**N016801**	**005**	Jan 19, 1988
AP	+	**2%**	**N016801**	**001**	
AP	+	**4%**	**N016801**	**002**	
AP	+	**20%**	**N016801**	**004**	

LIDOCAINE HYDROCHLORIDE
INJECTABLE;SPINAL
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

	+	HOSPIRA	5%	A083914 001	
JELLY;TOPICAL					
		GLYDO			
AT		SAGENT PHARMS	**2%**	**A201094 001**	Apr 28, 2014
		LIDOCAINE HYDROCHLORIDE			
AT		AKORN	**2%**	**A040433 001**	Feb 12, 2003
AT		INTL MEDICATION	**2%**	**A086283 001**	
AT		WATSON LABS INC	**2%**	**A040837 001**	Mar 23, 2011
		XYLOCAINE			
AT	+	OAK PHARMS	**2%**	**N008816 001**	
SOLUTION;ORAL					
		LIDOCAINE HYDROCHLORIDE			
AT		HI TECH PHARMA	**2%**	**A040014 001**	Jul 10, 1995
AT		WOCKHARDT	**2%**	**A087872 001**	Nov 18, 1982
		LIDOCAINE HYDROCHLORIDE VISCOUS			
AT	+	VINTAGE	**2%**	**A040708 001**	Feb 27, 2007
		LIDOCAINE VISCOUS			
AT		WEST-WARD PHARMS INT	**2%**	**A088802 001**	Apr 26, 1985
SOLUTION;TOPICAL					
		LARYNG-O-JET KIT			
AT		INTL MEDICATION	**4%**	**A086364 001**	
		LIDOCAINE HYDROCHLORIDE			
AT		TELIGENT PHARMA INC	**4%**	**A204494 001**	Mar 12, 2014
AT		VINTAGE	**4%**	**A040710 001**	Feb 27, 2007
AT		WEST-WARD PHARMS INT	**4%**	**A088803 001**	Apr 03, 1985
AT		WOCKHARDT	**4%**	**A087881 001**	Nov 18, 1982
		LTA II KIT			
AT		HOSPIRA	**4%**	**A080409 001**	
		XYLOCAINE 4% PRESERVATIVE FREE			
AT	+	FRESENIUS KABI USA	**4%**	**N010417 002**	
SYSTEM;INTRADERMAL					
		ZINGO			
		POWDER PHARMS	0.5MG	N022114 001	Aug 16, 2007

LIDOCAINE; PRILOCAINE
CREAM;TOPICAL

		EMLA			
AB	+	ACTAVIS LABS UT INC	**2.5%;2.5%**	**N019941 001**	Dec 30, 1992
		LIDOCAINE AND PRILOCAINE			
AB		FOUGERA PHARMS	**2.5%;2.5%**	**A076453 001**	Aug 18, 2003
AB		HI TECH PHARMA	**2.5%;2.5%**	**A076290 001**	Sep 25, 2003
AB		TOLMAR	**2.5%;2.5%**	**A076320 001**	Aug 27, 2003
GEL;PERIODONTAL					
		ORAQIX			
	+	DENTSPLY PHARM	2.5%;2.5%	N021451 001	Dec 19, 2003

LIDOCAINE; TETRACAINE
CREAM;TOPICAL

		PLIAGLIS			
	+	GALDERMA LABS LP	7%;7%	N021717 001	Jun 29, 2006
PATCH;TOPICAL					
		SYNERA			
	+	GALEN SPECIALTY	70MG;70MG	N021623 001	Jun 23, 2005

LIFITEGRAST
SOLUTION/DROPS;OPHTHALMIC

		XIIDRA			
	+	SHIRE DEV LLC	5%	N208073 001	Jul 11, 2016

LINACLOTIDE
CAPSULE;ORAL

		LINZESS			
		FOREST LABS LLC	145MCG	N202811 001	Aug 30, 2012
	+		290MCG	N202811 002	Aug 30, 2012

LINAGLIPTIN
TABLET;ORAL

		TRADJENTA			
	+	BOEHRINGER INGELHEIM	5MG	N201280 001	May 02, 2011

FDA data supplied by DrugPatentWatch.com

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL					
JENTADUETO					
	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012
		2.5MG;850MG	N201281	002	Jan 30, 2012
+		2.5MG;1GM	N201281	003	Jan 30, 2012
TABLET, EXTENDED RELEASE;ORAL					
JENTADUETO XR					
	BOEHRINGER INGELHEIM	2.5MG;1GM	N208026	001	May 27, 2016
+		5MG;1GM	N208026	002	May 27, 2016

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION						
LINCOCIN						
AP	**+**	PHARMACIA AND UPJOHN	**EQ 300MG BASE/ML**	**N050317**	**001**	
LINCOMYCIN						
AP		X-GEN PHARMS INC	**EQ 300MG BASE/ML**	**A201746**	**001**	Jun 04, 2015

LINDANE

LOTION;TOPICAL						
LINDANE						
AT		OLTA PHARMS	**1%**	**A087313**	**001**	
AT	**+**	WOCKHARDT	**1%**	**A088190**	**001**	Aug 16, 1984
SHAMPOO;TOPICAL						
LINDANE						
AT		OLTA PHARMS	**1%**	**A087266**	**001**	
AT	**+**	WOCKHARDT	**1%**	**A088191**	**001**	Sep 18, 1984

LINEZOLID

FOR SUSPENSION;ORAL						
LINEZOLID						
AB		WEST-WARD PHARMS INT	**100MG/5ML**	**A200068**	**001**	Jun 03, 2015
ZYVOX						
AB	**+**	PHARMACIA AND UPJOHN	**100MG/5ML**	**N021132**	**001**	Apr 18, 2000
SOLUTION;IV (INFUSION)						
LINEZOLID						
AP		AUROBINDO PHARMA LTD	**600MG/300ML (2MG/ML)**	**A206917**	**001**	Aug 04, 2016
AP		FRESENIUS KABI USA	**600MG/300ML (2MG/ML)**	**A204764**	**001**	Mar 15, 2016
AP		HOSPIRA INC	**600MG/300ML (2MG/ML)**	**A205442**	**001**	Jul 07, 2015
AP		NANG KUANG PHARM CO	**200MG/100ML (2MG/ML)**	**A207354**	**001**	Dec 20, 2016
AP			**600MG/300ML (2MG/ML)**	**A207354**	**002**	Dec 20, 2016
AP		SANDOZ INC	**200MG/100ML (2MG/ML)**	**A200904**	**001**	Jul 16, 2015
AP			**600MG/300ML (2MG/ML)**	**A200904**	**002**	Jul 16, 2015
AP		TEVA PHARMS	**600MG/300ML (2MG/ML)**	**A200222**	**001**	Jun 27, 2012
ZYVOX						
AP		PHARMACIA AND UPJOHN	**200MG/100ML (2MG/ML)**	**N021131**	**001**	Apr 18, 2000
AP	**+**		**600MG/300ML (2MG/ML)**	**N021131**	**003**	Apr 18, 2000
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	+	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015
ZYVOX						
		PHARMACIA AND UPJOHN	400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000
TABLET;ORAL						
LINEZOLID						
AB		ALEMBIC PHARMS LTD	**600MG**	**A205233**	**001**	Dec 21, 2015
AB		ALKEM LABS LTD	**600MG**	**A205517**	**001**	Dec 21, 2015
AB		AMNEAL PHARMS	**600MG**	**A204536**	**001**	Dec 21, 2015
AB		GATE PHARMS	**600MG**	**A091210**	**001**	Feb 05, 2016
AB		GLENMARK PHARMS	**600MG**	**A078987**	**001**	Dec 21, 2015
AB		HETERO LABS LTD V	**600MG**	**A204239**	**001**	Dec 21, 2015
AB		MYLAN PHARMS INC	**600MG**	**A078845**	**001**	Dec 21, 2015
AB		NOVEL LABS INC	**600MG**	**A207526**	**001**	Aug 22, 2016
AB		TEVA PHARMS USA	**600MG**	**A078061**	**001**	May 18, 2015
ZYVOX						
AB	**+**	PHARMACIA AND UPJOHN	**600MG**	**N021130**	**002**	Apr 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION						
LIOTHYRONINE SODIUM						
AP		X GEN PHARMS	**EQ 0.01MG BASE/ML**	**A076923**	**001**	Aug 17, 2005
TRIOSTAT						
AP	**+**	PAR STERILE PRODUCTS	**EQ 0.01MG BASE/ML**	**N020105**	**001**	Dec 31, 1991
TABLET;ORAL						
CYTOMEL						
AB		KING PHARMS R AND D	**EQ 0.005MG BASE**	**N010379**	**001**	

LIOTHYRONINE SODIUM
TABLET;ORAL
CYTOMEL

AB		**EQ 0.025MG BASE**	**N010379**	**002**	
AB	**+**	**EQ 0.05MG BASE**	**N010379**	**003**	
	LIOTHYRONINE SODIUM				
AB	MAYNE PHARMA INC	**EQ 0.005MG BASE**	**A090097**	**001**	Mar 20, 2009
AB		**EQ 0.025MG BASE**	**A090097**	**002**	Mar 20, 2009
AB		**EQ 0.05MG BASE**	**A090097**	**003**	Mar 20, 2009
AB	MYLAN	**EQ 0.005MG BASE**	**A090326**	**001**	Jul 14, 2009
AB		**EQ 0.025MG BASE**	**A090326**	**002**	Jul 14, 2009
AB		**EQ 0.05MG BASE**	**A090326**	**003**	Jul 14, 2009
AB	SIGMAPHARM LABS LLC	**EQ 0.005MG BASE**	**A200295**	**001**	Nov 29, 2012
AB		**EQ 0.025MG BASE**	**A200295**	**002**	Nov 29, 2012
AB		**EQ 0.05MG BASE**	**A200295**	**003**	Nov 29, 2012
AB	SUN PHARM INDS LTD	**EQ 0.005MG BASE**	**A091382**	**001**	Apr 20, 2016
AB		**EQ 0.025MG BASE**	**A091382**	**002**	Apr 20, 2016
AB		**EQ 0.05MG BASE**	**A091382**	**003**	Apr 20, 2016

LIOTRIX (T4;T3)
TABLET;ORAL

	THYROLAR-0.25				
	FOREST LABS	0.0125MG;0.0031MG	N016807	001	
	THYROLAR-0.5				
	FOREST LABS	0.025MG;0.0063MG	N016807	005	
	THYROLAR-1				
	FOREST LABS	0.05MG;0.0125MG	N016807	004	
	THYROLAR-2				
	FOREST LABS	0.1MG;0.025MG	N016807	002	
	THYROLAR-3				
+	FOREST LABS	0.15MG;0.0375MG	N016807	003	

LIRAGLUTIDE RECOMBINANT
SOLUTION;SUBCUTANEOUS

	SAXENDA				
+	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014
	VICTOZA				
+	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE
CAPSULE;ORAL
VYVANSE

	SHIRE DEVELOPMENT	10MG	N021977	007	Oct 30, 2014
		20MG	N021977	004	Dec 10, 2007
		30MG	N021977	001	Feb 23, 2007
		40MG	N021977	005	Dec 10, 2007
		50MG	N021977	002	Feb 23, 2007
		60MG	N021977	006	Dec 10, 2007
+		70MG	N021977	003	Feb 23, 2007

LISINOPRIL
SOLUTION;ORAL

	QBRELIS				
+	SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016

TABLET;ORAL
LISINOPRIL

AB	ACCORD HLTHCARE	**2.5MG**	**A202554**	**001**	Jul 30, 2013
AB		**5MG**	**A202554**	**002**	Jul 30, 2013
AB		**10MG**	**A202554**	**003**	Jul 30, 2013
AB		**20MG**	**A202554**	**004**	Jul 30, 2013
AB		**30MG**	**A202554**	**005**	Jul 30, 2013
AB		**40MG**	**A202554**	**006**	Jul 30, 2013
AB	APOTEX INC	**2.5MG**	**A076102**	**001**	Sep 30, 2002
AB		**5MG**	**A076102**	**002**	Sep 30, 2002
AB		**10MG**	**A076102**	**003**	Sep 30, 2002
AB		**20MG**	**A076102**	**004**	Sep 30, 2002
AB		**30MG**	**A076102**	**005**	Sep 30, 2002
AB		**40MG**	**A076102**	**006**	Sep 30, 2002
AB	AUROBINDO	**2.5MG**	**A077622**	**001**	Feb 22, 2006
AB		**5MG**	**A077622**	**002**	Feb 22, 2006
AB		**10MG**	**A077622**	**003**	Feb 22, 2006
AB		**20MG**	**A077622**	**004**	Feb 22, 2006
AB		**30MG**	**A077622**	**005**	Feb 22, 2006
AB		**40MG**	**A077622**	**006**	Feb 22, 2006

FDA data supplied by DrugPatentWatch.com

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002
AB		5MG	A076063	002	Jul 01, 2002
AB		10MG	A076063	003	Jul 01, 2002
AB		20MG	A076063	004	Jul 01, 2002
AB		30MG	A076063	006	Jun 27, 2003
AB		40MG	A076063	005	Jul 01, 2002
AB	INVAGEN PHARMS	2.5MG	A203508	001	Oct 29, 2013
AB		5MG	A203508	002	Oct 29, 2013
AB		10MG	A203508	003	Oct 29, 2013
AB		20MG	A203508	004	Oct 29, 2013
AB		30MG	A203508	005	Oct 29, 2013
AB		40MG	A203508	006	Oct 29, 2013
AB	IVAX SUB TEVA PHARMS	2.5MG	A075752	001	Jul 01, 2002
AB		5MG	A075752	002	Jul 01, 2002
AB		10MG	A075752	003	Jul 01, 2002
AB		20MG	A075752	004	Jul 01, 2002
AB		30MG	A075752	005	Jul 01, 2002
AB		40MG	A075752	006	Jul 01, 2002
AB	LUPIN	2.5MG	A077321	001	Sep 09, 2005
AB		5MG	A077321	002	Sep 09, 2005
AB		10MG	A077321	003	Sep 09, 2005
AB		20MG	A077321	004	Sep 09, 2005
AB		30MG	A077321	005	Sep 09, 2005
AB		40MG	A077321	006	Sep 09, 2005
AB	MYLAN	2.5MG	A076071	001	Jul 01, 2002
AB		5MG	A076071	002	Jul 01, 2002
AB		10MG	A076071	003	Jul 01, 2002
AB		20MG	A076071	004	Jul 01, 2002
AB		30MG	A076071	005	Jul 01, 2002
AB		40MG	A076071	006	Jul 01, 2002
AB	PRINSTON INC	2.5MG	A076180	001	Jul 01, 2002
AB		5MG	A076180	002	Jul 01, 2002
AB		10MG	A076180	003	Jul 01, 2002
AB		20MG	A076164	001	Jul 01, 2002
AB		30MG	A076164	002	Jul 01, 2002
AB		40MG	A076164	003	Jul 01, 2002
AB	SANDOZ	2.5MG	A075994	001	Jul 01, 2002
AB		5MG	A075994	002	Jul 01, 2002
AB		10MG	A075994	003	Jul 01, 2002
AB		20MG	A075994	004	Jul 01, 2002
AB		30MG	A075994	005	Jul 01, 2002
AB		40MG	A075994	006	Jul 01, 2002
AB	SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002
AB		5MG	A075944	002	Jul 01, 2002
AB		10MG	A075944	003	Jul 01, 2002
AB		20MG	A075944	004	Jul 01, 2002
AB		30MG	A075944	006	Feb 11, 2003
AB		40MG	A075944	005	Jul 01, 2002
AB	VINTAGE	2.5MG	A075743	001	Jul 01, 2002
AB		5MG	A075743	002	Jul 01, 2002
AB		10MG	A075743	003	Jul 01, 2002
AB		20MG	A075743	004	Jul 01, 2002
AB		30MG	A075743	005	Jul 01, 2002
AB		40MG	A075743	006	Jul 01, 2002
AB	WATSON LABS	2.5MG	A076059	001	Jul 01, 2002
AB		5MG	A076059	002	Jul 01, 2002
AB		10MG	A076059	003	Jul 01, 2002
AB		20MG	A076059	004	Jul 01, 2002
AB		30MG	A076059	005	Jul 01, 2002
AB		40MG	A076059	006	Jul 01, 2002
AB	WOCKHARDT	2.5MG	A078402	001	Apr 19, 2007
AB		5MG	A078402	002	Apr 19, 2007
AB		10MG	A078402	003	Apr 19, 2007
AB		20MG	A078402	004	Apr 19, 2007
AB		30MG	A078402	005	Apr 19, 2007
AB		40MG	A078402	006	Apr 19, 2007

PRINIVIL

AB	MERCK	5MG	N019558	001	Dec 29, 1987
AB		10MG	N019558	002	Dec 29, 1987

LISINOPRIL
TABLET;ORAL
PRINIVIL

AB		**20MG**	**N019558**	**003**	Dec 29, 1987
AB		**40MG**	**N019558**	**004**	Oct 25, 1988
ZESTRIL					
AB	ALVOGEN MALTA	**2.5MG**	**N019777**	**005**	Apr 29, 1993
AB		**5MG**	**N019777**	**001**	May 19, 1988
AB		**10MG**	**N019777**	**002**	May 19, 1988
AB		**20MG**	**N019777**	**003**	May 19, 1988
AB		**30MG**	**N019777**	**006**	Jan 20, 1999
AB +		**40MG**	**N019777**	**004**	May 19, 1988

LITHIUM CARBONATE
CAPSULE;ORAL
LITHIUM CARBONATE

AB	ALEMBIC LTD	**150MG**	**A079159**	**001**	Jan 12, 2009
AB		**300MG**	**A079159**	**002**	Jan 12, 2009
AB		**600MG**	**A079159**	**003**	Jan 12, 2009
AB	DELCOR ASSET CORP	**150MG**	**A076243**	**002**	Feb 24, 2003
AB		**300MG**	**A076243**	**001**	Jun 27, 2002
AB		**600MG**	**A078763**	**001**	Apr 15, 2008
AB	GLENMARK GENERICS	**150MG**	**A079139**	**001**	Feb 03, 2009
AB		**300MG**	**A079139**	**002**	Feb 03, 2009
AB		**600MG**	**A079139**	**003**	Feb 03, 2009
AB	HETERO LABS LTD III	**150MG**	**A090702**	**001**	Sep 25, 2009
AB		**300MG**	**A090702**	**002**	Sep 25, 2009
AB		**600MG**	**A090702**	**003**	Sep 25, 2009
AB	ROXANE	**150MG**	**N017812**	**002**	Jan 28, 1987
AB		**300MG**	**N017812**	**001**	
AB +		**600MG**	**N017812**	**003**	Jan 28, 1987

TABLET;ORAL
LITHIUM CARBONATE

AB +	ROXANE	**300MG**	**N018558**	**001**	Jan 29, 1982
AB	SUN PHARM INDS INC	**300MG**	**A091027**	**001**	Jun 24, 2010

TABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

AB	ALEMBIC PHARMS LTD	**300MG**	**A204445**	**001**	Jun 10, 2015
AB	GLENMARK GENERICS	**450MG**	**A091616**	**001**	Feb 14, 2011
AB	GLENMARK PHARMS INC	**300MG**	**A091544**	**001**	Dec 27, 2010
AB	HERITAGE PHARMA	**300MG**	**A205532**	**001**	Sep 29, 2016
AB	MYLAN PHARMS INC	**300MG**	**A202288**	**001**	Jun 29, 2012
AB		**450MG**	**A202219**	**001**	Aug 08, 2012
AB	UNIQUE PHARM LABS	**300MG**	**A204779**	**001**	Jul 27, 2015
AB	WEST-WARD PHARMS INT	**300MG**	**A076832**	**001**	Oct 28, 2004
AB +		**450MG**	**A076691**	**001**	Jan 05, 2004
LITHOBID					
AB +	ANI PHARMS INC	**300MG**	**N018027**	**001**	

LITHIUM CITRATE
SYRUP;ORAL
LITHIUM CITRATE

AA +	ROXANE	**EQ 300MG CARBONATE/5ML**	**N018421**	**001**	
AA	WOCKHARDT	**EQ 300MG CARBONATE/5ML**	**A070755**	**001**	May 21, 1986

LIXISENATIDE
SOLUTION;SUBCUTANEOUS
ADLYXIN

+	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016
+		0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016

LODOXAMIDE TROMETHAMINE
SOLUTION/DROPS;OPHTHALMIC
ALOMIDE

+	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020191	001	Sep 23, 1993

LOMITAPIDE MESYLATE
CAPSULE;ORAL
JUXTAPID

	AEGERION	EQ 5MG BASE	N203858	001	Dec 21, 2012
		EQ 10MG BASE	N203858	002	Dec 21, 2012
		EQ 20MG BASE	N203858	003	Dec 21, 2012
		EQ 30MG BASE	N203858	004	Apr 23, 2015
		EQ 40MG BASE	N203858	005	Apr 23, 2015
+		EQ 60MG BASE	N203858	006	Apr 23, 2015

FDA data supplied by DrugPatentWatch.com

LOMUSTINE
CAPSULE;ORAL
GLEOSTINE

		CORDEN PHARMA	5MG	N017588	004 Dec 19, 2014
			10MG	N017588	001
			40MG	N017588	002
	+		100MG	N017588	003

LOPERAMIDE HYDROCHLORIDE
CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

AB	+	MYLAN	**2MG**	**A072741**	**001** Sep 18, 1991
AB		TEVA	**2MG**	**A073192**	**001** Apr 30, 1992

LOPINAVIR; RITONAVIR
SOLUTION;ORAL
KALETRA

AA	+	ABBVIE	**80MG/ML;20MG/ML**	**N021251**	**001** Sep 15, 2000

LOPINAVIR AND RITONAVIR

AA		SILARX PHARMS INC	**80MG/ML;20MG/ML**	**A207407**	**001** Dec 27, 2016

TABLET;ORAL
KALETRA

		ABBVIE	100MG;25MG	N021906	002 Nov 09, 2007
	+		200MG;50MG	N021906	001 Oct 28, 2005

LORAZEPAM
CONCENTRATE;ORAL
LORAZEPAM

AA		AMNEAL PHARMS	**2MG/ML**	**A091383**	**001** Dec 23, 2009
AA		HI-TECH PHARMA CO	**2MG/ML**	**A200169**	**001** Jan 30, 2012
AA		LUPIN LTD	**2MG/ML**	**A091407**	**001** Feb 19, 2013
AA		PADDOCK LLC	**2MG/ML**	**A079244**	**001** Apr 28, 2009
AA		PHARM ASSOC	**2MG/ML**	**A090260**	**001** Jun 15, 2010

LORAZEPAM INTENSOL

AA	+	WEST-WARD PHARMS INT	**2MG/ML**	**A072755**	**001** Jun 28, 1991

INJECTABLE;INJECTION
ATIVAN

AP	+	WEST-WARD PHARMS INT	**2MG/ML**	**N018140**	**001**
AP	+		**4MG/ML**	**N018140**	**002**

LORAZEPAM

AP		AKORN	**2MG/ML**	**A075025**	**001** Jul 23, 1998
AP		HOSPIRA	**2MG/ML**	**A074243**	**001** Apr 12, 1994
AP			**2MG/ML**	**A074282**	**001** May 27, 1994
AP			**4MG/ML**	**A074243**	**002** Apr 12, 1994
AP			**4MG/ML**	**A074282**	**002** May 27, 1994
AP		INTL MEDICATION SYS	**2MG/ML**	**A076150**	**001** Nov 15, 2004

LORAZEPAM PRESERVATIVE FREE

AP		BEDFORD LABS	**2MG/ML**	**A077074**	**001** Jul 13, 2005
AP			**4MG/ML**	**A077074**	**002** Jul 13, 2005

TABLET;ORAL
ATIVAN

AB		VALEANT INTL	**0.5MG**	**N017794**	**001**
AB			**1MG**	**N017794**	**002**
AB	+		**2MG**	**N017794**	**003**

LORAZEPAM

AB		AMNEAL PHARMS	**0.5MG**	**A078826**	**001** Jun 23, 2010
AB			**1MG**	**A078826**	**002** Jun 23, 2010
AB			**2MG**	**A078826**	**003** Jun 23, 2010
AB		ANI PHARMS INC	**0.5MG**	**A077396**	**001** Dec 13, 2006
AB			**1MG**	**A077396**	**002** Dec 13, 2006
AB			**2MG**	**A077396**	**003** Dec 13, 2006
AB		LEADING PHARMA LLC	**0.5MG**	**A078203**	**001** Jul 30, 2007
AB			**1MG**	**A078203**	**002** Jul 30, 2007
AB			**2MG**	**A078203**	**003** Jul 30, 2007
AB		MYLAN	**0.5MG**	**A071589**	**001** Oct 13, 1987
AB			**0.5MG**	**A077657**	**001** Mar 16, 2006
AB			**1MG**	**A071590**	**001** Oct 13, 1987
AB			**1MG**	**A077657**	**002** Mar 16, 2006
AB			**2MG**	**A071591**	**001** Oct 13, 1987
AB			**2MG**	**A077657**	**003** Mar 16, 2006
AB		SANDOZ	**0.5MG**	**A071403**	**001** Apr 21, 1987
AB			**1MG**	**A071404**	**001** Apr 21, 1987
AB			**2MG**	**A071141**	**001** Apr 21, 1987
AB		SUN PHARM INDS LTD	**0.5MG**	**A076045**	**001** Aug 29, 2001

FDA data supplied by DrugPatentWatch.com

LORAZEPAM
TABLET;ORAL
LORAZEPAM

AB		**1MG**	**A076045**	**002**	Aug 29, 2001
AB		**2MG**	**A076045**	**003**	Aug 29, 2001
AB	VINTAGE PHARMS	**0.5MG**	**A077754**	**001**	May 10, 2006
AB		**1MG**	**A077754**	**002**	May 10, 2006
AB		**2MG**	**A077754**	**003**	May 10, 2006
AB	WATSON LABS	**0.5MG**	**A072926**	**001**	Oct 31, 1991
AB		**1MG**	**A072927**	**001**	Oct 31, 1991
AB		**2MG**	**A072928**	**001**	Oct 31, 1991

LORCASERIN HYDROCHLORIDE
TABLET;ORAL
BELVIQ

+	EISAI INC	10MG	N022529	001	Jun 27, 2012

TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR

+	EISAI INC	20MG	N208524	001	Jul 15, 2016

LOSARTAN POTASSIUM
TABLET;ORAL
COZAAR

AB	MERCK SHARP DOHME	**25MG**	**N020386**	**001**	Apr 14, 1995
AB		**50MG**	**N020386**	**002**	Apr 14, 1995
AB	**+**	**100MG**	**N020386**	**003**	Oct 13, 1998

LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	**25MG**	**A090428**	**001**	Oct 06, 2010
AB		**50MG**	**A090428**	**002**	Oct 06, 2010
AB		**100MG**	**A090428**	**003**	Oct 06, 2010
AB	APOTEX CORP	**25MG**	**A090790**	**001**	Oct 06, 2010
AB		**50MG**	**A090790**	**002**	Oct 06, 2010
AB		**100MG**	**A090790**	**003**	Oct 06, 2010
AB	AUROBINDO PHARMA	**25MG**	**A090083**	**001**	Oct 06, 2010
AB		**50MG**	**A090083**	**002**	Oct 06, 2010
AB		**100MG**	**A090083**	**003**	Oct 06, 2010
AB	CADISTA PHARMS	**25MG**	**A201170**	**001**	Sep 18, 2012
AB		**50MG**	**A201170**	**002**	Sep 18, 2012
AB		**100MG**	**A201170**	**003**	Sep 18, 2012
AB	IPCA LABS LTD	**25MG**	**A200290**	**001**	Aug 30, 2013
AB		**50MG**	**A200290**	**002**	Aug 30, 2013
AB		**100MG**	**A200290**	**003**	Aug 30, 2013
AB	LUPIN LTD	**25MG**	**A078232**	**001**	Oct 06, 2010
AB		**50MG**	**A078232**	**002**	Oct 06, 2010
AB		**100MG**	**A078232**	**003**	Oct 06, 2010
AB	MACLEODS PHARMS LTD	**25MG**	**A202230**	**001**	May 30, 2012
AB		**50MG**	**A202230**	**002**	May 30, 2012
AB		**100MG**	**A202230**	**003**	May 30, 2012
AB	MICRO LABS LTD INDIA	**25MG**	**A091541**	**001**	Sep 24, 2012
AB		**50MG**	**A091541**	**002**	Sep 24, 2012
AB		**100MG**	**A091541**	**003**	Sep 24, 2012
AB	MYLAN	**25MG**	**A091590**	**001**	Oct 06, 2010
AB		**50MG**	**A091590**	**002**	Oct 06, 2010
AB		**100MG**	**A091590**	**003**	Oct 06, 2010
AB	PRINSTON INC	**25MG**	**A091497**	**001**	Jun 06, 2011
AB		**50MG**	**A091497**	**002**	Jun 06, 2011
AB		**100MG**	**A091497**	**003**	Jun 06, 2011
AB	SANDOZ	**25MG**	**A077424**	**001**	Oct 06, 2010
AB		**50MG**	**A077424**	**002**	Oct 06, 2010
AB		**100MG**	**A077424**	**003**	Oct 06, 2010
AB	TEVA	**25MG**	**A076958**	**001**	Apr 06, 2010
AB		**50MG**	**A076958**	**002**	Apr 06, 2010
AB		**100MG**	**A076958**	**003**	Apr 06, 2010
AB	TORRENT PHARMS	**25MG**	**A090467**	**001**	Oct 06, 2010
AB		**50MG**	**A090467**	**002**	Oct 06, 2010
AB		**100MG**	**A090467**	**003**	Oct 06, 2010
AB	UNICHEM LABS LTD	**25MG**	**A203030**	**001**	Oct 14, 2015
AB		**50MG**	**A203030**	**002**	Oct 14, 2015
AB		**100MG**	**A203030**	**003**	Oct 14, 2015
AB	UPSHER SMITH	**25MG**	**A090544**	**001**	Oct 06, 2010
AB		**50MG**	**A090544**	**002**	Oct 06, 2010
AB		**100MG**	**A090544**	**003**	Oct 06, 2010
AB	VIVIMED LABS	**25MG**	**A090382**	**001**	Oct 06, 2010

FDA data supplied by DrugPatentWatch.com

LOSARTAN POTASSIUM
TABLET;ORAL
LOSARTAN POTASSIUM

AB		**50MG**	**A090382**	**002**	Oct 06, 2010
AB		**100MG**	**A090382**	**003**	Oct 06, 2010
AB	WATSON LABS	**25MG**	**A091129**	**001**	Oct 06, 2010
AB		**50MG**	**A091129**	**002**	Oct 06, 2010
AB		**100MG**	**A091129**	**003**	Oct 06, 2010
AB	WEST-WARD PHARMS INT	**25MG**	**A077459**	**001**	Oct 06, 2010
AB		**50MG**	**A077459**	**002**	Oct 06, 2010
AB		**100MG**	**A077459**	**003**	Oct 06, 2010
AB	ZYDUS PHARMS USA INC	**25MG**	**A078243**	**001**	Oct 06, 2010
AB		**50MG**	**A078243**	**002**	Oct 06, 2010
AB		**100MG**	**A078243**	**003**	Oct 06, 2010
BX	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015
BX		50MG	A203835	002	Aug 12, 2015
BX		100MG	A203835	003	Aug 12, 2015

LOTEPREDNOL ETABONATE
GEL;OPHTHALMIC
LOTEMAX
+ BAUSCH AND LOMB INC 0.5% N202872 001 Sep 28, 2012
OINTMENT;OPHTHALMIC
LOTEMAX
+ BAUSCH AND LOMB 0.5% N200738 001 Apr 15, 2011
SUSPENSION/DROPS;OPHTHALMIC
ALREX
+ BAUSCH AND LOMB 0.2% N020803 001 Mar 09, 1998
LOTEMAX
+ BAUSCH AND LOMB 0.5% N020583 001 Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN
SUSPENSION/DROPS;OPHTHALMIC
ZYLET
+ BAUSCH AND LOMB 0.5%;0.3% N050804 001 Dec 14, 2004

LOVASTATIN
TABLET;ORAL
LOVASTATIN

AB	ACTAVIS ELIZABETH	**10MG**	**A075828**	**001**	Dec 17, 2001
AB		**20MG**	**A075828**	**002**	Dec 17, 2001
AB		**40MG**	**A075828**	**003**	Dec 17, 2001
AB	APOTEX INC	**10MG**	**A077748**	**001**	Feb 28, 2007
AB		**20MG**	**A077748**	**002**	Feb 28, 2007
AB		**40MG**	**A077748**	**003**	Feb 28, 2007
AB	CARLSBAD	**10MG**	**A075991**	**001**	Jun 05, 2002
AB		**20MG**	**A075991**	**002**	Jun 05, 2002
AB	**+**	**40MG**	**A075991**	**003**	Jun 05, 2002
AB	LUPIN	**10MG**	**A078296**	**001**	Mar 14, 2008
AB		**20MG**	**A078296**	**002**	Nov 01, 2007
AB		**40MG**	**A078296**	**003**	Nov 01, 2007
AB	MYLAN	**10MG**	**A075451**	**001**	Dec 17, 2001
AB		**10MG**	**A075935**	**001**	Dec 17, 2001
AB		**20MG**	**A075451**	**002**	Dec 17, 2001
AB		**20MG**	**A075935**	**002**	Dec 17, 2001
AB		**40MG**	**A075451**	**003**	Dec 17, 2001
AB		**40MG**	**A075935**	**003**	Dec 17, 2001
AB	SANDOZ	**10MG**	**A075300**	**001**	Dec 17, 2001
AB		**10MG**	**A075636**	**001**	Dec 17, 2001
AB		**20MG**	**A075300**	**002**	Dec 17, 2001
AB		**20MG**	**A075636**	**002**	Dec 17, 2001
AB		**40MG**	**A075300**	**003**	Dec 17, 2001
AB		**40MG**	**A075636**	**003**	Dec 17, 2001
AB	SUN PHARM INDS	**10MG**	**A077520**	**001**	Apr 14, 2006
AB		**20MG**	**A077520**	**002**	Apr 14, 2006
AB		**40MG**	**A077520**	**003**	Apr 14, 2006
AB	TEVA	**10MG**	**A075551**	**003**	Dec 17, 2001
AB		**20MG**	**A075551**	**002**	Dec 17, 2001
AB		**40MG**	**A075551**	**001**	Dec 17, 2001

TABLET, EXTENDED RELEASE;ORAL
ALTOPREV
COVIS PHARMA SARL 20MG N021316 002 Jun 26, 2002
40MG N021316 003 Jun 26, 2002
+ 60MG N021316 004 Jun 26, 2002

FDA data supplied by DrugPatentWatch.com

LOXAPINE
POWDER;INHALATION
ADASUVE

	+	ALEXZA PHARMS	10MG	N022549	001 Dec 21, 2012

LOXAPINE SUCCINATE
CAPSULE;ORAL
LOXAPINE SUCCINATE

AB		ELITE LABS INC	**EQ 5MG BASE**	**A076868**	**001** Aug 04, 2005
AB			**EQ 10MG BASE**	**A076868**	**002** Aug 04, 2005
AB			**EQ 25MG BASE**	**A076868**	**003** Aug 04, 2005
AB			**EQ 50MG BASE**	**A076868**	**004** Aug 04, 2005
AB		LANNETT HOLDINGS INC	**EQ 5MG BASE**	**A090695**	**001** Sep 26, 2011
AB			**EQ 10MG BASE**	**A090695**	**002** Sep 26, 2011
AB			**EQ 25MG BASE**	**A090695**	**003** Sep 26, 2011
AB			**EQ 50MG BASE**	**A090695**	**004** Sep 26, 2011
AB		MYLAN	**EQ 5MG BASE**	**A076762**	**001** Nov 01, 2004
AB			**EQ 10MG BASE**	**A076762**	**002** Nov 01, 2004
AB			**EQ 25MG BASE**	**A076762**	**003** Nov 01, 2004
AB			**EQ 50MG BASE**	**A076762**	**004** Nov 01, 2004
AB		WATSON LABS	**EQ 5MG BASE**	**A072204**	**001** Jun 15, 1988
AB			**EQ 10MG BASE**	**A072205**	**001** Jun 15, 1988
AB	**+**		**EQ 25MG BASE**	**A072206**	**001** Jun 15, 1988
AB			**EQ 50MG BASE**	**A072062**	**001** Jun 15, 1988

LUBIPROSTONE
CAPSULE;ORAL
AMITIZA

		SUCAMPO PHARMA LLC	8MCG	N021908	002 Apr 29, 2008
	+		24MCG	N021908	001 Jan 31, 2006

LULICONAZOLE
CREAM;TOPICAL
LUZU

	+	MEDICIS	1%	N204153	001 Nov 14, 2013

LURASIDONE HYDROCHLORIDE
TABLET;ORAL
LATUDA

		SUNOVION PHARMS INC	20MG	N200603	003 Dec 07, 2011
	+		40MG	N200603	001 Oct 28, 2010
			60MG	N200603	005 Jul 12, 2013
			80MG	N200603	002 Oct 28, 2010
			120MG	N200603	004 Apr 26, 2012

MACITENTAN
TABLET;ORAL
OPSUMIT

	+	ACTELION PHARMS LTD	10MG	N204410	001 Oct 18, 2013

MAFENIDE ACETATE
CREAM;TOPICAL
SULFAMYLON

	+	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001

FOR SOLUTION;TOPICAL
MAFENIDE ACETATE

AT		PAR FORM	**5%**	**A201511**	**001** Feb 12, 2013

SULFAMYLON

AT	**+**	MYLAN INSTITUTIONAL	**5%**	**N019832**	**003** Jun 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
INJECTABLE;INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

	+	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696	001 Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
INJECTABLE;INJECTION
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML**	**N017378**	**001**

PLASMA-LYTE A IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML**	**N017378**	**002** Nov 22, 1982

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG /100ML;500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML;526MG /100ML;502MG/100ML	N017586	001	

SOLUTION;IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG /100ML;500MG/100ML	N019024	001	Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

	HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML;526MG /100ML;502MG/100ML	N017637	002	Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION;INJECTION

NORMOCARB HF 25

+	DIALYSIS SUPS	0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	N021910	001	Jul 26, 2006

NORMOCARB HF 35

+	DIALYSIS SUPS	0.21GM/100ML;3.97GM/100ML;8.3GM/100ML	N021910	002	Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**1GM/100ML**	**A206486**	**001**	Mar 07, 2016
AP	**+**	HOSPIRA	**1GM/100ML**	**N020488**	**001**	Jul 11, 1995
AP		HQ SPCLT PHARMA	**1GM/100ML**	**A207349**	**001**	Mar 02, 2016

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**4GM/100ML (40MG/ML)**	**A206485**	**001**	Mar 15, 2016
AP			**4GM/50ML (80MG/ML)**	**A206485**	**002**	Mar 15, 2016
AP			**2GM/50ML (40MG/ML)**	**A206485**	**003**	Mar 15, 2016
AP			**20GM/500ML (40MG/ML)**	**A206485**	**004**	Mar 15, 2016
AP			**40GM/1000ML (40MG/ML)**	**A206485**	**005**	Mar 15, 2016
AP		HOSPIRA	**2GM/50ML (40MG/ML)**	**N020309**	**003**	Jan 26, 2007
AP	**+**		**4GM/100ML (40MG/ML)**	**N020309**	**001**	Jun 24, 1994
AP	**+**		**4GM/50ML (80MG/ML)**	**N020309**	**002**	Jun 24, 1994
AP			**20GM/500ML (40MG/ML)**	**N020309**	**004**	Jan 18, 1995
AP			**40GM/1000ML(40MG/ML)**	**N020309**	**005**	Jan 18, 1995

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	HOSPIRA	2GM/100ML	N020488	002	Jul 11, 1995

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP		EXELA PHARMA SCS LLC	**5GM/10ML (500MG/ML)**	**A206039**	**001**	Dec 18, 2014
AP	**+**	FRESENIUS KABI USA	**5GM/10ML (500MG/ML)**	**N019316**	**001**	Sep 08, 1986
AP	**+**	HOSPIRA	**5GM/10ML (500MG/ML)**	**A075151**	**001**	Apr 25, 2000
	+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016
	+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016
		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SUPREP BOWEL PREP KIT

+	BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

TIS-U-SOL

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800M G/100ML;8.75MG/100ML**	**N018508**	**001**	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800M G/100ML;8.75MG/100ML**	**N018336**	**001**	

FDA data supplied by DrugPatentWatch.com

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE
POWDER;ORAL
COLPREP KIT

+	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553	001	Dec 27, 2016

MALATHION
LOTION;TOPICAL

	MALATHION				
AT	SUVEN LIFE	**0.5%**	**A091559**	**001**	May 23, 2012
	OVIDE				
AT	+ TARO PHARMS NORTH	**0.5%**	**N018613**	**001**	Aug 02, 1982

MANGANESE CHLORIDE
INJECTABLE;INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER

	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986

MANNITOL
INJECTABLE;INJECTION

	MANNITOL 10% IN PLASTIC CONTAINER				
AP	B BRAUN	**10GM/100ML**	**N020006**	**002**	Jul 26, 1993
AP	HOSPIRA	**10GM/100ML**	**N019603**	**002**	Jan 08, 1987
	MANNITOL 15% IN PLASTIC CONTAINER				
AP	B BRAUN	**15GM/100ML**	**N020006**	**003**	Jul 26, 1993
AP	HOSPIRA	**15GM/100ML**	**N019603**	**003**	Jan 08, 1990
	MANNITOL 20% IN PLASTIC CONTAINER				
AP	B BRAUN	**20GM/100ML**	**N020006**	**004**	Jul 26, 1993
AP	HOSPIRA	**20GM/100ML**	**N019603**	**004**	Jan 08, 1990
	MANNITOL 25%				
AP	FRESENIUS KABI USA	**12.5GM/50ML**	**A080677**	**001**	
AP	HOSPIRA	**12.5GM/50ML**	**N016269**	**006**	Aug 25, 1994
AP	INTL MEDICATION	**12.5GM/50ML**	**A083051**	**001**	
AP	LUITPOLD	**12.5GM/50ML**	**A087409**	**001**	Jan 21, 1982
	MANNITOL 5% IN PLASTIC CONTAINER				
AP	B BRAUN	**5GM/100ML**	**N020006**	**001**	Jul 26, 1993
AP	HOSPIRA	**5GM/100ML**	**N019603**	**001**	Jan 08, 1987
	OSMITROL 10% IN WATER				
AP	BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**002**	
	OSMITROL 10% IN WATER IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**006**	
	OSMITROL 15% IN WATER				
AP	BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**004**	
	OSMITROL 15% IN WATER IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**008**	
	OSMITROL 20% IN WATER				
AP	BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**003**	
	OSMITROL 20% IN WATER IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**007**	
	OSMITROL 5% IN WATER				
AP	BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**001**	
	OSMITROL 5% IN WATER IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**005**	

SOLUTION;IRRIGATION
RESECTISOL IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML	N016772	002	

MANNITOL; SORBITOL
SOLUTION;IRRIGATION
SORBITOL-MANNITOL IN PLASTIC CONTAINER

	HOSPIRA	540MG/100ML;2.7GM/100ML	N018316	001	

MAPROTILINE HYDROCHLORIDE
TABLET;ORAL
MAPROTILINE HYDROCHLORIDE

	MYLAN	25MG	A072285	002	Oct 03, 1988
+		50MG	A072285	001	Oct 03, 1988
		75MG	A072285	003	Oct 03, 1988

MARAVIROC
SOLUTION;ORAL
SELZENTRY

+	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016

TABLET;ORAL
SELZENTRY

	VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016

FDA data supplied by DrugPatentWatch.com

MARAVIROC
TABLET;ORAL
SELZENTRY

		75MG	N022128	004	Nov 04, 2016
		150MG	N022128	001	Aug 06, 2007
	+	300MG	N022128	002	Aug 06, 2007

MEBENDAZOLE
TABLET, CHEWABLE;ORAL
EMVERM

	+ AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995

VERMOX

	+ JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016

MECAMYLAMINE HYDROCHLORIDE
TABLET;ORAL
MECAMYLAMINE HYDROCHLORIDE

	NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013

MECASERMIN RECOMBINANT
INJECTABLE;SUBCUTANEOUS
INCRELEX

	+ IPSEN INC	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005

MECHLORETHAMINE HYDROCHLORIDE
GEL;TOPICAL
VALCHLOR

	+ ACTELION PHARMS LTD	EQ 0.016% BASE	N202317	001	Aug 23, 2013

INJECTABLE;INJECTION
MUSTARGEN

	+ RECORDATI RARE	10MG/VIAL	N006695	001	

MECLIZINE HYDROCHLORIDE
TABLET;ORAL
MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	**12.5MG**	**A201451**	**001**	Feb 23, 2011
AA		**25MG**	**A201451**	**002**	Feb 23, 2011
AA	EPIC PHARMA LLC	**12.5MG**	**A200294**	**001**	Apr 13, 2012
AA		**25MG**	**A200294**	**002**	Apr 13, 2012
AA	JUBILANT CADISTA	**12.5MG**	**A040659**	**001**	Jun 04, 2010
AA		**25MG**	**A040659**	**002**	Jun 04, 2010
AA	MYLAN PHARMS INC	**12.5MG**	**A202640**	**001**	Sep 17, 2012
AA		**25MG**	**A202640**	**002**	Sep 17, 2012
AA	PAR PHARM	**12.5MG**	**A087127**	**001**	
AA		**25MG**	**A087128**	**001**	
AA	SANDOZ	**12.5MG**	**A084843**	**002**	May 22, 1989
AA		**25MG**	**A084092**	**003**	May 22, 1989

MECLOFENAMATE SODIUM
CAPSULE;ORAL
MECLOFENAMATE SODIUM

	MYLAN	EQ 50MG BASE	A071081	002	Sep 03, 1986
	+	EQ 100MG BASE	A071081	001	Sep 03, 1986

MEDROXYPROGESTERONE ACETATE
INJECTABLE;INJECTION
DEPO-PROVERA

AB	**+** PHARMACIA AND UPJOHN	**150MG/ML**	**N020246**	**001**	Oct 29, 1992

MEDROXYPROGESTERONE ACETATE

AB	SANDOZ	**150MG/ML**	**A078711**	**001**	May 20, 2009
AB	TEVA PHARMS USA	**150MG/ML**	**A076553**	**001**	Jul 28, 2004

DEPO-PROVERA

	+ PHARMACIA AND UPJOHN	400MG/ML	N012541	003	

INJECTABLE;SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

	+ PHARMACIA AND UPJOHN	104MG/0.65ML	N021583	001	Dec 17, 2004

TABLET;ORAL
MEDROXYPROGESTERONE ACETATE

AB	BARR	**2.5MG**	**A040159**	**001**	Aug 09, 1996
AB		**5MG**	**A040159**	**002**	Aug 09, 1996
AB		**10MG**	**A040159**	**003**	Aug 09, 1996

PROVERA

AB	PHARMACIA AND UPJOHN	**2.5MG**	**N011839**	**001**	
AB		**5MG**	**N011839**	**003**	
AB	**+**	**10MG**	**N011839**	**004**	

MEFENAMIC ACID
CAPSULE;ORAL
MEFENAMIC ACID

AB		BRECKENRIDGE PHARM	**250MG**	**A090359**	**001**	Feb 05, 2013
AB		LUPIN LTD	**250MG**	**A091322**	**001**	Jul 22, 2011
AB		MICRO LABS LTD	**250MG**	**A090562**	**001**	Nov 19, 2010
AB		VINTAGE PHARMS LLC	**250MG**	**A091608**	**001**	Jun 02, 2014
PONSTEL						
AB	+	SHIONOGI INC	**250MG**	**N015034**	**003**	

MEFLOQUINE HYDROCHLORIDE
TABLET;ORAL
MEFLOQUINE HYDROCHLORIDE

AB		BARR	**250MG**	**A076392**	**001**	Dec 29, 2003
AB	+	SANDOZ	**250MG**	**A076175**	**001**	Feb 20, 2002
AB		WEST-WARD PHARMS INT	**250MG**	**A076523**	**001**	Oct 01, 2004

MEGESTROL ACETATE
SUSPENSION;ORAL
MEGACE

AB	+	BRISTOL MYERS SQUIBB	**40MG/ML**	**N020264**	**001**	Sep 10, 1993
MEGACE ES						
AB	+	ENDO PHARMS INC	**125MG/ML**	**N021778**	**001**	Jul 05, 2005
MEGESTROL ACETATE						
AB		PAR PHARM	**40MG/ML**	**A075671**	**001**	Jul 25, 2001
AB		TEVA PHARMS	**40MG/ML**	**A075681**	**001**	May 05, 2003
AB		TWI PHARMS INC	**125MG/ML**	**A203139**	**001**	Aug 27, 2014
AB		WEST-WARD PHARMS INT	**40MG/ML**	**A075997**	**001**	Feb 15, 2002
AB		WOCKHARDT	**40MG/ML**	**A076721**	**001**	Nov 01, 2004

TABLET;ORAL
MEGESTROL ACETATE

AB		BARR	**20MG**	**A074621**	**002**	Aug 16, 1996
AB			**40MG**	**A074621**	**001**	Nov 30, 1995
AB		PAR PHARM	**20MG**	**A072422**	**001**	Aug 08, 1988
AB	+		**40MG**	**A072423**	**001**	Aug 08, 1988
AB		WEST-WARD PHARMS INT	**20MG**	**A074458**	**001**	Sep 29, 1995
AB			**40MG**	**A074458**	**002**	Sep 29, 1995

MELOXICAM
CAPSULE;ORAL
VIVLODEX

		IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015
	+		10MG	N207233	002	Oct 22, 2015

SUSPENSION;ORAL
MOBIC

	+	BOEHRINGER INGELHEIM	7.5MG/5ML	N021530	001	Jun 01, 2004

TABLET;ORAL
MELOXICAM

AB		APOTEX INC	**7.5MG**	**A077882**	**001**	Jul 20, 2006
AB			**15MG**	**A077882**	**002**	Jul 20, 2006
AB		AUROBINDO PHARMA	**7.5MG**	**A078008**	**001**	Oct 02, 2006
AB			**15MG**	**A078008**	**002**	Oct 02, 2006
AB		BRECKENRIDGE PHARM	**7.5MG**	**A077920**	**001**	Jul 19, 2006
AB			**15MG**	**A077920**	**002**	Jul 19, 2006
AB		CIPLA LTD	**7.5MG**	**A077929**	**001**	Jul 19, 2006
AB			**15MG**	**A077929**	**002**	Jul 19, 2006
AB		DR REDDYS LABS INC	**7.5MG**	**A077931**	**001**	Jul 25, 2006
AB			**15MG**	**A077931**	**002**	Jul 25, 2006
AB		GLENMARK GENERICS	**7.5MG**	**A077932**	**001**	Jul 19, 2006
AB			**15MG**	**A077932**	**002**	Jul 19, 2006
AB		LUPIN PHARMS	**7.5MG**	**A077944**	**001**	Jul 19, 2006
AB			**15MG**	**A077944**	**002**	Jul 19, 2006
AB		MYLAN	**7.5MG**	**A077923**	**001**	Jul 19, 2006
AB			**15MG**	**A077923**	**002**	Jul 19, 2006
AB		PURACAP PHARM	**7.5MG**	**A077938**	**001**	Jul 19, 2006
AB			**15MG**	**A077938**	**002**	Jul 19, 2006
AB		STRIDES PHARMA	**7.5MG**	**A077928**	**001**	May 13, 2009
AB			**15MG**	**A077928**	**002**	May 13, 2009
AB		SUN PHARM INDS INC	**7.5MG**	**A077937**	**001**	Jul 19, 2006
AB			**15MG**	**A077937**	**002**	Jul 19, 2006
AB		TARO	**7.5MG**	**A078102**	**001**	Nov 07, 2006
AB			**15MG**	**A078102**	**002**	Nov 07, 2006
AB		TEVA PHARMS	**7.5MG**	**A077936**	**001**	Jul 19, 2006
AB			**15MG**	**A077936**	**002**	Jul 19, 2006

FDA data supplied by DrugPatentWatch.com

MELOXICAM
TABLET;ORAL

	MELOXICAM				
AB	UNICHEM	**7.5MG**	**A077927**	**001**	Dec 20, 2006
AB		**15MG**	**A077927**	**002**	Dec 20, 2006
AB	YUNG SHIN PHARM	**7.5MG**	**A077918**	**001**	Dec 07, 2006
AB		**15MG**	**A077918**	**002**	Dec 07, 2006
AB	ZYDUS PHARMS USA	**7.5MG**	**A077921**	**001**	Jul 19, 2006
AB		**15MG**	**A077921**	**002**	Jul 19, 2006
	MOBIC				
AB	BOEHRINGER INGELHEIM	**7.5MG**	**N020938**	**001**	Apr 13, 2000
AB +		**15MG**	**N020938**	**002**	Aug 23, 2000

MELPHALAN
TABLET;ORAL

	ALKERAN				
+	APOTEX INC	2MG	N014691	002	

MELPHALAN HYDROCHLORIDE
INJECTABLE;INJECTION

	ALKERAN				
AP +	APOTEX INC	**EQ 50MG BASE/VIAL**	**N020207**	**001**	Nov 18, 1992
	MELPHALAN HYDROCHLORIDE				
AP	ACTAVIS LLC	**EQ 50MG BASE/VIAL**	**A206018**	**001**	Dec 19, 2016
AP	MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A090270**	**001**	Jun 09, 2009
AP	PAR STERILE PRODUCTS	**EQ 50MG BASE/VIAL**	**A204773**	**001**	Aug 22, 2016
AP	WEST-WARD PHARMS INT	**EQ 50MG BASE/VIAL**	**A090303**	**001**	Oct 28, 2010

POWDER;IV (INFUSION)

	EVOMELA				
	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016

MEMANTINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL

	MEMANTINE HYDROCHLORIDE				
AB	AMNEAL PHARMS	**7MG**	**A205825**	**001**	Oct 12, 2016
AB		**14MG**	**A205825**	**002**	Oct 12, 2016
AB		**21MG**	**A205825**	**003**	Oct 12, 2016
AB		**28MG**	**A205825**	**004**	Oct 12, 2016
AB	APOTEX INC	**7MG**	**A206135**	**001**	Nov 22, 2016
AB		**14MG**	**A206135**	**002**	Nov 22, 2016
AB		**21MG**	**A206135**	**003**	Nov 22, 2016
AB		**28MG**	**A206135**	**004**	Nov 22, 2016
AB	LUPIN LTD	**7MG**	**A206028**	**001**	Sep 28, 2016
AB		**14MG**	**A206028**	**002**	Sep 28, 2016
AB		**21MG**	**A206028**	**003**	Sep 28, 2016
AB		**28MG**	**A206028**	**004**	Sep 28, 2016
AB	MYLAN PHARMS INC	**7MG**	**A206032**	**001**	Sep 28, 2016
AB		**14MG**	**A206032**	**002**	Sep 28, 2016
AB		**21MG**	**A206032**	**003**	Sep 28, 2016
AB		**28MG**	**A206032**	**004**	Sep 28, 2016
AB	SUN PHARMA GLOBAL	**7MG**	**A205905**	**001**	Sep 28, 2016
AB		**14MG**	**A205905**	**002**	Sep 28, 2016
AB		**21MG**	**A205905**	**003**	Sep 28, 2016
AB		**28MG**	**A205905**	**004**	Sep 28, 2016
	NAMENDA XR				
AB	FOREST LABS LLC	**7MG**	**N022525**	**001**	Jun 21, 2010
AB		**14MG**	**N022525**	**002**	Jun 21, 2010
AB		**21MG**	**N022525**	**003**	Jun 21, 2010
AB +		**28MG**	**N022525**	**004**	Jun 21, 2010

SOLUTION;ORAL

	MEMANTINE HYDROCHLORIDE				
AA	BIO-PHARM INC	**2MG/ML**	**A205446**	**001**	Dec 07, 2015
AA	MACLEODS PHARMS LTD	**2MG/ML**	**A202790**	**001**	Oct 13, 2015
AA	SILARX PHARMS INC	**2MG/ML**	**A204033**	**001**	Oct 13, 2015
	NAMENDA				
AA +	FOREST LABS LLC	**2MG/ML**	**N021627**	**001**	Apr 18, 2005

TABLET;ORAL

	MEMANTINE HYDROCHLORIDE				
AB	AJANTA PHARMA LTD	**5MG**	**A206528**	**001**	Nov 30, 2015
AB		**10MG**	**A206528**	**002**	Nov 30, 2015
AB	ALEMBIC PHARMS LTD	**5MG**	**A200891**	**001**	Oct 13, 2015
AB		**10MG**	**A200891**	**002**	Oct 13, 2015
AB	AMNEAL PHARMS	**5MG**	**A090041**	**001**	Apr 10, 2015
AB		**10MG**	**A090041**	**002**	Apr 10, 2015

MEMANTINE HYDROCHLORIDE
TABLET;ORAL

	MEMANTINE HYDROCHLORIDE				
AB	AUROBINDO PHARMA LTD	**5MG**	**A203175**	**001**	Oct 13, 2015
AB		**10MG**	**A203175**	**002**	Oct 13, 2015
AB	DR REDDYS LABS LTD	**5MG**	**A090048**	**001**	Apr 14, 2010
AB		**10MG**	**A090048**	**002**	Apr 14, 2010
AB	JUBILANT GENERICS	**5MG**	**A091585**	**001**	Oct 13, 2015
AB		**10MG**	**A091585**	**002**	Oct 13, 2015
AB	LUPIN LTD	**5MG**	**A090051**	**001**	Apr 10, 2015
AB		**10MG**	**A090051**	**002**	Apr 10, 2015
AB	MACLEODS PHARMS LTD	**5MG**	**A202840**	**001**	Oct 13, 2015
AB		**10MG**	**A202840**	**002**	Oct 13, 2015
AB	MYLAN PHARMS INC	**5MG**	**A079225**	**001**	Jan 30, 2015
AB		**10MG**	**A079225**	**002**	Jan 30, 2015
AB	PURACAP PHARM LLC	**5MG**	**A206855**	**001**	Nov 17, 2015
AB		**10MG**	**A206855**	**002**	Nov 17, 2015
AB	SILARX PHARMS INC	**5MG**	**A207236**	**001**	Nov 10, 2016
AB		**10MG**	**A207236**	**002**	Nov 10, 2016
AB	SUN PHARMA GLOBAL	**5MG**	**A090058**	**001**	May 05, 2010
AB		**10MG**	**A090058**	**002**	May 05, 2010
AB	TEVA PHARMS	**5MG**	**A090052**	**001**	Oct 25, 2011
AB		**10MG**	**A090052**	**002**	Oct 25, 2011
AB	TORRENT PHARMS LTD	**5MG**	**A200155**	**001**	Oct 13, 2015
AB		**10MG**	**A200155**	**002**	Oct 13, 2015
AB	UNICHEM LABS LTD	**5MG**	**A200022**	**001**	Oct 13, 2015
AB		**10MG**	**A200022**	**002**	Oct 13, 2015
AB	UPSHER-SMITH LABS	**5MG**	**A090043**	**001**	Jul 31, 2015
AB		**10MG**	**A090043**	**002**	Jul 31, 2015
AB	WOCKHARDT LTD	**5MG**	**A090073**	**001**	Sep 04, 2015
AB		**10MG**	**A090073**	**002**	Sep 04, 2015
	NAMENDA				
AB	FOREST LABS LLC	**5MG**	**N021487**	**001**	Oct 16, 2003
AB	**+**	**10MG**	**N021487**	**002**	Oct 16, 2003

MENOTROPINS (FSH;LH)
INJECTABLE;SUBCUTANEOUS

	MENOPUR				
	+ FERRING	75 IU/VIAL;75 IU/VIAL	N021663	001	Oct 29, 2004

MEPENZOLATE BROMIDE
TABLET;ORAL

	CANTIL				
	+ SANOFI AVENTIS US	25MG	N010679	003	

MEPERIDINE HYDROCHLORIDE
INJECTABLE;INJECTION

	DEMEROL				
AP	**+** HOSPIRA	**25MG/ML**	**N021171**	**001**	
AP	**+**	**50MG/ML**	**N021171**	**002**	
AP	**+**	**75MG/ML**	**N021171**	**003**	
AP	**+**	**100MG/ML**	**N021171**	**004**	
	MEPERIDINE HYDROCHLORIDE				
AP	EUROHLTH INTL SARL	**25MG/ML**	**A080445**	**001**	
AP		**25MG/ML**	**A080455**	**007**	
AP		**50MG/ML**	**A080445**	**002**	
AP		**50MG/ML**	**A080455**	**008**	
AP		**75MG/ML**	**A080445**	**003**	
AP		**75MG/ML**	**A080455**	**009**	
AP		**100MG/ML**	**A080445**	**004**	
AP		**100MG/ML**	**A080455**	**010**	
	MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE				
AP	EUROHLTH INTL SARL	**10MG/ML**	**A081002**	**001**	Jul 30, 1993
AP	**+** HOSPIRA	**10MG/ML**	**A088432**	**001**	Aug 16, 1984

SYRUP;ORAL

	MEPERIDINE HYDROCHLORIDE				
	+ WEST-WARD PHARMS INT	50MG/5ML	A088744	001	Jan 30, 1985

TABLET;ORAL

	DEMEROL				
AA	**+** US PHARM HOLDINGS	**50MG**	**N005010**	**001**	
AA	**+**	**100MG**	**N005010**	**004**	
	MEPERIDINE HYDROCHLORIDE				
AA	BARR	**50MG**	**A088639**	**001**	Jul 02, 1984
AA		**100MG**	**A088640**	**001**	Sep 19, 1984

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HYDROCHLORIDE
TABLET;ORAL
MEPERIDINE HYDROCHLORIDE

AA		EPIC PHARMA	50MG	A040331 001	May 28, 1999
AA			100MG	A040331 002	May 28, 1999
AA		MALLINCKRODT	50MG	A040352 001	Jun 13, 2000
AA			100MG	A040352 002	Jun 13, 2000
AA		MIKART	50MG	A040893 001	Jun 24, 2009
AA			100MG	A040893 003	Jun 24, 2009
AA		SUN PHARM INDS INC	50MG	A040446 001	Aug 08, 2002
AA			100MG	A040446 002	Aug 08, 2002
AA		VINTAGE PHARMS	50MG	A040191 001	Dec 17, 1998
AA			100MG	A040191 002	Dec 17, 1998
AA		WEST-WARD PHARMS INT	50MG	A040110 001	Mar 12, 1997
AA			100MG	A040110 002	Mar 12, 1997
		MIKART	75MG	A040893 002	Jun 24, 2009
			150MG	A040893 004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CARBOCAINE

AP	+	HOSPIRA	1%	N012250 001	
AP	+		1.5%	N012250 005	
AP	+		2%	N012250 002	

ISOCAINE HYDROCHLORIDE

AP	+	NOVOCOL	3%	A080925 001	

MEPIVACAINE HYDROCHLORIDE

AP		HOSPIRA INC	3%	A040806 001	Apr 28, 2008

POLOCAINE

AP		FRESENIUS KABI USA	1%	A089407 001	Dec 01, 1986
AP			2%	A089410 001	Dec 01, 1986

POLOCAINE-MPF

AP		FRESENIUS KABI USA	1%	A089406 001	Dec 01, 1986
AP			1.5%	A089408 001	Dec 01, 1986
AP			2%	A089409 001	Dec 01, 1986

SCANDONEST PLAIN

AP	+	DEPROCO	3%	A088387 001	Oct 10, 1984

MEPROBAMATE
TABLET;ORAL
MEPROBAMATE

AA		ALEMBIC PHARMS LTD	200MG	A090122 001	Feb 18, 2009
AA			400MG	A090122 002	Feb 18, 2009
AA		INVAGEN PHARMS	200MG	A040797 001	Feb 27, 2008
AA			400MG	A040797 002	Feb 27, 2008
AA	+	WATSON LABS	200MG	A083304 001	
AA	+		400MG	A083308 001	

MERCAPTOPURINE
SUSPENSION;ORAL
PURIXAN

	+	NOVA LABS LTD	20MG/ML	N205919 001	Apr 28, 2014

TABLET;ORAL
MERCAPTOPURINE

AB		DR REDDYS LABS INTL	50MG	A040461 001	Feb 11, 2004
AB		MYLAN	50MG	A040594 001	Jul 01, 2005
AB	+	WEST-WARD PHARMS INT	50MG	A040528 001	Feb 13, 2004

PURINETHOL

AB		STASON PHARMS	50MG	N009053 002	

MEROPENEM
INJECTABLE;INJECTION
MEROPENEM

AP		ACS DOBFAR	500MG/VIAL	A091404 001	Oct 26, 2011
AP			1GM/VIAL	A091404 002	Oct 26, 2011
AP		AMNEAL PHARMS	500MG/VIAL	A205883 001	Apr 12, 2016
AP			1GM/VIAL	A205883 002	Apr 12, 2016
AP		DAEWOONG PHARM CO	500MG/VIAL	A204854 001	Dec 18, 2015
AP			1GM/VIAL	A204854 002	Dec 18, 2015
AP		GLAND PHARMA LTD	500MG/VIAL	A206141 001	Jun 08, 2016
AP			1GM/VIAL	A206141 002	Jun 08, 2016
AP		HOSPIRA INC	500MG/VIAL	A090940 001	Jun 22, 2010
AP			1GM/VIAL	A090940 002	Jun 22, 2010
AP		PAR STERILE PRODUCTS	500MG/VIAL	A204139 001	Jun 09, 2016

MEROPENEM
INJECTABLE;INJECTION
MEROPENEM

AP		**1GM/VIAL**	**A204139**	**002**	Jun 09, 2016
AP	SANDOZ	**500MG/VIAL**	**A091201**	**001**	Mar 29, 2011
AP		**1GM/VIAL**	**A091201**	**002**	Mar 29, 2011
AP	SAVIOR LIFETEC CORP	**500MG/VIAL**	**A206086**	**001**	Apr 19, 2016
AP		**1GM/VIAL**	**A206086**	**002**	Apr 19, 2016

MERREM

AP	**+** ASTRAZENECA	**500MG/VIAL**	**N050706**	**003**	Jun 21, 1996
AP	**+**	**1GM/VIAL**	**N050706**	**001**	Jun 21, 1996

POWDER;IV (INFUSION)
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

	B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015
		1GM/VIAL	N202106	002	Apr 30, 2015

MESALAMINE
CAPSULE, DELAYED RELEASE;ORAL
DELZICOL

	+ APIL	400MG	N204412	001	Feb 01, 2013

CAPSULE, EXTENDED RELEASE;ORAL
APRISO

	+ VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008

PENTASA

	SHIRE	250MG	N020049	001	May 10, 1993
	+	500MG	N020049	002	Jul 08, 2004

ENEMA;RECTAL
MESALAMINE

AB	G AND W LABS INC	**4GM/60ML**	**A076841**	**001**	Sep 30, 2004
AB	PERRIGO ISRAEL	**4GM/60ML**	**A076751**	**001**	Sep 17, 2004

ROWASA

AB	**+** MEDA PHARMS	**4GM/60ML**	**N019618**	**001**	Dec 24, 1987

SFROWASA

AB	MEDA PHARMS	**4GM/60ML**	**N019618**	**002**	Jun 20, 2008

SUPPOSITORY;RECTAL
CANASA

AB	**+** FOREST LABS LLC	**1GM**	**N021252**	**002**	Nov 05, 2004

MESALAMINE

AB	MYLAN PHARMS INC	**1GM**	**A204354**	**001**	Nov 24, 2015

TABLET, DELAYED RELEASE;ORAL
ASACOL HD

	+ APIL	800MG	N021830	001	May 29, 2008

LIALDA

	+ SHIRE	1.2GM	N022000	001	Jan 16, 2007

MESNA
INJECTABLE;INTRAVENOUS
MESNA

AP	FRESENIUS KABI USA	**100MG/ML**	**A075811**	**001**	Apr 26, 2001
AP	MYLAN INSTITUTIONAL	**100MG/ML**	**A076488**	**001**	Mar 08, 2012
AP	MYLAN LABS LTD	**100MG/ML**	**A203364**	**001**	Jul 18, 2014
AP	SAGENT PHARMS	**100MG/ML**	**A090913**	**001**	Apr 13, 2010
AP	TEVA PHARMS USA	**100MG/ML**	**A075764**	**001**	Apr 27, 2001
AP	WEST-WARD PHARMS INT	**100MG/ML**	**A075739**	**001**	Jan 09, 2004

MESNEX

AP	**+** BAXTER HLTHCARE	**100MG/ML**	**N019884**	**001**	Dec 30, 1988

TABLET;ORAL
MESNEX

	+ BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002

MESTRANOL; NORETHINDRONE
TABLET;ORAL-28
NORINYL 1+50 28-DAY

	+ ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001	

METAPROTERENOL SULFATE
SYRUP;ORAL
METAPROTERENOL SULFATE

	+ SILARX	10MG/5ML	A073632	001	Jul 22, 1992

TABLET;ORAL
METAPROTERENOL SULFATE

	PAR PHARM	10MG	A072024	001	Jun 28, 1988
	+	20MG	A072025	001	Jun 28, 1988

METARAMINOL BITARTRATE
INJECTABLE;INJECTION
METARAMINOL BITARTRATE

	+	FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001

METAXALONE
TABLET;ORAL

		METAXALONE			
AB		AMNEAL PHARMS	**800MG**	**A203399**	**001** Jun 21, 2013
AB		LANNETT HOLDINGS INC	**800MG**	**A204770**	**001** Nov 22, 2016
AB		SANDOZ	**800MG**	**A040445**	**001** Mar 31, 2010
		SKELAXIN			
AB	**+**	KING PHARMS	**800MG**	**N013217**	**003** Aug 30, 2002
		METAXALONE			
		COREPHARMA	400MG	A040486	001 Feb 27, 2015

METFORMIN HYDROCHLORIDE
SOLUTION;ORAL

		RIOMET			
	+	SUN PHARM INDS LTD	500MG/5ML	N021591	001 Sep 11, 2003

TABLET;ORAL

		GLUCOPHAGE			
AB		BRISTOL MYERS SQUIBB	**500MG**	**N020357**	**001** Mar 03, 1995
AB			**850MG**	**N020357**	**002** Mar 03, 1995
AB	**+**		**1GM**	**N020357**	**005** Nov 05, 1998
		METFORMIN HYDROCHLORIDE			
AB		ALKEM	**500MG**	**A091184**	**001** Nov 01, 2010
AB			**850MG**	**A091184**	**002** Nov 01, 2010
AB			**1GM**	**A091184**	**003** Nov 01, 2010
AB		AMNEAL PHARMS NY	**500MG**	**A077880**	**001** Jun 05, 2006
AB			**850MG**	**A077880**	**002** Jun 05, 2006
AB			**1GM**	**A077880**	**003** Jun 05, 2006
AB		APOTEX	**500MG**	**A075984**	**001** Apr 23, 2002
AB			**500MG**	**A090666**	**001** Dec 07, 2011
AB			**850MG**	**A075984**	**002** Apr 23, 2002
AB			**850MG**	**A090666**	**002** Dec 07, 2011
AB			**1GM**	**A075984**	**003** Apr 23, 2002
AB			**1GM**	**A090666**	**003** Dec 07, 2011
AB		ATLAS PHARMS LLC	**500MG**	**A076033**	**001** Jan 24, 2002
AB			**850MG**	**A076033**	**002** Jan 24, 2002
AB			**1GM**	**A076033**	**003** Jan 24, 2002
AB		AUROBINDO	**500MG**	**A077095**	**001** Jan 14, 2005
AB			**850MG**	**A077095**	**002** Jan 14, 2005
AB			**1GM**	**A077095**	**003** Jan 14, 2005
AB		CHARTWELL LIFE SCI	**500MG**	**A075972**	**001** Jan 24, 2002
AB			**850MG**	**A075972**	**002** Jan 24, 2002
AB			**1GM**	**A075972**	**003** Jan 24, 2002
AB		CSPC OUYI PHARM CO	**500MG**	**A205096**	**001** Jul 11, 2016
AB			**850MG**	**A205096**	**002** Jul 11, 2016
AB			**1GM**	**A205096**	**003** Jul 11, 2016
AB		DR REDDYS LABS INC	**500MG**	**A077787**	**001** Aug 23, 2006
AB			**850MG**	**A077787**	**002** Aug 23, 2006
AB			**1GM**	**A077787**	**003** Aug 23, 2006
AB		GLENMARK GENERICS	**500MG**	**A078170**	**001** May 23, 2008
AB			**850MG**	**A078170**	**002** May 23, 2008
AB			**1GM**	**A078170**	**003** May 23, 2008
AB		GRANULES INDIA	**500MG**	**A090564**	**001** Apr 22, 2010
AB			**850MG**	**A090564**	**002** Apr 22, 2010
AB			**1GM**	**A090564**	**003** Apr 22, 2010
AB		INDICUS PHARMA	**500MG**	**A079148**	**001** Nov 25, 2008
AB			**850MG**	**A079148**	**002** Nov 25, 2008
AB			**1GM**	**A079148**	**003** Nov 25, 2008
AB		MARKSANS PHARMA	**500MG**	**A090888**	**001** Mar 12, 2012
AB			**850MG**	**A090888**	**002** Mar 12, 2012
AB			**1GM**	**A090888**	**003** Mar 12, 2012
AB		MYLAN	**500MG**	**A075973**	**001** Jan 25, 2002
AB			**500MG**	**A075976**	**001** Jan 24, 2002
AB			**850MG**	**A075973**	**002** Jan 25, 2002
AB			**850MG**	**A075976**	**002** Jan 24, 2002
AB			**1GM**	**A075973**	**003** Jan 25, 2002
AB			**1GM**	**A075976**	**003** Jan 24, 2002
AB		MYLAN PHARMS INC	**500MG**	**A075969**	**001** Jan 29, 2002
AB			**850MG**	**A075969**	**002** Jan 29, 2002

FDA data supplied by DrugPatentWatch.com

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB		1GM	A075969	003	Jan 29, 2002
AB	PROVIDENT PHARM	500MG	A077853	001	Jul 28, 2006
AB		850MG	A077853	002	Jul 28, 2006
AB		1GM	A077853	003	Jul 28, 2006
AB	SANDOZ	500MG	A075965	001	Jan 25, 2002
AB		500MG	A075985	001	Jan 25, 2002
AB		850MG	A075965	002	Jan 25, 2002
AB		850MG	A075985	002	Jan 25, 2002
AB		1GM	A075965	003	Jan 25, 2002
AB		1GM	A075985	003	Jan 25, 2002
AB	SCIEGEN PHARMS INC	500MG	A203769	001	Sep 11, 2013
AB		850MG	A203769	002	Sep 11, 2013
AB		1GM	A203769	003	Sep 11, 2013
AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002
AB		850MG	A076038	002	Feb 21, 2002
AB		1GM	A076038	003	Feb 21, 2002
AB	SUN PHARM INDS INC	500MG	A075967	001	Jan 29, 2002
AB		850MG	A075967	002	Jan 29, 2002
AB		1GM	A075967	003	Jan 29, 2002
AB	TEVA	500MG	A075978	001	Jan 25, 2002
AB		850MG	A075978	002	Jan 25, 2002
AB		1GM	A075978	003	Nov 05, 2002
AB	TORRENT PHARMS	500MG	A077711	001	Jan 24, 2007
AB		850MG	A077711	002	Jan 24, 2007
AB		1GM	A077711	003	Jan 24, 2007
AB	WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002
AB		850MG	A075961	002	Jan 25, 2002
AB		1GM	A075961	003	Jan 25, 2002
AB	ZYDUS HLTHCARE	500MG	A203686	001	Aug 28, 2014
AB		850MG	A203686	002	Aug 28, 2014
AB		1GM	A203686	003	Aug 28, 2014
AB	ZYDUS PHARMS USA	500MG	A077064	001	Apr 18, 2005
AB		850MG	A077064	002	Apr 18, 2005
AB		1GM	A077064	003	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE;ORAL

GLUCOPHAGE XR

AB	+ BRISTOL MYERS SQUIBB	750MG	N021202	004	Apr 11, 2003

METFORMIN HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	750MG	A076869	001	Apr 12, 2005
AB	AMNEAL PHARMS NY	750MG	A078596	002	Jan 03, 2008
AB	APOTEX	750MG	A076706	002	Dec 29, 2005
AB	AUROBINDO PHARMA LTD	750MG	A079118	002	Jul 20, 2012
AB	BARR	750MG	A076863	001	Oct 14, 2004
AB	BEXIMCO PHARMS USA	750MG	A207427	002	Dec 13, 2016
AB	CSPC OUYI PHARM CO	750MG	A078321	002	Apr 17, 2008
AB	MACLEODS PHARMS LTD	750MG	A206955	002	Dec 07, 2016
AB	MARKSANS PHARMA	750MG	A090295	002	Apr 29, 2016
AB	MYLAN	750MG	A077113	001	Sep 08, 2005
AB	NOSTRUM PHARMS LLC	750MG	A076756	002	Dec 12, 2011
AB	SUN PHARM INDS (IN)	750MG	A077336	002	Feb 09, 2006
AB	TEVA	750MG	A076864	001	Apr 12, 2005
AB	ZYDUS PHARMS USA	750MG	A077078	001	Apr 21, 2005

GLUCOPHAGE XR

AB1	BRISTOL MYERS SQUIBB	500MG	N021202	001	Oct 13, 2000

METFORMIN HYDROCHLORIDE

AB1	ACTAVIS LABS FL INC	500MG	A076172	001	Jun 16, 2004
AB1	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008
AB1	APOTEX	500MG	A076706	001	Dec 14, 2004
AB1	AUROBINDO PHARMA LTD	500MG	A079118	001	Jul 20, 2012
AB1	BEXIMCO PHARMS USA	500MG	A207427	001	Dec 13, 2016
AB1	CSPC OUYI PHARM CO	500MG	A078321	001	Apr 17, 2008
AB1	INVENTIA HLTHCARE	500MG	A201991	001	Jan 18, 2012
AB1	MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016
AB1	MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016
AB1	MYLAN	500MG	A076650	001	Sep 13, 2005
AB1	NOSTRUM PHARMS LLC	500MG	A076756	001	Jul 26, 2006
AB1	SANDOZ	500MG	A076873	001	Dec 14, 2004

FDA data supplied by DrugPatentWatch.com

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

	METFORMIN HYDROCHLORIDE				
AB1	SUN PHARM INDS (IN)	**500MG**	**A077336**	**001**	Feb 09, 2006
AB1	TEVA	**500MG**	**A076269**	**001**	Jun 18, 2004
AB1	TORRENT PHARM	**500MG**	**A090014**	**001**	Dec 30, 2009
AB1	ZYDUS PHARMS USA	**500MG**	**A077060**	**001**	Apr 20, 2005
	FORTAMET				
AB2	ANDRX LABS LLC	**500MG**	**N021574**	**001**	Apr 27, 2004
AB2	**+**	**1GM**	**N021574**	**002**	Apr 27, 2004
	METFORMIN HYDROCHLORIDE				
AB2	LUPIN LTD	**500MG**	**A090692**	**001**	Jun 29, 2011
AB2		**1GM**	**A090692**	**002**	Jun 29, 2011
AB2	MYLAN PHARMS INC	**500MG**	**A200690**	**001**	Aug 01, 2012
AB2		**1GM**	**A200690**	**002**	Aug 01, 2012
	GLUMETZA				
AB3	SANTARUS INC	**500MG**	**N021748**	**001**	Jun 03, 2005
AB3	**+**	**1GM**	**N021748**	**002**	Jun 03, 2005
	METFORMIN HYDROCHLORIDE				
AB3	ACTAVIS LABS FL INC	**500MG**	**A203755**	**001**	Aug 01, 2016
AB3		**1GM**	**A203755**	**002**	Aug 01, 2016
AB3	LUPIN LTD	**500MG**	**A091664**	**001**	Jul 19, 2013
AB3		**1GM**	**A091664**	**002**	Jul 19, 2013
AB3	SUN PHARMA GLOBAL	**500MG**	**A202917**	**001**	Aug 01, 2016
AB3		**1GM**	**A202917**	**002**	Aug 01, 2016

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

	ACTOPLUS MET				
AB	TAKEDA PHARMS USA	**500MG;EQ 15MG BASE**	**N021842**	**001**	Aug 29, 2005
AB	**+**	**850MG;EQ 15MG BASE**	**N021842**	**002**	Aug 29, 2005
	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE				
AB	AUROBINDO PHARMA LTD	**500MG;EQ 15MG BASE**	**A200823**	**001**	Feb 13, 2013
AB		**850MG;EQ 15MG BASE**	**A200823**	**002**	Feb 13, 2013
AB	MACLEODS PHARMS LTD	**500MG;EQ 15MG BASE**	**A204802**	**001**	Nov 05, 2015
AB		**850MG;EQ 15MG BASE**	**A204802**	**002**	Nov 05, 2015
AB	MYLAN	**500MG;EQ 15MG BASE**	**A090406**	**001**	Feb 25, 2011
AB		**850MG;EQ 15MG BASE**	**A090406**	**002**	Feb 25, 2011
AB	SANDOZ	**500MG;EQ 15MG BASE**	**A091273**	**001**	Apr 16, 2013
AB		**850MG;EQ 15MG BASE**	**A091273**	**002**	Apr 16, 2013
AB	TEVA PHARMS USA	**500MG;EQ 15MG BASE**	**A091155**	**001**	Mar 10, 2014
AB		**850MG;EQ 15MG BASE**	**A091155**	**002**	Mar 10, 2014
AB	TORRENT PHARMS LTD	**500MG;EQ 15MG BASE**	**A202001**	**001**	Feb 13, 2013
AB		**850MG;EQ 15MG BASE**	**A202001**	**002**	Feb 13, 2013

TABLET, EXTENDED RELEASE;ORAL

	ACTOPLUS MET XR				
	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

	PRANDIMET				
AB	NOVO NORDISK INC	**500MG;1MG**	**N022386**	**001**	Jun 23, 2008
AB	**+**	**500MG;2MG**	**N022386**	**002**	Jun 23, 2008
	REPAGLINIDE AND METFORMIN HYDROCHLORIDE				
AB	LUPIN LTD	**500MG;1MG**	**A200624**	**001**	Jul 15, 2015
AB		**500MG;2MG**	**A200624**	**002**	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

	ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE				
	TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014
		500MG;EQ 4MG BASE	A077337	002	May 07, 2014
+		1GM;EQ 4MG BASE	A077337	004	May 07, 2014
		1GM;EQ 2MG BASE	A077337	003	May 07, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

	KOMBIGLYZE XR				
	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010
		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL					
JANUMET					
		MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001 Mar 30, 2007
	+		1GM;EQ 50MG BASE	N022044	002 Mar 30, 2007
TABLET, EXTENDED RELEASE;ORAL					
JANUMET XR					
		MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001 Feb 02, 2012
			1GM;EQ 50MG BASE	N202270	002 Feb 02, 2012
	+		1GM;EQ 100MG BASE	N202270	003 Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION					
PROVOCHOLINE					
	+	METHAPHARM	100MG/VIAL	N019193	001 Oct 31, 1986
			1600MG/VIAL	N019193	002 Aug 29, 2016

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL					
METHADONE HYDROCHLORIDE					
AA		VISTAPHARM	**10MG/ML**	**A040088**	**001** Nov 30, 1994
AA		WEST-WARD PHARMS INT	**10MG/ML**	**A040180**	**001** Apr 30, 1998
METHADONE HYDROCHLORIDE INTENSOL					
AA		WEST-WARD PHARMS INT	**10MG/ML**	**A089897**	**001** Sep 06, 1988
METHADOSE					
AA	+	MALLINCKRODT	**10MG/ML**	**N017116**	**002**
INJECTABLE;INJECTION					
METHADONE HYDROCHLORIDE					
	+	MYLAN INSTITUTIONAL	10MG/ML	N021624	001
POWDER;FOR RX COMPOUNDING					
METHADONE HYDROCHLORIDE					
		MALLINCKRODT	50GM/BOT	N006383	002
			100GM/BOT	N006383	003
			500GM/BOT	N006383	004
SOLUTION;ORAL					
METHADONE HYDROCHLORIDE					
AA		VISTAPHARM	**5MG/5ML**	**A090707**	**001** Jun 30, 2010
AA			**10MG/5ML**	**A090707**	**002** Jun 30, 2010
AA	+	WEST-WARD PHARMS INT	**5MG/5ML**	**A087393**	**001**
AA	+		**10MG/5ML**	**A087997**	**001** Aug 30, 1982
TABLET;ORAL					
DOLOPHINE HYDROCHLORIDE					
AA	+	ROXANE	**5MG**	**N006134**	**002**
AA	+		**10MG**	**N006134**	**010**
METHADONE HYDROCHLORIDE					
AA		AUROLIFE PHARMA LLC	**5MG**	**A203502**	**001** Aug 31, 2015
AA			**10MG**	**A203502**	**002** Aug 31, 2015
AA		COREPHARMA	**5MG**	**A090065**	**001** Aug 18, 2015
AA			**10MG**	**A090065**	**002** Aug 18, 2015
AA		MALLINCKRODT	**5MG**	**A040517**	**001** Apr 27, 2004
AA			**10MG**	**A040517**	**002** Apr 27, 2004
AA		SANDOZ	**10MG**	**A040241**	**002** May 29, 1998
AA		THE PHARMANETWORK	**10MG**	**A090635**	**001** Nov 25, 2009
METHADOSE					
AA		MALLINCKRODT	**5MG**	**A040050**	**001** Apr 15, 1993
AA			**10MG**	**A040050**	**002** Apr 15, 1993
TABLET, FOR SUSPENSION;ORAL					
METHADONE HYDROCHLORIDE					
AA		MALLINCKRODT INC	**40MG**	**A077142**	**001** Jul 12, 2005
AA	+	ROXANE	**40MG**	**N017058**	**001**
AA		SANDOZ	**40MG**	**A075082**	**001** Mar 25, 1998
METHADOSE					
AA		MALLINCKRODT INC	**40MG**	**A074184**	**001** Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL					
DESOXYN					
AA	+	RECORDATI RARE	**5MG**	**N005378**	**002**
METHAMPHETAMINE HYDROCHLORIDE					
AA		MAYNE PHARMA INC	**5MG**	**A091189**	**001** Apr 21, 2010
AA		WEST-WARD PHARMS INT	**5MG**	**A203846**	**001** Nov 17, 2015

METHAZOLAMIDE
TABLET;ORAL
METHAZOLAMIDE

AB		ANI PHARMS INC	25MG	A040001 001	Jun 30, 1993
AB			50MG	A040001 002	Jun 30, 1993
AB		MIKART	25MG	A040062 001	Jan 27, 1994
AB	+		50MG	A040062 002	Jan 27, 1994
AB		SANDOZ	25MG	A040036 001	Jun 30, 1993
AB			50MG	A040036 002	Jun 30, 1993

METHENAMINE HIPPURATE
TABLET;ORAL
HIPREX

AB	+	US PHARM HOLDINGS	1GM	N017681 001	

METHENAMINE HIPPURATE

AB		AUROBINDO PHARMA LTD	1GM	A205661 001	Jul 05, 2016
AB		COREPHARMA	1GM	A076411 001	Jun 20, 2003

UREX

AB		CNTY LINE PHARMS	1GM	N016151 001	

METHIMAZOLE
TABLET;ORAL
METHIMAZOLE

AB		ECI PHARMS LLC	5MG	A040547 001	Feb 18, 2005
AB			10MG	A040547 002	Feb 18, 2005
AB		HERITAGE PHARMA	5MG	A040734 001	Dec 14, 2007
AB			10MG	A040734 002	Dec 14, 2007
AB		MYLAN	5MG	A040350 001	Mar 29, 2000
AB	+		10MG	A040350 002	Mar 29, 2000
AB		RISING PHARMS INC	5MG	A202068 001	Mar 07, 2012
AB			10MG	A202068 002	Mar 07, 2012
AB		SANDOZ	5MG	A040411 001	Mar 27, 2001
AB			10MG	A040411 002	Mar 27, 2001
AB		SUN PHARM INDS INC	5MG	A040870 001	Sep 25, 2007
AB			10MG	A040870 002	Sep 25, 2007

TAPAZOLE

AB		KING PHARMS	5MG	A040320 001	Mar 31, 2000
AB			10MG	A040320 002	Mar 31, 2000

METHOCARBAMOL
SOLUTION;IM-IV
METHOCARBAMOL

AP		AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128 001	May 27, 2016
AP		MONTEREY PHARMS LLC	1GM/10ML (100MG/ML)	A205354 001	Oct 27, 2016
AP		MYLAN INSTITUTIONAL	1GM/10ML (100MG/ML)	A204404 001	Dec 05, 2014

ROBAXIN

AP	+	WEST-WARD PHARMS INT	1GM/10ML (100MG/ML)	N011790 001	

TABLET;ORAL
METHOCARBAMOL

AA		AUSTARPHARMA LLC	500MG	A200958 001	Oct 21, 2011
AA			750MG	A200958 002	Oct 21, 2011
AA		HETERO LABS LTD III	500MG	A090200 001	Nov 06, 2009
AA			750MG	A090200 002	Nov 06, 2009
AA		HIKMA INTL PHARMS	500MG	A085159 001	
AA			750MG	A085123 001	
AA		PRINSTON INC	500MG	A086989 001	
AA			750MG	A086988 001	
AA		VINTAGE PHARMS	500MG	A040489 001	Jan 29, 2003
AA			750MG	A040489 002	Jan 29, 2003
AA		WATSON LABS	500MG	A084277 001	
AA			750MG	A084276 002	

ROBAXIN

AA	+	AUXILIUM PHARMS LLC	500MG	N011011 004	

ROBAXIN-750

AA	+	AUXILIUM PHARMS LLC	750MG	N011011 006	

METHOHEXITAL SODIUM
INJECTABLE;INJECTION
BREVITAL SODIUM

	+	PAR STERILE PRODUCTS	500MG/VIAL	N011559 001
	+		2.5GM/VIAL	N011559 002

FDA data supplied by DrugPatentWatch.com

METHOTREXATE

SOLUTION;SUBCUTANEOUS

	OTREXUP				
	ANTARES PHARMA INC	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016
		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016
		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013
		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016
+		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013
	RASUVO				
	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
		27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014
		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014

METHOTREXATE SODIUM

INJECTABLE;INJECTION

	METHOTREXATE PRESERVATIVE FREE				
AP	FRESENIUS KABI USA	**EQ 25MG BASE/ML**	**A040265**	**001**	Feb 26, 1999
AP		**EQ 1GM BASE/VIAL**	**A040266**	**001**	Feb 26, 1999
AP	PHARMACHEMIE BV	**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A200171**	**001**	Feb 27, 2012
	METHOTREXATE SODIUM				
AP +	FRESENIUS KABI USA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040263**	**001**	Feb 26, 1999
AP +		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040263**	**002**	Feb 26, 1999
AP +	HOSPIRA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**N011719**	**010**	Dec 15, 2004
AP +	WEST-WARD PHARMS INT	**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A089341**	**001**	Sep 16, 1986
	METHOTREXATE SODIUM PRESERVATIVE FREE				
AP +	ACCORD HLTHCARE	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040767**	**001**	Apr 30, 2007
AP +		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040768**	**001**	Apr 30, 2007
AP +		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040716**	**001**	Apr 30, 2007
AP +	HOSPIRA	**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**N011719**	**012**	Apr 13, 2005
AP	MYLAN LABS LTD	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A201529**	**001**	Mar 29, 2012
AP		**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A201529**	**002**	Mar 29, 2012
AP		**EQ 200MG BASE/8ML (EQ 25MG BASE/ML)**	**A201529**	**003**	Mar 29, 2012
AP		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A201529**	**004**	Mar 29, 2012
AP		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A201530**	**001**	Mar 29, 2012
AP	PHARMACHEMIE BV	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040850**	**001**	Jan 11, 2010
AP		**EQ 250MG/10ML (EQ 25MG BASE/ML)**	**A040853**	**001**	Jan 11, 2010
AP		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040843**	**001**	Jan 11, 2010
AP	SANDOZ INC	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A090039**	**001**	Mar 31, 2009
AP		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A090039**	**002**	Mar 31, 2009
AP		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A090029**	**001**	Mar 31, 2009
AP +	WEST-WARD PHARMS INT	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A089340**	**001**	Sep 16, 1986
AP +		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A089343**	**001**	Sep 16, 1986
	METHOTREXATE SODIUM				
+	WEST-WARD PHARMS INT	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
	METHOTREXATE SODIUM PRESERVATIVE FREE				
+	WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005

TABLET;ORAL

	METHOTREXATE SODIUM				
AB	BARR	**EQ 2.5MG BASE**	**A081099**	**001**	Oct 15, 1990
AB +	DAVA PHARMS INC	**EQ 2.5MG BASE**	**N008085**	**002**	
AB	HQ SPCLT PHARMA	**EQ 2.5MG BASE**	**A201749**	**001**	May 21, 2015
AB	MYLAN	**EQ 2.5MG BASE**	**A081235**	**001**	May 15, 1992
AB	WEST-WARD PHARMS INT	**EQ 2.5MG BASE**	**A040054**	**001**	Aug 01, 1994
	TREXALL				
	BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
		EQ 7.5MG BASE	A040385	002	Mar 21, 2001
		EQ 10MG BASE	A040385	003	Mar 21, 2001
+		EQ 15MG BASE	A040385	004	Mar 21, 2001

METHOXSALEN
CAPSULE;ORAL
METHOXSALEN

AB		ACTAVIS INC	**10MG**	**A202603**	**001** Jun 09, 2015
AB		STRIDES PHARMA	**10MG**	**A202687**	**001** Jun 05, 2014
		OXSORALEN-ULTRA			
AB	+	DOW PHARM	**10MG**	**N019600**	**001** Oct 30, 1986
		8-MOP			
	+	VALEANT PHARM INTL	10MG	N009048	001
		INJECTABLE;INJECTION			
		UVADEX			
	+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001 Feb 25, 1999
		LOTION;TOPICAL			
		OXSORALEN			
	+	VALEANT PHARM INTL	1%	N009048	002

METHSCOPOLAMINE BROMIDE
TABLET;ORAL
METHSCOPOLAMINE BROMIDE

AA		BAYSHORE PHARMS LLC	**2.5MG**	**A200602**	**001** Sep 24, 2012
AA			**5MG**	**A200602**	**002** Sep 24, 2012
AA		BRECKENRIDGE PHARM	**2.5MG**	**A040642**	**001** Dec 06, 2011
AA			**5MG**	**A040642**	**002** Dec 06, 2011
AA	+	VINTAGE PHARMS	**2.5MG**	**A040624**	**001** Dec 28, 2006
AA	+		**5MG**	**A040624**	**002** Dec 28, 2006

METHSUXIMIDE
CAPSULE;ORAL
CELONTIN

		PARKE DAVIS	150MG	N010596	007
	+		300MG	N010596	008

METHYCLOTHIAZIDE
TABLET;ORAL
METHYCLOTHIAZIDE

	+	MYLAN PHARMS INC	5MG	A087672	001 Aug 17, 1982

METHYLDOPA
TABLET;ORAL
METHYLDOPA

AB		ACCORD HLTHCARE	**250MG**	**A070084**	**001** Oct 15, 1985
AB			**500MG**	**A070085**	**001** Oct 15, 1985
AB		IVAX SUB TEVA PHARMS	**250MG**	**A070098**	**001** Feb 20, 1986
AB			**500MG**	**A070343**	**001** Feb 20, 1986
AB		MYLAN	**250MG**	**A070076**	**002** Apr 18, 1985
AB	+		**500MG**	**A070076**	**001** Apr 18, 1985
AB		WATSON LABS	**500MG**	**A070625**	**001** Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE
INJECTABLE;INJECTION
METHYLDOPATE HYDROCHLORIDE

AP	+	LUITPOLD	**50MG/ML**	**A071279**	**001** Oct 02, 1987

METHYLENE BLUE
SOLUTION;INTRAVENOUS
PROVAYBLUE

	+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001 Apr 08, 2016

METHYLERGONOVINE MALEATE
INJECTABLE;INJECTION
METHERGINE

AP	+	EDISON THERAPS LLC	**0.2MG/ML**	**N006035**	**004**
		METHYLERGONOVINE MALEATE			
AP		ERGOJECT	**0.2MG/ML**	**A040889**	**001** Sep 13, 2010
AP		LUITPOLD	**0.2MG/ML**	**A090193**	**001** Nov 24, 2008
		TABLET;ORAL			
		METHYLERGONOVINE MALEATE			
	+	NOVEL LABS INC	0.2MG	A091577	001 May 02, 2011

METHYLNALTREXONE BROMIDE
SOLUTION;SUBCUTANEOUS
RELISTOR

	+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002 Sep 27, 2010
	+		12MG/0.6ML (12MG/0.6ML)	N021964	001 Apr 24, 2008
	+		12MG/0.6ML (12MG/0.6ML)	N021964	003 Sep 27, 2010

FDA data supplied by DrugPatentWatch.com

METHYLNALTREXONE BROMIDE
TABLET;ORAL
RELISTOR

+	SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016

METHYLPHENIDATE
FILM, EXTENDED RELEASE;TRANSDERMAL
DAYTRANA

	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006
		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006
		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006
+		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006

METHYLPHENIDATE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL

	METHYLPHENIDATE HYDROCHLORIDE				
AB1	BARR LABS INC	**10MG**	**A079031**	**004**	Oct 15, 2014
AB1		**20MG**	**A079031**	**001**	Jul 13, 2012
AB1		**30MG**	**A079031**	**002**	Jul 13, 2012
AB1		**40MG**	**A079031**	**003**	Jul 13, 2012
AB1	MAYNE PHARMA	**20MG**	**A078458**	**001**	Dec 01, 2011
AB1		**30MG**	**A078458**	**002**	Dec 01, 2011
AB1		**40MG**	**A078458**	**003**	Dec 01, 2011
AB1		**60MG**	**A078458**	**004**	Jun 23, 2016
	RITALIN LA				
AB1	NOVARTIS	**10MG**	**N021284**	**004**	Apr 10, 2004
AB1		**20MG**	**N021284**	**001**	Jun 05, 2002
AB1		**30MG**	**N021284**	**002**	Jun 05, 2002
AB1		**40MG**	**N021284**	**003**	Jun 05, 2002
AB1	**+**	**60MG**	**N021284**	**005**	Oct 27, 2014
	METADATE CD				
AB2	UCB INC	**10MG**	**N021259**	**003**	May 27, 2003
AB2		**20MG**	**N021259**	**001**	Apr 03, 2001
AB2		**30MG**	**N021259**	**002**	Jun 19, 2003
AB2		**40MG**	**N021259**	**004**	Feb 19, 2006
AB2		**50MG**	**N021259**	**005**	Feb 19, 2006
AB2	**+**	**60MG**	**N021259**	**006**	Feb 19, 2006
	METHYLPHENIDATE HYDROCHLORIDE				
AB2	COREPHARMA	**10MG**	**A205105**	**001**	Jul 28, 2016
AB2		**20MG**	**A205105**	**002**	Jul 28, 2016
AB2		**30MG**	**A205105**	**003**	Jul 28, 2016
AB2		**40MG**	**A205105**	**004**	Jul 28, 2016
AB2		**50MG**	**A205105**	**005**	Jul 28, 2016
AB2		**60MG**	**A205105**	**006**	Jul 28, 2016
AB2	MALLINCKRODT INC	**10MG**	**A203583**	**001**	Sep 29, 2015
AB2		**20MG**	**A203583**	**002**	Sep 29, 2015
AB2		**30MG**	**A203583**	**003**	Sep 29, 2015
AB2		**40MG**	**A203583**	**004**	Sep 29, 2015
AB2		**50MG**	**A203583**	**005**	Sep 29, 2015
AB2		**60MG**	**A203583**	**006**	Sep 29, 2015
AB2	TEVA PHARMS	**10MG**	**A077707**	**001**	Jul 19, 2012
AB2		**20MG**	**A077707**	**002**	Jul 19, 2012
AB2		**30MG**	**A077707**	**003**	Jul 19, 2012
AB2		**40MG**	**A078873**	**001**	Jul 19, 2012
AB2		**50MG**	**A078873**	**002**	Jul 19, 2012
AB2		**60MG**	**A078873**	**003**	Jul 19, 2012
	APTENSIO XR				
	RHODES PHARMS	10MG	N205831	001	Apr 17, 2015
		15MG	N205831	002	Apr 17, 2015
		20MG	N205831	003	Apr 17, 2015
		30MG	N205831	004	Apr 17, 2015
		40MG	N205831	005	Apr 17, 2015
		50MG	N205831	006	Apr 17, 2015
+		60MG	N205831	007	Apr 17, 2015

FOR SUSPENSION, EXTENDED RELEASE;ORAL
QUILLIVANT XR

+	NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012

SOLUTION;ORAL

	METHYLIN				
AA	**+** MALLINCKRODT	**5MG/5ML**	**N021419**	**001**	Dec 19, 2002
AA	**+**	**10MG/5ML**	**N021419**	**002**	Dec 19, 2002
	METHYLPHENIDATE HYDROCHLORIDE				
AA	ABHAI	**5MG/5ML**	**A207485**	**001**	Nov 18, 2016

FDA data supplied by DrugPatentWatch.com

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA		10MG/5ML	A207485	002	Nov 18, 2016
AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013
AA		10MG/5ML	A201466	002	Nov 12, 2013
AA	NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015
AA		10MG/5ML	A204602	002	Aug 14, 2015
AA	TRIS PHARMA INC	5MG/5ML	A091601	001	Jul 23, 2010
AA		10MG/5ML	A091601	002	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	5MG	A040220	001	Aug 29, 1997
AB		10MG	A040220	002	Aug 29, 1997
AB		20MG	A040220	003	Aug 29, 1997
AB	ASCENT PHARMS INC	5MG	A207416	001	Sep 22, 2015
AB		10MG	A207416	002	Sep 22, 2015
AB		20MG	A207416	003	Sep 22, 2015
AB	CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016
AB		10MG	A206840	002	Sep 15, 2016
AB		20MG	A206840	003	Sep 15, 2016
AB	COREPHARMA	5MG	A091159	001	Mar 12, 2014
AB		10MG	A091159	002	Mar 12, 2014
AB		20MG	A091159	003	Mar 12, 2014
AB	MALLINCKRODT	5MG	A040300	001	Nov 27, 1998
AB		10MG	A040300	002	Nov 27, 1998
AB		20MG	A040300	003	Nov 27, 1998
AB	NOVEL LABS INC	5MG	A207884	001	Nov 13, 2015
AB		10MG	A207884	002	Nov 13, 2015
AB		20MG	A207884	003	Nov 13, 2015
AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012
AB		10MG	A090710	002	Mar 15, 2012
AB		20MG	A090710	003	Mar 15, 2012
AB	UCB INC	5MG	A086429	001	
AB		10MG	A085799	001	
AB		20MG	A086428	001	
AB	VINTAGE PHARMS	5MG	A202892	001	Sep 23, 2014
AB		10MG	A202892	002	Sep 23, 2014
AB		20MG	A202892	003	Sep 23, 2014

RITALIN

AB	NOVARTIS	5MG	N010187	003	
AB		10MG	N010187	006	
AB +		20MG	N010187	010	

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015
AB		5MG	A204115	002	Feb 25, 2015
AB +		10MG	A204115	003	Feb 25, 2015
AB	TEDOR PHARMA INC	2.5MG	A205756	001	Nov 07, 2016
AB		5MG	A205756	002	Nov 07, 2016
AB		10MG	A205756	003	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

AB	JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000
AB		27MG	N021121	004	Apr 01, 2002
AB		36MG	N021121	002	Aug 01, 2000
AB +		54MG	N021121	003	Dec 08, 2000

METADATE ER

AB +	UCB INC	20MG	A089601	001	Jun 01, 1988

METHYLIN ER

AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000
AB		20MG	A075629	002	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI	10MG	A207488	001	Jun 09, 2015
AB		20MG	A207488	002	Jun 09, 2015
AB	CNTY LINE PHARMS	10MG	A204772	001	Feb 29, 2016
AB		20MG	A204772	002	Feb 29, 2016
AB	MYLAN PHARMS INC	18MG	A206726	001	Oct 21, 2016
AB		27MG	A206726	002	Oct 21, 2016
AB		36MG	A206726	003	Oct 21, 2016
AB		54MG	A206726	004	Oct 21, 2016

FDA data supplied by DrugPatentWatch.com

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

	RITALIN-SR				
AB	NOVARTIS	**20MG**	**N018029**	**001**	Mar 30, 1982
	METHYLPHENIDATE HYDROCHLORIDE				
BX	KREMERS URBAN PHARMS	18MG	A091695	001	Jul 09, 2013
BX		27MG	A091695	002	Jul 09, 2013
BX		36MG	A091695	003	Sep 23, 2013
BX		54MG	A091695	004	Sep 23, 2013
BX	MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012
BX		36MG	A202608	002	Dec 28, 2012
BX		54MG	A202608	003	Dec 28, 2012

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

	QUILLICHEW ER				
	PFIZER INC	20MG	N207960	001	Dec 04, 2015
		30MG	N207960	002	Dec 04, 2015
+		40MG	N207960	003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

	MEDROL				
AB	PHARMACIA AND UPJOHN	**2MG**	**N011153**	**002**	
AB		**4MG**	**N011153**	**001**	
AB		**8MG**	**N011153**	**004**	
AB		**16MG**	**N011153**	**003**	
AB	**+**	**32MG**	**N011153**	**006**	
	METHYLPREDNISOLONE				
AB	DURAMED PHARMS BARR	**4MG**	**A088497**	**001**	Feb 21, 1984
AB	JUBILANT CADISTA	**4MG**	**A040189**	**001**	Oct 31, 1997
AB		**8MG**	**A040189**	**002**	Oct 31, 1997
AB		**16MG**	**A040189**	**003**	Jul 20, 2007
AB		**32MG**	**A040189**	**004**	Jul 20, 2007
AB	SANDOZ	**4MG**	**A040194**	**001**	Oct 31, 1997
AB	VINTAGE PHARMS	**4MG**	**A040183**	**001**	Dec 22, 1998
AB	WATSON LABS	**4MG**	**A040232**	**001**	Oct 16, 1997

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

	DEPO-MEDROL				
AB	**+** PHARMACIA AND UPJOHN	**40MG/ML**	**N011757**	**001**	
AB	**+**	**80MG/ML**	**N011757**	**004**	
	METHYLPREDNISOLONE ACETATE				
AB	SANDOZ	**40MG/ML**	**A040719**	**001**	Jan 29, 2009
AB		**40MG/ML**	**A040794**	**001**	Mar 05, 2009
AB		**80MG/ML**	**A040719**	**002**	Jan 29, 2009
AB		**80MG/ML**	**A040794**	**002**	Mar 05, 2009
AB	TEVA PHARMS USA	**40MG/ML**	**A040557**	**001**	Feb 23, 2005
AB		**40MG/ML**	**A040620**	**001**	Oct 27, 2006
AB		**80MG/ML**	**A040557**	**002**	Feb 23, 2005
AB		**80MG/ML**	**A040620**	**002**	Oct 27, 2006
	DEPO-MEDROL				
	+ PHARMACIA AND UPJOHN	20MG/ML	N011757	002	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

	A-METHAPRED				
AP	HOSPIRA	**EQ 40MG BASE/VIAL**	**A040664**	**001**	Dec 20, 2005
AP		**EQ 125MG BASE/VIAL**	**A040665**	**001**	Dec 20, 2005
AP	HOSPIRA INC	**EQ 40MG BASE/VIAL**	**A040793**	**001**	Nov 25, 2008
AP		**EQ 125MG BASE/VIAL**	**A040827**	**001**	Nov 25, 2008
	METHYLPREDNISOLONE SODIUM SUCCINATE				
AP	AMNEAL PHARMS CO	**EQ 40MG BASE/VIAL**	**A207549**	**001**	Nov 09, 2016
AP		**EQ 125MG BASE/VIAL**	**A207549**	**002**	Nov 09, 2016
AP	AUROBINDO PHARMA LTD	**EQ 40MG BASE/VIAL**	**A207667**	**001**	Dec 15, 2015
AP		**EQ 125MG BASE/VIAL**	**A207667**	**002**	Dec 15, 2015
AP		**EQ 500MG BASE/VIAL**	**A207667**	**003**	Dec 15, 2015
AP		**EQ 2GM BASE/VIAL**	**A207667**	**004**	Dec 15, 2015
AP	FRESENIUS KABI USA	**EQ 40MG BASE/VIAL**	**A040583**	**001**	Jul 30, 2004
AP		**EQ 125MG BASE/VIAL**	**A040583**	**002**	Jul 30, 2004
AP		**EQ 1GM BASE/VIAL**	**A040612**	**001**	Aug 12, 2004
AP	HIKMA FARMACEUTICA	**EQ 500MG BASE/VIAL**	**A202691**	**001**	Feb 16, 2016
AP		**EQ 1GM BASE/VIAL**	**A202691**	**002**	Feb 16, 2016
AP	SAGENT PHARMS	**EQ 40MG BASE/VIAL**	**A040888**	**001**	Jul 18, 2011
AP		**EQ 125MG BASE/VIAL**	**A040888**	**002**	Jul 18, 2011

FDA data supplied by DrugPatentWatch.com

METHYLPREDNISOLONE SODIUM SUCCINATE
INJECTABLE;INJECTION

		METHYLPREDNISOLONE SODIUM SUCCINATE			
AP		**EQ 500MG BASE/VIAL**	**A040888**	**003**	Jul 18, 2011
AP		**EQ 1GM BASE/VIAL**	**A040888**	**004**	Jul 18, 2011
AP		**EQ 2GM BASE/VIAL**	**A040888**	**005**	Jul 18, 2011
		SOLU-MEDROL			
AP	+ PHARMACIA AND UPJOHN	**EQ 40MG BASE/VIAL**	**N011856**	**003**	
AP	+	**EQ 125MG BASE/VIAL**	**N011856**	**004**	
AP	+	**EQ 500MG BASE/VIAL**	**N011856**	**005**	
AP	+	**EQ 1GM BASE/VIAL**	**N011856**	**006**	
AP	+	**EQ 2GM BASE/VIAL**	**N011856**	**007**	Feb 27, 1985

METHYLTESTOSTERONE
CAPSULE;ORAL

		METHYLTESTOSTERONE			
AB	IMPAX LABS INC	**10MG**	**A204851**	**001**	Sep 21, 2015
		TESTRED			
AB	+ VALEANT PHARM INTL	**10MG**	**A083976**	**001**	
TABLET;ORAL					
		ANDROID 25			
BP	VALEANT PHARM INTL	25MG	A087147	001	
		METHYLTESTOSTERONE			
BP	IMPAX LABS	10MG	A080767	002	

METIPRANOLOL HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

		METIPRANOLOL			
AT	ALCON RES LTD	**0.3%**	**A075720**	**001**	Aug 06, 2001
		OPTIPRANOLOL			
AT	+ BAUSCH AND LOMB	**0.3%**	**N019907**	**001**	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION

		METOCLOPRAMIDE			
AP	EMCURE PHARMS LTD	**EQ 5MG BASE/ML**	**A204756**	**001**	Dec 20, 2013
		METOCLOPRAMIDE HYDROCHLORIDE			
AP	FRESENIUS KABI USA	**EQ 5MG BASE/ML**	**A091392**	**001**	Apr 19, 2013
AP	+ HOSPIRA	**EQ 5MG BASE/ML**	**A073118**	**001**	Jan 17, 1991
AP	TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A073135**	**001**	Nov 27, 1991
SOLUTION;ORAL					
		METOCLOPRAMIDE HYDROCHLORIDE			
AA	ANI PHARMS	**EQ 5MG BASE/5ML**	**A071402**	**001**	Jun 25, 1993
AA	PHARM ASSOC	**EQ 5MG BASE/5ML**	**A072744**	**001**	May 28, 1991
AA	VISTAPHARM	**EQ 5MG BASE/5ML**	**A075051**	**001**	Jan 26, 2001
AA	+ WOCKHARDT	**EQ 5MG BASE/5ML**	**A074703**	**001**	Oct 31, 1997
TABLET;ORAL					
		METOCLOPRAMIDE HYDROCHLORIDE			
AB	IMPAX LABS INC	**EQ 5MG BASE**	**A071250**	**002**	Dec 28, 1995
AB		**EQ 10MG BASE**	**A071250**	**001**	Feb 03, 1988
AB	IPCA LABS LTD	**EQ 5MG BASE**	**A078807**	**001**	Jun 12, 2008
AB		**EQ 10MG BASE**	**A078807**	**002**	Jun 12, 2008
AB	NORTHSTAR HLTHCARE	**EQ 5MG BASE**	**A078374**	**001**	Nov 30, 2007
AB		**EQ 10MG BASE**	**A078374**	**002**	Nov 30, 2007
AB	PAR PHARM INC	**EQ 10MG BASE**	**A070581**	**001**	Oct 17, 1985
AB	SUN PHARM INDS	**EQ 5MG BASE**	**A071536**	**002**	Jan 16, 1997
AB	TEVA	**EQ 5MG BASE**	**A072801**	**001**	Jun 15, 1993
AB		**EQ 10MG BASE**	**A070184**	**001**	Jul 29, 1985
AB	VINTAGE PHARMS	**EQ 5MG BASE**	**A077878**	**001**	Aug 28, 2006
AB		**EQ 10MG BASE**	**A077878**	**002**	Aug 28, 2006
		REGLAN			
AB	ANI PHARMS	**EQ 5MG BASE**	**N017854**	**002**	May 05, 1987
AB	+	**EQ 10MG BASE**	**N017854**	**001**	
TABLET, ORALLY DISINTEGRATING;ORAL					
		METOCLOPRAMIDE HYDROCHLORIDE			
AB	NOVEL LABS INC	**EQ 5MG BASE**	**A202191**	**001**	Aug 15, 2014
		METOZOLV ODT			
AB	+ SALIX PHARMS	**EQ 5MG BASE**	**N022246**	**001**	Sep 04, 2009
		METOCLOPRAMIDE HYDROCHLORIDE			
	NOVEL LABS INC	EQ 10MG BASE	A202191	002	Aug 15, 2014

FDA data supplied by DrugPatentWatch.com

METOLAZONE

TABLET;ORAL

METOLAZONE					
AB	MYLAN	2.5MG	A076698	001	Dec 23, 2003
AB		5MG	A076698	002	Oct 19, 2004
AB		10MG	A076698	003	Oct 19, 2004
AB	SANDOZ	2.5MG	A076732	001	Dec 19, 2003
AB		5MG	A076466	001	Dec 19, 2003
AB		10MG	A076466	002	Dec 19, 2003
ZAROXOLYN					
AB	UCB INC	2.5MG	N017386	001	
AB +		5MG	N017386	002	
AB +		10MG	N017386	003	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE					
AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016
AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016
AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016
AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016
AB	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A077118	001	Aug 03, 2009
AB		EQ 50MG TARTRATE	A076862	001	Aug 03, 2009
AB		EQ 100MG TARTRATE	A077298	001	Apr 15, 2010
AB		EQ 200MG TARTRATE	A077298	002	Apr 15, 2010
AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617	001	Aug 01, 2012
AB		EQ 50MG TARTRATE	A090617	002	Aug 01, 2012
AB	MYLAN PHARMS INC	EQ 25MG TARTRATE	A202033	001	Dec 15, 2011
AB		EQ 50MG TARTRATE	A202033	002	Dec 15, 2011
AB		EQ 100MG TARTRATE	A202033	003	Dec 15, 2011
AB		EQ 200MG TARTRATE	A202033	004	Dec 15, 2011
AB	REDDYS	EQ 100MG TARTRATE	A078889	001	Aug 15, 2012
AB		EQ 200MG TARTRATE	A078889	002	Aug 15, 2012
AB	WOCKHARDT	EQ 25MG TARTRATE	A090615	001	Jul 22, 2010
AB		EQ 50MG TARTRATE	A090615	002	Jul 22, 2010
AB		EQ 100MG TARTRATE	A090615	003	Jul 22, 2010
AB		EQ 200MG TARTRATE	A090615	004	Jul 22, 2010
TOPROL-XL					
AB	ASTRAZENECA PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001
AB +		EQ 50MG TARTRATE	N019962	001	Jan 10, 1992
AB		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992
AB +		EQ 200MG TARTRATE	N019962	003	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE;INJECTION

LOPRESSOR					
AP +	NOVARTIS	1MG/ML	N018704	001	Mar 30, 1984
METOPROLOL TARTRATE					
AP	CLARIS	1MG/ML	A078950	001	Apr 29, 2013
AP	EUROHLTH INTL SARL	1MG/ML	A076495	001	Jul 07, 2003
AP	FRESENIUS KABI USA	1MG/ML	A091045	001	Oct 25, 2010
AP	GLAND PHARMA LTD	1MG/ML	A204205	001	Aug 27, 2014
AP	HIKMA FARMACEUTICA	1MG/ML	A077761	001	May 30, 2007
AP	HOSPIRA	1MG/ML	A074133	001	Dec 21, 1993
AP		1MG/ML	A075160	001	Jul 06, 1998
AP		1MG/ML	A078085	001	Apr 29, 2008
AP	LUITPOLD	1MG/ML	A090386	001	Sep 30, 2009
AP		1MG/ML	A091307	001	Dec 29, 2010
AP	SAGENT STRIDES	1MG/ML	A090317	001	Apr 19, 2010
AP	SANDOZ	1MG/ML	A077360	001	Oct 02, 2007

TABLET;ORAL

LOPRESSOR					
AB	US PHARMS HOLDINGS I	50MG	N017963	001	
AB		100MG	N017963	002	
METOPROLOL TARTRATE					
AB	ALEMBIC PHARMS LTD	25MG	A202871	001	May 28, 2013
AB		50MG	A202871	002	May 28, 2013
AB		100MG	A202871	003	May 28, 2013
AB	AUROBINDO PHARMA	25MG	A077739	001	Sep 11, 2007
AB		50MG	A077739	002	Sep 11, 2007
AB		100MG	A077739	003	Sep 11, 2007
AB	IPCA LABS LTD	25MG	A078459	001	Jun 17, 2008
AB		50MG	A078459	002	Jun 17, 2008

METOPROLOL TARTRATE

TABLET;ORAL

	METOPROLOL TARTRATE				
AB		**100MG**	**A078459**	**003**	Jun 17, 2008
AB	MUTUAL PHARM	**50MG**	**A073653**	**001**	Dec 21, 1993
AB	MYLAN	**25MG**	**A076704**	**001**	Jan 16, 2004
AB		**50MG**	**A076704**	**002**	Jan 16, 2004
AB +		**100MG**	**A076704**	**003**	Jan 16, 2004
AB	RUBICON RES PVT LTD	**25MG**	**A200981**	**001**	Oct 28, 2014
AB		**50MG**	**A200981**	**002**	Oct 28, 2014
AB		**100MG**	**A200981**	**003**	Oct 28, 2014
AB	SUN PHARM INDS	**25MG**	**A073654**	**002**	Jul 15, 2009
AB		**100MG**	**A073654**	**001**	Dec 21, 1993
AB	SUN PHARM INDS INC	**25MG**	**A076670**	**001**	Jan 15, 2004
AB		**50MG**	**A074644**	**001**	Dec 10, 1996
AB		**100MG**	**A074644**	**002**	Dec 10, 1996
AB	TEVA	**50MG**	**A074141**	**001**	Jan 31, 1995
AB		**100MG**	**A074141**	**002**	Jan 31, 1995
AB	WATSON LABS	**50MG**	**A074217**	**001**	May 27, 1994
AB		**100MG**	**A074217**	**002**	May 27, 1994
	MYLAN	37.5MG	A076704	004	Mar 18, 2015
		75MG	A076704	005	Mar 18, 2015

METRONIDAZOLE

CAPSULE;ORAL

	FLAGYL				
AB +	GD SEARLE LLC	**375MG**	**N020334**	**001**	May 03, 1995
	METRONIDAZOLE				
AB	ALEMBIC LTD	**375MG**	**A079065**	**001**	Jun 23, 2009
AB	PAR PHARM	**375MG**	**A076522**	**001**	Jan 29, 2004

CREAM;TOPICAL

	METROCREAM				
AB +	GALDERMA LABS LP	**0.75%**	**N020531**	**001**	Sep 20, 1995
	METRONIDAZOLE				
AB	FOUGERA PHARMS	**0.75%**	**A076408**	**001**	May 28, 2004
AB	G AND W LABS	**0.75%**	**A077549**	**001**	Dec 19, 2007
	NORITATE				
+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997

GEL;TOPICAL

	METROGEL				
AB +	GALDERMA LABS LP	**0.75%**	**N019737**	**001**	Nov 22, 1988
AB +		**1%**	**N021789**	**001**	Jun 30, 2005
	METRONIDAZOLE				
AB	FOUGERA PHARMS	**0.75%**	**A077018**	**001**	Jun 06, 2006
AB	G AND W LABS INC	**0.75%**	**A078178**	**001**	Jan 19, 2011
AB	TARO	**0.75%**	**A077819**	**001**	Jul 18, 2006
AB	TOLMAR	**0.75%**	**A077547**	**001**	Jul 13, 2006
AB		**1%**	**A090903**	**001**	Jul 22, 2011

GEL;VAGINAL

	METROGEL-VAGINAL				
AB +	MEDICIS	**0.75%**	**N020208**	**001**	Aug 17, 1992
	METRONIDAZOLE				
AB	TOLMAR	**0.75%**	**A077264**	**001**	Oct 31, 2006
	VANDAZOLE				
BX	TEVA PHARMS	0.75%	N021806	001	May 20, 2005
	NUVESSA				
+	ALLERGAN SALES LLC	1.3%	N205223	001	Mar 24, 2014

INJECTABLE;INJECTION

	FLAGYL I.V. RTU IN PLASTIC CONTAINER				
AP +	BAXTER HLTHCARE	**500MG/100ML**	**N018657**	**001**	
	METRO I.V. IN PLASTIC CONTAINER				
AP +	B BRAUN	**500MG/100ML**	**N018900**	**001**	Sep 29, 1983
	METRONIDAZOLE IN PLASTIC CONTAINER				
AP	CLARIS	**500MG/100ML**	**A078084**	**001**	Mar 31, 2008
AP +	HOSPIRA	**500MG/100ML**	**N018890**	**002**	Nov 18, 1983

LOTION;TOPICAL

	METROLOTION				
AB +	GALDERMA LABS LP	**0.75%**	**N020901**	**001**	Nov 24, 1998
	METRONIDAZOLE				
AB	FOUGERA PHARMS	**0.75%**	**A077197**	**001**	May 24, 2006

FDA data supplied by DrugPatentWatch.com

METRONIDAZOLE
TABLET;ORAL

	FLAGYL				
AB	GD SEARLE LLC	**250MG**	**N012623**	**001**	
AB	+	**500MG**	**N012623**	**003**	
	METRONIDAZOLE				
AB	ALEMBIC PHARMS LTD	**250MG**	**A079067**	**001**	Mar 13, 2009
AB		**500MG**	**A079067**	**002**	Mar 13, 2009
AB	ALLIED PHARMA INC	**250MG**	**A070772**	**001**	Jul 16, 1986
AB		**500MG**	**A070773**	**001**	Jul 16, 1986
AB	APPCO PHARMA LLC	**250MG**	**A205245**	**001**	Sep 23, 2015
AB		**500MG**	**A205245**	**002**	Sep 23, 2015
AB	AUROBINDO PHARMA LTD	**250MG**	**A203974**	**001**	May 29, 2015
AB		**500MG**	**A203974**	**002**	May 29, 2015
AB	FLAMINGO PHARMS	**250MG**	**A207309**	**001**	May 16, 2016
AB		**500MG**	**A207309**	**002**	May 16, 2016
AB	PLIVA	**500MG**	**A070033**	**001**	Dec 06, 1984
AB	STRIDES PHARMA	**250MG**	**A208162**	**001**	May 25, 2016
AB		**500MG**	**A208162**	**002**	May 25, 2016
AB	TEVA PHARMS USA	**250MG**	**A070027**	**001**	Nov 06, 1984
AB	UNICHEM LABS LTD	**250MG**	**A203458**	**001**	Jan 22, 2014
AB		**500MG**	**A203458**	**002**	Jan 22, 2014
AB	VIVIMED LABS	**250MG**	**A070040**	**001**	Jan 29, 1985
AB		**500MG**	**A070039**	**001**	Jan 29, 1985
AB	WATSON LABS	**250MG**	**A070035**	**001**	Dec 20, 1984
AB	WATSON LABS INC	**500MG**	**A070044**	**001**	Feb 08, 1985
AB	ZYDUS PHARMS USA INC	**250MG**	**A206560**	**001**	Nov 16, 2016
AB		**500MG**	**A206560**	**002**	Nov 16, 2016
	TABLET, EXTENDED RELEASE;ORAL				
	FLAGYL ER				
AB	+ GD SEARLE LLC	**750MG**	**N020868**	**001**	Nov 26, 1997
	METRONIDAZOLE				
AB	ALEMBIC LTD	**750MG**	**A090222**	**001**	May 05, 2010

METYRAPONE
CAPSULE;ORAL

	METOPIRONE				
+	HRA PHARMA	250MG	N012911	002	Aug 09, 1996

METYROSINE
CAPSULE;ORAL

	DEMSER				
+	ATON PHARMA VPNA	250MG	N017871	001	

MEXILETINE HYDROCHLORIDE
CAPSULE;ORAL

	MEXILETINE HYDROCHLORIDE				
	TEVA	150MG	A074377	001	May 16, 1995
		200MG	A074377	002	May 16, 1995
+		250MG	A074377	003	May 16, 1995

MICAFUNGIN SODIUM
INJECTABLE;IV (INFUSION)

	MYCAMINE				
+	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005
+		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006

MICONAZOLE
TABLET;BUCCAL

	ORAVIG				
+	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010

MICONAZOLE NITRATE
SUPPOSITORY;VAGINAL

	MICONAZOLE NITRATE				
AB	ACTAVIS MID ATLANTIC	**200MG**	**A073508**	**001**	Nov 19, 1993
	MONISTAT 3				
AB	+ MEDTECH PRODUCTS	**200MG**	**N018888**	**001**	Aug 15, 1984

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE
OINTMENT;TOPICAL

	VUSION				
+	DELCOR ASSET CORP	0.25%;81.35%;15%	N021026	001	Feb 16, 2006

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

AP		AKORN INC	**EQ 1MG BASE/ML**	**A075494**	**001**	Jun 30, 2000
AP			**EQ 5MG BASE/ML**	**A075481**	**001**	Jun 30, 2000
AP			**EQ 5MG BASE/ML**	**A075494**	**002**	Jun 30, 2000
AP		EUROHLTH INTL SARL	**EQ 1MG BASE/ML**	**A075243**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075247**	**002**	Jun 23, 2000
AP			**EQ 1MG BASE/ML**	**A075324**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075421**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075243**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075247**	**001**	Jun 23, 2000
AP			**EQ 5MG BASE/ML**	**A075324**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075421**	**001**	Jun 20, 2000
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075154**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075154**	**001**	Jun 20, 2000
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A090696**	**001**	Feb 29, 2012
AP			**EQ 5MG BASE/ML**	**A090850**	**001**	Jan 25, 2012
AP	+	HOSPIRA	**EQ 1MG BASE/ML**	**A075293**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075856**	**001**	Jun 13, 2002
AP	+		**EQ 5MG BASE/ML**	**A075293**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075856**	**002**	Jun 13, 2002

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A203460**	**001**	Aug 22, 2014
AP			**EQ 5MG BASE/ML**	**A203460**	**002**	Aug 22, 2014
AP	+	HOSPIRA	**EQ 1MG BASE/ML**	**A075857**	**001**	Jul 22, 2002
AP	+		**EQ 5MG BASE/ML**	**A075857**	**002**	Jul 22, 2002
AP		SAGENT STRIDES	**EQ 1MG BASE/ML**	**A090315**	**001**	Nov 29, 2010
AP			**EQ 5MG BASE/ML**	**A090315**	**002**	Nov 29, 2010

MIDOZALAM HYDROCHLORIDE

AP		SAGENT STRIDES	**EQ 1MG BASE/ML**	**A090316**	**001**	May 04, 2011
AP			**EQ 5MG BASE/ML**	**A090316**	**002**	May 04, 2011

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

AA		HI TECH PHARMA	**EQ 2MG BASE/ML**	**A075958**	**001**	Sep 04, 2003
AA		PADDOCK LLC	**EQ 2MG BASE/ML**	**A076379**	**001**	May 02, 2005
AA		SUN PHARM INDS LTD	**EQ 2MG BASE/ML**	**A076058**	**001**	Mar 15, 2002
AA	+	WEST-WARD PHARMS INT	**EQ 2MG BASE/ML**	**A075873**	**001**	Apr 30, 2002

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB		APOTEX INC	**2.5MG**	**A077746**	**001**	Sep 12, 2006
AB			**5MG**	**A077746**	**002**	Sep 12, 2006
AB			**10MG**	**A077746**	**003**	Sep 12, 2006
AB		IMPAX PHARMS	**2.5MG**	**A076449**	**001**	May 27, 2004
AB			**5MG**	**A076449**	**002**	May 27, 2004
AB			**10MG**	**A076449**	**003**	Dec 16, 2005
AB		MYLAN PHARMS INC	**2.5MG**	**A076577**	**001**	Sep 10, 2003
AB	+		**5MG**	**A076577**	**002**	Sep 10, 2003
AB			**10MG**	**A076577**	**003**	Sep 10, 2003
AB		SANDOZ	**2.5MG**	**A076514**	**001**	Sep 11, 2003
AB			**5MG**	**A076514**	**002**	Sep 11, 2003
AB			**10MG**	**A076514**	**003**	Jul 02, 2004

ORVATEN

AB		UPSHER SMITH	**2.5MG**	**A076725**	**001**	Nov 03, 2004
AB			**5MG**	**A076725**	**002**	Nov 03, 2004
AB			**10MG**	**A076725**	**003**	Nov 03, 2004

MIFEPRISTONE

TABLET;ORAL

KORLYM

	+	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012

MIFEPREX

	+	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000

MIGLITOL

TABLET;ORAL

GLYSET

AB	+	PHARMACIA AND UPJOHN	**25MG**	**N020682**	**001**	Dec 18, 1996
AB			**50MG**	**N020682**	**002**	Dec 18, 1996
AB			**100MG**	**N020682**	**003**	Dec 18, 1996

FDA data supplied by DrugPatentWatch.com

MIGLITOL
TABLET;ORAL
MIGLITOL

AB		ORIENT PHARMA CO LTD	**25MG**	**A203965**	**001** Feb 24, 2015
AB			**50MG**	**A203965**	**002** Feb 24, 2015
AB			**100MG**	**A203965**	**003** Feb 24, 2015

MIGLUSTAT
CAPSULE;ORAL
ZAVESCA

	+	ACTELION PHARMS LTD	100MG	N021348	001 Jul 31, 2003

MILNACIPRAN HYDROCHLORIDE
TABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS	**12.5MG**	**A205081**	**001** Apr 22, 2016
AB			**25MG**	**A205081**	**002** Apr 22, 2016
AB			**50MG**	**A205081**	**003** Apr 22, 2016
AB			**100MG**	**A205081**	**004** Apr 22, 2016

SAVELLA

AB		CYPRESS BIOSCIENCE	**12.5MG**	**N022256**	**001** Jan 14, 2009
AB			**25MG**	**N022256**	**002** Jan 14, 2009
AB	**+**		**50MG**	**N022256**	**003** Jan 14, 2009
AB			**100MG**	**N022256**	**004** Jan 14, 2009

MILRINONE LACTATE
INJECTABLE;INJECTION
MILRINONE LACTATE

AP		EUROHLTH INTL SARL	**EQ 1MG BASE/ML**	**A075530**	**001** May 28, 2002
AP			**EQ 1MG BASE/ML**	**A075660**	**001** May 28, 2002
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075936**	**001** May 28, 2002
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A077190**	**001** Oct 31, 2006
AP	**+**	HIKMA FARMACEUTICA	**EQ 1MG BASE/ML**	**A077966**	**001** Dec 03, 2010
AP		HOSPIRA INC	**EQ 1MG BASE/ML**	**A203280**	**001** Sep 03, 2014
AP		INTL MEDICATED	**EQ 1MG BASE/ML**	**A076013**	**001** Aug 02, 2002

MILRINONE LACTATE IN DEXTROSE 5%

AP		CLARIS	**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A077151**	**002** Jul 20, 2005

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075834**	**001** May 28, 2002
AP	**+**		**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075834**	**002** May 28, 2002
AP		EUROHLTH INTL SARL	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A078113**	**001** May 21, 2008
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A078113**	**002** May 21, 2008
AP		HOSPIRA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075885**	**001** May 28, 2002
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075885**	**002** May 28, 2002

MILRINONE LACTATE IN PLASTIC CONTAINER

AP		HIKMA FARMACEUTICA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A090038**	**001** Jan 21, 2010
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A090038**	**002** Jan 21, 2010

MILTEFOSINE
CAPSULE;ORAL
IMPAVIDO

	+	KNIGHT THERAPS	50MG	N204684	001 Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE
CAPSULE;ORAL
DYNACIN

AB		CNTY LINE PHARMS	**EQ 75MG BASE**	**A063067**	**002** Sep 15, 1999
AB			**EQ 100MG BASE**	**A063067**	**001** Jul 31, 1990

MINOCIN

AB		PRECISION DERMAT	**EQ 50MG BASE**	**N050649**	**001** May 31, 1990
AB			**EQ 100MG BASE**	**N050649**	**002** May 31, 1990

MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 50MG BASE**	**A065470**	**001** Mar 11, 2008
AB			**EQ 75MG BASE**	**A065470**	**002** Mar 11, 2008
AB			**EQ 100MG BASE**	**A065470**	**003** Mar 11, 2008
AB		IMPAX LABS	**EQ 50MG BASE**	**A065005**	**001** Mar 23, 1999
AB			**EQ 75MG BASE**	**A065005**	**003** Apr 18, 2001
AB			**EQ 100MG BASE**	**A065005**	**002** Mar 23, 1999
AB		SUN PHARM INDS INC	**EQ 50MG BASE**	**A090867**	**001** May 13, 2013
AB			**EQ 75MG BASE**	**A090867**	**002** May 13, 2013
AB			**EQ 100MG BASE**	**A090867**	**003** May 13, 2013
AB		TORRENT PHARMA INC	**EQ 50MG BASE**	**A065062**	**001** Nov 30, 2000
AB			**EQ 75MG BASE**	**A065062**	**002** Nov 30, 2000
AB			**EQ 100MG BASE**	**A065062**	**003** Nov 30, 2000
AB		WATSON LABS	**EQ 50MG BASE**	**A063181**	**001** Dec 30, 1991

FDA data supplied by DrugPatentWatch.com

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB			**EQ 75MG BASE**	**A063065**	**002**	Jun 10, 1999
AB			**EQ 100MG BASE**	**A063065**	**001**	Dec 30, 1991
AB		ZYDUS WORLDWIDE	**EQ 50MG BASE**	**A063011**	**001**	Mar 02, 1992
AB			**EQ 75MG BASE**	**A063009**	**002**	Aug 12, 2003
AB	**+**		**EQ 100MG BASE**	**A063009**	**001**	Mar 02, 1992

INJECTABLE;INJECTION

MINOCIN

	+	REMPEX PHARMS INC	EQ 100MG BASE/VIAL	N050444	001	

POWDER, EXTENDED RELEASE;DENTAL

ARESTIN

	+	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		DR REDDYS LABS LTD	**EQ 50MG BASE**	**A065436**	**001**	Dec 26, 2007
AB			**EQ 75MG BASE**	**A065436**	**002**	Dec 26, 2007
AB			**EQ 100MG BASE**	**A065436**	**003**	Dec 26, 2007
AB		PAR PHARM	**EQ 50MG BASE**	**A065131**	**001**	Apr 16, 2003
AB			**EQ 75MG BASE**	**A065131**	**002**	Apr 16, 2003
AB	**+**		**EQ 100MG BASE**	**A065131**	**003**	Apr 16, 2003
AB		SUN PHARM INDS	**EQ 50MG BASE**	**A090217**	**001**	Jan 29, 2016
AB			**EQ 75MG BASE**	**A090217**	**002**	Jan 29, 2016
AB			**EQ 100MG BASE**	**A090217**	**003**	Jan 29, 2016
AB		TORRENT PHARMA INC	**EQ 50MG BASE**	**A065156**	**001**	Jan 06, 2004
AB			**EQ 75MG BASE**	**A065156**	**002**	Jan 06, 2004
AB			**EQ 100MG BASE**	**A065156**	**003**	Jan 06, 2004

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		ALKEM LABS LTD	**EQ 45MG BASE**	**A204453**	**001**	Sep 28, 2016
AB			**EQ 80MG BASE**	**A204453**	**002**	Sep 28, 2016
AB			**EQ 90MG BASE**	**A204453**	**003**	Sep 28, 2016
AB			**EQ 105MG BASE**	**A204453**	**004**	Sep 28, 2016
AB			**EQ 135MG BASE**	**A204453**	**005**	Sep 28, 2016
AB		AUROBINDO PHARMA LTD	**EQ 45MG BASE**	**A202261**	**001**	Nov 19, 2012
AB			**EQ 80MG BASE**	**A202261**	**006**	Jun 13, 2016
AB			**EQ 90MG BASE**	**A202261**	**003**	Nov 19, 2012
AB			**EQ 105MG BASE**	**A202261**	**007**	Jun 13, 2016
AB			**EQ 135MG BASE**	**A202261**	**005**	Nov 19, 2012
AB		LUPIN LTD	**EQ 45MG BASE**	**A091424**	**001**	Nov 30, 2011
AB			**EQ 90MG BASE**	**A091424**	**003**	Nov 30, 2011
AB			**EQ 135MG BASE**	**A091424**	**004**	Nov 30, 2011
AB		MYLAN PHARMS INC	**EQ 45MG BASE**	**A090911**	**001**	Jul 20, 2010
AB			**EQ 80MG BASE**	**A203443**	**002**	Aug 22, 2014
AB			**EQ 90MG BASE**	**A090911**	**002**	Jul 20, 2010
AB			**EQ 105MG BASE**	**A203443**	**003**	Aug 22, 2014
AB			**EQ 135MG BASE**	**A090911**	**003**	Jul 20, 2010
AB		SANDOZ	**EQ 45MG BASE**	**A090422**	**001**	Aug 13, 2009
AB			**EQ 90MG BASE**	**A090422**	**002**	Aug 13, 2009
AB	**+**		**EQ 135MG BASE**	**A090422**	**003**	Aug 13, 2009
AB		SIDMAK LABS INDIA	**EQ 45MG BASE**	**A204394**	**001**	Dec 30, 2015
AB			**EQ 80MG BASE**	**A204394**	**004**	Dec 30, 2015
AB			**EQ 105MG BASE**	**A204394**	**005**	Dec 30, 2015
AB			**EQ 135MG BASE**	**A204394**	**007**	Dec 30, 2015
AB		SUN PHARM INDS LTD	**EQ 45MG BASE**	**A091118**	**001**	Sep 25, 2014
AB			**EQ 80MG BASE**	**A091118**	**004**	Sep 25, 2014
AB			**EQ 90MG BASE**	**A091118**	**005**	Sep 25, 2014
AB			**EQ 105MG BASE**	**A091118**	**006**	Sep 25, 2014
AB			**EQ 135MG BASE**	**A091118**	**008**	Sep 25, 2014

SOLODYN

AB		MEDICIS	**EQ 80MG BASE**	**N050808**	**007**	Aug 27, 2010
AB			**EQ 105MG BASE**	**N050808**	**006**	Aug 27, 2010
			EQ 55MG BASE	N050808	008	Aug 27, 2010
			EQ 65MG BASE	N050808	004	Jul 23, 2009
	+		EQ 115MG BASE	N050808	005	Jul 23, 2009

MINOXIDIL
TABLET;ORAL
MINOXIDIL

AB	MUTUAL PHARM	**2.5MG**	**A072708**	**001**	Dec 14, 1995
AB	PAR PHARM	**2.5MG**	**A071826**	**001**	Nov 14, 1988
AB		**10MG**	**A071839**	**001**	Nov 14, 1988
AB	SUN PHARM INDS	**10MG**	**A072709**	**001**	Dec 14, 1995
AB	WATSON LABS	**2.5MG**	**A071344**	**001**	Mar 03, 1987
AB +		**10MG**	**A071345**	**001**	Mar 03, 1987

MIPOMERSEN SODIUM
SOLUTION;SUBCUTANEOUS
KYNAMRO

+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013

MIRABEGRON
TABLET, EXTENDED RELEASE;ORAL
MYRBETRIQ

	APGDI	25MG	N202611	001	Jun 28, 2012
+		50MG	N202611	002	Jun 28, 2012

MIRTAZAPINE
TABLET;ORAL
MIRTAZAPINE

AB	APOTEX INC	**15MG**	**A077666**	**001**	Aug 22, 2007
AB		**30MG**	**A077666**	**002**	Aug 22, 2007
AB		**45MG**	**A077666**	**003**	Aug 22, 2007
AB	AUROBINDO	**7.5MG**	**A076921**	**001**	Oct 22, 2004
AB		**15MG**	**A076921**	**002**	Oct 22, 2004
AB		**30MG**	**A076921**	**003**	Oct 22, 2004
AB		**45MG**	**A076921**	**004**	Oct 22, 2004
AB	MYLAN	**15MG**	**A076122**	**001**	Jun 19, 2003
AB		**30MG**	**A076122**	**002**	Jun 19, 2003
AB		**45MG**	**A076122**	**003**	Jun 19, 2003
AB	MYLAN PHARMS INC	**15MG**	**A076176**	**001**	Jun 19, 2003
AB		**30MG**	**A076176**	**002**	Jun 19, 2003
AB		**45MG**	**A076176**	**003**	Jun 19, 2003
AB	SUN PHARM INDS INC	**7.5MG**	**A076541**	**004**	Apr 22, 2004
AB		**15MG**	**A076541**	**001**	Apr 22, 2004
AB		**30MG**	**A076541**	**002**	Apr 22, 2004
AB		**45MG**	**A076541**	**003**	Apr 22, 2004
AB	TEVA	**15MG**	**A076119**	**001**	Jan 24, 2003
AB		**30MG**	**A076119**	**002**	Jan 24, 2003
AB		**45MG**	**A076119**	**003**	Jun 19, 2003
AB	UPSHER-SMITH LABS	**15MG**	**A076219**	**001**	Jun 19, 2003
AB		**30MG**	**A076219**	**002**	Jun 19, 2003
AB		**45MG**	**A076219**	**003**	Jun 19, 2003
AB	WATSON LABS	**15MG**	**A076312**	**001**	Jun 19, 2003
AB		**30MG**	**A076312**	**002**	Jun 19, 2003
AB		**45MG**	**A076312**	**003**	Jun 19, 2003

REMERON

AB +	ORGANON USA INC	**15MG**	**N020415**	**001**	Jun 14, 1996
AB		**30MG**	**N020415**	**002**	Jun 14, 1996
AB		**45MG**	**N020415**	**003**	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

AB	ACTAVIS LABS FL INC	**15MG**	**A076307**	**001**	Dec 17, 2003
AB		**30MG**	**A076307**	**002**	Dec 17, 2003
AB		**45MG**	**A076307**	**003**	Feb 28, 2006
AB	AUROBINDO PHARMA LTD	**15MG**	**A077376**	**002**	Dec 08, 2005
AB		**30MG**	**A077376**	**003**	Dec 08, 2005
AB		**45MG**	**A077376**	**004**	Feb 28, 2006
AB	IMPAX LABS INC	**15MG**	**A076901**	**001**	Jun 28, 2005
AB		**30MG**	**A076901**	**002**	Jun 28, 2005
AB		**45MG**	**A076901**	**003**	Jun 28, 2005

REMERON SOLTAB

AB +	ORGANON USA INC	**15MG**	**N021208**	**001**	Jan 12, 2001
AB		**30MG**	**N021208**	**002**	Jan 12, 2001
AB		**45MG**	**N021208**	**003**	Jan 12, 2001

MISOPROSTOL
TABLET;ORAL

	CYTOTEC					
AB		GD SEARLE LLC	**0.1MG**	**N019268**	**003**	Sep 21, 1990
AB	**+**		**0.2MG**	**N019268**	**001**	Dec 27, 1988
	MISOPROSTOL					
AB		IVAX SUB TEVA PHARMS	**0.1MG**	**A076095**	**001**	Jul 10, 2002
AB			**0.2MG**	**A076095**	**002**	Jul 10, 2002
AB		NOVEL LABS INC	**0.1MG**	**A091667**	**001**	Jul 25, 2012
AB			**0.2MG**	**A091667**	**002**	Jul 25, 2012

MITOMYCIN
FOR SOLUTION;TOPICAL

	MITOSOL					
	+	MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012

INJECTABLE;INJECTION

	MITOMYCIN					
AP	**+**	ACCORD HLTHCARE	**5MG/VIAL**	**A064144**	**001**	Apr 30, 1998
AP	**+**		**20MG/VIAL**	**A064144**	**002**	Apr 30, 1998
AP	**+**		**40MG/VIAL**	**A064144**	**003**	Aug 11, 2009
AP		EUROHLTH INTL SARL	**5MG/VIAL**	**A064117**	**001**	Apr 19, 1995
AP			**5MG/VIAL**	**A064180**	**001**	Dec 23, 1999
AP			**20MG/VIAL**	**A064117**	**002**	Apr 19, 1995
AP			**20MG/VIAL**	**A064180**	**002**	Dec 23, 1999

MITOTANE
TABLET;ORAL

	LYSODREN					
	+	BRISTOL MYERS SQUIBB	500MG	N016885	001	

MITOXANTRONE HYDROCHLORIDE
INJECTABLE;INJECTION

	MITOXANTRONE HYDROCHLORIDE					
AP		FRESENIUS KABI USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077496**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077496**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077496**	**003**	Apr 11, 2006
AP	**+**	HOSPIRA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076871**	**001**	Apr 11, 2006
AP	**+**		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076871**	**002**	Apr 11, 2006
AP	**+**		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076871**	**003**	Apr 11, 2006
AP		MYLAN INSTITUTIONAL	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A078980**	**001**	Apr 13, 2009
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A078980**	**002**	Apr 13, 2009
AP		MYLAN LABS LTD	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A201014**	**001**	Dec 11, 2012
AP		TEVA PHARMS USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077356**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077356**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077356**	**003**	Apr 11, 2006
AP		WEST-WARD PHARMS INT	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076611**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076611**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076611**	**003**	Apr 11, 2006

MIVACURIUM CHLORIDE
SOLUTION;INTRAVENOUS

	MIVACRON					
		ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992
	+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992

MODAFINIL
TABLET;ORAL

	MODAFINIL					
AB		ALEMBIC LTD	**100MG**	**A202700**	**001**	Oct 18, 2012
AB			**200MG**	**A202700**	**002**	Oct 18, 2012
AB		APOTEX INC	**100MG**	**A077667**	**001**	Feb 03, 2014
AB			**200MG**	**A077667**	**002**	Feb 03, 2014
AB		AUROBINDO PHARMA LTD	**100MG**	**A202566**	**001**	Sep 27, 2012
AB			**200MG**	**A202566**	**002**	Sep 27, 2012
AB		HIKMA PHARMS	**100MG**	**A090543**	**001**	Sep 26, 2012
AB			**200MG**	**A090543**	**002**	Sep 26, 2012
AB		MYLAN PHARMS INC	**100MG**	**A076594**	**001**	Jul 16, 2012
AB			**200MG**	**A076594**	**002**	Jul 16, 2012
AB		ORCHID HLTHCARE	**100MG**	**A078963**	**001**	Sep 26, 2012
AB			**200MG**	**A078963**	**002**	Sep 26, 2012
AB		WATSON LABS INC	**100MG**	**A076715**	**001**	Nov 01, 2012
AB			**200MG**	**A076715**	**002**	Nov 01, 2012
	PROVIGIL					
AB		CEPHALON	**100MG**	**N020717**	**001**	Dec 24, 1998
AB	**+**		**200MG**	**N020717**	**002**	Dec 24, 1998

FDA data supplied by DrugPatentWatch.com

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

	MOEXIPRIL HYDROCHLORIDE				
AB	APOTEX INC	**7.5MG**	**A078454**	**001**	Jun 02, 2008
AB		**15MG**	**A078454**	**002**	Jun 02, 2008
AB	GLENMARK GENERICS	**7.5MG**	**A090416**	**001**	Mar 30, 2010
AB		**15MG**	**A090416**	**002**	Mar 30, 2010
AB	PADDOCK LLC	**7.5MG**	**A077536**	**001**	Nov 30, 2006
AB		**15MG**	**A077536**	**002**	Nov 30, 2006
AB	TEVA	**7.5MG**	**A076204**	**001**	May 08, 2003
AB	**+**	**15MG**	**A076204**	**002**	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

	MOLINDONE HYDROCHLORIDE				
	COREPHARMA	5MG	A090453	001	Mar 20, 2015
		10MG	A090453	002	Mar 20, 2015
	+	25MG	A090453	003	Mar 20, 2015

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

	ASMANEX HFA				
	MERCK SHARP DOHME	0.10MG/INH	N205641	001	Apr 25, 2014
	+	0.20MG/INH	N205641	002	Apr 25, 2014

CREAM;TOPICAL

	ELOCON				
AB	**+** MERCK SHARP DOHME	**0.1%**	**N019625**	**002**	Apr 19, 2013
	MOMETASONE FUROATE				
AB	FOUGERA PHARMS	**0.1%**	**A076171**	**001**	Apr 08, 2005
AB	G AND W LABS	**0.1%**	**A077447**	**001**	May 22, 2006
AB	GLENMARK GENERICS	**0.1%**	**A078541**	**001**	May 28, 2008
AB	TARO	**0.1%**	**A076679**	**001**	Dec 21, 2004
AB	TOLMAR	**0.1%**	**A076591**	**001**	Apr 18, 2007

LOTION;TOPICAL

	ELOCON				
AB	**+** MERCK SHARP DOHME	**0.1%**	**N019796**	**001**	Mar 30, 1989
	MOMETASONE FUROATE				
AB	FOUGERA PHARMS	**0.1%**	**A075919**	**001**	Nov 29, 2007
AB	G AND W LABS	**0.1%**	**A077678**	**001**	Nov 21, 2007
AB	GLENMARK GENERICS	**0.1%**	**A090506**	**001**	Aug 09, 2010
AB	PERRIGO	**0.1%**	**A077180**	**001**	Apr 06, 2005
AB	TARO	**0.1%**	**A076788**	**001**	Mar 15, 2006
AB	TOLMAR	**0.1%**	**A076499**	**001**	Nov 21, 2007

OINTMENT;TOPICAL

	ELOCON				
AB	**+** MERCK SHARP DOHME	**0.1%**	**N019543**	**001**	Apr 30, 1987
	MOMETASONE FUROATE				
AB	FOUGERA PHARMS	**0.1%**	**A077061**	**001**	Mar 28, 2005
AB	G AND W LABS	**0.1%**	**A077401**	**001**	Jun 20, 2006
AB	GLENMARK GENERICS	**0.1%**	**A078571**	**001**	May 28, 2008
AB	PERRIGO NEW YORK	**0.1%**	**A076067**	**001**	Mar 18, 2002
AB	TOLMAR	**0.1%**	**A076481**	**001**	Nov 14, 2003

POWDER;INHALATION

	ASMANEX TWISTHALER				
	MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008
	+	0.22MG/INH	N021067	001	Mar 30, 2005

SPRAY, METERED;NASAL

	MOMETASONE FUROATE				
AB	APOTEX INC	**EQ 0.05MG BASE/SPRAY**	**A091161**	**001**	Mar 22, 2016
	NASONEX				
AB	**+** MERCK SHARP DOHME	**EQ 0.05MG BASE/SPRAY**	**N020762**	**001**	Oct 01, 1997

MONTELUKAST SODIUM

GRANULE;ORAL

	MONTELUKAST SODIUM				
AB	AJANTA PHARMA LTD	**EQ 4MG BASE/PACKET**	**A203438**	**001**	Jul 31, 2015
AB	DR REDDYS LABS LTD	**EQ 4MG BASE/PACKET**	**A202906**	**001**	Sep 17, 2012
AB	MYLAN PHARMS INC	**EQ 4MG BASE/PACKET**	**A202776**	**001**	Dec 18, 2012
AB	TEVA PHARMS	**EQ 4MG BASE/PACKET**	**A090955**	**001**	Aug 03, 2012
	SINGULAIR				
AB	**+** MERCK	**EQ 4MG BASE/PACKET**	**N021409**	**001**	Jul 26, 2002

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	EQ 10MG BASE	A202717 001	Sep 21, 2012
AB		AJANTA PHARMA LTD	EQ 10MG BASE	A203432 001	Jul 31, 2015
AB		AMNEAL PHARMS	EQ 10MG BASE	A204604 001	Sep 04, 2015
AB		ANBISON LAB CO LTD	EQ 10MG BASE	A205683 001	Jan 12, 2016
AB		APOTEX CORP	EQ 10MG BASE	A201294 001	Aug 03, 2012
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A202468 001	Aug 03, 2012
AB		CIPLA LTD	EQ 10MG BASE	A207463 001	Oct 28, 2016
AB		DR REDDYS LABS LTD	EQ 10MG BASE	A201582 001	Aug 06, 2012
AB		GLENMARK GENERICS	EQ 10MG BASE	A090926 001	Aug 03, 2012
AB		HETERO LABS LTD V	EQ 10MG BASE	A202843 001	Sep 10, 2014
AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A201522 001	Aug 03, 2012
AB		MACLEODS PHARMS LTD	EQ 10MG BASE	A203366 001	Sep 11, 2014
AB		MYLAN PHARMS INC	EQ 10MG BASE	A079103 001	Aug 03, 2012
AB		SANDOZ INC	EQ 10MG BASE	A200889 001	Aug 03, 2012
AB		TEVA PHARMS	EQ 10MG BASE	A078605 001	Aug 03, 2012
AB		TORRENT PHARMS LTD	EQ 10MG BASE	A201515 001	Aug 03, 2012
AB		UNICHEM LABS LTD	EQ 10MG BASE	A204290 001	Oct 08, 2015
AB		UNIMARK REMEDIES LTD	EQ 10MG BASE	A202859 001	Oct 30, 2014
AB		VINTAGE PHARMS LLC	EQ 10MG BASE	A091576 001	Aug 03, 2012
AB		WEST-WARD PHARMS INT	EQ 10MG BASE	A090655 001	Aug 03, 2012

SINGULAIR

AB	+	MERCK	EQ 10MG BASE	N020829 002	Feb 20, 1998

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	EQ 4MG BASE	A203328 001	Jul 31, 2015
AB			EQ 5MG BASE	A203328 002	Jul 31, 2015
AB		ANBISON LAB CO LTD	EQ 4MG BASE	A205695 001	Nov 05, 2015
AB			EQ 5MG BASE	A205695 002	Nov 05, 2015
AB		APOTEX INC	EQ 4MG BASE	A201508 001	Aug 03, 2012
AB			EQ 5MG BASE	A201508 002	Aug 03, 2012
AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096 001	Aug 03, 2012
AB			EQ 5MG BASE	A202096 002	Aug 03, 2012
AB		DR REDDYS LABS LTD	EQ 4MG BASE	A201581 001	Aug 06, 2012
AB			EQ 5MG BASE	A201581 002	Aug 06, 2012
AB		HETERO LABS LTD V	EQ 4MG BASE	A204093 001	May 22, 2015
AB			EQ 5MG BASE	A204093 002	May 22, 2015
AB		JUBILANT GENERICS	EQ 4MG BASE	A203795 001	Feb 27, 2015
AB			EQ 5MG BASE	A203795 002	Feb 27, 2015
AB		KREMERS URBAN PHARMS	EQ 4MG BASE	A200405 001	Aug 03, 2012
AB			EQ 5MG BASE	A200405 002	Aug 03, 2012
AB		MACLEODS PHARMS LTD	EQ 4MG BASE	A203582 001	Mar 12, 2015
AB			EQ 5MG BASE	A203582 002	Mar 12, 2015
AB		MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012
AB			EQ 5MG BASE	A079142 002	Aug 03, 2012
AB		SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012
AB			EQ 5MG BASE	A091414 002	Aug 03, 2012
AB		TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012
AB			EQ 5MG BASE	A078723 002	Aug 03, 2012
AB		TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012
AB			EQ 5MG BASE	A090984 002	Aug 03, 2012
AB		UNIMARK REMEDIES LTD	EQ 4MG BASE	A203037 001	Oct 30, 2014
AB			EQ 5MG BASE	A203037 002	Oct 30, 2014
AB		VINTAGE PHARMS LLC	EQ 4MG BASE	A091588 001	Aug 03, 2012
AB			EQ 5MG BASE	A091588 002	Aug 03, 2012
AB		WEST-WARD PHARMS INT	EQ 4MG BASE	A091128 001	Aug 03, 2012
AB			EQ 5MG BASE	A091128 002	Aug 03, 2012

SINGULAIR

AB		MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000
AB	+		EQ 5MG BASE	N020830 001	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

AB	+	ALLERGAN SALES LLC	10MG	N020616 008	Apr 20, 2007
AB			20MG	N020616 001	Jul 03, 1996
AB			30MG	N020616 004	Mar 09, 2001
AB			40MG	N020616 009	Jul 09, 2012
AB			50MG	N020616 002	Jul 03, 1996
AB			60MG	N020616 005	Mar 09, 2001
AB			70MG	N020616 010	Jul 09, 2012

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

	KADIAN					
AB			**80MG**	**N020616**	**006**	Oct 27, 2006
AB	**+**		**100MG**	**N020616**	**003**	Jul 03, 1996
	MORPHINE SULFATE					
AB		IMPAX LABS INC	**20MG**	**A200411**	**001**	Apr 12, 2016
AB			**30MG**	**A200411**	**002**	Apr 12, 2016
AB			**50MG**	**A200411**	**003**	Apr 12, 2016
AB			**60MG**	**A200411**	**004**	Apr 12, 2016
AB			**80MG**	**A200411**	**005**	Apr 12, 2016
AB			**100MG**	**A200411**	**006**	Apr 12, 2016
AB		PAR PHARM INC	**20MG**	**A200812**	**001**	Nov 10, 2011
AB			**30MG**	**A200812**	**002**	Nov 10, 2011
AB			**50MG**	**A200812**	**003**	Nov 10, 2011
AB			**60MG**	**A200812**	**004**	Nov 10, 2011
AB			**80MG**	**A200812**	**005**	Nov 10, 2011
AB			**100MG**	**A200812**	**006**	Nov 10, 2011
AB		TEVA PHARMS USA	**20MG**	**A202718**	**001**	Dec 29, 2014
AB			**30MG**	**A202718**	**002**	Dec 29, 2014
AB			**40MG**	**A202718**	**007**	Jun 03, 2015
AB			**50MG**	**A202718**	**003**	Dec 29, 2014
AB			**60MG**	**A202718**	**004**	Dec 29, 2014
AB			**70MG**	**A202718**	**008**	Jun 03, 2015
AB			**80MG**	**A202718**	**005**	Dec 29, 2014
AB			**100MG**	**A202718**	**006**	Dec 29, 2014
AB		UPSHER SMITH	**10MG**	**A202104**	**001**	Jun 03, 2013
AB			**20MG**	**A202104**	**002**	Jun 03, 2013
AB			**30MG**	**A202104**	**003**	Jun 03, 2013
AB			**50MG**	**A202104**	**004**	Jun 03, 2013
AB			**60MG**	**A202104**	**005**	Jun 03, 2013
AB			**80MG**	**A202104**	**006**	Jun 03, 2013
AB			**100MG**	**A202104**	**007**	Jun 03, 2013
	KADIAN					
		ALLERGAN SALES LLC	130MG	N020616	011	Jul 09, 2012
			150MG	N020616	012	Jul 09, 2012
	+		200MG	N020616	007	Feb 27, 2007
	MORPHINE SULFATE					
		ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
			45MG	A079040	002	Jan 16, 2013
			60MG	A079040	003	Jan 16, 2013
			75MG	A079040	004	Jan 16, 2013
			90MG	A079040	005	Jan 16, 2013
	+		120MG	A079040	006	Jan 16, 2013

INJECTABLE;INJECTION

	ASTRAMORPH PF					
AP		FRESENIUS KABI USA	**0.5MG/ML**	**A071050**	**001**	Oct 07, 1986
AP			**0.5MG/ML**	**A071051**	**001**	Oct 07, 1986
AP			**1MG/ML**	**A071052**	**001**	Oct 07, 1986
AP			**1MG/ML**	**A071053**	**001**	Oct 07, 1986
	DURAMORPH PF					
AP	**+**	WEST-WARD PHARMS INT	**0.5MG/ML**	**N018565**	**001**	Sep 18, 1984
AP	**+**		**1MG/ML**	**N018565**	**002**	Sep 18, 1984
	MORPHINE SULFATE					
AP		EUROHLTH INTL SARL	**4MG/ML**	**A205758**	**001**	May 21, 2015
AP			**8MG/ML**	**A205758**	**002**	May 21, 2015
AP			**10MG/ML**	**A205758**	**003**	May 21, 2015
AP		HOSPIRA	**0.5MG/ML**	**A071849**	**001**	May 11, 1988
AP			**0.5MG/ML**	**A073509**	**001**	Sep 30, 1992
AP			**1MG/ML**	**A071850**	**001**	May 11, 1988
AP			**1MG/ML**	**A073510**	**001**	Sep 30, 1992
AP	**+**		**1MG/ML**	**N019916**	**001**	Oct 30, 1992
AP	**+**	HOSPIRA INC	**4MG/ML**	**N202515**	**002**	Nov 14, 2011
AP	**+**		**8MG/ML**	**N202515**	**003**	Nov 14, 2011
AP	**+**		**10MG/ML**	**N202515**	**004**	Nov 14, 2011
	INFUMORPH					
	+	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991
	+		25MG/ML	N018565	004	Jul 19, 1991
	MORPHINE SULFATE					
	+	HOSPIRA	5MG/ML	N019916	002	Oct 27, 2006
	+	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011
	+		15MG/ML	N202515	005	Nov 14, 2011

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE

INJECTABLE;INJECTION

MORPHINE SULFATE

	+	MERIDIAN MEDCL TECHN	15MG/ML	N019999	001 Jul 12, 1990

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

	+	FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223	001 Oct 30, 2013
	+		4MG/ML (4MG/ML)	N204223	002 Oct 30, 2013
	+		5MG/ML (5MG/ML)	N204223	003 Oct 30, 2013
	+		8MG/ML (8MG/ML)	N204223	004 Oct 30, 2013
	+		10MG/ML (10MG/ML)	N204223	005 Oct 30, 2013

SOLUTION;ORAL

MORPHINE SULFATE

AA		MALLINCKRODT INC	**100MG/5ML**	**A202348**	**001** Jul 15, 2011
AA		NOSTRUM LABS INC	**10MG/5ML**	**A201011**	**001** Feb 05, 2014
AA			**20MG/5ML**	**A201011**	**002** Feb 05, 2014
AA			**100MG/5ML**	**A204053**	**001** Oct 06, 2016
AA		PADDOCK LLC	**100MG/5ML**	**A201574**	**001** Aug 06, 2012
AA		PHARM ASSOC	**100MG/5ML**	**A206573**	**001** Nov 14, 2016
AA		RHODES PHARMS	**20MG/5ML**	**A206420**	**001** Jul 12, 2016
AA		ROXANE	**10MG/5ML**	**N022195**	**001** Mar 17, 2008
AA			**20MG/5ML**	**N022195**	**002** Mar 17, 2008
AA	**+**		**100MG/5ML**	**N022195**	**003** Jan 25, 2010
AA		TRIS PHARMA INC	**10MG/5ML**	**A203518**	**001** May 12, 2015
AA			**20MG/5ML**	**A203519**	**001** May 18, 2016
AA			**100MG/5ML**	**A203518**	**002** May 12, 2015
AA		VINTAGE PHARMS LLC	**10MG/5ML**	**A202309**	**001** Nov 25, 2015
AA			**20MG/5ML**	**A202310**	**001** Oct 30, 2015
AA		VISTAPHARM	**10MG/5ML**	**A201947**	**001** Jan 05, 2012
AA			**20MG/5ML**	**A201947**	**002** Jan 05, 2012
		LANNETT HOLDINGS INC	100MG/5ML	N201517	001 Jun 23, 2011

TABLET;ORAL

MORPHINE SULFATE

		ROXANE	15MG	N022207	001 Mar 17, 2008
	+		30MG	N022207	002 Mar 17, 2008

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	**15MG**	**A203849**	**001** Apr 06, 2015
AB			**30MG**	**A203849**	**002** Apr 06, 2015
AB			**60MG**	**A203849**	**003** Apr 06, 2015
AB			**100MG**	**A203849**	**004** Apr 06, 2015
AB			**200MG**	**A203849**	**005** Apr 06, 2015
AB		COREPHARMA	**15MG**	**A091357**	**001** Jun 23, 2016
AB			**30MG**	**A091357**	**002** Jun 23, 2016
AB			**60MG**	**A091357**	**003** Jun 23, 2016
AB			**100MG**	**A091357**	**004** Jun 23, 2016
AB			**200MG**	**A091357**	**005** Jun 23, 2016
AB		DAVA PHARMS INC	**15MG**	**A075407**	**001** Jan 28, 2000
AB		MALLINCKRODT	**15MG**	**A076412**	**001** Jul 31, 2003
AB			**30MG**	**A076412**	**002** Jul 31, 2003
AB			**60MG**	**A076412**	**003** Jul 31, 2003
AB			**100MG**	**A076438**	**001** Jul 03, 2003
AB			**200MG**	**A076438**	**002** Jul 03, 2003
AB		MAYNE PHARMA INC	**15MG**	**A205386**	**001** Oct 28, 2016
AB			**30MG**	**A205386**	**002** Oct 28, 2016
AB			**60MG**	**A205386**	**003** Oct 28, 2016
AB			**100MG**	**A205386**	**004** Oct 28, 2016
AB		MYLAN PHARMS INC	**15MG**	**A200824**	**001** Oct 18, 2011
AB			**30MG**	**A200824**	**002** Oct 18, 2011
AB			**60MG**	**A200824**	**003** Oct 18, 2011
AB			**100MG**	**A200824**	**004** Oct 18, 2011
AB			**200MG**	**A200824**	**005** Oct 18, 2011
AB		NESHER PHARMS	**15MG**	**A076733**	**001** May 19, 2004
AB			**30MG**	**A076720**	**002** Dec 23, 2005
AB			**60MG**	**A076720**	**001** May 19, 2004
AB			**100MG**	**A077855**	**001** Sep 27, 2007
AB			**200MG**	**A077855**	**002** Sep 27, 2007
AB		NOVEL LABS INC	**15MG**	**A203602**	**001** Dec 16, 2015
AB			**30MG**	**A203602**	**002** Dec 16, 2015
AB			**60MG**	**A203602**	**003** Dec 16, 2015
AB			**100MG**	**A203602**	**004** Dec 16, 2015
AB			**200MG**	**A203602**	**005** Dec 16, 2015

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

	MORPHINE SULFATE				
AB	RHODES PHARMS	**15MG**	**A074862**	**001**	Jul 07, 1998
AB		**30MG**	**A074862**	**002**	Jul 07, 1998
AB		**60MG**	**A074862**	**003**	Jul 07, 1998
AB		**100MG**	**A074769**	**001**	Jul 02, 1998
AB		**200MG**	**A074769**	**002**	Jul 02, 1998
AB	SUN PHARM INDS LTD	**15MG**	**A078761**	**001**	May 11, 2012
AB		**15MG**	**A205634**	**001**	Aug 25, 2016
AB		**30MG**	**A078761**	**002**	May 11, 2012
AB		**30MG**	**A205634**	**002**	Aug 25, 2016
AB		**60MG**	**A078761**	**003**	May 11, 2012
AB		**60MG**	**A205634**	**003**	Aug 25, 2016
AB		**100MG**	**A078761**	**004**	May 11, 2012
AB		**100MG**	**A205634**	**004**	Aug 25, 2016
AB		**200MG**	**A078761**	**005**	May 11, 2012
AB		**200MG**	**A205634**	**005**	Aug 25, 2016
AB	VINTAGE PHARMS LLC	**15MG**	**A075295**	**001**	Oct 28, 1998
AB		**30MG**	**A075295**	**002**	Oct 28, 1998
AB		**60MG**	**A075295**	**003**	Oct 28, 1998
AB		**100MG**	**A075295**	**004**	Sep 15, 2000
AB		**200MG**	**A075295**	**005**	Sep 15, 2000
	MS CONTIN				
AB	PURDUE PHARMA LP	**15MG**	**N019516**	**003**	Sep 12, 1989
AB		**30MG**	**N019516**	**001**	May 29, 1987
AB		**60MG**	**N019516**	**002**	Apr 08, 1988
AB	**+**	**100MG**	**N019516**	**004**	Jan 16, 1990
AB		**200MG**	**N019516**	**005**	Nov 08, 1993
	MORPHABOND				
	DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015
		30MG	N206544	002	Oct 02, 2015
		60MG	N206544	003	Oct 02, 2015
	+	100MG	N206544	004	Oct 02, 2015

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

	EMBEDA				
	ALPHARMA PHARMS	20MG;0.8MG	N022321	001	Aug 13, 2009
		30MG;1.2MG	N022321	002	Aug 13, 2009
		50MG;2MG	N022321	003	Aug 13, 2009
	+	60MG;2.4MG	N022321	004	Aug 13, 2009
		80MG;3.2MG	N022321	005	Aug 13, 2009
		100MG;4MG	N022321	006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER				
	+ BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001
	MOXIFLOXACIN HYDROCHLORIDE				
	+ FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015

SOLUTION/DROPS;OPHTHALMIC

	MOXIFLOXACIN HYDROCHLORIDE				
AT1	LUPIN LTD	**EQ 0.5% BASE**	**A202867**	**001**	Sep 04, 2014
AT1	WATSON LABS INC	**EQ 0.5% BASE**	**A202525**	**001**	Mar 06, 2015
	VIGAMOX				
AT1	**+** NOVARTIS PHARMS CORP	**EQ 0.5% BASE**	**N021598**	**001**	Apr 15, 2003
	MOXEZA				
AT2	**+** NOVARTIS PHARMS CORP	**EQ 0.5% BASE**	**N022428**	**001**	Nov 19, 2010
	MOXIFLOXACIN HYDROCHLORIDE				
AT2	LUPIN LTD	**EQ 0.5% BASE**	**A204079**	**001**	May 28, 2015

TABLET;ORAL

	AVELOX				
AB	**+** BAYER HLTHCARE	**EQ 400MG BASE**	**N021085**	**001**	Dec 10, 1999
	MOXIFLOXACIN HYDROCHLORIDE				
AB	AUROBINDO PHARMA LTD	**EQ 400MG BASE**	**A202632**	**001**	Mar 04, 2014
AB	CROSSMEDIKA SA	**EQ 400MG BASE**	**A205348**	**001**	Jan 14, 2016
AB	DR REDDYS LABS LTD	**EQ 400MG BASE**	**A076938**	**001**	Mar 04, 2014
AB	MYLAN PHARMS INC	**EQ 400MG BASE**	**A204635**	**001**	Aug 31, 2015
AB	TEVA PHARMS USA	**EQ 400MG BASE**	**A077437**	**001**	Feb 18, 2014
AB	TORRENT PHARMS LTD	**EQ 400MG BASE**	**A200160**	**001**	Apr 03, 2014

MUPIROCIN
OINTMENT;TOPICAL

	BACTROBAN				
AB	+ GLAXOSMITHKLINE	**2%**	**N050591**	**001**	Dec 31, 1987
	MUPIROCIN				
AB	FOUGERA PHARMS	**2%**	**A065192**	**001**	Nov 30, 2005
AB	GLENMARK PHARMS	**2%**	**A090480**	**001**	Jun 08, 2011
AB	PERRIGO NEW YORK	**2%**	**A065123**	**001**	Nov 07, 2003
AB	TARO	**2%**	**A065170**	**001**	Sep 23, 2005
AB	TEVA	**2%**	**A065085**	**001**	Nov 07, 2003
	CENTANY				
BX	PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002

MUPIROCIN CALCIUM
CREAM;TOPICAL

	BACTROBAN				
AB	+ GLAXOSMITHKLINE	**EQ 2% BASE**	**N050746**	**001**	Dec 11, 1997
	MUPIROCIN				
AB	GLENMARK GENERICS	**EQ 2% BASE**	**A201587**	**001**	Jan 24, 2013

OINTMENT;NASAL

	BACTROBAN				
	+ GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995

MYCOPHENOLATE MOFETIL
CAPSULE;ORAL

	CELLCEPT				
AB	+ ROCHE PALO	**250MG**	**N050722**	**001**	May 03, 1995
	MYCOPHENOLATE MOFETIL				
AB	ACCORD HLTHCARE	**250MG**	**A090253**	**001**	May 04, 2009
AB	ALKEM LABS LTD	**250MG**	**A200197**	**001**	Jun 13, 2013
AB	APOTEX CORP	**250MG**	**A090419**	**001**	Apr 22, 2009
AB	JUBILANT CADISTA	**250MG**	**A090762**	**001**	Dec 15, 2014
AB	MYLAN	**250MG**	**A065520**	**001**	May 04, 2009
AB	SANDOZ	**250MG**	**A065379**	**001**	Oct 15, 2008
AB	STRIDES PHARMA	**250MG**	**A090055**	**001**	Jun 10, 2010
AB	TEVA PHARMS	**250MG**	**A065491**	**001**	May 06, 2009
AB	VINTAGE PHARMS LLC	**250MG**	**A090111**	**001**	Dec 22, 2009
AB	WEST-WARD PHARMS INT	**250MG**	**A065410**	**001**	Jul 29, 2008

SUSPENSION;ORAL

	CELLCEPT				
AB	+ ROCHE PALO	**200MG/ML**	**N050759**	**001**	Oct 01, 1998
	MYCOPHENOLATE MOFETIL				
AB	ALKEM LABS LTD	**200MG/ML**	**A203005**	**001**	Nov 14, 2014

TABLET;ORAL

	CELLCEPT				
AB	+ ROCHE PALO	**500MG**	**N050723**	**001**	Jun 19, 1997
	MYCOPHENOLATE MOFETIL				
AB	ACCORD HLTHCARE	**500MG**	**A065416**	**001**	May 04, 2009
AB	ALKEM LABS LTD	**500MG**	**A091249**	**001**	Nov 04, 2011
AB	APOTEX	**500MG**	**A090499**	**001**	Apr 22, 2009
AB	JUBILANT CADISTA	**500MG**	**A090661**	**001**	Dec 15, 2014
AB	MYLAN	**500MG**	**A065521**	**001**	May 04, 2009
AB	SANDOZ	**500MG**	**A065451**	**001**	Oct 15, 2008
AB	STRIDES PHARMA	**500MG**	**A090456**	**001**	Jun 10, 2010
AB	TEVA PHARMS	**500MG**	**A065457**	**001**	May 04, 2009
AB	VINTAGE PHARMS LLC	**500MG**	**A090606**	**001**	Jul 16, 2010
AB	WEST-WARD PHARMS INT	**500MG**	**A065413**	**001**	Jul 29, 2008

MYCOPHENOLATE MOFETIL HYDROCHLORIDE
INJECTABLE;INJECTION

	CELLCEPT				
AP	+ ROCHE PALO	**500MG/VIAL**	**N050758**	**001**	Aug 12, 1998
	MYCOPHENOLATE MOFETIL HYDROCHLORIDE				
AP	PAR STERILE PRODUCTS	**500MG/VIAL**	**A203575**	**001**	Oct 28, 2016

MYCOPHENOLIC ACID
TABLET, DELAYED RELEASE;ORAL

	MYCOPHENOLIC ACID				
AB	APOTEX INC	**180MG**	**A091558**	**001**	Aug 21, 2012
AB		**360MG**	**A091558**	**002**	Aug 19, 2014
AB	MYLAN PHARMS INC	**180MG**	**A091248**	**002**	Jan 08, 2014
AB		**360MG**	**A091248**	**001**	Jan 08, 2014
AB	TEVA PHARMS USA	**180MG**	**A202720**	**001**	Oct 30, 2014
AB		**360MG**	**A202720**	**002**	Oct 30, 2014

MYCOPHENOLIC ACID
TABLET, DELAYED RELEASE;ORAL
MYFORTIC

AB		NOVARTIS	**180MG**	**N050791**	**001** Feb 27, 2004
AB	**+**		**360MG**	**N050791**	**002** Feb 27, 2004

NABILONE
CAPSULE;ORAL
CESAMET

	+	MEDA PHARMS	1MG	N018677	001 Dec 26, 1985

NABUMETONE
TABLET;ORAL
NABUMETONE

AB		APOTEX INC	**500MG**	**A090427**	**001** Dec 30, 2011
AB			**750MG**	**A090427**	**002** Dec 30, 2011
AB		CHARTWELL MOLECULES	**500MG**	**A076009**	**001** Jan 24, 2003
AB			**750MG**	**A076009**	**002** Jan 24, 2003
AB		IMPAX LABS INC	**500MG**	**A075189**	**001** May 26, 2000
AB	**+**		**750MG**	**A075189**	**002** Sep 24, 2001
AB		INVAGEN PHARMS	**500MG**	**A078671**	**001** Mar 07, 2008
AB			**750MG**	**A078671**	**002** Mar 07, 2008
AB		LUPIN LTD	**500MG**	**A090445**	**001** Jan 12, 2011
AB			**750MG**	**A090445**	**002** Jan 12, 2011
AB		MYLAN PHARMS INC	**500MG**	**A090516**	**001** Jul 12, 2010
AB			**750MG**	**A090516**	**002** Jul 12, 2010
AB		SANDOZ	**500MG**	**A075280**	**001** Feb 25, 2002
AB			**750MG**	**A075280**	**002** Feb 25, 2002
AB		WATSON LABS	**500MG**	**A091083**	**001** Jun 13, 2011
AB			**750MG**	**A091083**	**002** Jun 13, 2011

NADOLOL
TABLET;ORAL
CORGARD

AB		US WORLDMEDS LLC	**20MG**	**N018063**	**005** Oct 28, 1986
AB			**40MG**	**N018063**	**001**
AB	**+**		**80MG**	**N018063**	**002**

NADOLOL

AB		INVAGEN PHARMS	**20MG**	**A203455**	**001** Dec 18, 2015
AB			**40MG**	**A203455**	**002** Dec 18, 2015
AB			**80MG**	**A203455**	**003** Dec 18, 2015
AB		IVAX SUB TEVA PHARMS	**20MG**	**A074229**	**001** Aug 30, 1996
AB			**40MG**	**A074229**	**002** Aug 30, 1996
AB			**80MG**	**A074255**	**001** Jan 24, 1996
AB		MYLAN	**20MG**	**A074172**	**001** Oct 31, 1993
AB			**40MG**	**A074172**	**002** Oct 31, 1993
AB			**80MG**	**A074172**	**003** Oct 31, 1993
AB		ORION CORP ORION	**40MG**	**A201893**	**001** Sep 16, 2015
AB			**80MG**	**A201893**	**002** Sep 16, 2015
AB		SANDOZ	**20MG**	**A074501**	**001** Nov 09, 1995
AB			**40MG**	**A074501**	**002** Nov 09, 1995
AB			**80MG**	**A074501**	**003** Nov 09, 1995

NAFARELIN ACETATE
SPRAY, METERED;NASAL
SYNAREL

	+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001 Feb 13, 1990

NAFCILLIN SODIUM
INJECTABLE;INJECTION
NAFCILLIN SODIUM

AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL**	**A090560**	**001** Oct 03, 2011
AP			**EQ 2GM BASE/VIAL**	**A090560**	**002** Oct 03, 2011
AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A091613**	**001** Dec 26, 2012
AP			**EQ 2GM BASE/VIAL**	**A091613**	**002** Dec 26, 2012
AP			**EQ 10GM BASE/VIAL**	**A091614**	**001** Dec 26, 2012
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL**	**A090002**	**001** Jun 30, 2011
AP			**EQ 2GM BASE/VIAL**	**A090002**	**002** Jun 30, 2011
AP			**EQ 10GM BASE/VIAL**	**A090005**	**001** Apr 20, 2011
AP		MYLAN LABS LTD	**EQ 1GM BASE/VIAL**	**A200002**	**001** Apr 07, 2014
AP			**EQ 2GM BASE/VIAL**	**A200002**	**002** Apr 07, 2014
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A090582**	**001** Aug 24, 2012
AP			**EQ 2GM BASE/VIAL**	**A090582**	**002** Aug 24, 2012
AP			**EQ 10GM BASE/VIAL**	**A090580**	**001** Aug 24, 2012
AP	**+**	SANDOZ	**EQ 1GM BASE/VIAL**	**A062527**	**002** Aug 02, 1984

NAFCILLIN SODIUM
INJECTABLE;INJECTION
NAFCILLIN SODIUM

AP	**+**		**EQ 1GM BASE/VIAL**	**A062732**	**001** Dec 23, 1986
AP	**+**		**EQ 2GM BASE/VIAL**	**A062527**	**003** Aug 02, 1984
AP	**+**		**EQ 2GM BASE/VIAL**	**A062732**	**002** Dec 23, 1986
AP	**+**		**EQ 10GM BASE/VIAL**	**A062527**	**004** Aug 02, 1984
NALLPEN IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001 Oct 31, 1989
	+		EQ 2GM BASE/100ML	N050655	002 Oct 31, 1989

NAFTIFINE HYDROCHLORIDE
CREAM;TOPICAL
NAFTIFINE HYDROCHLORIDE

AB		TARO	**1%**	**A205975**	**001** Sep 08, 2016
AB			**2%**	**A206901**	**001** Jan 06, 2016
NAFTIN					
AB	**+**	SEBELA IRELAND LTD	**1%**	**N019599**	**001** Feb 29, 1988
AB	**+**		**2%**	**N019599**	**002** Jan 13, 2012
GEL;TOPICAL					
NAFTIN					
	+	SEBELA IRELAND LTD	1%	N019356	001 Jun 18, 1990
	+		2%	N204286	001 Jun 27, 2013

NALBUPHINE HYDROCHLORIDE
INJECTABLE;INJECTION
NALBUPHINE HYDROCHLORIDE

AP	**+**	HOSPIRA	**10MG/ML**	**A070914**	**001** Feb 03, 1989
AP	**+**		**10MG/ML**	**A070915**	**001** Feb 03, 1989
AP	**+**		**20MG/ML**	**A070916**	**001** Feb 03, 1989
AP	**+**		**20MG/ML**	**A070918**	**001** Feb 03, 1989

NALOXEGOL OXALATE
TABLET;ORAL
MOVANTIK

		ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760	001 Sep 16, 2014
	+		EQ 25MG BASE	N204760	002 Sep 16, 2014

NALOXONE HYDROCHLORIDE
INJECTABLE;INJECTION
NALOXONE

AP		WEST-WARD PHARMS INT	**0.4MG/ML**	**A070299**	**001** Sep 24, 1986
NALOXONE HYDROCHLORIDE					
AP	**+**	HOSPIRA	**0.4MG/ML**	**A070172**	**001** Sep 24, 1986
AP	**+**		**0.4MG/ML**	**A070254**	**001** Jan 07, 1987
AP	**+**		**0.4MG/ML**	**A070256**	**001** Jan 07, 1987
AP	**+**		**0.4MG/ML**	**A070257**	**001** Jan 07, 1987
AP		INTL MEDICATION	**0.4MG/ML**	**A070639**	**001** Sep 24, 1986
AP	**+**		**1MG/ML**	**A072076**	**001** Mar 24, 1988
AP		MYLAN INSTITUTIONAL	**0.4MG/ML**	**A204997**	**001** Mar 06, 2014
AP			**0.4MG/ML**	**A205014**	**001** Jun 29, 2016
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
EVZIO					
	+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001 Apr 03, 2014
	+		2MG/0.4ML (2MG/0.4ML)	N209862	001 Oct 19, 2016
SPRAY, METERED;NASAL					
NARCAN					
	+	ADAPT	4MG/SPRAY	N208411	001 Nov 18, 2015

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
TABLET;ORAL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		GAVIS PHARMS	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075735**	**001** Jul 11, 2001
AB		SUN PHARM INDS LTD	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075523**	**001** Mar 17, 2000
AB	**+**	WATSON LABS	**EQ 0.5MG BASE;EQ 50MG BASE**	**A074736**	**001** Jan 21, 1997

NALTREXONE
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
VIVITROL

	+	ALKERMES	380MG/VIAL	N021897	001 Apr 13, 2006

FDA data supplied by DrugPatentWatch.com

NALTREXONE HYDROCHLORIDE
TABLET;ORAL
NALTREXONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A091205**	**001**	Aug 17, 2011
AB		BARR	**50MG**	**A074918**	**001**	May 08, 1998
AB		ELITE LABS	**50MG**	**A075274**	**001**	May 26, 1999
AB	+	MALLINCKRODT	**50MG**	**A076264**	**002**	Mar 22, 2002
AB		SUN PHARMA GLOBAL	**50MG**	**A090356**	**001**	Feb 24, 2012
		MALLINCKRODT	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
TROXYCA ER

	PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016
		2.4MG;20MG	N207621	002	Aug 19, 2016
		3.6MG;30MG	N207621	003	Aug 19, 2016
		4.8MG;40MG	N207621	004	Aug 19, 2016
		7.2MG;60MG	N207621	005	Aug 19, 2016
		9.6MG;80MG	N207621	006	Aug 19, 2016

NANDROLONE DECANOATE
INJECTABLE;INJECTION
NANDROLONE DECANOATE

+	PHARMAFORCE	200MG/ML	A091252	001	Aug 30, 2010

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
NAPHAZOLINE HYDROCHLORIDE

+	AKORN INC	0.1%	A083590	001	

NAPROXEN
SUSPENSION;ORAL
NAPROSYN

AB	+	ATNAHS PHARMA US	**25MG/ML**	**N018965**	**001**	Mar 23, 1987

NAPROXEN

AB		WEST-WARD PHARMS INT	**25MG/ML**	**A074190**	**001**	Mar 30, 1994

TABLET;ORAL
NAPROSYN

AB		ATNAHS PHARMA US	**250MG**	**N017581**	**002**	
AB			**375MG**	**N017581**	**003**	
AB	+		**500MG**	**N017581**	**004**	Apr 15, 1982

NAPROXEN

AB		AMNEAL PHARMS NY	**250MG**	**A075927**	**001**	Dec 18, 2001
AB			**375MG**	**A075927**	**002**	Dec 18, 2001
AB			**500MG**	**A075927**	**003**	Dec 18, 2001
AB		AUROBINDO PHARMA USA	**250MG**	**A200429**	**001**	Nov 08, 2011
AB			**375MG**	**A200429**	**002**	Nov 08, 2011
AB			**500MG**	**A200429**	**003**	Nov 08, 2011
AB		GLENMARK GENERICS	**250MG**	**A078250**	**001**	Mar 28, 2007
AB			**375MG**	**A078250**	**002**	Mar 28, 2007
AB			**500MG**	**A078250**	**003**	Mar 28, 2007
AB		HIKMA INTL PHARMS	**250MG**	**A076494**	**001**	Jan 14, 2004
AB			**375MG**	**A076494**	**002**	Jan 14, 2004
AB			**500MG**	**A076494**	**003**	Jan 14, 2004
AB		INVAGEN PHARMS	**250MG**	**A091305**	**001**	Aug 24, 2011
AB			**375MG**	**A091305**	**002**	Aug 24, 2011
AB			**500MG**	**A091305**	**003**	Aug 24, 2011
AB		MARKSANS PHARMA	**250MG**	**A091416**	**001**	Feb 14, 2011
AB			**375MG**	**A091416**	**002**	Feb 14, 2011
AB			**500MG**	**A091416**	**003**	Feb 14, 2011
AB		MYLAN	**250MG**	**A074121**	**001**	Dec 21, 1993
AB			**375MG**	**A074121**	**002**	Dec 21, 1993
AB			**500MG**	**A074121**	**003**	Dec 21, 1993
AB		PERRIGO R AND D	**250MG**	**A077339**	**001**	Apr 27, 2005
AB			**375MG**	**A077339**	**002**	Apr 27, 2005
AB			**500MG**	**A077339**	**003**	Apr 27, 2005
AB		TEVA	**250MG**	**A074201**	**001**	Dec 21, 1993
AB			**375MG**	**A074201**	**002**	Dec 21, 1993
AB			**500MG**	**A074201**	**003**	Dec 21, 1993
AB		ZYDUS PHARMS USA	**250MG**	**A078620**	**001**	Jun 07, 2007
AB			**375MG**	**A078620**	**002**	Jun 07, 2007
AB			**500MG**	**A078620**	**003**	Jun 07, 2007

FDA data supplied by DrugPatentWatch.com

NAPROXEN

TABLET, DELAYED RELEASE;ORAL

	EC-NAPROSYN					
AB	+	ATNAHS PHARMA US	**375MG**	**N020067**	**002**	Oct 14, 1994
AB	+		**500MG**	**N020067**	**003**	Oct 14, 1994
	NAPROXEN					
AB		INVAGEN PHARMS	**375MG**	**A091432**	**001**	Sep 19, 2011
AB			**500MG**	**A091432**	**002**	Sep 19, 2011
AB		MYLAN PHARMS INC	**375MG**	**A075390**	**001**	Apr 19, 2001
AB			**500MG**	**A075390**	**002**	Apr 19, 2001
AB		PLIVA	**375MG**	**A075337**	**001**	May 26, 1999
AB			**500MG**	**A075337**	**002**	May 26, 1999
AB		TEVA	**375MG**	**A075227**	**001**	Jun 30, 1998
AB			**500MG**	**A075227**	**002**	Jun 30, 1998

NAPROXEN SODIUM

TABLET;ORAL

	ANAPROX					
AB		ATNAHS PHARMA US	**EQ 250MG BASE**	**N018164**	**001**	
	ANAPROX DS					
AB	+	ATNAHS PHARMA US	**EQ 500MG BASE**	**N018164**	**003**	Sep 30, 1987
	NAPROXEN SODIUM					
AB		AMNEAL PHARMS NY	**EQ 250MG BASE**	**A078432**	**001**	Apr 25, 2007
AB			**EQ 500MG BASE**	**A078432**	**002**	Apr 25, 2007
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A200629**	**001**	Oct 31, 2011
AB			**EQ 500MG BASE**	**A200629**	**002**	Oct 31, 2011
AB		DR REDDYS LABS LTD	**EQ 250MG BASE**	**A078486**	**001**	Jul 26, 2007
AB			**EQ 500MG BASE**	**A078486**	**002**	Jul 26, 2007
AB		GLENMARK GENERICS	**EQ 250MG BASE**	**A078314**	**001**	Apr 27, 2007
AB			**EQ 500MG BASE**	**A078314**	**002**	Apr 27, 2007
AB		TEVA	**EQ 250MG BASE**	**A074198**	**001**	Dec 21, 1993
AB			**EQ 500MG BASE**	**A074198**	**002**	Dec 21, 1993

TABLET, EXTENDED RELEASE;ORAL

	NAPRELAN					
AB		ALVOGEN MALTA	**EQ 375MG BASE**	**N020353**	**001**	Jan 05, 1996
AB			**EQ 500MG BASE**	**N020353**	**002**	Jan 05, 1996
AB	+		**EQ 750MG BASE**	**N020353**	**003**	Jan 05, 1996
	NAPROXEN SODIUM					
AB		ACTAVIS LABS FL INC	**EQ 375MG BASE**	**A075416**	**002**	Apr 23, 2003
AB			**EQ 500MG BASE**	**A075416**	**001**	Aug 27, 2002
AB			**EQ 750MG BASE**	**A075416**	**003**	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

	TREXIMET					
		PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015
	+		500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

	AMERGE					
AB		GLAXOSMITHKLINE LLC	**EQ 1MG BASE**	**N020763**	**002**	Feb 10, 1998
AB	+		**EQ 2.5MG BASE**	**N020763**	**001**	Feb 10, 1998
	NARATRIPTAN					
AB		APOTEX CORP	**EQ 1MG BASE**	**A091373**	**001**	Apr 22, 2011
AB			**EQ 2.5MG BASE**	**A091373**	**002**	Apr 22, 2011
AB		HERITAGE PHARMS INC	**EQ 1MG BASE**	**A200502**	**001**	Feb 28, 2011
AB			**EQ 2.5MG BASE**	**A200502**	**002**	Feb 28, 2011
AB		MYLAN PHARMS INC	**EQ 1MG BASE**	**A202431**	**001**	May 31, 2012
AB			**EQ 2.5MG BASE**	**A202431**	**002**	May 31, 2012
AB		ORCHID HLTHCARE	**EQ 1MG BASE**	**A091441**	**001**	Apr 30, 2012
AB			**EQ 2.5MG BASE**	**A091441**	**002**	Apr 30, 2012
AB		PADDOCK LLC	**EQ 1MG BASE**	**A091326**	**001**	Jul 08, 2010
AB			**EQ 2.5MG BASE**	**A091326**	**002**	Jul 08, 2010
AB		SANDOZ	**EQ 1MG BASE**	**A090288**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A090288**	**002**	Jul 07, 2010
AB		SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A091552**	**001**	Feb 14, 2011
AB		TEVA PHARMS	**EQ 1MG BASE**	**A078751**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A078751**	**002**	Jul 07, 2010
AB		WEST-WARD PHARMS INT	**EQ 1MG BASE**	**A090381**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A090381**	**002**	Jul 07, 2010

NATAMYCIN
SUSPENSION;OPHTHALMIC
NATACYN

+	ALCON	5%	N050514	001	

NATEGLINIDE
TABLET;ORAL
NATEGLINIDE

AB	ALVOGEN MALTA	**60MG**	**A205055**	**001**	Dec 11, 2015
AB		**120MG**	**A205055**	**002**	Dec 11, 2015
AB	DR REDDYS LABS LTD	**60MG**	**A077461**	**001**	Sep 09, 2009
AB		**120MG**	**A077461**	**002**	Sep 09, 2009
AB	PAR PHARM	**60MG**	**A077463**	**001**	Sep 09, 2009
AB		**120MG**	**A077463**	**002**	Sep 09, 2009
AB	WATSON LABS	**60MG**	**A077462**	**001**	Mar 30, 2011
AB		**120MG**	**A077462**	**002**	Mar 30, 2011
AB	ZYDUS PHARMS USA INC	**60MG**	**A205248**	**001**	Jul 06, 2016
AB		**120MG**	**A205248**	**002**	Jul 06, 2016

STARLIX

AB	NOVARTIS	**60MG**	**N021204**	**001**	Dec 22, 2000
AB +		**120MG**	**N021204**	**002**	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE
TABLET;ORAL
BYSTOLIC

	FOREST LABS	EQ 2.5MG BASE	N021742	002	Dec 17, 2007
		EQ 5MG BASE	N021742	003	Dec 17, 2007
		EQ 10MG BASE	N021742	004	Dec 17, 2007
+		EQ 20MG BASE	N021742	005	Oct 08, 2008

NEBIVOLOL HYDROCHLORIDE; VALSARTAN
TABLET;ORAL
BYVALSON

	FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016

NEDOCROMIL SODIUM
SOLUTION/DROPS;OPHTHALMIC
ALOCRIL

AT +	ALLERGAN	**2%**	**N021009**	**001**	Dec 08, 1999

NEDOCROMIL SODIUM

AT	AKORN	**2%**	**A090638**	**001**	Aug 22, 2012

NEFAZODONE HYDROCHLORIDE
TABLET;ORAL
NEFAZODONE HYDROCHLORIDE

AB	TEVA	**50MG**	**A076037**	**001**	Sep 16, 2003
AB		**100MG**	**A076037**	**002**	Sep 16, 2003
AB		**150MG**	**A076037**	**003**	Sep 16, 2003
AB		**200MG**	**A076037**	**004**	Sep 16, 2003
AB +		**250MG**	**A076037**	**005**	Sep 16, 2003
BX	DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003
BX		100MG	A076309	002	Sep 16, 2003
BX		150MG	A076309	003	Sep 16, 2003
BX		200MG	A076309	004	Sep 16, 2003
BX		250MG	A076309	005	Sep 16, 2003

NELARABINE
INJECTABLE;IV (INFUSION)
ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005

NELFINAVIR MESYLATE
TABLET;ORAL
VIRACEPT

+	AGOURON	EQ 250MG BASE	N020779	001	Mar 14, 1997
+		EQ 625MG BASE	N021503	001	Apr 30, 2003

NEOMYCIN SULFATE
SOLUTION;ORAL
NEO-FRADIN

+	X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010	001	May 23, 2002

TABLET;ORAL
NEOMYCIN SULFATE

AA	LANNETT HOLDINGS INC	**500MG**	**A204435**	**001**	Jun 10, 2016
AA	OMAN PHARM PRODUCTS	**500MG**	**A065468**	**001**	Mar 29, 2010
AA +	TEVA	**500MG**	**A060304**	**001**	

FDA data supplied by DrugPatentWatch.com

NEOMYCIN SULFATE
TABLET;ORAL
NEOMYCIN SULFATE

AA		X GEN PHARMS	**500MG**	**A065220**	**001** Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION;IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A062664**	**001** Apr 08, 1986
AT		X GEN PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065106**	**001** Jan 31, 2006
AT			**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065108**	**001** Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	**+**	MONARCH PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A060707**	**001**

NEOSTIGMINE METHYLSULFATE
SOLUTION;INTRAVENOUS
BLOXIVERZ

AP	**+**	ECLAT PHARMS LLC	**5MG/10ML (0.5MG/ML)**	**N204078**	**001** May 31, 2013
AP	**+**		**10MG/10ML (1MG/ML)**	**N204078**	**002** May 31, 2013

NEOSTIGMINE METHYLSULFATE

AP		EUROHLTH INTL SARL	**5MG/10ML (0.5MG/ML)**	**A207042**	**001** Dec 28, 2015
AP			**10MG/10ML (1MG/ML)**	**A207042**	**002** Dec 28, 2015
		FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001 Jan 08, 2015
			10MG/10ML (1MG/ML)	N203629	002 Jan 08, 2015

NEPAFENAC
SUSPENSION/DROPS;OPHTHALMIC
ILEVRO

	+	NOVARTIS PHARMS CORP	0.3%	N203491	001 Oct 16, 2012

NEVANAC

	+	NOVARTIS PHARMS CORP	0.1%	N021862	001 Aug 19, 2005

NESIRITIDE RECOMBINANT
FOR SOLUTION;INTRAVENOUS
NATRECOR

	+	SCIOS LLC	1.5MG/VIAL	N020920	001 Aug 10, 2001

NETUPITANT; PALONOSETRON HYDROCHLORIDE
CAPSULE;ORAL
AKYNZEO

	+	HELSINN HLTHCARE	300MG;EQ 0.5MG BASE	N205718	001 Oct 10, 2014

NEVIRAPINE
SUSPENSION;ORAL
NEVIRAPINE

AA		AUROBINDO	**50MG/5ML**	**A077702**	**001** May 22, 2012

VIRAMUNE

AA	**+**	BOEHRINGER INGELHEIM	**50MG/5ML**	**N020933**	**001** Sep 11, 1998

TABLET;ORAL
NEVIRAPINE

AB		APOTEX INC	**200MG**	**A203021**	**001** May 22, 2012
AB		AUROBINDO	**200MG**	**A077521**	**001** May 22, 2012
AB		CIPLA	**200MG**	**A077956**	**001** May 22, 2012
AB		HETERO LABS LTD III	**200MG**	**A078584**	**001** May 22, 2012
AB		MICRO LABS LTD	**200MG**	**A203080**	**001** May 22, 2012
AB		MYLAN LABS	**200MG**	**A078864**	**001** May 22, 2012
AB		MYLAN PHARMS INC	**200MG**	**A202523**	**001** May 22, 2012
AB		PRINSTON INC	**200MG**	**A078644**	**001** May 22, 2012
AB		SCIEGEN PHARMS INC	**200MG**	**A203176**	**001** May 22, 2012
AB		STRIDES PHARMA	**200MG**	**A078195**	**001** May 22, 2012

VIRAMUNE

AB	**+**	BOEHRINGER INGELHEIM	**200MG**	**N020636**	**001** Jun 21, 1996

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

AB		ALVOGEN MALTA	**100MG**	**A204621**	**002** Nov 09, 2015
AB			**400MG**	**A204621**	**001** Jul 10, 2015
AB		APOTEX INC	**400MG**	**A205258**	**001** Apr 03, 2014
AB		AUROBINDO PHARMA LTD	**100MG**	**A208616**	**001** Nov 23, 2016
AB		CIPLA LTD	**400MG**	**A206448**	**001** Oct 15, 2015
AB		MYLAN PHARMS INC	**100MG**	**A206271**	**001** Nov 09, 2015
AB			**400MG**	**A205651**	**001** Oct 27, 2014
AB		SANDOZ INC	**400MG**	**A203411**	**001** Apr 03, 2014

VIRAMUNE XR

AB		BOEHRINGER INGELHEIM	**100MG**	**N201152**	**002** Nov 08, 2012
AB	**+**		**400MG**	**N201152**	**001** Mar 25, 2011

NIACIN

TABLET;ORAL

NIACIN

AA		WOCKHARDT	**500MG**	**A081134**	**001** Apr 28, 1992

NIACOR

AA	+	UPSHER SMITH	**500MG**	**A040378**	**001** May 03, 2000

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB		AMNEAL PHARMS	**500MG**	**A203578**	**001** Jul 24, 2015
AB			**750MG**	**A204178**	**001** Dec 11, 2015
AB			**1GM**	**A203578**	**002** Jul 24, 2015
AB		BARR	**500MG**	**A076378**	**001** Apr 26, 2005
AB			**750MG**	**A076378**	**002** Apr 26, 2005
AB			**1GM**	**A076250**	**001** Apr 14, 2005
AB		LUPIN LTD	**500MG**	**A090860**	**001** Mar 20, 2014
AB			**750MG**	**A090892**	**001** Mar 20, 2014
AB			**1GM**	**A090446**	**001** Mar 20, 2014
AB		SUN PHARMA GLOBAL	**500MG**	**A200484**	**001** Apr 23, 2014
AB			**750MG**	**A201273**	**001** Apr 23, 2014
AB			**1GM**	**A200484**	**002** Apr 23, 2014

NIASPAN

AB		ABBVIE	**500MG**	**N020381**	**002** Jul 28, 1997
AB	+		**750MG**	**N020381**	**003** Jul 28, 1997
AB	+		**1GM**	**N020381**	**004** Jul 28, 1997

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		ANI PHARMS INC	**20MG**	**A074439**	**001** Dec 10, 1996
AB			**20MG**	**A074540**	**001** Oct 28, 1996
AB			**30MG**	**A074439**	**002** Dec 10, 1996
AB			**30MG**	**A074540**	**002** Oct 28, 1996
AB		EPIC PHARMA	**20MG**	**A074928**	**001** Mar 19, 1998
AB			**30MG**	**A074928**	**002** Mar 19, 1998
AB		MYLAN	**20MG**	**A074642**	**001** Jul 18, 1996
AB	+		**30MG**	**A074642**	**002** Jul 18, 1996

INJECTABLE;INJECTION

CARDENE

AP	+	CHIESI USA INC	**25MG/10ML (2.5MG/ML)**	**N019734**	**001** Jan 30, 1992

NICARDIPINE HYDROCHLORIDE

AP		EUROHLTH INTL SARL	**25MG/10ML (2.5MG/ML)**	**A078714**	**001** Dec 28, 2009
AP		EXELA PHARMA SCIENCE	**25MG/10ML (2.5MG/ML)**	**N022276**	**001** Jul 24, 2008
AP		LUITPOLD PHARMS INC	**25MG/10ML (2.5MG/ML)**	**A090534**	**001** Nov 17, 2009
AP		MYLAN INSTITUTIONAL	**25MG/10ML (2.5MG/ML)**	**A090664**	**001** Nov 17, 2009
AP		NAVINTA LLC	**25MG/10ML (2.5MG/ML)**	**A090125**	**001** Nov 17, 2009
AP		SUN PHARMA GLOBAL	**25MG/10ML (2.5MG/ML)**	**N078405**	**001** Nov 17, 2009
AP		WOCKHARDT	**25MG/10ML (2.5MG/ML)**	**A090671**	**001** Nov 17, 2009

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004 Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003 Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

	+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002 Jul 31, 2008

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

	+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005 Nov 07, 2008

NICOTINE

INHALANT;ORAL

NICOTROL

	+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001 May 02, 1997

SPRAY, METERED;NASAL

NICOTROL

	+	PFIZER INC	0.5MG/SPRAY	N020385	001 Mar 22, 1996

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		ACTAVIS ELIZABETH	**10MG**	**A072579**	**001** Jan 08, 1991
AB			**20MG**	**A072556**	**001** Sep 20, 1990
AB		HERITAGE PHARMA	**10MG**	**A202644**	**001** Apr 25, 2013
AB			**20MG**	**A202644**	**002** Apr 25, 2013
AB		INTERGEL PHARM	**10MG**	**A072781**	**001** Jul 30, 1993
AB		VALIDUS PHARMS	**10MG**	**A073250**	**001** Oct 08, 1991

FDA data supplied by DrugPatentWatch.com

NIFEDIPINE
CAPSULE;ORAL

	NIFEDIPINE				
AB			**20MG**	**A074045** **001**	Apr 30, 1992
	PROCARDIA				
AB	+	PFIZER	**10MG**	**N018482** **001**	
TABLET, EXTENDED RELEASE;ORAL					
	ADALAT CC				
AB1		ALVOGEN	**30MG**	**N020198** **001**	Apr 21, 1993
AB1	+		**60MG**	**N020198** **002**	Apr 21, 1993
AB1	+		**90MG**	**N020198** **003**	Apr 21, 1993
	AFEDITAB CR				
AB1		WATSON LABS	**30MG**	**A075128** **001**	Mar 10, 2000
AB1			**60MG**	**A075659** **001**	Oct 26, 2001
	NIFEDIPINE				
AB1		MYLAN	**30MG**	**A201071** **001**	Dec 03, 2010
AB1			**60MG**	**A201071** **002**	Dec 03, 2010
AB1			**90MG**	**A201071** **003**	Dec 03, 2010
AB1		NOVAST LABS LTD	**30MG**	**A202987** **001**	Aug 25, 2016
AB1			**60MG**	**A202987** **002**	Aug 25, 2016
AB1			**90MG**	**A202987** **003**	Aug 25, 2016
AB1		PAR PHARM	**30MG**	**A077899** **001**	Dec 13, 2006
AB1			**60MG**	**A077899** **002**	Dec 13, 2006
AB1			**90MG**	**A077899** **003**	May 25, 2012
AB1		VALEANT PHARMS NORTH	**30MG**	**A075269** **001**	Dec 04, 2000
AB1			**60MG**	**A075269** **002**	Dec 04, 2000
AB1			**90MG**	**A076070** **001**	Aug 16, 2002
AB2		MATRIX LABS LTD	**30MG**	**A090602** **001**	Sep 13, 2010
AB2			**60MG**	**A090602** **002**	Sep 13, 2010
AB2			**90MG**	**A090602** **003**	Sep 13, 2010
AB2		MYLAN	**30MG**	**A090649** **001**	Jun 21, 2010
AB2			**60MG**	**A090649** **002**	Jun 21, 2010
AB2			**90MG**	**A090649** **003**	Jun 21, 2010
AB2		OSMOTICA PHARM	**90MG**	**A077410** **001**	Oct 03, 2007
AB2		OSMOTICA PHARM US	**30MG**	**A077127** **001**	Nov 21, 2005
AB2			**60MG**	**A077127** **002**	Nov 21, 2005
AB2		TWI PHARMS INC	**30MG**	**A203126** **001**	Apr 03, 2014
AB2			**60MG**	**A203126** **002**	Apr 03, 2014
AB2			**90MG**	**A203126** **003**	Apr 03, 2014
AB2		VALEANT PHARMS NORTH	**30MG**	**A075289** **002**	Feb 06, 2001
AB2			**60MG**	**A075289** **001**	Sep 27, 2000
	PROCARDIA XL				
AB2		PFIZER	**30MG**	**N019684** **001**	Sep 06, 1989
AB2			**60MG**	**N019684** **002**	Sep 06, 1989
AB2	+		**90MG**	**N019684** **003**	Sep 06, 1989

NILOTINIB HYDROCHLORIDE MONOHYDRATE
CAPSULE;ORAL

	TASIGNA				
		NOVARTIS	EQ 150MG BASE	N022068 002	Jun 17, 2010
	+		EQ 200MG BASE	N022068 001	Oct 29, 2007

NILUTAMIDE
TABLET;ORAL

	NILANDRON				
AB	+	CONCORDIA PHARMS INC	**150MG**	**N020169** **002**	Apr 30, 1999
	NILUTAMIDE				
AB		ANI PHARMS INC	**150MG**	**A207631** **001**	Jul 15, 2016

NIMODIPINE
CAPSULE;ORAL

	NIMODIPINE				
AB	+	BIONPHARMA INC	**30MG**	**A076740** **001**	Jan 17, 2008
AB		HERITAGE PHARMS INC	**30MG**	**A077811** **001**	May 02, 2007
AB		SOFGEN PHARMS	**30MG**	**A201832** **001**	Jul 24, 2015
AB		SUN PHARM INDS INC	**30MG**	**A077067** **001**	Apr 17, 2007
AB		THEPHARMANETWORK LLC	**30MG**	**A090103** **001**	Apr 07, 2014
SOLUTION;ORAL					
	NYMALIZE				
	+	ARBOR PHARMS LLC	60MG/20ML	N203340 001	May 10, 2013

FDA data supplied by DrugPatentWatch.com

NINTEDANIB ESYLATE
CAPSULE;ORAL
OFEV

	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014
+		EQ 150MG BASE	N205832	002	Oct 15, 2014

NISOLDIPINE
TABLET, EXTENDED RELEASE;ORAL

	NISOLDIPINE				
AB	MYLAN	**8.5MG**	**A091001**	**001**	Jan 26, 2011
AB		**17MG**	**A091001**	**002**	Jan 26, 2011
AB		**34MG**	**A091001**	**004**	Jan 26, 2011
	SULAR				
AB	**+** COVIS PHARMA SARL	**8.5MG**	**N020356**	**008**	Jan 02, 2008
AB	**+**	**17MG**	**N020356**	**007**	Jan 02, 2008
AB	**+**	**34MG**	**N020356**	**005**	Jan 02, 2008
	NISOLDIPINE				
	MYLAN	20MG	A079051	001	Jul 25, 2008
		25.5MG	A091001	003	Jan 26, 2011
+		30MG	A079051	002	Jul 25, 2008
+		40MG	A079051	003	Jul 25, 2008

NITAZOXANIDE
FOR SUSPENSION;ORAL
ALINIA

+	ROMARK	100MG/5ML	N021498	001	Nov 22, 2002

TABLET;ORAL
ALINIA

+	ROMARK	500MG	N021497	001	Jul 21, 2004

NITISINONE
CAPSULE;ORAL
ORFADIN

	SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002
		5MG	N021232	002	Jan 18, 2002
+		10MG	N021232	003	Jan 18, 2002
+		20MG	N021232	004	Jun 13, 2016

SUSPENSION;ORAL
ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016

NITRIC OXIDE
GAS;INHALATION
INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999

NITROFURANTOIN
SUSPENSION;ORAL

	FURADANTIN				
AB	**+** CASPER PHARMA LLC	**25MG/5ML**	**N009175**	**001**	
	NITROFURANTOIN				
AB	ACTAVIS MID ATLANTIC	**25MG/5ML**	**A205180**	**001**	May 03, 2016
AB	AMNEAL PHARMS	**25MG/5ML**	**A201679**	**001**	May 11, 2011
AB	NOSTRUM LABS INC	**25MG/5ML**	**A201355**	**001**	Aug 14, 2013
AB	NOVEL LABS INC	**25MG/5ML**	**A201693**	**001**	Sep 08, 2014

NITROFURANTOIN, MACROCRYSTALLINE
CAPSULE;ORAL

	MACRODANTIN				
AB	ALVOGEN MALTA	**25MG**	**N016620**	**003**	
AB		**50MG**	**N016620**	**001**	
AB	**+**	**100MG**	**N016620**	**002**	
	NITROFURANTOIN				
AB	ACTAVIS LABS FL INC	**25MG**	**A091095**	**001**	Jun 18, 2015
AB		**50MG**	**A091095**	**002**	Jun 18, 2015
AB		**100MG**	**A091095**	**003**	Jun 18, 2015
AB	IMPAX LABS INC	**50MG**	**A073671**	**001**	Jan 28, 1993
AB		**100MG**	**A073652**	**001**	Jan 28, 1993
AB	MYLAN	**50MG**	**A074967**	**001**	Jul 09, 1997
AB		**100MG**	**A077025**	**001**	Aug 18, 2004
AB	SUN PHARM INDS	**25MG**	**A201722**	**001**	Feb 16, 2016
AB		**50MG**	**A201722**	**002**	Feb 16, 2016
AB		**100MG**	**A201722**	**003**	Feb 16, 2016

FDA data supplied by DrugPatentWatch.com

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL						
MACROBID						
AB	+	ALVOGEN MALTA	**75MG;25MG**	**N020064**	**001**	Dec 24, 1991
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)						
AB		MYLAN	**75MG;25MG**	**A076648**	**001**	Mar 22, 2004
AB		SANDOZ	**75MG;25MG**	**A077066**	**001**	Apr 05, 2005
AB		WATSON LABS INC	**75MG;25MG**	**A202250**	**001**	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL						
NITROMIST						
	+	MIST PHARMS LLC	0.4MG/SPRAY	N021780	001	Nov 02, 2006
FILM, EXTENDED RELEASE;TRANSDERMAL						
MINITRAN						
AB1		MEDICIS	**0.4MG/HR**	**A089773**	**001**	Aug 30, 1996
AB1		VALEANT PHARMS	**0.1MG/HR**	**A089771**	**001**	Aug 30, 1996
AB1			**0.6MG/HR**	**A089774**	**001**	Aug 30, 1996
AB1		VALEANT PHARMS NORTH	**0.2MG/HR**	**A089772**	**001**	Aug 30, 1996
NITRO-DUR						
AB1	+	MERCK SHARP DOHME	**0.1MG/HR**	**N020145**	**001**	Apr 04, 1995
AB1	+		**0.2MG/HR**	**N020145**	**002**	Apr 04, 1995
AB1	+		**0.4MG/HR**	**N020145**	**004**	Apr 04, 1995
AB1	+		**0.6MG/HR**	**N020145**	**005**	Apr 04, 1995
NITROGLYCERIN						
AB2		HERCON PHARM	**0.2MG/HR**	**A089884**	**001**	Oct 30, 1998
AB2			**0.4MG/HR**	**A089885**	**001**	Oct 30, 1998
AB2			**0.6MG/HR**	**A089886**	**001**	Oct 30, 1998
AB2	+	MYLAN TECHNOLOGIES	**0.2MG/HR**	**A074559**	**003**	Aug 30, 1996
AB2	+		**0.4MG/HR**	**A074559**	**002**	Aug 30, 1996
AB2	+		**0.6MG/HR**	**A074559**	**001**	Aug 30, 1996
NITRO-DUR						
	+	MERCK SHARP DOHME	0.3MG/HR	N020145	003	Apr 04, 1995
	+		0.8MG/HR	N020145	006	Apr 04, 1995
NITROGLYCERIN						
	+	MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998
INJECTABLE;INJECTION						
NITROGLYCERIN IN DEXTROSE 5%						
AP	+	BAXTER HLTHCARE	**10MG/100ML**	**N019970**	**001**	Dec 29, 1989
AP	+		**20MG/100ML**	**N019970**	**002**	Dec 29, 1989
AP	+		**40MG/100ML**	**N019970**	**003**	Dec 29, 1989
AP		HOSPIRA	**10MG/100ML**	**A071846**	**001**	Aug 31, 1990
AP			**20MG/100ML**	**A071847**	**001**	Aug 31, 1990
AP			**40MG/100ML**	**A071848**	**001**	Aug 31, 1990
NITROGLYCERIN						
	+	LUITPOLD	5MG/ML	A072034	001	May 24, 1988
OINTMENT;INTRA-ANAL						
RECTIV						
	+	FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011
OINTMENT;TRANSDERMAL						
NITROGLYCERIN						
	+	FOUGERA	2%	A087355	001	Jul 08, 1988
POWDER;SUBLINGUAL						
GONITRO						
	+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016
SPRAY, METERED;SUBLINGUAL						
NITROGLYCERIN						
AB		PERRIGO ISRAEL	**0.4MG/SPRAY**	**A091496**	**001**	Sep 20, 2013
NITROLINGUAL PUMPSPRAY						
AB	+	POHL BOSKAMP	**0.4MG/SPRAY**	**N018705**	**002**	Jan 10, 1997
TABLET;SUBLINGUAL						
NITROGLYCERIN						
AB		DR REDDYS LABS INC	**0.3MG**	**A208191**	**001**	Aug 26, 2016
AB			**0.4MG**	**A208191**	**002**	Aug 26, 2016
AB			**0.6MG**	**A208191**	**003**	Aug 26, 2016
NITROSTAT						
AB		PFIZER PHARMS	**0.3MG**	**N021134**	**001**	May 01, 2000
AB			**0.4MG**	**N021134**	**002**	May 01, 2000
AB	+		**0.6MG**	**N021134**	**003**	May 01, 2000

NIZATIDINE
CAPSULE;ORAL

	NIZATIDINE				
AB	ANI PHARMS INC	**150MG**	**A075668**	**001**	Sep 12, 2002
AB		**300MG**	**A075668**	**002**	Sep 12, 2002
AB	DR REDDYS LABS LTD	**150MG**	**A077314**	**001**	Sep 15, 2005
AB		**300MG**	**A077314**	**002**	Sep 15, 2005
AB	GLENMARK GENERICS	**150MG**	**A090618**	**001**	Jul 15, 2011
AB		**300MG**	**A090618**	**002**	Jul 15, 2011
AB	MYLAN PHARMS INC	**150MG**	**A075806**	**001**	Jul 05, 2002
AB +		**300MG**	**A075806**	**002**	Jul 05, 2002
AB	SANDOZ	**150MG**	**A076178**	**001**	Jul 05, 2002
AB		**300MG**	**A076178**	**002**	Jul 05, 2002
AB	WATSON LABS	**150MG**	**A075616**	**001**	Jul 09, 2002
AB		**300MG**	**A075616**	**002**	Jul 09, 2002

SOLUTION;ORAL

	NIZATIDINE				
+	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009

NOREPINEPHRINE BITARTRATE
INJECTABLE;INJECTION

	LEVOPHED				
AP +	HOSPIRA	**EQ 1MG BASE/ML**	**N007513**	**001**	
	NOREPINEPHRINE BITARTRATE				
AP	CLARIS	**EQ 1MG BASE/ML**	**A040859**	**001**	Mar 27, 2012
AP	EUROHLTH INTL SARL	**EQ 1MG BASE/ML**	**A040462**	**001**	Oct 31, 2003
AP	TEVA PHARMS USA	**EQ 1MG BASE/ML**	**A040455**	**001**	Mar 03, 2003

NORETHINDRONE
TABLET;ORAL-28

	CAMILA				
AB1	MAYNE PHARMA	**0.35MG**	**A076177**	**001**	Oct 21, 2002
	HEATHER				
AB1	GLENMARK GENERICS	**0.35MG**	**A090454**	**001**	Apr 23, 2010
	INCASSIA				
AB1	AUROBINDO PHARMA LTD	**0.35MG**	**A207304**	**001**	Sep 23, 2016
	NOR-QD				
AB1 +	APIL	**0.35MG**	**N017060**	**001**	
	NORETHINDRONE				
AB1	ACCORD HLTHCARE	**0.35MG**	**A206807**	**001**	Dec 13, 2016
AB1	AMNEAL PHARMS	**0.35MG**	**A202260**	**001**	Aug 01, 2013
AB1	JAI PHARMA LTD	**0.35MG**	**A201483**	**001**	Jun 24, 2013
AB1	LUPIN LTD	**0.35MG**	**A091325**	**001**	Sep 19, 2011
AB1	NOVAST LABS LTD	**0.35MG**	**A202014**	**001**	Sep 13, 2013
	ERRIN				
AB2	MAYNE PHARMA	**0.35MG**	**A076225**	**001**	Oct 21, 2002
	JENCYCLA				
AB2	LUPIN LTD	**0.35MG**	**A091323**	**001**	Mar 28, 2013
	MICRONOR				
AB2 +	JANSSEN PHARMS	**0.35MG**	**N016954**	**001**	
	NORETHINDRONE				
AB2	GLENMARK GENERICS	**0.35MG**	**A091209**	**001**	Jul 22, 2010
AB2	JAI PHARMA LTD	**0.35MG**	**A200980**	**001**	Jun 12, 2013
AB2	NOVAST LABS	**0.35MG**	**A200961**	**001**	Sep 13, 2013

NORETHINDRONE ACETATE
TABLET;ORAL

	AYGESTIN				
AB +	DURAMED RES	**5MG**	**N018405**	**001**	Apr 21, 1982
	NORETHINDRONE ACETATE				
AB	AMNEAL PHARMS	**5MG**	**A200275**	**001**	Jul 30, 2012
AB	AUROBINDO PHARMA LTD	**5MG**	**A204236**	**001**	Jan 08, 2016
AB	BARR	**5MG**	**A075951**	**001**	May 25, 2001
AB	GLENMARK GENERICS	**5MG**	**A091090**	**001**	Jul 21, 2010
AB	JAI PHARMA LTD	**5MG**	**A205278**	**001**	Nov 10, 2016

NORTRIPTYLINE HYDROCHLORIDE
CAPSULE;ORAL

	NORTRIPTYLINE HYDROCHLORIDE				
AB	MAYNE PHARMA	**EQ 10MG BASE**	**A073553**	**001**	Mar 30, 1992
AB		**EQ 25MG BASE**	**A073554**	**001**	Mar 30, 1992
AB		**EQ 50MG BASE**	**A073555**	**001**	Mar 30, 1992
AB		**EQ 75MG BASE**	**A073556**	**001**	Mar 30, 1992
AB	MYLAN	**EQ 10MG BASE**	**A074234**	**001**	Jul 26, 1993

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

	NORTRIPTYLINE HYDROCHLORIDE				
AB		**EQ 25MG BASE**	**A074234**	**002**	Jul 26, 1993
AB		**EQ 50MG BASE**	**A074234**	**003**	Jul 26, 1993
AB		**EQ 75MG BASE**	**A074234**	**004**	Jul 26, 1993
AB	TARO	**EQ 10MG BASE**	**A075520**	**004**	May 08, 2000
AB		**EQ 25MG BASE**	**A075520**	**003**	May 08, 2000
AB		**EQ 50MG BASE**	**A075520**	**001**	May 08, 2000
AB		**EQ 75MG BASE**	**A075520**	**002**	May 08, 2000
AB	TEVA	**EQ 10MG BASE**	**A074132**	**001**	Mar 27, 1995
AB		**EQ 25MG BASE**	**A074132**	**002**	Mar 27, 1995
AB		**EQ 50MG BASE**	**A074132**	**003**	Mar 27, 1995
AB		**EQ 75MG BASE**	**A074132**	**004**	Mar 27, 1995
	PAMELOR				
AB	MALLINCKRODT LLC	**EQ 10MG BASE**	**N018013**	**001**	
AB		**EQ 25MG BASE**	**N018013**	**002**	
AB		**EQ 50MG BASE**	**N018013**	**004**	
AB	**+**	**EQ 75MG BASE**	**N018013**	**003**	

SOLUTION;ORAL

	NORTRIPTYLINE HYDROCHLORIDE				
AA	**+** PHARM ASSOC	**EQ 10MG BASE/5ML**	**A075606**	**001**	Aug 28, 2000
AA	TARO	**EQ 10MG BASE/5ML**	**A077965**	**001**	Jun 20, 2006

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

	SPINRAZA				
	+ BIOGEN IDEC	12MG/5ML (2.4MG/ML)	N209531	001	Dec 23, 2016

NYSTATIN

CREAM;TOPICAL

	NYSTATIN				
AT	ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062949**	**001**	Jun 13, 1988
AT	FOUGERA PHARMS	**100,000 UNITS/GM**	**A062129**	**001**	
AT	G AND W LABS INC	**100,000 UNITS/GM**	**A061966**	**001**	
AT	PERRIGO NEW YORK	**100,000 UNITS/GM**	**A062225**	**001**	
AT	**+** TARO	**100,000 UNITS/GM**	**A064022**	**001**	Jan 29, 1993
AT	VINTAGE	**100,000 UNITS/GM**	**A065315**	**001**	May 31, 2006

OINTMENT;TOPICAL

	NYSTATIN				
AT	ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062840**	**001**	Nov 13, 1987
AT	**+** FOUGERA PHARMS	**100,000 UNITS/GM**	**A062124**	**002**	Sep 23, 1982
AT	PERRIGO NEW YORK	**100,000 UNITS/GM**	**A062472**	**001**	Feb 13, 1984

POWDER;TOPICAL

	NYSTATIN				
AT	GAVIS PHARMS	**100,000 UNITS/GM**	**A065138**	**001**	Jul 23, 2004
AT	**+** MAYNE PHARMA INC	**100,000 UNITS/GM**	**A065203**	**001**	Jul 15, 2004
AT	UPSHER SMITH	**100,000 UNITS/GM**	**A065183**	**001**	May 03, 2005
AT	X GEN PHARMS	**100,000 UNITS/GM**	**A065175**	**001**	Dec 17, 2004
	NYSTOP				
AT	PADDOCK LLC	**100,000 UNITS/GM**	**A064118**	**001**	Aug 16, 1996

SUSPENSION;ORAL

	NYSTATIN				
AA	FOUGERA	**100,000 UNITS/ML**	**A062517**	**001**	Jun 07, 1984
AA	G AND W LABS INC	**100,000 UNITS/ML**	**A062349**	**001**	Jul 14, 1982
AA	HI TECH PHARMA	**100,000 UNITS/ML**	**A064042**	**001**	Feb 28, 1994
AA	PHARM ASSOC	**100,000 UNITS/ML**	**A203621**	**001**	Jan 07, 2016
AA	TARO	**100,000 UNITS/ML**	**A062876**	**001**	Feb 29, 1988
AA	VINTAGE PHARMS	**100,000 UNITS/ML**	**A065148**	**001**	Jun 28, 2005
AA	VISTAPHARM	**100,000 UNITS/ML**	**A064142**	**001**	Jun 25, 1998
AA		**100,000 UNITS/ML**	**A065422**	**001**	Mar 07, 2011
AA	**+** WOCKHARDT	**100,000 UNITS/ML**	**A062512**	**001**	Oct 29, 1984

TABLET;ORAL

	NYSTATIN				
AA	HERITAGE PHARMS INC	**500,000 UNITS**	**A062474**	**001**	Dec 22, 1983
AA	SUN PHARM INDS	**500,000 UNITS**	**A062838**	**001**	Dec 22, 1988
AA	**+** TEVA	**500,000 UNITS**	**A062506**	**001**	Jan 16, 1984

TABLET;VAGINAL

	NYSTATIN				
	+ ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985

FDA data supplied by DrugPatentWatch.com

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

		MYKACET				
AT		G AND W LABS INC	**100,000 UNITS/GM;0.1%**	**A062367**	**001**	May 28, 1985
		NYSTATIN AND TRIAMCINOLONE ACETONIDE				
AT		DR REDDYS LABS LTD	**100,000 UNITS/GM;0.1%**	**A208326**	**001**	Oct 26, 2016
AT		FOUGERA	**100,000 UNITS/GM;0.1%**	**A062599**	**001**	Oct 08, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208136**	**001**	Oct 24, 2016
AT	+	TARO	**100,000 UNITS/GM;0.1%**	**A062364**	**001**	Dec 22, 1987

OINTMENT;TOPICAL

		MYKACET				
AT		G AND W LABS INC	**100,000 UNITS/GM;0.1%**	**A062733**	**001**	Mar 06, 1987
		NYSTATIN AND TRIAMCINOLONE ACETONIDE				
AT		FOUGERA	**100,000 UNITS/GM;0.1%**	**A062602**	**001**	Oct 09, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208300**	**001**	Jun 23, 2016
AT		PERRIGO UK FINCO	**100,000 UNITS/GM;0.1%**	**A207380**	**001**	Dec 20, 2016
AT		RICONPHARMA LLC	**100,000 UNITS/GM;0.1%**	**A206785**	**001**	Dec 29, 2016
AT	+	TARO	**100,000 UNITS/GM;0.1%**	**A063305**	**001**	Mar 29, 1993
AT		TELIGENT PHARMA INC	**100,000 UNITS/GM;0.1%**	**A208287**	**001**	Dec 30, 2016

OBETICHOLIC ACID

TABLET;ORAL

		OCALIVA				
		INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016
	+		10MG	N207999	002	May 27, 2016

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

		OCTREOTIDE ACETATE				
AP		FRESENIUS KABI USA	**EQ 0.2MG BASE/ML**	**A077450**	**001**	Feb 10, 2006
AP			**EQ 1MG BASE/ML**	**A077450**	**002**	Feb 10, 2006
AP		SAGENT PHARMS	**EQ 0.2MG BASE/ML**	**A091041**	**001**	Nov 12, 2013
AP			**EQ 1MG BASE/ML**	**A091041**	**002**	Nov 12, 2013
AP		SUN PHARM INDS	**EQ 0.05MG BASE/ML**	**A077329**	**001**	Mar 04, 2008
AP			**EQ 0.05MG BASE/ML**	**A077372**	**001**	Aug 14, 2007
AP			**EQ 0.1MG BASE/ML**	**A077329**	**002**	Mar 04, 2008
AP			**EQ 0.1MG BASE/ML**	**A077372**	**002**	Aug 14, 2007
AP			**EQ 0.2MG BASE/ML**	**A077330**	**001**	Mar 04, 2008
AP			**EQ 0.2MG BASE/ML**	**A077373**	**001**	Aug 14, 2007
AP			**EQ 0.5MG BASE/ML**	**A077329**	**003**	Mar 04, 2008
AP			**EQ 0.5MG BASE/ML**	**A077372**	**003**	Aug 14, 2007
AP			**EQ 1MG BASE/ML**	**A077331**	**001**	Mar 04, 2008
AP			**EQ 1MG BASE/ML**	**A077373**	**002**	Aug 14, 2007
AP		TEVA PHARMS USA	**EQ 0.05MG BASE/ML**	**A075957**	**001**	Oct 03, 2005
AP			**EQ 0.1MG BASE/ML**	**A075957**	**002**	Oct 03, 2005
AP			**EQ 0.2MG BASE/ML**	**A075959**	**001**	Nov 21, 2005
AP			**EQ 0.5MG BASE/ML**	**A075957**	**003**	Oct 03, 2005
AP			**EQ 1MG BASE/ML**	**A075959**	**002**	Nov 21, 2005
AP	+	WEST-WARD PHARMS INT	**EQ 0.2MG BASE/ML**	**A076330**	**001**	Apr 08, 2005
AP	+		**EQ 1MG BASE/ML**	**A076330**	**002**	Apr 08, 2005
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)				
AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A077457**	**001**	Feb 10, 2006
AP			**EQ 0.1MG BASE/ML**	**A077457**	**002**	Feb 10, 2006
AP			**EQ 0.5MG BASE/ML**	**A077457**	**003**	Feb 10, 2006
AP		MYLAN INSTITUTIONAL	**EQ 0.05MG BASE/ML**	**A079198**	**001**	Feb 10, 2011
AP			**EQ 0.1MG BASE/ML**	**A079198**	**002**	Feb 10, 2011
AP			**EQ 0.5MG BASE/ML**	**A079198**	**003**	Feb 10, 2011
AP		SAGENT PHARMS	**EQ 0.05MG BASE/ML**	**A090834**	**001**	Nov 12, 2013
AP			**EQ 0.1MG BASE/ML**	**A090834**	**002**	Nov 12, 2013
AP			**EQ 0.5MG BASE/ML**	**A090834**	**003**	Nov 12, 2013
AP	+	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**A076313**	**001**	Mar 28, 2005
AP	+		**EQ 0.1MG BASE/ML**	**A076313**	**003**	Mar 28, 2005
AP	+		**EQ 0.5MG BASE/ML**	**A076313**	**002**	Mar 28, 2005
		SANDOSTATIN				
AP	+	NOVARTIS	**EQ 0.05MG BASE/ML**	**N019667**	**001**	Oct 21, 1988
AP	+		**EQ 0.1MG BASE/ML**	**N019667**	**002**	Oct 21, 1988
AP	+		**EQ 0.2MG BASE/ML**	**N019667**	**004**	Jun 12, 1991
AP	+		**EQ 0.5MG BASE/ML**	**N019667**	**003**	Oct 21, 1988
AP	+		**EQ 1MG BASE/ML**	**N019667**	**005**	Jun 12, 1991
		SANDOSTATIN LAR				
		NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
			EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
	+		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

FDA data supplied by DrugPatentWatch.com

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OCUFLOX

AT	+	ALLERGAN	**0.3%**	**N019921**	**001**	Jul 30, 1993

OFLOXACIN

AT		AKORN	**0.3%**	**A076407**	**001**	Apr 15, 2008
AT		ALCON PHARMS LTD	**0.3%**	**A076231**	**001**	May 14, 2004
AT		ALTAIRE PHARMS INC	**0.3%**	**A202692**	**001**	Apr 29, 2013
AT		ALVOGEN	**0.3%**	**A076830**	**001**	Aug 31, 2004
AT		BAUSCH AND LOMB	**0.3%**	**A076622**	**001**	May 14, 2004
AT		FDC LTD	**0.3%**	**A078559**	**001**	Feb 25, 2009
AT		HI TECH PHARMA	**0.3%**	**A076615**	**001**	May 14, 2004

SOLUTION/DROPS;OTIC

OFLOXACIN

AT		ALCON PHARMS LTD	**0.3%**	**A078222**	**001**	Mar 17, 2008
AT		ALVOGEN	**0.3%**	**A090395**	**001**	Aug 11, 2009
AT		APOTEX INC	**0.3%**	**A076527**	**001**	Sep 28, 2007
AT	+	BAUSCH AND LOMB	**0.3%**	**A076128**	**001**	Mar 17, 2008
AT		HI TECH PHARMA	**0.3%**	**A076616**	**001**	Mar 17, 2008

TABLET;ORAL

OFLOXACIN

AB		CADILA PHARMS LTD	**200MG**	**A091656**	**001**	Sep 18, 2014
AB			**300MG**	**A091656**	**002**	Sep 18, 2014
AB			**400MG**	**A091656**	**003**	Sep 18, 2014
AB		DR REDDYS LABS LTD	**200MG**	**A077098**	**001**	Feb 10, 2006
AB			**300MG**	**A077098**	**002**	Feb 10, 2006
AB			**400MG**	**A077098**	**003**	Feb 10, 2006
AB		LARKEN LABS	**400MG**	**A076093**	**003**	Sep 02, 2003
AB		TEVA	**200MG**	**A076182**	**001**	Sep 02, 2003
AB			**300MG**	**A076182**	**002**	Sep 02, 2003
AB	+		**400MG**	**A076182**	**003**	Sep 02, 2003

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP		LUITPOLD	**10MG/VIAL**	**A201741**	**001**	Mar 20, 2012
AP		SANDOZ INC	**10MG/VIAL**	**A201588**	**001**	Oct 24, 2011

ZYPREXA

AP	+	LILLY	**10MG/VIAL**	**N021253**	**001**	Mar 29, 2004

TABLET;ORAL

OLANZAPINE

AB		AJANTA PHARMA LTD	**2.5MG**	**A206711**	**001**	Aug 30, 2016
AB			**5MG**	**A206711**	**002**	Aug 30, 2016
AB			**7.5MG**	**A206711**	**003**	Aug 30, 2016
AB			**10MG**	**A206711**	**004**	Aug 30, 2016
AB			**15MG**	**A206711**	**005**	Aug 30, 2016
AB			**20MG**	**A206711**	**006**	Aug 30, 2016
AB		ALKEM LABS LTD	**2.5MG**	**A202295**	**001**	Oct 20, 2015
AB			**5MG**	**A202295**	**002**	Oct 20, 2015
AB			**7.5MG**	**A202295**	**003**	Oct 20, 2015
AB			**10MG**	**A202295**	**004**	Oct 20, 2015
AB			**15MG**	**A202295**	**005**	Oct 20, 2015
AB			**20MG**	**A202295**	**006**	Oct 20, 2015
AB		APOTEX INC	**2.5MG**	**A090798**	**001**	Apr 23, 2012
AB			**5MG**	**A090798**	**002**	Apr 23, 2012
AB			**7.5MG**	**A090798**	**003**	Apr 23, 2012
AB			**10MG**	**A090798**	**004**	Apr 23, 2012
AB			**15MG**	**A090798**	**005**	Apr 23, 2012
AB			**20MG**	**A090798**	**006**	Apr 23, 2012
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A202050**	**001**	Apr 23, 2012
AB			**5MG**	**A202050**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202050**	**003**	Apr 23, 2012
AB			**10MG**	**A202050**	**004**	Apr 23, 2012
AB			**15MG**	**A202050**	**005**	Apr 23, 2012
AB			**20MG**	**A202050**	**006**	Apr 23, 2012
AB		DR REDDYS LABS LTD	**2.5MG**	**A076255**	**001**	Apr 23, 2012
AB			**5MG**	**A076255**	**002**	Apr 23, 2012
AB			**7.5MG**	**A076255**	**003**	Apr 23, 2012
AB			**10MG**	**A076255**	**004**	Apr 23, 2012
AB			**15MG**	**A076133**	**001**	Apr 23, 2012
AB			**20MG**	**A076133**	**002**	Oct 24, 2011
AB		INVAGEN PHARMS	**2.5MG**	**A203333**	**001**	Mar 15, 2016
AB			**5MG**	**A203333**	**002**	Mar 15, 2016

FDA data supplied by DrugPatentWatch.com

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB		7.5MG	A203333	003	Mar 15, 2016
AB		10MG	A203333	004	Mar 15, 2016
AB		15MG	A203333	005	Mar 15, 2016
AB		20MG	A203333	006	Mar 15, 2016
AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015
AB	MACLEODS PHARMS LTD	2.5MG	A202862	001	Aug 15, 2014
AB		5MG	A202862	002	Aug 15, 2014
AB		7.5MG	A202862	003	Aug 15, 2014
AB		10MG	A202862	004	Aug 15, 2014
AB		15MG	A202862	005	Aug 15, 2014
AB		20MG	A202862	006	Aug 15, 2014
AB	MYLAN	2.5MG	A076866	001	Apr 23, 2012
AB		5MG	A076866	002	Apr 23, 2012
AB		7.5MG	A076866	003	Apr 23, 2012
AB		10MG	A076866	004	Apr 23, 2012
AB		15MG	A076866	005	Apr 23, 2012
AB		20MG	A076866	006	Apr 23, 2012
AB	ORCHID HLTHCARE	2.5MG	A202287	001	Apr 23, 2012
AB		5MG	A202287	002	Apr 23, 2012
AB		7.5MG	A202287	003	Apr 23, 2012
AB		10MG	A202287	004	Apr 23, 2012
AB		15MG	A202287	005	Apr 23, 2012
AB		20MG	A202287	006	Apr 23, 2012
AB	QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016
AB		5MG	A204319	002	Jan 27, 2016
AB		7.5MG	A204319	003	Jan 27, 2016
AB		10MG	A204319	004	Jan 27, 2016
AB		15MG	A204319	005	Jan 27, 2016
AB		20MG	A204319	006	Jan 27, 2016
AB	SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012
AB		5MG	A091038	002	Apr 23, 2012
AB		7.5MG	A091038	003	Apr 23, 2012
AB		10MG	A091038	004	Apr 23, 2012
AB		15MG	A091038	005	Apr 23, 2012
AB		20MG	A091038	006	Apr 23, 2012
AB	TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011
AB		5MG	A076000	002	Oct 24, 2011
AB		7.5MG	A076000	003	Oct 24, 2011
AB		10MG	A076000	004	Oct 24, 2011
AB		15MG	A076000	005	Oct 24, 2011
AB	TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012
AB		5MG	A091434	002	Apr 23, 2012
AB		7.5MG	A091434	003	Apr 23, 2012
AB		10MG	A091434	004	Apr 23, 2012
AB		15MG	A091434	005	Apr 23, 2012
AB		20MG	A091434	006	Apr 23, 2012

ZYPREXA

AB	LILLY	2.5MG	N020592	001	Sep 30, 1996
AB +		5MG	N020592	002	Sep 30, 1996
AB		7.5MG	N020592	003	Sep 30, 1996
AB		10MG	N020592	004	Sep 30, 1996
AB		15MG	N020592	005	Sep 09, 1997
AB		20MG	N020592	006	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	APOTEX INC	5MG	A091265	001	Oct 24, 2011
AB		10MG	A091265	002	Oct 24, 2011
AB		15MG	A091265	003	Oct 24, 2011
AB		20MG	A091265	004	Oct 24, 2011
AB	AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014
AB		10MG	A203708	002	May 15, 2014
AB		15MG	A203708	003	May 15, 2014
AB		20MG	A203708	004	May 15, 2014
AB	BARR LABS INC	5MG	A077243	001	Jan 30, 2012
AB		10MG	A077243	002	Jan 30, 2012
AB		15MG	A077243	003	Jan 30, 2012
AB		20MG	A077243	004	Jan 30, 2012
AB	DR REDDYS LABS LTD	5MG	A076534	001	Oct 24, 2011
AB		10MG	A076534	002	Oct 24, 2011

FDA data supplied by DrugPatentWatch.com

OLANZAPINE
TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE					
AB		**15MG**	**A076534**	**003**	Oct 24, 2011
AB		**20MG**	**A076534**	**004**	Oct 24, 2011
AB	INVAGEN PHARMS	**5MG**	**A203456**	**001**	Mar 16, 2016
AB		**10MG**	**A203456**	**002**	Mar 16, 2016
AB		**15MG**	**A203456**	**003**	Mar 16, 2016
AB		**20MG**	**A203456**	**004**	Mar 16, 2016
AB	JUBILANT GENERICS	**5MG**	**A200221**	**001**	Sep 12, 2012
AB		**10MG**	**A200221**	**002**	Sep 12, 2012
AB		**15MG**	**A200221**	**003**	Sep 12, 2012
AB		**20MG**	**A200221**	**004**	Sep 12, 2012
AB	MACLEODS PHARMS LTD	**5MG**	**A203044**	**001**	Feb 20, 2015
AB		**10MG**	**A203044**	**002**	Feb 20, 2015
AB		**15MG**	**A203044**	**003**	Feb 20, 2015
AB		**20MG**	**A203044**	**004**	Feb 20, 2015
AB	MYLAN PHARMS INC	**5MG**	**A202285**	**001**	May 12, 2014
AB		**10MG**	**A202285**	**002**	May 12, 2014
AB		**15MG**	**A202285**	**003**	May 12, 2014
AB		**20MG**	**A202285**	**004**	May 12, 2014
AB	ORCHID HLTHCARE	**5MG**	**A202937**	**001**	Mar 02, 2015
AB		**10MG**	**A202937**	**002**	Mar 02, 2015
AB		**15MG**	**A202937**	**003**	Mar 02, 2015
AB		**20MG**	**A202937**	**004**	Mar 02, 2015
AB	PAR PHARM	**5MG**	**A078109**	**001**	Oct 24, 2011
AB		**10MG**	**A078109**	**002**	Oct 24, 2011
AB		**15MG**	**A078109**	**003**	Oct 24, 2011
AB		**20MG**	**A078109**	**004**	Oct 24, 2011
AB	SUN PHARM INDS	**5MG**	**A090881**	**001**	Feb 28, 2012
AB		**10MG**	**A090881**	**002**	Feb 28, 2012
AB		**15MG**	**A090881**	**003**	Feb 28, 2012
AB		**20MG**	**A090881**	**004**	Feb 28, 2012
AB	TORRENT PHARMS LLC	**5MG**	**A091415**	**001**	Oct 25, 2011
AB		**10MG**	**A091415**	**002**	Oct 25, 2011
AB		**15MG**	**A091415**	**003**	Oct 25, 2011
AB		**20MG**	**A091415**	**004**	Oct 25, 2011
ZYPREXA ZYDIS					
AB	**+** LILLY	**5MG**	**N021086**	**001**	Apr 06, 2000
AB		**10MG**	**N021086**	**002**	Apr 06, 2000
AB		**15MG**	**N021086**	**003**	Apr 06, 2000
AB		**20MG**	**N021086**	**004**	Apr 06, 2000

OLANZAPINE PAMOATE
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV					
	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLAPARIB
CAPSULE;ORAL

LYNPARZA					
	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014

OLIVE OIL; SOYBEAN OIL
INJECTABLE;INJECTION

CLINOLIPID 20%					
+	BAXTER HLTHCARE	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013

OLMESARTAN MEDOXOMIL
TABLET;ORAL

BENICAR					
AB	DAIICHI SANKYO	**5MG**	**N021286**	**001**	Apr 25, 2002
AB		**20MG**	**N021286**	**003**	Apr 25, 2002
AB	**+**	**40MG**	**N021286**	**004**	Apr 25, 2002
OLMESARTAN MEDOXOMIL					
AB	MYLAN PHARMS INC	**5MG**	**A078276**	**001**	Oct 26, 2016
AB		**20MG**	**A078276**	**002**	Oct 26, 2016
AB		**40MG**	**A078276**	**003**	Oct 26, 2016

OLODATEROL HYDROCHLORIDE
SPRAY, METERED;INHALATION
STRIVERDI RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
SPRAY, METERED;INHALATION
STIOLTO RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015

OLOPATADINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

		OLOPATADINE HYDROCHLORIDE				
AT		AKORN INC	**EQ 0.1% BASE**	**A204532**	**001**	Jan 10, 2017
AT		APOTEX INC	**EQ 0.1% BASE**	**A078350**	**001**	Dec 07, 2015
AT		AUROBINDO PHARMA LTD	**EQ 0.1% BASE**	**A204812**	**001**	Dec 18, 2015
AT		BARR LABS INC	**EQ 0.2% BASE**	**A090848**	**001**	Jul 13, 2015
AT		SOMERSET THERAPS LLC	**EQ 0.1% BASE**	**A206306**	**001**	Dec 07, 2015
AT		USV NORTH AMERICA	**EQ 0.1% BASE**	**A203152**	**001**	Dec 07, 2015
AT		ZACH SYSTEM SPA	**EQ 0.1% BASE**	**A204706**	**001**	Dec 07, 2015
		PATADAY				
AT	**+**	NOVARTIS PHARMS CORP	**EQ 0.2% BASE**	**N021545**	**001**	Dec 22, 2004
		PATANOL				
AT	**+**	NOVARTIS PHARMS CORP	**EQ 0.1% BASE**	**N020688**	**001**	Dec 18, 1996
		PAZEO				
	+	NOVARTIS PHARMS CORP	EQ 0.7% BASE	N206276	001	Jan 30, 2015

SPRAY, METERED;NASAL

		OLOPATADINE HYDROCHLORIDE				
AB		APOTEX INC	**0.665MG/SPRAY**	**A091572**	**001**	Oct 08, 2014
		PATANASE				
AB	**+**	NOVARTIS PHARMS CORP	**0.665MG/SPRAY**	**N021861**	**001**	Apr 15, 2008

OLSALAZINE SODIUM
CAPSULE;ORAL
DIPENTUM

+	MEDA PHARMS	250MG	N019715	001	Jul 31, 1990

OMACETAXINE MEPESUCCINATE
POWDER;SUBCUTANEOUS
SYNRIBO

+	IVAX INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012

OMBITASVIR; PARITAPREVIR; RITONAVIR
TABLET;ORAL
TECHNIVIE

+	ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015

OMEGA-3-ACID ETHYL ESTERS
CAPSULE;ORAL

		LOVAZA				
AB	**+**	SMITHKLINE BEECHAM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**N021654**	**001**	Nov 10, 2004
		OMEGA-3-ACID ETHYL ESTERS				
AB		AMNEAL PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A204940**	**001**	Nov 27, 2015
AB		APOTEX INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A090973**	**001**	Sep 30, 2014
AB		PAR PHARM INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A091018**	**001**	Jun 24, 2014
AB		TEVA PHARMS USA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A091028**	**001**	Apr 07, 2014

OMEGA-3-ACID ETHYL ESTERS TYPE A
CAPSULE;ORAL
OMTRYG

+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS
CAPSULE;ORAL
EPANOVA

+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014

FDA data supplied by DrugPatentWatch.com

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB	ACTAVIS LABS FL INC	**10MG**	**A075347**	**001**	May 30, 2008
AB		**20MG**	**A075347**	**002**	May 30, 2008
AB		**40MG**	**A075347**	**003**	May 30, 2008
AB	APOTEX	**10MG**	**A076048**	**001**	Oct 22, 2007
AB		**20MG**	**A076048**	**002**	Oct 22, 2007
AB		**40MG**	**A076048**	**003**	Jan 21, 2009
AB	AUROBINDO PHARMA USA	**10MG**	**A203270**	**001**	Aug 19, 2015
AB		**20MG**	**A203270**	**002**	Aug 19, 2015
AB		**40MG**	**A203270**	**003**	Aug 19, 2015
AB	DR REDDYS LABS LTD	**10MG**	**A075576**	**003**	Oct 22, 2007
AB		**10MG**	**A078490**	**002**	Mar 16, 2009
AB		**20MG**	**A075576**	**002**	Oct 22, 2007
AB		**20MG**	**A078490**	**003**	Mar 16, 2009
AB		**40MG**	**A075576**	**001**	Jan 21, 2009
AB		**40MG**	**A078490**	**001**	Apr 17, 2009
AB	GLENMARK GENERICS	**10MG**	**A091672**	**001**	Oct 31, 2014
AB		**20MG**	**A091672**	**002**	Oct 31, 2014
AB		**40MG**	**A091672**	**003**	Oct 31, 2014
AB	IMPAX LABS	**10MG**	**A075785**	**001**	Oct 22, 2007
AB		**20MG**	**A075785**	**002**	Oct 22, 2007
AB		**40MG**	**A075785**	**003**	Jan 21, 2009
AB	KREMERS URBAN PHARMS	**10MG**	**A075410**	**001**	Nov 01, 2002
AB		**20MG**	**A075410**	**002**	Nov 01, 2002
AB		**40MG**	**A075410**	**003**	Jan 23, 2009
AB	LUPIN LTD	**40MG**	**A202384**	**001**	Aug 25, 2015
AB	MYLAN	**10MG**	**A075876**	**001**	May 29, 2003
AB		**20MG**	**A075876**	**002**	May 29, 2003
AB		**40MG**	**A075876**	**003**	Jan 21, 2009
AB	SANDOZ	**10MG**	**A075757**	**001**	Jan 28, 2003
AB +		**20MG**	**A075757**	**002**	Jan 28, 2003
AB +		**40MG**	**A076515**	**001**	Jan 21, 2009
AB	ZYDUS PHARMS USA INC	**10MG**	**A091352**	**001**	Nov 19, 2012
AB		**20MG**	**A091352**	**002**	Nov 19, 2012
AB		**40MG**	**A091352**	**003**	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	**20MG;1.1GM**	**A204228**	**001**	Jul 15, 2016
AB		**40MG;1.1GM**	**A204228**	**002**	Jul 15, 2016
AB	AUROLIFE PHARMA LLC	**20MG;1.1GM**	**A204922**	**001**	Aug 19, 2016
AB		**40MG;1.1GM**	**A204922**	**002**	Aug 19, 2016
AB	DR REDDYS LABS LTD	**20MG;1.1GM**	**A204068**	**001**	Jul 15, 2016
AB		**40MG;1.1GM**	**A204068**	**002**	Jul 15, 2016
AB	PAR PHARM	**20MG;1.1GM**	**A078966**	**001**	May 25, 2010
AB		**40MG;1.1GM**	**A078966**	**002**	May 25, 2010
AB	SCIEGEN PHARMS INC	**20MG;1.1GM**	**A207476**	**001**	Dec 06, 2016
AB		**40MG;1.1GM**	**A207476**	**002**	Dec 06, 2016

ZEGERID

AB	SANTARUS INC	**20MG;1.1GM**	**N021849**	**001**	Feb 27, 2006
AB +		**40MG;1.1GM**	**N021849**	**002**	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AA	AJANTA PHARMA LTD	**20MG/PACKET;1.68GM/PACKET**	**A205545**	**001**	Jul 27, 2016
AA		**40MG/PACKET;1.68GM/PACKET**	**A205545**	**002**	Jul 27, 2016

ZEGERID

AA	SANTARUS INC	**20MG/PACKET;1.68GM/PACKET**	**N021636**	**001**	Jun 15, 2004
AA +		**40MG/PACKET;1.68GM/PACKET**	**N021636**	**002**	Dec 21, 2004

FDA data supplied by DrugPatentWatch.com

ONDANSETRON

FILM;ORAL

ZUPLENZ

	MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010
+		8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB	AUROBINDO PHARMA	**4MG**	**A090469**	**001**	Apr 12, 2010
AB		**8MG**	**A090469**	**002**	Apr 12, 2010
AB	BARR	**4MG**	**A076693**	**001**	Jun 25, 2007
AB		**8MG**	**A076693**	**002**	Jun 25, 2007
AB	GLENMARK GENERICS	**4MG**	**A078152**	**001**	Jun 27, 2007
AB		**8MG**	**A078152**	**002**	Jun 27, 2007
AB	MYLAN	**4MG**	**A078139**	**001**	Jun 25, 2007
AB		**8MG**	**A078139**	**002**	Jun 25, 2007
AB	SANDOZ	**4MG**	**A078050**	**001**	Aug 13, 2007
AB		**8MG**	**A078050**	**002**	Aug 13, 2007
AB	SUN PHARM INDS	**4MG**	**A077557**	**001**	Aug 02, 2007
AB		**8MG**	**A077557**	**002**	Aug 02, 2007
AB	SUN PHARM INDS LTD	**4MG**	**A078602**	**001**	Feb 24, 2011
AB		**8MG**	**A078602**	**002**	Feb 24, 2011
AB	TEVA	**4MG**	**A076810**	**001**	Jun 25, 2007
AB		**8MG**	**A076810**	**002**	Jun 25, 2007

ZOFRAN ODT

AB	NOVARTIS PHARMS CORP	**4MG**	**N020781**	**001**	Jan 27, 1999
AB +		**8MG**	**N020781**	**002**	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP	ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206846**	**001**	Jul 13, 2015
AP	AUROBINDO PHARMA LTD	**EQ 2MG BASE/ML**	**A202599**	**001**	Dec 21, 2012
AP +	CLARIS	**EQ 2MG BASE/ML**	**A078288**	**001**	Feb 22, 2013
AP	EMCURE PHARMS	**EQ 2MG BASE/ML**	**A090424**	**001**	Apr 16, 2010
AP	EUROHLTH INTL SARL	**EQ 2MG BASE/ML**	**A076967**	**001**	Dec 26, 2006
AP		**EQ 2MG BASE/ML**	**A077365**	**001**	Dec 26, 2006
AP	FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076974**	**001**	Dec 26, 2006
AP	GLAND PHARMA LTD	**EQ 2MG BASE/ML**	**A079224**	**001**	Sep 25, 2009
AP		**EQ 2MG BASE/ML**	**A090648**	**001**	Jun 15, 2012
AP	HIKMA FARMACEUTICA	**EQ 2MG BASE/ML**	**A076781**	**001**	Dec 26, 2006
AP	HOSPIRA	**EQ 2MG BASE/ML**	**A077473**	**001**	Dec 26, 2006
AP		**EQ 2MG BASE/ML**	**A077840**	**001**	Jan 19, 2007
AP	LUITPOLD	**EQ 2MG BASE/ML**	**A079039**	**001**	Nov 18, 2008
AP	MYLAN LABS LTD	**EQ 2MG BASE/ML**	**A078257**	**001**	Apr 23, 2008
AP	QILU PHARM CO LTD	**EQ 2MG BASE/ML**	**A203711**	**001**	Sep 08, 2014
AP	SANDOZ	**EQ 2MG BASE/ML**	**A077430**	**001**	Jun 27, 2007
AP	SUN PHARM INDS (IN)	**EQ 2MG BASE/ML**	**A077172**	**001**	Dec 26, 2006
AP	TEVA	**EQ 2MG BASE/ML**	**A076876**	**001**	Nov 22, 2006
AP	WOCKHARDT	**EQ 2MG BASE/ML**	**A077577**	**001**	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206845**	**001**	Mar 10, 2016
AP	AUROBINDO PHARMA LTD	**EQ 2MG BASE/ML**	**A202600**	**001**	Dec 21, 2012
AP +	CLARIS	**EQ 2MG BASE/ML**	**A078287**	**001**	Feb 22, 2013
AP	EMCURE PHARMS LTD	**EQ 2MG BASE/ML**	**A078945**	**001**	Jan 03, 2013
AP	EUROHLTH INTL SARL	**EQ 2MG BASE/ML**	**A077011**	**001**	Dec 26, 2006
AP		**EQ 2MG BASE/ML**	**A077541**	**001**	Dec 26, 2006
AP	FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076972**	**001**	Dec 26, 2006
AP		**EQ 2MG BASE/ML**	**A202253**	**001**	Jul 19, 2013
AP	HIKMA FARMACEUTICA	**EQ 2MG BASE/ML**	**A076780**	**001**	Dec 26, 2006
AP	HOSPIRA	**EQ 2MG BASE/ML**	**A077548**	**001**	Dec 26, 2006
AP	LUITPOLD	**EQ 2MG BASE/ML**	**A079032**	**001**	Nov 18, 2008
AP	MYLAN LABS LTD	**EQ 2MG BASE/ML**	**A078244**	**001**	Apr 23, 2008
AP	SANDOZ	**EQ 2MG BASE/ML**	**A077551**	**001**	Jun 27, 2007
AP	SUN PHARM INDS LTD	**EQ 2MG BASE/ML**	**A077173**	**001**	Dec 26, 2006
AP	TEVA	**EQ 2MG BASE/ML**	**A076759**	**001**	Nov 22, 2006
AP	WOCKHARDT	**EQ 2MG BASE/ML**	**A077716**	**001**	Dec 26, 2006

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	**EQ 4MG BASE/5ML**	**A091483**	**001**	Jan 31, 2011
AA	APOTEX	**EQ 4MG BASE/5ML**	**A078127**	**001**	Jun 25, 2007
AA	AUROBINDO PHARMA	**EQ 4MG BASE/5ML**	**A078776**	**001**	Nov 28, 2007
AA	SILARX	**EQ 4MG BASE/5ML**	**A091342**	**001**	Jan 27, 2011
AA	TARO	**EQ 4MG BASE/5ML**	**A077009**	**001**	Nov 30, 2007

FDA data supplied by DrugPatentWatch.com

ONDANSETRON HYDROCHLORIDE
SOLUTION;ORAL
ONDANSETRON HYDROCHLORIDE

AA		WEST-WARD PHARMS INT	**EQ 4MG BASE/5ML**	**A076960**	**001** Dec 26, 2006

ZOFRAN

AA	+	NOVARTIS PHARMS CORP	**EQ 4MG BASE/5ML**	**N020605**	**001** Jan 24, 1997

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE

AB		APOTEX	**EQ 4MG BASE**	**A077306**	**001** Jun 25, 2007
AB			**EQ 8MG BASE**	**A077306**	**002** Jun 25, 2007
AB		AUROBINDO PHARMA	**EQ 4MG BASE**	**A078539**	**001** Jul 31, 2007
AB			**EQ 8MG BASE**	**A078539**	**002** Jul 31, 2007
AB			**EQ 24MG BASE**	**A078539**	**003** Jul 31, 2007
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A076183**	**003** Dec 26, 2006
AB			**EQ 8MG BASE**	**A076183**	**002** Dec 26, 2006
AB			**EQ 24MG BASE**	**A076183**	**001** Dec 26, 2006
AB		GLENMARK GENERICS	**EQ 4MG BASE**	**A077535**	**001** Jun 25, 2007
AB			**EQ 8MG BASE**	**A077535**	**002** Jun 25, 2007
AB			**EQ 24MG BASE**	**A077535**	**003** Jun 25, 2007
AB		IPCA LABS LTD	**EQ 4MG BASE**	**A203761**	**001** Jan 23, 2014
AB			**EQ 8MG BASE**	**A203761**	**002** Jan 23, 2014
AB		MYLAN	**EQ 4MG BASE**	**A076930**	**001** Jun 25, 2007
AB			**EQ 8MG BASE**	**A076930**	**002** Jun 25, 2007
AB			**EQ 24MG BASE**	**A076930**	**004** Jun 25, 2007
AB		NATCO PHARMA LTD	**EQ 4MG BASE**	**A077851**	**001** Jun 25, 2007
AB			**EQ 8MG BASE**	**A077851**	**002** Jun 25, 2007
AB		PLIVA HRVATSKA DOO	**EQ 4MG BASE**	**A077112**	**001** Jun 25, 2007
AB			**EQ 8MG BASE**	**A077112**	**002** Jun 25, 2007
AB			**EQ 24MG BASE**	**A077112**	**003** Jun 25, 2007
AB		SANDOZ	**EQ 4MG BASE**	**A077517**	**001** Jun 25, 2007
AB			**EQ 8MG BASE**	**A077517**	**002** Jun 25, 2007
AB			**EQ 24MG BASE**	**A077517**	**003** Jun 25, 2007
AB		SUN PHARM INDS (IN)	**EQ 4MG BASE**	**A077050**	**001** Jun 25, 2007
AB			**EQ 8MG BASE**	**A077050**	**002** Jun 25, 2007
AB		TEVA	**EQ 4MG BASE**	**A076252**	**001** Jun 25, 2007
AB			**EQ 8MG BASE**	**A076252**	**002** Jun 25, 2007
AB			**EQ 24MG BASE**	**A076252**	**003** Jun 25, 2007

ZOFRAN

AB		NOVARTIS PHARMS CORP	**EQ 4MG BASE**	**N020103**	**001** Dec 31, 1992
AB			**EQ 8MG BASE**	**N020103**	**002** Dec 31, 1992
AB	+		**EQ 24MG BASE**	**N020103**	**003** Aug 27, 1999

ONDANSETRON HYDROCHLORIDE

		DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004 Dec 26, 2006

ORITAVANCIN DIPHOSPHATE
POWDER;IV (INFUSION)
ORBACTIV

	+	THE MEDICINES CO	EQ 400MG BASE/VIAL	N206334	001 Aug 06, 2014

ORLISTAT
CAPSULE;ORAL
XENICAL

	+	HOFFMANN LA ROCHE	120MG	N020766	001 Apr 23, 1999

ORPHENADRINE CITRATE
INJECTABLE;INJECTION
ORPHENADRINE CITRATE

AP	+	AKORN	**30MG/ML**	**A040484**	**001** May 24, 2006
AP		SAGENT PHARMS	**30MG/ML**	**A090585**	**001** Aug 30, 2011
AP		WATSON LABS	**30MG/ML**	**A084779**	**001** Mar 15, 1982
AP		WEST-WARD PHARMS INT	**30MG/ML**	**A040463**	**001** Mar 04, 2003

TABLET, EXTENDED RELEASE;ORAL
ORPHENADRINE CITRATE

AB		GAVIS PHARMS	**100MG**	**A040284**	**001** Jun 19, 1998
AB		IMPAX PHARMS	**100MG**	**A040368**	**001** Jun 23, 2000
AB		INVAGEN PHARMS	**100MG**	**A091158**	**001** Jul 27, 2012
AB	+	SANDOZ	**100MG**	**A040327**	**001** Feb 15, 2000
AB		TEDOR PHARMA INC	**100MG**	**A040249**	**001** Jan 29, 1999

OSELTAMIVIR PHOSPHATE
CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB		NATCO PHARMA LTD	**EQ 30MG BASE**	**A202595**	**001** Aug 03, 2016
AB			**EQ 45MG BASE**	**A202595**	**002** Aug 03, 2016
AB			**EQ 75MG BASE**	**A202595**	**003** Aug 03, 2016
TAMIFLU					
AB		ROCHE	**EQ 30MG BASE**	**N021087**	**003** Jul 02, 2007
AB			**EQ 45MG BASE**	**N021087**	**002** Jul 02, 2007
AB	**+**		**EQ 75MG BASE**	**N021087**	**001** Oct 27, 1999
FOR SUSPENSION;ORAL					
TAMIFLU					
	+	ROCHE	EQ 6MG BASE/ML	N021246	002 Mar 21, 2011

OSIMERTINIB MESYLATE
TABLET;ORAL
TAGRISSO

		ASTRAZENECA PHARMS	EQ 40MG BASE	N208065	001 Nov 13, 2015
	+		EQ 80MG BASE	N208065	002 Nov 13, 2015

OSPEMIFENE
TABLET;ORAL
OSPHENA

	+	SHIONOGI INC	60MG	N203505	001 Feb 26, 2013

OXACILLIN SODIUM
INJECTABLE;INJECTION
OXACILLIN SODIUM

AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A201539**	**001** Jan 18, 2013
AP			**EQ 2GM BASE/VIAL**	**A201539**	**002** Jan 18, 2013
AP			**EQ 10GM BASE/VIAL**	**A201538**	**001** Jan 18, 2013
AP		HOSPIRA INC	**EQ 1GM BASE/VIAL**	**A203950**	**001** Dec 11, 2015
AP			**EQ 2GM BASE/VIAL**	**A203950**	**002** Dec 11, 2015
AP		MYLAN LABS LTD	**EQ 1GM BASE/VIAL**	**A091486**	**001** Aug 25, 2014
AP			**EQ 2GM BASE/VIAL**	**A091486**	**002** Aug 25, 2014
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A091246**	**001** Mar 30, 2012
AP			**EQ 2GM BASE/VIAL**	**A091246**	**002** Mar 30, 2012
AP			**EQ 10GM BASE/VIAL**	**A091245**	**001** Mar 30, 2012
AP	**+**	SANDOZ	**EQ 1GM BASE/VIAL**	**A061490**	**003**
AP	**+**		**EQ 2GM BASE/VIAL**	**A061490**	**004**
AP	**+**		**EQ 10GM BASE/VIAL**	**A061490**	**006** May 09, 1991
BACTOCILL IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001 Oct 26, 1989
	+		EQ 40MG BASE/ML	N050640	002 Oct 26, 1989
POWDER;INTRAVENOUS					
OXACILLIN SODIUM					
AP	**+**	SANDOZ	**EQ 1GM BASE/VIAL**	**A062737**	**001** Dec 23, 1986
AP	**+**		**EQ 2GM BASE/VIAL**	**A062737**	**002** Dec 23, 1986

OXALIPLATIN
INJECTABLE;IV (INFUSION)
ELOXATIN

AP	**+**	SANOFI AVENTIS US	**50MG/10ML (5MG/ML)**	**N021759**	**001** Jan 31, 2005
AP	**+**		**100MG/20ML (5MG/ML)**	**N021759**	**002** Jan 31, 2005
OXALIPLATIN					
AP		ACTAVIS TOTOWA	**50MG/VIAL**	**A078803**	**001** Aug 08, 2012
AP			**100MG/VIAL**	**A078803**	**002** Aug 08, 2012
AP		FRESENIUS KABI ONCOL	**50MG/10ML (5MG/ML)**	**A078811**	**001** Jun 10, 2010
AP			**100MG/20ML (5MG/ML)**	**A078811**	**002** Jun 10, 2010
AP			**50MG/VIAL**	**A078810**	**001** Aug 07, 2009
AP			**100MG/VIAL**	**A078810**	**002** Aug 07, 2009
AP		FRESENIUS KABI USA	**50MG/VIAL**	**A078819**	**001** Jun 02, 2010
AP			**100MG/VIAL**	**A078819**	**002** Jun 02, 2010
AP		HOSPIRA INC	**50MG/VIAL**	**A078815**	**001** Sep 30, 2009
AP			**100MG/VIAL**	**A078815**	**002** Sep 30, 2009
AP		HOSPIRA WORLDWIDE	**50MG/10ML (5MG/ML)**	**A078813**	**001** Aug 07, 2009
AP			**100MG/20ML (5MG/ML)**	**A078813**	**002** Aug 07, 2009
AP		JIANGSU HENGRUI MED	**50MG/10ML (5MG/ML)**	**A203869**	**001** Jun 18, 2014
AP			**100MG/20ML (5MG/ML)**	**A203869**	**002** Jun 18, 2014
AP		MYLAN LABS LTD	**50MG/10ML (5MG/ML)**	**A091358**	**001** Aug 07, 2012
AP			**50MG/VIAL**	**A200979**	**001** Aug 08, 2012
AP			**100MG/20ML (5MG/ML)**	**A091358**	**002** Aug 07, 2012
AP			**100MG/VIAL**	**A200979**	**002** Aug 08, 2012
AP		QILU PHARM CO LTD	**50MG/10ML (5MG/ML)**	**A204368**	**001** Jun 07, 2016

FDA data supplied by DrugPatentWatch.com

OXALIPLATIN
INJECTABLE;IV (INFUSION)

		OXALIPLATIN				
AP			**50MG/VIAL**	**A204616**	**001**	May 11, 2016
AP			**100MG/20ML (5MG/ML)**	**A204368**	**002**	Jun 07, 2016
AP			**100MG/VIAL**	**A204616**	**002**	May 11, 2016
AP		SANDOZ	**50MG/10ML (5MG/ML)**	**A078817**	**001**	Jan 24, 2011
AP			**100MG/20ML (5MG/ML)**	**A078817**	**002**	Jan 24, 2011
AP	+	SUN PHARMA GLOBAL	**50MG/VIAL**	**A078818**	**001**	Aug 07, 2009
AP			**50MG/10ML (5MG/ML)**	**A202922**	**001**	Apr 08, 2014
AP	+		**100MG/VIAL**	**A078818**	**002**	Aug 07, 2009
AP			**100MG/20ML (5MG/ML)**	**A202922**	**002**	Apr 08, 2014
AP	+	TEVA PHARMS	**50MG/10ML (5MG/ML)**	**N022160**	**001**	Aug 07, 2009
AP	+		**100MG/20ML (5MG/ML)**	**N022160**	**002**	Aug 07, 2009
	+	QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016

OXANDROLONE
TABLET;ORAL

		OXANDRIN				
AB		GEMINI LABS LLC	**2.5MG**	**N013718**	**001**	
AB	+		**10MG**	**N013718**	**002**	Nov 05, 2001
		OXANDROLONE				
AB		PAR PHARM	**2.5MG**	**A077827**	**001**	Jun 22, 2007
AB			**10MG**	**A077827**	**002**	Jun 22, 2007
AB		UPSHER SMITH	**2.5MG**	**A076761**	**001**	Dec 01, 2006
AB			**10MG**	**A078033**	**001**	Mar 22, 2007

OXAPROZIN
TABLET;ORAL

		DAYPRO				
AB	+	GD SEARLE	**600MG**	**N018841**	**004**	Oct 29, 1992
		OXAPROZIN				
AB		APOTEX INC	**600MG**	**A075987**	**001**	Sep 02, 2004
AB		DR REDDYS LABS LTD	**600MG**	**A075855**	**001**	Jan 31, 2001
AB		IVAX SUB TEVA PHARMS	**600MG**	**A075846**	**001**	May 13, 2002
AB		SANDOZ	**600MG**	**A075845**	**001**	Jan 31, 2001
AB		SUN PHARM INDS INC	**600MG**	**A075844**	**001**	Jan 03, 2002
AB		TEVA	**600MG**	**A075849**	**001**	Jul 03, 2002

OXAZEPAM
CAPSULE;ORAL

		OXAZEPAM				
AB		ACTAVIS ELIZABETH	**10MG**	**A072251**	**001**	Apr 14, 1988
AB			**15MG**	**A072252**	**001**	Apr 14, 1988
AB	+		**30MG**	**A072253**	**001**	Apr 14, 1988
AB		SANDOZ	**10MG**	**A071813**	**001**	Apr 19, 1988
AB			**15MG**	**A071756**	**001**	Apr 19, 1988
AB			**30MG**	**A071814**	**001**	Apr 19, 1988

OXCARBAZEPINE
SUSPENSION;ORAL

		OXCARBAZEPINE				
AB		AMNEAL PHARMS	**300MG/5ML**	**A202961**	**001**	Sep 17, 2012
AB		SUN PHARM INDS LTD	**300MG/5ML**	**A078734**	**001**	Jun 26, 2009
AB		WEST-WARD PHARMS INT	**300MG/5ML**	**A201193**	**001**	Oct 03, 2012
		TRILEPTAL				
AB	+	NOVARTIS	**300MG/5ML**	**N021285**	**001**	May 25, 2001

TABLET;ORAL

		OXCARBAZEPINE				
AB		ANI PHARMS INC	**150MG**	**A078005**	**001**	Dec 11, 2007
AB			**300MG**	**A078005**	**002**	Dec 11, 2007
AB			**600MG**	**A078005**	**003**	Dec 11, 2007
AB		APOTEX INC	**150MG**	**A077747**	**001**	Apr 09, 2008
AB			**300MG**	**A077747**	**002**	Apr 09, 2008
AB			**600MG**	**A077747**	**003**	Apr 09, 2008
AB		BRECKENRIDGE PHARM	**150MG**	**A078069**	**001**	Jan 11, 2008
AB			**300MG**	**A078069**	**002**	Jan 11, 2008
AB			**600MG**	**A078069**	**003**	Jan 11, 2008
AB		CADISTA PHARMS	**150MG**	**A090239**	**001**	Jan 25, 2010
AB			**300MG**	**A090239**	**002**	Jan 25, 2010
AB			**600MG**	**A090239**	**003**	Jan 25, 2010
AB		GLENMARK GENERICS	**150MG**	**A077802**	**001**	Oct 09, 2007
AB			**300MG**	**A077802**	**002**	Oct 09, 2007
AB			**600MG**	**A077802**	**003**	Oct 09, 2007

OXCARBAZEPINE
TABLET;ORAL
OXCARBAZEPINE

AB	SUN PHARM INDS	**150MG**	**A077794**	**001**	Oct 09, 2007
AB		**300MG**	**A077794**	**002**	Oct 09, 2007
AB		**600MG**	**A077794**	**003**	Oct 09, 2007
AB	TARO	**150MG**	**A077801**	**001**	Nov 15, 2007
AB		**300MG**	**A077801**	**002**	Nov 15, 2007
AB		**600MG**	**A077801**	**003**	Nov 15, 2007
AB	WEST-WARD PHARMS INT	**150MG**	**A077795**	**001**	Oct 09, 2007
AB		**300MG**	**A077795**	**002**	Oct 09, 2007
AB		**600MG**	**A077795**	**003**	Oct 09, 2007

TRILEPTAL

AB	NOVARTIS	**150MG**	**N021014**	**001**	Jan 14, 2000
AB		**300MG**	**N021014**	**002**	Jan 14, 2000
AB +		**600MG**	**N021014**	**003**	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL
OXTELLAR XR

	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
		300MG	N202810	002	Oct 19, 2012
+		600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE
CREAM;TOPICAL
OXICONAZOLE NITRATE

AB	TARO	**EQ 1% BASE**	**A205076**	**001**	Mar 07, 2016

OXISTAT

AB +	FOUGERA PHARMS	**EQ 1% BASE**	**N019828**	**001**	Dec 30, 1988

LOTION;TOPICAL
OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXTRIPHYLLINE
TABLET, EXTENDED RELEASE;ORAL
CHOLEDYL SA

+	WARNER CHILCOTT LLC	400MG	A087863	001	May 24, 1983
+		600MG	A086742	001	

OXYBUTYNIN
FILM, EXTENDED RELEASE;TRANSDERMAL
OXYBUTYNIN

AB	BARR LABS DIV TEVA	**3.9MG/24HR**	**A090526**	**001**	Mar 04, 2014

OXYTROL

AB +	ALLERGAN SALES LLC	**3.9MG/24HR**	**N021351**	**002**	Feb 26, 2003

GEL, METERED;TRANSDERMAL
GELNIQUE 3%

+	ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011

OXYBUTYNIN CHLORIDE
GEL;TRANSDERMAL
GELNIQUE

+	ALLERGAN SALES LLC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009

SYRUP;ORAL
OXYBUTYNIN CHLORIDE

AA	PHARM ASSOC	**5MG/5ML**	**A075137**	**001**	Dec 18, 1998
AA	SILARX	**5MG/5ML**	**A074520**	**001**	Mar 29, 1996
AA	VINTAGE PHARMS	**5MG/5ML**	**A076682**	**001**	Dec 28, 2004
AA +	WOCKHARDT	**5MG/5ML**	**A074868**	**001**	Feb 12, 1997

TABLET;ORAL
OXYBUTYNIN CHLORIDE

AB	TEVA PHARMS USA	**5MG**	**A071655**	**001**	Nov 14, 1988
AB	USL PHARMA	**5MG**	**A074625**	**001**	Jul 31, 1996
AB +	VINTAGE PHARMS	**5MG**	**A075079**	**001**	Oct 31, 1997

TABLET, EXTENDED RELEASE;ORAL
DITROPAN XL

AB	JANSSEN PHARMS	**5MG**	**N020897**	**001**	Dec 16, 1998
AB		**10MG**	**N020897**	**002**	Dec 16, 1998
AB +		**15MG**	**N020897**	**003**	Jun 22, 1999

OXYBUTYNIN CHLORIDE

AB	ACCORD HLTHCARE	**5MG**	**A207138**	**001**	Feb 29, 2016
AB		**10MG**	**A207138**	**002**	Feb 29, 2016
AB		**15MG**	**A207138**	**003**	Feb 29, 2016
AB	AMNEAL PHARMS	**5MG**	**A204010**	**001**	Nov 23, 2015
AB		**10MG**	**A204010**	**002**	Nov 23, 2015

FDA data supplied by DrugPatentWatch.com

OXYBUTYNIN CHLORIDE
TABLET, EXTENDED RELEASE;ORAL
OXYBUTYNIN CHLORIDE

AB		**15MG**	**A204010**	**003**	Nov 23, 2015
AB	IMPAX PHARMS	**5MG**	**A076745**	**002**	May 09, 2007
AB		**10MG**	**A076745**	**003**	May 09, 2007
AB		**15MG**	**A076745**	**001**	Nov 09, 2006
AB	MYLAN	**5MG**	**A076702**	**001**	Nov 09, 2006
AB	MYLAN PHARMS INC	**10MG**	**A076644**	**001**	Nov 09, 2006
AB		**15MG**	**A076644**	**002**	May 10, 2007
AB	OSMOTICA PHARM US	**5MG**	**A078503**	**001**	Feb 04, 2009
AB		**10MG**	**A078503**	**002**	Feb 04, 2009
AB		**15MG**	**A078503**	**003**	Feb 04, 2009
AB	UNIQUE PHARM LABS	**5MG**	**A206121**	**001**	May 27, 2016
AB		**10MG**	**A206121**	**002**	May 27, 2016
AB		**15MG**	**A206121**	**003**	May 27, 2016

OXYCODONE
CAPSULE, EXTENDED RELEASE;ORAL
XTAMPZA ER

	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
		13.5MG	N208090	002	Apr 26, 2016
		18MG	N208090	003	Apr 26, 2016
		27MG	N208090	004	Apr 26, 2016
+		36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE
CAPSULE;ORAL
OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	**5MG**	**A205177**	**001**	Mar 31, 2016
AB	AVANTHI INC	**5MG**	**A202773**	**001**	Aug 17, 2015
AB	LANNETT HOLDINGS INC	**5MG**	**A203823**	**001**	Aug 01, 2014
AB +	LEHIGH VALLEY	**5MG**	**N200534**	**001**	Oct 20, 2010
AB	MAYNE PHARMA INC	**5MG**	**A203107**	**001**	Jul 26, 2012
AB	NOVEL LABS INC	**5MG**	**A204752**	**001**	Aug 24, 2015

SOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

AA	ANI PHARMS INC	**5MG/5ML**	**A204979**	**001**	Jun 01, 2015
AA	LANNETT HOLDINGS INC	**100MG/5ML**	**A204085**	**001**	Sep 09, 2014
AA	LEHIGH VALLEY	**5MG/5ML**	**N200535**	**002**	Aug 22, 2013
AA +		**100MG/5ML**	**N200535**	**001**	Oct 20, 2010
AA	MAYNE PHARMA INC	**100MG/5ML**	**A204092**	**001**	Jun 05, 2014
AA	NOVEL LABS INC	**100MG/5ML**	**A204603**	**001**	Apr 29, 2015
AA +	VISTAPHARM	**5MG/5ML**	**N201194**	**001**	Jan 12, 2012
AA		**100MG/5ML**	**A202537**	**001**	Jul 30, 2012
AA	WES PHARMA INC	**5MG/5ML**	**A207511**	**001**	Nov 23, 2016
AA	WEST-WARD PHARMS INT	**5MG/5ML**	**A204037**	**001**	Jul 15, 2013
AA		**100MG/5ML**	**A203208**	**001**	Jul 12, 2013
AA	WOCKHARDT BIO AG	**5MG/5ML**	**A206456**	**001**	Jun 16, 2015

TABLET;ORAL
OXYCODONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	**5MG**	**A076636**	**003**	Apr 07, 2015
AB		**15MG**	**A076636**	**001**	Feb 06, 2004
AB		**30MG**	**A076636**	**002**	Feb 06, 2004
AB	ALVOGEN MALTA	**5MG**	**A202116**	**001**	Dec 30, 2011
AB		**15MG**	**A202116**	**002**	Dec 30, 2011
AB		**30MG**	**A202116**	**003**	Dec 30, 2011
AB	AMNEAL PHARMS	**5MG**	**A203638**	**001**	Jun 03, 2014
AB		**10MG**	**A203638**	**002**	Jun 03, 2014
AB		**15MG**	**A203638**	**003**	Jun 03, 2014
AB		**20MG**	**A203638**	**004**	Jun 03, 2014
AB		**30MG**	**A203638**	**005**	Jun 03, 2014
AB	AUROLIFE PHARMA LLC	**5MG**	**A202160**	**001**	Nov 19, 2012
AB		**15MG**	**A202160**	**002**	Nov 19, 2012
AB		**30MG**	**A202160**	**003**	Nov 19, 2012
AB	AVANTHI INC	**5MG**	**A091393**	**001**	Aug 31, 2009
AB		**10MG**	**A091393**	**002**	Aug 31, 2009
AB		**15MG**	**A091393**	**003**	Aug 31, 2009
AB		**20MG**	**A091393**	**004**	Aug 31, 2009
AB		**30MG**	**A091393**	**005**	Aug 31, 2009
AB	COREPHARMA	**5MG**	**A090895**	**001**	Aug 24, 2009
AB		**15MG**	**A090895**	**002**	Aug 24, 2009
AB		**30MG**	**A090895**	**003**	Aug 24, 2009

FDA data supplied by DrugPatentWatch.com

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB	EPIC PHARMA LLC	**5MG**	**A202662**	**001**	Sep 22, 2015
AB		**10MG**	**A202662**	**002**	Sep 22, 2015
AB		**15MG**	**A202662**	**003**	Sep 22, 2015
AB		**30MG**	**A202662**	**004**	Sep 22, 2015
AB	KEN LIFESCIENCE	**5MG**	**A207119**	**001**	Apr 12, 2016
AB		**10MG**	**A207119**	**002**	Apr 12, 2016
AB		**15MG**	**A207119**	**003**	Apr 12, 2016
AB		**20MG**	**A207119**	**004**	Apr 12, 2016
AB		**30MG**	**A207119**	**005**	Apr 12, 2016
AB	MALLINCKRODT INC	**5MG**	**A076758**	**003**	Mar 19, 2007
AB		**15MG**	**A076758**	**001**	Jun 30, 2004
AB		**30MG**	**A076758**	**002**	Jun 30, 2004
AB	MAYNE PHARMA INC	**5MG**	**A091313**	**001**	Feb 18, 2011
AB		**10MG**	**A091313**	**004**	Apr 29, 2016
AB		**15MG**	**A091313**	**002**	Feb 18, 2011
AB		**20MG**	**A091313**	**005**	Apr 29, 2016
AB		**30MG**	**A091313**	**003**	Feb 18, 2011
AB	NESHER PHARMS	**5MG**	**A077290**	**001**	Dec 08, 2005
AB		**10MG**	**A077290**	**002**	Dec 08, 2005
AB		**15MG**	**A077290**	**003**	Dec 08, 2005
AB		**20MG**	**A077290**	**004**	Dec 08, 2005
AB		**30MG**	**A077290**	**005**	Dec 08, 2005
AB	RHODES PHARMS	**5MG**	**A091490**	**001**	Mar 09, 2011
AB		**10MG**	**A091490**	**002**	Mar 09, 2011
AB		**15MG**	**A091490**	**003**	Mar 09, 2011
AB		**20MG**	**A091490**	**004**	Mar 09, 2011
AB		**30MG**	**A091490**	**005**	Mar 09, 2011
AB	SUN PHARM INDS INC	**5MG**	**A090659**	**001**	Apr 10, 2009
AB		**10MG**	**A090659**	**005**	Nov 06, 2012
AB		**15MG**	**A090659**	**002**	Apr 10, 2009
AB		**20MG**	**A090659**	**004**	Nov 06, 2012
AB		**30MG**	**A090659**	**003**	Apr 10, 2009
AB	VINTAGE PHARMS	**5MG**	**A077712**	**003**	Mar 02, 2009
AB		**10MG**	**A077712**	**004**	Apr 13, 2015
AB		**15MG**	**A077712**	**001**	Jan 31, 2007
AB		**20MG**	**A077712**	**005**	Apr 13, 2015
AB		**30MG**	**A077712**	**002**	Jan 31, 2007

ROXICODONE

AB	MALLINCKRODT INC	**5MG**	**N021011**	**003**	May 15, 2009
AB +		**15MG**	**N021011**	**001**	Aug 31, 2000
AB		**30MG**	**N021011**	**002**	Aug 31, 2000

OXAYDO

	EGALET US INC	5MG	N202080	001	Jun 17, 2011
		7.5MG	N202080	002	Jun 17, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYCONTIN

	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
		15MG	N022272	002	Apr 05, 2010
		20MG	N022272	003	Apr 05, 2010
		30MG	N022272	004	Apr 05, 2010
+		40MG	N022272	005	Apr 05, 2010
		60MG	N022272	006	Apr 05, 2010
		80MG	N022272	007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

+	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+	MEDA PHARMS	50MG	N016848	001

OXYMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

OPANA

+	ENDO PHARMS	1MG/ML	N011707	002

FDA data supplied by DrugPatentWatch.com

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OPANA

AB	ENDO PHARMS	**5MG**	**N021611**	**001**	Jun 22, 2006
AB	+	**10MG**	**N021611**	**002**	Jun 22, 2006

OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	**5MG**	**A204459**	**001**	Apr 26, 2016
AB		**10MG**	**A204459**	**002**	Apr 26, 2016
AB	AVANTHI INC	**5MG**	**A203601**	**001**	Jan 30, 2013
AB		**10MG**	**A203601**	**002**	Jan 30, 2013
AB	COREPHARMA	**5MG**	**A201187**	**001**	Dec 15, 2014
AB		**10MG**	**A201187**	**002**	Dec 15, 2014
AB	MALLINCKRODT INC	**5MG**	**A202321**	**001**	Apr 25, 2013
AB		**10MG**	**A202321**	**002**	Apr 25, 2013
AB	TEVA	**5MG**	**A091443**	**002**	Feb 15, 2011
AB		**10MG**	**A091443**	**001**	Feb 15, 2011
AB	WEST-WARD PHARMS INT	**5MG**	**A090964**	**001**	Sep 27, 2010
AB		**10MG**	**A090964**	**002**	Sep 27, 2010

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	**5MG**	**A079046**	**003**	Jul 11, 2013
AB		**7.5MG**	**A079046**	**001**	Dec 13, 2010
AB		**10MG**	**A079046**	**004**	Jul 11, 2013
AB		**15MG**	**A079046**	**002**	Dec 13, 2010
AB		**20MG**	**A079046**	**005**	Jul 11, 2013
AB		**30MG**	**A079046**	**006**	Jul 11, 2013
AB		**40MG**	**A079046**	**007**	Jul 11, 2013
AB	IMPAX LABS	**5MG**	**A079087**	**001**	Jun 14, 2010
AB		**7.5MG**	**A079087**	**002**	Dec 21, 2010
AB		**10MG**	**A079087**	**003**	Jun 14, 2010
AB		**15MG**	**A079087**	**004**	Dec 21, 2010
AB		**20MG**	**A079087**	**005**	Jun 14, 2010
AB		**30MG**	**A079087**	**006**	Jul 22, 2010
AB		**40MG**	**A079087**	**007**	Jun 14, 2010
AB	MALLINCKRODT INC	**5MG**	**A202946**	**001**	Jun 27, 2014
AB		**7.5MG**	**A202946**	**002**	Jun 27, 2014
AB		**10MG**	**A202946**	**003**	Jun 27, 2014
AB		**15MG**	**A202946**	**004**	Jun 27, 2014
AB		**20MG**	**A202946**	**005**	Jun 27, 2014
AB		**30MG**	**A202946**	**006**	Jun 27, 2014
AB		**40MG**	**A202946**	**007**	Jun 27, 2014
AB	PAR PHARM	**5MG**	**A200792**	**001**	Oct 24, 2014
AB		**7.5MG**	**A200792**	**002**	Oct 24, 2014
AB		**10MG**	**A200792**	**003**	Oct 24, 2014
AB		**15MG**	**A200792**	**004**	Oct 24, 2014
AB		**20MG**	**A200792**	**005**	Oct 24, 2014
AB		**30MG**	**A200792**	**006**	Oct 24, 2014
AB		**40MG**	**A200792**	**007**	Oct 24, 2014
AB	SUN PHARM INDS LTD	**5MG**	**A203506**	**001**	Apr 24, 2015
AB		**7.5MG**	**A203506**	**002**	Apr 24, 2015
AB		**10MG**	**A203506**	**003**	Apr 24, 2015
AB		**15MG**	**A203506**	**004**	Apr 24, 2015
AB		**20MG**	**A203506**	**005**	Apr 24, 2015
AB		**30MG**	**A203506**	**006**	Apr 24, 2015
AB		**40MG**	**A203506**	**007**	Apr 24, 2015
AB	WEST-WARD PHARMS INT	**5MG**	**A200822**	**002**	Jul 15, 2013
AB		**7.5MG**	**A200822**	**003**	Jul 15, 2013
AB		**10MG**	**A200822**	**004**	Jul 15, 2013
AB		**15MG**	**A200822**	**005**	Jul 15, 2013
AB		**20MG**	**A200822**	**006**	Jul 15, 2013
AB		**30MG**	**A200822**	**007**	Jul 15, 2013
AB		**40MG**	**A200822**	**001**	Jul 15, 2013

OPANA ER

	ENDO PHARMS	5MG	N201655	001	Dec 09, 2011
		7.5MG	N201655	002	Dec 09, 2011
		10MG	N201655	003	Dec 09, 2011
		15MG	N201655	004	Dec 09, 2011
		20MG	N201655	005	Dec 09, 2011
		30MG	N201655	006	Dec 09, 2011
+		40MG	N201655	007	Dec 09, 2011

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE
OINTMENT;OPHTHALMIC
TERRAMYCIN W/ POLYMYXIN B SULFATE

	+	PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015 001	

OXYTOCIN
INJECTABLE;INJECTION

		OXYTOCIN			
AP	+	FRESENIUS KABI USA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018248 001**	
AP	+		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018248 002**	
AP		HIKMA FARMACEUTICA	**10USP UNITS/ML (10USP UNITS/ML)**	**A200219 001**	Feb 13, 2013
AP	+	WEST-WARD PHARMS INT	**10USP UNITS/ML (10USP UNITS/ML)**	**N018243 001**	
AP	+		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018243 002**	Jan 10, 2007
		PITOCIN			
AP	+	PAR STERILE PRODUCTS	**10USP UNITS/ML (10USP UNITS/ML)**	**N018261 001**	
AP			**100USP UNITS/10ML (10USP UNITS/ML)**	**N018261 002**	Jul 27, 2007
		OXYTOCIN			
	+	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248 003	Jul 27, 2007
		PITOCIN			
		PAR STERILE PRODUCTS	500USP UNITS/50ML (10USP UNITS/ML)	N018261 003	Sep 05, 2012

PACLITAXEL
FOR SUSPENSION;IV (INFUSION)

		ABRAXANE			
	+	ABRAXIS BIOSCIENCE	100MG/VIAL	N021660 001	Jan 07, 2005

INJECTABLE;INJECTION

		PACITAXEL			
AP		GLAND PHARMA LTD	**6MG/ML**	**A207326 001**	Aug 23, 2016
		PACLITAXEL			
AP		ACTAVIS TOTOWA	**6MG/ML**	**A090130 001**	Dec 09, 2009
AP		FRESENIUS KABI ONCOL	**6MG/ML**	**A077574 001**	Nov 27, 2006
AP	+	HOSPIRA	**6MG/ML**	**A076131 001**	May 08, 2002
AP		MYLAN LABS LTD	**6MG/ML**	**A091540 001**	Sep 29, 2011
AP		SANDOZ INC	**6MG/ML**	**A078167 001**	Dec 26, 2007
AP		TEVA PHARMS	**6MG/ML**	**A075184 001**	Jan 25, 2002
AP		WEST-WARD PHARMS INT	**6MG/ML**	**A075190 001**	Jan 28, 2002
		TAXOL			
AP		HQ SPCLT PHARMA	**6MG/ML**	**N020262 001**	Dec 29, 1992

PALBOCICLIB
CAPSULE;ORAL

		IBRANCE			
		PFIZER INC	75MG	N207103 001	Feb 03, 2015
			100MG	N207103 002	Feb 03, 2015
	+		125MG	N207103 003	Feb 03, 2015

PALIPERIDONE
TABLET, EXTENDED RELEASE;ORAL

		INVEGA			
AB		JANSSEN PHARMS	**1.5MG**	**N021999 006**	Aug 26, 2008
AB			**3MG**	**N021999 001**	Dec 19, 2006
AB	+		**6MG**	**N021999 002**	Dec 19, 2006
AB			**9MG**	**N021999 003**	Dec 19, 2006
		PALIPERIDONE			
AB		ACTAVIS LABS FL INC	**1.5MG**	**A202645 001**	Aug 03, 2015
AB			**3MG**	**A202645 002**	Aug 03, 2015
AB			**6MG**	**A202645 003**	Aug 03, 2015
AB			**9MG**	**A202645 004**	Aug 03, 2015
AB		MYLAN PHARMS INC	**1.5MG**	**A203802 001**	Sep 24, 2015
AB			**3MG**	**A203802 002**	Sep 24, 2015
AB			**6MG**	**A203802 003**	Sep 24, 2015
AB			**9MG**	**A203802 004**	Sep 24, 2015

PALIPERIDONE PALMITATE
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

		INVEGA SUSTENNA			
		JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001	Jul 31, 2009
			78MG/0.5ML (78MG/0.5ML)	N022264 002	Jul 31, 2009
			117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009
	+		156MG/ML (156MG/ML)	N022264 004	Jul 31, 2009
			234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009
		INVEGA TRINZA			
		JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946 001	May 18, 2015
			410MG/1.315ML (311.79MG/ML)	N207946 002	May 18, 2015
			546MG/1.75ML (312MG/ML)	N207946 003	May 18, 2015

PALIPERIDONE PALMITATE
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA

	+		819MG/2.625ML (312MG/ML)	N207946	004 May 18, 2015

PALONOSETRON HYDROCHLORIDE
INJECTABLE;INTRAVENOUS
ALOXI

AP	**+**	HELSINN HLTHCARE	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**N021372**	**002** Feb 29, 2008
AP	**+**		**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**N021372**	**001** Jul 25, 2003

PALONOSETRON HYDROCHLORIDE

AP		DR REDDYS LABS LTD	**EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)**	**A201533**	**001** Apr 21, 2016
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A201533**	**002** Apr 21, 2016
AP		SANDOZ INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202521**	**001** Oct 13, 2015

SOLUTION;INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

		DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001 Mar 01, 2016
			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002 Mar 01, 2016
		EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001 Aug 22, 2016

PAMIDRONATE DISODIUM
INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP		AREVA PHARMS	**30MG/VIAL**	**A077433**	**001** Nov 26, 2008
AP			**60MG/VIAL**	**A077433**	**002** Nov 26, 2008
AP			**90MG/VIAL**	**A077433**	**003** Nov 26, 2008
AP		FRESENIUS KABI USA	**30MG/VIAL**	**A075773**	**001** May 06, 2002
AP			**30MG/10ML (3MG/ML)**	**A076207**	**001** May 17, 2002
AP			**90MG/VIAL**	**A075773**	**002** May 06, 2002
AP			**90MG/10ML (9MG/ML)**	**A076207**	**002** May 17, 2002
AP	**+**	HOSPIRA	**30MG/10ML (3MG/ML)**	**A075841**	**001** Jun 27, 2002
AP	**+**		**60MG/10ML (6MG/ML)**	**A075841**	**002** Jun 27, 2002
AP	**+**		**90MG/10ML (9MG/ML)**	**A075841**	**003** Jun 27, 2002
AP		LUITPOLD	**30MG/10ML (3MG/ML)**	**A078942**	**001** Jul 25, 2008
AP			**90MG/10ML (9MG/ML)**	**A078942**	**002** Jul 25, 2008
AP		MYLAN LABS LTD	**30MG/10ML (3MG/ML)**	**A078520**	**001** Oct 31, 2008
AP			**90MG/10ML (9MG/ML)**	**A078520**	**002** Oct 31, 2008
AP		PLIVA LACHEMA	**30MG/10ML (3MG/ML)**	**A078156**	**001** Aug 19, 2008
AP			**60MG/10ML (6MG/ML)**	**A078156**	**002** Aug 19, 2008
AP			**90MG/10ML (9MG/ML)**	**A078156**	**003** Aug 19, 2008
AP		SAGENT PHARMS	**30MG/10ML (3MG/ML)**	**A078373**	**001** Dec 23, 2008
AP			**90MG/10ML (9MG/ML)**	**A078373**	**002** Dec 23, 2008
AP		SUN PHARMA GLOBAL	**30MG/VIAL**	**A077703**	**001** Dec 24, 2008
AP			**90MG/VIAL**	**A077703**	**002** Dec 24, 2008
AP		TEVA PHARMS USA	**30MG/10ML (3MG/ML)**	**A076153**	**001** Mar 27, 2002
AP			**90MG/10ML (9MG/ML)**	**A076153**	**002** Mar 27, 2002
AP		WEST-WARD PHARMS INT	**30MG/VIAL**	**A075290**	**001** Apr 30, 2001
AP	**+**		**30MG/10ML (3MG/ML)**	**N021113**	**001** Mar 04, 2002
AP			**90MG/VIAL**	**A075290**	**003** Apr 30, 2001
AP	**+**		**90MG/10ML (9MG/ML)**	**N021113**	**002** Mar 04, 2002

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
CAPSULE, DELAYED RELEASE;ORAL
CREON

		ABBVIE	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725	002 Apr 30, 2009
			15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725	004 Jul 12, 2011
			30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725	001 Apr 30, 2009
			180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725	005 Mar 14, 2013
	+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725	003 Apr 30, 2009

PANCREAZE

		JANSSEN PHARMS	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523	005 Mar 07, 2014
			17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523	001 Apr 12, 2010
			43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523	002 Apr 12, 2010
	+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523	003 Apr 12, 2010

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

	PANCREAZE				
		70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523	004	Apr 12, 2010
	PERTZYE				
	DIGESTIVE CARE INC	30,250USP UNITS;8,000USP UNITS;28,750USP UNITS	N022175	001	May 17, 2012
+		60,500USP UNITS;16,000USP UNITS;57,500USP UNITS	N022175	002	May 17, 2012
		15,125USP UNITS;4,000USP UNITS;14,375USP UNITS	N022175	003	Oct 06, 2016
	ULTRESA				
	FOREST LABS INC	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012
		41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012
+		46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012
	ZENPEP				
	FOREST LABS INC	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014
		16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011
		55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210	002	Aug 27, 2009
		82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210	003	Aug 27, 2009
		27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009
		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009
+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011

TABLET;ORAL

	VIOKACE				
	FOREST LABS INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

	PANCURONIUM BROMIDE				
AP	HOSPIRA	**1MG/ML**	**A072320**	**001**	Jan 19, 1989
AP +	TEVA PHARMS USA	**1MG/ML**	**A072759**	**001**	Jul 31, 1990
AP +		**2MG/ML**	**A072760**	**001**	Jul 31, 1990

PANOBINOSTAT LACTATE

CAPSULE;ORAL

	FARYDAK				
	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015
		EQ 15MG BASE	N205353	002	Feb 23, 2015
+		EQ 20MG BASE	N205353	003	Feb 23, 2015

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

	PROTONIX				
+	WYETH PHARMS INC	EQ 40MG BASE	N022020	001	Nov 14, 2007

INJECTABLE;IV (INFUSION)

	PANTOPRAZOLE SODIUM				
AP	AKORN INC	**EQ 40MG BASE/VIAL**	**A079197**	**001**	Nov 08, 2012
AP	AUROBINDO PHARMA LTD	**EQ 40MG BASE/VIAL**	**A205675**	**001**	Mar 30, 2016
AP	SANDOZ INC	**EQ 40MG BASE/VIAL**	**A090296**	**001**	Jul 14, 2015
	PROTONIX IV				
AP +	WYETH PHARMS INC	**EQ 40MG BASE/VIAL**	**N020988**	**001**	Mar 22, 2001

TABLET, DELAYED RELEASE;ORAL

	PANTOPRAZOLE SODIUM				
AB	ACTAVIS TOTOWA	**EQ 20MG BASE**	**A090797**	**001**	Feb 07, 2011
AB		**EQ 40MG BASE**	**A090797**	**002**	Feb 07, 2011
AB	AMNEAL PHARMS	**EQ 20MG BASE**	**A205119**	**001**	Jan 26, 2016
AB		**EQ 40MG BASE**	**A205119**	**002**	Jan 26, 2016
AB	APOTEX INC	**EQ 20MG BASE**	**A090807**	**001**	May 02, 2012
AB		**EQ 40MG BASE**	**A090807**	**002**	May 02, 2012
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A202038**	**001**	Sep 28, 2012
AB		**EQ 40MG BASE**	**A202038**	**002**	Sep 28, 2012
AB	DR REDDYS LABS LTD	**EQ 20MG BASE**	**A077619**	**001**	Jan 19, 2011

FDA data supplied by DrugPatentWatch.com

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		EQ 40MG BASE	A077619	002	Jan 19, 2011
AB	HETERO LABS LTD V	EQ 20MG BASE	A202882	001	Sep 10, 2014
AB		EQ 40MG BASE	A202882	002	Sep 10, 2014
AB	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011
AB		EQ 40MG BASE	A090901	002	Aug 30, 2011
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012
AB		EQ 40MG BASE	A200821	002	Feb 16, 2012
AB	MYLAN PHARMS INC	EQ 20MG BASE	A090970	001	Jan 19, 2011
AB		EQ 40MG BASE	A090970	002	Jan 19, 2011
AB	ORCHID HLTHCARE	EQ 20MG BASE	A202052	001	Dec 02, 2014
AB		EQ 40MG BASE	A202052	002	Dec 02, 2014
AB	PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012
AB		EQ 40MG BASE	A200794	002	May 02, 2012
AB	SUN PHARMA GLOBAL	EQ 20MG BASE	A077058	001	Sep 10, 2007
AB		EQ 40MG BASE	A077058	002	Sep 10, 2007
AB	TEVA	EQ 20MG BASE	A077056	001	Aug 02, 2007
AB		EQ 40MG BASE	A077056	002	Aug 02, 2007
AB	TORRENT PHARMS	EQ 20MG BASE	A090074	001	Jan 19, 2011
AB		EQ 40MG BASE	A090074	002	Jan 19, 2011
AB	WOCKHARDT	EQ 20MG BASE	A091231	001	Jan 19, 2011
AB		EQ 40MG BASE	A091231	002	Jan 19, 2011

PROTONIX

AB	WYETH PHARMS INC	EQ 20MG BASE	N020987	002	Jun 12, 2001
AB +		EQ 40MG BASE	N020987	001	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016
AB		2MCG	A204327	002	Jan 13, 2016
AB		4MCG	A204327	003	Jan 13, 2016
AB	AUROBINDO PHARMA LTD	1MCG	A207672	001	Jan 14, 2016
AB		2MCG	A207672	002	Jan 14, 2016
AB		4MCG	A207672	003	Jan 14, 2016
AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014
AB		2MCG	A202539	002	Mar 27, 2014
AB		4MCG	A202539	003	Mar 27, 2014
AB	DR REDDYS LABS LTD	1MCG	A091412	001	Jun 24, 2014
AB		2MCG	A091412	002	Jun 24, 2014
AB		4MCG	A091412	003	Jun 24, 2014
AB	ECI PHARMS LLC	1MCG	A206710	001	Feb 24, 2016
AB		2MCG	A206710	002	Feb 24, 2016
AB		4MCG	A206710	003	Feb 24, 2016
AB	MARKSANS PHARMA	1MCG	A204948	001	Oct 07, 2016
AB		2MCG	A204948	002	Oct 07, 2016
AB		4MCG	A204948	003	Oct 07, 2016
AB	RISING PHARMS INC	1MCG	A202124	001	Jun 24, 2014
AB		2MCG	A202124	002	Jun 24, 2014
AB		4MCG	A202124	003	Jun 24, 2014
AB	TEVA PHARMS USA	1MCG	A090829	001	Sep 27, 2013
AB		2MCG	A090829	002	Sep 27, 2013
AB +		4MCG	A090829	003	Sep 27, 2013

ZEMPLAR

AB	ABBVIE	1MCG	N021606	001	May 26, 2005
AB		2MCG	N021606	002	May 26, 2005

SOLUTION;INTRAVENOUS

PARICALCITOL

AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016
AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016
AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016
AP	DR REDDYS LABS LTD	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016
AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016
AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016
AP	HIKMA PHARMS	0.002MG/ML (0.002MG/ML)	N205917	001	Nov 18, 2014
AP		0.005MG/ML (0.005MG/ML)	N205917	002	Nov 18, 2014
AP		0.01MG/2ML (0.005MG/ML)	N205917	003	Nov 18, 2014
AP	HOSPIRA INC	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014

FDA data supplied by DrugPatentWatch.com

PARICALCITOL

SOLUTION;INTRAVENOUS

		PARICALCITOL				
AP			**0.005MG/ML (0.005MG/ML)**	**N201657**	**002**	Oct 21, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N201657**	**003**	Oct 21, 2014
AP		SANDOZ CANADA INC	**0.002MG/ML (0.002MG/ML)**	**A091108**	**001**	Jul 27, 2011
AP			**0.005MG/ML (0.005MG/ML)**	**A091108**	**002**	Jul 27, 2011
AP			**0.01MG/2ML (0.005MG/ML)**	**A091108**	**003**	Jul 27, 2011
		ZEMPLAR				
AP	+	ABBVIE	**0.002MG/ML (0.002MG/ML)**	**N020819**	**002**	Feb 01, 2000
AP	+		**0.005MG/ML (0.005MG/ML)**	**N020819**	**001**	Apr 17, 1998
AP	+		**0.01MG/2ML (0.005MG/ML)**	**N020819**	**003**	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE;ORAL

		PAROMOMYCIN SULFATE				
AA		HERITAGE PHARMS INC	**EQ 250MG BASE**	**A065173**	**001**	Dec 14, 2007
AA	+	SUN PHARM INDS INC	**EQ 250MG BASE**	**A064171**	**001**	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

		PAXIL				
AB	+	APOTEX TECHNOLOGIES	**EQ 10MG BASE/5ML**	**N020710**	**001**	Jun 25, 1997

TABLET;ORAL

		PAROXETINE				
AB		PRINSTON INC	**EQ 10MG BASE**	**A203854**	**001**	Oct 31, 2014
AB			**EQ 20MG BASE**	**A203854**	**002**	Oct 31, 2014
AB			**EQ 30MG BASE**	**A203854**	**003**	Oct 31, 2014
AB			**EQ 40MG BASE**	**A203854**	**004**	Oct 31, 2014
		PAROXETINE HYDROCHLORIDE				
AB		APOTEX	**EQ 10MG BASE**	**A075356**	**001**	Jul 30, 2003
AB			**EQ 20MG BASE**	**A075356**	**002**	Jul 30, 2003
AB			**EQ 30MG BASE**	**A075356**	**003**	Jul 30, 2003
AB			**EQ 40MG BASE**	**A075356**	**004**	Jul 30, 2003
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078406**	**001**	Jul 25, 2007
AB			**EQ 20MG BASE**	**A078406**	**002**	Jul 25, 2007
AB			**EQ 30MG BASE**	**A078406**	**003**	Jul 25, 2007
AB			**EQ 40MG BASE**	**A078406**	**004**	Jul 25, 2007
AB		JUBILANT GENERICS	**EQ 10MG BASE**	**A205528**	**001**	Nov 27, 2015
AB			**EQ 20MG BASE**	**A205528**	**002**	Nov 27, 2015
AB			**EQ 30MG BASE**	**A205528**	**003**	Nov 27, 2015
AB			**EQ 40MG BASE**	**A205528**	**004**	Nov 27, 2015
AB		MYLAN	**EQ 10MG BASE**	**A078902**	**001**	Mar 13, 2008
AB			**EQ 20MG BASE**	**A078902**	**002**	Mar 13, 2008
AB			**EQ 30MG BASE**	**A078902**	**003**	Mar 13, 2008
AB			**EQ 40MG BASE**	**A078902**	**004**	Mar 13, 2008
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A075716**	**001**	Mar 08, 2004
AB			**EQ 20MG BASE**	**A075716**	**002**	Mar 08, 2004
AB			**EQ 30MG BASE**	**A075716**	**003**	Mar 08, 2004
AB			**EQ 40MG BASE**	**A075716**	**004**	Mar 08, 2004
AB		OXFORD PHARMS	**EQ 10MG BASE**	**A076968**	**001**	Jun 21, 2010
AB			**EQ 20MG BASE**	**A076968**	**002**	Jun 21, 2010
AB			**EQ 30MG BASE**	**A076968**	**003**	Jun 21, 2010
AB			**EQ 40MG BASE**	**A076968**	**004**	Jun 21, 2010
AB		SUN PHARM INDS INC	**EQ 10MG BASE**	**A078194**	**001**	Jun 29, 2007
AB			**EQ 20MG BASE**	**A078194**	**002**	Jun 29, 2007
AB			**EQ 30MG BASE**	**A078194**	**003**	Jun 29, 2007
AB			**EQ 40MG BASE**	**A078194**	**004**	Jun 29, 2007
AB		TEVA	**EQ 10MG BASE**	**A076618**	**001**	Aug 15, 2005
AB			**EQ 20MG BASE**	**A076618**	**002**	Aug 15, 2005
AB			**EQ 30MG BASE**	**A076618**	**003**	Aug 15, 2005
AB			**EQ 40MG BASE**	**A076618**	**004**	Aug 15, 2005
AB		ZYDUS PHARMS USA	**EQ 10MG BASE**	**A077584**	**001**	Mar 07, 2007
AB			**EQ 20MG BASE**	**A077584**	**002**	Mar 07, 2007
AB			**EQ 30MG BASE**	**A077584**	**003**	Mar 07, 2007
AB			**EQ 40MG BASE**	**A077584**	**004**	Mar 07, 2007
		PAXIL				
AB		APOTEX TECHNOLOGIES	**EQ 10MG BASE**	**N020031**	**001**	Dec 29, 1992
AB			**EQ 20MG BASE**	**N020031**	**002**	Dec 29, 1992
AB			**EQ 30MG BASE**	**N020031**	**003**	Dec 29, 1992
AB	+		**EQ 40MG BASE**	**N020031**	**005**	Dec 29, 1992

FDA data supplied by DrugPatentWatch.com

PAROXETINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL

	PAROXETINE HYDROCHLORIDE				
AB	KREMERS URBAN PHARMS	**EQ 12.5MG BASE**	**A204744**	**001**	Jun 10, 2016
AB		**EQ 25MG BASE**	**A204744**	**002**	Jun 10, 2016
AB		**EQ 37.5MG BASE**	**A204744**	**003**	Jun 10, 2016
AB	MYLAN	**EQ 12.5MG BASE**	**A077873**	**001**	Jun 29, 2007
AB		**EQ 25MG BASE**	**A077873**	**002**	Jun 29, 2007
AB		**EQ 37.5MG BASE**	**A091427**	**001**	Apr 14, 2011
	PAXIL CR				
AB	APOTEX TECHNOLOGIES	**EQ 12.5MG BASE**	**N020936**	**001**	Feb 16, 1999
AB		**EQ 25MG BASE**	**N020936**	**002**	Feb 16, 1999
AB +		**EQ 37.5MG BASE**	**N020936**	**003**	Dec 06, 2000

PAROXETINE MESYLATE
CAPSULE;ORAL

	BRISDELLE				
+	SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013

TABLET;ORAL

	PEXEVA				
	SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003
		EQ 20MG BASE	N021299	002	Jul 03, 2003
		EQ 30MG BASE	N021299	003	Jul 03, 2003
+		EQ 40MG BASE	N021299	004	Jul 03, 2003

PASIREOTIDE DIASPARTATE
SOLUTION;SUBCUTANEOUS

	SIGNIFOR				
	NOVARTIS	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012
		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012
+		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012

PASIREOTIDE PAMOATE
POWDER;INTRAMUSCULAR

	SIGNIFOR LAR				
	NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014
		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014
+		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014

PATIROMER SORBITEX CALCIUM
POWDER;ORAL

	VELTASSA				
	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015
		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015
+		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015

PAZOPANIB HYDROCHLORIDE
TABLET;ORAL

	VOTRIENT				
+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009

PEGADEMASE BOVINE
INJECTABLE;INJECTION

	ADAGEN				
+	SIGMA TAU	250 UNITS/ML	N019818	001	Mar 21, 1990

PEGAPTANIB SODIUM
INJECTABLE;INTRAVITREAL

	MACUGEN				
+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004

PEGVISOMANT
INJECTABLE;SUBCUTANEOUS

	SOMAVERT				
+	PHARMACIA AND UPJOHN	10MG/VIAL	N021106	001	Mar 25, 2003
+		15MG/VIAL	N021106	002	Mar 25, 2003
+		20MG/VIAL	N021106	003	Mar 25, 2003
+		25MG/VIAL	N021106	004	Jul 31, 2014
+		30MG/VIAL	N021106	005	Jul 31, 2014

PEMETREXED DISODIUM
INJECTABLE;IV (INFUSION)

	ALIMTA				
+	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007
+		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004

FDA data supplied by DrugPatentWatch.com

PENCICLOVIR
CREAM;TOPICAL
DENAVIR
+ DENCO ASSET 1% N020629 001 Sep 24, 1996

PENICILLAMINE
CAPSULE;ORAL
CUPRIMINE
+ ATON 250MG N019853 001
TABLET;ORAL
DEPEN
+ MEDA PHARMS 250MG N019854 001

PENICILLIN G BENZATHINE
INJECTABLE;INJECTION
BICILLIN L-A
BC + KING PHARMS 600,000 UNITS/ML N050141 001
PERMAPEN
BC PFIZER 600,000 UNITS/ML A060014 001
BICILLIN L-A
+ KING PHARMS 300,000 UNITS/ML N050141 003

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE
INJECTABLE;INJECTION
BICILLIN C-R
+ KING PHARMS 150,000 UNITS/ML;150,000 UNITS/ML N050138 002
+ 300,000 UNITS/ML;300,000 UNITS/ML N050138 001
BICILLIN C-R 900/300
+ KING PHARMS 900,000 UNITS/2ML;300,000 UNITS/2ML N050138 003

PENICILLIN G POTASSIUM
INJECTABLE;INJECTION
PENICILLIN G POTASSIUM
AP HANFORD GC **5,000,000 UNITS/VIAL** **A065149 002** Jul 23, 2009
AP **20,000,000 UNITS/VIAL** **A065149 003** Jul 23, 2009
AP ISTITUTO BIO ITA SPA **5,000,000 UNITS/VIAL** **A065448 001** Aug 18, 2009
AP **20,000,000 UNITS/VIAL** **A065448 002** Aug 18, 2009
AP SANDOZ **5,000,000 UNITS/VIAL** **A065079 002** Aug 30, 2002
AP **20,000,000 UNITS/VIAL** **A065079 003** Aug 30, 2002
PFIZERPEN
AP **+** PFIZER **5,000,000 UNITS/VIAL** **A060657 002**
AP **+** **20,000,000 UNITS/VIAL** **A060657 003**
PENICILLIN G POTASSIUM
HANFORD GC 1,000,000 UNITS/VIAL A065149 001 Jul 23, 2009
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 20,000 UNITS/ML N050638 001 Jun 25, 1990
+ 40,000 UNITS/ML N050638 002 Jun 25, 1990
+ 60,000 UNITS/ML N050638 003 Jun 25, 1990

PENICILLIN G PROCAINE
INJECTABLE;INJECTION
PENICILLIN G PROCAINE
+ KING PHARMS 300,000 UNITS/ML A060101 002
+ 600,000 UNITS/ML A060101 001

PENICILLIN G SODIUM
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
PENICILLIN G SODIUM
+ SANDOZ 5,000,000 UNITS/VIAL A065068 001 Feb 26, 2001

PENICILLIN V POTASSIUM
FOR SOLUTION;ORAL
PENICILLIN V POTASSIUM
AA DAVA PHARMS INC **EQ 125MG BASE/5ML** **A062981 001** Feb 10, 1989
AA **EQ 250MG BASE/5ML** **A062981 002** Feb 10, 1989
PENICILLIN-VK
AA TEVA **EQ 125MG BASE/5ML** **A060456 001**
AA **+** **EQ 250MG BASE/5ML** **A060456 002**
TABLET;ORAL
PENICILLIN V POTASSIUM
AB AUROBINDO PHARMA **EQ 250MG BASE** **A065435 001** Apr 29, 2008
AB **EQ 500MG BASE** **A065435 002** Apr 29, 2008
AB DAVA PHARMS INC **EQ 250MG BASE** **A062936 001** Nov 25, 1988
AB **EQ 500MG BASE** **A062935 001** Nov 23, 1988
AB HIKMA PHARMS **EQ 250MG BASE** **A090549 001** Oct 11, 2013
AB **EQ 500MG BASE** **A090549 002** Oct 11, 2013

PENICILLIN V POTASSIUM
TABLET;ORAL
PENICILLIN V POTASSIUM

AB	SANDOZ	**EQ 250MG BASE**	**A064071**	**001**	Nov 30, 1995
AB	**+**	**EQ 500MG BASE**	**A064071**	**002**	Nov 30, 1995

PENICILLIN-VK

AB	TEVA	**EQ 250MG BASE**	**A060711**	**002**	
AB		**EQ 500MG BASE**	**A060711**	**003**	

PENTAMIDINE ISETHIONATE
FOR SOLUTION;INHALATION
NEBUPENT

+	FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989

INJECTABLE;INJECTION
PENTAM

+	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984

PENTAZOCINE LACTATE
INJECTABLE;INJECTION
TALWIN

+	HOSPIRA	EQ 30MG BASE/ML	N016194	001	

PENTETATE CALCIUM TRISODIUM
SOLUTION;INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004

PENTETATE ZINC TRISODIUM
SOLUTION;INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004

PENTOBARBITAL SODIUM
INJECTABLE;INJECTION
NEMBUTAL SODIUM

AP	**+** OAK PHARMS	**50MG/ML**	**A083246**	**001**	

PENTOBARBITAL SODIUM

AP	MYLAN INSTITUTIONAL	**50MG/ML**	**A206404**	**001**	May 23, 2016

PENTOSAN POLYSULFATE SODIUM
CAPSULE;ORAL
ELMIRON

+	JANSSEN PHARMS	100MG	N020193	001	Sep 26, 1996

PENTOSTATIN
INJECTABLE;INJECTION
NIPENT

AP	**+** HOSPIRA INC	**10MG/VIAL**	**N020122**	**001**	Oct 11, 1991

PENTOSTATIN

AP	MYLAN INSTITUTIONAL	**10MG/VIAL**	**A203554**	**001**	Sep 19, 2014
AP	WEST-WARD PHARMS INT	**10MG/VIAL**	**A077841**	**001**	Aug 07, 2007

PENTOXIFYLLINE
TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB	**+** APOTEX	**400MG**	**A075191**	**001**	Jun 09, 1999
AB	MYLAN	**400MG**	**A074425**	**001**	Jul 08, 1997
AB	VALEANT PHARMS	**400MG**	**A075028**	**001**	Jul 20, 1998

PENTOXIL

AB	UPSHER SMITH	**400MG**	**A074962**	**001**	Mar 31, 1999

PERAMIVIR
SOLUTION;IV (INFUSION)
RAPIVAB

+	BIOCRYST	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014

PERAMPANEL
SUSPENSION;ORAL
FYCOMPA

+	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016

TABLET;ORAL
FYCOMPA

	EISAI INC	2MG	N202834	001	Oct 22, 2012
		4MG	N202834	002	Oct 22, 2012
		6MG	N202834	003	Oct 22, 2012
		8MG	N202834	004	Oct 22, 2012
		10MG	N202834	005	Oct 22, 2012

FDA data supplied by DrugPatentWatch.com

PERAMPANEL
TABLET;ORAL
FYCOMPA

+		12MG	N202834	006	Oct 22, 2012

PERFLUTREN
INJECTABLE;INTRAVENOUS
DEFINITY

+	LANTHEUS MEDCL	6.52MG/ML	N021064	001	Jul 31, 2001

PERINDOPRIL ERBUMINE
TABLET;ORAL

	ACEON				
AB	SYMPLMED PHARMS LLC	**2MG**	**N020184**	**001**	Dec 30, 1993
AB		**4MG**	**N020184**	**002**	Dec 30, 1993
AB	+	**8MG**	**N020184**	**003**	Dec 30, 1993
	PERINDOPRIL ERBUMINE				
AB	ANI PHARMS INC	**2MG**	**A078138**	**001**	Nov 10, 2009
AB		**4MG**	**A078138**	**002**	Nov 10, 2009
AB		**8MG**	**A078138**	**003**	Nov 10, 2009
AB	APOTEX	**2MG**	**A090463**	**001**	Aug 30, 2010
AB		**4MG**	**A090463**	**002**	Aug 30, 2010
AB		**8MG**	**A090463**	**003**	Aug 30, 2010
AB	AUROBINDO PHARMA	**2MG**	**A079070**	**001**	Nov 10, 2009
AB		**4MG**	**A079070**	**002**	Nov 10, 2009
AB		**8MG**	**A079070**	**003**	Nov 10, 2009
AB	WEST-WARD PHARMS INT	**2MG**	**A090072**	**001**	Nov 10, 2009
AB		**4MG**	**A090072**	**002**	Nov 10, 2009
AB		**8MG**	**A090072**	**003**	Nov 10, 2009

PERMETHRIN
CREAM;TOPICAL

	ELIMITE				
AB	+ RENAISSANCE PHARMA	**5%**	**N019855**	**001**	Aug 25, 1989
	PERMETHRIN				
AB	ACTAVIS MID ATLANTIC	**5%**	**A074806**	**001**	Jan 23, 1998
AB	PERRIGO NEW YORK	**5%**	**A076369**	**001**	Apr 21, 2003

PERPHENAZINE
TABLET;ORAL

	PERPHENAZINE				
AB	SANDOZ	**2MG**	**A089685**	**002**	Dec 08, 1988
AB		**4MG**	**A089685**	**003**	Dec 08, 1988
AB		**8MG**	**A089685**	**001**	Dec 08, 1988
AB	+	**16MG**	**A089685**	**004**	Dec 08, 1988
AB	VINTAGE PHARMS	**2MG**	**A040226**	**001**	Dec 31, 1998
AB		**4MG**	**A040226**	**002**	Dec 31, 1998
AB		**8MG**	**A040226**	**003**	Dec 31, 1998
AB		**16MG**	**A040226**	**004**	Dec 31, 1998
AB	WATSON LABS INC	**2MG**	**A207582**	**001**	Oct 17, 2016
AB		**4MG**	**A207582**	**002**	Oct 17, 2016
AB		**8MG**	**A207582**	**003**	Oct 17, 2016
AB		**16MG**	**A207582**	**004**	Oct 17, 2016
AB	WILSHIRE PHARMS INC	**2MG**	**A205973**	**001**	Dec 17, 2015
AB		**4MG**	**A205973**	**002**	Dec 17, 2015
AB		**8MG**	**A205973**	**003**	Dec 17, 2015
AB		**16MG**	**A205973**	**004**	Dec 17, 2015

PHENDIMETRAZINE TARTRATE
CAPSULE, EXTENDED RELEASE;ORAL
PHENDIMETRAZINE TARTRATE

+	SANDOZ	105MG	N018074	001	

TABLET;ORAL

	BONTRIL PDM				
AA	+ VALEANT	**35MG**	**A085272**	**001**	
	PHENDIMETRAZINE TARTRATE				
AA	ELITE LABS INC	**35MG**	**A040762**	**001**	Jan 28, 2008
AA	KVK TECH	**35MG**	**A091042**	**001**	Aug 31, 2010
AA	MIKART	**35MG**	**A089452**	**001**	Oct 30, 1991
AA	SANDOZ	**35MG**	**A085588**	**001**	

PHENELZINE SULFATE

TABLET;ORAL

	NARDIL				
AB	+ PARKE DAVIS	**EQ 15MG BASE**	**N011909**	**002**	
	PHENELZINE SULFATE				
AB	NOVEL LABS INC	**EQ 15MG BASE**	**A200181**	**001**	Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

	DIBENZYLINE				
AB	+ CONCORDIA PHARMS INC	**10MG**	**N008708**	**001**	
	PHENOXYBENZAMINE HYDROCHLORIDE				
AB	WEST-WARD PHARMS INT	**10MG**	**A201050**	**001**	Jul 16, 2012

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

	ADIPEX-P				
AA	+ TEVA	**37.5MG**	**A088023**	**001**	Aug 02, 1983
	PHENTERMINE HYDROCHLORIDE				
AA	AUROLIFE PHARMA LLC	**15MG**	**A204318**	**001**	Nov 09, 2016
AA		**30MG**	**A204318**	**002**	Nov 09, 2016
AA	BARR	**15MG**	**A090591**	**001**	Mar 18, 2010
AA		**30MG**	**A090591**	**002**	Mar 18, 2010
AA	ELITE LABS	**15MG**	**A202248**	**001**	Sep 28, 2012
AA		**30MG**	**A202248**	**002**	Sep 28, 2012
AA	INVAGEN PHARMS	**15MG**	**A202858**	**001**	Feb 14, 2014
AA		**30MG**	**A202858**	**002**	Feb 14, 2014
AA		**30MG**	**A204414**	**001**	May 05, 2014
AA		**37.5MG**	**A202846**	**001**	Feb 05, 2014
AA	KEN LIFESCIENCE	**15MG**	**A205019**	**001**	Dec 05, 2014
AA		**30MG**	**A205019**	**002**	Dec 05, 2014
AA		**37.5MG**	**A205017**	**001**	Sep 25, 2014
AA	KVK TECH	**15MG**	**A040886**	**002**	Mar 31, 2008
AA		**30MG**	**A040875**	**001**	Mar 21, 2008
AA		**30MG**	**A040886**	**001**	Mar 31, 2008
AA		**37.5MG**	**A040887**	**001**	Apr 24, 2008
AA	LANNETT	**15MG**	**A087022**	**002**	Jan 20, 2012
AA		**30MG**	**A087022**	**001**	Feb 03, 1983
AA		**30MG**	**A091359**	**001**	Jul 16, 2010
AA	LANNETT HOLDINGS INC	**37.5MG**	**A201961**	**001**	Jul 20, 2011
AA	MIKAH PHARMA LLC	**37.5MG**	**A040228**	**001**	Jun 19, 1997
AA	+ SANDOZ	**15MG**	**A087190**	**002**	
AA	+	**30MG**	**A086945**	**001**	Jul 20, 1983
AA	+	**30MG**	**A087190**	**001**	
AA	SUN PHARM INDS	**30MG**	**A040525**	**001**	Oct 23, 2003

TABLET;ORAL

	ADIPEX-P				
AA	+ TEVA	**37.5MG**	**A085128**	**001**	
	PHENTERMINE HYDROCHLORIDE				
AA	AUROLIFE PHARMA LLC	**37.5MG**	**A203068**	**001**	Aug 06, 2014
AA	BARR	**37.5MG**	**A090470**	**001**	Aug 31, 2009
AA	ELITE LABS	**37.5MG**	**A200272**	**001**	Jan 31, 2011
AA	INGENUS PHARMS NJ	**37.5MG**	**A091451**	**001**	Sep 21, 2012
AA	INVAGEN PHARMS	**37.5MG**	**A202942**	**001**	Feb 05, 2014
AA	KEN LIFESCIENCE	**37.5MG**	**A205008**	**001**	Sep 25, 2014
AA	KVK TECH	**37.5MG**	**A040876**	**001**	Mar 31, 2008
AA	LANNETT	**37.5MG**	**A040555**	**001**	Apr 15, 2005
AA	MIKAH PHARMA	**37.5MG**	**A040190**	**001**	May 30, 1997
AA	POLYGEN PHARMS	**37.5MG**	**A206342**	**001**	Nov 18, 2016
AA	SUN PHARM INDS	**37.5MG**	**A040526**	**001**	Oct 23, 2003
AA	SUN PHARM INDS INC	**37.5MG**	**A040790**	**001**	Aug 21, 2007
AA	VINTAGE PHARMS	**37.5MG**	**A040377**	**001**	Jan 04, 2002
	LOMAIRA				
	+ AVANTHI INC	8MG	A203495	001	Sep 12, 2016

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

	QSYMIA				
	VIVUS	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012
		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012
		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012
	+	EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012

FDA data supplied by DrugPatentWatch.com

PHENTOLAMINE MESYLATE
INJECTABLE;INJECTION

		PHENTOLAMINE MESYLATE				
AP		WEST-WARD PHARMS INT	**5MG/VIAL**	**A040235**	**001**	Mar 11, 1998
		REGITINE				
AP	**+**	NOVARTIS	**5MG/VIAL**	**N008278**	**003**	
		ORAVERSE				
	+	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE
SOLUTION;IV (INFUSION)

		PHENYLEPHRINE HYDROCHLORIDE				
	+	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012
		VAZCULEP				
		ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014
			50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014
	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014

SOLUTION/DROPS;OPHTHALMIC

		PHENYLEPHRINE HYDROCHLORIDE				
	+	AKORN INC	2.5%	N207926	001	Jan 15, 2015
	+		10%	N207926	002	Jan 15, 2015
	+	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013
	+		10%	N203510	002	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SYRUP;ORAL

		PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE				
AA		HI-TECH PHARMACAL	**5MG/5ML;6.25MG/5ML**	**A040675**	**001**	Dec 23, 2014
AA		VINTAGE	**5MG/5ML;6.25MG/5ML**	**A040654**	**001**	Dec 07, 2006
		PROMETH VC PLAIN				
AA	**+**	G AND W LABS INC	**5MG/5ML;6.25MG/5ML**	**A088761**	**001**	Nov 08, 1984
		PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE				
AA		AMNEAL PHARMS	**5MG/5ML;6.25MG/5ML**	**A040902**	**001**	Aug 25, 2009

PHENYTOIN
SUSPENSION;ORAL

		DILANTIN-125				
AB	**+**	PARKE DAVIS	**125MG/5ML**	**N008762**	**001**	
		PHENYTOIN				
AB		TARO	**125MG/5ML**	**A040521**	**001**	Mar 08, 2004
AB		VISTAPHARM	**125MG/5ML**	**A040342**	**001**	Jan 31, 2001
AB			**125MG/5ML**	**A040610**	**001**	Aug 18, 2005
AB		WOCKHARDT	**125MG/5ML**	**A040420**	**001**	Apr 19, 2002

TABLET, CHEWABLE;ORAL

		DILANTIN				
AB	**+**	PFIZER PHARMS	**50MG**	**A084427**	**001**	
		PHENYTOIN				
AB		COREPHARMA	**50MG**	**A040884**	**001**	Nov 28, 2014
AB		MYLAN PHARMS INC	**50MG**	**A200691**	**001**	Dec 26, 2012
AB		TARO	**50MG**	**A200565**	**001**	Apr 17, 2014

PHENYTOIN SODIUM
CAPSULE;ORAL

		DILANTIN				
AB	**+**	PARKE DAVIS	**30MG EXTENDED**	**A084349**	**001**	
AB	**+**		**100MG EXTENDED**	**A084349**	**002**	
		EXTENDED PHENYTOIN SODIUM				
AB		AMNEAL PHARMS NY	**100MG EXTENDED**	**A040765**	**001**	Nov 12, 2008
AB		MYLAN	**100MG EXTENDED**	**A040298**	**001**	Dec 28, 1998
AB		SUN PHARM INDS	**200MG EXTENDED**	**A040731**	**001**	Jun 30, 2008
AB			**300MG EXTENDED**	**A040731**	**002**	Jun 30, 2008
AB		SUN PHARM INDS (IN)	**100MG EXTENDED**	**A040621**	**001**	Dec 11, 2006
AB		TARO	**100MG EXTENDED**	**A040684**	**001**	Sep 05, 2006
		PHENYTEK				
AB		MYLAN	**200MG EXTENDED**	**A040298**	**002**	Dec 06, 2001
AB	**+**		**300MG EXTENDED**	**A040298**	**003**	Dec 06, 2001
		PHENYTOIN SODIUM				
AB		AUROBINDO PHARMA LTD	**100MG EXTENDED**	**A204309**	**001**	Jun 10, 2015

INJECTABLE;INJECTION

		PHENYTOIN SODIUM				
AP	**+**	EUROHLTH INTL SARL	**50MG/ML**	**A084307**	**001**	
AP		HOSPIRA	**50MG/ML**	**A089521**	**001**	Mar 17, 1987
AP		LUITPOLD	**50MG/ML**	**A040781**	**001**	Dec 04, 2007
AP		X-GEN PHARMS	**50MG/ML**	**A040573**	**001**	Sep 13, 2006

FDA data supplied by DrugPatentWatch.com

PHYTONADIONE
INJECTABLE;INJECTION
PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001	

VITAMIN K1

BP	+	HOSPIRA	1MG/0.5ML	A087954 001	Jul 25, 1983
	+		10MG/ML	A087955 001	Jul 25, 1983

TABLET;ORAL
MEPHYTON

	+	VALEANT PHARMS	5MG	N010104 003	

PILOCARPINE HYDROCHLORIDE
SOLUTION;OPHTHALMIC
ISOPTO CARPINE

		NOVARTIS PHARMS CORP	1%	N200890 001	Jun 22, 2010
			2%	N200890 002	Jun 22, 2010
	+		4%	N200890 003	Jun 22, 2010

TABLET;ORAL
PILOCARPINE HYDROCHLORIDE

AB		ELAN PHARMA INTL LTD	**5MG**	**A076746 001**	Nov 16, 2004
AB		IMPAX LABS	**5MG**	**A077248 001**	Mar 31, 2006
AB			**7.5MG**	**A077248 002**	Mar 31, 2006
AB		LANNETT	**5MG**	**A077220 001**	Oct 14, 2005
AB			**7.5MG**	**A077220 002**	May 06, 2009
AB		ROXANE	**5MG**	**A076963 001**	Dec 22, 2004
AB			**7.5MG**	**A076963 002**	Feb 27, 2007

SALAGEN

AB		EISAI INC	**5MG**	**N020237 001**	Mar 22, 1994
AB	**+**		**7.5MG**	**N020237 002**	Apr 18, 2003

PIMAVANSERIN TARTRATE
TABLET;ORAL
NUPLAZID

	+	ACADIA PHARMS INC	EQ 17MG BASE	N207318 001	Apr 29, 2016

PIMECROLIMUS
CREAM;TOPICAL
ELIDEL

	+	VALEANT BERMUDA	1%	N021302 001	Dec 13, 2001

PIMOZIDE
TABLET;ORAL
ORAP

AB		TEVA	**1MG**	**N017473 003**	Aug 27, 1997
AB	**+**		**2MG**	**N017473 001**	Jul 31, 1984

PIMOZIDE

AB		PAR PHARM	**1MG**	**A204521 001**	Sep 28, 2015
AB			**2MG**	**A204521 002**	Sep 28, 2015

PINDOLOL
TABLET;ORAL
PINDOLOL

AB		MYLAN PHARMS INC	**5MG**	**A074019 001**	Sep 03, 1992
AB	**+**		**10MG**	**A074019 002**	Sep 03, 1992
AB		NOSTRUM LABS INC	**5MG**	**A205415 001**	Jan 13, 2016
AB			**10MG**	**A205415 002**	Jan 13, 2016
AB		SUN PHARM INDS	**5MG**	**A074063 001**	Jan 27, 1994
AB			**10MG**	**A074063 002**	Jan 27, 1994

PIOGLITAZONE HYDROCHLORIDE
TABLET;ORAL
ACTOS

AB		TAKEDA PHARMS USA	**EQ 15MG BASE**	**N021073 001**	Jul 15, 1999
AB			**EQ 30MG BASE**	**N021073 002**	Jul 15, 1999
AB	**+**		**EQ 45MG BASE**	**N021073 003**	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 15MG BASE**	**A200044 001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200044 002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200044 003**	Feb 13, 2013
AB		AUROBINDO PHARMA LTD	**EQ 15MG BASE**	**A200268 001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200268 002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200268 003**	Feb 13, 2013
AB		BRECKENRIDGE PHARM	**EQ 15MG BASE**	**A078472 001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A078472 002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A078472 003**	Feb 13, 2013

FDA data supplied by DrugPatentWatch.com

PIOGLITAZONE HYDROCHLORIDE
TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	**EQ 15MG BASE**	**A078383**	**001**	Mar 12, 2013
AB		**EQ 30MG BASE**	**A078383**	**002**	Mar 12, 2013
AB		**EQ 45MG BASE**	**A078383**	**003**	Mar 12, 2013
AB	LUPIN LTD	**EQ 15MG BASE**	**A204133**	**001**	Apr 07, 2014
AB		**EQ 30MG BASE**	**A204133**	**002**	Apr 07, 2014
AB		**EQ 45MG BASE**	**A204133**	**003**	Apr 07, 2014
AB	MACLEODS PHARMS LTD	**EQ 15MG BASE**	**A202467**	**001**	Feb 06, 2013
AB		**EQ 30MG BASE**	**A202467**	**002**	Feb 06, 2013
AB		**EQ 45MG BASE**	**A202467**	**003**	Feb 06, 2013
AB	MYLAN PHARMS INC	**EQ 15MG BASE**	**A076801**	**001**	Aug 17, 2012
AB		**EQ 30MG BASE**	**A076801**	**002**	Aug 17, 2012
AB		**EQ 45MG BASE**	**A076801**	**003**	Aug 17, 2012
AB	SANDOZ	**EQ 15MG BASE**	**A078670**	**001**	Feb 13, 2013
AB		**EQ 30MG BASE**	**A078670**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A078670**	**003**	Feb 13, 2013
AB	TEVA PHARMS USA	**EQ 15MG BASE**	**A077210**	**001**	Jan 10, 2014
AB		**EQ 30MG BASE**	**A077210**	**002**	Jan 10, 2014
AB		**EQ 45MG BASE**	**A077210**	**003**	Jan 10, 2014
AB	TORRENT PHARMS LTD	**EQ 15MG BASE**	**A091298**	**001**	Feb 13, 2013
AB		**EQ 30MG BASE**	**A091298**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A091298**	**003**	Feb 13, 2013
AB	WATSON LABS	**EQ 15MG BASE**	**A076798**	**001**	Oct 26, 2012
AB		**EQ 30MG BASE**	**A076798**	**002**	Oct 26, 2012
AB		**EQ 45MG BASE**	**A076798**	**003**	Oct 26, 2012
AB	ZYDUS PHARMS USA INC	**EQ 15MG BASE**	**A202456**	**001**	Feb 13, 2013
AB		**EQ 30MG BASE**	**A202456**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A202456**	**003**	Feb 13, 2013

PIPERACILLIN SODIUM
INJECTABLE;INJECTION
PIPERACILLIN

+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
INJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAM

AP	AUROBINDO PHARMA LTD	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065498**	**001**	May 23, 2011
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065498**	**002**	May 23, 2011
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065498**	**003**	May 23, 2011
AP	HOSPIRA INC	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065386**	**001**	Sep 15, 2009
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065386**	**002**	Sep 15, 2009
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065386**	**003**	Sep 15, 2009
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A065446**	**001**	Sep 15, 2009
AP	ISTITUTO BIO ITA SPA	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065523**	**001**	May 31, 2011
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065523**	**002**	May 31, 2011
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065523**	**003**	May 31, 2011
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A090498**	**001**	May 31, 2011
AP	MYLAN LABS LTD	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065458**	**001**	Aug 15, 2014
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065458**	**002**	Aug 15, 2014
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065458**	**003**	Aug 15, 2014
AP	SANDOZ	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065362**	**001**	Oct 21, 2010
AP		**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065363**	**001**	Oct 21, 2010
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065362**	**002**	Oct 21, 2010
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065363**	**002**	Oct 21, 2010
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065362**	**003**	Oct 21, 2010
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065363**	**003**	Oct 21, 2010

ZOSYN

AP	**+** WYETH PHARMS INC	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**N050684**	**001**	Oct 22, 1993
AP	**+**	**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**N050684**	**002**	Oct 22, 1993
AP	**+**	**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**N050684**	**003**	Oct 22, 1993
AP	**+**	**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**N050684**	**004**	Oct 22, 1993

ZOSYN IN PLASTIC CONTAINER

+	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
INJECTABLE;IV (INFUSION)
PIPERACILLIN AND TAZOBACTAM

	SANDOZ INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014

PIRFENIDONE
CAPSULE;ORAL
ESBRIET

+	GENENTECH INC	267MG	N022535	001	Oct 15, 2014

PIROXICAM
CAPSULE;ORAL

	FELDENE				
AB	PFIZER	**10MG**	**N018147**	**002**	Apr 06, 1982
AB	**+**	**20MG**	**N018147**	**003**	Apr 06, 1982
	PIROXICAM				
AB	FLAMINGO PHARMS	**10MG**	**A207938**	**001**	Sep 09, 2016
AB		**20MG**	**A207938**	**002**	Sep 09, 2016
AB	MUTUAL PHARM	**10MG**	**A073535**	**001**	Mar 12, 1993
AB	MYLAN	**10MG**	**A074102**	**001**	Jul 31, 1992
AB		**20MG**	**A074102**	**002**	Jul 31, 1992
AB	MYLAN IRELAND LTD	**10MG**	**A074116**	**001**	Jun 15, 1993
AB		**20MG**	**A074118**	**001**	Jun 15, 1993
AB	TEVA	**10MG**	**A074131**	**001**	Dec 11, 1992
AB		**20MG**	**A074131**	**002**	Dec 11, 1992

PITAVASTATIN CALCIUM
TABLET;ORAL

	LIVALO				
AB	KOWA CO	**EQ 1MG BASE**	**N022363**	**001**	Aug 03, 2009
AB		**EQ 2MG BASE**	**N022363**	**002**	Aug 03, 2009
AB	**+**	**EQ 4MG BASE**	**N022363**	**003**	Aug 03, 2009
	PITAVASTATIN CALCIUM				
AB	AUROBINDO PHARMA LTD	**EQ 1MG BASE**	**A206015**	**001**	Dec 20, 2016
AB		**EQ 2MG BASE**	**A206015**	**002**	Dec 20, 2016
AB		**EQ 4MG BASE**	**A206015**	**003**	Dec 20, 2016

PLERIXAFOR
SOLUTION;SUBCUTANEOUS
MOZOBIL

+	GENZYME	24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008

PODOFILOX
GEL;TOPICAL
CONDYLOX

+	ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997

SOLUTION;TOPICAL

	CONDYLOX				
AT	**+** ALLERGAN SALES LLC	**0.5%**	**N019795**	**001**	Dec 13, 1990
	PODOFILOX				
AT	BAUSCH AND LOMB INC	**0.5%**	**A090184**	**001**	Jul 21, 2010
AT	PADDOCK LLC	**0.5%**	**A075600**	**001**	Jan 29, 2002

POLIDOCANOL
SOLUTION;INTRAVENOUS
ASCLERA

	CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201	001	Mar 30, 2010
+		20MG/2ML (10MG/ML)	N021201	002	Mar 30, 2010

VARITHENA

+	PROVENSIS	180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013

POLYETHYLENE GLYCOL 3350
FOR SOLUTION;ORAL

	GLYCOLAX				
AA	KREMERS URBAN PHARMS	**17GM/SCOOPFUL**	**A076652**	**001**	Jul 02, 2004
	POLYETHYLENE GLYCOL 3350				
AA	BRECKENRIDGE PHARM	**17GM/SCOOPFUL**	**A077736**	**001**	May 26, 2006
AA	NEXGEN PHARMA INC	**17GM/SCOOPFUL**	**A077706**	**001**	Sep 27, 2006
AA	PADDOCK LLC	**17GM/SCOOPFUL**	**A077893**	**001**	May 26, 2006

FDA data supplied by DrugPatentWatch.com

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
FOR SOLUTION;ORAL

	LAX-LYTE WITH FLAVOR PACKS				
AA	PADDOCK LLC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A079232**	**001**	Feb 25, 2010
	NULYTELY				
AA	+ BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**001**	Apr 22, 1991
	NULYTELY-FLAVORED				
AA	+ BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**002**	Nov 18, 1994
	PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
AA	MYLAN	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A090409**	**001**	Apr 02, 2010
AA	NOVEL LABS INC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A090019**	**001**	May 27, 2009
AA	STRIDES ARCOLAB LTD	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A204559**	**001**	Apr 13, 2015
	TRILYTE				
AA	MEDA PHARMS	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A076491**	**001**	Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS
FOR SOLUTION;ORAL

	COLYTE WITH FLAVOR PACKS				
AA	MEDA PHARMS	**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**N018983**	**012**	Oct 08, 1998
	GOLYTELY				
AA	+ BRAINTREE	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**N019011**	**001**	Jul 13, 1984
	PEG 3350 AND ELECTROLYTES				
AA	MYLAN	**236GM;2.97GM;6.74GM;5.86GM;22.74GM**	**A090928**	**001**	Jan 28, 2010
AA	NOVEL LABS INC	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A090231**	**001**	Jun 01, 2009
AA		**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**A090186**	**001**	Jun 01, 2009
	GOLYTELY				
	+ BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011	002	Jun 02, 1992

POLYMYXIN B SULFATE
INJECTABLE;INJECTION

	POLYMYCIN B SULFATE				
AP	SAGENT STRIDES	**EQ 500,000 UNITS BASE/VIAL**	**A090110**	**001**	Jun 29, 2011
	POLYMYXIN B SULFATE				
AP	AUROBINDO PHARMA LTD	**EQ 500,000 UNITS BASE/VIAL**	**A206589**	**001**	Apr 04, 2016
AP	FRESENIUS KABI USA	**EQ 500,000 UNITS BASE/VIAL**	**A065372**	**001**	Jan 10, 2008
AP	GLAND PHARMA LTD	**EQ 500,000 UNITS BASE/VIAL**	**A207322**	**001**	Apr 14, 2016
AP	+ WEST-WARD PHARMS INT	**EQ 500,000 UNITS BASE/VIAL**	**A060716**	**001**	
AP	X GEN PHARMS	**EQ 500,000 UNITS BASE/VIAL**	**A063000**	**001**	Sep 30, 1994
AP	XELLIA PHARMS APS	**EQ 500,000 UNITS BASE/VIAL**	**A202766**	**001**	Jan 15, 2014

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE
SOLUTION/DROPS;OPHTHALMIC

	POLYTRIM				
AT	+ ALLERGAN	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**N050567**	**001**	Oct 20, 1988
	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE				
AT	AKORN INC	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A065006**	**001**	Dec 17, 1998
AT	ALCON RES LTD	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064211**	**001**	Apr 13, 1998
AT	BAUSCH AND LOMB	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064120**	**001**	Feb 14, 1997

POMALIDOMIDE
CAPSULE;ORAL

	POMALYST				
	CELGENE	1MG	N204026	001	Feb 08, 2013
		2MG	N204026	002	Feb 08, 2013
		3MG	N204026	003	Feb 08, 2013
	+	4MG	N204026	004	Feb 08, 2013

PONATINIB HYDROCHLORIDE
TABLET;ORAL

	ICLUSIG				
	ARIAD	EQ 15MG BASE	N203469	001	Dec 14, 2012
		EQ 30MG BASE	N203469	003	Apr 23, 2015
	+	EQ 45MG BASE	N203469	002	Dec 14, 2012

FDA data supplied by DrugPatentWatch.com

PORACTANT ALFA
SUSPENSION;INTRATRACHEAL
CUROSURF

	+	CHIESI USA INC	80MG/ML	N020744	001 Nov 18, 1999

PORFIMER SODIUM
INJECTABLE;INJECTION
PHOTOFRIN

		CONCORDIA LABS INC	75MG/VIAL	N020451	001 Dec 27, 1995

POSACONAZOLE
SOLUTION;IV (INFUSION)
NOXAFIL

	+	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001 Mar 13, 2014

SUSPENSION;ORAL
NOXAFIL

	+	SCHERING	40MG/ML	N022003	001 Sep 15, 2006

TABLET, DELAYED RELEASE;ORAL
NOXAFIL

	+	MERCK SHARP DOHME	100MG	N205053	001 Nov 25, 2013

POTASSIUM ACETATE
INJECTABLE;INJECTION
POTASSIUM ACETATE

AP		EXELA PHARMA SCS LLC	**2MEQ/ML**	**A206203**	**001** Dec 29, 2015
AP	**+**	HOSPIRA	**2MEQ/ML**	**N018896**	**001** Jul 20, 1984

POTASSIUM CHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
KLOR-CON

AB		UPSHER-SMITH LABS	**8MEQ**	**A203106**	**001** Jul 10, 2015
AB			**10MEQ**	**A203106**	**002** Jul 10, 2015

MICRO-K

AB		NESHER PHARMS	**8MEQ**	**N018238**	**001**

MICRO-K 10

AB		NESHER PHARMS	**10MEQ**	**N018238**	**002** May 14, 1984

POTASSIUM CHLORIDE

AB		ACTAVIS LABS FL INC	**8MEQ**	**A077419**	**001** Jun 02, 2008
AB	**+**		**10MEQ**	**A077419**	**002** Jun 02, 2008
AB		AMNEAL PHARMS	**10MEQ**	**A202128**	**001** Feb 22, 2013
AB		ANCHEN PHARMS	**8MEQ**	**A202886**	**001** Dec 26, 2013
AB			**10MEQ**	**A202886**	**002** Dec 26, 2013
AB		GLENMARK PHARMS LTD	**10MEQ**	**A202868**	**001** Jan 19, 2016
AB		KREMERS URBAN PHARMS	**8MEQ**	**A204210**	**001** Mar 28, 2016
AB			**10MEQ**	**A204210**	**002** Mar 28, 2016
AB		LUPIN LTD	**8MEQ**	**A203002**	**001** Dec 18, 2015
AB			**10MEQ**	**A203002**	**002** Dec 18, 2015
AB		NOVEL LABS INC	**8MEQ**	**A204828**	**001** Aug 16, 2016
AB			**10MEQ**	**A204828**	**002** Aug 16, 2016
AB		PADDOCK LLC	**8MEQ**	**A200185**	**001** May 18, 2011
AB			**10MEQ**	**A200185**	**002** May 18, 2011
AB		PHARMACEUTICS INTL	**8MEQ**	**A205549**	**001** Dec 08, 2015
AB			**10MEQ**	**A205549**	**002** Dec 08, 2015
AB		TRIS PHARMA INC	**8MEQ**	**A201944**	**001** Mar 04, 2016
AB			**10MEQ**	**A201944**	**002** Mar 04, 2016

FOR SOLUTION;ORAL
POTASSIUM CHLORIDE

	+	PHARMA RES SOFTWARE	20MEQ	N208019	001 Aug 19, 2015

INJECTABLE;INJECTION
POTASSIUM CHLORIDE

AP		B BRAUN	**2MEQ/ML**	**A085870**	**001**
AP		BAXTER HLTHCARE	**2MEQ/ML**	**A085499**	**001**
AP		FRESENIUS KABI USA	**2MEQ/ML**	**A080225**	**001**
AP	**+**	HOSPIRA	**2MEQ/ML**	**A080205**	**001**

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**14.9MG/ML**	**N019904**	**001** Dec 26, 1989
AP	**+**		**746MG/100ML**	**N019904**	**005** Dec 17, 1990
AP		HOSPIRA	**14.9MG/ML**	**N020161**	**005** Nov 30, 1992
AP			**745MG/100ML**	**N020161**	**001** Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**29.8MG/ML**	**N019904**	**002** Dec 26, 1989
AP	**+**		**1.49GM/100ML**	**N019904**	**006** Dec 17, 1990
AP	**+**	HOSPIRA	**29.8MG/ML**	**N020161**	**006** Aug 11, 1998
AP			**1.49GM/100ML**	**N020161**	**002** Nov 30, 1992

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

INJECTABLE;INJECTION

		POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER				
AP	**+**	BAXTER HLTHCARE	**2.24GM/100ML**	**N019904**	**003**	Dec 26, 1989
AP	**+**	HOSPIRA	**2.24GM/100ML**	**N020161**	**003**	Aug 11, 1998
		POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER				
AP	**+**	BAXTER HLTHCARE	**2.98GM/100ML**	**N019904**	**004**	Dec 26, 1989
AP	**+**	HOSPIRA	**2.98GM/100ML**	**N020161**	**004**	Aug 11, 1998
		POTASSIUM CHLORIDE IN PLASTIC CONTAINER				
AP		FRESENIUS KABI USA	**2MEQ/ML**	**A088901**	**001**	Jan 25, 1985
AP			**2MEQ/ML**	**A088908**	**001**	Jan 25, 1985
		POTASSIUM CHLORIDE				
	+	FRESENIUS KABI USA	3MEQ/ML	A080225	003	

SOLUTION;ORAL

		POTASSIUM CHLORIDE				
		LEHIGH VALLEY	20MEQ/15ML	N206814	001	Dec 22, 2014
	+		40MEQ/15ML	N206814	002	Dec 22, 2014

TABLET, EXTENDED RELEASE;ORAL

		KLOR-CON M10				
AB1		UPSHER SMITH LABS	**10MEQ**	**A074726**	**002**	Aug 09, 2000
		KLOR-CON M20				
AB1	**+**	UPSHER SMITH LABS	**20MEQ**	**A074726**	**001**	Nov 20, 1998
		POTASSIUM CHLORIDE				
AB1		ACTAVIS LABS FL INC	**10MEQ**	**A075604**	**001**	Apr 10, 2002
AB1			**20MEQ**	**A075604**	**002**	Apr 10, 2002
AB1		ADARE PHARMS INC	**20MEQ**	**A076368**	**001**	Aug 18, 2004
AB1		GLENMARK PHARMS LTD	**10MEQ**	**A203562**	**001**	Jul 26, 2016
AB1			**20MEQ**	**A203562**	**002**	Jul 26, 2016
AB1		NOVEL LABS INC	**10MEQ**	**A206347**	**001**	Jan 21, 2016
AB1			**20MEQ**	**A206347**	**002**	Jan 21, 2016
		KLOR-CON				
AB2		UPSHER-SMITH LABS	**8MEQ**	**N019123**	**001**	Apr 17, 1986
AB2	**+**		**10MEQ**	**N019123**	**002**	Apr 17, 1986
		POTASSIUM CHLORIDE				
AB2		MYLAN PHARMS INC	**8MEQ**	**A204662**	**001**	Aug 21, 2014
AB2			**10MEQ**	**A204662**	**002**	Aug 21, 2014
AB2		NOVEL LABS INC	**8MEQ**	**A206759**	**001**	Aug 09, 2016
AB2			**10MEQ**	**A206759**	**002**	Aug 09, 2016
AB2		PADDOCK LLC	**8MEQ**	**A205993**	**001**	Nov 05, 2015
AB2			**10MEQ**	**A205993**	**002**	Nov 05, 2015
AB2		SIGMAPHARM LABS LLC	**8MEQ**	**A207528**	**001**	Aug 19, 2016
AB2			**10MEQ**	**A207528**	**002**	Aug 19, 2016
		K-TAB				
BC		ABBVIE	8MEQ	N018279	002	Aug 01, 1988
BC			10MEQ	N018279	001	
BC	+		20MEQ	N018279	003	Nov 25, 2013
		KLOR-CON M15				
		UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

		POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP		HOSPIRA	**149MG/100ML;450MG/100ML**	**A078446**	**001**	Sep 10, 2008
		POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	**+**	BAXTER HLTHCARE	**150MG/100ML;450MG/100ML**	**N017648**	**005**	Nov 26, 2002
		POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		B BRAUN	**150MG/100ML;900MG/100ML**	**N019708**	**004**	Sep 29, 1989
AP		BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N017648**	**001**	
		POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	**300MG/100ML;900MG/100ML**	**N017648**	**002**	
		POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		HOSPIRA	**149MG/100ML;900MG/100ML**	**N019686**	**001**	Oct 17, 1988
		POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		HOSPIRA	**298MG/100ML;900MG/100ML**	**N019686**	**002**	Oct 17, 1988
		POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%				
		BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003	

FDA data supplied by DrugPatentWatch.com

POTASSIUM CITRATE
TABLET, EXTENDED RELEASE;ORAL

	POTASSIUM CITRATE				
AB	COREPHARMA	**5MEQ**	**A077440**	**001**	Jun 09, 2006
AB		**10MEQ**	**A077440**	**002**	Jun 09, 2006
AB	ZYDUS PHARMS USA INC	**5MEQ**	**A203546**	**001**	Aug 06, 2014
AB		**10MEQ**	**A203546**	**002**	Aug 06, 2014
AB		**15MEQ**	**A203546**	**003**	Aug 06, 2014
	UROCIT-K				
AB	MISSION PHARMA	**5MEQ**	**N019071**	**001**	Aug 30, 1985
AB		**10MEQ**	**N019071**	**002**	Aug 31, 1992
AB	**+**	**15MEQ**	**N019071**	**003**	Dec 30, 2009

POVIDONE-IODINE
SOLUTION/DROPS;OPHTHALMIC

	BETADINE				
+	ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986

PRALATREXATE
SOLUTION;INTRAVENOUS

	FOLOTYN				
	ALLOS	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
+		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

PRALIDOXIME CHLORIDE
INJECTABLE;INJECTION

	PRALIDOXIME CHLORIDE				
+	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983
	PROTOPAM CHLORIDE				
+	BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	

PRAMIPEXOLE DIHYDROCHLORIDE
TABLET;ORAL

	MIRAPEX				
AB	BOEHRINGER INGELHEIM	**0.125MG**	**N020667**	**001**	Jul 01, 1997
AB	**+**	**0.25MG**	**N020667**	**002**	Jul 01, 1997
AB		**0.5MG**	**N020667**	**006**	Feb 12, 1998
AB		**0.75MG**	**N020667**	**007**	Jul 30, 2007
AB		**1MG**	**N020667**	**003**	Jul 01, 1997
AB		**1.5MG**	**N020667**	**005**	Jul 01, 1997
	PRAMIPEXOLE DIHYDROCHLORIDE				
AB	ACTAVIS GRP PTC	**0.125MG**	**A091254**	**001**	Nov 30, 2010
AB		**0.25MG**	**A091254**	**002**	Nov 30, 2010
AB		**0.5MG**	**A091254**	**003**	Nov 30, 2010
AB		**0.75MG**	**A091254**	**004**	Nov 30, 2010
AB		**1MG**	**A091254**	**005**	Nov 30, 2010
AB		**1.5MG**	**A091254**	**006**	Nov 30, 2010
AB	ALEMBIC LTD	**0.125MG**	**A078894**	**001**	Oct 08, 2010
AB		**0.25MG**	**A078894**	**002**	Oct 08, 2010
AB		**0.5MG**	**A078894**	**003**	Oct 08, 2010
AB		**1MG**	**A078894**	**004**	Oct 08, 2010
AB		**1.5MG**	**A078894**	**005**	Oct 08, 2010
AB	APOTEX INC	**0.125MG**	**A090151**	**001**	Apr 30, 2012
AB		**0.25MG**	**A090151**	**002**	Apr 30, 2012
AB		**0.5MG**	**A090151**	**003**	Apr 30, 2012
AB		**0.75MG**	**A090151**	**006**	Apr 30, 2012
AB		**1MG**	**A090151**	**004**	Apr 30, 2012
AB		**1.5MG**	**A090151**	**005**	Apr 30, 2012
AB	AUROBINDO PHARMA LTD	**0.125MG**	**A202633**	**001**	Oct 26, 2012
AB		**0.25MG**	**A202633**	**002**	Oct 26, 2012
AB		**0.5MG**	**A202633**	**003**	Oct 26, 2012
AB		**0.75MG**	**A202633**	**004**	Oct 26, 2012
AB		**1MG**	**A202633**	**005**	Oct 26, 2012
AB		**1.5MG**	**A202633**	**006**	Oct 26, 2012
AB	BARR	**0.125MG**	**A077724**	**001**	Feb 19, 2008
AB		**0.25MG**	**A077724**	**002**	Feb 19, 2008
AB		**0.5MG**	**A077724**	**003**	Feb 19, 2008
AB		**1MG**	**A077724**	**004**	Feb 19, 2008
AB		**1.5MG**	**A077724**	**005**	Feb 19, 2008
AB	BRECKENRIDGE PHARM	**0.125MG**	**A091450**	**001**	Oct 08, 2010
AB		**0.25MG**	**A091450**	**002**	Oct 08, 2010
AB		**0.5MG**	**A091450**	**003**	Oct 08, 2010
AB		**1MG**	**A091450**	**004**	Oct 08, 2010
AB		**1.5MG**	**A091450**	**005**	Oct 08, 2010

FDA data supplied by DrugPatentWatch.com

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	GLENMARK GENERICS	0.125MG	A090781	001	Oct 08, 2010
AB		0.25MG	A090781	002	Oct 08, 2010
AB		0.5MG	A090781	003	Oct 08, 2010
AB		0.75MG	A090781	006	Sep 11, 2015
AB		1MG	A090781	004	Oct 08, 2010
AB		1.5MG	A090781	005	Oct 08, 2010
AB	MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012
AB		0.25MG	A202164	002	Sep 20, 2012
AB		0.5MG	A202164	003	Sep 20, 2012
AB		1MG	A202164	004	Sep 20, 2012
AB		1.5MG	A202164	005	Sep 20, 2012
AB	MYLAN	0.125MG	A077854	001	Oct 08, 2010
AB		0.25MG	A077854	002	Oct 08, 2010
AB		0.5MG	A077854	003	Oct 08, 2010
AB		0.75MG	A090764	001	Apr 09, 2010
AB		1MG	A077854	004	Oct 08, 2010
AB		1.5MG	A077854	005	Oct 08, 2010
AB	SANDOZ	0.125MG	A090190	001	Jul 06, 2010
AB		0.25MG	A090190	002	Jul 06, 2010
AB		0.5MG	A090190	003	Jul 06, 2010
AB		0.75MG	A090190	006	Oct 08, 2010
AB		1MG	A090190	004	Jul 06, 2010
AB		1.5MG	A090190	005	Jul 06, 2010
AB	SCIEGEN PHARMS INC	0.125MG	A203855	001	Oct 28, 2014
AB		0.25MG	A203855	002	Oct 28, 2014
AB		0.5MG	A203855	003	Oct 28, 2014
AB		0.75MG	A203855	004	Oct 28, 2014
AB		1MG	A203855	005	Oct 28, 2014
AB		1.5MG	A203855	006	Oct 28, 2014
AB	STRIDES PHARMA	0.125MG	A202702	001	Jun 03, 2014
AB		0.25MG	A202702	002	Jun 03, 2014
AB		0.5MG	A202702	003	Jun 03, 2014
AB		0.75MG	A202702	004	Jun 03, 2014
AB		1MG	A202702	005	Jun 03, 2014
AB		1.5MG	A202702	006	Jun 03, 2014
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013
AB		0.25MG	A091683	002	Mar 27, 2013
AB		0.5MG	A091683	003	Mar 27, 2013
AB		0.75MG	A091683	004	Mar 27, 2013
AB		1MG	A091683	005	Mar 27, 2013
AB		1.5MG	A091683	006	Mar 27, 2013
AB	TEVA PHARMS	0.125MG	A090241	001	Oct 08, 2010
AB		0.25MG	A090241	002	Oct 08, 2010
AB		0.5MG	A090241	003	Oct 08, 2010
AB		0.75MG	A090241	004	Oct 08, 2010
AB		1MG	A090241	005	Oct 08, 2010
AB		1.5MG	A090241	006	Oct 08, 2010
AB	TORRENT PHARMS	0.125MG	A090865	001	Oct 08, 2010
AB		0.25MG	A090865	002	Oct 08, 2010
AB		0.5MG	A090865	003	Oct 08, 2010
AB		0.75MG	A090865	004	Oct 08, 2010
AB		1MG	A090865	005	Oct 08, 2010
AB		1.5MG	A090865	006	Oct 08, 2010
AB	ZYDUS PHARMS USA INC	0.125MG	A078920	001	Jul 06, 2010
AB		0.25MG	A078920	002	Jul 06, 2010
AB		0.5MG	A078920	003	Jul 06, 2010
AB		1MG	A078920	004	Jul 06, 2010
AB		1.5MG	A078920	005	Jul 06, 2010

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

AB	+ BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010
AB		0.75MG	N022421	002	Feb 19, 2010
AB		1.5MG	N022421	003	Feb 19, 2010
AB		2.25MG	N022421	006	Jun 17, 2011
AB		3MG	N022421	004	Feb 19, 2010
AB		3.75MG	N022421	007	Jun 17, 2011
AB		4.5MG	N022421	005	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016

PRAMIPEXOLE DIHYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB		**0.75MG**	**A201963**	**002**	Apr 21, 2016
AB		**1.5MG**	**A201963**	**003**	Apr 21, 2016
AB		**2.25MG**	**A203615**	**001**	Oct 14, 2016
AB		**3MG**	**A201963**	**004**	Apr 21, 2016
AB		**3.75MG**	**A203615**	**002**	Jan 03, 2017
AB		**4.5MG**	**A201963**	**005**	Apr 21, 2016
AB	ANCHEN PHARMS	**0.375MG**	**A202206**	**001**	Feb 06, 2014
AB		**0.75MG**	**A202206**	**002**	Feb 06, 2014
AB		**1.5MG**	**A202206**	**003**	Feb 06, 2014
AB		**2.25MG**	**A202206**	**004**	Feb 06, 2014
AB		**3MG**	**A202206**	**005**	Feb 06, 2014
AB		**3.75MG**	**A202206**	**006**	Feb 06, 2014
AB		**4.5MG**	**A202206**	**007**	Feb 06, 2014
AB	DR REDDYS LABS LTD	**0.375MG**	**A203354**	**001**	Aug 07, 2015
AB		**0.75MG**	**A203354**	**002**	Aug 07, 2015
AB		**1.5MG**	**A203354**	**003**	Aug 07, 2015
AB		**3MG**	**A203354**	**004**	Aug 07, 2015
AB		**4.5MG**	**A203354**	**005**	Aug 07, 2015
AB	MACLEODS PHARMS LTD	**0.375MG**	**A206156**	**001**	Jun 24, 2016
AB		**0.75MG**	**A206156**	**002**	Jun 24, 2016
AB		**1.5MG**	**A206156**	**003**	Jun 24, 2016
AB		**2.25MG**	**A206156**	**004**	Jun 24, 2016
AB		**3MG**	**A206156**	**005**	Jun 24, 2016
AB		**4.5MG**	**A206156**	**007**	Jun 24, 2016
AB	SANDOZ INC	**0.375MG**	**A202353**	**001**	Dec 04, 2014
AB		**0.75MG**	**A202353**	**002**	Dec 04, 2014
AB		**1.5MG**	**A202353**	**003**	Dec 04, 2014
AB		**3MG**	**A202353**	**004**	Dec 04, 2014
AB		**4.5MG**	**A202353**	**005**	Dec 04, 2014

PRAMLINTIDE ACETATE
INJECTABLE;SUBCUTANEOUS
SYMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007

PRASTERONE
INSERT;VAGINAL
INTRAROSA

+	ENDOCEUTICS INC	6.5MG	N208470	001	Nov 16, 2016

PRASUGREL HYDROCHLORIDE
TABLET;ORAL
EFFIENT

	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009
+		EQ 10MG BASE	N022307	002	Jul 10, 2009

PRAVASTATIN SODIUM
TABLET;ORAL
PRAVACHOL

AB	BRISTOL MYERS SQUIBB	**20MG**	**N019898**	**003**	Oct 31, 1991
AB		**40MG**	**N019898**	**004**	Mar 22, 1993
AB	**+**	**80MG**	**N019898**	**008**	Dec 18, 2001

PRAVASTATIN SODIUM

AB	ACCORD HLTHCARE	**10MG**	**A207068**	**001**	Nov 17, 2016
AB		**20MG**	**A207068**	**002**	Nov 17, 2016
AB		**40MG**	**A207068**	**003**	Nov 17, 2016
AB		**80MG**	**A207068**	**004**	Nov 17, 2016
AB	APOTEX INC	**10MG**	**A076341**	**001**	Oct 23, 2006
AB		**20MG**	**A076341**	**002**	Oct 23, 2006
AB		**40MG**	**A076341**	**003**	Oct 23, 2006
AB		**80MG**	**A076341**	**004**	Dec 28, 2007
AB	CIPLA LTD	**10MG**	**A077904**	**001**	Oct 23, 2006
AB		**20MG**	**A077904**	**002**	Oct 23, 2006
AB		**40MG**	**A077904**	**003**	Oct 23, 2006
AB		**80MG**	**A077904**	**004**	Mar 22, 2016
AB	DR REDDYS LABS INC	**10MG**	**A076714**	**001**	Oct 23, 2006
AB		**20MG**	**A076714**	**002**	Oct 23, 2006
AB		**40MG**	**A076714**	**003**	Oct 23, 2006
AB		**80MG**	**A076714**	**004**	Dec 28, 2007
AB	GLENMARK GENERICS	**10MG**	**A077987**	**001**	May 11, 2007

FDA data supplied by DrugPatentWatch.com

PRAVASTATIN SODIUM
TABLET;ORAL
PRAVASTATIN SODIUM

AB		**20MG**	**A077987**	**002**	May 11, 2007
AB		**40MG**	**A077987**	**003**	May 11, 2007
AB		**80MG**	**A077987**	**004**	Dec 28, 2007
AB	LUPIN PHARMS	**10MG**	**A077917**	**001**	Jan 08, 2008
AB		**20MG**	**A077917**	**002**	Jan 08, 2008
AB		**40MG**	**A077917**	**003**	Jan 08, 2008
AB		**80MG**	**A077917**	**004**	Jan 08, 2008
AB	MYLAN PHARMS INC	**10MG**	**A079187**	**001**	May 27, 2010
AB		**20MG**	**A079187**	**002**	May 27, 2010
AB		**40MG**	**A079187**	**003**	May 27, 2010
AB		**80MG**	**A079187**	**004**	May 27, 2010
AB	SANDOZ	**10MG**	**A076397**	**003**	Oct 23, 2006
AB		**20MG**	**A076397**	**002**	Oct 23, 2006
AB		**40MG**	**A076397**	**001**	Oct 23, 2006
AB		**80MG**	**A077491**	**001**	Feb 11, 2008
AB	TEVA	**10MG**	**A076056**	**001**	Apr 24, 2006
AB		**20MG**	**A076056**	**002**	Apr 24, 2006
AB		**40MG**	**A076056**	**003**	Apr 24, 2006
AB	TEVA PHARMS	**80MG**	**A077793**	**001**	Jan 15, 2008
AB	WATSON LABS	**10MG**	**A076939**	**004**	Oct 23, 2006
AB		**20MG**	**A076939**	**003**	Oct 23, 2006
AB		**40MG**	**A076939**	**002**	Oct 23, 2006
AB		**80MG**	**A076939**	**001**	Dec 28, 2007
AB	ZYDUS PHARMS USA	**10MG**	**A077751**	**001**	Apr 30, 2008
AB		**20MG**	**A077751**	**002**	Apr 30, 2008
AB		**40MG**	**A077751**	**003**	Apr 30, 2008
AB		**80MG**	**A077751**	**004**	Apr 30, 2008

PRAZIQUANTEL
TABLET;ORAL
BILTRICIDE

+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982

PRAZOSIN HYDROCHLORIDE
CAPSULE;ORAL
MINIPRESS

AB	PFIZER	**EQ 1MG BASE**	**N017442**	**002**	
AB	**+**	**EQ 2MG BASE**	**N017442**	**003**	
AB		**EQ 5MG BASE**	**N017442**	**001**	

PRAZOSIN HYDROCHLORIDE

AB	MYLAN	**EQ 1MG BASE**	**A072575**	**003**	May 16, 1989
AB		**EQ 2MG BASE**	**A072575**	**002**	May 16, 1989
AB		**EQ 5MG BASE**	**A072575**	**001**	May 16, 1989
AB	TEVA PHARMS	**EQ 1MG BASE**	**A071745**	**002**	Sep 12, 1988
AB		**EQ 2MG BASE**	**A071745**	**003**	Sep 12, 1988
AB		**EQ 5MG BASE**	**A071745**	**001**	Sep 12, 1988

PREDNICARBATE
CREAM;TOPICAL
DERMATOP E EMOLLIENT

AB	**+** VALEANT BERMUDA	**0.1%**	**N020279**	**001**	Oct 29, 1993

PREDNICARBATE

AB	FOUGERA PHARMS	**0.1%**	**A077287**	**001**	Sep 19, 2006

OINTMENT;TOPICAL
DERMATOP

AB	**+** VALEANT PHARMS NORTH	**0.1%**	**N019568**	**001**	Sep 23, 1991

PREDNICARBATE

AB	FOUGERA PHARMS	**0.1%**	**A077236**	**001**	Mar 09, 2007

PREDNISOLONE
SYRUP;ORAL
PREDNISOLONE

AA	ALPHARMA	**15MG/5ML**	**A040323**	**001**	May 13, 1999
AA	**+** HI TECH PHARMA CO	**15MG/5ML**	**A040401**	**001**	Feb 27, 2003
AA	PHARM ASSOC	**15MG/5ML**	**A040399**	**001**	Mar 05, 2003
AA	VINTAGE	**15MG/5ML**	**A040775**	**001**	Sep 21, 2007
AA	WOCKHARDT	**15MG/5ML**	**A040313**	**001**	Sep 10, 2003

PRELONE

AA	TEVA	**15MG/5ML**	**A089081**	**001**	Feb 04, 1986

PREDNISOLONE
TABLET;ORAL
PREDNISOLONE

	+	WATSON LABS	5MG	A080354	001

PREDNISOLONE ACETATE
SUSPENSION/DROPS;OPHTHALMIC

		OMNIPRED			
AB		NOVARTIS PHARMS CORP	**1%**	**N017469**	**001**
		PRED FORTE			
AB	**+**	ALLERGAN	**1%**	**N017011**	**001**
		PRED MILD			
	+	ALLERGAN	0.12%	N017100	001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT;OPHTHALMIC

		BLEPHAMIDE S.O.P.				
	+	ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986

SUSPENSION;OPHTHALMIC

		BLEPHAMIDE				
	+	ALLERGAN	0.2%;10%	N012813	002	

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION;ORAL

		PEDIAPRED				
AA	**+**	SETON PHARM	**EQ 5MG BASE/5ML**	**N019157**	**001**	May 28, 1986
		PREDNISOLONE SODIUM PHOSPHATE				
AA		AMNEAL PHARMS	**EQ 15MG BASE/5ML**	**A078345**	**001**	Mar 10, 2009
AA		EDENBRIDGE PHARMS	**EQ 10MG BASE/5ML**	**A203559**	**001**	Dec 20, 2016
AA			**EQ 20MG BASE/5ML**	**A203559**	**002**	Dec 20, 2016
AA		HI TECH PHARMA	**EQ 5MG BASE/5ML**	**A075183**	**001**	Mar 26, 2003
AA		PADDOCK LLC	**EQ 5MG BASE/5ML**	**A075988**	**001**	May 25, 2004
AA	**+**	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A078465**	**001**	Mar 07, 2008
AA			**EQ 15MG BASE/5ML**	**A076913**	**001**	Apr 25, 2005
AA	**+**		**EQ 20MG BASE/5ML**	**A078988**	**001**	Jun 09, 2008
AA		VINTAGE	**EQ 15MG BASE/5ML**	**A079010**	**001**	May 26, 2009
AA		WOCKHARDT	**EQ 5MG BASE/5ML**	**A075099**	**001**	Jun 28, 2002
AA	**+**		**EQ 15MG BASE/5ML**	**A076895**	**001**	Oct 04, 2004
	+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010

SOLUTION/DROPS;OPHTHALMIC

		PREDNISOLONE SODIUM PHOSPHATE				
	+	BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994

TABLET, ORALLY DISINTEGRATING;ORAL

		ORAPRED ODT				
AB		CONCORDIA PHARMS INC	**EQ 10MG BASE**	**N021959**	**001**	Jun 01, 2006
AB			**EQ 15MG BASE**	**N021959**	**002**	Jun 01, 2006
AB	**+**		**EQ 30MG BASE**	**N021959**	**003**	Jun 01, 2006
		PREDNISOLONE SODIUM PHOSPHATE				
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A202179**	**001**	Apr 10, 2013
AB			**EQ 15MG BASE**	**A202179**	**002**	Apr 10, 2013
AB			**EQ 30MG BASE**	**A202179**	**003**	Apr 10, 2013

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM
SOLUTION/DROPS;OPHTHALMIC

		SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE				
AT		ALCON PHARMS LTD	**EQ 0.23% PHOSPHATE;10%**	**A073630**	**001**	May 27, 1993
AT	**+**	BAUSCH AND LOMB	**EQ 0.23% PHOSPHATE;10%**	**A074449**	**001**	Dec 29, 1995

PREDNISONE
SOLUTION;ORAL

		PREDNISONE				
	+	WEST-WARD PHARMS INT	5MG/5ML	A088703	001	Nov 08, 1984
		PREDNISONE INTENSOL				
	+	WEST-WARD PHARMS INT	5MG/ML	A088810	001	Feb 20, 1985

TABLET;ORAL

		PREDNISONE				
AB		CONTRACT PHARMACAL	**5MG**	**A080209**	**001**	
AB		DELCOR ASSET CORP	**5MG**	**A080292**	**001**	
AB			**10MG**	**A088832**	**001**	Dec 04, 1985
AB			**20MG**	**A083677**	**001**	
AB		HIKMA PHARMS	**2.5MG**	**A040538**	**001**	Jan 08, 2004
AB			**50MG**	**A088465**	**001**	Jun 01, 1984
AB		JUBILANT CADISTA	**1MG**	**A040611**	**001**	Jun 06, 2005
AB			**5MG**	**A040362**	**002**	Aug 29, 2001
AB			**10MG**	**A040362**	**001**	Aug 29, 2001

FDA data supplied by DrugPatentWatch.com

PREDNISONE
TABLET;ORAL
PREDNISONE

AB			**20MG**	**A040362**	**003**	Jun 29, 2005
AB		MUTUAL PHARM	**5MG**	**A089245**	**001**	Dec 04, 1985
AB			**10MG**	**A089246**	**001**	Dec 04, 1985
AB		SUN PHARM INDS	**20MG**	**A089247**	**001**	Dec 04, 1985
AB		VINTAGE PHARMS	**1MG**	**A040584**	**001**	Dec 21, 2004
AB			**2.5MG**	**A040581**	**001**	Dec 21, 2004
AB			**5MG**	**A040256**	**001**	Jul 12, 2002
AB			**10MG**	**A040256**	**002**	Jul 12, 2002
AB			**20MG**	**A040392**	**001**	Feb 12, 2003
AB		WATSON LABS	**5MG**	**A080356**	**001**	
AB			**10MG**	**A085162**	**001**	
AB			**20MG**	**A085161**	**001**	
AB	+	WEST-WARD PHARMS INT	**1MG**	**A087800**	**001**	Apr 22, 1982
AB	+		**2.5MG**	**A087801**	**001**	Apr 22, 1982
AB	+		**5MG**	**A080352**	**001**	
AB	+		**10MG**	**A084122**	**001**	
AB	+		**20MG**	**A087342**	**001**	
AB	+		**50MG**	**A084283**	**001**	

TABLET, DELAYED RELEASE;ORAL
RAYOS

		HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012
			2MG	N202020	002	Jul 26, 2012
	+		5MG	N202020	003	Jul 26, 2012

PREGABALIN
CAPSULE;ORAL
LYRICA

		PF PRISM CV	25MG	N021446	001	Dec 30, 2004
			50MG	N021446	002	Dec 30, 2004
			75MG	N021446	003	Dec 30, 2004
			100MG	N021446	004	Dec 30, 2004
			150MG	N021446	005	Dec 30, 2004
			200MG	N021446	006	Dec 30, 2004
			225MG	N021446	007	Dec 30, 2004
	+		300MG	N021446	008	Dec 30, 2004

SOLUTION;ORAL
LYRICA

	+	PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010

PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
PRILOCAINE HYDROCHLORIDE

	+	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE
TABLET;ORAL
PRIMAQUINE

AB	+	SANOFI AVENTIS US	**EQ 15MG BASE**	**N008316**	**001**	

PRIMAQUINE PHOSPHATE

AB		ALVOGEN INC	**EQ 15MG BASE**	**A203924**	**001**	Feb 03, 2014
AB		BAYSHORE PHARMS LLC	**EQ 15MG BASE**	**A204476**	**001**	Feb 25, 2014
AB		INGENUS PHARMS NJ	**EQ 15MG BASE**	**A206043**	**001**	Jun 23, 2016

PRIMIDONE
TABLET;ORAL
MYSOLINE

AB	+	VALEANT	**50MG**	**N009170**	**003**	
AB			**250MG**	**N009170**	**002**	

PRIMIDONE

AB		AMNEAL PHARM	**50MG**	**A040866**	**001**	Apr 23, 2008
AB			**250MG**	**A040866**	**002**	Apr 23, 2008
AB		FRONTIDA BIOPHARM	**50MG**	**A040626**	**001**	Sep 29, 2005
AB			**250MG**	**A040626**	**002**	Sep 29, 2005
AB		HIKMA INTL PHARMS	**250MG**	**A040667**	**002**	Jul 27, 2006
AB		LANNETT	**50MG**	**A084903**	**002**	May 24, 2001
AB			**250MG**	**A084903**	**001**	
AB		VINTAGE PHARMS	**50MG**	**A040586**	**001**	Feb 24, 2005
AB			**250MG**	**A040586**	**002**	Feb 24, 2005
AB		WATSON LABS	**250MG**	**A083551**	**001**	

FDA data supplied by DrugPatentWatch.com

PROBENECID
TABLET;ORAL

	PROBALAN				
AB		LANNETT	**500MG**	**A080966** **001**	
	PROBENECID				
AB	+	MYLAN	**500MG**	**A084211** **002**	
AB		WATSON LABS	**500MG**	**A084442** **004**	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION

	PROCAINAMIDE HYDROCHLORIDE				
AP	+	HOSPIRA	**100MG/ML**	**A089069** **001**	Feb 12, 1986
AP		INTL MEDICATION	**100MG/ML**	**A088636** **001**	Jul 31, 1984
	+	HOSPIRA	500MG/ML	A089070 001	Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE
CAPSULE;ORAL

	MATULANE				
	+	SIGMA TAU	EQ 50MG BASE	N016785 001	

PROCHLORPERAZINE
SUPPOSITORY;RECTAL

	COMPRO				
AB		PADDOCK LLC	**25MG**	**A040246** **001**	Jun 28, 2000
	PROCHLORPERAZINE				
AB	+	G AND W LABS	**25MG**	**A040058** **001**	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE
INJECTABLE;INJECTION

	PROCHLORPERAZINE EDISYLATE				
AP	+	EMCURE PHARMS LTD	**EQ 5MG BASE/ML**	**A204147** **001**	Oct 15, 2013
AP		EUROHLTH INTL SARL	**EQ 5MG BASE/ML**	**A089903** **001**	Aug 29, 1989

PROCHLORPERAZINE MALEATE
TABLET;ORAL

	PROCHLORPERAZINE MALEATE				
AB		MYLAN	**EQ 5MG BASE**	**A040185** **002**	Oct 28, 1996
AB			**EQ 10MG BASE**	**A040185** **001**	Oct 28, 1996
AB		SANDOZ	**EQ 5MG BASE**	**A040101** **001**	Jul 19, 1996
AB	+		**EQ 10MG BASE**	**A040101** **002**	Jul 19, 1996
AB		TEVA PHARMS	**EQ 5MG BASE**	**A040120** **001**	Jul 11, 1996
AB			**EQ 10MG BASE**	**A040120** **002**	Jul 11, 1996
	PROCOMP				
AB		JUBILANT CADISTA	**EQ 5MG BASE**	**A040268** **001**	Feb 27, 1998
AB			**EQ 10MG BASE**	**A040268** **002**	Feb 27, 1998

PROGESTERONE
CAPSULE;ORAL

	PROGESTERONE				
AB		BIONPHARMA INC	**100MG**	**A200900** **001**	Aug 16, 2013
AB			**200MG**	**A200900** **002**	Aug 16, 2013
AB		SOFGEN PHARMS	**100MG**	**A200456** **001**	Sep 28, 2012
AB			**200MG**	**A200456** **002**	Sep 28, 2012
AB		TEVA PHARMS	**100MG**	**A202121** **001**	Feb 29, 2012
AB			**200MG**	**A202121** **002**	Feb 29, 2012
	PROMETRIUM				
AB		VIRTUS PHARMS	**100MG**	**N019781** **001**	May 14, 1998
AB	+		**200MG**	**N019781** **002**	Oct 15, 1999

GEL;VAGINAL

	CRINONE				
	+	ALLERGAN SALES LLC	4%	N020701 001	Jul 31, 1997
	+		8%	N020701 002	Jul 31, 1997

INJECTABLE;INJECTION

	PROGESTERONE				
AO	+	ALLERGAN SALES LLC	**50MG/ML**	**N017362** **002**	
AO		FRESENIUS KABI USA	**50MG/ML**	**A075906** **001**	Apr 25, 2001
AO		HIKMA FARMACEUTICA	**50MG/ML**	**A091033** **001**	Oct 28, 2010
AO		LUITPOLD	**50MG/ML**	**A090845** **001**	Jun 22, 2009

INSERT;VAGINAL

	ENDOMETRIN				
	+	FERRING	100MG	N022057 001	Jun 21, 2007

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

		PROMETHAZINE HYDROCHLORIDE				
AP	+	EUROHLTH INTL SARL	**25MG/ML**	**A083312**	**001**	
AP	+		**50MG/ML**	**A083312**	**002**	
AP		X-GEN PHARMS	**25MG/ML**	**A040737**	**001**	Apr 24, 2008
AP			**50MG/ML**	**A040737**	**002**	Apr 24, 2008

SUPPOSITORY;RECTAL

		PROMETHAZINE HYDROCHLORIDE				
AB		G AND W LABS	**12.5MG**	**A040428**	**002**	Mar 31, 2003
AB	+		**25MG**	**A040428**	**001**	Feb 05, 2002
AB		PERRIGO NEW YORK	**12.5MG**	**A040500**	**001**	Jun 30, 2003
AB			**25MG**	**A040500**	**002**	Jun 30, 2003
AB		TARO	**12.5MG**	**A040603**	**001**	Oct 26, 2006
AB			**25MG**	**A040603**	**002**	Oct 26, 2006
AB		WATSON LABS INC	**12.5MG**	**A040479**	**001**	Jun 24, 2003
AB			**25MG**	**A040479**	**002**	Jun 24, 2003
		PROMETHEGAN				
	+	G AND W LABS	50MG	A087165	001	Aug 14, 1987

SYRUP;ORAL

		PROMETHAZINE HYDROCHLORIDE				
AA		AMNEAL PHARMS	**6.25MG/5ML**	**A040882**	**001**	Dec 30, 2009
AA		HI TECH PHARMA	**6.25MG/5ML**	**A040026**	**001**	Sep 25, 1998
AA		NOSTRUM LABS INC	**6.25MG/5ML**	**A040891**	**001**	Mar 13, 2009
AA		TARO	**6.25MG/5ML**	**A040718**	**001**	Apr 04, 2007
AA		TRIS PHARMA INC	**6.25MG/5ML**	**A091675**	**001**	Jun 28, 2012
AA		VINTAGE	**6.25MG/5ML**	**A040643**	**001**	Apr 26, 2006
		PROMETHAZINE PLAIN				
AA	+	WOCKHARDT	**6.25MG/5ML**	**A087953**	**001**	Nov 15, 1982

TABLET;ORAL

		PROMETHAZINE HYDROCHLORIDE				
AB		AMNEAL PHARMS NY	**12.5MG**	**A091179**	**001**	Dec 13, 2010
AB			**25MG**	**A091179**	**002**	Dec 13, 2010
AB			**50MG**	**A091179**	**003**	Dec 13, 2010
AB		HERITAGE PHARMA	**12.5MG**	**A040673**	**001**	Mar 05, 2008
AB			**25MG**	**A040673**	**002**	Mar 05, 2008
AB			**50MG**	**A040673**	**003**	Mar 05, 2008
AB		KVK TECH	**12.5MG**	**A040712**	**002**	May 04, 2007
AB			**25MG**	**A040712**	**001**	Jul 31, 2006
AB			**50MG**	**A040712**	**003**	Jul 31, 2006
AB		MYLAN	**12.5MG**	**A091054**	**001**	Aug 30, 2011
AB			**25MG**	**A091054**	**002**	Aug 30, 2011
AB			**50MG**	**A091054**	**003**	Aug 30, 2011
AB		SANDOZ	**25MG**	**A084176**	**003**	
AB	+		**50MG**	**A084176**	**001**	
AB		SUN PHARM INDS INC	**12.5MG**	**A040863**	**001**	Dec 30, 2008
AB			**25MG**	**A040863**	**002**	Dec 30, 2008
AB			**50MG**	**A040863**	**003**	Dec 30, 2008
AB		VINTAGE PHARMS	**12.5MG**	**A040622**	**001**	Jul 18, 2006
AB			**25MG**	**A040622**	**002**	Jul 18, 2006
AB			**50MG**	**A040622**	**003**	Jul 18, 2006
AB		WATSON LABS	**25MG**	**A083426**	**001**	
AB			**50MG**	**A083711**	**001**	
AB		ZYDUS PHARMS USA	**12.5MG**	**A040596**	**001**	Nov 18, 2005
AB			**25MG**	**A040596**	**002**	Nov 18, 2005
AB			**50MG**	**A040596**	**003**	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

		PROPAFENONE HYDROCHLORIDE				
AB		MYLAN PHARMS INC	**225MG**	**A203803**	**001**	Apr 29, 2016
AB			**325MG**	**A203803**	**002**	Apr 29, 2016
AB			**425MG**	**A203803**	**003**	Apr 29, 2016
AB		PAR PHARM	**225MG**	**A078540**	**001**	Oct 18, 2010
AB			**325MG**	**A078540**	**002**	Oct 18, 2010
AB			**425MG**	**A078540**	**003**	Oct 18, 2010
AB		WATSON LABS INC	**225MG**	**A202688**	**001**	Aug 24, 2015
AB			**325MG**	**A202688**	**002**	Aug 24, 2015
AB			**425MG**	**A202688**	**003**	Aug 24, 2015
		RYTHMOL SR				
AB		GLAXOSMITHKLINE LLC	**225MG**	**N021416**	**001**	Sep 04, 2003
AB			**325MG**	**N021416**	**002**	Sep 04, 2003
AB	+		**425MG**	**N021416**	**003**	Sep 04, 2003

PROPAFENONE HYDROCHLORIDE
TABLET;ORAL

	PROPAFENONE HYDROCHLORIDE				
AB	ANI PHARMS INC	**150MG**	**A076550**	**001**	Apr 23, 2004
AB		**225MG**	**A076550**	**002**	Apr 23, 2004
AB		**300MG**	**A076550**	**003**	Apr 23, 2004
AB	ORION CORP ORION	**150MG**	**A202445**	**001**	May 11, 2016
AB		**225MG**	**A202445**	**002**	May 11, 2016
AB		**300MG**	**A202445**	**003**	May 11, 2016
AB	SUN PHARM INDS	**150MG**	**A075998**	**001**	Nov 29, 2001
AB		**225MG**	**A075998**	**002**	Nov 29, 2001
AB		**300MG**	**A075998**	**003**	Nov 29, 2001
AB	VINTAGE PHARMS	**150MG**	**A075938**	**001**	Oct 17, 2002
AB		**225MG**	**A075938**	**002**	Oct 17, 2002
AB		**300MG**	**A075938**	**003**	Oct 17, 2002
AB	WATSON LABS	**150MG**	**A075203**	**001**	Oct 24, 2000
AB		**225MG**	**A075203**	**002**	Oct 24, 2000
	RYTHMOL				
AB	GLAXOSMITHKLINE LLC	**150MG**	**N019151**	**001**	Nov 27, 1989
AB		**225MG**	**N019151**	**003**	Nov 20, 1992
AB	**+**	**300MG**	**N019151**	**002**	Nov 27, 1989

PROPANTHELINE BROMIDE
TABLET;ORAL

	PROPANTHELINE BROMIDE				
	+ WEST-WARD PHARMS INT	15MG	A080927	002	

PROPARACAINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

	ALCAINE				
AT	**+** NOVARTIS PHARMS CORP	**0.5%**	**A080027**	**001**	
	PROPARACAINE HYDROCHLORIDE				
AT	AKORN INC	**0.5%**	**A040277**	**001**	Mar 16, 2000
AT	BAUSCH AND LOMB	**0.5%**	**A040074**	**001**	Sep 29, 1995

PROPOFOL
INJECTABLE;INJECTION

	DIPRIVAN				
AB	**+** FRESENIUS KABI USA	**10MG/ML**	**N019627**	**002**	Jun 11, 1996
	PROPOFOL				
AB	HOSPIRA	**10MG/ML**	**A077908**	**001**	Mar 17, 2006
AB	SAGENT PHARMS	**10MG/ML**	**A075102**	**001**	Jan 04, 1999
AB	WATSON LABS INC	**10MG/ML**	**A205307**	**001**	Dec 22, 2015

PROPRANOLOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL

	INDERAL LA				
AB	ANI PHARMS INC	**60MG**	**N018553**	**004**	Mar 18, 1987
AB		**80MG**	**N018553**	**002**	Apr 19, 1983
AB		**120MG**	**N018553**	**003**	Apr 19, 1983
AB	**+**	**160MG**	**N018553**	**001**	Apr 19, 1983
	PROPRANOLOL HYDROCHLORIDE				
AB	ACTAVIS ELIZABETH	**60MG**	**A078494**	**001**	Aug 10, 2007
AB		**80MG**	**A078494**	**002**	Aug 10, 2007
AB		**120MG**	**A078494**	**003**	Aug 10, 2007
AB		**160MG**	**A078494**	**004**	Aug 10, 2007
AB	MYLAN	**60MG**	**A078022**	**001**	Feb 15, 2007
AB		**80MG**	**A078022**	**002**	Feb 15, 2007
AB		**120MG**	**A078022**	**003**	Feb 15, 2007
AB		**160MG**	**A078022**	**004**	Feb 15, 2007
AB	NORTEC DEV ASSOC	**60MG**	**A078065**	**001**	Jan 26, 2007
AB		**80MG**	**A078065**	**002**	Jan 26, 2007
AB		**120MG**	**A078065**	**003**	Jan 26, 2007
AB		**160MG**	**A078065**	**004**	Jan 26, 2007
AB	RP SCHERER	**60MG**	**A078703**	**001**	Jul 15, 2011
AB		**80MG**	**A078703**	**002**	Jul 15, 2011
AB		**120MG**	**A078703**	**003**	Jul 15, 2011
AB		**160MG**	**A078703**	**004**	Jul 15, 2011
AB	ZYDUS PHARMS USA INC	**60MG**	**A090321**	**001**	Mar 25, 2011
AB		**80MG**	**A090321**	**002**	Mar 25, 2011
AB		**120MG**	**A090321**	**003**	Mar 25, 2011
AB		**160MG**	**A090321**	**004**	Mar 25, 2011
	INNOPRAN XL				
BX	GLAXOSMITHKLINE LLC	80MG	N021438	001	Mar 12, 2003

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INNOPRAN XL

BX		120MG	N021438	002	Mar 12, 2003

PROPRANOLOL HYDROCHLORIDE

BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009
BX		80MG	A078311	002	Mar 06, 2009
BX		120MG	A078311	003	Mar 06, 2009
BX		160MG	A078311	004	Mar 06, 2009

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	**1MG/ML**	**A075792**	**001**	Aug 29, 2000
AP	+ BAXTER HLTHCARE CORP	**1MG/ML**	**N016419**	**001**	
AP	FRESENIUS KABI USA	**1MG/ML**	**A075826**	**001**	Aug 31, 2001
AP	HIKMA FARMACEUTICA	**1MG/ML**	**A077760**	**001**	Jan 31, 2008

SOLUTION;ORAL

HEMANGEOL

	+ PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

	+ WEST-WARD PHARMS INT	20MG/5ML	A070979	001	May 15, 1987
	+	40MG/5ML	A070690	001	May 15, 1987

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB	IMPAX LABS INC	**10MG**	**A071972**	**001**	Apr 06, 1988
AB		**20MG**	**A071973**	**001**	Apr 06, 1988
AB		**40MG**	**A071974**	**001**	Apr 06, 1988
AB		**60MG**	**A071975**	**001**	Apr 06, 1988
AB	+	**80MG**	**A071976**	**001**	Apr 06, 1988
AB	IPCA LABS LTD	**10MG**	**A078955**	**001**	Jun 02, 2008
AB		**20MG**	**A078955**	**002**	Jun 02, 2008
AB		**40MG**	**A078955**	**003**	Jun 02, 2008
AB		**60MG**	**A078955**	**004**	Jun 02, 2008
AB		**80MG**	**A078955**	**005**	Jun 02, 2008
AB	MYLAN	**10MG**	**A070213**	**002**	Nov 19, 1985
AB		**20MG**	**A070213**	**003**	Nov 19, 1985
AB		**40MG**	**A070213**	**001**	Nov 19, 1985
AB		**60MG**	**A070213**	**005**	Apr 08, 2011
AB		**80MG**	**A070213**	**004**	Nov 19, 1985
AB	NORTHSTAR HLTHCARE	**10MG**	**A078213**	**001**	Jan 10, 2008
AB		**20MG**	**A078213**	**002**	Jan 10, 2008
AB		**40MG**	**A078213**	**003**	Jan 10, 2008
AB		**60MG**	**A078213**	**004**	Jan 10, 2008
AB		**80MG**	**A078213**	**005**	Jan 10, 2008
AB	VINTAGE PHARMS	**10MG**	**A070217**	**001**	Aug 01, 1986
AB		**20MG**	**A070218**	**001**	Aug 01, 1986
AB		**40MG**	**A070219**	**001**	Aug 01, 1986
AB		**60MG**	**A070220**	**001**	Sep 24, 1986
AB		**80MG**	**A070221**	**001**	Apr 14, 1986
AB	WATSON LABS	**10MG**	**A070175**	**001**	May 13, 1986
AB		**20MG**	**A070176**	**001**	May 13, 1986
AB		**40MG**	**A070177**	**001**	May 13, 1986
AB		**80MG**	**A070178**	**001**	May 13, 1986

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+ DAVA PHARMS INC	50MG	N006188	001	

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

	+ FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	**5MG**	**A202220**	**001**	Nov 19, 2012
AB		**10MG**	**A202220**	**002**	Nov 19, 2012
AB	SIGMAPHARM LABS LLC	**5MG**	**A090462**	**001**	May 03, 2010
AB		**10MG**	**A090462**	**002**	May 03, 2010
AB	WEST-WARD PHARMS INT	**5MG**	**A078913**	**001**	Sep 16, 2008
AB		**10MG**	**A078913**	**002**	Sep 16, 2008

FDA data supplied by DrugPatentWatch.com

PROTRIPTYLINE HYDROCHLORIDE
TABLET;ORAL
VIVACTIL

AB		ODYSSEY PHARMS	**5MG**	**A073644**	**001** Aug 24, 1995
AB	+		**10MG**	**A073645**	**001** Aug 24, 1995

PYRAZINAMIDE
TABLET;ORAL
PYRAZINAMIDE

AB		AKORN	**500MG**	**A081319**	**001** Jun 30, 1992
AB	+	DAVA PHARMS INC	**500MG**	**A080157**	**001**

PYRIDOSTIGMINE BROMIDE
INJECTABLE;INJECTION
MESTINON

AP	+	VALEANT PHARM INTL	**5MG/ML**	**N009830**	**001**

REGONOL

AP		SANDOZ	**5MG/ML**	**N017398**	**001**

SYRUP;ORAL
MESTINON

	+	VALEANT PHARMS	60MG/5ML	N015193	001

TABLET;ORAL
MESTINON

AB	+	VALEANT PHARMS LLC	**60MG**	**N009829**	**002**

PYRIDOSTIGMINE BROMIDE

AB		IMPAX LABS	**60MG**	**A040502**	**001** Apr 24, 2003
AB		ZYDUS PHARMS USA INC	**60MG**	**A205650**	**001** Jun 22, 2015

TABLET, EXTENDED RELEASE;ORAL
MESTINON

AB	+	VALEANT PHARMS LLC	**180MG**	**N011665**	**001**

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN MALTA	**180MG**	**A204737**	**001** Jun 26, 2015
AB		IMPAX LABS INC	**180MG**	**A203184**	**001** Sep 15, 2015

PYRIDOXINE HYDROCHLORIDE
INJECTABLE;INJECTION
PYRIDOXINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	**100MG/ML**	**A080618**	**001**
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A204879**	**001** Jul 14, 2016

PYRIMETHAMINE
TABLET;ORAL
DARAPRIM

	+	TURING PHARMS AG	25MG	N008578	001

QUAZEPAM
TABLET;ORAL
DORAL

	+	CUTIS HEALTH LLC	15MG	N018708	001 Dec 27, 1985

QUETIAPINE FUMARATE
TABLET;ORAL
QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	**EQ 25MG BASE**	**A202152**	**001** Mar 27, 2012
AB			**EQ 50MG BASE**	**A202152**	**002** Mar 27, 2012
AB			**EQ 100MG BASE**	**A202152**	**003** Mar 27, 2012
AB			**EQ 200MG BASE**	**A202152**	**004** Mar 27, 2012
AB			**EQ 300MG BASE**	**A202152**	**005** Mar 27, 2012
AB			**EQ 400MG BASE**	**A202152**	**006** Mar 27, 2012
AB		ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A203390**	**001** Oct 28, 2014
AB			**EQ 50MG BASE**	**A203390**	**002** Oct 28, 2014
AB			**EQ 100MG BASE**	**A203390**	**003** Oct 28, 2014
AB			**EQ 200MG BASE**	**A203390**	**004** Oct 28, 2014
AB			**EQ 300MG BASE**	**A203390**	**005** Oct 28, 2014
AB			**EQ 400MG BASE**	**A203390**	**006** Oct 28, 2014
AB		ALKEM LABS LTD	**EQ 25MG BASE**	**A201504**	**001** Feb 12, 2013
AB			**EQ 50MG BASE**	**A201504**	**002** Feb 12, 2013
AB			**EQ 100MG BASE**	**A201504**	**003** Feb 12, 2013
AB			**EQ 150MG BASE**	**A201504**	**004** Feb 12, 2013
AB			**EQ 200MG BASE**	**A201504**	**005** Feb 12, 2013
AB			**EQ 300MG BASE**	**A201504**	**006** Feb 12, 2013
AB			**EQ 400MG BASE**	**A201504**	**007** Feb 12, 2013
AB		APOTEX INC	**EQ 25MG BASE**	**A090960**	**001** Mar 27, 2012
AB			**EQ 50MG BASE**	**A090960**	**002** Mar 27, 2012
AB			**EQ 100MG BASE**	**A090960**	**003** Mar 27, 2012

FDA data supplied by DrugPatentWatch.com

QUETIAPINE FUMARATE
TABLET;ORAL
QUETIAPINE FUMARATE

AB		EQ 200MG BASE	A090960	004	Mar 27, 2012
AB		EQ 300MG BASE	A090960	005	Mar 27, 2012
AB		EQ 400MG BASE	A090960	006	Mar 27, 2012
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388	001	Mar 27, 2012
AB		EQ 50MG BASE	A091388	002	Mar 27, 2012
AB		EQ 100MG BASE	A091388	003	Mar 27, 2012
AB		EQ 150MG BASE	A091388	004	Mar 27, 2012
AB		EQ 200MG BASE	A091388	005	Mar 27, 2012
AB		EQ 300MG BASE	A091388	006	Mar 27, 2012
AB		EQ 400MG BASE	A091388	007	Mar 27, 2012
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380	001	Mar 27, 2012
AB		EQ 50MG BASE	A077380	002	Mar 27, 2012
AB		EQ 100MG BASE	A077380	003	Mar 27, 2012
AB		EQ 150MG BASE	A077380	004	Mar 27, 2012
AB		EQ 200MG BASE	A077380	005	Mar 27, 2012
AB		EQ 300MG BASE	A077380	006	Mar 27, 2012
AB		EQ 400MG BASE	A077380	007	Mar 27, 2012
AB	JUBILANT GENERICS	EQ 25MG BASE	A203150	001	Nov 26, 2013
AB	LUPIN LTD	EQ 25MG BASE	A201109	001	Mar 27, 2012
AB		EQ 50MG BASE	A201109	002	Mar 27, 2012
AB		EQ 100MG BASE	A201109	003	Mar 27, 2012
AB		EQ 200MG BASE	A201109	004	Mar 27, 2012
AB		EQ 300MG BASE	A201109	005	Mar 27, 2012
AB		EQ 400MG BASE	A201109	006	Mar 27, 2012
AB	MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016
AB		EQ 50MG BASE	A203359	002	May 17, 2016
AB		EQ 100MG BASE	A203359	003	May 17, 2016
AB		EQ 200MG BASE	A203359	004	May 17, 2016
AB		EQ 300MG BASE	A203359	005	May 17, 2016
AB		EQ 400MG BASE	A203359	006	May 17, 2016
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012
AB	SANDOZ	EQ 25MG BASE	A078679	001	Dec 14, 2012
AB		EQ 50MG BASE	A078679	002	Dec 14, 2012
AB		EQ 100MG BASE	A078679	003	Dec 14, 2012
AB		EQ 150MG BASE	A078679	004	Dec 14, 2012
AB		EQ 200MG BASE	A078679	005	Dec 14, 2012
AB		EQ 300MG BASE	A078679	006	Dec 14, 2012
AB		EQ 400MG BASE	A078679	007	Dec 14, 2012
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190	001	Mar 27, 2012
AB		EQ 50MG BASE	A201190	002	Mar 27, 2012
AB		EQ 100MG BASE	A201190	003	Mar 27, 2012
AB		EQ 200MG BASE	A201190	004	Mar 27, 2012
AB		EQ 300MG BASE	A201190	005	Mar 27, 2012
AB		EQ 400MG BASE	A201190	006	Mar 27, 2012
AB	TEVA PHARMS	EQ 25MG BASE	A077745	001	Mar 27, 2012
AB		EQ 50MG BASE	A077745	002	Mar 27, 2012
AB		EQ 100MG BASE	A077745	003	Mar 27, 2012
AB		EQ 150MG BASE	A077745	004	Mar 27, 2012
AB		EQ 200MG BASE	A077745	005	Mar 27, 2012
AB		EQ 300MG BASE	A077745	006	Mar 27, 2012
AB		EQ 400MG BASE	A077745	007	Mar 27, 2012
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363	001	Mar 27, 2012
AB		EQ 50MG BASE	A200363	002	Mar 27, 2012
AB		EQ 100MG BASE	A200363	003	Mar 27, 2012
AB		EQ 200MG BASE	A200363	004	Mar 27, 2012
AB		EQ 300MG BASE	A200363	005	Mar 27, 2012
AB		EQ 400MG BASE	A200363	006	Mar 27, 2012
AB	UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016
AB		EQ 50MG BASE	A202674	002	Mar 08, 2016
AB		EQ 100MG BASE	A202674	003	Mar 08, 2016
AB		EQ 200MG BASE	A202674	004	Mar 08, 2016
AB		EQ 300MG BASE	A202674	005	Mar 08, 2016
AB		EQ 400MG BASE	A202674	006	Mar 08, 2016
AB	WEST-WARD PHARMS INT	EQ 25MG BASE	A090120	001	Mar 27, 2012
AB		EQ 50MG BASE	A090749	001	Mar 27, 2012
AB		EQ 100MG BASE	A090749	002	Mar 27, 2012
AB		EQ 200MG BASE	A090749	003	Mar 27, 2012
AB		EQ 300MG BASE	A090749	004	Mar 27, 2012
AB		EQ 400MG BASE	A090749	005	Mar 27, 2012

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

AB	+	ASTRAZENECA PHARMS	**EQ 25MG BASE**	**N020639**	**001**	Sep 26, 1997
AB			**EQ 50MG BASE**	**N020639**	**007**	Oct 04, 2005
AB			**EQ 100MG BASE**	**N020639**	**002**	Sep 26, 1997
AB			**EQ 200MG BASE**	**N020639**	**003**	Sep 26, 1997
AB	+		**EQ 300MG BASE**	**N020639**	**005**	Jul 26, 2000
AB			**EQ 400MG BASE**	**N020639**	**006**	Oct 04, 2005

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE INC	**EQ 400MG BASE**	**A090681**	**004**	Nov 01, 2016

SEROQUEL XR

AB		ASTRAZENECA	**EQ 400MG BASE**	**N022047**	**004**	May 17, 2007
			EQ 50MG BASE	N022047	001	May 17, 2007
			EQ 150MG BASE	N022047	005	Aug 11, 2008
	+		EQ 200MG BASE	N022047	002	May 17, 2007
			EQ 300MG BASE	N022047	003	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRIL

AB		PFIZER PHARMS	**EQ 5MG BASE**	**N019885**	**001**	Nov 19, 1991
AB			**EQ 10MG BASE**	**N019885**	**002**	Nov 19, 1991
AB			**EQ 20MG BASE**	**N019885**	**003**	Nov 19, 1991
AB	+		**EQ 40MG BASE**	**N019885**	**004**	Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202725**	**001**	Apr 29, 2013
AB			**EQ 10MG BASE**	**A202725**	**002**	Apr 29, 2013
AB			**EQ 20MG BASE**	**A202725**	**003**	Apr 29, 2013
AB			**EQ 40MG BASE**	**A202725**	**004**	Apr 29, 2013
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078457**	**001**	Aug 24, 2007
AB			**EQ 10MG BASE**	**A078457**	**002**	Aug 24, 2007
AB			**EQ 20MG BASE**	**A078457**	**003**	Aug 24, 2007
AB			**EQ 40MG BASE**	**A078457**	**004**	Aug 24, 2007
AB		LUPIN	**EQ 5MG BASE**	**A077690**	**001**	Jun 20, 2006
AB			**EQ 10MG BASE**	**A077690**	**002**	Jun 20, 2006
AB			**EQ 20MG BASE**	**A077690**	**003**	Jun 20, 2006
AB			**EQ 40MG BASE**	**A077690**	**004**	Jun 20, 2006
AB		MYLAN	**EQ 5MG BASE**	**A076694**	**001**	Dec 23, 2004
AB			**EQ 10MG BASE**	**A076694**	**002**	Dec 23, 2004
AB			**EQ 20MG BASE**	**A076694**	**003**	Dec 23, 2004
AB			**EQ 40MG BASE**	**A076694**	**004**	Dec 23, 2004
AB		PRINSTON INC	**EQ 5MG BASE**	**A205823**	**001**	Sep 15, 2016
AB			**EQ 10MG BASE**	**A205823**	**002**	Sep 15, 2016
AB			**EQ 20MG BASE**	**A205823**	**003**	Sep 15, 2016
AB			**EQ 40MG BASE**	**A205823**	**004**	Sep 15, 2016
AB		SUN PHARM INDS LTD	**EQ 5MG BASE**	**A076607**	**001**	Dec 15, 2004
AB			**EQ 5MG BASE**	**A090800**	**001**	Jun 18, 2009
AB			**EQ 10MG BASE**	**A076607**	**002**	Dec 15, 2004
AB			**EQ 10MG BASE**	**A090800**	**002**	Jun 18, 2009
AB			**EQ 20MG BASE**	**A076607**	**003**	Dec 15, 2004
AB			**EQ 20MG BASE**	**A090800**	**003**	Jun 18, 2009
AB			**EQ 40MG BASE**	**A076607**	**004**	Dec 15, 2004
AB			**EQ 40MG BASE**	**A090800**	**004**	Jun 18, 2009
AB		TEVA	**EQ 5MG BASE**	**A075504**	**001**	Aug 24, 2007
AB			**EQ 10MG BASE**	**A075504**	**002**	Aug 24, 2007
AB			**EQ 20MG BASE**	**A075504**	**003**	Aug 24, 2007
AB			**EQ 40MG BASE**	**A075504**	**004**	Aug 24, 2007

QUINIDINE GLUCONATE

INJECTABLE;INJECTION

QUINIDINE GLUCONATE

	+	LILLY	80MG/ML	N007529	002	Feb 10, 1989

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

BX	+	SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987

QUINIDINE SULFATE

TABLET;ORAL

	QUINIDINE SULFATE				
AB	SANDOZ	**200MG**	**A088072**	**002**	
AB		**300MG**	**A088072**	**001**	Sep 26, 1983
AB	SUN PHARM INDS	**200MG**	**A081030**	**001**	Apr 14, 1989
AB		**300MG**	**A081031**	**001**	Apr 14, 1989
AB	+ WATSON LABS	**200MG**	**A083288**	**001**	
AB	+	**300MG**	**A085583**	**001**	

TABLET, EXTENDED RELEASE;ORAL

	QUINIDINE SULFATE				
	+ G AND W LABS INC	300MG	A040045	001	Jun 30, 1994

QUININE SULFATE

CAPSULE;ORAL

	QUALAQUIN				
AB	+ SUN PHARM INDS	**324MG**	**N021799**	**001**	Aug 12, 2005
	QUININE SULFATE				
AB	AMNEAL PHARMS	**324MG**	**A203729**	**001**	Jul 15, 2015
AB	LUPIN LTD	**324MG**	**A203112**	**001**	Apr 24, 2015
AB	MYLAN PHARMS INC	**324MG**	**A202581**	**001**	Dec 14, 2012
AB	RICONPHARMA LLC	**324MG**	**A204372**	**001**	Jul 22, 2015
AB	TEVA PHARMS	**324MG**	**A091661**	**001**	Sep 28, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL

	ACIPHEX SPRINKLE				
	FSC THERAP	5MG	N204736	001	Mar 26, 2013
	+	10MG	N204736	002	Mar 26, 2013

TABLET, DELAYED RELEASE;ORAL

	ACIPHEX				
AB	+ EISAI INC	**20MG**	**N020973**	**002**	Aug 19, 1999
	RABEPRAZOLE SODIUM				
AB	AMNEAL PHARMS	**20MG**	**A204179**	**001**	Jul 31, 2015
AB	BRECKENRIDGE PHARM	**20MG**	**A204237**	**001**	Nov 18, 2015
AB	DR REDDYS LABS LTD	**20MG**	**A076824**	**001**	Nov 08, 2013
AB	KREMERS URBAN DEV	**20MG**	**A090678**	**001**	Nov 08, 2013
AB	LUPIN LTD	**20MG**	**A078964**	**001**	Nov 08, 2013
AB	MYLAN PHARMS INC	**20MG**	**A076885**	**001**	Nov 08, 2013
AB	TEVA PHARMS USA	**20MG**	**A076822**	**001**	Nov 08, 2013
AB	TORRENT PHARMS LTD	**20MG**	**A202376**	**001**	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION;INTRAVENOUS

	XOFIGO				
	+ BAYER HLTHCARE	162mCi/6ML (27mCi/ML)	N203971	001	May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

	EVISTA				
AB	+ LILLY	**60MG**	**N020815**	**001**	Dec 09, 1997
	RALOXIFENE HYDROCHLORIDE				
AB	AMNEAL PHARMS	**60MG**	**A208206**	**001**	Apr 08, 2016
AB	AUROBINDO PHARMA LTD	**60MG**	**A204310**	**001**	Aug 28, 2015
AB	GLENMARK PHARMS LTD	**60MG**	**A204491**	**001**	Mar 22, 2016
AB	INVAGEN PHARMS	**60MG**	**A090842**	**001**	Sep 24, 2014
AB	SCIEGEN PHARMS INC	**60MG**	**A206384**	**001**	Oct 12, 2016
AB	TEVA PHARMS USA	**60MG**	**A078193**	**001**	Mar 04, 2014
AB	WATSON LABS INC	**60MG**	**A200825**	**001**	Jan 21, 2015

RALTEGRAVIR POTASSIUM

POWDER;ORAL

	ISENTRESS				
	+ MERCK SHARP DOHME	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013

TABLET;ORAL

	ISENTRESS				
	+ MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007

TABLET, CHEWABLE;ORAL

	ISENTRESS				
	MERCK SHARP DOHME	EQ 25MG BASE	N203045	001	Dec 21, 2011
	+	EQ 100MG BASE	N203045	002	Dec 21, 2011

FDA data supplied by DrugPatentWatch.com

RAMELTEON

TABLET;ORAL

	RAMELTEON				
AB	ACTAVIS LABS FL INC	**8MG**	**A091610**	**001**	Aug 19, 2015
AB	DR REDDYS LABS INTL	**8MG**	**A091693**	**001**	Jul 26, 2013
	ROZEREM				
AB +	TAKEDA PHARMS USA	**8MG**	**N021782**	**001**	Jul 22, 2005

RAMIPRIL

CAPSULE;ORAL

	ALTACE				
AB	KING PHARMS	**1.25MG**	**N019901**	**001**	Jan 28, 1991
AB		**2.5MG**	**N019901**	**002**	Jan 28, 1991
AB		**5MG**	**N019901**	**003**	Jan 28, 1991
AB +		**10MG**	**N019901**	**004**	Jan 28, 1991
	RAMIPRIL				
AB	ACCORD HLTHCARE INC	**1.25MG**	**A202392**	**001**	Apr 15, 2014
AB		**2.5MG**	**A202392**	**002**	Apr 15, 2014
AB		**5MG**	**A202392**	**003**	Apr 15, 2014
AB		**10MG**	**A202392**	**004**	Apr 15, 2014
AB	APOTEX	**1.25MG**	**A079116**	**001**	Jun 20, 2008
AB		**2.5MG**	**A079116**	**002**	Jun 20, 2008
AB		**5MG**	**A079116**	**003**	Jun 20, 2008
AB		**10MG**	**A079116**	**004**	Jun 20, 2008
AB	AUROBINDO PHARMA LTD	**1.25MG**	**A091604**	**001**	Jun 08, 2011
AB		**2.5MG**	**A091604**	**002**	Jun 08, 2011
AB		**5MG**	**A091604**	**003**	Jun 08, 2011
AB		**10MG**	**A091604**	**004**	Jun 08, 2011
AB	DR REDDYS LABS LTD	**1.25MG**	**A078191**	**001**	Jun 18, 2008
AB		**2.5MG**	**A078191**	**002**	Jun 18, 2008
AB		**5MG**	**A078191**	**003**	Jun 18, 2008
AB		**10MG**	**A078191**	**004**	Jun 18, 2008
AB	INVAGEN PHARMS	**1.25MG**	**A078745**	**001**	Jun 18, 2008
AB		**2.5MG**	**A078745**	**002**	Jun 18, 2008
AB		**5MG**	**A078745**	**003**	Jun 18, 2008
AB		**10MG**	**A078745**	**004**	Jun 18, 2008
AB	LUPIN	**1.25MG**	**A077626**	**001**	Jun 09, 2008
AB		**2.5MG**	**A077626**	**002**	Jun 09, 2008
AB		**5MG**	**A077626**	**003**	Jun 09, 2008
AB		**10MG**	**A077626**	**004**	Jun 09, 2008
AB	TEVA PHARMS	**1.25MG**	**A077470**	**001**	Jun 18, 2008
AB		**2.5MG**	**A077470**	**002**	Jun 18, 2008
AB		**5MG**	**A077470**	**003**	Jun 18, 2008
AB		**10MG**	**A077470**	**004**	Jun 18, 2008
AB	WATSON LABS	**1.25MG**	**A076549**	**001**	Oct 24, 2005
AB		**2.5MG**	**A076549**	**002**	Oct 24, 2005
AB		**5MG**	**A076549**	**003**	Oct 24, 2005
AB		**10MG**	**A076549**	**004**	Oct 24, 2005
AB	WEST-WARD PHARMS INT	**1.25MG**	**A077900**	**001**	Jun 18, 2008
AB		**2.5MG**	**A077900**	**002**	Jun 18, 2008
AB		**5MG**	**A077900**	**003**	Jun 18, 2008
AB		**10MG**	**A077900**	**004**	Jun 18, 2008
AB	ZYDUS PHARMS USA	**1.25MG**	**A078832**	**001**	Sep 02, 2008
AB		**2.5MG**	**A078832**	**002**	Sep 02, 2008
AB		**5MG**	**A078832**	**003**	Sep 02, 2008
AB		**10MG**	**A078832**	**004**	Sep 02, 2008

TABLET;ORAL

	RAMIPRIL				
	APOTEX INC	1.25MG	A091069	001	Dec 02, 2015
		2.5MG	A091069	002	Dec 02, 2015
		5MG	A091069	003	Dec 02, 2015
+		10MG	A091069	004	Dec 02, 2015

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

	RANITIDINE HYDROCHLORIDE				
AB	DR REDDYS LABS LTD	**EQ 150MG BASE**	**A075742**	**001**	Nov 29, 2000
AB		**EQ 300MG BASE**	**A075742**	**002**	Nov 29, 2000
AB	SANDOZ	**EQ 150MG BASE**	**A074655**	**001**	Oct 22, 1997
AB +		**EQ 300MG BASE**	**A074655**	**002**	Oct 22, 1997

INJECTABLE;INJECTION

	RANITIDINE HYDROCHLORIDE				
AP	MYLAN LABS LTD	**EQ 25MG BASE/ML**	**A079076**	**001**	Jun 09, 2016

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE					
AP	WEST-WARD PHARMS INT	**EQ 25MG BASE/ML**	**A074777**	**001**	Mar 02, 2005
AP		**EQ 25MG BASE/ML**	**A077458**	**001**	Feb 16, 2006
AP	ZYDUS PHARMS USA INC	**EQ 25MG BASE/ML**	**A091534**	**001**	Feb 22, 2013
ZANTAC					
AP +	IGI LABS INC	**EQ 25MG BASE/ML**	**N019090**	**001**	Oct 19, 1984

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE					
AA	ACTAVIS MID ATLANTIC	**EQ 15MG BASE/ML**	**A076124**	**001**	Feb 21, 2007
AA	AMNEAL PHARMS	**EQ 15MG BASE/ML**	**A078312**	**001**	Sep 02, 2008
AA	AUROBINDO PHARM	**EQ 15MG BASE/ML**	**A090623**	**001**	Jul 28, 2010
AA	BIO PHARM INC	**EQ 15MG BASE/ML**	**A090102**	**001**	May 26, 2009
AA	BRECKENRIDGE PHARM	**EQ 15MG BASE/ML**	**A078684**	**001**	Aug 27, 2009
AA	HI TECH PHARMA	**EQ 15MG BASE/ML**	**A091078**	**001**	Mar 22, 2011
AA	NOSTRUM LABS INC	**EQ 15MG BASE/ML**	**A091091**	**001**	Sep 20, 2011
AA	PHARM ASSOC	**EQ 15MG BASE/ML**	**A077405**	**001**	Sep 21, 2007
AA	SILARX	**EQ 15MG BASE/ML**	**A091288**	**001**	Dec 09, 2010
AA	TARO	**EQ 15MG BASE/ML**	**A077476**	**001**	Jun 13, 2011
AA	TOLMAR	**EQ 15MG BASE/ML**	**A090054**	**001**	Nov 15, 2010
AA	VINTAGE PHARMS	**EQ 15MG BASE/ML**	**A078890**	**001**	Jul 01, 2010
ZANTAC					
AA +	GLAXO GRP LTD	**EQ 15MG BASE/ML**	**N019675**	**001**	Dec 30, 1988

TABLET;ORAL

RANITIDINE HYDROCHLORIDE					
AB	AMNEAL PHARMS NY	**EQ 150MG BASE**	**A077824**	**001**	Oct 13, 2006
AB		**EQ 300MG BASE**	**A077824**	**002**	Oct 13, 2006
AB	APOTEX	**EQ 150MG BASE**	**A074680**	**001**	Sep 12, 1997
AB		**EQ 300MG BASE**	**A074680**	**002**	Sep 12, 1997
AB	DR REDDYS LABS INC	**EQ 150MG BASE**	**A076705**	**001**	Jul 27, 2005
AB		**EQ 300MG BASE**	**A076705**	**002**	Jul 27, 2005
AB	GLENMARK GENERICS	**EQ 150MG BASE**	**A078542**	**001**	Nov 19, 2008
AB		**EQ 300MG BASE**	**A078542**	**002**	Nov 19, 2008
AB	IVAX SUB TEVA PHARMS	**EQ 150MG BASE**	**A075165**	**001**	Sep 30, 1998
AB		**EQ 300MG BASE**	**A075165**	**002**	Sep 30, 1998
AB	PAR PHARM	**EQ 150MG BASE**	**A075180**	**001**	Jan 28, 1999
AB		**EQ 300MG BASE**	**A075180**	**002**	Jan 28, 1999
AB	SANDOZ	**EQ 150MG BASE**	**A074467**	**001**	Aug 29, 1997
AB		**EQ 300MG BASE**	**A074467**	**002**	Aug 29, 1997
AB	STRIDES PHARMA	**EQ 150MG BASE**	**A205512**	**001**	Aug 22, 2016
AB		**EQ 300MG BASE**	**A205512**	**002**	Aug 22, 2016
AB	TEVA	**EQ 150MG BASE**	**A074488**	**001**	Jul 31, 1997
AB		**EQ 300MG BASE**	**A074488**	**002**	Jul 31, 1997
AB	WOCKHARDT	**EQ 150MG BASE**	**A075208**	**001**	Dec 17, 1998
AB		**EQ 300MG BASE**	**A075208**	**002**	Dec 17, 1998
ZANTAC 150					
AB	GLAXO GRP LTD	**EQ 150MG BASE**	**N018703**	**001**	Jun 09, 1983
ZANTAC 300					
AB +	GLAXO GRP LTD	**EQ 300MG BASE**	**N018703**	**002**	Dec 09, 1985

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA					
AB	GILEAD	**500MG**	**N021526**	**002**	Jan 27, 2006
AB +		**1GM**	**N021526**	**001**	Feb 12, 2007
RANOLAZINE					
AB	LUPIN LTD	**500MG**	**A201046**	**001**	Jul 29, 2013
AB		**1GM**	**A201046**	**002**	Jul 29, 2013

RASAGILINE MESYLATE

TABLET;ORAL

AZILECT					
AB	TEVA	**EQ 0.5MG BASE**	**N021641**	**001**	May 16, 2006
AB +		**EQ 1MG BASE**	**N021641**	**002**	May 16, 2006
RASAGILINE MESYLATE					
AB	APOTEX INC	**EQ 0.5MG BASE**	**A201950**	**001**	Sep 12, 2013
AB		**EQ 1MG BASE**	**A201950**	**002**	Sep 12, 2013
AB	ORCHID HLTHCARE	**EQ 0.5MG BASE**	**A201970**	**001**	Mar 15, 2016
AB		**EQ 1MG BASE**	**A201970**	**002**	Mar 15, 2016
AB	WATSON LABS INC	**EQ 0.5MG BASE**	**A201823**	**001**	Jul 01, 2013
AB		**EQ 1MG BASE**	**A201823**	**002**	Jul 01, 2013

FDA data supplied by DrugPatentWatch.com

REGADENOSON
SOLUTION;INTRAVENOUS
LEXISCAN

	+	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161 001	Apr 10, 2008

REGORAFENIB
TABLET;ORAL
STIVARGA

	+	BAYER HLTHCARE	40MG	N203085 001	Sep 27, 2012

REMIFENTANIL HYDROCHLORIDE
INJECTABLE;INJECTION
ULTIVA

		MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630 001	Jul 12, 1996
			EQ 2MG BASE/VIAL	N020630 002	Jul 12, 1996
	+		EQ 5MG BASE/VIAL	N020630 003	Jul 12, 1996

REPAGLINIDE
TABLET;ORAL

		PRANDIN			
AB		NOVO NORDISK INC	**0.5MG**	**N020741 001**	Dec 22, 1997
AB			**1MG**	**N020741 002**	Dec 22, 1997
AB	**+**		**2MG**	**N020741 003**	Dec 22, 1997
		REPAGLINIDE			
AB		ACTAVIS TOTOWA	**0.5MG**	**A090008 001**	Jan 22, 2014
AB			**1MG**	**A090008 002**	Jan 22, 2014
AB			**2MG**	**A090008 003**	Jan 22, 2014
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A203820 001**	Jan 22, 2014
AB			**1MG**	**A203820 002**	Jan 22, 2014
AB			**2MG**	**A203820 003**	Jan 22, 2014
AB		MYLAN PHARMS INC	**0.5MG**	**A090252 001**	Aug 23, 2013
AB			**1MG**	**A090252 002**	Jan 22, 2014
AB			**2MG**	**A090252 003**	Jan 22, 2014
AB		PADDOCK LLC	**0.5MG**	**A201189 001**	Jul 17, 2013
AB			**1MG**	**A201189 002**	Jan 22, 2014
AB			**2MG**	**A201189 003**	Jan 22, 2014
AB		SANDOZ INC	**0.5MG**	**A078555 001**	Nov 22, 2013
AB			**1MG**	**A078555 002**	Jan 22, 2014
AB			**2MG**	**A078555 003**	Jan 22, 2014
AB		STANDARD CHEM PHARM	**0.5MG**	**A091517 001**	Apr 24, 2015
AB			**1MG**	**A091517 002**	Apr 24, 2015
AB			**2MG**	**A091517 003**	Apr 24, 2015
AB		SUN PHARM INDS INC	**1MG**	**A077571 002**	Jul 11, 2013
AB			**2MG**	**A077571 003**	Jul 11, 2013

RESERPINE
TABLET;ORAL
RESERPINE

BP		SANDOZ	0.1MG	N009838 001	
BP	+		0.25MG	N009838 002	

RETAPAMULIN
OINTMENT;TOPICAL
ALTABAX

	+	AQUA PHARMS LLC	1%	N022055 001	Apr 12, 2007

RIBAVIRIN
CAPSULE;ORAL

		REBETOL			
AB	**+**	MERCK SHARP DOHME	**200MG**	**N020903 002**	Jul 25, 2001
		RIBASPHERE			
AB		THREE RIVERS PHARMS	**200MG**	**A076203 001**	Apr 06, 2004
		RIBAVARIN			
AB		AUROBINDO PHARMA	**200MG**	**A079117 001**	Sep 17, 2009
		RIBAVIRIN			
AB		SANDOZ	**200MG**	**A076192 001**	Apr 06, 2004
AB		TEVA	**200MG**	**A076277 001**	Oct 04, 2004
AB		ZYDUS PHARMS USA	**200MG**	**A077224 001**	Oct 28, 2005

FOR SOLUTION;INHALATION

		RIBAVIRIN			
AN		NAVINTA LLC	**6GM/VIAL**	**A207366 001**	Oct 06, 2016
		VIRAZOLE			
AN	**+**	VALEANT PHARM INTL	**6GM/VIAL**	**N018859 001**	Dec 31, 1985

RIBAVIRIN
SOLUTION;ORAL
REBETOL
+ SCHERING 40MG/ML N021546 001 Jul 29, 2003
TABLET;ORAL
COPEGUS
AB ROCHE **200MG** **N021511 001** Dec 03, 2002
RIBAVIRIN
AB AUROBINDO PHARMA **200MG** **A079111 001** Sep 17, 2009
AB SANDOZ **200MG** **A077743 001** Oct 03, 2006
AB SANDOZ INC **200MG** **A202546 001** Aug 12, 2014
AB **400MG** **A202546 002** Aug 12, 2014
AB **500MG** **A202546 003** Aug 12, 2014
AB **600MG** **A202546 004** Aug 12, 2014
AB TEVA **200MG** **A077053 001** Dec 05, 2005
AB THREE RIVERS PHARMS **200MG** **A077456 001** Dec 05, 2005
AB **400MG** **A077456 002** Dec 05, 2005
AB **+** **600MG** **A077456 003** Dec 05, 2005
AB ZYDUS PHARMS USA **200MG** **A077094 001** Dec 05, 2005
AB **400MG** **A077094 002** Mar 16, 2007
AB **500MG** **A077094 004** Apr 18, 2008
AB **600MG** **A077094 003** Mar 16, 2007

RIBOFLAVIN 5'-PHOSPHATE SODIUM
SOLUTION/DROPS;OPHTHALMIC
PHOTREXA
+ AVEDRO INC 0.146% N203324 001 Apr 15, 2016
PHOTREXA VISCOUS IN DEXTRAN 20%
+ AVEDRO INC 0.146% N203324 002 Apr 15, 2016

RIFABUTIN
CAPSULE;ORAL
MYCOBUTIN
AB **+** PHARMACIA AND UPJOHN **150MG** **N050689 001** Dec 23, 1992
RIFABUTIN
AB LUPIN LTD **150MG** **A090033 001** Feb 24, 2014

RIFAMPIN
CAPSULE;ORAL
RIFADIN
AB SANOFI AVENTIS US **150MG** **A062303 001**
AB **+** **300MG** **N050420 001**
RIFAMPIN
AB AKORN **150MG** **A065028 001** Mar 14, 2001
AB **300MG** **A065028 002** Mar 14, 2001
AB LANNETT **150MG** **A065390 001** Mar 28, 2008
AB **300MG** **A065390 002** Mar 28, 2008
AB LUPIN PHARMS **150MG** **A090034 001** Aug 21, 2013
AB **300MG** **A090034 002** Aug 21, 2013
AB SANDOZ **150MG** **A064150 002** Jan 02, 1998
AB **300MG** **A064150 001** May 28, 1997
RIMACTANE
AB OXFORD PHARMS **300MG** **N050429 001**
INJECTABLE;INJECTION
RIFADIN
AP **+** SANOFI AVENTIS US **600MG/VIAL** **N050627 001** May 25, 1989
RIFAMPIN
AP AKORN **600MG/VIAL** **A065502 001** Sep 21, 2010
AP EMCURE PHARMS LTD **600MG/VIAL** **A204101 001** Aug 18, 2014
AP EUROHLTH INTL SARL **600MG/VIAL** **A064217 001** Oct 29, 1999
AP FRESENIUS KABI USA **600MG/VIAL** **A091181 001** Aug 21, 2014
AP HIKMA PHARMS **600MG/VIAL** **A205039 001** Mar 03, 2016
AP MYLAN LABS LTD **600MG/VIAL** **A065421 001** May 22, 2008
AP WATSON PHARMS INC **600MG/VIAL** **A206736 001** Jan 19, 2016

RIFAPENTINE
TABLET;ORAL
PRIFTIN
+ SANOFI AVENTIS US 150MG N021024 001 Jun 22, 1998

RIFAXIMIN
TABLET;ORAL
XIFAXAN

	+	SALIX PHARMS	200MG	N021361 001	May 25, 2004
	+		550MG	N022554 001	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE
TABLET;ORAL
EDURANT

	+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011

RILUZOLE
TABLET;ORAL

		RILUTEK			
AB	+	COVIS PHARMA SARL	**50MG**	**N020599 001**	Dec 12, 1995
		RILUZOLE			
AB		ALKEM LABS LTD	**50MG**	**A204048 001**	Mar 30, 2016
AB		APOTEX CORP	**50MG**	**A091300 001**	Jun 18, 2013
AB		GLENMARK GENERICS	**50MG**	**A091394 001**	Jun 18, 2013
AB		IMPAX LABS	**50MG**	**A076173 001**	Jan 29, 2003
AB		MYLAN PHARMS INC	**50MG**	**A203042 001**	Jul 01, 2013
AB		SUN PHARM INDS LTD	**50MG**	**A091417 001**	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE
TABLET;ORAL

		FLUMADINE			
AB	+	CARACO	**100MG**	**N019649 001**	Sep 17, 1993
		RIMANTADINE HYDROCHLORIDE			
AB		IMPAX LABS	**100MG**	**A076132 001**	Aug 30, 2002

RIOCIGUAT
TABLET;ORAL
ADEMPAS

		BAYER HLTHCARE	0.5MG	N204819 001	Oct 08, 2013
			1MG	N204819 002	Oct 08, 2013
			1.5MG	N204819 003	Oct 08, 2013
			2MG	N204819 004	Oct 08, 2013
	+		2.5MG	N204819 005	Oct 08, 2013

RISEDRONATE SODIUM
TABLET;ORAL

		ACTONEL			
AB		APIL	**5MG**	**N020835 002**	Apr 14, 2000
AB			**30MG**	**N020835 001**	Mar 27, 1998
AB	+		**35MG**	**N020835 003**	May 25, 2002
AB	+		**150MG**	**N020835 005**	Apr 22, 2008
		RISEDRONATE SODIUM			
AB		APOTEX INC	**35MG**	**A090877 001**	Nov 30, 2015
AB			**75MG**	**A090877 002**	Jun 10, 2014
AB			**150MG**	**A090877 003**	Jun 10, 2014
AB		AUROBINDO PHARMA LTD	**5MG**	**A200296 001**	Nov 30, 2015
AB			**30MG**	**A200296 002**	Nov 30, 2015
AB			**35MG**	**A200296 003**	Nov 30, 2015
AB			**150MG**	**A206768 001**	Oct 21, 2016
AB		MACLEODS PHARMS LTD	**5MG**	**A203533 001**	Dec 09, 2015
AB			**30MG**	**A203533 002**	Dec 09, 2015
AB			**35MG**	**A203533 003**	Nov 29, 2016
AB		MYLAN PHARMS INC	**5MG**	**A200477 001**	Nov 30, 2015
AB			**30MG**	**A200477 002**	Nov 30, 2015
AB			**35MG**	**A200477 003**	Nov 30, 2015
AB			**75MG**	**A200477 004**	Jun 10, 2014
AB			**150MG**	**A200477 005**	Jun 10, 2014
AB		SUN PHARMA GLOBAL	**5MG**	**A090886 001**	Nov 30, 2015
AB			**30MG**	**A090886 002**	Nov 30, 2015
AB			**35MG**	**A090886 003**	Nov 30, 2015
AB			**75MG**	**A090886 004**	Jun 10, 2014
AB			**150MG**	**A090886 005**	Jun 10, 2014
AB		TEVA PHARMS USA	**5MG**	**A077132 001**	Oct 05, 2007
AB			**30MG**	**A077132 002**	Oct 05, 2007
AB			**35MG**	**A077132 003**	Oct 05, 2007
AB			**150MG**	**A079215 001**	Jun 13, 2014

TABLET, DELAYED RELEASE;ORAL

		ATELVIA			
AB	+	APIL	**35MG**	**N022560 001**	Oct 08, 2010

FDA data supplied by DrugPatentWatch.com

RISEDRONATE SODIUM
TABLET, DELAYED RELEASE;ORAL
RISEDRONATE SODIUM

AB		TEVA PHARMS USA	**35MG**	**A203217**	**001** May 18, 2015

RISPERIDONE
INJECTABLE;INTRAMUSCULAR
RISPERDAL CONSTA

		JANSSEN PHARMS	12.5MG/VIAL	N021346	004 Apr 12, 2007
	+		25MG/VIAL	N021346	001 Oct 29, 2003
			37.5MG/VIAL	N021346	002 Oct 29, 2003
			50MG/VIAL	N021346	003 Oct 29, 2003

SOLUTION;ORAL
RISPERDAL

AA	+	JANSSEN PHARMS	**1MG/ML**	**N020588**	**001** Jun 10, 1996

RISPERIDONE

AA		AMNEAL PHARMS	**1MG/ML**	**A091384**	**001** May 25, 2011
AA		ANI PHARMS INC	**1MG/ML**	**A076440**	**001** Jan 30, 2009
AA		APOTEX INC	**1MG/ML**	**A077719**	**001** Jul 29, 2009
AA		BIO PHARM INC	**1MG/ML**	**A078909**	**001** Jul 29, 2009
AA		LIFESTAR PHARMA	**1MG/ML**	**A078452**	**001** Sep 04, 2009
AA		PRECISION DOSE	**1MG/ML**	**A076797**	**001** Jun 28, 2010
AA		TARO	**1MG/ML**	**A090347**	**001** Feb 07, 2011
AA		TRIS PHARMA INC	**1MG/ML**	**A079059**	**001** Dec 12, 2012
AA		VINTAGE	**1MG/ML**	**A079158**	**001** Dec 03, 2010
AA		WEST-WARD PHARMS INT	**1MG/ML**	**A076904**	**001** Jul 29, 2009

TABLET;ORAL
RISPERDAL

AB		JANSSEN PHARMS	**0.25MG**	**N020272**	**008** May 10, 1999
AB			**0.5MG**	**N020272**	**007** Jan 27, 1999
AB	+		**1MG**	**N020272**	**001** Dec 29, 1993
AB			**2MG**	**N020272**	**002** Dec 29, 1993
AB			**3MG**	**N020272**	**003** Dec 29, 1993
AB			**4MG**	**N020272**	**004** Dec 29, 1993

RISPERIDONE

AB		AJANTA PHARMA LTD	**0.25MG**	**A201003**	**001** Aug 24, 2011
AB			**0.5MG**	**A201003**	**002** Aug 24, 2011
AB			**1MG**	**A201003**	**003** Aug 24, 2011
AB			**2MG**	**A201003**	**004** Aug 24, 2011
AB			**3MG**	**A201003**	**005** Aug 24, 2011
AB			**4MG**	**A201003**	**006** Aug 24, 2011
AB		APOTEX INC	**0.25MG**	**A077953**	**001** Sep 15, 2008
AB			**0.5MG**	**A077953**	**002** Sep 15, 2008
AB			**1MG**	**A077953**	**003** Sep 15, 2008
AB			**2MG**	**A077953**	**004** Sep 15, 2008
AB			**3MG**	**A077953**	**005** Sep 15, 2008
AB			**4MG**	**A077953**	**006** Sep 15, 2008
AB		AUROBINDO PHARMA	**0.25MG**	**A078269**	**001** Oct 08, 2008
AB			**0.5MG**	**A078269**	**002** Oct 08, 2008
AB			**1MG**	**A078269**	**003** Oct 08, 2008
AB			**2MG**	**A078269**	**004** Oct 08, 2008
AB			**3MG**	**A078269**	**005** Oct 08, 2008
AB			**4MG**	**A078269**	**006** Oct 08, 2008
AB		CIPLA	**0.25MG**	**A077543**	**001** May 18, 2011
AB			**0.5MG**	**A077543**	**002** May 18, 2011
AB			**1MG**	**A077543**	**003** May 18, 2011
AB			**2MG**	**A077543**	**004** May 18, 2011
AB			**3MG**	**A077543**	**005** May 18, 2011
AB			**4MG**	**A077543**	**006** May 18, 2011
AB		DR REDDYS LABS LTD	**0.25MG**	**A076879**	**001** Oct 24, 2008
AB			**0.5MG**	**A076879**	**002** Oct 24, 2008
AB			**1MG**	**A076879**	**003** Oct 24, 2008
AB			**2MG**	**A076879**	**004** Oct 24, 2008
AB			**3MG**	**A076879**	**005** Oct 24, 2008
AB			**4MG**	**A076879**	**006** Oct 24, 2008
AB		MYLAN	**0.25MG**	**A076288**	**001** Sep 15, 2008
AB			**0.5MG**	**A076288**	**002** Sep 15, 2008
AB			**1MG**	**A076288**	**003** Sep 15, 2008
AB			**2MG**	**A076288**	**004** Sep 15, 2008
AB			**3MG**	**A076288**	**005** Sep 15, 2008
AB			**4MG**	**A076288**	**006** Sep 15, 2008
AB		OXFORD PHARMS	**0.25MG**	**A078071**	**001** Jun 17, 2009
AB			**0.5MG**	**A078071**	**002** Jun 17, 2009

FDA data supplied by DrugPatentWatch.com

RISPERIDONE

TABLET;ORAL

RISPERIDONE

AB		1MG	A078071	003	Jun 17, 2009
AB		2MG	A078071	004	Jun 17, 2009
AB		3MG	A078071	005	Jun 17, 2009
AB		4MG	A078071	006	Jun 17, 2009
AB	PLIVA HRVATSKA DOO	0.25MG	A077769	001	Oct 16, 2008
AB		0.5MG	A077769	002	Oct 16, 2008
AB		1MG	A077769	003	Oct 16, 2008
AB		2MG	A077769	004	Oct 16, 2008
AB		3MG	A077769	005	Oct 16, 2008
AB		4MG	A077769	006	Oct 16, 2008
AB	PRINSTON INC	0.25MG	A077493	001	Nov 29, 2011
AB		0.5MG	A077493	002	Nov 29, 2011
AB		1MG	A077493	003	Nov 29, 2011
AB		2MG	A077493	004	Nov 29, 2011
AB		3MG	A077493	005	Nov 29, 2011
AB		4MG	A077493	006	Nov 29, 2011
AB	SANDOZ	0.25MG	A078528	001	Oct 16, 2009
AB		0.5MG	A078528	002	Oct 16, 2009
AB		1MG	A078528	003	Oct 16, 2009
AB		2MG	A078528	004	Oct 16, 2009
AB		3MG	A078528	005	Oct 16, 2009
AB		4MG	A078528	006	Oct 16, 2009
AB	SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014
AB		0.5MG	A078036	002	Mar 10, 2014
AB		1MG	A078036	003	Mar 10, 2014
AB		2MG	A078036	004	Mar 10, 2014
AB		3MG	A078036	005	Mar 10, 2014
AB		4MG	A078036	006	Mar 10, 2014
AB	TEVA	0.25MG	A076228	001	Jun 30, 2008
AB		0.5MG	A076228	002	Jun 30, 2008
AB		1MG	A076228	003	Jun 30, 2008
AB		2MG	A076228	004	Jun 30, 2008
AB		3MG	A076228	005	Jun 30, 2008
AB		4MG	A076228	006	Jun 30, 2008
AB	TORRENT PHARMS	0.25MG	A079088	001	Oct 30, 2008
AB		0.5MG	A079088	002	Oct 30, 2008
AB		1MG	A079088	003	Oct 30, 2008
AB		2MG	A079088	004	Oct 30, 2008
AB		3MG	A079088	005	Oct 30, 2008
AB		4MG	A079088	006	Oct 30, 2008
AB	VINTAGE	0.25MG	A078707	001	Dec 29, 2008
AB		0.5MG	A078707	002	Dec 29, 2008
AB		1MG	A078707	003	Dec 29, 2008
AB		2MG	A078707	004	Dec 29, 2008
AB		3MG	A078707	005	Dec 29, 2008
AB		4MG	A078707	006	Dec 29, 2008
AB	WOCKHARDT	0.25MG	A078871	001	Oct 09, 2008
AB		0.5MG	A078871	002	Oct 09, 2008
AB		1MG	A078871	003	Oct 09, 2008
AB		2MG	A078871	004	Oct 09, 2008
AB		3MG	A078871	005	Oct 09, 2008
AB		4MG	A078871	006	Oct 09, 2008
AB	ZYDUS PHARMS USA INC	0.25MG	A078040	001	Oct 16, 2008
AB		0.5MG	A078040	002	Oct 16, 2008
AB		1MG	A078040	003	Oct 16, 2008
AB		2MG	A078040	004	Oct 16, 2008
AB		3MG	A078040	005	Oct 16, 2008
AB		4MG	A078040	006	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERDAL

AB	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003
AB +		1MG	N021444	002	Apr 02, 2003
AB		2MG	N021444	003	Apr 02, 2003
AB		3MG	N021444	004	Dec 23, 2004
AB		4MG	N021444	005	Dec 23, 2004

RISPERIDONE

AB	ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011
AB		1MG	A076996	002	Apr 19, 2011
AB		2MG	A076996	003	Apr 19, 2011

FDA data supplied by DrugPatentWatch.com

RISPERIDONE
TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB		**3MG**	**A076996**	**004**	Apr 19, 2011
AB		**4MG**	**A076996**	**005**	Apr 19, 2011
AB	DR REDDYS LABS LTD	**0.5MG**	**A077328**	**001**	Feb 24, 2009
AB		**1MG**	**A077328**	**002**	Oct 05, 2009
AB		**2MG**	**A077328**	**003**	Feb 24, 2009
AB		**3MG**	**A077328**	**004**	Nov 30, 2009
AB		**4MG**	**A077328**	**005**	Nov 30, 2009
AB	JUBILANT GENERICS	**0.5MG**	**A090839**	**001**	Nov 04, 2011
AB		**1MG**	**A090839**	**002**	Nov 04, 2011
AB		**2MG**	**A090839**	**003**	Nov 04, 2011
AB		**3MG**	**A090839**	**004**	Nov 04, 2011
AB		**4MG**	**A090839**	**005**	Nov 04, 2011
AB	MYLAN PHARMS INC	**0.25MG**	**A091537**	**006**	Feb 12, 2013
AB		**0.5MG**	**A091537**	**001**	Mar 30, 2011
AB		**1MG**	**A091537**	**002**	Mar 30, 2011
AB		**2MG**	**A091537**	**003**	Mar 30, 2011
AB		**3MG**	**A091537**	**004**	Mar 30, 2011
AB		**4MG**	**A091537**	**005**	Mar 30, 2011
AB	PAR PHARM	**0.25MG**	**A077494**	**001**	Apr 30, 2009
AB		**0.5MG**	**A077494**	**002**	Apr 30, 2009
AB		**1MG**	**A077494**	**003**	Oct 26, 2009
AB		**2MG**	**A077494**	**004**	Apr 30, 2009
AB		**3MG**	**A077494**	**005**	Apr 30, 2009
AB		**4MG**	**A077494**	**006**	Apr 30, 2009
AB	SANDOZ	**0.5MG**	**A078116**	**001**	Dec 22, 2009
AB		**1MG**	**A078116**	**002**	Dec 22, 2009
AB		**2MG**	**A078116**	**003**	Dec 22, 2009
AB		**3MG**	**A078116**	**004**	Dec 22, 2009
AB		**4MG**	**A078116**	**005**	Dec 22, 2009
AB	SUN PHARM INDS LTD	**0.5MG**	**A077542**	**001**	Aug 06, 2010
AB		**0.5MG**	**A078464**	**001**	Apr 08, 2013
AB		**1MG**	**A077542**	**002**	Aug 06, 2010
AB		**1MG**	**A078464**	**002**	Apr 08, 2013
AB		**2MG**	**A077542**	**003**	Aug 06, 2010
AB		**2MG**	**A078464**	**003**	Apr 08, 2013
AB		**3MG**	**A078464**	**004**	Apr 08, 2013
AB		**3MG**	**A078474**	**001**	Aug 06, 2010
AB		**4MG**	**A078464**	**005**	Apr 08, 2013
AB		**4MG**	**A078474**	**002**	Aug 06, 2010
AB	TEVA	**0.5MG**	**A076908**	**001**	Mar 12, 2012
AB		**1MG**	**A076908**	**002**	Mar 12, 2012
AB		**2MG**	**A076908**	**003**	Mar 12, 2012
AB	ZYDUS PHARMS USA	**0.5MG**	**A078516**	**001**	May 01, 2009
AB		**2MG**	**A078516**	**003**	May 01, 2009

RITONAVIR
CAPSULE;ORAL
NORVIR

+	ABBVIE	100MG	N020945	001	Jun 29, 1999

SOLUTION;ORAL
NORVIR

+	ABBVIE	80MG/ML	N020659	001	Mar 01, 1996

TABLET;ORAL
NORVIR

AB	**+** ABBVIE	**100MG**	**N022417**	**001**	Feb 10, 2010

RITONAVIR

AB	WEST-WARD PHARMS INT	**100MG**	**A202573**	**001**	Jan 15, 2015

RIVAROXABAN
TABLET;ORAL
XARELTO

	JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011
		15MG	N022406	002	Nov 04, 2011
+		20MG	N022406	003	Nov 04, 2011

FDA data supplied by DrugPatentWatch.com

RIVASTIGMINE
FILM, EXTENDED RELEASE;TRANSDERMAL

	EXELON				
AB		NOVARTIS	**4.6MG/24HR**	**N022083**	**001** Jul 06, 2007
AB	+		**9.5MG/24HR**	**N022083**	**002** Jul 06, 2007
AB			**13.3MG/24HR**	**N022083**	**005** Aug 31, 2012
	RIVASTIGMINE				
AB		ALVOGEN MALTA	**4.6MG/24HR**	**A204403**	**001** Sep 03, 2015
AB			**9.5MG/24HR**	**A204403**	**002** Sep 03, 2015
AB			**13.3MG/24HR**	**A204403**	**003** Aug 31, 2015

RIVASTIGMINE TARTRATE
CAPSULE;ORAL

	EXELON				
AB	+	NOVARTIS	**EQ 1.5MG BASE**	**N020823**	**003** Apr 21, 2000
AB			**EQ 3MG BASE**	**N020823**	**004** Apr 21, 2000
AB			**EQ 4.5MG BASE**	**N020823**	**005** Apr 21, 2000
AB	+		**EQ 6MG BASE**	**N020823**	**006** Apr 21, 2000
	RIVASTIGMINE TARTRATE				
AB		ALEMBIC PHARMS LTD	**EQ 1.5MG BASE**	**A091689**	**001** Jun 12, 2012
AB			**EQ 3MG BASE**	**A091689**	**002** Jun 12, 2012
AB			**EQ 4.5MG BASE**	**A091689**	**003** Jun 12, 2012
AB			**EQ 6MG BASE**	**A091689**	**004** Jun 12, 2012
AB		APOTEX INC	**EQ 1.5MG BASE**	**A091072**	**001** May 16, 2013
AB			**EQ 3MG BASE**	**A091072**	**002** May 16, 2013
AB			**EQ 4.5MG BASE**	**A091072**	**003** May 16, 2013
AB			**EQ 6MG BASE**	**A091072**	**004** May 16, 2013
AB		AUROBINDO PHARMA LTD	**EQ 1.5MG BASE**	**A204572**	**001** Mar 25, 2016
AB			**EQ 3MG BASE**	**A204572**	**002** Mar 25, 2016
AB			**EQ 4.5MG BASE**	**A204572**	**003** Mar 25, 2016
AB			**EQ 6MG BASE**	**A204572**	**004** Mar 25, 2016
AB		DR REDDYS LABS INC	**EQ 1.5MG BASE**	**A077130**	**001** Oct 31, 2007
AB			**EQ 3MG BASE**	**A077130**	**002** Oct 31, 2007
AB			**EQ 4.5MG BASE**	**A077130**	**003** Oct 31, 2007
AB			**EQ 6MG BASE**	**A077130**	**004** Oct 31, 2007
AB		MACLEODS PHARMS LTD	**EQ 1.5MG BASE**	**A203148**	**001** Aug 22, 2014
AB			**EQ 3MG BASE**	**A203148**	**002** Aug 22, 2014
AB			**EQ 4.5MG BASE**	**A203148**	**003** Aug 22, 2014
AB			**EQ 6MG BASE**	**A203148**	**004** Aug 22, 2014
AB		ORCHID HLTHCARE	**EQ 1.5MG BASE**	**A090879**	**001** Jun 10, 2015
AB			**EQ 3MG BASE**	**A090879**	**002** Jun 10, 2015
AB			**EQ 4.5MG BASE**	**A090879**	**003** Jun 10, 2015
AB			**EQ 6MG BASE**	**A090879**	**004** Jun 10, 2015
AB		SUN PHARM INDS	**EQ 1.5MG BASE**	**A077131**	**001** Oct 22, 2007
AB			**EQ 3MG BASE**	**A077131**	**002** Oct 22, 2007
AB			**EQ 4.5MG BASE**	**A077131**	**003** Oct 22, 2007
AB			**EQ 6MG BASE**	**A077131**	**004** Oct 22, 2007
AB		WATSON LABS	**EQ 1.5MG BASE**	**A077129**	**001** Jan 08, 2008
AB			**EQ 3MG BASE**	**A077129**	**002** Jan 08, 2008
AB			**EQ 4.5MG BASE**	**A077129**	**003** Jan 08, 2008
AB			**EQ 6MG BASE**	**A077129**	**004** Jan 08, 2008

RIZATRIPTAN BENZOATE
TABLET;ORAL

	MAXALT				
AB		MERCK	**EQ 5MG BASE**	**N020864**	**001** Jun 29, 1998
AB	+		**EQ 10MG BASE**	**N020864**	**002** Jun 29, 1998
	RIZATRIPTAN BENZOATE				
AB		ALKEM LABS LTD	**EQ 5MG BASE**	**A203269**	**001** Feb 18, 2016
AB			**EQ 10MG BASE**	**A203269**	**002** Feb 18, 2016
AB		APOTEX INC	**EQ 5MG BASE**	**A202244**	**001** Dec 31, 2012
AB			**EQ 10MG BASE**	**A202244**	**002** Dec 31, 2012
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202490**	**001** Dec 31, 2012
AB			**EQ 10MG BASE**	**A202490**	**002** Dec 31, 2012
AB		CIPLA LTD	**EQ 5MG BASE**	**A077526**	**001** Mar 26, 2013
AB			**EQ 10MG BASE**	**A077526**	**002** Mar 26, 2013
AB		EMCURE PHARMS LTD	**EQ 5MG BASE**	**A204090**	**001** Nov 26, 2013
AB			**EQ 10MG BASE**	**A204090**	**002** Nov 26, 2013
AB		GLENMARK GENERICS	**EQ 5MG BASE**	**A201967**	**001** Dec 31, 2012
AB			**EQ 10MG BASE**	**A201967**	**002** Dec 31, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A204339**	**001** Jul 01, 2013
AB			**EQ 10MG BASE**	**A204339**	**002** Jul 01, 2013
AB		JUBILANT GENERICS	**EQ 5MG BASE**	**A203252**	**001** Dec 31, 2014

RIZATRIPTAN BENZOATE
TABLET;ORAL
RIZATRIPTAN BENZOATE

AB		EQ 10MG BASE	A203252	002	Dec 31, 2014
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014
AB		EQ 10MG BASE	A203147	002	Feb 11, 2014
AB	MYLAN PHARMS INC	EQ 5MG BASE	A201993	001	Dec 31, 2012
AB		EQ 10MG BASE	A201993	002	Dec 31, 2012
AB	NATCO PHARMA LTD	EQ 5MG BASE	A200482	001	Dec 31, 2012
AB		EQ 10MG BASE	A200482	002	Dec 31, 2012
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012
AB	SANDOZ	EQ 5MG BASE	A079230	001	Dec 31, 2012
AB		EQ 10MG BASE	A079230	002	Dec 31, 2012
AB	TEVA PHARMS	EQ 5MG BASE	A077263	001	Dec 31, 2012
AB		EQ 10MG BASE	A077263	002	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING;ORAL
MAXALT-MLT

AB	MERCK	EQ 5MG BASE	N020865	001	Jun 29, 1998
AB +		EQ 10MG BASE	N020865	002	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013
AB		EQ 10MG BASE	A202477	002	Jul 01, 2013
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A203062	001	Jul 01, 2013
AB		EQ 10MG BASE	A203062	002	Jul 01, 2013
AB	GLENMARK GENERICS	EQ 5MG BASE	A201914	001	Jul 01, 2013
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013
AB	JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015
AB		EQ 10MG BASE	A203334	002	Oct 16, 2015
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203146	001	Sep 19, 2014
AB		EQ 10MG BASE	A203146	002	Sep 19, 2014
AB	MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012
AB		EQ 10MG BASE	A078173	002	Dec 31, 2012
AB	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013
AB		EQ 10MG BASE	A203478	002	Jul 01, 2013
AB	SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013
AB		EQ 10MG BASE	A078739	002	Jul 01, 2013

ROCURONIUM BROMIDE
INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A078651	001	Dec 29, 2008
AP		100MG/10ML (10MG/ML)	A078651	002	Dec 29, 2008
AP	HOSPIRA	50MG/5ML (10MG/ML)	A078519	001	Nov 26, 2008
AP		100MG/10ML (10MG/ML)	A078519	002	Nov 26, 2008
AP	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008
AP		100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008
AP	SAGENT PHARMS	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010
AP +	SANDOZ	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008
AP +		100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008
AP	TAMARANG	50MG/5ML (10MG/ML)	A091115	001	Aug 27, 2012
AP		100MG/10ML (10MG/ML)	A091115	002	Aug 27, 2012
AP	TEVA PHARMS	50MG/5ML (10MG/ML)	A078717	001	Nov 26, 2008
AP		100MG/10ML (10MG/ML)	A078717	002	Nov 26, 2008

ROFLUMILAST
TABLET;ORAL
DALIRESP

+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011

ROLAPITANT HYDROCHLORIDE
TABLET;ORAL
VARUBI

+	TESARO INC	EQ 90MG BASE	N206500	001	Sep 01, 2015

ROMIDEPSIN
POWDER;IV (INFUSION)
ISTODAX

+	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009

FDA data supplied by DrugPatentWatch.com

ROPINIROLE HYDROCHLORIDE
TABLET;ORAL

	REQUIP					
AB	+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997
AB			EQ 0.5MG BASE	N020658	002	Sep 19, 1997
AB			EQ 1MG BASE	N020658	003	Sep 19, 1997
AB			EQ 2MG BASE	N020658	004	Sep 19, 1997
AB			EQ 3MG BASE	N020658	006	Jan 27, 1999
AB			EQ 4MG BASE	N020658	007	Jan 27, 1999
AB			EQ 5MG BASE	N020658	005	Sep 19, 1997
	ROPINIROLE HYDROCHLORIDE					
AB		ALEMBIC LTD	EQ 0.25MG BASE	A090429	001	Mar 24, 2010
AB			EQ 0.5MG BASE	A090429	002	Mar 24, 2010
AB			EQ 1MG BASE	A090429	003	Mar 24, 2010
AB			EQ 2MG BASE	A090429	004	Mar 24, 2010
AB			EQ 3MG BASE	A090429	005	Mar 24, 2010
AB			EQ 4MG BASE	A090429	006	Mar 24, 2010
AB			EQ 5MG BASE	A090429	007	Mar 24, 2010
AB		APOTEX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012
AB			EQ 0.5MG BASE	A079165	002	Feb 07, 2012
AB			EQ 1MG BASE	A079165	003	Feb 07, 2012
AB			EQ 2MG BASE	A079165	004	Feb 07, 2012
AB			EQ 3MG BASE	A079165	005	Feb 07, 2012
AB			EQ 4MG BASE	A079165	006	Feb 07, 2012
AB			EQ 5MG BASE	A079165	007	Feb 07, 2012
AB		G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008
AB			EQ 0.5MG BASE	A077460	002	May 05, 2008
AB			EQ 1MG BASE	A077460	003	May 05, 2008
AB			EQ 2MG BASE	A077460	004	May 05, 2008
AB			EQ 3MG BASE	A077460	005	May 05, 2008
AB			EQ 4MG BASE	A077460	006	May 05, 2008
AB			EQ 5MG BASE	A077460	007	May 19, 2008
AB		GLENMARK GENERICS	EQ 0.25MG BASE	A090135	001	Feb 25, 2010
AB			EQ 0.5MG BASE	A090135	002	Feb 25, 2010
AB			EQ 1MG BASE	A090135	003	Feb 25, 2010
AB			EQ 2MG BASE	A090135	004	Feb 25, 2010
AB			EQ 3MG BASE	A090135	005	Feb 25, 2010
AB			EQ 4MG BASE	A090135	006	Feb 25, 2010
AB			EQ 5MG BASE	A090135	007	Feb 25, 2010
AB		MYLAN	EQ 0.25MG BASE	A078881	001	May 05, 2008
AB			EQ 0.5MG BASE	A078881	002	May 05, 2008
AB			EQ 1MG BASE	A078881	003	May 05, 2008
AB			EQ 2MG BASE	A078881	004	May 05, 2008
AB			EQ 3MG BASE	A078881	005	May 05, 2008
AB			EQ 4MG BASE	A078881	006	May 05, 2008
AB			EQ 5MG BASE	A078881	007	May 19, 2008
AB		ORCHID HLTHCARE	EQ 0.25MG BASE	A079229	001	Nov 28, 2012
AB			EQ 0.5MG BASE	A079229	002	Nov 28, 2012
AB			EQ 1MG BASE	A079229	003	Nov 28, 2012
AB			EQ 2MG BASE	A079229	004	Nov 28, 2012
AB			EQ 3MG BASE	A079229	005	Nov 28, 2012
AB			EQ 4MG BASE	A079229	006	Nov 28, 2012
AB			EQ 5MG BASE	A079229	007	Nov 28, 2012
AB		PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008
AB			EQ 0.5MG BASE	A078110	002	May 05, 2008
AB			EQ 1MG BASE	A078110	003	May 05, 2008
AB			EQ 2MG BASE	A078110	004	May 05, 2008
AB			EQ 3MG BASE	A078110	005	May 05, 2008
AB			EQ 4MG BASE	A078110	006	May 05, 2008
AB			EQ 5MG BASE	A078110	007	Jul 11, 2008
AB		WEST-WARD PHARMS INT	EQ 0.25MG BASE	A077852	001	May 05, 2008
AB			EQ 0.5MG BASE	A077852	002	May 05, 2008
AB			EQ 1MG BASE	A077852	003	May 05, 2008
AB			EQ 2MG BASE	A077852	004	May 05, 2008
AB			EQ 3MG BASE	A077852	005	May 05, 2008
AB			EQ 4MG BASE	A077852	006	May 05, 2008
AB			EQ 5MG BASE	A077852	007	May 19, 2008
AB		WOCKHARDT	EQ 0.25MG BASE	A079050	001	May 29, 2008
AB			EQ 0.5MG BASE	A079050	002	May 29, 2008
AB			EQ 1MG BASE	A079050	003	May 29, 2008
AB			EQ 2MG BASE	A079050	004	May 29, 2008
AB			EQ 3MG BASE	A079050	005	May 29, 2008

FDA data supplied by DrugPatentWatch.com

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		EQ 4MG BASE	A079050	006	May 29, 2008
AB		EQ 5MG BASE	A079050	007	May 29, 2008
AB	ZYDUS PHARMS USA INC	EQ 0.25MG BASE	A090411	001	Jun 01, 2009
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

AB	+ GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008
AB		EQ 4MG BASE	N022008	003	Jun 13, 2008
AB		EQ 6MG BASE	N022008	006	Apr 10, 2009
AB		EQ 8MG BASE	N022008	004	Jun 13, 2008
AB		EQ 12MG BASE	N022008	005	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012
AB		EQ 4MG BASE	A090869	002	May 17, 2012
AB		EQ 6MG BASE	A090869	003	May 17, 2012
AB		EQ 8MG BASE	A090869	004	May 17, 2012
AB		EQ 12MG BASE	A090869	005	May 17, 2012
AB	ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013
AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012
AB		EQ 4MG BASE	A201576	002	Jun 06, 2012
AB		EQ 6MG BASE	A201576	003	Jun 06, 2012
AB		EQ 8MG BASE	A201576	004	Jun 06, 2012
AB		EQ 12MG BASE	A201576	005	Jun 06, 2012
AB	MYLAN PHARMS INC	EQ 2MG BASE	A200462	001	Oct 15, 2012
AB		EQ 4MG BASE	A200462	003	Oct 15, 2012
AB		EQ 6MG BASE	A200462	004	Oct 15, 2012
AB		EQ 8MG BASE	A200462	005	Oct 15, 2012
AB		EQ 12MG BASE	A200462	006	Oct 15, 2012
AB	SANDOZ INC	EQ 2MG BASE	A201047	001	Jun 06, 2012
AB		EQ 4MG BASE	A201047	003	Jun 06, 2012
AB		EQ 6MG BASE	A201047	004	Jun 06, 2012
AB		EQ 8MG BASE	A201047	005	Jun 06, 2012
AB		EQ 12MG BASE	A201047	006	Jun 06, 2012
AB	WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012
AB		EQ 4MG BASE	A200431	002	Jun 06, 2012
AB		EQ 6MG BASE	A200431	003	Jun 06, 2012
AB		EQ 8MG BASE	A200431	004	Jun 06, 2012
AB		EQ 12MG BASE	A200431	005	Jun 06, 2012
AB	WOCKHARDT LTD	EQ 2MG BASE	A091395	001	Aug 27, 2012
AB		EQ 4MG BASE	A091395	002	Aug 27, 2012
AB		EQ 6MG BASE	A091395	003	Aug 27, 2012
AB		EQ 8MG BASE	A091395	004	Aug 27, 2012
AB		EQ 12MG BASE	A091395	005	Aug 27, 2012
	MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016

SOLUTION;INJECTION

NAROPIN

AP	FRESENIUS KABI USA	20MG/10ML (2MG/ML)	N020533	001	May 01, 1998
AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996
AP		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998
AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996
AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996
AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996
AP		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996
AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996

FDA data supplied by DrugPatentWatch.com

ROPIVACAINE HYDROCHLORIDE
SOLUTION;INJECTION

	ROPIVACAINE HYDROCHLORIDE				
AP	AUROBINDO PHARMA LTD	**40MG/20ML (2MG/ML)**	**A205612**	**001**	Jul 13, 2016
AP		**100MG/20ML (5MG/ML)**	**A205612**	**003**	Jul 13, 2016
AP		**100MG/10ML (10MG/ML)**	**A205612**	**006**	Jul 13, 2016
AP		**150MG/30ML (5MG/ML)**	**A205612**	**004**	Jul 13, 2016
AP		**150MG/20ML (7.5MG/ML)**	**A205612**	**005**	Jul 13, 2016
AP		**200MG/100ML (2MG/ML)**	**A205612**	**002**	Jul 13, 2016
AP		**200MG/20ML (10MG/ML)**	**A205612**	**007**	Jul 13, 2016
AP	HOSPIRA	**20MG/10ML (2MG/ML)**	**A090194**	**001**	Sep 23, 2014
AP		**40MG/20ML (2MG/ML)**	**A090194**	**005**	Sep 23, 2014
AP		**100MG/10ML (10MG/ML)**	**A090194**	**004**	Sep 23, 2014
AP		**150MG/30ML (5MG/ML)**	**A090194**	**002**	Sep 23, 2014
AP		**150MG/20ML (7.5MG/ML)**	**A090194**	**003**	Sep 23, 2014
AP		**200MG/20ML (10MG/ML)**	**A090194**	**006**	Sep 23, 2014
AP	NAVINTA LLC	**150MG/30ML (5MG/ML)**	**A078601**	**002**	Jul 17, 2014
AP		**200MG/20ML (10MG/ML)**	**A078601**	**003**	Jul 17, 2014
AP	SAGENT STRIDES	**40MG/20ML (2MG/ML)**	**A090318**	**001**	Sep 23, 2014
AP		**150MG/30ML (5MG/ML)**	**A090318**	**002**	Sep 23, 2014
AP		**150MG/20ML (7.5MG/ML)**	**A090318**	**003**	Sep 23, 2014
AP		**200MG/20ML (10MG/ML)**	**A090318**	**004**	Sep 23, 2014
	NAROPIN				
	FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996
		500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011
		1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011

ROSIGLITAZONE MALEATE
TABLET;ORAL

	AVANDIA				
AB	SB PHARMCO	**EQ 2MG BASE**	**N021071**	**002**	May 25, 1999
AB		**EQ 4MG BASE**	**N021071**	**003**	May 25, 1999
AB	**+**	**EQ 8MG BASE**	**N021071**	**004**	May 25, 1999
	ROSIGLITAZONE MALEATE				
AB	TEVA	**EQ 2MG BASE**	**A076747**	**001**	Jan 25, 2013
AB		**EQ 4MG BASE**	**A076747**	**002**	Jan 25, 2013
AB		**EQ 8MG BASE**	**A076747**	**003**	Jan 25, 2013

ROSUVASTATIN CALCIUM
TABLET;ORAL

	CRESTOR				
AB	IPR	**5MG**	**N021366**	**002**	Aug 12, 2003
AB		**10MG**	**N021366**	**003**	Aug 12, 2003
AB		**20MG**	**N021366**	**004**	Aug 12, 2003
AB	**+**	**40MG**	**N021366**	**005**	Aug 12, 2003
	ROSUVASTATIN CALCIUM				
AB	ACCORD HLTHCARE INC	**5MG**	**A206434**	**001**	Oct 31, 2016
AB		**10MG**	**A206434**	**002**	Oct 31, 2016
AB		**20MG**	**A206434**	**003**	Oct 31, 2016
AB		**40MG**	**A206434**	**004**	Oct 31, 2016
AB	APOTEX INC	**5MG**	**A079145**	**001**	Jul 19, 2016
AB		**10MG**	**A079145**	**002**	Jul 19, 2016
AB		**20MG**	**A079145**	**003**	Jul 19, 2016
AB		**40MG**	**A079145**	**004**	Jul 19, 2016
AB	AUROBINDO PHARMA LTD	**5MG**	**A079170**	**001**	Jul 19, 2016
AB		**10MG**	**A079170**	**002**	Jul 19, 2016
AB		**20MG**	**A079170**	**003**	Jul 19, 2016
AB		**40MG**	**A079170**	**004**	Jul 19, 2016
AB	BIOCON LTD	**5MG**	**A207752**	**001**	Oct 31, 2016
AB		**10MG**	**A207752**	**002**	Oct 31, 2016
AB		**20MG**	**A207752**	**003**	Oct 31, 2016
AB		**40MG**	**A207752**	**004**	Oct 31, 2016
AB	CADILA PHARMS LTD	**5MG**	**A207453**	**001**	Nov 23, 2016
AB		**10MG**	**A207453**	**002**	Nov 23, 2016
AB		**20MG**	**A207453**	**003**	Nov 23, 2016
AB		**40MG**	**A207453**	**004**	Nov 23, 2016
AB	CHANGZHOU PHARM	**5MG**	**A207408**	**001**	Oct 31, 2016
AB		**10MG**	**A207408**	**002**	Oct 31, 2016
AB		**20MG**	**A207408**	**003**	Oct 31, 2016
AB		**40MG**	**A207408**	**004**	Oct 31, 2016
AB	GLENMARK PHARMS	**5MG**	**A079172**	**001**	Jul 19, 2016
AB		**10MG**	**A079172**	**002**	Jul 19, 2016
AB		**20MG**	**A079172**	**003**	Jul 19, 2016

FDA data supplied by DrugPatentWatch.com

ROSUVASTATIN CALCIUM
TABLET;ORAL
ROSUVASTATIN CALCIUM

AB		**40MG**	**A079172**	**004**	Jul 19, 2016
AB	HETERO LABS LTD V	**5MG**	**A207616**	**001**	Oct 31, 2016
AB		**10MG**	**A207616**	**002**	Oct 31, 2016
AB		**20MG**	**A207616**	**003**	Oct 31, 2016
AB		**40MG**	**A207616**	**004**	Oct 31, 2016
AB	JUBILANT GENERICS	**5MG**	**A207062**	**001**	Oct 31, 2016
AB		**10MG**	**A207062**	**002**	Oct 31, 2016
AB		**20MG**	**A207062**	**003**	Oct 31, 2016
AB		**40MG**	**A207062**	**004**	Oct 31, 2016
AB	MYLAN PHARMS INC	**5MG**	**A079161**	**001**	Jul 19, 2016
AB		**10MG**	**A079161**	**002**	Jul 19, 2016
AB		**20MG**	**A079161**	**003**	Jul 19, 2016
AB		**40MG**	**A079161**	**004**	Jul 19, 2016
AB	PAR PHARM INC	**5MG**	**A079168**	**001**	Jul 19, 2016
AB		**10MG**	**A079168**	**002**	Jul 19, 2016
AB		**20MG**	**A079168**	**003**	Jul 19, 2016
AB		**40MG**	**A079168**	**004**	Jul 19, 2016
AB	SANDOZ INC	**5MG**	**A079171**	**001**	Jul 19, 2016
AB		**10MG**	**A079171**	**002**	Jul 19, 2016
AB		**20MG**	**A079171**	**003**	Jul 19, 2016
AB		**40MG**	**A079171**	**004**	Jul 19, 2016
AB	SUN PHARMA GLOBAL	**5MG**	**A079169**	**001**	Jul 19, 2016
AB		**10MG**	**A079169**	**002**	Jul 19, 2016
AB		**20MG**	**A079169**	**003**	Jul 19, 2016
AB		**40MG**	**A079169**	**004**	Jul 19, 2016
AB	TEVA PHARMS USA	**5MG**	**A079166**	**001**	Jul 19, 2016
AB		**10MG**	**A079166**	**002**	Jul 19, 2016
AB		**20MG**	**A079166**	**003**	Jul 19, 2016
AB		**40MG**	**A079166**	**004**	Jul 19, 2016
AB	TORRENT PHARMS LLC	**5MG**	**A201619**	**001**	Oct 31, 2016
AB		**10MG**	**A201619**	**002**	Oct 31, 2016
AB		**20MG**	**A201619**	**003**	Oct 31, 2016
AB		**40MG**	**A201619**	**004**	Oct 31, 2016
AB	WATSON LABS INC	**5MG**	**A079167**	**001**	Apr 29, 2016
AB		**10MG**	**A079167**	**002**	Apr 29, 2016
AB		**20MG**	**A079167**	**003**	Apr 29, 2016
AB		**40MG**	**A079167**	**004**	Apr 29, 2016

ROTIGOTINE
FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO

	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+		2MG/24HR	N021829	001	May 09, 2007
		3MG/24HR	N021829	005	Apr 02, 2012
		4MG/24HR	N021829	002	May 09, 2007
		6MG/24HR	N021829	003	May 09, 2007
		8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82
INJECTABLE;INJECTION
CARDIOGEN-82

	BRACCO	N/A	N019414	001	Dec 29, 1989

SOLUTION;INTRAVENOUS
RUBY-FILL

	JUBILANT DRAXIMAGE	N/A	N202153	001	Sep 30, 2016

RUCAPARIB CAMSYLATE
TABLET;ORAL
RUBRACA

	CLOVIS ONCOLOGY INC	EQ 200MG BASE	N209115	001	Dec 19, 2016
+		EQ 300MG BASE	N209115	002	Dec 19, 2016

RUFINAMIDE
SUSPENSION;ORAL
BANZEL

+	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011

TABLET;ORAL
BANZEL

AB	EISAI INC	**200MG**	**N021911**	**002**	Nov 14, 2008
AB	**+**	**400MG**	**N021911**	**003**	Nov 14, 2008

RUFINAMIDE
TABLET;ORAL
RUFINAMIDE

AB	GLENMARK PHARMS LTD	**200MG**	**A205075**	**001**	May 16, 2016
AB		**400MG**	**A205075**	**002**	May 16, 2016
AB	MYLAN PHARMS INC	**200MG**	**A205095**	**001**	May 16, 2016
AB		**400MG**	**A205095**	**002**	May 16, 2016
AB	WEST-WARD PHARMS INT	**200MG**	**A204988**	**001**	May 16, 2016
AB		**400MG**	**A204988**	**002**	May 16, 2016

RUXOLITINIB PHOSPHATE
TABLET;ORAL
JAKAFI

	INCYTE CORP	EQ 5MG BASE	N202192	001	Nov 16, 2011
		EQ 10MG BASE	N202192	002	Nov 16, 2011
		EQ 15MG BASE	N202192	003	Nov 16, 2011
		EQ 20MG BASE	N202192	004	Nov 16, 2011
+		EQ 25MG BASE	N202192	005	Nov 16, 2011

SACROSIDASE
SOLUTION;ORAL
SUCRAID

+	QOL MEDCL	8,500 IU/ML	N020772	001	Apr 09, 1998

SACUBITRIL; VALSARTAN
TABLET;ORAL
ENTRESTO

	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015
		49MG;51MG	N207620	002	Jul 07, 2015
+		97MG;103MG	N207620	003	Jul 07, 2015

SALMETEROL XINAFOATE
POWDER;INHALATION
SEREVENT

+	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
INJECTABLE;INJECTION
QUADRAMET

+	LANTHEUS MEDICAL	50mCi/ML	N020570	001	Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE
POWDER;ORAL
KUVAN

+	BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013
		500MG/PACKET	N205065	002	Oct 27, 2015

TABLET;ORAL
KUVAN

+	BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007

SAQUINAVIR MESYLATE
CAPSULE;ORAL
INVIRASE

+	HOFFMANN LA ROCHE	EQ 200MG BASE	N020628	001	Dec 06, 1995

TABLET;ORAL
INVIRASE

+	HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004

SAXAGLIPTIN HYDROCHLORIDE
TABLET;ORAL
ONGLYZA

	ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009
+		EQ 5MG BASE	N022350	002	Jul 31, 2009

SCOPOLAMINE
FILM, EXTENDED RELEASE;TRANSDERMAL
SCOPOLAMINE

AB	PERRIGO PHARMS CO	**1MG/72HR**	**A078830**	**001**	Jan 30, 2015

TRANSDERM SCOP

AB	**+** GLAXOSMITHKLINE CON	**1MG/72HR**	**N017874**	**001**	

SECOBARBITAL SODIUM
CAPSULE;ORAL
SECONAL SODIUM

+	VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983
+		100MG	A086101	002	Oct 03, 1983

SECRETIN SYNTHETIC HUMAN
FOR SOLUTION;INTRAVENOUS
CHIRHOSTIM

+	CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
		40MCG/VIAL	N021256	002	Jun 21, 2007

SELEGILINE
FILM, EXTENDED RELEASE;TRANSDERMAL
EMSAM

+	SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
		9MG/24HR	N021336	002	Feb 27, 2006
		12MG/24HR	N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE
CAPSULE;ORAL
ELDEPRYL

AB	**+**	SOMERSET	**5MG**	**N020647**	**001**	May 15, 1996

SELEGILINE HYDROCHLORIDE

AB		APOTEX	**5MG**	**A075321**	**001**	Dec 04, 1998
AB		DAVA PHARMS INC	**5MG**	**A075352**	**001**	Nov 30, 1998

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

AB	**+**	APOTEX INC	**5MG**	**A074871**	**001**	Jun 06, 1997
AB		MYLAN	**5MG**	**A074866**	**001**	Nov 26, 1997
AB		STASON	**5MG**	**A074912**	**001**	Apr 30, 1998

TABLET, ORALLY DISINTEGRATING;ORAL
ZELAPAR

+	VALEANT PHARM INTL	1.25MG	N021479	001	Jun 14, 2006

SELENIUM SULFIDE
LOTION/SHAMPOO;TOPICAL
SELENIUM SULFIDE

AT		PERRIGO NEW YORK	**2.5%**	**A089996**	**001**	Jan 10, 1991
AT		WOCKHARDT	**2.5%**	**A088228**	**001**	Sep 01, 1983

SELSUN

AT	**+**	CHATTEM	**2.5%**	**N007936**	**001**	

SELEXIPAG
TABLET;ORAL
UPTRAVI

	ACTELION PHARMS LTD	0.2MG	N207947	001	Dec 21, 2015
		0.4MG	N207947	002	Dec 21, 2015
		0.6MG	N207947	003	Dec 21, 2015
		0.8MG	N207947	004	Dec 21, 2015
		1MG	N207947	005	Dec 21, 2015
		1.2MG	N207947	006	Dec 21, 2015
		1.4MG	N207947	007	Dec 21, 2015
+		1.6MG	N207947	008	Dec 21, 2015

SERTACONAZOLE NITRATE
CREAM;TOPICAL
ERTACZO

+	VALEANT LUXEMBOURG	2%	N021385	001	Dec 10, 2003

SERTRALINE HYDROCHLORIDE
CONCENTRATE;ORAL
SERTRALINE HYDROCHLORIDE

AA		AUROBINDO PHARMA	**EQ 20MG BASE/ML**	**A078861**	**001**	Oct 31, 2008

ZOLOFT

AA	**+**	PFIZER	**EQ 20MG BASE/ML**	**N020990**	**001**	Dec 07, 1999

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 25MG BASE**	**A202825**	**001**	Nov 07, 2014
AB			**EQ 50MG BASE**	**A202825**	**002**	Nov 07, 2014
AB			**EQ 100MG BASE**	**A202825**	**003**	Nov 07, 2014
AB		APOTEX INC	**EQ 25MG BASE**	**A076882**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A076882**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A076882**	**003**	Feb 06, 2007
AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A077206**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A077206**	**002**	Feb 06, 2007

FDA data supplied by DrugPatentWatch.com

SERTRALINE HYDROCHLORIDE
TABLET;ORAL

	SERTRALINE HYDROCHLORIDE				
AB		**EQ 100MG BASE**	**A077206**	**003**	Feb 06, 2007
AB	AUSTARPHARMA LLC	**EQ 25MG BASE**	**A078677**	**001**	Mar 04, 2009
AB		**EQ 50MG BASE**	**A078677**	**002**	Mar 04, 2009
AB		**EQ 100MG BASE**	**A078677**	**003**	Mar 04, 2009
AB	INVAGEN PHARMS	**EQ 25MG BASE**	**A077397**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077397**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077397**	**003**	Feb 06, 2007
AB	LUPIN	**EQ 25MG BASE**	**A077670**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077670**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077670**	**003**	Feb 06, 2007
AB	MYLAN	**EQ 25MG BASE**	**A076671**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A076671**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A076671**	**003**	Feb 06, 2007
AB	MYLAN PHARMS INC	**EQ 25MG BASE**	**A078626**	**001**	Jan 31, 2008
AB		**EQ 50MG BASE**	**A078626**	**002**	Jan 31, 2008
AB		**EQ 100MG BASE**	**A078626**	**003**	Jan 31, 2008
AB	OXFORD PHARMS	**EQ 25MG BASE**	**A078175**	**001**	Jul 21, 2010
AB		**EQ 50MG BASE**	**A078175**	**002**	Jul 21, 2010
AB		**EQ 100MG BASE**	**A078175**	**003**	Jul 21, 2010
AB	SUN PHARM INDS (IN)	**EQ 25MG BASE**	**A078108**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A078108**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A078108**	**003**	Feb 06, 2007
AB	SUN PHARM INDS LTD	**EQ 25MG BASE**	**A077977**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077977**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077977**	**003**	Feb 06, 2007
AB	TEVA	**EQ 25MG BASE**	**A076465**	**001**	Aug 11, 2006
AB		**EQ 50MG BASE**	**A076465**	**002**	Aug 11, 2006
AB		**EQ 100MG BASE**	**A076465**	**003**	Aug 11, 2006
AB	TORRENT PHARMS	**EQ 25MG BASE**	**A077765**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077765**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077765**	**003**	Feb 06, 2007
AB	WOCKHARDT	**EQ 25MG BASE**	**A078403**	**001**	Jan 08, 2008
AB		**EQ 50MG BASE**	**A078403**	**002**	Jan 08, 2008
AB		**EQ 100MG BASE**	**A078403**	**003**	Jan 08, 2008
AB	ZYDUS PHARMS USA	**EQ 25MG BASE**	**A077106**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077106**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077106**	**003**	Feb 06, 2007
	ZOLOFT				
AB	PFIZER	**EQ 25MG BASE**	**N019839**	**005**	Mar 06, 1996
AB		**EQ 50MG BASE**	**N019839**	**001**	Dec 30, 1991
AB +		**EQ 100MG BASE**	**N019839**	**002**	Dec 30, 1991
	SERTRALINE HYDROCHLORIDE				
	SUN PHARM INDS LTD	EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007

SEVELAMER CARBONATE
FOR SUSPENSION;ORAL

	RENVELA				
	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009
+		2.4GM/PACKET	N022318	002	Feb 18, 2009

TABLET;ORAL

	RENVELA				
+	GENZYME	800MG	N022127	001	Oct 19, 2007

SEVELAMER HYDROCHLORIDE
TABLET;ORAL

	RENAGEL				
	GENZYME	400MG	N021179	001	Jul 12, 2000
+		800MG	N021179	002	Jul 12, 2000

SEVOFLURANE
LIQUID;INHALATION

	SEVOFLURANE				
AN	BAXTER HLTHCARE	**100%**	**A075895**	**001**	Jul 02, 2002
AN	HALOCARBON PRODS	**100%**	**A078650**	**001**	Nov 19, 2007
AN	SHANGHAI HENGRUI	**100%**	**A203793**	**001**	Nov 03, 2015
	SOJOURN				
AN	PIRAMAL CRITICAL	**100%**	**A077867**	**001**	May 02, 2007
	ULTANE				
AN +	ABBVIE	**100%**	**N020478**	**001**	Jun 07, 1995

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL					
REVATIO					
+	PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012
SOLUTION;INTRAVENOUS					
REVATIO					
AP **+**	PFIZER	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**N022473**	**001**	Nov 18, 2009
SILDENAFIL CITRATE					
AP	AUROBINDO PHARMA LTD	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**A203988**	**001**	Apr 01, 2015
TABLET;ORAL					
REVATIO					
AB **+**	PFIZER	**EQ 20MG BASE**	**N021845**	**001**	Jun 03, 2005
SILDENAFIL CITRATE					
AB	AMNEAL PHARMS	**EQ 20MG BASE**	**A202025**	**001**	Feb 28, 2013
AB	APOTEX CORP	**EQ 20MG BASE**	**A091379**	**001**	Nov 06, 2012
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A203963**	**001**	Nov 18, 2015
AB	DR REDDYS LABS LTD	**EQ 20MG BASE**	**A202598**	**001**	Nov 06, 2012
AB	HETERO LABS LTD V	**EQ 20MG BASE**	**A203623**	**001**	Nov 26, 2014
AB	MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A203814**	**001**	Dec 17, 2013
AB	MYLAN PHARMS INC	**EQ 20MG BASE**	**A201150**	**001**	Nov 09, 2012
AB	RUBICON RES PVT LTD	**EQ 20MG BASE**	**A204883**	**001**	Jun 20, 2016
AB	TEVA PHARMS	**EQ 20MG BASE**	**A078380**	**001**	Jan 07, 2013
AB	TORRENT PHARMS LTD	**EQ 20MG BASE**	**A091479**	**001**	Nov 06, 2012
AB	WATSON LABS INC	**EQ 20MG BASE**	**A202503**	**001**	Nov 06, 2012
VIAGRA					
	PFIZER IRELAND	EQ 25MG BASE	N020895	001	Mar 27, 1998
		EQ 50MG BASE	N020895	002	Mar 27, 1998
+		EQ 100MG BASE	N020895	003	Mar 27, 1998

SILODOSIN

CAPSULE;ORAL					
RAPAFLO					
+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008
		8MG	N022206	002	Oct 08, 2008

SILVER SULFADIAZINE

CREAM;TOPICAL					
SILVADENE					
AB **+**	KING PHARMS	**1%**	**N017381**	**001**	
SSD					
AB	DR REDDYS LA	**1%**	**N018578**	**001**	Feb 25, 1982
THERMAZENE					
AB	THEPHARMANETWORK LLC	**1%**	**N018810**	**001**	Dec 23, 1985
SSD AF					
BX	DR REDDYS LA	1%	N018578	003	Jul 11, 1990

SIMEPREVIR SODIUM

CAPSULE;ORAL					
OLYSIO					
+	JANSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013

SIMVASTATIN

SUSPENSION;ORAL					
SIMVASTATIN					
	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016
+		40MG/5ML	N206679	002	Apr 21, 2016
TABLET;ORAL					
SIMVASTATIN					
AB	ACCORD HLTHCARE	**5MG**	**A078155**	**005**	Apr 05, 2013
AB		**10MG**	**A078155**	**002**	Feb 26, 2008
AB		**20MG**	**A078155**	**003**	Feb 26, 2008
AB		**40MG**	**A078155**	**004**	Feb 26, 2008
AB		**80MG**	**A078155**	**001**	Feb 26, 2008
AB	AUROBINDO PHARMA	**5MG**	**A077691**	**001**	Dec 20, 2006
AB		**10MG**	**A077691**	**002**	Dec 20, 2006
AB		**20MG**	**A077691**	**003**	Dec 20, 2006
AB		**40MG**	**A077691**	**004**	Dec 20, 2006
AB		**80MG**	**A077691**	**005**	Dec 20, 2006
AB	BIOCON LIMITED	**5MG**	**A078034**	**001**	Dec 20, 2006
AB		**10MG**	**A078034**	**002**	Dec 20, 2006
AB		**20MG**	**A078034**	**003**	Dec 20, 2006
AB		**40MG**	**A078034**	**004**	Dec 20, 2006
AB		**80MG**	**A078034**	**005**	Dec 20, 2006
AB	DR REDDYS LABS INC	**5MG**	**A077752**	**005**	Jan 23, 2008

FDA data supplied by DrugPatentWatch.com

SIMVASTATIN
TABLET;ORAL
SIMVASTATIN

AB		**10MG**	**A077752**	**001**	Dec 20, 2006
AB		**20MG**	**A077752**	**002**	Dec 20, 2006
AB		**40MG**	**A077752**	**003**	Dec 20, 2006
AB		**80MG**	**A077752**	**004**	Dec 20, 2006
AB	HETERO LABS LTD III	**5MG**	**A200895**	**001**	Nov 25, 2014
AB		**10MG**	**A200895**	**002**	Nov 25, 2014
AB		**20MG**	**A200895**	**003**	Nov 25, 2014
AB		**40MG**	**A200895**	**004**	Nov 25, 2014
AB		**80MG**	**A200895**	**005**	Nov 25, 2014
AB	IVAX SUB TEVA PHARMS	**5MG**	**A076052**	**001**	Jun 23, 2006
AB		**10MG**	**A076052**	**002**	Jun 23, 2006
AB		**20MG**	**A076052**	**003**	Jun 23, 2006
AB		**40MG**	**A076052**	**004**	Jun 23, 2006
AB		**80MG**	**A076052**	**005**	Dec 20, 2006
AB	LUPIN	**5MG**	**A078103**	**005**	Apr 14, 2009
AB		**10MG**	**A078103**	**001**	May 11, 2007
AB		**20MG**	**A078103**	**002**	May 11, 2007
AB		**40MG**	**A078103**	**003**	May 11, 2007
AB		**80MG**	**A078103**	**004**	May 11, 2007
AB	MICRO LABS LTD	**5MG**	**A090383**	**001**	Sep 16, 2011
AB		**10MG**	**A090383**	**002**	Sep 16, 2011
AB		**20MG**	**A090383**	**003**	Sep 16, 2011
AB		**40MG**	**A090383**	**004**	Sep 16, 2011
AB		**80MG**	**A090383**	**005**	Sep 16, 2011
AB	MYLAN PHARMS INC	**5MG**	**A090868**	**001**	Jun 08, 2010
AB		**10MG**	**A090868**	**002**	Jun 08, 2010
AB		**20MG**	**A090868**	**003**	Jun 08, 2010
AB		**40MG**	**A090868**	**004**	Jun 08, 2010
AB		**80MG**	**A090868**	**005**	Jun 08, 2010
AB	OXFORD PHARMS	**5MG**	**A078735**	**001**	Aug 30, 2010
AB		**10MG**	**A078735**	**002**	Aug 30, 2010
AB		**20MG**	**A078735**	**003**	Aug 30, 2010
AB		**40MG**	**A078735**	**004**	Aug 30, 2010
AB		**80MG**	**A078735**	**005**	Aug 30, 2010
AB	WATSON LABS	**5MG**	**A076685**	**001**	Dec 20, 2006
AB		**10MG**	**A076685**	**002**	Dec 20, 2006
AB		**20MG**	**A076685**	**003**	Dec 20, 2006
AB		**40MG**	**A076685**	**004**	Dec 20, 2006
AB		**80MG**	**A076685**	**005**	Dec 20, 2006
AB	ZYDUS PHARMS USA	**5MG**	**A077837**	**001**	Dec 20, 2006
AB		**10MG**	**A077837**	**002**	Dec 20, 2006
AB		**20MG**	**A077837**	**003**	Dec 20, 2006
AB		**40MG**	**A077837**	**004**	Dec 20, 2006
AB		**80MG**	**A077837**	**005**	Dec 20, 2006

ZOCOR

AB	MERCK	**5MG**	**N019766**	**001**	Dec 23, 1991
AB		**10MG**	**N019766**	**002**	Dec 23, 1991
AB		**20MG**	**N019766**	**003**	Dec 23, 1991
AB		**40MG**	**N019766**	**004**	Dec 23, 1991
AB +		**80MG**	**N019766**	**005**	Jul 10, 1998

SINCALIDE
INJECTABLE;INJECTION
KINEVAC

+	BRACCO	0.005MG/VIAL	N017697	001	

SINECATECHINS
OINTMENT;TOPICAL
VEREGEN

+	MEDIGENE AG	15%	N021902	001	Oct 31, 2006

SIROLIMUS
SOLUTION;ORAL
RAPAMUNE

+	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999

TABLET;ORAL
RAPAMUNE

AB	PF PRISM CV	**0.5MG**	**N021110**	**004**	Jan 25, 2010
AB		**1MG**	**N021110**	**001**	Aug 25, 2000
AB +		**2MG**	**N021110**	**002**	Aug 22, 2002

FDA data supplied by DrugPatentWatch.com

SIROLIMUS
TABLET;ORAL
SIROLIMUS

AB		DR REDDYS LABS LTD	**1MG**	**A201578**	**001** Oct 27, 2014
AB			**2MG**	**A201578**	**002** Oct 27, 2014
AB		ZYDUS PHARMS USA INC	**0.5MG**	**A201676**	**003** Jan 08, 2014

SITAGLIPTIN PHOSPHATE
TABLET;ORAL
JANUVIA

		MERCK SHARP DOHME	EQ 25MG BASE	N021995	001 Oct 16, 2006
			EQ 50MG BASE	N021995	002 Oct 16, 2006
	+		EQ 100MG BASE	N021995	003 Oct 16, 2006

SODIUM ACETATE ANHYDROUS
INJECTABLE;INJECTION
SODIUM ACETATE IN PLASTIC CONTAINER

	+	HOSPIRA	2MEQ/ML	N018893	001 May 04, 1983

SODIUM BENZOATE; SODIUM PHENYLACETATE
SOLUTION;IV (INFUSION)
AMMONUL

AP	**+**	MEDICIS	**10%;10% (5GM/50ML;5GM/50ML)**	**N020645**	**001** Feb 17, 2005

SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP		AILEX PHARMS PVT LTD	**10%;10% (5GM/50ML;5GM/50ML)**	**A207096**	**001** Feb 24, 2016
AP		NAVINTA LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A205880**	**001** Aug 04, 2016

SODIUM BICARBONATE
INJECTABLE;INJECTION
SODIUM BICARBONATE

	+	HOSPIRA	0.9MEQ/ML	A077394	001 Nov 09, 2005
	+		1MEQ/ML	A077394	002 Nov 09, 2005
		HOSPIRA INC	0.5MEQ/ML	A202981	001 Mar 04, 2016

SODIUM CHLORIDE
INJECTABLE;INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**9MG/ML**	**A088911**	**001** Feb 07, 1985
AP	**+**	HOSPIRA	**9MG/ML**	**N018800**	**001** Oct 29, 1982

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	**450MG/100ML**	**N019635**	**001** Mar 09, 1988
AP		BAXTER HLTHCARE	**450MG/100ML**	**N018016**	**001**
AP	**+**	HOSPIRA	**450MG/100ML**	**N018090**	**001**
AP			**450MG/100ML**	**N019759**	**001** Jun 08, 1988

SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	**9MG/ML**	**A201850**	**001** Jan 20, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+**	B BRAUN	**900MG/100ML**	**N017464**	**001**
AP	**+**		**900MG/100ML**	**N019635**	**002** Mar 09, 1988
AP	**+**	BAXTER HLTHCARE	**9MG/ML**	**N016677**	**004** Oct 30, 1985
AP			**9MG/ML**	**N020178**	**002** Dec 07, 1992
AP	**+**		**900MG/100ML**	**N016677**	**001**
AP	**+**		**900MG/100ML**	**N020178**	**001** Dec 07, 1992
AP	**+**	FRESENIUS KABI USA	**9MG/ML**	**A088912**	**001** Jan 10, 1985
AP		FRESENIUS MEDCL	**900MG/100ML**	**A078177**	**001** Apr 12, 2007
AP		HAEMONETICS	**900MG/100ML**	**A076316**	**001** Oct 27, 2004
AP	**+**	HOSPIRA	**9MG/ML**	**N018803**	**001** Oct 29, 1982
AP	**+**		**9MG/ML**	**N019217**	**001** Jul 13, 1984
AP			**9MG/ML**	**N019465**	**002** Jul 15, 1985
AP	**+**		**900MG/100ML**	**N016366**	**001**
AP	**+**		**900MG/100ML**	**N019465**	**001** Jul 15, 1985
AP	**+**		**900MG/100ML**	**N019480**	**001** Sep 17, 1985
AP		JUBILANT HOLLISTRSTR	**9MG/ML**	**A203352**	**001** May 18, 2016
AP	**+**	TARO PHARMS IRELAND	**9MG/ML**	**A077407**	**001** Aug 11, 2006

SODIUM CHLORIDE 0.9%

		B BRAUN	900MG/10ML	N019635	005 Aug 11, 2016
		MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006 Jan 06, 2012

SODIUM CHLORIDE 0.9%

		EUROHLTH INTL SARL	9MG/ML	A201833	001 Sep 24, 2013

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001 Jul 27, 2006
			1012.5MG/125ML (9MG/ML)	N021569	002 Jul 27, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	3GM/100ML	N019022	001 Nov 01, 1983

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5GM/100ML	N019022	002 Nov 01, 1983

SODIUM CHLORIDE IN PLASTIC CONTAINER

		HOSPIRA	2.5MEQ/ML	N018897	001 Jul 20, 1984

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT		B BRAUN	**900MG/100ML**	**N016733**	**001**
AT		BAXTER HLTHCARE	**900MG/100ML**	**N017427**	**001**
AT			**900MG/100ML**	**N017867**	**001**
AT		HOSPIRA	**900MG/100ML**	**N017514**	**001**
AT			**900MG/100ML**	**N018314**	**001**

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

		BAXTER HLTHCARE	900MG/100ML	N019319	002 May 17, 1985

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

FERRLECIT

AB	**+**	SANOFI AVENTIS US	**62.5MG/5ML**	**N020955**	**001** Feb 18, 1999

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	**62.5MG/5ML**	**A078215**	**001** Mar 31, 2011

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		3D IMAGING DRUG	**10-200mCi/ML**	**A203777**	**001** Oct 19, 2015
AP		BIOMEDCL RES FDN	**10-200mCi/ML**	**A204351**	**001** Jan 09, 2015
AP		CARDINAL HEALTH 414	**10-200mCi/ML**	**A203780**	**001** Jul 30, 2015
AP		ESSENTIAL ISOTOPES	**10-200mCi/ML**	**A204541**	**001** Oct 29, 2014
AP		GLOBAL ISOTOPES LLC	**10-200mCi/ML**	**A204464**	**001** Oct 21, 2014
AP		HOT SHOTS NM LLC	**10-200mCi/ML**	**A204530**	**001** Jul 29, 2015
AP	**+**	HOUSTON CYCLOTRON	**10-200mCi/ML**	**A203544**	**001** Dec 26, 2012
AP		KREITCHMAN PET CTR	**10-200mCi/ML**	**A203936**	**001** May 19, 2016
AP		MIDWEST MEDCL	**10-200mCi/ML**	**A204440**	**001** Nov 17, 2015
AP		MIPS CRF	**10-200mCi/ML**	**A204517**	**001** Jul 21, 2015
AP		NCM USA BRONX LLC	**10-200mCi/ML**	**A204513**	**001** Nov 28, 2014
AP		PETNET	**10-200mCi/ML**	**A203890**	**001** Sep 28, 2015
AP		PRECISION NUCLEAR	**10-200mCi/ML**	**A204542**	**001** Feb 27, 2015
AP		SHERTECH LABS LLC	**10-200mCi/ML**	**A204315**	**001** Sep 22, 2014
AP		SPECTRON MRC LLC	**10-200mCi/ML**	**A203912**	**001** Apr 22, 2015
AP		TRIAD ISOTOPES INC	**10-200mCi/ML**	**A203968**	**001** Oct 23, 2015
AP		UCSF RODIOPHARM	**10-200mCi/ML**	**A204437**	**001** Mar 13, 2014
AP		UIHC PET IMAGING	**10-200mCi/ML**	**A204462**	**001** Nov 17, 2015
AP		UNIV TX MD ANDERSON	**10-200mCi/ML**	**A203247**	**001** Dec 23, 2013
AP		UNIV UTAH CYCLOTRON	**10-200mCi/ML**	**A204497**	**001** Apr 20, 2015
AP		ZEVACOR PHARMA INC	**10-200mCi/ML**	**A203592**	**001** Aug 18, 2015
	+	MCPRF	10-91.5mCi/ML	A203605	001 Jun 28, 2013
		THE FEINSTEIN INST	20-600mCi/ML	A204328	001 Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	**+**	CARDINAL HEALTH 418	**100uCi**	**N018671**	**001** May 27, 1982
AA	**+**		**200uCi**	**N018671**	**002** May 27, 1982
AA		MALLINKRODT NUCLEAR	**100uCi**	**A071909**	**001** Feb 28, 1989
AA			**200uCi**	**A071910**	**001** Feb 28, 1989

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

		JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006 May 19, 2005
	+	MALLINKRODT NUCLEAR	0.8-100mCi	N016517	001

SOLUTION;ORAL

HICON

	+	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007 Dec 05, 2011

SODIUM IODIDE I 131

	+	MALLINKRODT NUCLEAR	3.5-150mCi/VIAL	N016515	001

FDA data supplied by DrugPatentWatch.com

SODIUM LACTATE
INJECTABLE;INJECTION
SODIUM LACTATE IN PLASTIC CONTAINER
+ HOSPIRA 5MEQ/ML N018947 001 Sep 05, 1984

SODIUM NITRITE
SOLUTION;INTRAVENOUS
SODIUM NITRITE
+ HOPE PHARMS 300MG/10ML (30MG/ML) N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE
SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS
NITHIODOTE
+ HOPE PHARMS 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML (250MG/ML) N201444 001 Jan 14, 2011

SODIUM NITROPRUSSIDE
INJECTABLE;INJECTION
NITROPRESS
AP + HOSPIRA 25MG/ML A071961 001 Aug 01, 1988
SODIUM NITROPRUSSIDE
AP NAMIGEN LLC **25MG/ML A207426 001** Dec 08, 2016

SODIUM OXYBATE
SOLUTION;ORAL
XYREM
+ JAZZ PHARMS 500MG/ML N021196 001 Jul 17, 2002

SODIUM PHENYLBUTYRATE
POWDER;ORAL
BUPHENYL
AB + HORIZON PHARMA INC 3GM/TEASPOONFUL N020573 001 Apr 30, 1996
SODIUM PHENYLBUTYRATE
AB PAR PHARM **3GM/TEASPOONFUL A203918 001** Jun 15, 2016
AB SIGMAPHARM LABS LLC **3GM/TEASPOONFUL A202819 001** Mar 22, 2013
TABLET;ORAL
BUPHENYL
AB + HORIZON PHARMA INC 500MG N020572 001 May 13, 1996
SODIUM PHENYLBUTYRATE
AB FERA PHARMS LLC **500MG A090910 001** Nov 18, 2011
AB PAR PHARM **500MG A204395 001** Apr 15, 2016

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
TABLET;ORAL
OSMOPREP
+ SALIX PHARMS 0.398GM;1.102GM N021892 001 Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
INJECTABLE;INJECTION
SODIUM PHOSPHATES IN PLASTIC CONTAINER
+ HOSPIRA 142MG/ML;276MG/ML N018892 001 May 10, 1983

SODIUM POLYSTYRENE SULFONATE
POWDER;ORAL, RECTAL
KALEXATE
AA KVK TECH **454GM/BOT A040905 001** Mar 30, 2009
KAYEXALATE
AA + CONCORDIA PHARMS INC 453.6GM/BOT N011287 001
KIONEX
AA PADDOCK LLC **454GM/BOT A040029 001** Feb 06, 1998
SODIUM POLYSTYRENE SULFONATE
AA BELCHER PHARMS LLC **454GM/BOT A205727 001** Feb 23, 2016
AA CAROLINA MEDCL **454GM/BOT A089910 001** Jan 19, 1989
AA CEDAR PHARMS **453.6GM/BOT A090313 001** Dec 21, 2011
AA EPIC PHARMA LLC **453.6GM/BOT A202333 001** Mar 19, 2014
AA INVATECH PHARMA **454GM/BOT A206815 001** Feb 18, 2016
AA NUVO PHARM INC **454GM/BOT A204071 001** Nov 28, 2014
KALEXATE
KVK TECH 15GM/BOT A040905 002 Apr 03, 2015
SODIUM POLYSTYRENE SULFONATE
NUVO PHARM INC 15GM/BOT A204071 002 Nov 28, 2014
SUSPENSION;ORAL, RECTAL
KIONEX
AA PADDOCK LLC **15GM/60ML A040028 001** Sep 17, 2007
SODIUM POLYSTYRENE SULFONATE
AA PADDOCK LLC **15GM/60ML A090590 001** May 13, 2011
AA WEST-WARD PHARMS INT **15GM/60ML A089049 001** Nov 17, 1986

FDA data supplied by DrugPatentWatch.com

SODIUM POLYSTYRENE SULFONATE
SUSPENSION;ORAL, RECTAL
SPS

AA	**+**	CAROLINA MEDCL	**15GM/60ML**	**A087859**	**001**	Dec 08, 1982

SODIUM TETRADECYL SULFATE
INJECTABLE;INJECTION
SOTRADECOL

	+	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004
	+		60MG/2ML (30MG/ML)	A040541	002	Nov 12, 2004

SODIUM THIOSULFATE
SOLUTION;INTRAVENOUS
SODIUM THIOSULFATE

	+	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012

SOFOSBUVIR
TABLET;ORAL
SOVALDI

	+	GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013

SOFOSBUVIR; VELPATASVIR
TABLET;ORAL
EPCLUSA

	+	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016

SOLIFENACIN SUCCINATE
TABLET;ORAL
SOLIFENACIN SUCCINATE

AB		TEVA PHARMS USA	**5MG**	**A091464**	**001**	Apr 02, 2014
AB			**10MG**	**A091464**	**002**	Apr 02, 2014

VESICARE

AB		ASTELLAS	**5MG**	**N021518**	**001**	Nov 19, 2004
AB	**+**		**10MG**	**N021518**	**002**	Nov 19, 2004

SOMATROPIN RECOMBINANT
INJECTABLE;INJECTION
GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995

GENOTROPIN PRESERVATIVE FREE

BX		PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280	004	Aug 24, 1995

HUMATROPE

BX	+	LILLY	5MG/VIAL	N019640	004	Mar 08, 1987
BX			6MG/VIAL	N019640	005	Feb 04, 1999

NORDITROPIN FLEXPRO

BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010
BX			10MG/1.5ML	N021148	009	Mar 01, 2010

OMNITROPE

BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006
BX			5MG/1.5ML	N021426	003	Jan 16, 2008
BX			5.8MG/VIAL	N021426	001	May 30, 2006
BX			10MG/1.5ML	N021426	004	Aug 25, 2008

SAIZEN

BX		EMD SERONO	5MG/VIAL	N019764	002	Oct 08, 1996

SEROSTIM

BX		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997
BX			5MG/VIAL	N020604	002	Aug 23, 1996
BX			6MG/VIAL	N020604	001	Aug 23, 1996

VALTROPIN

BX		LG LIFE	5MG/VIAL	N021905	001	Apr 19, 2007

ZOMACTON

BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002
BX			10MG/VIAL	N019774	003	Mar 07, 2012

GENOTROPIN

	+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280	007	Oct 23, 1996

GENOTROPIN PRESERVATIVE FREE

		PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998
			0.4MG/VIAL	N020280	002	Jan 27, 1998
			0.6MG/VIAL	N020280	003	Jan 27, 1998
			0.8MG/VIAL	N020280	005	Jan 27, 1998
			1MG/VIAL	N020280	008	Jan 27, 1998
			1.2MG/VIAL	N020280	009	Jan 27, 1998
			1.4MG/VIAL	N020280	010	Jan 27, 1998
			1.6MG/VIAL	N020280	011	Jan 27, 1998
			1.8MG/VIAL	N020280	012	Jan 27, 1998

SOMATROPIN RECOMBINANT
INJECTABLE;INJECTION

GENOTROPIN PRESERVATIVE FREE					
+		2MG/VIAL	N020280	013	Jan 27, 1998
HUMATROPE					
+	LILLY	12MG/VIAL	N019640	006	Feb 04, 1999
+		24MG/VIAL	N019640	007	Feb 04, 1999
NORDITROPIN FLEXPRO					
	NOVO NORDISK INC	15MG/1.5ML	N021148	010	Mar 01, 2010
		30MG/3ML	N021148	011	Jan 23, 2015
NUTROPIN AQ NUSPIN					
+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008
+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008
NUTROPIN AQ PEN					
+	GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002
+		20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008
SAIZEN					
+	EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
ZORBTIVE					
+	EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003

SONIDEGIB PHOSPHATE
CAPSULE;ORAL

ODOMZO					
+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015

SORAFENIB TOSYLATE
TABLET;ORAL

NEXAVAR					
+	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005

SORBITOL
SOLUTION;IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	3GM/100ML	N017863	001
SORBITOL 3.3% IN PLASTIC CONTAINER				
	B BRAUN	3.3GM/100ML	N016741	001

SOTALOL HYDROCHLORIDE
SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE					
+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009

SOLUTION;ORAL

SOTYLIZE					
+	ARBOR PHARMS LLC	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014

TABLET;ORAL

	BETAPACE					
AB1		COVIS PHARMA SARL	**80MG**	**N019865**	**001**	Oct 30, 1992
AB1			**120MG**	**N019865**	**005**	Apr 20, 1994
AB1	**+**		**160MG**	**N019865**	**002**	Oct 30, 1992
AB1			**240MG**	**N019865**	**003**	Oct 30, 1992
	SORINE					
AB1		UPSHER SMITH	**80MG**	**A075500**	**001**	Apr 27, 2001
AB1			**120MG**	**A075500**	**004**	Apr 27, 2001
AB1			**160MG**	**A075500**	**002**	Apr 27, 2001
AB1			**240MG**	**A075500**	**003**	Apr 27, 2001
	SOTALOL HYDROCHLORIDE					
AB1		APOTEX INC	**80MG**	**A076140**	**001**	Sep 26, 2002
AB1			**120MG**	**A076140**	**002**	Sep 26, 2002
AB1			**160MG**	**A076140**	**003**	Sep 26, 2002
AB1			**240MG**	**A076140**	**004**	Sep 26, 2002
AB1		BEXIMCO PHARMS USA	**80MG**	**A207428**	**001**	Oct 21, 2016
AB1			**120MG**	**A207428**	**002**	Oct 21, 2016
AB1			**160MG**	**A207428**	**003**	Oct 21, 2016
AB1		MYLAN	**80MG**	**A075237**	**001**	May 01, 2000
AB1			**80MG**	**A075725**	**001**	Dec 19, 2000
AB1			**120MG**	**A075237**	**002**	May 01, 2000
AB1			**120MG**	**A075725**	**002**	Dec 19, 2000
AB1			**160MG**	**A075237**	**003**	May 01, 2000
AB1			**160MG**	**A075725**	**003**	Dec 19, 2000
AB1			**240MG**	**A075237**	**004**	May 01, 2000
AB1			**240MG**	**A075725**	**004**	Dec 19, 2000
AB1		TEVA	**80MG**	**A075429**	**001**	May 01, 2000

FDA data supplied by DrugPatentWatch.com

SOTALOL HYDROCHLORIDE
TABLET;ORAL

	SOTALOL HYDROCHLORIDE				
AB1		**120MG**	**A075429**	**002**	May 01, 2000
AB1		**160MG**	**A075429**	**003**	May 01, 2000
AB1		**240MG**	**A075429**	**004**	May 01, 2000
AB1	UPSHER-SMITH LABS	**80MG**	**A075366**	**001**	May 01, 2000
AB1		**120MG**	**A075366**	**002**	May 01, 2000
AB1		**160MG**	**A075366**	**003**	May 01, 2000
AB1		**240MG**	**A075366**	**004**	May 01, 2000
AB1	VINTAGE PHARMS	**80MG**	**A075563**	**001**	Nov 07, 2003
AB1		**120MG**	**A075563**	**002**	Nov 07, 2003
AB1		**160MG**	**A075563**	**003**	Nov 07, 2003
AB1		**240MG**	**A075563**	**004**	Nov 07, 2003
	BETAPACE AF				
AB2	COVIS PHARMA SARL	**80MG**	**N021151**	**001**	Feb 22, 2000
AB2		**120MG**	**N021151**	**002**	Feb 22, 2000
AB2	+	**160MG**	**N021151**	**003**	Feb 22, 2000
	SOTALOL HYDROCHLORIDE				
AB2	APOTEX	**80MG**	**A076214**	**001**	Aug 27, 2003
AB2		**120MG**	**A076214**	**002**	Aug 27, 2003
AB2		**160MG**	**A076214**	**003**	Aug 27, 2003
AB2	EPIC PHARMA INC	**80MG**	**A077070**	**001**	Nov 04, 2005
AB2		**120MG**	**A077070**	**002**	Nov 04, 2005
AB2		**160MG**	**A077070**	**003**	Nov 04, 2005
AB2	MYLAN	**80MG**	**A077616**	**001**	Feb 07, 2007
AB2		**120MG**	**A077616**	**002**	Feb 07, 2007
AB2		**160MG**	**A077616**	**003**	Feb 07, 2007
AB2	TEVA	**80MG**	**A076883**	**001**	Jul 26, 2004
AB2		**120MG**	**A076883**	**002**	Jul 26, 2004
AB2		**160MG**	**A076883**	**003**	Jul 26, 2004

SOYBEAN OIL
INJECTABLE;INJECTION

	INTRALIPID 10%				
AP	+ FRESENIUS	**10%**	**N017643**	**001**	
	INTRALIPID 20%				
AP	+ FRESENIUS	**20%**	**N018449**	**001**	
AP	+	**20%**	**N020248**	**001**	Aug 07, 1996
	INTRALIPID 30%				
AP	+ FRESENIUS	**30%**	**N019942**	**001**	Dec 30, 1993
	NUTRILIPID 10%				
AP	+ B BRAUN	**10%**	**N019531**	**001**	May 28, 1993
	NUTRILIPID 20%				
AP	+ B BRAUN	**20%**	**N019531**	**002**	May 28, 1993

SPINOSAD
SUSPENSION;TOPICAL

	NATROBA				
	+ PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011

SPIRONOLACTONE
TABLET;ORAL

	ALDACTONE				
AB	GD SEARLE LLC	**25MG**	**N012151**	**009**	Dec 30, 1983
AB		**50MG**	**N012151**	**008**	Dec 30, 1982
AB	+	**100MG**	**N012151**	**010**	Dec 30, 1983
	SPIRONOLACTONE				
AB	ACCORD HLTHCARE INC	**25MG**	**A203512**	**001**	Sep 19, 2016
AB		**50MG**	**A203512**	**002**	Sep 19, 2016
AB		**100MG**	**A203512**	**003**	Sep 19, 2016
AB	ACTAVIS ELIZABETH	**25MG**	**A040353**	**003**	Mar 15, 2006
AB		**50MG**	**A040353**	**001**	Jul 29, 1999
AB		**100MG**	**A040353**	**002**	Jul 29, 1999
AB	AMNEAL PHARMS	**25MG**	**A091426**	**001**	Jun 08, 2010
AB		**50MG**	**A091426**	**002**	Jun 08, 2010
AB		**100MG**	**A091426**	**003**	Jun 08, 2010
AB	JUBILANT GENERICS	**25MG**	**A203253**	**001**	Apr 23, 2014
AB		**50MG**	**A203253**	**002**	Apr 23, 2014
AB		**100MG**	**A203253**	**003**	Apr 23, 2014
AB	MYLAN	**25MG**	**A040424**	**001**	Aug 20, 2001
AB		**50MG**	**A040424**	**002**	Aug 20, 2001
AB		**100MG**	**A040424**	**003**	Aug 20, 2001
AB	ORION CORP ORION	**25MG**	**A202187**	**001**	Mar 06, 2014

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE
TABLET;ORAL

	SPIRONOLACTONE					
AB			**50MG**	**A202187**	**002**	Mar 06, 2014
AB			**100MG**	**A202187**	**003**	Mar 06, 2014
AB		SANDOZ	**25MG**	**A086809**	**001**	
AB		SUN PHARM INDS	**25MG**	**A089424**	**001**	Jul 23, 1986
AB			**50MG**	**A089424**	**002**	Aug 11, 1999
AB			**100MG**	**A089424**	**003**	Aug 11, 1999
AB		VINTAGE	**25MG**	**A040750**	**001**	Aug 29, 2006
AB			**50MG**	**A040750**	**002**	Aug 29, 2006
AB			**100MG**	**A040750**	**003**	Aug 29, 2006

STAVUDINE
CAPSULE;ORAL

	STAVUDINE					
AB		AUROBINDO PHARMA	**15MG**	**A077672**	**003**	Dec 29, 2008
AB			**20MG**	**A077672**	**004**	Dec 29, 2008
AB			**30MG**	**A077672**	**001**	Dec 29, 2008
AB			**40MG**	**A077672**	**002**	Dec 29, 2008
AB		HETERO LABS LTD III	**15MG**	**A078957**	**001**	Dec 29, 2008
AB			**20MG**	**A078957**	**002**	Dec 29, 2008
AB			**30MG**	**A078957**	**003**	Dec 29, 2008
AB			**40MG**	**A078957**	**004**	Dec 29, 2008
AB		MATRIX LABS LTD	**30MG**	**A078775**	**001**	Jan 05, 2009
AB			**40MG**	**A078775**	**002**	Jan 05, 2009
AB		MYLAN	**15MG**	**A079069**	**001**	Dec 29, 2008
AB			**20MG**	**A079069**	**002**	Dec 29, 2008
AB			**30MG**	**A079069**	**003**	Dec 29, 2008
AB			**40MG**	**A079069**	**004**	Dec 29, 2008
	ZERIT					
AB		BRISTOL MYERS SQUIBB	**15MG**	**N020412**	**002**	Jun 24, 1994
AB			**20MG**	**N020412**	**003**	Jun 24, 1994
AB			**30MG**	**N020412**	**004**	Jun 24, 1994
AB	+		**40MG**	**N020412**	**005**	Jun 24, 1994

FOR SOLUTION;ORAL

	STAVUDINE					
AA		AUROBINDO PHARMA	**1MG/ML**	**A077774**	**001**	Dec 29, 2008
AA		CIPLA LTD	**1MG/ML**	**A078030**	**001**	Mar 20, 2009
	ZERIT					
AA	+	BRISTOL MYERS SQUIBB	**1MG/ML**	**N020413**	**001**	Sep 06, 1996

STERILE WATER FOR INJECTION
LIQUID;N/A

	BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER					
AP	+	HOSPIRA	**100%**	**N018802**	**001**	Oct 27, 1982
	STERILE WATER FOR INJECTION					
AP		EUROHLTH INTL SARL	**100%**	**A206369**	**001**	Sep 02, 2015
	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER					
AP	+	B BRAUN	**100%**	**N019633**	**001**	Feb 29, 1988
AP	+	BAXTER HLTHCARE	**100%**	**N018632**	**001**	Jun 30, 1982
AP	+		**100%**	**N018632**	**002**	Apr 19, 1988
AP		FRESENIUS KABI USA	**100%**	**A088400**	**001**	Jan 16, 1984
AP	+	HOSPIRA	**100%**	**N018233**	**001**	
AP	+		**100%**	**N018801**	**001**	Oct 27, 1982
AP	+		**100%**	**N019869**	**001**	Dec 26, 1989
AP		TARO PHARMS IRELAND	**100%**	**A077393**	**001**	Aug 11, 2006

STERILE WATER FOR IRRIGATION
LIQUID;IRRIGATION

	STERILE WATER				
AT		BAXTER HLTHCARE	**100%**	**N017428**	**001**
	STERILE WATER IN PLASTIC CONTAINER				
AT		B BRAUN	**100%**	**N016734**	**001**
AT		BAXTER HLTHCARE	**100%**	**N017866**	**001**
AT		HOSPIRA	**100%**	**N017513**	**001**
AT			**100%**	**N018313**	**001**

STREPTOMYCIN SULFATE
INJECTABLE;INJECTION
STREPTOMYCIN SULFATE

	+	X GEN PHARMS	EQ 1GM BASE/VIAL	A064210	001 Jun 30, 1998

STREPTOZOCIN
INJECTABLE;INJECTION
ZANOSAR

	+	TEVA PHARMS USA	1GM/VIAL	N050577	001 May 07, 1982

STRONTIUM CHLORIDE SR-89
INJECTABLE;INJECTION

		METASTRON			
AP	+	GE HEALTHCARE	**1mCi/ML**	**N020134**	**001** Jun 18, 1993
		STRONTIUM CHLORIDE SR-89			
AP		BIO NUCLEONICS	**1mCi/ML**	**A075941**	**001** Jan 06, 2003

SUCCIMER
CAPSULE;ORAL
CHEMET

	+	RECORDATI RARE	100MG	N019998	002 Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE
INJECTABLE;INJECTION

		ANECTINE			
AP	+	SANDOZ	**20MG/ML**	**N008453**	**002**
		QUELICIN			
AP	+	HOSPIRA	**20MG/ML**	**N008845**	**006**
		QUELICIN PRESERVATIVE FREE			
AP	+	HOSPIRA	**20MG/ML**	**N008845**	**001**

SUCRALFATE
SUSPENSION;ORAL
CARAFATE

	+	FOREST LABS INC	1GM/10ML	N019183	001 Dec 16, 1993

TABLET;ORAL

		CARAFATE			
AB	+	FOREST LABS INC	**1GM**	**N018333**	**001**
		SUCRALFATE			
AB		MYLAN IRELAND LTD	**1GM**	**A074415**	**001** Jun 08, 1998
AB		TEVA	**1GM**	**A070848**	**001** Mar 29, 1996

SUCROFERRIC OXYHYDROXIDE
TABLET, CHEWABLE;ORAL
VELPHORO

	+	VIFOR FRESENIUS	500MG	N205109	001 Nov 27, 2013

SUFENTANIL CITRATE
INJECTABLE;INJECTION

		SUFENTA PRESERVATIVE FREE			
AP	+	AKORN	**EQ 0.05MG BASE/ML**	**N019050**	**001** May 04, 1984
		SUFENTANIL CITRATE			
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A074534**	**001** Dec 11, 1996
AP		WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**A074413**	**001** Dec 15, 1995

SUGAMMADEX SODIUM
SOLUTION;INTRAVENOUS
BRIDION

		ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002 Dec 15, 2015
	+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001 Dec 15, 2015

SULCONAZOLE NITRATE
CREAM;TOPICAL
EXELDERM

	+	RANBAXY	1%	N018737	001 Feb 28, 1989

SOLUTION;TOPICAL
EXELDERM

	+	SUN PHARM INDS LTD	1%	N018738	001 Aug 30, 1985

SULFACETAMIDE SODIUM
LOTION;TOPICAL

		KLARON			
AB	+	VALEANT PHARMS NORTH	**10%**	**N019931**	**001** Dec 23, 1996
		SULFACETAMIDE SODIUM			
AB		FOUGERA PHARMS	**10%**	**A077015**	**001** Nov 17, 2006
AB		PERRIGO CO TENNESSEE	**10%**	**A078649**	**001** Mar 23, 2009
AB		TARO	**10%**	**A078668**	**001** May 20, 2009

FDA data supplied by DrugPatentWatch.com

SULFACETAMIDE SODIUM

	OINTMENT;OPHTHALMIC				
	SULFACETAMIDE SODIUM				
	+ PERRIGO CO TENNESSEE	10%	A080029	001	
	SOLUTION/DROPS;OPHTHALMIC				
	BLEPH-10				
AT	**+** ALLERGAN	**10%**	**A080028**	**001**	
	SULFACETAMIDE SODIUM				
AT	AKORN	**10%**	**A040215**	**001**	May 25, 1999
AT	ALCON PHARMS LTD	**10%**	**A089560**	**001**	Oct 18, 1988
AT	BAUSCH AND LOMB	**10%**	**A040066**	**001**	Dec 28, 1994

SULFADIAZINE

	TABLET;ORAL				
	SULFADIAZINE				
	+ SANDOZ	500MG	A040091	001	Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

	INJECTABLE;INJECTION				
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				
	+ TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991
	SUSPENSION;ORAL				
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				
AB	AUROBINDO PHARMA	**200MG/5ML;40MG/5ML**	**A091348**	**001**	Jun 08, 2010
AB	**+** HI TECH PHARMA	**200MG/5ML;40MG/5ML**	**A074650**	**001**	Dec 29, 1997
AB	VINTAGE	**200MG/5ML;40MG/5ML**	**A077785**	**001**	Jan 24, 2007
	SULFATRIM PEDIATRIC				
AB	STI PHARMA LLC	**200MG/5ML;40MG/5ML**	**N018615**	**001**	Jan 07, 1983
	TABLET;ORAL				
	BACTRIM				
AB	SUN PHARM INDS	**400MG;80MG**	**N017377**	**001**	
	BACTRIM DS				
AB	**+** SUN PHARM INDS	**800MG;160MG**	**N017377**	**002**	
	SEPTRA				
AB	MONARCH PHARMS	**400MG;80MG**	**N017376**	**001**	
	SEPTRA DS				
AB	MONARCH PHARMS	**800MG;160MG**	**N017376**	**002**	
	SULFAMETHOXAZOLE AND TRIMETHOPRIM				
AB	AMNEAL PHARMS NY	**400MG;80MG**	**A076899**	**001**	Jan 27, 2005
AB		**800MG;160MG**	**A076899**	**002**	Jan 27, 2005
AB	AUROBINDO PHARMA	**400MG;80MG**	**A090624**	**001**	Feb 16, 2010
AB		**800MG;160MG**	**A090624**	**002**	Feb 16, 2010
AB	GLENMARK GENERICS	**400MG;80MG**	**A090828**	**002**	Dec 22, 2010
AB		**800MG;160MG**	**A090828**	**001**	Dec 22, 2010
AB	SUN PHARM INDS	**800MG;160MG**	**A071017**	**001**	Aug 25, 1986
AB	VINTAGE	**400MG;80MG**	**A078060**	**002**	Jan 25, 2007
AB		**800MG;160MG**	**A078060**	**001**	Jan 25, 2007
AB	VISTA PHARMS	**400MG;80MG**	**A076817**	**001**	Oct 07, 2005
AB		**800MG;160MG**	**A076817**	**002**	Oct 07, 2005
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH				
AB	TEVA	**800MG;160MG**	**A070037**	**001**	Jun 02, 1987
	SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH				
AB	TEVA PHARMS	**400MG;80MG**	**A070030**	**001**	Jun 02, 1987

SULFANILAMIDE

	CREAM;VAGINAL				
	AVC				
	+ MEDA PHARMS	15%	N006530	003	Jan 27, 1987

SULFASALAZINE

	SUSPENSION;ORAL				
	AZULFIDINE				
	+ PHARMACIA AND UPJOHN	250MG/5ML	A086983	001	
	TABLET;ORAL				
	AZULFIDINE				
AB	**+** PHARMACIA AND UPJOHN	**500MG**	**N007073**	**001**	
	SULFASALAZINE				
AB	VINTAGE PHARMS	**500MG**	**A040349**	**001**	Jan 11, 2002
AB	WATSON LABS	**500MG**	**A085828**	**001**	
	TABLET, DELAYED RELEASE;ORAL				
	AZULFIDINE EN-TABS				
AB	**+** PHARMACIA AND UPJOHN	**500MG**	**N007073**	**002**	Apr 06, 1983
	SULFASALAZINE				
AB	VINTAGE PHARMS	**500MG**	**A075339**	**001**	Jan 11, 2002

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
FOR SUSPENSION;INTRAVENOUS
LUMASON

	+	BRACCO	60.7MG/25MG	N203684	001 Oct 15, 2014

SULINDAC
TABLET;ORAL
SULINDAC

AB		EPIC PHARMA	150MG	A072710	001 Mar 25, 1991
AB			200MG	A072711	001 Mar 25, 1991
AB		HERITAGE PHARMS INC	150MG	A073262	002 Sep 06, 1991
AB			200MG	A073262	001 Sep 06, 1991
AB		MYLAN	150MG	A073039	002 Jun 22, 1993
AB			200MG	A073039	001 Jun 22, 1993
AB		SUN PHARM INDS	150MG	A072050	001 Apr 17, 1991
AB			200MG	A072051	001 Apr 17, 1991
AB		WATSON LABS	150MG	A071891	001 Apr 03, 1990
AB	+		200MG	A071795	001 Apr 03, 1990

SUMATRIPTAN
SPRAY;NASAL
IMITREX

AB	+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001 Aug 26, 1997
AB	+		20MG/SPRAY	N020626	003 Aug 26, 1997

SUMATRIPTAN

AB		LANNETT	5MG/SPRAY	A204841	001 Feb 19, 2016
AB			20MG/SPRAY	A204841	002 Feb 19, 2016

SUMATRIPTAN SUCCINATE
INJECTABLE;SUBCUTANEOUS
IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002 Feb 01, 2006
AB	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003 Dec 23, 1996

SUMATRIPTAN SUCCINATE

AB		ANTARES PHARMA INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078319	001 Dec 10, 2015
AB			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078319	002 Dec 10, 2015
AB		DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090495	001 Jan 29, 2014
AB		SUN PHARMA GLOBAL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001 Jun 21, 2011

IMITREX

AP	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	001 Dec 28, 1992

SUMATRIPTAN SUCCINATE

AP		AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001 Apr 23, 2013
AP		EUROHLTH INTL SARL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001 Feb 06, 2009
AP		FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079242	001 Mar 02, 2009
AP		HIKMA FARMACEUTICA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A200183	001 Sep 16, 2013
AP		INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001 Aug 11, 2010
AP		MYLAN LABS LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001 Apr 14, 2014
AP		PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001 Oct 09, 2009
AP		PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001 Jul 09, 2009
AP		SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001 Jul 28, 2010
AP		SAGENT STRIDES	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001 Jun 10, 2010
AP		TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001 Feb 06, 2009
AP		WOCKHARDT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078593	001 Feb 06, 2009

SUMAVEL DOSEPRO

BX	+	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002 Nov 26, 2013
BX	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001 Jul 15, 2009

POWDER;INHALATION
ONZETRA XSAIL

	+	AVANIR PHARMS	EQ 11MG BASE	N206099	001 Jan 27, 2016

SOLUTION;SUBCUTANEOUS
ZEMBRACE SYMTOUCH

		DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001 Jan 28, 2016

SYSTEM;IONTOPHORESIS
ZECUITY

	+	TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001 Jan 17, 2013

TABLET;ORAL
IMITREX

AB		GLAXOSMITHKLINE	EQ 25MG BASE	N020132	002 Jun 01, 1995
AB			EQ 50MG BASE	N020132	003 Jun 01, 1995
AB	+		EQ 100MG BASE	N020132	001 Jun 01, 1995

SUMATRIPTAN SUCCINATE

AB		APOTEX INC	EQ 25MG BASE	A200263	001 Jun 19, 2012
AB			EQ 50MG BASE	A200263	002 Jun 19, 2012
AB			EQ 100MG BASE	A200263	003 Jun 19, 2012

FDA data supplied by DrugPatentWatch.com

SUMATRIPTAN SUCCINATE
TABLET;ORAL
SUMATRIPTAN SUCCINATE

AB	AUROBINDO PHARMA	**EQ 25MG BASE**	**A078327**	**001**	Aug 10, 2009
AB		**EQ 50MG BASE**	**A078327**	**002**	Aug 10, 2009
AB		**EQ 100MG BASE**	**A078327**	**003**	Aug 10, 2009
AB	DR REDDYS LABS INC	**EQ 25MG BASE**	**A076847**	**001**	Aug 10, 2009
AB		**EQ 50MG BASE**	**A076847**	**002**	Aug 10, 2009
AB		**EQ 100MG BASE**	**A076847**	**003**	Aug 10, 2009
AB	MYLAN	**EQ 25MG BASE**	**A077744**	**001**	Aug 10, 2009
AB		**EQ 50MG BASE**	**A077744**	**002**	Aug 10, 2009
AB		**EQ 100MG BASE**	**A077744**	**003**	Aug 10, 2009
AB	ORCHID HLTHCARE	**EQ 25MG BASE**	**A078284**	**001**	Aug 10, 2009
AB		**EQ 50MG BASE**	**A078284**	**002**	Aug 10, 2009
AB		**EQ 100MG BASE**	**A078284**	**003**	Aug 10, 2009
AB	SUN PHARM INDS	**EQ 25MG BASE**	**A078295**	**001**	Aug 10, 2009
AB		**EQ 50MG BASE**	**A078295**	**002**	Aug 10, 2009
AB		**EQ 100MG BASE**	**A078295**	**003**	Aug 10, 2009
AB	SUN PHARM INDS LTD	**EQ 25MG BASE**	**A076554**	**001**	Aug 10, 2009
AB		**EQ 50MG BASE**	**A076554**	**002**	Aug 10, 2009
AB		**EQ 100MG BASE**	**A076572**	**001**	Feb 09, 2009
AB	WATSON LABS	**EQ 25MG BASE**	**A076933**	**001**	Aug 10, 2009
AB		**EQ 50MG BASE**	**A076933**	**002**	Aug 10, 2009
AB		**EQ 100MG BASE**	**A076933**	**003**	Aug 10, 2009

SUNITINIB MALATE
CAPSULE;ORAL
SUTENT

AB	CPPI CV	**EQ 12.5MG BASE**	**N021938**	**001**	Jan 26, 2006
AB		**EQ 25MG BASE**	**N021938**	**002**	Jan 26, 2006
AB		**EQ 37.5MG BASE**	**N021938**	**004**	Mar 31, 2009
AB +		**EQ 50MG BASE**	**N021938**	**003**	Jan 26, 2006

SUVOREXANT
TABLET;ORAL
BELSOMRA

	MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014
		10MG	N204569	002	Aug 13, 2014
		15MG	N204569	003	Aug 13, 2014
+		20MG	N204569	004	Aug 13, 2014

TACROLIMUS
CAPSULE;ORAL
PROGRAF

AB	ASTELLAS	**EQ 0.5MG BASE**	**N050708**	**003**	Aug 24, 1998
AB		**EQ 1MG BASE**	**N050708**	**001**	Apr 08, 1994
AB +		**EQ 5MG BASE**	**N050708**	**002**	Apr 08, 1994

TACROLIMUS

AB	ACCORD HLTHCARE	**EQ 0.5MG BASE**	**A091195**	**001**	Aug 31, 2011
AB		**EQ 1MG BASE**	**A091195**	**002**	Aug 31, 2011
AB		**EQ 5MG BASE**	**A091195**	**003**	Aug 31, 2011
AB	DR REDDYS LABS LTD	**EQ 0.5MG BASE**	**A090509**	**001**	May 12, 2010
AB		**EQ 1MG BASE**	**A090509**	**002**	May 12, 2010
AB		**EQ 5MG BASE**	**A090509**	**003**	May 12, 2010
AB	MYLAN	**EQ 0.5MG BASE**	**A090596**	**001**	Sep 17, 2010
AB		**EQ 1MG BASE**	**A090596**	**002**	Sep 17, 2010
AB		**EQ 5MG BASE**	**A090596**	**003**	Sep 17, 2010
AB	PANACEA BIOTEC LTD	**EQ 0.5MG BASE**	**A090802**	**001**	Sep 28, 2012
AB		**EQ 1MG BASE**	**A090802**	**002**	Sep 28, 2012
AB		**EQ 5MG BASE**	**A090802**	**003**	Sep 28, 2012
AB	SANDOZ	**EQ 0.5MG BASE**	**A065461**	**001**	Aug 10, 2009
AB		**EQ 1MG BASE**	**A065461**	**002**	Aug 10, 2009
AB		**EQ 5MG BASE**	**A065461**	**003**	Aug 10, 2009
AB	STRIDES PHARMA	**EQ 0.5MG BASE**	**A090687**	**001**	Jul 22, 2014
AB		**EQ 1MG BASE**	**A090687**	**002**	Jul 22, 2014
AB		**EQ 5MG BASE**	**A090687**	**003**	Jul 22, 2014

CAPSULE, EXTENDED RELEASE;ORAL
ASTAGRAF XL

	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013
		EQ 1MG BASE	N204096	002	Jul 19, 2013
+		EQ 5MG BASE	N204096	003	Jul 19, 2013

TACROLIMUS						
INJECTABLE;INJECTION						
PROGRAF						
	+	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994
OINTMENT;TOPICAL						
PROTOPIC						
AB	**+**	LEO PHARMA AS	**0.03%**	**N050777**	**001**	Dec 08, 2000
AB	**+**		**0.1%**	**N050777**	**002**	Dec 08, 2000
TACROLIMUS						
AB		FOUGERA PHARMS INC	**0.03%**	**A200744**	**001**	Sep 09, 2014
AB			**0.1%**	**A200744**	**002**	Sep 09, 2014
TABLET, EXTENDED RELEASE;ORAL						
ENVARSUS XR						
		VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015
			EQ 1MG BASE	N206406	002	Jul 10, 2015
	+		EQ 4MG BASE	N206406	003	Jul 10, 2015
TADALAFIL						
TABLET;ORAL						
ADCIRCA						
	+	ELI LILLY CO	20MG	N022332	001	May 22, 2009
CIALIS						
		LILLY	2.5MG	N021368	004	Jan 07, 2008
			5MG	N021368	001	Nov 21, 2003
			10MG	N021368	002	Nov 21, 2003
	+		20MG	N021368	003	Nov 21, 2003
TAFLUPROST						
SOLUTION/DROPS;OPHTHALMIC						
ZIOPTAN						
	+	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012
TALC						
AEROSOL, METERED;INTRAPLEURAL						
SCLEROSOL						
	+	LYMOL MEDCL	400MG/SPRAY	N020587	001	Dec 24, 1997
POWDER;INTRAPLEURAL						
TALC						
	+	LYMOL MEDCL	5GM/BOT	N021388	001	Dec 15, 2003
TALIGLUCERASE ALFA						
POWDER;IV (INFUSION)						
ELELYSO						
	+	PFIZER	200 UNITS/VIAL	N022458	001	May 01, 2012
TAMOXIFEN CITRATE						
SOLUTION;ORAL						
SOLTAMOX						
		MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005
TABLET;ORAL						
TAMOXIFEN CITRATE						
AB		ACTAVIS LABS FL INC	**EQ 10MG BASE**	**A070929**	**001**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A070929**	**002**	Feb 20, 2003
AB		APOTEX	**EQ 10MG BASE**	**A090878**	**001**	Sep 23, 2011
AB			**EQ 20MG BASE**	**A090878**	**002**	Sep 23, 2011
AB		MAYNE PHARMA	**EQ 10MG BASE**	**A075797**	**001**	Feb 20, 2003
AB	**+**		**EQ 20MG BASE**	**A074858**	**001**	Feb 20, 2003
AB		MYLAN	**EQ 10MG BASE**	**A074732**	**002**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A074732**	**001**	Feb 20, 2003
TAMSULOSIN HYDROCHLORIDE						
CAPSULE;ORAL						
FLOMAX						
AB	**+**	BOEHRINGER INGELHEIM	**0.4MG**	**N020579**	**001**	Apr 15, 1997
TAMSULOSIN HYDROCHLORIDE						
AB		ANCHEN PHARMS	**0.4MG**	**A202010**	**001**	Jan 04, 2013
AB		AUROBINDO PHARMA LTD	**0.4MG**	**A202433**	**001**	Apr 30, 2013
AB		IMPAX LABS	**0.4MG**	**A090377**	**001**	Mar 02, 2010
AB		MYLAN	**0.4MG**	**A090408**	**001**	Apr 27, 2010
AB		SANDOZ	**0.4MG**	**A078015**	**001**	Apr 27, 2010
AB		SUN PHARM INDS LTD	**0.4MG**	**A090931**	**001**	Jul 15, 2010
AB		SYNTHON PHARMS	**0.4MG**	**A078801**	**001**	Apr 27, 2010
AB		TEVA PHARMS	**0.4MG**	**A077630**	**001**	Apr 27, 2010
AB		WOCKHARDT	**0.4MG**	**A078938**	**001**	Apr 27, 2010
AB		ZYDUS PHARMS USA INC	**0.4MG**	**A078225**	**001**	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE
SOLUTION;ORAL
NUCYNTA
+ DEPOMED INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012
TABLET;ORAL
NUCYNTA
DEPOMED INC EQ 50MG BASE N022304 001 Nov 20, 2008
EQ 75MG BASE N022304 002 Nov 20, 2008
+ EQ 100MG BASE N022304 003 Nov 20, 2008
TABLET, EXTENDED RELEASE;ORAL
NUCYNTA ER
DEPOMED INC EQ 50MG BASE N200533 001 Aug 25, 2011
EQ 100MG BASE N200533 002 Aug 25, 2011
EQ 150MG BASE N200533 003 Aug 25, 2011
EQ 200MG BASE N200533 004 Aug 25, 2011
+ EQ 250MG BASE N200533 005 Aug 25, 2011

TASIMELTEON
CAPSULE;ORAL
HETLIOZ
+ VANDA PHARMS INC 20MG N205677 001 Jan 31, 2014

TAVABOROLE
SOLUTION;TOPICAL
KERYDIN
+ ANACOR PHARMS INC 5% N204427 001 Jul 07, 2014

TAZAROTENE
AEROSOL, FOAM;TOPICAL
FABIOR
+ STIEFEL LABS INC 0.1% N202428 001 May 11, 2012
CREAM;TOPICAL
AVAGE
+ ALLERGAN 0.1% N021184 003 Sep 30, 2002
TAZORAC
+ ALLERGAN 0.05% N021184 001 Sep 29, 2000
+ 0.1% N021184 002 Sep 29, 2000
GEL;TOPICAL
TAZORAC
+ ALLERGAN 0.05% N020600 001 Jun 13, 1997
+ 0.1% N020600 002 Jun 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
INJECTABLE;INJECTION
PULMOLITE
BS JUBILANT DRAXIMAGE N/A N017776 001
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
BS DRAXIMAGE N/A N017881 001 Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT
INJECTABLE;INJECTION
NEUROLITE
LANTHEUS MEDCL N/A N020256 001 Nov 23, 1994

TECHNETIUM TC-99M DISOFENIN KIT
INJECTABLE;INJECTION
HEPATOLITE
PHARMALUCENCE N/A N018467 001 Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT
INJECTABLE;INJECTION
CERETEC
+ GE HEALTHCARE N/A N019829 001 Dec 30, 1988

TECHNETIUM TC-99M MEBROFENIN KIT
INJECTABLE;INJECTION
CHOLETEC
AP **+** BRACCO **N/A** **N018963** **001** Jan 21, 1987
TECHNETIUM TC-99M MEBROFENIN
AP PHARMALUCENCE **N/A** **A078242** **001** Jan 29, 2008

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-25
+ JUBILANT DRAXIMAGE N/A N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
CIS-MDP
AP PHARMALUCENCE **N/A** **N018124 001**
MDP-BRACCO
AP BRACCO **N/A** **N018107 001**

TECHNETIUM TC-99M MERTIATIDE KIT
INJECTABLE;INJECTION
TECHNESCAN MAG3
+ MALLINKRODT NUCLEAR N/A N019882 001 Jun 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT
INJECTABLE;INJECTION
TECHNESCAN
+ MALLINKRODT NUCLEAR N/A N018321 001

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
AN-DTPA
AP JUBILANT DRAXIMAGE **N/A** **N017714 001**
DTPA
AP DRAXIMAGE **N/A** **N018511 001** Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
CIS-PYRO
AP PHARMALUCENCE **N/A** **N019039 001** Jun 30, 1987
TECHNESCAN PYP KIT
AP MALLINKRODT NUCLEAR **N/A** **N017538 001**

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
ULTRATAG
MALLINKRODT NUCLEAR N/A N019981 001 Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
CARDIOLITE
AP **+** LANTHEUS MEDCL **N/A** **N019785 001** Dec 21, 1990
TECHNETIUM TC 99M SESTAMIBI
AP CARDINAL HEALTH 414 **N/A** **A078809 001** Apr 28, 2009
AP DRAXIMAGE **N/A** **A078806 001** Apr 29, 2009
AP PHARMALUCENCE **10-30mCi** **A079157 001** Jul 10, 2009
TECHNETIUM TC-99M SESTAMIBI
AP MALLINKRODT NUCLEAR **N/A** **A078098 001** Sep 22, 2008

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INTRAVENOUS
TECHNELITE
+ LANTHEUS MEDCL 1-20 CI/GENERATOR N017771 002 Feb 12, 2014
ULTRA-TECHNEKOW FM
+ MALLINKRODT NUCLEAR 1-19 CI/GENERATOR N017243 003 Feb 18, 2014
SOLUTION;INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR
+ GE HEALTHCARE 68-2703mCi/GENERATOR N017693 002 Dec 13, 2013

TECHNETIUM TC-99M SULFUR COLLOID KIT
SOLUTION;INJECTION, ORAL
AN-SULFUR COLLOID
+ PHARMALUCENCE N/A N017858 001

TECHNETIUM TC-99M TETROFOSMIN KIT
INJECTABLE;INJECTION
MYOVIEW
+ GE HEALTHCARE N/A N020372 001 Feb 09, 1996
MYOVIEW 30ML
+ GE HEALTHCARE N/A N020372 002 Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT
INJECTABLE;INJECTION
LYMPHOSEEK KIT

+	NAVIDEA BIOPHARMS	N/A	N202207	001	Mar 13, 2013

TEDIZOLID PHOSPHATE
POWDER;IV (INFUSION)
SIVEXTRO

+	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014

TABLET;ORAL
SIVEXTRO

+	CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014

TEDUGLUTIDE RECOMBINANT
POWDER;SUBCUTANEOUS
GATTEX KIT

+	NPS PHARMS INC	5MG/VIAL	N203441	001	Dec 21, 2012

TELAVANCIN HYDROCHLORIDE
POWDER;IV (INFUSION)
VIBATIV

	THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009
+		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009

TELBIVUDINE
TABLET;ORAL
TYZEKA

+	NOVARTIS	600MG	N022011	001	Oct 25, 2006

TELMISARTAN
TABLET;ORAL

	MICARDIS				
AB	BOEHRINGER INGELHEIM	**20MG**	**N020850**	**003**	Apr 04, 2000
AB		**40MG**	**N020850**	**001**	Nov 10, 1998
AB	**+**	**80MG**	**N020850**	**002**	Nov 10, 1998
	TELMISARTAN				
AB	ALEMBIC PHARMS LTD	**20MG**	**A202130**	**001**	Jul 07, 2014
AB		**40MG**	**A202130**	**002**	Jul 07, 2014
AB		**80MG**	**A202130**	**003**	Jul 07, 2014
AB	AMNEAL PHARMS	**20MG**	**A204415**	**001**	Sep 08, 2015
AB		**40MG**	**A204415**	**002**	Sep 08, 2015
AB		**80MG**	**A204415**	**003**	Sep 08, 2015
AB	AUROBINDO PHARMA LTD	**20MG**	**A206511**	**001**	Sep 03, 2015
AB		**40MG**	**A206511**	**002**	Sep 03, 2015
AB		**80MG**	**A206511**	**003**	Sep 03, 2015
AB	GLENMARK GENERICS	**20MG**	**A090032**	**001**	Jul 07, 2014
AB		**40MG**	**A090032**	**002**	Jul 07, 2014
AB		**80MG**	**A090032**	**003**	Jul 07, 2014
AB	HETERO LABS LTD V	**20MG**	**A205901**	**001**	Apr 22, 2016
AB		**40MG**	**A205901**	**002**	Apr 22, 2016
AB		**80MG**	**A205901**	**003**	Apr 22, 2016
AB	INVENTIA HLTHCARE	**20MG**	**A205150**	**001**	Oct 30, 2015
AB		**40MG**	**A205150**	**002**	Oct 30, 2015
AB		**80MG**	**A205150**	**003**	Oct 30, 2015
AB	JUBILANT GENERICS	**20MG**	**A204164**	**001**	Aug 22, 2016
AB		**40MG**	**A204164**	**002**	Aug 22, 2016
AB		**80MG**	**A204164**	**003**	Aug 22, 2016
AB	MYLAN PHARMS INC	**20MG**	**A202397**	**001**	Jul 07, 2014
AB		**40MG**	**A202397**	**002**	Jul 07, 2014
AB		**80MG**	**A202397**	**003**	Jul 07, 2014
AB	SANDOZ INC	**20MG**	**A203867**	**001**	Nov 03, 2014
AB		**40MG**	**A203867**	**002**	Nov 03, 2014
AB		**80MG**	**A203867**	**003**	Nov 03, 2014
AB	TORRENT PHARMS LTD	**20MG**	**A203171**	**001**	Jul 07, 2014
AB		**40MG**	**A203171**	**002**	Jul 07, 2014
AB		**80MG**	**A203171**	**003**	Jul 07, 2014
AB	WATSON LABS	**20MG**	**A078710**	**001**	Jan 08, 2014
AB		**40MG**	**A078710**	**002**	Jan 08, 2014
AB		**80MG**	**A078710**	**003**	Jan 08, 2014
AB	ZYDUS PHARMS USA INC	**20MG**	**A203325**	**001**	Aug 26, 2014
AB		**40MG**	**A203325**	**002**	Aug 26, 2014
AB		**80MG**	**A203325**	**003**	Aug 26, 2014

FDA data supplied by DrugPatentWatch.com

TEMAZEPAM

CAPSULE;ORAL

RESTORIL					
AB	MALLINCKRODT INC	7.5MG	N018163	003	Oct 25, 1991
AB		15MG	N018163	001	
AB		22.5MG	N018163	004	Nov 02, 2004
AB +		30MG	N018163	002	
TEMAZEPAM					
AB	ACTAVIS ELIZABETH	15MG	A071638	001	Aug 07, 1987
AB		30MG	A071620	001	Aug 07, 1987
AB	AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016
AB		15MG	A203482	002	May 23, 2016
AB		22.5MG	A203482	003	May 23, 2016
AB		30MG	A203482	004	May 23, 2016
AB	MYLAN	7.5MG	A070920	002	May 21, 2010
AB		15MG	A070920	004	Jul 07, 1986
AB		22.5MG	A070920	003	Jun 12, 2009
AB		30MG	A070920	001	Jul 10, 1986
AB	NOVEL LABS INC	7.5MG	A071457	002	Jun 22, 2012
AB		15MG	A071456	001	Apr 21, 1987
AB		22.5MG	A071457	003	Jun 22, 2012
AB		30MG	A071457	001	Apr 21, 1987
AB	SANDOZ	15MG	A071427	001	Jan 12, 1988
AB		30MG	A071428	001	Jan 12, 1988
AB	SUN PHARM INDS	7.5MG	A078581	001	Sep 08, 2009
AB		22.5MG	A071175	002	Sep 14, 2009
AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015
AB		15MG	A201781	002	Jun 04, 2015
AB		22.5MG	A201781	003	Jun 04, 2015
AB		30MG	A201781	004	Jun 04, 2015

TEMOZOLOMIDE

CAPSULE;ORAL

TEMODAR					
AB	MERCK SHARP DOHME	5MG	N021029	001	Aug 11, 1999
AB		20MG	N021029	002	Aug 11, 1999
AB		100MG	N021029	003	Aug 11, 1999
AB		140MG	N021029	005	Oct 19, 2006
AB		180MG	N021029	006	Oct 19, 2006
AB +		250MG	N021029	004	Aug 11, 1999
TEMOZOLOMIDE					
AB	AMERIGEN PHARMS LTD	5MG	A203490	001	Jul 13, 2016
AB		20MG	A203490	002	Jul 13, 2016
AB		100MG	A203490	003	Jul 13, 2016
AB		140MG	A203490	004	Jul 13, 2016
AB		180MG	A203490	005	Jul 13, 2016
AB		250MG	A203490	006	Jul 13, 2016
AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015
AB		20MG	A203691	002	May 08, 2015
AB		100MG	A203691	003	May 08, 2015
AB		140MG	A203691	004	May 08, 2015
AB		180MG	A203691	005	May 08, 2015
AB		250MG	A203691	006	May 08, 2015
AB	BARR	5MG	A078879	001	Mar 01, 2010
AB		20MG	A078879	002	Mar 01, 2010
AB		100MG	A078879	003	Mar 01, 2010
AB		140MG	A078879	005	Mar 01, 2010
AB		180MG	A078879	006	Mar 01, 2010
AB		250MG	A078879	004	Mar 01, 2010
AB	CHEMI SPA	5MG	A204639	001	Nov 23, 2016
AB		20MG	A204639	002	Nov 23, 2016
AB		100MG	A204639	003	Nov 23, 2016
AB		140MG	A204639	004	Nov 23, 2016
AB		180MG	A204639	005	Nov 23, 2016
AB		250MG	A204639	006	Nov 23, 2016
AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016
AB		20MG	A206413	002	Apr 12, 2016
AB		100MG	A206413	003	Apr 12, 2016
AB		140MG	A206413	004	Apr 12, 2016
AB		180MG	A206413	005	Apr 12, 2016
AB		250MG	A206413	006	Apr 12, 2016
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016
AB		20MG	A203898	002	Feb 10, 2016

TEMOZOLOMIDE
CAPSULE;ORAL
TEMOZOLOMIDE

AB		**100MG**	**A203898**	**003**	Feb 10, 2016
AB		**140MG**	**A203898**	**004**	Feb 10, 2016
AB		**180MG**	**A203898**	**005**	Feb 10, 2016
AB		**250MG**	**A203898**	**006**	Feb 10, 2016
AB	MYLAN PHARMS INC	**5MG**	**A205227**	**001**	Jun 29, 2016
AB		**20MG**	**A205227**	**002**	Jun 29, 2016
AB		**100MG**	**A205227**	**003**	Jun 29, 2016
AB		**140MG**	**A205227**	**004**	Jun 29, 2016
AB		**180MG**	**A205227**	**005**	Jun 29, 2016
AB		**250MG**	**A205227**	**006**	Jun 29, 2016
AB	RISING PHARMS INC	**5MG**	**A206309**	**001**	Apr 27, 2016
AB		**20MG**	**A206309**	**002**	Apr 27, 2016
AB		**100MG**	**A206309**	**003**	Apr 27, 2016
AB		**140MG**	**A206309**	**004**	Apr 27, 2016
AB		**180MG**	**A206309**	**005**	Apr 27, 2016
AB		**250MG**	**A206309**	**006**	Apr 27, 2016
AB	SUN PHARMA GLOBAL	**5MG**	**A201742**	**001**	Feb 12, 2014
AB		**20MG**	**A201742**	**002**	Feb 12, 2014
AB		**100MG**	**A201742**	**003**	Feb 12, 2014
AB		**140MG**	**A201742**	**004**	Feb 12, 2014
AB		**180MG**	**A201742**	**005**	Feb 12, 2014
AB		**250MG**	**A201742**	**006**	Feb 12, 2014

POWDER;INTRAVENOUS
TEMODAR

+	MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009

TEMSIROLIMUS
SOLUTION;INTRAVENOUS
TORISEL

+	PF PRISM CV	25MG/ML (25MG/ML)	N022088	001	May 30, 2007

TENIPOSIDE
INJECTABLE;INJECTION
VUMON

+	HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992

TENOFOVIR ALAFENAMIDE FUMARATE
TABLET;ORAL
VEMLIDY

+	GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE
POWDER;ORAL
VIREAD

+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012

TABLET;ORAL
TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	**300MG**	**A091612**	**001**	Mar 18, 2015

VIREAD

AB	**+** GILEAD SCIENCES INC	**300MG**	**N021356**	**001**	Oct 26, 2001
		150MG	N021356	002	Jan 18, 2012
		200MG	N021356	003	Jan 18, 2012
		250MG	N021356	004	Jan 18, 2012

TERAZOSIN HYDROCHLORIDE
CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE

AB	APOTEX	**EQ 1MG BASE**	**A075498**	**001**	Apr 12, 2001
AB		**EQ 2MG BASE**	**A075498**	**002**	Apr 12, 2001
AB		**EQ 5MG BASE**	**A075498**	**003**	Apr 12, 2001
AB		**EQ 10MG BASE**	**A075498**	**004**	Apr 12, 2001
AB	IVAX SUB TEVA PHARMS	**EQ 1MG BASE**	**A075614**	**002**	Jan 30, 2001
AB		**EQ 2MG BASE**	**A075614**	**001**	Jan 30, 2001
AB		**EQ 5MG BASE**	**A075614**	**003**	Jan 30, 2001
AB		**EQ 10MG BASE**	**A075614**	**004**	Jan 30, 2001
AB	JUBILANT CADISTA	**EQ 1MG BASE**	**A075317**	**001**	Dec 20, 2004
AB		**EQ 2MG BASE**	**A075317**	**002**	Dec 20, 2004
AB		**EQ 5MG BASE**	**A075317**	**003**	Dec 20, 2004
AB		**EQ 10MG BASE**	**A075317**	**004**	Dec 20, 2004
AB	MYLAN	**EQ 1MG BASE**	**A075140**	**002**	Feb 11, 2000
AB		**EQ 2MG BASE**	**A075140**	**003**	Feb 11, 2000
AB		**EQ 5MG BASE**	**A075140**	**001**	Feb 11, 2000

TERAZOSIN HYDROCHLORIDE
CAPSULE;ORAL
TERAZOSIN HYDROCHLORIDE

AB			**EQ 10MG BASE**	**A075140**	**004** Feb 11, 2000
AB		SANDOZ	**EQ 1MG BASE**	**A074823**	**001** Mar 30, 1998
AB	**+**		**EQ 2MG BASE**	**A074823**	**002** Mar 30, 1998
AB			**EQ 5MG BASE**	**A074823**	**003** Mar 30, 1998
AB			**EQ 10MG BASE**	**A074823**	**004** Mar 30, 1998

TERBINAFINE HYDROCHLORIDE
GRANULE;ORAL
LAMISIL

		NOVARTIS	EQ 125MG BASE/PACKET	N022071	001 Sep 28, 2007
	+		EQ 187.5MG BASE/PACKET	N022071	002 Sep 28, 2007

TABLET;ORAL
LAMISIL

AB	**+**	NOVARTIS	**EQ 250MG BASE**	**N020539**	**001** May 10, 1996

TERBINAFINE HYDROCHLORIDE

AB		APOTEX	**EQ 250MG BASE**	**A078199**	**001** Jul 02, 2007
AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A078297**	**001** Jul 02, 2007
AB		BRECKENRIDGE PHARM	**EQ 250MG BASE**	**A077714**	**001** Jun 04, 2010
AB		CIPLA LTD	**EQ 250MG BASE**	**A077137**	**001** Jul 02, 2007
AB		DR REDDYS LABS INC	**EQ 250MG BASE**	**A076390**	**001** Jul 02, 2007
AB		GLENMARK GENERICS	**EQ 250MG BASE**	**A078157**	**001** Jul 02, 2007
AB		HARRIS PHARM	**EQ 250MG BASE**	**A077919**	**001** Jul 02, 2007
AB		INVAGEN PHARMS	**EQ 250MG BASE**	**A077533**	**001** Jul 02, 2007
AB		MYLAN	**EQ 250MG BASE**	**A077195**	**001** Jul 02, 2007
AB		ORCHID HLTHCARE	**EQ 250MG BASE**	**A078163**	**001** Jul 02, 2007
AB		TEVA	**EQ 250MG BASE**	**A076377**	**001** Jul 02, 2007

TERBUTALINE SULFATE
INJECTABLE;INJECTION
TERBUTALINE SULFATE

AP		AKORN	**1MG/ML**	**A078151**	**001** Jan 07, 2008
AP	**+**	AMPHASTAR PHARMS INC	**1MG/ML**	**A076770**	**001** Apr 23, 2004
AP		FRESENIUS KABI USA	**1MG/ML**	**A076887**	**001** May 26, 2004
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078630**	**001** May 20, 2009
AP		UNITED BIOMEDCL	**1MG/ML**	**A200122**	**001** Nov 08, 2013

TABLET;ORAL
TERBUTALINE SULFATE

		LANNETT	2.5MG	A077152	001 Mar 25, 2005
			5MG	A077152	002 Mar 25, 2005

TERCONAZOLE
CREAM;VAGINAL
TERAZOL 3

AB	**+**	JANSSEN PHARMS	**0.8%**	**N019964**	**001** Feb 21, 1991

TERAZOL 7

AB	**+**	JANSSEN PHARMS	**0.4%**	**N019579**	**001** Dec 31, 1987

TERCONAZOLE

AB		FOUGERA PHARMS	**0.4%**	**A076712**	**001** Feb 18, 2005
AB		TARO	**0.4%**	**A076043**	**001** Jan 19, 2005
AB			**0.8%**	**A075953**	**001** Apr 06, 2004
BX	+	NYCOMED US	0.8%	N021735	001 Oct 01, 2004

SUPPOSITORY;VAGINAL
TERAZOL 3

AB	**+**	JANSSEN PHARMS	**80MG**	**N019641**	**001** May 24, 1988

TERCONAZOLE

AB		PERRIGO NEW YORK	**80MG**	**A077149**	**001** Mar 17, 2006
AB		TARO	**80MG**	**A077553**	**001** Mar 09, 2007

TERIFLUNOMIDE
TABLET;ORAL
AUBAGIO

		SANOFI AVENTIS US	7MG	N202992	001 Sep 12, 2012
	+		14MG	N202992	002 Sep 12, 2012

TERIPARATIDE RECOMBINANT HUMAN
INJECTABLE;SUBCUTANEOUS
FORTEO

	+	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002 Jun 25, 2008

FDA data supplied by DrugPatentWatch.com

TESAMORELIN ACETATE
POWDER;SUBCUTANEOUS
EGRIFTA

	+	THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001 Nov 10, 2010

TESTOSTERONE
FILM, EXTENDED RELEASE;TRANSDERMAL
ANDRODERM

	+	ALLERGAN SALES LLC	2MG/24HR	N020489	003 Oct 20, 2011
	+		4MG/24HR	N020489	004 Oct 20, 2011

GEL;TRANSDERMAL
ANDROGEL

AB1		ABBVIE	**25MG/2.5GM PACKET**	**N021015**	**001** Feb 28, 2000
AB1	**+**		**50MG/5GM PACKET**	**N021015**	**002** Feb 28, 2000

TESTOSTERONE

AB1		ACTAVIS LABS UT INC	**25MG/2.5GM PACKET**	**A076737**	**001** Jan 27, 2006
AB1			**50MG/5GM PACKET**	**A076737**	**002** Jan 27, 2006
AB1		PAR PHARM	**25MG/2.5GM PACKET**	**A076744**	**001** May 23, 2007
AB1			**50MG/5GM PACKET**	**A076744**	**002** May 23, 2007
AB1		PERRIGO ISRAEL	**25MG/2.5GM PACKET**	**N203098**	**002** Jan 31, 2013
AB1			**50MG/5GM PACKET**	**N203098**	**003** Jan 31, 2013

TESTIM

AB2	**+**	AUXILIUM PHARMS	**50MG/5GM PACKET**	**N021454**	**001** Oct 31, 2002

VOGELXO

AB2		UPSHER-SMITH LABS	**50MG/5GM PACKET**	**N204399**	**002** Jun 04, 2014

TESTOSTERONE

BX		ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001 Feb 14, 2012
BX			50MG/5GM PACKET	N202763	002 Feb 14, 2012

ANDROGEL

		ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002 Sep 07, 2012
	+		1.62% (40.5MG/2.5GM PACKET)	N022309	003 Sep 07, 2012

GEL, METERED;NASAL
NATESTO

		AYTU BIOSCIENCE INC	5.5MG/0.122GM ACTUATION	N205488	001 May 28, 2014

GEL, METERED;TRANSDERMAL
ANDROGEL

AB	**+**	ABBVIE	**1.62% (20.25MG/1.25GM ACTUATION)**	**N022309**	**001** Apr 29, 2011
AB	**+**		**12.5MG/1.25GM ACTUATION**	**N021015**	**003** Sep 26, 2003

FORTESTA

AB	**+**	ENDO PHARMS	**10MG/0.5GM ACTUATION**	**N021463**	**001** Dec 29, 2010

TESTOSTERONE

AB		ACTAVIS LABS UT INC	**10MG/0.5GM ACTUATION**	**A204571**	**001** Aug 05, 2015
AB			**12.5MG/1.25GM ACTUATION**	**A076737**	**003** Mar 09, 2015
AB		PERRIGO ISRAEL	**12.5MG/1.25GM ACTUATION**	**N203098**	**001** Jan 31, 2013
AB			**1.62% (20.25MG/1.25GM ACTUATION)**	**A204268**	**001** Aug 04, 2015

VOGELXO

BX		UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003 Jun 04, 2014

PELLET;IMPLANTATION
TESTOPEL

	+	AUXILIUM PHARMS INC	75MG	A080911	001

SOLUTION, METERED;TRANSDERMAL
AXIRON

	+	ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001 Nov 23, 2010

TABLET, EXTENDED RELEASE;BUCCAL
STRIANT

	+	AUXILIUM PHARMS INC	30MG	N021543	001 Jun 19, 2003

TESTOSTERONE CYPIONATE
INJECTABLE;INJECTION
DEPO-TESTOSTERONE

AO	**+**	PHARMACIA AND UPJOHN	**100MG/ML**	**A085635**	**002**
AO	**+**		**200MG/ML**	**A085635**	**003**

TESTOSTERONE CYPIONATE

AO		EUROHLTH INTL SARL	**100MG/ML**	**A090387**	**001** Jul 15, 2010
AO			**200MG/ML**	**A090387**	**002** Jul 15, 2010
AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091244**	**001** May 01, 2012
AO		MYLAN INSTITUTIONAL	**200MG/ML**	**A040652**	**001** Dec 11, 2006
AO		PADDOCK LLC	**200MG/ML**	**A040530**	**001** Jan 31, 2005
AO		SANDOZ	**100MG/ML**	**A040615**	**001** Aug 10, 2006
AO			**200MG/ML**	**A040615**	**002** Aug 10, 2006
AO		SUN PHARM INDS LTD	**100MG/ML**	**A201720**	**001** Jun 03, 2013
AO			**200MG/ML**	**A201720**	**002** Jun 03, 2013
AO		WATSON LABS	**200MG/ML**	**A086030**	**001**

FDA data supplied by DrugPatentWatch.com

TESTOSTERONE ENANTHATE
INJECTABLE;INJECTION

	DELATESTRYL				
AO	+ ENDO PHARMS	**200MG/ML**	**N009165**	**003**	
	TESTOSTERONE ENANTHATE				
AO	HIKMA FARMACEUTICA	**200MG/ML**	**A091120**	**001**	Sep 18, 2012
AO	MYLAN INSTITUTIONAL	**200MG/ML**	**A040647**	**001**	Oct 05, 2009
AO	PADDOCK LLC	**200MG/ML**	**A040575**	**001**	Jun 14, 2006
AO	WATSON LABS	**200MG/ML**	**A085598**	**001**	

TESTOSTERONE UNDECANOATE
INJECTABLE;INTRAMUSCULAR

	AVEED				
	+ ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014

TETRABENAZINE
TABLET;ORAL

	TETRABENAZINE				
AB	HETERO LABS LTD V	**12.5MG**	**A204574**	**001**	Feb 03, 2016
AB		**25MG**	**A204574**	**002**	Feb 03, 2016
AB	SUN PHARMA GLOBAL	**12.5MG**	**A206129**	**001**	Aug 17, 2015
AB		**25MG**	**A206129**	**002**	Aug 17, 2015
	XENAZINE				
AB	VALEANT PHARMS NORTH	**12.5MG**	**N021894**	**001**	Aug 15, 2008
AB	+	**25MG**	**N021894**	**002**	Aug 15, 2008

TETRACAINE HYDROCHLORIDE
SOLUTION;OPHTHALMIC

	TETRACAINE HYDROCHLORIDE				
	+ NOVARTIS PHARMS CORP	0.5%	N208135	001	Feb 29, 2016

TETRACYCLINE HYDROCHLORIDE
CAPSULE;ORAL

	ACHROMYCIN V				
AB	HERITAGE PHARMS INC	**250MG**	**N050278**	**003**	
AB	+	**500MG**	**N050278**	**001**	
	TETRACYCLINE HYDROCHLORIDE				
AB	CHARTWELL CIENCA	**250MG**	**A062752**	**001**	Aug 12, 1988
AB		**500MG**	**A062752**	**002**	Aug 12, 1988
AB	IMPAX LABS	**250MG**	**A060469**	**001**	
AB		**500MG**	**A060469**	**003**	
AB	WATSON LABS	**250MG**	**A061837**	**001**	
AB		**500MG**	**A061837**	**002**	
	IMPAX LABS	100MG	A060469	002	

TETRAHYDROZOLINE HYDROCHLORIDE
SOLUTION;NASAL

	TYZINE				
	+ FOUGERA PHARMS	0.05%	A086576	002	
		0.1%	A086576	001	

SPRAY;NASAL

	TYZINE				
	+ FOUGERA PHARMS	0.1%	A086576	003	

THALIDOMIDE
CAPSULE;ORAL

	THALOMID				
	CELGENE	50MG	N020785	001	Jul 16, 1998
		100MG	N020785	002	Jan 17, 2003
		150MG	N020785	004	Jan 10, 2007
	+	200MG	N020785	003	Jan 17, 2003

THALLOUS CHLORIDE TL-201
INJECTABLE;INJECTION

	THALLOUS CHLORIDE TL 201				
AP	+ GE HEALTHCARE	**1mCi/ML**	**N018110**	**002**	Feb 27, 1996
AP	+ LANTHEUS MEDCL	**1mCi/ML**	**N017806**	**001**	
AP	+ MALLINKRODT NUCLEAR	**1mCi/ML**	**N018150**	**001**	

INJECTABLE;INTRAVENOUS

	THALLOUS CHLORIDE TL 201				
AP	+ LANTHEUS MEDCL	**2mCi/ML**	**N017806**	**002**	Oct 09, 1998

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

THEO-24

		ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983
	+	AUXILIUM PHARMS INC	400MG	A081034	001	Feb 28, 1992
		AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983
			300MG	A087944	001	Aug 22, 1983

INJECTABLE;INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	**40MG/100ML**	**N019826**	**001**	Aug 14, 1992

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	**80MG/100ML**	**N019826**	**002**	Aug 14, 1992

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	**160MG/100ML**	**N019826**	**003**	Aug 14, 1992

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	**320MG/100ML**	**N019826**	**006**	Aug 14, 1992

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA INC	**4MG/ML**	**N019211**	**007**	Dec 14, 1984
AP	+		**40MG/100ML**	**N019211**	**001**	Dec 14, 1984
AP	+		**160MG/100ML**	**N019211**	**003**	Dec 14, 1984
AP	+		**320MG/100ML**	**N019211**	**006**	Jan 20, 1988

SOLUTION;ORAL

THEOPHYLLINE

AA	+	SILARX	**80MG/15ML**	**A091156**	**001**	Apr 13, 2011
AA		TRIS PHARMA INC	**80MG/15ML**	**A091586**	**001**	Jun 15, 2012

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

AA	+	NOSTRUM LABS INC	**80MG/15ML**	**A085186**	**001**	

THEOPHYLLINE

AA		PHARM ASSOC	**80MG/15ML**	**A206344**	**001**	Dec 16, 2016

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

AB		NOSTRUM LABS INC	**100MG**	**A088320**	**001**	Feb 21, 1985
AB			**200MG**	**A088321**	**001**	Feb 21, 1985

THEOPHYLLINE

AB		ALEMBIC LTD	**300MG**	**A090430**	**001**	Oct 27, 2010
AB			**450MG**	**A090430**	**002**	Oct 27, 2010
AB		GLENMARK GENERICS	**400MG**	**A090355**	**001**	Jul 13, 2010
AB			**600MG**	**A090355**	**002**	Jul 13, 2010
AB		MYLAN IRELAND LTD	**400MG**	**A040560**	**003**	Apr 21, 2006
AB	+		**600MG**	**A040560**	**002**	Apr 21, 2006
AB	+	PLIVA	**100MG**	**A089807**	**001**	Apr 30, 1990
AB	+		**200MG**	**A089808**	**001**	Apr 30, 1990
AB			**300MG**	**A089763**	**001**	Apr 30, 1990
AB		RHODES PHARMS	**400MG**	**A087571**	**001**	Sep 01, 1982
AB			**600MG**	**A040086**	**001**	Apr 15, 1996

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	**100MG/ML**	**A080556**	**001**	
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091623**	**001**	Jun 25, 2012

THIOGUANINE

TABLET;ORAL

THIOGUANINE

	+	ASPEN GLOBAL INC	40MG	N012429	001	

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

AB		MYLAN	**10MG**	**A088004**	**002**	Mar 15, 1983
AB			**25MG**	**A088004**	**003**	Mar 15, 1983
AB			**50MG**	**A088004**	**004**	Mar 15, 1983
AB	+		**100MG**	**A088004**	**001**	Nov 18, 1983
AB		SUN PHARM INDS	**10MG**	**A089953**	**004**	Aug 01, 1986
AB			**25MG**	**A089953**	**003**	Aug 01, 1986
AB			**50MG**	**A089953**	**002**	Aug 01, 1986
AB			**100MG**	**A089953**	**001**	Oct 07, 1988

FDA data supplied by DrugPatentWatch.com

THIOTEPA
INJECTABLE;INJECTION
THIOTEPA

	+	WEST-WARD PHARMS INT	15MG/VIAL	A075547	001 Apr 02, 2001

THIOTHIXENE
CAPSULE;ORAL
THIOTHIXENE

		MYLAN	1MG	A071093	002 Jun 23, 1987
			2MG	A071093	003 Jun 23, 1987
	+		5MG	A071093	004 Jun 23, 1987
			10MG	A071093	001 Jun 23, 1987

THYROTROPIN ALFA
INJECTABLE;INJECTION
THYROGEN

	+	GENZYME	1.1MG/VIAL	N020898	001 Nov 30, 1998

TIAGABINE HYDROCHLORIDE
TABLET;ORAL
GABITRIL

AB		CEPHALON	**2MG**	**N020646**	**005** Apr 16, 1999
AB	**+**		**4MG**	**N020646**	**001** Sep 30, 1997

TIAGABINE HYDROCHLORIDE

AB		SUN PHARM INDS	**2MG**	**A077555**	**001** Nov 04, 2011
AB			**4MG**	**A077555**	**002** Nov 04, 2011

GABITRIL

		CEPHALON	12MG	N020646	002 Sep 30, 1997
			16MG	N020646	003 Sep 30, 1997

TICAGRELOR
TABLET;ORAL
BRILINTA

		ASTRAZENECA LP	60MG	N022433	002 Sep 03, 2015
	+		90MG	N022433	001 Jul 20, 2011

TICLOPIDINE HYDROCHLORIDE
TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

AB		APOTEX	**250MG**	**A075089**	**001** Jul 01, 1999
AB		SUN PHARM INDS INC	**250MG**	**A075526**	**001** Sep 26, 2002
AB	**+**	TEVA	**250MG**	**A075149**	**001** Aug 20, 1999

TIGECYCLINE
INJECTABLE;IV (INFUSION)
TIGECYCLINE

AP		SANDOZ INC	**50MG/VIAL**	**A091620**	**001** May 27, 2015

TYGACIL

AP	**+**	PF PRISM CV	**50MG/VIAL**	**N021821**	**001** Jun 15, 2005

POWDER;IV (INFUSION)
TIGECYCLINE

AP		FRESENIUS KABI USA	**50MG/VIAL**	**N205645**	**001** Dec 01, 2016

TIMOLOL
SOLUTION/DROPS;OPHTHALMIC
BETIMOL

AT	**+**	OAK PHARMS INC	**EQ 0.25% BASE**	**N020439**	**001** Mar 31, 1995
AT	**+**		**EQ 0.5% BASE**	**N020439**	**002** Mar 31, 1995

TIMOLOL

AT		AKORN	**EQ 0.25% BASE**	**A205309**	**001** Sep 30, 2016
AT			**EQ 0.5% BASE**	**A205309**	**002** Sep 30, 2016

TIMOLOL MALEATE
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AB		ALCON RES LTD	**EQ 0.25% BASE**	**N020963**	**001** Oct 21, 1998
AB			**EQ 0.5% BASE**	**N020963**	**002** Oct 21, 1998

TIMOPTIC-XE

AB	**+**	VALEANT PHARMS LLC	**EQ 0.25% BASE**	**N020330**	**001** Nov 04, 1993
AB	**+**		**EQ 0.5% BASE**	**N020330**	**002** Nov 04, 1993

SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AT		ALCON RES LTD	**EQ 0.25% BASE**	**A074261**	**001** Apr 28, 1995
AT		BAUSCH AND LOMB	**EQ 0.25% BASE**	**A074778**	**001** Mar 25, 1997
AT		FDC LTD	**EQ 0.25% BASE**	**A077259**	**001** Apr 30, 2008
AT		PACIFIC PHARMA	**EQ 0.25% BASE**	**A074746**	**001** Mar 25, 1997

TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC

	TIMOLOL MALEATE				
AT	WOCKHARDT	**EQ 0.25% BASE**	**A078771**	**001**	Sep 28, 2009
	TIMOPTIC				
AT	+ ATON	**EQ 0.25% BASE**	**N018086**	**001**	
	TIMOLOL MALEATE				
AT1	AKORN	**EQ 0.5% BASE**	**A074466**	**001**	Mar 25, 1997
AT1		**EQ 0.5% BASE**	**A074516**	**001**	Mar 25, 1997
AT1	ALCON RES LTD	**EQ 0.5% BASE**	**A074262**	**001**	Apr 28, 1995
AT1	BAUSCH AND LOMB	**EQ 0.5% BASE**	**A074776**	**001**	Mar 25, 1997
AT1	FDC LTD	**EQ 0.5% BASE**	**A077259**	**002**	Apr 30, 2008
AT1	HI TECH PHARMA	**EQ 0.5% BASE**	**A075163**	**001**	Sep 10, 2002
AT1	PACIFIC PHARMA	**EQ 0.5% BASE**	**A074747**	**001**	Mar 25, 1997
AT1	WOCKHARDT	**EQ 0.5% BASE**	**A078771**	**002**	Sep 28, 2009
	TIMOPTIC				
AT1	+ ATON	**EQ 0.5% BASE**	**N018086**	**002**	
	ISTALOL				
AT2	+ BAUSCH AND LOMB	**EQ 0.5% BASE**	**N021516**	**001**	Jun 04, 2004
	TIMOLOL MALEATE				
AT2	APOTEX INC	**EQ 0.5% BASE**	**A204936**	**001**	Apr 17, 2015
	TIMOPTIC IN OCUDOSE				
	+ ATON	EQ 0.25% BASE	N019463	001	Nov 05, 1986
	+	EQ 0.5% BASE	N019463	002	Nov 05, 1986

TABLET;ORAL

	TIMOLOL MALEATE				
	MYLAN	5MG	A072668	002	Jun 08, 1990
		10MG	A072668	003	Jun 08, 1990
	+	20MG	A072668	001	Jun 08, 1990

TINIDAZOLE
TABLET;ORAL

	TINDAMAX				
AB	MISSION PHARMA	**250MG**	**N021618**	**001**	May 17, 2004
AB	+	**500MG**	**N021618**	**002**	May 17, 2004
	TINIDAZOLE				
AB	EDENBRIDGE PHARMS	**250MG**	**A203808**	**001**	Aug 04, 2015
AB		**500MG**	**A203808**	**002**	Aug 04, 2015
AB	NOVEL LABS INC	**250MG**	**A202044**	**001**	Apr 30, 2012
AB		**500MG**	**A202044**	**002**	Apr 30, 2012
AB	WEST-WARD PHARMS INT	**250MG**	**A201172**	**001**	Apr 30, 2012
AB		**500MG**	**A201172**	**002**	Apr 30, 2012
BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013
BX		500MG	A202489	002	Oct 09, 2013

TIOPRONIN
TABLET;ORAL

	THIOLA				
	+ MISSION PHARMA	100MG	N019569	001	Aug 11, 1988

TIOTROPIUM BROMIDE
POWDER;INHALATION

	SPIRIVA				
	+ BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004

SPRAY, METERED;INHALATION

	SPIRIVA RESPIMAT				
	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015
	+	EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE
TABLET;ORAL

	LONSURF				
	TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015
	+	EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015

TIPRANAVIR
CAPSULE;ORAL

	APTIVUS				
	+ BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005

SOLUTION;ORAL

	APTIVUS				
	+ BOEHRINGER INGELHEIM	100MG/ML	N022292	001	Jun 23, 2008

FDA data supplied by DrugPatentWatch.com

TIROFIBAN HYDROCHLORIDE

INJECTABLE;INJECTION					
AGGRASTAT					
	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002
+		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000
SOLUTION;INJECTION					
AGGRASTAT					
+	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL					
TIZANIDINE HYDROCHLORIDE					
AB	APOTEX INC	**EQ 2MG BASE**	**A078868**	**001**	Feb 03, 2012
AB		**EQ 4MG BASE**	**A078868**	**002**	Feb 03, 2012
AB		**EQ 6MG BASE**	**A078868**	**003**	Feb 03, 2012
AB	MYLAN PHARMS INC	**EQ 2MG BASE**	**A091502**	**001**	Nov 09, 2012
AB		**EQ 4MG BASE**	**A091502**	**002**	Nov 09, 2012
AB		**EQ 6MG BASE**	**A091502**	**003**	Nov 09, 2012
ZANAFLEX					
AB	ACORDA	**EQ 2MG BASE**	**N021447**	**001**	Aug 29, 2002
AB		**EQ 4MG BASE**	**N021447**	**002**	Aug 29, 2002
AB	**+**	**EQ 6MG BASE**	**N021447**	**003**	Aug 29, 2002
TABLET;ORAL					
TIZANIDINE HYDROCHLORIDE					
AB	APOTEX	**EQ 2MG BASE**	**A076533**	**001**	Jan 16, 2004
AB		**EQ 4MG BASE**	**A076533**	**002**	Jan 16, 2004
AB	COREPHARMA	**EQ 2MG BASE**	**A076347**	**001**	Oct 11, 2002
AB		**EQ 4MG BASE**	**A076347**	**002**	Oct 11, 2002
AB	DR REDDYS LABS INC	**EQ 2MG BASE**	**A076286**	**001**	Jul 03, 2002
AB		**EQ 4MG BASE**	**A076286**	**002**	Jul 03, 2002
AB	MYLAN	**EQ 2MG BASE**	**A076354**	**001**	Mar 28, 2003
AB		**EQ 4MG BASE**	**A076354**	**002**	Mar 28, 2003
AB	OXFORD PHARMS	**EQ 2MG BASE**	**A076281**	**001**	Oct 20, 2003
AB		**EQ 4MG BASE**	**A076281**	**002**	Oct 20, 2003
AB	SANDOZ INC	**EQ 2MG BASE**	**A076280**	**001**	Nov 26, 2002
AB		**EQ 4MG BASE**	**A076280**	**002**	Jun 27, 2002
AB	SUN PHARM INDS INC	**EQ 2MG BASE**	**A076416**	**001**	Sep 29, 2003
AB		**EQ 4MG BASE**	**A076416**	**002**	Sep 29, 2003
AB	TEVA	**EQ 2MG BASE**	**A076284**	**001**	Jul 03, 2002
AB		**EQ 4MG BASE**	**A076284**	**002**	Jul 03, 2002
AB	UNICHEM LABS LTD	**EQ 2MG BASE**	**A091283**	**001**	Nov 28, 2012
AB		**EQ 4MG BASE**	**A091283**	**002**	Nov 28, 2012
ZANAFLEX					
AB	**+** ACORDA	**EQ 4MG BASE**	**N020397**	**001**	Nov 27, 1996

TOBRAMYCIN

OINTMENT;OPHTHALMIC					
TOBREX					
+	NOVARTIS PHARMS CORP	0.3%	N050555	001	
POWDER;INHALATION					
TOBI PODHALER					
+	NOVARTIS	28MG	N201688	001	Mar 22, 2013
SOLUTION;INHALATION					
KITABIS PAK					
AN	PULMOFLOW INC	**300MG/5ML**	**N205433**	**001**	Dec 02, 2014
TOBI					
AN	**+** NOVARTIS PHARMS	**300MG/5ML**	**N050753**	**001**	Dec 22, 1997
TOBRAMYCIN					
AN	AKORN INC	**300MG/5ML**	**A201422**	**001**	May 28, 2014
AN	AMNEAL PHARMS	**300MG/5ML**	**A205501**	**001**	Jul 13, 2015
AN	TEVA PHARMS USA	**300MG/5ML**	**A091589**	**001**	Oct 10, 2013
BETHKIS					
+	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012
SOLUTION/DROPS;OPHTHALMIC					
AKTOB					
AT	AKORN	**0.3%**	**A064096**	**001**	Jan 31, 1996
TOBRAMYCIN					
AT	BAUSCH AND LOMB	**0.3%**	**A064052**	**001**	Nov 29, 1993
AT	FERA PHARMS	**0.3%**	**A065026**	**001**	Sep 11, 2001
TOBREX					
AT	ALCON	**0.3%**	**A062535**	**001**	Dec 13, 1984
AT	**+** NOVARTIS PHARMS CORP	**0.3%**	**N050541**	**001**	

TOBRAMYCIN SULFATE
INJECTABLE;INJECTION
TOBRAMYCIN SULFATE

AP		AKORN	**EQ 40MG BASE/ML**	**A205179**	**001** Sep 16, 2014
AP		CLARIS	**EQ 40MG BASE/ML**	**A206965**	**001** Jul 01, 2016
AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A065122**	**001** Nov 29, 2002
AP	+		**EQ 40MG BASE/ML**	**A065122**	**002** Nov 29, 2002
AP			**EQ 1.2GM BASE/VIAL**	**N050789**	**001** Jul 13, 2004
AP	+	HOSPIRA	**EQ 10MG BASE/ML**	**A063112**	**001** Apr 30, 1991
AP			**EQ 40MG BASE/ML**	**A063111**	**001** Apr 30, 1991
AP		MYLAN LABS LTD	**EQ 40MG BASE/ML**	**A065407**	**001** Mar 11, 2008
AP		TEVA PHARMS USA	**EQ 40MG BASE/ML**	**A063100**	**001** Jan 30, 1992
AP		WEST-WARD PHARMS INT	**EQ 40MG BASE/ML**	**A063117**	**001** Apr 26, 1991
AP	+	X GEN PHARMS	**EQ 1.2GM BASE/VIAL**	**A065013**	**001** Aug 17, 2001
AP		XELLIA PHARMS APS	**EQ 1.2GM BASE/VIAL**	**A205685**	**001** Sep 16, 2014
		TOBRAMYCIN SULFATE (PHARMACY BULK)			
	+	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001 Nov 29, 2002
		TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	+	HOSPIRA	EQ 1.2MG BASE/ML	A063081	003 Jul 31, 1990
	+		EQ 1.6MG BASE/ML	A063081	006 Jun 02, 1993
	+		EQ 80MG BASE/100ML	A063081	001 Jul 31, 1990

TOFACITINIB CITRATE
TABLET;ORAL
XELJANZ

	+	PF PRISM CV	EQ 5MG BASE	N203214	001 Nov 06, 2012

TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR

	+	PFIZER INC	EQ 11MG BASE	N208246	001 Feb 23, 2016

TOLAZAMIDE
TABLET;ORAL
TOLAZAMIDE

		MYLAN PHARMS INC	250MG	A070259	001 Jan 02, 1986
	+		500MG	A070259	003 Mar 17, 1986

TOLBUTAMIDE
TABLET;ORAL
TOLBUTAMIDE

	+	MYLAN PHARMS INC	500MG	A086445	001

TOLCAPONE
TABLET;ORAL
TASMAR

AB	+	VALEANT PHARMS LLC	**100MG**	**N020697**	**001** Jan 29, 1998

TOLCAPONE

AB		PAR PHARM INC	**100MG**	**A204584**	**001** Mar 26, 2015

TOLMETIN SODIUM
CAPSULE;ORAL
TOLMETIN SODIUM

AB		MYLAN	**EQ 400MG BASE**	**A073393**	**001** May 27, 1993
AB	+	TEVA	**EQ 400MG BASE**	**A073290**	**001** Nov 27, 1991

TABLET;ORAL
TOLMETIN SODIUM

AB	+	MYLAN	**EQ 600MG BASE**	**A074473**	**001** Aug 30, 1994
AB		SUN PHARM INDS	**EQ 200MG BASE**	**A073310**	**001** Nov 27, 1991

TOLTERODINE TARTRATE
CAPSULE, EXTENDED RELEASE;ORAL
DETROL LA

AB		PHARMACIA AND UPJOHN	**2MG**	**N021228**	**001** Dec 22, 2000
AB	+		**4MG**	**N021228**	**002** Dec 22, 2000

TOLTERODINE TARTRATE

AB		MYLAN PHARMS INC	**2MG**	**A201486**	**001** Oct 31, 2013
AB			**4MG**	**A201486**	**002** Oct 31, 2013
AB		TEVA PHARMS USA	**2MG**	**A079141**	**001** Nov 22, 2016
AB			**4MG**	**A079141**	**002** Nov 22, 2016
AB		TORRENT PHARMS LTD	**2MG**	**A203016**	**001** Aug 11, 2015
AB			**4MG**	**A203016**	**002** Aug 11, 2015

TABLET;ORAL
DETROL

AB		PHARMACIA AND UPJOHN	**1MG**	**N020771**	**001** Mar 25, 1998
AB	+		**2MG**	**N020771**	**002** Mar 25, 1998

FDA data supplied by DrugPatentWatch.com

TOLTERODINE TARTRATE
TABLET;ORAL
TOLTERODINE TARTRATE

AB	APOTEX CORP	**1MG**	**A200164**	**001**	Sep 25, 2012
AB		**2MG**	**A200164**	**002**	Sep 25, 2012
AB	IVAX SUB TEVA PHARMS	**1MG**	**A077006**	**001**	Feb 23, 2015
AB		**2MG**	**A077006**	**002**	Feb 23, 2015
AB	MACLEODS PHARMS LTD	**1MG**	**A203409**	**001**	Aug 31, 2015
AB		**2MG**	**A203409**	**002**	Aug 31, 2015
AB	MYLAN PHARMS INC	**1MG**	**A202641**	**001**	Nov 27, 2012
AB		**2MG**	**A202641**	**002**	Nov 27, 2012

TOLVAPTAN
TABLET;ORAL
SAMSCA

	OTSUKA AMERICA PHARM	15MG	N022275	001	May 19, 2009
+		30MG	N022275	002	May 19, 2009

TOPIRAMATE
CAPSULE;ORAL
TOPAMAX

AB	JANSSEN PHARMS	**15MG**	**N020844**	**001**	Oct 26, 1998
AB	**+**	**25MG**	**N020844**	**002**	Oct 26, 1998

TOPIRAMATE

AB	MYLAN	**15MG**	**A078418**	**001**	Oct 14, 2009
AB		**25MG**	**A078418**	**002**	Oct 14, 2009
AB	TEVA	**15MG**	**A076575**	**001**	Apr 17, 2009
AB		**25MG**	**A076575**	**002**	Apr 17, 2009
AB	WATSON LABS	**15MG**	**A077868**	**001**	Apr 15, 2009
AB		**25MG**	**A077868**	**002**	Apr 15, 2009
AB	ZYDUS PHARMS USA INC	**15MG**	**A078877**	**001**	Oct 14, 2009
AB		**25MG**	**A078877**	**002**	Oct 14, 2009

CAPSULE, EXTENDED RELEASE;ORAL
QUDEXY XR

	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014
		50MG	N205122	002	Mar 11, 2014
		100MG	N205122	003	Mar 11, 2014
		150MG	N205122	004	Mar 11, 2014
+		200MG	N205122	005	Mar 11, 2014

TROKENDI XR

	SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013
		50MG	N201635	002	Aug 16, 2013
		100MG	N201635	003	Aug 16, 2013
+		200MG	N201635	004	Aug 16, 2013

TABLET;ORAL
TOPAMAX

AB	JANSSEN PHARMS	**25MG**	**N020505**	**004**	Dec 24, 1996
AB		**50MG**	**N020505**	**005**	Dec 24, 1996
AB	**+**	**100MG**	**N020505**	**001**	Dec 24, 1996
AB		**200MG**	**N020505**	**002**	Dec 24, 1996

TOPIRAMATE

AB	ACCORD HLTHCARE	**25MG**	**A076311**	**001**	Mar 27, 2009
AB		**50MG**	**A076311**	**002**	Mar 27, 2009
AB		**100MG**	**A076311**	**003**	Mar 27, 2009
AB		**200MG**	**A076311**	**004**	Mar 27, 2009
AB	APOTEX INC	**25MG**	**A077733**	**001**	Mar 27, 2009
AB		**50MG**	**A077733**	**002**	Mar 27, 2009
AB		**100MG**	**A077733**	**003**	Mar 27, 2009
AB		**200MG**	**A077733**	**004**	Mar 27, 2009
AB	AUROBINDO PHARMA	**25MG**	**A078462**	**001**	Mar 27, 2009
AB		**50MG**	**A078462**	**002**	Mar 27, 2009
AB		**100MG**	**A078462**	**003**	Mar 27, 2009
AB		**200MG**	**A078462**	**004**	Mar 27, 2009
AB	CIPLA LTD	**25MG**	**A076343**	**001**	Mar 27, 2009
AB		**50MG**	**A076343**	**002**	Mar 27, 2009
AB		**100MG**	**A076343**	**003**	Mar 27, 2009
AB		**200MG**	**A076343**	**004**	Mar 27, 2009
AB	GLENMARK GENERICS	**25MG**	**A077627**	**001**	Mar 27, 2009
AB		**50MG**	**A077627**	**002**	Mar 27, 2009
AB		**100MG**	**A077627**	**003**	Mar 27, 2009
AB		**200MG**	**A077627**	**004**	Mar 27, 2009
AB	INVAGEN PHARMS	**25MG**	**A079162**	**001**	Mar 27, 2009
AB		**50MG**	**A079162**	**002**	Mar 27, 2009

TOPIRAMATE
TABLET;ORAL
TOPIRAMATE

AB		**100MG**	**A079162**	**003**	Mar 27, 2009
AB		**200MG**	**A079162**	**004**	Mar 27, 2009
AB	LUPIN	**25MG**	**A078410**	**001**	Sep 11, 2013
AB		**50MG**	**A078410**	**002**	Sep 11, 2013
AB		**100MG**	**A078410**	**003**	Sep 11, 2013
AB		**200MG**	**A078410**	**004**	Sep 11, 2013
AB	MYLAN	**25MG**	**A076314**	**001**	Mar 27, 2009
AB		**50MG**	**A076314**	**002**	Mar 27, 2009
AB		**100MG**	**A076314**	**003**	Mar 27, 2009
AB		**200MG**	**A076314**	**004**	Mar 27, 2009
AB	SUN PHARM INDS LTD	**25MG**	**A076327**	**001**	Mar 27, 2009
AB		**100MG**	**A076327**	**002**	Mar 27, 2009
AB		**200MG**	**A076327**	**003**	Mar 27, 2009
AB	SUN PHARMA GLOBAL	**25MG**	**A090278**	**001**	Mar 27, 2009
AB		**50MG**	**A090278**	**002**	Mar 27, 2009
AB		**100MG**	**A090278**	**003**	Mar 27, 2009
AB		**200MG**	**A090278**	**004**	Mar 27, 2009
AB	TEVA	**25MG**	**A076317**	**001**	Mar 27, 2009
AB		**50MG**	**A076317**	**002**	Mar 27, 2009
AB		**100MG**	**A076317**	**003**	Mar 27, 2009
AB		**200MG**	**A076317**	**004**	Mar 27, 2009
AB	TORRENT PHARMS	**25MG**	**A079153**	**001**	Mar 27, 2009
AB		**50MG**	**A079153**	**002**	Mar 27, 2009
AB		**100MG**	**A079153**	**003**	Mar 27, 2009
AB		**200MG**	**A079153**	**004**	Mar 27, 2009
AB	UNICHEM LABS LTD	**25MG**	**A090162**	**001**	Mar 27, 2009
AB		**50MG**	**A090162**	**002**	Mar 27, 2009
AB		**100MG**	**A090162**	**003**	Mar 27, 2009
AB		**200MG**	**A090162**	**004**	Feb 19, 2013
AB	UPSHER SMITH	**25MG**	**A078499**	**001**	Jan 07, 2010
AB		**50MG**	**A078499**	**002**	Jan 07, 2010
AB		**100MG**	**A078499**	**003**	Jan 07, 2010
AB		**200MG**	**A078499**	**004**	Jan 07, 2010
AB	ZYDUS PHARMS USA INC	**25MG**	**A078235**	**001**	Mar 27, 2009
AB		**50MG**	**A078235**	**002**	Mar 27, 2009
AB		**100MG**	**A078235**	**003**	Mar 27, 2009
AB		**200MG**	**A078235**	**004**	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE
CAPSULE;ORAL
HYCAMTIN

		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007
	+		EQ 1MG BASE	N020981	002	Oct 11, 2007

INJECTABLE;INJECTION
HYCAMTIN

AP	**+**	NOVARTIS PHARMS CORP	**EQ 4MG BASE/VIAL**	**N020671**	**001**	May 28, 1996

TOPOTECAN HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 4MG BASE/VIAL**	**A202351**	**001**	Jun 26, 2013
AP		ACTAVIS TOTOWA	**EQ 4MG BASE/VIAL**	**A090620**	**001**	Dec 02, 2010
AP		CHEM WERTH INC	**EQ 4MG BASE/VIAL**	**A201166**	**001**	Aug 08, 2012
AP		CIPLA LTD	**EQ 4MG BASE/VIAL**	**A091199**	**001**	Dec 01, 2010
AP		DR REDDYS LABS LTD	**EQ 4MG BASE/VIAL**	**A201191**	**001**	Mar 09, 2011
AP		FRESENIUS KABI USA	**EQ 4MG BASE/VIAL**	**A091089**	**001**	Nov 29, 2010
AP		INGENUS PHARMS LLC	**EQ 4MG BASE/VIAL**	**A206962**	**001**	Nov 30, 2016
AP		MYLAN LABS LTD	**EQ 4MG BASE/VIAL**	**A091542**	**001**	Aug 28, 2012
AP		SAGENT PHARMS	**EQ 4MG BASE/VIAL**	**A091284**	**001**	Jan 26, 2011
AP		SUN PHARM INDS LTD	**EQ 4MG BASE/VIAL**	**A202203**	**001**	Aug 29, 2013

SOLUTION;INTRAVENOUS
TOPOTECAN HYDROCHLORIDE

AP	**+**	HOSPIRA INC	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N200582**	**001**	Feb 02, 2011
AP		TEVA PHARMS USA	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N022453**	**001**	Dec 20, 2012

TOREMIFENE CITRATE
TABLET;ORAL
FARESTON

+	PROSTRAKAN INC	EQ 60MG BASE	N020497	001	May 29, 1997

TORSEMIDE
TABLET;ORAL
DEMADEX

AB	MEDA PHARMS	**5MG**	**N020136**	**001**	Aug 23, 1993
AB		**10MG**	**N020136**	**002**	Aug 23, 1993
AB	+	**20MG**	**N020136**	**003**	Aug 23, 1993
AB		**100MG**	**N020136**	**004**	Aug 23, 1993

TORSEMIDE

AB	APOTEX INC	**5MG**	**A076894**	**001**	May 31, 2005
AB		**10MG**	**A076894**	**002**	May 31, 2005
AB		**20MG**	**A076894**	**003**	May 31, 2005
AB		**100MG**	**A076894**	**004**	May 31, 2005
AB	AUROBINDO PHARMA	**5MG**	**A078249**	**001**	Oct 17, 2007
AB		**10MG**	**A078249**	**002**	Oct 17, 2007
AB		**20MG**	**A078249**	**003**	Oct 17, 2007
AB		**100MG**	**A078249**	**004**	Oct 17, 2007
AB	HETERO LABS LTD III	**5MG**	**A079234**	**001**	Jan 27, 2009
AB		**10MG**	**A079234**	**002**	Jan 27, 2009
AB		**20MG**	**A079234**	**003**	Jan 27, 2009
AB		**100MG**	**A079234**	**004**	Jan 27, 2009
AB	PAR PHARM	**5MG**	**A076226**	**001**	May 27, 2003
AB		**10MG**	**A076226**	**002**	May 27, 2003
AB		**20MG**	**A076226**	**003**	May 27, 2003
AB		**100MG**	**A076226**	**004**	May 27, 2003
AB	PLIVA PHARM IND	**5MG**	**A076346**	**001**	May 30, 2003
AB		**10MG**	**A076346**	**002**	May 30, 2003
AB		**20MG**	**A076346**	**003**	May 30, 2003
AB		**100MG**	**A076346**	**004**	Oct 19, 2004
AB	SUN PHARM INDS	**5MG**	**A078478**	**001**	Feb 26, 2008
AB		**10MG**	**A078478**	**002**	Feb 26, 2008
AB		**20MG**	**A078478**	**003**	Feb 26, 2008
AB		**100MG**	**A078478**	**004**	Feb 26, 2008
AB	TEVA	**5MG**	**A076110**	**001**	May 14, 2002
AB		**10MG**	**A076110**	**002**	May 14, 2002
AB		**20MG**	**A076110**	**003**	May 14, 2002
AB		**100MG**	**A076110**	**004**	May 14, 2002
AB	VINTAGE PHARMS	**5MG**	**A090613**	**001**	Mar 22, 2011
AB		**10MG**	**A090613**	**002**	Mar 22, 2011
AB		**20MG**	**A090613**	**003**	Mar 22, 2011
AB		**100MG**	**A090613**	**004**	Mar 22, 2011
AB	WEST-WARD PHARMS INT	**5MG**	**A076943**	**001**	Mar 01, 2005
AB		**10MG**	**A076943**	**002**	Mar 01, 2005
AB		**20MG**	**A076943**	**003**	Mar 01, 2005

TRABECTEDIN
POWDER;IV (INFUSION)
YONDELIS

+	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015

TRAMADOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
CONZIP

+	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
		150MG	N022370	004	Aug 01, 2011
		200MG	N022370	002	May 07, 2010
		300MG	N022370	003	May 07, 2010

TABLET;ORAL
TRAMADOL HYDROCHLORIDE

AB	ACCORD HLTHCARE INC	**50MG**	**A202390**	**001**	May 16, 2013
AB	ACI HEALTHCARE LTD	**50MG**	**A202075**	**001**	Nov 28, 2011
AB	AMNEAL PHARMS	**50MG**	**A076003**	**001**	Jun 20, 2002
AB	APOTEX	**50MG**	**A075981**	**001**	Jul 10, 2002
AB	AUROBINDO PHARMA LTD	**50MG**	**A203494**	**001**	Mar 31, 2014
AB	CSPC OUYI PHARM CO	**50MG**	**A091498**	**001**	Mar 29, 2013
AB	IPCA LABS LTD	**50MG**	**A201973**	**001**	Nov 16, 2012
AB	MACLEODS PHARMS LTD	**50MG**	**A205702**	**001**	Sep 25, 2015
AB	MALLINCKRODT	**50MG**	**A075983**	**001**	Jun 25, 2002
AB	MYLAN	**50MG**	**A075986**	**001**	Jun 21, 2002
AB	MYLAN PHARMS INC	**50MG**	**A075980**	**001**	Nov 21, 2002
AB	NORTHSTAR HLTHCARE	**50MG**	**A078935**	**001**	May 26, 2010
AB	PLIVA	**50MG**	**A075982**	**001**	Jul 01, 2002
AB	SUN PHARM INDS	**50MG**	**A076100**	**001**	Jun 20, 2002
AB	SUN PHARM INDS INC	**50MG**	**A075964**	**001**	Jun 19, 2002

FDA data supplied by DrugPatentWatch.com

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

		TRAMADOL HYDROCHLORIDE				
AB		TEVA	**50MG**	**A075977**	**001**	Jun 19, 2002
AB		ZYDUS PHARMS USA INC	**50MG**	**A090404**	**001**	Jan 31, 2011
		ULTRAM				
AB	+	JANSSEN PHARMS	**50MG**	**N020281**	**002**	Mar 03, 1995

TABLET, EXTENDED RELEASE;ORAL

		TRAMADOL HYDROCHLORIDE				
AB1		AUROBINDO PHARMA LTD	**100MG**	**A204421**	**001**	Oct 20, 2015
AB1			**200MG**	**A204421**	**002**	Oct 20, 2015
AB1			**300MG**	**A204421**	**003**	Oct 20, 2015
AB1	+	LUPIN LTD	**100MG**	**A200503**	**001**	Aug 29, 2011
AB1			**200MG**	**A200503**	**002**	Aug 29, 2011
AB1			**300MG**	**A200503**	**003**	Aug 29, 2011
AB1		MYLAN PHARMS INC	**100MG**	**A205257**	**001**	Dec 22, 2015
AB1			**200MG**	**A205257**	**002**	Dec 22, 2015
AB1			**300MG**	**A205257**	**003**	Dec 22, 2015
AB1		PAR PHARM INC	**100MG**	**A078783**	**001**	Nov 13, 2009
AB1			**200MG**	**A078783**	**002**	Nov 13, 2009
AB1			**300MG**	**A078783**	**003**	Sep 20, 2011
AB1		SUN PHARMA GLOBAL	**100MG**	**A201384**	**001**	Dec 07, 2011
AB1			**200MG**	**A201384**	**002**	Dec 07, 2011
AB1			**300MG**	**A201384**	**003**	Dec 07, 2011
AB2		ACTAVIS ELIZABETH	**100MG**	**A091609**	**001**	Jun 27, 2012
AB2			**200MG**	**A091609**	**002**	Jun 27, 2012
AB2			**300MG**	**A091609**	**003**	Jun 27, 2012
AB2		ANCHEN PHARMS	**100MG**	**A200491**	**001**	Jun 27, 2012
AB2			**200MG**	**A200491**	**002**	Jun 27, 2012
AB2			**300MG**	**A200491**	**003**	Jun 27, 2012
AB2	+	SUN PHARMA GLOBAL	**100MG**	**A091607**	**001**	Dec 30, 2011
AB2			**200MG**	**A091607**	**002**	Dec 30, 2011
AB2			**300MG**	**A091607**	**003**	Dec 30, 2011

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

		MEKINIST				
		NOVARTIS PHARMS CORP	EQ 0.5MG	N204114	001	May 29, 2013
			EQ 1MG	N204114	002	May 29, 2013
	+		EQ 2MG	N204114	003	May 29, 2013

TRANDOLAPRIL

TABLET;ORAL

		MAVIK				
AB		ABBVIE	**1MG**	**N020528**	**001**	Apr 26, 1996
AB			**2MG**	**N020528**	**002**	Apr 26, 1996
AB	+		**4MG**	**N020528**	**003**	Apr 26, 1996
		TRANDOLAPRIL				
AB		AUROBINDO PHARMA	**1MG**	**A078438**	**001**	Jun 12, 2007
AB			**2MG**	**A078438**	**002**	Jun 12, 2007
AB			**4MG**	**A078438**	**003**	Jun 12, 2007
AB		EPIC PHARMA	**1MG**	**A078508**	**003**	Jun 18, 2008
AB			**2MG**	**A078508**	**001**	Jun 18, 2008
AB			**4MG**	**A078508**	**002**	Jun 18, 2008
AB		INVAGEN PHARMS	**1MG**	**A078320**	**001**	Jun 12, 2007
AB			**2MG**	**A078320**	**002**	Jun 12, 2007
AB			**4MG**	**A078320**	**003**	Jun 12, 2007
AB		LUPIN	**1MG**	**A077522**	**001**	Jun 12, 2007
AB			**2MG**	**A077522**	**002**	Jun 12, 2007
AB			**4MG**	**A077522**	**003**	Jun 12, 2007
AB		MYLAN	**1MG**	**A078346**	**001**	Apr 28, 2008
AB			**2MG**	**A078346**	**002**	Apr 28, 2008
AB			**4MG**	**A078346**	**003**	Apr 28, 2008
AB		TEVA PHARMS	**1MG**	**A077489**	**001**	Dec 12, 2006
AB			**2MG**	**A077489**	**002**	Dec 12, 2006
AB			**4MG**	**A077489**	**003**	Dec 12, 2006
AB		WATSON LABS	**1MG**	**A077805**	**001**	Jun 12, 2007
AB			**2MG**	**A077805**	**002**	Jun 12, 2007
AB			**4MG**	**A077805**	**003**	Jun 12, 2007

FDA data supplied by DrugPatentWatch.com

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

		TARKA				
AB		ABBVIE	**1MG;240MG**	**N020591**	**003**	Oct 22, 1996
AB			**2MG;180MG**	**N020591**	**001**	Oct 22, 1996
AB			**2MG;240MG**	**N020591**	**004**	Oct 22, 1996
AB	+		**4MG;240MG**	**N020591**	**002**	Oct 22, 1996
		TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE				
AB		GLENMARK GENERICS	**1MG;240MG**	**A079135**	**004**	Aug 30, 2010
AB			**2MG;180MG**	**A079135**	**001**	May 26, 2010
AB			**2MG;240MG**	**A079135**	**002**	May 26, 2010
AB			**4MG;240MG**	**A079135**	**003**	May 05, 2010

TRANEXAMIC ACID

INJECTABLE;INJECTION

		CYKLOKAPRON				
AP	+	PHARMACIA AND UPJOHN	**100MG/ML**	**N019281**	**001**	Dec 30, 1986
		TRANEXAMIC ACID				
AP		ACIC FINE CHEMS	**100MG/ML**	**A202436**	**001**	Feb 11, 2014
AP		AKORN	**100MG/ML**	**A202373**	**001**	Nov 17, 2011
AP			**100MG/ML**	**A206634**	**001**	Jun 09, 2016
AP		AUROBINDO PHARMA LTD	**100MG/ML**	**A205035**	**001**	Jan 14, 2016
AP		EMCURE PHARMS LTD	**100MG/ML**	**A203521**	**001**	Aug 12, 2014
AP		FRESENIUS KABI USA	**100MG/ML**	**A091596**	**001**	Mar 02, 2012
AP		LUITPOLD	**100MG/ML**	**A201885**	**001**	Aug 10, 2011
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091657**	**001**	Nov 03, 2011
AP		NORTH CREEK PHARMS	**100MG/ML**	**A202755**	**001**	Feb 25, 2016
AP		X-GEN PHARMS INC	**100MG/ML**	**A201580**	**001**	Jun 14, 2013

TABLET;ORAL

		LYSTEDA				
AB	+	FERRING PHARMS AS	**650MG**	**N022430**	**001**	Nov 13, 2009
		TRANEXAMIC ACID				
AB		ACTAVIS LABS FL INC	**650MG**	**A202093**	**001**	Dec 27, 2012
AB		APOTEX INC	**650MG**	**A202286**	**001**	Jan 27, 2014
AB		MYLAN	**650MG**	**A205133**	**001**	Sep 21, 2015

TRANYLCYPROMINE SULFATE

TABLET;ORAL

		PARNATE				
AB	+	CONCORDIA PHARMS INC	**EQ 10MG BASE**	**N012342**	**003**	Aug 16, 1985
		TRANYLCYPROMINE SULFATE				
AB		PAR PHARM	**EQ 10MG BASE**	**A040640**	**001**	Jun 29, 2006

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

		TRAVATAN Z				
AT	+	NOVARTIS PHARMS CORP	**0.004%**	**N021994**	**001**	Sep 21, 2006
		TRAVOPROST				
AT		APOTEX INC	**0.004%**	**A203431**	**001**	Jul 10, 2015
	+	PAR PHARM	0.004%	A091340	001	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

		TRAZODONE HYDROCHLORIDE				
AB		ALVOGEN	**50MG**	**A071636**	**001**	Apr 18, 1988
AB			**100MG**	**A071514**	**001**	Apr 18, 1988
AB		APOTEX	**50MG**	**A071258**	**001**	Mar 25, 1987
AB	+	APOTEX INC	**100MG**	**A071196**	**001**	Mar 25, 1987
AB			**150MG**	**A071196**	**002**	Apr 26, 1999
AB			**300MG**	**A071196**	**003**	Apr 26, 1999
AB		MYLAN PHARMS INC	**50MG**	**A090514**	**001**	Jun 02, 2009
AB			**100MG**	**A090514**	**002**	Jun 02, 2009
AB			**150MG**	**A090514**	**003**	Jun 02, 2009
AB			**300MG**	**A090514**	**004**	Jun 02, 2009
AB		PLIVA	**150MG**	**A071525**	**001**	Mar 09, 1988
AB		SUN PHARM INDS	**50MG**	**A073137**	**002**	Mar 24, 1993
AB			**100MG**	**A073137**	**001**	Mar 24, 1993
AB			**150MG**	**A073137**	**003**	Dec 22, 1995
AB		TEVA PHARMS USA	**50MG**	**A071523**	**001**	Dec 11, 1987
AB			**100MG**	**A071524**	**001**	Dec 11, 1987
AB		TORRENT PHARMS LTD	**50MG**	**A202180**	**001**	Nov 27, 2013
AB			**100MG**	**A202180**	**002**	Nov 27, 2013
AB			**150MG**	**A202180**	**003**	Nov 27, 2013
AB			**300MG**	**A202180**	**004**	Nov 27, 2013

FDA data supplied by DrugPatentWatch.com

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

		TRAZODONE HYDROCHLORIDE				
AB		VINTAGE	**50MG**	**A072192**	**001**	Feb 02, 1989
AB			**100MG**	**A072193**	**001**	Feb 02, 1989

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

		REMODULIN				
		UNITED THERAP	1MG/ML	N021272	001	May 21, 2002
			2.5MG/ML	N021272	002	May 21, 2002
			5MG/ML	N021272	003	May 21, 2002
	+		10MG/ML	N021272	004	May 21, 2002

SOLUTION;INHALATION

		TYVASO				
	+	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

		ORENITRAM				
		UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
			EQ 0.25MG BASE	N203496	002	Dec 20, 2013
			EQ 1MG BASE	N203496	003	Dec 20, 2013
	+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
			EQ 5MG BASE	N203496	005	Oct 07, 2016

TRETINOIN

CAPSULE;ORAL

		TRETINOIN				
AB		ANCHEN PHARMS	**10MG**	**A201687**	**001**	Oct 24, 2012
AB	+	BARR LABS INC	**10MG**	**A077684**	**001**	Jun 22, 2007
AB		GLENMARK GENERICS	**10MG**	**A208279**	**001**	Dec 23, 2016

CREAM;TOPICAL

		AVITA				
AB		MYLAN PHARMS INC	**0.025%**	**N020404**	**003**	Jan 14, 1997
		RETIN-A				
AB	+	VALEANT BERMUDA	**0.025%**	**N019049**	**001**	Sep 16, 1988
AB	+	VALEANT PHARMS NORTH	**0.1%**	**N017340**	**001**	
		TRETINOIN				
AB		PERRIGO PHARMA INTL	**0.025%**	**A075264**	**001**	Dec 24, 1998
AB			**0.1%**	**A075213**	**001**	Dec 24, 1998
		RETIN-A				
AB1	+	VALEANT BERMUDA	**0.05%**	**N017522**	**001**	
		TRETINOIN				
AB1		PERRIGO PHARMA INTL	**0.05%**	**A075265**	**001**	Dec 24, 1998
		RENOVA				
AB2	+	VALEANT PHARMS NORTH	**0.05%**	**N019963**	**001**	Dec 29, 1995
		TRETINOIN				
AB2		SUNEVA MEDCL	**0.05%**	**A076498**	**001**	Sep 15, 2005
		RENOVA				
	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000
		TRETINOIN				
	+	ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010
			0.075%	A202209	001	Oct 11, 2012

GEL;TOPICAL

		ATRALIN				
AB	+	DOW PHARM	**0.05%**	**N022070**	**001**	Jul 26, 2007
		RETIN-A				
AB	+	VALEANT INTL	**0.01%**	**N017955**	**001**	
AB	+		**0.025%**	**N017579**	**002**	
		RETIN-A MICRO				
AB	+	VALEANT INTL	**0.04%**	**N020475**	**002**	May 10, 2002
AB	+		**0.1%**	**N020475**	**001**	Feb 07, 1997
		TRETINOIN				
AB		PERRIGO PHARMA INTL	**0.01%**	**A075589**	**001**	Jun 11, 2002
AB			**0.025%**	**A075529**	**001**	Feb 22, 2000
AB		SPEAR PHARMS INC	**0.04%**	**A202567**	**001**	Jul 17, 2013
AB			**0.05%**	**A207955**	**001**	Aug 13, 2015
AB			**0.1%**	**A202026**	**001**	Jul 17, 2013
		AVITA				
BT		MYLAN	0.025%	N020400	001	Jan 29, 1998
		RETIN-A-MICRO				
	+	VALEANT INTL	0.08%	N020475	003	Jan 28, 2014

FDA data supplied by DrugPatentWatch.com

TRETINOIN
SOLUTION;TOPICAL
RETIN-A

	+	VALEANT INTL	0.05%	N016921	001	

TRIAMCINOLONE ACETONIDE
CREAM;TOPICAL

		TRIAMCINOLONE ACETONIDE				
AT		DELCOR ASSET CORP	**0.025%**	**N011601**	**003**	
AT			**0.1%**	**N011601**	**006**	
AT	+	FOUGERA PHARMS	**0.025%**	**A085692**	**001**	
AT	+		**0.1%**	**A085692**	**003**	
AT	+		**0.5%**	**A085692**	**002**	
AT		G AND W LABS	**0.025%**	**A089797**	**001**	May 31, 1991
AT			**0.1%**	**A089798**	**001**	May 31, 1991
AT		GLENMARK PHARMS LTD	**0.1%**	**A207117**	**001**	Aug 05, 2016
AT		PERRIGO NEW YORK	**0.025%**	**A086415**	**001**	
AT			**0.1%**	**A086414**	**001**	
AT			**0.5%**	**A086413**	**001**	
AT		TARO	**0.1%**	**A040039**	**001**	Nov 26, 1997
AT		VINTAGE	**0.025%**	**A040671**	**001**	Jun 09, 2006
AT			**0.1%**	**A040671**	**002**	Jun 09, 2006
		TRIDERM				
AT		CROWN LABS	**0.025%**	**A088042**	**002**	Mar 25, 2015
AT			**0.1%**	**A088042**	**001**	Mar 19, 1984
AT			**0.5%**	**A088042**	**003**	Mar 25, 2015
INJECTABLE;INJECTION						
KENALOG-10						
		APOTHECON	10MG/ML	N012041	001	
KENALOG-40						
	+	APOTHECON	40MG/ML	N014901	001	
INJECTABLE;INTRAVITREAL						
TRIESENCE						
	+	NOVARTIS PHARMS CORP	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007
LOTION;TOPICAL						
		TRIAMCINOLONE ACETONIDE				
AT		AKORN	**0.025%**	**A202374**	**001**	May 08, 2013
AT			**0.1%**	**A202374**	**002**	May 08, 2013
AT		FOUGERA PHARMS	**0.025%**	**A040467**	**001**	Apr 21, 2003
AT			**0.1%**	**A040467**	**002**	Apr 21, 2003
AT		G AND W LABS INC	**0.1%**	**A089129**	**001**	Aug 14, 1986
AT		TELIGENT PHARMA INC	**0.025%**	**A204608**	**001**	Jul 07, 2016
AT			**0.1%**	**A204606**	**001**	Jul 07, 2016
AT		VINTAGE	**0.1%**	**A040672**	**002**	Dec 13, 2006
AT	+	WOCKHARDT	**0.1%**	**A088451**	**001**	Apr 03, 1985
AT	+	WOCKHARDT EU OPERATN	**0.025%**	**A088450**	**001**	Apr 01, 1985
OINTMENT;TOPICAL						
		KENALOG				
AT		DELCOR ASSET CORP	**0.025%**	**N011600**	**003**	
AT			**0.1%**	**N011600**	**001**	
		TRIAMCINOLONE ACETONIDE				
AT		FOUGERA PHARMS	**0.025%**	**A085691**	**001**	
AT			**0.1%**	**A085691**	**003**	
AT			**0.5%**	**A085691**	**002**	
AT		G AND W LABS	**0.025%**	**A089795**	**001**	Dec 23, 1988
AT			**0.1%**	**A089796**	**001**	Dec 23, 1988
AT		GLENMARK PHARMS LTD	**0.5%**	**A206379**	**001**	Jul 22, 2016
AT	+	PERRIGO NEW YORK	**0.025%**	**A087356**	**001**	
AT	+		**0.1%**	**A087357**	**001**	
AT	+		**0.5%**	**A087385**	**001**	
AT		TARO	**0.1%**	**A040037**	**001**	Sep 30, 1994
AT		TELIGENT PHARMA INC	**0.1%**	**A205373**	**001**	May 13, 2016
TRIAMCINOLONE ACETONIDE IN ABSORBASE						
	+	CAROLINA MEDCL	0.05%	A089595	001	Mar 23, 1995
PASTE;DENTAL						
		TRIAMCINOLONE ACETONIDE				
AT		AKORN	**0.1%**	**A206312**	**001**	Aug 11, 2016
AT		LYNE	**0.1%**	**A040771**	**001**	Jul 01, 2010
AT	+	TARO	**0.1%**	**A070730**	**001**	Oct 01, 1986
SPRAY;TOPICAL						
		KENALOG				
AT	+	RANBAXY LABS LTD	**0.147MG/GM**	**N012104**	**001**	

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE
SPRAY;TOPICAL
TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.147MG/GM**	**A207094**	**001** Dec 07, 2016
AT		PERRIGO UK FINCO	**0.147MG/GM**	**A205782**	**001** Apr 13, 2015

TRIAMCINOLONE HEXACETONIDE
INJECTABLE;INJECTION
ARISTOSPAN

	+	SANDOZ	5MG/ML	N016466 001
	+		20MG/ML	N016466 002

TRIAMTERENE
CAPSULE;ORAL
DYRENIUM

		CONCORDIA PHARMS INC	50MG	N013174 001
	+		100MG	N013174 002

TRIAZOLAM
TABLET;ORAL
HALCION

AB		PHARMACIA AND UPJOHN	**0.125MG**	**N017892**	**003** Apr 26, 1985
AB	**+**		**0.25MG**	**N017892**	**001** Nov 15, 1982

TRIAZOLAM

AB		MYLAN PHARMS INC	**0.125MG**	**A074031**	**001** Mar 25, 1994
AB			**0.25MG**	**A074031**	**002** Mar 25, 1994
AB		WEST-WARD PHARMS INT	**0.125MG**	**A074224**	**001** Jun 01, 1994
AB			**0.25MG**	**A074224**	**002** Jun 01, 1994

TRIENTINE HYDROCHLORIDE
CAPSULE;ORAL
SYPRINE

	+	ATON	250MG	N019194 001 Nov 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE
TABLET;ORAL
TRIFLUOPERAZINE HYDROCHLORIDE

AB		MYLAN	**EQ 1MG BASE**	**A040209**	**001** Jul 07, 1997
AB			**EQ 2MG BASE**	**A040209**	**002** Jul 07, 1997
AB			**EQ 5MG BASE**	**A040209**	**003** Jul 07, 1997
AB	**+**		**EQ 10MG BASE**	**A040209**	**004** Jul 07, 1997
AB		SANDOZ	**EQ 1MG BASE**	**A085785**	**001**
AB			**EQ 2MG BASE**	**A085786**	**001**
AB			**EQ 5MG BASE**	**A085789**	**001**
AB			**EQ 10MG BASE**	**A085788**	**001**

TRIFLURIDINE
SOLUTION/DROPS;OPHTHALMIC
TRIFLURIDINE

AT		ALCON PHARMS LTD	**1%**	**A074311**	**001** Oct 06, 1995

VIROPTIC

AT	**+**	MONARCH PHARMS	**1%**	**N018299**	**001**

TRIHEXYPHENIDYL HYDROCHLORIDE
ELIXIR;ORAL
TRIHEXYPHENIDYL HYDROCHLORIDE

AA		MIKART	**2MG/5ML**	**A040251**	**001** Sep 27, 1999
AA	**+**	PHARM ASSOC	**2MG/5ML**	**A040177**	**001** Apr 17, 1997

TABLET;ORAL
TRIHEXYPHENIDYL HYDROCHLORIDE

AA		NATCO PHARMA LTD	**2MG**	**A091630**	**001** Nov 17, 2010
AA			**5MG**	**A091630**	**002** Nov 17, 2010
AA		VINTAGE PHARMS	**2MG**	**A040254**	**001** Dec 24, 1998
AA			**5MG**	**A040254**	**002** Dec 24, 1998
AA	**+**	WATSON LABS	**2MG**	**A084363**	**001**
AA	**+**		**5MG**	**A084364**	**001**

TRIMETHADIONE
TABLET;ORAL
TRIDIONE

	+	ABBVIE	150MG	N005856 009

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

		TIGAN				
AB	+	KING PHARMS	**300MG**	**N017531**	**006**	Dec 13, 2001
		TRIMETHOBENZAMIDE HYDROCHLORIDE				
AB		GAVIS PHARMS	**300MG**	**A076546**	**001**	Aug 20, 2003
AB		SUN PHARM INDS	**300MG**	**A076570**	**001**	Aug 28, 2003

INJECTABLE;INJECTION

		TIGAN				
AP	+	PAR STERILE PRODUCTS	**100MG/ML**	**N017530**	**001**	
		TRIMETHOBENZAMIDE HYDROCHLORIDE				
AP		LUITPOLD	**100MG/ML**	**A091330**	**001**	Mar 08, 2011
		TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE				
AP		LUITPOLD	**100MG/ML**	**A091329**	**001**	Mar 08, 2011

TRIMETHOPRIM

TABLET;ORAL

		TRIMETHOPRIM				
AB	+	MAYNE PHARMA	**100MG**	**N018679**	**001**	Jul 30, 1982
AB		NOVEL LABS INC	**100MG**	**A091437**	**001**	Jun 15, 2011
AB		WATSON LABS	**100MG**	**A070049**	**001**	Jun 06, 1985

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

		PRIMSOL				
	+	AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

		SURMONTIL				
AB		ODYSSEY PHARMS	**EQ 25MG BASE**	**N016792**	**001**	
AB	+		**EQ 50MG BASE**	**N016792**	**002**	
AB			**EQ 100MG BASE**	**N016792**	**003**	Sep 15, 1982
		TRIMIPRAMINE MALEATE				
AB		CROSSMEDIKA SA	**EQ 25MG BASE**	**A208127**	**001**	Apr 15, 2016
AB			**EQ 50MG BASE**	**A208127**	**002**	Apr 15, 2016
AB			**EQ 100MG BASE**	**A208127**	**003**	Apr 15, 2016
AB		MIKAH PHARMA	**EQ 25MG BASE**	**A077361**	**001**	Aug 02, 2006
AB			**EQ 50MG BASE**	**A077361**	**002**	Aug 02, 2006
AB			**EQ 100MG BASE**	**A077361**	**003**	Aug 02, 2006

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

		TRELSTAR				
	+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000
	+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001
	+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010

TROMETHAMINE

INJECTABLE;INJECTION

		THAM				
	+	HOSPIRA	3.6GM/100ML	N013025	002	

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

		MYDRIACYL				
AT	+	ALCON	**0.5%**	**A084305**	**001**	
AT	+	NOVARTIS PHARMS CORP	**1%**	**A084306**	**001**	
		TROPICACYL				
AT		AKORN	**0.5%**	**A040314**	**001**	Sep 29, 2000
AT			**1%**	**A040315**	**001**	Sep 29, 2000
		TROPICAMIDE				
AT		BAUSCH AND LOMB	**0.5%**	**A040067**	**001**	Jul 27, 1994
AT			**1%**	**A040064**	**001**	Jul 27, 1994

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

		TROSPIUM CHLORIDE				
AB	+	ACTAVIS LABS FL INC	**60MG**	**A091289**	**001**	Oct 12, 2012
AB		PADDOCK LLC	**60MG**	**A201291**	**001**	May 24, 2013

TABLET;ORAL

		TROSPIUM CHLORIDE				
AB		APOTEX	**20MG**	**A091513**	**001**	Dec 06, 2011
AB	+	GLENMARK GENERICS	**20MG**	**A091575**	**001**	Aug 13, 2010
AB		HERITAGE PHARMS INC	**20MG**	**A204945**	**001**	Aug 30, 2016
AB		INVAGEN PHARMS	**20MG**	**A091688**	**001**	Aug 23, 2016

FDA data supplied by DrugPatentWatch.com

TROSPIUM CHLORIDE
TABLET;ORAL
TROSPIUM CHLORIDE

AB		PADDOCK LLC	**20MG**	**A091573**	**001** Nov 17, 2010

TRYPAN BLUE
SOLUTION;OPHTHALMIC
MEMBRANEBLUE

	+	DORC	0.15%	N022278	001 Feb 20, 2009

VISIONBLUE

	+	DORC	0.06%	N021670	001 Dec 16, 2004

ULIPRISTAL ACETATE
TABLET;ORAL
ELLA

	+	LAB HRA PHARMA	30MG	N022474	001 Aug 13, 2010

UMECLIDINIUM BROMIDE
POWDER;INHALATION
INCRUSE ELLIPTA

	+	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001 Apr 30, 2014

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
POWDER;INHALATION
ANORO ELLIPTA

	+	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975	001 Dec 18, 2013

UREA, C-14
CAPSULE;ORAL
PYTEST

	+	AVENT	1uCi	N020617	001 May 09, 1997

PYTEST KIT

	+	AVENT	1uCi	N020617	002 May 09, 1997

URIDINE TRIACETATE
GRANULE;ORAL
VISTOGARD

	+	WELLSTAT THERAP	10GM/PACKET	N208159	001 Dec 11, 2015

XURIDEN

	+	WELLSTAT THERAP	2GM/PACKET	N208169	001 Sep 04, 2015

UROFOLLITROPIN
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE

	+	FERRING	75 IU/VIAL	N021289	001 May 06, 2002

URSODIOL
CAPSULE;ORAL
ACTIGALL

AB	**+**	ALLERGAN SALES LLC	**300MG**	**N019594**	**002** Dec 31, 1987

URSODIOL

AB		COREPHARMA	**300MG**	**A077895**	**001** Jul 27, 2006
AB		EPIC PHARMA	**300MG**	**A075517**	**001** Mar 14, 2000
AB		LANNETT	**300MG**	**A079082**	**001** Dec 15, 2008
AB		MYLAN	**300MG**	**A090530**	**001** Feb 17, 2010
AB		TEVA PHARMS	**300MG**	**A075592**	**001** May 25, 2000

TABLET;ORAL
URSO 250

AB		FOREST LABS INC	**250MG**	**N020675**	**001** Dec 10, 1997

URSO FORTE

AB	**+**	FOREST LABS INC	**500MG**	**N020675**	**002** Jul 21, 2004

URSODIOL

AB		GLENMARK GENERICS	**250MG**	**A090801**	**001** Jul 12, 2011
AB			**500MG**	**A090801**	**002** Jul 12, 2011
AB		IMPAX LABS INC	**250MG**	**A200826**	**001** Dec 23, 2011
AB			**500MG**	**A200826**	**002** Dec 23, 2011
AB		PAR PHARM	**250MG**	**A202540**	**001** Feb 14, 2013
AB			**500MG**	**A202540**	**002** Feb 14, 2013

VALACYCLOVIR HYDROCHLORIDE
TABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

AB		APOTEX INC	**EQ 500MG BASE**	**A090500**	**001** Apr 04, 2014
AB			**EQ 1GM BASE**	**A090500**	**002** Apr 04, 2014
AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A090682**	**001** May 24, 2010
AB			**EQ 1GM BASE**	**A090682**	**002** May 24, 2010

FDA data supplied by DrugPatentWatch.com

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	CIPLA LTD	EQ 500MG BASE	A077135	001	May 24, 2010
AB		EQ 1GM BASE	A077135	002	May 24, 2010
AB	DR REDDYS LABS LTD	EQ 500MG BASE	A079012	001	May 24, 2010
AB		EQ 1GM BASE	A079012	002	May 24, 2010
AB	HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015
AB		EQ 1GM BASE	A203047	002	Apr 08, 2015
AB	JUBILANT GENERICS	EQ 500MG BASE	A201506	001	Apr 03, 2012
AB		EQ 1GM BASE	A201506	002	Apr 03, 2012
AB	MYLAN	EQ 500MG BASE	A078070	001	May 24, 2010
AB		EQ 1GM BASE	A078070	002	May 24, 2010
AB	MYLAN PHARMS INC	EQ 500MG BASE	A078518	001	May 24, 2010
AB		EQ 1GM BASE	A078518	002	May 24, 2010
AB	SANDOZ	EQ 500MG BASE	A077478	001	May 24, 2010
AB		EQ 1GM BASE	A077478	002	May 24, 2010
AB	SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007
AB		EQ 1GM BASE	A076588	002	Jan 31, 2007
AB	TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010
AB		EQ 1GM BASE	A077655	002	May 24, 2010
AB	WATSON LABS INC	EQ 500MG BASE	A090370	001	Mar 16, 2011
AB		EQ 1GM BASE	A090370	002	Mar 16, 2011
AB	WEST-WARD PHARMS INT	EQ 500MG BASE	A078656	001	May 24, 2010
AB		EQ 1GM BASE	A078656	002	May 24, 2010
AB	WOCKHARDT	EQ 500MG BASE	A090216	001	May 24, 2010
AB		EQ 1GM BASE	A090216	002	May 24, 2010

VALTREX

AB	GLAXOSMITHKLINE	EQ 500MG BASE	N020487	001	Jun 23, 1995
AB +		EQ 1GM BASE	N020487	002	Jun 23, 1995

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALCYTE

AB +	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009

VALGANCICLOVIR HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	50MG/ML	A205220	001	Jul 18, 2016

TABLET;ORAL

VALCYTE

AB +	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29, 2001

VALGANCICLOVIR HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016
AB	DR REDDYS LABS LTD	EQ 450MG BASE	A203511	001	Nov 04, 2014
AB	ENDO PHARMS INC	EQ 450MG BASE	A200790	001	Nov 04, 2014
AB	HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016

VALPROATE SODIUM

INJECTABLE;INJECTION

DEPACON

AP +	ABBVIE	EQ 100MG BASE/ML	N020593	001	Dec 30, 1996

VALPROATE SODIUM

AP	AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002
AP	FRESENIUS KABI USA	EQ 100MG BASE/ML	A076539	001	Jun 26, 2003
AP	HIKMA FARMACEUTICA	EQ 100MG BASE/ML	A078523	001	Feb 17, 2010

VALPROIC ACID

CAPSULE;ORAL

DEPAKENE

AB +	ABBVIE	250MG	N018081	001	

VALPROIC ACID

AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993
AB	CATALENT	250MG	A073229	001	Oct 29, 1991
AB	SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013

SYRUP;ORAL

DEPAKENE

AA +	ABBVIE	250MG/5ML	N018082	001	

VALPROIC ACID

AA	ALPHARMA	250MG/5ML	A075782	001	Dec 22, 2000
AA	ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992
AA	HIGH TECH PHARMA	250MG/5ML	A074060	001	Jan 13, 1995
AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010
AA	PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000
AA	VINTAGE	250MG/5ML	A077960	001	Oct 13, 2006
AA	WOCKHARDT	250MG/5ML	A070868	001	Jul 01, 1986

FDA data supplied by DrugPatentWatch.com

VALRUBICIN
SOLUTION;INTRAVESICAL
VALSTAR PRESERVATIVE FREE

+	ENDO PHARM	40MG/ML	N020892	001	Sep 25, 1998

VALSARTAN
TABLET;ORAL

	DIOVAN				
AB	NOVARTIS	**40MG**	**N021283**	**004**	Aug 14, 2002
AB		**80MG**	**N021283**	**001**	Jul 18, 2001
AB		**160MG**	**N021283**	**002**	Jul 18, 2001
AB	+	**320MG**	**N021283**	**003**	Jul 18, 2001
	VALSARTAN				
AB	ALEMBIC PHARMS LTD	**40MG**	**A091367**	**001**	Jan 05, 2015
AB		**80MG**	**A091367**	**002**	Jan 05, 2015
AB		**160MG**	**A091367**	**003**	Jan 05, 2015
AB		**320MG**	**A091367**	**004**	Jan 05, 2015
AB	AMNEAL PHARMS	**40MG**	**A204011**	**001**	Jan 11, 2016
AB		**80MG**	**A204011**	**002**	Jan 11, 2016
AB		**160MG**	**A204011**	**003**	Jan 11, 2016
AB		**320MG**	**A204011**	**004**	Jan 11, 2016
AB	AUROBINDO PHARMA LTD	**40MG**	**A202223**	**001**	Jan 05, 2015
AB		**80MG**	**A202223**	**002**	Jan 05, 2015
AB		**160MG**	**A202223**	**003**	Jan 05, 2015
AB		**320MG**	**A202223**	**004**	Jan 05, 2015
AB	HETERO LABS LTD V	**40MG**	**A203311**	**001**	Jan 05, 2015
AB		**80MG**	**A203311**	**002**	Jan 05, 2015
AB		**160MG**	**A203311**	**003**	Jan 05, 2015
AB		**320MG**	**A203311**	**004**	Jan 05, 2015
AB	IVAX PHARMS	**40MG**	**A077530**	**001**	Jan 04, 2016
AB		**80MG**	**A077530**	**002**	Jan 04, 2016
AB		**160MG**	**A077530**	**003**	Jan 04, 2016
AB		**320MG**	**A077530**	**004**	Jan 04, 2016
AB	JUBILANT GENERICS	**40MG**	**A203536**	**001**	Jan 05, 2015
AB		**80MG**	**A203536**	**002**	Jan 05, 2015
AB		**160MG**	**A203536**	**003**	Jan 05, 2015
AB		**320MG**	**A203536**	**004**	Jan 05, 2015
AB	LUPIN LTD	**40MG**	**A201677**	**001**	Jan 05, 2015
AB		**80MG**	**A201677**	**002**	Jan 05, 2015
AB		**160MG**	**A201677**	**003**	Jan 05, 2015
AB		**320MG**	**A201677**	**004**	Jan 05, 2015
AB	MACLEODS PHARMS LTD	**40MG**	**A202696**	**001**	Sep 16, 2016
AB		**80MG**	**A202696**	**002**	Sep 16, 2016
AB		**160MG**	**A202696**	**003**	Sep 16, 2016
AB		**320MG**	**A202696**	**004**	Sep 16, 2016
AB	MYLAN LABS LTD	**40MG**	**A090866**	**001**	Jan 05, 2015
AB		**80MG**	**A090866**	**002**	Jan 05, 2015
AB		**160MG**	**A090866**	**003**	Jan 05, 2015
AB		**320MG**	**A090866**	**004**	Jan 05, 2015
AB	OHM LABS INC	**40MG**	**A077492**	**001**	Jun 26, 2014
AB		**80MG**	**A077492**	**002**	Jun 26, 2014
AB		**160MG**	**A077492**	**003**	Jun 26, 2014
AB		**320MG**	**A077492**	**004**	Jun 26, 2014
AB	PRINSTON INC	**40MG**	**A204821**	**001**	Jun 09, 2015
AB		**80MG**	**A204821**	**002**	Jun 09, 2015
AB		**160MG**	**A204821**	**003**	Jun 09, 2015
AB		**320MG**	**A204821**	**004**	Jun 09, 2015
AB	TORRENT PHARMS LTD	**40MG**	**A202728**	**001**	Jan 05, 2015
AB		**80MG**	**A202728**	**002**	Jan 05, 2015
AB		**160MG**	**A202728**	**003**	Jan 05, 2015
AB		**320MG**	**A202728**	**004**	Jan 05, 2015
AB	WATSON LABS INC	**40MG**	**A090642**	**001**	Jan 05, 2015
AB		**80MG**	**A090642**	**002**	Jan 05, 2015
AB		**160MG**	**A090642**	**003**	Jan 05, 2015
AB		**320MG**	**A090642**	**004**	Jan 05, 2015

VANCOMYCIN HYDROCHLORIDE
CAPSULE;ORAL

	VANCOCIN HYDROCHLORIDE				
AB	ANI PHARMS INC	**EQ 125MG BASE**	**N050606**	**001**	Apr 15, 1986
AB	+	**EQ 250MG BASE**	**N050606**	**002**	Apr 15, 1986
	VANCOMYCIN HYDROCHLORIDE				
AB	AKORN	**EQ 125MG BASE**	**A065478**	**001**	Apr 09, 2012

FDA data supplied by DrugPatentWatch.com

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB			EQ 250MG BASE	A065478	002	Apr 09, 2012
AB		FRESENIUS KABI USA	EQ 125MG BASE	A065453	001	Jun 18, 2012
AB			EQ 250MG BASE	A065453	002	Jun 18, 2012
AB		LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015
AB			EQ 250MG BASE	A090439	002	Jan 28, 2015
AB		STRIDES PHARMA	EQ 125MG BASE	A065490	001	Apr 09, 2012
AB			EQ 250MG BASE	A065490	002	Apr 09, 2012
AB		WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012
AB			EQ 250MG BASE	A065510	002	Apr 09, 2012

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008
AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008
AP		AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016
AP			EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016
AP			EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016
AP			EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016
AP		CFT PHARMS LLC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015
AP			EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015
AP			EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015
AP			EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015
AP		EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202275	001	Oct 31, 2013
AP			EQ 1GM BASE/VIAL	A202275	002	Oct 31, 2013
AP			EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013
AP			EQ 5GM BASE/VIAL	A202274	001	Oct 31, 2013
AP	+	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A062663	001	Mar 17, 1987
AP			EQ 750MG BASE/VIAL	A062663	005	Aug 17, 2016
AP	+		EQ 1GM BASE/VIAL	A062663	002	Jul 31, 1987
AP	+		EQ 5GM BASE/VIAL	A062663	003	Jun 03, 1988
AP	+		EQ 10GM BASE/VIAL	A062663	004	Nov 28, 1997
AP		GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016
AP			EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016
AP	+	HOSPIRA	EQ 500MG BASE/VIAL	A062911	001	Aug 04, 1988
AP	+		EQ 500MG BASE/VIAL	A062931	001	Oct 29, 1992
AP	+		EQ 750MG BASE/VIAL	A062912	002	Jan 07, 2009
AP	+		EQ 750MG BASE/VIAL	A062933	002	May 27, 2009
AP	+		EQ 1GM BASE/VIAL	A062912	001	Aug 04, 1988
AP	+		EQ 1GM BASE/VIAL	A062933	001	Oct 29, 1992
AP	+		EQ 5GM BASE/VIAL	A063076	001	Dec 21, 1990
AP		HOSPIRA INC	EQ 10GM BASE/VIAL	A065455	001	Apr 29, 2009
AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008
AP			EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008
AP			EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008
AP			EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011
AP			EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011
AP		SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837	001	Aug 10, 2012
AP			EQ 10GM BASE/VIAL	A200837	002	Sep 02, 2014
AP		SANDOZ	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010
AP			EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010
AP		SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012
AP			EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012
AP		TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015
AP			EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015
AP			EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015
AP			EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015
AP		XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015
AP			EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015
AP			EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015
AP			EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
	+		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010

POWDER;IV (INFUSION)

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

		SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016

FDA data supplied by DrugPatentWatch.com

VANDETANIB
TABLET;ORAL
CAPRELSA

	GENZYME CORP	100MG	N022405	001	Apr 06, 2011
+		300MG	N022405	002	Apr 06, 2011

VARDENAFIL HYDROCHLORIDE
TABLET;ORAL

	LEVITRA				
AB	BAYER HLTHCARE	**2.5MG**	**N021400**	**003**	Aug 19, 2003
AB		**5MG**	**N021400**	**001**	Aug 19, 2003
AB		**10MG**	**N021400**	**002**	Aug 19, 2003
AB	+	**20MG**	**N021400**	**004**	Aug 19, 2003
	VARDENAFIL HYDROCHLORIDE				
AB	TEVA PHARMS	**2.5MG**	**A091347**	**001**	May 03, 2012
AB		**5MG**	**A091347**	**002**	May 03, 2012
AB		**10MG**	**A091347**	**003**	May 03, 2012
AB		**20MG**	**A091347**	**004**	May 03, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

	STAXYN				
AB	+ BAYER HLTHCARE	**10MG**	**N200179**	**001**	Jun 17, 2010
	VARDENAFIL HYDROCHLORIDE				
AB	WATSON LABS INC	**10MG**	**A203689**	**001**	Apr 22, 2015

VARENICLINE TARTRATE
TABLET;ORAL
CHANTIX

	PFIZER INC	EQ 0.5MG BASE	N021928	001	May 10, 2006
+		EQ 1MG BASE	N021928	002	May 10, 2006

VASOPRESSIN
SOLUTION;IV (INFUSION)
VASOSTRICT

+	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014

VECURONIUM BROMIDE
INJECTABLE;INJECTION

	VECURONIUM BROMIDE				
AP	EUROHLTH INTL SARL	**10MG/VIAL**	**A075549**	**001**	Jun 13, 2000
AP		**20MG/VIAL**	**A075549**	**002**	Jun 13, 2000
AP	GLAND PHARMA LTD	**10MG/VIAL**	**A205390**	**001**	May 26, 2016
AP		**20MG/VIAL**	**A205390**	**002**	May 26, 2016
AP	HOSPIRA	**10MG/VIAL**	**A075164**	**001**	Oct 21, 1999
AP		**20MG/VIAL**	**A075164**	**002**	Oct 21, 1999
AP	MYLAN LABS LTD	**10MG/VIAL**	**A090243**	**001**	May 11, 2010
AP		**20MG/VIAL**	**A090243**	**002**	May 11, 2010
AP	SAGENT PHARMS	**10MG/VIAL**	**A078274**	**001**	Dec 29, 2008
AP		**20MG/VIAL**	**A078274**	**002**	Dec 29, 2008
AP	+ SUN PHARMA GLOBAL	**10MG/VIAL**	**A079001**	**001**	Jun 17, 2009
AP	+	**20MG/VIAL**	**A079001**	**002**	Jun 17, 2009
AP	TEVA PHARMS USA	**10MG/VIAL**	**A074688**	**001**	Aug 25, 1999
AP		**20MG/VIAL**	**A074688**	**002**	Aug 25, 1999

VELAGLUCERASE ALFA
INJECTABLE;IV (INFUSION)
VPRIV

	SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010

VEMURAFENIB
TABLET;ORAL
ZELBORAF

+	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011

VENETOCLAX
TABLET;ORAL
VENCLEXTA

	ABBVIE INC	10MG	N208573	001	Apr 11, 2016
		50MG	N208573	002	Apr 11, 2016
+		100MG	N208573	003	Apr 11, 2016

FDA data supplied by DrugPatentWatch.com

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

AB	WYETH PHARMS INC	EQ 37.5MG BASE	N020699	001	Oct 20, 1997
AB		EQ 75MG BASE	N020699	002	Oct 20, 1997
AB +		EQ 150MG BASE	N020699	004	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012
AB		EQ 75MG BASE	A078087	002	Mar 16, 2012
AB		EQ 150MG BASE	A078087	003	Mar 16, 2012
AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834	001	Apr 14, 2011
AB		EQ 75MG BASE	A200834	002	Apr 14, 2011
AB		EQ 150MG BASE	A200834	003	Apr 14, 2011
AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421	001	May 06, 2011
AB		EQ 75MG BASE	A078421	002	May 06, 2011
AB		EQ 150MG BASE	A078421	003	May 06, 2011
AB	MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011
AB		EQ 75MG BASE	A078789	002	Jun 01, 2011
AB		EQ 150MG BASE	A078789	003	Jun 01, 2011
AB	ORCHID HLTHCARE	EQ 37.5MG BASE	A091123	001	Jul 11, 2011
AB		EQ 75MG BASE	A091123	002	Jul 11, 2011
AB		EQ 150MG BASE	A091123	003	Jul 11, 2011
AB	TEVA	EQ 37.5MG BASE	A076565	001	Jun 28, 2010
AB		EQ 75MG BASE	A076565	002	Jun 28, 2010
AB		EQ 150MG BASE	A076565	003	Jun 28, 2010
AB	TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899	001	Jun 01, 2011
AB		EQ 75MG BASE	A090899	002	Jun 01, 2011
AB		EQ 150MG BASE	A090899	003	Jun 01, 2011
AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011
AB	WOCKHARDT	EQ 37.5MG BASE	A078865	001	Apr 14, 2011
AB		EQ 75MG BASE	A078865	002	Apr 14, 2011
AB		EQ 150MG BASE	A078865	003	Apr 14, 2011
AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174	001	Apr 14, 2011
AB		EQ 75MG BASE	A090174	002	Apr 14, 2011
AB		EQ 150MG BASE	A090174	003	Apr 14, 2011

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A078932	001	Dec 14, 2010
AB		EQ 37.5MG BASE	A078932	002	Dec 14, 2010
AB		EQ 50MG BASE	A078932	003	Dec 14, 2010
AB		EQ 75MG BASE	A078932	004	Dec 14, 2010
AB		EQ 100MG BASE	A078932	005	Dec 14, 2010
AB	AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010
AB		EQ 37.5MG BASE	A079098	002	May 11, 2010
AB		EQ 50MG BASE	A079098	003	May 11, 2010
AB		EQ 75MG BASE	A079098	004	May 11, 2010
AB		EQ 100MG BASE	A079098	005	May 11, 2010
AB	AUROBINDO PHARMA	EQ 25MG BASE	A090555	001	Apr 07, 2010
AB		EQ 37.5MG BASE	A090555	002	Apr 07, 2010
AB		EQ 50MG BASE	A090555	003	Apr 07, 2010
AB		EQ 75MG BASE	A090555	004	Apr 07, 2010
AB		EQ 100MG BASE	A090555	005	Apr 07, 2010
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A078301	001	Jun 13, 2008
AB		EQ 37.5MG BASE	A078301	002	Jun 13, 2008
AB		EQ 50MG BASE	A078301	003	Jun 13, 2008
AB		EQ 75MG BASE	A078301	004	Jun 13, 2008
AB		EQ 100MG BASE	A078301	005	Jun 13, 2008
AB	HERITAGE PHARMS INC	EQ 25MG BASE	A078554	001	Jan 09, 2009
AB		EQ 37.5MG BASE	A078554	002	Jan 09, 2009
AB		EQ 50MG BASE	A078554	003	Jan 09, 2009
AB		EQ 75MG BASE	A078554	004	Jan 09, 2009
AB		EQ 100MG BASE	A078554	005	Jan 09, 2009
AB	MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008
AB		EQ 37.5MG BASE	A077166	002	Jun 13, 2008
AB		EQ 50MG BASE	A077166	003	Jun 13, 2008
AB		EQ 75MG BASE	A077166	004	Jun 13, 2008
AB		EQ 100MG BASE	A077166	005	Jun 13, 2008
AB	SUN PHARM INDS INC	EQ 25MG BASE	A078627	001	Jun 13, 2008
AB		EQ 37.5MG BASE	A078627	002	Jun 13, 2008
AB		EQ 50MG BASE	A078627	003	Jun 13, 2008

FDA data supplied by DrugPatentWatch.com

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB			EQ 75MG BASE	A078627	004	Jun 13, 2008
AB			EQ 100MG BASE	A078627	005	Jun 13, 2008
AB		TEVA	EQ 25MG BASE	A076690	001	Aug 03, 2006
AB			EQ 37.5MG BASE	A076690	002	Aug 03, 2006
AB	+		EQ 50MG BASE	A076690	003	Aug 03, 2006
AB			EQ 75MG BASE	A076690	004	Aug 03, 2006
AB			EQ 100MG BASE	A076690	005	Aug 03, 2006
AB		VINTAGE	EQ 25MG BASE	A090027	001	Aug 04, 2010
AB			EQ 37.5MG BASE	A090027	002	Aug 04, 2010
AB			EQ 50MG BASE	A090027	003	Aug 04, 2010
AB			EQ 75MG BASE	A090027	004	Aug 04, 2010
AB			EQ 100MG BASE	A090027	005	Aug 04, 2010
AB		YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015
AB			EQ 37.5MG BASE	A202036	002	May 28, 2015
AB			EQ 50MG BASE	A202036	003	May 28, 2015
AB			EQ 75MG BASE	A202036	004	May 28, 2015
AB			EQ 100MG BASE	A202036	005	May 28, 2015
AB		ZYDUS PHARMS USA	EQ 25MG BASE	A077653	001	Jun 13, 2008
AB			EQ 37.5MG BASE	A077653	002	Jun 13, 2008
AB			EQ 50MG BASE	A077653	003	Jun 13, 2008
AB			EQ 75MG BASE	A077653	004	Jun 13, 2008
AB			EQ 100MG BASE	A077653	005	Jun 13, 2008

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		OSMOTICA PHARM	EQ 37.5MG BASE	N022104	001	May 20, 2008
AB			EQ 75MG BASE	N022104	002	May 20, 2008
AB	+		EQ 150MG BASE	N022104	003	May 20, 2008
AB		SUN PHARMA GLOBAL	EQ 37.5MG BASE	A091272	001	Aug 18, 2010
AB			EQ 75MG BASE	A091272	002	Aug 18, 2010
AB			EQ 150MG BASE	A091272	003	Aug 18, 2010
		OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB		MYLAN	100MG	A078306	001	Aug 09, 2007
AB			120MG	A075138	001	Apr 20, 1999
AB			180MG	A075138	002	Apr 20, 1999
AB			200MG	A078306	002	Aug 09, 2007
AB			240MG	A075138	003	Apr 20, 1999
AB			300MG	A078306	003	Aug 09, 2007

VERELAN

AB		RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990
AB			180MG	N019614	003	Jan 09, 1992
AB			240MG	N019614	002	May 29, 1990

VERELAN PM

AB		RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998
AB			200MG	N020943	002	Nov 25, 1998
AB	+		300MG	N020943	003	Nov 25, 1998

VERELAN

	+	RECRO GAINESVILLE	360MG	N019614	004	May 10, 1996

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984
AP	+	HOSPIRA	10MG/4ML (2.5MG/ML)	A070738	001	May 06, 1987
AP	+		5MG/2ML (2.5MG/ML)	A075136	001	Oct 20, 1998
AP	+		5MG/2ML (2.5MG/ML)	A070737	001	May 06, 1987
AP	+		10MG/4ML (2.5MG/ML)	A070737	002	May 06, 1987

TABLET;ORAL

CALAN

AB		GD SEARLE LLC	80MG	N018817	001	Sep 10, 1984
AB	+		120MG	N018817	002	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

AB		HERITAGE PHARMS INC	40MG	A071881	002	Oct 14, 2015
AB			80MG	A071880	001	Apr 05, 1988
AB			120MG	A071881	001	Apr 05, 1988
AB		MYLAN	80MG	A071483	002	Feb 15, 1989
AB			120MG	A071483	001	Feb 15, 1989
AB		WATSON LABS	40MG	A072924	001	Jun 29, 1993
AB			80MG	A070995	001	Oct 01, 1986

VERAPAMIL HYDROCHLORIDE

TABLET;ORAL

	VERAPAMIL HYDROCHLORIDE				
AB		**120MG**	**A070994**	**001**	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

	CALAN SR				
AB	+ PFIZER	**120MG**	**N019152**	**003**	Mar 06, 1991
AB	+	**240MG**	**N019152**	**001**	Dec 16, 1986
	VERAPAMIL HYDROCHLORIDE				
AB	APOTEX CORP	**120MG**	**A200878**	**001**	Apr 20, 2012
AB		**180MG**	**A200878**	**002**	Apr 20, 2012
AB		**240MG**	**A200878**	**003**	Apr 20, 2012
AB	GLENMARK GENERICS	**120MG**	**A090700**	**001**	Aug 03, 2011
AB	+	**180MG**	**A090700**	**002**	Aug 03, 2011
AB		**240MG**	**A078906**	**001**	Sep 17, 2009
AB	IVAX SUB TEVA PHARMS	**120MG**	**A073568**	**002**	Oct 10, 1997
AB		**180MG**	**A074330**	**001**	Jan 31, 1994
AB		**240MG**	**A073568**	**001**	Jul 31, 1992
AB	MYLAN	**120MG**	**A074587**	**002**	Feb 21, 1997
AB		**180MG**	**A074587**	**003**	Sep 09, 1997
AB		**240MG**	**A074587**	**001**	Mar 23, 1996
AB	PAR PHARM	**120MG**	**A075072**	**001**	May 25, 1999
AB		**240MG**	**A075072**	**003**	May 25, 1999
AB	SUN PHARM INDS INC	**120MG**	**A090529**	**001**	Dec 30, 2011
AB		**180MG**	**A090529**	**002**	Dec 30, 2011
AB		**240MG**	**A090529**	**003**	Dec 30, 2011
	COVERA-HS				
BC	+ GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996
BC	+	240MG	N020552	002	Feb 26, 1996

VERTEPORFIN

INJECTABLE;INJECTION

	VISUDYNE				
	+ VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000

VIGABATRIN

FOR SOLUTION;ORAL

	SABRIL				
	+ LUNDBECK LLC	500MG/PACKET	N022006	001	Aug 21, 2009

TABLET;ORAL

	SABRIL				
	+ LUNDBECK LLC	500MG	N020427	001	Aug 21, 2009

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

	VIIBRYD				
	+ FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011
		20MG	N022567	002	Jan 21, 2011
		40MG	N022567	003	Jan 21, 2011

VINBLASTINE SULFATE

INJECTABLE;INJECTION

	VINBLASTINE SULFATE				
	+ FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987
	+ WEST-WARD PHARMS INT	10MG/VIAL	A089395	001	Apr 09, 1987

VINCRISTINE SULFATE

INJECTABLE;INJECTION

	VINCRISTINE SULFATE PFS				
AP	+ HOSPIRA	**1MG/ML**	**A071484**	**001**	Apr 19, 1988
AP	TEVA PHARMS USA	**1MG/ML**	**A075493**	**001**	Sep 01, 1999

INJECTABLE, LIPOSOMAL;INTRAVENOUS

	MARQIBO KIT				
	+ TALON THERAP	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012

VINORELBINE TARTRATE

INJECTABLE;INJECTION

	NAVELBINE				
AP	+ PIERRE FABRE	**EQ 10MG BASE/ML**	**N020388**	**001**	Dec 23, 1994
	VINORELBINE TARTRATE				
AP	ACTAVIS TOTOWA	**EQ 10MG BASE/ML**	**A078011**	**001**	Jul 22, 2009
AP	DR REDDYS LABS LTD	**EQ 10MG BASE/ML**	**A202017**	**001**	Sep 12, 2013
AP	EUROHLTH INTL SARL	**EQ 10MG BASE/ML**	**A075992**	**001**	Jun 10, 2003
AP		**EQ 10MG BASE/ML**	**A076461**	**001**	Dec 11, 2003
AP	FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A076849**	**001**	Apr 18, 2005

FDA data supplied by DrugPatentWatch.com

VINORELBINE TARTRATE
INJECTABLE;INJECTION
VINORELBINE TARTRATE

AP	HOSPIRA	**EQ 10MG BASE/ML**	**A076827**	**001**	Jun 02, 2005
AP	JIANGSU HANSOH PHARM	**EQ 10MG BASE/ML**	**A091106**	**001**	Sep 26, 2012
AP	MYLAN LABS LTD	**EQ 10MG BASE/ML**	**A200148**	**001**	Aug 31, 2012
AP	TEVA PHARMS USA	**EQ 10MG BASE/ML**	**A076028**	**001**	Feb 03, 2003

VISMODEGIB
CAPSULE;ORAL
ERIVEDGE

+	GENENTECH	150MG	N203388	001	Jan 30, 2012

VITAMIN A PALMITATE
INJECTABLE;INJECTION
AQUASOL A

+	HOSPIRA	EQ 50,000 UNITS BASE/ML	N006823	001	

VORAPAXAR SULFATE
TABLET;ORAL
ZONTIVITY

+	ARALEZ PHARMS	EQ 2.08MG BASE	N204886	001	May 08, 2014

VORICONAZOLE
FOR SUSPENSION;ORAL
VFEND

AB	**+** PF PRISM CV	**200MG/5ML**	**N021630**	**001**	Dec 19, 2003

VORICONAZOLE

AB	AMNEAL PHARMS	**200MG/5ML**	**A205034**	**001**	Apr 13, 2016
AB	MYLAN PHARMS INC	**200MG/5ML**	**A202361**	**001**	May 28, 2013
AB	NOVEL LABS INC	**200MG/5ML**	**A206799**	**001**	May 31, 2016

INJECTABLE;IV (INFUSION)
VFEND

AP	**+** PF PRISM CV	**200MG/VIAL**	**N021267**	**001**	May 24, 2002

VORICONAZOLE

AP	ALVOGEN INC	**200MG/VIAL**	**A206398**	**001**	Mar 23, 2016
AP	SANDOZ INC	**200MG/VIAL**	**A090862**	**001**	May 30, 2012

TABLET;ORAL
VFEND

AB	PF PRISM CV	**50MG**	**N021266**	**001**	May 24, 2002
AB	**+**	**200MG**	**N021266**	**002**	May 24, 2002

VORICONAZOLE

AB	AJANTA PHARMA LTD	**50MG**	**A206181**	**001**	May 24, 2016
AB		**200MG**	**A206181**	**002**	May 24, 2016
AB	AKORN	**50MG**	**A207049**	**001**	Sep 07, 2016
AB		**200MG**	**A207049**	**002**	Sep 07, 2016
AB	APPCO PHARMA LLC	**50MG**	**A206762**	**001**	May 24, 2016
AB		**200MG**	**A206762**	**002**	May 24, 2016
AB	AUROBINDO PHARMA LTD	**50MG**	**A206837**	**001**	Jan 22, 2016
AB		**200MG**	**A206837**	**002**	Jan 22, 2016
AB	GLENMARK PHARMS LTD	**50MG**	**A203503**	**001**	Sep 02, 2015
AB		**200MG**	**A203503**	**002**	Sep 02, 2015
AB	MYLAN PHARMS INC	**50MG**	**A090547**	**001**	Apr 22, 2010
AB		**200MG**	**A090547**	**002**	Apr 22, 2010
AB	NOVEL LABS INC	**50MG**	**A207371**	**001**	May 24, 2016
AB		**200MG**	**A207371**	**002**	May 24, 2016
AB	PRINSTON INC	**50MG**	**A206654**	**001**	Aug 08, 2016
AB		**200MG**	**A206654**	**002**	Aug 08, 2016
AB	SANDOZ INC	**50MG**	**A200265**	**001**	Dec 12, 2011
AB		**200MG**	**A200265**	**002**	Dec 12, 2011
AB	TEVA PHARMS	**50MG**	**A091658**	**001**	Apr 06, 2012
AB		**200MG**	**A091658**	**002**	Apr 06, 2012
AB	ZYDUS PHARMS USA INC	**50MG**	**A206747**	**001**	May 24, 2016
AB		**200MG**	**A206747**	**002**	May 24, 2016

VORINOSTAT
CAPSULE;ORAL
ZOLINZA

+	MERCK	100MG	N021991	001	Oct 06, 2006

VORTIOXETINE HYDROBROMIDE
TABLET;ORAL
TRINTELLIX

	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013
		EQ 10MG BASE	N204447	002	Sep 30, 2013
		EQ 15MG BASE	N204447	003	Sep 30, 2013
+		EQ 20MG BASE	N204447	004	Sep 30, 2013

WARFARIN SODIUM
TABLET;ORAL

	COUMADIN				
AB	BRISTOL MYERS SQUIBB	**1MG**	**N009218**	**022**	Mar 01, 1990
AB		**2MG**	**N009218**	**013**	
AB		**2.5MG**	**N009218**	**018**	
AB		**3MG**	**N009218**	**025**	Nov 18, 1996
AB		**4MG**	**N009218**	**023**	Aug 24, 1993
AB		**5MG**	**N009218**	**007**	
AB		**6MG**	**N009218**	**026**	Nov 18, 1996
AB		**7.5MG**	**N009218**	**016**	
AB	+	**10MG**	**N009218**	**005**	
	JANTOVEN				
AB	USL PHARMA	**1MG**	**A040416**	**001**	Oct 02, 2003
AB		**2MG**	**A040416**	**002**	Oct 02, 2003
AB		**2.5MG**	**A040416**	**003**	Oct 02, 2003
AB		**3MG**	**A040416**	**004**	Oct 02, 2003
AB		**4MG**	**A040416**	**005**	Oct 02, 2003
AB		**5MG**	**A040416**	**006**	Oct 02, 2003
AB		**6MG**	**A040416**	**007**	Oct 02, 2003
AB		**7.5MG**	**A040416**	**008**	Oct 02, 2003
AB		**10MG**	**A040416**	**009**	Oct 02, 2003
	WARFARIN SODIUM				
AB	AMNEAL PHARMS	**1MG**	**A202202**	**001**	Mar 04, 2013
AB		**2MG**	**A202202**	**002**	Mar 04, 2013
AB		**2.5MG**	**A202202**	**003**	Mar 04, 2013
AB		**3MG**	**A202202**	**004**	Mar 04, 2013
AB		**4MG**	**A202202**	**005**	Mar 04, 2013
AB		**5MG**	**A202202**	**006**	Mar 04, 2013
AB		**6MG**	**A202202**	**007**	Mar 04, 2013
AB		**7.5MG**	**A202202**	**008**	Mar 04, 2013
AB		**10MG**	**A202202**	**009**	Mar 04, 2013
AB	BARR	**1MG**	**A040145**	**001**	Mar 26, 1997
AB		**2MG**	**A040145**	**002**	Mar 26, 1997
AB		**2.5MG**	**A040145**	**003**	Mar 26, 1997
AB		**3MG**	**A040145**	**008**	Nov 05, 1998
AB		**4MG**	**A040145**	**004**	Mar 26, 1997
AB		**5MG**	**A040145**	**005**	Mar 26, 1997
AB		**6MG**	**A040145**	**009**	Nov 05, 1998
AB		**7.5MG**	**A040145**	**006**	Mar 26, 1997
AB		**10MG**	**A040145**	**007**	Mar 26, 1997
AB	INVAGEN PHARMS	**1MG**	**A090935**	**001**	May 25, 2011
AB		**2MG**	**A090935**	**002**	May 25, 2011
AB		**2.5MG**	**A090935**	**003**	May 25, 2011
AB		**3MG**	**A090935**	**004**	May 25, 2011
AB		**4MG**	**A090935**	**005**	May 25, 2011
AB		**5MG**	**A090935**	**006**	May 25, 2011
AB		**6MG**	**A090935**	**007**	May 25, 2011
AB		**7.5MG**	**A090935**	**008**	May 25, 2011
AB		**10MG**	**A090935**	**009**	May 25, 2011
AB	IPCA LABS LTD	**1MG**	**A200104**	**001**	Jun 27, 2013
AB		**2MG**	**A200104**	**002**	Jun 27, 2013
AB		**2.5MG**	**A200104**	**003**	Jun 27, 2013
AB		**3MG**	**A200104**	**004**	Jun 27, 2013
AB		**4MG**	**A200104**	**005**	Jun 27, 2013
AB		**5MG**	**A200104**	**006**	Jun 27, 2013
AB		**6MG**	**A200104**	**007**	Jun 27, 2013
AB		**7.5MG**	**A200104**	**008**	Jun 27, 2013
AB		**10MG**	**A200104**	**009**	Jun 27, 2013
AB	MYLAN	**1MG**	**A040415**	**001**	Sep 27, 2004
AB		**2MG**	**A040415**	**002**	Sep 27, 2004
AB		**2.5MG**	**A040415**	**003**	Sep 29, 2004
AB		**3MG**	**A040415**	**004**	Sep 27, 2004
AB		**4MG**	**A040415**	**005**	Sep 27, 2004
AB		**5MG**	**A040415**	**006**	Sep 27, 2004

FDA data supplied by DrugPatentWatch.com

WARFARIN SODIUM
TABLET;ORAL

	WARFARIN SODIUM				
AB		**6MG**	**A040415**	**007**	Sep 27, 2004
AB		**7.5MG**	**A040415**	**008**	Sep 27, 2004
AB		**10MG**	**A040415**	**009**	Sep 27, 2004
AB	PLIVA	**1MG**	**A040616**	**009**	Jul 05, 2006
AB		**2MG**	**A040616**	**001**	Jul 05, 2006
AB		**2.5MG**	**A040616**	**002**	Jul 05, 2006
AB		**3MG**	**A040616**	**003**	Jul 05, 2006
AB		**4MG**	**A040616**	**004**	Jul 05, 2006
AB		**5MG**	**A040616**	**005**	Jul 05, 2006
AB		**6MG**	**A040616**	**006**	Jul 05, 2006
AB		**7.5MG**	**A040616**	**007**	Jul 05, 2006
AB		**10MG**	**A040616**	**008**	Jul 05, 2006
AB	TARO	**1MG**	**A040301**	**002**	Jul 15, 1999
AB		**2MG**	**A040301**	**003**	Jul 15, 1999
AB		**2.5MG**	**A040301**	**004**	Jul 15, 1999
AB		**3MG**	**A040301**	**005**	Jul 15, 1999
AB		**4MG**	**A040301**	**006**	Jul 15, 1999
AB		**5MG**	**A040301**	**007**	Jul 15, 1999
AB		**6MG**	**A040301**	**008**	Jul 15, 1999
AB		**7.5MG**	**A040301**	**009**	Jul 15, 1999
AB		**10MG**	**A040301**	**001**	Jul 15, 1999
AB	ZYDUS PHARMS USA	**1MG**	**A040663**	**001**	May 30, 2006
AB		**2MG**	**A040663**	**002**	May 30, 2006
AB		**2.5MG**	**A040663**	**003**	May 30, 2006
AB		**3MG**	**A040663**	**004**	May 30, 2006
AB		**4MG**	**A040663**	**005**	May 30, 2006
AB		**5MG**	**A040663**	**006**	May 30, 2006
AB		**6MG**	**A040663**	**007**	May 30, 2006
AB		**7.5MG**	**A040663**	**008**	May 30, 2006
AB		**10MG**	**A040663**	**009**	May 30, 2006

XENON XE-133
GAS;INHALATION

	XENON XE 133				
	LANTHEUS MEDCL	10mCi/VIAL	N017284	001	
		20mCi/VIAL	N017284	002	
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982
		20mCi/VIAL	N018327	002	Mar 09, 1982

ZAFIRLUKAST
TABLET;ORAL

	ACCOLATE				
AB	PAR PHARM INC	**10MG**	**N020547**	**003**	Sep 17, 1999
AB	**+**	**20MG**	**N020547**	**001**	Sep 26, 1996
	ZAFIRLUKAST				
AB	DR REDDYS LABS LTD	**10MG**	**A090372**	**001**	Nov 18, 2010
AB		**20MG**	**A090372**	**002**	Nov 18, 2010

ZALEPLON
CAPSULE;ORAL

	SONATA				
AB	PFIZER	**5MG**	**N020859**	**001**	Aug 13, 1999
AB	**+**	**10MG**	**N020859**	**002**	Aug 13, 1999
	ZALEPLON				
AB	AUROBINDO PHARMA	**5MG**	**A078829**	**001**	Jun 06, 2008
AB		**10MG**	**A078829**	**002**	Jun 06, 2008
AB	CIPLA LTD	**5MG**	**A077505**	**001**	Jun 20, 2008
AB		**10MG**	**A077505**	**002**	Jun 20, 2008
AB	HIKMA PHARMS LLC	**5MG**	**A078147**	**001**	Nov 25, 2008
AB		**10MG**	**A078147**	**002**	Nov 25, 2008
AB	MYLAN	**5MG**	**A077238**	**001**	Jun 06, 2008
AB		**10MG**	**A077238**	**002**	Jun 06, 2008
AB	ORCHID HLTHCARE	**5MG**	**A090374**	**001**	Sep 17, 2009
AB		**10MG**	**A090374**	**002**	Sep 17, 2009
AB	TEVA PHARMS	**5MG**	**A077239**	**001**	Jun 06, 2008
AB		**10MG**	**A077239**	**002**	Jun 06, 2008
AB	UNICHEM	**5MG**	**A078989**	**001**	Jun 06, 2008
AB		**10MG**	**A078989**	**002**	Jun 06, 2008
AB	WEST-WARD PHARMS INT	**5MG**	**A077237**	**001**	Jun 06, 2008
AB		**10MG**	**A077237**	**002**	Jun 06, 2008

ZANAMIVIR
POWDER;INHALATION
RELENZA

	+	GLAXOSMITHKLINE	5MG	N021036	001 Jul 26, 1999

ZICONOTIDE ACETATE
INJECTABLE;INTRATHECAL
PRIALT

	+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002 Dec 28, 2004
	+		500MCG/20ML (25MCG/ML)	N021060	001 Dec 28, 2004
	+		500MCG/5ML (100MCG/ML)	N021060	004 Dec 28, 2004

ZIDOVUDINE
CAPSULE;ORAL

		RETROVIR			
AB	+	VIIV HLTHCARE	**100MG**	**N019655**	**001** Mar 19, 1987
		ZIDOVUDINE			
AB		AUROBINDO PHARMA LTD	**100MG**	**A078128**	**001** Mar 27, 2006
AB		CIPLA LTD	**100MG**	**A078349**	**001** May 23, 2007

INJECTABLE;INJECTION

		RETROVIR			
AP	+	VIIV HLTHCARE	**10MG/ML**	**N019951**	**001** Feb 02, 1990
		ZIDOVUDINE			
AP		LUITPOLD	**10MG/ML**	**A091457**	**001** May 06, 2010

SYRUP;ORAL

		RETROVIR			
AA	+	VIIV HLTHCARE	**50MG/5ML**	**N019910**	**001** Sep 28, 1989
		ZIDOVUDINE			
AA		AUROBINDO	**50MG/5ML**	**A077268**	**001** Sep 19, 2005
AA		CIPLA LTD	**50MG/5ML**	**A077981**	**001** Jun 26, 2008

TABLET;ORAL

		ZIDOVUDINE			
AB		AUROBINDO	**300MG**	**A077267**	**001** Sep 19, 2005
AB		CIPLA	**300MG**	**A090561**	**001** Oct 27, 2010
AB	+	HETERO LABS LTD III	**300MG**	**A090092**	**001** Apr 25, 2008
AB		MYLAN PHARMS INC	**300MG**	**A078922**	**001** Feb 14, 2008
AB		WEST-WARD PHARMS INT	**300MG**	**A076844**	**001** Sep 19, 2005

ZILEUTON
TABLET;ORAL
ZYFLO

	+	CHIESI USA INC	600MG	N020471	003 Dec 09, 1996

TABLET, EXTENDED RELEASE;ORAL
ZYFLO CR

	+	CHIESI USA INC	600MG	N022052	001 May 30, 2007

ZINC ACETATE
CAPSULE;ORAL
GALZIN

		TEVA	EQ 25MG ZINC	N020458	001 Jan 28, 1997
	+		EQ 50MG ZINC	N020458	002 Jan 28, 1997

ZINC CHLORIDE
INJECTABLE;INJECTION
ZINC CHLORIDE IN PLASTIC CONTAINER

	+	HOSPIRA	EQ 1MG ZINC/ML	N018959	001 Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE
CAPSULE;ORAL

		GEODON			
AB	+	PFIZER	**EQ 20MG BASE**	**N020825**	**001** Feb 05, 2001
AB			**EQ 40MG BASE**	**N020825**	**002** Feb 05, 2001
AB			**EQ 60MG BASE**	**N020825**	**003** Feb 05, 2001
AB			**EQ 80MG BASE**	**N020825**	**004** Feb 05, 2001
		ZIPRASIDONE HYDROCHLORIDE			
AB		APOTEX INC	**EQ 20MG BASE**	**A077561**	**001** Mar 02, 2012
AB			**EQ 40MG BASE**	**A077561**	**002** Mar 02, 2012
AB			**EQ 60MG BASE**	**A077561**	**003** Mar 02, 2012
AB			**EQ 80MG BASE**	**A077561**	**004** Mar 02, 2012
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A204117**	**001** Dec 27, 2016
AB			**EQ 40MG BASE**	**A204117**	**002** Dec 27, 2016
AB			**EQ 60MG BASE**	**A204117**	**003** Dec 27, 2016
AB			**EQ 80MG BASE**	**A204117**	**004** Dec 27, 2016
AB		DR REDDYS LABS INC	**EQ 20MG BASE**	**A077565**	**001** Mar 02, 2012
AB			**EQ 40MG BASE**	**A077565**	**002** Mar 02, 2012

ZIPRASIDONE HYDROCHLORIDE
CAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

AB		**EQ 60MG BASE**	**A077565**	**003**	Mar 02, 2012
AB		**EQ 80MG BASE**	**A077565**	**004**	Mar 02, 2012
AB	LUPIN PHARMS	**EQ 20MG BASE**	**A077560**	**001**	Mar 02, 2012
AB		**EQ 40MG BASE**	**A077560**	**002**	Mar 02, 2012
AB		**EQ 60MG BASE**	**A077560**	**003**	Mar 02, 2012
AB		**EQ 80MG BASE**	**A077560**	**004**	Mar 02, 2012
AB	MYLAN PHARMS INC	**EQ 20MG BASE**	**A202395**	**001**	Oct 10, 2013
AB		**EQ 40MG BASE**	**A202395**	**002**	Oct 10, 2013
AB		**EQ 60MG BASE**	**A202395**	**003**	Oct 10, 2013
AB		**EQ 80MG BASE**	**A202395**	**004**	Oct 10, 2013
AB	SANDOZ INC	**EQ 20MG BASE**	**A077562**	**001**	Jun 01, 2012
AB		**EQ 40MG BASE**	**A077562**	**002**	Jun 01, 2012
AB		**EQ 60MG BASE**	**A077562**	**003**	Jun 01, 2012
AB		**EQ 80MG BASE**	**A077562**	**004**	Jun 01, 2012
AB	WOCKHARDT LTD	**EQ 20MG BASE**	**A090348**	**001**	Sep 05, 2012
AB		**EQ 40MG BASE**	**A090348**	**002**	Sep 05, 2012
AB		**EQ 60MG BASE**	**A090348**	**003**	Sep 05, 2012
AB		**EQ 80MG BASE**	**A090348**	**004**	Sep 05, 2012

ZIPRASIDONE MESYLATE
INJECTABLE;INTRAMUSCULAR
GEODON

+	PFIZER	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002

ZOLEDRONIC ACID
INJECTABLE;IV (INFUSION)
RECLAST

AP	**+** NOVARTIS	**EQ 5MG BASE/100ML**	**N021817**	**001**	Apr 16, 2007

ZOLEDRONIC ACID

AP	ACCORD HLTHCARE	**EQ 4MG BASE/5ML**	**A205279**	**001**	Nov 28, 2016
AP	ACS DOBFAR INFO SA	**EQ 4MG BASE/100ML**	**N203231**	**001**	Aug 02, 2013
AP		**EQ 5MG BASE/100ML**	**A202828**	**001**	Sep 23, 2013
AP	ACTAVIS INC	**EQ 4MG BASE/5ML**	**A202472**	**001**	Mar 04, 2013
AP	AKORN	**EQ 5MG BASE/100ML**	**A200918**	**001**	Aug 21, 2014
AP	AKORN INC	**EQ 4MG BASE/5ML**	**A202548**	**001**	May 22, 2014
AP	APOTEX INC	**EQ 5MG BASE/100ML**	**A204367**	**001**	Dec 24, 2015
AP	AUROBINDO PHARMA LTD	**EQ 4MG BASE/5ML**	**A207751**	**001**	Sep 26, 2016
AP	DR REDDYS LABS LTD	**EQ 4MG BASE/5ML**	**A091186**	**001**	Mar 04, 2013
AP		**EQ 5MG BASE/100ML**	**A091363**	**001**	Mar 29, 2013
AP	EMCURE PHARMS LTD	**EQ 4MG BASE/5ML**	**A201783**	**001**	Mar 12, 2013
AP		**EQ 5MG BASE/100ML**	**A201801**	**001**	Mar 29, 2013
AP	FRESENIUS KABI USA	**EQ 4MG BASE/5ML**	**A091516**	**001**	Apr 23, 2015
AP	GLAND PHARMA LTD	**EQ 4MG BASE/5ML**	**A202930**	**001**	Aug 05, 2013
AP		**EQ 5MG BASE/100ML**	**A204217**	**001**	Aug 18, 2016
AP	HIKMA FARMACEUTICA	**EQ 4MG BASE/5ML**	**A202182**	**001**	Jun 03, 2013
AP	HOSPIRA INC	**EQ 4MG BASE/5ML**	**A090621**	**001**	Mar 19, 2015
AP		**EQ 5MG BASE/100ML**	**A202837**	**001**	Apr 05, 2013
AP	MYLAN LABS LTD	**EQ 4MG BASE/5ML**	**A202650**	**001**	Mar 04, 2013
AP	PHARMACEUTICS	**EQ 4MG BASE/5ML**	**A091170**	**001**	Mar 04, 2013
AP		**EQ 5MG BASE/100ML**	**A202163**	**001**	Aug 05, 2013
AP	PHARMS	**EQ 4MG BASE/5ML**	**A202571**	**001**	May 07, 2013
AP	SAGENT PHARMS	**EQ 4MG BASE/5ML**	**A091493**	**001**	Nov 24, 2014
AP	**+** SUN PHARMA GLOBAL	**EQ 4MG BASE/VIAL**	**A090018**	**001**	Mar 04, 2013
AP		**EQ 4MG BASE/5ML**	**A202746**	**001**	Mar 04, 2013
AP	USV NORTH AMERICA	**EQ 4MG BASE/5ML**	**A202923**	**001**	Sep 04, 2014

ZOMETA

AP	**+** NOVARTIS	**EQ 4MG BASE/5ML**	**N021223**	**002**	Mar 07, 2003
AP	**+**	**EQ 4MG BASE/100ML**	**N021223**	**003**	Jun 17, 2011

SOLUTION;IV (INFUSION)
ZOLEDRONIC ACID

	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015

ZOLMITRIPTAN
SPRAY;NASAL
ZOMIG

	ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013
+		5MG/SPRAY	N021450	004	Sep 30, 2003

TABLET;ORAL
ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	**2.5MG**	**A204041**	**001**	May 20, 2016
AB		**5MG**	**A204041**	**002**	May 20, 2016

FDA data supplied by DrugPatentWatch.com

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	ALEMBIC PHARMS LTD	2.5MG	A204232	001	Sep 30, 2015
AB		5MG	A204232	002	Sep 30, 2015
AB	APOTEX INC	2.5MG	A202078	001	May 14, 2013
AB		5MG	A202078	002	May 14, 2013
AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016
AB		5MG	A207021	002	May 11, 2016
AB	GLENMARK GENERICS	2.5MG	A201779	001	May 14, 2013
AB		5MG	A201779	002	May 14, 2013
AB	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014
AB		5MG	A204284	002	Apr 09, 2014
AB	JUBILANT GENERICS	2.5MG	A202279	001	Nov 20, 2014
AB		5MG	A202279	002	Nov 20, 2014
AB	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015
AB		5MG	A203772	002	Sep 30, 2015
AB	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013
AB		5MG	A203186	002	May 14, 2013
AB	SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014
AB		5MG	A203476	002	Nov 13, 2014
AB	TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014
AB		5MG	A090861	002	Mar 04, 2014

ZOMIG

AB	IPR	2.5MG	N020768	001	Nov 25, 1997
AB +		5MG	N020768	002	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB	ALEMBIC PHARMS LTD	2.5MG	A205074	001	Dec 01, 2016
AB		5MG	A205074	002	Dec 01, 2016
AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013
AB		5MG	A202476	002	May 14, 2013
AB	GLENMARK GENERICS	2.5MG	A202560	001	May 14, 2013
AB		5MG	A202560	002	May 14, 2013
AB	JUBILANT GENERICS	2.5MG	A202956	001	Sep 17, 2015
AB		5MG	A202956	002	Sep 17, 2015
AB	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015
AB		5MG	A204336	002	Oct 22, 2015
AB	ZYDUS PHARMS USA INC	2.5MG	A202890	001	May 15, 2013
AB		5MG	A202890	002	May 15, 2013

ZOMIG-ZMT

AB	ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001
AB +		5MG	N021231	002	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+	AMHERST PHARMS LLC	5MG/SPRAY	N022196	001	Dec 19, 2008

TABLET;ORAL

AMBIEN

AB	SANOFI AVENTIS US	5MG	N019908	001	Dec 16, 1992
AB +		10MG	N019908	002	Dec 16, 1992

ZOLPIDEM TARTRATE

AB	APOTEX INC	5MG	A077884	001	Apr 23, 2007
AB		10MG	A077884	002	Apr 23, 2007
AB	AUROBINDO PHARMA	5MG	A078413	001	May 04, 2007
AB		10MG	A078413	002	May 04, 2007
AB	CIPLA LTD	5MG	A077388	001	Jul 30, 2012
AB		10MG	A077388	002	Jul 30, 2012
AB	INVAGEN PHARMS	5MG	A078184	001	Sep 07, 2007
AB		10MG	A078184	002	Sep 07, 2007
AB	MYLAN	5MG	A076578	001	Apr 23, 2007
AB		10MG	A076578	002	Apr 23, 2007
AB	ROXANE	5MG	A077214	001	Apr 23, 2007
AB		10MG	A077214	002	Apr 23, 2007
AB	SANDOZ INC	5MG	A077322	001	Apr 23, 2007
AB		10MG	A077322	002	Apr 23, 2007
AB	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007
AB		10MG	A077359	002	Apr 23, 2007
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007
AB		10MG	A078055	002	Apr 23, 2007
AB	TEVA	5MG	A076410	001	Apr 23, 2007
AB		10MG	A076410	002	Apr 23, 2007

FDA data supplied by DrugPatentWatch.com

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB	TORRENT PHARMS	5MG	A077903	001	Aug 17, 2007
AB		10MG	A077903	002	Aug 17, 2007
AB	VINTAGE	5MG	A078616	001	Nov 21, 2008
AB		10MG	A078616	002	Nov 21, 2008
AB	WOCKHARDT	5MG	A078426	001	May 15, 2007
AB		10MG	A078426	002	May 15, 2007
AB	YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007
AB		10MG	A077990	002	Apr 23, 2007

TABLET;SUBLINGUAL

EDLUAR

AB	MEDA PHARMS	5MG	N021997	001	Mar 13, 2009
AB +		10MG	N021997	002	Mar 13, 2009

INTERMEZZO

AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011
AB +		3.5MG	N022328	002	Nov 23, 2011

ZOLPIDEM TARTRATE

AB	DR REDDYS LABS INC	1.75MG	A204503	001	Nov 18, 2016
AB		3.5MG	A204503	002	Nov 18, 2016
AB	MYLAN PHARMS INC	5MG	A202657	001	Aug 08, 2016
AB		10MG	A202657	002	Aug 08, 2016
AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015
AB		3.5MG	A204299	002	Jun 03, 2015
AB	PAR FORM	5MG	A201509	001	Aug 01, 2016
AB		10MG	A201509	002	Aug 01, 2016

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

AB	SANOFI AVENTIS US	6.25MG	N021774	002	Sep 02, 2005
AB +		12.5MG	N021774	001	Sep 02, 2005

ZOLPIDEM TARTRATE

AB	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010
AB		12.5MG	A078179	001	Jun 06, 2011
AB	ACTAVIS LABS FL INC	6.25MG	A090153	001	Mar 25, 2013
AB		12.5MG	A090153	002	Mar 25, 2013
AB	ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011
AB		12.5MG	A078148	001	Dec 03, 2010
AB	APOTEX INC	6.25MG	A200266	001	Sep 10, 2013
AB		12.5MG	A200266	002	Sep 10, 2013
AB	LUPIN LTD	6.25MG	A078970	001	Sep 11, 2013
AB		12.5MG	A078970	002	Sep 11, 2013
AB	SANDOZ	6.25MG	A090107	001	Jul 01, 2011
AB		12.5MG	A090107	002	Jul 01, 2011
AB	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011
AB		12.5MG	A078483	002	Jun 06, 2011

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003
AB		50MG	N020789	002	Aug 22, 2003
AB +		100MG	N020789	001	Mar 27, 2000

ZONISAMIDE

AB	APOTEX INC	25MG	A077642	001	Dec 22, 2005
AB		50MG	A077642	002	Dec 22, 2005
AB		100MG	A077642	003	Dec 22, 2005
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006
AB		50MG	A077813	002	Aug 16, 2006
AB		100MG	A077813	003	Aug 16, 2006
AB	GLENMARK GENERICS	25MG	A077651	001	Jan 30, 2006
AB		50MG	A077651	002	Jan 30, 2006
AB		100MG	A077651	003	Jan 30, 2006
AB	INVAGEN PHARMS	25MG	A077869	001	May 31, 2006
AB		50MG	A077869	002	May 31, 2006
AB		100MG	A077869	003	May 31, 2006
AB	MYLAN	25MG	A077637	001	Dec 22, 2005
AB		50MG	A077637	002	Dec 22, 2005
AB		100MG	A077637	003	Dec 22, 2005
AB	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005
AB		50MG	A077647	002	Dec 22, 2005
AB		100MG	A077647	003	Dec 22, 2005
AB	SUN PHARM INDS (IN)	25MG	A077634	001	Mar 17, 2006

FDA data supplied by DrugPatentWatch.com

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB		**50MG**	**A077634**	**002**	Mar 17, 2006
AB		**100MG**	**A077634**	**003**	Mar 17, 2006
AB	WOCKHARDT	**25MG**	**A077636**	**003**	Jul 27, 2006
AB		**50MG**	**A077636**	**002**	Jul 27, 2006
AB		**100MG**	**A077636**	**001**	Dec 22, 2005
AB	ZYDUS PHARMS USA	**25MG**	**A077625**	**001**	Oct 16, 2006
AB		**50MG**	**A077625**	**002**	Oct 16, 2006
AB		**100MG**	**A077625**	**003**	Oct 16, 2006

FDA data supplied by DrugPatentWatch.com

OTC DRUG PRODUCT LIST

ACETAMINOPHEN
SUPPOSITORY;RECTAL
ACEPHEN

G AND W LABS	120MG	N018060 001	
	325MG	A072344 001	Mar 27, 1992
	325MG	N018060 003	Dec 18, 1986
	650MG	A072237 001	Mar 27, 1992
	650MG	N018060 002	

ACETAMINOPHEN

PERRIGO NEW YORK	120MG	A070607 001	Apr 06, 1987
	650MG	A070608 001	Dec 01, 1986
TARO PHARMS NORTH	120MG	N018337 003	Sep 12, 1983
	325MG	N018337 002	
+	650MG	N018337 001	

INFANTS' FEVERALL

TARO PHARMS NORTH	80MG	N018337 004	Aug 26, 1992

NEOPAP

POLYMEDICA	120MG	N016401 001	

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

AUROBINDO PHARMA LTD	650MG	A207229 001	Nov 09, 2016
OHM LABS	650MG	A076200 001	Mar 19, 2002
PERRIGO	650MG	A075077 001	Feb 25, 2000
SUN PHARM INDS LTD	650MG	A078569 001	Dec 14, 2011

TYLENOL

+ J AND J CONSUMER INC	650MG	N019872 001	Jun 08, 1994
+	650MG	N019872 002	Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE
TABLET;ORAL
ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO	250MG;250MG;65MG	A075794 001	Nov 26, 2001

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802 001	Jan 14, 1998

ADAPALENE
GEL;TOPICAL
DIFFERIN

+ GALDERMA LABS LP	0.1%	N020380 002	Jul 08, 2016

ALCOHOL; CHLORHEXIDINE GLUCONATE
SOLUTION;TOPICAL
AVAGARD

+ 3M	61%;1%	N021074 001	Jun 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE
TABLET, CHEWABLE;ORAL
FOAMCOAT

GUARDIAN DRUG	80MG;20MG	A071793 001	Sep 04, 1987

GAVISCON

SANOFI AVENTIS US	80MG;20MG	N018685 001	Dec 09, 1983
+	160MG;40MG	N018685 002	Dec 09, 1983

ASPIRIN
CAPSULE;ORAL
ASPIRIN

+ PLX PHARMA	325MG	N203697 001	Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE
CREAM;TOPICAL
ANTHELIOS SX

+ LOREAL USA	2%;2%;10%	N021502 001	Jul 21, 2006

CAPITAL SOLEIL 15

+ LOREAL USA	2%;3%;10%	N021501 001	Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE
CREAM;TOPICAL
ANTHELIOS 20

+ LOREAL USA	2%;2%;10%;2%	N021471 001	Oct 05, 2006

ANTHELIOS 40

+ LOREAL USA	2%;3%;10%;5%	N022009 001	Mar 31, 2008
+	2%;3%;10%;5%	N022009 002	Oct 29, 2009

AVOBENZONE; OCTINOXATE; OXYBENZONE
LOTION;TOPICAL
SHADE UVAGUARD

+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045 001	Dec 07, 1992

BENTOQUATAM
LOTION;TOPICAL
IVY BLOCK

+	STAND HOMEOPATH	5%	N020532 001	Aug 26, 1996

BUDESONIDE
SPRAY, METERED;NASAL
BUDESONIDE

	APOTEX INC	0.032MG/SPRAY	A078949 002	Nov 20, 2015

RHINOCORT ALLERGY

+	ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746 003	Mar 23, 2015

BUTENAFINE HYDROCHLORIDE
CREAM;TOPICAL
LOTRIMIN ULTRA

+	BAYER HEALTHCARE LLC	1%	N021307 001	Dec 07, 2001

BUTOCONAZOLE NITRATE
CREAM;VAGINAL
FEMSTAT 3

+	BAYER	2%	N020421 001	Dec 21, 1995

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE
TABLET, CHEWABLE;ORAL
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

	PERRIGO R AND D	800MG;10MG;165MG	A077355 001	Feb 06, 2008
		800MG;10MG;165MG	A204782 001	Aug 29, 2016

PEPCID COMPLETE

+	J AND J CONSUMER INC	800MG;10MG;165MG	N020958 001	Oct 16, 2000

CETIRIZINE HYDROCHLORIDE
CAPSULE;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

	APOTEX INC	10MG	A207235 001	Aug 12, 2016
	BIONPHARMA INC	5MG	N022429 001	Jul 23, 2009
+		10MG	N022429 004	Jul 23, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	BIONPHARMA INC	5MG	N022429 003	Jul 23, 2009
+		10MG	N022429 002	Jul 23, 2009

SYRUP;ORAL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS	5MG/5ML	A090765 002	Oct 07, 2009
	AUROBINDO PHARMA	5MG/5ML	A090750 002	Feb 02, 2010
	BIO PHARM INC	5MG/5ML	A090474 002	Mar 30, 2009
	NOSTRUM LABS INC	5MG/5ML	A091327 001	Oct 17, 2011
	PERRIGO R AND D	5MG/5ML	A204226 001	Sep 09, 2013
		5MG/5ML	A090254 002	Apr 09, 2008
	SILARX	5MG/5ML	A091130 001	Apr 22, 2011
	TARO	5MG/5ML	A090182 002	Apr 22, 2008
		5MG/5ML	A201546 001	May 20, 2011
	TRIS PHARMA INC	5MG/5ML	A090572 001	Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AMNEAL PHARMS	5MG/5ML	A090765 001	Oct 07, 2009
	AUROBINDO PHARMA	5MG/5ML	A090750 001	Feb 02, 2010
	BIO PHARM INC	5MG/5ML	A090474 001	Mar 30, 2009
	NOSTRUM LABS INC	5MG/5ML	A091327 002	Oct 17, 2011
	PERRIGO R AND D	5MG/5ML	A090254 001	Apr 09, 2008
	SILARX	5MG/5ML	A091130 002	Apr 22, 2011
	TARO	5MG/5ML	A090182 001	Apr 22, 2008
		5MG/5ML	A201546 002	May 20, 2011
	TRIS PHARMA INC	5MG/5ML	A090572 002	Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+	J AND J CONSUMER INC	5MG/5ML	N022155 002	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+	J AND J CONSUMER INC	5MG/5ML	N022155 001	Nov 16, 2007

TABLET;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS NY	5MG	A078780 001	Jan 21, 2010
		10MG	A078780 004	Jan 21, 2010
	APOTEX INC	5MG	A078317 001	Dec 27, 2007

FDA data supplied by DrugPatentWatch.com

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY				
	10MG	A078317	002	Dec 27, 2007
AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015
	10MG	A090760	003	Aug 05, 2015
CADISTA PHARMS	5MG	A078933	001	Jun 15, 2010
	10MG	A078933	002	Jun 15, 2010
CIPLA LTD	5MG	A077318	001	Jul 25, 2013
	10MG	A077318	002	Jul 25, 2013
CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
	10MG	A202277	004	Mar 11, 2014
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007
CETIRIZINE HYDROCHLORIDE HIVES				
CADISTA PHARMS	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009
CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
	10MG	A090760	004	Aug 05, 2015
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010
ZYRTEC ALLERGY				
J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007
+	10MG	N019835	004	Nov 16, 2007

FDA data supplied by DrugPatentWatch.com

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL				
ZYRTEC HIVES RELIEF				
J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007
TABLET, CHEWABLE;ORAL				
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY				
JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015
	10MG	A091116	002	Feb 19, 2015
NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016
	10MG	A206793	002	Mar 08, 2016
SANDOZ	5MG	A078692	001	Feb 14, 2008
+	10MG	A078692	002	Feb 14, 2008
SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011
	10MG	A090142	002	Aug 30, 2011
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015
	10MG	A091116	004	Feb 19, 2015
SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011
	10MG	A090142	004	Aug 30, 2011
TABLET, ORALLY DISINTEGRATING;ORAL				
CETIRIZINE HYDROCHLORIDE ALLERGY				
PAR PHARM INC	10MG	A205490	001	Sep 02, 2015
ZYRTEC ALLERGY				
+ J AND J CONSUMER INC	10MG	N022578	001	Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008
SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR				
+ J AND J CONSUMER INC	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL				
EXIDINE				
+ XTTRIUM	4%	N019127	001	Dec 24, 1984
CLOTH;TOPICAL				
CHLORHEXIDINE GLUCONATE				
+ SAGE PRODS	2%	N021669	001	Apr 25, 2005
SOLUTION;TOPICAL				
BRIAN CARE				
SOAPCO	4%	A071419	001	Dec 17, 1987
CHG SCRUB				
ECOLAB	4%	N019258	002	Jul 22, 1986
CIDA-STAT				
ECOLAB	2%	N019258	001	Jul 22, 1986
DYNA-HEX				
BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997
EXIDINE				
+ XTTRIUM	2%	N019422	001	Dec 17, 1985
	4%	N019125	001	Dec 24, 1984
HIBICLENS				
+ MOLNLYCKE HLTH	4%	N017768	001	
HIBISTAT				
+ MOLNLYCKE HLTH	0.5%	N018300	001	
SPONGE;TOPICAL				
BIOSCRUB				
GRIFFEN	4%	N019822	001	Mar 31, 1989
CHLORHEXIDINE GLUCONATE				
+ BECTON DICKINSON	4%	A072525	001	Oct 24, 1989

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL				
CHLORAPREP ONE-STEP				
+ BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000
+	2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+	2%;70% (26ML)	N020832	006	Nov 21, 2006
CHLORAPREP ONE-STEP FREPP				
+ BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002

FDA data supplied by DrugPatentWatch.com

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP WITH TINT

+	BECTON DICKINSON CO	2%;70% (26ML)	N020832 002	May 03, 2005
+		2%;70% (10.5ML)	N020832 005	Apr 03, 2006
+		2%;70% (3ML)	N020832 007	Oct 10, 2006

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555 001	Oct 07, 2002

CHLORAPREP SINGLE SWABSTICK

+	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555 002	May 10, 2005

CHLORAPREP TRIPLE SWABSTICK

+	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555 003	Jun 10, 2009

PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005

PREVANTICS SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524 001	Jun 03, 2005

PREVANTICS SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+	BAYER HEALTHCARE LLC	12MG	N007638 002	

CHLORPHENIRAMINE MALEATE

	AVANTHI INC	12MG	A040829 001	May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+	PFIZER	4MG;200MG;10MG	N022113 001	Dec 21, 2011

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+	PFIZER	1MG/5ML;100MG/5ML;15MG/5ML	N021587 001	Feb 24, 2004

TABLET;ORAL

ADVIL ALLERGY SINUS

+	PFIZER	2MG;200MG;30MG	N021441 001	Dec 19, 2002

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+	BAYER HEALTHCARE LLC	8MG;120MG	N018397 001	

CIMETIDINE

TABLET;ORAL

CIMETIDINE

	APOTEX	100MG	A074948 001	Jun 19, 1998
		200MG	A074948 002	Jul 26, 2002
	CONTRACT PHARMACAL	200MG	A074961 001	Jun 19, 1998
		200MG	A074963 001	Jun 19, 1998
	IVAX SUB TEVA PHARMS	200MG	A075345 001	Jun 16, 1999
	PERRIGO	200MG	A075285 001	Oct 29, 1998

TAGAMET HB

+	MEDTECH PRODUCTS	200MG	N020238 002	Aug 21, 1996

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

	PERRIGO	1.34MG	A074512 001	Nov 22, 1995
	SANDOZ	1.34MG	A073458 001	Oct 31, 1993

TAVIST-1

+	NOVARTIS	1.34MG	N020925 001	Aug 21, 1992

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

	ACTAVIS MID ATLANTIC	1%	A074165 001	Jul 16, 1993
	TARO	1%	A072641 001	Dec 04, 1995

GYNE-LOTRIMIN

+	BAYER HEALTHCARE LLC	1%	N018052 002	Nov 30, 1990

GYNE-LOTRIMIN 3

+	BAYER HEALTHCARE LLC	2%	N020574 001	Nov 24, 1998

CLOTRIMAZOLE

CREAM;VAGINAL				
MYCELEX-7				
BAYER HEALTHCARE LLC	1%	N018230	002	Dec 26, 1991
TRIVAGIZOLE 3				
TARO	2%	N021143	001	Apr 12, 2000
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,200MG	N020526	002	Jul 29, 1996
GYNE-LOTRIMIN COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993
MYCELEX-7 COMBINATION PACK				
BAYER HEALTHCARE LLC	1%,100MG	N020389	002	Jun 23, 1994
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996
MYCELEX-7				
BAYER HEALTHCARE LLC	100MG	N018182	002	Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED;NASAL				
CROMOLYN SODIUM				
+ BAUSCH AND LOMB	5.2MG/SPRAY	A075702	001	Jul 03, 2001
PERRIGO	5.2MG/SPRAY	A075427	001	Dec 12, 2001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE				
+ AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL				
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE				
ACTAVIS LABS FL INC	30MG;600MG	A091070	001	Aug 31, 2015
	60MG;1.2GM	A091070	002	Aug 31, 2015
MUCINEX DM				
RECKITT BENCKISER	30MG;600MG	N021620	002	Apr 29, 2004
+	60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL				
DELSYM				
+ RECKITT BENCKISER	EQ 30MG HBR/5ML	N018658	001	Oct 08, 1982
DEXTROMETHORPHAN POLISTIREX				
TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL				
ADVIL PM				
+ PFIZER	38MG;200MG	N021394	001	Dec 21, 2005
IBUPROFEN AND DIPHENHYDRAMINE CITRATE				
DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL				
ADVIL PM				
+ PFIZER	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE				
BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010
STRIDES PHARMA	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL				
ALEVE PM				
+ BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014

FDA data supplied by DrugPatentWatch.com

DOCOSANOL
CREAM;TOPICAL
ABREVA

+	GLAXOSMITHKLINE	10%	N020941 001	Jul 25, 2000

DOXYLAMINE SUCCINATE
TABLET;ORAL
DOXYLAMINE SUCCINATE

	LNK	25MG	A040564 001	Aug 27, 2004
	PERRIGO	25MG	A040167 001	Sep 18, 1996

UNISOM

+	CHATTEM	25MG	N018066 001	

ESOMEPRAZOLE MAGNESIUM
CAPSULE, DELAYED RELEASE;ORAL
NEXIUM 24HR

+	ASTRAZENECA LP	EQ 20MG BASE	N204655 001	Mar 28, 2014

TABLET, DELAYED RELEASE;ORAL
NEXIUM 24HR

+	ASTRAZENECA LP	EQ 20MG BASE	N207920 01	Nov 23, 2015

FAMOTIDINE
TABLET;ORAL
FAMOTIDINE

	AUROBINDO PHARMA LTD	10MG	A206531 001	Apr 26, 2016
		20MG	A206531 002	Apr 26, 2016
	DR REDDYS LABS LTD	10MG	A075758 001	Aug 17, 2001
		20MG	A077367 001	Sep 25, 2006
	IVAX SUB TEVA PHARMS	10MG	A075512 001	Jul 26, 2001
	MYLAN	10MG	A075674 001	Dec 21, 2001
	PERRIGO	10MG	A075400 001	Mar 18, 2005
		20MG	A077351 001	Sep 25, 2006
	SUN PHARM INDS LTD	10MG	A090283 001	Nov 17, 2009
		20MG	A090283 002	Nov 17, 2009
	TEVA	10MG	A075312 001	May 31, 2001
	WOCKHARDT	10MG	A077146 001	Mar 07, 2005
		20MG	A090837 001	Aug 04, 2010

PEPCID AC

	J AND J CONSUMER INC	10MG	N020325 001	Apr 28, 1995
+		20MG	N020325 002	Sep 23, 2003

PEPCID AC

	J AND J CONSUMER INC	10MG	N020902 001	Aug 05, 1999

TABLET, CHEWABLE;ORAL
FAMOTIDINE

	PERRIGO	10MG	A075715 001	Aug 22, 2003

PEPCID AC

+	J AND J CONSUMER INC	20MG	N020801 002	Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE
SUSPENSION;ORAL
CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG/5ML	N201373 001	Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG/5ML	N201373 002	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	ACTAVIS MID ATLANTIC	30MG/5ML	A203330 001	Nov 18, 2014

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	ACTAVIS MID ATLANTIC	30MG/5ML	A203330 002	Nov 18, 2014

TABLET;ORAL
ALLEGRA ALLERGY

	SANOFI AVENTIS US	60MG	N020872 007	Jan 24, 2011
+		180MG	N020872 010	Jan 24, 2011

ALLEGRA HIVES

	SANOFI AVENTIS US	60MG	N020872 008	Jan 24, 2011
+		180MG	N020872 009	Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

	SANOFI AVENTIS US	30MG	N020872 005	Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

	SANOFI AVENTIS US	30MG	N020872 006	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	AUROLIFE PHARMA LLC	30MG	A202039 001	Nov 19, 2014
	DR REDDYS LABS LTD	30MG	A076502 004	Apr 12, 2011
	HETERO LABS LTD V	30MG	A204097 001	Aug 19, 2016
	MYLAN	30MG	A077081 004	Jul 21, 2011

FDA data supplied by DrugPatentWatch.com

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	30MG	A091567 002	Feb 06, 2012
TEVA	30MG	A076447 004	Apr 13, 2011
WOCKHARDT LTD	30MG	A079112 002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502 005	Apr 12, 2011
MYLAN	30MG	A077081 005	Jul 21, 2011
SUN PHARM INDS	30MG	A091567 001	Feb 06, 2012
TEVA	30MG	A076447 005	Apr 13, 2011
WOCKHARDT LTD	30MG	A079112 001	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	60MG	A202039 002	Nov 19, 2014
	180MG	A202039 003	Nov 19, 2014
DR REDDYS LABS LTD	60MG	A076502 006	Apr 12, 2011
	180MG	A076502 008	Apr 12, 2011
HETERO LABS LTD V	60MG	A204097 002	Aug 19, 2016
	180MG	A204097 003	Aug 19, 2016
MYLAN	60MG	A077081 006	Jul 21, 2011
	180MG	A077081 008	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507 002	Sep 16, 2015
	180MG	A204507 003	Sep 16, 2015
SUN PHARM INDS	60MG	A091567 004	Feb 06, 2012
	180MG	A091567 006	Feb 06, 2012
TEVA	60MG	A076447 006	Apr 13, 2011
	180MG	A076447 008	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112 004	Feb 08, 2012
	180MG	A079112 006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502 007	Apr 12, 2011
	180MG	A076502 009	Apr 12, 2011
MYLAN	60MG	A077081 007	Jul 21, 2011
	180MG	A077081 009	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507 004	Sep 16, 2015
	180MG	A204507 005	Sep 16, 2015
SUN PHARM INDS	60MG	A091567 003	Feb 06, 2012
	180MG	A091567 005	Feb 06, 2012
TEVA	60MG	A076447 007	Apr 13, 2011
	180MG	A076447 009	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112 003	Feb 08, 2012
	180MG	A079112 005	Feb 08, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG	N021909 002	Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG	N021909 003	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A202978 001	Jan 18, 2013

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A202978 002	Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786 002	Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704 002	Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	60MG;120MG	A076667 001	Nov 18, 2014
	180MG;240MG	A079043 002	Jun 22, 2011
SUN PHARMA GLOBAL	60MG;120MG	A090818 001	Jan 29, 2015

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+ GLAXOSMITHKLINE	0.0275MG/SPRAY	N022051 002	Aug 02, 2016

FDA data supplied by DrugPatentWatch.com

FLUTICASONE PROPIONATE
SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF				
+ GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014
FLUTICASONE PROPIONATE				
APOTEX INC	0.05MG/SPRAY	A208150	001	Feb 29, 2016
WEST-WARD PHARMS INT	0.05MG/SPRAY	A207957	001	May 26, 2016

GUAIFENESIN
TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN				
ACTAVIS LABS FL INC	1.2GM	A091009	002	Sep 03, 2015
PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011
MUCINEX				
RECKITT BENCKISER	600MG	N021282	001	Jul 12, 2002
+	1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
ACTAVIS LABS FL INC	600MG;60MG	A091071	001	May 27, 2015
	1.2GM;120MG	A091071	002	May 27, 2015
MUCINEX D				
RECKITT BENCKISER	600MG;60MG	N021585	001	Jun 22, 2004
+	1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN
CAPSULE;ORAL

ADVIL LIQUI-GELS				
+ PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995
ADVIL MIGRAINE LIQUI-GELS				
+ PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000
IBUPROFEN				
AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011
BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009
+ CONTRACT PHARMACAL	200MG	A074782	001	Jul 06, 1998
HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016
MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009
P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009
SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016
MIDOL LIQUID GELS				
+ BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL				
PFIZER	100MG/5ML	N020589	001	Jun 27, 1996
CHILDREN'S ADVIL-FLAVORED				
PFIZER	100MG/5ML	N020589	002	Nov 07, 1997
CHILDREN'S ELIXSURE				
MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004
CHILDREN'S IBUPROFEN				
PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998
CHILDREN'S MOTRIN				
+ J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995
IBUPROFEN				
ACTAVIS MID ATLANTIC	100MG/5ML	A074916	001	Apr 30, 1999
AMNEAL PHARMS	100MG/5ML	A200457	001	Aug 18, 2011

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN				
+ J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996
IBUPROFEN				
PERRIGO	40MG/ML	A075217	001	Dec 16, 1998
TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009
PEDIATRIC ADVIL				
+ PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998

TABLET;ORAL

ADVIL				
PFIZER	200MG	N018989	001	May 18, 1984
IBU-TAB 200				
ALRA	200MG	A071057	001	Aug 11, 1988
IBUPROFEN				
AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014
AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
	200MG	A072199	001	May 23, 1988
AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET;ORAL

IBUPROFEN

CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987
	200MG	A071735	001	Sep 10, 1987
	200MG	A072299	001	Jul 01, 1988
	200MG	A074931	001	Jul 20, 1998
DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001
GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016
LNK	100MG	A076741	001	Jun 17, 2004
	200MG	A075010	001	Mar 01, 1999
	200MG	A075139	001	Mar 01, 1999
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
	200MG	A091239	001	Feb 01, 2011
MCNEIL	200MG	A073019	001	Mar 30, 1994
MERRO PHARM	200MG	A070985	001	Oct 02, 1987
OHM	200MG	A071163	001	Jul 15, 1986
PAR PHARM	200MG	A070481	001	Sep 24, 1986
PERRIGO	200MG	A072096	001	Dec 08, 1987
	200MG	A075995	001	Mar 14, 2002
PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011
	200MG	A091355	001	Apr 04, 2011
VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
	200MG	A071639	001	Feb 02, 1988

IBUPROHM

OHM LABS	200MG	A071214	001	Dec 01, 1986

JUNIOR STRENGTH ADVIL

PFIZER	100MG	N020267	002	Dec 13, 1996

JUNIOR STRENGTH IBUPROFEN

PERRIGO	100MG	A075367	001	Apr 22, 1999

JUNIOR STRENGTH MOTRIN

J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996

MOTRIN IB

+ J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990

PROFEN

CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986

TAB-PROFEN

PERRIGO	200MG	A072095	001	Dec 08, 1987

TABLET, CHEWABLE;ORAL

CHILDREN'S ADVIL

PFIZER	50MG	N020944	001	Dec 18, 1998

CHILDREN'S MOTRIN

J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996

IBUPROFEN

PERRIGO	50MG	A076359	001	Jan 16, 2004
	100MG	A076359	002	Jan 16, 2004

JUNIOR STRENGTH ADVIL

PFIZER	100MG	N020944	002	Dec 18, 1998

JUNIOR STRENGTH MOTRIN

+ J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996

IBUPROFEN SODIUM

TABLET;ORAL

ADVIL

+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012

IBUPROFEN SODIUM

PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL CONGESTION RELIEF

+ PFIZER	200MG;10MG	N022565	001	May 27, 2010

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL				
ADVIL COLD AND SINUS				
+	PFIZER	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374 001	May 30, 2002
SUSPENSION;ORAL				
CHILDREN'S ADVIL COLD				
	PFIZER	100MG/5ML;15MG/5ML	N021373 001	Apr 18, 2002
CHILDREN'S MOTRIN COLD				
+	J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128 001	Aug 01, 2000
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
	PERRIGO	100MG/5ML;15MG/5ML	A076478 001	Nov 05, 2003
TABLET;ORAL				
ADVIL COLD AND SINUS				
+	PFIZER	200MG;30MG	N019771 001	Sep 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
	CONTRACT PHARMACAL	200MG;30MG	A075588 001	Apr 08, 2002
	DR REDDYS LABS LTD	200MG;30MG	A077628 001	Aug 14, 2006
IBUPROHM COLD AND SINUS				
	OHM LABS	200MG;30MG	A074567 001	Apr 17, 2001
SINE-AID IB				
	J AND J CONSUMER INC	200MG;30MG	N019899 001	Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION				
HUMULIN R PEN				
+	LILLY	100 UNITS/ML	N018780 005	Aug 06, 1998
NOVOLIN R				
+	NOVO NORDISK INC	100 UNITS/ML	N019938 001	Jun 25, 1991

INSULIN RECOMBINANT HUMAN

INJECTABLE;INJECTION				
HUMULIN R				
+	LILLY	100 UNITS/ML	N018780 001	Oct 28, 1982

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION				
HUMULIN 70/30				
+	LILLY	30 UNITS/ML;70 UNITS/ML	N019717 001	Apr 25, 1989
HUMULIN 70/30 PEN				
+	LILLY	30 UNITS/ML;70 UNITS/ML	N019717 002	Aug 06, 1998
NOVOLIN 70/30				
+	NOVO NORDISK INC	30 UNITS/ML;70 UNITS/ML	N019991 001	Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE;INJECTION				
HUMULIN N				
+	LILLY	100 UNITS/ML	N018781 001	Oct 28, 1982
NOVOLIN N				
+	NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL				
DURAPREP				
+	3M	EQ 0.7% IODINE;74% (6ML)	N021586 001	Sep 29, 2006
+		EQ 0.7% IODINE;74% (26ML)	N021586 002	Sep 29, 2006

KETOCONAZOLE

SHAMPOO;TOPICAL				
NIZORAL A-D				
+	JOHNSON AND JOHNSON	1%	N020310 001	Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC				
ALAWAY				
+	BAUSCH AND LOMB	EQ 0.025% BASE	N021996 001	Dec 01, 2006
		EQ 0.035% BASE	N021996 002	Feb 11, 2015
KETOTIFEN FUMARATE				
	AKORN	EQ 0.025% BASE	A077958 001	Jul 26, 2007
+	ALCON PHARMS LTD	EQ 0.025% BASE	A077200 001	Sep 02, 2008

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE				
DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016
NATCO PHARMA LTD	15MG	A203306	001	Jan 13, 2016
PERRIGO R AND D	15MG	A202319	001	May 18, 2012
WOCKHARDT LTD	15MG	A202727	001	May 18, 2012
PREVACID 24 HR				
+ GLAXOSMITHKLINE CONS	15MG	N022327	001	May 18, 2009

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE				
DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT				
AUROBINDO PHARMA LTD	1.5MG	A206867	001	Dec 08, 2015
FALLBACK SOLO				
LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014
HER STYLE				
NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016
LEVONORGESTREL				
GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016
	1.5MG	A202739	001	Oct 31, 2014
LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016
	1.5MG	A202246	001	Jun 05, 2015
NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
OC PHARMA	1.5MG	A202380	001	May 29, 2015
+ PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010
	1.5MG	A202334	001	Aug 20, 2014
WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012
OPCICON ONE-STEP				
SUN PHARM INDS LTD	1.5MG	A202635	001	Sep 11, 2014
PLAN B ONE-STEP				
+ TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE				
BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005
+	2MG	N021855	002	Aug 04, 2005

SOLUTION;ORAL

IMODIUM A-D				
+ J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988
LOPERAMIDE HYDROCHLORIDE				
HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
ROXANE	1MG/5ML	A073079	001	Apr 30, 1992
WOCKHARDT	1MG/5ML	A074730	001	Aug 28, 1997

SUSPENSION;ORAL

IMODIUM A-D				
+ J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004
LOPERAMIDE HYDROCHLORIDE				
PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011

TABLET;ORAL

IMODIUM A-D				
+ J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE				
AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015
CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
LNK	2MG	A076497	001	Jun 10, 2003
OHM LABS	2MG	A074091	001	Dec 10, 1992
PERRIGO	2MG	A075232	001	Jan 06, 2000

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS				
+ J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL				
IMODIUM MULTI-SYMPTOM RELIEF				
+ J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE				
SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006
TABLET, CHEWABLE;ORAL				
IMODIUM MULTI-SYMPTOM RELIEF				
+ J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE				
PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002

LORATADINE

CAPSULE;ORAL				
CLARITIN				
+ BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008
LORATADINE				
MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016
SUSPENSION;ORAL				
LORATADINE				
+ TARO	1MG/ML	N021734	001	Oct 04, 2005
SYRUP;ORAL				
CLARITIN				
+ BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002
LORATADINE				
PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
SILARX	1MG/ML	A077421	001	Jun 29, 2006
TARO	1MG/ML	A076805	001	Aug 20, 2004
	1MG/ML	A201865	001	Jul 31, 2015
TEVA	1MG/ML	A075505	001	Nov 07, 2003
WOCKHARDT	1MG/ML	A075815	001	Aug 20, 2004
TABLET;ORAL				
CLARITIN				
+ BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002
CLARITIN HIVES RELIEF				
+ BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003
LORATADINE				
APOTEX INC	10MG	A076471	001	Feb 14, 2006
MYLAN	10MG	A075790	001	Nov 07, 2008
	10MG	A076154	001	Aug 20, 2003
	10MG	A078447	001	Aug 12, 2011
PERRIGO	10MG	A076301	001	Jun 25, 2004
SANDOZ	10MG	A075209	001	Jan 21, 2003
SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003
TABLET, CHEWABLE;ORAL				
CHILDREN'S CLARITIN				
+ BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006
TABLET, ORALLY DISINTEGRATING;ORAL				
ALAVERT				
PFIZER	10MG	N021375	001	Dec 19, 2002
CLARITIN HIVES RELIEF REDITAB				
+ BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003
CLARITIN REDITABS				
+ BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006
+	10MG	N020704	002	Nov 27, 2002
LORATADINE				
ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003
PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003
PFIZER	10MG	A075822	001	Feb 10, 2003
LORATADINE REDIDOSE				
SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
CLARITIN-D				
+ BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002
CLARITIN-D 24 HOUR				
+ BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002
LORATADINE AND PSEUDOEPHEDRINE SULFATE				
ACTAVIS LABS FL INC	10MG;240MG	A075706	001	Feb 21, 2003
PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003
	10MG;240MG	A075989	001	Mar 04, 2004
SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004

FDA data supplied by DrugPatentWatch.com

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

+ HISAMITSU PHARM CO	3%;10%	N022029	001	Feb 20, 2008
	3%;10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO	2%,4%	A076357	001	Mar 30, 2004

MONISTAT 3 COMBINATION PACK

MEDTECH PRODUCTS	2%,4%	N021261	003	Jun 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ MEDTECH PRODUCTS	2%,4%	N021261	001	Feb 02, 2001

CREAM;VAGINAL

MICONAZOLE 3

TARO	4%	A076773	001	Mar 02, 2005

MICONAZOLE 7

ACTAVIS MID ATLANTIC	2%	A074164	001	Mar 29, 1996

MICONAZOLE NITRATE

G AND W LABS INC	2%	A074366	001	Feb 22, 1996
PERRIGO	2%	A074760	001	May 15, 1997
PERRIGO R AND D	4%	A091366	001	Jan 15, 2010
TARO	2%	A074444	001	Jan 13, 1997

MONISTAT 3

+ MEDTECH PRODUCTS	4%	N020827	001	Mar 30, 1998

MONISTAT 7

+ MEDTECH PRODUCTS	2%	N017450	002	Feb 15, 1991

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC	2%,200MG	A074926	001	Apr 16, 1999

MICONAZOLE 7 COMBINATION PACK

G AND W LABS	2%,100MG	A076585	001	Mar 26, 2004

MICONAZOLE NITRATE

PERRIGO R AND D	2%,1.2GM	A079114	001	Jun 02, 2010

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO	2%,200MG	A075329	001	Apr 20, 1999

MONISTAT 1 COMBINATION PACK

+ MEDTECH PRODUCTS	2%,1.2GM	N021308	001	Jun 29, 2001

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996

MONISTAT 7 COMBINATION PACK

+ MEDTECH PRODUCTS	2%,100MG	N020288	002	Apr 26, 1993

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC	100MG	A073507	001	Nov 19, 1993
G AND W LABS	100MG	A074414	001	Apr 30, 1997
+ PERRIGO	100MG	A074395	001	Mar 20, 1997

MONISTAT 7

+ MEDTECH PRODUCTS	100MG	N018520	002	Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE

+ JOHNSON AND JOHNSON	5%	N021812	001	Jan 20, 2006

MINOXIDIL

PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011

WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC	2%	A074588	001	Apr 05, 1996
HI TECH PHARMA	2%	A074731	001	Dec 24, 1996
PERRIGO	2%	A075357	001	Jul 30, 1999
WOCKHARDT	2%	A074767	001	Feb 28, 1997

MINOXIDIL (FOR WOMEN)

HI TECH PHARMA	2%	A074731	002	May 11, 2005
PERRIGO	2%	A075357	002	Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC	5%	A075518	001	Nov 17, 2000
AVACOR PRODS	5%	A075619	001	Nov 17, 2000
PERRIGO	5%	A075598	001	Jun 13, 2001
PERRIGO NEW YORK	5%	A075737	001	Mar 15, 2002

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)				
WOCKHARDT	5%	A075438	001	Feb 27, 2003
ROGAINE (FOR MEN)				
+ JOHNSON AND JOHNSON	2%	N019501	002	Feb 09, 1996
ROGAINE (FOR WOMEN)				
+ JOHNSON AND JOHNSON	2%	N019501	003	Feb 09, 1996
ROGAINE EXTRA STRENGTH (FOR MEN)				
+ JOHNSON AND JOHNSON	5%	N020834	001	Nov 14, 1997
THEROXIDIL				
EI INC	2%	A078176	001	Nov 09, 2007
	5%	A076239	001	Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE				
AKORN INC	0.025%;0.3%	A202795	001	Jan 24, 2013
ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
NAPHCON-A				
+ ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994
OPCON-A				
+ BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994
VISINE-A				
+ JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM				
+ BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006

TABLET;ORAL

ALEVE				
+ BAYER	EQ 200MG BASE	N020204	002	Jan 11, 1994
NAPROXEN SODIUM				
AMNEAL PHARMS NY	EQ 200MG BASE	A079096	001	Dec 16, 2008
AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016
CONTRACT PHARMACAL	EQ 200MG BASE	A074635	001	Jan 13, 1997
	EQ 200MG BASE	A074789	001	Feb 27, 1997
DR REDDYS LABS INC	EQ 200MG BASE	A075168	001	Jul 28, 1998
GRANULES INDIA	EQ 200MG BASE	A091353	001	Sep 20, 2011
MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011
PERRIGO	EQ 200MG BASE	A074661	001	Jan 13, 1997
SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD				
+ BAYER	200MG;120MG	N021076	001	Nov 29, 1999
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE				
DR REDDYS LABS INC	EQ 220MG BASE;120MG	A077381	001	Sep 27, 2006
PERRIGO	EQ 200MG BASE;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL				
DR REDDYS LABS INC	7MG/24HR	N020076	004	Nov 12, 1999
	14MG/24HR	N020076	005	Nov 12, 1999
+	21MG/24HR	N020076	006	Nov 12, 1999
NICODERM CQ				
SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
	14MG/24HR	N020165	005	Aug 02, 1996
+	21MG/24HR	N020165	004	Aug 02, 1996
NICOTINE				
AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
	14MG/24HR	A074612	003	Oct 20, 1997
	21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE				
+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
	EQ 2MG BASE	N018612	004	Sep 25, 2000
+	EQ 4MG BASE	N020066	002	Feb 09, 1996
	EQ 4MG BASE	N020066	004	Sep 25, 2000

FDA data supplied by DrugPatentWatch.com

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL				
NICORETTE (MINT)				
	GLAXOSMITHKLINE	EQ 2MG BASE	N018612 003	Dec 23, 1998
		EQ 4MG BASE	N020066 003	Dec 23, 1998
NICOTINE POLACRILEX				
	ACTAVIS LABS NY INC	EQ 2MG BASE	A074507 001	Mar 15, 1999
		EQ 2MG BASE	A076569 001	Jul 29, 2004
		EQ 2MG BASE	A078699 001	Dec 29, 2008
		EQ 2MG BASE	A079216 001	Jul 08, 2009
		EQ 2MG BASE	A204794 001	May 10, 2016
		EQ 4MG BASE	A074707 001	Mar 19, 1999
		EQ 4MG BASE	A076568 002	Jul 29, 2004
		EQ 4MG BASE	A078697 001	Dec 29, 2008
		EQ 4MG BASE	A079038 001	Jul 08, 2009
		EQ 4MG BASE	A079219 001	Jul 08, 2009
		EQ 4MG BASE	A204833 001	Feb 26, 2016
	PERRIGO	EQ 2MG BASE	A076775 001	Sep 16, 2004
		EQ 2MG BASE	A076776 001	Sep 16, 2004
		EQ 2MG BASE	A076777 001	Sep 16, 2004
		EQ 4MG BASE	A076778 001	Sep 16, 2004
		EQ 4MG BASE	A076779 001	Sep 16, 2004
		EQ 4MG BASE	A076789 001	Sep 16, 2004
	PERRIGO R AND D	EQ 2MG BASE	A078325 001	Oct 30, 2006
		EQ 2MG BASE	A078547 001	May 24, 2007
		EQ 2MG BASE	A078967 001	Apr 23, 2008
		EQ 2MG BASE	A091349 001	Jul 20, 2011
		EQ 2MG BASE	A206394 001	Dec 15, 2016
		EQ 4MG BASE	A078326 001	Oct 30, 2006
		EQ 4MG BASE	A078546 001	May 24, 2007
		EQ 4MG BASE	A078968 001	Apr 23, 2008
		EQ 4MG BASE	A091354 001	Jul 20, 2011
		EQ 4MG BASE	A206393 001	Dec 15, 2016
	WATSON LABS	EQ 2MG BASE	A079044 001	Jul 08, 2009
THRIVE				
	NOVARTIS	EQ 2MG BASE	A077658 001	Jun 19, 2007
		EQ 4MG BASE	A077656 001	Jun 19, 2007
TROCHE/LOZENGE;ORAL				
COMMIT				
	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330 001	Oct 31, 2002
+		EQ 4MG BASE	N021330 002	Oct 31, 2002
NICORETTE				
	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N022360 001	May 18, 2009
+		EQ 4MG BASE	N022360 002	May 18, 2009
NICOTINE POLACRILEX				
	PERRIGO R AND D	EQ 2MG BASE	A077007 001	Jan 31, 2006
		EQ 2MG BASE	A090711 001	Jul 10, 2009
		EQ 2MG BASE	A090821 001	Jul 10, 2009
		EQ 2MG BASE	A203690 001	Oct 09, 2012
		EQ 4MG BASE	A077007 002	Jan 31, 2006
		EQ 4MG BASE	A090711 002	Jul 10, 2009
		EQ 4MG BASE	A090821 002	Jul 10, 2009
		EQ 4MG BASE	A203690 002	Oct 09, 2012

NIZATIDINE

TABLET;ORAL				
AXID AR				
+	PFIZER	75MG	N020555 001	May 09, 1996

NONOXYNOL-9

SPONGE;VAGINAL				
TODAY				
+	MAYER LABS INC	1GM	N018683 001	Apr 01, 1983

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL				
OMEPRAZOLE				
+	DEXCEL PHARMA	20MG	N022032 001	Dec 04, 2007

OMEPRAZOLE MAGNESIUM
CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

+	DR REDDYS LABS LTD	EQ 20MG BASE	A078878 001	Jun 05, 2009

TABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

	PERRIGO R AND D	EQ 20MG BASE	A204152 001	Jul 30, 2015

PRILOSEC OTC

+	ASTRAZENECA PHARMS	EQ 20MG BASE	N021229 001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE
CAPSULE;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

	ACTAVIS ELIZABETH	20MG;1.1GM	A204137 001	Jul 15, 2016
	AUROLIFE PHARMA LLC	20MG;1.1GM	A204923 001	Nov 07, 2016
	PAR PHARM	20MG;1.1GM	A201946 001	Jul 15, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361 001	Jul 15, 2016

ZEGERID OTC

+	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281 001	Dec 01, 2009

FOR SUSPENSION;ORAL
ZEGERID OTC

+	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283 001	Jun 17, 2013

ORLISTAT
CAPSULE;ORAL
ALLI

+	GLAXOSMITHKLINE CONS	60MG	N021887 001	Feb 07, 2007

OXYBUTYNIN
FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

+	ALLERGAN SALES LLC	3.9MG/24HR	N202211 001	Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR

	BAYER HEALTHCARE LLC	0.025%	N018471 001	May 30, 1986

VISINE L.R.

+	JOHNSON AND JOHNSON	0.025%	N019407 001	Mar 31, 1989

PERMETHRIN
LOTION;TOPICAL
NIX

+	MEDTECH PRODUCTS	1%	N019918 001	May 02, 1990

PERMETHRIN

	ACTAVIS MID ATLANTIC	1%	A075014 001	Mar 28, 2000
	PERRIGO NEW YORK	1%	A076090 001	Dec 20, 2001

POLYETHYLENE GLYCOL 3350
FOR SOLUTION;ORAL
GLYCOLAX

	KREMERS URBAN PHARMS	17GM/PACKET	A090600 001	Oct 06, 2009
		17GM/SCOOPFUL	A090600 002	Oct 06, 2009

MIRALAX

+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015 001	Oct 06, 2006

POLYETHYLENE GLYCOL 3350

	ANI PHARMS INC	17GM/SCOOPFUL	A202850 001	Dec 15, 2015
	MYLAN	17GM/PACKET	A078915 001	Oct 06, 2009
		17GM/SCOOPFUL	A078915 002	Oct 06, 2009
	NEXGEN PHARMA	17GM/SCOOPFUL	A090812 001	Oct 07, 2009
	NOVEL LABS INC	17GM/SCOOPFUL	A091077 001	Oct 06, 2009
	NUVO PHARM INC	17GM/SCOOPFUL	A206105 001	Oct 28, 2016
	PAR PHARM	17GM/SCOOPFUL	A079214 001	Jan 31, 2013
	PERRIGO R AND D	17GM/PACKET	A090685 001	Oct 06, 2009
		17GM/SCOOPFUL	A090685 002	Oct 06, 2009
	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071 001	Dec 28, 2012
	STRIDES PHARMA	17GM/SCOOPFUL	A203928 001	Aug 24, 2016
		17GM/PACKET	A203928 002	Aug 24, 2016

POTASSIUM IODIDE
SOLUTION;ORAL
POTASSIUM IODIDE

	MISSION PHARMACAL CO	65MG/ML	A206211 001	Mar 24, 2016

THYROSHIELD

+	ARCO PHARMS LLC	65MG/ML	A077218 001	Jan 12, 2005

FDA data supplied by DrugPatentWatch.com

POTASSIUM IODIDE
TABLET;ORAL
IOSAT

ANBEX	65MG	N018664	002	May 12, 2011
+	130MG	N018664	001	Oct 14, 1982

THYROSAFE

+ RECIP	65MG	A076350	001	Sep 10, 2002

POVIDONE-IODINE
SOLUTION;TOPICAL
POVIDONE IODINE

+ ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989

SPONGE;TOPICAL
E-Z SCRUB 201

+ BECTON DICKINSON	20%	N019240	001	Nov 29, 1985

E-Z SCRUB 241

+ BECTON DICKINSON	10%	N019476	001	Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO	120MG	A075153	001	Feb 26, 1999
SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005

SUDAFED 12 HOUR

+ MCNEIL CONS	120MG	A073585	001	Oct 31, 1991

SUDAFED 24 HOUR

+ J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992

PSEUDOEPHEDRINE SULFATE
TABLET, EXTENDED RELEASE;ORAL
AFRINOL

+ SCHERING PLOUGH	120MG	N018191	001	

PURIFIED WATER
SOLUTION;OPHTHALMIC
PUR-WASH

+ NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011

RANITIDINE HYDROCHLORIDE
TABLET;ORAL
RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 75MG BASE	A075167	001	May 04, 2000
	EQ 150MG BASE	A200172	001	May 31, 2012
CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
	EQ 150MG BASE	A078192	001	Aug 31, 2007
IVAX SUB TEVA PHARMS	EQ 75MG BASE	A075296	001	Jan 14, 2000
MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
	EQ 150MG BASE	A091429	002	May 11, 2011
STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012
SVADS HOLDINGS SA	EQ 150MG BASE	A200536	001	Jun 28, 2011
WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006

ZANTAC 150

+ BOEHRINGER INGELHEIM	EQ 150MG BASE	N021698	001	Aug 31, 2004
	EQ 150MG BASE	N021698	002	Mar 13, 2007

ZANTAC 75

BOEHRINGER INGELHEIM	EQ 75MG BASE	N020520	001	Dec 19, 1995

SODIUM CHLORIDE
AEROSOL, METERED;INHALATION
BRONCHO SALINE

+ BLAIREX	0.9%	N019912	001	Sep 03, 1992

SODIUM FLUORIDE; TRICLOSAN
PASTE;DENTAL
COLGATE TOTAL

+ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997

FDA data supplied by DrugPatentWatch.com

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+ NOVARTIS	1%	N021958	001	Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL

+ NOVARTIS	1%	N020980	001	Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO	1%	A077511	001	Jul 02, 2007

SOLUTION;TOPICAL

LAMISIL AT

+ NOVARTIS	1%	N021124	001	Mar 17, 2000

SPRAY;TOPICAL

LAMISIL AT

+ NOVARTIS	1%	N021124	002	Mar 17, 2000

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE

PERRIGO	6.5%	A075915	001	Nov 21, 2001

VAGISTAT-1

+ NOVARTIS	6.5%	N020676	001	Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+ SANOFI AVENTIS US	0.055MG/SPRAY	N020468	002	Oct 11, 2013

TRIAMCINOLONE ACETONIDE

TEVA PHARMS	0.055MG/SPRAY	A078104	002	Nov 14, 2014

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS MANUFACTURING INC	N760305	Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC	N020037	Aug 26, 2003
ACD-A SOLUTION		
TERUMO BCT INC	A010228	Feb 25, 2002
ADSOL WITH ACD-A		
FENWAL INC	N000922	Aug 29, 2002
ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A		
HAEMONETICS CORP	A980728	Feb 06, 2002
AS3 SOLUTION/ACD-A		
TERUMO BCT INC	N001214	May 29, 2002
NONE		
HAEMONETICS MANUFACTURING INC	A710497	Nov 06, 1987

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC	N160918	Mar 17, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL SYSTEMS, INC	A110057	May 11, 2012

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP	N000127	Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP	N820528	Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC	N770420	May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC	N940404	Jul 28, 1994

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS MANUFACTURING INC	N800077	Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC	N900223	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC	N900224	Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS	N040083	Nov 21, 2005

NONE

TERUMO BCT INC	A070025	Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC	N170401	Dec 06, 1977
	N811012	Jun 28, 1983
HAEMONETICS MANUFACTURING INC	N800222	Aug 23, 1982
TERUMO MEDICAL CORP	N781211	Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC	N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP	N880217	Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS MANUFACTURING INC	0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML	N820915	Oct 19, 1984

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS CORPORATION		N980123	Mar 03, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL LABORATORIES INC		N010409	Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N770923	Jan 20, 1978
TERUMO MEDICAL CORP		N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA		N125552	Dec 21, 2016

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB		N830715	Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC	10GM/100ML;5GM/100ML	A720563	Oct 30, 1992

NONE

B BRAUN MEDICAL INC	10GM/100ML;5GM/100ML	N160767	Apr 06, 1970

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	Oct 30, 1992

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC	6GM/100ML;0.9GM/100ML	A740193	Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N890105	Apr 04, 1991

NONE

TEVA PARENTERAL MEDICINES INC	6GM/100ML;0.9GM/100ML	A740592	Nov 12, 1998

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

NONE

B. BRAUN MEDICAL		A110013	Jan 09, 2015

VOLUVEN

FRESENIUS KABI DEUTSCHLAND GMBH	6GM/100ML;0.9GM/100ML	N070012	Dec 27, 2007

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION

HAEMONETICS CORP		N090067	Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL

HAEMONETICS CORP		N110059	Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTION

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL

CITRA LABS LLC		N950522	Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION

FENWAL INC.	2.26G/500ML; 2.21G/500ML; 1.59G/500ML; 1.53G/500ML; 0.465G/500ML	N080041	Dec 09, 2009

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

ABARELIX
INJECTABLE;INTRAMUSCULAR
PLENAXIS

SPECIALITY EUROPEAN	100MG/VIAL	N021320 001	Nov 25, 2003

ACAMPROSATE CALCIUM
TABLET, DELAYED RELEASE;ORAL
CAMPRAL

FOREST LABS	333MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021431 001	Jul 29, 2004

ACEBUTOLOL HYDROCHLORIDE
CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE

WATSON LABS	EQ 200MG BASE	A074007 001	Oct 18, 1995
	EQ 400MG BASE	A074007 002	Oct 18, 1995

ACETAMINOPHEN
INJECTABLE;INJECTION
INJECTAPAP

ORTHO MCNEIL PHARM	100MG/ML	N017785 001	Mar 07, 1986

SUPPOSITORY;RECTAL
ACEPHEN

G AND W LABS	120MG	A072218 001	Mar 27, 1992

ACETAMINOPHEN

ABLE	120MG	A073106 001	Feb 27, 1995
	325MG	A073107 001	Feb 27, 1995
	650MG	A073108 001	Feb 27, 1995
ROXANE	120MG	A071010 001	May 12, 1987
	650MG	A071011 001	May 12, 1987

TYLENOL

J AND J CONSUMER INC	120MG	N017756 002	
	650MG	N017756 001	

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

SUN PHARM INDS LTD	650MG	A090205 001	Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE
CAPSULE;ORAL
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART	150MG;180MG;15MG	A081095 001	Oct 26, 1990
	150MG;180MG;30MG	A081096 001	Oct 26, 1990
	150MG;180MG;60MG	A081097 001	Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS	150MG;180MG;15MG	A085640 001	

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS	150MG;180MG;30MG	A085639 001	

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS	150MG;180MG;60MG	A085638 001	

ACETAMINOPHEN; BUTALBITAL
CAPSULE;ORAL
BANCAP

FOREST PHARMS	325MG;50MG	A088889 001	Jan 16, 1986

BUCET

MALLINCKRODT	650MG;50MG	A088991 001	Jun 28, 1985

PHRENILIN FORTE

VALEANT	650MG;50MG	A088831 001	Jun 19, 1985

TENCON

MALLINCKRODT	650MG;50MG	A089405 001	May 15, 1990

TRIAPRIN

DUNHALL	325MG;50MG	A089268 001	Jul 02, 1987

TABLET;ORAL
BUTALBITAL AND ACETAMINOPHEN

HALSEY	325MG;50MG	A089568 001	Oct 05, 1988
WATSON LABS	325MG;50MG	A087550 001	Oct 19, 1984

BUTAPAP

MIKART	650MG;50MG	A089988 001	Oct 26, 1992

PHRENILIN

VALEANT	325MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A087811 001	Jun 19, 1985

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

SEDAPAP

MAYRAND	650MG;50MG	A088944	001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

ANOQUAN

SHIRE	325MG;50MG;40MG	A087628	001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM	325MG;50MG;40MG	A088743	001 Jul 18, 1985
	325MG;50MG;40MG	A088765	001 Mar 27, 1985
	325MG;50MG;40MG	A089067	001 Apr 19, 1985
HIKMA PHARMS LLC	500MG;50MG;40MG	A040261	001 Oct 28, 1998
MALLINCKRODT	325MG;50MG;40MG	A088758	001 Mar 27, 1985

BUTALIBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS	325MG;50MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A088825	001 Dec 05, 1984

ESGIC-PLUS

MIKART	500MG;50MG;40MG	A040085	001 Mar 28, 1996

FEMCET

MALLINCKRODT	325MG;50MG;40MG	A089102	001 Jun 19, 1985

MEDIGESIC PLUS

US CHEM	325MG;50MG;40MG	A089115	001 Jan 14, 1986

TRIAD

MALLINCKRODT	325MG;50MG;40MG	A089023	001 Jun 19, 1985

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE	325MG;50MG;40MG	A040390	001 Jul 23, 2001
	500MG;50MG;40MG	A040394	001 Jul 23, 2001
GILBERT LABS	325MG;50MG;40MG	A087629	001 Nov 13, 1984
HIKMA PHARMS LLC	500MG;50MG;40MG	A040336	001 Aug 18, 1999
INGENUS PHARMS NJ	325MG;50MG;40MG	A040864	001 Dec 01, 2008
MIKART	750MG;50MG;40MG	A040496	001 Dec 23, 2003
MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001 Dec 23, 2008
SUN PHARM INDS	325MG;50MG;40MG	A040601	001 Jul 29, 2005
VINTAGE PHARMS	500MG;50MG;40MG	A040513	001 Aug 25, 2003
WATSON LABS	325MG;50MG;40MG	A089536	001 Feb 16, 1988
	500MG;50MG;40MG	A040267	001 Jul 30, 1998

ESGIC

FOREST PHARMS	325MG;50MG;40MG	A089660	001 Dec 23, 1988

ESGIC-PLUS

MIKART	500MG;50MG;40MG	A089451	001 May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE	325MG;50MG;40MG;30MG	A076528	001 Aug 21, 2003

PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT	325MG;50MG;40MG;30MG	A074911	001 Aug 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART	356.4MG;30MG;16MG	A040109	001 Aug 26, 1997
WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001 Apr 03, 2007

DHC PLUS

PHARM RES ASSOC	356.4MG;30MG;16MG	A088584	001 Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS	356.4MG;30MG;16MG	A089166	001 May 14, 1986

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC	712.8MG;60MG;32MG	A040701	001 Apr 03, 2007
MIKART	712.8MG;60MG;32MG	A040316	001 Apr 28, 1999
WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001 Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082	001 Mar 01, 2001

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA	300MG;15MG	A088537 001	Jun 04, 1984
	300MG;30MG	A088324 001	Dec 29, 1983
	300MG;60MG	A088599 001	Jun 01, 1984

PHENAPHEN W/ CODEINE NO. 2

ROBINS AH	325MG;15MG	A084444 001	

PHENAPHEN W/ CODEINE NO. 3

ROBINS AH	325MG;30MG	A084445 001	

PHENAPHEN W/ CODEINE NO. 4

ROBINS AH	325MG;60MG	A084446 001	

PROVAL #3

SOLVAY	325MG;30MG	A085685 001	

TYLENOL W/ CODEINE NO. 3

ORTHO MCNEIL PHARM	300MG;30MG	A087422 001	

TYLENOL W/ CODEINE NO. 4

ORTHO MCNEIL PHARM	300MG;60MG	A087421 001	

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861 001	
DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098 001	Sep 20, 1996
ROXANE	120MG/5ML;12MG/5ML	A086366 001	

TYLENOL W/ CODEINE

ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057 001	

SUSPENSION;ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883 001	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE	300MG;30MG	A040452 001	Aug 01, 2002
	300MG;60MG	A040459 001	Aug 01, 2002
AM THERAP	300MG;15MG	A089478 001	Mar 03, 1987
	300MG;15MG	A089481 001	Mar 03, 1987
	300MG;30MG	A089479 001	Mar 03, 1987
	300MG;30MG	A089482 001	Mar 03, 1987
	300MG;60MG	A089480 001	Mar 03, 1987
	300MG;60MG	A089483 001	Mar 03, 1987
DURAMED PHARMS BARR	300MG;15MG	A040223 001	Nov 18, 1997
	300MG;15MG	A088353 001	Feb 06, 1984
	300MG;30MG	A040223 002	Nov 18, 1997
	300MG;30MG	A088354 001	Feb 06, 1984
	300MG;60MG	A040223 003	Nov 18, 1997
	300MG;60MG	A088355 001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217 001	
FRONTIDA BIOPHARM	300MG;15MG	A089671 001	Feb 10, 1988
	300MG;30MG	A089672 001	Feb 10, 1988
	300MG;60MG	A089673 001	Feb 10, 1988
HALSEY	300MG;15MG	A083871 001	
	300MG;30MG	A083872 001	
	300MG;60MG	A086549 001	
KV PHARM	300MG;30MG	A085288 001	
	300MG;60MG	A085365 001	
	325MG;15MG	A085364 001	
	325MG;45MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085363 001	
LEDERLE	300MG;30MG	A087141 001	
MIKART	300MG;30MG	A089238 001	Feb 25, 1986
	300MG;60MG	A089244 001	Feb 25, 1986
	650MG;30MG	A089231 001	Mar 03, 1986
	650MG;60MG	A089363 001	Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795 001	
	300MG;30MG	A085794 001	
	300MG;60MG	A087653 001	Apr 13, 1982
PURACAP PHARM	300MG;30MG	A087762 001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681 001	
	300MG;30MG	A089080 001	Jul 17, 1986
	300MG;60MG	A086683 001	
ROXANE	300MG;15MG	A084659 001	
	300MG;30MG	A084656 001	
	300MG;60MG	A084667 001	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE				
		500MG;15MG	A089511 001	Apr 25, 1989
		500MG;30MG	A089512 001	Apr 25, 1989
		500MG;60MG	A089513 001	Apr 25, 1989
	SANDOZ	300MG;15MG	A087433 001	
		300MG;30MG	A081250 001	Jul 16, 1992
		300MG;30MG	A085291 002	
		300MG;30MG	A085917 001	
		300MG;60MG	A081249 001	Jul 16, 1992
		300MG;60MG	A085964 001	
		300MG;60MG	A087423 001	
	SUPERPHARM	300MG;15MG	A089183 001	Oct 18, 1985
		300MG;30MG	A089184 001	Oct 18, 1985
		300MG;30MG	A089253 001	May 19, 1986
		300MG;60MG	A089185 001	Oct 18, 1985
		300MG;60MG	A089254 001	May 19, 1986
	USL PHARMA	300MG;30MG	A087919 001	Jun 22, 1982
		300MG;60MG	A087920 001	Jun 22, 1982
	VALEANT PHARM INTL	300MG;30MG	A085896 001	
	VITARINE	300MG;30MG	A085676 001	
	WARNER CHILCOTT	300MG;15MG	A085992 001	
		300MG;30MG	A085218 002	
		300MG;60MG	A087306 001	
	WATSON LABS	300MG;15MG	A087277 001	May 26, 1982
		300MG;15MG	A089997 001	Dec 28, 1994
		300MG;30MG	A087276 001	May 26, 1982
		300MG;30MG	A089998 001	Dec 28, 1994
		300MG;60MG	A087275 001	May 26, 1982
		300MG;60MG	A089999 001	Dec 28, 1994
	WATSON LABS FLORIDA	300MG;15MG	A040443 001	Jan 22, 2003
		300MG;30MG	A040443 002	Jan 22, 2003
		300MG;60MG	A040443 003	Jan 22, 2003
	WHITEWORTH TOWN PLSN	300MG;30MG	A084360 001	
		300MG;60MG	A085607 001	
CAPITAL AND CODEINE				
	CARNRICK	325MG;30MG	A083643 001	
CODRIX				
	WATSON LABS FLORIDA	500MG;15MG	A040447 001	Feb 26, 2003
		500MG;30MG	A040441 001	Mar 27, 2003
		500MG;60MG	A040488 001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
	GLAXOSMITHKLINE	300MG;30MG	A083951 001	
EMPRACET W/ CODEINE PHOSPHATE #4				
	GLAXOSMITHKLINE	300MG;60MG	A083951 002	
PAPA-DEINE #3				
	VANGARD	300MG;30MG	A088037 001	Mar 20, 1984
PAPA-DEINE #4				
	VANGARD	300MG;60MG	A088715 001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
	ROBINS AH	650MG;30MG	A085856 001	
TYLENOL W/ CODEINE				
	ORTHO MCNEIL PHARM	325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 001	
		325MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 002	
		325MG;30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 003	
		325MG;60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 004	
TYLENOL W/ CODEINE NO. 1				
	JANSSEN PHARMS	300MG;7.5MG	A085055 001	
TYLENOL W/ CODEINE NO. 2				
	JANSSEN PHARMS	300MG;15MG	A085055 002	

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DRIXORAL PLUS

SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE;ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS	500MG;5MG	A088898	001	Mar 27, 1985

ALLAY

IVAX PHARMS	500MG;5MG	A089907	001	Jan 13, 1989

BANCAP HC

FOREST PHARMS	500MG;5MG	A087961	001	Mar 17, 1983

CO-GESIC

CENT PHARMS	500MG;5MG	A089360	001	Mar 02, 1988

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT	500MG;5MG	A088956	001	Jul 19, 1985
	500MG;5MG	A089006	001	Aug 09, 1985
MIKART	500MG;5MG	A081067	001	Nov 30, 1989
	500MG;5MG	A081068	001	Nov 30, 1989
	500MG;5MG	A081069	001	Nov 30, 1989
	500MG;5MG	A081070	001	Nov 30, 1989
	500MG;5MG	A089008	001	Feb 21, 1986

LORCET-HD

MALLINCKRODT	500MG;5MG	A087336	001	Jul 08, 1982

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418	001	Jun 27, 2001
MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003
MIKART	500MG/15ML;5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML;5MG/15ML	A089557	001	Apr 29, 1992
	500MG/15ML;7.5MG/15ML	A081051	001	Aug 28, 1992
NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002
PHARM ASSOC	500MG/15ML;7.5MG/15ML	A040182	001	Mar 13, 1998
VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	A040520	001	Oct 30, 2003

TABLET;ORAL

ANEXSIA

MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987
	750MG;10MG	A040468	001	Oct 31, 2002

ANEXSIA 7.5/650

MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987

CO-GESIC

UCB INC	500MG;5MG	A087757	001	May 03, 1982

DURADYNE DHC

FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983

HY-PHEN

ASCHER	500MG;5MG	A087677	001	May 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ABLE	325MG;5MG	A040478	001	Nov 08, 2002
	325MG;7.5MG	A040464	001	Oct 23, 2002
	325MG;10MG	A040464	002	Oct 23, 2002
	500MG;5MG	A040477	001	Nov 06, 2002
	500MG;7.5MG	A040490	001	May 21, 2003
	500MG;10MG	A040473	001	Nov 06, 2002
	650MG;7.5MG	A040474	001	Jan 02, 2003
	650MG;10MG	A040476	001	Oct 23, 2002
	750MG;7.5MG	A040469	001	Oct 25, 2002
AMNEAL PHARMS NY	500MG;5MG	A040729	001	Aug 25, 2006
	500MG;7.5MG	A040748	001	Aug 25, 2006
	500MG;10MG	A040813	001	Feb 23, 2007
	650MG;7.5MG	A040754	001	Aug 25, 2006
	650MG;10MG	A040757	001	Aug 25, 2006
	750MG;7.5MG	A040769	001	Aug 28, 2006
APIL	500MG;10MG	A040148	002	Feb 14, 1997
BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996
	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL				
LORTAB				
	UCB INC	500MG;5MG	A087722 001	Jul 09, 1982
		500MG;10MG	A040100 001	Jan 26, 1996
NORCET				
	ABANA	500MG;5MG	A088871 001	May 15, 1986
TYCOLET				
	ORTHO MCNEIL PHARM	500MG;5MG	A089385 001	Aug 27, 1986
VICODIN				
	ABBOTT	500MG;5MG	A085667 001	
	ABBVIE	500MG;5MG	A088058 001	Jan 07, 1983
VICODIN ES				
	ABBVIE	750MG;7.5MG	A089736 001	Dec 09, 1988
VICODIN HP				
	ABBVIE	660MG;10MG	A040117 001	Sep 23, 1996
ZYDONE				
	VINTAGE PHARMS LLC	400MG;5MG	A040288 001	Nov 27, 1998
		400MG;7.5MG	A040288 002	Nov 27, 1998
		400MG;10MG	A040288 003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL				
OXYCODONE AND ACETAMINOPHEN				
	ACTAVIS ELIZABETH	500MG;5MG	A040199 001	Dec 30, 1998
	BARR	500MG;5MG	A040304 001	Oct 02, 2000
	DURAMED PHARMS BARR	500MG;5MG	A040289 001	Mar 16, 1999
	HALSEY	500MG;5MG	A089994 001	May 04, 1989
	MALLINCKRODT	500MG;5MG	A040257 001	Aug 04, 1998
	MUTUAL PHARM	500MG;5MG	A040219 001	Jan 22, 1998
	VINTAGE PHARMS	500MG;5MG	A040106 001	Jul 30, 1996
	VINTAGE PHARMS LLC	500MG;5MG	A040303 001	Dec 30, 1999
	WATSON LABS	500MG;5MG	A040234 001	Oct 30, 1997
ROXILOX				
	ROXANE	500MG;5MG	A040061 001	Jul 03, 1995
TYLOX				
	JANSSEN PHARMS	500MG;5MG	A088790 001	Dec 12, 1984
TYLOX-325				
	ORTHO MCNEIL PHARM	325MG;5MG	A088246 001	Nov 08, 1984
SOLUTION;ORAL				
ROXICET				
	WEST-WARD PHARMS INT	325MG/5ML;5MG/5ML	A089351 001	Dec 03, 1986
TABLET;ORAL				
OXYCODONE 2.5/APAP 500				
	BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910 001	
OXYCODONE 5/APAP 500				
	BRISTOL MYERS SQUIBB	500MG;5MG	A085911 001	
OXYCODONE AND ACETAMINOPHEN				
	ACTAVIS ELIZABETH	325MG;5MG	A040203 001	Mar 15, 1999
		325MG;7.5MG	A040800 001	Apr 03, 2012
		325MG;10MG	A040800 002	Apr 03, 2012
	AMNEAL PHARMS NY	500MG;7.5MG	A040789 001	Nov 27, 2007
		650MG;10MG	A040789 002	Nov 27, 2007
	BARR	325MG;5MG	A087406 001	
	DURAMED PHARMS BARR	325MG;5MG	A040272 001	Jun 30, 1998
	MALLINCKRODT	500MG;7.5MG	A040550 001	Jun 30, 2004
		650MG;10MG	A040550 002	Jun 30, 2004
	MAYNE PHARMA INC	500MG;7.5MG	A090177 005	Oct 20, 2008
		650MG;10MG	A090177 006	Oct 20, 2008
	MIKART	400MG;2.5MG	A040679 001	May 16, 2006
		400MG;5MG	A040687 001	Apr 27, 2006
		400MG;7.5MG	A040698 001	Apr 27, 2006
		400MG;10MG	A040692 001	Apr 27, 2006
		500MG;10MG	A040676 001	Apr 19, 2006
	WATSON LABS	500MG;7.5MG	A040371 001	Dec 29, 2000
		650MG;10MG	A040371 002	Dec 29, 2000
PERCOCET				
	VINTAGE PHARMS LLC	325MG;5MG	A085106 002	
		500MG;7.5MG	A040341 001	Jul 26, 1999
		650MG;10MG	A040341 002	Jul 26, 1999
ROXICET 5/500				
	ROXANE	500MG;5MG	A089775 001	Jan 12, 1989

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE;ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375 001	

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

GAVIS PHARMS	650MG;EQ 25MG BASE	A076202 001	Aug 02, 2002
WATSON LABS	650MG;EQ 25MG BASE	A074699 001	Mar 24, 2000

TALACEN

SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458 001	Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET;ORAL

DARVOCET

AAIPHARMA LLC	325MG;32.5MG	N016844 001	

DOLENE AP-65

LEDERLE	650MG;65MG	A085100 001	

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG;32MG	A083689 001	
	650MG;65MG	A083978 001	
SANDOZ	650MG;65MG	A089959 001	Jul 18, 1989
VINTAGE PHARMS	650MG;65MG	A040507 001	Jul 30, 2003
WATSON LABS	650MG;65MG	A040139 001	Dec 16, 1996

WYGESIC

CARACO	650MG;65MG	A084999 001	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET;ORAL

DARVOCET A500

XANODYNE PHARM	500MG;100MG	A076429 001	Sep 10, 2003

DARVOCET-N 100

XANODYNE PHARM	650MG;100MG	N017122 002	

DARVOCET-N 50

XANODYNE PHARM	325MG;50MG	N017122 001	

PROPACET 100

TEVA	650MG;100MG	A070107 001	Jun 12, 1985

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE	650MG;100MG	A075838 001	Jul 11, 2001
ACTAVIS ELIZABETH	650MG;100MG	A070910 001	Jan 02, 1987
CORNERSTONE	325MG;100MG	A076743 001	May 07, 2004
	500MG;100MG	A076750 001	Jun 28, 2004
HALSEY	325MG;50MG	A072105 001	May 13, 1988
	650MG;100MG	A072106 001	May 13, 1988
IVAX SUB TEVA PHARMS	650MG;100MG	A070146 001	Aug 02, 1985
MALLINCKRODT	650MG;100MG	A075738 001	Feb 02, 2001
MIRROR PHARMS	650MG;100MG	A077821 001	Feb 11, 2008
MUTUAL PHARM	325MG;50MG	A070115 001	Jun 12, 1985
	650MG;100MG	A070116 001	Jun 12, 1985
	650MG;100MG	A070615 001	Mar 21, 1986
	650MG;100MG	A070771 001	Mar 21, 1986
	650MG;100MG	A070775 001	Mar 21, 1986
MYLAN	650MG;100MG	A072195 001	Feb 16, 1988
MYLAN PHARMS INC	650MG;100MG	A070145 001	Jun 12, 1985
SANDOZ	650MG;100MG	A070443 001	Jan 23, 1986
SUPERPHARM	650MG;100MG	A071319 001	Jan 06, 1987
TEVA	650MG;100MG	A070732 001	Jan 03, 1986
	650MG;100MG	A074119 001	Dec 19, 1994
VINTAGE PHARMS	325MG;50MG	A074843 002	Feb 15, 2001
	650MG;100MG	A074843 001	Feb 12, 1997
WATSON LABS	325MG;50MG	A070398 001	Dec 18, 1986
	650MG;100MG	A070399 001	Dec 18, 1986
WATSON LABS FLORIDA	500MG;100MG	A077196 001	Jun 28, 2005
	650MG;100MG	A076609 001	Nov 16, 2004
WOCKHARDT LTD	325MG;50MG	A077677 001	Mar 16, 2007
	650MG;100MG	A077677 002	Mar 16, 2007

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE
TABLET;ORAL
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

WATSON LABS	325MG;37.5MG	A076914 001	Jul 26, 2006

ACETAZOLAMIDE
TABLET;ORAL
ACETAZOLAMIDE

ALRA	250MG	A083320 001	
ASCOT	250MG	A087686 001	Oct 20, 1982
SUN PHARM INDS	250MG	A089753 001	Jun 22, 1988
VANGARD	250MG	A087654 001	Feb 05, 1982
WATSON LABS	250MG	A084498 002	
	250MG	A088882 001	Oct 22, 1985

DIAMOX

TEVA BRANDED PHARM	125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008943 001	
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008943 002	

ACETAZOLAMIDE SODIUM
INJECTABLE;INJECTION
ACETAZOLAMIDE SODIUM

HOSPIRA	EQ 500MG BASE/VIAL	A040108 001	Oct 30, 1995

DIAMOX

TEVA WOMENS	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009388 001	Dec 05, 1990

ACETIC ACID, GLACIAL
SOLUTION/DROPS;OTIC
ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146 001	

ACETIC ACID

KV PHARM	2%	A085493 001	

ORLEX

WARNER CHILCOTT	2%	A086845 001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE
SOLUTION/DROPS;OTIC
BOROFAIR

PHARMAFAIR	2%;0.79%	A088606 001	Aug 21, 1985

DOMEBORO

BAYER PHARMS	2%;0.79%	A084476 001	

ACETIC ACID, GLACIAL; DESONIDE
SOLUTION/DROPS;OTIC
TRIDESILON

BAYER PHARMS	2%;0.05%	N017914 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE
SOLUTION/DROPS;OTIC
ACETIC ACID W/ HYDROCORTISONE

KV PHARM	2%;1%	A085492 001	

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB	2%;1%	A040097 001	Oct 31, 1994
WOCKHARDT	2%;1%	A040168 001	Aug 30, 1996

ORLEX HC

WARNER CHILCOTT	2%;1%	A086844 001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE
SUSPENSION/DROPS;OTIC
NEO-CORT-DOME

BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238 001	

ACETOHEXAMIDE
TABLET;ORAL
ACETOHEXAMIDE

ANI PHARMS INC	250MG	A070869 001	Feb 09, 1987
	500MG	A070870 001	Feb 09, 1987
USL PHARMA	250MG	A070753 001	Nov 03, 1986
	500MG	A070754 001	Nov 03, 1986
WATSON LABS	250MG	A071893 001	Nov 25, 1987

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

ACETOHEXAMIDE
TABLET;ORAL
ACETOHEXAMIDE

	500MG	A071894 001	Nov 25, 1987

DYMELOR

LILLY	250MG	N013378 002	
	500MG	N013378 001	

ACETOPHENAZINE MALEATE
TABLET;ORAL
TINDAL

SCHERING	20MG	N012254 002	

ACETRIZOATE SODIUM
SOLUTION;INTRAUTERINE
SALPIX

ORTHO MCNEIL PHARM	53%	N009008 001	

ACETYLCHOLINE CHLORIDE
FOR SOLUTION;OPHTHALMIC
MIOCHOL

NOVARTIS	20MG/VIAL	N016211 001	

ACETYLCYSTEINE
SOLUTION;INHALATION, ORAL
ACETYLCYSTEINE

HOSPIRA	10%	A071364 001	May 01, 1989
	20%	A071365 001	May 01, 1989
ROXANE	10%	A072323 001	Apr 30, 1992
	10%	A072621 001	Sep 30, 1992
	20%	A072324 001	Apr 30, 1992
	20%	A072622 001	Sep 30, 1992

MUCOMYST

APOTHECON	10% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013601 002	
	20% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013601 001	

MUCOSIL-10

DEY	10%	A070575 001	Oct 14, 1986

MUCOSIL-20

DEY	20%	A070576 001	Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE
SOLUTION;INHALATION
MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON	10%;0.05%	N017366 001	

ACETYLDIGITOXIN
TABLET;ORAL
ACYLANID

NOVARTIS	0.1MG	N009436 001	

ACRISORCIN
CREAM;TOPICAL
AKRINOL

SCHERING	2MG/GM	N012470 001	

ACYCLOVIR
CAPSULE;ORAL
ACYCLOVIR

ACTAVIS ELIZABETH	200MG	A074906 001	Aug 26, 1997
DAVA PHARMS INC	200MG	A074872 001	Apr 22, 1997
HERITAGE PHARMS INC	200MG	A074889 001	Oct 31, 1997
IVAX SUB TEVA PHARMS	200MG	A074674 001	Apr 22, 1997
LEK PHARM	200MG	A074750 001	Apr 22, 1997
MYLAN	200MG	A074977 001	Apr 13, 1998
RANBAXY	200MG	A074975 001	Sep 30, 1998
ROXANE	200MG	A074570 002	Apr 22, 1997
TEVA	200MG	A074828 001	Apr 22, 1997
TEVA PHARMS	200MG	A074914 001	Nov 26, 1997
WATSON LABS	200MG	A075101 001	Apr 15, 1998

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR
TABLET;ORAL
ACYCLOVIR

ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
	800MG	A074870	002	Jun 05, 1997
DAVA PHARMS INC	400MG	A074834	001	Apr 24, 1997
	800MG	A074834	002	Apr 24, 1997
HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997
	800MG	A074891	002	Oct 31, 1997
IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
	800MG	A074836	002	Apr 22, 1997
LEK PHARM	400MG	A074658	001	Apr 22, 1997
	800MG	A074658	002	Apr 22, 1997
MYLAN	400MG	A074976	001	Apr 13, 1998
	800MG	A074976	002	Apr 13, 1998
SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998
	800MG	A074980	002	Sep 30, 1998
TEVA	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A074556	001	Apr 22, 1997
TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
	800MG	A075021	002	Mar 18, 1998

ACYCLOVIR SODIUM
INJECTABLE;INJECTION
ACYCLOVIR

ABBVIE	EQ 50MG BASE/ML	A075114	001	Jul 26, 1999

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
	EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997

ACYCLOVIR SODIUM

AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997
APOTHECON	EQ 500MG BASE/VIAL	A074897	001	Feb 27, 1998
	EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997
	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997
HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997
	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999
	EQ 500MG BASE/VIAL	A074663	001	Apr 22, 1997
	EQ 500MG BASE/VIAL	A074758	001	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074663	002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074758	002	Apr 22, 1997
TEVA PARENTERAL	EQ 50MG BASE/ML	A075627	001	Mar 28, 2001
	EQ 500MG BASE/VIAL	A074969	001	Aug 26, 1997
	EQ 1GM BASE/VIAL	A074969	002	Aug 26, 1997

ZOVIRAX

GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603	003	Aug 30, 1983
	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603	001	Oct 22, 1982
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603	002	Jun 29, 1989

ADAPALENE
SOLUTION;TOPICAL
DIFFERIN

GALDERMA LABS LP	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020338	001	May 31, 1996

ADENOSINE
INJECTABLE;INJECTION
ADENOSINE

EUROHLTH INTL SARL	3MG/ML	A076501	001	Jun 16, 2004
TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004
	3MG/ML	A078676	001	Jul 31, 2008
WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009

FDA data supplied by DrugPatentWatch.com

ADENOSINE
SOLUTION;IV (INFUSION)
ADENOSCAN

ASTELLAS	60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020059 001	May 18, 1995
	90MG/30ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020059 002	May 18, 1995

ALATROFLOXACIN MESYLATE
INJECTABLE;INJECTION
TROVAN PRESERVATIVE FREE

PFIZER	EQ 200MG BASE/VIAL	N020760 001	Dec 18, 1997
	EQ 300MG BASE/VIAL	N020760 002	Dec 18, 1997

ALBENDAZOLE
TABLET, CHEWABLE;ORAL
ALBENZA

AMEDRA PHARMS LLC	200MG	N207844 001	Jun 11, 2015

ALBUMIN CHROMATED CR-51 SERUM
INJECTABLE;INJECTION
CHROMALBIN

ISO TEX	100uCi/VIAL	N017835 001
	250uCi/VIAL	N017835 002
	500uCi/VIAL	N017835 003

ALBUMIN IODINATED I-125 SERUM
INJECTABLE;INJECTION
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS	2.5uCi/AMP	N017846 001

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT	6.67uCi/ML	N017844 003
	10uCi/ML	N017844 001
	100uCi/ML	N017844 002

ALBUMIN IODINATED I-131 SERUM
INJECTABLE;INJECTION
MEGATOPE

ISO TEX	2mCi/VIAL	N017837 003
	5uCi/AMP	N017837 004
	20uCi/AMP	N017837 005

ALBUTEROL
AEROSOL, METERED;INHALATION
ALBUTEROL

ARMSTRONG PHARMS	0.09MG/INH	A072273 001	Aug 14, 1996
GENPHARM	0.09MG/INH	A073045 001	Aug 19, 1997
IVAX SUB TEVA PHARMS	0.09MG/INH	A073272 001	Dec 28, 1995
PLIVA	0.09MG/INH	A074072 001	Aug 01, 1996

PROVENTIL

SCHERING	0.09MG/INH	N017559 001

VENTOLIN

GLAXOSMITHKLINE	0.09MG/INH	N018473 001

ALBUTEROL SULFATE
CAPSULE;INHALATION
VENTOLIN ROTACAPS

GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489 001	May 04, 1988

SOLUTION;INHALATION
ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533 001	Sep 26, 1995
APOTEX INC	EQ 0.021% BASE	A078623 001	Apr 05, 2010
	EQ 0.042% BASE	A078623 002	Apr 05, 2010
	EQ 0.083% BASE	A075717 001	Feb 02, 2007
	EQ 0.5% BASE	A076391 001	Apr 01, 2003
BAUSCH AND LOMB	EQ 0.083% BASE	A075358 001	Mar 29, 2000
COPLEY PHARM	EQ 0.083% BASE	A073495 001	May 28, 1993
	EQ 0.5% BASE	A073307 001	Nov 27, 1991
HI TECH PHARMA	EQ 0.083% BASE	A075063 001	Feb 09, 1999
LANDELA PHARM	EQ 0.083% BASE	A077569 001	Apr 04, 2006
MYLAN SPECLT	EQ 0.083% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or	A072652 001	Feb 21, 1992

ALBUTEROL SULFATE

SOLUTION;INHALATION			
ALBUTEROL SULFATE			
	efficacy reasons**		
ROXANE	EQ 0.083% BASE	A075129 001	Feb 13, 2001
TEVA PHARMS	EQ 0.083% BASE	A075343 001	Nov 09, 1999
WATSON LABS INC	EQ 0.083% BASE	A076370 001	Nov 24, 2003
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394 001	Nov 22, 1999
PROVENTIL			
SCHERING	EQ 0.083% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019243 002	Jan 14, 1987
	EQ 0.5% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019243 001	Jan 14, 1987
VENTOLIN			
GLAXOSMITHKLINE	EQ 0.083% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019773 001	Apr 23, 1992
	EQ 0.5% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019269 002	Jan 16, 1987
SYRUP;ORAL			
ALBUTEROL SULFATE			
ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262 001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302 001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165 001	Apr 29, 1993
PROVENTIL			
SCHERING	EQ 2MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018062 001	Jan 19, 1983
VENTOLIN			
GLAXOSMITHKLINE	EQ 2MG BASE/5ML	N019621 001	Jun 10, 1987
TABLET;ORAL			
ALBUTEROL SULFATE			
AM THERAP	EQ 2MG BASE	A072449 001	Dec 05, 1989
	EQ 4MG BASE	A072450 001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966 001	Nov 22, 1991
	EQ 4MG BASE	A072967 001	Nov 22, 1991
DAVA PHARMS INC	EQ 2MG BASE	A072860 002	Dec 20, 1989
	EQ 4MG BASE	A072860 001	Dec 20, 1989
PLIVA	EQ 2MG BASE	A072316 001	Dec 05, 1989
	EQ 4MG BASE	A072317 001	Dec 05, 1989
SANDOZ	EQ 2MG BASE	A072151 001	Dec 05, 1989
	EQ 4MG BASE	A072152 001	Dec 05, 1989
TEVA	EQ 2MG BASE	A072619 001	Dec 05, 1989
	EQ 2MG BASE	A072779 001	Jun 25, 1993
	EQ 2MG BASE	A072938 001	Mar 30, 1990
	EQ 4MG BASE	A072620 001	Dec 05, 1989
	EQ 4MG BASE	A072780 001	Jun 25, 1993
	EQ 4MG BASE	A072939 001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120 001	Sep 29, 1992
	EQ 4MG BASE	A073121 001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817 001	Jan 09, 1990
	EQ 4MG BASE	A072818 001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629 001	Jan 31, 1991
	EQ 2MG BASE	A072764 001	Aug 28, 1991
	EQ 4MG BASE	A072630 001	Jan 31, 1991
	EQ 4MG BASE	A072765 001	Aug 28, 1991
PROVENTIL			
SCHERING	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017853 001	May 07, 1982
	EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017853 002	May 07, 1982
VENTOLIN			
GLAXOSMITHKLINE	EQ 2MG BASE	N019112 001	Jul 10, 1986

ALBUTEROL SULFATE
TABLET;ORAL
VENTOLIN

	EQ 4MG BASE	N019112 002	Jul 10, 1986

TABLET, EXTENDED RELEASE;ORAL
PROVENTIL

SCHERING	EQ 4MG BASE	N019383 001	Jul 13, 1987

VOLMAX

MURO	EQ 4MG BASE	N019604 002	Dec 23, 1992
	EQ 8MG BASE	N019604 001	Dec 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
AEROSOL, METERED;INHALATION
COMBIVENT

BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291 001	Oct 24, 1996

SOLUTION;INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC	EQ 0.083% BASE;0.017%	A077117 001	Dec 31, 2007
SANDOZ INC	EQ 0.083% BASE;0.017%	A076867 001	Dec 21, 2006

DUONEB

MYLAN SPECLT	EQ 0.083% BASE;0.017% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020950 001	Mar 21, 2001

ALCLOMETASONE DIPROPIONATE
CREAM;TOPICAL
ACLOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018707 001	Dec 14, 1982

OINTMENT;TOPICAL
ACLOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018702 001	Dec 14, 1982

ALCOHOL
INJECTABLE;INJECTION
ALCOHOL 5% IN DEXTROSE 5%

MILES	5ML/100ML	A083483 001	

ALCOHOL; DEXTROSE
INJECTABLE;INJECTION
ALCOHOL 10% AND DEXTROSE 5%

B BRAUN	10ML/100ML;5GM/100ML	N004589 006	

ALCOHOL 5% AND DEXTROSE 5%

B BRAUN	5ML/100ML;5GM/100ML	N004589 004	

ALCOHOL 5% IN D5-W

HOSPIRA	5ML/100ML;5GM/100ML	A083263 001	

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE	5ML/100ML;5GM/100ML	A083256 001	

ALENDRONATE SODIUM
SOLUTION;ORAL
FOSAMAX

MERCK	EQ 70MG BASE/75ML	N021575 001	Sep 17, 2003

TABLET;ORAL
ALENDRONATE SODIUM

MYLAN	EQ 35MG BASE	A078638 001	Aug 04, 2008
	EQ 70MG BASE	A078638 002	Aug 04, 2008
TEVA PHARMS	EQ 35MG BASE	A076184 002	Aug 04, 2008
	EQ 70MG BASE	A076184 001	Feb 06, 2008
UPSHER-SMITH LABS	EQ 5MG BASE	A075871 001	Apr 22, 2009
	EQ 10MG BASE	A075871 002	Apr 22, 2009
	EQ 35MG BASE	A075871 004	Apr 22, 2009
	EQ 40MG BASE	A075871 003	Apr 22, 2009
	EQ 70MG BASE	A075871 005	Apr 22, 2009

FOSAMAX

MERCK AND CO INC	EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020560 003	Apr 25, 1997
	EQ 10MG BASE **Federal Register determination that product was not	N020560 001	Sep 29, 1995

ALENDRONATE SODIUM
TABLET;ORAL
FOSAMAX

	discontinued or withdrawn for safety or efficacy reasons**		
	EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020560 004	Oct 20, 2000
	EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020560 002	Sep 29, 1995

ALFUZOSIN HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
ALFUZOSIN HYDROCHLORIDE

WOCKHARDT LTD	10MG	A090221 001	Aug 10, 2012

ALGLUCERASE
INJECTABLE;INJECTION
CEREDASE

GENZYME	10 UNITS/ML	N020057 004	May 08, 1992
	80 UNITS/ML	N020057 003	Apr 05, 1991

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE
TABLET;ORAL
TEKAMLO

NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545 001	Aug 26, 2010
	EQ 150MG BASE;EQ 10MG BASE	N022545 002	Aug 26, 2010
	EQ 300MG BASE;EQ 5MG BASE	N022545 003	Aug 26, 2010
	EQ 300MG BASE;EQ 10MG BASE	N022545 004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
AMTURNIDE

NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045 001	Dec 21, 2010
	EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045 002	Dec 21, 2010
	EQ 300MG BASE;EQ 5MG BASE;25MG	N200045 003	Dec 21, 2010
	EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045 004	Dec 21, 2010
	EQ 300MG BASE;EQ 10MG BASE;25MG	N200045 005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; VALSARTAN
TABLET;ORAL
VALTURNA

NOVARTIS	EQ 150MG BASE;160MG	N022217 001	Sep 16, 2009
	EQ 300MG BASE;320MG	N022217 002	Sep 16, 2009

ALKAVERVIR
TABLET;ORAL
VERILOID

3M	2MG	N007336 002	
	3MG	N007336 003	

ALLOPURINOL
TABLET;ORAL
ALLOPURINOL

MUTUAL PHARM	100MG	A070466 001	Dec 24, 1985
	300MG	A070467 001	Dec 24, 1985
PURACAP PHARM	100MG	A070150 001	Dec 10, 1985
	300MG	A070147 001	Dec 10, 1985
PUREPAC PHARM	100MG	A070579 001	Apr 14, 1986
	300MG	A070580 001	Apr 14, 1986
SANDOZ	100MG	A070268 001	Dec 31, 1985
	300MG	A070269 001	Dec 31, 1985
SUPERPHARM	100MG	A070950 001	Nov 30, 1988
	300MG	A070951 001	Nov 30, 1988
WATSON LABS	100MG	N018241 001	Nov 16, 1984
	100MG	N018785 001	Sep 28, 1984
	300MG	N018241 002	Nov 16, 1984
	300MG	N018785 002	Sep 28, 1984

LOPURIN

ABBOTT	100MG	N018297 001	
	300MG	N018297 002	

ALPRAZOLAM

SOLUTION;ORAL

ALPRAZOLAM

ROXANE	0.5MG/5ML	A074314 001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

ANI PHARMS INC	0.25MG	A074085 001	Feb 16, 1994
	0.5MG	A074085 002	Feb 16, 1994
	1MG	A074085 003	Feb 16, 1994
	2MG	A074085 004	Feb 26, 1996
IVAX SUB TEVA PHARMS	0.25MG	A074294 001	Jul 29, 1994
	0.5MG	A074294 002	Jul 29, 1994
	1MG	A074294 003	Jul 29, 1994
	2MG	A074294 004	Jul 29, 1994
ROXANE	0.25MG	A074199 001	Oct 19, 1993
	0.5MG	A074199 002	Oct 19, 1993
	1MG	A074199 003	Oct 19, 1993
WATSON LABS	0.25MG	A074456 001	Aug 31, 1995
	0.25MG	A074479 001	Jan 21, 1997
	0.5MG	A074456 002	Aug 31, 1995
	0.5MG	A074479 002	Jan 21, 1997
	1MG	A074456 003	Aug 31, 1995
	1MG	A074479 003	Jan 21, 1997

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

ACTAVIS LABS FL INC	0.5MG	A077198 001	May 13, 2010
	1MG	A077198 002	May 13, 2010
	2MG	A077198 003	May 13, 2010
	3MG	A077198 004	May 13, 2010
ANI PHARMS INC	0.5MG	A077979 001	Feb 28, 2007
	1MG	A077979 002	Feb 28, 2007
	2MG	A077979 003	Feb 28, 2007
	3MG	A077979 004	Feb 28, 2007
COREPHARMA	0.5MG	A077996 001	Jan 31, 2007
	1MG	A077996 002	Jan 31, 2007
	2MG	A077996 003	Jan 31, 2007
	3MG	A077996 004	Jan 31, 2007
IMPAX LABS	0.5MG	A077968 004	May 24, 2007
	1MG	A077968 003	May 24, 2007
	2MG	A077968 002	May 24, 2007
	3MG	A077968 001	May 24, 2007
SANDOZ INC	0.5MG	A077777 001	Jun 30, 2006
	1MG	A077777 002	Jun 30, 2006
	2MG	A077777 003	Jun 30, 2006
	3MG	A077777 004	Jun 30, 2006
VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007
	1MG	A078442 002	Oct 15, 2007
	2MG	A078442 003	Oct 15, 2007
	3MG	A078442 004	Oct 15, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

NIRAVAM

UCB INC	0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021726 001	Jan 19, 2005
	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021726 002	Jan 19, 2005
	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021726 003	Jan 19, 2005
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021726 004	Jan 19, 2005

FDA data supplied by DrugPatentWatch.com

ALPROSTADIL
INJECTABLE;INJECTION
CAVERJECT

PFIZER	0.005MG/ML	N020755 001	Oct 31, 1997
	0.01MG/ML	N020755 002	Oct 01, 1997
	0.02MG/ML	N020755 003	Oct 01, 1997

EDEX

AUXILIUM PHARMS INC	0.005MG/VIAL	N020649 001	Jun 12, 1997

ALSEROXYLON
TABLET;ORAL
RAUTENSIN

NOVARTIS	2MG	N009215 001	

RAUWILOID

3M	2MG	N008867 001	

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE
TABLET, CHEWABLE;ORAL
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX	80MG;20MG	A089449 001	Nov 27, 1987

FOAMICON

NOVARTIS	80MG;20MG	A072687 001	Jun 28, 1989

AMANTADINE HYDROCHLORIDE
CAPSULE;ORAL
AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH	100MG	A077659 001	Feb 23, 2006
WATSON LABS	100MG	A071382 001	Jan 21, 1987

SYMADINE

SOLVAY	100MG	A071000 001	Sep 04, 1986

SYMMETREL

ENDO PHARMS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016020 001	

SYRUP;ORAL
AMANTADINE HYDROCHLORIDE

G AND W LABS INC	50MG/5ML	A072655 001	Oct 30, 1990
SILARX	50MG/5ML	A076352 001	Sep 10, 2004
TEVA PHARMS	50MG/5ML	A073115 001	Aug 23, 1991
VINTAGE	50MG/5ML	A077992 001	Dec 12, 2006

SYMMETREL

ENDO PHARMS	50MG/5ML	N016023 002	

TABLET;ORAL
SYMMETREL

ENDO PHARMS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018101 001	

AMBENONIUM CHLORIDE
TABLET;ORAL
MYTELASE

SANOFI AVENTIS US	10MG	N010155 002	

AMCINONIDE
CREAM;TOPICAL
CYCLOCORT

ASTELLAS	0.025%	N018116 001	
	0.1%	N018116 002	

LOTION;TOPICAL
CYCLOCORT

ASTELLAS	0.1%	N019729 001	Jun 13, 1988

OINTMENT;TOPICAL
CYCLOCORT

ASTELLAS	0.1%	N018498 001	

AMDINOCILLIN
INJECTABLE;INJECTION
COACTIN

ROCHE	250MG/VIAL	N050565 001	Dec 21, 1984
	500MG/VIAL	N050565 002	Dec 21, 1984
	1GM/VIAL	N050565 003	Dec 21, 1984

FDA data supplied by DrugPatentWatch.com

AMIFOSTINE
INJECTABLE;INJECTION
ETHYOL

CLINIGEN HLTHCARE	375MG/VIAL	N020221 002	Sep 10, 1999

AMIKACIN SULFATE
INJECTABLE;INJECTION
AMIKACIN SULFATE

ABBOTT	EQ 250MG BASE/ML	A063265 001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266 001	Oct 31, 1994
HOSPIRA	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994
	EQ 50MG BASE/ML	A063350 001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283 001	Oct 31, 1994
	EQ 250MG BASE/ML	A063264 001	Nov 30, 1994
	EQ 250MG BASE/ML	A063350 002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098 001	Jun 26, 1995
	EQ 250MG BASE/ML	A064099 001	Jun 20, 1995
IGI LABS INC	EQ 50MG BASE/ML	A063167 001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169 001	Dec 14, 1995
TEVA PHARMS USA	EQ 50MG BASE/ML	A064045 001	Sep 28, 1993
WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274 001	May 18, 1992
	EQ 250MG BASE/ML	A063275 001	May 18, 1992

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 500MG BASE/100ML	A064146 001	Apr 02, 1997

AMIKIN

APOTHECON	EQ 50MG BASE/ML	A062311 001	
	EQ 50MG BASE/ML	A062562 001	Sep 20, 1984
	EQ 50MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050495 001	
	EQ 250MG BASE/ML	A062311 002	
	EQ 250MG BASE/ML	A062562 002	Sep 20, 1984
	EQ 250MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050495 002	

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTHECON	EQ 5MG BASE/ML	N050618 002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618 001	Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ	EQ 5MG ANHYDROUS;50MG	A073357 001	Nov 27, 1991
TEVA	EQ 5MG ANHYDROUS;50MG	A070795 001	Apr 17, 1988
WATSON LABS	EQ 5MG ANHYDROUS;50MG	A073334 001	Jul 19, 1991

HYDRO-RIDE

PAR PHARM	EQ 5MG ANHYDROUS;50MG	A070347 001	Dec 25, 1990

MODURETIC 5-50

MERCK	EQ 5MG ANHYDROUS;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018201 001	

AMINO ACIDS
INJECTABLE;INJECTION
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA	5.2% (5.2GM/100ML)	N018901 001	Apr 06, 1984

AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT	3.5% (3.5GM/100ML)	N018804 001	May 15, 1984
	3.5% (3.5GM/100ML)	N018875 001	Aug 08, 1984

AMINOSYN II 3.5%

HOSPIRA	3.5% (3.5GM/100ML)	N019438 001	Apr 03, 1986

AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT	3.5% (3.5GM/100ML)	N019491 001	Oct 10, 1986

AMINOSYN II 5%

HOSPIRA	5% (5GM/100ML)	N019438 002	Apr 03, 1986

AMINOSYN-HBC 7% IN PLASTIC CONTAINER

ABBOTT	7% (7GM/100ML)	N019400 001	Jul 23, 1986

BRANCHAMIN 4%

BAXTER HLTHCARE	4% (4GM/100ML)	N018678 001	Sep 28, 1984

BRANCHAMIN 4% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4% (4GM/100ML)	N018684 001	Sep 28, 1984

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS

INJECTABLE;INJECTION

FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML)	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986
	3.5%;25GM/100ML	N019713	006	Sep 09, 1988
HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986
	3.5%;5GM/100ML	N019713	002	Sep 09, 1988
HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986
	4.25%;25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986
	5%;25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712	001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML N020147 002 Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;15GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML N020147 003 Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;20GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML N020147 004 Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML N020147 005 Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML;51MG/100ML;261MG/100ML;216MG/100ML;112MG/100ML N020147 001 Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML N020147 007 Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;15GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML N020147 008 Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML N020147 009 Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML N020147 010 Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML N020147 006 Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER
ABBOTT 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N018804 002 May 15, 1984
3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N018875 002 Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M
HOSPIRA 3.5%;21MG/100ML;128MG/100ML;234MG/100ML N017789 005

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER
ABBOTT 3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML N019493 001 Oct 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

VEINAMINE 8%
HOSPIRA INC 8%;61MG/100ML;211MG/100ML;56MG/100ML;38MG/100ML N017957 001

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 7% W/ ELECTROLYTES
HOSPIRA 7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML N019437 006 Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M
HOSPIRA 3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML N019437 007 Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML N020177 001 Oct 23, 1995

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION			
TRAVASOL 3.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493 003	
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N020173 001	Oct 27, 1995
TRAVASOL 5.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493 001	
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173 002	Oct 27, 1995
TRAVASOL 8.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N017493 002	

AMINOCAPROIC ACID

INJECTABLE;INJECTION			
AMICAR			
CLOVER PHARMS	250MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015229 002	
AMINOCAPROIC ACID			
ABRAXIS PHARM	250MG/ML	A070522 001	Jun 17, 1986
BAXTER HLTHCARE	250MG/ML	N018590 001	Oct 29, 1982
HOSPIRA	250MG/ML	A070888 001	Jun 16, 1988

AMINOGLUTETHIMIDE

TABLET;ORAL			
CYTADREN			
NOVARTIS	250MG	N018202 001	

AMINOHIPPURATE SODIUM

INJECTABLE;INJECTION			
AMINOHIPPURATE SODIUM			
MERCK	20%	N005619 001	

AMINOPHYLLINE

ENEMA;RECTAL			
SOMOPHYLLIN			
FISONS	300MG/5ML	N018232 001	Apr 02, 1982
INJECTABLE;INJECTION			
AMINOPHYLLIN			
GD SEARLE LLC	25MG/ML	A087243 001	May 24, 1982
	25MG/ML	A087621 001	May 24, 1982
AMINOPHYLLINE			
ABRAXIS PHARM	25MG/ML	A084568 001	
	25MG/ML	A087200 001	
	25MG/ML	A087250 001	Jan 06, 1982
	25MG/ML	A087886 001	Aug 30, 1983
	25MG/ML	A088407 001	Jan 25, 1984
ELKINS SINN	25MG/ML	A087239 001	
HOSPIRA	25MG/ML	A087601 001	Jul 23, 1982
INTL MEDICATION	25MG/ML	A087209 001	Feb 01, 1982
	25MG/ML	A087867 001	Nov 10, 1983
	25MG/ML	A087868 001	Nov 10, 1983
KING PHARMS	25MG/ML	A086606 001	
LUITPOLD	25MG/ML	A087240 001	
LYPHOMED	25MG/ML	A087431 001	
PHARMA SERVE NY	25MG/ML	A087387 001	Jun 03, 1983
	25MG/ML	A087392 001	Dec 15, 1983
SMITH AND NEPHEW	25MG/ML	A088429 001	May 30, 1985
	25MG/ML	A088749 001	May 30, 1985
TEVA PARENTERAL	25MG/ML	A081142 001	Sep 25, 1991
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%			
HOSPIRA	100MG/100ML	A088147 002	May 03, 1983
	200MG/100ML	A088147 003	May 03, 1983
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
HOSPIRA	100MG/100ML	N018924 001	Dec 12, 1984
	200MG/100ML	N018924 002	Dec 12, 1984
	400MG/100ML	N018924 003	Dec 12, 1984
	500MG/100ML	N018924 004	Dec 12, 1984

FDA data supplied by DrugPatentWatch.com

AMINOPHYLLINE

SOLUTION;ORAL			
AMINOPHYLLINE			
MORTON GROVE	105MG/5ML	A088156 001	Dec 05, 1983
ROXANE	105MG/5ML	A088126 001	Aug 19, 1983
AMINOPHYLLINE DYE FREE			
ACTAVIS MID ATLANTIC	105MG/5ML	A087727 001	Apr 16, 1982
SOMOPHYLLIN			
FISONS	105MG/5ML	A086466 001	
SOMOPHYLLIN-DF			
FISONS	105MG/5ML	A087045 001	
SUPPOSITORY;RECTAL			
TRUPHYLLINE			
G AND W LABS	250MG	A085498 001	Mar 23, 1983
	500MG	A085498 002	Jan 03, 1983
TABLET;ORAL			
AMINOPHYLLIN			
GD SEARLE LLC	100MG	N002386 002	
	200MG	N002386 003	
AMINOPHYLLINE			
ASCOT	100MG	A087522 001	Feb 12, 1982
	200MG	A087523 001	Feb 12, 1982
BARR	100MG	A088297 001	Aug 19, 1983
	200MG	A088298 001	Aug 19, 1983
DURAMED PHARMS BARR	100MG	A088182 001	Mar 31, 1983
	200MG	A088183 001	Mar 31, 1983
HALSEY	100MG	A084674 001	
HIKMA INTL PHARMS	100MG	A084540 001	
	200MG	A085003 001	
IDT AUSTRALIA LTD	100MG	A085261 003	
	100MG	A085262 002	
	200MG	A085261 002	
IMPAX LABS	100MG	A084574 001	
	200MG	A084576 001	
KV PHARM	100MG	A085284 001	
	200MG	A085289 001	
LANNETT	100MG	A084588 001	
	200MG	A084588 002	
PAL PAK	100MG	A084533 001	
PANRAY	100MG	A084552 001	
	200MG	A084552 002	
PUREPAC PHARM	100MG	A084699 001	
	200MG	A085333 001	
ROXANE	100MG	A087500 001	Feb 09, 1982
	200MG	A087501 001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563 001	
VANGARD	100MG	A088314 001	Oct 03, 1983
	200MG	A088319 001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409 001	
	200MG	A085410 001	
WATSON LABS	100MG	A085567 001	
	200MG	A085564 001	
TABLET, DELAYED RELEASE;ORAL			
AMINOPHYLLINE			
IMPAX LABS	100MG	A084577 001	
	200MG	A084575 001	
TABLICAPS	100MG	A084632 002	
VALE	100MG	A084531 001	
	200MG	A084530 001	
TABLET, EXTENDED RELEASE;ORAL			
PHYLLOCONTIN			
PHARM RES ASSOC	225MG	A086760 001	

AMINOSALICYLATE SODIUM

POWDER;ORAL			
P.A.S. SODIUM			
CENTURY PHARMS	4GM/PACKET	A080947 001	
SODIUM AMINOSALICYLATE			
HEXCEL	100%	A080097 001	
TABLET;ORAL			
PARASAL SODIUM			
PANRAY	500MG	N006811 006	
	1GM	N006811 011	

FDA data supplied by DrugPatentWatch.com

AMINOSALICYLATE SODIUM
TABLET;ORAL
SODIUM P.A.S.

LANNETT	500MG	A080138 002	

TEEBACIN

CONSOLIDATED MIDLAND	500MG	N007320 002	

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID
TABLET;ORAL
NEOPASALATE

MEDPOINTE PHARM HLC	846MG;112MG	A080059 002	

AMINOSALICYLIC ACID
TABLET;ORAL
PARASAL

PANRAY	500MG	N006811 001	
	1GM	N006811 002	

AMINOSALICYLIC ACID RESIN COMPLEX
POWDER;ORAL
REZIPAS

BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM	N009052 001	

AMIODARONE HYDROCHLORIDE
INJECTABLE;INJECTION
AMIODARONE HYDROCHLORIDE

BEDFORD	50MG/ML	A076018 001	Oct 15, 2002
BEDFORD LABS	50MG/ML	A076299 001	Oct 24, 2002
BEN VENUE	50MG/ML	A076088 001	Oct 15, 2002
HOSPIRA	50MG/ML	A076108 001	Oct 15, 2002
INTL MEDICATION SYS	50MG/ML	N021594 001	Feb 04, 2004
PAR STERILE PRODUCTS	50MG/ML	A076394 001	Apr 25, 2003
TEVA PHARMS USA	50MG/ML	A076163 001	Sep 05, 2003

CORDARONE

WYETH PHARMS INC	50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020377 001	Aug 03, 1995

TABLET;ORAL
AMIODARONE HYDROCHLORIDE

TEVA	200MG	A074895 001	Apr 16, 1999

AMITRIPTYLINE HYDROCHLORIDE
CONCENTRATE;ORAL
ENDEP

ROCHE	40MG/ML	A085749 001	

INJECTABLE;INJECTION
AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS	10MG/ML	A085594 001	

ELAVIL

ASTRAZENECA	10MG/ML	N012704 001	

TABLET;ORAL
AMITID

BRISTOL MYERS SQUIBB	10MG	A086454 001	
	25MG	A086454 002	
	50MG	A086454 003	
	75MG	A086454 004	
	100MG	A086454 005	

AMITRIL

WARNER CHILCOTT	10MG	A083939 001	
	25MG	A083937 001	
	50MG	A083938 002	
	75MG	A084957 001	
	100MG	A085093 001	
	150MG	A086295 001	

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP	25MG	A088672 001	Nov 20, 1984
	50MG	A088673 001	Nov 20, 1984
	75MG	A088674 001	Nov 20, 1984
	100MG	A088675 001	Nov 20, 1984
ANI PHARMS INC	10MG	A085031 002	
	25MG	A085031 001	
	50MG	A085031 003	
	75MG	A085031 004	
COPLEY PHARM	10MG	A088421 001	Apr 30, 1984

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	25MG	A088422	001	Apr 30, 1984
	50MG	A088423	001	Apr 30, 1984
	75MG	A088424	001	Apr 30, 1984
	100MG	A088425	001	Apr 30, 1984
	150MG	A088426	001	Apr 30, 1984
HALSEY	10MG	A085923	001	
	25MG	A085922	001	
	50MG	A085925	001	
	50MG	A087557	001	Mar 05, 1982
	75MG	A085926	001	May 20, 1983
	100MG	A085927	001	May 20, 1983
LEDERLE	10MG	A086744	001	
	10MG	A087366	001	Jan 04, 1982
	25MG	A086746	001	
	25MG	A087367	001	May 03, 1982
	50MG	A086743	001	
	50MG	A087181	001	Jan 04, 1982
	75MG	A086745	001	
	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	
	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008
	10MG	A089399	002	Jul 14, 1987
	25MG	A040816	001	Jun 27, 2008
	25MG	A089399	001	Jul 14, 1987
	50MG	A040816	003	Jun 27, 2008
	50MG	A089399	003	Jul 14, 1987
	75MG	A040816	004	Jun 27, 2008

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	75MG	A089399 004	Jul 14, 1987
	100MG	A040816 005	Jun 27, 2008
	100MG	A089399 005	Jul 14, 1987
	150MG	A040816 006	Jun 27, 2008
	150MG	A089399 006	Jul 14, 1987
SUPERPHARM	10MG	A088853 001	Nov 13, 1984
	25MG	A088854 001	Nov 13, 1984
	50MG	A088855 001	Nov 13, 1984
	75MG	A088856 001	Nov 13, 1984
	100MG	A088857 001	Nov 13, 1984
TEVA	10MG	A086610 001	
	25MG	A086859 001	
	50MG	A086857 001	
	75MG	A086860 001	
	100MG	A085836 001	
	100MG	A086854 001	
	150MG	A086853 001	
UCB INC	10MG	A085864 001	
	25MG	A085935 001	
	50MG	A085936 001	
	75MG	A086337 001	
	100MG	A086336 001	
	150MG	A086335 001	
USL PHARMA	25MG	A087775 001	Feb 10, 1982
VANGARD	10MG	A087632 001	Feb 01, 1982
	50MG	A087616 001	Feb 08, 1982
	75MG	A087617 001	Feb 05, 1982
	100MG	A087639 001	Feb 08, 1982
WATSON LABS	10MG	A085816 001	
	10MG	A088620 001	Mar 02, 1984
	25MG	A085817 001	
	25MG	A088621 001	Mar 02, 1984
	50MG	A085815 001	
	50MG	A088622 001	Mar 02, 1984
	75MG	A085819 001	
	75MG	A088633 001	Mar 02, 1984
	100MG	A085820 001	
	100MG	A088634 001	Mar 02, 1984
	150MG	A085821 001	
	150MG	A088635 001	Mar 02, 1984
WEST WARD	10MG	A087647 001	Mar 05, 1982
	25MG	A087278 001	

ELAVIL

ASTRAZENECA	10MG	N012703 001	
	25MG	N012703 003	
	50MG	N012703 004	
	75MG	N012703 005	
	100MG	N012703 006	
	150MG	N012703 007	

ENDEP

ROCHE	10MG	A083639 001	
	25MG	A083639 002	
	50MG	A083639 003	
	75MG	A083639 004	
	100MG	A083639 005	
	150MG	A085303 001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988
	EQ 25MG BASE;10MG	A072278 001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL			
HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG	N016949 001	
LIMBITROL DS			
HERITAGE PHARMS INC	EQ 25MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

ETRAFON 2-10			
SCHERING	10MG;2MG	N014713 007	
ETRAFON 2-25			
SCHERING	25MG;2MG	N014713 004	
ETRAFON-A			
SCHERING	10MG;4MG	N014713 002	
ETRAFON-FORTE			
SCHERING	25MG;4MG	N014713 006	
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE			
IVAX SUB TEVA PHARMS	10MG;2MG	A070935 001	Sep 11, 1986
	10MG;4MG	A070937 001	Sep 11, 1986
	25MG;2MG	A070936 001	Sep 11, 1986
	25MG;4MG	A070938 001	Sep 11, 1986
	50MG;4MG	A070939 001	Sep 12, 1986
PAR PHARM	10MG;2MG	A070565 001	Sep 11, 1986
	10MG;4MG	A070620 001	Sep 11, 1986
	25MG;2MG	A070621 001	Sep 11, 1986
	25MG;4MG	A070595 001	Sep 11, 1986
	50MG;4MG	A070574 001	Sep 11, 1986
SANDOZ	10MG;2MG	A071062 001	Nov 27, 1987
	10MG;4MG	A071862 001	Dec 21, 1987
	25MG;2MG	A071063 001	Nov 27, 1987
	25MG;4MG	A071064 001	Nov 27, 1987
	50MG;4MG	A071863 001	Dec 21, 1987
SUN PHARM INDS	10MG;2MG	A071077 001	Nov 12, 1986
	10MG;4MG	A071078 001	Nov 12, 1986
	25MG;2MG	A070297 001	Nov 12, 1986
	25MG;4MG	A071079 001	Nov 12, 1986
WATSON LABS	10MG;2MG	A070373 001	Aug 25, 1986
	10MG;2MG	A072539 001	Feb 15, 1989
	10MG;2MG	A073007 001	Oct 17, 1991
	10MG;4MG	A070375 001	Aug 25, 1986
	10MG;4MG	A072540 001	Feb 15, 1989
	10MG;4MG	A073009 001	Oct 17, 1991
	25MG;2MG	A070374 001	Aug 25, 1986
	25MG;2MG	A072541 001	Feb 15, 1989
	25MG;2MG	A073008 001	Oct 17, 1991
	25MG;4MG	A070376 001	Aug 25, 1986
	25MG;4MG	A072134 001	Feb 15, 1989
	25MG;4MG	A073010 001	Oct 17, 1991
	50MG;4MG	A070377 001	Nov 04, 1986
	50MG;4MG	A071558 001	Mar 02, 1987
	50MG;4MG	A072135 001	Feb 15, 1989
TRIAVIL 2-10			
NEW RIVER	10MG;2MG	N014715 004	
TRIAVIL 2-25			
NEW RIVER	25MG;2MG	N014715 002	
TRIAVIL 4-10			
NEW RIVER	10MG;4MG	N014715 003	
TRIAVIL 4-25			
NEW RIVER	25MG;4MG	N014715 005	
TRIAVIL 4-50			
NEW RIVER	50MG;4MG	N014715 006	

AMLEXANOX

PASTE;DENTAL

APHTHASOL			
ULURU	5%	N020511 001	Dec 17, 1996

PATCH;TOPICAL

AMLEXANOX			
ULURU	2MG	N021727 001	Sep 29, 2004

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

GEDEON RICHTER USA	EQ 2.5MG BASE	A077333 001	Jul 17, 2007
	EQ 5MG BASE	A077333 002	Jul 17, 2007
	EQ 10MG BASE	A077333 003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362 001	Jul 09, 2007
	EQ 5MG BASE	A077362 002	Jul 09, 2007
	EQ 10MG BASE	A077362 003	Jul 09, 2007
PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007
	EQ 5MG BASE	A078131 002	Sep 04, 2007
	EQ 10MG BASE	A078131 003	Sep 04, 2007
SANDOZ	EQ 2.5MG BASE	A076859 001	Sep 10, 2007
	EQ 5MG BASE	A076859 002	Sep 10, 2007
	EQ 10MG BASE	A076859 003	Sep 10, 2007
SUN PHARM INDS	EQ 2.5MG BASE	A078081 001	Jan 31, 2008
	EQ 5MG BASE	A078081 002	Jan 31, 2008
	EQ 10MG BASE	A078081 003	Jan 31, 2008
SYNTHON PHARMS	EQ 2.5MG BASE	A077080 001	Jun 27, 2007
	EQ 5MG BASE	A077080 002	Jun 27, 2007
	EQ 10MG BASE	A077080 003	Jun 27, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS	EQ 2.5MG BASE	N022026 001	Sep 27, 2007
	EQ 5MG BASE	N022026 002	Sep 27, 2007
	EQ 10MG BASE	N022026 003	Sep 27, 2007

AMLODIPINE MALEATE

TABLET;ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435 001	Oct 31, 2003
	5MG	N021435 002	Oct 31, 2003
	10MG	N021435 003	Oct 31, 2003

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539 001	Jun 23, 2015

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE

ABBOTT	5MEQ/ML	A083130 001	
GD SEARLE LLC	3MEQ/ML	A086205 001	

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

MCGAW	900MG/100ML	N006580 001	

AMMONIUM CHLORIDE 2.14%

B BRAUN	40MEQ/100ML	A085734 001	

AMMONIUM LACTATE

CREAM;TOPICAL

LAC-HYDRIN

RANBAXY	EQ 12% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020508 001	Aug 29, 1996

LOTION;TOPICAL

LAC-HYDRIN

RANBAXY	EQ 12% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019155 001	Apr 24, 1985

AMODIAQUINE HYDROCHLORIDE

TABLET;ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS	EQ 200MG BASE	N006441 001	

AMOXAPINE

TABLET;ORAL

AMOXAPINE

UPSHER-SMITH LABS	25MG	A072943 001	Jun 28, 1991
	50MG	A072944 001	Jun 28, 1991
	100MG	A072878 001	Jun 28, 1991
	150MG	A072879 001	Jun 28, 1991
WATSON LABS	25MG	A072418 001	May 11, 1989

FDA data supplied by DrugPatentWatch.com

AMOXAPINE
TABLET;ORAL

AMOXAPINE			
	50MG	A072419 001	May 11, 1989
	100MG	A072420 001	May 11, 1989
	150MG	A072421 001	May 11, 1989
ASENDIN			
LEDERLE	25MG	N018021 001	
	50MG	N018021 002	
	100MG	N018021 003	
	150MG	N018021 004	

AMOXICILLIN
CAPSULE;ORAL

AMOXICILLIN			
LABS ATRAL	250MG	A062528 001	Aug 07, 1985
	500MG	A062528 002	Aug 07, 1985
MYLAN	250MG	A062067 001	
	500MG	A062067 002	
SUN PHARM INDS LTD	250MG	A065016 001	Apr 08, 1999
	500MG	A065016 002	Apr 08, 1999
TEVA	250MG	A062853 001	Dec 22, 1987
	250MG	A063030 001	Feb 28, 1989
	500MG	A062854 001	Dec 22, 1987
	500MG	A063031 001	Feb 28, 1989
AMOXIL			
GLAXOSMITHKLINE	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050459 001	
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050459 002	
TRIMOX			
APOTHECON	250MG	A061885 001	
	250MG	A062098 001	
	250MG	A062152 001	
	250MG	A063099 001	Mar 20, 1992
	500MG	A061885 002	
	500MG	A062098 002	
	500MG	A062152 002	
	500MG	A063099 002	Mar 20, 1992
UTIMOX			
PARKE DAVIS	250MG	A062107 001	
	500MG	A062107 002	
WYMOX			
WYETH AYERST	250MG	A062120 001	
	500MG	A062120 002	

FOR SUSPENSION;ORAL

AMOXICILLIN			
AM ANTIBIOTICS	125MG/5ML	A062059 001	
	250MG/5ML	A062059 002	
MYLAN	125MG/5ML	A062090 001	
	250MG/5ML	A062090 002	
SUN PHARM INDS LTD	200MG/5ML	A065113 001	Nov 29, 2002
	400MG/5ML	A065113 002	Nov 29, 2002
TEVA	125MG/5ML	A062946 001	Nov 01, 1988
	250MG/5ML	A063001 001	Jan 06, 1989
AMOXIL			
GLAXOSMITHKLINE	50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050460 005	
	125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050460 001	
	250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050460 002	
LAROTID			
GLAXOSMITHKLINE	50MG/ML **Federal Register determination that product was not	N050460 006	

AMOXICILLIN

FOR SUSPENSION;ORAL			
LAROTID			
	discontinued or withdrawn for safety or efficacy reasons**		
POLYMOX			
APOTHECON	125MG/5ML	A061851 001	
	125MG/5ML	A062323 001	
	250MG/5ML	A061851 002	
	250MG/5ML	A062323 002	
TRIMOX			
APOTHECON	50MG/ML	A061886 001	
	125MG/5ML	A061886 002	
	125MG/5ML	A062099 001	
	125MG/5ML	A062154 001	
	125MG/5ML	A062885 001	Mar 08, 1988
	250MG/5ML	A061886 003	
	250MG/5ML	A062099 002	
	250MG/5ML	A062154 002	
	250MG/5ML	A062885 002	Mar 08, 1988
UTIMOX			
PARKE DAVIS	125MG/5ML	A062127 001	
	250MG/5ML	A062127 002	
WYMOX			
WYETH AYERST	125MG/5ML	A062131 001	
	250MG/5ML	A062131 002	
TABLET;ORAL			
AMOXICILLIN			
DAVA PHARMS INC	875MG	A065344 001	Jan 15, 2009
SUN PHARM INDS LTD	500MG	A065059 001	Nov 24, 2000
	875MG	A065059 002	Nov 24, 2000
TABLET, CHEWABLE;ORAL			
AMOXICILLIN			
APOTHECON	125MG	A064131 001	May 06, 1996
	250MG	A064131 002	May 06, 1996
DAVA PHARMS INC	125MG	A064139 001	Jan 29, 1996
	250MG	A064139 002	Jan 29, 1996
SUN PHARM INDS LTD	125MG	A065021 001	Dec 23, 1999
	200MG	A065060 001	Nov 29, 2000
	250MG	A065021 002	Dec 23, 1999
	400MG	A065060 002	Nov 29, 2000
TEVA	125MG	A064031 001	Dec 19, 1996
	250MG	A064031 002	Dec 19, 1996
AMOXIL			
DR REDDYS LABS INC	200MG	N050761 001	Apr 15, 1999
	400MG	N050761 002	Apr 15, 1999
TABLET, FOR SUSPENSION;ORAL			
AMOXICILLIN			
AUROBINDO PHARMA LTD	200MG	A065324 001	Jan 17, 2007
	400MG	A065324 002	Jan 17, 2007
DISPERMOX			
RANBAXY LABS LTD	200MG	A065080 002	Aug 11, 2003
	400MG	A065080 001	Aug 11, 2003
	600MG	A065159 001	Dec 04, 2003

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL			
AMOXICILLIN AND CLAVULANATE POTASSIUM			
SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132 001	Mar 19, 2003
	400MG/5ML;EQ 57MG BASE/5ML	A065132 002	Mar 19, 2003
	600MG/5ML;EQ 42.9MG BASE/5ML	A065207 002	Jan 30, 2007
TABLET;ORAL			
AMOXICILLIN AND CLAVULANATE POTASSIUM			
APOTEX INC	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009
	500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009
	875MG;EQ 125MG BASE	A065317 003	Oct 20, 2008
SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109 001	Nov 04, 2002
	875MG;EQ 125MG BASE	A065102 001	Sep 17, 2002
TABLET, CHEWABLE;ORAL			
AMOXICILLIN AND CLAVULANATE POTASSIUM			
SANDOZ	200MG;EQ 28.5MG BASE	A065065 001	Apr 18, 2002
	400MG;EQ 57MG BASE	A065065 002	Apr 18, 2002
SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161 001	Dec 03, 2003

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM				
		400MG;EQ 57MG BASE	A065161 002	Dec 03, 2003
AUGMENTIN '125'				
	DR REDDYS LABS INC	125MG;EQ 31.25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050597 001	Jul 22, 1985
AUGMENTIN '250'				
	DR REDDYS LABS INC	250MG;EQ 62.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050597 002	Jul 22, 1985

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DELCOBESE				
	TEVA	1.25MG;1.25MG;1.25MG;1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083564 001	
		2.5MG;2.5MG;2.5MG;2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083564 002	
		3.75MG;3.75MG;3.75MG;3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083564 003	
		5MG;5MG;5MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083564 004	

TABLET;ORAL

DELCOBESE				
	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A083563 004	
		2.5MG;2.5MG;2.5MG;2.5MG	A083563 003	
		3.75MG;3.75MG;3.75MG;3.75MG	A083563 002	
		5MG;5MG;5MG;5MG	A083563 001	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

ADDERALL 10				
	TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011522 007	Feb 13, 1996
ADDERALL 12.5				
	TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011522 012	Aug 31, 2000
ADDERALL 15				
	TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011522 013	Aug 31, 2000
ADDERALL 20				
	TEVA WOMENS	5MG;5MG;5MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011522 008	Feb 13, 1996
ADDERALL 30				
	TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011522 010	May 12, 1997
ADDERALL 5				
	TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011522 009	May 12, 1997
ADDERALL 7.5				
	TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG **Federal Register determination that product was not discontinued or	N011522 011	Aug 31, 2000

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

ADDERALL 7.5

	withdrawn for safety or efficacy reasons**		

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472 001	Sep 30, 2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040472 002	Sep 30, 2003
	5MG;5MG;5MG;5MG	A040472 003	Sep 30, 2003
	7.5MG;7.5MG;7.5MG;7.5MG	A040472 004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

BIPHETAMINE 12.5

UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093 007	

BIPHETAMINE 20

UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093 003	

BIPHETAMINE 7.5

UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093 009	

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

LANNETT	5MG	A083901 001	Aug 31, 1984
	10MG	A083901 002	Aug 31, 1984

AMPHOTERICIN B

CREAM;TOPICAL

FUNGIZONE

APOTHECON	3%	N050314 001	

INJECTABLE;INJECTION

AMPHOTERICIN B

ABBOTT	50MG/VIAL	A064141 001	Dec 23, 1996
ABRAXIS PHARM	50MG/VIAL	A062728 001	Apr 13, 1987
TEVA PARENTERAL	50MG/VIAL	A064062 001	Mar 31, 1995

FUNGIZONE

APOTHECON	50MG/VIAL	A060517 001	

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996
	100MG/VIAL	N050729 002	Nov 22, 1996

LOTION;TOPICAL

FUNGIZONE

APOTHECON	3%	A060570 001	

OINTMENT;TOPICAL

FUNGIZONE

APOTHECON	3%	N050313 001	

SUSPENSION;ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB	100MG/ML	N050341 003	

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

APOTHECON	EQ 125MG BASE/VIAL	A062860 001	Feb 05, 1988
	EQ 250MG BASE/VIAL	A062860 002	Feb 05, 1988
	EQ 500MG BASE/VIAL	A062860 003	Feb 05, 1988
	EQ 1GM BASE/VIAL	A062860 004	Feb 05, 1988
	EQ 2GM BASE/VIAL	A062860 005	Feb 05, 1988
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	A061936 005	
	EQ 250MG BASE/VIAL	A061936 001	
	EQ 500MG BASE/VIAL	A061936 002	
	EQ 1GM BASE/VIAL	A061936 003	
	EQ 2GM BASE/VIAL	A061936 004	
EUROHLTH INTL SARL	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986
	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986
HANFORD GC	EQ 125MG BASE/VIAL	A063143 001	Apr 15, 1993
	EQ 500MG BASE/VIAL	A063147 001	Apr 15, 1993
	EQ 1GM BASE/VIAL	A063139 001	Apr 15, 1993
	EQ 2GM BASE/VIAL	A063141 001	Apr 15, 1993

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

INTL MEDICATION	EQ 1GM BASE/VIAL	A062634 002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634 003	Jan 09, 1987
LILLY	EQ 500MG BASE/VIAL	A062565 001	Apr 04, 1985
	EQ 1GM BASE/VIAL	A062565 002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565 003	Jun 24, 1986
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816 001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816 002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816 003	Oct 24, 1988
	EQ 1GM BASE/VIAL	A062816 004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816 005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994 001	Sep 15, 1988

OMNIPEN-N

WYETH AYERST	EQ 125MG BASE/VIAL	A060626 001	
	EQ 125MG BASE/VIAL	A062718 001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626 002	
	EQ 250MG BASE/VIAL	A062718 002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626 003	
	EQ 500MG BASE/VIAL	A062718 003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626 004	
	EQ 1GM BASE/VIAL	A062718 004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626 005	
	EQ 2GM BASE/VIAL	A062718 005	Dec 16, 1986

PENBRITIN-S

WYETH AYERST	EQ 125MG BASE/VIAL	N050072 001
	EQ 250MG BASE/VIAL	N050072 002
	EQ 500MG BASE/VIAL	N050072 003
	EQ 1GM BASE/VIAL	N050072 004
	EQ 2GM BASE/VIAL	N050072 005
	EQ 4GM BASE/VIAL	N050072 006

POLYCILLIN-N

BRISTOL	EQ 125MG BASE/VIAL	N050309 001
	EQ 250MG BASE/VIAL	N050309 002
	EQ 500MG BASE/VIAL	N050309 003
	EQ 1GM BASE/VIAL	N050309 004
	EQ 2GM BASE/VIAL	N050309 005

TOTACILLIN-N

GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677 001	
	EQ 250MG BASE/VIAL	A060677 002	
	EQ 500MG BASE/VIAL	A060677 003	
	EQ 1GM BASE/VIAL	A060677 004	
	EQ 1GM BASE/VIAL	A062727 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677 005	
	EQ 2GM BASE/VIAL	A062727 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677 006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

UNASYN

PFIZER	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608 003	Dec 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMCILL

PARKE DAVIS	EQ 250MG BASE	A062041 001
	EQ 500MG BASE	A062041 002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS	EQ 250MG BASE	A061602 001
	EQ 500MG BASE	A061602 002
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765 001
	EQ 500MG BASE	A060765 002
LEDERLE	EQ 250MG BASE	A062208 001
	EQ 500MG BASE	A062208 002
MYLAN	EQ 250MG BASE	A061755 001
	EQ 500MG BASE	A061755 002
PUREPAC PHARM	EQ 250MG BASE	A061853 001
	EQ 500MG BASE	A061853 002
TEVA	EQ 250MG BASE	A061502 001
	EQ 500MG BASE	A061502 002
VITARINE	EQ 250MG BASE	A061387 001
	EQ 500MG BASE	A061387 003

FDA data supplied by DrugPatentWatch.com

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

OMNIPEN (AMPICILLIN)			
WYETH AYERST	250MG	A060624 001	
	500MG	A060624 002	
PENBRITIN			
WYETH AYERST	EQ 250MG BASE	A060908 001	
	EQ 500MG BASE	A060908 002	
PFIZERPEN-A			
PFIZER	EQ 250MG BASE	A062050 001	
	EQ 500MG BASE	A062050 002	
POLYCILLIN			
BRISTOL	EQ 250MG BASE	N050310 001	
	EQ 500MG BASE	N050310 002	
PRINCIPEN			
APOTHECON	EQ 250MG BASE	A062888 001	Mar 04, 1988
	EQ 500MG BASE	A062888 002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392 001	
	EQ 500MG BASE	A061392 002	
PRINCIPEN '250'			
APOTHECON	EQ 250MG BASE	A062157 002	
	EQ 250MG BASE	N050056 001	
PRINCIPEN '500'			
APOTHECON	EQ 500MG BASE	A062157 001	
	EQ 500MG BASE	N050056 002	
TOTACILLIN			
GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001	
	EQ 250MG BASE	A062212 001	
	EQ 500MG BASE	A060060 002	
	EQ 500MG BASE	A062212 002	

FOR SUSPENSION;ORAL

AMCILL			
PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001	
	EQ 250MG BASE/5ML	A062030 002	
AMPICILLIN TRIHYDRATE			
AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061601 001	
	EQ 250MG BASE/5ML	A061601 002	
MYLAN	EQ 125MG BASE/5ML	A061829 002	
	EQ 250MG BASE/5ML	A061829 001	
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980 001	
	EQ 250MG BASE/5ML	A061980 002	
TEVA	EQ 125MG BASE/5ML	A061370 001	
	EQ 250MG BASE/5ML	A061370 002	
OMNIPEN (AMPICILLIN)			
WYETH AYERST	100MG/ML	A060625 001	
	125MG/5ML	A060625 002	
	250MG/5ML	A060625 003	
	500MG/5ML	A060625 004	
PENBRITIN			
WYETH AYERST	EQ 100MG BASE/ML	N050019 001	
	EQ 125MG BASE/5ML	N050019 002	
	EQ 250MG BASE/5ML	N050019 003	
PFIZERPEN-A			
PFIZER	EQ 125MG BASE/5ML	A062049 001	
	EQ 250MG BASE/5ML	A062049 002	
POLYCILLIN			
APOTHECON	EQ 125MG BASE/5ML	A062297 001	
	EQ 250MG BASE/5ML	A062297 002	
BRISTOL	EQ 100MG BASE/ML	N050308 004	
	EQ 125MG BASE/5ML	N050308 001	
	EQ 250MG BASE/5ML	N050308 002	
	EQ 500MG BASE/5ML	N050308 003	
PRINCIPEN			
APOTHECON	EQ 100MG BASE/ML	A061394 001	
	EQ 125MG BASE/5ML	A061394 002	
	EQ 250MG BASE/5ML	A061394 003	
PRINCIPEN '125'			
APOTHECON	EQ 125MG BASE/5ML	A060127 002	
	EQ 125MG BASE/5ML	A062151 001	
PRINCIPEN '250'			
APOTHECON	EQ 250MG BASE/5ML	A060127 001	
	EQ 250MG BASE/5ML	A062151 002	

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL			
TOTACILLIN			
GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666 001	
	EQ 125MG BASE/5ML	A062223 001	
	EQ 250MG BASE/5ML	A060666 002	
	EQ 250MG BASE/5ML	A062223 002	
TABLET, CHEWABLE;ORAL			
POLYCILLIN			
BRISTOL	EQ 125MG BASE	N050093 001	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL			
PRINCIPEN W/ PROBENECID			
APOTHECON	EQ 389MG BASE;111MG	A062150 001	
	EQ 389MG BASE;111MG	N050488 001	
FOR SUSPENSION;ORAL			
POLYCILLIN-PRB			
APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898 001	
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457 001	
PROBAMPACIN			
G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741 001	

AMPRENAVIR

CAPSULE;ORAL			
AGENERASE			
GLAXOSMITHKLINE	50MG	N021007 001	Apr 15, 1999
	150MG	N021007 002	Apr 15, 1999
SOLUTION;ORAL			
AGENERASE			
GLAXOSMITHKLINE	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021039 001	Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL			
AGRYLIN			
SHIRE LLC	EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020333 002	Mar 14, 1997
ANAGRELIDE HYDROCHLORIDE			
ROXANE	EQ 0.5MG BASE	A076489 001	Apr 18, 2005
	EQ 1MG BASE	A076489 002	Apr 18, 2005
UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683 001	Apr 18, 2005
	EQ 1MG BASE	A076683 002	Apr 18, 2005
WATSON LABS	EQ 0.5MG BASE	A076417 001	Apr 18, 2005
	EQ 1MG BASE	A076417 002	Apr 18, 2005

ANASTROZOLE

TABLET;ORAL			
ANASTROZOLE			
IMPAX LABS INC	1MG	A091242 001	May 31, 2012
KREMERS URBAN PHARMS	1MG	A091331 001	Jan 05, 2011
SANDOZ	1MG	A079007 001	Jun 28, 2010
SYNTHON PHARMS	1MG	A078322 001	Jun 28, 2010
WATSON LABS	1MG	A078984 001	Jun 28, 2010

ANILERIDINE HYDROCHLORIDE

TABLET;ORAL			
LERITINE			
MERCK	EQ 25MG BASE	N010585 002	

ANILERIDINE PHOSPHATE

INJECTABLE;INJECTION			
LERITINE			
MERCK	25MG/ML	N010520 003	

ANISINDIONE

TABLET;ORAL			
MIRADON			
SCHERING	50MG	N010909 003	

ANISOTROPINE METHYLBROMIDE
TABLET;ORAL
ANISOTROPINE METHYLBROMIDE

WATSON LABS	50MG	A086046	001

VALPIN 50

ENDO PHARMS	50MG	N013428	001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
VASOCON-A

NOVARTIS	0.5%;0.05%	N018746	002	Jul 11, 1994

APOMORPHINE HYDROCHLORIDE
INJECTABLE;SUBCUTANEOUS
APOKYN

US WORLDMEDS	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004

APROTININ
INJECTABLE;INJECTION
TRASYLOL

BAYER HLTHCARE	10,000KIU/ML	N020304	001	Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
GENESA

GENSIA AUTOMEDICS	0.05MG/ML	N020420	001	Sep 12, 1997

ARDEPARIN SODIUM
INJECTABLE;INJECTION
NORMIFLO

PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020227	002	May 23, 1997
	10,000 UNITS/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020227	001	May 23, 1997

ARGATROBAN
SOLUTION;IV (INFUSION)
ARGATROBAN IN DEXTROSE

SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011

ARIPIPRAZOLE
INJECTABLE;INTRAMUSCULAR
ABILIFY

OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006

SOLUTION;ORAL
ABILIFY

OTSUKA	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021713	001	Dec 10, 2004

TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY

OTSUKA	10MG	N021729	002	Jun 07, 2006
	15MG	N021729	003	Jun 07, 2006
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021729	004	Jun 07, 2006
	30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021729	005	Jun 07, 2006

ARMODAFINIL
TABLET;ORAL
ARMODAFINIL

WATSON LABS INC	100MG	A200156	002	Aug 29, 2012
	200MG	A200156	004	Aug 29, 2012

NUVIGIL

CEPHALON	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021875	002	Mar 26, 2009

FDA data supplied by DrugPatentWatch.com

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

BEROCCA PN

ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071 003	Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.C. 9+3

ABRAXIS PHARM	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018440 002	Aug 08, 1985

M.V.I.-12

HOSPIRA	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N008809 004	Aug 08, 1985

MVC PLUS

WATSON LABS	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018439 002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12

HOSPIRA	20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M	N008809 005	Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT PHARMA INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933 002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

VITAPED

HOSPIRA	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A	N020176 001	Dec 29, 1993

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145 001	Jan 25, 2012

ASPIRIN

TABLET;ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER	500MG	N021317 001	Oct 18, 2001

TABLET, EXTENDED RELEASE;ORAL

8-HOUR BAYER

BAYER	650MG	N016030 001	

MEASURIN

BAYER	650MG	N016030 002	

ASPIRIN; BUTALBITAL

TABLET;ORAL

AXOTAL

SAVAGE LABS	650MG;50MG	A088305 001	Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

NOSTRUM LABS INC	325MG;50MG;40MG	A078149 001	Jun 13, 2007
WATSON LABS	325MG;50MG;40MG	A086231 002	Feb 12, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710 002	Aug 23, 1983
HALSEY	325MG;50MG;40MG	A089448 001	Dec 01, 1986
IVAX PHARMS	325MG;50MG;40MG	A085441 002	Oct 31, 1984
PURACAP PHARM	325MG;50MG;40MG	A087048 002	Dec 09, 1983
QUANTUM PHARMICS	325MG;50MG;40MG	A088972 001	Jun 18, 1985
SANDOZ	325MG;50MG;40MG	A086398 002	Apr 06, 1984
WATSON LABS	325MG;50MG;40MG	A086237 002	Mar 23, 1984

FIORINAL

ALLERGAN SALES LLC	325MG;50MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017534 003	Apr 16, 1986

LANORINAL

LANNETT	325MG;50MG;40MG	A086986 002	Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC	325MG;50MG;40MG;30MG	A075351 001	Mar 05, 1999
WATSON LABS	325MG;50MG;40MG;30MG	A074359 001	Aug 31, 1995

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

INVAGESIC

SANDOZ	385MG;30MG;25MG	A074817 001	Nov 27, 1996

INVAGESIC FORTE

SANDOZ	770MG;60MG;50MG	A074817 002	Nov 27, 1996

NORGESIC

MEDICIS	385MG;30MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013416 003	Oct 27, 1982

NORGESIC FORTE

MEDICIS	770MG;60MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013416 004	Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

STEVENS J	385MG;30MG;25MG	A074988 001	Apr 30, 1999
	770MG;60MG;50MG	A074988 002	Apr 30, 1999

ORPHENGESIC

PRINSTON INC	385MG;30MG;25MG	A075141 001	May 29, 1998

ORPHENGESIC FORTE

PRINSTON INC	770MG;60MG;50MG	A075141 002	May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

COMPOUND 65

ALRA	389MG;32.4MG;65MG	A084553 002	Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM	389MG;32.4MG;32MG	N010996 006	Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM	389MG;32.4MG;65MG	N010996 007	Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS	389MG;32.4MG;65MG	A083077 002	Dec 07, 1984
SANDOZ	389MG;32.4MG;65MG	A080044 002	Sep 16, 1983
TEVA	389MG;32.4MG;65MG	A089025 001	Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ	389MG;32.4MG;65MG	A083101 002	Jun 24, 1985

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS	389MG;32.4MG;65MG	A085732 002	Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL COMPOUND

WATSON LABS	325MG;200MG	A088809 001	Oct 03, 1985

SOMA COMPOUND

MEDA PHARMS	325MG;200MG	N012365 005	Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

OXFORD PHARMS	325MG;200MG;16MG	A040283 001	Dec 29, 1998

SOMA COMPOUND W/ CODEINE

MEDA PHARMS	325MG;200MG;16MG	N012366 002	Jul 11, 1983

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

AZDONE

SCHWARZ PHARMA	500MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A089420 001	Jan 25, 1988

VICOPRIN

ABBOTT	500MG;5MG	A086333 001	Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET;ORAL

EQUAGESIC

CARACO	325MG;200MG	N011702 003	Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ	325MG;200MG	A089127 001	Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM	325MG;200MG	A089126 001	Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC	325MG;200MG	A084978 001	

Q-GESIC

QUANTUM PHARMICS	325MG;200MG	A088740 001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS	325MG;400MG	A087211 001	Dec 22, 1982
MCNEIL	325MG;400MG	A089193 001	Feb 12, 1986
PAR PHARM	325MG;400MG	A089657 001	Nov 04, 1988

ROBAXISAL

ROBINS AH	325MG;400MG	N012281 001	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

CODOXY

HALSEY	325MG;4.5MG;0.38MG	A087464 001	Jul 01, 1982

OXYCODONE AND ASPIRIN

SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260 001	Jul 17, 1998
	325MG;4.5MG;0.38MG	A087794 001	May 26, 1982
WATSON LABS	325MG;4.5MG;0.38MG	A040255 001	Feb 27, 1998

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE	325MG;2.25MG;0.19MG	A087742 001	Jun 04, 1982

PERCODAN

ENDO PHARMS	325MG;4.5MG;0.38MG	N007337 006	

PERCODAN-DEMI

ENDO PHARMS	325MG;2.25MG;0.19MG	N007337 005	

ROXIPRIN

ROXANE	325MG;4.5MG;0.38MG	A087743 001	Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

TALWIN COMPOUND

SANOFI AVENTIS US	325MG;EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016891 001	

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET;ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	325MG,N/A;N/A,80MG	N021387 006	Jun 24, 2003

TABLET, TABLET, TABLET;ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG,N/A;N/A,20MG	N021387 001	Jun 24, 2003
	81MG,N/A;N/A,40MG	N021387 002	Jun 24, 2003
	81MG,N/A;N/A,80MG	N021387 003	Jun 24, 2003
	325MG,N/A;N/A,20MG	N021387 004	Jun 24, 2003
	325MG,N/A;N/A,40MG	N021387 005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE
CAPSULE;ORAL
DARVON W/ ASA

XANODYNE PHARM	325MG;65MG	N010996 005	

ASPIRIN; PROPOXYPHENE NAPSYLATE
CAPSULE;ORAL
DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016829 001	

TABLET;ORAL
DARVON-N W/ ASA

AAIPHARMA LLC	325MG;100MG	N016863 001	

ATAZANAVIR SULFATE
CAPSULE;ORAL
REYATAZ

BRISTOL MYERS SQUIBB	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021567 001	Jun 20, 2003

ATENOLOL
INJECTABLE;INJECTION
TENORMIN

ASTRAZENECA	0.5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019058 001	Sep 13, 1989

TABLET;ORAL
ATENOLOL

ABLE	25MG	A076907 001	Jul 30, 2004
	50MG	A076907 002	Jul 30, 2004
	100MG	A076907 003	Jul 30, 2004
APOTHECON	50MG	A073317 001	Mar 20, 1992
	100MG	A073318 001	Mar 20, 1992
DAVA PHARMS INC	25MG	A074099 001	Apr 28, 1992
MYLAN	25MG	A074126 003	Aug 26, 1998
	50MG	A074126 001	Mar 23, 1994
	100MG	A074126 002	Mar 23, 1994
NORTHSTAR HLTHCARE	25MG	A078254 001	Sep 25, 2009
	50MG	A078254 002	Sep 25, 2009
	100MG	A078254 003	Sep 25, 2009
NOSTRUM LABS	50MG	A074127 001	Feb 21, 1995
	100MG	A074127 002	Feb 21, 1995
PLIVA	25MG	A074101 001	Jul 17, 1997
	50MG	A074101 002	Jul 17, 1997
	100MG	A074101 003	Jul 17, 1997
SANDOZ	25MG	A074265 001	Feb 28, 1994
	50MG	A074265 002	Feb 28, 1994
	100MG	A074265 003	Feb 28, 1994
SCS	50MG	A073676 001	Oct 30, 1992
	100MG	A073676 002	Oct 30, 1992
TEVA	50MG	A073315 001	May 28, 1993
	100MG	A073316 001	May 28, 1993
TEVA PHARMS	50MG	A074120 001	Feb 24, 1995
	100MG	A074120 002	Feb 24, 1995
WATSON LABS	50MG	A073352 001	Dec 27, 1991
	100MG	A073353 001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE
TABLET;ORAL
ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG;25MG	A074404 001	May 14, 1998
	100MG;25MG	A074404 002	May 14, 1998
PLIVA	50MG;25MG	A074107 001	Sep 24, 1997
	100MG;25MG	A074107 002	Sep 24, 1997

ATOMOXETINE HYDROCHLORIDE
CAPSULE;ORAL
ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC	18MG	A079017 001	Sep 17, 2010
	25MG	A079017 002	Sep 17, 2010
	40MG	A079017 003	Sep 17, 2010
	60MG	A079017 004	Sep 17, 2010
	80MG	A079017 005	Sep 17, 2010
	100MG	A079017 006	Sep 17, 2010

FDA data supplied by DrugPatentWatch.com

ATOMOXETINE HYDROCHLORIDE
CAPSULE;ORAL
STRATTERA

LILLY	5MG	N021411 001	Nov 26, 2002

ATORVASTATIN CALCIUM
TABLET;ORAL
ATORVASTATIN CALCIUM

TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012
	EQ 20MG BASE	A078773 002	May 29, 2012
	EQ 40MG BASE	A078773 003	May 29, 2012
	EQ 80MG BASE	A078773 004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE
TABLET;ORAL
LIPTRUZET

MERCK SHARP DOHME	EQ 10MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200153 001	May 03, 2013
	EQ 20MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200153 002	May 03, 2013
	EQ 40MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200153 003	May 03, 2013
	EQ 80MG BASE;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200153 004	May 03, 2013

ATOVAQUONE
TABLET;ORAL
MEPRON

GLAXOSMITHKLINE LLC	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020259 001	Nov 25, 1992

ATRACURIUM BESYLATE
INJECTABLE;INJECTION
ATRACURIUM BESYLATE

BAXTER HLTHCARE	10MG/ML	A074824 001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074753 001	Jan 23, 1997
HOSPIRA	10MG/ML	A074632 001	Dec 23, 1996
	10MG/ML	A074740 001	Mar 28, 1997
TEVA PARENTERAL	10MG/ML	A074784 001	Jun 11, 1997
WATSON LABS INC	10MG/ML	A074945 001	Jul 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE	10MG/ML	A074825 001	Sep 30, 1997
BAXTER HLTHCARE CORP	10MG/ML	A074768 001	Jan 23, 1997
HOSPIRA	10MG/ML	A074633 001	Dec 23, 1996
	10MG/ML	A074639 001	Mar 25, 1997
	10MG/ML	A074741 001	Mar 28, 1997
WATSON LABS INC	10MG/ML	A074944 001	Jul 28, 1998

TRACRIUM

HOSPIRA	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018831 002	Jun 20, 1985

TRACRIUM PRESERVATIVE FREE

HOSPIRA	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018831 001	Nov 23, 1983

ATROPINE
INJECTABLE;INJECTION
ATROPINE

ABBVIE	EQ 2MG SULFATE/0.7ML	A071295 001	Jan 30, 1987

FDA data supplied by DrugPatentWatch.com

ATROPINE SULFATE

AEROSOL, METERED;INHALATION

ATROPINE SULFATE

US ARMY	EQ 0.36MG BASE/INH	N020056 001	Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN HALF-STRENGTH

SEBELA IRELAND LTD	0.025MG;0.5MG	N017744 001	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP	0.025MG;2.5MG	A086440 001	

SOLUTION;ORAL

COLONAID

MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735 001	

LOMANATE

ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746 001	

LOMOTIL

GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001	

TABLET;ORAL

COLONAID

MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737 001	

DI-ATRO

MD PHARM	0.025MG;2.5MG	A085266 001	

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE	0.025MG;2.5MG	A040395 001	Nov 27, 2000
ANI PHARMS INC	0.025MG;2.5MG	A086727 001	
ASCOT	0.025MG;2.5MG	A087934 001	Jul 19, 1983
HEATHER	0.025MG;2.5MG	A086798 001	
HIKMA PHARMS LLC	0.025MG;2.5MG	A087765 001	Mar 15, 1982
INWOOD LABS	0.025MG;2.5MG	A085509 001	
KV PHARM	0.025MG;2.5MG	A085659 001	
LEDERLE	0.025MG;2.5MG	A086950 001	
PARKE DAVIS	0.025MG;2.5MG	A087131 001	
PVT FORM	0.025MG;2.5MG	A085766 001	
R AND S PHARMA	0.025MG;2.5MG	A085035 001	
ROXANE	0.025MG;2.5MG	A086057 001	
SANDOZ	0.025MG;2.5MG	A086173 001	
SUN PHARM INDS	0.025MG;2.5MG	A085506 001	
USL PHARMA	0.025MG;2.5MG	A087842 001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG;2.5MG	A087195 001	Feb 16, 1982
WATSON LABS	0.025MG;2.5MG	A085876 001	

LO-TROL

VANGARD	0.025MG;2.5MG	A088009 001	Mar 25, 1983

LOGEN

SUPERPHARM	0.025MG;2.5MG	A088962 001	May 10, 1985

LONOX

SANDOZ	0.025MG;2.5MG	A085311 002	

LOW-QUEL

HALSEY	0.025MG;2.5MG	A085211 001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677 001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ATROPINE AND DEMEROL

ABBVIE	0.4MG/ML;50MG/ML	A087853 001	Nov 26, 1982
	0.4MG/ML;75MG/ML	A087847 001	Nov 26, 1982
	0.4MG/ML;100MG/ML	A087848 001	Nov 26, 1982

MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST	0.4MG/ML;50MG/ML	A085121 001	
	0.4MG/ML;75MG/ML	A085121 002	
	0.4MG/ML;100MG/ML	A085121 003	

ATROPINE; PRALIDOXIME CHLORIDE
INJECTABLE;INTRAMUSCULAR
ATNAA

US ARMY	2.1MG/0.7ML;600MG/0.7ML	N021175 001	Jan 17, 2002

AZATADINE MALEATE
TABLET;ORAL
OPTIMINE

SCHERING	1MG	N017601 001	

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE
TABLET, EXTENDED RELEASE;ORAL
TRINALIN

SCHERING	1MG;120MG	N018506 001	Mar 23, 1982

AZATHIOPRINE
TABLET;ORAL
IMURAN

SEBELA IRELAND LTD	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016324 002	

AZATHIOPRINE SODIUM
INJECTABLE;INJECTION
IMURAN

SEBELA IRELAND LTD	EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017391 001	

AZELASTINE HYDROCHLORIDE
SPRAY, METERED;NASAL
ASTEPRO

MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N022203 001	Oct 15, 2008

AZITHROMYCIN
CAPSULE;ORAL
ZITHROMAX

PFIZER	EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050670 001	Nov 01, 1991

FOR SUSPENSION;ORAL
AZITHROMYCIN

SANDOZ	EQ 100MG BASE/5ML	A065297 001	Sep 18, 2006
	EQ 200MG BASE/5ML	A065297 002	Sep 18, 2006

INJECTABLE;INJECTION
AZITHROMYCIN

PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265 001	Jan 18, 2007
TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006
	EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE
FOR SUSPENSION, TABLET;ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER	EQ 1GM BASE,N/A;N/A,EQ 100MG BASE	N050762 001	Dec 18, 1998

AZLOCILLIN SODIUM
INJECTABLE;INJECTION
AZLIN

BAYER PHARMS	EQ 2GM BASE/VIAL	A062388 001	Sep 08, 1982
	EQ 2GM BASE/VIAL	A062417 001	Oct 12, 1982
	EQ 2GM BASE/VIAL	N050562 001	Sep 03, 1982
	EQ 3GM BASE/VIAL	A062388 002	Sep 08, 1982
	EQ 3GM BASE/VIAL	A062417 002	Oct 12, 1982
	EQ 3GM BASE/VIAL	N050562 002	Sep 03, 1982
	EQ 4GM BASE/VIAL	A062388 003	Sep 08, 1982
	EQ 4GM BASE/VIAL	A062417 003	Oct 12, 1982
	EQ 4GM BASE/VIAL	N050562 003	Sep 03, 1982

AZTREONAM
INJECTABLE;INJECTION
AZACTAM

BRISTOL MYERS SQUIBB	500MG/VIAL	N050580 001	Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB	10MG/ML	N050632 003	May 24, 1989

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

AZTREONAM
INJECTABLE;INJECTION
AZTREONAM

WEST-WARD PHARMS INT	1GM/VIAL	A065286 001	Mar 23, 2011
	2GM/VIAL	A065286 002	Mar 23, 2011

BACAMPICILLIN HYDROCHLORIDE
FOR SUSPENSION;ORAL
SPECTROBID

PFIZER	125MG/5ML	N050556 001	Mar 23, 1982

TABLET;ORAL
SPECTROBID

PFIZER	400MG	N050520 001	
	800MG	N050520 002	Sep 12, 1983

BACITRACIN
INJECTABLE;INJECTION
BACITRACIN

PFIZER	50,000 UNITS/VIAL	A060282 001	

OINTMENT;OPHTHALMIC
BACIGUENT

PHARMACIA AND UPJOHN	500 UNITS/GM	A060734 001	

BACITRACIN

LILLY	500 UNITS/GM	A060687 001	
PHARMADERM	500 UNITS/GM	A062158 001	
PHARMAFAIR	500 UNITS/GM	A062453 001	Mar 28, 1984

OINTMENT;TOPICAL
BACITRACIN

COMBE	500 UNITS/GM	A062799 001	May 14, 1987
NASKA	500 UNITS/GM	A062857 001	Nov 13, 1987

POWDER;FOR RX COMPOUNDING
BACI-RX

X GEN PHARMS	5,000,000 UNITS/BOT	A061580 001	

BACITRACIN

APOTHEKERNES	5,000,000 UNITS/BOT	A061699 001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456 001	Jul 27, 1983

BACITRACIN ZINC
POWDER;FOR RX COMPOUNDING
ZIBA-RX

X GEN PHARMS	500,000 UNITS/BOT	A061737 001	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT;OPHTHALMIC
CORTISPORIN

CASPER PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050416 002	

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389 001	Jul 02, 1982

OINTMENT;TOPICAL
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381 001	Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT;TOPICAL
LANABIOTIC

COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499 001	Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT;OPHTHALMIC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386 001	Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167 001	

NEO-POLYCIN

DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647 001	

NEOSPORIN

CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000	N050417 001	

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
NEOSPORIN				
		UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for s or e reasons**		
OINTMENT;TOPICAL				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
	NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833 001	Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL				
POLYSPORIN				
	GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167 002	Mar 01, 1985
OINTMENT;OPHTHALMIC				
OCUMYCIN				
	PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430 001	Apr 08, 1983
POLYSPORIN				
	MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for s or e reasons**	A061229 001	
OINTMENT;TOPICAL				
BACITRACIN ZINC-POLYMYXIN B SULFATE				
	NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849 001	Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE				
	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731 002	

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
MYCITRACIN				
	PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048 001	

BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL				
LANABIOTIC				
	COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598 001	Sep 22, 1986

BACLOFEN

TABLET;ORAL				
BACLOFEN				
	TEVA	10MG	A073043 001	Feb 27, 1992
		20MG	A073044 001	Feb 27, 1992
	USL PHARMA	10MG	A071260 001	May 06, 1988
		20MG	A071261 001	May 06, 1988
	WATSON LABS	10MG	A072824 001	Sep 18, 1991
		10MG	A073092 001	Jan 28, 1994
		10MG	A074698 001	Aug 20, 1996
		20MG	A072825 001	Sep 18, 1991
		20MG	A073093 001	Jan 28, 1994
		20MG	A074698 002	Aug 20, 1996
LIORESAL				
	NOVARTIS	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017851 001	
		20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017851 003	Jan 20, 1982
TABLET, ORALLY DISINTEGRATING;ORAL				
KEMSTRO				
	UCB INC	10MG	N021589 001	Oct 30, 2003
		20MG	N021589 002	Oct 30, 2003

FDA data supplied by DrugPatentWatch.com

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

BECLOVENT

GLAXOSMITHKLINE	0.042MG/INH	N018153 001	

VANCERIL

SCHERING	0.042MG/INH	N017573 001	

VANCERIL DOUBLE STRENGTH

SCHERING	0.084MG/INH	N020486 001	Dec 24, 1996

AEROSOL, METERED;NASAL

BECONASE

GLAXOSMITHKLINE	0.042MG/INH	N018584 001	

VANCENASE

SCHERING	0.042MG/INH	N018521 001	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

VANCENASE AQ

SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589 001	Dec 23, 1987
	EQ 0.084MG DIPROP/SPRAY	N020469 001	Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

ACTAVIS LABS FL INC	5MG	A076267 001	Feb 11, 2004
	10MG	A076267 002	Feb 11, 2004
	20MG	A076267 003	Feb 11, 2004
	40MG	A076267 004	Feb 11, 2004
GENPHARM	5MG	A076476 001	Feb 11, 2004
	10MG	A076476 002	Feb 11, 2004
	20MG	A076476 003	Feb 11, 2004
	40MG	A076476 004	Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS LABS FL INC	5MG;6.25MG	A076342 001	Feb 11, 2004
	10MG;12.5MG	A076342 002	Feb 11, 2004
	20MG;12.5MG	A076342 003	Feb 11, 2004
	20MG;25MG	A076342 004	Feb 11, 2004
IVAX SUB TEVA PHARMS	5MG;6.25MG	A076348 001	Feb 11, 2004
	10MG;12.5MG	A076348 002	Feb 11, 2004
	20MG;12.5MG	A076348 003	Feb 11, 2004
	20MG;25MG	A076348 004	Feb 11, 2004
MYLAN PHARMS INC	5MG;6.25MG	A076612 001	Feb 11, 2004
	10MG;12.5MG	A076612 002	Feb 11, 2004
	20MG;12.5MG	A076612 003	Feb 11, 2004
	20MG;25MG	A076612 004	Feb 11, 2004
SUN PHARM INDS LTD	5MG;6.25MG	A077483 001	Sep 08, 2005
	10MG;12.5MG	A077483 002	Sep 08, 2005
	20MG;12.5MG	A077483 003	Sep 08, 2005
	20MG;25MG	A077483 004	Sep 08, 2005

BENDROFLUMETHIAZIDE

TABLET;ORAL

NATURETIN-10

APOTHECON	10MG	N012164 003	

NATURETIN-2.5

APOTHECON	2.5MG	N012164 001	

NATURETIN-5

APOTHECON	5MG	N012164 002	

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND	0.4%	A084149 001	

BENTIROMIDE

SOLUTION;ORAL

CHYMEX

SAVAGE LABS	500MG/7.5ML	N018366 001	Dec 29, 1983

FDA data supplied by DrugPatentWatch.com

BENZONATATE
CAPSULE;ORAL
BENZONATATE

NESHER PHARMS	100MG	A040795 001	Oct 31, 2007
	200MG	A040795 002	Oct 31, 2007

TESSALON

PFIZER	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011210 003	Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE
GEL;TOPICAL
BENZACLIN

VALEANT BERMUDA	5%;EQ 1% BASE	N050756 002	Apr 20, 2007

BENZPHETAMINE HYDROCHLORIDE
TABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE

COREPHARMA	50MG	A040714 001	Oct 29, 2007
IMPAX LABS	50MG	A040845 001	Nov 18, 2008

DIDREX

PHARMACIA AND UPJOHN	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012427 003	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012427 002	

BENZQUINAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
EMETE-CON

PFIZER	EQ 50MG BASE/VIAL	N016820 001	

SUPPOSITORY;RECTAL
EMETE-CON

ROERIG	EQ 100MG BASE	N016818 006	

BENZTHIAZIDE
TABLET;ORAL
AQUATAG

SOLVAY	25MG	N016001 001	
	50MG	N016001 002	

BENZTHIAZIDE

PVT FORM	50MG	A083206 001	

EXNA

AH ROBINS INC	50MG	N012489 001	

FOVANE

PFIZER	50MG	N012128 002	

URESE

PFIZER	25MG	N012128 003	

BENZTROPINE MESYLATE
TABLET;ORAL
BENZTROPINE MESYLATE

FRONTIDA BIOPHARM	1MG	A081264 001	Jan 23, 1992
	2MG	A081265 001	Jan 23, 1992
LANNETT HOLDINGS INC	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A088877 001	Apr 11, 1985
	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A088894 001	Apr 11, 1985
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A088895 001	Apr 11, 1985
OXFORD PHARMS	0.5MG	A040699 001	Feb 14, 2008
	1MG	A040705 001	Feb 14, 2008
	2MG	A040706 001	Feb 14, 2008
QUANTUM PHARMICS	0.5MG	A088514 001	Jan 31, 1984
	1MG	A088510 001	Jan 31, 1984
	2MG	A088511 001	Jan 31, 1984
USL PHARMA	0.5MG	A089211 001	Jun 14, 1988

BENZTROPINE MESYLATE
TABLET;ORAL
BENZTROPINE MESYLATE

	1MG	A089212 001	Jun 14, 1988
	2MG	A089213 001	Jun 14, 1988

COGENTIN

MERCK	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009193 004	
	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009193 003	
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009193 002	

BENZYL BENZOATE
EMULSION;TOPICAL
BENZYL BENZOATE

LANNETT	50%	A084535 001	

BEPRIDIL HYDROCHLORIDE
TABLET;ORAL
BEPADIN

MEDPOINTE PHARM HLC	200MG	N019001 001	Dec 28, 1990
	300MG	N019001 002	Dec 28, 1990
	400MG	N019001 003	Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON	200MG	N019002 001	Dec 28, 1990
	300MG	N019002 002	Dec 28, 1990
	400MG	N019002 003	Dec 28, 1990

BETA CAROTENE
CAPSULE;ORAL
SOLATENE

ROCHE	30MG	N017589 001	

BETAMETHASONE
CREAM;TOPICAL
CELESTONE

SCHERING	0.2%	N014762 001	

SYRUP;ORAL
CELESTONE

MERCK SHARP DOHME	0.6MG/5ML	N014215 002	

TABLET;ORAL
CELESTONE

SCHERING	0.6MG	N012657 003	

BETAMETHASONE BENZOATE
CREAM;TOPICAL
UTICORT

PARKE DAVIS	0.025%	N016998 002	

GEL;TOPICAL
UTICORT

PARKE DAVIS	0.025%	N017244 001	

LOTION;TOPICAL
UTICORT

PARKE DAVIS	0.025%	N017528 001	

OINTMENT;TOPICAL
UTICORT

PARKE DAVIS	0.025%	N018089 001	

BETAMETHASONE DIPROPIONATE
CREAM;TOPICAL
ALPHATREX

SAVAGE LABS	EQ 0.05% BASE	N019138 001	Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK	EQ 0.05% BASE	A072536 001	Jan 31, 1990
	EQ 0.05% BASE	A074579 001	Nov 26, 1997
PHARMADERM	EQ 0.05% BASE	N019136 001	Jun 26, 1984
TARO	EQ 0.05% BASE	A071143 001	Jun 17, 1987
TEVA	EQ 0.05% BASE	A071476 001	Aug 10, 1987

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL			
DIPROSONE			
SCHERING	EQ 0.05% BASE	N017536 001	
CREAM, AUGMENTED;TOPICAL			
DIPROLENE			
SCHERING	EQ 0.05% BASE	N019408 001	Jan 31, 1986
DISC;TOPICAL			
DIPROSONE			
SCHERING	EQ 0.1% BASE	N017829 001	
GEL, AUGMENTED;TOPICAL			
DIPROLENE			
SCHERING	EQ 0.05% BASE	N019408 002	Nov 22, 1991
LOTION;TOPICAL			
ALPHATREX			
SAVAGE LABS	EQ 0.05% BASE	A070273 001	Aug 12, 1985
BETAMETHASONE DIPROPIONATE			
ALPHARMA US PHARMS	EQ 0.05% BASE	A071085 001	Feb 03, 1987
G AND W LABS INC	EQ 0.05% BASE	A071882 001	Jun 06, 1988
PHARMADERM	EQ 0.05% BASE	A070274 001	Aug 12, 1985
TARO	EQ 0.05% BASE	A072276 001	Aug 24, 1988
	EQ 0.05% BASE	A074272 001	Sep 30, 1994
DIPROSONE			
SCHERING	EQ 0.05% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017781 001	
OINTMENT;TOPICAL			
ALPHATREX			
SAVAGE LABS	EQ 0.05% BASE	N019143 001	Sep 04, 1984
BETAMETHASONE DIPROPIONATE			
PERRIGO NEW YORK	EQ 0.05% BASE	A072526 001	Jan 31, 1990
PHARMADERM	EQ 0.05% BASE	N019140 001	Sep 04, 1984
TEVA	EQ 0.05% BASE	A071477 001	Aug 10, 1987
DIPROSONE			
SCHERING	EQ 0.05% BASE	N017691 001	

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION			
BETAMETHASONE SODIUM PHOSPHATE			
WATSON LABS	EQ 3MG BASE/ML	A085738 001	
CELESTONE			
SCHERING	EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017561 001	

BETAMETHASONE VALERATE

CREAM;TOPICAL			
BETADERM			
ROACO	EQ 0.1% BASE	N018839 001	Jun 30, 1983
BETAMETHASONE VALERATE			
PERRIGO NEW YORK	EQ 0.1% BASE	A070053 001	Jun 10, 1986
PHARMADERM	EQ 0.1% BASE	N018860 002	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070485 001	May 29, 1987
TARO	EQ 0.1% BASE	A070062 001	May 14, 1985
BETATREX			
SAVAGE LABS	EQ 0.1% BASE	N018862 001	Aug 31, 1983
VALISONE			
SCHERING	EQ 0.01% BASE	N016322 002	
	EQ 0.1% BASE	N016322 001	
LOTION;TOPICAL			
BETAMETHASONE VALERATE			
PHARMADERM	EQ 0.1% BASE	N018870 001	Aug 31, 1983
PHARMAFAIR	EQ 0.1% BASE	A070484 001	May 29, 1987
TEVA PHARMS	EQ 0.1% BASE	A071883 001	Apr 22, 1988
BETATREX			
SAVAGE LABS	EQ 0.1% BASE	N018867 001	Aug 31, 1983
VALISONE			
SCHERING	EQ 0.1% BASE	N016932 001	
OINTMENT;TOPICAL			
BETAMETHASONE VALERATE			
PERRIGO NEW YORK	EQ 0.1% BASE	A071478 001	Dec 23, 1987
PHARMADERM	EQ 0.1% BASE	N018864 001	Aug 31, 1983

BETAMETHASONE VALERATE
OINTMENT;TOPICAL
BETAMETHASONE VALERATE

PHARMAFAIR	EQ 0.1% BASE	A070486 001	May 29, 1987

BETATREX

SAVAGE LABS	EQ 0.1% BASE	N018863 001	Aug 31, 1983

VALISONE

SCHERING	EQ 0.1% BASE	N016740 001	

BETAXOLOL HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

APOTEX INC	EQ 0.5% BASE	A075446 001	Sep 28, 2000

TABLET;ORAL
KERLONE

SANOFI AVENTIS US	10MG	N019507 001	Oct 27, 1989
	20MG	N019507 002	Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE
TABLET;ORAL
KERLEDEX

SANOFI AVENTIS US	5MG;12.5MG	N019807 001	Oct 30, 1992
	10MG;12.5MG	N019807 002	Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE
SUSPENSION/DROPS;OPHTHALMIC
BETOPTIC PILO

ALCON	EQ 0.25% BASE;1.75%	N020619 001	Apr 17, 1997

BETAZOLE HYDROCHLORIDE
INJECTABLE;INJECTION
HISTALOG

LILLY	50MG/ML	N009344 001	

BETHANECHOL CHLORIDE
INJECTABLE;INJECTION
URECHOLINE

ODYSSEY PHARMS	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536 001	

TABLET;ORAL
BETHANECHOL CHLORIDE

ABLE	5MG	A040492 001	Jul 27, 2004
	10MG	A040483 001	Jul 27, 2004
	25MG	A040485 001	Jul 27, 2004
	50MG	A040509 001	Jul 27, 2004
ACTAVIS ELIZABETH	5MG	A040552 001	Oct 28, 2004
	10MG	A040553 001	Oct 28, 2004
	25MG	A040554 001	Oct 28, 2004
	50MG	A040551 001	Oct 28, 2004
ASCOT	10MG	A088288 001	Jun 08, 1983
	25MG	A088289 001	Jun 08, 1983
IMPAX LABS	5MG	A040739 001	Nov 01, 2006
	10MG	A040741 001	Nov 01, 2006
	25MG	A040740 001	Nov 01, 2006
	50MG	A040721 004	Nov 01, 2006
IVAX SUB TEVA PHARMS	25MG	A084689 001	
LANNETT	5MG	A084702 001	
	10MG	A084712 001	
	25MG	A084074 001	
SANDOZ	5MG	A084353 001	
	10MG	A084378 001	
	10MG	A084379 001	
	25MG	A084383 001	
	25MG	A084384 001	
SUN PHARM INDS INC	5MG	A040897 001	Apr 22, 2009
	10MG	A040897 002	Apr 22, 2009
	25MG	A040897 003	Apr 22, 2009
	50MG	A040897 004	Apr 22, 2009
WATSON LABS	5MG	A084402 001	
	5MG	A085230 002	
	5MG	A085841 001	
	10MG	A084408 001	
	10MG	A085228 001	

FDA data supplied by DrugPatentWatch.com

BETHANECHOL CHLORIDE
TABLET;ORAL
BETHANECHOL CHLORIDE

	10MG	A085842 001	
	25MG	A084441 001	
	25MG	A085229 001	
	25MG	A085839 001	
	50MG	A087397 001	
	50MG	A087444 001	

MYOTONACHOL

GLENWOOD	5MG	A084188 001	
	10MG	A084188 003	
	25MG	A084188 004	

URECHOLINE

ODYSSEY PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536 003	
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536 002	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536 004	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536 005	

BETHANIDINE SULFATE
TABLET;ORAL
TENATHAN

ROBINS AH	10MG	N017675 001	
	25MG	N017675 002	

BICALUTAMIDE
TABLET;ORAL
BICALUTAMIDE

KUDCO IRELAND	50MG	A077995 001	Jul 06, 2009
ROXANE	50MG	A078285 001	Mar 24, 2011
SYNTHON PHARMS	50MG	A077973 001	Jul 06, 2009

BIMATOPROST
SOLUTION/DROPS;OPHTHALMIC
LUMIGAN

ALLERGAN	0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021275 001	Mar 16, 2001

BIPERIDEN HYDROCHLORIDE
TABLET;ORAL
AKINETON

ABBVIE	2MG	N012003 001	

BIPERIDEN LACTATE
INJECTABLE;INJECTION
AKINETON

ABBVIE	5MG/ML	N012418 002	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL
HALFLYTELY

BRAINTREE	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021551 003	Jul 16, 2010

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE
TABLET, CHEWABLE, TABLET, CAPSULE;ORAL
HELIDAC

SEBELA IRELAND LTD	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050719 001	Aug 15, 1996

FDA data supplied by DrugPatentWatch.com

BISOPROLOL FUMARATE
TABLET;ORAL
BISOPROLOL FUMARATE

FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002
	10MG	A075474	002	Oct 25, 2002

ZEBETA

TEVA WOMENS	5MG	N019982	002	Jul 31, 1992
	10MG	N019982	001	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH	2.5MG;6.25MG	A075672	001	Sep 25, 2000
	5MG;6.25MG	A075672	002	Sep 25, 2000
	10MG;6.25MG	A075672	003	Sep 25, 2000
APOTHECON	2.5MG;6.25MG	A075642	002	Dec 27, 2000
	5MG;6.25MG	A075642	001	Dec 27, 2000
	10MG;6.25MG	A075642	003	Dec 27, 2000
IVAX SUB TEVA PHARMS	2.5MG;6.25MG	A075632	001	Sep 27, 2000
	5MG;6.25MG	A075632	002	Sep 27, 2000
	10MG;6.25MG	A075632	003	Sep 27, 2000
SANDOZ	2.5MG;6.25MG	A075527	001	Sep 25, 2000
	5MG;6.25MG	A075527	003	Sep 25, 2000
	10MG;6.25MG	A075527	002	Sep 25, 2000
TEVA	2.5MG;6.25MG	A075686	001	Jan 19, 2001
	5MG;6.25MG	A075686	002	Jan 19, 2001
	10MG;6.25MG	A075686	003	Jan 19, 2001
WATSON LABS	2.5MG;6.25MG	A075469	001	Sep 25, 2000
	5MG;6.25MG	A075469	002	Sep 25, 2000
	10MG;6.25MG	A075469	003	Sep 25, 2000

BITOLTEROL MESYLATE
AEROSOL, METERED;INHALATION
TORNALATE

SANOFI AVENTIS US	0.37MG/INH	N018770	001	Dec 28, 1984

SOLUTION;INHALATION
TORNALATE

SANOFI AVENTIS US	0.2%	N019548	001	Feb 19, 1992

BLEOMYCIN SULFATE
INJECTABLE;INJECTION
BLENOXANE

BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050443	001	
	EQ 30 UNITS BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050443	002	Sep 07, 1995

BLEOMYCIN SULFATE

PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007
TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
	EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996

BOCEPREVIR
CAPSULE;ORAL
VICTRELIS

MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011

BRETYLIUM TOSYLATE
INJECTABLE;INJECTION
BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
EUROHLTH INTL SARL	50MG/ML	A070545	001	May 14, 1986
	50MG/ML	A070546	001	May 14, 1986
HOSPIRA	50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019030	001	Apr 29, 1986
	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986

FDA data supplied by DrugPatentWatch.com

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE			
LUITPOLD	50MG/ML	A070891 001	Jul 26, 1988
BRETYLIUM TOSYLATE IN DEXTROSE 5%			
ABBOTT	200MG/100ML	N019005 002	Apr 29, 1986
	400MG/100ML	N019005 003	Apr 29, 1986
	800MG/100ML	N019005 001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	100MG/100ML	N019121 001	Apr 29, 1986
	200MG/100ML	N019121 002	Apr 29, 1986
	400MG/100ML	N019121 003	Apr 29, 1986
BAXTER HLTHCARE	200MG/100ML	N019837 002	Apr 12, 1989
	400MG/100ML	N019837 001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008 002	Apr 29, 1986
	400MG/100ML	N019008 003	Apr 29, 1986
	800MG/100ML	N019008 001	Apr 29, 1986
BRETYLOL			
HOSPIRA	50MG/ML	N017954 001	

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

ALPHAGAN			
ALLERGAN	0.2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020613 001	Sep 06, 1996
	0.5%	N020490 001	Mar 13, 1997
BRIMONIDINE TARTRATE			
TEVA PARENTERAL	0.2%	A076372 001	Sep 10, 2004

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY			
BAUSCH AND LOMB INC	EQ 0.09% ACID **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021664 002	Oct 16, 2010
XIBROM			
BAUSCH AND LOMB INC	EQ 0.09% ACID **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021664 001	Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE			
LEK PHARM	EQ 5MG BASE	A075100 001	Dec 10, 1998

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

AMBODRYL			
PARKE DAVIS	25MG	N007984 001	

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP;ORAL

AMBENYL			
FOREST LABS	12.5MG/5ML;10MG/5ML	N009319 006	Jan 10, 1984
BROMANYL			
ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343 001	Aug 15, 1984
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE			
WOCKHARDT	12.5MG/5ML;10MG/5ML	A088626 001	Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR;ORAL

BROMPHENIRAMINE MALEATE			
ALPHARMA US PHARMS	2MG/5ML	A086936 001	
KV PHARM	2MG/5ML	A085466 001	
PHARM ASSOC	2MG/5ML	A087517 001	
USL PHARMA	2MG/5ML	A087964 001	Jan 25, 1983

INJECTABLE;INJECTION

BROMPHENIRAMINE MALEATE			
WATSON LABS	10MG/ML	A083821 001	
	100MG/ML	A083820 001	
DIMETANE-TEN			
WYETH AYERST	10MG/ML	N011418 002	

FDA data supplied by DrugPatentWatch.com

BROMPHENIRAMINE MALEATE

TABLET;ORAL

BROMPHENIRAMINE MALEATE

BARR	4MG	A084468 001	
IVAX SUB TEVA PHARMS	4MG	A084351 001	
NEWTRON PHARMS	4MG	A086987 001	
NEXGEN PHARMA INC	4MG	A086187 001	
PAR PHARM	4MG	A087009 001	
PIONEER PHARMS	4MG	A088604 001	Jul 13, 1984
UPSHER-SMITH LABS	4MG	A083215 001	
VITARINE	4MG	A085850 001	
WATSON LABS	4MG	A083123 001	
	4MG	A085769 001	

DIMETANE

WYETH CONS	4MG	N010799 003	

TABLET, EXTENDED RELEASE;ORAL

DIMETANE

WYETH CONS	8MG	N010799 010	Jun 10, 1983
	12MG	N010799 011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMANATE DM

ALPHARMA US PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A088722 001	Mar 07, 1985

BROMFED-DM

WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A089681 001	Dec 22, 1988

DIMETANE-DX

ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019279 001	Aug 24, 1984

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA	16MG;240MG	N019672 001	Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET;ORAL

BUCLADIN-S

STUART PHARMS	50MG	N010911 006	

BUDESONIDE

AEROSOL, METERED;NASAL

RHINOCORT

ASTRAZENECA	0.032MG/INH	N020233 001	Feb 14, 1994

POWDER, METERED;INHALATION

PULMICORT

ASTRAZENECA	0.16MG/INH	N020441 002	Jun 24, 1997
	0.32MG/INH	N020441 003	Jun 24, 1997

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

HOSPIRA	0.25MG/ML	A074160 001	Oct 30, 1997
TEVA PARENTERAL	0.25MG/ML	A074613 001	Nov 18, 1997

BUMEX

VALIDUS PHARMS INC	0.25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018226 001	Feb 28, 1983

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

HOSPIRA	0.75%	A070587 001	Mar 03, 1987

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA	0.075%	N019978 001	Sep 03, 1992
	0.114%	N019978 002	Sep 03, 1992
	0.23%	N019978 003	Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED	0.25%	A076012 001	Jan 09, 2002
	0.5%	A076012 002	Jan 09, 2002
	0.75%	A076012 003	Jan 09, 2002

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA	0.25%;0.005MG/ML	A071166 001	Jun 16, 1988
	0.5%;0.005MG/ML	A071169 001	Jun 16, 1988
	0.75%;0.005MG/ML	A071171 001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

DUOCAINE

AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496 001	May 23, 2003

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

SUBUTEX

INDIVIOR INC	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020732 002	Oct 08, 2002
	EQ 8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020732 003	Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

SUBOXONE

INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020733 001	Oct 08, 2002
	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

SANDOZ	75MG	A075613 002	Oct 10, 2000
	100MG	A075613 001	Oct 10, 2000
TEVA	75MG	A075310 001	Nov 29, 1999
	100MG	A075310 002	Nov 29, 1999

WELLBUTRIN

GLAXOSMITHKLINE	50MG	N018644 001	Dec 30, 1985
	75MG	N018644 002	Dec 30, 1985
	100MG	N018644 003	Dec 30, 1985

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

ACTAVIS LABS FL INC	300MG	A077715 002	Jun 13, 2007
IMPAX LABS	300MG	A077415 002	Dec 15, 2006
SANDOZ	100MG	A076845 001	Jul 14, 2005
	150MG	A076834 001	Jul 14, 2005
	150MG	A076845 002	Jul 14, 2005
WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012
	150MG	A201331 002	Aug 30, 2012
	200MG	A201331 003	Aug 30, 2012

WELLBUTRIN SR

GLAXOSMITHKLINE	50MG	N020358 001	Oct 04, 1996

ZYBAN

GLAXOSMITHKLINE	100MG	N020711 002	May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG	N021190 001	Dec 20, 2000
	7.5MG	N021190 002	Dec 20, 2000
	10MG	N021190 003	Dec 20, 2000
	15MG	N021190 004	Dec 20, 2000

TABLET;ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018731 001	Sep 29, 1986
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018731 002	Sep 29, 1986

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL				
BUSPAR				
		15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018731 003	Apr 22, 1996
		30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018731 004	Apr 22, 1996
BUSPIRONE HYDROCHLORIDE				
	APOTEX	5MG	A075521 001	Apr 05, 2002
		10MG	A075521 002	Apr 05, 2002
		15MG	A075521 003	Apr 05, 2002
	EGIS	5MG	A075119 001	Mar 14, 2002
		10MG	A075119 002	Mar 14, 2002
		15MG	A075119 003	Jan 23, 2003
	IVAX SUB TEVA PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075385 001	Mar 01, 2002
		10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075385 002	Mar 01, 2002
		15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075385 003	Mar 01, 2002
	NESHER PHARMS	5MG	A075572 001	Feb 27, 2002
		10MG	A075572 002	Feb 27, 2002
		15MG	A075572 003	Feb 27, 2002
	OXFORD PHARMS	5MG	A075388 001	May 09, 2002
		10MG	A075388 002	May 09, 2002
		15MG	A075388 003	May 09, 2002
	SANDOZ	5MG	A075413 001	Mar 19, 2002
		10MG	A075413 002	Mar 19, 2002
		15MG	A075413 003	Mar 19, 2002

BUTABARBITAL SODIUM

CAPSULE;ORAL				
BUTICAPS				
	MEDPOINTE PHARM HLC	15MG	A085381 001	
		30MG	A085381 002	
		50MG	A085381 003	
		100MG	A085381 004	
ELIXIR;ORAL				
BUTABARB				
	ALPHARMA US PHARMS	30MG/5ML	A085873 001	
BUTABARBITAL SODIUM				
	WOCKHARDT	30MG/5ML	A085383 001	
BUTALAN				
	LANNETT	33.3MG/5ML	A085880 001	
BUTISOL SODIUM				
	MEDA PHARMS	30MG/5ML	A085380 001	
SARISOL				
	HALSEY	30MG/5ML	A084723 001	
TABLET;ORAL				
BUTABARBITAL				
	BUNDY	30MG	A085550 001	
BUTABARBITAL SODIUM				
	SANDOZ	15MG	A084292 003	Feb 09, 1982
		15MG	A085938 001	
		30MG	A084272 002	
		30MG	A085934 001	
	SOLVAY	16.2MG	A083606 001	
		32.4MG	A083898 001	
		48.6MG	A083897 001	
		97.2MG	A083896 001	
	TEVA	15MG	A088632 001	May 18, 1985
		30MG	A088631 001	May 01, 1985
	WATSON LABS	15MG	A085764 001	
		30MG	A085772 001	
	WHITEWORTH TOWN PLSN	15MG	A083325 002	

BUTABARBITAL SODIUM
TABLET;ORAL

BUTABARBITAL SODIUM			
	30MG	A083337 001	
BUTISOL SODIUM			
MEDA PHARMS	15MG	N000793 002	
	50MG	N000793 003	
	100MG	N000793 005	
SARISOL NO. 1			
HALSEY	15MG	A084719 001	
SARISOL NO. 2			
HALSEY	30MG	A084719 002	
SODIUM BUTABARBITAL			
HIKMA PHARMS LLC	15MG	A085418 001	
	30MG	A085432 001	
IVAX SUB TEVA PHARMS	15MG	A083484 001	
	30MG	A084040 001	
LANNETT	15MG	A085849 001	
	30MG	A085866 001	
	100MG	A085881 001	
MARSHALL PHARMA	16.2MG	A083524 001	
	32.4MG	A083858 001	

BUTENAFINE HYDROCHLORIDE
CREAM;TOPICAL

MENTAX-TC			
MYLAN	1%	N021408 001	Oct 17, 2002

BUTOCONAZOLE NITRATE
CREAM;VAGINAL

BUTOCONAZOLE NITRATE			
PERRIGO PHARMA INTL	2%	N019881 001	Feb 07, 1997
FEMSTAT			
ROCHE PALO	2%	N019215 001	Nov 25, 1985

SUPPOSITORY;VAGINAL

FEMSTAT			
ROCHE PALO	100MG	N019359 001	Nov 25, 1985

BUTORPHANOL TARTRATE
INJECTABLE;INJECTION

BUTORPHANOL TARTRATE			
CLARIS	2MG/ML	A075697 001	Oct 23, 2001
HIKMA FARMACEUTICA	2MG/ML	A078247 001	Apr 29, 2009
HOSPIRA	1MG/ML	A075342 001	Nov 04, 1999
	1MG/ML	A075559 001	Mar 20, 2000
	2MG/ML	A075342 002	Nov 04, 1999
	2MG/ML	A075559 002	Mar 20, 2000
BUTORPHANOL TARTRATE PRESERVATIVE FREE			
CLARIS	1MG/ML	A075695 001	Oct 23, 2001
	2MG/ML	A075695 002	Oct 23, 2001
HOSPIRA	1MG/ML	A074620 001	Jan 22, 1997
	1MG/ML	A075170 001	Sep 28, 1998
	2MG/ML	A074620 002	Jan 22, 1997
	2MG/ML	A075170 002	Sep 28, 1998
STADOL			
APOTHECON	2MG/ML	N017857 004	
STADOL PRESERVATIVE FREE			
APOTHECON	1MG/ML	N017857 001	
	2MG/ML	N017857 002	

SPRAY, METERED;NASAL

STADOL			
BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890 001	Dec 12, 1991

CABERGOLINE
TABLET;ORAL

CABERGOLINE			
IMPAX LABS INC	0.5MG	A077843 001	Jul 03, 2007
DOSTINEX			
PHARMACIA AND UPJOHN	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020664 001	Dec 23, 1996

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL			
CAFERGOT			
NOVARTIS	100MG;2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009000 002	
TABLET;ORAL			
CAFERGOT			
NOVARTIS	100MG;1MG	N006620 001	
WIGRAINE			
ORGANON USA INC	100MG;1MG	A086562 001	

CALCIFEDIOL

CAPSULE;ORAL			
CALDEROL			
ORGANON USA INC	0.02MG	N018312 001	
	0.05MG	N018312 002	

CALCIPOTRIENE

OINTMENT;TOPICAL			
DOVONEX			
LEO PHARMA AS	0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020273 001	Dec 29, 1993
SOLUTION;TOPICAL			
DOVONEX			
LEO PHARM	0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020611 001	Mar 03, 1997

CALCITONIN HUMAN

INJECTABLE;INJECTION			
CIBACALCIN			
NOVARTIS	0.5MG/VIAL	N018470 001	Oct 31, 1986

CALCITONIN SALMON

INJECTABLE;INJECTION			
CALCIMAR			
SANOFI AVENTIS US	200 IU/ML	N017769 001	
	400 IU/VIAL	N017497 001	
CALCITONIN-SALMON			
IGI LABS INC	200 IU/ML	A073690 001	Apr 14, 1995
MIACALCIN			
MYLAN IRELAND LTD	100 IU/ML	N017808 001	Jul 03, 1986

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL			
FORTICAL			
UPSHER SMITH	200 IU/SPRAY	N021406 001	Aug 12, 2005

CALCITRIOL

INJECTABLE;INJECTION			
CALCIJEX			
ABBVIE	0.001MG/ML	N018874 001	Sep 25, 1986
	0.002MG/ML	N018874 002	Sep 25, 1986
CALCITRIOL			
AKORN	0.002MG/ML	A078066 002	Jan 29, 2008
FRESENIUS KABI USA	0.001MG/ML	A075836 001	Dec 31, 2002
	0.002MG/ML	A075836 002	Dec 31, 2002
FRESENIUS MEDCL	0.001MG/ML	A075766 001	Feb 20, 2003
	0.002MG/ML	A075766 002	Feb 20, 2003
HOSPIRA	0.001MG/ML	A075816 001	Jan 16, 2004
	0.002MG/ML	A075816 002	Jan 16, 2004
LUITPOLD	0.001MG/ML	A075746 001	Sep 26, 2003
	0.002MG/ML	A075746 002	Sep 26, 2003
ROCKWELL MEDCL	0.001MG/ML	A076206 001	Sep 17, 2003
SAGENT PHARMS	0.001MG/ML	A077102 001	Feb 08, 2006
TEVA PARENTERAL	0.001MG/ML	A075823 001	Mar 31, 2003
	0.002MG/ML	A075823 002	Mar 31, 2003

FDA data supplied by DrugPatentWatch.com

CALCIUM ACETATE

CAPSULE;ORAL

PHOSLO

FRESENIUS MEDCL	333.5MG	N021160 001	Apr 02, 2001
	667MG	N021160 002	Apr 02, 2001

TABLET;ORAL

CALCIUM ACETATE

WEST-WARD PHARMS INT	667MG	A077693 001	Jan 30, 2008

PHOSLO

FRESENIUS MEDCL	667MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019976 001	Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET;ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

WARNER CHILCOTT	EQ 500MG BASE,N/A;N/A,35MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021823 001	Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703 012	Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703 005	Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703 008	Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703 007	Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703 009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193 001	Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864 001	Jun 10, 1993

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N018271 001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019867 001	Dec 20, 1993

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269 002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML	N017390 001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807 001	Aug 26, 1983
	510MG/100ML;30GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807 003	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807 002	Aug 26, 1983
	510MG/100ML;50GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807 004	Aug 26, 1983

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460 006	Jan 29, 1986

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460 001	

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N018460 003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379 002	

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379 003	

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379 007	Jun 24, 1988

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379 001	

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379 004	Jul 07, 1982

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379 005	Jul 07, 1982

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379 008	Jun 24, 1988

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379 006	Jul 07, 1982

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460 007	Jan 29, 1986
	26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460 002	

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460 005	Nov 02, 1983
	26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460 008	Jan 29, 1986

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N018460 009	Jan 29, 1986
	26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N018460 004	

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374 001	Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374 002	Jun 13, 1994

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374 003	Jun 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	A020374 004	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018258 001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N018256 001	
BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML	N016695 001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML	N019634 002	Feb 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017510 001	
MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018499 001	

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685 005	Oct 17, 1988
	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685 006	Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685 007	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685 003	Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685 001	Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395 001	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395 002	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395 003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399 001	Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899 001	Oct 31, 1983
	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718 001	Sep 29, 1989

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION
PLASMA-LYTE R IN PLASTIC CONTAINER

BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML; 640MG/100ML;496MG/100ML;89.6MG/100ML	N017438 001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION
ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG /100ML	N018725 001	Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION
RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721 001	Nov 09, 1982

SOLUTION;IRRIGATION
RINGER'S IN PLASTIC CONTAINER

ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462 001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N019485 001	Oct 24, 1985
B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N018023 001	
MILES	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N018417 001	

SOLUTION;IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG /100ML	N019933 001	Aug 29, 1989

CALCIUM GLUCEPTATE

INJECTABLE;INJECTION
CALCIUM GLUCEPTATE

ABBOTT	EQ 90MG CALCIUM/5ML	A080001 001	
	EQ 90MG CALCIUM/5ML	A083159 001	
ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373 001	Apr 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N006470 001	

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE;INJECTION
ISOPAQUE 440

GE HEALTHCARE	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N016847 001	

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE;INJECTION
ISOPAQUE 280

GE HEALTHCARE	0.35MG/ML;140.1MG/ML;461.8MG/ML	N017506 001	

CANDICIDIN

OINTMENT;VAGINAL
VANOBID

SANOFI AVENTIS US	0.6MG/GM	A061596 001	

TABLET;VAGINAL
VANOBID

SANOFI AVENTIS US	3MG	A061613 001	

CAPTOPRIL

TABLET;ORAL
CAPOTEN

PAR PHARM	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343 005	Jan 17, 1985
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343 002	
	37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343 006	Sep 17, 1986
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy	N018343 001	

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL
TABLET;ORAL
CAPOTEN

	reasons**		
	75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343 007	Jun 13, 1995
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343 003	
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343 004	Jun 13, 1995

CAPTOPRIL

APOTEX	12.5MG	A074737 001	Oct 28, 1998
	25MG	A074737 002	Oct 28, 1998
	50MG	A074737 003	Oct 28, 1998
	100MG	A074737 004	Oct 28, 1998
APOTHECON	12.5MG	A074472 001	Mar 31, 1995
	25MG	A074472 002	Mar 31, 1995
	50MG	A074472 003	Mar 31, 1995
	100MG	A074472 004	Mar 31, 1995
DAVA PHARMS INC	12.5MG	A074423 001	Feb 13, 1996
	25MG	A074423 002	Feb 13, 1996
	50MG	A074423 003	Feb 13, 1996
	100MG	A074423 004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748 004	May 29, 1997
	25MG	A074748 002	May 29, 1997
	50MG	A074748 001	May 29, 1997
	100MG	A074748 003	May 29, 1997
G AND W LABS INC	12.5MG	A074433 001	Feb 13, 1996
	12.5MG	A074462 001	Feb 13, 1996
	12.5MG	A074483 001	Feb 13, 1996
	12.5MG	A074590 004	Aug 30, 1996
	25MG	A074433 002	Feb 13, 1996
	25MG	A074462 002	Feb 13, 1996
	25MG	A074483 002	Feb 13, 1996
	25MG	A074590 002	Aug 30, 1996
	50MG	A074433 003	Feb 13, 1996
	50MG	A074462 003	Feb 13, 1996
	50MG	A074483 003	Feb 13, 1996
	50MG	A074590 001	Aug 30, 1996
	100MG	A074433 004	Feb 13, 1996
	100MG	A074462 004	Feb 13, 1996
	100MG	A074483 004	Feb 13, 1996
	100MG	A074590 003	Aug 30, 1996
PAR PHARM	12.5MG	A074493 001	Feb 13, 1996
	25MG	A074493 002	Feb 13, 1996
	50MG	A074493 003	Feb 13, 1996
	100MG	A074493 004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640 001	Mar 31, 1997
	25MG	A074640 002	Mar 31, 1997
	50MG	A074640 003	Mar 31, 1997
	100MG	A074640 004	Mar 31, 1997
SANDOZ	12.5MG	A074363 001	Nov 09, 1995
	12.5MG	A074481 001	Feb 13, 1996
	12.5MG	A074519 001	Feb 13, 1996
	25MG	A074363 002	Nov 09, 1995
	25MG	A074481 002	Feb 13, 1996
	25MG	A074519 002	Feb 13, 1996
	50MG	A074363 003	Nov 09, 1995
	50MG	A074481 003	Feb 13, 1996
	50MG	A074519 003	Feb 13, 1996
	100MG	A074363 004	Nov 09, 1995
	100MG	A074481 004	Feb 13, 1996
	100MG	A074519 004	Feb 13, 1996
STASON	12.5MG	A074677 004	May 30, 1997
	25MG	A074677 002	May 30, 1997
	50MG	A074677 001	May 30, 1997
	100MG	A074677 003	May 30, 1997
VINTAGE PHARMS LLC	12.5MG	A074418 001	Feb 13, 1996

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL
TABLET;ORAL
CAPTOPRIL

	25MG	A074418 002	Feb 13, 1996
	50MG	A074418 003	Feb 13, 1996
	100MG	A074418 004	Feb 13, 1996
WATSON LABS	12.5MG	A074451 001	Feb 13, 1996
	12.5MG	A074576 001	Apr 23, 1996
	25MG	A074451 002	Feb 13, 1996
	25MG	A074576 002	Apr 23, 1996
	50MG	A074451 003	Feb 13, 1996
	50MG	A074576 003	Apr 23, 1996
	100MG	A074451 004	Feb 13, 1996
	100MG	A074576 004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE
TABLET;ORAL

CAPOZIDE 25/15			
APOTHECON	25MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 001	Oct 12, 1984
CAPOZIDE 25/25			
APOTHECON	25MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 002	Oct 12, 1984
CAPOZIDE 50/15			
APOTHECON	50MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 004	Oct 12, 1984
CAPOZIDE 50/25			
APOTHECON	50MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 003	Oct 12, 1984
CAPTOPRIL AND HYDROCHLOROTHIAZIDE			
IVAX SUB TEVA PHARMS	25MG;15MG	A075055 001	Jun 18, 1998
	25MG;25MG	A075055 002	Jun 18, 1998
	50MG;15MG	A075055 004	Jun 18, 1998
	50MG;25MG	A075055 003	Jun 18, 1998
VINTAGE PHARMS LLC	25MG;15MG	A074788 001	Dec 29, 1997
	25MG;25MG	A074788 002	Dec 29, 1997
	50MG;15MG	A074788 004	Dec 29, 1997
	50MG;25MG	A074788 003	Dec 29, 1997
WATSON LABS	50MG;25MG	A074832 001	Dec 29, 1997

CARBACHOL
SOLUTION;INTRAOCULAR

CARBACHOL			
PHARMAFAIR	0.01%	A070292 001	May 21, 1986
CARBASTAT			
NOVARTIS	0.01%	A073677 001	Apr 28, 1995

CARBAMAZEPINE
SUSPENSION;ORAL

CARBAMAZEPINE			
TARO	100MG/5ML	A075875 001	Dec 21, 2000

TABLET;ORAL

CARBAMAZEPINE			
ACTAVIS ELIZABETH	200MG	A071696 001	Nov 09, 1987
INWOOD LABS	200MG	A070231 001	Aug 14, 1986
PLIVA	200MG	A071479 001	Jul 24, 1987
USL PHARMA	200MG	A070300 001	May 15, 1986
WARNER CHILCOTT	200MG	A070429 001	Jan 02, 1987
TERIL			
TARO	200MG	A076525 001	Sep 26, 2003

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE			
JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988

FDA data supplied by DrugPatentWatch.com

CARBENICILLIN DISODIUM

INJECTABLE;INJECTION			
GEOPEN			
ROERIG	EQ 1GM BASE/VIAL	N050306 001	
	EQ 2GM BASE/VIAL	N050306 004	
	EQ 5GM BASE/VIAL	N050306 002	
	EQ 10GM BASE/VIAL	N050306 006	
	EQ 30GM BASE/VIAL	N050306 007	
PYOPEN			
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298 001	
	EQ 2GM BASE/VIAL	N050298 002	
	EQ 5GM BASE/VIAL	N050298 003	
	EQ 10GM BASE/VIAL	N050298 006	
	EQ 20GM BASE/VIAL	N050298 007	

CARBENICILLIN INDANYL SODIUM

TABLET;ORAL			
GEOCILLIN			
PFIZER	EQ 382MG BASE	N050435 001	

CARBIDOPA; LEVODOPA

TABLET;ORAL			
CARBIDOPA AND LEVODOPA			
IDT AUSTRALIA LTD	10MG;100MG	A073586 001	Jun 29, 1995
	25MG;100MG	A073587 001	Jun 29, 1995
	25MG;250MG	A073620 001	Jun 29, 1995
SCS	10MG;100MG	A074080 001	Mar 25, 1994
	25MG;100MG	A074080 002	Mar 25, 1994
	25MG;250MG	A074080 003	Mar 25, 1994
WATSON LABS	10MG;100MG	A073381 001	Sep 28, 1993
	25MG;100MG	A073382 001	Sep 28, 1993
	25MG;250MG	A073383 001	Sep 28, 1993
TABLET, EXTENDED RELEASE;ORAL			
CARBIDOPA AND LEVODOPA			
KV PHARM	50MG;200MG	A076663 001	Jun 24, 2004
TABLET, FOR SUSPENSION;ORAL			
CARBILEV			
RANBAXY	10MG;100MG	A076643 001	Jun 10, 2005
	25MG;100MG	A076643 002	Jun 10, 2005
	25MG;250MG	A076643 003	Jun 10, 2005
TABLET, ORALLY DISINTEGRATING;ORAL			
CARBIDOPA AND LEVODOPA			
IMPAX LABS	10MG;100MG	A090631 001	Jun 08, 2010
	25MG;100MG	A090631 002	Jun 08, 2010
	25MG;250MG	A090631 003	Jun 08, 2010
PARCOPA			
UCB INC	10MG;100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A076699 001	Aug 27, 2004
	25MG;100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A076699 002	Aug 27, 2004
	25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A076699 003	Aug 27, 2004

CARBINOXAMINE MALEATE

ELIXIR;ORAL			
CLISTIN			
MCNEIL	4MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008955 001	
TABLET;ORAL			
CLISTIN			
ORTHO MCNEIL PHARM	4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008915 001	

CARBOPLATIN

INJECTABLE;INJECTION

CARBOPLATIN

CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006
	150MG/VIAL	A077383	002	Jan 27, 2006
	450MG/VIAL	A077383	003	Jan 27, 2006
FRESENIUS KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004
	150MG/VIAL	A076235	002	Oct 14, 2004
	450MG/VIAL	A076235	003	Oct 14, 2004
HOSPIRA	50MG/VIAL	A076473	001	Oct 27, 2004
	150MG/VIAL	A076473	002	Oct 27, 2004
	450MG/VIAL	A076473	003	Oct 27, 2004
MYLAN LABS LTD	50MG/VIAL	A091510	001	May 29, 2012
	150MG/VIAL	A091510	002	May 29, 2012
	450MG/VIAL	A091510	003	May 29, 2012
PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004
	150MG/VIAL	A076602	002	Nov 16, 2004
	450MG/VIAL	A076602	003	Nov 16, 2004
SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005
	150MG/VIAL	A076959	002	Mar 18, 2005
	450MG/VIAL	A076959	003	Mar 18, 2005
WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004
	150MG/VIAL	A076162	002	Oct 14, 2004
	450MG/VIAL	A076162	003	Oct 14, 2004
WEST-WARD PHARMS INT	50MG/VIAL	A076099	001	Oct 14, 2004
	150MG/VIAL	A076099	002	Oct 14, 2004
	450MG/VIAL	A076099	003	Oct 14, 2004

PARAPLATIN

CORDEN PHARMA	50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019880	001	Mar 03, 1989
	150MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019880	002	Mar 03, 1989
	450MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019880	003	Mar 03, 1989

INJECTABLE;IV (INFUSION)

CARBOPLATIN

ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012
	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012
	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012
	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012
FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004
	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006
	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009
	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009
	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007

PARAPLATIN

CORDENPHARMA	50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020452	001	Jul 14, 2003
	150MG/15ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020452	002	Jul 14, 2003
	450MG/45ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020452	003	Jul 14, 2003
	600MG/60ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020452	004	Jan 15, 2004

FDA data supplied by DrugPatentWatch.com

CARISOPRODOL
CAPSULE;ORAL
SOMA

MEDA PHARMS	250MG	N011792 003	

TABLET;ORAL
CARISOPRODOL

ABLE	350MG	A040421 001	Jun 21, 2001
COREPHARMA	350MG	A040397 001	Sep 21, 2000
HIKMA INTL PHARMS	350MG	A040124 001	Jan 24, 1996
OXFORD PHARMS	350MG	A040188 001	Mar 07, 1997
PIONEER PHARMS	350MG	A089390 001	Oct 13, 1988
SANDOZ	350MG	A081025 001	Apr 13, 1989
	350MG	A089566 001	Aug 30, 1988
WATSON LABS	350MG	A040152 001	Dec 03, 1996
	350MG	A085433 001	
	350MG	A086179 001	

RELA

SCHERING	350MG	N012155 001	

CARPHENAZINE MALEATE
CONCENTRATE;ORAL
PROKETAZINE

WYETH AYERST	50MG/ML	N014173 001	

TABLET;ORAL
PROKETAZINE

WYETH AYERST	12.5MG	N012768 001	
	25MG	N012768 002	
	50MG	N012768 004	

CARPROFEN
TABLET;ORAL
RIMADYL

ROCHE	100MG	N018550 002	Dec 31, 1987
	150MG	N018550 003	Dec 31, 1987

CARTEOLOL HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

APOTEX INC	1%	A076097 001	Feb 06, 2002

TABLET;ORAL
CARTROL

ABBVIE	2.5MG	N019204 001	Dec 28, 1988
	5MG	N019204 002	Dec 28, 1988
	10MG	N019204 003	Dec 28, 1988

CARVEDILOL
TABLET;ORAL
CARVEDILOL

HIKMA	3.125MG	A077887 001	Sep 07, 2007
	6.25MG	A077887 002	Sep 07, 2007
	12.5MG	A077887 003	Sep 07, 2007
	25MG	A077887 004	Sep 07, 2007
WOCKHARDT LTD	3.125MG	A078786 001	Dec 22, 2009
	6.25MG	A078786 002	Dec 22, 2009
	12.5MG	A078786 003	Dec 22, 2009
	25MG	A078786 004	Dec 22, 2009

CEFACLOR
CAPSULE;ORAL
CECLOR

LILLY	EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050521 001	
	EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050521 002	

CEFACLOR

CEPH INTL	EQ 250MG BASE	A062205 001	
	EQ 500MG BASE	A062205 002	
DAVA PHARMS INC	EQ 250MG BASE	A064107 001	Apr 27, 1995
	EQ 500MG BASE	A064107 002	Apr 27, 1995
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A064061 001	Apr 27, 1995
	EQ 500MG BASE	A064061 002	Apr 27, 1995
RANBAXY	EQ 250MG BASE	A064156 001	Aug 28, 1997

CEFACLOR

CAPSULE;ORAL			
CEFACLOR			
	EQ 500MG BASE	A064156 002	Aug 28, 1997
TEVA	EQ 250MG BASE	A064081 001	Sep 16, 1996
	EQ 250MG BASE	A064145 001	Jun 24, 1996
	EQ 500MG BASE	A064081 002	Sep 16, 1996
	EQ 500MG BASE	A064145 002	Jun 24, 1996
WATSON LABS INC	EQ 250MG BASE	A064148 001	May 23, 1996
	EQ 500MG BASE	A064148 002	May 23, 1996
FOR SUSPENSION;ORAL			
CECLOR			
LILLY	EQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050522 001	
	EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050522 002	
CEFACLOR			
DAVA PHARMS INC	EQ 125MG BASE/5ML	A064114 001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064115 001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064116 001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064110 001	Apr 28, 1995
FACTA FARMA	EQ 125MG BASE/5ML	A062206 001	
	EQ 187MG BASE/5ML	A062206 003	Apr 20, 1988
	EQ 250MG BASE/5ML	A062206 002	
	EQ 375MG BASE/5ML	A062206 004	Apr 20, 1988
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087 001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064086 001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064085 001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064070 001	Apr 28, 1995
RANBAXY	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997
	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997
	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997
	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997
WATSON LABS INC	EQ 125MG BASE/5ML	A064204 001	Feb 18, 1998
	EQ 187MG BASE/5ML	A064205 001	Feb 18, 1998
	EQ 250MG BASE/5ML	A064206 001	Feb 18, 1998
	EQ 375MG BASE/5ML	A064207 001	Feb 18, 1998
TABLET, CHEWABLE;ORAL			
RANICLOR			
RANBAXY LABS LTD	EQ 125MG BASE	A065092 001	Dec 22, 2003
	EQ 187MG BASE	A065092 002	Dec 22, 2003
	EQ 250MG BASE	A065092 003	Dec 22, 2003
	EQ 375MG BASE	A065092 004	Dec 22, 2003
TABLET, EXTENDED RELEASE;ORAL			
CECLOR CD			
LILLY	EQ 375MG BASE	N050673 001	Jun 28, 1996
	EQ 500MG BASE	N050673 002	Jun 28, 1996
CEFACLOR			
WORLD GEN	EQ 500MG BASE	A065057 001	Jan 05, 2001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL			
CEFADROXIL			
IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017 001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999
TEVA	EQ 500MG BASE	A062695 001	Feb 10, 1989
DURICEF			
WARNER CHILCOTT	EQ 250MG BASE	N050512 002	
	EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050512 001	
ULTRACEF			
BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982
FOR SUSPENSION;ORAL			
CEFADROXIL			
ANI PHARMS INC	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL

CEFADROXIL

	EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
	EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML	A062334 001	
	EQ 250MG BASE/5ML	A062334 002	
	EQ 500MG BASE/5ML	A062334 003	
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115 001	Mar 26, 2003
	EQ 250MG BASE/5ML	A065115 002	Mar 26, 2003
	EQ 500MG BASE/5ML	A065115 003	Mar 26, 2003

DURICEF

WARNER CHILCOTT	EQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050527 002	
	EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050527 003	
	EQ 500MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050527 001	

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982

TABLET;ORAL

CEFADROXIL

RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999

DURICEF

WARNER CHILCOTT	EQ 1GM BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050528 001	

ULTRACEF

APOTHECON	EQ 1GM BASE	A062390 001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408 001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE;INJECTION

MANDOL

LILLY	EQ 500MG BASE/VIAL	N050504 001	
	EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504 002	
	EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504 003	
	EQ 10GM BASE/VIAL	N050504 004	

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

ANCEF

GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 001	
	EQ 500MG BASE/VIAL	N050461 002	
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 003	
	EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 004	
	EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 005	

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 004	Jun 08, 1983

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

CEFAZOLIN SODIUM
INJECTABLE;INJECTION

CEFAZOLIN AND DEXTROSE			
B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000
CEFAZOLIN SODIUM			
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
	EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008
BEDFORD	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
	EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
FRESENIUS KABI USA	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A064169 001	Aug 14, 1998
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A064169 002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
STERI PHARMA	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991
TEVA PHARMS	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989
	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990
WATSON LABS INC	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
	EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988
KEFZOL			
ACS DOBFAR	EQ 250MG BASE/VIAL	A061773 001	
	EQ 20GM BASE/VIAL	A061773 005	Sep 08, 1987
LILLY	EQ 500MG BASE/VIAL	A062557 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557 002	Sep 10, 1985

CEFDINIR
CAPSULE;ORAL

OMNICEF			
ABBVIE	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050739 001	Dec 04, 1997

FOR SUSPENSION;ORAL

OMNICEF			
ABBVIE	125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050749 001	Dec 04, 1997
	250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050749 002	Jul 29, 2004

CEFDITOREN PIVOXIL
TABLET;ORAL
SPECTRACEF

VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001
	400MG	N021222 002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE
INJECTABLE;INJECTION
CEFEPIME HYDROCHLORIDE

SANDOZ	EQ 500MG BASE/VIAL	A090291 001	Dec 21, 2010
	EQ 1GM BASE/VIAL	A090291 002	Dec 21, 2010
	EQ 2GM BASE/VIAL	A090291 003	Dec 21, 2010

CEFIXIME
FOR SUSPENSION;ORAL
SUPRAX

LEDERLE	100MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050622 001	Apr 28, 1989

TABLET;ORAL
SUPRAX

LEDERLE	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050621 001	Apr 28, 1989
	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050621 002	Apr 28, 1989

CEFMENOXIME HYDROCHLORIDE
INJECTABLE;INJECTION
CEFMAX

TAP PHARM	EQ 500MG BASE/VIAL	N050571 001	Dec 30, 1987
	EQ 1GM BASE/VIAL	N050571 002	Dec 30, 1987
	EQ 2GM BASE/VIAL	N050571 003	Dec 30, 1987

CEFMETAZOLE SODIUM
INJECTABLE;INJECTION
ZEFAZONE

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050637 001	Dec 11, 1989
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050637 002	Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN	EQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050683 001	Dec 29, 1992
	EQ 40MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050683 002	Dec 29, 1992

CEFONICID SODIUM
INJECTABLE;INJECTION
MONOCID

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579 001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295 001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579 002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579 003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579 004	May 23, 1984

CEFOPERAZONE SODIUM
INJECTABLE;INJECTION
CEFOBID

PFIZER	EQ 1GM BASE/VIAL	A063333 001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551 001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333 002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551 002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551 003	Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER	EQ 20MG BASE/ML	N050613 002	Jul 31, 1987

FDA data supplied by DrugPatentWatch.com

CEFOPERAZONE SODIUM
INJECTABLE;INJECTION
CEFOBID IN PLASTIC CONTAINER

	EQ 40MG BASE/ML	N050613	001	Jul 23, 1986

CEFORANIDE
INJECTABLE;INJECTION
PRECEF

APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984

CEFOTAXIME SODIUM
INJECTABLE;INJECTION
CEFOTAXIME

FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200	001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200	002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200	003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201	001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004

CEFOTAXIME SODIUM

AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	EQ 40MG BASE/ML	N050596	004	May 20, 1985

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

CEFOTETAN DISODIUM
INJECTABLE;INJECTION
CEFOTAN

TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988

CEFOTAN IN PLASTIC CONTAINER

IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993

CEFOTIAM HYDROCHLORIDE
INJECTABLE;INJECTION
CERADON

TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988

CEFOXITIN SODIUM
INJECTABLE;INJECTION
CEFOXITIN

FRESENIUS KABI USA	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A065012	001	Jul 03, 2000
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A065012	002	Jul 03, 2000
	EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000

MEFOXIN

MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or	N050517	001	

FDA data supplied by DrugPatentWatch.com

CEFOXITIN SODIUM
INJECTABLE;INJECTION
MEFOXIN

	efficacy reasons**		
	EQ 2GM BASE/VIAL	A062757 002	Jan 08, 1987
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050517 002	
	EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050517 003	

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

MERCK	EQ 20MG BASE/ML	N050581 003	Sep 20, 1984
	EQ 40MG BASE/ML	N050581 004	Sep 20, 1984

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MERCK	EQ 20MG BASE/ML	N050581 002	Sep 20, 1984
	EQ 40MG BASE/ML	N050581 001	Sep 20, 1984

CEFPIRAMIDE SODIUM
INJECTABLE;INJECTION
CEFPIRAMIDE SODIUM

WYETH AYERST	EQ 1GM BASE/VIAL	N050633 002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633 003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633 005	Jan 31, 1989

CEFPODOXIME PROXETIL
FOR SUSPENSION;ORAL
BANAN

SANKYO	EQ 50MG BASE/5ML	N050688 002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688 001	Aug 07, 1992

CEFPODOXIME PROXETIL

SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082 001	May 31, 2002
	EQ 100MG BASE/5ML	A065082 002	May 31, 2002

VANTIN

PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050675 001	Aug 07, 1992
	EQ 100MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050675 002	Aug 07, 1992

TABLET;ORAL
BANAN

SANKYO	EQ 100MG BASE	N050687 001	Aug 07, 1992
	EQ 200MG BASE	N050687 002	Aug 07, 1992

CEFPODOXIME PROXETIL

SUN PHARM INDS LTD	EQ 100MG BASE	A065083 001	Aug 20, 2003
	EQ 200MG BASE	A065083 002	Aug 20, 2003

VANTIN

PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992
	EQ 200MG BASE	N050674 002	Aug 07, 1992

CEFPROZIL
FOR SUSPENSION;ORAL
CEFPROZIL

RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006
	250MG/5ML	A065202 002	Jun 30, 2006

CEFZIL

CORDEN PHARMA	125MG/5ML	N050665 001	Dec 23, 1991
	250MG/5ML	N050665 002	Dec 23, 1991

TABLET;ORAL
CEFPROZIL

RANBAXY LABS LTD	250MG	A065198 001	Dec 13, 2006
	500MG	A065198 002	Dec 13, 2006

CEFZIL

CORDEN PHARMA	250MG	N050664 001	Dec 23, 1991
	500MG	N050664 002	Dec 23, 1991

CEFTAZIDIME
INJECTABLE;INJECTION
CEFTAZIDIME

AUROBINDO PHARMA LTD	500MG/VIAL	A065481 001	May 28, 2010
	1GM/VIAL	A065481 002	May 28, 2010
	2GM/VIAL	A065481 003	May 28, 2010
	6GM/VIAL	A065482 001	May 28, 2010

CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N050646 001	Sep 27, 1990
	1GM/VIAL	N050646 002	Sep 27, 1990
	2GM/VIAL	N050646 003	Sep 27, 1990
	10GM/VIAL	N050646 004	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322 001	Nov 07, 1995
	1GM/VIAL	A064006 001	Mar 31, 1992
	2GM/VIAL	A063322 002	Nov 07, 1995
	2GM/VIAL	A064006 002	Mar 31, 1992
	6GM/VIAL	A064008 001	Mar 31, 1992
	10GM/VIAL	A064008 002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655 001	Nov 20, 1985
	2GM/VIAL	A062655 002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739 001	Jul 10, 1986
	2GM/VIAL	A062739 002	Jul 10, 1986

CEFTAZIDIME SODIUM
INJECTABLE;INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221 001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221 002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221 003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

IGI LABS INC	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989

CEFTIBUTEN DIHYDRATE
CAPSULE;ORAL
CEDAX

PERNIX THERAP	EQ 400MG BASE	N050685 002	Dec 20, 1995

FOR SUSPENSION;ORAL
CEDAX

PERNIX THERAP	EQ 90MG BASE/5ML	N050686 001	Dec 20, 1995
	EQ 180MG BASE/5ML	N050686 002	Dec 20, 1995

CEFTIZOXIME SODIUM
INJECTABLE;INJECTION
CEFIZOX

ASTELLAS	EQ 500MG BASE/VIAL	N050560 001	Sep 15, 1983
	EQ 1GM BASE/VIAL	A063294 002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560 002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294 003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560 003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560 005	Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589 001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589 002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589 003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589 004	Apr 13, 1995

CEFTRIAXONE SODIUM
INJECTABLE;INJECTION
CEFTRIAXONE

AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068 001	Jan 07, 2013
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504 001	Jul 31, 2008
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252 001	Feb 15, 2006
HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005
	EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012
	EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005
	EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012
TEVA	EQ 10GM BASE/VIAL	A065274 001	May 01, 2006

ROCEPHIN

HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239 001	Aug 13, 1993
	EQ 500MG BASE/VIAL	A062654 001	Apr 30, 1987

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

ROCEPHIN

	EQ 500MG BASE/VIAL	A063239 002	Aug 13, 1993
	EQ 1GM BASE/VIAL	A062654 002	Apr 30, 1987
	EQ 1GM BASE/VIAL	A063239 003	Aug 13, 1993
	EQ 2GM BASE/VIAL	A062654 003	Apr 30, 1987
	EQ 10GM BASE/VIAL	N050585 005	Dec 21, 1984
ROCHE	EQ 250MG BASE/VIAL	A062510 001	Mar 12, 1985
	EQ 500MG BASE/VIAL	A062510 002	Mar 12, 1985
	EQ 1GM BASE/VIAL	A062510 003	Mar 12, 1985

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

HOFFMANN LA ROCHE	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050624 001	Feb 11, 1987
	EQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050624 002	Feb 11, 1987
	EQ 40MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050624 003	Feb 11, 1987

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505 001	Jul 31, 2008
	EQ 500MG BASE/VIAL	A065505 002	Jul 31, 2008
	EQ 1GM BASE/VIAL	A065505 003	Jul 31, 2008
	EQ 2GM BASE/VIAL	A065505 004	Jul 31, 2008
BEDFORD	EQ 250MG BASE/VIAL	A065465 001	Aug 18, 2008
	EQ 500MG BASE/VIAL	A065465 002	Aug 18, 2008
	EQ 1GM BASE/VIAL	A065465 003	Aug 18, 2008
	EQ 2GM BASE/VIAL	A065465 004	Aug 18, 2008
CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294 001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294 002	Mar 26, 2007
	EQ 1GM BASE/VIAL	A065294 003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294 004	Mar 26, 2007
FACTA FARMA	EQ 1GM BASE/VIAL	A065268 001	Feb 28, 2007
	EQ 2GM BASE/VIAL	A065268 002	Feb 28, 2007
FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245 001	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245 002	Feb 15, 2006
	EQ 1GM BASE/VIAL	A065245 003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245 004	Feb 15, 2006
TEVA	EQ 1GM BASE/VIAL	A065262 001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262 002	Jun 29, 2006
TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007
	EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007
	EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007
	EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007

ROCEPHIN

HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	N050585 001	Dec 21, 1984
	EQ 500MG BASE/VIAL	N050585 002	Dec 21, 1984
	EQ 1GM BASE/VIAL	N050585 003	Dec 21, 1984
	EQ 2GM BASE/VIAL	N050585 004	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE;INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N050585 007	May 08, 1996
	EQ 1GM BASE/VIAL,N/A;N/A,1%	N050585 006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFUROXIME AXETIL

SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323 001	Feb 05, 2008
	EQ 250MG BASE/5ML	A065323 002	Feb 05, 2008

TABLET;ORAL

CEFUROXIME AXETIL

RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002
	EQ 250MG BASE	A065043 002	Feb 15, 2002
	EQ 500MG BASE	A065043 001	Feb 15, 2002
SANDOZ	EQ 250MG BASE	A065126 001	Oct 28, 2003
	EQ 500MG BASE	A065126 002	Oct 28, 2003
SUN PHARM INDS LTD	EQ 125MG BASE	A065118 001	Apr 25, 2003

CEFUROXIME AXETIL
TABLET;ORAL
CEFUROXIME AXETIL

	EQ 250MG BASE	A065118 002	Apr 25, 2003
	EQ 500MG BASE	A065118 003	Apr 25, 2003

CEFUROXIME SODIUM
INJECTABLE;INJECTION
CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035 002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036 001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251 001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251 002	Dec 30, 2009

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591 002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591 003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592 002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590 002	Jan 10, 1986

ZINACEF IN PLASTIC CONTAINER

IGI LABS INC	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035 001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591 001	Jan 10, 1986

INJECTABLE;INTRAVENOUS
KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592 001	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590 001	Jan 10, 1986

CELLULOSE SODIUM PHOSPHATE
POWDER;ORAL
CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757 002	Dec 28, 1982
	300GM/BOT	N018757 003	Oct 16, 1984

CEPHALEXIN
CAPSULE;ORAL
CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973 001	Nov 08, 1988
	EQ 250MG BASE	A063063 001	Sep 29, 1989
	EQ 250MG BASE	A063186 001	Dec 30, 1994
	EQ 500MG BASE	A062974 001	Nov 23, 1988
	EQ 500MG BASE	A063063 002	Sep 29, 1989
	EQ 500MG BASE	A063186 002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773 001	Jun 26, 1987
	EQ 500MG BASE	A062775 001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118 001	
	EQ 500MG BASE	A062118 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969 001	
	EQ 500MG BASE	A061969 002	
PUREPAC PHARM	EQ 250MG BASE	A062809 001	Apr 22, 1987
	EQ 500MG BASE	A062809 002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870 001	Mar 17, 1988
	EQ 500MG BASE	A062869 001	Mar 17, 1988
SUN PHARM INDS LTD	EQ 250MG BASE	A065007 001	Sep 16, 1999
	EQ 500MG BASE	A065007 002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760 001	Apr 24, 1987
	EQ 250MG BASE	A062821 001	Feb 05, 1988
	EQ 500MG BASE	A062761 001	Apr 24, 1987
	EQ 500MG BASE	A062823 001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872 001	Jun 20, 1988
	EQ 500MG BASE	A062871 001	Jul 05, 1988

CEPHALEXIN

CAPSULE;ORAL

KEFLEX

PRAGMA PHARMS LLC	EQ 333MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050405 004	May 12, 2006

FOR SUSPENSION;ORAL

CEPHALEXIN

APOTHECON	EQ 125MG BASE/5ML	A062986 001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987 001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778 001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777 001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	A062117 001	
	EQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	A062117 002	
	EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	A062117 003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444 001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444 002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081 001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081 002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767 001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873 001	May 23, 1988
	EQ 250MG BASE/5ML	A062768 001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867 001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779 001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781 001	Dec 22, 1987
YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336 001	Jul 25, 2007
	EQ 250MG BASE/5ML	A065336 002	Jul 25, 2007

KEFLEX

PRAGMA PHARMS LLC	EQ 100MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	N050406 003	
	EQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050406 001	
	EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	N050406 002	

TABLET;ORAL

CEPHALEXIN

BARR	EQ 250MG BASE	A062826 001	Aug 17, 1987
	EQ 500MG BASE	A062827 001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863 001	Aug 11, 1988
	EQ 500MG BASE	A062863 002	Aug 11, 1988
	EQ 1GM BASE	A062863 003	Aug 11, 1988

KEFLET

LILLY	EQ 250MG BASE	A062745 001	Dec 01, 1986
	EQ 250MG BASE	N050440 003	Feb 26, 1987
	EQ 500MG BASE	A062745 002	Dec 01, 1986
	EQ 500MG BASE	N050440 001	
	EQ 1GM BASE	N050440 002	

TABLET, FOR SUSPENSION;ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003
	EQ 250MG BASE	A065100 001	Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL

KEFTAB

LILLY	EQ 250MG BASE	N050614 001	Oct 29, 1987
	EQ 333MG BASE	N050614 003	May 16, 1988
	EQ 500MG BASE	N050614 002	Oct 29, 1987

FDA data supplied by DrugPatentWatch.com

CEPHALOGLYCIN
CAPSULE;ORAL
KAFOCIN

LILLY	250MG	N050219 001	

CEPHALOTHIN SODIUM
INJECTABLE;INJECTION
CEPHALOTHIN

INTL MEDICATION	EQ 500MG BASE/VIAL	A062426 001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426 002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426 003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426 004	May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT	EQ 1GM BASE/VIAL	A062547 001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548 001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547 002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548 002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666 002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666 001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464 001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464 002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464 003	May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422 005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730 001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422 004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730 002	Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422 001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422 002	Jan 31, 1984

KEFLIN

LILLY	EQ 1GM BASE/VIAL	N050482 001	
	EQ 2GM BASE/VIAL	N050482 002	
	EQ 4GM BASE/VIAL	N050482 003	
	EQ 20GM BASE/VIAL	N050482 007	

KEFLIN IN PLASTIC CONTAINER

LILLY	EQ 1GM BASE/VIAL	A062549 001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549 002	Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435 001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435 002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435 003	Nov 15, 1983

CEPHAPIRIN SODIUM
INJECTABLE;INJECTION
CEFADYL

APOTHECON	EQ 500MG BASE/VIAL	A062961 001	Sep 20, 1988
	EQ 500MG BASE/VIAL	N050446 005	
	EQ 1GM BASE/VIAL	A061769 001	
	EQ 1GM BASE/VIAL	A062724 001	Dec 23, 1986
	EQ 1GM BASE/VIAL	A062961 002	Sep 20, 1988
	EQ 1GM BASE/VIAL	N050446 001	
	EQ 2GM BASE/VIAL	A061769 002	
	EQ 2GM BASE/VIAL	A062724 002	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062961 003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446 002	
	EQ 4GM BASE/VIAL	A061769 003	
	EQ 4GM BASE/VIAL	A062961 004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446 003	
	EQ 20GM BASE/VIAL	N050446 004	

CEPHAPIRIN SODIUM

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062723 001	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062723 002	Nov 17, 1986
	EQ 2GM BASE/VIAL	A062723 003	Nov 17, 1986
	EQ 4GM BASE/VIAL	A062723 004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062723 005	Nov 17, 1986
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987
	EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987
	EQ 2GM BASE/VIAL	A062720 003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720 004	Jul 02, 1987

CEPHRADINE
CAPSULE;ORAL
ANSPOR

GLAXOSMITHKLINE	250MG	A061859 001	
	500MG	A061859 002	

CEPHRADINE

BARR	250MG	A062850 001	Apr 22, 1988
	500MG	A062851 001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762 001	Mar 06, 1987
	500MG	A062762 002	Mar 06, 1987
TEVA	250MG	A062683 001	Jan 09, 1987
	500MG	A062683 002	Jan 09, 1987
VITARINE	250MG	A062813 001	Feb 25, 1988
	500MG	A062813 002	Feb 25, 1988

VELOSEF

APOTHECON	250MG	A061764 001	
	500MG	A061764 002	

VELOSEF '250'

ERSANA	250MG	N050548 001	

VELOSEF '500'

ERSANA	500MG	N050548 002	

FOR SUSPENSION;ORAL
ANSPOR

GLAXOSMITHKLINE	125MG/5ML	A061866 001	
	250MG/5ML	A061866 002	

CEPHRADINE

BARR	125MG/5ML	A062858 001	May 19, 1988
	250MG/5ML	A062859 001	May 19, 1988
TEVA	125MG/5ML	A062693 001	Jan 09, 1987
	250MG/5ML	A062693 002	Jan 09, 1987

VELOSEF '125'

APOTHECON	125MG/5ML	A061763 001	

VELOSEF '250'

APOTHECON	250MG/5ML	A061763 002	

INJECTABLE;INJECTION
VELOSEF

APOTHECON	250MG/VIAL	A061976 001	
	500MG/VIAL	A061976 002	
	1GM/VIAL	A061976 004	
	2GM/VIAL	A061976 003	
	4GM/VIAL	A061976 005	

TABLET;ORAL
VELOSEF

BRISTOL MYERS SQUIBB	1GM	N050530 001	

CERIVASTATIN SODIUM
TABLET;ORAL
BAYCOL

BAYER PHARMS	0.05MG	N020740 001	Jun 26, 1997
	0.1MG	N020740 002	Jun 26, 1997
	0.2MG	N020740 003	Jun 26, 1997
	0.3MG	N020740 004	Jun 26, 1997
	0.4MG	N020740 005	May 24, 1999
	0.8MG	N020740 006	Jul 24, 2000

CERULETIDE DIETHYLAMINE
INJECTABLE;INJECTION
TYMTRAN

PHARMACIA AND UPJOHN	0.02MG/ML	N018296 001	

CETIRIZINE HYDROCHLORIDE
SYRUP;ORAL
CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	5MG/5ML	A078617 001	Feb 02, 2010
APOTEX INC	5MG/5ML	A078412 001	Jun 18, 2008
AUROBINDO PHARMA LTD	5MG/5ML	A090751 001	Dec 16, 2009
RANBAXY LABS LTD	5MG/5ML	A077472 001	Jun 18, 2008
WOCKHARDT	5MG/5ML	A078757 001	Aug 28, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC	5MG/5ML	A090378 002	May 09, 2008
APOTEX INC	5MG/5ML	A090188 002	Apr 22, 2008
CYPRESS PHARM	5MG/5ML	A090300 001	Oct 10, 2008
RANBAXY LABS LTD	5MG/5ML	A090183 002	Apr 24, 2008

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC	5MG/5ML	A090378 001	May 09, 2008
APOTEX INC	5MG/5ML	A090188 001	Apr 22, 2008
CYPRESS PHARM	5MG/5ML	A090300 002	Oct 10, 2008
RANBAXY LABS LTD	5MG/5ML	A090183 001	Apr 24, 2008

ZYRTEC

J AND J CONSUMER INC	5MG/5ML	N020346 001	Sep 27, 1996

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH	5MG	A078615 003	Dec 28, 2007
	10MG	A078615 004	Dec 28, 2007

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC	5MG	A077631 004	Jan 11, 2008
	10MG	A077631 003	Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC	5MG	A077631 001	Jan 11, 2008
	10MG	A077631 002	Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

J AND J CONSUMER INC	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621 003	Nov 16, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621 004	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

J AND J CONSUMER INC	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621 005	Nov 16, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621 006	Nov 16, 2007

CETRORELIX

INJECTABLE;INJECTION

CETROTIDE

EMD SERONO INC	EQ 3MG BASE/ML	N021197 002	Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION;INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N020044 001	Aug 02, 1990

CHENODIOL

TABLET;ORAL

CHENIX

SIGMA TAU	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018513 002	Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP;ORAL

ULO

3M	25MG/5ML	N012126 001	

CHLORAMPHENICOL

CREAM;TOPICAL

CHLOROMYCETIN

PARKE DAVIS	1%	N050183 001	

FOR SOLUTION;OPHTHALMIC

CHLOROMYCETIN

PARKEDALE	25MG/VIAL	N050143 001	

INJECTABLE;INJECTION

CHLOROMYCETIN

PARKE DAVIS	250MG/ML	N050153 001	

OINTMENT;OPHTHALMIC

CHLORAMPHENICOL

ALTANA	1%	A060133 001	

FDA data supplied by DrugPatentWatch.com

CHLORAMPHENICOL

OINTMENT;OPHTHALMIC

CHLOROFAIR			
PHARMAFAIR	1%	A062439 001	Apr 21, 1983
CHLOROMYCETIN			
PARKEDALE	1%	N050156 001	
CHLOROPTIC S.O.P.			
ALLERGAN	1%	A061187 001	
ECONOCHLOR			
ALCON	1%	A061648 001	

SOLUTION/DROPS;OPHTHALMIC

CHLORAMPHENICOL			
AKORN	0.5%	A062042 001	
ALCON	0.5%	A062628 001	Sep 25, 1985
CHLOROFAIR			
PHARMAFAIR	0.5%	A062437 001	Apr 14, 1983
CHLOROPTIC			
ALLERGAN	0.5%	N050091 001	
ECONOCHLOR			
ALCON	0.5%	A061645 001	
OPHTHOCHLOR			
PARKEDALE	0.5%	A061220 001	
OPTOMYCIN			
OPTOPICS	0.5%	A062171 001	Mar 31, 1982

SOLUTION/DROPS;OTIC

CHLOROMYCETIN			
PARKEDALE	0.5%	N050205 001	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLORAMPHENICOL			
ELKINS SINN	EQ 1GM BASE/VIAL	A062406 001	Nov 09, 1982
CHLORAMPHENICOL SODIUM SUCCINATE			
GRUPPO LEPETIT	EQ 1GM BASE/VIAL	A062278 001	
CHLOROMYCETIN			
PARKEDALE	EQ 1GM BASE/VIAL	N050155 001	
MYCHEL-S			
ANGUS	EQ 1GM BASE/VIAL	A060132 001	

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT;TOPICAL

ELASE-CHLOROMYCETIN			
PARKE DAVIS	10MG/GM;666 UNITS/GM;1 UNITS/GM	N050294 001	

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION;OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE			
PARKEDALE	12.5MG/VIAL;25MG/VIAL	N050202 001	

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

OPHTHOCORT			
PARKEDALE	10MG/GM;5MG/GM;10,000 UNITS/GM	N050201 002	

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CHLOROMYXIN			
PARKE DAVIS	1%;10,000 UNITS/GM	N050203 002	

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT;OPHTHALMIC

CHLOROPTIC-P S.O.P.			
ALLERGAN	1%;0.5%	A061188 001	

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE;ORAL

LIBRELEASE			
VALEANT PHARM INTL	30MG	N017813 001	Sep 12, 1983

TABLET;ORAL

LIBRITABS			
VALEANT PHARM INTL	5MG	A085482 001	
	10MG	A085481 001	
	25MG	A085488 001	

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

A-POXIDE

ABBOTT	5MG	A085447 001	
	5MG	A085517 001	
	10MG	A085447 002	
	10MG	A085518 001	
	25MG	A085447 003	
	25MG	A085513 001	

CHLORDIAZACHEL

RACHELLE	5MG	A085086 001	
	10MG	A084639 001	
	25MG	A085087 001	

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT	5MG	A087525 001	Jan 07, 1982
	10MG	A087524 001	Jan 07, 1982
	25MG	A087512 001	Jan 07, 1982
FERRANTE	5MG	A085118 001	
	10MG	A085119 001	
	25MG	A085120 001	
HALSEY	5MG	A085340 001	
	10MG	A085339 001	
	25MG	A084685 001	
HIKMA PHARMS LLC	5MG	A085014 001	
	10MG	A085000 001	
	25MG	A085294 001	
IMPAX LABS	5MG	A086213 001	
	10MG	A085113 001	
	25MG	A086212 001	
IVAX SUB TEVA PHARMS	5MG	A083741 001	
	10MG	A083742 001	
	25MG	A083570 001	
LEDERLE	5MG	A086892 001	
	5MG	A087234 001	
	10MG	A086876 001	
	10MG	A087037 001	
	25MG	A086893 001	
	25MG	A087231 001	
MAST MM	10MG	A086217 001	
MYLAN	5MG	A084886 001	
	10MG	A084601 001	
	25MG	A084887 001	
PARKE DAVIS	5MG	A085163 001	
	10MG	A084598 001	
	25MG	A085164 001	
PIONEER PHARMS	10MG	A089533 001	Jul 15, 1988
	25MG	A089558 001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155 001	
	10MG	A084939 002	
	25MG	A085144 001	
ROXANE	5MG	A084706 001	
	10MG	A084700 001	
	25MG	A084705 001	
SANDOZ	5MG	A084919 001	
	10MG	A084920 001	
	25MG	A084823 001	
SUPERPHARM	5MG	A088987 001	Apr 25, 1985
	10MG	A088986 001	Apr 25, 1985
	25MG	A088988 001	Apr 25, 1985
TEVA	5MG	A088705 001	Jan 18, 1985
	10MG	A088706 001	Jan 18, 1985
	25MG	A086494 001	
	25MG	A088707 001	Jan 18, 1985
UPSHER-SMITH LABS	5MG	A084678 001	
	10MG	A084041 001	
	25MG	A084679 002	
USL PHARMA	5MG	A084644 001	
	25MG	A084645 001	
VANGARD	5MG	A088129 001	Mar 28, 1983
	10MG	A088010 001	Mar 28, 1983
	25MG	A088130 001	Mar 28, 1983
WATSON LABS	5MG	A086383 001	

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL			
CHLORDIAZEPOXIDE HYDROCHLORIDE			
	10MG	A086294 001	
	25MG	A086382 001	
LIBRIUM			
VALEANT PHARM INTL	5MG	N012249 002	
	10MG	N012249 001	
	25MG	N012249 003	
LYGEN			
ALRA	5MG	A085107 001	
	10MG	A085009 001	
	25MG	A085108 001	
INJECTABLE;INJECTION			
LIBRIUM			
VALEANT PHARMS LLC	100MG/AMP	N012301 001	

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET;ORAL			
MENRIUM 10-4			
ROCHE	10MG;0.4MG	N014740 006	
MENRIUM 5-2			
ROCHE	5MG;0.2MG	N014740 002	
MENRIUM 5-4			
ROCHE	5MG;0.4MG	N014740 004	

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL			
CHLORHEXIDINE GLUCONATE			
APOTEX INC	0.12%	A075561 001	Nov 14, 2000
SOLUTION;TOPICAL			
EXIDINE			
XTTRIUM	2.5%	N019421 001	Dec 17, 1985
MICRODERM			
J AND J	4%	A072255 001	Apr 15, 1991
PREVACARE R			
J AND J	0.5%	A072292 001	Jan 28, 1992
STERI-STAT			
MATRIX MEDCL	4%	A070104 001	Jul 24, 1986
SPONGE;TOPICAL			
CHLORHEXIDINE GLUCONATE			
KENDALL IL	4%	N019490 001	Mar 27, 1987
E-Z SCRUB			
BECTON DICKINSON	4%	A073416 001	Mar 14, 2000
HIBICLENS			
MOLNLYCKE HLTH	4% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018423 001	
MICRODERM			
J AND J	4%	A072295 001	Feb 28, 1991
PHARMASEAL SCRUB CARE			
CAREFUSION	4%	N019793 001	Dec 02, 1988

CHLORMERODRIN HG-197

INJECTABLE;INJECTION			
CHLORMERODRIN HG 197			
BRACCO	0.6-1.4mCi/ML	N017269 001	

CHLORMEZANONE

TABLET;ORAL			
TRANCOPAL			
SANOFI AVENTIS US	100MG	N011467 003	
	200MG	N011467 005	

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION			
NESACAINE-MPF			
FRESENIUS KABI USA	2%	N009435 003	
	3%	N009435 004	

CHLOROQUINE HYDROCHLORIDE
INJECTABLE;INJECTION
ARALEN HYDROCHLORIDE

SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002 002	

CHLOROQUINE PHOSPHATE
TABLET;ORAL
CHLOROQUINE PHOSPHATE

IMPAX LABS	EQ 150MG BASE	A080880 001	
	EQ 300MG BASE	A040516 001	Aug 29, 2003
MD PHARM	EQ 150MG BASE	A087228 001	
PUREPAC PHARM	EQ 150MG BASE	A080886 001	
TEVA	EQ 150MG BASE	A087504 001	Jan 13, 1982
WATSON LABS	EQ 150MG BASE	A087979 001	Dec 21, 1982
	EQ 300MG BASE	A088030 001	Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
TABLET;ORAL
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860 002	

CHLOROTHIAZIDE
TABLET;ORAL
CHLOROTHIAZIDE

ABC HOLDING	250MG	A085569 001	
HIKMA INTL PHARMS	250MG	A086028 001	Jul 14, 1982
	500MG	A087736 001	Jul 14, 1982
LEDERLE	250MG	A086940 001	
	500MG	A086938 001	
SANDOZ	250MG	A085485 001	
WATSON LABS	250MG	A085165 001	
	250MG	A085173 001	
	250MG	A086795 001	Aug 15, 1983
	500MG	A084026 001	Sep 01, 1982
	500MG	A086796 001	Aug 15, 1983

DIURIL

OAK PHARMS AKORN	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011145 004	
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011145 002	

CHLOROTHIAZIDE; METHYLDOPA
TABLET;ORAL
ALDOCLOR-150

MERCK	150MG;250MG	N016016 001	

ALDOCLOR-250

MERCK	250MG;250MG	N016016 002	

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM	150MG;250MG	A070783 001	Nov 06, 1987
	250MG;250MG	A070654 001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE
TABLET;ORAL
CHLOROTHIAZIDE AND RESERPINE

HIKMA PHARMS LLC	250MG;0.125MG	A088557 001	Dec 22, 1983
	500MG;0.125MG	A088365 001	Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	250MG;0.125MG	A084853 001	
	500MG;0.125MG	A088151 001	Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN	250MG;0.125MG	A087744 001	May 06, 1982
	500MG;0.125MG	A087745 001	May 06, 1982

DIUPRES-250

MERCK	250MG;0.125MG	N011635 003	Aug 26, 1987

DIUPRES-500

MERCK	500MG;0.125MG	N011635 006	Aug 26, 1987

FDA data supplied by DrugPatentWatch.com

CHLOROTRIANISENE
CAPSULE;ORAL
CHLOROTRIANISENE
BANNER PHARMACAPS 12MG A084652 001
TACE
SANOFI AVENTIS US 12MG N008102 004
25MG N011444 001
72MG N016235 001

CHLOROXINE
SHAMPOO;TOPICAL
CAPITROL
WESTWOOD SQUIBB 2% N017594 001

CHLORPHENESIN CARBAMATE
TABLET;ORAL
MAOLATE
PHARMACIA AND UPJOHN 400MG N014217 002

CHLORPHENIRAMINE MALEATE
CAPSULE, EXTENDED RELEASE;ORAL
CHLORPHENIRAMINE MALEATE
AUROLIFE PHARMA LLC 12MG A070797 001 Aug 12, 1988
TELDRIN
GLAXOSMITHKLINE 8MG N017369 001
12MG N017369 002
INJECTABLE;INJECTION
CHLOR-TRIMETON
SCHERING PLOUGH 10MG/ML N008826 001
100MG/ML N008794 001
CHLORPHENIRAMINE MALEATE
BEL MAR 10MG/ML A080821 001
ELKINS SINN 10MG/ML A080797 001
WATSON LABS 10MG/ML A083593 001
10MG/ML A086096 001
100MG/ML A086095 001
PYRIDAMAL 100
BEL MAR 100MG/ML A083733 001
SYRUP;ORAL
CHLOR-TRIMETON
SCHERING 2MG/5ML N006921 006
CHLORPHENIRAMINE MALEATE
PHARM ASSOC 2MG/5ML A087520 001 Feb 10, 1982
TABLET;ORAL
ANTAGONATE
BAYER PHARMS 4MG A083381 001
CHLOR-TRIMETON
SCHERING 4MG N006921 002
CHLORPHENIRAMINE MALEATE
ANABOLIC 4MG A083078 001
AUROLIFE PHARMA LLC 4MG A080961 001
BELL PHARMA 4MG A083062 001
ELKINS SINN 4MG A080938 001
IMPAX LABS 4MG A080809 001
IVAX SUB TEVA PHARMS 4MG A080779 001
KV PHARM 4MG A087164 001
LEDERLE 4MG A086941 001
NEWTRON PHARMS 4MG A086519 001
PANRAY 4MG A083243 001
PHARMAVITE 4MG A085104 001
PHARMERAL 4MG A083753 001
PIONEER PHARMS 4MG A088556 001 Jul 13, 1984
PUREPAC PHARM 4MG A086306 001
PVT FORM 4MG A080786 001
ROXANE 4MG A080626 001
SUN PHARM INDS 4MG A080700 001
VITARINE 4MG A085837 001
WATSON LABS 4MG A080696 001
4MG A080791 001
4MG A085139 001
WEST WARD 4MG A083787 001
KLOROMIN
HALSEY 4MG A083629 001

FDA data supplied by DrugPatentWatch.com

CHLORPHENIRAMINE MALEATE
TABLET;ORAL
PHENETRON
LANNETT 4MG A080846 001
TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON
BAYER HEALTHCARE LLC 8MG N007638 001
EFIDAC 24 CHLORPHENIRAMINE MALEATE
ALZA 16MG N019746 002 Nov 18, 1994

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE
TABLET, EXTENDED RELEASE;ORAL
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE
SPRIASO LLC 8MG;54.3MG N206323 001 Jun 22, 2015

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
COLD CAPSULE IV
GRAHAM DM 12MG;75MG N018793 001 Apr 25, 1985
COLD CAPSULE V
GRAHAM DM 8MG;75MG N018794 001 Apr 23, 1985
TABLET, EXTENDED RELEASE;ORAL
TRIAMINIC-12
NOVARTIS 12MG;75MG N018115 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
CODIMAL-L.A. 12
SCHWARZ PHARMA 12MG;120MG N018935 001 Apr 15, 1985
ISOCLOR
FISONS 8MG;120MG N018747 001 Mar 06, 1986
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE
CENT PHARMS 8MG;120MG N019428 001 Aug 02, 1988
GRAHAM DM 8MG;120MG N018844 001 Mar 20, 1985
12MG;120MG N018843 001 Mar 18, 1985
KV PHARM 12MG;120MG A071455 001 Mar 01, 1989

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX
SUSPENSION, EXTENDED RELEASE;ORAL
CODEPREX
UCB INC EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML N021369 001 Jun 21, 2004
PENNTUSS
FISONS EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML N018928 001 Aug 14, 1985

CHLORPHENTERMINE HYDROCHLORIDE
TABLET;ORAL
PRE-SATE
PARKE DAVIS EQ 65MG BASE N014696 001

CHLORPROMAZINE
SUPPOSITORY;RECTAL
THORAZINE
GLAXOSMITHKLINE 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N009149 024
100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N009149 033

CHLORPROMAZINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
THORAZINE
GLAXOSMITHKLINE 30MG N011120 016
75MG N011120 017
150MG N011120 018
200MG N011120 019
300MG N011120 020
CONCENTRATE;ORAL
CHLORPROMAZINE HYDROCHLORIDE
ACTAVIS MID ATLANTIC 100MG/ML A086863 001
PHARM ASSOC 30MG/ML A040231 001 Dec 30, 1999
100MG/ML A040224 001 Jan 26, 1999
WOCKHARDT 30MG/ML A087032 001 Jul 08, 1982
100MG/ML A087053 001

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL				
CHLORPROMAZINE HYDROCHLORIDE INTENSOL				
	CYCLE PHARMS LTD	30MG/ML	A088157 001	Apr 27, 1983
		100MG/ML	A088158 001	Apr 27, 1983
SONAZINE				
	SANDOZ	30MG/ML	A080983 004	
		100MG/ML	A080983 005	
THORAZINE				
	GLAXOSMITHKLINE	30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 032	
		100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 043	
INJECTABLE;INJECTION				
CHLORPROMAZINE HYDROCHLORIDE				
	ABRAXIS PHARM	25MG/ML	A084911 001	
	MARSAM PHARMS LLC	25MG/ML	A089563 001	Apr 15, 1988
	WATSON LABS	25MG/ML	A080365 001	
		25MG/ML	A085591 001	
	WYETH AYERST	25MG/ML	A080370 001	
THORAZINE				
	GLAXOSMITHKLINE	25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 011	
SYRUP;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	10MG/5ML	A086712 001	
SONAZINE				
	SANDOZ	10MG/5ML	A083040 001	
THORAZINE				
	GLAXOSMITHKLINE	10MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 022	
TABLET;ORAL				
CHLORPROMAZINE HYDROCHLORIDE				
	ABBOTT	10MG	A084414 001	
		25MG	A084415 001	
		50MG	A084411 001	
		100MG	A084412 001	
		200MG	A084413 001	
	CYCLE PHARMS LTD	10MG	A085331 001	
		25MG	A085331 002	
		50MG	A085331 003	
		100MG	A085331 004	
		200MG	A085331 005	
	IVAX SUB TEVA PHARMS	10MG	A083549 001	
		25MG	A083549 002	
		50MG	A083549 003	
		100MG	A083574 001	
		200MG	A083575 001	
	KV PHARM	10MG	A085750 002	Jan 04, 1982
		25MG	A085751 001	
		50MG	A085484 001	
		100MG	A085752 001	
		200MG	A085748 002	Jan 04, 1982
	LEDERLE	10MG	A084803 001	
		25MG	A084801 001	
		50MG	A084800 001	
		100MG	A084789 001	
		200MG	A084802 001	
	PUREPAC PHARM	10MG	A080403 004	
		25MG	A080403 001	
		50MG	A080403 002	
		100MG	A080403 003	
		200MG	A080403 005	
	PVT FORM	25MG	A080340 001	
		50MG	A080340 002	
		200MG	A080340 003	

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

SANDOZ	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 001	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 002	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 003	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 004	
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982

PROMAPAR

PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	

THORAZINE

GLAXOSMITHKLINE	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 002	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 007	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 013	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 018	
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 020	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A089446 001	Nov 17, 1986
	250MG	A088813 001	Oct 19, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A089447 001	Nov 17, 1986
AUROLIFE PHARMA LLC	100MG	A088725 001	Aug 31, 1984
	250MG	A088726 001	Aug 31, 1984

FDA data supplied by DrugPatentWatch.com

CHLORPROPAMIDE
TABLET;ORAL
CHLORPROPAMIDE

DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987
HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
SANDOZ	250MG	A084669 001	
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
TEVA PHARMS USA	250MG	A087353 001	
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS INC	100MG	A088852 001	Sep 26, 1984
	250MG	A088826 001	Sep 26, 1984

GLUCAMIDE

ANI PHARMS INC	250MG	A088641 001	Oct 11, 1984

CHLORPROTHIXENE
CONCENTRATE;ORAL
TARACTAN

ROCHE	100MG/5ML	N016149 002	

INJECTABLE;INJECTION
TARACTAN

ROCHE	12.5MG/ML	N012487 001	

TABLET;ORAL
TARACTAN

ROCHE	10MG	N012486 005	
	25MG	N012486 004	
	50MG	N012486 003	
	100MG	N012486 001	

CHLORTETRACYCLINE HYDROCHLORIDE
OINTMENT;OPHTHALMIC
AUREOMYCIN

LEDERLE	1%	N050404 001	

CHLORTHALIDONE
TABLET;ORAL
CHLORTHALIDONE

ABBOTT	25MG	A087364 001	
	50MG	A087384 001	
ASCOT	25MG	A087698 001	Oct 20, 1982
	50MG	A087699 001	Oct 20, 1982
BARR LABS INC	25MG	A088902 001	Sep 19, 1985
	50MG	A088903 001	Sep 19, 1985
DAVA PHARMS INC	25MG	A087451 001	
	50MG	A087450 001	
G AND W LABS INC	50MG	A088651 001	May 30, 1985
IVAX PHARMS	25MG	A087555 001	
	25MG	A088164 001	Jan 09, 1984
	50MG	A087176 001	
	50MG	A087947 001	Feb 27, 1984
KV PHARM	25MG	A087311 001	
	50MG	A087312 001	
MUTUAL PHARM	25MG	A087292 001	
	25MG	A089738 001	Sep 19, 1988
	50MG	A087293 001	
	50MG	A089739 001	Sep 19, 1988
PIONEER PHARMS	50MG	A089591 001	Jul 21, 1988
PUREPAC PHARM	25MG	A088139 001	Jul 16, 1986
	50MG	A088140 001	Aug 11, 1983
SANDOZ	25MG	A087380 001	
	50MG	A087118 001	
	50MG	A087381 001	
SUPERPHARM	25MG	A087473 001	Feb 09, 1983
	50MG	A087247 001	Feb 09, 1983
USL PHARMA	25MG	A089051 001	Jun 01, 1987

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE
TABLET;ORAL
CHLORTHALIDONE

	50MG	A089052 001	Jun 01, 1987
VANGARD	25MG	A088012 001	Jul 14, 1982
	50MG	A088073 001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515 001	Jan 24, 1983
	50MG	A087516 001	Feb 09, 1983
WATSON LABS	25MG	A087050 001	
	25MG	A087100 001	
	25MG	A087296 001	
	25MG	A087706 001	
	50MG	A087029 001	
	50MG	A087082 001	
	50MG	A087521 001	
	50MG	A087689 001	

HYGROTON

SANOFI AVENTIS US	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012283 004	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012283 003	

THALITONE

CASPER PHARMA LLC	15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019574 001	Dec 20, 1988
	25MG	N019574 002	Feb 12, 1992
MONARCH PHARMS	25MG	A088051 001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
TABLET;ORAL
CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG;0.1MG	A071179 001	Dec 16, 1987
	15MG;0.2MG	A071178 001	Dec 16, 1987
	15MG;0.3MG	A071142 001	Dec 16, 1987

COMBIPRES

BOEHRINGER INGELHEIM	15MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017503 001	
	15MG;0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017503 002	
	15MG;0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017503 003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE
CAPSULE;ORAL
LOPRESSIDONE

NOVARTIS	25MG;100MG	N019451 001	Dec 31, 1987
	25MG;200MG	N019451 002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE
TABLET;ORAL
DEMI-REGROTON

SANOFI AVENTIS US	25MG;0.125MG	N015103 002	

REGROTON

SANOFI AVENTIS US	50MG;0.25MG	N015103 001	

CHLORZOXAZONE
TABLET;ORAL
CHLORZOXAZONE

ACTAVIS ELIZABETH	250MG	A088928 001	May 08, 1987
	500MG	A040113 001	Sep 29, 1995
AUROLIFE PHARMA LLC	250MG	A089852 001	May 04, 1988
	500MG	A089853 001	May 04, 1988
OHM LABS	250MG	A081298 001	Dec 29, 1993
	500MG	A081299 001	Dec 29, 1993
PAR PHARM	250MG	A087981 001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592 001	Jan 06, 1989

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE			
	500MG	A089948 001	Jan 06, 1989
SUN PHARM INDS	500MG	A089970 001	Sep 27, 1990
WATSON LABS	250MG	A086901 001	
	250MG	A086948 001	Aug 09, 1982
	500MG	A040137 001	Aug 09, 1996
	500MG	A081019 001	Jul 29, 1991
	500MG	A081040 001	Aug 22, 1989
PARAFLEX			
ORTHO MCNEIL PHARM	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011300 003	
PARAFON FORTE DSC			
JANSSEN R AND D	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011529 002	Jun 15, 1987
STRIFON FORTE DSC			
FERNDALE LABS	500MG	A081008 001	Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE;ORAL

CHOLYBAR			
PARKE DAVIS	EQ 4GM RESIN/BAR	A071621 001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739 001	May 26, 1988

POWDER;ORAL

CHOLESTYRAMINE			
ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554 001	Oct 02, 1996
	EQ 4GM RESIN/SCOOPFUL	A074554 002	Oct 02, 1996
IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771 001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771 002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347 001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347 002	May 28, 1998
CHOLESTYRAMINE LIGHT			
TEVA	EQ 4GM RESIN/PACKET	A074348 001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348 002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555 001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555 002	Sep 30, 1998
LOCHOLEST			
SANDOZ	EQ 4GM RESIN/PACKET	A074561 001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074561 002	Aug 15, 1996
LOCHOLEST LIGHT			
SANDOZ	EQ 4GM RESIN/PACKET	A074562 001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074562 002	Aug 15, 1996
QUESTRAN			
BRISTOL MYERS	EQ 4GM RESIN/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016640 001	
	EQ 4GM RESIN/SCOOPFUL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016640 003	
QUESTRAN LIGHT			
BRISTOL MYERS	EQ 4GM RESIN/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019669 001	Dec 05, 1988
	EQ 4GM RESIN/SCOOPFUL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019669 003	Dec 05, 1988

TABLET;ORAL

QUESTRAN			
APOTHECON	EQ 800MG RESIN	A073403 002	Dec 27, 1999
	EQ 1GM RESIN	A073403 001	Apr 28, 1994

FDA data supplied by DrugPatentWatch.com

CHORIOGONADOTROPIN ALFA
INJECTABLE;INJECTION
OVIDREL

EMD SERONO	0.25MG/VIAL	N021149 001	Sep 20, 2000

CHROMIC CHLORIDE
INJECTABLE;INJECTION
CHROMIC CHLORIDE

ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271 001	May 05, 1987

CHROMIC PHOSPHATE P-32
INJECTABLE;INJECTION
PHOSPHOCOL P32

MALLINKRODT NUCLEAR	5mCi/ML	N017084 001	

CHYMOPAPAIN
INJECTABLE;INJECTION
CHYMODIACTIN

CHART MEDCL	4,000 UNITS/VIAL	N018663 002	Aug 21, 1984
	10,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018663 001	Nov 10, 1982

DISCASE

ABBOTT	12,500 UNITS/VIAL	N018625 001	Jan 18, 1984

CHYMOTRYPSIN
FOR SOLUTION;OPHTHALMIC
ALPHA CHYMAR

SOLA BARNES HIND	750 UNITS/VIAL	N011837 001	

CATARASE

CIBA	300 UNITS/VIAL	N016938 001	
NOVARTIS	150 UNITS/VIAL	N018121 001	

ZOLYSE

ALCON	750 UNITS/VIAL	N011903 001	

CICLOPIROX
SOLUTION;TOPICAL
CICLOPIROX

MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007
TEVA PHARMS	8%	A078079 001	Sep 18, 2007

CIDOFOVIR
INJECTABLE;INJECTION
VISTIDE

GILEAD SCIENCES INC	EQ 75MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020638 001	Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM
INJECTABLE;INJECTION
PRIMAXIN

MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	A062756 001	Jan 08, 1987
	EQ 500MG BASE/VIAL;500MG/VIAL	A062756 002	Jan 08, 1987

POWDER;INTRAMUSCULAR
PRIMAXIN

MERCK	EQ 500MG BASE/VIAL;500MG/VIAL	N050630 001	Dec 14, 1990
	EQ 750MG BASE/VIAL;750MG/VIAL	N050630 002	Dec 14, 1990

CILOSTAZOL
TABLET;ORAL
CILOSTAZOL

ACTAVIS ELIZABETH	100MG	A077028 002	Nov 26, 2004
COREPHARMA	50MG	A077150 001	Mar 11, 2005
	100MG	A077022 001	Nov 23, 2004
FRONTIDA BIOPHARM	50MG	A077208 002	Mar 29, 2006
	100MG	A077208 001	Mar 29, 2006
IVAX SUB TEVA PHARMS	100MG	A077020 002	Mar 01, 2005

PLETAL

OTSUKA	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020863 001	Jan 15, 1999
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020863 002	Jan 15, 1999

CIMETIDINE

SUSPENSION;ORAL

TAGAMET HB 200

GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999

TABLET;ORAL

CIMETIDINE

CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994
	400MG	A074361	002	Dec 23, 1994
	800MG	A074371	001	Dec 23, 1994
DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995
	400MG	A074340	002	Jun 23, 1995
	800MG	A074339	001	Jun 23, 1995
IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	200MG	A074424	001	Jul 28, 1995
	300MG	A074401	002	May 30, 1995
	300MG	A074424	002	Jul 28, 1995
	400MG	A074401	003	May 30, 1995
	400MG	A074424	003	Jul 28, 1995
	800MG	A074402	001	May 30, 1995
	800MG	A074424	004	Jul 28, 1995
LEK PHARMS	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995
	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
PERRIGO	100MG	A074972	001	Jun 19, 1998
PLIVA	200MG	A074568	001	Feb 27, 1997
	300MG	A074568	002	Feb 27, 1997
	400MG	A074568	003	Feb 27, 1997
SANDOZ	200MG	A074100	001	Jan 31, 1995
	300MG	A074100	002	Jan 31, 1995
	400MG	A074100	003	Jan 31, 1995
	800MG	A074100	004	Jan 31, 1995
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995
	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995
UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996
	300MG	A074506	002	Jan 24, 1996
	400MG	A074506	003	Jan 24, 1996
	800MG	A074506	004	Jan 24, 1996
VINTAGE PHARMS LLC	200MG	A074281	001	May 17, 1994
	300MG	A074281	002	May 17, 1994
	400MG	A074281	003	May 17, 1994
	800MG	A074329	001	May 17, 1994
WATSON LABS	200MG	A075425	001	Jul 29, 1999
WATSON LABS INC	200MG	A074349	001	Aug 30, 1996
	300MG	A074349	002	Aug 30, 1996
	400MG	A074349	003	Aug 30, 1996
	800MG	A074316	001	Feb 28, 1996

TAGAMET

GLAXOSMITHKLINE	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017920	002	
	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017920	003	
	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017920	004	Dec 14, 1983
	800MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017920	005	Apr 30, 1986

TAGAMET HB

MEDTECH PRODUCTS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020238	001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422 001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353 001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252 001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 6MG BASE/ML	A074269 001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468 005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468 006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468 003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468 004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468 001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468 002	Dec 29, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017939 002	

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 6MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019434 001	Oct 31, 1985

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

ANI PHARMS INC	EQ 300MG BASE/5ML	A074859 001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110 001	Jun 18, 1998
APOTEX INC	EQ 300MG BASE/5ML	A075560 001	Mar 15, 2000
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541 001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML	A074176 001	Jun 01, 1994
VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017924 001	

CINOXACIN

CAPSULE;ORAL

CINOBAC

LILLY	250MG	N018067 001	
	500MG	N018067 002	

CINOXACIN

TEVA	250MG	A073005 001	Feb 28, 1992
	500MG	A073006 001	Feb 28, 1992

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPRO

BAYER HLTHCARE	1200MG/120ML (10MG/ML)	N019847 003	Dec 26, 1990

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS	200MG/100ML	N019858 001	Dec 26, 1990

CIPROFLOXACIN

BEDFORD LABS	200MG/20ML (10MG/ML)	A076992 001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076992 002	Aug 28, 2006
	1200MG/120ML (10MG/ML)	A076993 001	Aug 28, 2006
FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484 001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076484 002	Aug 28, 2006
TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA	200MG/100ML	A076757 001	Apr 21, 2008

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008
	400MG/200ML	A077888 002	Mar 18, 2008
BEDFORD	200MG/100ML	A078114 001	Mar 18, 2008
	400MG/200ML	A078114 002	Mar 18, 2008
TEVA PHARMS	200MG/100ML	A077138 001	Mar 18, 2008
	400MG/200ML	A077138 002	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC			
CIPROFLOXACIN HYDROCHLORIDE			
APOTEX INC	EQ 0.3% BASE	A075928 001	Jun 09, 2004
TABLET;ORAL			
CIPROFLOXACIN HYDROCHLORIDE			
BARR	EQ 250MG BASE	A074124 001	Jun 09, 2004
	EQ 500MG BASE	A074124 002	Jun 09, 2004
	EQ 750MG BASE	A074124 003	Jun 09, 2004
IDT AUSTRALIA LTD	EQ 100MG BASE	A075939 001	Mar 03, 2005
	EQ 250MG BASE	A075939 002	Jun 09, 2004
	EQ 500MG BASE	A075939 003	Jun 09, 2004
	EQ 750MG BASE	A075939 004	Jun 09, 2004
NOSTRUM LABS	EQ 250MG BASE	A076138 001	Jun 09, 2004
	EQ 500MG BASE	A076138 002	Jun 09, 2004
	EQ 750MG BASE	A076138 003	Jun 09, 2004
PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005
	EQ 250MG BASE	A076426 002	Jun 15, 2005
	EQ 500MG BASE	A076426 003	Jun 15, 2005
	EQ 750MG BASE	A076426 004	Jun 15, 2005
SANDOZ	EQ 250MG BASE	A076593 002	Jun 09, 2004
	EQ 500MG BASE	A076593 003	Jun 09, 2004
	EQ 750MG BASE	A076593 004	Jun 09, 2004
TEVA	EQ 250MG BASE	A076136 001	Jun 09, 2004
	EQ 500MG BASE	A076136 002	Jun 09, 2004
	EQ 750MG BASE	A076136 003	Jun 09, 2004
TABLET, EXTENDED RELEASE;ORAL			
PROQUIN XR			
DEPOMED INC	EQ 500MG BASE	N021744 001	May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL			
CIPRO XR			
BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE	N021473 001	Dec 13, 2002
	425.2MG;EQ 574.9MG BASE	N021473 002	Aug 28, 2003
CIPROFLOXACIN EXTENDED RELEASE			
ACTAVIS LABS FL INC	212.6MG;EQ 287.5MG BASE	A077417 001	Nov 30, 2010
	425.2MG;EQ 574.9MG BASE	A077809 001	Nov 30, 2010
DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007
SANDOZ	212.6MG;EQ 287.5MG BASE	A078712 001	Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION;ORAL			
PROPULSID			
JANSSEN PHARMS	EQ 1MG BASE/ML	N020398 001	Sep 15, 1995
TABLET;ORAL			
PROPULSID			
JANSSEN PHARMS	EQ 10MG BASE	N020210 001	Jul 29, 1993
	EQ 20MG BASE	N020210 002	Dec 23, 1993
TABLET, ORALLY DISINTEGRATING;ORAL			
PROPULSID QUICKSOLV			
JANSSEN PHARMA	EQ 20MG BASE	N020767 001	Nov 07, 1997

CISPLATIN

INJECTABLE;INJECTION			
CISPLATIN			
BEDFORD	10MG/VIAL	A074713 001	Nov 14, 2000
	50MG/VIAL	A074713 002	Nov 14, 2000
TEVA PHARMS USA	1MG/ML	A074814 001	May 16, 2000
PLATINOL			
HQ SPCLT PHARMA	10MG/VIAL	N018057 001	
	50MG/VIAL	N018057 002	
PLATINOL-AQ			
HQ SPCLT PHARMA	0.5MG/ML	N018057 003	Jul 18, 1984

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL			
CELEXA			
FOREST LABS	EQ 10MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021046 001	Dec 22, 1999
CITALOPRAM HYDROBROMIDE			
APOTEX INC	EQ 10MG BASE/5ML	A077601 001	Nov 15, 2005

FDA data supplied by DrugPatentWatch.com

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

FOREST LABS	EQ 60MG BASE	N020822 004	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 10MG BASE	A077033 001	Oct 28, 2004
	EQ 20MG BASE	A077033 002	Oct 28, 2004
	EQ 40MG BASE	A077033 003	Oct 28, 2004
COREPHARMA	EQ 10MG BASE	A077036 001	Oct 28, 2004
	EQ 20MG BASE	A077036 002	Oct 28, 2004
	EQ 40MG BASE	A077036 003	Oct 28, 2004
NATCO PHARMA LTD	EQ 20MG BASE	A077141 002	Apr 10, 2008
	EQ 40MG BASE	A077141 001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041 001	Nov 23, 2004
	EQ 20MG BASE	A077041 002	Nov 23, 2004
	EQ 40MG BASE	A077041 003	Nov 23, 2004
SANDOZ	EQ 10MG BASE	A077035 001	Oct 28, 2004
	EQ 10MG BASE	A077040 001	Aug 17, 2005
	EQ 20MG BASE	A077035 002	Oct 28, 2004
	EQ 20MG BASE	A077040 002	Aug 17, 2005
	EQ 40MG BASE	A077035 003	Oct 28, 2004
	EQ 40MG BASE	A077040 003	Aug 17, 2005
SUN PHARM INDS	EQ 10MG BASE	A077052 001	Jul 03, 2006
	EQ 20MG BASE	A077052 002	Jul 03, 2006
	EQ 40MG BASE	A077052 003	Jul 03, 2006
TARO	EQ 10MG BASE	A077278 001	Mar 22, 2006
	EQ 20MG BASE	A077278 002	Mar 22, 2006
	EQ 40MG BASE	A077278 003	Mar 22, 2006
TEVA PHARMS	EQ 10MG BASE	A077213 001	Mar 31, 2006
	EQ 20MG BASE	A077213 002	Mar 31, 2006
	EQ 40MG BASE	A077213 003	Mar 31, 2006
WATSON LABS	EQ 10MG BASE	A077034 001	Jun 30, 2005
	EQ 20MG BASE	A077034 002	Jun 30, 2005
	EQ 40MG BASE	A077034 003	Jun 30, 2005

TABLET, ORALLY DISINTEGRATING;ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL	EQ 10MG BASE	N021763 001	Dec 20, 2005
	EQ 20MG BASE	N021763 002	Dec 20, 2005
	EQ 40MG BASE	N021763 003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION;IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519 001	Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904 001	May 27, 1983

CLADRIBINE

INJECTABLE;INJECTION

LEUSTATIN

JANSSEN PHARMS	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020229 001	Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION;ORAL

BIAXIN

ABBVIE	187MG/5ML	N050698 003	Sep 30, 1998

TABLET;ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS	250MG	A065137 001	May 31, 2005
	500MG	A065137 002	May 31, 2005

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

ABBVIE	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050775 001	Mar 03, 2000

CLARITHROMYCIN

IDT AUSTRALIA LTD	500MG	A065250 001	Aug 25, 2005
RANBAXY	1GM	A065210 001	Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION				
TIMENTIN				
GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
	EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985
	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
TIMENTIN IN PLASTIC CONTAINER				
GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP;ORAL				
CLEMASTINE FUMARATE				
ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993
APOTEX INC	EQ 0.5MG BASE/5ML	A075703	001	Nov 27, 2000
SILARX	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997
TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095	001	Apr 21, 1992
TAVIST				
NOVARTIS	EQ 0.5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018675	001	Jun 28, 1985
TABLET;ORAL				
CLEMASTINE FUMARATE				
ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992
	1.34MG	A073282	002	Dec 03, 1992
TAVIST				
NOVARTIS	2.68MG	N017661	001	
TAVIST-1				
NOVARTIS	1.34MG	N017661	002	
	1.34MG	N017661	003	Aug 21, 1992

CLIDINIUM BROMIDE

CAPSULE;ORAL				
QUARZAN				
ROCHE	2.5MG	N010355	001	
	5MG	N010355	002	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE	A061809	001	
	EQ 150MG BASE	A061809	002	
CLINDAMYCIN HYDROCHLORIDE				
TEVA	EQ 75MG BASE	A063027	001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE	A063082	001	Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061827	001	

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 2% BASE	N050680	001	Aug 11, 1992
INJECTABLE;INJECTION				
CLEOCIN PHOSPHATE				
PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A061839	001	
CLINDAMYCIN PHOSPHATE				
ABRAXIS PHARM	EQ 150MG BASE/ML	A062747	001	Jun 03, 1988
BEDFORD	EQ 150MG BASE/ML	A063163	001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	A062908	001	Feb 01, 1989
IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989
LOCH	EQ 150MG BASE/ML	A062905	001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913	001	Oct 20, 1988
SOLOPAK	EQ 150MG BASE/ML	A062819	001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852	001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041	001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282	001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900	001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079	001	Mar 05, 1990
WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE
INJECTABLE;INJECTION
CLINDAMYCIN PHOSPHATE

	EQ 150MG BASE/ML	A062953 001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068 001	Aug 28, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM	EQ 12MG BASE/ML	N050636 001	Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE	EQ 6MG BASE/ML	A065027 001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027 002	Jun 29, 2001
	EQ 18MG BASE/ML	A065027 003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648 001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648 002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648 003	Dec 29, 1989

SOLUTION;TOPICAL
CLEOCIN T

PHARMACIA AND UPJOHN	EQ 1% BASE	A062363 001	Feb 08, 1982

CLINDAMYCIN PHOSPHATE

BOCA PHARMA LLC	EQ 1% BASE	A062944 001	Jan 11, 1989
INGENUS PHARMS LLC	EQ 1% BASE	A064108 001	Sep 27, 1996
VINTAGE PHARMS	EQ 1% BASE	A062930 001	Jun 28, 1989

CLIOQUINOL; NYSTATIN
OINTMENT;TOPICAL
NYSTAFORM

BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235 001	

CLOBAZAM
TABLET;ORAL
ONFI

LUNDBECK LLC	5MG	N202067 001	Oct 21, 2011

CLOBETASOL PROPIONATE
CREAM;TOPICAL
CLOBETASOL PROPIONATE

RENAISSANCE PHARMA	0.05%	A075338 001	Feb 09, 2001
TEVA PHARMS USA	0.05%	A074087 001	Feb 16, 1994

CLOBETASOL PROPIONATE (EMOLLIENT)

INGENUS PHARMS LLC	0.05%	A075733 001	Aug 22, 2001

TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019322 001	Dec 27, 1985

TEMOVATE E

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020340 001	Jun 17, 1994

GEL;TOPICAL
TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020337 001	Apr 29, 1994

OINTMENT;TOPICAL
CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC	0.05%	A074128 001	Aug 03, 1994
RENAISSANCE PHARMA	0.05%	A075057 001	Aug 12, 1998

TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019323 001	Dec 27, 1985

SOLUTION;TOPICAL
TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019966 001	Feb 22, 1990

CLOFAZIMINE
CAPSULE;ORAL
LAMPRENE

NOVARTIS	100MG	N019500 001	Dec 15, 1986

CLOFIBRATE
CAPSULE;ORAL
ATROMID-S

WYETH AYERST	500MG	N016099 002	

CLOFIBRATE

BANNER PHARMACAPS	500MG	A073396 001	Mar 20, 1992
SANDOZ	500MG	A072191 001	May 02, 1988
TEVA	500MG	A072600 001	Jul 25, 1991
USL PHARMA	500MG	A070531 001	Jun 16, 1986
WATSON LABS	500MG	A071603 001	Sep 18, 1987

CLOMIPHENE CITRATE
TABLET;ORAL
MILOPHENE

MILEX	50MG	A072196 001	Dec 20, 1988

SEROPHENE

EMD SERONO	50MG	N018361 001	Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE;ORAL
CLOMIPRAMINE HYDROCHLORIDE

SANDOZ	25MG	A074953 001	Jun 25, 1997
	50MG	A074953 002	Jun 25, 1997
	75MG	A074953 003	Jun 25, 1997
TEVA	25MG	A074849 001	Apr 04, 1997
	50MG	A074849 002	Apr 04, 1997
	75MG	A074849 003	Apr 04, 1997
WATSON LABS	25MG	A074600 001	Nov 27, 1996
	25MG	A074751 001	Sep 30, 1998
	50MG	A074600 002	Nov 27, 1996
	50MG	A074751 002	Sep 30, 1998
	75MG	A074600 003	Nov 27, 1996
	75MG	A074751 003	Sep 30, 1998

CLONAZEPAM
TABLET;ORAL
CLONAZEPAM

APOTEX INC	0.5MG	A075468 001	Oct 06, 2000
	1MG	A075468 002	Oct 06, 2000
	2MG	A075468 003	Oct 06, 2000
SANDOZ	0.5MG	A074925 001	Sep 30, 1997
	1MG	A074925 002	Sep 30, 1997
	2MG	A074925 003	Sep 30, 1997
TEVA	0.5MG	A074920 001	Aug 04, 1998
	1MG	A074920 002	Aug 04, 1998
	2MG	A074920 003	Aug 04, 1998

KLONOPIN

ROCHE	0.125MG	N017533 005	Apr 09, 1997
	0.25MG	N017533 006	Apr 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL
KLONOPIN RAPIDLY DISINTEGRATING

ROCHE	0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020813 001	Dec 23, 1997
	0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020813 002	Dec 23, 1997
	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020813 003	Dec 23, 1997
	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020813 004	Dec 23, 1997
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020813 005	Dec 23, 1997

FDA data supplied by DrugPatentWatch.com

CLONIDINE
SUSPENSION, EXTENDED RELEASE;ORAL
CLONIDINE

TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE

TRIS PHARMA INC	EQ 0.17MG BASE	N022500	001	Dec 03, 2009
	EQ 0.26MG BASE	N022500	002	Dec 03, 2009

CLONIDINE HYDROCHLORIDE
TABLET;ORAL
CLONIDINE HYDROCHLORIDE

AM THERAP	0.1MG	A070881	001	Jul 08, 1986
	0.2MG	A070882	001	Jul 08, 1986
	0.3MG	A070883	001	Jul 08, 1986
AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988
	0.2MG	A070886	001	Aug 31, 1988
	0.3MG	A071294	001	Aug 31, 1988
CHARTWELL MOLECULES	0.2MG	A071784	001	Apr 05, 1988
DAVA PHARMS INC	0.1MG	A071783	001	Apr 05, 1988
	0.3MG	A071785	001	Apr 05, 1988
DURAMED PHARMS BARR	0.1MG	A071103	001	Aug 14, 1986
	0.2MG	A071102	001	Aug 14, 1986
	0.3MG	A071101	001	Aug 14, 1986
INTERPHARM	0.1MG	A071252	001	Oct 01, 1986
	0.2MG	A071253	001	Oct 01, 1986
	0.3MG	A071254	001	Oct 01, 1986
PAR PHARM	0.1MG	A070461	001	Jul 08, 1986
	0.2MG	A070460	001	Jul 08, 1986
	0.3MG	A070459	001	Jul 08, 1986
TEVA	0.1MG	A070747	001	Jul 08, 1986
	0.2MG	A070702	001	Jul 08, 1986
	0.3MG	A070659	001	Jul 08, 1986
WARNER CHILCOTT	0.1MG	A072138	001	Jun 13, 1988
	0.2MG	A072139	001	Jun 13, 1988
	0.3MG	A072140	001	Jun 13, 1988
WATSON LABS	0.1MG	A070395	001	Mar 23, 1987
	0.1MG	A070965	001	Jul 08, 1986
	0.2MG	A070396	001	Mar 23, 1987
	0.2MG	A070964	001	Jul 08, 1986
	0.3MG	A070397	001	Mar 23, 1987
	0.3MG	A070963	001	Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	0.2MG	A202792	002	May 15, 2015
	0.2MG	A203320	002	May 15, 2015
ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014
	0.2MG	A202983	002	Apr 02, 2014

CLONIDINE HYDROCHLORIDE

ANCHEN PHARMS	0.2MG	A202984	002	Sep 30, 2013

JENLOGA

CONCORDIA PHARMS INC	0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022331	001	Sep 30, 2009
	0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022331	002	May 25, 2010

KAPVAY

CONCORDIA PHARMS INC	0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022331	004	Sep 28, 2010

CLOPIDOGREL BISULFATE
TABLET;ORAL
CLOPIDOGREL BISULFATE

ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777	001	Jul 14, 1987
	7.5MG	A071778	001	Jul 14, 1987
	15MG	A071779	001	Jul 14, 1987
AM THERAP	3.75MG	A071429	001	Jun 23, 1987
	7.5MG	A071430	001	Jun 23, 1987
	15MG	A071431	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072219	001	Aug 26, 1988
	7.5MG	A072220	001	Aug 26, 1988
	15MG	A072112	001	Aug 26, 1988
DAVA PHARMS INC	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988

TRANXENE

RECORDATI RARE	3.75MG	N017105	001
	7.5MG	N017105	002
	15MG	N017105	003

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072512	001	May 11, 1990
	7.5MG	A072513	001	May 11, 1990
	15MG	A072514	001	May 11, 1990
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
	7.5MG	A071853	001	Feb 09, 1988
	15MG	A071854	001	Feb 09, 1988

TRANXENE

RECORDATI RARE	3.75MG	N017105	006

TRANXENE SD

RECORDATI RARE	11.25MG	N017105	005
	22.5MG	N017105	004

FDA data supplied by DrugPatentWatch.com

CLOTRIMAZOLE

CREAM;TOPICAL			
LOTRIMIN			
SCHERING PLOUGH	1%	N017619 001	
MYCELEX			
BAYER HEALTHCARE LLC	1%	N018183 001	
LOTION;TOPICAL			
LOTRIMIN			
SCHERING	1%	N018813 001	Feb 17, 1984
SOLUTION;TOPICAL			
LOTRIMIN			
SCHERING PLOUGH	1%	N017613 001	
MYCELEX			
BAYER HLTHCARE	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018181 001	
TABLET;VAGINAL			
GYNIX			
TEVA PHARMS	100MG	A073249 001	Feb 13, 1998
MYCELEX-G			
BAYER PHARMS	500MG	N019069 001	Apr 19, 1985
TROCHE/LOZENGE;ORAL			
MYCELEX			
BAYER HLTHCARE	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018713 001	Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE;ORAL			
CLOXACILLIN SODIUM			
APOTHECON	EQ 250MG BASE	A061452 001	
	EQ 500MG BASE	A061452 002	
TEVA	EQ 250MG BASE	A062240 001	
	EQ 500MG BASE	A062240 002	
CLOXAPEN			
GLAXOSMITHKLINE	EQ 250MG BASE	A061806 001	
	EQ 250MG BASE	A062233 001	
	EQ 500MG BASE	A061806 002	
	EQ 500MG BASE	A062233 002	
FOR SOLUTION;ORAL			
CLOXACILLIN SODIUM			
TEVA	EQ 125MG BASE/5ML	A062268 001	
	EQ 125MG BASE/5ML	A062978 001	Apr 06, 1989
TEGOPEN			
APOTHECON	EQ 125MG BASE/5ML	A061453 001	
	EQ 125MG BASE/5ML	N050192 001	

CLOZAPINE

TABLET;ORAL			
CLOZAPINE			
PAR PHARM	25MG	A075162 001	Apr 26, 2005
	100MG	A075162 002	Apr 26, 2005
SANDOZ	25MG	A074546 001	Aug 30, 1996
	100MG	A074546 002	Aug 30, 1996
TABLET, ORALLY DISINTEGRATING;ORAL			
FAZACLO ODT			
JAZZ PHARMS III	50MG	N021590 003	Jun 03, 2005

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A;N/A			
RUBRATOPE-57 KIT			
BRACCO	N/A;N/A;N/A;N/A	N016089 001	

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A;N/A			
RUBRATOPE-60 KIT			
BRACCO	N/A;N/A;N/A;N/A	N016090 001	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC W/ CODEINE

ANI PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008306 005	Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY	10MG/5ML;5MG/5ML;6.25MG/5ML	A088870 001	Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI	10MG/5ML;5MG/5ML;6.25MG/5ML	A088816 001	Nov 22, 1985
WOCKHARDT	10MG/5ML;5MG/5ML;6.25MG/5ML	A088896 001	Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

ANI PHARMS	10MG/5ML;6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008306 004	Apr 02, 1984

PHERAZINE W/ CODEINE

HALSEY	10MG/5ML;6.25MG/5ML	A088739 001	Dec 23, 1988

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647 001	Dec 22, 1988

PROMETHAZINE W/ CODEINE

CENCI	10MG/5ML;6.25MG/5ML	A088814 001	Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE

GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML	N012575 003	Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018 001	Jul 23, 1986

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833 001	Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

ROXANE	30MG/5ML	N202245 001	Jun 30, 2011

COLCHICINE; PROBENECID

TABLET;ORAL

COLBENEMID

MERCK	0.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012383 001	

PROBEN-C

WATSON LABS	0.5MG;500MG	A085552 001	

PROBENECID AND COLCHICINE

ANI PHARMS INC	0.5MG;500MG	A083734 001	
BEECHAM	0.5MG;500MG	A084321 001	
IMPAX LABS	0.5MG;500MG	A083720 002	
SANDOZ	0.5MG;500MG	A086130 001	

PROBENECID W/ COLCHICINE

LEDERLE	0.5MG;500MG	A086954 001	
WATSON LABS	0.5MG;500MG	A083221 001	

COLESEVELAM HYDROCHLORIDE

CAPSULE;ORAL

WELCHOL

DAIICHI SANKYO	375MG	N021141 001	May 26, 2000

COLISTIN SULFATE

SUSPENSION;ORAL

COLY-MYCIN S

PARKE DAVIS	EQ 25MG BASE/5ML	N050355 001	

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;IV (INFUSION)

VAPRISOL

CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697 001	Dec 29, 2005

FDA data supplied by DrugPatentWatch.com

COPPER
INTRAUTERINE DEVICE;INTRAUTERINE
CU-7
GD SEARLE LLC 89MG N017408 001
TATUM-T
GD SEARLE LLC 120MG N018205 001

CORTICOTROPIN
INJECTABLE;INJECTION
ACTH
PARKEDALE 25 UNITS/VIAL N008317 002
40 UNITS/VIAL N008317 004
ACTHAR
SANOFI AVENTIS US 25 UNITS/VIAL N007504 002
40 UNITS/VIAL N007504 003
CORTICOTROPIN
ORGANICS LAGRANGE 40 UNITS/ML N010831 001
80 UNITS/ML N010831 002
WATSON LABS 40 UNITS/VIAL A088772 001 Nov 21, 1984
H.P. ACTHAR GEL
MALLINCKRODT ARD 40 UNITS/ML N008372 006
PURIFIED CORTROPHIN GEL
ANI PHARMS 40 UNITS/ML N008975 001
80 UNITS/ML N008975 002

CORTICOTROPIN-ZINC HYDROXIDE
INJECTABLE;INJECTION
CORTROPHIN-ZINC
ANI PHARMS 40 UNITS/ML N009854 001

CORTISONE ACETATE
INJECTABLE;INJECTION
CORTISONE ACETATE
PHARMACIA AND UPJOHN 25MG/ML N008126 002
WATSON LABS 25MG/ML A083147 003
25MG/ML A085677 001
50MG/ML A083147 004
50MG/ML A085677 002
CORTONE
MERCK 25MG/ML N007110 002
50MG/ML N007110 003
TABLET;ORAL
CORTISONE ACETATE
BARR 25MG A083471 001
ELKINS SINN 25MG A080836 001
EVERYLIFE 25MG A084246 001
HEATHER 25MG A085736 001
IMPAX LABS 25MG N009458 001
INWOOD LABS 25MG A080731 001
IVAX SUB TEVA PHARMS 25MG A080630 001
25MG A083536 001
LANNETT 25MG A080694 001
PANRAY 5MG N008284 002
25MG N008284 001
PHARMACIA AND UPJOHN 5MG N008126 003
10MG N008126 004
25MG N008126 001
PUREPAC PHARM 25MG A080493 001
VITARINE 25MG A080333 001
WATSON LABS 25MG A085884 001
WHITEWORTH TOWN PLSN 25MG A080341 001
CORTONE
MERCK 25MG N007750 003

COSYNTROPIN
SOLUTION;INTRAVENOUS
COSYNTROPIN
SANDOZ 0.25MG/ML (0.25MG/ML) N022028 001 Feb 21, 2008

FDA data supplied by DrugPatentWatch.com

CROMOLYN SODIUM

AEROSOL, METERED;INHALATION			
INTAL			
KING PFIZER	0.8MG/INH	N018887 001	Dec 05, 1985
CAPSULE;INHALATION			
INTAL			
SANOFI AVENTIS US	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016990 001	
CAPSULE;ORAL			
GASTROCROM			
UCB INC	100MG	N019188 001	Dec 22, 1989
CONCENTRATE;ORAL			
CROMOLYN SODIUM			
GENERA PHARMS	100MG/5ML	A090954 001	Dec 18, 2009
SOLUTION;INHALATION			
CROMOLYN SODIUM			
ACTAVIS MID ATLANTIC	10MG/ML	A075067 001	Jul 19, 1999
APOTEX INC	10MG/ML	A075333 001	Apr 30, 2002
PHARMASCIENCE INC	10MG/ML	A075437 001	Apr 21, 2000
ROXANE	10MG/ML	A075175 001	Sep 30, 1999
WATSON LABS	10MG/ML	A076469 001	Jun 17, 2005
INTAL			
KING PHARMS	10MG/ML	N018596 001	May 28, 1982
SOLUTION/DROPS;OPHTHALMIC			
CROMOLYN SODIUM			
APOTEX INC	4%	A075615 001	Jan 26, 2001
CROMOPTIC			
KING PHARMS	4%	A075088 001	Apr 27, 1999
OPTICROM			
ALLERGAN	4% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018155 001	Oct 03, 1984
SPRAY, METERED;NASAL			
CROMOLYN SODIUM			
ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800 001	Jul 26, 2001
HH AND P	5.2MG/SPRAY	A077976 001	Sep 07, 2007
NASALCROM			
BLACKSMITH BRANDS	5.2MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020463 001	Jan 03, 1997

CRYPTENAMINE ACETATES

INJECTABLE;INJECTION			
UNITENSEN			
MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814 001	

CRYPTENAMINE TANNATES

TABLET;ORAL			
UNITENSEN			
MEDPOINTE PHARM HLC	260CSR UNIT	N009217 001	

CUPRIC SULFATE

INJECTABLE;INJECTION			
CUPRIC SULFATE			
ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350 001	May 05, 1987

CYANOCOBALAMIN

GEL, METERED;NASAL			
NASCOBAL			
PAR PHARM	0.5MG/INH	N019722 001	Nov 05, 1996
INJECTABLE;INJECTION			
BERUBIGEN			
PHARMACIA AND UPJOHN	1MG/ML	N006798 001	
BETALIN 12			
LILLY	0.1MG/ML	A080855 001	
	1MG/ML	A080855 002	
COBAVITE			
WATSON LABS	0.1MG/ML	A083013 001	
	1MG/ML	A083064 001	
CYANOCOBALAMIN			
ABRAXIS PHARM	0.03MG/ML	A080510 003	
	0.1MG/ML	A080510 001	

FDA data supplied by DrugPatentWatch.com

CYANOCOBALAMIN
INJECTABLE;INJECTION
CYANOCOBALAMIN

	1MG/ML	A080510 002	
AKORN	1MG/ML	A087969 001	Nov 10, 1983
DELL LABS	0.03MG/ML	A080689 001	
	0.1MG/ML	A080689 002	
	1MG/ML	A080689 003	
FRESENIUS KABI USA	0.1MG/ML	A080557 002	
LUITPOLD	0.03MG/ML	A080668 001	
LYPHOMED	1MG/ML	A083075 001	
MYLAN INSTITUTIONAL	1MG/ML	A040451 001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564 001	
SOLOPAK	1MG/ML	A087551 001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085 002	
WATSON LABS	0.1MG/ML	A080573 002	
	0.1MG/ML	A083120 001	
	1MG/ML	A080573 001	
	1MG/ML	A083120 002	
WYETH AYERST	0.1MG/ML	A080554 001	
	1MG/ML	A080554 002	

DODEX

ORGANON SUB MERCK	1MG/ML	A083022 001	

REDISOL

MERCK	1MG/ML	N006668 010	

RUBIVITE

BEL MAR	0.03MG/ML	N010791 004	
	0.05MG/ML	N010791 001	
	0.1MG/ML	N010791 002	
	0.12MG/ML	N010791 005	
	1MG/ML	N010791 003	

RUBRAMIN PC

BRISTOL MYERS SQUIBB	0.1MG/ML	N006799 002	
	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006799 004	
	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006799 010	Apr 28, 1988

RUVITE

SAVAGE LABS	1MG/ML	A080570 002	

VI-TWEL

BAYER HLTHCARE	1MG/ML	N007012 002	

SPRAY, METERED;NASAL
CALOMIST

PAR PHARM	25MCG/SPRAY	N022102 001	Jul 27, 2007

TABLET;ORAL
CYANOCOBALAMIN

WEST WARD	1MG	A084264 001	

CYANOCOBALAMIN CO-57
CAPSULE;ORAL
RUBRATOPE-57

BRACCO	0.5-1uCi	N016089 002	

CYANOCOBALAMIN CO-60
CAPSULE;ORAL
RUBRATOPE-60

BRACCO	0.5-1uCi	N016090 002	

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58
N/A;N/A
DICOPAC KIT

GE HEALTHCARE	N/A;N/A;N/A	N017406 001	

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR
N/A;N/A
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT	0.1MG;0.5uCi;60MG	N016635 001	

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE;INJECTION				
DEPINAR				
	ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N011208 001	

CYCLACILLIN

FOR SUSPENSION;ORAL				
CYCLAPEN-W				
	WYETH AYERST	125MG/5ML	N050508 001	
		250MG/5ML	N050508 002	
		500MG/5ML	N050508 003	
TABLET;ORAL				
CYCLACILLIN				
	TEVA	250MG	A062895 001	Aug 04, 1988
		500MG	A062895 002	Aug 04, 1988
CYCLAPEN-W				
	WYETH AYERST	250MG	N050509 001	
		500MG	N050509 002	

CYCLIZINE LACTATE

INJECTABLE;INJECTION				
MAREZINE				
	GLAXOSMITHKLINE	50MG/ML	N009495 001	

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
CYCLOBENZAPRINE HYDROCHLORIDE				
	TWI PHARMS INC	15MG	A091281 001	Jan 31, 2013
		30MG	A091281 002	Jan 31, 2013
TABLET;ORAL				
CYCLOBENZAPRINE HYDROCHLORIDE				
	OXFORD PHARMS	5MG	A077291 001	Feb 03, 2006
	SANDOZ	10MG	A073683 001	Feb 26, 1993
	UPSHER-SMITH LABS	5MG	A072854 002	Feb 03, 2006
		10MG	A072854 001	Nov 19, 1991
	WATSON LABS	10MG	A073143 001	Nov 27, 1991
		10MG	A074436 001	Nov 30, 1994
FLEXERIL				
	JANSSEN RES AND DEV	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017821 001	
		10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017821 002	

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
AK-PENTOLATE				
	AKORN	1%	A085555 001	
AKPENTOLATE				
	AKORN	2%	A040165 001	Jan 13, 1997
CYCLOPENTOLATE HYDROCHLORIDE				
	ALCON PHARMS LTD	1%	A089162 001	Jan 24, 1991
	SOLA BARNES HIND	1%	A084150 001	
		1%	A084863 001	
PENTOLAIR				
	PHARMAFAIR	0.5%	A088643 001	Feb 09, 1987
		1%	A088150 001	Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE;INJECTION				
CYCLOPHOSPHAMIDE				
	BAXTER HLTHCARE	100MG/VIAL	A088371 001	Jul 03, 1986
		200MG/VIAL	A088372 001	Jul 03, 1986
		500MG/VIAL	A088373 001	Jul 03, 1986
		1GM/VIAL	A088374 001	Sep 24, 1986
CYTOXAN				
	BAXTER HLTHCARE	100MG/VIAL	N012142 001	
		200MG/VIAL	N012142 002	
CYTOXAN (LYOPHILIZED)				
	BAXTER HLTHCARE	500MG/VIAL	N012142 003	
		500MG/VIAL	N012142 008	Jan 04, 1984
		1GM/VIAL	N012142 004	Aug 30, 1982
		1GM/VIAL	N012142 010	Sep 24, 1985

CYCLOPHOSPHAMIDE
INJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)

	2GM/VIAL	N012142 005	Aug 30, 1982
	2GM/VIAL	N012142 009	Dec 10, 1985

LYOPHILIZED CYTOXAN

BAXTER HLTHCARE	100MG/VIAL	N012142 006	Dec 05, 1985
	200MG/VIAL	N012142 007	Dec 10, 1985

NEOSAR

BEDFORD	100MG/VIAL	A087442 001	Feb 16, 1982
	200MG/VIAL	A087442 002	Feb 16, 1982
	500MG/VIAL	A087442 003	Feb 16, 1982
	1GM/VIAL	A087442 004	Jul 08, 1983
	2GM/VIAL	A087442 005	Mar 30, 1989
TEVA PARENTERAL	100MG/VIAL	A040015 001	Apr 29, 1993
	200MG/VIAL	A040015 002	Apr 29, 1993
	500MG/VIAL	A040015 003	Apr 29, 1993
	1GM/VIAL	A040015 004	Apr 29, 1993
	2GM/VIAL	A040015 005	Apr 29, 1993

TABLET;ORAL
CYCLOPHOSPHAMIDE

ROXANE	25MG	A040032 001	Aug 17, 1999
	50MG	A040032 002	Aug 17, 1999

CYTOXAN

BAXTER HLTHCARE	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012141 002	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012141 001	

CYCLOSPORINE
CAPSULE;ORAL
NEORAL

NOVARTIS	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050715 003	Jul 14, 1995

SOLUTION;ORAL
CYCLOSPORINE

APOTEX INC	100MG/ML	A065167 001	Jan 05, 2005

CYCLOTHIAZIDE
TABLET;ORAL
ANHYDRON

LILLY	2MG	N013157 002	

FLUIDIL

PHARMACIA AND UPJOHN	2MG	N018173 001	

CYCRIMINE HYDROCHLORIDE
TABLET;ORAL
PAGITANE

LILLY	1.25MG	N008951 001	
	2.5MG	N008951 002	

CYPROHEPTADINE HYDROCHLORIDE
SYRUP;ORAL
CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	2MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A086833 001	
HALSEY	2MG/5ML	A089199 001	Jul 03, 1986
MORTON GROVE	2MG/5ML	A087001 001	Nov 04, 1982
NASKA	2MG/5ML	A089021 001	Dec 21, 1987

PERIACTIN

MERCK	2MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013220 002	

TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AM THERAP	4MG	A088798 001	Feb 15, 1985
ASCOT	4MG	A087685 001	Oct 25, 1982

CYPROHEPTADINE HYDROCHLORIDE
TABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

DURAMED PHARMS BARR	4MG	A088232 001	Oct 25, 1983
HALSEY	4MG	A089057 001	Jul 03, 1986
KV PHARM	4MG	A086737 001	
MD PHARM	4MG	A087566 001	Nov 10, 1982
MYLAN	4MG	A086678 001	
PIONEER PHARMS	4MG	A087839 001	Feb 08, 1984
PLIVA	4MG	A088205 001	Jul 26, 1983
SANDOZ	4MG	A086808 001	
SUPERPHARM	4MG	A087405 001	
TG UNITED LABS	4MG	A088212 001	May 26, 1983
VITARINE	4MG	A087284 001	
WATSON LABS	4MG	A085245 001	
	4MG	A086165 001	
	4MG	A086580 001	

PERIACTIN

MERCK	4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012649 001	

CYSTEINE HYDROCHLORIDE
INJECTABLE;INJECTION
CYSTEINE HYDROCHLORIDE

HOSPIRA	7.25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019523 001	Oct 22, 1986

CYTARABINE
INJECTABLE;INJECTION
CYTARABINE

TEVA PARENTERAL	100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016793 001	
	500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016793 002	
	1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016793 003	Dec 21, 1987
	2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016793 004	Dec 21, 1987

DACARBAZINE
INJECTABLE;INJECTION
DACARBAZINE

ABRAXIS PHARM	100MG/VIAL	A070962 001	Aug 28, 1986
	200MG/VIAL	A070990 001	Aug 28, 1986

DACTINOMYCIN
INJECTABLE;INJECTION
DACTINOMYCIN

WEST-WARD PHARMS INT	0.5MG/VIAL	A090304 001	Mar 16, 2010

DALFOPRISTIN; QUINUPRISTIN
INJECTABLE;IV (INFUSION)
SYNERCID

KING PHARMS	420MG/VIAL;180MG/VIAL	N050748 002	Aug 24, 2000

DALTEPARIN SODIUM
INJECTABLE;INJECTION
FRAGMIN

PFIZER INC	7,500 IU/0.75ML	N020287 008	Apr 04, 2002

INJECTABLE;SUBCUTANEOUS
FRAGMIN

PFIZER INC	10,000IU/0.4ML (25,000IU/ML)	N020287 002	May 01, 2007
	95,000IU/9.5ML (10,000IU/ML)	N020287 007	Apr 04, 2002

FDA data supplied by DrugPatentWatch.com

DANAPAROID SODIUM
INJECTABLE;INJECTION
ORGARAN

ASPEN GLOBAL INC	750 UNITS/0.6ML	N020430 001	Dec 24, 1996

DANAZOL
CAPSULE;ORAL
DANAZOL

AM THERAP	200MG	A071569 001	Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US	50MG	N017557 003	
	100MG	N017557 004	
	200MG	N017557 002	

DAPIPRAZOLE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

FERA PHARMS	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019849 001	Dec 31, 1990

DAPTOMYCIN
POWDER;IV (INFUSION)
CUBICIN

CUBIST PHARMS LLC	250MG/VIAL	N021572 001	Sep 12, 2003

DARUNAVIR ETHANOLATE
TABLET;ORAL
PREZISTA

JANSSEN PRODS	EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021976 001	Jun 23, 2006
	EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021976 003	Oct 21, 2008

DAUNORUBICIN CITRATE
INJECTABLE, LIPOSOMAL;INJECTION
DAUNOXOME

GALEN (UK)	EQ 2MG BASE/ML	N050704 002	Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
CERUBIDINE

SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876 001	
WYETH AYERST	EQ 20MG BASE/VIAL	N050484 001	

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212 001	Jun 23, 1998
	EQ 50MG BASE/VIAL	A064212 002	May 03, 1999

DECAMETHONIUM BROMIDE
INJECTABLE;INJECTION
SYNCURINE

GLAXOSMITHKLINE	1MG/ML	N006931 002	

DEFEROXAMINE MESYLATE
INJECTABLE;INJECTION
DEFEROXAMINE MESYLATE

WATSON LABS	500MG/VIAL	A076806 001	Mar 31, 2006
	2GM/VIAL	A076806 002	Mar 31, 2006

DEMECARIUM BROMIDE
SOLUTION/DROPS;OPHTHALMIC
HUMORSOL

MERCK	0.125%	N011860 002	
	0.25%	N011860 001	

DEMECLOCYCLINE HYDROCHLORIDE
CAPSULE;ORAL
DECLOMYCIN

LEDERLE	150MG	N050262 001	

SYRUP;ORAL
DECLOMYCIN

LEDERLE	75MG/5ML	N050257 001	

FDA data supplied by DrugPatentWatch.com

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL				
DECLOMYCIN				
	COREPHARMA	75MG	N050261 001	
		150MG	N050261 002	
		300MG	N050261 003	
DEMECLOCYCLINE HYDROCHLORIDE				
	IMPAX LABS	150MG	A065094 001	Mar 22, 2004
		300MG	A065094 002	Mar 22, 2004

DESERPIDINE

TABLET;ORAL				
HARMONYL				
	ABBVIE	0.1MG	N010796 001	
		0.25MG	N010796 002	

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
ORETICYL 25				
	ABBVIE	0.125MG;25MG	N012148 001	
ORETICYL 50				
	ABBVIE	0.125MG;50MG	N012148 003	
ORETICYL FORTE				
	ABBVIE	0.25MG;25MG	N012148 002	

DESERPIDINE; METHYCLOTHIAZIDE

TABLET;ORAL				
ENDURONYL				
	ABBOTT	0.25MG;5MG	N012775 001	
ENDURONYL FORTE				
	ABBOTT	0.5MG;5MG	N012775 002	
METHYCLOTHIAZIDE AND DESERPIDINE				
	WATSON LABS	0.25MG;5MG	A088486 001	Aug 10, 1984
		0.5MG;5MG	A088452 001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
PERTOFRANE				
	SANOFI AVENTIS US	25MG	N013621 001	
		50MG	N013621 002	
TABLET;ORAL				
DESIPRAMINE HYDROCHLORIDE				
	ANI PHARMS INC	100MG	A071803 001	May 29, 1997
	USL PHARMA	25MG	A071864 001	Sep 09, 1987
		50MG	A071865 001	Sep 09, 1987
		75MG	A071866 001	Sep 09, 1987
		100MG	A071867 001	Sep 09, 1987

DESLANOSIDE

INJECTABLE;INJECTION				
CEDILANID-D				
	NOVARTIS	0.2MG/ML	N009282 002	

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION				
DDAVP				
	FERRING PHARMS INC	0.015MG/ML	N018938 002	Apr 25, 1995
DESMOPRESSIN ACETATE				
	BEDFORD	0.004MG/ML	A074575 001	Feb 18, 2000
DESMOPRESSIN ACETATE PRESERVATIVE FREE				
	BEDFORD	0.004MG/ML	A074574 001	Feb 18, 2000
SOLUTION;NASAL				
CONCENTRAID				
	FERRING	0.01%	N019776 001	Dec 26, 1990
SPRAY, METERED;NASAL				
DDAVP				
	FERRING PHARMS INC	0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017922 002	Feb 06, 1989
STIMATE				
	CSL BEHRING	0.15MG/SPRAY	N020355 001	Mar 07, 1994
TABLET;ORAL				
DESMOPRESSIN ACETATE				
	FERRING	0.1MG	N021795 001	May 08, 2008
		0.2MG	N021795 002	May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21

DESOGEN

ORGANON USA INC	0.15MG;0.03MG	N020071 001	Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR	0.15MG;0.03MG	A075256 001	Aug 12, 1999

ORTHO-CEPT

JANSSEN PHARMS	0.15MG;0.03MG	N020301 001	Dec 14, 1992

TABLET;ORAL-28

MIRCETTE

TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020713 001	Apr 22, 1998

ORTHO-CEPT

JANSSEN PHARMS	0.15MG;0.03MG	N020301 002	Dec 14, 1992

DESOXIMETASONE

CREAM;TOPICAL

TOPICORT

TARO PHARMS NORTH	0.25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017856 001	

TOPICORT LP

TARO PHARMS NORTH	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018309 001	

GEL;TOPICAL

TOPICORT

TARO PHARMS NORTH	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018586 001	Mar 29, 1982

OINTMENT;TOPICAL

DESOXIMETASONE

ALTANA	0.25%	A073440 001	Apr 01, 1998

TOPICORT

TARO PHARMS NORTH	0.25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018763 001	Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE;INJECTION

DOCA

ORGANON USA INC	5MG/ML	N001104 001	

PELLET;IMPLANTATION

PERCORTEN

NOVARTIS	125MG	N005151 001	

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE;INJECTION

PERCORTEN

NOVARTIS	25MG/ML	N008822 001	

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

TEVA PHARMS USA	EQ 50MG BASE	N205208 001	Oct 11, 2013
	EQ 100MG BASE	N205208 002	Oct 11, 2013

DEXAMETHASONE

AEROSOL;TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT	0.01% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083296 002	

DECASPRAY

MERCK	0.04% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012731 002	

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE

ELIXIR;ORAL			
DECADRON			
MERCK	0.5MG/5ML	N012376 002	
DEXAMETHASONE			
ALPHARMA US PHARMS	0.5MG/5ML	A088997 001	Oct 10, 1986
HEXADROL			
ORGANON USA INC	0.5MG/5ML	N012674 001	
GEL;TOPICAL			
DECADERM			
MERCK	0.1%	N013538 001	
SUSPENSION/DROPS;OPHTHALMIC			
DEXAMETHASONE			
WATSON LABS	0.1%	A089170 001	May 09, 1989
TABLET;ORAL			
DECADRON			
MERCK	0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 004	
	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 001	
	0.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 002	
	1.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 003	
	4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 005	
	6MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011664 006	Jul 30, 1982
DEXAMETHASONE			
IDT AUSTRALIA LTD	0.75MG	A080399 001	
IMPAX LABS	0.75MG	A085376 001	
PAR PHARM	0.25MG	A088149 001	Apr 28, 1983
PHOENIX LABS NY	0.75MG	A083806 001	
PVT FORM	0.75MG	A083420 001	
ROXANE	0.25MG	A084614 001	
SUN PHARM INDS	0.25MG	A084013 001	
	0.25MG	A084764 001	
	0.5MG	A084084 001	
	0.5MG	A084766 001	
	0.75MG	A084081 001	
	0.75MG	A084765 001	
	1.5MG	A084086 001	
	1.5MG	A084763 001	
UPSHER SMITH	0.75MG	A087534 001	
	1.5MG	A087533 001	
WATSON LABS	0.25MG	A085455 001	
	0.5MG	A085458 001	
	0.75MG	A080968 001	
	0.75MG	A084457 001	
	0.75MG	A085818 001	
	1.5MG	A085456 001	
	1.5MG	A085840 001	
WHITEWORTH TOWN PLSN	0.75MG	A084327 001	
DEXONE 0.5			
SOLVAY	0.5MG	A084991 001	
DEXONE 0.75			
SOLVAY	0.75MG	A084993 001	
DEXONE 1.5			
SOLVAY	1.5MG	A084990 001	
DEXONE 4			
SOLVAY	4MG	A084992 001	

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE
TABLET;ORAL
HEXADROL

ORGANON USA INC	0.5MG	N012675 004	
	0.75MG	N012675 007	
	1.5MG	N012675 009	
	4MG	N012675 010	

DEXAMETHASONE ACETATE
INJECTABLE;INJECTION
DECADRON-LA

MERCK	EQ 8MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016675 001	

DEXAMETHASONE ACETATE

WATSON LABS	EQ 8MG BASE/ML	A084315 001	
	EQ 16MG BASE/ML	A087711 001	May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE
AEROSOL;NASAL
DEXACORT

UCB INC	EQ 0.1MG PHOSPHATE/INH	N014242 001	

AEROSOL, METERED;INHALATION
DEXACORT

UCB INC	EQ 0.1MG PHOSPHATE/INH	N013413 001	

CREAM;TOPICAL
DECADRON

MERCK	EQ 0.1% PHOSPHATE	N011983 002	

INJECTABLE;INJECTION
DECADRON

MERCK	EQ 4MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012071 002	
	EQ 24MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012071 004	

DEXACEN-4

CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342 001	

DEXAMETHASONE

ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448 001	Jan 25, 1984
FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469 001	Jan 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 4MG PHOSPHATE/ML	A084493 001	
BEL MAR	EQ 4MG PHOSPHATE/ML	A084752 001	
DELL LABS	EQ 4MG PHOSPHATE/ML	A083161 001	
INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522 001	Feb 17, 1984
LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065 001	
TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125 001	Aug 31, 1990
	EQ 10MG PHOSPHATE/ML	A081126 001	Aug 31, 1990
WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702 001	
	EQ 4MG PHOSPHATE/ML	A084355 001	
	EQ 4MG PHOSPHATE/ML	A089169 001	Apr 09, 1986
	EQ 10MG PHOSPHATE/ML	A087668 001	Jul 01, 1982
	EQ 24MG PHOSPHATE/ML	A085606 001	
WEST-WARD PHARMS INT	EQ 4MG PHOSPHATE/ML	A084282 001	
WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641 001	

HEXADROL

ORGANON USA INC	EQ 4MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014694 002	
	EQ 10MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014694 003	
	EQ 20MG PHOSPHATE/ML	N014694 004	

OINTMENT;OPHTHALMIC
DECADRON

MERCK	EQ 0.05% PHOSPHATE	N011977 001	

DEXAIR

PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001	Dec 28, 1982

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC			
MAXIDEX			
ALCON	EQ 0.05% PHOSPHATE	A083342 001	
SOLUTION/DROPS;OPHTHALMIC			
DEXAIR			
PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001	Dec 15, 1983
DEXAMETHASONE SODIUM PHOSPHATE			
SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001	
	EQ 0.1% PHOSPHATE	A084173 001	
SOLUTION/DROPS;OPHTHALMIC, OTIC			
DECADRON			
MERCK	EQ 0.1% PHOSPHATE	N011984 001	
SOLUTION/DROPS;OTIC			
DEXAMETHASONE SODIUM PHOSPHATE			
AKORN	EQ 0.1% PHOSPHATE	A084855 001	

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION			
DECADRON W/ XYLOCAINE			
MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334 002	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC			
NEODECADRON			
MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324 001	
SOLUTION/DROPS;OPHTHALMIC			
NEODECADRON			
MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322 001	
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE			
BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055 001	Oct 30, 1995
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE			
ALCON PHARMS LTD	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714 001	Jul 21, 1986
PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539 001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC			
DEXACIDIN			
NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566 001	Feb 22, 1985
DEXASPORIN			
PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411 001	May 16, 1983
SUSPENSION/DROPS;OPHTHALMIC			
DEXACIDIN			
NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544 001	Oct 29, 1984
DEXASPORIN			
PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428 001	May 18, 1983
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE			
ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL			
DISOMER			
SCHERING	2MG/5ML	N011814 002	
TABLET;ORAL			
DISOMER			
SCHERING	2MG	N011814 001	

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL			
DISOPHROL			
SCHERING	2MG;60MG	N012394 002	
TABLET, EXTENDED RELEASE;ORAL			
BROMPHERIL			
COPLEY PHARM	6MG;120MG	A089116 001	Jan 22, 1987
DISOBROM			
SANDOZ	6MG;120MG	A070770 001	Sep 30, 1991
DISOPHROL			
SCHERING PLOUGH	6MG;120MG	N013483 004	Sep 13, 1982
DRIXORAL			
SCHERING PLOUGH	6MG;120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013483 003	Sep 13, 1982
RESPORAL			
PIONEER PHARMS	6MG;120MG	A089139 001	Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL			
POLARAMINE			
SCHERING	2MG/5ML	A086837 001	Jul 19, 1982
TABLET;ORAL			
DEXCHLORPHENIRAMINE MALEATE			
ANI PHARMS INC	2MG	A088682 001	Jan 17, 1986
POLARAMINE			
SCHERING	2MG	A086835 001	

DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL			
DEXAMPEX			
TEVA	15MG	A085355 001	
CAPSULE, EXTENDED RELEASE;ORAL			
DEXTROAMPHETAMINE SULFATE			
ABLE	5MG	A076814 001	Aug 25, 2004
	10MG	A076814 002	Aug 25, 2004
	15MG	A076814 003	Aug 25, 2004
ELIXIR;ORAL			
DEXEDRINE			
GLAXOSMITHKLINE	5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083902 001	
TABLET;ORAL			
DEXAMPEX			
TEVA	5MG	A083735 001	
	10MG	A083735 002	
DEXEDRINE			
GLAXOSMITHKLINE	5MG	A084935 001	
DEXTROAMPHETAMINE SULFATE			
COREPHARMA	5MG	A090652 001	Mar 07, 2014
	10MG	A090652 002	Mar 07, 2014
HALSEY	10MG	A083930 001	
IDT AUSTRALIA LTD	5MG	A085370 001	
LANNETT	5MG	A083903 001	
	10MG	A083903 003	
	15MG	A085652 001	
MAST MM	5MG	A086521 001	
NESHER PHARMS	5MG	A040365 001	Oct 31, 2002
	10MG	A040367 001	Oct 31, 2002
PUREPAC PHARM	5MG	A084125 001	
SANDOZ	10MG	A085371 001	
VINTAGE PHARMS LLC	5MG	A040299 001	May 13, 1999
VITARINE	5MG	A084986 001	
	10MG	A085892 001	
DEXTROSTAT			
SHIRE	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A084051 001	
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A084051 002	
FERNDEX			
FERNDALE LABS	5MG	A084001 001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL			
PHERAZINE DM			
HALSEY	15MG/5ML;6.25MG/5ML	A088913 001	Mar 02, 1987
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE			
AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575 001	Feb 08, 2011
ANI PHARMS	15MG/5ML;6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011265 002	Apr 02, 1984
TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687 001	Jun 28, 2012

FDA data supplied by DrugPatentWatch.com

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046 001	
MILES	10GM/100ML	N018504 001	

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML	N018358 001	
	2.5GM/100ML	N019626 001	Feb 02, 1988

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT	38.5GM/100ML	N018923 001	Sep 19, 1984

DEXTROSE 5% IN PLASTIC CONTAINER

DHL	5GM/100ML	N019971 001	Sep 28, 1995

DEXTROSE 50% IN PLASTIC CONTAINER

HOSPIRA	50GM/100ML	N019894 001	Dec 26, 1989

DEXTROSE 60%

B BRAUN	60GM/100ML	N017995 002	Sep 22, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN	60GM/100ML	N017995 001	
BAXTER HLTHCARE	60GM/100ML	N020047 002	Jul 02, 1991
HOSPIRA	60GM/100ML	N019346 001	Jan 25, 1985

DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN	7.7GM/100ML	N019626 003	Feb 02, 1988

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025 001	Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515 001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273 001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019843 001	Aug 09, 1993

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274 001	

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451 001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;37MG/100ML	N019699 001	Sep 29, 1989

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML	N018744 001	Nov 09, 1982
	5GM/100ML;75MG/100ML	N019699 002	Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;110MG/100ML	N019699 003	Sep 29, 1989

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML	N018744 002	Nov 09, 1982

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML	N018744 003	Nov 09, 1982
	5GM/100ML;220MG/100ML	N019699 005	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML	N018744 004	Nov 09, 1982

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG /100ML;207MG/100ML	N019514 001	May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML	N018270 001	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG /100ML;220MG/100ML	N018840 001	Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268 009	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268 004	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268 005	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268 006	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268 011	Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N018268 012	Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML	N018268 013	Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N018268 014	Jan 18, 1986

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N018268 010	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N018268 001	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML	N018268 002	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N018268 003	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 003	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 001	

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 002	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;200MG/100ML	N018386 001	

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;450MG/100ML	N018229 001	

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;900MG/100ML	N018047 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML;450MG/100ML	N018030 001	
HOSPIRA	2.5GM/100ML;450MG/100ML	N018096 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML;900MG/100ML	N018376 001	

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	3.3GM/100ML;300MG/100ML	N018055 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;110MG/100ML	N018030 005	

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;200MG/100ML	N018030 004	
MILES	5GM/100ML;200MG/100ML	N018399 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;225MG/100ML	N019482 001	Oct 04, 1985

FDA data supplied by DrugPatentWatch.com

DEXTROSE; SODIUM CHLORIDE
INJECTABLE;INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;300MG/100ML	N019486 001	Oct 04, 1985
MILES	5GM/100ML;300MG/100ML	N018501 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML;330MG/100ML	N018030 003	

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;450MG/100ML	N019484 001	Oct 04, 1985
B BRAUN	5GM/100ML;450MG/100ML	N018030 002	
MILES	5GM/100ML;450MG/100ML	N018400 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML;900MG/100ML	N019483 001	Oct 04, 1985
B BRAUN	5GM/100ML;900MG/100ML	N018026 001	
MILES	5GM/100ML;900MG/100ML	N018500 001	

DEXTROTHYROXINE SODIUM
TABLET;ORAL
CHOLOXIN

ABBVIE	1MG	N012302 005	
	2MG	N012302 002	
	4MG	N012302 004	
	6MG	N012302 006	

DEZOCINE
INJECTABLE;INJECTION
DALGAN

ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989
	10MG/ML	N019082 002	Dec 29, 1989
	15MG/ML	N019082 003	Dec 29, 1989

DIATRIZOATE MEGLUMINE
INJECTABLE;INJECTION
ANGIOVIST 282

BAYER HLTHCARE	60%	A087726 001	Sep 23, 1982

CARDIOGRAFIN

BRACCO	85%	N011620 002	

DIATRIZOATE MEGLUMINE

BRACCO	76%	N010040 017	

HYPAQUE

GE HEALTHCARE	30%	N016403 002	
	60%	N016403 001	

RENO-60

BRACCO	60%	N010040 016	

RENO-DIP

BRACCO	30%	N010040 012	

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE	30%	A087739 001	Sep 23, 1982

SOLUTION;URETERAL
RENO-30

BRACCO	30%	N010040 021	

UROVIST CYSTO

BAYER HLTHCARE	30%	A087729 001	Sep 23, 1982

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE	30%	A087731 001	Sep 23, 1982

SOLUTION;URETHRAL
HYPAQUE-CYSTO

GE HEALTHCARE	30%	N016403 003	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM
INJECTABLE;INJECTION
ANGIOVIST 292

BAYER HLTHCARE	52%;8%	A087724 001	Sep 23, 1982

ANGIOVIST 370

BAYER HLTHCARE	66%;10%	A087723 001	Sep 23, 1982

DIATRIZOATE-60

INTL MEDICATION	52%;8%	A088166 001	Jun 17, 1983

HYPAQUE-76

GE HEALTHCARE	66%;10%	A086505 001	

HYPAQUE-M,75%

GE HEALTHCARE	50%;25%	N010220 003	

HYPAQUE-M,90%

GE HEALTHCARE	60%;30%	N010220 002	

FDA data supplied by DrugPatentWatch.com

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION			
MD-60			
MALLINCKRODT	52%;8%	A087074 001	
MD-76			
MALLINCKRODT	66%;10%	A087073 001	
RENOCAL-76			
BRACCO	66%;10%	A089347 001	Jun 01, 1988
RENOGRAFIN-60			
BRACCO	52%;8%	N010040 006	
RENOVIST			
BRACCO	34.3%;35%	N010040 020	
RENOVIST II			
BRACCO	28.5%;29.1%	N010040 019	
SOLUTION;ORAL, RECTAL			
GASTROVIST			
BAYER HLTHCARE	66%;10%	A087728 001	Sep 23, 1982

DIATRIZOATE SODIUM

FOR SOLUTION;ORAL, RECTAL			
HYPAQUE			
GE HEALTHCARE	100%	N011386 001	
INJECTABLE;INJECTION			
HYPAQUE			
GE HEALTHCARE	25%	N009561 003	
	50%	N009561 001	
MD-50			
MALLINCKRODT	50%	A087075 001	
UROVIST SODIUM 300			
BAYER HLTHCARE	50%	A087725 001	Sep 23, 1982
SOLUTION;ORAL, RECTAL			
HYPAQUE			
GE HEALTHCARE	40%	N011386 003	
SOLUTION;URETERAL			
HYPAQUE SODIUM 20%			
GE HEALTHCARE	20%	N009561 002	

DIAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL			
VALRELEASE			
ROCHE	15MG	N018179 001	
GEL;RECTAL			
DIASTAT			
VALEANT PHARMS NORTH	5MG/ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020648 002	Jul 29, 1997
	10MG/2ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020648 003	Jul 29, 1997
	15MG/3ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020648 004	Jul 29, 1997
	20MG/4ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020648 005	Jul 29, 1997
INJECTABLE;INJECTION			
DIAZEPAM			
ABRAXIS PHARM	5MG/ML	A070662 001	Jun 25, 1986
HOSPIRA	5MG/ML	A071584 001	Oct 13, 1987
MARSAM PHARMS LLC	5MG/ML	A072371 001	Jan 29, 1993
PARENTA PHARMS	5MG/ML	A076815 001	Apr 15, 2004
US ARMY	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020124 001	Dec 05, 1990
WARNER CHILCOTT	5MG/ML	A071613 001	Oct 22, 1987
	5MG/ML	A071614 001	Oct 22, 1987
WATSON LABS	5MG/ML	A070296 001	Feb 12, 1986
	5MG/ML	A070911 001	Aug 28, 1986
	5MG/ML	A070912 001	Aug 28, 1986
	5MG/ML	A070930 001	Dec 01, 1986

FDA data supplied by DrugPatentWatch.com

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

WATSON LABS INC	5MG/ML	A072370 001	Jan 29, 1993
	5MG/ML	A072397 001	Jan 29, 1993
WEST-WARD PHARMS INT	5MG/ML	A070311 001	Dec 16, 1985
	5MG/ML	A070312 001	Dec 16, 1985
	5MG/ML	A070313 001	Dec 16, 1985
	5MG/ML	A071308 001	Jul 17, 1987
	5MG/ML	A071309 001	Jul 17, 1987
	5MG/ML	A071310 001	Jul 17, 1987

DIZAC

PHARMACIA AND UPJOHN	5MG/ML	N019287 001	Jun 18, 1993

VALIUM

ROCHE	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016087 001	

TABLET;ORAL

DIAZEPAM

ACTAVIS ELIZABETH	2MG	A070781 001	Mar 19, 1986
	5MG	A070706 001	Mar 19, 1986
	10MG	A070707 001	Mar 19, 1986
DAVA PHARMS INC	10MG	A070228 001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894 001	Aug 27, 1986
	5MG	A070895 001	Aug 27, 1986
	10MG	A070896 001	Aug 27, 1986
FERNDALE LABS	2MG	A070903 001	Apr 01, 1987
	5MG	A070904 001	Apr 01, 1987
	10MG	A070905 001	Apr 01, 1987
HALSEY	2MG	A070987 001	Aug 15, 1986
	5MG	A070996 001	Aug 15, 1986
	10MG	A070956 001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360 001	Sep 04, 1985
	5MG	A070361 001	Sep 04, 1985
	10MG	A070362 001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402 001	Apr 25, 1989
PAR PHARM	2MG	A070462 001	Feb 25, 1986
	5MG	A070463 001	Feb 25, 1986
	10MG	A070464 001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787 001	Aug 02, 1988
	5MG	A070788 001	Aug 02, 1988
	10MG	A070776 001	Aug 02, 1988
ROXANE	2MG	A070356 001	Jun 17, 1986
	5MG	A070357 001	Jun 17, 1986
	10MG	A070358 001	Jun 17, 1986
TEVA PHARMS	5MG	A070153 001	Nov 01, 1985
UPSHER-SMITH LABS	2MG	A070302 001	Dec 20, 1985
	5MG	A070303 001	Dec 20, 1985
	10MG	A070304 001	Dec 20, 1985
WARNER CHILCOTT	2MG	A070209 001	Sep 04, 1985
	5MG	A070210 001	Sep 04, 1985
	10MG	A070222 001	Sep 04, 1985
WATSON LABS	2MG	A070456 001	Nov 01, 1985
	5MG	A070457 001	Nov 01, 1985
	10MG	A070458 001	Nov 01, 1985

Q-PAM

QUANTUM PHARMICS	2MG	A070423 001	Dec 12, 1985
	2MG	A072431 001	Apr 29, 1988
	5MG	A070424 001	Dec 12, 1985
	5MG	A072432 001	Apr 29, 1988
	10MG	A070425 001	Dec 12, 1985
	10MG	A072433 001	Apr 29, 1988

DIAZOXIDE

CAPSULE;ORAL

PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425 001	
	100MG	N017425 002	

INJECTABLE;INJECTION

DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519 001	Aug 26, 1987

FDA data supplied by DrugPatentWatch.com

DIAZOXIDE
INJECTABLE;INJECTION
HYPERSTAT

SCHERING	15MG/ML	N016996 001	

DIBUCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
HEAVY SOLUTION NUPERCAINE

NOVARTIS	2.5MG/ML	N006203 001	

DICHLORPHENAMIDE
TABLET;ORAL
DARANIDE

STRONGBRIDGE US	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011366 001	

DICLOFENAC POTASSIUM
TABLET;ORAL
CATAFLAM

NOVARTIS	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020142 001	Nov 24, 1993
	50MG	N020142 002	Nov 24, 1993

DICLOFENAC POTASSIUM

SANDOZ	50MG	A075582 001	Feb 23, 2001
SUN PHARM INDS	50MG	A075470 001	Feb 21, 2002
WATSON LABS	50MG	A075152 001	Nov 27, 1998

DICLOFENAC SODIUM
SOLUTION/DROPS;OPHTHALMIC
DICLOFENAC SODIUM

APOTEX INC	0.1%	A077600 001	Nov 13, 2008
FALCON PHARMS	0.1%	N020809 001	May 04, 1998

TABLET, DELAYED RELEASE;ORAL
DICLOFENAC SODIUM

NOSTRUM LABS	50MG	A074986 001	Feb 26, 1999
	75MG	A074986 002	Feb 26, 1999
PLIVA	50MG	A074432 002	Jul 29, 1999
	75MG	A074432 003	Jul 29, 1999
ROXANE	25MG	A074391 001	Jun 29, 1995
	50MG	A074391 002	Jun 29, 1995
	75MG	A074391 003	Jun 29, 1995
TEVA	50MG	A074723 001	Mar 30, 1999
	75MG	A074390 001	Aug 15, 1996
TEVA PHARMS	25MG	A074459 001	Jun 25, 1997
	50MG	A074459 002	Jun 25, 1997
	75MG	A074459 003	Jun 25, 1997

VOLTAREN

NOVARTIS	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019201 001	Jul 28, 1988
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019201 002	Jul 28, 1988
	75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019201 003	Jul 28, 1988

TABLET, EXTENDED RELEASE;ORAL
VOLTAREN-XR

NOVARTIS	100MG	N020254 001	Mar 08, 1996

DICLOXACILLIN SODIUM
CAPSULE;ORAL
DYCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A060254 002	
	EQ 250MG BASE	A062238 001	
	EQ 500MG BASE	A060254 003	
	EQ 500MG BASE	A062238 002	

PATHOCIL

WYETH AYERST	EQ 250MG BASE	N050011 002	
	EQ 500MG BASE	N050011 003	Mar 28, 1983

DICLOXACILLIN SODIUM

FOR SUSPENSION;ORAL			
DICLOXACILLIN SODIUM			
APOTHECON	EQ 62.5MG BASE/5ML	A061455 001	
DYNAPEN			
APOTHECON	EQ 62.5MG BASE/5ML	N050337 002	
PATHOCIL			
WYETH AYERST	EQ 62.5MG BASE/5ML	N050092 001	

DICUMAROL

CAPSULE;ORAL			
DICUMAROL			
LILLY	25MG	N005509 003	
	50MG	N005509 001	
TABLET;ORAL			
DICUMAROL			
ABBVIE	25MG	N005545 003	
	50MG	N005545 004	
	100MG	N005545 005	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL			
DICYCLOMINE HYDROCHLORIDE			
HIKMA PHARMS LLC	10MG	A040204 001	Feb 28, 1997
PIONEER PHARMS	10MG	A089361 001	Jan 10, 1989
SUN PHARM INDS	10MG	A084505 001	Oct 21, 1986
WATSON LABS	10MG	A083179 001	Feb 12, 1986
INJECTABLE;INJECTION			
DICYCLOMINE HYDROCHLORIDE			
WATSON LABS	10MG/ML	A080614 001	Feb 11, 1986
SYRUP;ORAL			
BENTYL			
APTALIS PHARMA US	10MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007961 002	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE			
ALPHARMA US PHARMS	10MG/5ML	A084479 001	
TABLET;ORAL			
DICYCLOMINE HYDROCHLORIDE			
HIKMA PHARMS LLC	20MG	A040161 001	Oct 01, 1996
PIONEER PHARMS	20MG	A088585 001	Aug 20, 1986
SUN PHARM INDS	20MG	A084600 001	Jul 29, 1985
WATSON LABS	20MG	A084361 001	Feb 06, 1986

DIDANOSINE

FOR SOLUTION;ORAL			
VIDEX			
BRISTOL MYERS SQUIBB	100MG/PACKET	N020155 003	Oct 09, 1991
	167MG/PACKET	N020155 004	Oct 09, 1991
	250MG/PACKET	N020155 005	Oct 09, 1991
	375MG/PACKET	N020155 006	Oct 09, 1991
TABLET, CHEWABLE;ORAL			
VIDEX			
BRISTOL MYERS SQUIBB	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154 002	Oct 09, 1991
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154 003	Oct 09, 1991
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154 004	Oct 09, 1991
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154 005	Oct 09, 1991
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154 006	Oct 28, 1999

DIENESTROL
CREAM;VAGINAL
DIENESTROL
ORTHO MCNEIL PHARM 0.01% N006110 005
DV
SANOFI AVENTIS US 0.01% A083518 001
ESTRAGUARD
SOLVAY 0.01% A084436 001
SUPPOSITORY;VAGINAL
DV
SANOFI AVENTIS US 0.7MG A083517 001

DIETHYLCARBAMAZINE CITRATE
TABLET;ORAL
HETRAZAN
LEDERLE 50MG N006459 001

DIETHYLPROPION HYDROCHLORIDE
TABLET;ORAL
DIETHYLPROPION HYDROCHLORIDE
COREPHARMA 25MG A040828 001 Nov 05, 2008
SANDOZ 25MG A085916 001
TEVA 25MG A088642 001 Sep 20, 1984
TG UNITED LABS 25MG A088267 001 Aug 25, 1983
25MG A088268 001 Aug 25, 1983
UCB INC 25MG A085544 001
WATSON LABS 25MG A085741 001
TENUATE
SANOFI AVENTIS US 25MG N017668 001
TEPANIL
3M 25MG N011673 001
TABLET, EXTENDED RELEASE;ORAL
TENUATE
SANOFI AVENTIS US 75MG N017669 001
TEPANIL TEN-TAB
3M 75MG N017956 001

DIETHYLSTILBESTROL
INJECTABLE;INJECTION
STILBESTROL
BRISTOL MYERS SQUIBB 0.2MG/ML N004056 003
0.5MG/ML N004056 004
1MG/ML N004056 005
5MG/ML N004056 006
SUPPOSITORY;VAGINAL
DIETHYLSTILBESTROL
LILLY 0.1MG N004040 001
0.5MG N004040 002
STILBESTROL
BRISTOL MYERS SQUIBB 0.1MG N004056 001
0.5MG N004056 002
TABLET;ORAL
DIETHYLSTILBESTROL
LILLY 0.1MG N004041 002
0.5MG N004041 003
1MG N004041 004
5MG N004041 005
STILBESTROL
TABLICAPS 0.5MG A083004 001
1MG A083002 001
5MG A083006 001
STILBETIN
BRISTOL MYERS SQUIBB 0.1MG N004056 007
0.25MG N004056 017
0.5MG N004056 008
1MG N004056 009
5MG N004056 010
TABLET, DELAYED RELEASE;ORAL
DIETHYLSTILBESTROL
LILLY 0.1MG N004039 002
0.25MG N004039 005
0.5MG N004039 003
1MG N004039 004
5MG N004039 006

DIETHYLSTILBESTROL
TABLET, DELAYED RELEASE;ORAL

STILBESTROL			
TABLICAPS	0.5MG	A083003 001	
	1MG	A083005 001	
	5MG	A083007 001	
STILBETIN			
BRISTOL MYERS SQUIBB	0.1MG	N004056 011	
	0.5MG	N004056 012	
	1MG	N004056 013	
	5MG	N004056 014	

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE;INJECTION			
STILPHOSTROL			
BAYER PHARMS	250MG/5ML	N010010 001	
TABLET;ORAL			
STILPHOSTROL			
BAYER PHARMS	50MG	N010010 002	

DIFLORASONE DIACETATE

CREAM;TOPICAL			
DIFLORASONE DIACETATE			
FOUGERA PHARMS	0.05%	A075187 001	Mar 30, 1998
FLORONE			
PHARMACIA AND UPJOHN	0.05%	N017741 001	
FLORONE E			
PHARMACIA AND UPJOHN	0.05%	N019259 001	Aug 28, 1985
PSORCON			
TARO PHARMS NORTH	0.05%	N020205 001	Nov 20, 1992
OINTMENT;TOPICAL			
PSORCON			
PHARMACIA AND UPJOHN	0.05%	N019260 001	Aug 28, 1985
PSORCON E			
PHARMACIA AND UPJOHN	0.05%	N017994 001	

DIFLUNISAL

TABLET;ORAL			
DIFLUNISAL			
IDT AUSTRALIA LTD	500MG	A074604 001	Jun 10, 1996
PUREPAC PHARM	250MG	A074285 001	May 07, 1996
	500MG	A074285 002	May 07, 1996
ROXANE	250MG	A073562 001	Nov 27, 1992
	500MG	A073563 001	Nov 27, 1992
TEVA	250MG	A073679 001	Jul 31, 1992
WATSON LABS	250MG	A074400 001	Jul 17, 1997
	500MG	A074400 002	Jul 17, 1997
DOLOBID			
MERCK	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018445 001	Apr 19, 1982
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018445 002	Apr 19, 1982

DIGITOXIN

INJECTABLE;INJECTION			
CRYSTODIGIN			
LILLY	0.2MG/ML	A084100 005	

DIGOXIN

CAPSULE;ORAL			
LANOXICAPS			
GLAXOSMITHKLINE LLC	0.05MG	N018118 002	Jul 26, 1982
	0.1MG	N018118 003	Jul 26, 1982
	0.15MG	N018118 004	Sep 24, 1984
	0.2MG	N018118 001	Jul 26, 1982
INJECTABLE;INJECTION			
DIGOXIN			
ABRAXIS PHARM	0.25MG/ML	A083217 001	
HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996
	0.25MG/ML	A040206 001	Aug 28, 1998
WYETH AYERST	0.25MG/ML	A084386 001	

DIGOXIN
INJECTABLE;INJECTION
DIGOXIN PEDIATRIC

HOSPIRA	0.1MG/ML	A040092 001	Apr 25, 1996

TABLET;ORAL
LANOXIN

CONCORDIA PHARMS INC	0.375MG	N020405 005	Sep 30, 1997
	0.5MG	N020405 006	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
EMBOLEX

NOVARTIS	0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML	N018885 001	Nov 30, 1984
	0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML	N018885 002	Nov 30, 1984

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
CARDIZEM SR

BIOVAIL	60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019471 001	Jan 23, 1989
	90MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019471 002	Jan 23, 1989
	120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019471 003	Jan 23, 1989
	180MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019471 004	Jan 23, 1989

DILACOR XR

ALLERGAN SALES LLC	120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020092 001	May 29, 1992
	180MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020092 002	May 29, 1992
	240MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020092 003	May 29, 1992

DILT-CD

APOTEX	120MG	A076151 001	May 20, 2004
	180MG	A076151 002	May 20, 2004
	240MG	A076151 003	May 20, 2004
	300MG	A076151 004	May 20, 2004

DILTIAZEM HYDROCHLORIDE

ACTAVIS LABS FL INC	120MG	A074852 001	Oct 10, 1997
	180MG	A074852 002	Oct 10, 1997
	240MG	A074852 003	Oct 10, 1997
BIOVAIL	60MG	A074845 001	Sep 15, 1999
	90MG	A074845 002	Sep 15, 1999
	120MG	A074845 003	Sep 15, 1999
	120MG	N020939 001	Jan 28, 2000
	180MG	N020939 002	Jan 28, 2000
	240MG	N020939 003	Jan 28, 2000
	300MG	N020939 004	Jan 28, 2000
	360MG	N020939 005	Sep 14, 2001
	420MG	N020939 006	Sep 14, 2001
NESHER PHARMS	120MG	A076563 002	Sep 12, 2006
	180MG	A076563 003	Sep 12, 2006
	240MG	A076563 004	Sep 12, 2006
	300MG	A076563 005	Sep 12, 2006
	360MG	A076563 006	Sep 12, 2006
	420MG	A076563 001	Sep 12, 2006
TEVA	60MG	A074079 001	Nov 30, 1993
	90MG	A074079 002	Nov 30, 1993
	120MG	A074079 003	Nov 30, 1993

DILTIAZEM HYDROCHLORIDE

INJECTABLE;INJECTION				
CARDIZEM				
BIOVAIL	100MG/VIAL	N020792	001	Sep 05, 1997
BIOVAIL LABS INTL	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020027	001	Oct 24, 1991
	25MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020027	003	Aug 18, 1995
DILTIAZEM HYDROCHLORIDE				
HOSPIRA	5MG/ML	A075004	001	Feb 16, 2000
	5MG/ML	A075106	001	Apr 29, 1999
MYLAN LABS LTD	5MG/ML	A075375	001	Sep 30, 1999
TEVA PHARMS USA	5MG/ML	A074894	001	Aug 26, 1997
TABLET;ORAL				
DILTIAZEM HYDROCHLORIDE				
APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
DAVA PHARMS INC	30MG	A074093	001	Nov 05, 1992
	60MG	A074093	002	Nov 05, 1992
	90MG	A074093	003	Nov 05, 1992
	120MG	A074093	004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995
TEVA	30MG	A074084	001	Feb 25, 1994
	60MG	A074084	002	Feb 25, 1994
TEVA PHARMS	30MG	A074067	001	Nov 05, 1992
	60MG	A074067	002	Nov 05, 1992
	90MG	A074067	003	Nov 05, 1992
	120MG	A074067	004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE;ORAL				
TIAMATE				
MERCK	EQ 120MG HCL	N020506	001	Oct 04, 1996
	EQ 180MG HCL	N020506	002	Oct 04, 1996
	EQ 240MG HCL	N020506	003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE;ORAL				
TECZEM				
BIOVAIL	EQ 180MG HCL;5MG	N020507	001	Oct 04, 1996

DIMENHYDRINATE

INJECTABLE;INJECTION				
DIMENHYDRINATE				
BAXTER HLTHCARE	50MG/ML	A084767	001	
WATSON LABS	50MG/ML	A080615	001	
	50MG/ML	A083531	001	
WYETH AYERST	50MG/ML	A084316	001	
LIQUID;ORAL				
DIMENHYDRINATE				
ALRA	12.5MG/4ML	A080715	001	
TABLET;ORAL				
DIMENHYDRINATE				
HEATHER	50MG	A080841	001	
NEXGEN PHARMA INC	50MG	A085985	001	
WATSON LABS	50MG	A085166	001	

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE;INTRAVENOUS				
IMAGENT				
VESSELON SPV LLC	0.92MG/VIAL;0.092MG/VIAL	N021191	001	May 31, 2002

FDA data supplied by DrugPatentWatch.com

DINOPROST TROMETHAMINE
INJECTABLE;INJECTION
PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434 001	

DIPHEMANIL METHYLSULFATE
TABLET;ORAL
PRANTAL

SCHERING	100MG	N008114 004	

DIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE;ORAL
BENADRYL

MCNEIL CONS	25MG	N005845 007	
	50MG	N005845 001	

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA	25MG	A080519 004	
	50MG	A080519 003	
ANABOLIC	50MG	A083275 001	
ELKINS SINN	25MG	A085701 001	
	50MG	A085701 002	
HALSEY	50MG	A087914 001	Jun 04, 1984
HEATHER	25MG	A084524 001	
	50MG	A083953 001	
HIKMA INTL PHARMS	50MG	A083567 001	
IMPAX LABS	25MG	A080807 001	
	50MG	A080807 002	
IVAX SUB TEVA PHARMS	25MG	A080762 001	
	50MG	A080762 002	
LANNETT	25MG	A080868 001	
	50MG	A080868 002	
LEDERLE	25MG	A086874 001	
	50MG	A086875 001	
LNK	25MG	A087977 001	Jan 27, 1983
	50MG	A087978 001	Jan 27, 1983
MK LABS	25MG	A083087 001	
	50MG	A083087 002	
MUTUAL PHARM	25MG	A084506 001	
NEWTRON PHARMS	25MG	A086543 001	
	50MG	A086544 001	
NEXGEN PHARMA INC	25MG	A083634 001	
PERRIGO	25MG	A083061 001	
	50MG	A083061 002	
PIONEER PHARMS	25MG	A089101 001	Dec 20, 1985
	50MG	A088880 001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156 001	
	50MG	A085150 001	
PVT FORM	25MG	A083027 001	
	50MG	A083027 002	
ROXANE	50MG	A080635 001	
SANDOZ	25MG	A080832 001	
	25MG	A080845 002	
	50MG	A080832 002	
	50MG	A080845 001	
SUN PHARM INDS	25MG	A089488 001	Jan 02, 1987
	50MG	A089489 001	Jan 02, 1987
SUPERPHARM	25MG	A089040 001	May 15, 1985
	50MG	A089041 001	May 15, 1985
TEVA	25MG	A085874 001	
	50MG	A085874 002	
VALEANT PHARM INTL	25MG	A080596 001	
	50MG	A080592 001	
VANGARD	25MG	A088034 001	Oct 27, 1982
	50MG	A087630 001	
WATSON LABS	25MG	A080728 001	
	25MG	A083797 001	
	25MG	A085138 001	
	50MG	A080727 001	
	50MG	A083797 002	
	50MG	A085083 001	
WHITEWORTH TOWN PLSN	25MG	A083441 001	
	50MG	A080800 001	

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL			
BELIX			
HALSEY	12.5MG/5ML	A086586 001	Oct 03, 1983
BENADRYL			
MCNEIL CONS	12.5MG/5ML	N005845 004	
DIBENIL			
CENCI	12.5MG/5ML	A088304 001	Dec 16, 1983
DIPHEN			
USL PHARMA	12.5MG/5ML	A084640 001	
DIPHENHYDRAMINE HYDROCHLORIDE			
BUNDY	12.5MG/5ML	A083674 001	
CENCI	12.5MG/5ML	A087941 001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621 001	
LANNETT	12.5MG/5ML	A080939 002	
LEDERLE	12.5MG/5ML	A086937 001	
MK LABS	12.5MG/5ML	A083088 002	
NASKA	12.5MG/5ML	A088680 001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063 001	
PUREPAC PHARM	12.5MG/5ML	A083237 001	Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287 001	
ROXANE	12.5MG/5ML	A080643 001	
HYDRAMINE			
ALPHARMA US PHARMS	12.5MG/5ML	A080763 002	
INJECTABLE;INJECTION			
BENADRYL			
MCNEIL CONS	10MG/ML	N006146 001	
	50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006146 002	
BENADRYL PRESERVATIVE FREE			
MCNEIL CONS	50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009486 001	
DIPHENHYDRAMINE HYDROCHLORIDE			
BEL MAR	10MG/ML	A080822 001	
EUROHLTH INTL SARL	50MG/ML	A083183 001	
LYPHOMED	10MG/ML	A087066 001	
WATSON LABS	10MG/ML	A083533 001	
WATSON LABS INC	10MG/ML	A080873 001	
	50MG/ML	A080873 002	
WYETH AYERST	50MG/ML	A080577 001	
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE			
ABRAXIS PHARM	50MG/ML	A080586 002	
INTL MEDICATION	50MG/ML	A084094 001	
WATSON LABS INC	50MG/ML	A080873 003	
SYRUP;ORAL			
ANTITUSSIVE			
PERRIGO	12.5MG/5ML	A071292 001	Apr 10, 1987
BELDIN			
HALSEY	12.5MG/5ML	A089179 001	Jun 05, 1986
BENYLIN			
PARKE DAVIS	12.5MG/5ML	N006514 004	
DIPHEN			
MORTON GROVE	12.5MG/5ML	A070118 001	Oct 01, 1985
DIPHENHYDRAMINE HYDROCHLORIDE			
ALPHARMA US PHARMS	12.5MG/5ML	A070497 001	Apr 25, 1989
CUMBERLAND SWAN	12.5MG/5ML	A073611 001	Aug 20, 1992
HI TECH PHARMA	12.5MG/5ML	A072416 001	Sep 28, 1990
HYDRAMINE			
ALPHARMA US PHARMS	12.5MG/5ML	A070205 001	Jan 28, 1986
SILPHEN			
SILARX	12.5MG/5ML	A072646 001	Feb 27, 1992
VICKS FORMULA 44			
WARNER CHILCOTT	12.5MG/5ML	A070524 001	Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
BENYLIN				
PARKE DAVIS	12.5MG/5ML;30MG/5ML	N019014	001	Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET;ORAL				
VONTROL				
GLAXOSMITHKLINE	EQ 25MG BASE	N016033	001	

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
HISPRIL				
GLAXOSMITHKLINE	5MG	N011945	001	

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
AKPRO				
AKORN	0.1%	A074382	001	Sep 29, 1995
DIPIVEFRIN HYDROCHLORIDE				
BAUSCH AND LOMB	0.1%	A074188	001	May 19, 1995
FALCON PHARMS	0.1%	A073636	001	Jun 30, 1994
PROPINE				
ALLERGAN	0.1%	N018239	001	

DIPYRIDAMOLE

INJECTABLE;INJECTION				
DIPYRIDAMOLE				
HOSPIRA	5MG/ML	A074601	001	Dec 19, 1997
MYLAN LABS LTD	5MG/ML	A075769	001	Nov 27, 2002
TEVA PHARMS USA	5MG/ML	A074952	001	Nov 26, 1997
IV PERSANTINE				
BOEHRINGER INGELHEIM	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019817	001	Dec 13, 1990
TABLET;ORAL				
DIPYRIDAMOLE				
GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991
	50MG	A089000	001	Feb 05, 1991
	75MG	A089001	001	Feb 05, 1991
IDT AUSTRALIA LTD	25MG	A086944	002	Apr 16, 1991
	50MG	A087562	001	Feb 25, 1992
	75MG	A087561	001	Feb 25, 1992
LANNETT	25MG	A040898	001	Apr 23, 2008
	50MG	A040898	002	Apr 23, 2008
	75MG	A040898	003	Apr 23, 2008
OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006
	50MG	A040542	002	Apr 21, 2006
	75MG	A040542	003	Apr 21, 2006
PUREPAC PHARM	25MG	A089425	001	Jul 12, 1990
	50MG	A089426	001	Jul 12, 1990
	75MG	A089427	001	Jul 12, 1990
WATSON LABS	50MG	A087160	001	Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL				
DYNABAC				
LILLY RES LABS	250MG	N050678	001	Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL				
DISOPYRAMIDE PHOSPHATE				
AUROLIFE PHARMA LLC	EQ 100MG BASE	A070470	001	Dec 10, 1985
	EQ 150MG BASE	A070471	001	Dec 10, 1985
INTERPHARM	EQ 100MG BASE	A071190	001	Jan 15, 1987
	EQ 150MG BASE	A071191	001	Jan 15, 1987
IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186	001	Nov 18, 1985
	EQ 150MG BASE	A070187	001	Nov 18, 1985
MYLAN	EQ 100MG BASE	A070138	001	Jun 14, 1985
	EQ 150MG BASE	A070139	001	Jun 14, 1985
SUN PHARM INDS	EQ 100MG BASE	A070351	001	Dec 17, 1985
	EQ 150MG BASE	A070352	001	Dec 17, 1985
SUPERPHARM	EQ 100MG BASE	A070940	001	Feb 09, 1987
	EQ 150MG BASE	A070941	001	Feb 09, 1987
WATSON LABS	EQ 100MG BASE	A070240	001	Feb 02, 1986

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

	EQ 150MG BASE	A070241 001	Feb 02, 1986

CAPSULE, EXTENDED RELEASE;ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987

DISULFIRAM

TABLET;ORAL

ANTABUSE

TEVA WOMENS	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007883 003	
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007883 002	

DISULFIRAM

PAR PHARM	250MG	A088792 001	Aug 14, 1984
	500MG	A088793 001	Aug 14, 1984
WATSON LABS	250MG	A086889 001	
	250MG	A087973 001	Aug 05, 1983
	500MG	A086890 001	
	500MG	A087974 001	Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE CP

ABBOTT	EQ 250MG BASE	N019794 001	Jul 11, 1990
	EQ 500MG BASE	N019794 002	Jul 11, 1990

DIVALPROEX SODIUM

MYLAN	EQ 125MG VALPROIC ACID	A077254 001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A077254 002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A077254 003	Jul 29, 2008

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700 001	Aug 03, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381 001	Sep 26, 1996
HOSPIRA	EQ 1.25GM BASE/100ML	A074634 001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545 001	Jun 25, 1998
TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A074098 001	Feb 21, 1995
TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206 001	Oct 19, 1993
WATSON LABS	EQ 12.5MG BASE/ML	A074114 001	Nov 30, 1993
WATSON LABS INC	EQ 12.5MG BASE/ML	A074279 001	Feb 18, 1998
	EQ 12.5MG BASE/ML	A074995 001	Mar 31, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA	EQ 50MG BASE/100ML	N020269 001	Oct 19, 1993
	EQ 100MG BASE/100ML	N020269 002	Oct 19, 1993
	EQ 200MG BASE/100ML	N020269 003	Oct 19, 1993

DOBUTREX

LILLY	EQ 12.5MG BASE/ML	N017820 002	

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012
	80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012

TAXOTERE

SANOFI AVENTIS US	40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020449 001	May 14, 1996

DOLASETRON MESYLATE

INJECTABLE;INJECTION

ANZEMET

US PHARM HOLDINGS	500MG/25ML (20MG/ML)	N020624 003	Dec 11, 2001

DONEPEZIL HYDROCHLORIDE
SOLUTION;ORAL
ARICEPT

EISAI INC	5MG/5ML	N021719 001	Oct 18, 2004

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE	5MG	A201335 001	Aug 29, 2011
	10MG	A201335 002	Aug 29, 2011
HIKMA PHARMS	5MG	A090247 001	May 31, 2011
	10MG	A090247 002	May 31, 2011

TABLET, ORALLY DISINTEGRATING;ORAL
DONEPEZIL HYDROCHLORIDE

SUN PHARM INDS	5MG	A077975 002	Dec 11, 2009
	10MG	A077975 001	Dec 11, 2009

DOPAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656 001	Jan 24, 1989
	80MG/ML	A070657 001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012 001	Jun 12, 1985
	40MG/ML	A070058 001	Mar 20, 1985
	80MG/ML	A070013 001	Jun 12, 1985
	80MG/ML	A070059 001	Mar 20, 1985
	160MG/ML	A070364 001	Dec 04, 1985
BAXTER HLTHCARE	40MG/ML	N018398 001	
	80MG/ML	N018398 002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403 001	May 23, 1996
IGI LABS INC	40MG/ML	A070087 001	Oct 23, 1985
	40MG/ML	N018656 001	Jun 28, 1983
	80MG/ML	A070089 001	Oct 23, 1985
	80MG/ML	A070090 001	Oct 23, 1985
	80MG/ML	A070091 001	Oct 23, 1985
	160MG/ML	A070092 001	Oct 23, 1985
	160MG/ML	A070093 001	Oct 23, 1985
	160MG/ML	A070094 001	Oct 23, 1985
INTL MEDICATION	40MG/ML	N018014 001	
LYPHOMED	40MG/ML	N018549 001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011 001	Aug 29, 1985
	40MG/ML	A070046 001	Aug 29, 1985
	80MG/ML	A070047 001	Aug 29, 1985
TEVA PARENTERAL	40MG/ML	A072999 001	Oct 23, 1991
	80MG/ML	A073000 001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558 001	Sep 20, 1985
	40MG/ML	N018138 001	
	80MG/ML	A070559 001	Sep 20, 1985

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA	1.6MG/ML	N020542 001	Aug 30, 1995

INTROPIN

HOSPIRA	40MG/ML	N017395 001	
	80MG/ML	N017395 002	
	160MG/ML	N017395 003	

DORZOLAMIDE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

APOTEX INC	EQ 2% BASE	A078395 001	Oct 28, 2008

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

APOTEX INC	EQ 2% BASE;EQ 0.5% BASE	A078201 001	Oct 28, 2008
LANNETT HOLDINGS INC	EQ 2% BASE;EQ 0.5% BASE	A201998 001	Dec 17, 2014

DOXACURIUM CHLORIDE
INJECTABLE;INJECTION
NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946 001	Mar 07, 1991

DOXAPRAM HYDROCHLORIDE
INJECTABLE;INJECTION
DOXAPRAM HYDROCHLORIDE

WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992

DOXAZOSIN MESYLATE
TABLET;ORAL
DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000
	EQ 2MG BASE	A075574	002	Oct 18, 2000
	EQ 4MG BASE	A075574	003	Oct 18, 2000
	EQ 8MG BASE	A075574	004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000
	EQ 2MG BASE	A075432	002	Oct 18, 2000
	EQ 4MG BASE	A075432	003	Oct 18, 2000
	EQ 8MG BASE	A075432	004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453	001	Oct 18, 2000
	EQ 2MG BASE	A075453	002	Oct 18, 2000
	EQ 4MG BASE	A075453	003	Oct 18, 2000
	EQ 8MG BASE	A075453	004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000
	EQ 2MG BASE	A075609	002	Oct 18, 2000
	EQ 4MG BASE	A075609	003	Oct 18, 2000
	EQ 8MG BASE	A075609	004	Oct 18, 2000
SANDOZ	EQ 1MG BASE	A075646	001	Oct 18, 2000
	EQ 2MG BASE	A075646	002	Oct 18, 2000
	EQ 4MG BASE	A075646	003	Oct 18, 2000
	EQ 8MG BASE	A075646	004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353	001	Jan 12, 2001
	EQ 2MG BASE	A075353	002	Jan 12, 2001
	EQ 4MG BASE	A075353	003	Jan 12, 2001
	EQ 8MG BASE	A075353	004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000
	EQ 2MG BASE	A075426	002	Oct 18, 2000
	EQ 4MG BASE	A075426	003	Oct 18, 2000
	EQ 8MG BASE	A075426	004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE
CAPSULE;ORAL
DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685	001	Jan 05, 1988
	EQ 25MG BASE	A071686	001	Jan 05, 1988
	EQ 50MG BASE	A071673	001	Jan 05, 1988
	EQ 75MG BASE	A071674	001	Jan 05, 1988
	EQ 100MG BASE	A071675	001	Jan 05, 1988
	EQ 150MG BASE	A071676	001	Jan 05, 1988
NEW RIVER	EQ 10MG BASE	N016987	001	
	EQ 25MG BASE	N016987	002	
	EQ 50MG BASE	N016987	003	
	EQ 75MG BASE	N016987	006	
	EQ 100MG BASE	N016987	004	
	EQ 150MG BASE	N016987	007	Apr 13, 1987
PAR PHARM	EQ 10MG BASE	A071697	001	Nov 09, 1987
	EQ 25MG BASE	A071437	001	Nov 09, 1987
	EQ 50MG BASE	A071595	001	Nov 09, 1987
	EQ 75MG BASE	A071608	001	Nov 09, 1987
	EQ 100MG BASE	A071422	001	Nov 09, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054	001	Dec 28, 1990
	EQ 25MG BASE	A072109	001	Dec 28, 1990
	EQ 50MG BASE	A073055	001	Dec 28, 1990
	EQ 75MG BASE	A072386	001	Sep 08, 1988
	EQ 100MG BASE	A072110	001	Sep 08, 1988
	EQ 150MG BASE	A072387	001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972	001	Sep 29, 1987
	EQ 25MG BASE	A070973	001	Sep 29, 1987
	EQ 50MG BASE	A070931	001	Sep 29, 1987
	EQ 75MG BASE	A070932	001	Sep 29, 1987
	EQ 100MG BASE	A072375	001	Mar 15, 1989
	EQ 150MG BASE	A072376	001	Mar 15, 1989

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
SUN PHARM INDS	EQ 25MG BASE	A071502 001	Feb 18, 1988
	EQ 50MG BASE	A071653 001	Feb 18, 1988
	EQ 75MG BASE	A071654 001	Feb 18, 1988
	EQ 100MG BASE	A071521 001	Feb 18, 1988
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 50MG BASE	A072987 001	Mar 29, 1991
	EQ 75MG BASE	A071326 001	Apr 30, 1987
	EQ 75MG BASE	A071763 001	Feb 09, 1988
	EQ 100MG BASE	A070955 001	May 15, 1986
	EQ 100MG BASE	A071239 001	Apr 30, 1987
	EQ 150MG BASE	A071764 001	Feb 09, 1988

SINEQUAN

PFIZER	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016798 003	
	EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016798 001	
	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016798 002	
	EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016798 006	
	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016798 005	
	EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016798 007	

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

PHARM ASSOC	EQ 10MG BASE/ML	A075924 001	Jan 15, 2004

SINEQUAN

PFIZER	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017516 001	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN	2MG/ML	A063165 001	Jan 30, 1991
	200MG/100ML	A063165 002	Jan 30, 1991

DOXORUBICIN HYDROCHLORIDE

PHARMACIA AND UPJOHN	10MG/VIAL	N050467 001	
	20MG/VIAL	N050467 003	May 20, 1985
	50MG/VIAL	N050467 002	
	150MG/VIAL	N050467 004	Jul 22, 1987
SANDOZ INC	2MG/ML	A200146 001	Jul 18, 2012

RUBEX

BRISTOL MYERS SQUIBB	10MG/VIAL	A062926 001	Apr 13, 1989
	50MG/VIAL	A062926 002	Apr 13, 1989
	100MG/VIAL	A062926 003	Apr 13, 1989

DOXYCYCLINE

CAPSULE;ORAL			
DOXYCYCLINE			
PAR PHARM	EQ 75MG BASE	A065055 004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000
	EQ 100MG BASE	A065032 002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041 001	Apr 28, 2000
	EQ 100MG BASE	A065041 002	Apr 28, 2000
FOR SUSPENSION;ORAL			
DOXYCHEL			
RACHELLE	EQ 25MG BASE/5ML	A061720 001	
TABLET;ORAL			
DOXYCYCLINE			
SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006
	EQ 75MG BASE	A065353 002	Nov 27, 2006
	EQ 100MG BASE	A065353 003	Nov 27, 2006
SUN PHARM INDS	EQ 50MG BASE	A065471 001	Apr 17, 2009
	EQ 75MG BASE	A065471 002	Apr 17, 2009
	EQ 100MG BASE	A065471 003	Apr 17, 2009

DOXYCYCLINE HYCLATE

CAPSULE;ORAL			
DOXY-LEMMON			
TEVA	EQ 50MG BASE	A062497 001	Aug 23, 1984
	EQ 100MG BASE	A062497 002	Jun 15, 1984
DOXYCYCLINE HYCLATE			
HALSEY	EQ 50MG BASE	A062119 002	May 24, 1985
	EQ 100MG BASE	A062119 001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463 001	Dec 07, 1983
	EQ 100MG BASE	A062463 002	Dec 07, 1983
INTERPHARM	EQ 50MG BASE	A062763 001	Sep 02, 1988
	EQ 100MG BASE	A062763 002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418 001	Jan 28, 1983
	EQ 100MG BASE	A062418 002	Jan 28, 1983
PAR PHARM	EQ 50MG BASE	A062434 001	Oct 19, 1984
	EQ 100MG BASE	A062442 001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631 001	Jul 24, 1986
	EQ 100MG BASE	A062631 002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479 001	Dec 23, 1983
	EQ 100MG BASE	A062479 002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469 001	Oct 31, 1984
	EQ 100MG BASE	A062469 002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594 001	Dec 05, 1985
	EQ 100MG BASE	A062594 002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717 001	
	EQ 50MG BASE	A062142 001	
	EQ 100MG BASE	A061717 002	
	EQ 100MG BASE	A062142 002	
VIBRAMYCIN			
PFIZER	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050007 001	
CAPSULE, COATED PELLETS;ORAL			
DOXYCYCLINE HYCLATE			
PLIVA	EQ 100MG BASE	A063187 001	Jun 30, 1992
CAPSULE, DELAYED RELEASE;ORAL			
DORYX			
MAYNE PHARMA INTL	EQ 75MG BASE	N050582 002	Aug 13, 2001
	EQ 100MG BASE	N050582 001	Jul 22, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062653 001	Oct 30, 1985
INJECTABLE;INJECTION			
DOXYCHEL HYCLATE			
RACHELLE	EQ 100MG BASE/VIAL	A061953 001	
DOXYCYCLINE			
WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062569 002	Mar 09, 1988
DOXYCYCLINE HYCLATE			
WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989
	EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989
VIBRAMYCIN			
PFIZER	EQ 100MG BASE/VIAL **Federal Register	N050442 002	

DOXYCYCLINE HYCLATE
INJECTABLE;INJECTION
VIBRAMYCIN

	determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050442 001	

TABLET;ORAL
DOXY-LEMMON

TEVA	EQ 100MG BASE	A062581 001	Mar 15, 1985

DOXYCYCLINE HYCLATE

BLU CARIBE INC	EQ 50MG BASE	A062269 003	
COREPHARMA	EQ 20MG BASE	A065182 001	May 13, 2005
HEATHER	EQ 100MG BASE	A062462 001	May 11, 1983
INTERPHARM	EQ 100MG BASE	A062764 001	Sep 02, 1988
MUTUAL PHARM	EQ 100MG BASE	A062391 001	Sep 30, 1982
SUPERPHARM	EQ 100MG BASE	A062494 001	Feb 20, 1985
VINTAGE PHARMS	EQ 100MG BASE	A062538 001	Apr 07, 1986
WARNER CHILCOTT	EQ 100MG BASE	A062593 001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392 001	Mar 31, 1983
	EQ 100MG BASE	A062392 002	Mar 31, 1983

PERIOSTAT

COLLAGENEX	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050744 001	Sep 30, 1998
GALDERMA LABS LP	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050783 001	Feb 02, 2001

VIBRA-TABS

PFIZER	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050533 001	

TABLET, DELAYED RELEASE;ORAL
DOXYCYCLINE HYCLATE

IMPAX LABS INC	EQ 75MG BASE	A090505 001	Dec 28, 2010
	EQ 100MG BASE	A090505 002	Dec 28, 2010

DOXYLAMINE SUCCINATE
CAPSULE;ORAL
UNISOM

PFIZER	25MG	N019440 001	Feb 05, 1986

TABLET;ORAL
DECAPRYN

SANOFI AVENTIS US	12.5MG	N006412 015	
	25MG	N006412 014	

DOXY-SLEEP-AID

PAR PHARM	25MG	A070156 001	Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM	25MG	A088900 002	Feb 12, 1988
QUANTUM PHARMICS	25MG	A088603 001	Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
BENDECTIN

SANOFI AVENTIS US	10MG;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010598 002	

DROMOSTANOLONE PROPIONATE
INJECTABLE;INJECTION
DROLBAN

LILLY	50MG/ML	N012936 001	

DRONABINOL
CAPSULE;ORAL
DRONABINOL

INSYS THERAP	2.5MG	A078501 001	Aug 19, 2011
	5MG	A078501 002	Aug 19, 2011
	10MG	A078501 003	Aug 19, 2011

DROPERIDOL
INJECTABLE;INJECTION
DROPERIDOL

ABRAXIS PHARM	2.5MG/ML	A070992 001	Nov 17, 1986
	2.5MG/ML	A070993 001	Nov 17, 1986
ASTRAZENECA	2.5MG/ML	A072018 001	Oct 20, 1988
HOSPIRA	2.5MG/ML	A071645 001	Apr 07, 1988
	2.5MG/ML	A072272 001	Aug 31, 1995
IGI LABS INC	2.5MG/ML	A072019 001	Oct 19, 1988
	2.5MG/ML	A072020 001	Oct 19, 1988
	2.5MG/ML	A072021 001	Oct 19, 1988
LUITPOLD	2.5MG/ML	A072335 001	Oct 24, 1988
SMITH AND NEPHEW	2.5MG/ML	A071750 001	Sep 06, 1988
SOLOPAK	2.5MG/ML	A071754 001	Sep 06, 1988
	2.5MG/ML	A071755 001	Sep 06, 1988
WATSON LABS	2.5MG/ML	A073520 001	Nov 27, 1991
	2.5MG/ML	A073521 001	Nov 27, 1991
	2.5MG/ML	A073523 001	Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE
INJECTABLE;INJECTION
FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028 001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982 001	May 04, 1988

INNOVAR

AKORN MFG	2.5MG/ML;EQ 0.05MG BASE/ML	N016049 001	

DYCLONINE HYDROCHLORIDE
SOLUTION;TOPICAL
DYCLONE

ASTRAZENECA	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009925 002	
	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009925 001	

DYDROGESTERONE
TABLET;ORAL
GYNOREST

SOLVAY	5MG	N017388 001	
	10MG	N017388 002	

DYPHYLLINE
ELIXIR;ORAL
NEOTHYLLINE

TEVA	160MG/15ML	N007794 003	

INJECTABLE;INJECTION
NEOTHYLLINE

TEVA	250MG/ML	N009088 001	

TABLET;ORAL
DILOR

SAVAGE LABS	200MG	A084514 001	

DILOR-400

SAVAGE LABS	400MG	A084751 001	

LUFYLLIN

MEDA PHARMS	200MG	A084566 001	
	400MG	A084566 002	

NEOTHYLLINE

TEVA	200MG	N007794 001	
	400MG	N007794 002	

ECHOTHIOPHATE IODIDE
FOR SOLUTION;OPHTHALMIC
PHOSPHOLINE IODIDE

WYETH PHARMS INC	0.03%	N011963 002	
	0.06%	N011963 004	
	0.25%	N011963 003	

FDA data supplied by DrugPatentWatch.com

ECONAZOLE NITRATE
CREAM;TOPICAL
SPECTAZOLE

ALVOGEN MALTA	1%	N018751 001	Dec 23, 1982

EDETATE CALCIUM DISODIUM
TABLET;ORAL
CALCIUM DISODIUM VERSENATE

MEDICIS	500MG	N008922 002	

EDROPHONIUM CHLORIDE
INJECTABLE;INJECTION
EDROPHONIUM CHLORIDE

HOSPIRA	10MG/ML	A040131 001	Feb 24, 1998
WATSON LABS	10MG/ML	A040044 001	Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS	10MG/ML	A040043 001	Mar 20, 1996

REVERSOL

ORGANON USA INC	10MG/ML	A089624 001	May 13, 1988

TENSILON

TELIGENT PHARMA INC	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007959 001	

TENSILON PRESERVATIVE FREE

TELIGENT PHARMA INC	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007959 002	

EFAVIRENZ
CAPSULE;ORAL
SUSTIVA

BRISTOL MYERS SQUIBB	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020972 002	Sep 17, 1998

TABLET;ORAL
SUSTIVA

BRISTOL MYERS SQUIBB	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021360 001	Feb 01, 2002

EFLORNITHINE HYDROCHLORIDE
INJECTABLE;INJECTION
ORNIDYL

SANOFI AVENTIS US	200MG/ML	N019879 002	Nov 28, 1990

ENALAPRIL MALEATE
TABLET;ORAL
ENALAPRIL MALEATE

APOTHECON	2.5MG	A075583 001	Aug 22, 2000
	5MG	A075583 002	Aug 22, 2000
	10MG	A075583 003	Aug 22, 2000
	20MG	A075583 004	Aug 22, 2000
IVAX SUB TEVA PHARMS	2.5MG	A075482 001	Aug 22, 2000
	5MG	A075482 002	Aug 22, 2000
	10MG	A075482 003	Aug 22, 2000
	20MG	A075482 004	Aug 22, 2000
KRKA DD NOVO MESTO	2.5MG	A075370 001	Aug 22, 2000
	5MG	A075370 002	Aug 22, 2000
	10MG	A075369 001	Aug 22, 2000
	20MG	A075369 002	Aug 22, 2000
MYLAN	2.5MG	A075472 001	Aug 22, 2000
	5MG	A075472 002	Aug 22, 2000
	10MG	A075472 003	Aug 22, 2000
	20MG	A075472 004	Aug 22, 2000
SANDOZ	2.5MG	A075048 001	Aug 22, 2000
	5MG	A075048 002	Aug 22, 2000
	10MG	A075048 003	Aug 22, 2000
	20MG	A075048 004	Aug 22, 2000
SANDOZ INC	2.5MG	A075621 001	Aug 22, 2000
	5MG	A075621 002	Aug 22, 2000
	10MG	A075621 003	Aug 22, 2000
	20MG	A075621 004	Aug 22, 2000

ENALAPRIL MALEATE
TABLET;ORAL
ENALAPRIL MALEATE

SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000
	5MG	A075556	002	Aug 22, 2000
	10MG	A075556	003	Aug 22, 2000
	20MG	A075556	004	Aug 22, 2000
WATSON LABS	2.5MG	A075501	001	Aug 22, 2000
	5MG	A075501	002	Aug 22, 2000
	10MG	A075501	003	Aug 22, 2000
	20MG	A075501	004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE
TABLET, EXTENDED RELEASE;ORAL
LEXXEL

ASTRAZENECA	5MG;2.5MG	N020668	002	Oct 28, 1998
	5MG;5MG	N020668	001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG;12.5MG	A075736	001	Mar 25, 2003
	10MG;25MG	A075736	002	Mar 25, 2003
UPSHER-SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001
	10MG;25MG	A076116	002	Sep 19, 2001

ENALAPRILAT
INJECTABLE;INJECTION
ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456	001	Aug 22, 2000
	1.25MG/ML	A075571	001	Aug 22, 2000

VASOTEC

BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988

ENFLURANE
LIQUID;INHALATION
ENFLURANE

ABBOTT	99.9%	A070803	001	Sep 08, 1987
PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994

ETHRANE

BAXTER HLTHCARE	99.9%	N017087	001	

ENOXACIN
TABLET;ORAL
PENETREX

SANOFI AVENTIS US	200MG	N019616	004	Dec 31, 1991
	400MG	N019616	005	Dec 31, 1991

ENOXAPARIN SODIUM
INJECTABLE;SUBCUTANEOUS
LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020164	006	Jun 02, 2000

EPINEPHRINE
AEROSOL, METERED;INHALATION
BRONKAID MIST

STERLING	0.25MG/INH	N016803	001	

EPINEPHRINE

ARMSTRONG PHARMS	0.2MG/INH	A087907	001	May 23, 1984

PRIMATENE MIST

WYETH CONS	0.2MG/INH	N016126	001	

INJECTABLE;INJECTION
SUS-PHRINE SULFITE FREE

FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999
	5MG/ML	N007942	001	

INJECTABLE;INTRAMUSCULAR
EPI E Z PEN JR

MYLAN SPECLT	0.15MG/DELIVERY	N019430	004	Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPECLT	0.3MG/DELIVERY	N019430	003	Aug 03, 1995

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
TWINJECT 0.15

AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004

FDA data supplied by DrugPatentWatch.com

EPINEPHRINE
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
TWINJECT 0.3

AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003

EPINEPHRINE BITARTRATE
AEROSOL, METERED;INHALATION
BRONITIN MIST

WYETH CONS	0.3MG/INH	N016126 002	

MEDIHALER-EPI

3M	0.3MG/INH	N010374 003	

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
DURANEST

ASTRAZENECA	0.005MG/ML;1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017751 006	
	0.005MG/ML;1.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017751 007	
DENTSPLY PHARM	0.005MG/ML;1.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021384 001	

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CITANEST FORTE

ASTRAZENECA	0.005MG/ML;4%	N014763 008	

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
DURANEST

ASTRAZENECA	0.005MG/ML;0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017751 004	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE	0.01MG/ML;2%	A084720 001	
	0.02MG/ML;2%	A084732 001	

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EUROHLTH INTL SARL	0.01MG/ML;1%	A080406 001	
	0.01MG/ML;2%	A080406 002	
GRAHAM CHEM	0.01MG/ML;2%	A080504 004	Oct 19, 1983
	0.02MG/ML;2%	A080504 005	Oct 19, 1983
HOSPIRA	0.005MG/ML;1%	A089649 001	Jun 21, 1988
	0.005MG/ML;1.5%	A089650 001	Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT	0.01MG/ML;1%	A083154 001	
BEL MAR	0.01MG/ML;1%	A080820 001	
	0.01MG/ML;2%	A080757 001	
DELL LABS	0.01MG/ML;1%	A083389 001	
	0.01MG/ML;2%	A083390 001	
INTL MEDICATION	0.01MG/ML;1%	A086402 001	
WATSON LABS	0.01MG/ML;1%	A080377 003	
	0.01MG/ML;1%	A085463 001	
	0.01MG/ML;2%	A080377 004	

LIDOCATON

PHARMATON	0.01MG/ML;2%	A084729 001	Aug 17, 1983
	0.02MG/ML;2%	A084728 001	Aug 17, 1983

XYLOCAINE DENTAL WITH EPINEPHRINE

DENTSPLY PHARM	0.01MG/ML;2%	N021381 001	
	0.02MG/ML;2%	N021381 002	

XYLOCAINE W/ EPINEPHRINE

ASTRAZENECA	0.005MG/ML;1%	N010418 006	
	0.005MG/ML;1.5%	N010418 010	
	0.005MG/ML;2%	N010418 008	
FRESENIUS KABI USA	0.01MG/ML;2%	N006488 003	

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
PATCH;IONTOPHORESIS, TOPICAL
LIDOSITE TOPICAL SYSTEM KIT

VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504	001	May 06, 2004

SOLUTION;IONTOPHORESIS
IONTOCAINE

IOMED	0.01MG/ML;2%	N020530	001	Dec 21, 1995

SOLUTION;IONTOPHORESIS, TOPICAL
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI	0.01MG/ML;2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR	0.02MG/ML;1%	A080758	001	
	0.02MG/ML;2%	A080759	001	

EPIRUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007
	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007

INJECTABLE;IV (INFUSION)
EPIRUBICIN HYDROCHLORIDE

HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006
	200MG/VIAL	N050807	002	Sep 15, 2006

EPLERENONE
TABLET;ORAL
INSPRA

GD SEARLE LLC	100MG	N021437	003	Sep 27, 2002

EPROSARTAN MESYLATE
TABLET;ORAL
TEVETEN

ABBVIE	EQ 300MG BASE	N020738	004	Dec 22, 1997

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
TEVETEN HCT

ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001
	600MG;25MG	N021268	002	Nov 01, 2001

EPTIFIBATIDE
INJECTABLE;INJECTION
EPTIFIBATIDE

TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015

ERGOCALCIFEROL
CAPSULE;ORAL
DELTALIN

LILLY	50,000 IU	A080884	001	

VITAMIN D

CHASE CHEM	50,000 IU	A080747	001	
EVERYLIFE	50,000 IU	A080956	001	
IMPAX LABS	50,000 IU	A080951	001	
LANNETT	50,000 IU	A080825	001	
VITARINE	50,000 IU	A084053	001	
WEST WARD	50,000 IU	A083102	001	

ERGOLOID MESYLATES
CAPSULE;ORAL
HYDERGINE LC

NOVARTIS	1MG	N018706	001	Jan 18, 1983

SOLUTION;ORAL
HYDERGINE

NOVARTIS	1MG/ML	N018418	001	

TABLET;ORAL
ERGOLOID MESYLATES

MUTUAL PHARM	1MG	A088891	001	Nov 01, 1985
WATSON LABS	1MG	A086433	001	May 27, 1982

ERGOLOID MESYLATES

TABLET;ORAL			
ERGOLOID MESYLATES			
	1MG	A087244 001	Aug 16, 1982
GERIMAL			
WATSON LABS	1MG	A088207 001	Mar 22, 1984
HYDERGINE			
NOVARTIS	0.5MG	N017993 003	
TABLET;SUBLINGUAL			
ALKERGOT			
SANDOZ	0.5MG	A085153 001	
	1MG	A087417 001	
CIRCANOL			
3M	0.5MG	A084868 001	
	1MG	A085809 001	
DEAPRIL-ST			
BRISTOL MYERS SQUIBB	1MG	A085020 002	
ERGOLOID MESYLATES			
KV PHARM	0.5MG	A085899 001	
	0.5MG	A086265 001	
	1MG	A085900 001	
	1MG	A086264 001	
LEDERLE	0.5MG	A086984 001	
	1MG	A086985 001	
SUN PHARM INDS	0.5MG	A087407 001	
	1MG	A087552 001	
SUPERPHARM	0.5MG	A089233 001	Sep 23, 1986
	1MG	A089234 001	Sep 23, 1986
VANGARD	0.5MG	A088013 001	Sep 20, 1982
	1MG	A088014 001	Sep 20, 1982
WATSON LABS	0.5MG	A084930 001	
	0.5MG	A087233 001	
	1MG	A085177 001	
	1MG	A087183 001	
GERIMAL			
WATSON LABS	0.5MG	A086189 001	
	1MG	A086188 001	
HYDERGINE			
NOVARTIS	0.5MG	N009087 002	
	1MG	N009087 001	
HYDROGENATED ERGOT ALKALOIDS			
IVAX PHARMS	0.5MG	A087186 001	
	1MG	A087185 001	

ERGOTAMINE TARTRATE

AEROSOL, METERED;INHALATION			
MEDIHALER ERGOTAMINE			
3M	0.36MG/INH	N012102 001	
TABLET;SUBLINGUAL			
ERGOSTAT			
WATSON LABS INC	2MG	A088337 001	Jun 08, 1984
WIGRETTES			
ORGANON USA INC	2MG	A086750 001	Jul 29, 1982

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL			
ERLOTINIB HYDROCHLORIDE			
MYLAN PHARMS INC	EQ 25MG BASE	A091002 001	Jun 11, 2014
	EQ 100MG BASE	A091002 002	Jun 11, 2014
	EQ 150MG BASE	A091002 003	Jun 11, 2014
TEVA PHARMS USA	EQ 100MG BASE	A091059 002	Aug 28, 2015
	EQ 150MG BASE	A091059 003	Aug 28, 2015

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL			
ERYC			
PARKE DAVIS	250MG	A062546 001	Jul 25, 1985
	250MG	A062618 001	Sep 25, 1985
WARNER CHILCOTT LLC	250MG	A062338 001	
ERYC 125			
PARKE DAVIS	125MG	A062648 001	Oct 24, 1985
ERYC SPRINKLES			
HOSPIRA	125MG	N050593 001	Jul 22, 1985

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL				
ERYTHROMYCIN				
BARR	250MG	A063098	001	May 04, 1989
GEL;TOPICAL				
E-GLADES				
RENAISSANCE PHARMA	2%	A065009	001	Mar 18, 2002
EMGEL				
ALTANA	2%	A063107	001	Aug 23, 1991
LOTION;TOPICAL				
E-SOLVE 2				
SYOSSET	2%	A062467	001	Jul 03, 1985
OINTMENT;OPHTHALMIC				
ERYTHROMYCIN				
PHARMADERM	5MG/GM	A062446	001	Sep 26, 1983
PHARMAFAIR	5MG/GM	A062481	001	Apr 05, 1984
ILOTYCIN				
DISTA	0.5%	N050368	001	
POWDER;FOR RX COMPOUNDING				
ERYTHROMYCIN				
PADDOCK LLC	100%	N050610	001	Nov 07, 1986
SOLUTION;TOPICAL				
A/T/S				
TARO PHARMS NORTH	2%	A062405	001	Nov 18, 1982
C-SOLVE-2				
FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985
ERYDERM				
ARBOR PHARMS INC	2%	A062290	001	
ERYMAX				
MERZ PHARMS	2%	A062508	002	Jul 11, 1985
ERYTHRA-DERM				
PADDOCK LLC	2%	A062687	001	Feb 05, 1988
ERYTHRO-STATIN				
HI TECH PHARMA	2%	A064101	001	Oct 22, 1996
ERYTHROMYCIN				
ALPHARMA US PHARMS	1.5%	A062328	001	Apr 19, 1982
	2%	A062326	001	Apr 19, 1982
	2%	A062327	001	Apr 19, 1982
	2%	A062342	001	Feb 25, 1982
	2%	A062957	001	Jul 21, 1988
BAUSCH AND LOMB	2%	A064039	001	Jan 27, 1994
LILLY	2%	N050532	001	
PHARMAFAIR	1.5%	A062485	001	Jul 11, 1984
	2%	A062616	001	Jul 25, 1985
RENAISSANCE PHARMA	2%	A064127	001	Feb 14, 1997
SANSAC				
DOW PHARM	2%	A062522	001	Jan 24, 1985
STATICIN				
WESTWOOD SQUIBB	1.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050526	001	
T-STAT				
WESTWOOD SQUIBB	2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062436	001	Mar 09, 1983
SWAB;TOPICAL				
C-SOLVE-2				
IVAX SUB TEVA PHARMS	2%	A062751	001	Jul 30, 1993
ERYCETTE				
JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985
ERYTHROMYCIN				
FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006
RENAISSANCE PHARMA	2%	A064128	001	Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%	A062748	001	Jul 23, 1987
TABLET, DELAYED RELEASE;ORAL				
E-BASE				
BARR	333MG	A063028	001	May 15, 1990
	333MG	A063086	001	May 15, 1990
	500MG	A062999	001	Nov 25, 1988

ERYTHROMYCIN
TABLET, DELAYED RELEASE;ORAL

E-MYCIN			
ARBOR PHARMS INC	250MG	A060272 001	
	333MG	A060272 002	
ILOTYCIN			
DISTA	250MG	A061910 001	
R-P MYCIN			
SOLVAY	250MG	A061659 001	
ROBIMYCIN			
ROBINS AH	250MG	A061633 001	

ERYTHROMYCIN ESTOLATE

CAPSULE;ORAL			
ERYTHROMYCIN ESTOLATE			
BARR	EQ 125MG BASE	A062162 001	
	EQ 250MG BASE	A062162 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237 001	
WATSON LABS	EQ 250MG BASE	A062087 001	
ILOSONE			
LILLY	EQ 125MG BASE	A061897 001	
	EQ 250MG BASE	A061897 002	
FOR SUSPENSION;ORAL			
ILOSONE			
DISTA	EQ 125MG BASE/5ML	A061893 001	
SUSPENSION;ORAL			
ERYTHROMYCIN ESTOLATE			
ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353 001	Nov 18, 1982
	EQ 250MG BASE/5ML	A062409 001	Dec 16, 1982
G AND W LABS INC	EQ 125MG BASE/5ML	A062169 001	Oct 17, 1990
	EQ 250MG BASE/5ML	A062169 002	Oct 17, 1990
LIFE LABS	EQ 250MG BASE/5ML	A062362 001	Dec 17, 1982
ILOSONE			
LILLY	EQ 125MG BASE/5ML	A061894 001	
	EQ 125MG BASE/5ML	N050010 001	
	EQ 250MG BASE/5ML	A061894 002	
	EQ 250MG BASE/5ML	N050010 002	
SUSPENSION/DROPS;ORAL			
ILOSONE			
LILLY	EQ 100MG BASE/ML	A061894 003	
TABLET;ORAL			
ILOSONE			
LILLY	EQ 500MG BASE	A061896 001	
TABLET, CHEWABLE;ORAL			
ILOSONE			
DISTA	EQ 125MG BASE	A061895 001	
	EQ 250MG BASE	A061895 002	

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL			
ILOSONE SULFA			
LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599 001	Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL			
ERYTHROMYCIN ETHYLSUCCINATE			
ANI PHARMS INC	EQ 200MG BASE/5ML	A062055 001	
PEDIAMYCIN			
ROSS LABS	EQ 200MG BASE/5ML	A062305 001	
SUSPENSION;ORAL			
E-MYCIN E			
PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198 001	
	EQ 400MG BASE/5ML	A062198 002	
E.E.S. 200			
ARBOR PHARMS LLC	EQ 200MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061639 001	
E.E.S. 400			
ARBOR PHARMS LLC	EQ 400MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061639 002	

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION;ORAL			
ERYTHROMYCIN ETHYLSUCCINATE			
ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200 001	
	EQ 400MG BASE/5ML	A062200 002	
DISTA	EQ 200MG BASE/5ML	A062177 001	
	EQ 400MG BASE/5ML	A062177 002	
NASKA	EQ 400MG BASE/5ML	A062674 001	Mar 10, 1987
PARKE DAVIS	EQ 200MG BASE/5ML	A062231 001	
	EQ 400MG BASE/5ML	A062231 002	
PHARMAFAIR	EQ 200MG BASE/5ML	A062559 001	Mar 15, 1985
	EQ 400MG BASE/5ML	A062558 001	Mar 15, 1985
PEDIAMYCIN			
ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304 001	
PEDIAMYCIN 400			
ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304 002	
WYAMYCIN E			
WYETH AYERST	EQ 200MG BASE/5ML	A062123 002	
	EQ 400MG BASE/5ML	A062123 001	
SUSPENSION/DROPS;ORAL			
PEDIAMYCIN			
ROSS LABS	EQ 100MG BASE/2.5ML	A062305 002	
TABLET;ORAL			
E.E.S. 400			
ARBOR PHARMS LLC	EQ 400MG BASE	A061905 001	
ERYTHROMYCIN ETHYLSUCCINATE			
BARR	EQ 400MG BASE	A062256 001	
MYLAN	EQ 400MG BASE	A062847 001	Sep 14, 1988
TABLET, CHEWABLE;ORAL			
E.E.S.			
ARBOR PHARMS INC	EQ 200MG BASE	N050297 002	
ERYPED			
ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988
PEDIAMYCIN			
ROSS LABS	EQ 200MG BASE	A062306 001	

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL			
ERYZOLE			
ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	A062758 001	Jun 15, 1988
PEDIAZOLE			
ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N050529 001	

ERYTHROMYCIN GLUCEPTATE

INJECTABLE;INJECTION			
ILOTYCIN GLUCEPTATE			
DISTA	EQ 250MG BASE/VIAL	N050370 001	
	EQ 500MG BASE/VIAL	N050370 002	
	EQ 1GM BASE/VIAL	N050370 003	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION			
ERYTHROCIN			
ABBOTT	EQ 500MG BASE/VIAL	A062586 001	Jan 04, 1988
	EQ 1GM BASE/VIAL	A062586 002	Jan 04, 1988
HOSPIRA	EQ 500MG BASE/VIAL	N050182 002	
	EQ 1GM BASE/VIAL	N050182 003	
	EQ 1GM BASE/VIAL	N050609 002	Sep 24, 1986
ERYTHROMYCIN			
ELKINS SINN	EQ 500MG BASE/VIAL	A062563 001	Mar 28, 1985
	EQ 1GM BASE/VIAL	A062563 002	Mar 28, 1985
ERYTHROMYCIN LACTOBIONATE			
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062604 001	Nov 24, 1986
	EQ 1GM BASE/VIAL	A062604 002	Nov 24, 1986
BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A062993 001	May 09, 1989
	EQ 1GM BASE/VIAL	A062993 002	May 09, 1989
TEVA PARENTERAL	EQ 500MG BASE/VIAL	A063253 001	Jul 30, 1993
	EQ 1GM BASE/VIAL	A063253 002	Jul 30, 1993

ERYTHROMYCIN STEARATE
TABLET;ORAL

BRISTAMYCIN			
BRISTOL	EQ 250MG BASE	A061304 001	
	EQ 250MG BASE	A061887 001	
ERYPAR			
PARKE DAVIS	EQ 250MG BASE	A062032 001	
	EQ 500MG BASE	A062032 002	
WARNER CHILCOTT	EQ 250MG BASE	A062322 001	
ERYTHROCIN STEARATE			
ARBOR PHARMS LLC	EQ 125MG BASE	A060359 002	
	EQ 500MG BASE	A060359 003	
ERYTHROMYCIN STEARATE			
ANI PHARMS INC	EQ 250MG BASE	A061461 001	
	EQ 250MG BASE	A061591 001	
	EQ 500MG BASE	A061461 002	
	EQ 500MG BASE	A063179 001	May 15, 1990
LEDERLE	EQ 250MG BASE	A062089 001	
	EQ 500MG BASE	A062089 002	
MYLAN	EQ 250MG BASE	A061505 001	
	EQ 500MG BASE	A061505 002	
PUREPAC PHARM	EQ 250MG BASE	A061743 001	
WATSON LABS	EQ 250MG BASE	A062121 002	
	EQ 500MG BASE	A062121 001	
ETHRIL 250			
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605 001	
ETHRIL 500			
BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605 002	
PFIZER-E			
PFIZER	EQ 250MG BASE	A061791 001	
	EQ 500MG BASE	A061791 002	
WYAMYCIN S			
WYETH AYERST	EQ 250MG BASE	A061675 001	
	EQ 500MG BASE	A061675 002	

ESCITALOPRAM OXALATE
CAPSULE;ORAL

ESCITALOPRAM OXALATE			
MYLAN PHARMS INC	EQ 5MG BASE	A077660 001	Jul 31, 2007
	EQ 10MG BASE	A077660 002	Jul 31, 2007
	EQ 20MG BASE	A077660 003	Jul 31, 2007

ESMOLOL HYDROCHLORIDE
INJECTABLE;INJECTION

BREVIBLOC			
BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988
	20MG/ML	N019386 007	May 28, 2003

ESTAZOLAM
TABLET;ORAL

PROSOM			
ABBOTT	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019080 001	Dec 26, 1990
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019080 002	Dec 26, 1990

ESTRADIOL
FILM, EXTENDED RELEASE;TRANSDERMAL

ESCLIM			
WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847 001	Aug 04, 1998
	0.0375MG/24HR	N020847 002	Aug 04, 1998
	0.05MG/24HR	N020847 003	Aug 04, 1998
	0.075MG/24HR	N020847 004	Aug 04, 1998
	0.1MG/24HR	N020847 005	Aug 04, 1998
ESTRADIOL			
ORTHO MCNEIL PHARM	0.05MG/24HR	N021048 001	Sep 20, 1999
	0.075MG/24HR	N021048 002	Sep 20, 1999
	0.1MG/24HR	N021048 003	Sep 20, 1999
FEMPATCH			
PARKE DAVIS	0.025MG/24HR	N020417 001	Dec 03, 1996

FDA data supplied by DrugPatentWatch.com

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL			
VIVELLE			
NOVARTIS	0.025MG/24HR	N020323 005	Aug 16, 2000
	0.0375MG/24HR	N020323 001	Oct 28, 1994
	0.075MG/24HR	N020323 003	Oct 28, 1994
GEL;TOPICAL			
ESTROGEL			
ASCEND THERAPS US	0.06%	N021166 001	Feb 09, 2004
TABLET;ORAL			
ESTRACE			
BRISTOL MYERS SQUIBB	0.5MG	A081295 001	Jun 30, 1993
	1MG	A084499 001	
	2MG	A084500 001	
ESTRADIOL			
LANNETT HOLDINGS INC	0.5MG	A040138 001	Jan 30, 1998
	1MG	A040138 002	Jan 30, 1998
	2MG	A040138 003	Jan 30, 1998
USL PHARMA	0.5MG	A040297 001	Apr 17, 2002
	1MG	A040297 002	Apr 17, 2002
	2MG	A040297 003	Apr 17, 2002
GYNODIOL			
DURAMED PHARMS BARR	0.5MG	A040212 001	Dec 29, 1997
	1MG	A040212 002	Dec 29, 1997
	1.5MG	A040212 003	Dec 29, 1997
	2MG	A040212 004	Dec 29, 1997
INNOFEM			
NOVO NORDISK INC	0.5MG	A040312 001	Nov 19, 1999
	1MG	A040312 002	Nov 19, 1999
	2MG	A040312 003	Nov 19, 1999
TABLET;VAGINAL			
VAGIFEM			
NOVO NORDISK INC	25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020908 001	Mar 26, 1999

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION			
DEPO-ESTRADIOL			
PHARMACIA AND UPJOHN	1MG/ML	A085470 001	
	3MG/ML	A085470 002	
ESTRADIOL CYPIONATE			
WATSON LABS	5MG/ML	A085620 001	

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE;INTRAMUSCULAR			
LUNELLE			
PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874 001	Oct 05, 2000

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION			
DEPO-TESTADIOL			
PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968 001	
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE			
WATSON LABS	2MG/ML;50MG/ML	A085603 001	Mar 13, 1986

ESTRADIOL VALERATE

INJECTABLE;INJECTION			
ESTRADIOL VALERATE			
SANDOZ	10MG/ML	A040628 001	Oct 04, 2007
	20MG/ML	A040628 002	Oct 04, 2007
	40MG/ML	A040628 003	Oct 04, 2007
WATSON LABS	10MG/ML	A083546 001	
	40MG/ML	A083714 001	
WATSON LABS INC	20MG/ML	A083547 001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION			
DITATE-DS			
SAVAGE LABS	8MG/ML;180MG/ML	A086423 001	
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE			
WATSON LABS	4MG/ML;90MG/ML	A085865 001	
	8MG/ML;180MG/ML	A085860 001	

FDA data supplied by DrugPatentWatch.com

ESTRADIOL; NORGESTIMATE
TABLET;ORAL
PREFEST

TEVA WOMENS	1MG,1MG;N/A,0.09MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021040 001	Oct 22, 1999

ESTROGENS, CONJUGATED
TABLET;ORAL
PREMARIN

WYETH PHARMS INC	2.5MG	N004782 002	

ESTROGENS, CONJUGATED SYNTHETIC A
CREAM;VAGINAL
SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS	0.625MG/GM	N021788 001	Nov 28, 2008

TABLET;ORAL
CENESTIN

TEVA BRANDED PHARM	0.3MG	N020992 001	Jun 21, 2002
	0.45MG	N020992 005	Feb 05, 2004
	0.625MG	N020992 002	Mar 24, 1999
	0.9MG	N020992 003	Mar 24, 1999
	1.25MG	N020992 004	Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B
TABLET;ORAL
ENJUVIA

TEVA WOMENS	0.625MG	N021443 003	May 10, 2004
	1.25MG	N021443 004	May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET;ORAL-28
PREMPHASE (PREMARIN;CYCRIN 14/14)

WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303 002	Dec 30, 1994

PREMPRO (PREMARIN;CYCRIN)

WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303 001	Dec 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE
TABLET;ORAL
MILPREM-200

MEDPOINTE PHARM HLC	0.45MG;200MG	N011045 002

MILPREM-400

MEDPOINTE PHARM HLC	0.45MG;400MG	N011045 001

PMB 200

WYETH AYERST	0.45MG;200MG	N010971 005

PMB 400

WYETH AYERST	0.45MG;400MG	N010971 003

ESTROGENS, ESTERIFIED
TABLET;ORAL
AMNESTROGEN

BRISTOL MYERS SQUIBB	0.3MG	A083266 001
	0.625MG	A083266 002
	1.25MG	A083266 003
	2.5MG	A083266 004

ESTERIFIED ESTROGENS

PVT FORM	0.625MG	A083414 001
	1.25MG	A083765 001
	2.5MG	A085907 001
SANDOZ	1.25MG	A085302 001

ESTRATAB

SOLVAY	0.3MG	A086715 001
	0.625MG	A083209 001
	1.25MG	A083856 001
	2.5MG	A083857 001

EVEX

ROCHE PALO	0.625MG	A084215 001
	1.25MG	A083376 002

FEMOGEN

PVT FORM	0.625MG	A085076 001
	1.25MG	A085008 001
	2.5MG	A085007 001

FDA data supplied by DrugPatentWatch.com

ESTRONE
INJECTABLE;INJECTION
ESTROGENIC SUBSTANCE

WYETH AYERST	2MG/ML	A083488 001	

ESTRONE

WATSON LABS	2MG/ML	A083397 001	
	5MG/ML	A085239 001	

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS	2MG/ML	A085237 001	Nov 23, 1982

THEELIN

PARKEDALE	1MG/ML	N003977 001	
	2MG/ML	N003977 002	
	5MG/ML	N003977 003	

ESTROPIPATE
CREAM;VAGINAL
OGEN

PHARMACIA AND UPJOHN	1.5MG/GM	A084710 001	

TABLET;ORAL
ESTROPIPATE

DURAMED PHARMS BARR	0.75MG	A040296 001	Nov 01, 1999
	1.5MG	A040296 002	Nov 01, 1999
	3MG	A040296 003	Nov 01, 1999
MYLAN	3MG	A040359 003	Aug 26, 1999
WATSON LABS	6MG	A081216 001	Sep 23, 1993

ORTHO-EST

SUN PHARM INDS INC	0.75MG	A089567 001	Feb 27, 1991
	1.5MG	A089582 001	Jul 17, 1991

ESZOPICLONE
TABLET;ORAL
ESZOPICLONE

WOCKHARDT LTD	1MG	A091165 001	Jul 14, 2011
	2MG	A091165 002	Jul 14, 2011
	3MG	A091165 003	Jul 14, 2011

ETHACRYNIC ACID
TABLET;ORAL
EDECRIN

ATON	50MG	N016092 002	

ETHAMBUTOL HYDROCHLORIDE
TABLET;ORAL
MYAMBUTOL

STI PHARMA LLC	200MG	N016320 002	
	500MG	N016320 004	

ETHCHLORVYNOL
CAPSULE;ORAL
ETHCHLORVYNOL

BANNER PHARMACAPS	100MG	A084463 001	
	200MG	A084463 002	
	500MG	A084463 003	
	750MG	A084463 004	

PLACIDYL

ABBVIE	100MG	N010021 004	
	200MG	N010021 007	
	500MG	N010021 002	
	750MG	N010021 010	

ETHINAMATE
CAPSULE;ORAL
VALMID

DISTA	500MG	N009750 001	

ETHINYL ESTRADIOL
TABLET;ORAL
ESTINYL

SCHERING	0.02MG	N005292 001	
	0.05MG	N005292 002	
	0.5MG	N005292 003	

FEMINONE

PHARMACIA AND UPJOHN	0.05MG	N016649 001	

LYNORAL

ORGANON USA INC	0.01MG	N005490 003	
	0.05MG	N005490 002	

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21				
DEMULEN 1/35-21				
	GD SEARLE LLC	0.035MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018168 001	
DEMULEN 1/50-21				
	GD SEARLE LLC	0.05MG;1MG	N016927 001	
ZOVIA 1/35E-21				
	WATSON LABS	0.035MG;1MG	A072720 001	Dec 30, 1991
ZOVIA 1/50E-21				
	WATSON LABS	0.05MG;1MG	A072722 001	Dec 30, 1991
TABLET;ORAL-28				
DEMULEN 1/35-28				
	GD SEARLE LLC	0.035MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018160 001	
DEMULEN 1/50-28				
	GD SEARLE LLC	0.05MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016936 001	

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28				
NORQUEST FE				
	GD SEARLE LLC	0.035MG;75MG;1MG	N018926 001	Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28				
NORLESTRIN FE 1/50				
	PARKE DAVIS	0.05MG;75MG;1MG	N016766 001	
NORLESTRIN FE 2.5/50				
	PARKE DAVIS	0.05MG;75MG;2.5MG	N016854 001	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL				
LYBREL				
	WYETH PHARMS INC	0.02MG;0.09MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021864 001	May 22, 2007
PREVEN EMERGENCY CONTRACEPTIVE KIT				
	TEVA BRANDED PHARM	0.05MG;0.25MG	N020946 001	Sep 01, 1998
TABLET;ORAL-21				
ALESSE				
	WYETH PHARMS	0.02MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020683 001	Mar 27, 1997
AVIANE-21				
	DURAMED PHARMS BARR	0.02MG;0.1MG	A075796 002	Apr 30, 2001
ENPRESSE-21				
	DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809 001	Jul 16, 2001
LESSINA-21				
	BARR	0.02MG;0.1MG	A075803 001	Mar 20, 2002
LEVLITE				
	BAYER HLTHCARE	0.02MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020860 001	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL				
	BARR	0.02MG;0.1MG	A075862 001	Apr 29, 2003
LEVORA 0.15/30-21				
	WATSON LABS	0.03MG;0.15MG	A073592 001	Dec 13, 1993
NORDETTE-21				
	TEVA BRANDED PHARM	0.03MG;0.15MG	N018668 001	May 10, 1982
PORTIA-21				
	BARR	0.03MG;0.15MG	A075866 001	May 23, 2002
TRIPHASIL-21				
	WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or	N019192 001	Nov 01, 1984

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-21

TRIPHASIL-21			
	efficacy reasons**		
TRIVORA-21			
MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538 001	Dec 18, 1997

TABLET;ORAL-28

ALESSE			
WYETH PHARMS	0.02MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020683 002	Mar 27, 1997
LEVLITE			
BAYER HLTHCARE	0.02MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020860 002	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL			
BARR	0.02MG;0.1MG	A075862 002	Apr 29, 2003
NORDETTE-28			
TEVA BRANDED PHARM	0.03MG;0.15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018782 001	Jul 21, 1982
TRIPHASIL-28			
WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019190 001	Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA			
JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021180 001	Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BALZIVA-21			
BARR	0.035MG;0.4MG	A076198 001	Apr 22, 2004
BREVICON 21-DAY			
ALLERGAN SALES LLC	0.035MG;0.5MG	N017566 001	
GENCEPT 10/11-21			
BARR	0.035MG,0.035MG;0.5MG,1MG	A072694 001	Feb 28, 1992
MODICON 21			
ORTHO MCNEIL PHARM	0.035MG;0.5MG	N017488 001	
N.E.E. 1/35 21			
LPI	0.035MG;1MG	A071541 001	Dec 14, 1987
NORCEPT-E 1/35 21			
ORTHO MCNEIL PHARM	0.035MG;1MG	A071545 001	Feb 09, 1989
NORETHIN 1/35E-21			
WATSON LABS	0.035MG;1MG	A071480 001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL			
WATSON LABS	0.035MG;0.4MG	A078379 001	Feb 23, 2010
	0.035MG;0.5MG	A070684 001	Jan 29, 1987
	0.035MG;1MG	A070685 001	Jan 29, 1987
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043 001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071041 001	Sep 24, 1991
NORTREL 0.5/35-21			
BARR	0.035MG;0.5MG	A072692 001	Feb 28, 1992
ORTHO-NOVUM 1/35-21			
ORTHO MCNEIL PHARM	0.035MG;1MG	N017489 002	
ORTHO-NOVUM 10/11-21			
ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018354 001	Jan 11, 1982
ORTHO-NOVUM 7/14-21			
ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N019004 001	Apr 04, 1984

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21				
ORTHO-NOVUM 7/7/7-21				
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	N018985 001	Apr 04, 1984
OVCON-35				
	WARNER CHILCOTT	0.035MG;0.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018127 001	
OVCON-50				
	WARNER CHILCOTT	0.05MG;1MG	N018128 001	
TRI-NORINYL 21-DAY				
	MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977 001	Apr 13, 1984
TABLET;ORAL-28				
GENCEPT 10/11-28				
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072697 001	Feb 28, 1992
N.E.E. 1/35 28				
	LPI	0.035MG;1MG	A071542 001	Dec 14, 1987
NORCEPT-E 1/35 28				
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071546 001	Feb 09, 1989
NORETHIN 1/35E-28				
	WATSON LABS	0.035MG;1MG	A071481 001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL				
	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076393 001	Feb 04, 2010
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)				
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042 001	Sep 24, 1991
ORTHO-NOVUM 10/11-28				
	ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N018354 002	Jan 11, 1982
ORTHO-NOVUM 7/14-28				
	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N019004 002	Apr 04, 1984
OVCON-35				
	WARNER CHILCOTT LLC	0.035MG;0.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017716 001	
OVCON-50				
	WARNER CHILCOTT LLC	0.05MG;1MG	N017576 001	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL				
FEMHRT				
	APIL	0.005MG;1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021065 002	Oct 15, 1999
TABLET;ORAL-21				
ESTROSTEP 21				
	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020130 001	Oct 09, 1996
NORLESTRIN 21 1/50				
	PARKE DAVIS	0.05MG;1MG	N016749 001	
NORLESTRIN 21 2.5/50				
	PARKE DAVIS	0.05MG;2.5MG	N016852 001	
TABLET;ORAL-28				
NORLESTRIN 28 1/50				
	PARKE DAVIS	0.05MG;1MG	N016723 001	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21				
ORTHO CYCLEN-21				
	JANSSEN PHARMS	0.035MG;0.25MG	N019653 001	Dec 29, 1989
ORTHO TRI-CYCLEN				
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N019697 002	Jul 03, 1992
TABLET;ORAL-28				
NORGESTIMATE AND ETHINYL ESTRADIOL				
	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479 001	Mar 09, 2011
		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076626 001	Aug 17, 2006
		0.035MG;0.25MG	A076627 001	Aug 17, 2006

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21			
LO/OVRAL			
PELAGIUS	0.03MG;0.3MG	N017612 001	
LOW-OGESTREL-21			
MAYNE PHARMA	0.03MG;0.3MG	A075288 001	Jul 28, 1999
OGESTREL 0.5/50-21			
WATSON LABS	0.05MG;0.5MG	A075406 001	Dec 15, 1999
OVRAL			
WYETH PHARMS	0.05MG;0.5MG	N016672 001	
TABLET;ORAL-28			
LO/OVRAL-28			
WYETH PHARMS	0.03MG;0.3MG	N017802 001	
OVRAL-28			
WYETH PHARMS	0.05MG;0.5MG	N016806 001	

ETHOPROPAZINE HYDROCHLORIDE

TABLET;ORAL			
PARSIDOL			
PARKE DAVIS	10MG	N009078 003	
	50MG	N009078 006	
	100MG	N009078 008	

ETHOTOIN

TABLET;ORAL			
PEGANONE			
RECORDATI RARE	500MG	N010841 003	

ETHOXZOLAMIDE

TABLET;ORAL			
CARDRASE			
PHARMACIA AND UPJOHN	62.5MG	N011047 002	
	125MG	N011047 001	
ETHAMIDE			
ALLERGAN	125MG	N016144 001	

ETHYLESTRENOL

ELIXIR;ORAL			
MAXIBOLIN			
ORGANON USA INC	2MG/5ML	N014006 002	
TABLET;ORAL			
MAXIBOLIN			
ORGANON USA INC	2MG	N014005 002	

ETHYNODIOL DIACETATE; MESTRANOL

TABLET;ORAL-20			
OVULEN			
GD SEARLE LLC	1MG;0.1MG	N016029 002	
TABLET;ORAL-21			
OVULEN-21			
GD SEARLE LLC	1MG;0.1MG	N016029 003	
TABLET;ORAL-28			
OVULEN-28			
GD SEARLE LLC	1MG;0.1MG	N016705 001	

ETIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION			
DURANEST			
ASTRAZENECA	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017751 003	
	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017751 005	

ETIDRONATE DISODIUM

INJECTABLE;INJECTION			
DIDRONEL			
MGI PHARMA INC	50MG/ML	N019545 001	Apr 20, 1987

ETODOLAC

CAPSULE;ORAL

ETODOLAC

ANI PHARMS INC	200MG	A074899 001	Jul 08, 1997
	300MG	A074899 002	Jul 08, 1997
IDT AUSTRALIA LTD	200MG	A074840 001	Aug 29, 1997
	300MG	A074840 002	Aug 29, 1997
LEHIGH VALLEY	300MG	A074929 001	Jan 30, 1998
MYLAN	200MG	A074932 001	May 16, 1997
	200MG	A075071 001	Sep 30, 1998
	300MG	A074932 002	May 16, 1997
	300MG	A075071 002	Sep 30, 1998
SANDOZ	200MG	A074942 001	Sep 30, 1997
	300MG	A074942 002	Sep 30, 1997
VINTAGE PHARMS LLC	200MG	A074842 001	Jul 17, 1997
	300MG	A074842 002	Jul 17, 1997
WATSON LABS	200MG	A074844 001	Dec 23, 1997
	300MG	A074844 002	Dec 23, 1997

LODINE

WYETH PHARMS INC	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018922 002	Jan 31, 1991
	300MG	N018922 003	Jan 31, 1991

TABLET;ORAL

ETODOLAC

IVAX SUB TEVA PHARMS	400MG	A074883 001	Feb 28, 1997
	500MG	A074883 002	Nov 20, 1998
LEHIGH VALLEY	400MG	A074927 001	Oct 30, 1997
MYLAN	400MG	A075012 001	Sep 30, 1998
	500MG	A075012 002	Sep 30, 1998
OXFORD PHARMS	400MG	A074819 001	Feb 28, 1997
	500MG	A074819 002	Apr 28, 1998
RANBAXY LABS LTD	400MG	A075226 001	Nov 24, 1998
	500MG	A075226 002	Nov 24, 1998
SANDOZ	400MG	A074839 001	Jul 11, 1997
	400MG	A074846 001	Feb 28, 1997
TEVA	400MG	A074847 001	Apr 23, 1999
	500MG	A074847 002	Apr 23, 1999
VINTAGE PHARMS LLC	400MG	A074841 001	Jun 27, 1997
WATSON LABS	400MG	A074892 001	Apr 16, 1997
	400MG	A075069 001	Apr 16, 1998
	500MG	A074892 002	Oct 29, 1998

LODINE

WYETH PHARMS INC	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018922 004	Jul 29, 1993
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018922 005	Jun 28, 1996

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000
IDT AUSTRALIA LTD	400MG	A075943 001	Jul 26, 2002
	500MG	A075943 002	Jul 26, 2002
	600MG	A075943 003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829 001	Nov 30, 2001
	500MG	A075829 002	Nov 30, 2001

LODINE XL

WYETH PHARMS INC	400MG	N020584 001	Oct 25, 1996
	500MG	N020584 003	Jan 20, 1998
	600MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020584 002	Oct 25, 1996

FDA data supplied by DrugPatentWatch.com

ETONOGESTREL
IMPLANT;IMPLANTATION
IMPLANON

ORGANON USA INC	68MG/IMPLANT	N021529 001	Jul 17, 2006

ETOPOSIDE
CAPSULE;ORAL
VEPESID

DAVA PHARMS INC	50MG	N019557 001	Dec 30, 1986
	100MG	N019557 002	Dec 30, 1986

INJECTABLE;INJECTION
ETOPOSIDE

HOSPIRA	20MG/ML	A074320 001	Aug 30, 1995
	20MG/ML	A074351 001	Aug 30, 1995
PHARMACHEMIE BV	20MG/ML	A074227 001	Feb 22, 1996
PIERRE FABRE	20MG/ML	A074813 001	Jul 09, 1997
TEVA PARENTERAL	20MG/ML	A074510 001	Jun 29, 1995
TEVA PHARMS USA	20MG/ML	A074284 001	Feb 10, 1994
WATSON LABS	20MG/ML	A074228 001	Oct 15, 1996
WATSON LABS INC	20MG/ML	A074968 001	Jan 09, 1998

TOPOSAR

TEVA PARENTERAL	20MG/ML	A074166 001	Feb 27, 1995

VEPESID

CORDEN PHARMA	20MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018768 001	Nov 10, 1983

ETOPOSIDE PHOSPHATE
INJECTABLE;INJECTION
ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N020906 001	Feb 27, 1998
	EQ 1GM BASE/VIAL	N020906 002	Feb 27, 1998

ETRETINATE
CAPSULE;ORAL
TEGISON

ROCHE	10MG	N019369 001	Sep 30, 1986
	25MG	N019369 002	Sep 30, 1986

EVANS BLUE
INJECTABLE;INJECTION
EVANS BLUE

PARKE DAVIS	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008041 001	

FAMOTIDINE
INJECTABLE;INJECTION
FAMOTIDINE

APOTEX INC	10MG/ML	A075942 001	Aug 02, 2002
APOTHECON	10MG/ML	A075707 001	Apr 16, 2001
EUROHLTH INTL SARL	10MG/ML	A075799 001	Apr 30, 2002
HOSPIRA	10MG/ML	A075705 001	Apr 16, 2001
	10MG/ML	A075870 001	Nov 23, 2001
	10MG/ML	A075905 001	Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

APOTEX INC	10MG/ML	A076324 001	Nov 27, 2002
APOTHECON	10MG/ML	A075708 001	Apr 16, 2001
EUROHLTH INTL SARL	10MG/ML	A075789 001	Apr 30, 2002
HOSPIRA	10MG/ML	A075669 001	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

APOTEX INC	10MG/ML	A076322 001	Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE	0.4MG/ML	A075729 001	Dec 17, 2001

PEPCID

MERCK	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019510 001	Nov 04, 1986

PEPCID PRESERVATIVE FREE

MERCK	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019510 004	Nov 04, 1986

FAMOTIDINE

INJECTABLE;INJECTION

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

MERCK SHARP DOHME	0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020249	001	Feb 18, 1994

TABLET;ORAL

FAMOTIDINE

ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001
	40MG	A075650	002	Sep 14, 2001
APOTEX	10MG	A075610	001	Mar 12, 2002
MYLAN PHARMS INC	20MG	A075457	001	Apr 18, 2001
	40MG	A075457	002	Apr 18, 2001
SANDOZ	10MG	A076101	001	Oct 21, 2002
	20MG	A075302	001	Apr 16, 2001
	20MG	A075607	001	May 10, 2001
	20MG	A075793	001	Apr 16, 2001
	40MG	A075302	002	Apr 16, 2001
	40MG	A075607	002	May 10, 2001
	40MG	A075793	002	Apr 16, 2001
SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001
	40MG	A075639	001	Dec 12, 2001
WATSON LABS	10MG	A075404	001	Nov 28, 2001
	20MG	A075062	002	Apr 16, 2001
	40MG	A075062	001	Apr 16, 2001

TABLET, CHEWABLE;ORAL

PEPCID AC

J AND J CONSUMER INC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020801	001	Sep 24, 1998

TABLET, ORALLY DISINTEGRATING;ORAL

FLUXID

UCB INC	20MG	N021712	001	Sep 24, 2004
	40MG	N021712	002	Sep 24, 2004

PEPCID RPD

MERCK	20MG	N020752	001	May 28, 1998
	40MG	N020752	002	May 28, 1998

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012
	5MG	A091484	002	Aug 15, 2012
	10MG	A091484	003	Aug 15, 2012

PLENDIL

ASTRAZENECA	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019834	004	Sep 22, 1994
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019834	001	Jul 25, 1991
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019834	002	Jul 25, 1991

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS	87MG	N021695	002	Nov 30, 2004

LIPIDIL

ABBVIE	100MG	N019304	001	Dec 31, 1993

LIPOFEN

CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006

TRICOR (MICRONIZED)

ABBVIE	67MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019304	002	Feb 09, 1998
	134MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy	N019304	003	Jun 30, 1999

FENOFIBRATE
CAPSULE;ORAL
TRICOR (MICRONIZED)

	reasons**		
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019304 004	Jun 30, 1999

TABLET;ORAL
FENOFIBRATE

MYLAN	107MG	A076520 002	Dec 29, 2005

TRICOR

ABBOTT	54MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021203 001	Sep 04, 2001
	160MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021203 003	Sep 04, 2001

TRIGLIDE

SKYEPHARMA AG	50MG	N021350 001	May 07, 2005

FENOLDOPAM MESYLATE
INJECTABLE;INJECTION
FENOLDOPAM MESYLATE

LUITPOLD	EQ 10MG BASE/ML	A076656 001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826 001	Mar 07, 2007

FENOPROFEN CALCIUM
CAPSULE;ORAL
FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307 001	Aug 22, 1988
	EQ 300MG BASE	A072308 001	Aug 22, 1988
AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394 001	Oct 17, 1988
	EQ 300MG BASE	A072395 001	Oct 17, 1988
HALSEY	EQ 200MG BASE	A072355 001	Aug 17, 1988
	EQ 300MG BASE	A072356 001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437 001	Aug 22, 1988
	EQ 300MG BASE	A072438 001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214 001	Aug 17, 1988
	EQ 300MG BASE	A071738 001	Aug 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946 001	Apr 30, 1991
	EQ 300MG BASE	A072472 001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294 001	Aug 17, 1988
	EQ 200MG BASE	A072981 001	Aug 19, 1991
	EQ 300MG BASE	A072293 001	Aug 17, 1988
	EQ 300MG BASE	A072982 001	Aug 19, 1991

NALFON

XSPIRE	EQ 300MG BASE	N017604 002	

TABLET;ORAL
FENOPROFEN CALCIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A072274 001	May 02, 1988
AM THERAP	EQ 600MG BASE	A072309 001	Aug 17, 1988
AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396 001	Oct 17, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326 001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357 001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557 001	Aug 29, 1988
PAR PHARM	EQ 600MG BASE	A072429 001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194 001	Aug 17, 1988
SUN PHARM INDS	EQ 600MG BASE	A072902 001	Dec 21, 1990
USL PHARMA	EQ 600MG BASE	A072362 001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165 001	Aug 17, 1988
	EQ 600MG BASE	A072407 001	Aug 17, 1988
	EQ 600MG BASE	A072602 001	Oct 11, 1988

NALFON

DISTA	EQ 600MG BASE	N017710 001	

FENTANYL
FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

NOVEN	100MCG/HR	A077775 004	Oct 16, 2009

FENTANYL-25

NOVEN	25MCG/HR	A077775 001	Oct 16, 2009

FENTANYL
FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-50

NOVEN	50MCG/HR	A077775 002	Oct 16, 2009

FENTANYL-75

NOVEN	75MCG/HR	A077775 003	Oct 16, 2009

FENTANYL CITRATE
FILM;BUCCAL
ONSOLIS

BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266 001	Jul 16, 2009
	EQ 0.4MG BASE	N022266 002	Jul 16, 2009
	EQ 0.6MG BASE	N022266 003	Jul 16, 2009
	EQ 0.8MG BASE	N022266 004	Jul 16, 2009
	EQ 1.2MG BASE	N022266 005	Jul 16, 2009

INJECTABLE;INJECTION
FENTANYL CITRATE

ABBOTT	EQ 0.05MG BASE/ML	A070636 001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637 001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488 001	Jun 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

WATSON LABS INC	EQ 0.05MG BASE/ML	A074917 001	Feb 03, 1998

TABLET;BUCCAL, SUBLINGUAL
FENTANYL CITRATE

WATSON LABS	EQ 0.1MG BASE	A079075 001	Jan 07, 2011
	EQ 0.2MG BASE	A079075 002	Jan 07, 2011
	EQ 0.4MG BASE	A079075 003	Jan 07, 2011
	EQ 0.6MG BASE	A079075 004	Jan 07, 2011
	EQ 0.8MG BASE	A079075 005	Jan 07, 2011

FENTORA

CEPHALON	EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021947 006	Mar 02, 2007

TROCHE/LOZENGE;ORAL
FENTANYL

CEPHALON	EQ 0.1MG BASE	N020195 007	Oct 30, 1995
	EQ 0.2MG BASE	N020195 001	Oct 04, 1993
	EQ 0.3MG BASE	N020195 002	Oct 04, 1993
	EQ 0.4MG BASE	N020195 003	Oct 04, 1993

FERRIC AMMONIUM CITRATE
FOR SOLUTION;ORAL
FERRISELTZ

OTSUKA	600MG/PACKET	N020292 001	Oct 14, 1997

FERROUS CITRATE, FE-59
INJECTABLE;INJECTION
FERROUS CITRATE FE 59

MALLINCKRODT	25uCi/ML	N016729 001	

FERROUS SULFATE; FOLIC ACID
CAPSULE;ORAL
FOLVRON

LEDERLE	182MG;0.33MG	N006012 003	

FERUMOXIDES
INJECTABLE;INJECTION
FERIDEX I.V.

AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416 001	Aug 30, 1996

FERUMOXSIL
SUSPENSION;ORAL
GASTROMARK

AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410 001	Dec 06, 1996

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

ALKEM LABS LTD	4MG	A204827 001	Dec 10, 2015
	8MG	A204827 002	Dec 10, 2015

FDA data supplied by DrugPatentWatch.com

FEXOFENADINE HYDROCHLORIDE
CAPSULE;ORAL
ALLEGRA
SANOFI AVENTIS US 60MG N020625 001 Jul 25, 1996
FEXOFENADINE HYDROCHLORIDE
BARR 60MG A076169 001 Jul 13, 2005

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
BARR 60MG;120MG A076236 001 Apr 14, 2005
IMPAX PHARMS 60MG;120MG A076298 001 Nov 12, 2010

FIBRINOGEN, I-125
INJECTABLE;INJECTION
IBRIN
GE HEALTHCARE 154uCi/VIAL N017879 001
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR
ABBOTT 140uCi/ML N017787 001

FINASTERIDE
TABLET;ORAL
FINASTERIDE
IVAX SUB TEVA PHARMS 5MG A076340 001 Jun 19, 2006

FLAVOXATE HYDROCHLORIDE
TABLET;ORAL
FLAVOXATE HYDROCHLORIDE
IMPAX PHARMS 100MG A076234 001 Aug 28, 2003
URISPAS
ORTHO MCNEIL JANSSEN 100MG N016769 001

FLECAINIDE ACETATE
TABLET;ORAL
FLECAINIDE ACETATE
APOTEX INC 50MG A079164 001 Jul 09, 2009
100MG A079164 002 Jul 09, 2009
150MG A079164 003 Jul 09, 2009
IDT AUSTRALIA LTD 50MG A076030 001 Oct 28, 2002
100MG A076030 002 Oct 28, 2002
150MG A076030 003 Oct 28, 2002
TAMBOCOR
CNTY LINE PHARMS 200MG N018830 002 Oct 31, 1985

FLORBETAPIR F-18
SOLUTION;INTRAVENOUS
AMYVID
AVID RADIOPHARMS INC 10ML (13.5-51mCi/ML) N202008 001 Apr 06, 2012

FLOXURIDINE
INJECTABLE;INJECTION
FUDR
HOSPIRA 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N016929 001

FLUCONAZOLE
FOR SUSPENSION;ORAL
FLUCONAZOLE
SUN PHARM INDS LTD 50MG/5ML A076332 001 Jul 29, 2004
200MG/5ML A076332 002 Jul 29, 2004
TARO PHARM INDS 50MG/5ML A076918 001 Dec 18, 2006
200MG/5ML A076918 002 Dec 18, 2006
INJECTABLE;INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER
MYLAN LABS LTD 200MG/100ML (2MG/ML) A076888 001 Mar 25, 2005
400MG/200ML (2MG/ML) A076888 002 Mar 25, 2005
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%
TEVA PHARMS USA 200MG/100ML (2MG/ML) A076653 001 Jul 29, 2004
400MG/200ML (2MG/ML) A076653 002 Jul 29, 2004
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
HOSPIRA 200MG/100ML (2MG/ML) A076617 001 Jul 29, 2004
400MG/200ML (2MG/ML) A076617 002 Jul 29, 2004
MYLAN LABS LTD 200MG/100ML (2MG/ML) A076889 001 Mar 25, 2005
400MG/200ML (2MG/ML) A076889 002 Mar 25, 2005
TEVA PHARMS 200MG/100ML (2MG/ML) A076837 001 Jan 13, 2005

FDA data supplied by DrugPatentWatch.com

FLUCONAZOLE
INJECTABLE;INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		400MG/200ML (2MG/ML)	A076837	002 Jan 13, 2005

TABLET;ORAL
FLUCONAZOLE

	GEDEON RICHTER USA	50MG	A076432	001 Jul 29, 2004
		100MG	A076432	002 Jul 29, 2004
		150MG	A076432	003 Jul 29, 2004
		200MG	A076432	004 Jul 29, 2004
	IDT AUSTRALIA LTD	50MG	A076086	001 Jul 29, 2004
		100MG	A076086	002 Jul 29, 2004
		150MG	A076086	003 Jul 29, 2004
		200MG	A076086	004 Jul 29, 2004
	MYLAN PHARMS INC	50MG	A076042	001 Jul 29, 2004
		100MG	A076042	002 Jul 29, 2004
		150MG	A076042	003 Jul 29, 2004
		200MG	A076042	004 Jul 29, 2004
	PLIVA	50MG	A076424	001 Jul 29, 2004
		100MG	A076424	002 Jul 29, 2004
		150MG	A076424	003 Jul 29, 2004
		200MG	A076424	004 Jul 29, 2004
	RANBAXY LABS LTD	50MG	A076386	001 Jul 29, 2004
		100MG	A076386	002 Jul 29, 2004
		150MG	A076386	003 Jul 29, 2004
		200MG	A076386	004 Jul 29, 2004
	ROXANE	50MG	A076213	001 Jul 29, 2004
		100MG	A076213	002 Jul 29, 2004
		150MG	A076213	003 Jul 29, 2004
		200MG	A076213	004 Jul 29, 2004

FLUDARABINE PHOSPHATE
INJECTABLE;INJECTION
FLUDARA

	GENZYME CORP	50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020038	001 Apr 18, 1991

TABLET;ORAL
OFORTA

	SANOFI AVENTIS US	10MG	N022273	001 Dec 18, 2008

FLUDEOXYGLUCOSE F-18
INJECTABLE;INJECTION
FLUDEOXYGLUCOSE F18

	DOWNSTATE CLINCL	4-40mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020306	001 Aug 19, 1994
		4-90mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020306	002 Sep 25, 2001

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

	WEILL MEDCL COLL	10-100mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021768	001 Aug 05, 2004

FLUDROCORTISONE ACETATE
TABLET;ORAL
FLORINEF

	CASPER PHARMA LLC	0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010060	001

FLUMAZENIL
INJECTABLE;INJECTION
FLUMAZENIL

	CLARIS	0.5MG/5ML (0.1MG/ML)	A076755	002 Oct 12, 2004
		1MG/10ML (0.1MG/ML)	A076755	001 Oct 12, 2004
	TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589	002 Oct 12, 2004
		1MG/10ML (0.1MG/ML)	A076589	001 Oct 12, 2004

FLUMAZENIL
INJECTABLE;INJECTION
ROMAZICON

HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020073 001	Dec 20, 1991
	0.5MG/5ML (0.1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020073 002	Dec 20, 1991

FLUMETHASONE PIVALATE
CREAM;TOPICAL
LOCORTEN

NOVARTIS	0.03%	N016379 001	

FLUNISOLIDE
AEROSOL, METERED;INHALATION
AEROBID

ROCHE PALO	0.25MG/INH	N018340 001	Aug 17, 1984

SPRAY, METERED;NASAL
NASALIDE

IVAX RES	0.025MG/SPRAY	N018148 001	

NASAREL

TEVA BRANDED PHARM	0.029MG/SPRAY	N020409 001	Mar 08, 1995

FLUOCINOLONE ACETONIDE
CREAM;TOPICAL
FLUOCET

ALPHARMA US PHARMS	0.025%	A088360 001	Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.01%	A088361 001	Jan 16, 1984
PERRIGO NEW YORK	0.01%	A086810 001	Mar 04, 1982
	0.025%	A086811 001	Mar 04, 1982
PHARMADERM	0.01%	A088047 001	Dec 16, 1982
	0.025%	A088045 001	Dec 16, 1982
PHARMAFAIR	0.01%	A088499 001	Aug 02, 1984
	0.025%	A088506 001	Aug 02, 1984
TARO	0.01%	A040035 001	Oct 31, 1994
	0.01%	A087102 001	Apr 27, 1982
	0.025%	A040042 001	Oct 31, 1994
USL PHARMA	0.01%	A088757 001	Feb 11, 1985
	0.025%	A088756 001	Mar 28, 1985

FLUONID

ALLERGAN HERBERT	0.025%	A087156 002	Sep 06, 1984

FLUOTREX

SAVAGE LABS	0.01%	A088174 001	May 06, 1983
	0.025%	A088173 001	Mar 09, 1983

SYNALAR-HP

MEDIMETRIKS PHARMS	0.2%	N016161 002	

GEL;TOPICAL
FLUONID

ALLERGAN HERBERT	0.025%	A087300 001	May 27, 1982

OINTMENT;TOPICAL
FLUOCINOLONE ACETONIDE

PHARMADERM	0.025%	A088046 001	Dec 16, 1982
PHARMAFAIR	0.025%	A088507 001	Feb 27, 1984
USL PHARMA	0.025%	A088742 001	Feb 08, 1985

FLUONID

ALLERGAN HERBERT	0.025%	A087157 001	Sep 06, 1984

FLUOTREX

SAVAGE LABS	0.025%	A088172 001	Mar 09, 1983

SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.01%	A087159 001	Jun 16, 1982
BAUSCH AND LOMB	0.01%	A040059 001	Dec 20, 1993
MORTON GROVE	0.01%	A088312 001	Jan 27, 1984
PHARMADERM	0.01%	A088048 001	Dec 16, 1982
PHARMAFAIR	0.01%	A088449 001	Feb 08, 1984

FLUONID

ALLERGAN HERBERT	0.01%	A087158 001	Mar 17, 1983

FLUOTREX

SAVAGE LABS	0.01%	A088171 001	Mar 09, 1983

FLUOCINONIDE
CREAM;TOPICAL
FLUOCINONIDE

PERRIGO NEW YORK	0.05%	A071790 001	Jul 13, 1988
TARO	0.05%	A071500 001	Jun 10, 1987

FLUOCINONIDE EMULSIFIED BASE

G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995

LIDEX

CNTY LINE PHARMS	0.05%	N016908 002	

LIDEX-E

CNTY LINE PHARMS	0.05%	N016908 003	

GEL;TOPICAL
LIDEX

CNTY LINE PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017373 001	

SOLUTION;TOPICAL
FLUOCINONIDE

TARO	0.05%	A072857 001	Aug 02, 1989
TEVA PHARMS	0.05%	A072522 001	Sep 28, 1990

FLUORESCEIN SODIUM
INJECTABLE;INJECTION
FUNDUSCEIN-25

NOVARTIS	25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017869 001	

FLUOROMETHOLONE
CREAM;TOPICAL
OXYLONE

PHARMACIA AND UPJOHN	0.025%	N011748 001	

SUSPENSION/DROPS;OPHTHALMIC
FLUOR-OP

NOVARTIS	0.1%	A070185 001	Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN
SUSPENSION/DROPS;OPHTHALMIC
TOBRASONE

ALCON	0.1%;0.3%	N050628 001	Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM
SUSPENSION/DROPS;OPHTHALMIC
FML-S

ALLERGAN	0.1%;10%	N019525 001	Sep 29, 1989

FLUOROURACIL
INJECTABLE;INJECTION
ADRUCIL

PHARMACIA AND UPJOHN	50MG/ML	A081222 001	Jun 28, 1991
	50MG/ML	N017959 001	
TEVA PARENTERAL	50MG/ML	A040023 001	Oct 18, 1991
	50MG/ML	A081225 001	Aug 28, 1991

FLUOROURACIL

ABIC	50MG/ML	A088929 001	Mar 04, 1986
ABRAXIS PHARM	50MG/ML	A089152 001	Mar 21, 1986
	50MG/ML	A089428 001	Jan 12, 1987
	50MG/ML	A089519 001	Mar 12, 1987
BEDFORD	50MG/ML	A089508 001	Jan 26, 1988
EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772 001	Aug 11, 2008
FRESENIUS KABI USA	50MG/ML	A040291 001	Mar 24, 1999
	50MG/ML	A040379 001	Nov 15, 2000
MARCHAR	50MG/ML	A087791 001	Jan 18, 1983
SMITH AND NEPHEW	50MG/ML	A088766 001	Dec 28, 1984
	50MG/ML	A088767 001	Dec 28, 1984
	50MG/ML	A089434 001	Mar 26, 1987
SPECTRUM PHARMS	50MG/ML	A087792 001	Oct 13, 1982
	500MG/10ML (50MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012209 001	

SOLUTION;TOPICAL
FLUOROPLEX

ELORAC	1%	N016765 001	

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL				
FLUOXETINE				
SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002
	EQ 20MG BASE	A075787	002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
	EQ 20MG BASE	A075662	002	Jan 29, 2002
FLUOXETINE HYDROCHLORIDE				
ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008
	EQ 20MG BASE	A076287	002	May 20, 2008
BARR	EQ 40MG BASE	A076251	001	May 18, 2005
CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
	EQ 20MG BASE	A076022	002	Jan 30, 2002
CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002
	EQ 20MG BASE	A076165	002	Feb 01, 2002
PAR PHARM	EQ 10MG BASE	A076922	001	Dec 16, 2004
	EQ 20MG BASE	A076922	002	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A075807	001	Jan 29, 2002
	EQ 10MG BASE	A077469	001	Nov 17, 2008
	EQ 20MG BASE	A075807	002	Jan 29, 2002
	EQ 20MG BASE	A077469	002	Nov 17, 2008
WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008
	EQ 20MG BASE	A078143	002	Jan 16, 2008
	EQ 40MG BASE	A078143	003	Jan 16, 2008
PROZAC				
ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999
SARAFEM				
ELI LILLY AND CO	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018936	007	Jul 06, 2000
	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018936	008	Jul 06, 2000
SOLUTION;ORAL				
FLUOXETINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002
LANNETT	EQ 20MG BASE/5ML	A076458	001	May 14, 2004
PROZAC				
LILLY	EQ 20MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020101	001	Apr 24, 1991
TABLET;ORAL				
FLUOXETINE HYDROCHLORIDE				
BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
	EQ 40MG BASE	A075865	003	Aug 30, 2004
SANDOZ	EQ 10MG BASE	A076024	001	Jan 29, 2002
PROZAC				
LILLY	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020974	001	Mar 09, 1999
	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020974	002	Mar 09, 1999

FLUOXYMESTERONE

TABLET;ORAL				
ANDROID-F				
VALEANT PHARM INTL	10MG	A087196	001	
FLUOXYMESTERONE				
VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983
HALOTESTIN				
PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	

FDA data supplied by DrugPatentWatch.com

FLUOXYMESTERONE
TABLET;ORAL
ORA-TESTRYL

BRISTOL MYERS SQUIBB	2MG	N011359 001	
	5MG	N011359 002	

FLUPHENAZINE DECANOATE
INJECTABLE;INJECTION
FLUPHENAZINE DECANOATE

HOSPIRA	25MG/ML	A074966 001	Apr 16, 1998
MYLAN LABS LTD	25MG/ML	A075918 001	Aug 17, 2001
TEVA PARENTERAL	25MG/ML	A074795 001	Sep 10, 1996

PROLIXIN DECANOATE

BRISTOL MYERS SQUIBB	25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016727 001	

FLUPHENAZINE ENANTHATE
INJECTABLE;INJECTION
PROLIXIN ENANTHATE

APOTHECON	25MG/ML	N016110 001	

FLUPHENAZINE HYDROCHLORIDE
CONCENTRATE;ORAL
FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	5MG/ML	A073058 001	Aug 30, 1991

PERMITIL

SCHERING	5MG/ML	N016008 001	

PROLIXIN

APOTHECON	5MG/ML	A070533 001	Nov 07, 1985

ELIXIR;ORAL
FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC	2.5MG/5ML	A081310 001	Apr 29, 1993

PROLIXIN

APOTHECON	2.5MG/5ML	N012145 003	

INJECTABLE;INJECTION
PROLIXIN

APOTHECON	2.5MG/ML	N011751 005	

TABLET;ORAL
FLUPHENAZINE HYDROCHLORIDE

WATSON LABS	1MG	A088555 001	Dec 18, 1987
	2.5MG	A088544 001	Dec 18, 1987
	5MG	A088527 001	Dec 18, 1987
	10MG	A088550 001	Dec 18, 1987

PERMITIL

SCHERING	0.25MG	N012034 001	
	2.5MG	N012034 004	
	5MG	N012034 005	
	10MG	N012034 006	

PROLIXIN

APOTHECON	1MG	N011751 004	
	2.5MG	N011751 001	
	5MG	N011751 003	
	10MG	N011751 002	

TABLET, EXTENDED RELEASE;ORAL
PERMITIL

SCHERING	1MG	N012419 004	

FLUPREDNISOLONE
TABLET;ORAL
ALPHADROL

PHARMACIA AND UPJOHN	1.5MG	N012259 002	

FLURANDRENOLIDE
LOTION;TOPICAL
FLURANDRENOLIDE

ALPHARMA US PHARMS	0.05%	A087203 001	Apr 29, 1982

OINTMENT;TOPICAL
CORDRAN

AQUA PHARMS	0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012806 004	

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM;TOPICAL			
CORDRAN N			
LILLY	0.05%;EQ 3.5MG BASE/GM	N050346 001	
OINTMENT;TOPICAL			
CORDRAN N			
LILLY	0.05%;EQ 3.5MG BASE/GM	N050345 001	

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL			
DALMANE			
VALEANT PHARM INTL	15MG	N016721 001	
	30MG	N016721 002	
FLURAZEPAM HYDROCHLORIDE			
AUROLIFE PHARMA LLC	15MG	A071716 001	Jul 31, 1991
	30MG	A071717 001	Jul 31, 1991
HALSEY	15MG	A071808 001	Jan 07, 1988
	30MG	A071809 001	Jan 07, 1988
HIKMA INTL PHARMS	15MG	A071107 001	Dec 08, 1986
HIKMA PHARMS LLC	30MG	A071108 001	Dec 08, 1986
PAR PHARM	15MG	A070444 001	Mar 20, 1986
	30MG	A070445 001	Mar 20, 1986
PUREPAC PHARM	15MG	A071927 001	Sep 09, 1987
	30MG	A071551 001	Sep 09, 1987
SUN PHARM INDS	15MG	A070454 001	Aug 04, 1986
	30MG	A070455 001	Aug 04, 1986
SUPERPHARM	15MG	A071659 001	Aug 04, 1988
	30MG	A071660 001	Aug 04, 1988
USL PHARMA	15MG	A070562 001	Jul 09, 1987
	30MG	A070563 001	Jul 09, 1987
WARNER CHILCOTT	15MG	A071767 001	Dec 04, 1987
	30MG	A071768 001	Dec 04, 1987
WATSON LABS	15MG	A071205 001	Nov 25, 1986
	15MG	A072368 001	Mar 30, 1989
	30MG	A071068 001	Nov 25, 1986
	30MG	A072369 001	Mar 30, 1989

FLURBIPROFEN

TABLET;ORAL			
ANSAID			
PHARMACIA AND UPJOHN	50MG	N018766 002	Oct 31, 1988
	100MG	N018766 003	Oct 31, 1988
FLURBIPROFEN			
AUROLIFE PHARMA LLC	50MG	A074448 001	Jul 28, 1995
	100MG	A074448 002	Jul 28, 1995
IVAX SUB TEVA PHARMS	50MG	A074411 001	May 31, 1995
	100MG	A074411 002	May 31, 1995
PLIVA	50MG	A074647 001	Apr 01, 1997
	100MG	A074647 002	Apr 01, 1997
TEVA	50MG	A074405 002	May 24, 1995
	100MG	A074405 001	May 24, 1995
THERAGEN	100MG	A074560 002	May 16, 1997

FLUTAMIDE

CAPSULE;ORAL			
EULEXIN			
SCHERING	125MG	N018554 001	Jan 27, 1989
FLUTAMIDE			
SANDOZ	125MG	A075818 001	Sep 18, 2001

FLUTICASONE PROPIONATE

AEROSOL, METERED;INHALATION			
FLOVENT			
GLAXOSMITHKLINE	0.044MG/INH	N020548 001	Mar 27, 1996
	0.11MG/INH	N020548 002	Mar 27, 1996
	0.22MG/INH	N020548 003	Mar 27, 1996
CREAM;TOPICAL			
CUTIVATE			
FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019958 001	Dec 18, 1990
FLUTICASONE PROPIONATE			
NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004

FDA data supplied by DrugPatentWatch.com

FLUTICASONE PROPIONATE

OINTMENT;TOPICAL				
FLUTICASONE PROPIONATE				
TARO PHARM INDS	0.005%	A077145	001	Jun 14, 2005
POWDER;INHALATION				
FLOVENT				
GLAXOSMITHKLINE	0.044MG/INH	N020549	001	Nov 07, 1997
	0.088MG/INH	N020549	002	Nov 07, 1997
	0.22MG/INH	N020549	003	Nov 07, 1997
SPRAY, METERED;NASAL				
FLONASE				
GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994

FLUVOXAMINE MALEATE

TABLET;ORAL				
FLUVOXAMINE MALEATE				
ACTAVIS ELIZABETH	25MG	A075901	001	Dec 28, 2000
	50MG	A075901	002	Dec 28, 2000
	100MG	A075901	003	Dec 28, 2000
ANI PHARMS INC	25MG	A075898	001	Mar 12, 2001
	50MG	A075898	002	Mar 12, 2001
	100MG	A075898	003	Mar 12, 2001
MYLAN	50MG	A075950	001	Oct 15, 2001
	100MG	A075950	002	Oct 15, 2001
NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006
	50MG	A075900	002	Feb 23, 2006
	100MG	A075900	003	Feb 23, 2006
SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002
	50MG	A076125	002	Apr 29, 2002
	100MG	A076125	003	Apr 29, 2002
SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
	50MG	A075899	002	Jan 17, 2001
	100MG	A075899	003	Jan 17, 2001
UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001
	50MG	A075887	002	Jan 05, 2001
	100MG	A075887	003	Jan 05, 2001
WATSON LABS	25MG	A075894	001	Apr 18, 2001
	50MG	A075894	002	Apr 18, 2001
	100MG	A075894	003	Apr 18, 2001
LUVOX				
SOLVAY	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020243	001	Dec 05, 1994
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020243	002	Dec 05, 1994
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020243	003	Dec 05, 1994
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020243	004	Dec 05, 1994

FOLIC ACID

INJECTABLE;INJECTION				
FOLIC ACID				
BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993
FOLVITE				
WYETH PHARMS INC	5MG/ML	N005897	008	
TABLET;ORAL				
FOLIC ACID				
BARR	1MG	A089177	001	Jan 08, 1986
EVERYLIFE	1MG	A080755	001	
HALSEY	1MG	A083598	001	
IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
LANNETT	1MG	A080816	001	
LILLY	1MG	N006135	003	
MK LABS	1MG	A083526	001	
NEXGEN PHARMA INC	1MG	A084915	001	

FDA data supplied by DrugPatentWatch.com

FOLIC ACID
TABLET;ORAL
FOLIC ACID

PHARMERAL	1MG	A084158 001	
PIONEER PHARMS	1MG	A088949 001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784 001	
SANDOZ	1MG	A084472 001	
SUN PHARM INDS	1MG	A040582 001	Jul 18, 2005
TABLICAPS	1MG	A083133 002	
UDL	1MG	A088199 001	Mar 29, 1983
USL PHARMA	1MG	A087828 001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903 001	
VANGARD	1MG	A088730 001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296 001	
WATSON LABS	1MG	A083141 001	
	1MG	A085141 002	
WHITEWORTH TOWN PLSN	1MG	A080691 002	

FOLICET

MISSION PHARMA	1MG	A087438 001	

FOLVITE

WYETH PHARMS INC	1MG	N005897 004	

FOLLITROPIN ALFA/BETA
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
FOLLISTIM

ORGANON USA INC	75 IU/VIAL	N020582 001	Sep 29, 1997
	150 IU/VIAL	N020582 002	Sep 29, 1997

INJECTABLE;SUBCUTANEOUS
FOLLISTIM AQ

ORGANON USA INC	75 IU/0.5ML	N021273 001	Aug 26, 2005
	150 IU/0.18ML	N021211 003	Feb 11, 2004
	150 IU/0.5ML	N021273 002	Aug 26, 2005

GONAL-F

EMD SERONO	37.5 IU/VIAL	N020378 003	May 25, 2000
	37.5 IU/VIAL	N021765 001	Mar 25, 2004
	75 IU/VIAL	N020378 001	Sep 29, 1997
	150 IU/VIAL	N020378 002	Sep 29, 1997
	150 IU/VIAL	N021765 003	Mar 25, 2004

FOMEPIZOLE
INJECTABLE;INJECTION
FOMEPIZOLE

MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033 001	Apr 07, 2009

FOMIVIRSEN SODIUM
INJECTABLE;INJECTION
VITRAVENE PRESERVATIVE FREE

NOVARTIS	6.6MG/ML	N020961 001	Aug 26, 1998

FORMOTEROL FUMARATE
POWDER;INHALATION
FORADIL CERTIHALER

NOVARTIS	0.0085MG/INH	N021592 001	Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE
POWDER;INTRAVENOUS
EMEND

MERCK AND CO INC	EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022023 001	Jan 25, 2008

FOSINOPRIL SODIUM
TABLET;ORAL
FOSINOPRIL SODIUM

ACTAVIS LABS FL INC	10MG	A076620 001	Oct 15, 2004
	20MG	A076620 002	Oct 15, 2004
	40MG	A076620 003	Oct 15, 2004
RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004
	20MG	A076580 002	Apr 23, 2004
	40MG	A076580 003	Apr 23, 2004
UPSHER-SMITH LABS	10MG	A076188 001	Oct 08, 2004
	20MG	A076188 002	Oct 08, 2004
	40MG	A076188 003	Oct 08, 2004
WATSON LABS	10MG	A076987 001	Dec 23, 2004
	10MG	A077531 001	Aug 31, 2006

FDA data supplied by DrugPatentWatch.com

FOSINOPRIL SODIUM
TABLET;ORAL
FOSINOPRIL SODIUM

	20MG	A076987 002	Dec 23, 2004
	20MG	A077531 002	Aug 31, 2006
	40MG	A076987 003	Dec 23, 2004
	40MG	A077531 003	Aug 31, 2006

MONOPRIL

BRISTOL MYERS SQUIBB	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019915 002	May 16, 1991
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019915 003	May 16, 1991
	40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019915 004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
TABLET;ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

ACTAVIS LABS FL INC	10MG;12.5MG	A076608 001	Dec 03, 2004
	20MG;12.5MG	A076608 002	Dec 03, 2004
MYLAN	10MG;12.5MG	A077705 001	Aug 14, 2006
	20MG;12.5MG	A077705 002	Aug 14, 2006
SUN PHARM INDS LTD	10MG;12.5MG	A076739 001	Dec 17, 2004
	20MG;12.5MG	A076739 002	Dec 17, 2004
TEVA	10MG;12.5MG	A076945 001	Jul 05, 2006
	20MG;12.5MG	A076945 002	Jul 05, 2006
WATSON LABS	10MG;12.5MG	A077144 001	Aug 16, 2005
	20MG;12.5MG	A077144 002	Aug 16, 2005

MONOPRIL-HCT

BRISTOL MYERS SQUIBB	10MG;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020286 002	Nov 30, 1994
	20MG;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020286 001	Nov 30, 1994

FOSPHENYTOIN SODIUM
INJECTABLE;INJECTION
FOSPHENYTOIN SODIUM

APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126 001	Aug 06, 2007
FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052 001	Aug 06, 2007
TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007

FOSPROPOFOL DISODIUM
SOLUTION;INTRAVENOUS
LUSEDRA

EISAI INC	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008

FURAZOLIDONE
SUSPENSION;ORAL
FUROXONE

SHIRE	50MG/15ML	N011323 002	

TABLET;ORAL
FUROXONE

SHIRE	100MG	N011270 002	

FUROSEMIDE
INJECTABLE;INJECTION
FUROSEMIDE

ABRAXIS PHARM	10MG/ML	N018507 001	Jul 30, 1982
	10MG/ML	N019036 001	Aug 13, 1984
ASTRAZENECA	10MG/ML	A070014 001	Sep 09, 1985
HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987
	10MG/ML	A072080 001	Aug 13, 1991
	10MG/ML	A074337 001	Oct 31, 1994
IGI LABS INC	10MG/ML	A070095 001	Sep 09, 1985
	10MG/ML	A070096 001	Sep 09, 1985
INTL MEDICATION	10MG/ML	N018025 001	
LUITPOLD	10MG/ML **Federal Register	N018579 001	Nov 30, 1983

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

		determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	MARSAM PHARMS LLC	10MG/ML	A074017 001	Jun 30, 1994
	ORGANON USA INC	10MG/ML	A070017 001	Dec 15, 1986
	SMITH AND NEPHEW	10MG/ML	A070023 001	Feb 05, 1986
		10MG/ML	A070078 001	Feb 05, 1986
	WARNER CHILCOTT	10MG/ML	N018420 001	Feb 26, 1982
	WATSON LABS	10MG/ML	A070019 001	Sep 22, 1986
		10MG/ML	A070604 001	Jan 02, 1987
	WEST-WARD PHARMS INT	10MG/ML	A071439 001	Sep 14, 1990
		10MG/ML	N018267 001	
	WYETH AYERST	10MG/ML	N018670 001	Jul 20, 1982

LASIX

	SANOFI AVENTIS US	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016363 001	

SOLUTION;ORAL

LASIX

	SANOFI AVENTIS US	10MG/ML	N017688 001	

TABLET;ORAL

FUROSEMIDE

	DAVA PHARMS INC	20MG	N018415 001	Jul 27, 1982
		40MG	N018415 002	Jul 27, 1982
		80MG	N018415 003	Nov 26, 1984
	INTL MEDICATION	20MG	N018753 001	Feb 28, 1984
		40MG	N018753 002	Feb 28, 1984
	KALAPHARM	20MG	N018868 001	Jun 28, 1983
		40MG	N018868 002	Jun 28, 1983
	MUTUAL PHARM	40MG	N018790 001	Nov 29, 1983
	SANDOZ	40MG	N018750 002	Jul 30, 1984
	SUN PHARM INDS	20MG	A070043 001	Sep 26, 1985
		80MG	A070100 001	Jan 26, 1988
	SUPERPHARM	20MG	N018370 002	Jun 26, 1984
		40MG	N018370 001	Feb 10, 1983
	WARNER CHILCOTT	20MG	N018419 001	Jan 31, 1983
		40MG	N018419 002	Jan 31, 1983
		80MG	N018419 003	Nov 13, 1984
	WATSON LABS	20MG	A070412 001	Feb 26, 1986
		20MG	A070449 001	Nov 22, 1985
		20MG	A071379 001	Jan 02, 1987
		20MG	N018369 001	May 14, 1982
		40MG	A070413 001	Feb 26, 1986
		40MG	A070450 001	Nov 22, 1985
		40MG	N018369 002	May 14, 1982
		80MG	A070528 001	Jan 07, 1986
		80MG	A071594 001	Feb 09, 1988

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

	HIKMA	100MG	A078150 001	Sep 25, 2007
		300MG	A078150 002	Sep 25, 2007
		400MG	A078150 003	Sep 25, 2007
	IVAX SUB TEVA PHARMS	100MG	A075477 001	Mar 23, 2005
		300MG	A075477 002	Mar 23, 2005
		400MG	A075477 003	Mar 23, 2005
	SANDOZ	100MG	A075428 001	Jan 24, 2006
		100MG	A075539 001	Apr 06, 2005
		300MG	A075428 002	Jan 24, 2006
		300MG	A075539 002	Apr 06, 2005
		400MG	A075428 003	Jan 24, 2006
		400MG	A075539 003	Apr 06, 2005
	SUN PHARM INDS	100MG	A076537 001	Jun 30, 2005
		300MG	A076537 002	Jun 30, 2005
		400MG	A076537 003	Jun 30, 2005
	SUN PHARM INDS LTD	100MG	A076606 001	Oct 07, 2005
		300MG	A076606 002	Oct 07, 2005
		400MG	A076606 003	Oct 07, 2005
	WATSON LABS	100MG	A075485 003	May 11, 2007

FDA data supplied by DrugPatentWatch.com

GABAPENTIN
CAPSULE;ORAL
GABAPENTIN

	300MG	A075485 002	May 11, 2007
	400MG	A075485 001	May 11, 2007

TABLET;ORAL
GABAPENTIN

HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011
	800MG	A078782 002	Jul 21, 2011
RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	600MG	A076877 001	Jul 06, 2006
	800MG	A076120 002	Jan 27, 2006
	800MG	A076877 002	Jul 06, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004

GADODIAMIDE
INJECTABLE;INJECTION
OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066 001	Sep 05, 2007

GADOFOSVESET TRISODIUM
SOLUTION;INTRAVENOUS
ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711 001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711 002	Dec 22, 2008

GALANTAMINE HYDROBROMIDE
CAPSULE, EXTENDED RELEASE;ORAL
GALANTAMINE HYDROBROMIDE

IMPAX LABS	EQ 8MG BASE	A078484 001	May 27, 2009
	EQ 16MG BASE	A078484 002	May 27, 2009
	EQ 24MG BASE	A078484 003	May 27, 2009

SOLUTION;ORAL
RAZADYNE

JANSSEN PHARMS	4MG/ML	N021224 001	Jun 22, 2001

TABLET;ORAL
GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009
	EQ 8MG BASE	A077585 002	Sep 15, 2009
	EQ 12MG BASE	A077585 003	Sep 15, 2009
YABAO PHARM	EQ 4MG BASE	A077604 001	Feb 06, 2009
	EQ 8MG BASE	A077604 002	Feb 06, 2009
	EQ 12MG BASE	A077604 003	Feb 06, 2009

GALLAMINE TRIETHIODIDE
INJECTABLE;INJECTION
FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842 001	
	100MG/ML	N007842 002	

GALLIUM CITRATE GA-67
INJECTABLE;INJECTION
GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700 001	

NEOSCAN

GE HEALTHCARE	2mCi/ML	N017655 001	

GALLIUM NITRATE
INJECTABLE;INJECTION
GANITE

CHAPTER 7 TRUSTEE	25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019961 002	Jan 17, 1991

GANCICLOVIR
CAPSULE;ORAL
CYTOVENE

ROCHE PALO	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 001	Dec 22, 1994
	500MG **Federal Register determination that product was not discontinued or	N020460 002	Dec 12, 1997

FDA data supplied by DrugPatentWatch.com

GANCICLOVIR
CAPSULE;ORAL
CYTOVENE
withdrawn for safety or efficacy reasons**
GANCICLOVIR
RANBAXY LABS LTD 250MG A076457 001 Jun 27, 2003
500MG A076457 002 Jun 27, 2003
IMPLANT;IMPLANTATION
VITRASERT
BAUSCH AND LOMB 4.5MG N020569 001 Mar 04, 1996

GANCICLOVIR SODIUM
INJECTABLE;INJECTION
GANCICLOVIR SODIUM
WEST-WARD PHARMS INT EQ 500MG BASE/VIAL A076222 001 Jul 16, 2003

GATIFLOXACIN
SOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN
APOTEX INC 0.3% A079084 001 Aug 19, 2011

GEFITINIB
TABLET;ORAL
IRESSA
ASTRAZENECA 250MG N021399 001 May 05, 2003

GEMFIBROZIL
CAPSULE;ORAL
GEMFIBROZIL
MYLAN 300MG A073466 001 Jan 25, 1993
PUREPAC PHARM 300MG A072929 001 Jan 29, 1993
LOPID
PFIZER PHARMS 200MG N018422 001
300MG N018422 002
TABLET;ORAL
GEMFIBROZIL
MYLAN 600MG A074452 001 Feb 16, 1995
PUREPAC PHARM 600MG A074360 001 Aug 31, 1994
SANDOZ 600MG A074615 001 Sep 29, 1995
WATSON LABS 600MG A074156 001 Oct 24, 1994
600MG A074442 001 Apr 28, 1995

GEMTUZUMAB OZOGAMICIN
INJECTABLE;INJECTION
MYLOTARG
WYETH PHARMS INC 5MG/VIAL N021174 001 May 17, 2000

GENTAMICIN SULFATE
CREAM;TOPICAL
GARAMYCIN
SCHERING EQ 0.1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** A060462 001
GENTAFAIR
PHARMAFAIR EQ 0.1% BASE A062458 001 Sep 01, 1983
GENTAMICIN SULFATE
ALPHARMA US PHARMS EQ 0.1% BASE A062471 001 Sep 27, 1983
PHARMADERM EQ 1MG BASE/GM A062530 001 Jul 05, 1984
INJECTABLE;INJECTION
APOGEN
KING PHARMS EQ 10MG BASE/ML A062289 001
EQ 40MG BASE/ML A062289 002
BRISTAGEN
BRISTOL EQ 40MG BASE/ML A062288 001
GARAMYCIN
SCHERING EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** A061716 002
EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** A061739 001
EQ 40MG BASE/ML **Federal Register determination that product was not A061716 001

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GARAMYCIN			
	discontinued or withdrawn for safety or efficacy reasons**		
GENTAFAIR			
PHARMAFAIR	EQ 40MG BASE/ML	A062493 001	Aug 28, 1985
GENTAMICIN			
INTL MEDICATION	EQ 1MG BASE/ML	A062325 003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325 001	
	EQ 100MG BASE/100ML	A062325 004	Jun 23, 1982
GENTAMICIN SULFATE			
ABBOTT	EQ 1.2MG BASE/ML	A062413 001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413 002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413 003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413 004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413 005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413 006	Aug 11, 1983
	EQ 70MG BASE/100ML	A062413 007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413 008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413 009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413 010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356 001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356 002	Mar 04, 1982
KALAPHARM	EQ 40MG BASE/ML	A062354 001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340 001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507 001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507 002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149 001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106 002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318 002	
	EQ 40MG BASE/ML	A062318 001	
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A062251 002	
	EQ 40MG BASE/ML	A062251 001	
WYETH AYERST	EQ 10MG BASE/ML	A062264 001	
	EQ 40MG BASE/ML	A062264 002	
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	EQ 0.8MG BASE/ML	A062814 001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814 002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814 003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814 004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814 005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814 006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814 007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814 008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814 009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814 010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814 011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814 012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814 013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814 014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373 001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373 010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373 003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373 004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588 001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414 002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588 002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588 003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414 004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588 004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414 005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588 005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062414 006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588 006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414 007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588 007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588 008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062414 009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588 009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588 010	Jan 06, 1986

GENTAMICIN SULFATE

INJECTABLE;INJECTION			
U-GENCIN			
PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248 001	
	EQ 40MG BASE/ML	A062248 002	
INJECTABLE;INTRATHECAL			
GARAMYCIN			
SCHERING	EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050505 001	
OINTMENT;OPHTHALMIC			
GARAMYCIN			
SCHERING	EQ 0.3% BASE	N050425 001	
GENTACIDIN			
NOVARTIS	EQ 0.3% BASE	A062501 001	Jul 26, 1984
GENTAFAIR			
PHARMAFAIR	EQ 3MG BASE/GM	A062443 001	May 26, 1983
OINTMENT;TOPICAL			
GARAMYCIN			
SCHERING	EQ 0.1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060463 001	
GENTAFAIR			
PHARMAFAIR	EQ 0.1% BASE	A062444 001	May 26, 1983
GENTAMICIN SULFATE			
ALPHARMA US PHARMS	EQ 0.1% BASE	A062496 001	Mar 14, 1984
G AND W LABS INC	EQ 0.1% BASE	A064054 001	Apr 29, 1994
PHARMADERM	EQ 0.1% BASE	A062534 001	Oct 10, 1984
SOLUTION/DROPS;OPHTHALMIC			
GARAMYCIN			
SCHERING	EQ 0.3% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050039 002	
GENTACIDIN			
NOVARTIS	EQ 0.3% BASE	A062480 001	Mar 30, 1984
GENTAFAIR			
PHARMAFAIR	EQ 0.3% BASE	A062440 001	May 03, 1983
GENTAMICIN SULFATE			
ALCON PHARMS LTD	EQ 0.3% BASE	A062523 001	Nov 25, 1985
PACO	EQ 3MG BASE/ML	A062932 001	Nov 07, 1988

GENTIAN VIOLET

SUPPOSITORY;VAGINAL			
GVS			
SAVAGE LABS	0.4%	A083513 001	
TAMPON;VAGINAL			
GENAPAX			
KEY PHARMS	5MG	A085017 001	

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS			
COPAXONE			
TEVA PHARMS USA	20MG/VIAL	N020622 001	Dec 20, 1996

GLIMEPIRIDE

TABLET;ORAL			
GLIMEPIRIDE			
ACTAVIS LABS FL INC	1MG	A076995 001	Apr 27, 2010
	2MG	A076995 002	Apr 27, 2010
	4MG	A076995 003	Apr 27, 2010
COREPHARMA	1MG	A077274 001	Oct 06, 2005
	2MG	A077274 002	Oct 06, 2005
	4MG	A077274 003	Oct 06, 2005
HIKMA PHARMS	1MG	A078952 001	Aug 01, 2013
	2MG	A078952 002	Aug 01, 2013
	4MG	A078952 003	Aug 01, 2013
MYLAN	1MG	A077486 001	Feb 10, 2006
	2MG	A077486 002	Feb 10, 2006
	4MG	A077486 003	Feb 10, 2006
RANBAXY	3MG	A077366 001	Oct 06, 2005
	6MG	A077366 002	Oct 06, 2005
RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005

FDA data supplied by DrugPatentWatch.com

GLIMEPIRIDE
TABLET;ORAL
GLIMEPIRIDE

	2MG	A076875 002	Oct 06, 2005
	4MG	A076875 003	Oct 06, 2005
	8MG	A076875 004	Oct 06, 2005
WATSON LABS	1MG	A077280 001	Feb 03, 2006
	2MG	A077280 002	Feb 03, 2006
	4MG	A077280 003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE
TABLET;ORAL
AVANDARYL

SB PHARMCO	1MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 001	Nov 23, 2005
	2MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 002	Nov 23, 2005
	2MG;8MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 004	Mar 30, 2007
	4MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 003	Nov 23, 2005
	4MG;8MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 005	Mar 30, 2007

GLIPIZIDE
TABLET;ORAL
GLIPIZIDE

ANI PHARMS INC	5MG	A074387 001	Mar 04, 1996
	10MG	A074387 002	Mar 04, 1996
BARR LABS INC	5MG	A074619 001	Apr 04, 1997
	10MG	A074619 002	Apr 04, 1997
SANDOZ	5MG	A074542 001	Jun 20, 1995
	10MG	A074542 002	Jun 20, 1995
VINTAGE PHARMS LLC	5MG	A074378 001	Nov 28, 1994
	10MG	A074378 002	Nov 28, 1994
WATSON LABS	5MG	A074370 001	Nov 22, 1994
	10MG	A074370 002	Nov 22, 1994

GLUCOTROL

PFIZER	2.5MG	N017783 003	May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDE
TABLET;ORAL
METAGLIP

BRISTOL MYERS SQUIBB	2.5MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021460 001	Oct 21, 2002
	2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021460 002	Oct 21, 2002
	5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021460 003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE
INJECTABLE;INJECTION
GLUCAGON

LILLY	EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012122 001	
	EQ 10MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012122 002	

GLUTETHIMIDE
CAPSULE;ORAL
DORIDEN

SANOFI AVENTIS US	500MG	N009519 008	

TABLET;ORAL
DORIDEN

SANOFI AVENTIS US	250MG	N009519 002	
	500MG	N009519 005	

GLUTETHIMIDE

HALSEY	250MG	A089458 001	Oct 10, 1986
	500MG	A089459 001	Oct 10, 1986
LANNETT	250MG	A083475 001	
	500MG	A085571 001	
UCB INC	500MG	A085171 001	
UPSHER-SMITH LABS	500MG	A083234 002	
VITARINE	500MG	A087297 001	
WATSON LABS	500MG	A084362 001	
	500MG	A085763 001	

GLYBURIDE
TABLET;ORAL
GLYBURIDE

ACTAVIS ELIZABETH	1.5MG	A075947 001	Nov 14, 2002
	3MG	A075947 002	Nov 14, 2002
	6MG	A075947 003	Nov 14, 2002

GLYBURIDE (MICRONIZED)

SANDOZ	1.5MG	A075174 001	Jun 22, 1998
	3MG	A075174 002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055 001	Apr 17, 1992
	3MG	N020055 002	Apr 17, 1992
	6MG	N020055 003	Mar 08, 2000

GLYNASE

PHARMACIA AND UPJOHN	4.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020051 003	Sep 24, 1993

MICRONASE

PHARMACIA AND UPJOHN	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017498 001	May 01, 1984
	2.5MG	N017498 002	May 01, 1984
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017498 003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE
TABLET;ORAL
GLUCOVANCE

BRISTOL MYERS SQUIBB	1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021178 001	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

COREPHARMA	1.25MG;250MG	A076731 001	Nov 19, 2004
	2.5MG;500MG	A076731 002	Nov 19, 2004
	5MG;500MG	A076731 003	Nov 19, 2004
TEVA	1.25MG;250MG	A076821 001	Jan 27, 2005
	2.5MG;500MG	A076821 002	Jan 27, 2005
	5MG;500MG	A076821 003	Jan 27, 2005

GLYCINE
SOLUTION;IRRIGATION
GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633 001	

GLYCOPYRROLATE
INJECTABLE;INJECTION
GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475 001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393 001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169 001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947 001	Jun 24, 1983

GLYCOPYRROLATE
INJECTABLE;INJECTION
ROBINUL

ROBINS AH	0.2MG/ML	N014764 001	
WEST-WARD PHARMS INT	0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017558 001	

TABLET;ORAL
GLYCOPYRROLATE

COREPHARMA	1MG	A040568 001	Dec 22, 2004
	2MG	A040568 002	Dec 22, 2004
HIKMA INTL PHARMS	1MG	A040836 001	Mar 05, 2009
	2MG	A040836 002	Mar 05, 2009
WATSON LABS	1MG	A085562 001	
	1MG	A086902 001	
	2MG	A085563 001	
	2MG	A086178 001	
	2MG	A086900 001	

GONADORELIN ACETATE
INJECTABLE;INJECTION
LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687 001	Oct 10, 1989
	3.2MG/VIAL	N019687 002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE
INJECTABLE;INJECTION
FACTREL

HIKMA (MAPLE)	EQ 0.1MG BASE/VIAL	N018123 001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123 002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123 003	Sep 30, 1982

GONADOTROPIN, CHORIONIC
INJECTABLE;INJECTION
A.P.L.

FERRING	5,000 UNITS/VIAL	N017055 001	
	10,000 UNITS/VIAL	N017055 002	
	20,000 UNITS/VIAL	N017055 003	

CHORIONIC GONADOTROPIN

BEL MAR	5,000 UNITS/VIAL	N017054 001	
	10,000 UNITS/VIAL	N017054 002	
FERRING	2,000 UNITS/VIAL	N017016 009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016 011	Feb 16, 1990
	5,000 UNITS/VIAL	N017016 006	
	15,000 UNITS/VIAL	N017016 010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016 004	
FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067 001	
	15,000 UNITS/VIAL	N017067 004	
	20,000 UNITS/VIAL	N017067 003	

FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056 001	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS;OPHTHALMIC
NEO-POLYCIN

DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427 001	

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818 001	Oct 11, 1988
WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788 001	Jun 11, 1987

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383 001	Aug 31, 1982

GRANISETRON HYDROCHLORIDE
INJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008
SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION			
KYTRIL			
ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020239 003	Sep 17, 2004
	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020239 004	Mar 11, 1994
	EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020239 001	Dec 29, 1993
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020239 002	Mar 11, 1994
SOLUTION;ORAL			
GRANISOL			
PEDIATRX	EQ 2MG BASE/10ML	A078334 001	Feb 28, 2008
KYTRIL			
ROCHE	EQ 2MG BASE/10ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021238 001	Jun 27, 2001
TABLET;ORAL			
GRANISETRON HYDROCHLORIDE			
BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007
COREPHARMA	EQ 1MG BASE	A078260 001	Dec 31, 2007
KYTRIL			
ROCHE	EQ 1MG BASE **Federal Register determination that product was not withdrawn or discontinued for safety or efficacy reasons**	N020305 001	Mar 16, 1995
	EQ 2MG BASE **Federal Register determination that product was not withdrawn or discontinued for safety or efficacy reasons**	N020305 002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET;ORAL			
RAXAR			
OTSUKA	EQ 200MG BASE	N020695 001	Nov 06, 1997
	EQ 400MG BASE	N020695 002	May 14, 1998
	EQ 600MG BASE	N020695 003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL			
GRISACTIN			
WYETH AYERST	125MG	N050051 002	
	250MG	N050051 001	
SUSPENSION;ORAL			
GRIFULVIN V			
JOHNSON AND JOHNSON	125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050448 001	
TABLET;ORAL			
FULVICIN-U/F			
ELORAC	250MG	A060569 002	
	500MG	A060569 001	
GRIFULVIN V			
J AND J	125MG	A060618 001	
	250MG	A060618 002	
	500MG	A060618 003	
VALEANT LUXEMBOURG	125MG	A062279 001	
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062279 002	
GRISACTIN			
WYETH AYERST	500MG	A060212 001	

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL				
GRIFULVIN V				
VALEANT LUXEMBOURG	125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062483	001	Jan 26, 1984
TABLET;ORAL				
GRIFULVIN V				
VALEANT LUXEMBOURG	500MG	A062279	003	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL				
FULVICIN P/G				
ELORAC	125MG	A061996	001	
	250MG	A061996	002	
FULVICIN P/G 165				
ELORAC	165MG	A061996	003	Apr 06, 1982
FULVICIN P/G 330				
ELORAC	330MG	A061996	004	Apr 06, 1982
GRISACTIN ULTRA				
WYETH AYERST	125MG	A062178	001	
	165MG	A062438	001	Nov 17, 1983
	250MG	A062178	002	
	330MG	A062438	002	Nov 17, 1983
ULTRAGRIS-165				
PLIVA	165MG	A062645	001	Jun 30, 1992
ULTRAGRIS-330				
PLIVA	330MG	A062646	001	Jun 30, 1992

GUANABENZ ACETATE

TABLET;ORAL				
GUANABENZ ACETATE				
ANI PHARMS INC	EQ 4MG BASE	A074267	001	Jun 01, 1994
	EQ 8MG BASE	A074267	002	Jun 01, 1994
SANDOZ	EQ 4MG BASE	A074517	001	Sep 30, 1998
	EQ 8MG BASE	A074517	002	Sep 30, 1998
WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994
	EQ 8MG BASE	A074025	002	Feb 28, 1994
WYTENSIN				
WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982
	EQ 8MG BASE	N018587	002	Sep 07, 1982
	EQ 16MG BASE	N018587	003	Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL				
HYLOREL				
PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982
	25MG	N018104	002	Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL				
GUANETHIDINE MONOSULFATE				
WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985
	EQ 25MG SULFATE	A086114	001	Mar 26, 1985
ISMELIN				
NOVARTIS	EQ 10MG SULFATE	N012329	001	
	EQ 25MG SULFATE	N012329	002	

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
ESIMIL				
NOVARTIS	10MG;25MG	N013553	001	

GUANFACINE HYDROCHLORIDE

TABLET;ORAL				
GUANFACINE HYDROCHLORIDE				
WATSON LABS	EQ 1MG BASE	A074762	001	Jun 25, 1997
	EQ 2MG BASE	A074762	002	Jun 25, 1997
TENEX				
PROMIUS PHARMA	EQ 3MG BASE	N019032	003	Nov 07, 1988
TABLET, EXTENDED RELEASE;ORAL				
GUANFACINE HYDROCHLORIDE				
IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015
	EQ 2MG BASE	A202238	002	Oct 20, 2015
	EQ 3MG BASE	A202238	003	Oct 20, 2015

FDA data supplied by DrugPatentWatch.com

GUANFACINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

	EQ 4MG BASE	A202238 004	Oct 20, 2015

HALAZEPAM
TABLET;ORAL
PAXIPAM

SCHERING	20MG	N017736 003	
	40MG	N017736 004	

HALCINONIDE
CREAM;TOPICAL
HALOG

WESTWOOD SQUIBB	0.025%	N017818 001	

HALOG-E

RANBAXY	0.1%	N018234 001	

OINTMENT;TOPICAL
HALOG

BRISTOL MYERS SQUIBB	0.025%	N018125 001	

SOLUTION;TOPICAL
HALOG

RANBAXY	0.1%	N017823 001	

HALOBETASOL PROPIONATE
OINTMENT;TOPICAL
HALOBETASOL PROPIONATE

FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004
G AND W LABS INC	0.05%	A077109 001	Jun 14, 2005

HALOFANTRINE HYDROCHLORIDE
TABLET;ORAL
HALFAN

GLAXOSMITHKLINE	250MG	N020250 001	Jul 24, 1992

HALOPERIDOL
TABLET;ORAL
HALDOL

ORTHO MCNEIL	0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015921 001	
	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015921 002	
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015921 003	
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015921 004	
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015921 005	
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015921 006	Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM	1MG	N017079 001	

HALOPERIDOL

CYCLE PHARMS LTD	0.5MG	A071128 001	Feb 17, 1987
	1MG	A071129 001	Feb 17, 1987
	2MG	A071130 001	Feb 17, 1987
	5MG	A071131 001	Feb 17, 1987
	10MG	A071132 001	May 12, 1987
	20MG	A071133 001	May 12, 1987
DURAMED PHARMS BARR	0.5MG	A071216 001	Dec 04, 1986
	1MG	A071217 001	Dec 04, 1986
	2MG	A071218 001	Dec 04, 1986
	5MG	A071219 001	Dec 04, 1986
	10MG	A071220 001	Jul 07, 1987
	20MG	A071221 001	Jul 07, 1987

HALOPERIDOL
TABLET;ORAL
HALOPERIDOL

FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987
	1MG	A071157	001	Jan 02, 1987
	2MG	A071172	001	Jan 02, 1987
	5MG	A071212	001	Jan 07, 1988
	10MG	A071173	001	Jan 07, 1988
LEDERLE	0.5MG	A072727	001	Sep 19, 1989
	1MG	A072728	001	Sep 19, 1989
	2MG	A072729	001	Sep 19, 1989
	5MG	A072730	001	Sep 19, 1989
	10MG	A072731	001	Sep 19, 1989
	20MG	A072732	001	Sep 19, 1989
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
SUN PHARM INDS	20MG	A071177	001	Jan 07, 1988
VINTAGE	0.5MG	A071235	002	Nov 03, 1986
	1MG	A071235	003	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071235	004	Nov 03, 1986
	10MG	A071235	005	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE
INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE
CONCENTRATE;ORAL
HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001	

HALOPERIDOL

ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987

HALOPERIDOL LACTATE

CONCENTRATE;ORAL			
HALOPERIDOL INTENSOL			
CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045 001	Apr 12, 1988
INJECTABLE;INJECTION			
HALOPERIDOL			
ABRAXIS PHARM	EQ 5MG BASE/ML	A071187 001	Jan 20, 1987
CLARIS	EQ 5MG BASE/ML	A076791 001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828 001	Aug 25, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516 001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517 001	Feb 25, 1993
SANDOZ	EQ 5MG BASE/ML	A076464 001	Sep 29, 2004
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802 001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864 001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713 001	May 17, 1988
	EQ 5MG BASE/ML	A070714 001	May 17, 1988
	EQ 5MG BASE/ML	A070744 001	May 17, 1988
SOLUTION;ORAL			
HALOPERIDOL LACTATE			
ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536 001	Nov 02, 1995

HALOPROGIN

CREAM;TOPICAL			
HALOTEX			
WESTWOOD SQUIBB	1%	N016942 001	
SOLUTION;TOPICAL			
HALOTEX			
WESTWOOD SQUIBB	1%	N016943 001	

HALOTHANE

LIQUID;INHALATION			
FLUOTHANE			
WYETH AYERST	99.99%	N011338 001	
HALOTHANE			
BH	99.99%	A084977 001	
HALOCARBON	99.99%	A080810 001	
HOSPIRA	99.99%	A083254 001	

HEPARIN CALCIUM

INJECTABLE;INJECTION			
CALCIPARINE			
SANOFI AVENTIS US	25,000 UNITS/ML	N018237 001	

HEPARIN SODIUM

INJECTABLE;INJECTION			
HEPARIN LOCK FLUSH			
HOSPIRA	100 UNITS/ML	N005264 010	
INTL MEDICATION	10 UNITS/ML	A086357 001	
	500 UNITS/ML	A086357 002	
LUITPOLD	10 UNITS/ML	A089063 001	Oct 09, 1985
	100 UNITS/ML	A089064 001	Oct 09, 1985
PARKE DAVIS	10 UNITS/ML	N017346 006	
SMITH AND NEPHEW	10 UNITS/ML	A087904 001	Apr 20, 1983
	10 UNITS/ML	A087958 001	Apr 20, 1983
	10 UNITS/ML	A088458 001	Jul 26, 1984
	10 UNITS/ML	A088580 001	Oct 25, 1984
	100 UNITS/ML	A087906 001	Apr 20, 1983
	100 UNITS/ML	A087959 001	Apr 20, 1983
	100 UNITS/ML	A088460 001	Jul 26, 1984
	100 UNITS/ML	A088581 001	Oct 25, 1984
SOLOPAK	10 UNITS/ML	A087903 001	Apr 20, 1983
	10 UNITS/ML	A088457 001	Oct 25, 1984
	100 UNITS/ML	A087905 001	Apr 20, 1983
	100 UNITS/ML	A088459 001	Jul 26, 1984
HEPARIN SODIUM			
ABRAXIS PHARM	1,000 UNITS/ML	N017033 001	
	1,000 UNITS/ML	N017979 001	
	5,000 UNITS/ML	N017979 003	
	10,000 UNITS/ML	N017979 002	
AKORN	1,000 UNITS/ML	N017486 001	
	5,000 UNITS/ML	N017486 002	
	10,000 UNITS/ML	N017486 003	

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM
INJECTABLE;INJECTION
HEPARIN SODIUM

	20,000 UNITS/ML	N017486 004	
	40,000 UNITS/ML	N017486 005	
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130 001	
	5,000 UNITS/ML	N017130 002	
	10,000 UNITS/ML	N017130 003	
	20,000 UNITS/ML	N017130 004	
DELL LABS	1,000 UNITS/ML	N017540 001	
	5,000 UNITS/ML	N017540 002	
	10,000 UNITS/ML	N017540 003	
	20,000 UNITS/ML	N017540 004	
	40,000 UNITS/ML	N017540 005	
EUROHLTH INTL SARL	1,000 UNITS/ML	N017007 001	
	2,500 UNITS/ML	N017007 007	
	5,000 UNITS/ML	N017007 002	
	5,000 UNITS/0.5ML	N017007 010	
	7,500 UNITS/ML	N017007 003	
	10,000 UNITS/ML	N017007 004	
	15,000 UNITS/ML	N017007 005	
	20,000 UNITS/ML	N017007 006	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651 005	
	5,000 UNITS/ML	N017029 002	
	10,000 UNITS/ML	N017651 003	
	20,000 UNITS/ML	N017651 008	
HOSPIRA	2,500 UNITS/ML	A088099 001	Apr 28, 1983
	10,000 UNITS/ML	A040095 001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521 001	
	10,000 UNITS/ML	N005521 002	
	20,000 UNITS/ML	N005521 004	
LUITPOLD	1,000 UNITS/ML	A087452 001	Oct 31, 1983
ORGANON USA INC	1,000 UNITS/ML	N000552 008	
	5,000 UNITS/ML	N000552 009	
	10,000 UNITS/ML	N000552 010	
PARKE DAVIS	1,000 UNITS/ML	N017346 001	
	5,000 UNITS/ML	N017346 002	
	7,500 UNITS/ML	N017346 003	
	10,000 UNITS/ML	N017346 004	
	20,000 UNITS/ML	N017346 005	
PHARM SPEC	1,000 UNITS/ML	N017780 001	
	5,000 UNITS/ML	N017780 002	
	10,000 UNITS/ML	N017780 003	
	20,000 UNITS/ML	N017780 004	
	40,000 UNITS/ML	N017780 005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570 001	
	5,000 UNITS/ML	N004570 002	
	10,000 UNITS/ML	N004570 003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239 001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043 001	
	5,000 UNITS/ML	A087077 001	
	5,000 UNITS/0.5ML	A087395 001	
	10,000 UNITS/ML	A087107 001	
	10,000 UNITS/0.5ML	A087363 001	
WATSON LABS	1,000 UNITS/ML	N017064 002	
	2,500 UNITS/ML	N017064 015	
	3,000 UNITS/ML	N017064 016	
	4,000 UNITS/ML	N017064 017	
	5,000 UNITS/ML	N017064 003	
	6,000 UNITS/ML	N017064 018	
	7,500 UNITS/ML	N017064 019	
	10,000 UNITS/ML	N017064 004	
	20,000 UNITS/ML	N017064 005	
	40,000 UNITS/ML	N017064 006	
WATSON LABS INC	1,000 UNITS/ML	A040007 001	Jun 07, 1996
	1,000 UNITS/ML	A040008 001	Oct 10, 1995
WEST-WARD PHARMS INT	5,000 UNITS/0.5ML	N017037 013	Apr 07, 1986

HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	200 UNITS/100ML	N019130 001	Dec 31, 1984

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	200 UNITS/100ML	N019042 001	Mar 29, 1985

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%				
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
WATSON LABS INC	1,000 UNITS/ML	A089464	001	Jun 03, 1986
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM
INJECTABLE;INJECTION

LIQUAEMIN SODIUM			
ORGANON USA INC	1,000 UNITS/ML	N000552 004	
	5,000 UNITS/ML	N000552 003	
	10,000 UNITS/ML	N000552 005	
	20,000 UNITS/ML	N000552 001	
	40,000 UNITS/ML	N000552 002	
LIQUAEMIN SODIUM PRESERVATIVE FREE			
ORGANON USA INC	1,000 UNITS/ML	N000552 011	Apr 11, 1986
	5,000 UNITS/ML	N000552 012	Apr 11, 1986
	10,000 UNITS/ML	N000552 013	Apr 11, 1986
PANHEPRIN			
HOSPIRA	1,000 UNITS/ML	N005264 004	
	5,000 UNITS/ML	N005264 006	
	10,000 UNITS/ML	N005264 007	
	20,000 UNITS/ML	N005264 008	
	40,000 UNITS/ML	N005264 009	
SODIUM HEPARIN			
ABRAXIS PHARM	5,000 UNITS/ML	N017033 002	
	10,000 UNITS/ML	N017033 003	
	20,000 UNITS/ML	N017033 004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036 001	Mar 04, 1988

HETACILLIN
FOR SUSPENSION;ORAL

VERSAPEN			
BRISTOL	EQ 112.5MG AMPICIL/ML	A061398 001	
	EQ 112.5MG AMPICIL/5ML	N050060 001	
	EQ 112.5MG AMPICIL/ML	N050060 003	
	EQ 225MG AMPICIL/5ML	A061398 002	

HETACILLIN POTASSIUM
CAPSULE;ORAL

VERSAPEN-K			
BRISTOL	EQ 225MG AMPICIL	A061396 001	
	EQ 450MG AMPICIL	A061396 002	

HEXACHLOROPHENE

AEROSOL;TOPICAL			
SEPTISOL			
VESTAL LABS	0.23%	N017424 001	
TURGEX			
XTTRIUM	3%	N018375 001	
EMULSION;TOPICAL			
HEXA-GERM			
HUNTINGTON LABS	3%	N017411 001	
PHISOHEX			
SANOFI AVENTIS US	3%	N006882 001	
	3%	N008402 001	
SOY-DOME			
BAYER PHARMS	3%	N017405 001	
TURGEX			
XTTRIUM	3%	N019055 001	Nov 30, 1984
SOAP;TOPICAL			
GAMOPHEN			
ARBROOK	2%	N006270 003	
SOLUTION;TOPICAL			
DIAL			
DIAL	0.25%	N017421 002	
GERMA-MEDICA			
HUNTINGTON LABS	1%	N017412 001	
GERMA-MEDICA "MG"			
HUNTINGTON LABS	0.25%	N017412 002	
SEPTI-SOFT			
CALGON	0.25%	N017460 001	
SEPTISOL			
VESTAL LABS	0.25%	N017423 001	
SPONGE;TOPICAL			
E-Z SCRUB			
BECTON DICKINSON	450MG	N017452 001	
HEXASCRUB			
PROF DSPLS	3%	N018363 001	

HEXACHLOROPHENE
SPONGE;TOPICAL
PHISO-SCRUB

SANOFI AVENTIS US	3%	N017446 001	

SCRUBTEAM SURGICAL SPONGEBRUSH

3M	330MG	N017413 001	

HEXAFLUORENIUM BROMIDE
INJECTABLE;INJECTION
MYLAXEN

MEDPOINTE PHARM HLC	20MG/ML	N009789 003	

HEXOCYCLIUM METHYLSULFATE
TABLET;ORAL
TRAL

ABBVIE	25MG	N010599 001	

HEXYLCAINE HYDROCHLORIDE
SOLUTION;TOPICAL
CYCLAINE

MERCK	5%	N008472 001	

HISTAMINE PHOSPHATE
INJECTABLE;INJECTION
HISTAMINE PHOSPHATE

LILLY	EQ 0.1MG BASE/ML	N000734 003	
	EQ 0.2MG BASE/ML	N000734 002	
	EQ 1MG BASE/ML	N000734 001	

HISTRELIN ACETATE
INJECTABLE;INJECTION
SUPPRELIN

SHIRE	EQ 0.2MG BASE/ML	N019836 001	Dec 24, 1991
	EQ 0.5MG BASE/ML	N019836 002	Dec 24, 1991
	EQ 1MG BASE/ML	N019836 003	Dec 24, 1991

HOMATROPINE METHYLBROMIDE
TABLET;ORAL
HOMAPIN-10

MISSION PHARMA	10MG	A086308 001	

HOMAPIN-5

MISSION PHARMA	5MG	A086309 001	

TABLET, CHEWABLE;ORAL
EQUIPIN

MISSION PHARMA	3MG	A086310 001	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE
SYRUP;ORAL
HYCODAN

ENDO PHARMS	1.5MG/5ML;5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005213 002	Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS	1.5MG/5ML;5MG/5ML	A040285 001	Jul 19, 1999

HYDROPANE

HALSEY	1.5MG/5ML;5MG/5ML	A088066 001	Jun 28, 1985

TABLET;ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH	1.5MG;5MG	A040295 001	Dec 01, 2000

HYCODAN

ENDO PHARMS	1.5MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005213 001	Jul 26, 1988

HYALURONIDASE
INJECTABLE;INJECTION
HYDASE

AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005

VITRASE

BAUSCH AND LOMB	6,200 UNITS/VIAL	N021640 001	May 05, 2004

WYDASE

BAXTER HLTHCARE	150 UNITS/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006343 002	
	150 UNITS/VIAL **Federal Register	N006343 006	

FDA data supplied by DrugPatentWatch.com

HYALURONIDASE
INJECTABLE;INJECTION
WYDASE

	determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	1,500 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006343 005	

HYDRALAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
APRESOLINE

NOVARTIS	20MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008303 003	

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM	20MG/ML	A089532 001	Aug 11, 1987
SMITH AND NEPHEW	20MG/ML	A088518 001	Apr 20, 1984
SOLOPAK	20MG/ML	A088517 001	Aug 22, 1985
TEVA PARENTERAL	20MG/ML	A040373 001	Feb 23, 2000

TABLET;ORAL
APRESOLINE

NOVARTIS	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008303 004	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008303 001	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008303 002	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008303 005	

DRALZINE

TEVA	25MG	A084301 001	

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH	25MG	A088560 001	Oct 04, 1984
	50MG	A088649 001	Oct 18, 1984
ACTAVIS GRP PTC	10MG	A091679 001	Mar 04, 2013
	25MG	A091679 002	Mar 04, 2013
	50MG	A091679 003	Mar 04, 2013
	100MG	A091679 004	Mar 04, 2013
ASCOT	25MG	A088310 001	Dec 19, 1984
	50MG	A088311 001	Dec 19, 1984
FRONTIDA BIOPHARM	10MG	A089359 001	Jul 25, 1986
	25MG	A089258 001	May 05, 1986
	50MG	A089259 001	May 05, 1986
	100MG	A088729 001	Apr 11, 1985
HALSEY	10MG	A089218 001	Jan 22, 1986
	25MG	A089130 001	Jan 15, 1986
	50MG	A089222 001	Jan 22, 1986
	100MG	A089178 001	Jan 15, 1986
HERITAGE PHARMS INC	10MG	A040858 001	Feb 26, 2010
	25MG	A040858 002	Feb 26, 2010
	50MG	A040858 003	Feb 26, 2010
	100MG	A040858 004	Feb 26, 2010
IMPAX LABS	25MG	A084922 001	
	50MG	A084923 001	
IVAX SUB TEVA PHARMS	10MG	A084443 001	
	25MG	A084437 001	
	50MG	A084469 002	
	100MG	A084581 001	
MUTUAL PHARM	10MG	A088728 001	Apr 11, 1985
	25MG	A084106 002	
	50MG	A084107 002	
PUREPAC PHARM	25MG	A088177 001	Jul 29, 1983
	50MG	A088178 001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671 001	May 01, 1984

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

	25MG	A088657 001	Jun 15, 1984
	50MG	A088652 001	May 08, 1984
	100MG	A088686 001	May 01, 1984
SANDOZ	50MG	A085088 001	
SUPERPHARM	10MG	A088787 001	Aug 28, 1984
	25MG	A088788 001	Aug 28, 1984
	50MG	A088789 001	Aug 28, 1984
TG UNITED LABS	10MG	A088846 001	Feb 26, 1985
	25MG	A088847 001	Feb 26, 1985
	50MG	A088848 001	Feb 26, 1985
	100MG	A088849 001	Feb 26, 1985
UPSHER-SMITH LABS	10MG	A083241 001	
	25MG	A083560 001	
	50MG	A083561 001	
USL PHARMA	25MG	A087780 001	Mar 29, 1982
	50MG	A087751 001	Mar 29, 1982
VANGARD	25MG	A087712 001	
	50MG	A087908 001	May 07, 1982
VITARINE	25MG	A086088 001	
WATSON LABS	25MG	A084504 001	
	25MG	A085532 002	May 24, 1982
	50MG	A084503 001	
	50MG	A085533 002	May 25, 1982
WEST WARD	25MG	A088240 001	May 27, 1983
	50MG	A088241 001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

APRESAZIDE

NOVARTIS	25MG;25MG	A084735 001	
	50MG;50MG	A084810 001	
	100MG;50MG	A084811 001	

HYDRA-ZIDE

PAR PHARM	100MG;50MG	A088961 001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG;25MG	A087608 001	Feb 08, 1982
	50MG;50MG	A087213 001	Feb 08, 1982
	100MG;50MG	A087609 001	Feb 08, 1982
SUPERPHARM	25MG;25MG	A089200 001	Feb 09, 1987
	50MG;50MG	A089201 001	Feb 09, 1987
WATSON LABS	25MG;25MG	A085457 001	Mar 04, 1982
	50MG;50MG	A085446 001	Mar 04, 1982
	100MG;50MG	A085440 001	Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG;50MG	A088358 001	Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG;25MG	A088356 001	Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG;50MG	A088357 001	Apr 10, 1984

TABLET;ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG;15MG	N012026 002	

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG;15MG	A085827 001	

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG;15MG	A085373 001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

CAM-AP-ES

TG UNITED LABS	25MG;15MG;0.1MG	A084897 001	

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291 001	

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN	25MG;15MG;0.1MG	A087085 001	

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	25MG;15MG;0.1MG	A085771 001	

HYDRAP-ES

SANDOZ	25MG;15MG;0.1MG	A084876 001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS	25MG;15MG;0.1MG	A083770 001	

HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877 001	

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG;15MG;0.1MG	A088376 001	Oct 28, 1983
SUN PHARM INDS	25MG;15MG;0.1MG	A088570 001	Apr 10, 1984
WATSON LABS	25MG;15MG;0.1MG	A085549 001	
	25MG;15MG;0.1MG	A087556 001	

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE	25MG;15MG;0.1MG	A087709 001	May 13, 1982

SER-A-GEN

SOLVAY	25MG;15MG;0.1MG	A087210 001	

SER-AP-ES

NOVARTIS	25MG;15MG;0.1MG	N012193 005	

UNIPRES

SOLVAY	25MG;15MG;0.1MG	A085893 001	
	25MG;15MG;0.1MG	A086298 001	

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET;ORAL

DRALSERP

SANDOZ	25MG;0.1MG	A084617 001	

SERPASIL-APRESOLINE

NOVARTIS	25MG;0.1MG	N009296 004	
	50MG;0.2MG	N009296 002	

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

HIKMA INTL PHARMS	12.5MG	A077885 001	Nov 26, 2007
LANNETT HOLDINGS INC	12.5MG	A091662 001	Jan 27, 2012

SOLUTION;ORAL

HYDROCHLOROTHIAZIDE

MORTON GROVE	50MG/5ML	A089661 001	Jun 20, 1988
ROXANE	50MG/5ML	A088587 001	Jul 02, 1984

HYDROCHLOROTHIAZIDE INTENSOL

ROXANE	100MG/ML	A088588 001	Jul 02, 1984

TABLET;ORAL

ESIDRIX

NOVARTIS	25MG	N011793 005	
	50MG	N011793 008	
	100MG	N011793 009	

HYDRO-D

HALSEY	25MG	A086504 001	
	50MG	A083891 002	

HYDROCHLOROTHIAZIDE

ABC HOLDING	50MG	A085672 001	
ACTAVIS ELIZABETH	25MG	A085054 002	
	50MG	A085208 001	
ALRA	25MG	A086369 001	
	50MG	A083554 001	
ASCOT	25MG	A087539 001	Feb 03, 1982
	50MG	A087540 001	Feb 03, 1982
AUROLIFE PHARMA LLC	25MG	A083899 001	
	50MG	A085219 001	
BARR	50MG	A084771 001	
DAVA PHARMS INC	100MG	A087060 001	
ELKINS SINN	50MG	A085152 002	
HEATHER	50MG	A084135 001	
HIKMA INTL PHARMS	25MG	A084878 002	Jul 12, 2006
IMPAX LABS	25MG	A084029 001	
	50MG	A083607 002	
	100MG	A085098 001	
INWOOD LABS	25MG	A084776 001	
	25MG	A085067 001	
	50MG	A084776 002	
IVAX SUB TEVA PHARMS	50MG	A084658 001	
	100MG	A085022 001	
LANNETT	25MG	A084325 001	
	50MG	A084324 001	

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

MAST MM	25MG	A086192 001	
	50MG	A086192 002	
MYLAN	25MG	A084880 001	
	50MG	A085112 001	
PVT FORM	50MG	A086597 001	
ROXANE	25MG	A085004 001	
	50MG	A084536 002	
	50MG	A085005 001	
SANDOZ	25MG	A087565 001	Mar 09, 1982
	50MG	A084912 001	
SOLVAY	25MG	A085323 001	
SUN PHARM INDS	25MG	A083972 001	
	50MG	A083972 002	
	100MG	A083972 003	
SUPERPHARM	25MG	A088827 001	Dec 28, 1984
	50MG	A088828 001	Dec 28, 1984
	100MG	A088829 001	Dec 28, 1984
TEVA	25MG	A088924 001	Feb 07, 1985
	50MG	A088923 001	Feb 07, 1985
TG UNITED LABS	25MG	A085683 001	
	50MG	A083965 001	
USL PHARMA	25MG	A087827 001	Apr 19, 1982
	50MG	A087752 001	Apr 19, 1982
VANGARD	25MG	A087638 001	
	50MG	A087610 001	
WARNER CHILCOTT	25MG	A087586 001	May 03, 1982
	50MG	A087587 001	May 03, 1982
WATSON LABS	25MG	A081189 001	Jan 24, 1992
	25MG	A083458 001	
	25MG	A085232 002	
	50MG	A083232 001	
	50MG	A083456 001	
	50MG	A085233 001	
	50MG	A086087 001	
	50MG	A086594 001	
	100MG	A081190 001	Jan 24, 1992
	100MG	A085099 001	
	100MG	A087002 001	
WEST WARD	25MG	A084899 001	
WHITEWORTH TOWN PLSN	25MG	A083809 002	
	50MG	A083809 001	
	100MG	A085347 001	

HYDRODIURIL

MERCK	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011835 003	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011835 006	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011835 007	

ORETIC

ABBVIE	25MG	N011971 001	
	50MG	N011971 002	

ZIDE

SOLVAY	50MG	A083925 001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

SANOFI AVENTIS US	12.5MG;75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758 001	Sep 30, 1997
	25MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758 004	Mar 15, 2005

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

TEVA	25MG;300MG	A077369 003	Mar 30, 2012
WATSON LABS INC	12.5MG;150MG	A091539 001	Oct 22, 2012
	12.5MG;300MG	A091539 002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET;ORAL

NORMOZIDE

SCHERING	25MG;100MG	N019046 001	Apr 06, 1987
	25MG;200MG	N019046 002	Apr 06, 1987
	25MG;300MG	N019046 003	Apr 06, 1987
	25MG;400MG	N019046 004	Apr 06, 1987

TRANDATE HCT

GLAXOSMITHKLINE	25MG;100MG	N019174 001	Apr 10, 1987
	25MG;200MG	N019174 002	Apr 10, 1987
	25MG;300MG	N019174 003	Apr 10, 1987
	25MG;400MG	N019174 004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ	12.5MG;10MG	A075926 001	Jul 01, 2002
	12.5MG;20MG	A075926 002	Jul 01, 2002
	25MG;20MG	A075926 003	Jul 01, 2002
TEVA	12.5MG;10MG	A075869 001	Jul 01, 2002
	12.5MG;20MG	A075869 002	Jul 01, 2002
	25MG;20MG	A075869 003	Jul 01, 2002

PRINZIDE

MERCK	12.5MG;10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019778 003	Nov 18, 1993
	12.5MG;20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019778 001	Feb 16, 1989
	25MG;20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019778 002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

WATSON LABS	12.5MG;50MG	A200180 001	Jan 12, 2011
	12.5MG;100MG	A200180 002	Jan 12, 2011
	25MG;100MG	A200180 003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

ALDORIL 15

MERCK	15MG;250MG	N013402 001	

ALDORIL 25

MERCK	25MG;250MG	N013402 002	

ALDORIL D30

MERCK	30MG;500MG	N013402 003	

ALDORIL D50

MERCK	50MG;500MG	N013402 004	

METHYLDOPA AND HYDROCHLOROTHIAZIDE

DAVA PHARMS INC	15MG;250MG	A072507 001	Jun 02, 1989
	25MG;250MG	A072508 001	Jun 02, 1989
	30MG;500MG	A072509 001	Jun 02, 1989
	50MG;500MG	A072510 001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG;250MG	A071458 001	Mar 08, 1988
	25MG;250MG	A071459 001	Mar 08, 1988
	30MG;500MG	A071460 001	Mar 08, 1988
	50MG;500MG	A071461 001	Mar 08, 1988
PAR PHARM	15MG;250MG	A070616 001	Feb 02, 1987
	25MG;250MG	A070612 001	Feb 02, 1987
	30MG;500MG	A070613 001	Feb 02, 1987
	50MG;500MG	A070614 001	Feb 02, 1987
PARKE DAVIS	15MG;250MG	A071897 001	Nov 23, 1987
	25MG;250MG	A071898 001	Nov 23, 1987
	30MG;500MG	A071899 001	Nov 23, 1987

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	50MG;500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
	25MG;250MG	A070688	001	Apr 24, 1986
	30MG;500MG	A070854	001	Oct 08, 1986
	50MG;500MG	A070689	001	Apr 24, 1986
SANDOZ	15MG;250MG	A070182	001	Jan 15, 1986
	15MG;250MG	A070829	001	Mar 09, 1987
	25MG;250MG	A070183	001	Jan 15, 1986
	25MG;250MG	A070830	001	Mar 09, 1987
	30MG;500MG	A070543	001	Jan 15, 1986
	50MG;500MG	A070544	001	Jan 15, 1986
TEVA	15MG;250MG	A071819	001	Apr 08, 1988
	25MG;250MG	A071820	001	Apr 08, 1988
	30MG;500MG	A071821	001	Apr 08, 1988
	50MG;500MG	A071822	001	Apr 08, 1988
WATSON LABS	15MG;250MG	A070365	001	Mar 19, 1986
	15MG;250MG	A070958	001	Feb 06, 1989
	15MG;250MG	A071920	001	Aug 29, 1988
	25MG;250MG	A070366	001	Apr 16, 1986
	25MG;250MG	A070959	001	Jan 19, 1989
	25MG;250MG	A071921	001	Aug 29, 1988
	30MG;500MG	A070367	001	Mar 19, 1986
	30MG;500MG	A071069	001	Jan 19, 1989
	30MG;500MG	A071922	001	Aug 29, 1988
	50MG;500MG	A070368	001	Apr 16, 1986
	50MG;500MG	A070960	001	Feb 06, 1989
	50MG;500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

US PHARMS HOLDINGS I	50MG;100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018303	003	Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

PADDOCK LLC	12.5MG;7.5MG	A090096	001	Sep 25, 2008
	12.5MG;15MG	A090096	002	Sep 25, 2008
	25MG;15MG	A090096	003	Sep 25, 2008

UNIRETIC

UCB INC	12.5MG;7.5MG	N020729	001	Jun 27, 1997
	12.5MG;15MG	N020729	003	Feb 14, 2002
	25MG;15MG	N020729	002	Jun 27, 1997

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET;ORAL

VISKAZIDE

NOVARTIS	25MG;5MG	N018872	001	Jul 22, 1987
	25MG;10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERIDE LA 120/50

WYETH AYERST	50MG;120MG	N019059	002	Jul 03, 1985

INDERIDE LA 160/50

WYETH AYERST	50MG;160MG	N019059	003	Jul 03, 1985

INDERIDE LA 80/50

WYETH AYERST	50MG;80MG	N019059	001	Jul 03, 1985

TABLET;ORAL

INDERIDE-40/25

WYETH PHARMS INC	25MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018031	001

INDERIDE-80/25

WYETH PHARMS INC	25MG;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018031	002

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE

DURAMED PHARMS BARR	25MG;40MG	A071126 001	Mar 02, 1987
	25MG;80MG	A071127 001	Mar 02, 1987

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH	25MG;40MG	A070851 001	May 15, 1986
	25MG;80MG	A070852 001	May 15, 1986
ANI PHARMS INC	25MG;40MG	A070704 001	Oct 01, 1986
	25MG;80MG	A070705 001	Oct 01, 1986
IVAX SUB TEVA PHARMS	25MG;40MG	A071552 001	Dec 01, 1988
	25MG;80MG	A071553 001	Dec 01, 1988
SANDOZ	25MG;40MG	A071060 001	Aug 26, 1987
	25MG;80MG	A071061 001	Aug 26, 1987
WARNER CHILCOTT	25MG;40MG	A071771 001	Jan 26, 1988
	25MG;80MG	A071772 001	Jan 26, 1988
WATSON LABS	25MG;40MG	A070301 001	Apr 18, 1986
	25MG;40MG	A071498 001	Dec 18, 1991
	25MG;80MG	A070305 001	Apr 18, 1986
	25MG;80MG	A071501 001	Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

H.R.-50

WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338 001	

HYDRO-RESERP

ABC HOLDING	50MG;0.125MG	A084714 002	Jun 29, 1982

HYDRO-SERP "25"

SANDOZ	25MG;0.125MG	A084827 001	

HYDRO-SERP "50"

SANDOZ	50MG;0.125MG	A085213 001	

HYDROCHLOROTHIAZIDE W/ RESERPINE

IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572 001	
	25MG;0.125MG	A083571 001	
	50MG;0.1MG	A083568 001	
	50MG;0.125MG	A083573 001	
PHARMERAL	25MG;0.125MG	A085421 001	
	50MG;0.125MG	A085420 001	
ROXANE	50MG;0.125MG	A084603 001	
WATSON LABS	25MG;0.125MG	A084466 001	
	25MG;0.125MG	A085317 001	
	25MG;0.125MG	A086330 002	
	50MG;0.125MG	A083666 001	
	50MG;0.125MG	A084467 001	
	50MG;0.125MG	A086331 001	

HYDROPRES 25

MERCK	25MG;0.125MG	N011958 002	

HYDROPRES 50

MERCK	50MG;0.125MG	N011958 003	

RESERPINE AND HYDROCHLOROTHIAZIDE

BARR	25MG;0.125MG	A084580 001	
	50MG;0.125MG	A084579 001	
SANDOZ	50MG;0.125MG	A088200 001	Jan 31, 1984

RESERPINE AND HYDROCHLOROTHIAZIDE-50

WEST WARD	50MG;0.125MG	A088189 001	May 10, 1984

SERPASIL-ESIDRIX #1

NOVARTIS	25MG;0.1MG	N011878 003	

SERPASIL-ESIDRIX #2

NOVARTIS	50MG;0.1MG	N011878 005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG;25MG	A088025 001	Nov 23, 1984
MUTUAL PHARM	25MG;25MG	A087267 001	
PUREPAC PHARM	25MG;25MG	A087999 001	Nov 06, 1985
SANDOZ	25MG;25MG	A086881 001	
SUPERPHARM	25MG;25MG	A089137 001	Aug 26, 1985
WATSON LABS	25MG;25MG	A087398 001	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

IVAX PHARMS	25MG;25MG	A087004 002	May 24, 1982
LEDERLE	25MG;25MG	A087511 001	
PARKE DAVIS	25MG;25MG	A087948 001	Feb 22, 1983

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL			
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE			
PUREPAC PHARM	25MG;25MG	A088054 001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553 001	
USL PHARMA	25MG;25MG	A087651 001	
VANGARD	25MG;25MG	A087655 001	
WATSON LABS	25MG;25MG	A085974 001	
	25MG;25MG	A086026 001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET;ORAL			
TIMOLIDE 10-25			
MERCK	25MG;10MG	N018061 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL			
DYAZIDE			
GLAXOSMITHKLINE LLC	25MG;50MG	N016042 002	
TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
ANI PHARMS INC	25MG;37.5MG	A074970 001	Jan 06, 1998
NOVARTIS	25MG;37.5MG	A074857 001	Sep 09, 1997
VITARINE	25MG;50MG	A071737 001	Feb 12, 1988
TABLET;ORAL			
TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AM THERAP	50MG;75MG	A072022 001	Apr 17, 1988
QUANTUM PHARMICS	50MG;75MG	A071980 001	Apr 17, 1988
WATSON LABS	50MG;75MG	A071969 001	Apr 17, 1988

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL			
HYDROCODONE BITARTRATE AND IBUPROFEN			
ACTAVIS LABS FL INC	5MG;200MG	A077454 001	Jun 23, 2010

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP;ORAL			
CODAMINE			
ALPHARMA US PHARMS	5MG/5ML;25MG/5ML	A075103 001	Sep 29, 2000

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT;TOPICAL			
MAGNACORT			
PFIZER	0.5%	N010554 001	

HYDROCORTISONE

AEROSOL;TOPICAL			
AEROSEB-HC			
ALLERGAN HERBERT	0.5%	A085805 001	
CREAM;TOPICAL			
CORT-DOME			
BAYER PHARMS	0.5%	N009585 003	
	1%	N009585 001	
DERMACORT			
MONARCH PHARMS	1%	A083011 002	
ELDECORT			
VALEANT PHARM INTL	1%	A080459 001	
	2.5%	A084055 001	
FLEXICORT			
WESTWOOD SQUIBB	0.5%	A087136 003	Apr 08, 1982
	1%	A087136 002	Apr 08, 1982
	2.5%	A087136 001	Apr 08, 1982
H-CORT			
PHARM ASSOC	0.5%	A086823 001	
HC #1			
BAYER PHARMS	0.5%	A080438 001	
HC #4			
BAYER PHARMS	1%	A080438 002	
HC (HYDROCORTISONE)			
C AND M PHARMA	0.5%	A080482 003	
	1%	A080482 004	
HI-COR			
C AND M PHARMA	2.5%	A080483 001	
HYDROCORTISONE			
ALPHARMA US PHARMS	2.5%	A089754 001	Feb 01, 1989
ALTANA	0.5%	A080848 002	

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

CREAM;TOPICAL			
HYDROCORTISONE			
	1%	A080848 003	
AMBIX	1%	A086080 001	
	2.5%	A086271 001	
EVERYLIFE	0.5%	A080452 001	
	1%	A080452 002	
G AND W LABS	1%	A084059 001	
INGRAM PHARM	0.5%	A080456 002	
	1%	A080456 003	
IVAX PHARMS	1%	A085733 001	
NASKA	1%	A089706 001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084970 002	
	1%	A085026 001	
PHARMADERM	1%	A088845 001	Feb 27, 1986
	2.5%	A089413 001	Dec 16, 1986
PHARMAFAIR	1%	A087838 001	Jul 28, 1982
STIEFEL	1%	A086170 001	
SYOSSET	0.5%	A085527 001	
TARO	0.5%	A086154 001	
	1%	A086155 001	
TEVA	0.5%	A080400 002	
	1%	A080400 003	
	1%	A085191 001	
	2.5%	A080400 004	
TOPIDERM	1%	A089273 001	Feb 17, 1989
USL PHARMA	1%	A088027 001	Sep 27, 1983
	2.5%	A088029 001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496 002	
HYTONE			
VALEANT INTL	1%	A080472 003	
	2.5%	A080472 004	
NOGENIC HC			
IVAX PHARMS	1%	A087427 001	Apr 04, 1988
NUTRACORT			
DOW PHARM	0.5%	A080442 002	
	1%	A080442 003	
PENECORT			
ALLERGAN HERBERT	1%	A088216 001	Jun 06, 1984
PROCTOCORT			
MONARCH PHARMS	1%	A083011 001	
SYNACORT			
MEDICIS	0.5%	A087459 001	
GEL;TOPICAL			
NUTRACORT			
HEALTHPOINT	1%	A084698 001	
PENECORT			
ALLERGAN HERBERT	1%	A088215 001	Jun 06, 1984
INJECTABLE;INJECTION			
CORTEF			
PHARMACIA AND UPJOHN	50MG/ML	N009864 001	
LOTION;TOPICAL			
ACTICORT			
BAKER NORTON	1%	A086535 001	
ALA-CORT			
CROWN LABS	1%	A083201 001	
BALNEOL-HC			
SOLVAY	1%	A088041 001	Dec 03, 1982
BETA-HC			
BETA DERMAC	1%	A089495 001	Jan 25, 1988
CETACORT			
DOW PHARM	0.5%	A080426 002	
	1%	A080426 001	
CORT-DOME			
BAYER PHARMS	0.5%	N009895 003	
	1%	N009895 001	
DERMACORT			
SOLVAY	0.5%	A084573 002	
	1%	A086462 001	
EPICORT			
BLULINE	0.5%	A083219 002	

HYDROCORTISONE

LOTION;TOPICAL			
GLYCORT			
HERAN	1%	A087489 001	Oct 03, 1983
H-CORT			
PHARM ASSOC	0.5%	A086824 001	
HYDROCORTISONE			
ALPHARMA US PHARMS	0.5%	A087317 001	Jun 07, 1982
	1%	A087315 001	Jun 07, 1982
MERICON	0.5%	A085282 001	
	1%	A085282 002	Feb 26, 1987
NASKA	1%	A089705 001	Apr 25, 1988
PERRIGO NEW YORK	0.5%	A085662 001	
	1%	A085663 001	
TARO	1%	A089024 001	Feb 12, 1986
HYTONE			
VALEANT INTL	1%	A080473 003	
	2.5%	A080473 004	Nov 30, 1982
NUTRACORT			
DOW PHARM	0.5%	A080443 002	
	1%	A080443 003	
	2.5%	A087644 001	Aug 24, 1982
STIE-CORT			
PERRIGO CO	1%	A089066 001	Nov 25, 1985
OINTMENT;TOPICAL			
CORTRIL			
PFIZER GLOBAL	1%	N009176 001	
	2.5%	N009176 002	
HC (HYDROCORTISONE)			
C AND M PHARMA	0.5%	A080481 001	
	1%	A080481 002	
HYDROCORTISONE			
ALTANA	0.5%	A080489 002	
	1%	A080489 003	
AMBIX	1%	A086079 001	
	2.5%	A086272 001	
NASKA	1%	A089704 001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969 003	
	1%	A085028 001	
PHARMADERM	1%	A088842 001	Feb 09, 1987
TARO	0.5%	A086256 001	
	2.5%	A040310 001	Dec 29, 2000
USL PHARMA	1%	A088061 001	Sep 27, 1983
	2.5%	A088039 001	Sep 27, 1983
HYTONE			
DERMIK LABS	1%	A080474 003	
	2.5%	A080474 004	
PENECORT			
ALLERGAN HERBERT	2.5%	A088217 001	Jun 06, 1984
POWDER;FOR RX COMPOUNDING			
H-CORT			
TORCH	100%	A087834 001	Mar 29, 1982
HYDRO-RX			
X GEN PHARMS	100%	A085982 001	
HYDROCORTISONE			
PADDOCK LLC	100%	A088082 001	Apr 08, 1983
SOLUTION;TOPICAL			
PENECORT			
ALLERGAN HERBERT	1%	A088214 001	Jun 06, 1984
TEXACORT			
MISSION PHARMA	1%	A080425 001	
TABLET;ORAL			
CORTRIL			
PFIZER	10MG	N009127 005	
	20MG	N009127 003	
HYDROCORTISONE			
BARR	20MG	A083999 001	
ELKINS SINN	20MG	A080624 001	
FERRANTE	10MG	A080568 001	
	20MG	A080568 002	
IMPAX LABS	20MG	A080781 001	
INWOOD LABS	20MG	A080732 001	

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

TABLET;ORAL			
HYDROCORTISONE			
LANNETT	20MG	A085070 001	
NEXGEN PHARMA INC	20MG	A083140 001	
PANRAY	10MG	N009659 001	
	20MG	N009659 002	
PARKE DAVIS	20MG	A084243 001	
PUREPAC PHARM	10MG	A084247 003	Aug 31, 1982
	20MG	A080395 001	
	20MG	A084247 002	
ROXANE	10MG	A088539 001	Mar 21, 1984
SANDOZ	20MG	A080642 002	
WATSON LABS	20MG	A080355 001	
WHITEWORTH TOWN PLSN	10MG	A080344 001	
	20MG	A080344 002	
HYDROCORTONE			
MERCK	10MG	N008506 007	
	20MG	N008506 011	
TABLET;VAGINAL			
CORTRIL			
PFIPHARMECS	10MG	N009796 001	

HYDROCORTISONE ACETATE

CREAM;TOPICAL			
HEMSOL-HC			
ABLE	1%	A081274 001	Jun 19, 1992
HYDROCORTISONE ACETATE			
CENCI	1%	A080419 001	Jan 25, 1982
PARKE DAVIS	1%	A089914 001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050 001	
	1%	A086052 001	
INJECTABLE;INJECTION			
CORTEF ACETATE			
PHARMACIA AND UPJOHN	50MG/ML	N009378 002	
CORTRIL			
PFIZER	25MG/ML	N009164 001	
HYDROCORTISONE ACETATE			
AKORN	25MG/ML	N009637 001	
	50MG/ML	N009637 002	
BEL MAR	25MG/ML	A083739 001	
	50MG/ML	A083739 002	
WATSON LABS	25MG/ML	A083128 001	
	25MG/ML	A083759 001	
	50MG/ML	A083759 002	
	50MG/ML	A085214 001	
HYDROCORTONE			
MERCK	25MG/ML	N008228 001	
	50MG/ML	N008228 004	
LOTION;TOPICAL			
DRICORT			
INGRAM PHARM	0.5%	A086207 001	
OINTMENT;OPHTHALMIC			
HYDROCORTISONE ACETATE			
FERA PHARMS	0.5%	A080828 001	
OINTMENT;OPHTHALMIC, OTIC			
HYDROCORTONE			
MERCK	1.5%	N009018 003	
OINTMENT;TOPICAL			
CORTEF ACETATE			
PHARMACIA AND UPJOHN	1%	N008917 002	
	2.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008917 001	
PASTE;TOPICAL			
ORABASE HCA			
COLGATE	0.5%	A083205 001	
POWDER;FOR RX COMPOUNDING			
HYDROCORTISONE ACETATE			
X GEN PHARMS	100%	A085981 001	

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL			
NEO-CORTEF			
PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049 001	
	2.5%;EQ 3.5MG BASE/GM	A061049 002	
OINTMENT;OPHTHALMIC			
NEO-CORTEF			
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610 001	
	1.5%;EQ 3.5MG BASE/GM	A060610 002	
OINTMENT;TOPICAL			
NEO-CORTEF			
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751 001	
	1%;EQ 3.5MG BASE/GM	A060751 002	
	2.5%;EQ 3.5MG BASE/GM	A060751 003	
SUSPENSION/DROPS;OPHTHALMIC			
COR-OTICIN			
AKORN	1.5%;EQ 3.5MG BASE/ML	A060188 001	
NEO-CORTEF			
PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612 002	
	1.5%;EQ 3.5MG BASE/ML	A060612 001	

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION;OPHTHALMIC			
TERRA-CORTRIL			
PFIZER	1.5%;EQ 5MG BASE/ML	A061016 001	

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL			
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%			
VINTAGE PHARMS	1%;1%	A089440 001	May 17, 1988
LOTION;TOPICAL			
PRAMOSONE			
FERNDALE LABS	0.5%;1%	A083213 002	

HYDROCORTISONE ACETATE; UREA

CREAM;TOPICAL			
CARMOL HC			
FOUGERA PHARMS	1%;10%	A080505 001	

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N018795 001	Jan 07, 1983
OINTMENT;TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N019106 001	Jul 03, 1984
SOLUTION;TOPICAL			
LOCOID			
YAMANOUCHI	0.1%	N019819 001	Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION;ORAL			
CORTEF			
PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900 001	

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION			
HYDROCORTONE			
MERCK	EQ 50MG BASE/ML	N012052 001	

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION			
A-HYDROCORT			
ABBOTT	EQ 100MG BASE/VIAL	A085928 001	
	EQ 100MG BASE/VIAL	A089577 001	Apr 11, 1989
	EQ 250MG BASE/VIAL	A089578 001	Apr 11, 1989
	EQ 500MG BASE/VIAL	A089579 001	Apr 11, 1989
	EQ 1GM BASE/VIAL	A089580 001	Apr 11, 1989
HOSPIRA	EQ 100MG BASE/VIAL	A085929 001	
	EQ 250MG BASE/VIAL	A085930 001	
	EQ 500MG BASE/VIAL	A085931 001	
	EQ 1GM BASE/VIAL	A085932 001	
HYDROCORTISONE SODIUM SUCCINATE			
ABRAXIS PHARM	EQ 100MG BASE/VIAL	A088667 001	Jun 08, 1984
	EQ 100MG BASE/VIAL	A088712 001	Jun 08, 1984
	EQ 250MG BASE/VIAL	A088668 001	Jun 08, 1984

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

HYDROCORTISONE SODIUM SUCCINATE

	EQ 500MG BASE/VIAL	A088669 001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A088670 001	Jun 08, 1984
BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A086619 001	
	EQ 250MG BASE/VIAL	A087567 001	
	EQ 500MG BASE/VIAL	A087568 001	
	EQ 1GM BASE/VIAL	A087569 001	
INTL MEDICATION	EQ 100MG BASE/VIAL	A087532 001	Mar 19, 1982
WATSON LABS	EQ 100MG BASE/VIAL	A084737 002	
	EQ 100MG BASE/VIAL	A084738 001	
	EQ 250MG BASE/VIAL	A084737 001	
	EQ 500MG BASE/VIAL	A084747 001	
	EQ 1GM BASE/VIAL	A084748 001	

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

G AND W LABS INC	0.2%	A074489 001	Aug 12, 1998

WESTCORT

RANBAXY LABS LTD	0.2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017950 001	

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001

WESTCORT

RANBAXY	0.2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018726 001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-CORT-DOME

BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237 006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237 005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394 001	Sep 29, 1982

OTOCORT

WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730 002	

SUSPENSION/DROPS;OPHTHALMIC

CORTISPORIN

MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169 001	

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623 001	Sep 24, 1985

SUSPENSION/DROPS;OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617 001	Sep 18, 1985

OTICAIR

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399 001	Nov 18, 1982

OTOBIONE

SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816 001	

OTOCORT

ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521 001	Jul 11, 1985

PEDIOTIC

MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822 001	Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

OTOBIOTIC

SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302 001	

PYOCIDIN

FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606 001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE
OINTMENT;OPHTHALMIC
ACHROMYCIN

LEDERLE	1.5%;1%	N050272 001	

HYDROCORTISONE; UREA
CREAM;TOPICAL
ALPHADERM

BIOGLAN	1%;10%	A086008 001	

CALMURID HC

PHARMACIA AND UPJOHN	1%;10%	A083947 001	

HYDROFLUMETHIAZIDE
TABLET;ORAL
DIUCARDIN

WYETH AYERST	50MG	A083383 001	

HYDROFLUMETHIAZIDE

PAR PHARM	50MG	A088850 001	May 31, 1985
WATSON LABS	50MG	A088031 001	Apr 06, 1983
	50MG	A088528 001	Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE
TABLET;ORAL
HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA	50MG;0.125MG	A088195 001	Oct 26, 1983
WATSON LABS	25MG;0.125MG	A088127 001	Mar 22, 1983
	50MG;0.125MG	A088110 001	Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS	50MG;0.125MG	A088932 001	Jan 11, 1985
PAR PHARM	50MG;0.125MG	A088907 001	Sep 20, 1985

SALUTENSIN

SHIRE	50MG;0.125MG	N012359 003	

SALUTENSIN-DEMI

SHIRE	25MG;0.125MG	N012359 004	

HYDROMORPHONE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
PALLADONE

PURDUE PHARMA LP	12MG	N021044 001	Sep 24, 2004
	16MG	N021044 002	Sep 24, 2004
	24MG	N021044 003	Sep 24, 2004
	32MG	N021044 004	Sep 24, 2004

INJECTABLE;INJECTION
DILAUDID-HP

PURDUE PHARM PRODS	250MG/VIAL	N019034 002	Aug 04, 1994

HYDROMORPHONE HYDROCHLORIDE

WATSON LABS	10MG/ML	A074317 001	Aug 23, 1995

TABLET;ORAL
HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS	2MG	A077311 001	Nov 09, 2005
	4MG	A077311 002	Nov 09, 2005
	8MG	A077311 003	Nov 09, 2005

HYDROXOCOBALAMIN
INJECTABLE;INJECTION
ALPHAREDISOL

MERCK	1MG/ML	A080778 001	

CYANOKIT

SERB SA	2.5GM/VIAL (5GM/KIT)	N022041 002	Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM	1MG/ML	A084921 001	
WATSON LABS	1MG/ML	A085528 001	

HYDROXOMIN

BEL MAR	1MG/ML	A084629 001	

HYDROXYAMPHETAMINE HYDROBROMIDE
SOLUTION/DROPS;OPHTHALMIC
PAREDRINE

PHARMICS	1%	N000004 004	

FDA data supplied by DrugPatentWatch.com

HYDROXYCHLOROQUINE SULFATE
TABLET;ORAL
HYDROXYCHLOROQUINE SULFATE

SANDOZ	200MG	A040150 001	Jan 27, 1996

HYDROXYPROGESTERONE CAPROATE
INJECTABLE;INJECTION
DELALUTIN

BRISTOL MYERS SQUIBB	125MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010347 004	
	125MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016911 001	
	250MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010347 002	
	250MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016911 002	

HYDROXYPROGESTERONE CAPROATE

AKORN	125MG/ML	N018004 001	
ALLERGAN SALES LLC	125MG/ML	N017439 001	
	250MG/ML	N017439 002	

HYDROXYSTILBAMIDINE ISETHIONATE
INJECTABLE;INJECTION
HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US	225MG/AMP	N009166 001	

HYDROXYUREA
CAPSULE;ORAL
HYDROXYUREA

BARR	250MG	A075143 002	Sep 21, 2000
BARR LABS INC	250MG	A075020 002	Jun 26, 2000
	500MG	A075020 001	Jul 30, 1998
ROXANE	500MG	A074476 001	Aug 18, 1995

TABLET;ORAL
HYDROXYUREA

BARR	1GM	A075734 001	Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE
INJECTABLE;INJECTION
HYDROXYZINE

BAXTER HLTHCARE	50MG/ML	A085551 002	

HYDROXYZINE HYDROCHLORIDE

ALTANA	25MG/ML	A087273 001	Apr 20, 1982
	50MG/ML	A087273 002	Apr 20, 1982
BAXTER HLTHCARE	25MG/ML	A085551 001	
FRESENIUS KABI USA	25MG/ML	A088184 001	Mar 31, 1983
	50MG/ML	A088185 001	Mar 31, 1983
HOSPIRA	25MG/ML	A087416 001	
	50MG/ML	A086821 001	
	50MG/ML	A087546 001	
PHARMAFAIR	25MG/ML	A088862 001	Feb 14, 1986
	25MG/ML	A089106 001	Feb 14, 1986
	50MG/ML	A088881 001	Feb 14, 1986
	50MG/ML	A089107 001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592 001	
SOLOPAK	25MG/ML	A086822 001	
	25MG/ML	A087591 001	
	50MG/ML	A087310 001	
	50MG/ML	A087593 001	
	50MG/ML	A087595 001	
	50MG/ML	A087596 001	
WATSON LABS	25MG/ML	A085778 001	
	25MG/ML	A087274 001	
	50MG/ML	A085779 001	
	50MG/ML	A087274 002	
WYETH AYERST	25MG/ML	A086258 001	
	50MG/ML	A086258 002	

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION			
ORGATRAX			
ORGANON USA INC	25MG/ML	A087014 001	
	50MG/ML	A087014 002	
VISTARIL			
PFIZER	25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011111 001	
	50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011111 002	
SYRUP;ORAL			
ATARAX			
ROERIG	10MG/5ML	N010485 001	
HYDROXYZINE HYDROCHLORIDE			
ALPHARMA US PHARMS	10MG/5ML	A088785 001	Feb 03, 1988
KV PHARM	10MG/5ML	A087730 001	Jul 01, 1982
STI PHARMA LLC	10MG/5ML	A086880 001	
TABLET;ORAL			
ATARAX			
PFIZER	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010392 001	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010392 004	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010392 006	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010392 005	
HYDROXYZINE HYDROCHLORIDE			
ABLE	10MG	A040559 001	Jul 22, 2004
	25MG	A040562 001	Jul 22, 2004
	50MG	A040563 001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071 001	Jul 22, 1986
	25MG	A089072 001	Jul 22, 1986
	50MG	A089073 001	Jul 22, 1986
AUROLIFE PHARMA LLC	10MG	A087869 001	Dec 20, 1982
	25MG	A087870 001	Dec 20, 1982
	50MG	A087871 001	Dec 20, 1982
HALSEY	10MG	A089366 001	May 02, 1988
	25MG	A089117 001	May 02, 1988
	50MG	A089396 001	May 02, 1988
IVAX PHARMS	10MG	A087216 001	
	25MG	A087410 001	
	50MG	A087411 001	
KV PHARM	10MG	A087819 001	Jun 23, 1982
	25MG	A087820 001	Jun 23, 1982
	50MG	A087821 001	Jun 23, 1982
	100MG	A087822 001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409 001	Nov 15, 1983
	25MG	A087857 001	Apr 18, 1983
	50MG	A087860 001	Apr 18, 1983
PLIVA	100MG	A081054 001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120 001	Sep 25, 1984
	25MG	A088121 001	Sep 25, 1984
	50MG	A088122 001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540 001	Oct 22, 1985
	25MG	A088551 001	Oct 22, 1985
	50MG	A088529 001	Oct 22, 1985
SANDOZ	10MG	A087246 002	
	25MG	A085247 001	
	50MG	A087245 001	
SUN PHARM INDS	10MG	A089381 001	May 19, 1986
	25MG	A089382 001	May 19, 1986
	50MG	A089383 001	May 19, 1986

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

	100MG	A087862	001	Apr 18, 1983
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
VINTAGE	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	10MG	A088348	001	Sep 15, 1983
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	25MG	A088349	001	Sep 15, 1983
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	
	50MG	A088350	001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HY-PAM "25"

TEVA	EQ 25MG HCL	A088713	001	Mar 04, 1985

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR	EQ 25MG HCL	A088593	001	Feb 29, 1984
	EQ 50MG HCL	A088594	001	Feb 29, 1984
	EQ 100MG HCL	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761	001	Mar 05, 1982
	EQ 50MG HCL	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HCL	A087656	001	Jun 11, 1982
	EQ 25MG HCL	A089145	001	Mar 17, 1986
	EQ 50MG HCL	A087657	001	Jun 11, 1982
	EQ 50MG HCL	A089146	001	Mar 17, 1986
	EQ 100MG HCL	A087658	001	Jun 11, 1982
SANDOZ	EQ 25MG HCL	A081127	001	Jun 28, 1991
	EQ 50MG HCL	A081128	001	Jun 28, 1991
	EQ 100MG HCL	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HCL	A089031	001	Jan 02, 1987
	EQ 50MG HCL	A089032	001	Jan 02, 1987
	EQ 100MG HCL	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HCL	A088392	001	Sep 19, 1983
	EQ 50MG HCL	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HCL	A086698	001	
	EQ 25MG HCL	A086840	001	Jul 01, 1982
	EQ 50MG HCL	A086695	001	
	EQ 50MG HCL	A086705	001	Jul 01, 1982
	EQ 50MG HCL	A087767	001	Aug 16, 1982
	EQ 100MG HCL	A086697	001	
	EQ 100MG HCL	A086728	001	Oct 05, 1982
	EQ 100MG HCL	A087790	001	Aug 16, 1982

VISTARIL

PFIZER	EQ 100MG HCL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011459	006

SUSPENSION;ORAL

VISTARIL

PFIZER	EQ 25MG HCL/5ML	N011795	001

IBANDRONATE SODIUM

TABLET;ORAL

BONIVA

HOFFMANN LA ROCHE	EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021455	001	May 16, 2003

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

CAPSULE;ORAL				
MIDOL				
	BAYER	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A070626 001	Sep 02, 1987
		200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A071002 001	Sep 02, 1987
SOLUTION;INTRAVENOUS				
CALDOLOR				
	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009
SUSPENSION;ORAL				
CHILDREN'S ADVIL				
	WYETH CONS	100MG/5ML	N019833 002	Sep 19, 1989
IBU				
	ABBOTT	100MG/5ML	N019784 001	Dec 18, 1989
MOTRIN				
	MCNEIL CONSUMER	100MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019842 001	Sep 19, 1989
SUSPENSION/DROPS;ORAL				
MOTRIN				
	MCNEIL	40MG/ML	N020476 001	May 25, 1995
TABLET;ORAL				
ACHES-N-PAIN				
	LEDERLE	200MG	A071065 001	May 28, 1987
CAP-PROFEN				
	PERRIGO	200MG	A072097 001	Dec 08, 1987
IBU				
	BASF	400MG	A070083 001	Feb 22, 1985
		400MG	N018197 001	
		600MG	A070088 001	Feb 08, 1985
		600MG	A070099 001	Mar 29, 1985
		800MG	A070745 001	Jul 23, 1986
IBU-TAB				
	ALRA	800MG	A071965 001	Aug 11, 1988
IBUPRIN				
	PLIVA	200MG	A071773 001	Jul 16, 1987
IBUPROFEN				
	ABBOTT	600MG	A070556 001	Jun 14, 1985
		800MG	A071264 001	Jul 25, 1986
	ANI PHARMS INC	200MG	A071144 001	Jan 20, 1987
		200MG	A072901 001	Dec 19, 1991
		200MG	A072903 001	Dec 19, 1991
	AUROLIFE PHARMA LLC	300MG	A070736 002	Jun 12, 1986
		400MG	A070736 003	Jun 12, 1986
		600MG	A070736 001	Jun 12, 1986
		800MG	A071938 001	Jan 14, 1988
	CONTRACT PHARMACAL	200MG	A073691 001	Feb 25, 1994
	HALSEY	200MG	A071027 001	Sep 29, 1987
		300MG	A071028 001	Mar 23, 1987
		400MG	A071029 001	Mar 23, 1987
		600MG	A071030 001	Mar 23, 1987
		800MG	A072137 001	Feb 05, 1988
	IVAX SUB TEVA PHARMS	200MG	A071154 001	Oct 27, 1987
		200MG	A072040 001	Apr 29, 1988
		400MG	A071145 001	Sep 23, 1986
		600MG	A071146 001	Sep 23, 1986
		800MG	A071769 001	May 08, 1987
	J AND J CONSUMER INC	400MG	A070081 001	Jun 16, 1986
	LEDERLE	400MG	A070629 001	Sep 19, 1986
		600MG	A070630 001	Sep 19, 1986
	LEINER	300MG	A071266 001	Oct 15, 1986
	MCNEIL	600MG	A070476 001	Jun 16, 1986
	MYLAN	200MG	A071870 001	May 05, 1988
		400MG	A070045 001	Sep 24, 1985
		600MG	A070057 001	Sep 24, 1985
		800MG	A071999 001	Dec 03, 1987
	NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007
		600MG	A078132 002	Sep 10, 2007

IBUPROFEN
TABLET;ORAL
IBUPROFEN

	800MG	A078132 003	Sep 10, 2007
OHM LABS	400MG	A070818 001	Dec 26, 1985
PAR PHARM	200MG	A071575 001	May 08, 1987
	300MG	A070328 001	Aug 06, 1985
	400MG	A070329 001	Aug 06, 1985
	600MG	A070330 001	Aug 06, 1985
	800MG	A070986 001	Jul 25, 1986
PERRIGO	200MG	A072098 001	Dec 08, 1987
PLIVA	400MG	A071666 001	Jun 18, 1987
	600MG	A071667 001	Jun 18, 1987
	800MG	A071668 001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122 001	Oct 03, 1986
	200MG	A071664 001	Feb 03, 1987
	300MG	A071123 001	Sep 19, 1986
	400MG	A071124 001	Sep 19, 1986
	600MG	A071125 001	Sep 19, 1986
	800MG	A071964 001	Feb 01, 1988
SANDOZ	200MG	A070733 001	Sep 19, 1986
	200MG	A071807 001	Feb 25, 1988
	200MG	A074525 001	Dec 15, 1995
	200MG	A074533 001	Dec 15, 1995
	400MG	A072064 001	Jan 14, 1988
	600MG	A072065 001	Jan 14, 1988
	800MG	A072169 001	Dec 11, 1987
SUN PHARM INDS	200MG	A070493 001	Dec 24, 1985
	200MG	A070908 001	Sep 26, 1986
	200MG	A071462 001	Oct 02, 1986
	400MG	A070079 001	Jul 24, 1985
	600MG	A070080 001	Jul 24, 1985
	800MG	A071448 001	Feb 18, 1987
SUPERPHARM	600MG	A070709 001	Apr 25, 1986
TEVA	200MG	A073141 001	May 29, 1992
	400MG	A073343 001	Jun 30, 1992
	600MG	A073344 001	Jun 30, 1992
	800MG	A073345 001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249 001	Jan 10, 1989
	300MG	A071230 001	Oct 22, 1986
	400MG	A071231 001	Oct 22, 1986
	600MG	A071232 001	Oct 22, 1986
	800MG	A072004 001	Nov 18, 1987
WATSON LABS	200MG	A070435 001	Mar 05, 1986
	200MG	A071765 001	Sep 04, 1987
	200MG	A071905 001	Mar 08, 1988
	300MG	A071338 001	Dec 01, 1986
	400MG	A070038 001	Sep 06, 1985
	400MG	A070436 001	Aug 21, 1985
	600MG	A070041 001	Sep 06, 1985
	600MG	A070437 001	Aug 21, 1985
	800MG	A071547 001	Jul 02, 1987
	800MG	A071911 001	Oct 13, 1987
IBUPROHM			
OHM LABS	400MG	A070469 001	Aug 29, 1985
MEDIPREN			
MCNEIL	200MG	A070475 001	Feb 06, 1986
	200MG	A071215 001	Jun 26, 1986
MIDOL			
BAYER	200MG	A070591 001	Sep 02, 1987
	200MG	A071001 001	Sep 02, 1987
MOTRIN			
MCNEIL CONSUMER	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017463 003	
	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017463 002	
	600MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy	N017463 004	

IBUPROFEN
TABLET;ORAL
MOTRIN

	reasons**		
	800MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017463 005	May 22, 1985
MCNEIL PED	100MG	N020418 001	Nov 16, 1994
MOTRIN MIGRAINE PAIN			
J AND J CONSUMER INC	200MG	N019012 004	Feb 25, 2000
NUPRIN			
BRISTOL MYERS	200MG	A072035 001	Feb 16, 1988
	200MG	A072036 001	Feb 16, 1988
J AND J CONSUMER INC	200MG	N019012 001	May 18, 1984
	200MG	N019012 002	Jul 29, 1987
RUFEN			
BASF	600MG	N018197 002	Mar 05, 1984

TABLET, CHEWABLE;ORAL
MOTRIN

MCNEIL PED	50MG	N020135 001	Nov 16, 1994
	100MG	N020135 002	Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE
TABLET;ORAL
COMBUNOX

FOREST LABS	400MG;5MG	N021378 001	Nov 26, 2004

IDARUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
IDAMYCIN

PHARMACIA AND UPJOHN	5MG/VIAL	N050661 002	Sep 27, 1990
	10MG/VIAL	N050661 001	Sep 27, 1990
	20MG/VIAL	N050661 003	Apr 25, 1995
IDARUBICIN HYDROCHLORIDE			
SANDOZ	1MG/ML	A091293 001	Mar 29, 2011
TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002
	10MG/VIAL	A065037 002	May 01, 2002
	20MG/VIAL	A065037 001	May 01, 2002

IDOXURIDINE
OINTMENT;OPHTHALMIC
STOXIL

GLAXOSMITHKLINE	0.5%	N015868 001	

SOLUTION/DROPS;OPHTHALMIC
HERPLEX

ALLERGAN	0.1%	N013935 002	

STOXIL

GLAXOSMITHKLINE	0.1%	N013934 001	

IFOSFAMIDE; MESNA
INJECTABLE;INJECTION
IFEX/MESNEX KIT

BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N019763 003	Oct 10, 1992
	3GM/VIAL;100MG/ML	N019763 004	Oct 10, 1992

ILOPROST
SOLUTION;INHALATION
VENTAVIS

ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779 001	Dec 29, 2004

IMATINIB MESYLATE
CAPSULE;ORAL
GLEEVEC

NOVARTIS	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021335 001	May 10, 2001
	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021335 002	May 10, 2001

FDA data supplied by DrugPatentWatch.com

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE;ORAL			
IMIPRAMINE HYDROCHLORIDE			
NOVARTIS	25MG/ML	A086765 001	
INJECTABLE;INJECTION			
TOFRANIL			
NOVARTIS	12.5MG/ML	N011838 002	
TABLET;ORAL			
IMIPRAMINE HYDROCHLORIDE			
LEDERLE	10MG	A086269 001	
	25MG	A086267 001	
	50MG	A086268 001	
OXFORD PHARMS	10MG	A040753 001	Feb 28, 2008
	25MG	A040752 001	Feb 28, 2008
	50MG	A040751 001	Feb 28, 2008
PAR PHARM	25MG	A089497 001	Jul 14, 1987
ROXANE	10MG	A083799 001	
	25MG	A083799 002	
	50MG	A083799 003	
SANDOZ	10MG	A085200 001	
	25MG	A084869 002	
	50MG	A085133 001	
TEVA	10MG	A083729 001	
	25MG	A083729 004	
	50MG	A083729 003	
USL PHARMA	25MG	A087776 001	Feb 10, 1982
VANGARD	10MG	A088036 001	Nov 03, 1982
	25MG	A087619 001	Feb 09, 1982
	50MG	A087631 001	Jan 04, 1982
WATSON LABS	10MG	A085220 001	
	10MG	A085875 001	
	25MG	A084252 002	
	25MG	A085878 001	
	50MG	A085221 001	
	50MG	A085877 001	
WEST WARD	25MG	A088222 001	May 26, 1983
	50MG	A088223 001	May 26, 1983
JANIMINE			
ABBOTT	10MG	N017895 001	
	25MG	N017895 002	
	50MG	N017895 003	
PRAMINE			
ALRA	10MG	A083827 001	
	25MG	A083827 002	
	50MG	A083827 003	
PRESAMINE			
SANOFI AVENTIS US	10MG	N011836 006	
	25MG	N011836 003	
	50MG	N011836 007	

IMIPRAMINE PAMOATE

CAPSULE;ORAL			
TOFRANIL-PM			
MALLINCKRODT INC	EQ 75MG HCL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017090 001	
	EQ 100MG HCL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017090 004	
	EQ 125MG HCL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017090 003	
	EQ 150MG HCL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017090 002	

INAMRINONE LACTATE
INJECTABLE;INJECTION
AMRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542 001	May 10, 2000
HOSPIRA	EQ 5MG BASE/ML	A074616 001	Aug 03, 1998

INOCOR

SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700 001	Jul 31, 1984

INDAPAMIDE
TABLET;ORAL
INDAPAMIDE

ANI PHARMS INC	1.25MG	A074498 002	Feb 12, 1998
	2.5MG	A074498 001	Oct 31, 1996
SANDOZ	1.25MG	A074594 001	May 23, 1996
	2.5MG	A074594 002	May 23, 1996
TEVA	1.25MG	A074665 001	Apr 04, 1997
	2.5MG	A074665 002	Apr 04, 1997
WATSON LABS	1.25MG	A074585 001	Sep 26, 1996
	2.5MG	A074585 002	Sep 26, 1996

LOZOL

SANOFI AVENTIS US	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 002	Apr 29, 1993
	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
DECABID

LILLY	EQ 50MG BASE	N019693 001	Dec 29, 1989
	EQ 75MG BASE	N019693 002	Dec 29, 1989
	EQ 100MG BASE	N019693 003	Dec 29, 1989

INDINAVIR SULFATE
CAPSULE;ORAL
CRIXIVAN

MERCK SHARP DOHME	EQ 100MG BASE	N020685 006	Apr 19, 2000
	EQ 333MG BASE	N020685 005	Dec 17, 1998

INDOCYANINE GREEN
INJECTABLE;INJECTION
IC-GREEN

AKORN	10MG/VIAL	N011525 003	
	40MG/VIAL	N011525 004	
	50MG/VIAL	N011525 002	

INDOMETHACIN
CAPSULE;ORAL
INDO-LEMMON

TEVA	25MG	A070266 001	Nov 07, 1985
	50MG	A070267 001	Nov 07, 1985

INDOCIN

IROKO PHARMS LLC	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016059 001	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016059 002	

INDOMETHACIN

ABLE	25MG	A076666 001	Dec 17, 2003
	50MG	A076666 002	Dec 17, 2003
CYCLE PHARMS LTD	25MG	A070353 001	Jun 18, 1985
	50MG	A070354 001	Jun 18, 1985
DURAMED PHARMS BARR	25MG	A070326 001	Oct 18, 1985
	50MG	A070327 001	Oct 18, 1985
HALSEY	25MG	A070782 001	Jun 03, 1987
	50MG	A070635 001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730 001	May 04, 1984
	50MG	N018730 002	May 04, 1984
MUTUAL PHARM	25MG	A070067 001	Oct 03, 1986
	50MG	A070068 001	Oct 03, 1986

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

MYLAN	50MG	N018858	002	Apr 20, 1984
PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
	50MG	N018806	002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
	50MG	A070592	001	Aug 11, 1986
PLIVA	25MG	A071148	001	Mar 18, 1987
	50MG	A071149	001	Mar 18, 1987
SUN PHARM INDS	25MG	A070900	002	Feb 09, 1987
	50MG	A070900	001	Feb 09, 1987
SUPERPHARM	25MG	A070487	001	Oct 10, 1986
	50MG	A070488	001	Oct 10, 1986
TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988
VINTAGE	25MG	N018829	002	Aug 06, 1984
	50MG	A070651	001	Mar 05, 1986
	50MG	N018829	001	Aug 06, 1984
WATSON LABS	25MG	A070529	001	Oct 18, 1985
	25MG	A070784	001	Aug 20, 1986
	25MG	A072996	001	Jul 31, 1991
	25MG	N018690	001	Jul 31, 1984
	50MG	A070530	001	Oct 18, 1985
	50MG	A070785	001	Aug 20, 1986
	50MG	A071635	001	May 18, 1987
	50MG	A072997	001	Jul 31, 1991
	50MG	N018690	002	Jul 31, 1984

CAPSULE, EXTENDED RELEASE;ORAL

INDOCIN SR

IROKO PHARMS	75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018185	001	Feb 23, 1982

INDOMETHACIN

ABLE	75MG	A076114	001	Feb 06, 2002
INWOOD LABS	75MG	A072410	001	Mar 15, 1989

SUPPOSITORY;RECTAL

INDOCIN

IROKO PHARMS	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017814	001	Aug 13, 1984

SUSPENSION;ORAL

INDOMETHACIN

CYCLE PHARMS LTD	25MG/5ML	A071412	001	Mar 18, 1987

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG MIX 50/50

NOVO NORDISK INC	50 UNITS/ML;50 UNITS/ML	N021810	001	Aug 26, 2008

NOVOLOG MIX 70/30 PENFILL

NOVO NORDISK INC	210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	002	Nov 01, 2001
	210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	003	Nov 01, 2001

INSULIN ASPART RECOMBINANT

INJECTABLE;SUBCUTANEOUS

NOVOLOG INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	004	Apr 23, 2004

INSULIN DETEMIR RECOMBINANT

INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXPEN

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005

LEVEMIR INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	003	Jun 16, 2005

LEVEMIR PENFILL

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	004	Jun 16, 2005

FDA data supplied by DrugPatentWatch.com

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
INJECTABLE;INJECTION
HUMALOG MIX 50/50 PEN
LILLY 50 UNITS/ML;50 UNITS/ML N021018 003 Dec 22, 1999
HUMALOG MIX 75/25 PEN
LILLY 75 UNITS/ML;25 UNITS/ML N021017 003 Dec 22, 1999

INSULIN LISPRO RECOMBINANT
INJECTABLE;INJECTION
HUMALOG PEN
LILLY 100 UNITS/ML N020563 002 Aug 06, 1998

INSULIN PORK
INJECTABLE;INJECTION
ILETIN I
LILLY 500 UNITS/ML N017931 001
INSULIN
NOVO NORDISK INC 40 UNITS/ML N017926 001
REGULAR INSULIN
NOVO NORDISK INC 100 UNITS/ML N017926 003

INSULIN PURIFIED BEEF
INJECTABLE;INJECTION
REGULAR ILETIN II
LILLY 100 UNITS/ML N018478 001

INSULIN PURIFIED PORK
INJECTABLE;INJECTION
ILETIN II
LILLY 500 UNITS/ML N018344 002
REGULAR ILETIN II (PORK)
LILLY 100 UNITS/ML N018344 001
REGULAR PURIFIED PORK INSULIN
NOVO NORDISK INC 100 UNITS/ML N018381 001
VELOSULIN
NOVO NORDISK INC 100 UNITS/ML N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK
INJECTABLE;INJECTION
INSULIN NORDISK MIXTARD (PORK)
NOVO NORDISK INC 30 UNITS/ML;70 UNITS/ML N018195 001

INSULIN RECOMBINANT HUMAN
INJECTABLE;INJECTION
HUMULIN BR
LILLY 100 UNITS/ML N019529 001 Apr 28, 1986
VELOSULIN BR
NOVO NORDISK INC 100 UNITS/ML N021028 001 Jul 19, 1999
POWDER;INHALATION
EXUBERA
PFIZER 1MG/INH N021868 001 Jan 27, 2006
3MG/INH N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
INJECTABLE;INJECTION
HUMULIN 50/50
LILLY 50 UNITS/ML;50 UNITS/ML N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN
INJECTABLE;INJECTION
NOVOLIN R
NOVO NORDISK INC 100 UNITS/ML N018778 001 Aug 30, 1983
VELOSULIN BR HUMAN
NOVO NORDISK INC 100 UNITS/ML N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN
INJECTABLE;INJECTION
MIXTARD HUMAN 70/30
BAYER PHARMS 30 UNITS/ML;70 UNITS/ML N019585 001 Mar 11, 1988
NOVOLIN 70/30
NOVO NORDISK INC 30 UNITS/ML;70 UNITS/ML N019441 001 Jul 11, 1986

FDA data supplied by DrugPatentWatch.com

INSULIN SUSP ISOPHANE BEEF
INJECTABLE;INJECTION
NPH INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017929 001	
	100 UNITS/ML	N017929 003	

INSULIN SUSP ISOPHANE BEEF/PORK
INJECTABLE;INJECTION
NPH ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N017936 001	
	100 UNITS/ML	N017936 002	

INSULIN SUSP ISOPHANE PURIFIED BEEF
INJECTABLE;INJECTION
NPH ILETIN II

LILLY	100 UNITS/ML	N018479 001	

INSULIN SUSP ISOPHANE PURIFIED PORK
INJECTABLE;INJECTION
INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC	100 UNITS/ML	N018194 001	

NPH ILETIN II (PORK)

LILLY	100 UNITS/ML	N018345 001	

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N018623 001	

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN
INJECTABLE;INJECTION
INSULATARD NPH HUMAN

NOVO NORDISK INC	100 UNITS/ML	N019449 001	May 30, 1986

NOVOLIN N

NOVO NORDISK INC	100 UNITS/ML	N019065 001	Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK
INJECTABLE;INJECTION
PROTAMINE ZINC & ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N017932 001	
	100 UNITS/ML	N017932 002	

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF
INJECTABLE;INJECTION
PROTAMINE ZINC AND ILETIN II

LILLY	100 UNITS/ML	N018476 001	

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB	40 UNITS/ML	N017928 001	
	100 UNITS/ML	N017928 003	

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK
INJECTABLE;INJECTION
PROTAMINE ZINC AND ILETIN II (PORK)

LILLY	100 UNITS/ML	N018346 001	

INSULIN ZINC SUSP BEEF
INJECTABLE;INJECTION
LENTE INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017998 001	
	100 UNITS/ML	N017998 003	

INSULIN ZINC SUSP EXTENDED BEEF
INJECTABLE;INJECTION
ULTRALENTE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017997 003	

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF
INJECTABLE;INJECTION
ULTRALENTE

NOVO NORDISK INC	100 UNITS/ML	N018385 001	

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN
INJECTABLE;INJECTION
HUMULIN U

LILLY	40 UNITS/ML	N019571 001	Jun 10, 1987
	100 UNITS/ML	N019571 002	Jun 10, 1987

FDA data supplied by DrugPatentWatch.com

INSULIN ZINC SUSP PROMPT BEEF
INJECTABLE;INJECTION
SEMILENTE INSULIN
NOVO NORDISK INC 100 UNITS/ML N017996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK
INJECTABLE;INJECTION
SEMILENTE
NOVO NORDISK INC 100 UNITS/ML N018382 001

INSULIN ZINC SUSP PURIFIED BEEF
INJECTABLE;INJECTION
LENTE ILETIN II
LILLY 100 UNITS/ML N018477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK
INJECTABLE;INJECTION
LENTARD
NOVO NORDISK INC 100 UNITS/ML N018384 001

INSULIN ZINC SUSP PURIFIED PORK
INJECTABLE;INJECTION
LENTE
NOVO NORDISK INC 100 UNITS/ML N018383 001
LENTE ILETIN II (PORK)
LILLY 100 UNITS/ML N018347 001

INSULIN ZINC SUSP RECOMBINANT HUMAN
INJECTABLE;INJECTION
HUMULIN L
LILLY 100 UNITS/ML N019377 002 Sep 30, 1985
NOVOLIN L
NOVO NORDISK INC 100 UNITS/ML N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN
INJECTABLE;INJECTION
NOVOLIN L
NOVO NORDISK INC 100 UNITS/ML N018777 001 Aug 30, 1983

INULIN
INJECTABLE;INJECTION
INULIN AND SODIUM CHLORIDE
ISO TEX 100MG/ML N002282 001

INVERT SUGAR
INJECTABLE;INJECTION
TRAVERT 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10GM/100ML N016717 001

IOBENGUANE SULFATE I-131
INJECTABLE;INJECTION
IOBENGUANE SULFATE I 131
PHARMALUCENCE 2.3mCi/ML N020084 001 Mar 25, 1994

IOCETAMIC ACID
TABLET;ORAL
CHOLEBRINE
MALLINCKRODT 750MG N017129 001

IODAMIDE MEGLUMINE
INJECTABLE;INJECTION
RENOVUE-65
BRACCO 65% N017902 001
RENOVUE-DIP
BRACCO 24% N017903 001

IODIPAMIDE MEGLUMINE
INJECTABLE;INJECTION
CHOLOGRAFIN MEGLUMINE
BRACCO 10.3% N009321 007

IODIPAMIDE SODIUM
INJECTABLE;INJECTION
CHOLOGRAFIN SODIUM
BRACCO 20% N009321 001

FDA data supplied by DrugPatentWatch.com

IODOHIPPURATE SODIUM I-123
INJECTABLE;INJECTION
NEPHROFLOW

GE HEALTHCARE	1mCi/ML	N018289 001	Dec 28, 1984

IODOHIPPURATE SODIUM I-131
INJECTABLE;INJECTION
HIPPURAN I 131

MALLINCKRODT	0.25mCi/ML	N016666 001	

HIPPUTOPE

BRACCO	1-2mCi/VIAL	N015419 002	

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE	0.2mCi/ML	N017313 001	

IODOXAMATE MEGLUMINE
INJECTABLE;INJECTION
CHOLOVUE

BRACCO	9.9%	N018077 001	
	40.3%	N018076 001	

IOFETAMINE HYDROCHLORIDE I-123
INJECTABLE;INJECTION
SPECTAMINE

IMP	1mCi/ML	N019432 001	Dec 24, 1987

IOHEXOL
INJECTABLE;INJECTION
OMNIPAQUE 210

GE HEALTHCARE	45.3%	N018956 006	Jun 30, 1989

SOLUTION;URETHRAL
OMNIPAQUE 70

GE HEALTHCARE	15.1%	N018956 007	Jun 01, 1994

IOPAMIDOL
INJECTABLE;INJECTION
IOPAMIDOL

BAXTER HLTHCARE	41%	A074629 001	Nov 06, 1996
	51%	A074629 004	Mar 31, 1998
	61%	A074629 002	Nov 06, 1996
	76%	A074629 003	Nov 06, 1996
HOSPIRA	61%	A074734 001	Dec 10, 1996
	76%	A074734 002	Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING	41%	A074881 001	Jul 28, 2000
HOSPIRA	41%	A074898 001	Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA	41%	A074636 001	Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING	51%	A074881 002	Jul 28, 2000
FRESENIUS KABI USA	51%	A074679 001	Apr 02, 1997
HOSPIRA	51%	A074898 002	Dec 30, 1997
	51%	A075005 001	Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA	51%	A074636 002	Dec 30, 1997

IOPAMIDOL-300

ABBVIE	61%	A074638 001	Apr 30, 1997
COOK IMAGING	61%	A074881 003	Jul 28, 2000
FRESENIUS KABI USA	61%	A074679 002	Apr 02, 1997
HOSPIRA	61%	A074898 003	Dec 30, 1997
	61%	A075005 002	Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA	61%	A074636 003	Dec 30, 1997
	61%	A074637 001	Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING	76%	A074881 004	Jul 28, 2000
FRESENIUS KABI USA	76%	A074679 003	Apr 02, 1997
HOSPIRA	76%	A074898 004	Dec 30, 1997
	76%	A075005 003	Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA	76%	A074636 004	Dec 30, 1997

ISOVUE-128

BRACCO	26%	N018735 005	Oct 21, 1986

ISOVUE-200

BRACCO	41%	N020327 001	Oct 12, 1994

FDA data supplied by DrugPatentWatch.com

IOPANOIC ACID
TABLET;ORAL
TELEPAQUE

GE HEALTHCARE	500MG	N008032 001	

IOPHENDYLATE
INJECTABLE;INJECTION
PANTOPAQUE

ALCON	100%	N005319 001	

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM
INJECTABLE;INJECTION
VASCORAY

MALLINCKRODT	52%;26%	N016783 001	

IOTHALAMATE SODIUM
INJECTABLE;INJECTION
ANGIO-CONRAY

MALLINCKRODT	80%	N013319 001	

CONRAY 325

MALLINCKRODT	54.3%	N017685 001	

CONRAY 400

MALLINCKRODT	66.8%	N014295 001	

IOTROLAN
INJECTABLE;INTRATHECAL
OSMOVIST 190

BAYER HLTHCARE	40.6%	N019580 001	Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE	51.3%	N019580 002	Dec 07, 1989

IOVERSOL
INJECTABLE;INJECTION
OPTIRAY 160

LIEBEL-FLARSHEIM	34%	N019710 003	Dec 30, 1988

OPTIRAY 240

LIEBEL-FLARSHEIM	51%	N020923 001	May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM
INJECTABLE;INJECTION
HEXABRIX

GUERBET	39.3%;19.6%	N018905 002	Jul 26, 1985

IOXILAN
INJECTABLE;INJECTION
OXILAN-300

GUERBET	62%	N020316 001	Dec 21, 1995

OXILAN-350

GUERBET	73%	N020316 002	Dec 21, 1995

IPODATE CALCIUM
GRANULE;ORAL
ORAGRAFIN CALCIUM

BRACCO	3GM/PACKET	N012968 001	

IPODATE SODIUM
CAPSULE;ORAL
BILIVIST

BAYER HLTHCARE	500MG	A087768 001	Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO	500MG	N012967 001	

IPRATROPIUM BROMIDE
AEROSOL, METERED;INHALATION
ATROVENT

BOEHRINGER INGELHEIM	0.018MG/INH	N019085 001	Dec 29, 1986

SOLUTION;INHALATION
ATROVENT

BOEHRINGER INGELHEIM	0.02% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020228 001	Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC	0.02%	A075111 001	Apr 22, 1999
APOTEX INC	0.02%	A075441 001	Mar 28, 2001
MYLAN SPECLT	0.02%	A074755 001	Jan 10, 1997
PHARMASCIENCE INC	0.02%	A075507 001	Jan 19, 2001
ROXANE	0.02%	A075867 001	Jul 22, 2002

IPRATROPIUM BROMIDE
SOLUTION;INHALATION
IPRATROPIUM BROMIDE

TEVA PHARMS USA	0.02%	A075313 001	Feb 07, 2000

SPRAY, METERED;NASAL
IPRATROPIUM BROMIDE

APOTEX INC	0.021MG/SPRAY	A076156 001	Apr 18, 2003
	0.042MG/SPRAY	A076155 001	Apr 18, 2003

IRBESARTAN
TABLET;ORAL
IRBESARTAN

WATSON LABS INC	75MG	A090720 001	Oct 12, 2012
	150MG	A090720 002	Oct 12, 2012
	300MG	A090720 003	Oct 12, 2012

IRINOTECAN HYDROCHLORIDE
INJECTABLE;INJECTION
IRINOTECAN HYDROCHLORIDE

SANDOZ	40MG/2ML (20MG/ML)	A077994 001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A077994 002	Feb 27, 2008

IRON DEXTRAN
INJECTABLE;INJECTION
IRON DEXTRAN

SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787 002	

IRON SUCROSE
INJECTABLE;INTRAVENOUS
VENOFER

LUITPOLD	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135 005	Mar 29, 2013
	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135 003	Mar 29, 2005

ISOETHARINE HYDROCHLORIDE
SOLUTION;INHALATION
BETA-2

NEPHRON	1%	A086711 001	

BRONKOSOL

SANOFI AVENTIS US	0.25%	N012339 009	
	1%	N012339 008	

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS	1%	A087101 001	
ASTRAZENECA	0.062%	A087937 001	Nov 15, 1982
	0.062%	A089614 001	Jun 13, 1991
	0.125%	A087938 001	Nov 15, 1982
	0.125%	A089615 001	Jun 13, 1991
	0.167%	A088470 001	Mar 14, 1984
	0.167%	A089616 001	Jun 13, 1991
	0.2%	A088471 001	Mar 14, 1984
	0.2%	A089617 001	Jun 13, 1991
	0.25%	A088472 001	Mar 14, 1984
	0.25%	A089618 001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144 001	Jul 29, 1983
	0.14%	A088145 001	Mar 26, 1984
	0.25%	A088146 001	Aug 01, 1983
DEY	0.08%	A088187 001	Dec 03, 1982
	0.1%	A087389 001	
	0.17%	A087390 001	
	0.25%	A088188 001	Dec 03, 1982
	1%	A086763 001	
INTL MEDICATION	0.077%	A086651 001	
	0.08%	A086651 002	
	0.1%	A086651 003	
	0.143%	A086651 004	
	0.167%	A086651 005	
	0.2%	A086651 006	
	0.25%	A086651 007	
	1%	A086651 008	
PARKE DAVIS	0.5%	A085997 001	
	1%	A085889 001	
ROXANE	0.1%	A087396 001	
	0.125%	A087025 001	
	0.167%	A088226 001	Sep 16, 1983
	0.2%	A087324 001	
	0.25%	A088275 001	Jun 03, 1983

ISOETHARINE HYDROCHLORIDE
SOLUTION;INHALATION
ISOETHARINE HYDROCHLORIDE

	1%	A086899 001	

ISOETHARINE HYDROCHLORIDE S/F

DEY	0.08%	A089817 001	Nov 22, 1988
	0.1%	A089818 001	Nov 22, 1988
	0.17%	A089819 001	Nov 22, 1988
	0.25%	A089820 001	Nov 22, 1988
	1%	A089252 001	Sep 15, 1986

ISOETHARINE MESYLATE
AEROSOL, METERED;INHALATION
BRONKOMETER

SANOFI AVENTIS US	0.34MG/INH	N012339 007	

ISOETHARINE MESYLATE

ALPHARMA US PHARMS	0.34MG/INH	A087858 001	Aug 21, 1984

ISOFLURANE
LIQUID;INHALATION
ISOFLURANE

WATSON LABS INC	99.9%	A074393 001	May 12, 1995

ISOFLUROPHATE
OINTMENT;OPHTHALMIC
FLOROPRYL

MERCK	0.025%	N010656 001	

ISONIAZID
INJECTABLE;INJECTION
NYDRAZID

SANDOZ	100MG/ML	N008662 001	

RIMIFON

ROCHE	25MG/ML	N008420 002	
	100MG/ML	N008420 003	

SYRUP;ORAL
ISONIAZID

MIKART	50MG/5ML	A081118 001	Jul 21, 1997

LANIAZID

LANNETT	50MG/5ML	A089243 001	Feb 03, 1986

RIMIFON

ROCHE	50MG/5ML	N008420 001	

TABLET;ORAL
DOW-ISONIAZID

DOW PHARM	300MG	A080330 002	

HYZYD

MEDPOINTE PHARM HLC	100MG	A080134 003	
	300MG	A080134 004	

INH

NOVARTIS	300MG	A080935 001	

ISONIAZID

DURAMED PHARMS BARR	100MG	A088231 001	Mar 17, 1983
	300MG	A088119 001	Mar 17, 1983
HALSEY	50MG	A083632 001	
HIKMA INTL PHARMS	100MG	A080212 001	
	300MG	A087425 001	
IMPAX LABS	100MG	A080153 001	
IVAX SUB TEVA PHARMS	100MG	A080270 001	
	300MG	A083610 001	
LILLY	100MG	N008499 002	
	300MG	N008499 003	
MK LABS	100MG	A080941 001	
NEXGEN PHARMA INC	100MG	A084050 001	
PANRAY	50MG	N008428 001	
	100MG	N008428 002	
	300MG	N008428 003	
PERRIGO	100MG	A083060 001	
PHARMAVITE	100MG	A085091 001	
PHOENIX LABS NY	50MG	A080368 001	
	100MG	A080368 002	
PUREPAC PHARM	50MG	A080132 003	Jul 14, 1982
	100MG	A080132 004	Jul 14, 1982
SUN PHARM INDS	100MG	A080136 001	
	300MG	A083633 001	

FDA data supplied by DrugPatentWatch.com

ISONIAZID
TABLET;ORAL
ISONIAZID

WATSON LABS	50MG	A080522 001	
	100MG	A080401 001	
	100MG	A080523 001	
	100MG	A085790 001	
	300MG	A080521 001	
	300MG	A083178 001	
	300MG	A085784 001	
WHITEWORTH TOWN PLSN	100MG	A080120 002	

LANIAZID

LANNETT	50MG	A080140 001	
	100MG	A080140 002	

NYDRAZID

BRISTOL MYERS SQUIBB	100MG	N008392 003	

STANOZIDE

EVERYLIFE	100MG	A080126 001	
	300MG	A080126 002	

ISONIAZID; RIFAMPIN
CAPSULE;ORAL
RIFAMPIN AND ISONIAZID

HIKMA INTL PHARMS	150MG;300MG	A065221 001	Jul 29, 2005

ISOPROPAMIDE IODIDE
TABLET;ORAL
DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744 001	

ISOPROTERENOL HYDROCHLORIDE
AEROSOL, METERED;INHALATION
ISOPROTERENOL HYDROCHLORIDE

3M	0.12MG/INH	N010375 004	
ALPHARMA US PHARMS	0.12MG/INH	A085904 001	

ISUPREL

SANOFI AVENTIS US	0.103MG/INH	N011178 001	

DISC;INHALATION
NORISODRINE AEROTROL

ABBOTT	0.25%	N016814 001	

INJECTABLE;INJECTION
ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM	0.2MG/ML	A083431 001	
BAXTER HLTHCARE	0.2MG/ML	A083486 001	
HOSPIRA	0.02MG/ML	A083283 001	
	0.2MG/ML	A083346 001	
INTL MEDICATION	0.2MG/ML	A083724 001	

SOLUTION;INHALATION
AEROLONE

LILLY	0.25%	N007245 001	

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM	0.031%	A087935 001	Nov 18, 1982
	0.062%	A087936 001	Nov 18, 1982
DEY	0.5%	A086764 001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994 001	
	0.5%	A085540 001	

ISUPREL

SANOFI AVENTIS US	0.5%	N006327 002	
	1%	N006327 003	

VAPO-ISO

FISONS	0.5%	N016813 001	

TABLET;RECTAL, SUBLINGUAL
ISUPREL

SANOFI AVENTIS US	10MG	N006328 001	
	15MG	N006328 002	

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE
AEROSOL, METERED;INHALATION
DUO-MEDIHALER

3M	0.16MG/INH;0.24MG/INH	N013296 001	

ISOPROTERENOL SULFATE
AEROSOL, METERED;INHALATION
MEDIHALER-ISO

3M	0.08MG/INH	N010375 003	

POWDER;INHALATION
NORISODRINE

ABBVIE	10%	N006905 003	
	25%	N006905 002	

ISOSORBIDE
SOLUTION;ORAL
ISMOTIC

ALCON	100GM/220ML	N017063 001	

ISOSORBIDE DINITRATE
CAPSULE, EXTENDED RELEASE;ORAL
ISORDIL

WYETH AYERST	40MG	N012882 002	Jul 29, 1988

TABLET;ORAL
ISORDIL

VALEANT PHARMS NORTH	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012093 002	Jul 29, 1988
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012093 006	Jul 29, 1988
	30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012093 005	Jul 29, 1988

ISOSORBIDE DINITRATE

SUN PHARM INDS	5MG	A086166 002	Sep 19, 1986
	10MG	A086169 001	Sep 19, 1986
	20MG	A086167 001	Sep 19, 1986
	30MG	A087564 001	Sep 18, 1986
SUPERPHARM	5MG	A089190 001	Feb 17, 1987
	10MG	A089191 001	Feb 17, 1987
	20MG	A089192 001	Feb 17, 1987
WATSON LABS	5MG	A086034 001	Jan 06, 1988
	10MG	A086032 001	Jan 07, 1988

SORBITRATE

ASTRAZENECA	5MG	N016192 001	Apr 01, 1996
	10MG	N016192 002	Apr 01, 1996
	20MG	A086405 002	Aug 21, 1990
	30MG	A088124 001	Aug 21, 1990
	40MG	A088125 001	Aug 21, 1990

TABLET;SUBLINGUAL
ISORDIL

BIOVAIL	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012940 004	Jul 29, 1988
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012940 003	Jul 29, 1988
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012940 005	Jul 29, 1988

ISOSORBIDE DINITRATE

HIKMA INTL PHARMS	2.5MG	A086054 001	Oct 29, 1987
	5MG	A086055 001	Nov 02, 1987
SANDOZ	2.5MG	A086225 001	Feb 19, 1988
	5MG	A086222 001	Feb 19, 1988
SUN PHARM INDS	2.5MG	A084204 001	Sep 18, 1986
	5MG	A086168 001	Sep 18, 1986
	10MG	A087545 001	Sep 18, 1986
WATSON LABS	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A086033 001	Feb 26, 1988
	5MG **Federal Register determination that product was not discontinued or	A086031 001	Sep 29, 1987

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

	withdrawn for safety or efficacy reasons**		

SORBITRATE

ASTRAZENECA	2.5MG	N016191 002	Apr 01, 1996
	5MG	N016191 001	Apr 01, 1996

TABLET, CHEWABLE;ORAL

SORBITRATE

ASTRAZENECA	5MG	N016776 002	Apr 01, 1996
	10MG	N016776 003	Apr 01, 1996

TABLET, EXTENDED RELEASE;ORAL

ISORDIL

WYETH AYERST	40MG	N012882 001	Jul 29, 1988

ISOSORBIDE DINITRATE

COREPHARMA	40MG	A040723 001	Mar 17, 2008

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISMO

PROMIUS PHARMA	20MG	N019091 001	Dec 30, 1991

TABLET, EXTENDED RELEASE;ORAL

IMDUR

SCHERING PLOUGH	30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020225 001	Aug 12, 1993
	60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020225 002	Aug 12, 1993
	120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020225 003	Mar 30, 1995

ISOSORBIDE MONONITRATE

ACTAVIS ELIZABETH	30MG	A075306 001	Dec 31, 1998
	60MG	A075306 002	Dec 31, 1998
ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998
IVAX SUB TEVA PHARMS	30MG	A075448 002	Aug 07, 2001
	60MG	A075448 001	Jun 19, 2000
	120MG	A075448 003	Aug 07, 2001
SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999

ISOSULFAN BLUE

INJECTABLE;INJECTION

LYMPHAZURIN

COVIDIEN	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018310 001	

ISOTRETINOIN

CAPSULE;ORAL

ACCUTANE

HOFFMANN LA ROCHE	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018662 002	May 07, 1982
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018662 004	Mar 28, 1983
	40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018662 003	May 07, 1982

SOTRET

SUN PHARM INDS LTD	10MG	A076041 001	Dec 24, 2002
	20MG	A076041 002	Dec 24, 2002
	30MG	A076503 001	Jun 20, 2003
	40MG	A076041 003	Dec 24, 2002

ISRADIPINE
CAPSULE;ORAL
DYNACIRC

SMITHKLINE BEECHAM	2.5MG	N019546 001	Dec 20, 1990
	5MG	N019546 002	Dec 20, 1990

TABLET, EXTENDED RELEASE;ORAL
DYNACIRC CR

GLAXOSMITHKLINE LLC	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020336 001	Jun 01, 1994
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020336 002	Jun 01, 1994

ITRACONAZOLE
INJECTABLE;INJECTION
SPORANOX

JANSSEN PHARMS	10MG/ML	N020966 001	Mar 30, 1999

SOLUTION;ORAL
ITRACONAZOLE

AMNEAL PHARMS	10MG/ML	A205573 001	Oct 30, 2015

IVERMECTIN
TABLET;ORAL
STROMECTOL

MERCK SHARP DOHME	6MG	N050742 001	Nov 22, 1996

KANAMYCIN SULFATE
CAPSULE;ORAL
KANTREX

APOTHECON	EQ 500MG BASE	A060516 001	
	EQ 500MG BASE	A061911 001	
	EQ 500MG BASE	A062726 001	Mar 06, 1987

INJECTABLE;INJECTION
KANAMYCIN

EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324 001	
	EQ 500MG BASE/2ML	A062324 002	
	EQ 1GM BASE/3ML	A062324 003	

KANAMYCIN SULFATE

ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504 001	Apr 05, 1984
	EQ 500MG BASE/2ML	A062504 002	Apr 05, 1984
	EQ 1GM BASE/3ML	A062504 003	Apr 05, 1984
INTL MEDICATION	EQ 500MG BASE/2ML	A062466 001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466 002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML	A063021 001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022 001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025 001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668 001	May 07, 1987
	EQ 500MG BASE/2ML	A062672 001	May 07, 1987
	EQ 1GM BASE/3ML	A062669 001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605 003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605 001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605 002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092 001	Oct 11, 1989
WATSON LABS	EQ 1GM BASE/3ML	A062520 003	May 09, 1985

KANTREX

APOTHECON	EQ 75MG BASE/2ML	A061655 003	
	EQ 75MG BASE/2ML	A061901 003	
	EQ 75MG BASE/2ML	A062564 001	Sep 21, 1984
	EQ 500MG BASE/2ML	A061655 001	
	EQ 500MG BASE/2ML	A061901 001	
	EQ 500MG BASE/2ML	A062564 002	Sep 21, 1984
	EQ 1GM BASE/3ML	A061655 002	
	EQ 1GM BASE/3ML	A061901 002	
	EQ 1GM BASE/3ML	A062564 003	Sep 21, 1984

KLEBCIL

KING PHARMS	EQ 75MG BASE/2ML	A062170 001	
	EQ 500MG BASE/2ML	A062170 002	
	EQ 1GM BASE/3ML	A062170 003	

KETOCONAZOLE

CREAM;TOPICAL				
NIZORAL				
	JANSSEN PHARMA	2%	N019084 001	Dec 31, 1985
SUSPENSION;ORAL				
NIZORAL				
	JANSSEN PHARMA	100MG/5ML	A070767 001	Nov 07, 1986
TABLET;ORAL				
KETOCONAZOLE				
	AAIPHARMA LLC	200MG	A075341 001	Jul 27, 1999
	APOTEX	200MG	A075912 001	Jan 10, 2002
	PLIVA	200MG	A075362 001	Jun 15, 1999
	SUN PHARM INDS	200MG	A075314 001	Jun 15, 1999
	TEVA	200MG	A074971 001	Jun 15, 1999
NIZORAL				
	JANSSEN PHARMS	200MG	N018533 001	

KETOPROFEN

CAPSULE;ORAL				
KETOPROFEN				
	AUROLIFE PHARMA LLC	50MG	A074024 001	Dec 29, 1995
		75MG	A074024 002	Dec 29, 1995
	TEVA	25MG	A073515 001	Dec 22, 1992
ORUDIS				
	WYETH AYERST	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018754 001	Jul 31, 1987
		50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018754 002	Jan 09, 1986
		75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018754 003	Jan 09, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
KETOPROFEN				
	ALKERMES GAINESVILLE	200MG	A074879 001	Dec 10, 1997
ORUVAIL				
	WYETH PHARMS INC	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019816 003	Feb 08, 1995
		150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019816 002	Feb 08, 1995
		200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019816 001	Sep 24, 1993
FILM;ORAL				
NEXCEDE				
	NOVARTIS	12.5MG	N022470 001	Nov 25, 2009
TABLET;ORAL				
ACTRON				
	BAYER	12.5MG	N020499 001	Oct 06, 1995
KETOPROFEN				
	PERRIGO	12.5MG	A075364 001	Feb 07, 2002
ORUDIS KT				
	WYETH CONS	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020429 001	Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION				
KETOROLAC TROMETHAMINE				
	APOTEX INC	30MG/ML	A075626 001	Jul 24, 2001
		30MG/ML	A077201 001	Oct 14, 2005
	APOTHECON	15MG/ML	A075348 001	Nov 28, 2000
		30MG/ML	A075348 002	Nov 28, 2000
	BEDFORD	15MG/ML	A075230 002	Oct 25, 1999
		30MG/ML	A075230 001	Oct 25, 1999
	CLARIS	15MG/ML	A075631 002	Jun 29, 2001

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION				
KETOROLAC TROMETHAMINE				
		30MG/ML	A075631 001	Jun 29, 2001
	GLAND PHARMA LTD	15MG/ML	A076722 001	Jul 27, 2004
		30MG/ML	A076722 002	Jul 27, 2004
	HOSPIRA	15MG/ML	A074801 001	Jun 05, 1997
		30MG/ML	A074801 002	Jun 05, 1997
	LUITPOLD	15MG/ML	A078145 001	Jan 14, 2008
		30MG/ML	A078145 002	Jan 14, 2008
	SANDOZ	15MG/ML	A076271 001	Oct 06, 2004
	SUN PHARMA GLOBAL	15MG/ML	A078737 001	Oct 06, 2008
		30MG/ML	A078737 002	Oct 06, 2008
	WEST-WARD PHARMS INT	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075222 001	Apr 26, 1999
		15MG/ML	A075299 001	Nov 03, 1999
		15MG/ML	A075772 001	Jul 21, 2004
		30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075222 002	Apr 26, 1999
		30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075228 001	Apr 26, 1999
		30MG/ML	A075299 002	Nov 03, 1999
		30MG/ML	A075772 002	Jul 21, 2004
	WOCKHARDT	30MG/ML	A077943 001	Mar 27, 2007
TORADOL				
	ROCHE PALO	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019698 001	Nov 30, 1989
		30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019698 002	Nov 30, 1989
SOLUTION/DROPS;OPHTHALMIC				
ACULAR PRESERVATIVE FREE				
	ALLERGAN	0.5%	N020811 001	Nov 03, 1997
KETOROLAC TROMETHAMINE				
	AKORN	0.45%	A203376 001	Feb 10, 2014
TABLET;ORAL				
KETOROLAC TROMETHAMINE				
	CYCLE PHARMS LTD	10MG	A074790 001	Jun 26, 1997
	WATSON LABS	10MG	A074955 001	Sep 19, 1997
TORADOL				
	ROCHE PALO	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019645 001	Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC				
KETOTIFEN FUMARATE				
	APOTEX INC	EQ 0.025% BASE	A077354 001	May 09, 2006
ZADITOR				
	ALCON PHARMA	EQ 0.025% BASE	N021066 002	Oct 19, 2006

KRYPTON, KR-81M

GAS;INHALATION				
MPI KRYPTON 81M GENERATOR				
	GE HEALTHCARE	N/A	N018088 001	

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION				
LABETALOL HYDROCHLORIDE				
	APOTHECON	5MG/ML	A075355 001	Nov 29, 1999
	CLARIS	5MG/ML	A076051 001	Jul 05, 2002
	HOSPIRA	5MG/ML	A075242 001	Sep 30, 1999
NORMODYNE				
	SCHERING	5MG/ML	N018686 001	Aug 01, 1984
TRANDATE				
	SEBELA IRELAND LTD	5MG/ML **Federal Register determination	N019425 001	Dec 31, 1985

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

TRANDATE

that product was not discontinued or withdrawn for safety or efficacy reasons**

TABLET;ORAL

LABETALOL HYDROCHLORIDE

APOTHECON	100MG	A075223 001	Nov 20, 1998
	200MG	A075223 002	Nov 20, 1998
	300MG	A075223 003	Nov 20, 1998
TEVA	100MG	A074989 001	Sep 30, 1998
	200MG	A074989 002	Sep 30, 1998
	300MG	A074989 003	Sep 30, 1998

NORMODYNE

SCHERING	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018687 001	Aug 31, 1987
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018687 002	Aug 01, 1984
	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018687 003	Aug 01, 1984
	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018687 004	Aug 01, 1984

TRANDATE

CNTY LINE PHARMS	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018716 004	Aug 01, 1984

LACTULOSE

SOLUTION;ORAL

CHRONULAC

SANOFI AVENTIS US	10GM/15ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017884 001	

CONSTULOSE

ACTAVIS MID ATLANTIC	10GM/15ML	A070288 001	Aug 15, 1988

DUPHALAC

SOLVAY	10GM/15ML	A072372 001	Mar 22, 1989

EVALOSE

TEVA PHARMS	10GM/15ML	A073497 001	May 28, 1993

LACTULOSE

APOTEX INC	10GM/15ML	A075911 001	Feb 21, 2002
MORTON GROVE	10GM/15ML	A071841 001	Sep 22, 1988
PACO	10GM/15ML	A073160 001	Aug 25, 1992

LAXILOSE

NOSTRUM LABS	10GM/15ML	A073686 001	May 28, 1993

SOLUTION;ORAL, RECTAL

ACILAC

NOSTRUM LABS	10GM/15ML	A073685 001	May 28, 1993

CEPHULAC

SANOFI AVENTIS US	10GM/15ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017657 001	

GENERLAC

MORTON GROVE	10GM/15ML	A071842 001	Sep 27, 1988

HEPTALAC

TEVA PHARMS	10GM/15ML	A073504 001	May 28, 1993

LACTULOSE

APOTEX INC	10GM/15ML	A076645 001	Jul 28, 2003
PACO	10GM/15ML	A072029 001	Aug 25, 1992
ROXANE	10GM/15ML	A073590 001	May 29, 1992
SOLVAY	10GM/15ML	N017906 001	

PORTALAC

SOLVAY	10GM/15ML	A072374 001	Mar 22, 1989

FDA data supplied by DrugPatentWatch.com

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET;ORAL				
DUTREBIS				
MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015

LAMOTRIGINE

TABLET;ORAL				
LAMICTAL				
GLAXOSMITHKLINE LLC	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020241	006	Dec 27, 1994
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020241	004	Dec 27, 1994
LAMOTRIGINE				
ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
	100MG	A078669	002	Apr 08, 2011
	150MG	A078669	003	Apr 08, 2011
	200MG	A078669	004	Apr 08, 2011
HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
	100MG	A078134	002	Apr 19, 2011
	150MG	A078134	003	Apr 19, 2011
	200MG	A078134	004	Apr 19, 2011
MATRIX LABS LTD	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
MYLAN	25MG	A077428	001	Jan 27, 2009
	100MG	A077428	002	Jan 27, 2009
	150MG	A077428	003	Jan 27, 2009
	200MG	A077428	004	Jan 27, 2009
PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
SANDOZ	25MG	A078645	001	Jan 27, 2009
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
WOCKHARDT	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009
TABLET, CHEWABLE;ORAL				
LAMICTAL CD				
GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998
LAMOTRIGINE				
SANDOZ	5MG	A078409	002	Jan 22, 2009
	25MG	A078409	003	Jan 22, 2009

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL				
PREVACID				
TAKEDA PHARMS NA	15MG/PACKET	N021281	001	May 03, 2001
	30MG/PACKET	N021281	002	May 03, 2001
INJECTABLE;INTRAVENOUS				
PREVACID IV				
TAKEDA PHARMS NA	30MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021566	001	May 27, 2004
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL				
LANSOPRAZOLE				
ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010
	30MG	A078730	002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN
CAPSULE, DELAYED REL PELLETS, TABLET;ORAL
PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021507 002	Nov 14, 2003

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,375MG	N021507 003	Nov 14, 2003

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,500MG	N021507 004	Nov 14, 2003

LANTHANUM CARBONATE
TABLET, CHEWABLE;ORAL
FOSRENOL

SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX
SOLUTION;TOPICAL
VIRAC REX

CHESEBROUGH PONDS	0.5%;1.8%	N011914 001	

LATANOPROST
SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

APOTEX INC	0.005%	A077697 001	Mar 22, 2011

LEFLUNOMIDE
TABLET;ORAL
LEFLUNOMIDE

SANDOZ	10MG	A077085 001	Sep 13, 2005
	10MG	A077087 001	Sep 13, 2005
	20MG	A077085 002	Sep 13, 2005
	20MG	A077087 002	Sep 13, 2005

LEPIRUDIN RECOMBINANT
INJECTABLE;INJECTION
REFLUDAN

BAYER HLTHCARE	50MG/VIAL	N020807 001	Mar 06, 1998

LETROZOLE
TABLET;ORAL
LETROZOLE

ACTAVIS TOTOWA	2.5MG	A090292 001	Jul 13, 2011
IMPAX LABS	2.5MG	A091638 001	Jun 03, 2011
SYNTHON PHARMS	2.5MG	A090196 001	Jun 03, 2011

LEUCOVORIN CALCIUM
FOR SOLUTION;ORAL
LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL	N008107 003	Jan 30, 1987

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML	A089352 001	Jun 01, 1988
	EQ 50MG BASE/VIAL	A089353 001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939 001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL	A070480 001	Jan 02, 1987
	EQ 100MG BASE/VIAL	A081224 001	Jun 03, 1994
HOSPIRA	EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008107 001	
	EQ 50MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008107 002	
	EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008107 004	May 23, 1988
	EQ 350MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008107 005	Apr 05, 1989
PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262 001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628 001	Apr 17, 1997
	EQ 100MG BASE/VIAL	A089915 001	Apr 17, 1997
TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278 001	Sep 28, 1993

LEUCOVORIN CALCIUM
INJECTABLE;INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

HOSPIRA	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A040147 001	Jun 25, 1997
LUITPOLD	EQ 50MG BASE/VIAL	A040338 001	Jan 31, 2001
TEVA PARENTERAL	EQ 10MG BASE/ML	A040332 001	Jun 28, 1999

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439 001	Oct 19, 1982
	EQ 25MG BASE/VIAL	A089833 001	Jan 23, 1989
	EQ 50MG BASE/VIAL	A089465 001	Jan 23, 1989
	EQ 100MG BASE/VIAL	A089834 001	Jan 23, 1989

TABLET;ORAL
LEUCOVORIN CALCIUM

COREPHARMA	EQ 5MG BASE	A074544 001	Aug 28, 1997
	EQ 25MG BASE	A074544 002	Aug 28, 1997
IDT AUSTRALIA LTD	EQ 15MG BASE	A075327 001	Mar 24, 1999
PAR PHARM	EQ 5MG BASE	A071600 001	Oct 14, 1987
	EQ 25MG BASE	A071598 001	Oct 14, 1987
PHARMACHEMIE	EQ 5MG BASE	A073099 001	Mar 28, 1997
	EQ 25MG BASE	A073101 001	Mar 28, 1997
XANODYNE PHARM	EQ 5MG BASE	N018459 001	Jan 30, 1986
	EQ 10MG BASE	A071962 001	Nov 19, 1987
	EQ 15MG BASE	A071104 001	Mar 04, 1987

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE	N018342 001	Jul 08, 1983
	EQ 25MG BASE	N018342 002	Jul 08, 1983

LEUPROLIDE ACETATE
IMPLANT;IMPLANTATION
VIADUR

ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088 001	Mar 03, 2000

INJECTABLE;INJECTION
LEUPROLIDE ACETATE

GENZYME	1MG/0.2ML	A075721 001	Nov 29, 2001

LUPRON

ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010 001	Apr 09, 1985

LUPRON DEPOT

ABBVIE ENDOCRINE INC	3.75MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020011 001	Oct 22, 1990

LUPRON DEPOT-PED

ABBVIE ENDOCRINE INC	3.75MG/VIAL,7.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020263 003	Apr 16, 1993
	7.5MG/VIAL,7.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020263 004	Apr 16, 1993

LEVALLORPHAN TARTRATE
INJECTABLE;INJECTION
LORFAN

ROCHE	1MG/ML	N010423 001	

LEVAMISOLE HYDROCHLORIDE
TABLET;ORAL
ERGAMISOL

JANSSEN PHARMA	EQ 50MG BASE	N020035 001	Jun 18, 1990

LEVETIRACETAM
SOLUTION;ORAL
LEVETIRACETAM

APOTEX INC	100MG/ML	A090187 001	Aug 05, 2011

TABLET;ORAL
LEVETIRACETAM

ACTAVIS LABS FL INC	250MG	A077408 001	Mar 02, 2009
	500MG	A077408 002	Mar 02, 2009
	750MG	A077408 003	Mar 02, 2009
MYLAN	250MG	A078731 001	Feb 10, 2009
	500MG	A078731 002	Feb 10, 2009
	750MG	A078731 003	Feb 10, 2009

LEVETIRACETAM
TABLET;ORAL
LEVETIRACETAM

	1GM	A078731	004	Feb 10, 2009
SANDOZ	250MG	A077324	001	Jan 15, 2009
	500MG	A077324	002	Jan 15, 2009
	750MG	A077324	003	Jan 15, 2009
	1GM	A077324	004	Jan 15, 2009
WATSON LABS INC	250MG	A078797	002	Jan 15, 2009
	500MG	A078797	003	Jan 15, 2009
	750MG	A078797	004	Jan 15, 2009
	1GM	A078797	001	Jan 15, 2009

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

SANDOZ	500MG	A091668	001	Nov 01, 2012
	750MG	A091668	002	Nov 01, 2012

LEVOBETAXOLOL HYDROCHLORIDE
SUSPENSION/DROPS;OPHTHALMIC
BETAXON

ALCON PHARMS LTD	EQ 0.5% BASE	N021114	001	Feb 23, 2000

LEVOBUNOLOL HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

APOTEX INC	0.25%	A075473	001	Aug 03, 2000
	0.5%	A075475	001	Aug 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CHIROCAINE

PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999
	EQ 5MG BASE/ML	N020997	002	Aug 05, 1999
	EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE
SUSPENSION/DROPS;OPHTHALMIC
LIVOSTIN

NOVARTIS	EQ 0.05% BASE	N020219	001	Nov 10, 1993

LEVOCARNITINE
INJECTABLE;INJECTION
LEVOCARNITINE

TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001

SOLUTION;ORAL
CARNITOR

SIGMA TAU	1GM/10ML	N018948	002	Apr 27, 1988

LEVOCETIRIZINE DIHYDROCHLORIDE
TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

SANDOZ	5MG	A090486	001	Mar 26, 2013

LEVODOPA
CAPSULE;ORAL
BENDOPA

VALEANT PHARM INTL	100MG	N016948	003
	250MG	N016948	001
	500MG	N016948	002

DOPAR

SHIRE	100MG	N016913	003
	250MG	N016913	001
	500MG	N016913	002

LARODOPA

ROCHE	100MG	N016912	002
	250MG	N016912	001
	500MG	N016912	006

TABLET;ORAL
DOPAR

SHIRE	250MG	N016913	004
	500MG	N016913	005

LARODOPA

ROCHE	100MG	N016912	005
	250MG	N016912	003
	500MG	N016912	004

FDA data supplied by DrugPatentWatch.com

LEVOFLOXACIN
INJECTABLE;INJECTION
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020635 002	Dec 20, 1996
	EQ 500MG/100ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020635 003	Dec 20, 1996
	EQ 750MG/150ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020635 005	Dec 20, 1996

LEVOFLOXACIN

AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001	Jun 20, 2011
	EQ 750MG/30ML (EQ 25MG/ML)	A091644 002	Jun 20, 2011
HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577 001	Aug 12, 2015
	EQ 750MG/30ML (EQ 25MG/ML)	A078577 002	Aug 12, 2015

SOLUTION/DROPS;OPHTHALMIC
IQUIX

SANTEN	1.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021571 001	Mar 01, 2004

LEVOFLOXACIN

APOTEX INC	0.5%	A078282 001	Dec 20, 2010

QUIXIN

SANTEN	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021199 001	Aug 18, 2000

TABLET;ORAL
LEVOFLOXACIN

WATSON LABS INC	250MG	A201484 001	Nov 22, 2013
	500MG	A201484 002	Nov 22, 2013
	750MG	A201484 003	Nov 22, 2013

LEVOLEUCOVORIN CALCIUM
SOLUTION;IV (INFUSION)
FUSILEV

SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020140 002	Apr 29, 2011
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020140 003	Apr 29, 2011

LEVOMEPROMAZINE
INJECTABLE;INJECTION
LEVOPROME

IMMUNEX	20MG/ML	N015865 001	

LEVOMETHADYL ACETATE HYDROCHLORIDE
CONCENTRATE;ORAL
ORLAAM

ROXANE	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020315 001	Jul 09, 1993

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

SOLVAY	0.05MG/ML;2%	A085010 001	

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK	0.05MG/ML;2%	N012125 002	

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN

NOVOCOL	0.05MG/ML;2%	A084697 001	

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

GRAHAM CHEM	0.05MG/ML;2%	A084850 002	Oct 21, 1983

FDA data supplied by DrugPatentWatch.com

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
POLOCAINE W/ LEVONORDEFRIN

DENTSPLY PHARM	0.05MG/ML;2%	A089517 001	Apr 14, 1988

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK	0.05MG/ML;2%;0.4%	N008592 007	

LEVONORGESTREL
IMPLANT;IMPLANTATION
JADELLE

POPULATION COUNCIL	75MG/IMPLANT **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020544 001	Nov 01, 1996

LEVONORGESTREL

WYETH PHARMS INC	75MG/IMPLANT	N020627 001	Aug 15, 1996

NORPLANT

POPULATION COUNCIL	36MG/IMPLANT	N019897 001	Dec 10, 1990

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC	36MG/IMPLANT	N020088 001	Dec 10, 1990

TABLET;ORAL
LEVONORGESTREL

LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013
WATSON LABS	0.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A078665 001	Aug 28, 2009
	0.75MG	A078666 001	Jun 24, 2009

PLAN B

TEVA BRANDED PHARM	0.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021045 001	Jul 28, 1999
	0.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021045 002	Aug 24, 2006

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS
CAPSULE;ORAL
NOVRAD

LILLY	EQ 50MG BASE	N012928 006	
	EQ 100MG BASE	N012928 004	

SUSPENSION;ORAL
NOVRAD

LILLY	EQ 50MG BASE/5ML	N012928 002	

LEVORPHANOL TARTRATE
INJECTABLE;INJECTION
LEVO-DROMORAN

VALEANT PHARM INTL	2MG/ML	N008719 001	Dec 19, 1991

TABLET;ORAL
LEVO-DROMORAN

VALEANT PHARM INTL	2MG	N008720 001	Dec 19, 1991

LEVOTHYROXINE SODIUM
TABLET;ORAL
LEVOLET

LEHIGH VALLEY	0.025MG	N021137 001	Jun 06, 2003
	0.05MG	N021137 002	Jun 06, 2003
	0.075MG	N021137 003	Jun 06, 2003
	0.088MG	N021137 004	Jun 06, 2003
	0.1MG	N021137 005	Jun 06, 2003
	0.112MG	N021137 006	Jun 06, 2003
	0.125MG	N021137 007	Jun 06, 2003
	0.137MG	N021137 008	Jun 06, 2003
	0.15MG	N021137 009	Jun 06, 2003
	0.175MG	N021137 010	Jun 06, 2003
	0.2MG	N021137 011	Jun 06, 2003
	0.3MG	N021137 012	Jun 06, 2003

LEVOTHROID

LLOYD	0.025MG **Federal Register determination that product was not discontinued or withdrawn for safety or	N021116 001	Oct 24, 2002

FDA data supplied by DrugPatentWatch.com

LEVOTHYROXINE SODIUM

TABLET;ORAL

LEVOTHROID				
	efficacy reasons**			
	0.05MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	002	Oct 24, 2002
	0.075MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	003	Oct 24, 2002
	0.088MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	010	Oct 24, 2002
	0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	004	Oct 24, 2002
	0.112MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	011	Oct 24, 2002
	0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	005	Oct 24, 2002
	0.137MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	012	Dec 07, 2004
	0.15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	006	Oct 24, 2002
	0.175MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	007	Oct 24, 2002
	0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	008	Oct 24, 2002
	0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116	009	Oct 24, 2002
LEVOTHYROXINE SODIUM				
MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005
	0.05MG	A076752	002	Jun 16, 2005
	0.075MG	A076752	003	Jun 16, 2005
	0.088MG	A076752	004	Jun 16, 2005
	0.1MG	A076752	005	Jun 16, 2005
	0.112MG	A076752	006	Jun 16, 2005
	0.125MG	A076752	007	Jun 16, 2005
	0.15MG	A076752	008	Jun 16, 2005
	0.175MG	A076752	009	Jun 16, 2005
	0.2MG	A076752	010	Jun 16, 2005
	0.3MG	A076752	011	Jun 16, 2005
LEVOXYL				
KING PHARMS R AND D	0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021301	012	May 25, 2001
NOVOTHYROX				
MERCK KGAA	0.025MG	N021292	001	May 31, 2002
	0.05MG	N021292	002	May 31, 2002
	0.075MG	N021292	003	May 31, 2002
	0.088MG	N021292	004	May 31, 2002
	0.1MG	N021292	005	May 31, 2002
	0.112MG	N021292	006	May 31, 2002
	0.125MG	N021292	007	May 31, 2002
	0.137MG	N021292	008	May 31, 2002
	0.15MG	N021292	009	May 31, 2002
	0.175MG	N021292	010	May 31, 2002
	0.2MG	N021292	011	May 31, 2002

FDA data supplied by DrugPatentWatch.com

LEVOTHYROXINE SODIUM
TABLET;ORAL
NOVOTHYROX

	0.3MG	N021292 012	May 31, 2002

LIDOCAINE
AEROSOL;ORAL
XYLOCAINE

ASTRAZENECA	10%	N014394 001	

FILM, EXTENDED RELEASE;BUCCAL
DENTIPATCH

NOVEN	23MG/PATCH	N020575 001	May 21, 1996

OINTMENT;TOPICAL
ALPHACAINE

CARLISLE	5%	A084944 001	
	5%	A084946 001	
	5%	A084947 001	

LIDOCAINE

BELMORA LLC	5%	A080210 001	

XYLOCAINE

ASTRAZENECA	5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008048 001	

PATCH;TOPICAL
DENTIPATCH

NOVEN	46.1MG/PATCH	N020575 002	May 21, 1996

SOLUTION;TOPICAL
XYLOCAINE

ASTRAZENECA	5%	N014127 001	

SUPPOSITORY;RECTAL
XYLOCAINE

ASTRAZENECA	100MG	N013077 001	

LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
ALPHACAINE HYDROCHLORIDE

CARLISLE	2%	A084721 001	

LIDOCAINE HYDROCHLORIDE

ABBOTT	10%	A087980 001	Feb 02, 1983
	20%	A089362 001	May 25, 1988
ABRAXIS PHARM	1%	A080420 001	
	1%	A086761 001	
	1.5%	A080420 005	
	2%	A080420 002	
	2%	A080420 004	
	2%	A086761 002	
	2%	N017508 001	
	4%	N017508 002	
	20%	N017508 004	
AKORN	1%	A085037 001	
	2%	A085037 002	
BEL MAR	1%	A080710 001	
	2%	A080760 001	
DELL LABS	1%	A083387 001	
	2%	A083388 001	
ELKINS SINN	0.5%	A085131 001	
	4%	A084626 001	
GD SEARLE LLC	1%	A083135 001	
	2%	A083135 002	
GRAHAM CHEM	2%	A080504 001	
HOSPIRA	1%	A040013 001	Jun 23, 1995
	1.5%	A088330 001	May 17, 1984
	2%	A088331 001	May 17, 1984
INTL MEDICATION	1%	N017701 002	
	2%	N017701 001	
	1GM/VIAL	N018543 001	
	2GM/VIAL	N018543 002	
LUITPOLD	2%	A083198 001	
LYPHOMED	1%	A080390 001	
	2%	A080390 002	
MILES	1%	A080414 001	
	2%	A080414 002	
WATSON LABS	1%	A080377 001	

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
LIDOCAINE HYDROCHLORIDE				
		1%	A083627 001	
		2%	A080377 002	
		2%	A083627 002	
	WEST-WARD PHARMS INT	1%	A080407 001	
		2%	A080407 002	
	WYETH AYERST	1%	A083083 001	
		2%	A083083 002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	100MG/100ML	N018461 001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
	B BRAUN	200MG/100ML	N018967 001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%				
	HOSPIRA	200MG/100ML	A083158 005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER				
	ABBOTT	200MG/100ML	N018954 001	Jul 09, 1985
	HOSPIRA	200MG/100ML	N018388 001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
	B BRAUN	400MG/100ML	N018967 002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%				
	HOSPIRA	400MG/100ML	A083158 006	
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HOSPIRA	400MG/100ML	N018388 002	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER				
	B BRAUN	800MG/100ML	N018967 003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HOSPIRA	800MG/100ML	N018388 003	Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER				
	HOSPIRA	1.5%	A088326 001	Jul 31, 1984
		10%	A088367 001	Jul 31, 1984
		20%	A088368 001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE				
	INTL MEDICATION	4%	N017702 002	
	WEST-WARD PHARMS INT	1%	A084625 001	
		2%	A084625 002	
LIDOCATON				
	PHARMATON	2%	A084727 001	Aug 17, 1983
LIDOPEN				
	MERIDIAN MEDCL TECHN	10%	N017549 001	
XYLOCAINE				
	ASTRAZENECA	1%	N010418 005	
		1.5%	N010418 009	
		2%	N010418 007	
XYLOCAINE DENTAL				
	DENTSPLY PHARM	2%	N021380 001	
XYLOCAINE PRESERVATIVE FREE				
	FRESENIUS KABI USA	10%	N016801 003	
INJECTABLE;SPINAL				
XYLOCAINE 1.5% W/ DEXTROSE 7.5%				
	FRESENIUS KABI USA	1.5%	N016297 001	
XYLOCAINE 5% W/ GLUCOSE 7.5%				
	ASTRAZENECA	5%	N010496 002	Jul 07, 1982
JELLY;TOPICAL				
ANESTACON				
	BIONPHARMA INC	2%	A080429 001	
LIDOCAINE HYDROCHLORIDE				
	G AND W LABS INC	2%	A081318 001	Apr 29, 1993
SOLUTION;ORAL				
LIDOCAINE HYDROCHLORIDE VISCOUS				
	ACTAVIS MID ATLANTIC	2%	A086578 001	
	INTL MEDICATION	2%	A086389 001	Feb 02, 1982
XYLOCAINE VISCOUS				
	FRESENIUS KABI USA	2%	N009470 001	
SOLUTION;TOPICAL				
LARYNGOTRACHEAL ANESTHESIA KIT				
	KENDALL IL	4%	A087931 001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE				
	PACO	4%	A089688 001	Jun 30, 1989
LTA II KIT				
	HOSPIRA	4%	A088542 001	Jul 31, 1984

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE
SOLUTION;TOPICAL
PEDIATRIC LTA KIT

ABBOTT	2%	A088572 001	Jul 31, 1984
HOSPIRA	2%	A085995 001	

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE
INJECTABLE;INJECTION
TERRAMYCIN

PFIZER	2%;50MG/ML	A060567 001	
	2%;125MG/ML	A060567 002	

LIDOCAINE; PRILOCAINE
DISC;TOPICAL
EMLA

ASTRAZENECA	2.5%;2.5%	N020962 001	Feb 04, 1998

LINCOMYCIN HYDROCHLORIDE
CAPSULE;ORAL
LINCOCIN

PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316 001	
	EQ 500MG BASE	N050316 002	

INJECTABLE;INJECTION
LINCOMYCIN HYDROCHLORIDE

WATSON LABS	EQ 300MG BASE/ML	A063180 001	Apr 16, 1991

LINDANE
CREAM;TOPICAL
KWELL

REED AND CARNRICK	1%	A084218 001	
	1%	N006309 001	

LOTION;TOPICAL
GAMENE

SOLA BARNES HIND	1%	A084989 001	

KWELL

REED AND CARNRICK	1%	A084218 002	
	1%	N006309 003	

SCABENE

STIEFEL	1%	A086769 001	

SHAMPOO;TOPICAL
GAMENE

SOLA BARNES HIND	1%	A084988 001	

KWELL

REED AND CARNRICK	1%	A084219 001	
	1%	N010718 001	

SCABENE

STIEFEL	1%	A087940 001	Apr 08, 1983

LINEZOLID
TABLET;ORAL
ZYVOX

PHARMACIA AND UPJOHN	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021130 001	Apr 18, 2000

LIOTHYRONINE SODIUM
TABLET;ORAL
LIOTHYRONINE SODIUM

WATSON LABS	EQ 0.025MG BASE	A085755 001	Jan 25, 1982
	EQ 0.05MG BASE	A085753 001	Feb 03, 1982

LIOTRIX (T4;T3)
TABLET;ORAL
EUTHROID-0.5

PARKE DAVIS	0.03MG;0.0075MG	N016680 001	

EUTHROID-1

PARKE DAVIS	0.06MG;0.015MG	N016680 002	

EUTHROID-2

PARKE DAVIS	0.12MG;0.03MG	N016680 003	

EUTHROID-3

PARKE DAVIS	0.18MG;0.045MG	N016680 004	

THYROLAR-5

FOREST LABS	0.25MG;0.0625MG	N016807 006	

LISINOPRIL
TABLET;ORAL
LISINOPRIL

SANDOZ	2.5MG	A075903 001	Jul 01, 2002
	2.5MG	A075999 001	Jul 01, 2002
	5MG	A075903 002	Jul 01, 2002
	5MG	A075999 002	Jul 01, 2002
	10MG	A075903 003	Jul 01, 2002
	10MG	A075999 003	Jul 01, 2002
	20MG	A075903 004	Jul 01, 2002
	20MG	A075999 004	Jul 01, 2002
	30MG	A075903 005	Jul 01, 2002
	30MG	A075999 005	Jul 01, 2002
	40MG	A075903 006	Jul 01, 2002
	40MG	A075999 006	Jul 01, 2002
TEVA	2.5MG	A075783 001	Jul 01, 2002
	5MG	A075783 002	Jul 01, 2002
	10MG	A075783 003	Jul 01, 2002
	20MG	A075783 004	Jul 01, 2002
	30MG	A075783 005	Jul 01, 2002
	40MG	A075783 006	Jul 01, 2002

PRINIVIL

MERCK	2.5MG	N019558 006	Jan 28, 1994

LITHIUM CARBONATE
CAPSULE;ORAL
ESKALITH

NOVEN THERAP	300MG	N016860 001	

LITHIUM CARBONATE

ABLE	150MG	A076823 001	Jun 29, 2004
	300MG	A076121 001	Sep 27, 2001
	300MG	A076823 002	Jun 29, 2004
	600MG	A076823 003	Jun 29, 2004
APOTEX INC	300MG	A076795 001	Nov 22, 2004
USL PHARMA	300MG	A072542 001	Feb 01, 1989
WATSON LABS	300MG	A070407 001	Mar 19, 1987

LITHONATE

SOLVAY	300MG	N016782 001	

TABLET;ORAL
ESKALITH

JDS PHARMS	300MG	N017971 001	

LITHANE

BAYER PHARMS	300MG	N018833 001	Jul 18, 1985

LITHIUM CARBONATE

HIKMA INTL PHARMS	300MG	A078715 001	Dec 28, 2010
PFIZER	300MG	N016834 001	

LITHOTABS

SOLVAY	300MG	N016980 001	

TABLET, EXTENDED RELEASE;ORAL
ESKALITH CR

JDS PHARMS	450MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018152 001	Mar 29, 1982

LITHIUM CARBONATE

ABLE	300MG	A076382 001	Apr 21, 2003
BARR	300MG	A076170 001	Jun 10, 2002
	450MG	A076366 001	Aug 21, 2003
HIKMA INTL PHARMS	450MG	A076490 001	Jun 17, 2003

LITHIUM CITRATE
SYRUP;ORAL
LITHONATE

SOLVAY	EQ 300MG CARBONATE/5ML	N017672 001	

LOMEFLOXACIN HYDROCHLORIDE
TABLET;ORAL
MAXAQUIN

PHARMACIA	EQ 400MG BASE	N020013 001	Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE
CAPSULE;ORAL
IMODIUM

J AND J CONSUMER INC	2MG	N017690 001	
	2MG	N017694 001	

LOPERAMIDE HYDROCHLORIDE

ROXANE	2MG	A073080 001	Nov 27, 1991
SANDOZ	2MG	A072993 001	Aug 28, 1992
TEVA	2MG	A073122 001	Aug 30, 1991

SOLUTION;ORAL
IMODIUM

JANSSEN PHARMS	1MG/5ML	N019037 001	Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

ALPHARMA US PHARMS	1MG/5ML	A073187 001	Sep 15, 1992
DURAMED PHARMS BARR	1MG/5ML	A074991 001	Dec 29, 1997
TEVA	1MG/5ML	A073478 001	Jun 23, 1995
WATSON LABS	1MG/5ML	A073062 001	May 28, 1993

TABLET;ORAL
LOPERAMIDE HYDROCHLORIDE

ABLE	2MG	A073528 001	Nov 30, 1993
PERRIGO	2MG	A074194 001	Oct 30, 1992

LOPINAVIR; RITONAVIR
CAPSULE;ORAL
KALETRA

ABBVIE	133.3MG;33.3MG	N021226 001	Sep 15, 2000

LORACARBEF
CAPSULE;ORAL
LORABID

KING PHARMS	200MG	N050668 001	Dec 31, 1991
	400MG	N050668 002	Apr 05, 1996

FOR SUSPENSION;ORAL
LORABID

KING PHARMS	100MG/5ML	N050667 001	Dec 31, 1991
	200MG/5ML	N050667 002	Dec 31, 1991

LORATADINE
SYRUP;ORAL
CLARITIN HIVES RELIEF

BAYER HEALTHCARE LLC	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020641 003	Nov 19, 2003

LORATADINE

APOTEX INC	1MG/ML	A075565 001	Oct 05, 2004
RANBAXY LABS LTD	1MG/ML	A076529 001	Aug 20, 2004

TABLET;ORAL
LORATADINE

PERRIGO	10MG	N021512 001	Jun 24, 2004

LORATADINE; PSEUDOEPHEDRINE SULFATE
TABLET, EXTENDED RELEASE;ORAL
LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC	5MG;120MG	A076208 001	Jan 28, 2004

LORAZEPAM
INJECTABLE;INJECTION
LORAZEPAM

AKORN	2MG/ML	A074974 001	Jul 23, 1998
BEDFORD	2MG/ML	A077076 001	Jul 13, 2005
	4MG/ML	A077076 002	Jul 13, 2005
DAVA PHARMS INC	2MG/ML	A074793 001	Mar 16, 2000
	4MG/ML	A074793 002	Mar 16, 2000
EUROHLTH INTL SARL	2MG/ML	A074496 001	Sep 28, 1998
	4MG/ML	A074496 002	Sep 28, 1998
HOSPIRA	2MG/ML	A074280 001	May 27, 1994
	2MG/ML	A074300 001	Apr 12, 1994
	4MG/ML	A074280 002	May 27, 1994
	4MG/ML	A074300 003	Mar 19, 1997
WATSON LABS	2MG/ML	A074276 001	Apr 15, 1994
	4MG/ML	A074276 002	Apr 15, 1994
WATSON LABS INC	1MG/0.5ML	A074551 003	Sep 12, 1996
	2MG/ML	A074535 001	Sep 12, 1996
	2MG/ML	A074551 001	Sep 12, 1996

FDA data supplied by DrugPatentWatch.com

LORAZEPAM
INJECTABLE;INJECTION
LORAZEPAM

	4MG/ML	A074535	002	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996

SOLUTION;ORAL
LORAZEPAM

ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997

TABLET;ORAL
LORAZ

QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985

LORAZEPAM

AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
FRONTIDA BIOPHARM	0.5MG	A072553	001	Mar 29, 1991
	1MG	A072554	001	Mar 29, 1991
	2MG	A072555	001	Mar 29, 1991
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985
	2MG	A070474	001	Dec 10, 1985
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
SANDOZ	0.5MG	A071193	001	Apr 15, 1988
	1MG	A071194	001	Apr 15, 1988
	2MG	A071195	001	Apr 15, 1988
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	1MG	A071118	001	Jul 24, 1986
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986

LOTEPREDNOL ETABONATE
SUSPENSION/DROPS;OPHTHALMIC
LOTEMAX

PHARMOS	0.5%	N020841	001	Mar 09, 1998

LOVASTATIN
TABLET;ORAL
MEVACOR

MERCK	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019643	002	Mar 28, 1991
	20MG **Federal Register notice that product was not discontinued or withdrawn for safety or efficacy reasons**	N019643	003	Aug 31, 1987
	40MG **Federal Register notice that product was not discontinued or withdrawn for safety or efficacy reasons**	N019643	004	Dec 14, 1988

TABLET, EXTENDED RELEASE;ORAL
ALTOPREV

COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002

LOXAPINE HYDROCHLORIDE
CONCENTRATE;ORAL
LOXITANE C

ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001

INJECTABLE;INJECTION
LOXITANE IM

ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001

LOXAPINE SUCCINATE
CAPSULE;ORAL
LOXITANE

ACTAVIS LABS UT INC	EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017525	001
	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017525	002
	EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017525	003
	EQ 50MG BASE *Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017525	004

TABLET;ORAL
LOXITANE

ACTAVIS LABS UT INC	EQ 10MG BASE **Federal Register determination that product was discontinued or withdrawn for s or e reasons**	N017525	006
	EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017525	007
	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017525	008

LUCINACTANT
SUSPENSION;INTRATRACHEAL
SURFAXIN

WINDTREE THERAP	8.5ML	N021746	001	Mar 06, 2012

LUTROPIN ALFA
INJECTABLE;SUBCUTANEOUS
LUVERIS

EMD SERONO	75 IU/VIAL	N021322	001	Oct 08, 2004

LYPRESSIN
SOLUTION;NASAL
DIAPID

NOVARTIS	0.185MG/ML	N016755	001

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
INJECTABLE;INJECTION
PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
INJECTABLE;INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019006	001	Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
INJECTABLE;INJECTION
ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018252	001

SOLUTION;IRRIGATION
PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC	14MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	001

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION;IRRIGATION

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG /100ML;502MG/100ML	N018406 002	Jul 08, 1982

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG /100ML;502MG/100ML	N019326 001	Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET;ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG;20MG;750MG	N022456 001	Dec 04, 2009
	343MG;40MG;750MG	N022456 002	Dec 04, 2009

TABLET, CHEWABLE;ORAL

ZEGERID

SANTARUS	700MG;20MG;600MG	N021850 001	Mar 24, 2006
	700MG;40MG;600MG	N021850 002	Mar 24, 2006

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION;ORAL

SUCLEAR

BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A ,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86G M,5.6GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N203595 001	Jan 18, 2013

MALATHION

LOTION;TOPICAL

MALATHION

MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009

MANGAFODIPIR TRISODIUM

INJECTABLE;INJECTION

TESLASCAN

GE HEALTHCARE	37.9MG/ML	N020652 001	Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION;ORAL

LUMENHANCE

BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997

MANGANESE SULFATE

INJECTABLE;INJECTION

MANGANESE SULFATE

ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML	N019228 001	May 05, 1987

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10%

B BRAUN	10GM/100ML	N016080 002	
HOSPIRA	10GM/100ML	N016269 002	
MILES	10GM/100ML	N016472 002	

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

B BRAUN	10GM/100ML	N016080 006	

MANNITOL 15%

B BRAUN	15GM/100ML	N016080 003	
HOSPIRA	15GM/100ML	N016269 003	
MILES	15GM/100ML	N016472 005	

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

B BRAUN	15GM/100ML	N016080 005	

MANNITOL 20%

B BRAUN	20GM/100ML	N014738 001	
	20GM/100ML	N016080 004	
HOSPIRA	20GM/100ML	N016269 004	
MILES	20GM/100ML	N016472 004	

MANNITOL 25%

ABRAXIS PHARM	12.5GM/50ML	A086754 001	
HOSPIRA	12.5GM/50ML	N016269 005	
IGI LABS INC	12.5GM/50ML	A089239 001	May 06, 1987
	12.5GM/50ML	A089240 001	May 06, 1987
MERCK	12.5GM/50ML	N005620 001	
WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983

MANNITOL
INJECTABLE;INJECTION
MANNITOL 5%

B BRAUN	5GM/100ML	N016080 001	
HOSPIRA	5GM/100ML	N016269 001	

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN	5GM/100ML	N016080 007	

POWDER;INHALATION
ARIDOL KIT

PHARMAXIS LTD	N/A,5MG,10MG,20MG,40MG	N022368 001	Oct 05, 2010

SOLUTION;IRRIGATION
RESECTISOL

B BRAUN	5GM/100ML	N016704 002	

MANNITOL; SORBITOL
SOLUTION;IRRIGATION
SORBITOL-MANNITOL

HOSPIRA	540MG/100ML;2.7GM/100ML	A080224 001	

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML;2.7GM/100ML	N017636 001	

MAPROTILINE HYDROCHLORIDE
TABLET;ORAL
LUDIOMIL

NOVARTIS	25MG	N017543 001	
	50MG	N017543 002	
	75MG	N017543 003	Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP	25MG	A072129 001	Jan 14, 1988
	50MG	A072130 001	Jan 14, 1988
	75MG	A072131 001	Jan 14, 1988
WATSON LABS	25MG	A071943 001	Dec 30, 1987
	25MG	A072162 001	Jun 01, 1988
	50MG	A071944 001	Dec 30, 1987
	50MG	A072163 001	Jun 01, 1988
	75MG	A071945 001	Dec 30, 1987
	75MG	A072164 001	Jun 01, 1988

MASOPROCOL
CREAM;TOPICAL
ACTINEX

UNIV AZ CANCER CTR	10%	N019940 001	Sep 04, 1992

MAZINDOL
TABLET;ORAL
MAZANOR

WYETH AYERST	1MG	N017980 002	
	2MG	N017980 001	

SANOREX

NOVARTIS	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017247 001	
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017247 002	

MEBENDAZOLE
TABLET, CHEWABLE;ORAL
VERMOX

JANSSEN PHARMS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017481 001	

MEBUTAMATE
TABLET;ORAL
DORMATE

MEDPOINTE PHARM HLC	600MG	N017374 001	

FDA data supplied by DrugPatentWatch.com

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL			
INVERSINE			
TARGACEPT	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010251 001	

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE;SUBCUTANEOUS			
IPLEX			
INSMED	36MG/0.6ML	N021884 001	Dec 12, 2005

MECLIZINE HYDROCHLORIDE

TABLET;ORAL			
ANTIVERT			
CASPER PHARMA LLC	12.5MG	N010721 006	
	25MG	N010721 004	
	50MG	N010721 001	Jan 20, 1982
MECLIZINE HYDROCHLORIDE			
ABC HOLDING	12.5MG	A085253 001	
	25MG	A085252 001	
AMNEAL PHARMS	50MG	A201451 003	Feb 23, 2011
ANABOLIC	25MG	A085891 001	
ANI PHARMS INC	12.5MG	A084975 001	
	25MG	A084657 001	
BUNDY	12.5MG	A084382 001	
	25MG	A084872 001	
IVAX SUB TEVA PHARMS	12.5MG	A083784 001	
KV PHARM	12.5MG	A085524 001	
	25MG	A085523 001	
MYLAN PHARMS INC	50MG	A202640 003	Sep 17, 2012
PAR PHARM	50MG	A089674 001	Mar 31, 1988
PLIVA	12.5MG	A088732 001	Dec 11, 1985
	25MG	A088734 001	Dec 11, 1985
RISING PHARMS INC	12.5MG	A040179 001	Jan 30, 1997
	25MG	A040179 002	Jan 30, 1997
SUPERPHARM	12.5MG	A089113 001	Aug 20, 1985
	25MG	A089114 001	Aug 20, 1985
UDL	12.5MG	A088256 001	Jun 13, 1983
	25MG	A088257 001	Jun 13, 1983
VANGARD	12.5MG	A087877 001	Apr 20, 1982
	25MG	A087620 001	Jan 04, 1982
WATSON LABS	12.5MG	A085195 001	
	12.5MG	A085269 001	
	25MG	A085740 001	
TABLET, CHEWABLE;ORAL			
ANTIVERT			
CASPER PHARMA LLC	25MG	N010721 005	
MECLIZINE HYDROCHLORIDE			
IVAX SUB TEVA PHARMS	25MG	A084976 001	
NEXGEN PHARMA INC	25MG	A086392 001	
PLIVA	25MG	A088733 001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM;TOPICAL			
MECLAN			
JOHNSON AND JOHNSON	1%	N050518 001	

MECLOFENAMATE SODIUM

CAPSULE;ORAL			
MECLODIUM			
QUANTUM PHARMICS	EQ 50MG BASE	A071380 001	Jul 14, 1987
	EQ 100MG BASE	A071381 001	Jul 14, 1987
MECLOFENAMATE SODIUM			
AM THERAP	EQ 50MG BASE	A071362 001	Feb 10, 1987
	EQ 100MG BASE	A071363 001	Feb 10, 1987
BARR	EQ 50MG BASE	A072848 001	Mar 20, 1989
	EQ 100MG BASE	A072809 001	Mar 20, 1989
PAR PHARM	EQ 50MG BASE	A072077 001	Mar 10, 1988
	EQ 100MG BASE	A072078 001	Mar 10, 1988
SANDOZ	EQ 50MG BASE	A072262 001	Nov 29, 1988
	EQ 100MG BASE	A072263 001	Nov 29, 1988
USL PHARMA	EQ 50MG BASE	A071007 001	Mar 25, 1988
	EQ 100MG BASE	A071008 001	Mar 25, 1988

FDA data supplied by DrugPatentWatch.com

MECLOFENAMATE SODIUM

CAPSULE;ORAL				
MECLOFENAMATE SODIUM				
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 50MG BASE	A071468	001	Apr 15, 1987
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071469	001	Apr 15, 1987
	EQ 100MG BASE	A071641	001	Aug 11, 1987
MECLOMEN				
PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION				
DEPO-PROVERA				
PHARMACIA AND UPJOHN	100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012541	002	
MEDROXYPROGESTERONE ACETATE				
TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004
TABLET;ORAL				
AMEN				
AMARIN PHARMS	10MG	A083242	001	
CURRETAB				
SOLVAY	10MG	A085686	001	
CYCRIN				
ESI	2.5MG	A081239	001	Oct 30, 1992
	5MG	A081240	001	Oct 30, 1992
	10MG	A089386	001	Sep 09, 1987
MEDROXYPROGESTERONE ACETATE				
DURAMED PHARMS BARR	2.5MG	A040311	001	Dec 01, 1999
	5MG	A040311	002	Dec 01, 1999
	10MG	A040311	003	Dec 01, 1999
USL PHARMA	10MG	A088484	001	Jul 26, 1984

MEDRYSONE

SUSPENSION;OPHTHALMIC				
HMS				
ALLERGAN	1%	N016624	003	

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL				
LARIAM				
ROCHE	250MG	N019591	001	May 02, 1989
MEFLOQUINE HYDROCHLORIDE				
HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010
US ARMY WALTER REED	250MG	N019578	001	May 02, 1989

MEGESTROL ACETATE

SUSPENSION;ORAL				
MEGESTROL ACETATE				
APOTEX INC	40MG/ML	A077404	001	Feb 16, 2006
TABLET;ORAL				
MEGACE				
BRISTOL MYERS SQUIBB	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016979	001	
	40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016979	002	
MEGESTROL ACETATE				
TEVA	40MG	A074745	001	Feb 27, 1998
USL PHARMA	20MG	A070646	001	Oct 02, 1987
	40MG	A070647	001	Oct 02, 1987

FDA data supplied by DrugPatentWatch.com

MELOXICAM
TABLET;ORAL
MELOXICAM

COREPHARMA	7.5MG	A077930 001	Jul 19, 2006
	15MG	A077930 002	Jul 19, 2006
CR DOUBLE CRANE	7.5MG	A078039 001	Dec 14, 2006
	15MG	A078039 002	Dec 14, 2006
FRONTIDA BIOPHARM	7.5MG	A077935 001	Jul 19, 2006
	15MG	A077935 002	Jul 19, 2006
MYLAN	7.5MG	A077934 001	Jul 20, 2006
	15MG	A077934 002	Jul 20, 2006
ROXANE	7.5MG	A077925 001	Jul 19, 2006
	15MG	A077925 002	Jul 19, 2006
YABAO PHARM	7.5MG	A077933 001	Jul 19, 2006
	15MG	A077933 002	Jul 19, 2006

MELPHALAN HYDROCHLORIDE
INJECTABLE;INJECTION
MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299 001	Oct 27, 2009

MEMANTINE HYDROCHLORIDE
TABLET;ORAL
MEMANTINE HYDROCHLORIDE

ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012
	10MG	A090044 002	Mar 12, 2012

MENADIOL SODIUM DIPHOSPHATE
INJECTABLE;INJECTION
KAPPADIONE

LILLY	10MG/ML	N005725 001	

SYNKAYVITE

ROCHE	5MG/ML	N003718 004	
	10MG/ML	N003718 006	
	37.5MG/ML	N003718 008	

TABLET;ORAL
SYNKAYVITE

ROCHE	5MG	N003718 010	

MENADIONE
TABLET;ORAL
MENADIONE

LILLY	5MG	N002139 003	

MENOTROPINS (FSH;LH)
INJECTABLE;INJECTION
HUMEGON

ORGANON USA INC	75 IU/VIAL;75 IU/VIAL	N020328 001	Sep 01, 1994
	150 IU/VIAL;150 IU/VIAL	N020328 002	Sep 01, 1994

MENOTROPINS

FERRING	75 IU/VIAL;75 IU/VIAL	A073598 001	Jan 30, 1997
	150 IU/VIAL;150 IU/VIAL	A073599 001	Jan 30, 1997

PERGONAL

SERONO	75 IU/AMP;75 IU/AMP	N017646 001	
	150 IU/AMP;150 IU/AMP	N017646 002	May 20, 1985

REPRONEX

FERRING	150 IU/VIAL;150 IU/VIAL	N021047 002	Aug 27, 1999

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
REPRONEX

FERRING	75 IU/VIAL;75 IU/VIAL	N021047 001	Aug 27, 1999

MEPENZOLATE BROMIDE
SOLUTION;ORAL
CANTIL

SANOFI AVENTIS US	25MG/5ML	N010679 004	

MEPERIDINE HYDROCHLORIDE
INJECTABLE;INJECTION
DEMEROL

US PHARM HOLDINGS	25MG/ML	N005010 007	
	50MG/ML	N005010 002	
	75MG/ML	N005010 009	
	100MG/ML	N005010 003	

MEPERIDINE HYDROCHLORIDE

ABBOTT	25MG/ML	A080388 001	
	50MG/ML	A080385 001	

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION			
MEPERIDINE HYDROCHLORIDE			
	50MG/ML	A080387 001	
	75MG/ML	A080389 001	
	100MG/ML	A080386 001	
BAXTER HLTHCARE	25MG/ML	A088279 001	Jun 15, 1984
	50MG/ML	A088280 001	Jun 15, 1984
	75MG/ML	A088281 001	Jun 15, 1984
	100MG/ML	A088282 001	Jun 15, 1984
IGI LABS INC	25MG/ML	A089781 001	Mar 31, 1989
	50MG/ML	A089782 001	Mar 31, 1989
	50MG/ML	A089783 001	Mar 31, 1989
	50MG/ML	A089784 001	Mar 31, 1989
	75MG/ML	A089785 001	Mar 31, 1989
	100MG/ML	A089786 001	Mar 31, 1989
	100MG/ML	A089787 001	Mar 31, 1989
	100MG/ML	A089788 001	Mar 31, 1989
INTL MEDICATION	10MG/ML	A086332 001	
PARKE DAVIS	50MG/ML	A080364 002	
	75MG/ML	A080364 003	
	100MG/ML	A080364 001	
WATSON LABS	50MG/ML	A073444 001	Mar 17, 1992
	100MG/ML	A073445 001	Mar 17, 1992
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE			
HOSPIRA	10MG/ML	A040305 001	Mar 10, 1999
INTL MEDICATION	10MG/ML	A081309 001	Aug 30, 1993
MALLINCKRODT	10MG/ML	A040163 001	May 12, 1997
WATSON LABS	10MG/ML	A073443 001	Mar 17, 1992
SYRUP;ORAL			
DEMEROL			
US PHARM HOLDINGS	50MG/5ML	N005010 005	
TABLET;ORAL			
MEPERIDINE HYDROCHLORIDE			
DURAMED PHARMS BARR	50MG	A040318 001	Oct 05, 1999
	100MG	A040318 002	Oct 05, 1999
SUN PHARM INDS	50MG	A080448 001	
	100MG	A080448 002	
WATSON LABS	50MG	A040186 001	Jun 30, 1997
	100MG	A040186 002	Jun 30, 1997
WYETH AYERST	50MG	A080454 001	

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION			
MEPERGAN			
WEST-WARD PHARMS INT	25MG/ML;25MG/ML	N011730 001	

MEPHENTERMINE SULFATE

INJECTABLE;INJECTION			
WYAMINE SULFATE			
BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248 002	
	EQ 30MG BASE/ML	N008248 001	

MEPHENYTOIN

TABLET;ORAL			
MESANTOIN			
NOVARTIS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006008 001	

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION			
ARESTOCAINE HYDROCHLORIDE			
SOLVAY	3%	A084777 002	Apr 18, 1982
CARBOCAINE			
EASTMAN KODAK	3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012125 003	
MEPIVACAINE HYDROCHLORIDE			
GRAHAM CHEM	3%	A083559 001	
INTL MEDICATION SYS	1%	A087509 001	Oct 05, 1982
WATSON LABS	1%	A088769 001	Nov 20, 1984
	2%	A088770 001	Nov 20, 1984

FDA data supplied by DrugPatentWatch.com

MEPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
POLOCAINE

DENTSPLY PHARM	3%	A088653 001	Aug 21, 1984

MEPREDNISONE
TABLET;ORAL
BETAPAR

SCHERING	4MG	N016053 002	

MEPROBAMATE
CAPSULE;ORAL
EQUANIL

WYETH AYERST	400MG	N012455 002	

CAPSULE, EXTENDED RELEASE;ORAL
MEPROSPAN

MEDPOINTE PHARM HLC	200MG	N011284 001	
	400MG	N011284 002	

TABLET;ORAL
AMOSENE

FERNDALE LABS	400MG	A084030 001	

BAMATE

ALRA	200MG	A080380 001	
	400MG	A080380 002	

EQUANIL

WYETH AYERST	200MG	N010028 005	
	400MG	N010028 004	

MEPRIAM

TEVA	400MG	N016069 001	

MEPROBAMATE

AUROLIFE PHARMA LLC	400MG	A080655 001	
BARR	600MG	A084230 001	
ELKINS SINN	200MG	N015426 002	
	400MG	N015426 001	
HEATHER	400MG	N016928 003	
	600MG	A084329 001	
IMPAX LABS	200MG	N014322 002	
	400MG	N014322 001	
IVAX SUB TEVA PHARMS	200MG	N015438 001	
	400MG	N015438 002	
	600MG	A084181 001	
IVC INDS	400MG	A084153 001	
LANNETT	200MG	N014882 002	
	400MG	N014882 001	
LEDERLE	400MG	A086299 001	
LEE KM	400MG	A089538 001	Nov 25, 1987
MALLARD	400MG	N015072 002	
MK LABS	200MG	N014368 004	
	400MG	N014368 002	
MYLAN	400MG	A083618 001	
NEXGEN PHARMA INC	200MG	A084220 001	
	400MG	A084589 001	
PARKE DAVIS	200MG	A084744 001	
	400MG	A084744 002	
PERRIGO	200MG	A084546 001	
	400MG	A084547 001	
PHARMAVITE	400MG	A084438 001	
PUREPAC PHARM	200MG	A084804 001	
	400MG	A084804 002	
PVT FORM	400MG	N014601 001	
ROXANE	600MG	A084332 001	
SANDOZ	200MG	N014547 002	
	400MG	N014547 001	
SCHERER LABS	400MG	A083343 001	
SOLVAY	200MG	A084435 001	
STANLABS PHARM	200MG	N014474 002	
	400MG	N014474 004	
SUN PHARM INDS	200MG	A080699 001	
	400MG	A080699 002	
TABLICAPS	400MG	A083494 001	
TARO	200MG	A200998 001	May 23, 2011
	400MG	A200998 002	May 23, 2011
USL PHARMA	200MG	A087825 001	Mar 18, 1982

MEPROBAMATE
TABLET;ORAL
MEPROBAMATE

	400MG	A087826 001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139 006	
	400MG	N015139 005	
VANGARD	400MG	A088011 001	Jul 14, 1982
WATSON LABS	200MG	A085720 001	
	400MG	A085721 001	
	600MG	A084274 001	
	600MG	A085719 001	
WEST WARD	200MG	N015417 003	
	400MG	N015417 002	
WHITEWORTH TOWN PLSN	200MG	A083830 001	
	400MG	A083442 001	
MILTOWN			
MEDPOINTE PHARM HLC	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009698 004	
	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009698 002	
	600MG	A083919 001	
NEURAMATE			
HALSEY	200MG	N014359 002	
	400MG	N014359 001	
TRANMEP			
SOLVAY	400MG	A084369 001	
	400MG	N016249 001	

MEQUINOL; TRETINOIN
SOLUTION;TOPICAL
SOLAGE

AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999

MERSALYL SODIUM; THEOPHYLLINE
INJECTABLE;INJECTION
MERSALYL-THEOPHYLLINE

WATSON LABS	100MG/ML;50MG/ML	A084875 001	

MESALAMINE
SUPPOSITORY;RECTAL
CANASA

FOREST LABS LLC	500MG	N021252 001	Jan 05, 2001

ROWASA

MEDA PHARMS	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019919 001	Dec 18, 1990

TABLET, DELAYED RELEASE;ORAL
ASACOL

APIL	400MG	N019651 001	Jan 31, 1992

MESORIDAZINE BESYLATE
CONCENTRATE;ORAL
SERENTIL

NOVARTIS	EQ 25MG BASE/ML	N016997 001

INJECTABLE;INJECTION
SERENTIL

NOVARTIS	EQ 25MG BASE/ML	N016775 001

TABLET;ORAL
SERENTIL

NOVARTIS	EQ 10MG BASE	N016774 001
	EQ 25MG BASE	N016774 002
	EQ 50MG BASE	N016774 003
	EQ 100MG BASE	N016774 004

MESTRANOL; NORETHINDRONE
TABLET;ORAL-20
NORINYL

ACTAVIS LABS UT INC	0.1MG;2MG	N013625 004

TABLET;ORAL-21
NORETHIN 1/50M-21

WATSON LABS	0.05MG;1MG	A071539 001	Apr 12, 1988

MESTRANOL; NORETHINDRONE

TABLET;ORAL-21				
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070758 001	Jul 01, 1988
NORINYL 1+50 21-DAY				
	ACTAVIS LABS UT INC	0.05MG;1MG	N013625 002	
NORINYL 1+80 21-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016724 001	
ORTHO-NOVUM 1/50 21				
	ORTHO MCNEIL PHARM	0.05MG;1MG	N012728 004	
ORTHO-NOVUM 1/80 21				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 001	
ORTHO-NOVUM 10-21				
	ORTHO MCNEIL PHARM	0.06MG;10MG	N012728 001	
ORTHO-NOVUM 2-21				
	ORTHO MCNEIL PHARM	0.1MG;2MG	N012728 005	
TABLET;ORAL-28				
NORETHIN 1/50M-28				
	WATSON LABS	0.05MG;1MG	A071540 001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070759 001	Jul 01, 1988
NORINYL 1+80 28-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016725 001	
ORTHO-NOVUM 1/50 28				
	ORTHO MCNEIL JANSSEN	0.05MG;1MG	N016709 001	
ORTHO-NOVUM 1/80 28				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 002	

MESTRANOL; NORETHYNODREL

TABLET;ORAL				
ENOVID				
	GD SEARLE LLC	0.075MG;5MG	N010976 008	
		0.15MG;9.85MG	N010976 005	
TABLET;ORAL-20				
ENOVID				
	GD SEARLE LLC	0.075MG;5MG	N010976 004	
ENOVID-E				
	GD SEARLE LLC	0.1MG;2.5MG	N010976 006	
TABLET;ORAL-21				
ENOVID-E 21				
	GD SEARLE LLC	0.1MG;2.5MG	N010976 007	

METAPROTERENOL SULFATE

AEROSOL, METERED;INHALATION				
ALUPENT				
	BOEHRINGER INGELHEIM	0.65MG/INH	N016402 001	
SOLUTION;INHALATION				
ALUPENT				
	BOEHRINGER INGELHEIM	0.4%	N018761 002	Oct 10, 1986
		0.6%	N018761 001	Jun 30, 1983
		5%	N017659 001	
METAPROTERENOL SULFATE				
	APOTEX INC	0.4%	A075402 001	Feb 28, 2001
		0.6%	A075403 001	Feb 28, 2001
	ASTRAZENECA	0.4%	A071275 001	Jul 27, 1988
		0.6%	A071018 001	Jul 27, 1988
	DEY	0.33%	A071806 001	Aug 05, 1988
		0.5%	A071805 001	Aug 05, 1988
		5%	A070805 001	Aug 17, 1987
	MYLAN SPECLT	0.4%	A071786 001	Aug 05, 1988
		0.6%	A070804 001	Aug 17, 1987
	NEPHRON	0.4%	A071855 001	Jul 14, 1988
		0.6%	A071726 001	Jul 14, 1988
	WOCKHARDT	0.4%	A075586 001	May 30, 2002
		0.6%	A075586 002	May 30, 2002
		5%	A072190 001	Jun 07, 1988
PROMETA				
	MURO	5%	A073340 001	Mar 30, 1992
SYRUP;ORAL				
ALUPENT				
	BOEHRINGER INGELHEIM	10MG/5ML	N017571 001	
METAPROTERENOL SULFATE				
	APOTEX INC	10MG/5ML	A075235 001	Jan 27, 2000

METAPROTERENOL SULFATE

SYRUP;ORAL				
METAPROTERENOL SULFATE				
G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992
	10MG/5ML	A073034	001	Aug 30, 1991
MORTON GROVE	10MG/5ML	A071656	001	Oct 13, 1987
WOCKHARDT	10MG/5ML	A074702	001	Mar 24, 1997
PROMETA				
MURO	10MG/5ML	A072023	001	Sep 15, 1988
TABLET;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG	N015874	002	
	20MG	N015874	001	
METAPROTERENOL SULFATE				
AM THERAP	10MG	A072054	001	Jun 23, 1988
	20MG	A072055	001	Jun 23, 1988
TEVA	10MG	A072519	001	Mar 30, 1990
	20MG	A072520	001	Mar 30, 1990
USL PHARMA	10MG	A071013	001	Jan 25, 1988
	20MG	A071014	001	Jan 25, 1988
WATSON LABS	10MG	A073013	001	Jan 31, 1991
	20MG	A072795	001	Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE;INJECTION				
ARAMINE				
MERCK	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009509	002	Dec 22, 1987
METARAMINOL BITARTRATE				
ABRAXIS PHARM	EQ 10MG BASE/ML	A080431	001	
ELKINS SINN	EQ 10MG BASE/ML	A083363	001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418	001	
	EQ 20MG BASE/ML	A086418	002	

METAXALONE

TABLET;ORAL				
METAXALONE				
COREPHARMA	640MG	N022503	001	Jun 01, 2015
SKELAXIN				
KING PHARMS	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013217	001	

METFORMIN HYDROCHLORIDE

TABLET;ORAL				
GLUCOPHAGE				
BRISTOL MYERS SQUIBB	625MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020357	003	Nov 05, 1998
	750MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020357	004	Nov 05, 1998
METFORMIN HYDROCHLORIDE				
BARR	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
	1GM	A075971	003	Jan 25, 2002
IPCA LABS LTD	500MG	A078422	001	Aug 06, 2007
	850MG	A078422	002	Aug 06, 2007
	1GM	A078422	003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG	A075975	001	Jan 24, 2002
	625MG	A075975	004	Jan 24, 2002
	750MG	A075975	005	Jan 24, 2002
	850MG	A075975	002	Jan 24, 2002
	1GM	A075975	003	Jan 24, 2002
TEVA	500MG	A076328	001	Dec 16, 2002
	850MG	A076328	002	Dec 16, 2002
	1GM	A076328	003	Dec 16, 2002
WATSON LABS	500MG	A075979	001	Jan 24, 2002
	850MG	A075979	002	Jan 24, 2002
	1GM	A075979	003	Jan 24, 2002

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH	500MG	A076450 001	Oct 01, 2004
	750MG	A076878 001	Apr 13, 2005
BARR	500MG	A076496 001	Nov 25, 2005
IMPAX LABS	500MG	A076249 001	Jul 30, 2004
	750MG	A076985 001	Sep 13, 2005
IVAX SUB TEVA PHARMS	500MG	A076545 001	Dec 01, 2003
RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004
	750MG	A077211 001	Jun 29, 2005
SANDOZ	500MG	A076223 001	Dec 14, 2004
SUN PHARM INDS	500MG	A077124 001	Dec 21, 2005
TORRENT PHARMS LTD	750MG	A079226 001	Feb 18, 2010
WATSON LABS INC	500MG	A076818 001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

SB PHARMCO	500MG;EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 001	Oct 10, 2002
	500MG;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 002	Oct 10, 2002
	500MG;EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 003	Oct 10, 2002
	1GM;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 004	Aug 25, 2003
	1GM;EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 005	Aug 25, 2003

METHACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

RONDOMYCIN

MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641 001
	EQ 280MG BASE	A060641 002

SYRUP;ORAL

RONDOMYCIN

MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641 003

METHADONE HYDROCHLORIDE

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

ROXANE	10MG/30ML	N006134 004	

TABLET;ORAL

METHADONE HYDROCHLORIDE

ROXANE	5MG	A088108 001	Mar 08, 1983
	10MG	A088109 001	Mar 08, 1983
	40MG	A074081 001	Apr 28, 1995
SANDOZ	5MG	A040241 001	May 29, 1998

TABLET, DISPERSIBLE;ORAL

WESTADONE

SANDOZ	2.5MG	N017108 001	

TABLET, EFFERVESCENT;ORAL

WESTADONE

SANDOZ	5MG	N017108 002	
	10MG	N017108 003	
	40MG	N017108 004	

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

METHAMPEX

TEVA	10MG	A083889 001	

METHAMPHETAMINE HYDROCHLORIDE

ABLE	5MG	A040529 001	Feb 25, 2004
REXAR	5MG	A084931 001	
	10MG	A084931 002	

FDA data supplied by DrugPatentWatch.com

METHAMPHETAMINE HYDROCHLORIDE
TABLET;ORAL
METHAMPHETAMINE HYDROCHLORIDE

TEVA	5MG	A086359 001	

TABLET, EXTENDED RELEASE;ORAL
DESOXYN

RECORDATI RARE	5MG	N005378 004	
	10MG	N005378 003	
	15MG	N005378 005	

METHANTHELINE BROMIDE
TABLET;ORAL
BANTHINE

SHIRE	50MG	N007390 001	

METHARBITAL
TABLET;ORAL
GEMONIL

ABBVIE	100MG	N008322 001	

METHAZOLAMIDE
TABLET;ORAL
METHAZOLAMIDE

APPLIED ANAL	25MG	A040011 001	Jul 17, 1997
	50MG	A040011 002	Jul 17, 1997
SANDOZ	25MG	A040102 001	Aug 28, 1996
	50MG	A040102 002	Aug 28, 1996

NEPTAZANE

LEDERLE	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011721 002	Nov 25, 1991
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011721 001	

METHDILAZINE
TABLET, CHEWABLE;ORAL
TACARYL

WESTWOOD SQUIBB	3.6MG	N011950 009	

METHDILAZINE HYDROCHLORIDE
SYRUP;ORAL
METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	4MG/5ML	A087122 001	

TACARYL

WESTWOOD SQUIBB	4MG/5ML	N011950 007	

TABLET;ORAL
TACARYL

WESTWOOD SQUIBB	8MG	N011950 006	

METHICILLIN SODIUM
INJECTABLE;INJECTION
STAPHCILLIN

APOTHECON	EQ 900MG BASE/VIAL	A061449 001	
	EQ 900MG BASE/VIAL	N050117 001	
	EQ 3.6GM BASE/VIAL	A061449 002	
	EQ 3.6GM BASE/VIAL	N050117 002	
	EQ 5.4GM BASE/VIAL	A061449 003	
	EQ 5.4GM BASE/VIAL	N050117 003	

METHIMAZOLE
TABLET;ORAL
METHIMAZOLE

CEDAR PHARMS	15MG	A040619 003	Jul 12, 2005
ECI PHARMS LLC	20MG	A040547 004	Feb 18, 2005
MYLAN	20MG	A040350 003	Jun 07, 2001

TAPAZOLE

KING PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007517 002	
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007517 004	

FDA data supplied by DrugPatentWatch.com

METHIXENE HYDROCHLORIDE
TABLET;ORAL
TREST

NOVARTIS	1MG	N013420 001	

METHOCARBAMOL
INJECTABLE;INJECTION
METHOCARBAMOL

MARSAM PHARMS LLC	100MG/ML	A089849 001	Dec 27, 1991
WATSON LABS	100MG/ML	A086459 001	

TABLET;ORAL
DELAXIN

FERNDALE LABS	500MG	A085454 001	

FORBAXIN

FOREST LABS	750MG	A085136 001	

METHOCARBAMOL

ABLE	500MG	A040413 001	Mar 17, 2003
	750MG	A040413 002	Mar 17, 2003
AM THERAP	500MG	A089417 001	Feb 11, 1987
	750MG	A089418 001	Feb 11, 1987
ASCOT	500MG	A087660 001	Oct 27, 1982
	750MG	A087661 001	Oct 27, 1982
CLONMEL HLTHCARE	500MG	A085961 001	
	750MG	A085963 001	
HEATHER	500MG	A084675 001	
	750MG	A084924 001	
IMPAX LABS	500MG	A084927 001	
	750MG	A084928 001	
INWOOD LABS	500MG	A085137 001	
IVAX SUB TEVA PHARMS	500MG	A084648 001	
	750MG	A084649 001	
KV PHARM	500MG	A085660 001	
	750MG	A085658 001	
LANNETT HOLDINGS INC	500MG	A084756 002	Mar 31, 2003
	750MG	A084756 001	
MYLAN	500MG	A084259 001	
	750MG	A084323 001	
NYLOS	750MG	A085033 001	
PIONEER PHARMS	500MG	A088731 001	Dec 13, 1985
	750MG	A089082 001	Dec 13, 1985
PURACAP PHARM	500MG	A084231 002	
	750MG	A084471 001	
PUREPAC PHARM	500MG	A085718 001	
	750MG	A085718 002	
ROXANE	500MG	A088646 001	Feb 29, 1984
	750MG	A088647 001	Feb 29, 1984
SANDOZ	500MG	A084616 001	
	500MG	A087283 001	
	750MG	A084615 001	
	750MG	A087282 001	
SOLVAY	500MG	A084448 001	
	750MG	A084449 001	
SUN PHARM INDS	500MG	A084488 001	
	750MG	A084486 001	
SUPERPHARM	500MG	A087589 001	Jan 22, 1982
	750MG	A087590 001	Jan 22, 1982
TABLICAPS	500MG	A084846 001	
UPSHER SMITH	500MG	A087453 001	
	750MG	A087454 001	
WATSON LABS	500MG	A083605 001	
	500MG	A085180 001	
	750MG	A083605 002	
	750MG	A085192 001	

METHOHEXITAL SODIUM
INJECTABLE;INJECTION
BREVITAL SODIUM

PAR STERILE PRODUCTS	200MG/VIAL	N011559 004	Dec 21, 2012
	5GM/VIAL	N011559 003	

METHOTREXATE
SOLUTION;SUBCUTANEOUS
OTREXUP

ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824 005	Nov 07, 2014

METHOTREXATE SODIUM
INJECTABLE;INJECTION
ABITREXATE

ABIC	EQ 25MG BASE/ML	A089161 001	Mar 10, 1987
	EQ 50MG BASE/VIAL	A089354 001	Jul 17, 1987
	EQ 100MG BASE/VIAL	A089355 001	Jul 17, 1987
	EQ 250MG BASE/VIAL	A089356 001	Jul 17, 1987

FOLEX

PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695 001	Apr 08, 1983
	EQ 50MG BASE/VIAL	A087695 002	Apr 08, 1983
	EQ 100MG BASE/VIAL	A087695 003	Apr 08, 1983
	EQ 250MG BASE/VIAL	A088954 001	Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242 001	Aug 23, 1991
	EQ 25MG BASE/ML	A089180 001	Jan 03, 1986

METHOTREXATE LPF

HOSPIRA	EQ 25MG BASE/ML	N011719 007	Mar 31, 1982

METHOTREXATE PRESERVATIVE FREE

HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719 014	Apr 13, 2005
	EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011719 013	Apr 13, 2005
	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719 011	Apr 13, 2005

METHOTREXATE SODIUM

ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323 001	Jun 13, 1986
	EQ 20MG BASE/VIAL	A088935 001	Oct 11, 1985
	EQ 25MG BASE/ML	A089263 001	Jun 13, 1986
	EQ 25MG BASE/ML	A089322 001	Jun 13, 1986
	EQ 50MG BASE/VIAL	A088936 001	Oct 11, 1985
	EQ 100MG BASE/VIAL	A088937 001	Oct 11, 1985
HOSPIRA	EQ 2.5MG BASE/ML	N011719 004	
	EQ 20MG BASE/VIAL	N011719 001	
	EQ 25MG BASE/ML	N011719 005	
	EQ 50MG BASE/VIAL	N011719 003	
	EQ 100MG BASE/VIAL	N011719 006	
NORBROOK	EQ 25MG BASE/ML	A088648 001	May 09, 1986
PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158 001	Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA	EQ 1GM BASE/VIAL	N011719 009	Apr 07, 1988

MEXATE

BRISTOL	EQ 20MG BASE/VIAL	A086358 001	
	EQ 50MG BASE/VIAL	A086358 002	
	EQ 100MG BASE/VIAL	A086358 003	
	EQ 250MG BASE/VIAL	A086358 004	

MEXATE-AQ

BRISTOL MYERS	EQ 25MG BASE/ML	A088760 001	Feb 14, 1985

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887 001	Apr 14, 1989

TABLET;ORAL
METHOTREXATE SODIUM

DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233 001	Jun 17, 1999

METHOXAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
VASOXYL

GLAXOSMITHKLINE	10MG/ML	N006772 002	
	20MG/ML	N006772 001	

METHOXSALEN
CAPSULE;ORAL
METHOXSALEN

IDT AUSTRALIA LTD	10MG	A087781 001	Jun 08, 1982

METHSCOPOLAMINE BROMIDE
TABLET;ORAL
METHSCOPOLAMINE BROMIDE

PVT FORM	2.5MG	A080970 001	

PAMINE

FOUGERA PHARMS	2.5MG	N008848 001	

PAMINE FORTE

FOUGERA PHARMS	5MG	N008848 002	Mar 25, 2003

METHYCLOTHIAZIDE
TABLET;ORAL
AQUATENSEN

MEDPOINTE PHARM HLC	5MG	N017364 001	

ENDURON

ABBVIE	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012524 001	
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012524 004	

METHYCLOTHIAZIDE

IVAX PHARMS	2.5MG	A087913 001	Jun 03, 1982
	5MG	A087786 001	May 18, 1982
MYLAN	2.5MG	A087671 001	Aug 17, 1982
PAR PHARM	2.5MG	A089135 001	Feb 12, 1986
	5MG	A089136 001	Feb 12, 1986
SANDOZ	2.5MG	A089835 001	Aug 18, 1988
	5MG	A089837 001	Aug 18, 1988
USL PHARMA	5MG	A088745 001	Mar 21, 1985
WATSON LABS	2.5MG	A085487 001	Mar 11, 1982
	2.5MG	A088750 001	Sep 06, 1984
	5MG	A085476 001	Mar 11, 1982
	5MG	A088724 001	Sep 06, 1984

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE
TABLET;ORAL
EUTRON

ABBOTT	5MG;25MG	N016047 001	

METHYCLOTHIAZIDE; RESERPINE
TABLET;ORAL
DIUTENSEN-R

MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708 005	

METHYL AMINOLEVULINATE HYDROCHLORIDE
CREAM;TOPICAL
METVIXIA

GALDERMA LABS LP	EQ 16.8% BASE	N021415 001	Jul 27, 2004

METHYLDOPA
SUSPENSION;ORAL
ALDOMET

MERCK	250MG/5ML	N018389 001	

TABLET;ORAL
ALDOMET

MERCK	125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013400 003	
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013400 001	
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013400 002	

METHYLDOPA

ACCORD HLTHCARE	125MG	A070070 003	Oct 15, 1985
DURAMED PHARMS BARR	250MG	A071006 001	Dec 16, 1986
	500MG	A071009 001	Dec 16, 1986
HALSEY	125MG	A071751 001	Mar 28, 1988
	250MG	A071752 001	Mar 28, 1988
	500MG	A071753 001	Mar 28, 1988
PAR PHARM	125MG	A070535 001	Jan 02, 1987

FDA data supplied by DrugPatentWatch.com

METHYLDOPA
TABLET;ORAL
METHYLDOPA

	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SANDOZ	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE
INJECTABLE;INJECTION
ALDOMET

MERCK	50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013401	001	

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLERGONOVINE MALEATE
TABLET;ORAL
METHERGINE

EDISON THERAPS LLC	0.2MG	N006035	003	

METHYLPHENIDATE HYDROCHLORIDE
TABLET;ORAL
METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002

TABLET, CHEWABLE;ORAL
METHYLIN

MALLINCKRODT	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021475	001	Apr 15, 2003
	5MG **Federal Register determination	N021475	002	Apr 15, 2003

FDA data supplied by DrugPatentWatch.com

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL				
METHYLIN				
		that product was not discontinued or withdrawn for safety or efficacy reasons**		
		10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021475 003	Apr 15, 2003
TABLET, EXTENDED RELEASE;ORAL				
METADATE ER				
	UCB INC	10MG	A040306 001	Oct 20, 1999
METHYLPHENIDATE HYDROCHLORIDE				
	ABLE	20MG	A076032 001	May 09, 2001
	ACTAVIS ELIZABETH	20MG	A075450 001	Dec 21, 2001
	WATSON LABS	20MG	A040410 001	Feb 09, 2001

METHYLPREDNISOLONE

TABLET;ORAL				
MEDROL				
	PHARMACIA AND UPJOHN	24MG	N011153 005	
METHYLPREDNISOLONE				
	HEATHER	4MG	A085650 001	
	PAR PHARM	16MG	A089207 001	Apr 25, 1988
		24MG	A089208 001	Apr 25, 1988
		32MG	A089209 001	Apr 25, 1988
	SANDOZ	4MG	A087341 001	
	WATSON LABS	4MG	A086161 001	Feb 09, 1982
		16MG	A086159 001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA;RECTAL				
MEDROL				
	PHARMACIA AND UPJOHN	40MG/BOT	N018102 001	
INJECTABLE;INJECTION				
M-PREDROL				
	BEL MAR	40MG/ML	A086666 001	
		80MG/ML	A087135 001	
METHYLPREDNISOLONE ACETATE				
	AKORN	40MG/ML	A086903 001	Oct 20, 1982
		80MG/ML	A086903 002	Oct 20, 1982
	WATSON LABS	20MG/ML	A085597 001	
		20MG/ML	A087248 001	
		40MG/ML	A085374 001	
		40MG/ML	A085600 001	
		80MG/ML	A085595 001	
		80MG/ML	A086507 001	
OINTMENT;TOPICAL				
MEDROL ACETATE				
	PHARMACIA AND UPJOHN	0.25%	N012421 001	
		1%	N012421 002	

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-MEDROL ACETATE				
	PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611 002	
		1%;EQ 3.5MG BASE/GM	A060611 001	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION				
A-METHAPRED				
	ABBOTT	EQ 40MG BASE/VIAL	A089573 001	Feb 22, 1991
		EQ 125MG BASE/VIAL	A089574 001	Feb 22, 1991
		EQ 500MG BASE/VIAL	A089575 001	Feb 22, 1991
		EQ 1GM BASE/VIAL	A089576 001	Feb 22, 1991
	HOSPIRA	EQ 40MG BASE/VIAL	A085853 001	
		EQ 125MG BASE/VIAL	A085855 001	
		EQ 500MG BASE/VIAL	A085854 001	
		EQ 500MG BASE/VIAL	A089173 001	Aug 18, 1987
		EQ 1GM BASE/VIAL	A085852 001	
		EQ 1GM BASE/VIAL	A089174 001	Aug 18, 1987
METHYLPREDNISOLONE				
	ELKINS SINN	EQ 125MG BASE/VIAL	A086906 002	
		EQ 500MG BASE/VIAL	A086906 003	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE

	EQ 1GM BASE/VIAL	A086906 004	
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535 001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535 002	Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676 001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143 001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677 001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144 001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678 001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186 001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187 001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679 001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188 001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A089189 001	Mar 28, 1986
BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007
	EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007
ELKINS SINN	EQ 40MG BASE/VIAL	A086906 001	
INTL MEDICATION	EQ 40MG BASE/VIAL	A087812 001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813 001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851 001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852 001	Feb 09, 1983
TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992
	EQ 500MG BASE/VIAL	A081267 001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268 001	Nov 30, 1992
WATSON LABS	EQ 40MG BASE/VIAL	A086953 001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030 001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523 001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524 001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645 001	

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

HEATHER	10MG	A084967 001	

VIRILON

STAR PHARMS FL	10MG	A087750 001	Nov 24, 1982

TABLET;BUCCAL

ANDROID 5

VALEANT PHARM INTL	5MG	A087222 001	

ORETON

SCHERING	10MG	A080281 001	

TABLET;BUCCAL, SUBLINGUAL

METANDREN

NOVARTIS	5MG	N003240 004	
	10MG	N003240 001	
	10MG	N003240 005	
	25MG	N003240 003	

METHYLTESTOSTERONE

IMPAX LABS	10MG	A084287 001	
LILLY	10MG	A080256 001	
	25MG	A080256 002	
PUREPAC PHARM	10MG	A080308 001	
	10MG	A080475 001	
	10MG	A080475 002	
	25MG	A080475 003	
PVT FORM	5MG	A083836 001	
TABLICAPS	10MG	A085125 001	
USL PHARMA	10MG	A080271 001	

TABLET;ORAL

ANDROID 10

VALEANT PHARM INTL	10MG	A086450 001	

METHYLTESTOSTERONE
TABLET;ORAL
METHYLTESTOSTERONE

IMPAX LABS	25MG	A084310 001	
INWOOD LABS	10MG	A080839 001	
	25MG	A080973 001	
KV PHARM	10MG	A084312 001	
LANNETT	10MG	A087092 001	Nov 05, 1982
	25MG	A087111 001	Jan 27, 1983
PARKE DAVIS	10MG	A084244 001	
	25MG	A084241 001	
PUREPAC PHARM	10MG	A080309 001	
	25MG	A080310 001	
PVT FORM	5MG	A080214 001	
	10MG	A080214 002	
	25MG	A080214 003	
TABLICAPS	10MG	A080313 001	
	25MG	A085270 001	
WATSON LABS	10MG	A080933 001	
	25MG	A080931 001	
WEST WARD	10MG	A084331 001	
	25MG	A084331 002	
	25MG	A084642 001	

ORETON METHYL

SCHERING	10MG	N003158 001	
	25MG	N003158 002	

METHYPRYLON
CAPSULE;ORAL
NOLUDAR

ROCHE	300MG	N009660 008	

ELIXIR;ORAL
NOLUDAR

ROCHE	50MG/5ML	N009660 007	

TABLET;ORAL
NOLUDAR

ROCHE	50MG	N009660 002	
	200MG	N009660 004	

METHYSERGIDE MALEATE
TABLET;ORAL
SANSERT

NOVARTIS	2MG	N012516 001	

METOCLOPRAMIDE HYDROCHLORIDE
CONCENTRATE;ORAL
METOCLOPRAMIDE INTENSOL

ROXANE	EQ 10MG BASE/ML	A072995 001	Jan 30, 1992

INJECTABLE;INJECTION
METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD	EQ 5MG BASE/ML	A072155 001	Mar 30, 1992
	EQ 5MG BASE/ML	A072244 001	Mar 30, 1992
	EQ 5MG BASE/ML	A072247 001	May 18, 1992
HOSPIRA	EQ 5MG BASE/ML	A070505 001	Jun 23, 1989
	EQ 5MG BASE/ML	A070506 001	Jun 22, 1989
	EQ 5MG BASE/ML	A070847 001	Nov 07, 1988
	EQ 5MG BASE/ML	A071291 001	Mar 03, 1989
	EQ 5MG BASE/ML	A071990 001	Jan 18, 1989
	EQ 5MG BASE/ML	A073117 001	Jan 17, 1991
	EQ 5MG BASE/ML	A074147 001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML	A070293 001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML	A070892 001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623 001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622 001	Mar 02, 1987

REGLAN

WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862 001	
	EQ 10MG BASE/ML	N017862 004	May 28, 1987

SOLUTION;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340 001	Aug 18, 1988
MORTON GROVE	EQ 5MG BASE/5ML	A070949 001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665 001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038 001	Dec 05, 1988
SILARX	EQ 5MG BASE/5ML	A073680 001	Oct 27, 1992

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL			
METOCLOPRAMIDE HYDROCHLORIDE			
TEVA	EQ 5MG BASE/5ML	A070819 001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315 001	Jun 30, 1993
REGLAN			
ROBINS AH	EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018821 001	Mar 25, 1983
TABLET;ORAL			
CLOPRA			
QUANTUM PHARMICS	EQ 5MG BASE	A072384 001	Jun 02, 1988
	EQ 10MG BASE	A070294 001	Jul 29, 1985
CLOPRA-"YELLOW"			
QUANTUM PHARMICS	EQ 10MG BASE	A070632 001	Oct 28, 1985
MAXOLON			
KING PHARMS	EQ 10MG BASE	A070106 001	Mar 04, 1986
METOCLOPRAMIDE HYDROCHLORIDE			
CLONMEL	EQ 10MG BASE	A072639 001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906 001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213 001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660 001	Feb 10, 1987
PAR PHARM	EQ 10MG BASE	A070342 001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436 001	Jun 22, 1989
	EQ 5MG BASE	A074478 001	Oct 05, 1995
	EQ 10MG BASE	A070850 001	Feb 03, 1987
	EQ 10MG BASE	A072215 001	Jan 30, 1990
	EQ 10MG BASE	A074478 002	Oct 05, 1995
SCHERING	EQ 10MG BASE	A070598 001	Feb 02, 1987
SUN PHARM INDS	EQ 10MG BASE	A071536 001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926 001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339 001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363 001	Mar 02, 1987
	EQ 10MG BASE	A070453 001	Jun 06, 1986
	EQ 10MG BASE	A070511 001	Jan 22, 1986
	EQ 10MG BASE	A070645 001	May 11, 1987
TABLET, ORALLY DISINTEGRATING;ORAL			
METOZOLV ODT			
SALIX PHARMS	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022246 002	Sep 04, 2009
REGLAN ODT			
MEDA PHARMS	EQ 5MG BASE	N021793 001	Jun 10, 2005
	EQ 10MG BASE	N021793 002	Jun 10, 2005

METOCURINE IODIDE

INJECTABLE;INJECTION			
METUBINE IODIDE			
LILLY	2MG/ML	N006632 003	

METOLAZONE

TABLET;ORAL			
DIULO			
GD SEARLE LLC	2.5MG	N018535 001	
	5MG	N018535 002	
	10MG	N018535 003	
METOLAZONE			
ROXANE	10MG	A076482 002	Apr 29, 2004
TEVA	2.5MG	A076600 001	Jan 06, 2004
	5MG	A076833 001	Mar 01, 2004
	10MG	A075543 003	Dec 24, 2003
WATSON LABS	10MG	A076891 001	Jul 21, 2004
MYKROX			
UCB INC	0.5MG	N019532 001	Oct 30, 1987

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE;ORAL			
LOPRESSOR			
NOVARTIS	EQ 100MG TARTRATE	N019786 001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786 002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786 003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786 004	Dec 27, 1989

FDA data supplied by DrugPatentWatch.com

METOPROLOL SUCCINATE
TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176	001	May 14, 2008
	EQ 100MG TARTRATE	A076640	002	May 18, 2007
	EQ 200MG TARTRATE	A076640	001	May 18, 2007
SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969	002	May 18, 2007
	EQ 100MG TARTRATE	A076969	003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969	004	Mar 20, 2008

METOPROLOL TARTRATE
INJECTABLE;INJECTION
METOPROLOL TARTRATE

WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993

TABLET;ORAL
METOPROLOL TARTRATE

APOTHECON	50MG	A074258	001	Jan 27, 1994
	100MG	A074258	002	Jan 27, 1994
MYLAN	50MG	A073666	001	Dec 21, 1993
	100MG	A073666	002	Dec 21, 1993
PRINSTON INC	50MG	A074453	001	Apr 27, 1995
	100MG	A074453	002	Apr 27, 1995
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994
SANDOZ	50MG	A073288	001	Mar 25, 1994
	100MG	A073289	001	Mar 25, 1994
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994

METRIZAMIDE
INJECTABLE;INJECTION
AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983

METRONIDAZOLE
CAPSULE;ORAL
METRONIDAZOLE

ABLE	375MG	A076505	001	Nov 13, 2003

INJECTABLE;INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

PFIZER	500MG/100ML	N018353	002	

METRO I.V.

B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986

TABLET;ORAL
METROMIDOL

LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996

METRONIDAZOLE

ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
PAR PHARM	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983
SANDOZ	250MG	N018620	001	Mar 04, 1982

METRONIDAZOLE
TABLET;ORAL
METRONIDAZOLE

	250MG	N018740	001	Oct 22, 1982
	500MG	N018620	002	Jun 02, 1983
	500MG	N018740	002	Oct 22, 1982
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	250MG	N018764	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984
	500MG	N018764	002	Dec 20, 1982

PROTOSTAT

ORTHO MCNEIL PHARM	250MG	N018871	001	Mar 02, 1983
	500MG	N018871	002	Mar 02, 1983

SATRIC

SAVAGE LABS	250MG	A070029	001	Mar 19, 1985
	500MG	A070731	001	Jun 08, 1987

TABLET, EXTENDED RELEASE;ORAL
METRONIDAZOLE

ABLE	750MG	A076462	001	Jun 25, 2003

METRONIDAZOLE HYDROCHLORIDE
INJECTABLE;INJECTION
FLAGYL I.V.

PFIZER	EQ 500MG BASE/VIAL	N018353	001	

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295	001	Oct 15, 1985

METYRAPONE
TABLET;ORAL
METOPIRONE

HRA PHARMA	250MG	N012911	001	

MEXILETINE HYDROCHLORIDE
CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

IDT AUSTRALIA LTD	150MG	A074450	001	May 16, 1996
	200MG	A074450	002	May 16, 1996
	250MG	A074450	003	May 16, 1996
WATSON LABS	150MG	A074711	001	Feb 26, 1997
	150MG	A074865	001	Apr 13, 1998
	200MG	A074711	002	Feb 26, 1997
	200MG	A074865	002	Apr 13, 1998
	250MG	A074711	003	Feb 26, 1997
	250MG	A074865	003	Apr 13, 1998

MEXITIL

BOEHRINGER INGELHEIM	150MG	N018873	002	Dec 30, 1985
	200MG	N018873	003	Dec 30, 1985
	250MG	N018873	004	Dec 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE
INJECTABLE;INJECTION
MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988

FDA data supplied by DrugPatentWatch.com

MICONAZOLE
INJECTABLE;INJECTION
MONISTAT

JANSSEN PHARMA	10MG/ML	N018040 001	

MICONAZOLE NITRATE
CREAM;TOPICAL
MONISTAT-DERM

INSIGHT PHARMS	2%	N017494 001	

CREAM;VAGINAL
MICONAZOLE NITRATE

TEVA	2%	A074136 001	Jan 04, 1995
TEVA PHARMS	2%	A074030 001	Oct 30, 1992

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC	2%,100MG	A074586 001	Jul 17, 1997

LOTION;TOPICAL
MONISTAT-DERM

INSIGHT PHARMS	2%	N017739 001	

TAMPON;VAGINAL
MONISTAT 5

PERSONAL PRODS	100MG	N018592 001	Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE
INJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

APOTHECON	EQ 1MG BASE/ML	A075620 001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620 002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641 001	Oct 19, 2000
BEDFORD	EQ 5MG BASE/ML	A075249 001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455 001	Jun 20, 2000
CLARIS	EQ 1MG BASE/ML	A075637 001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637 002	Oct 31, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396 001	Jun 20, 2000
	EQ 5MG BASE/ML	A075396 002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484 001	Jun 20, 2000
HOSPIRA INC	EQ 1MG BASE/ML	A075409 002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409 001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263 001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144 001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144 002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020 001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020 002	Jul 16, 2004
WOCKHARDT	EQ 1MG BASE/ML	A078141 001	May 30, 2008
	EQ 1MG BASE/ML	A078511 001	Nov 10, 2008
	EQ 5MG BASE/ML	A078141 002	May 30, 2008
	EQ 5MG BASE/ML	A078511 002	Nov 10, 2008

VERSED

HLR	EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018654 002	May 26, 1987
	EQ 5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018654 001	Dec 20, 1985

SYRUP;ORAL
MIDAZOLAM HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077115 001	Sep 09, 2005

VERSED

ROCHE	EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020942 001	Oct 15, 1998

MIDODRINE HYDROCHLORIDE
TABLET;ORAL
PROAMATINE

SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996
	5MG	N019815 002	Sep 06, 1996
	10MG	N019815 003	Mar 20, 2002

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

LIBERTY PHARMA INC	12.5MG	A205071 001	Jan 27, 2016
	25MG	A205071 002	Jan 27, 2016
	50MG	A205071 003	Jan 27, 2016
	100MG	A205071 004	Jan 27, 2016

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

APOTEX INC	EQ 1MG BASE/ML	A076427 001	Sep 21, 2004
EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075852 001	May 28, 2002
HOSPIRA	EQ 1MG BASE/ML	A075830 001	May 28, 2002
	EQ 1MG BASE/ML	A075884 001	May 28, 2002
MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428 001	Jun 16, 2003

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414 001	Aug 18, 2004
BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259 001	Aug 08, 2002
CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151 001	Jul 20, 2005
EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510 001	May 28, 2002

PRIMACOR

SANOFI AVENTIS US	EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019436 001	Dec 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

SANOFI AVENTIS US	EQ 10MG BASE/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020343 001	Aug 09, 1994
	EQ 15MG BASE/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020343 002	Aug 09, 1994
	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020343 003	Aug 09, 1994
	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020343 004	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

DYNACIN

CNTY LINE PHARMS	EQ 50MG BASE	A063067 003	Aug 14, 1990

MINOCIN

PRECISION DERMAT	EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050649 003	Feb 12, 2001
TRIAX PHARMS	EQ 50MG BASE	N050315 002	
	EQ 100MG BASE	N050315 001	

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

SUN PHARM INDS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012
	EQ 67.5MG BASE	N201922 002	Jul 11, 2012
	EQ 90MG BASE	N201922 003	Jul 11, 2012
	EQ 112.5MG BASE	N201922 004	Jul 11, 2012
	EQ 135MG BASE	N201922 005	Jul 11, 2012

INJECTABLE;INJECTION

MINOCIN

LEDERLE	EQ 100MG BASE/VIAL	A062139 001	

SUSPENSION;ORAL

MINOCIN

PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001	

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

TRIAX PHARMS	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050451 003	Aug 10, 1982

FDA data supplied by DrugPatentWatch.com

MINOCYCLINE HYDROCHLORIDE

TABLET;ORAL				
MINOCYCLINE HYDROCHLORIDE				
		EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050451	002 Aug 10, 1982
TABLET, EXTENDED RELEASE;ORAL				
MINOCYCLINE HYDROCHLORIDE				
	BARR LABS INC	EQ 45MG BASE	A065485	001 Mar 17, 2009
		EQ 65MG BASE	A065485	004 May 18, 2012
		EQ 90MG BASE	A065485	002 Mar 17, 2009
		EQ 115MG BASE	A065485	005 May 18, 2012
		EQ 135MG BASE	A065485	003 Mar 17, 2009
	IMPAX LABS INC	EQ 45MG BASE	A090024	001 Feb 03, 2009
		EQ 90MG BASE	A090024	002 Feb 03, 2009
		EQ 135MG BASE	A090024	003 Feb 03, 2009
	LUPIN LTD	EQ 55MG BASE	A091424	002 Nov 30, 2011
SOLODYN				
	MEDICIS	EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050808	001 May 08, 2006
		EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050808	002 May 08, 2006
		EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050808	003 May 08, 2006

MINOXIDIL

SOLUTION;TOPICAL				
MINOXIDIL (FOR MEN)				
	APOTEX INC	2%	A074924	001 Apr 29, 1998
	BAUSCH AND LOMB	2%	A074643	001 Apr 09, 1996
	COPLEY PHARM	2%	A074500	001 May 23, 1996
	SIGHT PHARMS	2%	A074743	002 Oct 18, 1996
	TEVA	2%	A074589	001 Apr 05, 1996
MINOXIDIL (FOR WOMEN)				
	APOTEX INC	2%	A074924	002 Apr 29, 1998
	SIGHT PHARMS	2%	A074743	001 Oct 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)				
	APOTEX INC	5%	A075839	001 Oct 01, 2001
TABLET;ORAL				
LONITEN				
	PHARMACIA AND UPJOHN	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018154	001
		10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018154	003
MINODYL				
	QUANTUM PHARMICS	2.5MG	A072153	001 Jul 13, 1988
		10MG	A071534	001 Mar 19, 1987
MINOXIDIL				
	ROYCE LABS	2.5MG	A071799	001 Nov 10, 1987
		10MG	A071796	001 Nov 10, 1987
	USL PHARMA	2.5MG	A071537	001 Dec 16, 1988

MIRTAZAPINE

TABLET;ORAL				
MIRTAZAPINE				
	ACTAVIS ELIZABETH	15MG	A076241	001 Jun 25, 2003
		15MG	A076308	001 Jun 20, 2003
		30MG	A076241	002 Jun 25, 2003
		30MG	A076308	002 Jun 20, 2003
		45MG	A076241	003 Jun 25, 2003
		45MG	A076308	003 Jun 20, 2003
	ACTAVIS LABS FL INC	15MG	A076336	001 Jun 20, 2003
		30MG	A076336	002 Jun 20, 2003
		45MG	A076336	003 Jun 20, 2003
	IVAX SUB TEVA PHARMS	15MG	A076244	001 Dec 22, 2003

MIRTAZAPINE
TABLET;ORAL
MIRTAZAPINE

	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
	15MG	A077959	001	Feb 14, 2011
	30MG	A076689	002	Aug 31, 2005
	30MG	A077959	002	Feb 14, 2011
	45MG	A076689	003	Aug 31, 2005
	45MG	A077959	003	Feb 14, 2011

MITOMYCIN
INJECTABLE;INJECTION
MITOMYCIN

HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995

MITOZYTREX

SUPERGEN	5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050763	001	Nov 14, 2002

MUTAMYCIN

BRISTOL	5MG/VIAL	N050450	001	
	20MG/VIAL	N050450	002	
BRISTOL MYERS	5MG/VIAL	A062336	001	
	20MG/VIAL	A062336	002	
	40MG/VIAL	A062336	003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE
INJECTABLE;INJECTION
MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008

NOVANTRONE

EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019297	002	Dec 23, 1987
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019297	003	Dec 23, 1987

MIVACURIUM CHLORIDE
INJECTABLE;INJECTION
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE	EQ 0.5MG BASE/ML	N020098	002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098	003	Jan 22, 1992

MIVACURIUM CHLORIDE

MYLAN LABS LTD	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009

SOLUTION;INTRAVENOUS
MIVACRON

ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020098	001	Jan 22, 1992

FDA data supplied by DrugPatentWatch.com

MOEXIPRIL HYDROCHLORIDE
TABLET;ORAL
UNIVASC

UCB INC	7.5MG	N020312 001	Apr 19, 1995
	15MG	N020312 002	Apr 19, 1995

MOLINDONE HYDROCHLORIDE
CAPSULE;ORAL
MOBAN

ENDO PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 001	
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 002	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 003	

CONCENTRATE;ORAL
MOBAN

ENDO PHARMS	20MG/ML	N017938 001	

TABLET;ORAL
MOBAN

ENDO PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 004	
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 005	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 006	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 007	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017111 008	

MOMETASONE FUROATE
CREAM;TOPICAL
ELOCON

MERCK SHARP DOHME	0.1%	N019625 001	May 06, 1987

OINTMENT;TOPICAL
MOMETASONE FUROATE

TARO	0.1%	A076624 001	Dec 03, 2004

MONOBENZONE
CREAM;TOPICAL
BENOQUIN

VALEANT PHARM INTL	20%	N008173 003	

MONOCTANOIN
LIQUID;PERFUSION, BILIARY
MOCTANIN

ETHITEK	100%	N019368 001	Oct 29, 1985

MORICIZINE HYDROCHLORIDE
TABLET;ORAL
ETHMOZINE

SHIRE	200MG	N019753 001	Jun 19, 1990
	250MG	N019753 002	Jun 19, 1990
	300MG	N019753 003	Jun 19, 1990

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE;ORAL
AVINZA

KING PHARMS LLC	30MG	N021260 001	Mar 20, 2002
	45MG	N021260 005	Dec 18, 2008
	60MG	N021260 002	Mar 20, 2002
	75MG	N021260 006	Dec 18, 2008

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE;ORAL
AVINZA

	90MG	N021260 003	Mar 20, 2002
	120MG	N021260 004	Mar 20, 2002

INJECTABLE;INJECTION
MORPHINE SULFATE

HOSPIRA	0.5MG/ML	N019917 001	Oct 30, 1992
MALLINCKRODT	1MG/ML	N020631 001	Jul 03, 1996
	2MG/ML	N020631 002	Jul 03, 1996
WATSON LABS	0.5MG/ML	A073373 001	Sep 30, 1991
	0.5MG/ML	A073375 001	Sep 30, 1991
	1MG/ML	A073374 001	Sep 30, 1991
	1MG/ML	A073376 001	Sep 30, 1991

INJECTABLE, LIPOSOMAL;EPIDURAL
DEPODUR

PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004
	15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004
	20MG/2ML (10MG/ML)	N021671 003	May 18, 2004

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

WATSON LABS	100MG	A075656 001	Jan 30, 2001

ORAMORPH SR

XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994
	30MG	N019977 001	Aug 15, 1991
	60MG	N019977 002	Aug 15, 1991
	100MG	N019977 003	Aug 15, 1991

MOXALACTAM DISODIUM
INJECTABLE;INJECTION
MOXAM

LILLY	EQ 250MG BASE/VIAL	N050550 001	
	EQ 500MG BASE/VIAL	N050550 002	
	EQ 1GM BASE/VIAL	N050550 003	
	EQ 2GM BASE/VIAL	N050550 004	
	EQ 10GM BASE/VIAL	N050550 008	

MYCOPHENOLATE MOFETIL
CAPSULE;ORAL
MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD	250MG	A091315 001	Oct 27, 2011
ZYDUS PHARMS USA INC	250MG	A065433 001	May 04, 2009

TABLET;ORAL
MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD	500MG	A090464 001	Sep 13, 2010
ZYDUS PHARMS USA INC	500MG	A065477 001	May 04, 2009

NABUMETONE
TABLET;ORAL
NABUMETONE

COPLEY PHARM	750MG	A075179 001	Jun 06, 2000
DR REDDYS LABS LTD	500MG	A078420 001	Sep 24, 2008
	750MG	A078420 002	Sep 24, 2008
OXFORD PHARMS	500MG	A079093 001	Feb 27, 2009
	750MG	A079093 002	Feb 27, 2009
SANDOZ	500MG	A075590 001	Feb 25, 2002
	750MG	A075590 002	Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019583 001	Dec 24, 1991
	750MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019583 002	Dec 24, 1991

NADOLOL
TABLET;ORAL
CORGARD

US WORLDMEDS LLC	120MG	N018063 003	
	160MG	N018063 004	

NADOLOL

IVAX SUB TEVA PHARMS	120MG	A074255 002	Jan 24, 1996
	160MG	A074255 003	Jan 24, 1996

NADOLOL
TABLET;ORAL
NADOLOL

TEVA PHARMS	80MG	A074368 001	Aug 31, 1994
	120MG	A074368 002	Aug 31, 1994
	160MG	A074368 003	Aug 31, 1994

NAFCILLIN SODIUM
CAPSULE;ORAL
UNIPEN

WYETH AYERST	EQ 250MG BASE	N050111 001	

FOR SOLUTION;ORAL
UNIPEN

WYETH AYERST	EQ 250MG BASE/5ML	N050199 001	

INJECTABLE;INJECTION
NAFCILLIN SODIUM

APOTHECON	EQ 500MG BASE/VIAL	A061984 001	
	EQ 1GM BASE/VIAL	A061984 002	
	EQ 2GM BASE/VIAL	A061984 003	
	EQ 4GM BASE/VIAL	A061984 005	
SANDOZ	EQ 500MG BASE/VIAL	A062527 001	Aug 02, 1984
WATSON LABS INC	EQ 500MG BASE/VIAL	A062844 001	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062844 002	Oct 26, 1988
	EQ 1.5GM BASE/VIAL	A062844 003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062844 004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062844 005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A063008 001	Sep 29, 1988

NALLPEN

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061999 001	
	EQ 1GM BASE/VIAL	A061999 002	
	EQ 1GM BASE/VIAL	A062755 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A061999 003	
	EQ 2GM BASE/VIAL	A062755 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A061999 004	

UNIPEN

WYETH AYERST	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062717 001	Dec 16, 1986
	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050320 001	
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062717 002	Dec 16, 1986
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062717 004	Dec 16, 1986
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050320 003	
	EQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050320 004	
	EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050320 005	
	EQ 20GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050320 006	

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050320 002	

TABLET;ORAL
UNIPEN

WYETH AYERST	EQ 500MG BASE	N050462 001	

NALBUPHINE HYDROCHLORIDE
INJECTABLE;INJECTION
NALBUPHINE

ABRAXIS PHARM	10MG/ML	A070751 001	Jul 02, 1986
	20MG/ML	A070752 001	Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT	20MG/ML	A070917 001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200 001	Mar 12, 1993
BARR	10MG/ML	A074471 001	Mar 19, 1998
	20MG/ML	A074471 002	Mar 19, 1998
IGI LABS INC	10MG/ML	A072070 001	Apr 10, 1989
	10MG/ML	A072071 001	Apr 10, 1989
	10MG/ML	A072072 001	Apr 10, 1989
	20MG/ML	A072073 001	Apr 10, 1989
	20MG/ML	A072074 001	Apr 10, 1989
	20MG/ML	A072075 001	Apr 10, 1989

NUBAIN

PAR PHARM INC	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018024 001	
	20MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018024 002	May 27, 1982

NALIDIXIC ACID
SUSPENSION;ORAL
NEGGRAM

SANOFI AVENTIS US	250MG/5ML	N017430 001	

TABLET;ORAL
NALIDIXIC ACID

SUN PHARM INDS	250MG	A070270 001	Jun 29, 1988
	500MG	A070271 001	Jun 29, 1988
	1GM	A070272 001	Jun 29, 1988
WATSON LABS	250MG	A071936 001	Jun 29, 1988
	500MG	A072061 001	Jun 29, 1988
	1GM	A071919 001	Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US	250MG	N014214 002	
	500MG	N014214 004	
	1GM	N014214 005	

NALMEFENE HYDROCHLORIDE
INJECTABLE;INJECTION
REVEX

EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459 001	Apr 17, 1995
	EQ 1MG BASE/ML	N020459 002	Apr 17, 1995

NALOXONE HYDROCHLORIDE
INJECTABLE;INJECTION
NALOXONE

EUROHLTH INTL SARL	0.4MG/ML	A070298 001	Sep 24, 1986
	0.4MG/ML	A070496 001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188 001	Sep 24, 1986
	0.02MG/ML	A070189 001	Sep 24, 1986
	0.4MG/ML	A070190 001	Sep 24, 1986
	0.4MG/ML	A070191 001	Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM	0.02MG/ML	A070648 001	Nov 17, 1986
	0.02MG/ML	A070661 001	Nov 17, 1986
	0.4MG/ML	A070649 001	Nov 17, 1986
	1MG/ML	A071604 001	Dec 16, 1988
ASTRAZENECA	0.02MG/ML	A072081 001	Apr 11, 1989
EUROHLTH INTL SARL	0.02MG/ML	A071272 001	May 24, 1988
	1MG/ML	A071273 001	May 24, 1988
	1MG/ML	A071274 001	May 24, 1988
	1MG/ML	A071287 001	May 24, 1988
HOSPIRA	0.02MG/ML	A070171 001	Sep 24, 1986
	0.02MG/ML	A070252 001	Jan 16, 1987
	0.02MG/ML	A070253 001	Jan 16, 1987
	0.4MG/ML	A070255 001	Jan 07, 1987
IGI LABS INC	0.02MG/ML	A072082 001	Apr 11, 1989
	0.02MG/ML	A072083 001	Apr 11, 1989
	0.02MG/ML	A072084 001	Apr 11, 1989

FDA data supplied by DrugPatentWatch.com

NALOXONE HYDROCHLORIDE
INJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

	0.02MG/ML	A072085	001	Apr 11, 1989
	0.4MG/ML	A072086	001	Apr 11, 1989
	0.4MG/ML	A072087	001	Apr 11, 1989
	0.4MG/ML	A072088	001	Apr 11, 1989
	0.4MG/ML	A072089	001	Apr 11, 1989
	0.4MG/ML	A072090	001	Apr 11, 1989
	1MG/ML	A072091	001	Apr 11, 1989
	1MG/ML	A072092	001	Apr 11, 1989
	1MG/ML	A072093	001	Apr 11, 1989
INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
	1MG/ML	A072115	001	Apr 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
	0.4MG/ML	A071681	001	Nov 17, 1987
	0.4MG/ML	A071682	001	Nov 17, 1987
SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
	0.4MG/ML	A071683	001	Nov 17, 1987
WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987

NARCAN

ADAPT	0.02MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	002	
	0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	001	
	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	003	Jun 14, 1982
BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
	1MG/ML	A071084	001	Jul 28, 1988
	1MG/ML	A071311	001	Jul 28, 1988

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
TARGINIQ

PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014
	10MG;20MG	N205777	002	Jul 23, 2014
	20MG;40MG	N205777	003	Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
TABLET;ORAL
TALWIN NX

SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE	N018733	001	Dec 16, 1982

NALTREXONE HYDROCHLORIDE
TABLET;ORAL
NALTREXONE HYDROCHLORIDE

SANDOZ	50MG	A075434	001	Mar 08, 2000

REVIA

TEVA WOMENS	50MG	N018932	001	Nov 20, 1984

NANDROLONE DECANOATE
INJECTABLE;INJECTION
DECA-DURABOLIN

ASPEN GLOBAL INC	50MG/ML	N013132	001	Jun 12, 1986
	100MG/ML	N013132	002	Jun 12, 1986
	200MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013132	003	Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
	200MG/ML	A088317	001	Oct 14, 1983
AKORN	100MG/ML	A087519	001	Sep 28, 1983
WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
	50MG/ML	A087598	001	Oct 06, 1983
	50MG/ML	A088554	001	Feb 10, 1986
	100MG/ML	A086598	001	Jan 13, 1984
	100MG/ML	A087599	001	Oct 06, 1983
	200MG/ML	A088128	001	Dec 05, 1983

FDA data supplied by DrugPatentWatch.com

NANDROLONE PHENPROPIONATE

INJECTABLE;INJECTION

DURABOLIN			
ORGANON USA INC	25MG/ML	N011891 001	
	50MG/ML	N011891 002	
NANDROLONE PHENPROPIONATE			
WATSON LABS	25MG/ML	A086386 001	Jun 17, 1983
	50MG/ML	A087488 001	Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALBALON			
ALLERGAN	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080248 001	
NAFAZAIR			
BAUSCH AND LOMB	0.1%	A040073 001	May 25, 1994
PHARMAFAIR	0.1%	A088101 001	Apr 15, 1983
NAPHCON FORTE			
ALCON	0.1%	A080229 001	
OPCON			
BAUSCH AND LOMB	0.1%	A087506 001	
VASOCON			
NOVARTIS	0.1%	A080235 002	Mar 24, 1983

NAPROXEN

TABLET;ORAL

NAPROXEN			
DAVA PHARMS INC	250MG	A074105 001	Dec 21, 1993
	250MG	A074410 001	Apr 28, 1995
	375MG	A074105 002	Dec 21, 1993
	375MG	A074410 002	Apr 28, 1995
	500MG	A074105 003	Dec 21, 1993
	500MG	A074410 003	Apr 28, 1995
HAMILTON PHARMS	250MG	A074110 001	Oct 30, 1992
	375MG	A074110 002	Oct 30, 1992
	500MG	A074110 003	Oct 30, 1992
IVAX SUB TEVA PHARMS	250MG	A074111 001	Feb 28, 1995
	375MG	A074111 002	Feb 28, 1995
	500MG	A074111 003	Feb 28, 1995
PLIVA	250MG	A074182 001	Jun 27, 1996
	375MG	A074182 002	Jun 27, 1996
	500MG	A074182 003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263 001	Dec 21, 1993
	375MG	A074263 002	Dec 21, 1993
	500MG	A074263 003	Dec 21, 1993
ROXANE	250MG	A074211 001	Feb 28, 1994
	375MG	A074211 002	Feb 28, 1994
	500MG	A074211 003	Feb 28, 1994
SANDOZ	250MG	A074140 001	Dec 21, 1993
	375MG	A074140 002	Dec 21, 1993
	500MG	A074140 003	Dec 21, 1993
TEVA	250MG	A074129 001	Dec 21, 1993
	250MG	A074216 001	Apr 11, 1996
	375MG	A074129 002	Dec 21, 1993
	375MG	A074216 002	Apr 11, 1996
	500MG	A074129 003	Dec 21, 1993
	500MG	A074216 003	Apr 11, 1996
TEVA PHARMS	250MG	A074207 001	Dec 21, 1993
	375MG	A074207 002	Dec 21, 1993
	500MG	A074207 003	Dec 21, 1993
WATSON LABS	250MG	A074163 001	Feb 10, 1995
	250MG	A074457 001	May 31, 1995
	375MG	A074163 002	Feb 10, 1995
	375MG	A074457 002	May 31, 1995
	500MG	A074163 003	Feb 10, 1995
	500MG	A074457 003	May 31, 1995

TABLET, DELAYED RELEASE;ORAL

NAPROXEN			
ACTAVIS ELIZABETH	375MG	A074936 001	Feb 24, 1998
	500MG	A074936 002	Feb 24, 1998
SANDOZ	375MG	A075061 001	Feb 18, 1998
	500MG	A075061 002	Feb 18, 1998

NAPROXEN SODIUM
TABLET;ORAL
NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544	001	Aug 22, 2003
	EQ 500MG BASE	A076544	002	Aug 22, 2003
HAMILTON PHARMS	EQ 250MG BASE	A074106	001	Aug 31, 1993
	EQ 500MG BASE	A074106	002	Aug 31, 1993
HIKMA	EQ 250MG BASE	A074480	002	Feb 18, 1998
	EQ 500MG BASE	A074480	001	May 14, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230	001	Mar 14, 1995
	EQ 500MG BASE	A074230	002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367	001	Aug 31, 1994
	EQ 500MG BASE	A074367	002	Aug 31, 1994
PLIVA	EQ 250MG BASE	A074242	001	Jun 20, 1996
	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
SANDOZ	EQ 200MG BASE	A074646	001	Jan 13, 1997
	EQ 250MG BASE	A074162	001	Dec 21, 1993
	EQ 250MG BASE	A074495	001	Dec 05, 1994
	EQ 500MG BASE	A074162	002	Dec 21, 1993
	EQ 500MG BASE	A074495	002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 250MG BASE	A074455	001	May 31, 1995
	EQ 500MG BASE	A074195	002	Dec 21, 1993
	EQ 500MG BASE	A074455	002	May 31, 1995

NATEGLINIDE
TABLET;ORAL
NATEGLINIDE

TEVA PHARMS	60MG	A077467	001	Sep 09, 2009
	120MG	A077467	002	Sep 09, 2009

NEBIVOLOL HYDROCHLORIDE
TABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015
	EQ 5MG BASE	A203741	002	Jun 24, 2015
	EQ 10MG BASE	A203741	003	Jun 24, 2015
	EQ 20MG BASE	A203741	004	Jun 24, 2015
AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015
	EQ 5MG BASE	A203659	002	Apr 16, 2015
	EQ 10MG BASE	A203659	003	Apr 16, 2015
	EQ 20MG BASE	A203659	004	Apr 16, 2015
INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015
	EQ 5MG BASE	A203828	002	Jul 29, 2015
	EQ 10MG BASE	A203828	003	Jul 29, 2015
	EQ 20MG BASE	A203828	004	Jul 29, 2015
WATSON LABS INC	EQ 2.5MG BASE	A203683	001	Nov 27, 2015
	EQ 5MG BASE	A203683	002	Nov 27, 2015
	EQ 10MG BASE	A203683	003	Nov 27, 2015
	EQ 20MG BASE	A203683	004	Nov 27, 2015

NEDOCROMIL SODIUM
AEROSOL, METERED;INHALATION
TILADE

KING PHARMS	1.75MG/INH	N019660	001	Dec 30, 1992

SOLUTION;INHALATION
TILADE

SANOFI AVENTIS US	0.5%	N020750	001	Oct 01, 1997

NEFAZODONE HYDROCHLORIDE
TABLET;ORAL
NEFAZODONE HYDROCHLORIDE

IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003
	100MG	A076072	002	Sep 16, 2003
	150MG	A076072	003	Sep 16, 2003
	200MG	A076072	004	Sep 16, 2003

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	250MG	A076072 005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
	100MG	A075763 002	Sep 16, 2003
	150MG	A075763 003	Sep 16, 2003
	200MG	A075763 004	Sep 16, 2003
	250MG	A075763 005	Sep 16, 2003
MYLAN	100MG	A076129 002	Sep 16, 2003
	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003
	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SANDOZ	50MG	A076302 001	Sep 16, 2003
	100MG	A076302 002	Sep 16, 2003
	150MG	A076302 003	Sep 16, 2003
	200MG	A076302 004	Sep 16, 2003
	250MG	A076302 005	Sep 16, 2003
SUN PHARM INDS LTD	50MG	A076409 001	Sep 16, 2003
	100MG	A076409 002	Sep 16, 2003
	150MG	A076409 003	Sep 16, 2003
	200MG	A076409 004	Sep 16, 2003
	250MG	A076409 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003

SERZONE

BRISTOL MYERS SQUIBB	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 001	Dec 22, 1994
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 002	Dec 22, 1994
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 003	Dec 22, 1994
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 004	Dec 22, 1994
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 005	Dec 22, 1994
	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER;ORAL

VIRACEPT

AGOURON	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997

NEOMYCIN SULFATE

POWDER;FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS	100%	A061579 001

SOLUTION;ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001

TABLET;ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001

NEOBIOTIC

PFIZER	EQ 350MG BASE	A060475 001

NEOMYCIN SULFATE
TABLET;ORAL
NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	500MG	A060365 001	
LANNETT	500MG	A060607 001	
LILLY	500MG	A060385 001	
ROXANE	500MG	A062173 001	
SANDOZ	500MG	A061586 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE
CREAM;TOPICAL
NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176 002	Jan 14, 1985

OINTMENT;OPHTHALMIC
STATROL

ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344 002	

SOLUTION/DROPS;OPHTHALMIC
STATROL

ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339 001	Nov 30, 1984
	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
SUSPENSION/DROPS;OPHTHALMIC
POLY-PRED

ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081 002	

NEOMYCIN SULFATE; PREDNISOLONE ACETATE
OINTMENT;OPHTHALMIC
NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039 002	
	EQ 3.5MG BASE/GM;0.5%	A061039 001	

SUSPENSION/DROPS;OPHTHALMIC
NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037 001	

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE
OINTMENT;OPHTHALMIC
NEO-HYDELTRASOL

MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378 001	

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE
CREAM;TOPICAL
MYTREX A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598 001	Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600 001	Jul 21, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595 001	Jul 21, 1986

OINTMENT;TOPICAL
MYTREX A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609 001	May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608 001	May 23, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607 001	May 23, 1986

NETILMICIN SULFATE
INJECTABLE;INJECTION
NETROMYCIN

SCHERING	EQ 10MG BASE/ML	N050544 001	Feb 28, 1983
	EQ 25MG BASE/ML	N050544 002	Feb 28, 1983
	EQ 100MG BASE/ML	N050544 003	Feb 28, 1983

NIACIN
CAPSULE;ORAL
WAMPOCAP

MEDPOINTE PHARM HLC	500MG	N011073 003	

TABLET;ORAL
NIACIN

EVERYLIFE	500MG	A083203 001	
HALSEY	500MG	A083453 001	
HIKMA PHARMS LLC	500MG	A083718 001	
IMPAX LABS	500MG	A083115 001	
IVAX SUB TEVA PHARMS	500MG	A083180 001	
MK LABS	500MG	A083525 001	
PUREPAC PHARM	500MG	A083271 001	
SANDOZ	500MG	A083306 001	
TABLICAPS	500MG	A084237 001	

NIACIN
TABLET;ORAL
NIACIN

WATSON LABS	500MG	A083136 001	
	500MG	A083305 001	
	500MG	A085172 001	

NICOLAR

SANOFI AVENTIS US	500MG	A083823 001	

TABLET, EXTENDED RELEASE;ORAL
NIASPAN

ABBVIE	375MG	N020381 001	Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE	375MG;500MG;750MG	N020381 005	Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE
SUSPENSION;ORAL
TPN

INTL MINERALS	15MG/5ML;3.75MG/5ML;600MG/5ML	N008378 003	

NICARDIPINE HYDROCHLORIDE
CAPSULE;ORAL
CARDENE

CHIESI USA INC	20MG	N019488 001	Dec 21, 1988
	30MG	N019488 002	Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

WATSON LABS	20MG	A074670 001	Oct 28, 1996
	30MG	A074670 002	Oct 28, 1996

CAPSULE, EXTENDED RELEASE;ORAL
CARDENE SR

CHIESI USA INC	30MG	N020005 001	Feb 21, 1992
	45MG	N020005 002	Feb 21, 1992
	60MG	N020005 003	Feb 21, 1992

NICLOSAMIDE
TABLET, CHEWABLE;ORAL
NICLOCIDE

BAYER PHARMS	500MG	N018669 001	May 14, 1982

NICOTINE
FILM, EXTENDED RELEASE;TRANSDERMAL
NICOTROL

MCNEIL CONS	15MG/16HR	N020536 001	Jul 03, 1996

PROSTEP

AVEVA	11MG/24HR	N019983 003	Dec 23, 1998
	22MG/24HR	N019983 004	Dec 23, 1998

NICOTINE POLACRILEX
GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880 001	Feb 18, 2009
	EQ 4MG BASE	A077850 001	Feb 18, 2009

NIFEDIPINE
CAPSULE;ORAL
ADALAT

BAYER PHARMS	10MG	N019478 001	Nov 27, 1985
	20MG	N019478 002	Sep 17, 1986

NIFEDIPINE

CHASE LABS NJ	10MG	A072409 001	Jul 04, 1990
	20MG	A073421 001	Jun 19, 1991
TEVA	10MG	A072651 001	Feb 19, 1992

PROCARDIA

PFIZER	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018482 002	Jul 24, 1986

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

MARTEC USA LLC	90MG	A075414 003	Mar 23, 2004
MYLAN	30MG	A075108 001	Dec 17, 1999

FDA data supplied by DrugPatentWatch.com

NILUTAMIDE
TABLET;ORAL
NILANDRON

CONCORDIA PHARMS INC	50MG	N020169 001	Sep 19, 1996

NIMODIPINE
CAPSULE;ORAL
NIMOTOP

BAYER PHARMS	30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018869 001	Dec 28, 1988

NISOLDIPINE
TABLET, EXTENDED RELEASE;ORAL
SULAR

COVIS PHARMA SARL	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020356 001	Feb 02, 1995
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020356 002	Feb 02, 1995
	25.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020356 006	Jan 02, 2008
	30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020356 003	Feb 02, 1995
	40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020356 004	Feb 02, 1995

NITRIC OXIDE
GAS;INHALATION
INOMAX

MALLINCKRODT HOSP	100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020845 002	Dec 23, 1999

NITROFURANTOIN
CAPSULE;ORAL
NITROFURANTOIN

WATSON LABS	50MG	A084326 001	
	100MG	A084326 002	

TABLET;ORAL
FURADANTIN

PROCTER AND GAMBLE	50MG	N008693 001	
	100MG	N008693 002	

FURALAN

LANNETT	50MG	A080017 001	
	100MG	A080017 002	

NITROFURANTOIN

ELKINS SINN	50MG	A080003 001	
	100MG	A080003 002	
IVAX SUB TEVA PHARMS	50MG	A080078 002	
	100MG	A080078 001	
SANDOZ	50MG	A080043 001	
	100MG	A080043 002	
WATSON LABS	50MG	A080447 001	
	50MG	A085797 001	
	100MG	A080447 002	
	100MG	A085796 001	
WHITEWORTH TOWN PLSN	100MG	A084085 002	

NITROFURANTOIN SODIUM
INJECTABLE;INJECTION
IVADANTIN

PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402 001	

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL			
NITROFURANTOIN			
MYLAN	100MG	A074967 002	Jul 09, 1997
SANDOZ	25MG	A074336 001	Jan 25, 1995
	50MG	A074336 002	Jan 25, 1995
	100MG	A074336 003	Jan 25, 1995
WATSON LABS	25MG	A073696 001	Dec 31, 1992
	50MG	A073696 002	Dec 31, 1992
	100MG	A073696 003	Dec 31, 1992
NITROFURANTOIN MACROCRYSTALLINE			
WATSON LABS	50MG	A070248 001	Jun 24, 1988
	100MG	A070249 001	Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL			
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)			
RANBAXY LABS LTD	75MG;25MG	A076951 001	Mar 30, 2005

NITROFURAZONE

CREAM;TOPICAL			
FURACIN			
SHIRE	0.2%	A083789 001	
DRESSING;TOPICAL			
ACTIN-N			
SHERWOOD MEDCL	0.2%	N017343 001	
OINTMENT;TOPICAL			
FURACIN			
SHIRE	0.2%	N005795 001	
NITROFURAZONE			
AMBIX	0.2%	A086077 001	
LANNETT	0.2%	A084393 001	
PERRIGO NEW YORK	0.2%	A084968 001	
TARO	0.2%	A086156 001	
WENDT	0.2%	A086766 001	
POWDER;TOPICAL			
FURACIN			
SHIRE	0.2%	A083791 001	
SOLUTION;TOPICAL			
NITROFURAZONE			
PERRIGO NEW YORK	0.2%	A085130 001	
WENDT	0.2%	A087081 001	

NITROGLYCERIN

AEROSOL;SUBLINGUAL			
NITROLINGUAL			
POHL BOSKAMP	0.4MG/SPRAY	N018705 001	Oct 31, 1985
FILM, EXTENDED RELEASE;TRANSDERMAL			
NITROGLYCERIN			
KREMERS URBAN PHARMS	0.2MG/HR	A075115 001	Aug 10, 2004
	0.4MG/HR	A075115 002	Aug 10, 2004
MYLAN TECHNOLOGIES	0.1MG/HR	A074992 004	Nov 12, 1999
	0.2MG/HR	A074992 003	Nov 12, 1999
	0.4MG/HR	A074992 002	Nov 12, 1999
	0.6MG/HR	A074992 001	Nov 12, 1999
TRANSDERM-NITRO			
NOVARTIS	0.1MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020144 001	Feb 27, 1996
	0.2MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020144 002	Feb 27, 1996
	0.4MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020144 003	Feb 27, 1996
	0.6MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020144 004	Feb 27, 1996
	0.8MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020144 005	Feb 27, 1996

NITROGLYCERIN
INJECTABLE;INJECTION

NITRO IV				
POHL BOSKAMP	5MG/ML	N018672	002	Aug 30, 1983
NITRO-BID				
SANOFI AVENTIS US	5MG/ML	N018621	001	Jan 05, 1982
	10MG/ML	A071159	001	Feb 28, 1990
NITROGLYCERIN				
ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
	5MG/ML	A071203	001	May 08, 1987
HOSPIRA	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018531	001	
INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
LUITPOLD	5MG/ML	A071492	001	May 24, 1988
SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
	5MG/ML	A070634	001	Jun 19, 1986
NITROGLYCERIN IN DEXTROSE 5%				
HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
NITROL				
RORER	0.8MG/ML	N018774	001	Jan 19, 1983
NITRONAL				
POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983
NITROSTAT				
PARKE DAVIS	0.8MG/ML	N018588	001	
	5MG/ML	A070863	001	Jan 08, 1987
	5MG/ML	N018588	002	Dec 23, 1983
	10MG/ML	A070871	001	Jan 08, 1987
	10MG/ML	A070872	001	Jan 08, 1987
TRIDIL				
HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
	5MG/ML	N018537	001	

NIZATIDINE
CAPSULE;ORAL

AXID				
SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
	300MG	N019508	002	Apr 12, 1988
NIZATIDINE				
ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002
	300MG	A075461	002	Jul 08, 2002
APOTEX INC	150MG	A076383	001	Jan 23, 2003
	300MG	A076383	002	Jan 23, 2003
MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002
	300MG	A075934	002	Jul 09, 2002

SOLUTION;ORAL

AXID				
BRAINTREE	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021494	001	May 25, 2004

NONOXYNOL-9
AEROSOL;VAGINAL

DELFEN				
PERSONAL PRODS	12.5%	N014349	002	

NOREPINEPHRINE BITARTRATE
INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE				
METRICS PHARM	EQ 1MG BASE/ML	A040522	001	Sep 30, 2004

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE
INJECTABLE;INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED				
EASTMAN KODAK	EQ 0.033MG BASE/ML;2%;0.4%	N008592	003	

NORETHINDRONE
TABLET;ORAL

NORLUTIN				
PARKE DAVIS	5MG	N010895	002	

FDA data supplied by DrugPatentWatch.com

NORETHINDRONE ACETATE
TABLET;ORAL
NORLUTATE

PARKE DAVIS	5MG	N012184 002	

NORFLOXACIN
SOLUTION/DROPS;OPHTHALMIC
CHIBROXIN

MERCK	0.3%	N019757 001	Jun 17, 1991

TABLET;ORAL
NOROXIN

MERCK	400MG	N019384 002	Oct 31, 1986

NORGESTREL
TABLET;ORAL
OVRETTE

LABORATOIRE HRA	0.075MG	N017031 001	

NORTRIPTYLINE HYDROCHLORIDE
CAPSULE;ORAL
AVENTYL HYDROCHLORIDE

LILLY	EQ 10MG BASE	N014684 001	
	EQ 25MG BASE	N014684 002	

NORTRIPTYLINE HYDROCHLORIDE

AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835 001	Jun 30, 1997
	EQ 25MG BASE	A074835 002	Jun 30, 1997
	EQ 50MG BASE	A074835 003	Jun 30, 1997
	EQ 75MG BASE	A074835 004	Jun 30, 1997
IDT AUSTRALIA LTD	EQ 10MG BASE	A074054 001	Dec 31, 1992
	EQ 25MG BASE	A074054 002	Dec 31, 1992
	EQ 50MG BASE	A074054 003	Dec 31, 1992
	EQ 75MG BASE	A074054 004	Dec 31, 1992
TEVA	EQ 10MG BASE	A073667 001	Apr 11, 1996
	EQ 25MG BASE	A073667 002	Apr 11, 1996
	EQ 50MG BASE	A073667 003	Apr 11, 1996
	EQ 75MG BASE	A073667 004	Apr 11, 1996

SOLUTION;ORAL
AVENTYL

RANBAXY	EQ 10MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014685 001	

PAMELOR

MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012 001	

NYSTATIN
CREAM;TOPICAL
CANDEX

BAYER PHARMS	100,000 UNITS/GM	A061810 001	

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060575 001	

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062387 001	Jul 29, 1982

NILSTAT

LEDERLE	100,000 UNITS/GM	A061445 001	

NYSTATIN

TARO	100,000 UNITS/GM	A062457 001	Jul 28, 1983

LOTION;TOPICAL
CANDEX

BAYER PHARMS	100,000 UNITS/ML	N050233 001	

OINTMENT;TOPICAL
MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060571 001	

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986

NILSTAT

LEDERLE	100,000 UNITS/GM	A061444 001	

NYSTATIN

PASTILLE;ORAL				
MYCOSTATIN				
BRISTOL MYERS SQUIBB	200,000 UNITS	N050619	001	Apr 09, 1987
POWDER;ORAL				
BARSTATIN 100				
BARLAN	100%	A062489	001	Apr 27, 1988
NILSTAT				
DAVA PHARMS INC	100% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050576	001	Dec 22, 1983
NYSTATIN				
PADDOCK LLC	100%	A062613	001	Nov 26, 1985
POWDER;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060578	001	
NYSTATIN				
NESHER PHARMS	100,000 UNITS/GM	A065321	001	Aug 18, 2006
SUPPOSITORY;VAGINAL				
NYSERT				
WARNER CHILCOTT	100,000 UNITS	N050478	001	
SUSPENSION;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001	
NILSTAT				
GLENMARK GENERICS	100,000 UNITS/ML	N050299	001	
NYSTATIN				
ALPHARMA US PHARMS	100,000 UNITS/ML	A062571	001	Oct 29, 1985
G AND W LABS INC	100,000 UNITS/ML	A062776	001	Dec 17, 1987
MORTON GROVE	100,000 UNITS/ML	A062835	001	Nov 19, 1987
PHARMADERM	100,000 UNITS/ML	A062518	001	Jul 06, 1984
PHARMAFAIR	100,000 UNITS/ML	A062541	001	Jan 16, 1985
ROXANE	100,000 UNITS/ML	A062832	001	Dec 27, 1991
TEVA	100,000 UNITS/ML	A062670	001	Jun 18, 1987
NYSTEX				
SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984
TABLET;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	500,000 UNITS	A060574	001	
NILSTAT				
LEDERLE	500,000 UNITS	A061151	001	
NYSTATIN				
QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984
SANDOZ	500,000 UNITS	A062065	001	
USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985
WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982
TABLET;VAGINAL				
KOROSTATIN				
HOLLAND RANTOS	100,000 UNITS	A061718	001	
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS	A060577	001	
NILSTAT				
LEDERLE	100,000 UNITS	A061325	001	
NYSTATIN				
FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983
PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984
SANDOZ	100,000 UNITS	A061965	001	
TEVA	100,000 UNITS	A062502	001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176	001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%	A061954	002	Sep 20, 1985
MYCOLOG-II				
DELCOR ASSET CORP	100,000 UNITS/GM;0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	A060576	002	May 01, 1985

FDA data supplied by DrugPatentWatch.com

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYCOLOG-II				
		100,000 UNITS/GM;0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	A062606	001 May 15, 1985
MYTREX F				
	SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597	001 Oct 08, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
	ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010	001 Dec 20, 1988
	PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186	002 Jun 06, 1985
	PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657	001 Jul 30, 1986
	TARO	100,000 UNITS/GM;0.1%	A062347	001 Mar 30, 1987
NYSTATIN TRIAMCINOLONE ACETONIDE				
	PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001 Oct 08, 1985
OINTMENT;TOPICAL				
MYCO-TRIACET II				
	TEVA	100,000 UNITS/GM;0.1%	A062045	002 Nov 26, 1985
MYCOLOG-II				
	DELCOR ASSET CORP	100,000 UNITS/GM;0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060572	001 Jun 28, 1985
MYTREX F				
	SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601	001 Oct 09, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
	PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280	002 Oct 10, 1985
	PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656	001 Jul 30, 1986
NYSTATIN-TRIAMCINOLONE ACETONIDE				
	PHARMADERM	100,000 UNITS/GM;0.1%	A062603	001 Oct 09, 1985

OCTREOTIDE ACETATE

INJECTABLE;INJECTION				
OCTREOTIDE ACETATE				
	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001 May 11, 2011
		EQ 1MG BASE/ML	A090986	002 May 11, 2011
OCTREOTIDE ACETATE PRESERVATIVE FREE				
	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001 May 11, 2011
		EQ 0.1MG BASE/ML	A090985	002 May 11, 2011
		EQ 0.5MG BASE/ML	A090985	003 May 11, 2011

OFLOXACIN

INJECTABLE;INJECTION				
FLOXIN				
	ORTHO MCNEIL PHARM	20MG/ML	N020087	002 Mar 31, 1992
		40MG/ML	N020087	003 Mar 31, 1992
FLOXIN IN DEXTROSE 5%				
	ORTHO MCNEIL PHARM	400MG/100ML	N020087	001 Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	ORTHO MCNEIL PHARM	4MG/ML	N020087	004 Mar 31, 1992
		400MG/100ML	N020087	005 Mar 31, 1992
OFLOXACIN				
	BEDFORD	40MG/ML	A075762	001 Jan 16, 2002
SOLUTION/DROPS;OPHTHALMIC				
OFLOXACIN				
	APOTEX INC	0.3%	A076513	001 May 14, 2004
	SANDOZ	0.3%	A076848	001 Nov 25, 2008
SOLUTION/DROPS;OTIC				
FLOXIN OTIC				
	DAIICHI	0.3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020799	001 Dec 16, 1997
TABLET;ORAL				
FLOXIN				
	JANSSEN PHARMS	200MG	N019735	001 Dec 28, 1990
		300MG	N019735	002 Dec 28, 1990
		400MG	N019735	003 Dec 28, 1990
OFLOXACIN				
	LARKEN LABS	200MG	A076093	001 Sep 02, 2003
		300MG	A076093	002 Sep 02, 2003
	RANBAXY LABS LTD	200MG	A076220	001 Sep 02, 2003
		300MG	A076220	002 Sep 02, 2003
		400MG	A076220	003 Sep 02, 2003

FDA data supplied by DrugPatentWatch.com

OMEPRAZOLE
CAPSULE, DELAYED REL PELLETS;ORAL
PRILOSEC

ASTRAZENECA PHARMS	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019810 003	Oct 05, 1995
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019810 001	Sep 14, 1989
	40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019810 002	Jan 15, 1998

OMEPRAZOLE; SODIUM BICARBONATE
FOR SUSPENSION;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182 001	Apr 19, 2013
	40MG/PACKET;1.68GM/PACKET	A079182 002	Apr 19, 2013

ONDANSETRON
TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

CHARTWELL PHARMS LLC	4MG	A076506 001	Dec 26, 2006
	8MG	A076506 002	Dec 26, 2006
	16MG	A077406 001	Dec 26, 2006
	24MG	A077406 002	Dec 26, 2006
NESHER PHARMS	4MG	A077717 001	Jun 25, 2007
	8MG	A077717 002	Jun 25, 2007

ONDANSETRON HYDROCHLORIDE
INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077368 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076695 001	Dec 26, 2006
LANNETT	EQ 2MG BASE/ML	A090116 001	Apr 14, 2010
	EQ 2MG BASE/ML	A090883 001	Aug 05, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582 001	Dec 26, 2006
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544 001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.64MG BASE/ML	A076978 001	Feb 26, 2007

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

APOTEX INC	EQ 2MG BASE/ML	A077343 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696 001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387 001	Dec 26, 2006
TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014 001	Mar 21, 2008

ZOFRAN

NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007 001	Jan 04, 1991

ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020403 001	Jan 31, 1995

ZOFRAN PRESERVATIVE FREE

NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007 003	Dec 10, 1993

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE

CHARTWELL MOLECULES	EQ 4MG BASE	A077303 001	Jun 25, 2007
	EQ 8MG BASE	A077303 002	Jun 25, 2007
	EQ 24MG BASE	A077303 004	Jun 25, 2007
HIKMA INTL PHARMS	EQ 4MG BASE	A077545 001	Sep 06, 2007
	EQ 8MG BASE	A077545 002	Sep 06, 2007
	EQ 24MG BASE	A077545 003	Sep 06, 2007
TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011
	EQ 8MG BASE	A077729 002	Mar 28, 2011
	EQ 24MG BASE	A077729 003	Mar 28, 2011

ORPHENADRINE CITRATE
INJECTABLE;INJECTION
NORFLEX

IGI LABS INC	30MG/ML	N013055 001	

ORPHENADRINE CITRATE

WATSON LABS	30MG/ML	A087062 001	

TABLET, EXTENDED RELEASE;ORAL
NORFLEX

MEDICIS	100MG	N012157 001	

ORPHENADRINE CITRATE

ASCOT	100MG	A088067 001	Apr 06, 1983
SANDOZ	100MG	A085046 001	
WATSON LABS	100MG	A084303 001	

ORPHENADRINE HYDROCHLORIDE
TABLET;ORAL
DISIPAL

3M	50MG	N010653 001	

OSELTAMIVIR PHOSPHATE
FOR SUSPENSION;ORAL
TAMIFLU

ROCHE	EQ 12MG BASE/ML	N021246 001	Dec 14, 2000

OXACILLIN SODIUM
CAPSULE;ORAL
BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A061336 001	
	EQ 250MG BASE	A062241 001	
	EQ 500MG BASE	A061336 002	
	EQ 500MG BASE	A062241 002	

OXACILLIN SODIUM

ANI PHARMS INC	EQ 250MG BASE	A062222 001	
	EQ 500MG BASE	A062222 002	
APOTHECON	EQ 250MG BASE	A061450 002	
	EQ 500MG BASE	A061450 001	

PROSTAPHLIN

APOTHECON	EQ 500MG BASE	N050118 002	

FOR SOLUTION;ORAL
BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321 001	

OXACILLIN SODIUM

APOTHECON	EQ 250MG BASE/5ML	A061457 001	
TEVA	EQ 250MG BASE/5ML	A062252 001	

PROSTAPHLIN

APOTHECON	EQ 250MG BASE/5ML	N050194 001	

INJECTABLE;INJECTION
BACTOCILL

GLAXOSMITHKLINE	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061334 009	Mar 26, 1982
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061334 006	Mar 26, 1982
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062736 001	Dec 19, 1986
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061334 007	Mar 26, 1982
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062736 002	Dec 19, 1986
	EQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061334 008	Mar 26, 1982
	EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061334 010	

OXACILLIN SODIUM
INJECTABLE;INJECTION
OXACILLIN SODIUM

APOTHECON	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195 001	
	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195 002	
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195 003	
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195 004	
	EQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195 005	
ELKINS SINN	EQ 250MG BASE/VIAL	A062711 001	Feb 03, 1989
	EQ 500MG BASE/VIAL	A062711 002	Feb 03, 1989
	EQ 1GM BASE/VIAL	A062711 003	Feb 03, 1989
	EQ 2GM BASE/VIAL	A062711 004	Feb 03, 1989
	EQ 4GM BASE/VIAL	A062711 005	Feb 03, 1989
	EQ 10GM BASE/VIAL	A062711 006	Feb 03, 1989
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062798 003	Dec 11, 1995
	EQ 250MG BASE/VIAL	A062798 004	Dec 11, 1995
	EQ 500MG BASE/VIAL	A062798 005	Dec 11, 1995
	EQ 1GM BASE/VIAL	A062798 001	Dec 11, 1995
	EQ 2GM BASE/VIAL	A062798 002	Dec 11, 1995
SANDOZ	EQ 250MG BASE/VIAL	A061490 001	
	EQ 500MG BASE/VIAL	A061490 002	
WATSON LABS INC	EQ 250MG BASE/VIAL	A062856 001	Oct 26, 1988
	EQ 500MG BASE/VIAL	A062856 002	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062856 003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062856 004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062856 005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A062984 001	Sep 29, 1988

OXALIPLATIN
INJECTABLE;IV (INFUSION)
ELOXATIN

SANOFI AVENTIS US	50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021492 001	Aug 09, 2002
	100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021492 002	Aug 09, 2002
	200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021759 003	Nov 17, 2006

OXALIPLATIN

SANDOZ	50MG/VIAL	A090849 001	Apr 28, 2011
	100MG/VIAL	A090849 002	Apr 28, 2011
SANDOZ INC	50MG/10ML (5MG/ML)	A078812 001	Aug 07, 2009
	100MG/20ML (5MG/ML)	A078812 002	Aug 07, 2009

OXAMNIQUINE
CAPSULE;ORAL
VANSIL

PFIZER	250MG	N018069 001	

OXANDROLONE
TABLET;ORAL
OXANDROLONE

ROXANE	2.5MG	A077249 001	Jul 10, 2007
	10MG	A077249 002	Jul 10, 2007
SANDOZ	2.5MG	A076897 001	Dec 01, 2006
	10MG	A076897 002	Dec 01, 2006

OXAPROZIN
TABLET;ORAL
OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001
WATSON LABS	600MG	A075848	001	Feb 09, 2001

OXAPROZIN POTASSIUM
TABLET;ORAL
DAYPRO ALTA

GD SEARLE	600MG	N020776	001	Oct 17, 2002

OXAZEPAM
CAPSULE;ORAL
OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
WATSON LABS	10MG	A072952	001	Sep 28, 1990
	15MG	A072953	001	Sep 28, 1990
	30MG	A072954	001	Sep 28, 1990

SERAX

ALPHARMA US PHARMS	10MG	N015539	002	
	15MG	N015539	004	
	30MG	N015539	006	

ZAXOPAM

QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988

TABLET;ORAL
OXAZEPAM

FRONTIDA BIOPHARM	15MG	A070683	001	Jan 16, 1987
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987

SERAX

ALPHARMA US PHARMS	15MG	N015539	008	

OXPRENOLOL HYDROCHLORIDE
CAPSULE;ORAL
TRASICOR

NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

OXTRIPHYLLINE
SOLUTION;ORAL
CHOLEDYL

PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984

OXTRIPHYLLINE

MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983

SYRUP;ORAL
CHOLEDYL

PARKE DAVIS	50MG/5ML	N009268	011	

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE	50MG/5ML	A088242	001	Dec 05, 1983

TABLET, DELAYED RELEASE;ORAL
CHOLEDYL

PARKE DAVIS	100MG	N009268	003	
	200MG	N009268	007	

OXTRIPHYLLINE

WATSON LABS	100MG	A087866	001	Aug 25, 1983

FDA data supplied by DrugPatentWatch.com

OXTRIPHYLLINE
TABLET, DELAYED RELEASE;ORAL
OXTRIPHYLLINE

	200MG	A087835 001	Aug 25, 1983

OXYBUTYNIN CHLORIDE
SYRUP;ORAL
DITROPAN

ORTHO MCNEIL JANSSEN	5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018211 001	

OXYBUTYNIN CHLORIDE

APOTEX INC	5MG/5ML	A074997 001	Oct 15, 1997
MIKART	5MG/5ML	A075039 001	Jan 29, 1999

TABLET;ORAL
DITROPAN

JANSSEN PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017577 001	

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS	5MG	A072296 001	Dec 08, 1988
USL PHARMA	5MG	A070746 001	Mar 10, 1988
WATSON LABS	5MG	A072485 001	Apr 19, 1989

OXYCODONE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
ROXICODONE

ROXANE	10MG	N020932 001	Oct 26, 1998
	30MG	N020932 002	Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE
INJECTABLE;INJECTION
OPANA

ENDO PHARMS	1.5MG/ML	N011707 001	

SUPPOSITORY;RECTAL
NUMORPHAN

ENDO PHARMS	5MG	N011738 004	

TABLET, EXTENDED RELEASE;ORAL
OPANA ER

ENDO PHARMS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021610 001	Jun 22, 2006
	7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021610 005	Feb 29, 2008
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021610 002	Jun 22, 2006
	15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021610 006	Feb 29, 2008
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021610 003	Jun 22, 2006
	30MG	N021610 007	Feb 29, 2008
	40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021610 004	Jun 22, 2006

OXYPHENBUTAZONE
TABLET;ORAL
OXYPHENBUTAZONE

WATSON LABS	100MG	A088399 001	Sep 17, 1984

TANDEARIL

NOVARTIS	100MG	N012542 004	Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE
TABLET;ORAL
DARICON
PFIZER 10MG N011612 001

OXYPHENONIUM BROMIDE
TABLET;ORAL
ANTRENYL
NOVARTIS 5MG N008492 002

OXYTETRACYCLINE
TABLET;ORAL
TERRAMYCIN
PFIZER 250MG N050287 001

OXYTETRACYCLINE CALCIUM
SYRUP;ORAL
TERRAMYCIN
PFIZER EQ 125MG BASE/5ML A060595 001

OXYTETRACYCLINE HYDROCHLORIDE
CAPSULE;ORAL
OXY-KESSO-TETRA
FERRANTE EQ 250MG BASE A060179 001
OXYTETRACYCLINE HYDROCHLORIDE
HIKMA PHARMS LLC EQ 250MG BASE A060770 001
IMPAX LABS EQ 250MG BASE A060760 001
PROTER EQ 250MG BASE A060869 001
PUREPAC PHARM EQ 250MG BASE A060634 001
TERRAMYCIN
PFIZER EQ 125MG BASE N050286 001
EQ 250MG BASE N050286 002
INJECTABLE;INJECTION
TERRAMYCIN
PFIZER EQ 250MG BASE/VIAL A060586 001
EQ 500MG BASE/VIAL A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE
OINTMENT;OTIC
TERRAMYCIN W/ POLYMYXIN
PFIZER EQ 5MG BASE/GM;10,000 UNITS/GM A061841 001
TABLET;VAGINAL
TERRAMYCIN-POLYMYXIN
PFIZER EQ 100MG BASE;100,000 UNITS A061009 001

OXYTOCIN
INJECTABLE;INJECTION
OXYTOCIN
TEVA PHARMS USA 10USP UNITS/ML (10USP UNITS/ML) A077453 001 Jan 24, 2008
100USP UNITS/10ML (10USP UNITS/ML) A077453 002 Jan 24, 2008
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
ABBOTT 1USP UNITS/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N019185 004 Mar 29, 1985
2USP UNITS/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N019185 003 Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
ABBOTT 2USP UNITS/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N019185 002 Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%
ABBOTT 1USP UNITS/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N019185 001 Mar 29, 1985
SYNTOCINON
NOVARTIS 10USP UNITS/ML N018245 001
SOLUTION;NASAL
SYNTOCINON
RTRX 40USP UNITS/ML N012285 001

PACLITAXEL
INJECTABLE;INJECTION
PACLITAXEL

ACCORD HLTHCARE	6MG/ML	A075436 001	Nov 12, 2004
HOSPIRA	6MG/ML	A076233 001	Aug 01, 2002
MYLAN	6MG/ML	A075278 001	Jan 25, 2002
PLIVA LACHEMA	6MG/ML	A077413 001	Mar 12, 2008
TEVA PHARMS USA	6MG/ML	A075297 001	Jan 25, 2002

PALIPERIDONE
TABLET, EXTENDED RELEASE;ORAL
INVEGA

JANSSEN PHARMS	12MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021999 004	Dec 19, 2006

PALONOSETRON HYDROCHLORIDE
CAPSULE;ORAL
ALOXI

HELSINN HLTHCARE	EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022233 001	Aug 22, 2008

PAMIDRONATE DISODIUM
INJECTABLE;INJECTION
AREDIA

NOVARTIS	30MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020036 001	Oct 31, 1991
	60MG/VIAL	N020036 003	May 06, 1993
	90MG/VIAL	N020036 004	May 06, 1993

PAMIDRONATE DISODIUM

AESGEN	30MG/VIAL	A075594 001	May 06, 2002
	90MG/VIAL	A075594 002	May 06, 2002
MN PHARMS	30MG/VIAL	A078300 001	Mar 10, 2009
	90MG/VIAL	A078300 002	Mar 10, 2009

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
CAPSULE;ORAL
COTAZYM

ORGANON USA INC	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N020580 001	Dec 09, 1996

PANCURONIUM BROMIDE
INJECTABLE;INJECTION
PANCURONIUM BROMIDE

ELKINS SINN	1MG/ML	A072058 001	Mar 23, 1988
	2MG/ML	A072059 001	Mar 23, 1988
	2MG/ML	A072060 001	Mar 23, 1988
HOSPIRA	2MG/ML	A072321 001	Jan 19, 1989
IGI LABS INC	1MG/ML	A072210 001	Mar 31, 1988
	2MG/ML	A072211 001	Mar 31, 1988
	2MG/ML	A072212 001	Mar 31, 1988
	2MG/ML	A072213 001	Mar 31, 1988

PAVULON

ORGANON USA INC	1MG/ML	N017015 002	
	2MG/ML	N017015 001	

PARAMETHADIONE
CAPSULE;ORAL
PARADIONE

ABBVIE	150MG	N006800 003	
	300MG	N006800 001	

SOLUTION;ORAL
PARADIONE

ABBVIE	300MG/ML	N006800 002	

PARAMETHASONE ACETATE
TABLET;ORAL
HALDRONE

LILLY	1MG	N012772 005	
	2MG	N012772 006	

FDA data supplied by DrugPatentWatch.com

PARGYLINE HYDROCHLORIDE
TABLET;ORAL
EUTONYL

ABBOTT	10MG	N013448 002	
	25MG	N013448 003	
	50MG	N013448 004	

PARICALCITOL
CAPSULE;ORAL
ZEMPLAR

ABBVIE	4MCG	N021606 003	May 26, 2005

PAROMOMYCIN SULFATE
CAPSULE;ORAL
HUMATIN

KING PFIZER	EQ 250MG BASE	A062310 001	
PARKEDALE	EQ 250MG BASE	A060521 001	

SYRUP;ORAL
HUMATIN

PARKE DAVIS	EQ 125MG BASE/5ML	A060522 001	

PAROXETINE HYDROCHLORIDE
CAPSULE;ORAL
PAXIL

APOTEX TECHNOLOGIES	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020885 001	Oct 09, 1998
	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020885 002	Oct 09, 1998
	EQ 30MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020885 003	Oct 09, 1998
	EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020885 004	Oct 09, 1998

SUSPENSION;ORAL
PAROXETINE HYDROCHLORIDE

APOTEX INC	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006

TABLET;ORAL
PAROXETINE HYDROCHLORIDE

ROXANE	EQ 10MG BASE	A078026 001	Jun 29, 2007
	EQ 20MG BASE	A078026 002	Jun 29, 2007
	EQ 30MG BASE	A078026 003	Jun 29, 2007
	EQ 40MG BASE	A078026 004	Jun 29, 2007
TEVA PHARMS	EQ 10MG BASE	A077082 001	Jun 29, 2007
	EQ 20MG BASE	A077082 002	Jun 29, 2007
	EQ 30MG BASE	A077082 003	Jun 29, 2007
	EQ 40MG BASE	A077082 004	Jun 29, 2007
UPSHER-SMITH LABS	EQ 10MG BASE	A075566 001	Mar 08, 2004
	EQ 20MG BASE	A075566 002	Mar 08, 2004
	EQ 30MG BASE	A075566 003	Mar 08, 2004
	EQ 40MG BASE	A075566 004	Mar 08, 2004

PAXIL

APOTEX TECHNOLOGIES	EQ 50MG BASE	N020031 004	Dec 29, 1992

PAZOPANIB HYDROCHLORIDE
TABLET;ORAL
VOTRIENT

NOVARTIS PHARMS CORP	EQ 400MG BASE	N022465 002	Oct 19, 2009

PEGINESATIDE ACETATE
SOLUTION;INTRAVENOUS, SUBCUTANEOUS
OMONTYS

TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012
	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012
	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012

FDA data supplied by DrugPatentWatch.com

PEGINESATIDE ACETATE
SOLUTION;INTRAVENOUS, SUBCUTANEOUS
OMONTYS PRESERVATIVE FREE

	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012

PEMIROLAST POTASSIUM
SOLUTION/DROPS;OPHTHALMIC
ALAMAST

SANTEN	0.1%	N021079 001	Sep 24, 1999

PEMOLINE
TABLET;ORAL
CYLERT

ABBOTT	18.75MG	N016832 001	
	37.5MG	N016832 002	
	75MG	N016832 003	

PEMOLINE

ACTAVIS ELIZABETH	18.75MG	A075595 001	Feb 28, 2000
	37.5MG	A075595 002	Feb 28, 2000
	75MG	A075595 003	Feb 28, 2000
MALLINCKRODT	18.75MG	A075726 003	Mar 30, 2001
	37.5MG	A075726 002	Mar 30, 2001
	75MG	A075726 001	Mar 30, 2001
SANDOZ	18.75MG	A075286 001	Dec 27, 1999
	37.5MG	A075286 002	Jun 30, 1999
	75MG	A075286 003	Jun 30, 1999
TEVA PHARMS	18.75MG	A075030 003	Feb 22, 2000
	37.5MG	A075030 001	Jan 29, 1999
	75MG	A075030 002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328 001	Apr 19, 2000
	37.5MG	A075328 002	Apr 19, 2000
	75MG	A075328 003	Apr 19, 2000
WATSON LABS	18.75MG	A075287 001	Jun 13, 2001
	37.5MG	A075287 002	Sep 18, 2000
	75MG	A075287 003	Sep 18, 2000

TABLET, CHEWABLE;ORAL
CYLERT

ABBOTT	37.5MG	N017703 001	

PEMOLINE

ACTAVIS ELIZABETH	37.5MG	A075678 001	Jul 26, 2000
TEVA PHARMS	37.5MG	A075555 001	Feb 18, 2000

PENBUTOLOL SULFATE
TABLET;ORAL
LEVATOL

AUXILIUM PHARMS LLC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018976 001	Dec 30, 1987
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018976 004	Jan 05, 1989

PENICILLAMINE
CAPSULE;ORAL
CUPRIMINE

ATON	125MG	N019853 002	

PENICILLIN G BENZATHINE
INJECTABLE;INJECTION
BICILLIN L-A

WYETH AYERST	300,000 UNITS/ML	N050131 001	

SUSPENSION;ORAL
BICILLIN

WYETH AYERST	300,000 UNITS/5ML	N050126 002	

TABLET;ORAL
BICILLIN

WYETH AYERST	200,000 UNITS	N050128 001	

FDA data supplied by DrugPatentWatch.com

PENICILLIN G POTASSIUM

FOR SOLUTION;ORAL			
PENICILLIN			
TEVA	200,000 UNITS/5ML	A060307 002	
	400,000 UNITS/5ML	A060307 004	
PENICILLIN G POTASSIUM			
MYLAN	200,000 UNITS/5ML	A060752 003	
	250,000 UNITS/5ML	A060752 002	
	400,000 UNITS/5ML	A060752 001	
PUREPAC PHARM	250,000 UNITS/5ML	A061740 001	
	400,000 UNITS/5ML	A061740 002	
PENICILLIN-2			
TEVA	250,000 UNITS/5ML	A060307 003	
PENTIDS '200'			
APOTHECON	200,000 UNITS/5ML	A062149 001	
PENTIDS '400'			
APOTHECON	400,000 UNITS/5ML	A062149 002	
PFIZERPEN G			
PFIZER	400,000 UNITS/5ML	A060587 001	
INJECTABLE;INJECTION			
PENICILLIN G POTASSIUM			
APOTHECON	1,000,000 UNITS/VIAL	A060362 001	
	5,000,000 UNITS/VIAL	A060362 003	
	10,000,000 UNITS/VIAL	A060362 004	
	20,000,000 UNITS/VIAL	A060362 002	
CONSOLIDATED PHARM	500,000 UNITS/VIAL	A060806 001	
	1,000,000 UNITS/VIAL	A060806 002	
	5,000,000 UNITS/VIAL	A060806 003	
	10,000,000 UNITS/VIAL	A060806 004	
LILLY	200,000 UNITS/VIAL	A060384 004	
	500,000 UNITS/VIAL	A060384 003	
	1,000,000 UNITS/VIAL	A060384 002	
	5,000,000 UNITS/VIAL	A060384 001	
	20,000,000 UNITS/VIAL	A060384 005	
	20,000,000 UNITS/VIAL	A060601 001	
PARKE DAVIS	1,000,000 UNITS/VIAL	A062003 001	
	5,000,000 UNITS/VIAL	A062003 002	
PFIZER	20,000,000 UNITS/VIAL	A060074 003	
SANDOZ	1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A065079 001	Aug 30, 2002
WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001	Sep 13, 1988
	5,000,000 UNITS/VIAL	A062991 002	Sep 13, 1988
	10,000,000 UNITS/VIAL	A062991 003	Sep 13, 1988
	20,000,000 UNITS/VIAL	A062991 004	Sep 13, 1988
PFIZERPEN			
PFIZER	1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060657 001	
TABLET;ORAL			
PENICILLIN G POTASSIUM			
APOTHECON	250,000 UNITS	A060392 003	
IVAX SUB TEVA PHARMS	400,000 UNITS	A060073 004	
LILLY	250,000 UNITS	A060403 001	
MYLAN	200,000 UNITS	A060781 001	
	250,000 UNITS	A060781 002	
	400,000 UNITS	A060781 003	
	500,000 UNITS	A060781 005	
	800,000 UNITS	A060781 004	
PUREPAC PHARM	200,000 UNITS	A061588 001	
	250,000 UNITS	A061588 002	
	400,000 UNITS	A061588 003	
TEVA	200,000 UNITS	A060306 001	
	250,000 UNITS	A060306 002	
	400,000 UNITS	A060306 003	
	500,000 UNITS	A060306 004	
WYETH AYERST	200,000 UNITS	A060413 001	
	250,000 UNITS	A060413 002	
	400,000 UNITS	A060413 003	
PENTIDS '200'			
APOTHECON	200,000 UNITS	A062155 001	

FDA data supplied by DrugPatentWatch.com

PENICILLIN G POTASSIUM
TABLET;ORAL

PENTIDS '250'			
	APOTHECON	250,000 UNITS	A062155 002
PENTIDS '400'			
	APOTHECON	400,000 UNITS	A060392 004
		400,000 UNITS	A062155 003
PENTIDS '800'			
	APOTHECON	800,000 UNITS	A060392 005
		800,000 UNITS	A062155 004
PFIZERPEN G			
	PFIZER	50,000 UNITS	A060075 001
		100,000 UNITS	A060075 002
		200,000 UNITS	A060075 003
		250,000 UNITS	A060075 004
		400,000 UNITS	A060075 005
		800,000 UNITS	A060075 006

PENICILLIN G PROCAINE
INJECTABLE;INJECTION

DURACILLIN A.S.			
	LILLY	300,000 UNITS/ML	A060093 001
PENICILLIN G PROCAINE			
	CONSOLIDATED PHARM	300,000 UNITS/ML	A060800 001
		600,000 UNITS/1.2ML	A060800 002
	PARKE DAVIS	300,000 UNITS/ML	A062029 001
	PFIZER	300,000 UNITS/VIAL	A060099 001
		1,500,000 UNITS/VIAL	A060099 002
PFIZERPEN-AS			
	PFIZER	300,000 UNITS/ML	A060286 001
		600,000 UNITS/ML	A060286 002

PENICILLIN G SODIUM
INJECTABLE;INJECTION

PENICILLIN G SODIUM			
	BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935 001
	COPANOS	5,000,000 UNITS/VIAL	A061051 001
	PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046 001

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM				
	WATSON LABS INC	5,000,000 UNITS/VIAL	A063014 001	Sep 13, 1988

PENICILLIN V
FOR SUSPENSION;ORAL

V-CILLIN			
	LILLY	125MG/0.6ML	A060002 001

PENICILLIN V POTASSIUM
FOR SOLUTION;ORAL

BEEPEN-VK			
	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A062270 001
		EQ 250MG BASE/5ML	A062270 002
BETAPEN-VK			
	APOTHECON	EQ 125MG BASE/5ML	A061149 001
		EQ 250MG BASE/5ML	A061149 002
LEDERCILLIN VK			
	LEDERLE	EQ 125MG BASE/5ML	A060136 001
		EQ 250MG BASE/5ML	A060136 002
PEN-VEE K			
	WYETH AYERST	EQ 125MG BASE/5ML	A060007 001
		EQ 250MG BASE/5ML	A060007 002
PENAPAR-VK			
	PARKE DAVIS	EQ 125MG BASE/5ML	A062002 001
		EQ 250MG BASE/5ML	A062002 002
PENICILLIN V POTASSIUM			
	AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061529 001
		EQ 250MG BASE/5ML	A061529 002
	MYLAN	EQ 125MG BASE/5ML	A061624 002
		EQ 250MG BASE/5ML	A061624 001
	PUREPAC PHARM	EQ 125MG BASE/5ML	A061758 001
		EQ 250MG BASE/5ML	A061758 002
PFIZERPEN VK			
	PFIZER	EQ 125MG BASE/5ML	A061815 001
		EQ 250MG BASE/5ML	A061815 002

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL			
V-CILLIN K			
	LILLY	EQ 125MG BASE/5ML	A060004 001
		EQ 250MG BASE/5ML	A060004 002
VEETIDS			
	APOTHECON	EQ 125MG BASE/5ML	A061410 001
		EQ 250MG BASE/5ML	A061410 002
VEETIDS '125'			
	APOTHECON	EQ 125MG BASE/5ML	A061206 001
		EQ 125MG BASE/5ML	A062153 001
VEETIDS '250'			
	APOTHECON	EQ 250MG BASE/5ML	A061206 002
		EQ 250MG BASE/5ML	A062153 002
TABLET;ORAL			
BEEPEN-VK			
	GLAXOSMITHKLINE	EQ 250MG BASE	A062273 001
		EQ 500MG BASE	A062273 002
BETAPEN-VK			
	BRISTOL	EQ 250MG BASE	A061150 001
		EQ 500MG BASE	A061150 002
LEDERCILLIN VK			
	LEDERLE	EQ 250MG BASE	A060134 001
		EQ 500MG BASE	A060134 002
PEN-VEE K			
	WYETH AYERST	EQ 125MG BASE	A060006 001
		EQ 250MG BASE	A060006 002
		EQ 500MG BASE	A060006 003
PENAPAR-VK			
	PARKE DAVIS	EQ 250MG BASE	A062001 001
		EQ 500MG BASE	A062001 002
PENICILLIN V POTASSIUM			
	AM ANTIBIOTICS	EQ 250MG BASE	A061528 001
		EQ 500MG BASE	A061528 002
	IVAX SUB TEVA PHARMS	EQ 125MG BASE	A060518 001
		EQ 250MG BASE	A060518 002
		EQ 500MG BASE	A060518 003
	MYLAN	EQ 250MG BASE	A061530 001
		EQ 500MG BASE	A061530 002
	PUREPAC PHARM	EQ 125MG BASE	A061571 001
		EQ 250MG BASE	A061571 002
		EQ 500MG BASE	A061571 003
PFIZERPEN VK			
	PFIZER	EQ 250MG BASE	A061836 001
		EQ 500MG BASE	A061836 002
UTICILLIN VK			
	PHARMACIA AND UPJOHN	EQ 250MG BASE	A061651 001
		EQ 500MG BASE	A061651 002
V-CILLIN K			
	LILLY	EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060003 001
		EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060003 002
		EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060003 003
VEETIDS			
	APOTHECON	EQ 250MG BASE	A061411 001
		EQ 500MG BASE	A061411 002
VEETIDS '250'			
	APOTHECON	EQ 250MG BASE	A061164 001
		EQ 250MG BASE	A062156 002
VEETIDS '500'			
	APOTHECON	EQ 500MG BASE	A061164 002
		EQ 500MG BASE	A062156 001

FDA data supplied by DrugPatentWatch.com

PENTAGASTRIN
INJECTABLE;INJECTION
PEPTAVLON

WYETH AYERST	0.25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017048 001	

PENTAMIDINE ISETHIONATE
FOR SOLUTION;INHALATION
NEBUPENT

FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996

INJECTABLE;INJECTION
PENTACARINAT

ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992
WATSON LABS	300MG/VIAL	A074303 001	Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE
TABLET;ORAL
TALWIN 50

SANOFI AVENTIS US	EQ 50MG BASE	N016732 001	

PENTETATE CALCIUM TRISODIUM YB-169
INJECTABLE;INJECTION
YTTERBIUM YB 169 DTPA

3M	2mCi/ML	N017518 001	

PENTOBARBITAL
ELIXIR;ORAL
NEMBUTAL

OAK PHARMS	18.2MG/5ML	A083244 001	

PENTOBARBITAL SODIUM
CAPSULE;ORAL
NEMBUTAL SODIUM

OAK PHARMS	30MG	A084095 001	
	50MG	A084093 001	
	100MG	A083245 001	

PENTOBARBITAL SODIUM

LANNETT	50MG	A085937 001	
	100MG	A085915 001	
VITARINE	100MG	A083284 001	
WHITEWORTH TOWN PLSN	100MG	A083338 001	

SODIUM PENTOBARBITAL

ANABOLIC	100MG	A084590 001	
ELKINS SINN	100MG	A083368 001	
EVERYLIFE	100MG	A083259 001	
HALSEY	100MG	A084677 001	
IVAX SUB TEVA PHARMS	50MG	A083461 001	
	100MG	A083461 002	
PARKE DAVIS	100MG	A084156 001	
PERRIGO	100MG	A084560 001	
PUREPAC PHARM	100MG	A083301 001	
VALEANT PHARM INTL	100MG	A083264 001	
WATSON LABS	100MG	A085791 001	
WYETH AYERST	100MG	A083239 001	

INJECTABLE;INJECTION
PENTOBARBITAL SODIUM

ELKINS SINN	50MG/ML	A083270 001	

SODIUM PENTOBARBITAL

WYETH AYERST	50MG/ML	A083261 001	

SUPPOSITORY;RECTAL
NEMBUTAL

OAK PHARMS	30MG	A083247 001	Jan 25, 1982
	60MG	A083247 002	Jan 25, 1982
	120MG	A083247 003	Jan 25, 1982
	200MG	A083247 004	Jan 25, 1982

TABLET;ORAL
PENTOBARBITAL SODIUM

VITARINE	100MG	A083285 001	

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC	100MG	A084238 001	

FDA data supplied by DrugPatentWatch.com

PENTOLINIUM TARTRATE
INJECTABLE;INJECTION
ANSOLYSEN

WYETH AYERST	10MG/ML	N009372 001	

PENTOXIFYLLINE
TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

ACTAVIS ELIZABETH	400MG	A074878 001	Jul 09, 1997
HERITAGE PHARMS INC	400MG	A074877 001	Jul 08, 1997
IMPAX LABS	400MG	A075093 001	Aug 10, 1999
PLIVA	400MG	A074874 001	May 25, 1999
TEVA	400MG	A075199 001	Sep 03, 1999
WATSON LABS	400MG	A075107 001	Sep 04, 1998

TRENTAL

US PHARM HOLDINGS	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018631 001	Aug 30, 1984

PERFLUBRON
LIQUID;ORAL
IMAGENT

ALLIANCE PHARM	100%	N020091 001	Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE
PASTE;TOPICAL
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY	50%;50%	N021084 001	Feb 17, 2000

PERGOLIDE MESYLATE
TABLET;ORAL
PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094 001	Sep 04, 2003
	EQ 0.25MG BASE	A076094 002	Sep 04, 2003
	EQ 1MG BASE	A076094 003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE	A076061 001	Nov 27, 2002
	EQ 0.25MG BASE	A076061 002	Nov 27, 2002
	EQ 1MG BASE	A076061 003	Nov 27, 2002

PERMAX

VALEANT PHARM INTL	EQ 0.05MG BASE	N019385 001	Dec 30, 1988
	EQ 0.25MG BASE	N019385 002	Dec 30, 1988
	EQ 1MG BASE	N019385 003	Dec 30, 1988

PERINDOPRIL ERBUMINE
TABLET;ORAL
PERINDOPRIL ERBUMINE

LUPIN LTD	2MG	A078263 001	Jan 27, 2010
	4MG	A078263 002	Jan 27, 2010
	8MG	A078263 003	Jan 27, 2010

PERMETHRIN
LOTION;TOPICAL
NIX

GLAXOSMITHKLINE	1%	N019435 001	Mar 31, 1986

PERPHENAZINE
CONCENTRATE;ORAL
PERPHENAZINE

PHARM ASSOC	16MG/5ML	A040360 001	May 25, 2001

TRILAFON

SCHERING	16MG/5ML	N011557 001	

INJECTABLE;INJECTION
TRILAFON

SCHERING	5MG/ML	N011213 002	

SYRUP;ORAL
TRILAFON

SCHERING	2MG/5ML	N011294 002	

TABLET;ORAL
PERPHENAZINE

ANI PHARMS INC	2MG	A089707 001	Sep 10, 1987
	8MG	A089456 001	Sep 10, 1987
	16MG	A089457 001	Sep 10, 1987
TEVA PHARMS USA	4MG	A089708 001	Sep 10, 1987

TRILAFON

SCHERING	2MG **Federal Register determination	N010775 001	

FDA data supplied by DrugPatentWatch.com

PERPHENAZINE

TABLET;ORAL			
TRILAFON			
	that product was not discontinued or withdrawn for safety or efficacy reasons**		
	4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010775 002	
	8MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010775 003	
	16MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010775 004	
TABLET, EXTENDED RELEASE;ORAL			
TRILAFON			
SCHERING	8MG	N011361 002	

PHENACEMIDE

TABLET;ORAL			
PHENURONE			
ABBVIE	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007707 001	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET;ORAL			
AZO GANTANOL			
ROCHE	100MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013294 001	Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL			
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE			
ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105 001	Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET;ORAL			
AZO GANTRISIN			
ROCHE	50MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019358 001	Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL			
PHENAZINE			
MAST MM	35MG	A086523 001	
	35MG	A086524 001	
	35MG	A086525 001	
PHENDIMETRAZINE TARTRATE			
SANDOZ	35MG	A085633 001	
	35MG	A085694 001	
	35MG	A085695 001	
	35MG	A085702 001	
VITARINE	35MG	A085634 001	
	35MG	A085645 001	
	35MG	A085670 001	
	35MG	A086403 001	
	35MG	A086408 001	
	35MG	A086410 001	
	35MG	A087424 001	
SPRX-3			
SOLVAY	35MG	A085897 001	
STATOBEX			
TEVA	35MG	A085507 001	
X-TROZINE			
SHIRE RICHWOOD	35MG	A087394 001	Sep 22, 1982

FDA data supplied by DrugPatentWatch.com

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

BONTRIL				
VALEANT	105MG	A088021	001	Sep 21, 1982
MELFIAT-105				
NUMARK	105MG	A087487	001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
SANDOZ	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982

TABLET;ORAL

ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
TG UNITED LABS	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	
	35MG	A084743	001	
IVAX PHARMS	35MG	A085611	001	
	35MG	A085612	001	
IVAX SUB TEVA PHARMS	35MG	A083682	001	
KV PHARM	35MG	A084138	001	
	35MG	A084141	001	
	35MG	A085525	001	
MFG CHEMISTS	35MG	A085914	001	
NEXGEN PHARMA INC	35MG	A086020	001	
NUMARK	35MG	A083790	001	
PVT FORM	35MG	A085199	001	
	35MG	A085697	001	
SANDOZ	35MG	A085402	001	
	35MG	A085497	001	
	35MG	A085830	001	
	35MG	A086365	001	
	35MG	A086370	001	
SOLVAY	35MG	A083993	001	
TG UNITED LABS	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983

PHENDIMETRAZINE TARTRATE
TABLET;ORAL
PHENDIMETRAZINE TARTRATE

USL PHARMA	35MG	A083805 001	
	35MG	A084398 001	
	35MG	A084399 001	
VITARINE	35MG	A085519 001	
	35MG	A086005 001	
	35MG	A086106 001	
WATSON LABS	35MG	A085767 001	
	35MG	A085768 001	
	35MG	A085770 001	
	35MG	A085773 001	

PLEGINE

WYETH AYERST	35MG	N012248 001	

STATOBEX

TEVA	35MG	A086013 001	

STATOBEX-G

TEVA	35MG	A085095 001	

X-TROZINE

SHIRE RICHWOOD	35MG	A086550 001	
	35MG	A086551 001	
	35MG	A086552 001	
	35MG	A086553 001	
	35MG	A086554 001	

PHENINDIONE
TABLET;ORAL
HEDULIN

SANOFI AVENTIS US	50MG	N008767 002	

PHENMETRAZINE HYDROCHLORIDE
TABLET;ORAL
PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460 005	

TABLET, EXTENDED RELEASE;ORAL
PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752 004	
	75MG	N011752 003	

PHENPROCOUMON
TABLET;ORAL
LIQUAMAR

ORGANON USA INC	3MG	N011228 001	

PHENSUXIMIDE
CAPSULE;ORAL
MILONTIN

PARKE DAVIS	500MG	N008855 004	

PHENTERMINE HYDROCHLORIDE
CAPSULE;ORAL
FASTIN

GLAXOSMITHKLINE	30MG	N017352 001	

OBESTIN-30

FERNDALE LABS	30MG	A087144 001	

OBY-TRIM

SHIRE RICHWOOD	30MG	A087764 001	Mar 18, 1982

ONA-MAST

MAST MM	30MG	A086511 001	
	30MG	A086516 001	

PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG	A085411 001	
ABLE	15MG	A040497 001	Mar 13, 2003
	30MG	A040403 001	Aug 30, 2001
	30MG	A040427 001	Aug 30, 2001
CAMALL	15MG	A086735 001	
	30MG	A087226 001	
DURAMED PHARMS BARR	30MG	A088948 001	Apr 25, 1986
IVAX PHARMS	30MG	A086329 001	
MIKAH PHARMA	15MG	A040460 001	Jan 14, 2003
	30MG	A040227 001	Jun 18, 1997
	30MG	A040448 001	Jan 22, 2003
SANDOZ	30MG	A087208 001	
	30MG	A087223 001	

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL				
PHENTERMINE HYDROCHLORIDE				
		37.5MG	A088414 001	Oct 19, 1983
	SUN PHARM INDS	37.5MG	A040527 001	Oct 23, 2003
	TEVA	30MG	A086911 001	
		30MG	A087126 001	
		30MG	A087777 001	Nov 01, 1985
		30MG	A088612 001	Apr 04, 1984
		30MG	A088613 001	Apr 09, 1984
		30MG	A088614 001	Apr 09, 1984
	TG UNITED INC	30MG	A040083 001	Mar 07, 1997
	TG UNITED LABS	18.75MG	A088576 001	May 23, 1984
		30MG	A085417 001	
		30MG	A086732 002	
		30MG	A087215 001	
		37.5MG	A087915 001	Dec 22, 1983
		37.5MG	A087918 001	Dec 22, 1983
		37.5MG	A087930 001	Oct 14, 1983
		37.5MG	A088610 001	Jun 04, 1984
		37.5MG	A088611 001	Jun 04, 1984
		37.5MG	A088625 001	Aug 23, 1984
	USL PHARMA	30MG	A084487 001	Apr 09, 1982
		30MG	A088430 001	Mar 27, 1984
		30MG	A088797 001	Dec 10, 1984
	VITARINE	30MG	A087202 001	
		30MG	A087235 001	
	WATSON LABS	30MG	A086740 001	Mar 21, 1985
TABLET;ORAL				
ONA-MAST				
	MAST MM	8MG	A086260 001	
PHENTERMINE HYDROCHLORIDE				
	ABLE	37.5MG	A040402 001	Aug 30, 2001
	ACTAVIS ELIZABETH	37.5MG	A040276 001	Nov 25, 1998
	IVAX PHARMS	8MG	A085553 001	
	SANDOZ	8MG	A085671 001	
		8MG	A085689 001	
	SANDOZ INC	30MG	A088605 001	Sep 28, 1987
	TG UNITED LABS	8MG	A083923 001	
		8MG	A085319 001	
		37.5MG	A087805 001	Dec 06, 1982
		37.5MG	A088596 001	Apr 04, 1984
	USL PHARMA	8MG	A083804 001	
		37.5MG	A088910 001	Jul 17, 1985
		37.5MG	A088917 001	Jul 17, 1985
	VITARINE	8MG	A086453 001	
		8MG	A086456 001	
	WATSON LABS	8MG	A085739 001	
TORA				
	SOLVAY	8MG	A084035 001	
WILPO				
	SANDOZ	8MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012737 001	
TABLET, ORALLY DISINTEGRATING;ORAL				
SUPRENZA				
	CITIUS PHARMS	15MG	N202088 001	Jun 13, 2011
		30MG	N202088 002	Jun 13, 2011
		37.5MG	N202088 003	Mar 27, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL				
IONAMIN				
	UCB INC	EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011613 004	
		EQ 30MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011613 002	
PHENTERMINE RESIN 30				
	QUANTUM PHARMICS	EQ 30MG BASE	A089120 001	Feb 04, 1988

FDA data supplied by DrugPatentWatch.com

PHENTERMINE RESIN COMPLEX
CAPSULE, EXTENDED RELEASE;ORAL
PHENTERMINE RESIN COMPLEX

LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011
	EQ 30MG BASE	A040872 002	Jul 28, 2011

PHENYL AMINOSALICYLATE
POWDER;ORAL
PHENY-PAS-TEBAMIN

PHARM RES ASSOC	50%	N011695 002	

TABLET;ORAL
PHENY-PAS-TEBAMIN

PHARM RES ASSOC	500MG	N011695 003	

PHENYLBUTAZONE
CAPSULE;ORAL
AZOLID

SANOFI AVENTIS US	100MG	A087260 001	

BUTAZOLIDIN

NOVARTIS	100MG	N008319 009	

PHENYLBUTAZONE

IVAX PHARMS	100MG	A088218 001	Jun 24, 1983
SANDOZ	100MG	A087774 001	Jun 16, 1982
SUN PHARM INDS	100MG	A088994 001	Dec 04, 1985
WATSON LABS	100MG	A087756 001	Dec 17, 1982

TABLET;ORAL
AZOLID

SANOFI AVENTIS US	100MG	A087091 001	

BUTAZOLIDIN

NOVARTIS	100MG	N008319 008	

PHENYLBUTAZONE

SANDOZ	100MG	A084339 001	
SUN PHARM INDS	100MG	A088863 001	Dec 04, 1985
WATSON LABS	100MG	A086151 001	
	100MG	A087674 001	Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SYRUP;ORAL
PHENERGAN VC

ANI PHARMS	5MG/5ML;6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008604 003	Apr 02, 1984

PHERAZINE VC

HALSEY	5MG/5ML;6.25MG/5ML	A088868 001	Mar 02, 1987

PROMETHAZINE VC PLAIN

CENCI	5MG/5ML;6.25MG/5ML	A088815 001	Nov 22, 1985
WOCKHARDT	5MG/5ML;6.25MG/5ML	A088897 001	Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE
SOLUTION/DROPS;OPHTHALMIC
PREFRIN-A

ALLERGAN	0.12%;0.1%	N007953 001	

PHENYTOIN
SUSPENSION;ORAL
DILANTIN-30

PARKE DAVIS	30MG/5ML	N008762 002	

PHENYTOIN

ACTAVIS MID ATLANTIC	125MG/5ML	A089892 001	Sep 25, 1992

PHENYTOIN SODIUM
CAPSULE;ORAL
DIPHENYLAN SODIUM

LANNETT	30MG PROMPT	A080857 001	
	100MG PROMPT	A080857 002	

EXTENDED PHENYTOIN SODIUM

ANI PHARMS INC	100MG EXTENDED	A040435 001	Jun 20, 2003
	100MG EXTENDED	A089441 001	Dec 18, 1986
WOCKHARDT	30MG EXTENDED	A040759 001	Dec 18, 2007
WOCKHARDT USA	100MG EXTENDED	A040732 001	Jan 30, 2008

PHENYTEX

WATSON LABS	100MG EXTENDED	A088711 001	Dec 21, 1984

PHENYTOIN SODIUM

PHARMERAL	100MG PROMPT	A085435 001	
WATSON LABS	100MG PROMPT	A085894 001	

FDA data supplied by DrugPatentWatch.com

PHENYTOIN SODIUM
CAPSULE;ORAL
PROMPT PHENYTOIN SODIUM

ANI PHARMS INC	100MG PROMPT	A080259 001	
WATSON LABS	100MG PROMPT	A080905 001	

INJECTABLE;INJECTION
DILANTIN

PARKE DAVIS	50MG/ML	N010151 001	

PHENYTOIN SODIUM

FRESENIUS KABI USA	50MG/ML	A089003 001	May 31, 1985
HOSPIRA	50MG/ML	A089744 001	Dec 18, 1987
MARSAM PHARMS LLC	50MG/ML	A089501 001	Oct 13, 1987
	50MG/ML	A089779 001	Nov 27, 1992
SMITH AND NEPHEW	50MG/ML	A088519 001	Dec 19, 1984
	50MG/ML	A088521 001	Dec 18, 1984
SOLOPAK	50MG/ML	A088520 001	Dec 17, 1984
WARNER CHILCOTT	50MG/ML	A089900 001	Mar 30, 1990
WATSON LABS	50MG/ML	A085434 001	

PHYTONADIONE
INJECTABLE;INJECTION
AQUAMEPHYTON

TELIGENT PHARMA INC	1MG/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012223 002	
	10MG/ML ***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012223 001	

KONAKION

ROCHE	1MG/0.5ML	N011745 001	
	10MG/ML	N011745 003	

PHYTONADIONE

GLAXOSMITHKLINE	1MG/0.5ML	A084060 001	
	10MG/ML	A084060 002	

VITAMIN K1

HOSPIRA	10MG/ML	A087956 001	Jul 25, 1983

PILOCARPINE
INSERT, EXTENDED RELEASE;OPHTHALMIC
OCUSERT PILO-20

AKORN	5MG	N017431 001	

OCUSERT PILO-40

AKORN	11MG	N017548 001	

PILOCARPINE HYDROCHLORIDE
GEL;OPHTHALMIC
PILOPINE HS

ALCON	4%	N018796 001	Oct 01, 1984

PINACIDIL
CAPSULE, EXTENDED RELEASE;ORAL
PINDAC

LEO PHARM	12.5MG	N019456 001	Dec 28, 1989
	25MG	N019456 002	Dec 28, 1989

PINDOLOL
TABLET;ORAL
PINDOLOL

G AND W LABS INC	5MG	A073661 001	Oct 31, 1993
	5MG	A073687 001	Feb 26, 1993
	5MG	A074123 001	Apr 17, 1997
	10MG	A073661 002	Oct 31, 1993
	10MG	A073687 002	Feb 26, 1993
	10MG	A074123 002	Apr 17, 1997
IDT AUSTRALIA LTD	5MG	A073608 001	Mar 29, 1993
	10MG	A073609 001	Mar 29, 1993
MYLAN PHARMS INC	5MG	A074013 001	Sep 24, 1992
	10MG	A074018 001	Sep 24, 1992
NOSTRUM LABS	5MG	A074474 001	Oct 28, 1996
	10MG	A074474 002	Oct 28, 1996
PUREPAC PHARM	5MG	A074125 001	Apr 28, 1993
	10MG	A074125 002	Apr 28, 1993
WATSON LABS	5MG	A074437 001	Feb 27, 1995
	10MG	A074437 002	Feb 27, 1995

FDA data supplied by DrugPatentWatch.com

PINDOLOL
TABLET;ORAL
VISKEN

NOVARTIS	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018285 001	Sep 03, 1982
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018285 002	Sep 03, 1982

PIPECURONIUM BROMIDE
INJECTABLE;INJECTION
ARDUAN

ORGANON USA INC	10MG/VIAL	N019638 001	Jun 26, 1990

PIPERACETAZINE
TABLET;ORAL
QUIDE

DOW PHARM	10MG	N013615 001	
	25MG	N013615 002	

PIPERACILLIN SODIUM
INJECTABLE;INJECTION
PIPRACIL

WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750 001	Oct 13, 1987
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050545 002	
	EQ 3GM BASE/VIAL	A062750 002	Oct 13, 1987
	EQ 3GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050545 003	
	EQ 4GM BASE/VIAL	A062750 003	Oct 13, 1987
	EQ 4GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050545 004	
	EQ 40GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050545 006	Sep 30, 1985

PIPERAZINE CITRATE
SYRUP;ORAL
ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102 001

BRYREL

SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796 001

MULTIFUGE

BLULINE	EQ 500MG BASE/5ML	N009452 001

PIPERAZINE CITRATE

ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774 001
LANNETT	EQ 500MG BASE/5ML	A080963 001
LUITPOLD	EQ 500MG BASE/5ML	A080671 001

VERMIDOL

SOLVAY	EQ 500MG BASE/5ML	A080992 001

TABLET;ORAL
ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE	N009102 003

PIPERAZINE CITRATE

IMPAX LABS	EQ 250MG BASE	A080874 001

PIPERONYL BUTOXIDE; PYRETHRINS
AEROSOL;TOPICAL
RID MOUSSE

BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043 001	Mar 07, 2000

PIPOBROMAN
TABLET;ORAL
VERCYTE

ABBOTT	10MG	N016245 001
	25MG	N016245 002

FDA data supplied by DrugPatentWatch.com

PIRBUTEROL ACETATE
AEROSOL, METERED;INHALATION
MAXAIR

MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992
VALEANT PHARMS	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986

PIROXICAM
CAPSULE;ORAL
PIROXICAM

CYCLE PHARMS LTD	10MG	A073651	001	Feb 26, 1993
	20MG	A073651	002	Feb 26, 1993
EGIS	10MG	A074808	001	Jul 08, 1997
	20MG	A074808	002	Jul 08, 1997
IVAX SUB TEVA PHARMS	10MG	A074148	001	Jun 03, 1996
	20MG	A074148	002	Jun 03, 1996
MYLAN	10MG	A074043	001	Sep 22, 1992
	20MG	A074043	002	Sep 22, 1992
SCS	10MG	A074036	001	May 29, 1992
	20MG	A074036	002	May 29, 1992
SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993
TEVA	10MG	A073637	001	Jan 28, 1994
	20MG	A073638	001	Jan 28, 1994
TEVA PHARMS	10MG	A074103	001	Aug 28, 1992
	20MG	A074103	002	Aug 28, 1992
WATSON LABS	10MG	A074287	001	May 16, 1996
	10MG	A074460	001	Sep 29, 1995
	20MG	A074287	002	May 16, 1996
	20MG	A074460	002	Sep 29, 1995

PLICAMYCIN
INJECTABLE;INJECTION
MITHRACIN

PFIZER	2.5MG/VIAL	N050109	001	

POLYESTRADIOL PHOSPHATE
INJECTABLE;INJECTION
ESTRADURIN

WYETH AYERST	40MG/AMP	N010753	001	

POLYETHYLENE GLYCOL 3350
FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350

PADDOCK LLC	17GM/SCOOPFUL	A090567	001	Oct 15, 2009
TEVA PHARMS	17GM/SCOOPFUL	A077445	001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
FOR SOLUTION;ORAL
CLENZ-LYTE

PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769	001	Jun 07, 2010

SOLUTION;ORAL
OCL

HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML	N019284	001	Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS
FOR SOLUTION;ORAL
COLYTE

MEDA PHARMS	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984
	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984
	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987
	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984

COLYTE-FLAVORED

MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712	001	Feb 25, 2010

FDA data supplied by DrugPatentWatch.com

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION;ORAL				
CO-LAV				
	VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428 001	Jan 28, 1992
COLOVAGE				
	DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	A071320 001	Apr 20, 1988
E-Z-EM PREP LYTE				
	E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A071278 001	Nov 21, 1988
GLYCOPREP				
	GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A072319 001	Dec 23, 1988
GO-EVAC				
	VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433 001	Apr 28, 1992
PEG-LYTE				
	SANDOZ	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073098 001	Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE;INJECTION				
AEROSPORIN				
	GLAXOSMITHKLINE	EQ 500,000 U BASE/VIAL	A062036 001	
POWDER;FOR RX COMPOUNDING				
POLY-RX				
	X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001	
POLYMYXIN B SULFATE				
	PADDOCK LLC	100,000,000 UNITS/BOT	A062455 001	Jul 27, 1983

POLYTHIAZIDE

TABLET;ORAL				
RENESE				
	PFIZER	1MG	N012845 001	
		2MG	N012845 002	
		4MG	N012845 003	

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL				
MINIZIDE				
	PFIZER	0.5MG;EQ 1MG BASE	N017986 001	
		0.5MG;EQ 2MG BASE	N017986 002	
		0.5MG;EQ 5MG BASE	N017986 003	

POLYTHIAZIDE; RESERPINE

TABLET;ORAL				
RENESE-R				
	PFIZER	2MG;0.25MG	N013636 001	

POTASSIUM AMINOSALICYLATE

CAPSULE;ORAL				
PASKALIUM				
	GLENWOOD	500MG	N009395 004	
POWDER;ORAL				
POTASSIUM AMINOSALICYLATE				
	HEXCEL	100%	A080098 001	
TABLET;ORAL				
PASKALIUM				
	GLENWOOD	1GM	N009395 003	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
K-LEASE				
	SAVAGE LABS	8MEQ	A073398 001	Jan 28, 1992
		10MEQ	A072427 001	Mar 28, 1990
POTASSIUM CHLORIDE				
	NESHER PHARMS	10MEQ	A070980 001	Feb 17, 1987
	TEVA	8MEQ	A073531 001	Apr 26, 1996
		10MEQ	A073532 001	Apr 26, 1996
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
MICRO-K LS				
	KV PHARM	20MEQ/PACKET	N019561 003	Aug 26, 1988

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM	2MEQ/ML	A080204 001	
	2MEQ/ML	A084290 001	
	2MEQ/ML	A086713 001	
	2MEQ/ML	A086714 001	
	2MEQ/ML	A087787 001	Apr 20, 1982
	2MEQ/ML	A087885 001	Feb 03, 1983
AKORN	2MEQ/ML	A088286 001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203 001	
FRESENIUS KABI USA	2MEQ/ML	A087817 001	Oct 20, 1982
GD SEARLE LLC	1MEQ/ML	A086219 001	
	2MEQ/ML	A086219 002	
	2MEQ/ML	A086220 002	
	3MEQ/ML	A086219 003	
	3MEQ/ML	A086220 001	
	4MEQ/ML	A086219 004	
HOSPIRA	1MEQ/ML	A080205 003	
	1MEQ/ML	A083345 003	
	1.5MEQ/ML	A083345 001	
	2MEQ/ML	A083345 002	
	2.4MEQ/ML	A080205 004	
	3.2MEQ/ML	A080205 005	
INTL MEDICATION	2MEQ/ML	A083163 001	
LILLY	2MEQ/ML	N007865 002	
LUITPOLD	2MEQ/ML	A080221 001	
	2MEQ/ML	A080736 001	
	2MEQ/ML	A087584 001	
	2MEQ/ML	A087585 001	
MILES	1MEQ/ML	A080195 002	
	2MEQ/ML	A080195 001	
	3MEQ/ML	A080195 003	
	4MEQ/ML	A080195 004	
PHARMA SERVE NY	2MEQ/ML	A086297 001	
	2MEQ/ML	A087362 001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208 001	
	2MEQ/ML	A089163 001	Mar 10, 1988
	2MEQ/ML	A089421 001	Jan 02, 1987
	3MEQ/ML	A086210 001	

TABLET, EXTENDED RELEASE;ORAL

K+10

FUTURE PAK	10MEQ	A070999 001	Oct 22, 1987

K+8

FUTURE PAK	8MEQ	A070998 001	Jan 25, 1993

KAON CL

SAVAGE LABS	6.7MEQ	N017046 001	

KAON CL-10

SAVAGE LABS	10MEQ	N017046 002	

KLOTRIX

APOTHECON	10MEQ	N017850 001	

POTASSIUM CHLORIDE

COPLEY PHARM	8MEQ	A070618 001	Sep 09, 1987
NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002
SCHERING	10MEQ **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019439 002	Jun 13, 1986
	20MEQ **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019439 001	Jun 13, 1986

SLOW-K

NOVARTIS	8MEQ	N017476 002	

TEN-K

NOVARTIS	10MEQ	N019381 001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML;900MG/100ML	N019708 001	Sep 29, 1989

POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	75MG/100ML;900MG/100ML	N019708 002	Sep 29, 1989

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	110MG/100ML;900MG/100ML	N019708 003	Sep 29, 1989

POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	220MG/100ML;900MG/100ML	N019708 005	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	300MG/100ML;900MG/100ML	N019708 006	Sep 29, 1989

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	75MG/100ML;900MG/100ML	N018722 001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648 004	

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	150MG/100ML;900MG/100ML	N018722 002	Nov 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	220MG/100ML;900MG/100ML	N018722 003	Nov 09, 1982

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	300MG/100ML;900MG/100ML	N018722 004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE;INJECTION

THAM-E

HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025 001	

POTASSIUM CITRATE

FOR SOLUTION;ORAL

POTASSIUM CITRATE

UT SW MEDCTR	10MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019647 002	Oct 13, 1988
	20MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019647 001	Oct 13, 1988

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

ROXANE	1GM/ML	N018551 001	Feb 19, 1982

TABLET;ORAL

THYRO-BLOCK

MEDA PHARMS	130MG	N018307 001	

POTASSIUM PERCHLORATE

CAPSULE;ORAL

PERCHLORACAP

MALLINCKRODT	200MG	N017551 001	

POVIDONE-IODINE

SOLUTION;TOPICAL

E-Z PREP

CLINIPAD	10%	N019382 001	Jul 25, 1989

SPONGE;TOPICAL

E-Z PREP

CLINIPAD	5%	N019382 002	Jul 25, 1989

E-Z PREP 220

CLINIPAD	5%	N019382 003	Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP	300MG/ML	N018799 001	Dec 13, 1982

TABLET;ORAL

PROTOPAM CHLORIDE

WYETH AYERST	500MG	N014122 002	

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

MIRAPEX

BOEHRINGER INGELHEIM	1.25MG	N020667 004	Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

WATSON LABS	0.125MG	A078551 001	Oct 08, 2010
	0.25MG	A078551 002	Oct 08, 2010
	0.5MG	A078551 003	Oct 08, 2010
	1MG	A078551 004	Oct 08, 2010
	1.5MG	A078551 005	Oct 08, 2010

FDA data supplied by DrugPatentWatch.com

PRAMLINTIDE ACETATE
INJECTABLE;SUBCUTANEOUS
SYMLIN

ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332 001	Mar 16, 2005

PRAVASTATIN SODIUM
TABLET;ORAL
PRAVACHOL

BRISTOL MYERS SQUIBB	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019898 002	Oct 31, 1991

PRAVASTATIN SODIUM

MYLAN	10MG	A077013 001	Oct 23, 2006
	20MG	A077013 002	Oct 23, 2006
	40MG	A077013 003	Oct 23, 2006
	80MG	A077013 004	Dec 28, 2007
PLIVA HRVATSKA DOO	10MG	A077730 001	Nov 21, 2006
	20MG	A077730 002	Nov 21, 2006
	30MG	A077730 003	Nov 21, 2006
	40MG	A077730 005	Nov 21, 2006
RANBAXY LABS LTD	10MG	A076445 001	Apr 23, 2007
	20MG	A076445 002	Apr 23, 2007
	40MG	A076445 003	Apr 23, 2007
	80MG	A076445 004	Apr 23, 2007

PRAZEPAM
CAPSULE;ORAL
CENTRAX

PARKE DAVIS	5MG	N018144 001	
	10MG	N018144 002	
	20MG	N018144 003	May 10, 1982

PRAZEPAM

USL PHARMA	5MG	A070427 001	Nov 06, 1987
	10MG	A070428 001	Nov 06, 1987

TABLET;ORAL
CENTRAX

PARKE DAVIS	10MG	N017415 001	

PRAZOSIN HYDROCHLORIDE
CAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

AM THERAP	EQ 1MG BASE	A072782 001	May 16, 1989
	EQ 2MG BASE	A072783 001	May 16, 1989
	EQ 5MG BASE	A072784 001	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705 001	May 16, 1989
	EQ 2MG BASE	A072706 001	May 16, 1989
	EQ 5MG BASE	A072707 001	May 16, 1989
IDT AUSTRALIA LTD	EQ 1MG BASE	A072576 001	May 16, 1989
	EQ 2MG BASE	A072577 001	May 16, 1989
	EQ 5MG BASE	A072578 001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991 001	May 16, 1989
	EQ 2MG BASE	A072921 001	May 16, 1989
	EQ 5MG BASE	A072992 001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352 001	May 16, 1989
	EQ 2MG BASE	A072333 001	May 16, 1989
	EQ 5MG BASE	A072609 001	May 16, 1989

TABLET, EXTENDED RELEASE;ORAL
MINIPRESS XL

PFIZER	2.5MG	N019775 001	Jan 29, 1992
	5MG	N019775 002	Jan 29, 1992

PREDNISOLONE
CREAM;TOPICAL
METI-DERM

SCHERING	0.5%	N010209 002	

SYRUP;ORAL
PREDNISOLONE

APOTEX INC	5MG/5ML	A040570 001	Aug 25, 2005
	15MG/5ML	A040571 001	Aug 25, 2005
IVAX SUB TEVA PHARMS	15MG/5ML	A040287 001	May 28, 1999
NESHER PHARMS	5MG/5ML	A040423 001	Oct 22, 2001
	15MG/5ML	A040364 001	Apr 10, 2002
TEVA PHARMS	15MG/5ML	A040322 001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192 001	May 28, 1998

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE

SYRUP;ORAL				
PRELONE				
	MURO	5MG/5ML	A089654 001	Jan 17, 1989
TABLET;ORAL				
CORTALONE				
	HALSEY	1MG	A080304 003	
		2.5MG	A080304 002	
		5MG	A080304 001	
DELTA-CORTEF				
	PHARMACIA AND UPJOHN	5MG	N009987 004	
FERNISOLONE-P				
	FERNDALE LABS	5MG	A083941 001	
PREDNISOLONE				
	AUROLIFE PHARMA LLC	5MG	A084773 001	
	BARR	5MG	A084426 002	
	BUNDY	5MG	A083675 001	
	ELKINS SINN	5MG	A080625 001	
	EVERYLIFE	1MG	A084439 001	
		2.5MG	A084439 002	
		5MG	A084439 003	
	FERRANTE	2.5MG	A080562 001	
		5MG	A080562 002	
	HEATHER	5MG	A080326 001	
	IMPAX LABS	5MG	A080780 001	
	INWOOD LABS	5MG	A080748 001	
	IVAX SUB TEVA PHARMS	5MG	A080378 001	
	LANNETT	5MG	A080531 002	
	MARSHALL PHARMA	5MG	A080307 001	
	PANRAY	1MG	A080351 001	
		5MG	A080351 002	
	PERRIGO	5MG	A084542 001	
	PHOENIX LABS NY	5MG	A080322 001	
	PUREPAC PHARM	5MG	A080325 001	
	PVT FORM	5MG	A080211 001	
	ROXANE	5MG	A080327 002	
	SANDOZ	5MG	A080339 001	
	SPERTI	1MG	A080358 001	
		2.5MG	A080358 002	
		5MG	A080358 003	
	SUPERPHARM	5MG	A088892 001	Feb 26, 1985
	TABLICAPS	5MG	A085170 001	
	TEVA	5MG	A080398 001	
	UDL	5MG	A087987 001	Jan 18, 1983
	VALEANT PHARM INTL	5MG	A080236 001	
	VITARINE	5MG	A080534 001	
	WATSON LABS	5MG	A085085 002	
		5MG	A085415 001	
		5MG	A085416 001	
	WEST WARD	5MG	A080324 001	
	WHITEWORTH TOWN PLSN	5MG	A080342 001	
STERANE				
	PFIZER	5MG	N009996 001	

PREDNISOLONE ACETATE

INJECTABLE;INJECTION				
METICORTELONE				
	SCHERING	25MG/ML	N010255 002	
PREDNISOLONE ACETATE				
	AKORN	25MG/ML	A083032 001	
		50MG/ML	A084492 001	
	BEL MAR	25MG/ML	A083738 001	
		50MG/ML	A083738 002	
	CENT PHARMS	25MG/ML	A084717 001	
		50MG/ML	A084717 002	
	WATSON LABS	25MG/ML	A083398 001	
		25MG/ML	A083654 001	
		40MG/ML	A083767 001	
		50MG/ML	A083764 001	
		50MG/ML	A085781 001	
STERANE				
	PFIZER	25MG/ML	N011446 001	

PREDNISOLONE ACETATE

SUSPENSION;ORAL			
FLO-PRED			
TARO	EQ 5MG BASE/5ML	N022067 001	Jan 17, 2008
	EQ 15MG BASE/5ML	N022067 002	Jan 17, 2008
SUSPENSION/DROPS;OPHTHALMIC			
ECONOPRED			
ALCON	0.125%	N017468 001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC			
CETAPRED			
ALCON	0.25%;10%	A087771 001	Aug 06, 1993
METIMYD			
SCHERING	0.5%;10%	N010210 002	Sep 09, 1984
PREDSULFAIR			
PHARMAFAIR	0.5%;10%	A088032 001	Apr 15, 1983
VASOCIDIN			
NOVARTIS	0.5%;10%	A088791 001	Oct 05, 1984
SUSPENSION;OPHTHALMIC			
ISOPTO CETAPRED			
ALCON	0.25%;10%	A087547 001	
SUSPENSION/DROPS;OPHTHALMIC			
METIMYD			
SCHERING	0.5%;10%	N010210 001	
PREDAMIDE			
AKORN	0.5%;10%	A088059 001	Jul 29, 1983
PREDSULFAIR			
PHARMAFAIR	0.5%;10%	A088007 001	Apr 19, 1983
PREDSULFAIR II			
PHARMAFAIR	0.2%;10%	A088837 001	Dec 24, 1985
SULPHRIN			
BAUSCH AND LOMB	0.5%;10%	A088089 001	Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE;INJECTION			
HYDELTRASOL			
MERCK	EQ 20MG PHOSPHATE/ML	N011583 002	
PREDNISOLONE SODIUM PHOSPHATE			
WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517 001	
OINTMENT;OPHTHALMIC, OTIC			
HYDELTRASOL			
MERCK	EQ 0.25% PHOSPHATE	N011028 001	
SOLUTION;ORAL			
ORAPRED			
CONCORDIA PHARMS INC	EQ 15MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075117 001	Dec 14, 2000
PREDNISOLONE SODIUM PHOSPHATE			
MEDICIS PHARMS	EQ 15MG BASE/5ML	A075250 001	Jul 12, 2002
NESHER PHARMS	EQ 5MG BASE/5ML	A076982 001	May 24, 2005
	EQ 15MG BASE/5ML	A076988 001	May 24, 2005
PHARM ASSOC	EQ 5MG BASE/5ML	A076123 001	Dec 23, 2002
VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416 001	Oct 31, 2007
WE PHARMS	EQ 5MG BASE/5ML	A075181 001	Dec 23, 2002
SOLUTION/DROPS;OPHTHALMIC			
INFLAMASE FORTE			
NOVARTIS	EQ 0.9% PHOSPHATE	A080751 002	
INFLAMASE MILD			
NOVARTIS	EQ 0.11% PHOSPHATE	A080751 001	
METRETON			
SCHERING	EQ 0.5% PHOSPHATE	A083834 001	
PREDAIR			
PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415 001	Feb 29, 1984
PREDAIR FORTE			
PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165 001	Mar 28, 1983
PREDNISOLONE SODIUM PHOSPHATE			
AKORN	EQ 0.11% PHOSPHATE	A083358 001	
	EQ 0.9% PHOSPHATE	A083358 002	
ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043 001	Oct 24, 1991
	EQ 0.9% PHOSPHATE	A081044 001	Oct 24, 1991
BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065 001	Jul 29, 1994
SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171 001	

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC			
PREDNISOLONE SODIUM PHOSPHATE			
	EQ 0.9% PHOSPHATE	A084168 001	
	EQ 0.9% PHOSPHATE	A084169 001	
	EQ 0.9% PHOSPHATE	A084172 001	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC			
SULSTER			
AKORN	EQ 0.23% PHOSPHATE;10%	A074511 001	Jul 30, 1996
VASOCIDIN			
NOVARTIS	EQ 0.23% PHOSPHATE;10% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018988 001	Aug 26, 1988

PREDNISOLONE TEBUTATE

INJECTABLE;INJECTION			
HYDELTRA-TBA			
MERCK	20MG/ML	N010562 001	
PREDNISOLONE TEBUTATE			
WATSON LABS	20MG/ML	A083362 001	Feb 17, 1984

PREDNISONE

SOLUTION;ORAL			
PREDNISONE			
WOCKHARDT	5MG/5ML	A089726 001	Aug 02, 1988
SYRUP;ORAL			
LIQUID PRED			
MURO	5MG/5ML	A087611 002	Sep 07, 1982
TABLET;ORAL			
CORTAN			
HALSEY	20MG	A087480 001	
DELTA-DOME			
BAYER PHARMS	5MG	A080293 001	
DELTASONE			
PHARMACIA AND UPJOHN	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986 005	
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986 002	
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986 006	
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986 007	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986 008	
FERNISONE			
FERNDALE LABS	5MG	A083364 001	
METICORTEN			
SCHERING	1MG	N009766 002	
	5MG	N009766 001	
ORASONE			
SOLVAY	1MG	A083009 001	
	5MG	A083009 002	
	10MG	A083009 003	
	20MG	A083009 004	
	50MG	A085999 001	
PARACORT			
PARKE DAVIS	5MG	N010962 002	
PREDNICEN-M			
SCHWARZ PHARMA	5MG	A084655 001	
PREDNISONE			
AM THERAP	5MG	A089387 001	Nov 06, 1986
	10MG	A089388 001	Nov 06, 1986
	20MG	A089389 001	Nov 06, 1986

FDA data supplied by DrugPatentWatch.com

PREDNISONE
TABLET;ORAL
PREDNISONE

AMNEAL PHARMS NY	5MG	A089597 001	Oct 05, 1987
	10MG	A089598 001	Oct 05, 1987
	20MG	A089599 001	Oct 05, 1987
AUROLIFE PHARMA LLC	5MG	A084774 001	
	10MG	A089983 001	Jan 12, 1989
	20MG	A085813 001	
	50MG	A089984 001	Jan 12, 1989
BUNDY	5MG	A083676 001	
DURAMED PHARMS BARR	5MG	A088394 001	Oct 04, 1983
	10MG	A088395 001	Oct 04, 1983
	20MG	A088396 001	Oct 04, 1983
ELKINS SINN	5MG	A080491 001	
	20MG	A085811 001	
EVERYLIFE	1MG	A084440 001	
	2.5MG	A084440 002	
	5MG	A084440 003	
FERRANTE	2.5MG	A080563 001	
	5MG	A080563 002	
HALSEY	5MG	A080300 001	
HEATHER	5MG	A080320 001	
	10MG	A084341 001	
	20MG	A084417 001	
	20MG	A085543 001	
	50MG	A086946 001	
HIKMA PHARMS	1MG	A040890 001	Nov 01, 2010
IMPAX LABS	5MG	A080782 001	
INWOOD LABS	1MG	A080328 001	
	2.5MG	A080306 001	
	5MG	A080279 001	
IVAX SUB TEVA PHARMS	5MG	A080283 001	
	10MG	A084133 001	
	20MG	A084134 001	
KV PHARM	5MG	A084236 001	
LANNETT	5MG	A080514 001	
	20MG	A084275 001	
LEDERLE	5MG	A086968 001	
MARSHALL PHARMA	5MG	A080301 001	
MUTUAL PHARM	5MG	A080701 001	
	10MG	A086595 001	
	20MG	A084634 001	
NYLOS	5MG	A085115 001	
PANRAY	1MG	A080350 001	
	2.5MG	A080350 002	
	5MG	A080350 003	
PERRIGO	5MG	A083059 001	
PHARMAVITE	5MG	A084662 002	
PHOENIX LABS NY	5MG	A080321 001	
	20MG	A083807 001	
PUREPAC PHARM	5MG	A080353 001	
	10MG	A086062 001	
	20MG	A086061 001	
PVT FORM	20MG	A085151 001	
REXALL	5MG	A080232 001	
ROXANE	20MG	N017109 001	
	25MG	A087833 001	May 04, 1982
SANDOZ	5MG	A080336 002	
SCHERER LABS	5MG	A080371 001	
SPERTI	1MG	A080359 001	
	2.5MG	A080359 002	
	5MG	A080359 003	
SUN PHARM INDS	50MG	A086596 001	
SUPERPHARM	5MG	A088865 001	Oct 25, 1984
	10MG	A088866 001	Oct 25, 1984
	20MG	A088867 001	Oct 25, 1984
TEVA	5MG	A080397 001	
UDL	5MG	A087984 001	Jan 18, 1983
	10MG	A087985 001	Jan 18, 1983
	20MG	A087986 001	Jan 18, 1983
UPSHER SMITH	5MG	A087471 001	

FDA data supplied by DrugPatentWatch.com

PREDNISONE
TABLET;ORAL
PREDNISONE

	20MG	A087470 001	
VALEANT PHARM INTL	5MG	A080237 001	
VANGARD	5MG	A087682 001	Jan 15, 1982
	20MG	A087701 001	Jan 15, 1982
VITARINE	5MG	A080334 001	
	5MG	A080506 001	
WATSON LABS	5MG	A085084 002	
	10MG	A087773 001	Jul 13, 1982
	20MG	A086813 001	
	50MG	A086867 001	
	50MG	A087772 001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913 001	
	5MG	A080343 001	
	10MG	A089028 001	Jul 24, 1986
	20MG	A084913 002	

SERVISONE

LEDERLE	5MG	A080223 001	

PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CITANEST

ASTRAZENECA	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014763 004	
	2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014763 005	
	3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014763 003	

CITANEST PLAIN

ASTRAZENECA	4% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014763 007	

CITANEST PLAIN DENTAL

DENTSPLY PHARM	4%	N021382 001	

PRIMIDONE
SUSPENSION;ORAL
MYSOLINE

NURO PHARMA	250MG/5ML	N010401 001	

TABLET;ORAL
PRIMIDONE

DR REDDYS LABS LTD	50MG	A040862 001	Oct 03, 2008
	250MG	A040862 002	Oct 03, 2008
HIKMA INTL PHARMS	50MG	A040667 001	Jul 27, 2006
IMPAX LABS	50MG	A040717 001	Feb 12, 2008
	250MG	A040717 002	Feb 12, 2008
WATSON LABS	250MG	A085052 001	

PROBENECID
TABLET;ORAL
BENEMID

MERCK	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007898 004	

PROBENECID

IVAX SUB TEVA PHARMS	500MG	A083740 001	May 09, 1984
LEDERLE	500MG	A086917 001	
WATSON LABS	500MG	A086150 002	Apr 23, 1982

PROBUCOL
TABLET;ORAL
LORELCO

SANOFI AVENTIS US	250MG	N017535 001	
	500MG	N017535 002	Jul 06, 1988

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL

PROCAINAMIDE HYDROCHLORIDE			
ASCOT	250MG	A087542 001	Jan 08, 1982
	375MG	A087697 001	Mar 01, 1983
	500MG	A087543 001	Jan 08, 1982
IDT AUSTRALIA LTD	250MG	A089219 001	Jul 01, 1986
	375MG	A089220 001	Jul 01, 1986
	500MG	A089221 001	Jul 01, 1986
IVAX SUB TEVA PHARMS	250MG	A084604 001	
	375MG	A084595 001	
	500MG	A084606 001	
LANNETT	250MG	A083693 001	
	500MG	A084696 001	
LEDERLE	250MG	A086942 001	
	375MG	A086952 001	
	500MG	A086943 001	
ROXANE	250MG	A088989 001	Apr 26, 1985
	500MG	A088990 001	Apr 26, 1985
VANGARD	250MG	A087643 001	Jun 01, 1982
	500MG	A087875 001	Jun 01, 1982
WATSON LABS	250MG	A083287 001	
	250MG	A083795 001	
	250MG	A085167 001	
	375MG	A084403 001	
	375MG	A087020 001	
	500MG	A084280 001	
	500MG	A084357 001	
	500MG	A087021 001	
PROCAN			
PARKE DAVIS	250MG	A085804 001	
	375MG	A087502 001	
	500MG	A085079 001	
PROCAPAN			
PANRAY	250MG	A083553 002	
PRONESTYL			
APOTHECON	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 001	
	375MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 004	
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 003	

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE			
ABRAXIS PHARM	100MG/ML	A089415 001	Nov 17, 1986
	500MG/ML	A089416 001	Nov 17, 1986
EUROHLTH INTL SARL	100MG/ML	A089029 001	Apr 17, 1986
	500MG/ML	A089030 001	Apr 17, 1986
HOSPIRA	500MG/ML	A089537 001	Aug 25, 1987
INTL MEDICATION	500MG/ML	A088637 001	Jul 31, 1984
PHARMAFAIR	100MG/ML	A088824 001	Nov 20, 1985
	500MG/ML	A088830 001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530 001	Mar 04, 1985
	500MG/ML	A088531 001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532 001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528 001	May 03, 1988
	500MG/ML	A089529 001	May 03, 1988
WATSON LABS	100MG/ML	A087079 001	
	500MG/ML	A087080 001	
PRONESTYL			
APOTHECON	100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 002	
	500MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 005	

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HYDROCHLORIDE

TABLET;ORAL

PRONESTYL

APOTHECON	250MG	N017371 001	
	375MG	N017371 002	
	500MG	N017371 003	

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC	250MG	A088958 001	Dec 02, 1985
	500MG	A088959 001	Dec 02, 1985
	500MG	A088974 001	Jul 22, 1985
	750MG	A089438 001	Mar 23, 1987
	1GM	A040111 001	Dec 13, 1996
IDT AUSTRALIA LTD	250MG	A089369 001	Aug 14, 1987
	500MG	A089370 001	Jan 09, 1987
	750MG	A089371 001	Aug 14, 1987
INWOOD LABS	500MG	A089840 001	Mar 06, 1989
SANDOZ	500MG	A089284 001	Jun 23, 1986
WATSON LABS	250MG	A088533 001	Dec 03, 1984
	250MG	A089026 001	Oct 22, 1985
	500MG	A088534 001	Dec 03, 1984
	500MG	A089027 001	Oct 22, 1985
	750MG	A088535 001	Nov 03, 1984
	750MG	A089042 001	Oct 22, 1985
	1GM	A089520 001	Jan 15, 1987

PROCAN SR

PARKE DAVIS	250MG	A086468 001	
PARKEDALE	500MG	A086065 001	
	750MG	A087510 001	Apr 01, 1982
	1GM	A088489 001	Jan 16, 1985

PROCANBID

KING PHARMS	500MG	N020545 001	Jan 31, 1996
	1GM	N020545 002	Jan 31, 1996

PRONESTYL-SR

APOTHECON	500MG	A087361 001	

PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

NOVOCAIN

HOSPIRA	1%	A085362 003	
	2%	A085362 004	
	10%	A086797 001	

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM	1%	A080384 002	
	1%	A080421 001	
	2%	A080384 003	
	2%	A080421 002	
BEL MAR	1%	A080711 001	
	2%	A080756 001	
ELKINS SINN	1%	A083315 001	
	2%	A083315 002	
GD SEARLE LLC	1%	A086202 001	
	2%	A086202 002	
HOSPIRA	1%	A080416 001	
	2%	A080416 002	
MILES	1%	A080415 001	
	2%	A080415 002	
WATSON LABS	1%	A080658 001	
	1%	A083535 001	
	2%	A080658 002	
	2%	A083535 002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION

ACHROMYCIN

LEDERLE	40MG/VIAL;100MG/VIAL	N050276 001	
	40MG/VIAL;250MG/VIAL	N050276 003	

TETRACYN

PFIZER	40MG/VIAL;100MG/VIAL	A060285 002	
	40MG/VIAL;250MG/VIAL	A060285 003	

PROCAINE MERETHOXYLLINE; THEOPHYLLINE
INJECTABLE;INJECTION
DICURIN PROCAINE

LILLY	100MG/ML;50MG/ML	N008869 001	

PROCHLORPERAZINE
SUPPOSITORY;RECTAL
COMPAZINE

GLAXOSMITHKLINE	2.5MG	N011127 003	
	5MG	N011127 001	
	25MG	N011127 002	

PROCHLORPERAZINE

ABLE	2.5MG	A040407 001	Jul 11, 2001
	5MG	A040407 002	Jul 11, 2001
	25MG	A040407 003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATE
CONCENTRATE;ORAL
COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276 001	

PROCHLORPERAZINE

ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153 001	Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE	EQ 10MG BASE/ML	A088598 001	Oct 25, 1984

INJECTABLE;INJECTION
COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/ML	N010742 002	

PROCHLORPERAZINE

BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759 001	Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

AMPHASTAR PHARMS INC	EQ 5MG BASE/ML	A040540 001	May 28, 2004
EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089523 001	May 03, 1988
HOSPIRA	EQ 5MG BASE/ML	A089703 001	Apr 07, 1988
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675 001	Dec 05, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251 001	Dec 04, 1986
TEVA PARENTERAL	EQ 5MG BASE/ML	A040505 001	May 30, 2003
WATSON LABS	EQ 5MG BASE/ML	A089530 001	Jul 08, 1987
	EQ 5MG BASE/ML	A089605 001	Jul 08, 1987
	EQ 5MG BASE/ML	A089606 001	Jul 08, 1987
WYETH AYERST	EQ 5MG BASE/ML	A086348 001	

SYRUP;ORAL
COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188 001	

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154 001	Sep 01, 1982
MORTON GROVE	EQ 5MG BASE/5ML	A088597 001	Oct 25, 1984

PROCHLORPERAZINE MALEATE
CAPSULE, EXTENDED RELEASE;ORAL
COMPAZINE

GLAXOSMITHKLINE	EQ 10MG BASE	N011000 001	
	EQ 10MG BASE	N021019 001	Oct 06, 1999
	EQ 15MG BASE	N011000 002	
	EQ 15MG BASE	N021019 002	Oct 06, 1999
	EQ 30MG BASE	N011000 003	
	EQ 75MG BASE	N011000 004	

TABLET;ORAL
COMPAZINE

GLAXOSMITHKLINE	EQ 5MG BASE	N010571 001	
	EQ 10MG BASE	N010571 002	
	EQ 25MG BASE	N010571 003	

PROCHLORPERAZINE

WATSON LABS	EQ 5MG BASE	A085580 001	
	EQ 10MG BASE	A085178 001	
	EQ 25MG BASE	A085579 001	

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR	EQ 5MG BASE	A040207 001	May 01, 1997
	EQ 5MG BASE	A089484 001	Jan 20, 1987
	EQ 10MG BASE	A040207 002	May 01, 1997
	EQ 10MG BASE	A089485 001	Jan 20, 1987
	EQ 25MG BASE	A089486 001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162 001	Jan 20, 1998
	EQ 10MG BASE	A040162 002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101 003	Jul 19, 1996

FDA data supplied by DrugPatentWatch.com

PROCYCLIDINE HYDROCHLORIDE

TABLET;ORAL			
KEMADRIN			
MONARCH PHARMS	2MG	N009818 005	
	5MG	N009818 003	

PROGESTERONE

CAPSULE;ORAL			
PROMETRIUM			
VIRTUS PHARMS	300MG	N019781 003	Oct 15, 1999
INJECTABLE;INJECTION			
PROGESTERONE			
LILLY	25MG/ML	N009238 002	
	50MG/ML	N009238 001	
INSERT, EXTENDED RELEASE;INTRAUTERINE			
PROGESTASERT			
ALZA	38MG	N017553 001	

PROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL			
SPARINE			
WYETH AYERST	30MG/ML	N010942 001	
	100MG/ML	N010942 004	
INJECTABLE;INJECTION			
PROMAZINE HYDROCHLORIDE			
WATSON LABS	25MG/ML	A084510 001	
	50MG/ML	A084517 001	
SPARINE			
BAXTER HLTHCARE CORP	25MG/ML	N010349 008	
	50MG/ML	N010349 006	
SYRUP;ORAL			
SPARINE			
WYETH AYERST	10MG/5ML	N010942 003	
TABLET;ORAL			
SPARINE			
WYETH AYERST	10MG	N010348 006	
	25MG	N010348 001	
	50MG	N010348 002	
	100MG	N010348 003	
	200MG	N010348 004	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION			
PHENERGAN			
WYETH AYERST	25MG/ML	N008857 002	
	50MG/ML	N008857 003	
PROMETHAZINE HYDROCHLORIDE			
ABBOTT	25MG/ML	A084223 001	
	50MG/ML	A084222 001	
AKORN	25MG/ML	A083955 002	
	50MG/ML	A083955 001	
BEDFORD LABS	25MG/ML	A040524 001	Mar 17, 2004
	50MG/ML	A040524 002	Mar 17, 2004
HOSPIRA	25MG/ML	A040372 001	Jun 08, 2000
	50MG/ML	A040372 002	Jun 08, 2000
	50MG/ML	A083838 002	
LUITPOLD	25MG/ML	A040515 001	Mar 19, 2003
MARSAM PHARMS LLC	25MG/ML	A089463 001	May 02, 1988
	50MG/ML	A089477 001	May 02, 1988
MYLAN INSTITUTIONAL	25MG/ML	A040471 001	Nov 21, 2002
SANDOZ	25MG/ML	A040593 001	Nov 08, 2006
	50MG/ML	A040593 002	Nov 08, 2006
TEVA PHARMS USA	25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A040454 001	Aug 22, 2002
	50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A040454 002	Aug 22, 2002
WATSON LABS	25MG/ML	A083532 001	
	25MG/ML	A084591 001	
	50MG/ML	A080629 002	
	50MG/ML	A083532 002	
WOCKHARDT	25MG/ML	A040785 001	Sep 26, 2008

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION			
PROMETHAZINE HYDROCHLORIDE			
	50MG/ML	A040785 002	Sep 26, 2008
ZIPAN-25			
ALTANA	25MG/ML	A083997 001	
ZIPAN-50			
ALTANA	50MG/ML	A083997 002	
SUPPOSITORY;RECTAL			
PHENERGAN			
DELCOR ASSET CORP	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010926 002	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010926 001	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011689 001	
PROMETHACON			
POLYMEDICA	25MG	A084901 001	
	50MG	A084902 001	
PROMETHAZINE HYDROCHLORIDE			
ABLE	12.5MG	A040504 001	Apr 11, 2003
	25MG	A040504 002	Apr 11, 2003
	50MG	A040449 001	Feb 27, 2003
SYRUP;ORAL			
MYMETHAZINE FORTIS			
USL PHARMA	25MG/5ML	A087996 001	Jan 18, 1983
PROMETH FORTIS			
ALPHARMA US PHARMS	25MG/5ML	A084772 001	
PROMETH PLAIN			
ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953 001	
PROMETHAZINE			
CENCI	6.25MG/5ML	A089013 001	Sep 20, 1985
PROMETHAZINE HYDROCHLORIDE			
KV PHARM	6.25MG/5ML	A085388 001	
	25MG/5ML	A085385 001	
PHARM ASSOC	6.25MG/5ML	A087518 001	
WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395 001	
PROMETHAZINE HYDROCHLORIDE PLAIN			
ANI PHARMS	6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008381 004	Apr 18, 1984
	25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008381 003	
TABLET;ORAL			
PHENERGAN			
DELCOR ASSET CORP	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007935 002	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007935 003	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007935 004	
PROMETHAZINE HYDROCHLORIDE			
ABBOTT	12.5MG	A084160 001	
	25MG	A084166 001	
	50MG	A084539 001	
ABLE	12.5MG	A040558 001	Jul 01, 2004
	25MG	A040558 002	Jul 01, 2004
	50MG	A040558 003	Jul 01, 2004
IMPAX LABS	12.5MG	A040724 001	Feb 12, 2008
	25MG	A040724 002	Feb 12, 2008
	25MG	A084214 002	Jul 07, 1982

PROMETHAZINE HYDROCHLORIDE
TABLET;ORAL
PROMETHAZINE HYDROCHLORIDE

	50MG	A040791 001	May 20, 2008
IVAX SUB TEVA PHARMS	12.5MG	A083604 001	
	25MG	A083603 001	
	50MG	A083613 001	
LANNETT	12.5MG	A080949 001	
	25MG	A080949 002	
	50MG	A080949 003	
PVT FORM	12.5MG	A083214 001	
	25MG	A083658 001	
SANDOZ	12.5MG	A084176 002	May 22, 2009
	12.5MG	A084233 001	
	25MG	A085146 001	
	50MG	A085146 002	
SUN PHARM INDS	12.5MG	A084555 001	
	25MG	A084554 001	
	50MG	A084557 001	
TABLICAPS	12.5MG	A084080 001	
	25MG	A084027 001	
TEVA	25MG	A089109 001	Sep 10, 1985
WATSON LABS	12.5MG	A083401 001	
	12.5MG	A083712 001	
	12.5MG	A085986 001	
	25MG	A083204 001	
	25MG	A085684 001	
	50MG	A083403 001	
	50MG	A085664 001	

REMSED

BRISTOL MYERS SQUIBB	25MG	A083176 002	
	50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE
TABLET;ORAL
PROPAFENONE HYDROCHLORIDE

NESHER PHARMS	150MG	A076193 001	Feb 07, 2002
	225MG	A076193 002	Feb 07, 2002
	300MG	A076193 003	Feb 07, 2002

PROPANTHELINE BROMIDE
INJECTABLE;INJECTION
PRO-BANTHINE

GD SEARLE LLC	30MG/VIAL	N008843 001	

TABLET;ORAL
PRO-BANTHINE

SHIRE	7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008732 003	
	15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008732 002	

PROPANTHELINE BROMIDE

ASCOT	15MG	A087663 001	Oct 25, 1982
HEATHER	15MG	A085780 001	
IMPAX LABS	15MG	A084541 002	
MYLAN	15MG	A083706 001	
PAR PHARM	15MG	A088377 001	Dec 08, 1983
PVT FORM	15MG	A080977 001	
SANDOZ	15MG	A080928 001	
TABLICAPS	15MG	A084428 001	
WATSON LABS	15MG	A083029 002	
	15MG	A083151 001	
WEST-WARD PHARMS INT	7.5MG	A080927 001	

PROPARACAINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
KAINAIR

PHARMAFAIR	0.5%	A088087 001	Jun 07, 1983

OPHTHAINE

APOTHECON	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy	N008883 001	

FDA data supplied by DrugPatentWatch.com

PROPARACAINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC

OPHTHAINE			
	reasons**		
OPHTHETIC			
ALLERGAN	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012583 001	
PARACAINE			
OPTOPICS	0.5%	A087681 001	Aug 05, 1982
PROPARACAINE HYDROCHLORIDE			
SOLA BARNES HIND	0.5%	A084144 001	
	0.5%	A084151 001	

PROPIOLACTONE
SOLUTION;IRRIGATION

BETAPRONE			
FOREST LABS	N/A	N011657 001	

PROPIOMAZINE HYDROCHLORIDE
INJECTABLE;INJECTION

LARGON			
EUROHLTH INTL SARL	20MG/ML	N012382 002	

PROPOFOL
INJECTABLE;INJECTION

DIPRIVAN			
FRESENIUS KABI USA	10MG/ML	N019627 001	Oct 02, 1989
PROPOFOL			
TEVA PARENTERAL	10MG/ML	A075392 001	Sep 19, 2000
WEST-WARD PHARMS INT	10MG/ML	A074848 001	Apr 19, 2005

PROPOXYPHENE HYDROCHLORIDE
CAPSULE;ORAL

DARVON			
XANODYNE PHARM	32MG	N010997 001	
	65MG	N010997 003	
DOLENE			
HERITAGE PHARMS INC	65MG	A080530 001	
KESSO-GESIC			
MK LABS	65MG	A083544 001	
PROPHENE 65			
HALSEY	65MG	A083538 002	
PROPOXYPHENE HYDROCHLORIDE			
ALRA	65MG	A083184 001	
IMPAX LABS	65MG	A083317 001	
IVAX SUB TEVA PHARMS	32MG	A083597 001	
MUTUAL PHARM	65MG	A083186 001	
MYLAN	32MG	A083528 001	
	65MG	A040569 001	Dec 16, 2004
	65MG	A083299 001	
NEXGEN PHARMA INC	65MG	A083185 001	
PAR PHARM	65MG	A080269 001	
PUREPAC PHARM	65MG	A083278 001	
PVT FORM	32MG	A083464 001	
	65MG	A083113 001	
ROXANE	32MG	A083089 001	
	65MG	A083089 002	
SANDOZ	32MG	A084014 001	
	65MG	A083125 002	
	65MG	A083688 001	
	65MG	A083870 002	
	65MG	A086495 001	
TEVA	65MG	A088615 001	Oct 22, 1984
VALEANT PHARM INTL	65MG	A080783 001	
VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009
WATSON LABS	65MG	A080908 002	
	65MG	A085190 001	
WEST WARD	65MG	A083501 001	
WHITEWORTH TOWN PLSN	65MG	A084551 001	
PROPOXYPHENE HYDROCHLORIDE 65			
WARNER CHILCOTT	65MG	A083786 001	

FDA data supplied by DrugPatentWatch.com

PROPOXYPHENE NAPSYLATE

SUSPENSION;ORAL			
DARVON-N			
AAIPHARMA LLC	50MG/5ML	N016861 001	
TABLET;ORAL			
DARVON-N			
XANODYNE PHARM	100MG	N016862 002	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL			
PROPRANOLOL HYDROCHLORIDE			
INWOOD LABS	60MG	A072499 001	Apr 11, 1989
	80MG	A072500 001	Apr 11, 1989
	120MG	A072501 001	Apr 11, 1989
	160MG	A072502 001	Apr 11, 1989
CONCENTRATE;ORAL			
PROPRANOLOL HYDROCHLORIDE INTENSOL			
ROXANE	80MG/ML	A071388 001	May 15, 1987
INJECTABLE;INJECTION			
PROPRANOLOL HYDROCHLORIDE			
SANDOZ	1MG/ML	A076400 001	Feb 26, 2003
SMITH AND NEPHEW	1MG/ML	A070135 001	Apr 15, 1986
	1MG/ML	A070137 001	Apr 15, 1986
SOLOPAK	1MG/ML	A070136 001	Apr 15, 1986
SOLUTION;ORAL			
PROPRANOLOL HYDROCHLORIDE			
MORTON GROVE	20MG/5ML	A071984 001	Mar 03, 1989
	40MG/5ML	A071985 001	Mar 03, 1989
SUSPENSION;ORAL			
INDERAL			
WYETH AYERST	10MG/ML	N019536 001	Dec 12, 1986
TABLET;ORAL			
INDERAL			
WYETH PHARMS INC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016418 001	
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016418 003	
	40MG	N016418 002	
	60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016418 009	Oct 18, 1982
	80MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016418 004	
	90MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016418 010	Oct 18, 1982
PROPRANOLOL HYDROCHLORIDE			
ANI PHARMS INC	90MG	A071977 001	Apr 06, 1988
DAVA PHARMS INC	10MG	A070125 001	Jul 30, 1985
	20MG	A070126 001	Jul 30, 1985
	40MG	A070127 001	Jul 30, 1985
	60MG	A071495 001	Dec 31, 1987
	80MG	A070128 001	Jul 30, 1985
	90MG	A071496 001	Dec 31, 1987
DURAMED PHARMS BARR	10MG	A070306 001	Sep 09, 1985
	20MG	A070307 001	Sep 09, 1985
	40MG	A070308 001	Sep 09, 1985
	60MG	A070309 001	Oct 01, 1986
	80MG	A070310 001	Sep 09, 1985
	90MG	A071327 001	Oct 01, 1986
FRONTIDA BIOPHARM	10MG	A070319 001	Oct 22, 1985
	20MG	A070320 001	Oct 22, 1985
	40MG	A070103 001	Oct 22, 1985
	60MG	A070321 001	Sep 24, 1986
	80MG	A070322 001	Aug 04, 1986
INTERPHARM	10MG	A071368 001	May 05, 1987
	20MG	A071369 001	May 05, 1987

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	40MG	A071370	001	May 05, 1987
	80MG	A071371	001	May 05, 1987
IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988
	60MG	A072068	001	Jul 29, 1988
	80MG	A072069	001	Jul 29, 1988
LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MYLAN	60MG	A072275	001	Jun 09, 1989
PAR PHARM	90MG	A071288	001	Oct 22, 1986
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
SANDOZ	10MG	A070663	001	Jun 13, 1986
	10MG	A071658	001	Jul 05, 1988
	20MG	A070664	001	Jun 13, 1986
	20MG	A071687	001	Jul 05, 1988
	40MG	A070665	001	Jun 13, 1986
	40MG	A071688	001	Jul 05, 1988
	60MG	A070666	001	Oct 10, 1986
	60MG	A072197	001	Jul 05, 1988
	80MG	A070667	001	Jun 13, 1986
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	10MG	A070548	001	Jul 10, 1986
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	20MG	A070549	001	Apr 11, 1986
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	40MG	A070550	001	Apr 11, 1986
	60MG	A070143	001	Jan 15, 1987
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	60MG	A071791	001	Jul 15, 1987
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE
TABLET;ORAL
PROPRANOLOL HYDROCHLORIDE

	90MG	A071792 001	Jul 15, 1987

PROPYLIODONE
SUSPENSION;INTRATRACHEAL
DIONOSIL AQUEOUS

GLAXOSMITHKLINE	50%	N009309 001	

DIONOSIL OILY

GLAXOSMITHKLINE	60%	N009309 002	

PROPYLTHIOURACIL
TABLET;ORAL
PROPYLTHIOURACIL

ABBOTT	50MG	A084075 001	
ANABOLIC	50MG	A080285 001	
ANI PHARMS INC	50MG	A080215 001	
HALSEY	50MG	A080015 001	
HIKMA INTL PHARMS	50MG	A080154 001	
IMPAX LABS	50MG	A080159 001	
LANNETT	50MG	A080016 001	
LILLY	50MG	N006213 001	
PERRIGO	50MG	A084543 001	
SUN PHARM INDS	50MG	A083982 001	
TABLICAPS	50MG	A080840 001	
WATSON LABS	50MG	A080932 001	
	50MG	A085201 001	

PROTAMINE SULFATE
INJECTABLE;INJECTION
PROTAMINE SULFATE

EUROHLTH INTL SARL	10MG/ML	A089474 001	Nov 05, 1986
	10MG/ML	A089475 001	Nov 05, 1986
LILLY	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006460 002	
PHARMACIA AND UPJOHN	50MG/VIAL	N007413 001	
	250MG/VIAL	N007413 002	Aug 02, 1984

PROTEIN HYDROLYSATE
INJECTABLE;INJECTION
AMINOSOL 5%

ABBVIE	5%	N005932 012	Jan 31, 1985

HYPROTIGEN 5%

B BRAUN	5%	N006170 003	Jan 10, 1984

PROTIRELIN
INJECTABLE;INJECTION
THYPINONE

ABBOTT	0.5MG/ML	N017638 001	

THYREL TRH

FERRING	0.5MG/ML	N018087 001	

PROTOKYLOL HYDROCHLORIDE
TABLET;ORAL
VENTAIRE

SANOFI AVENTIS US	2MG	A083459 001	

PROTRIPTYLINE HYDROCHLORIDE
TABLET;ORAL
VIVACTIL

TEVA WOMENS	5MG	N016012 001	
	10MG	N016012 002	

PSEUDOEPHEDRINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
NOVAFED

SANOFI AVENTIS US	120MG	N017603 001	

SUDAFED 12 HOUR

GLAXOSMITHKLINE	120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017941 002	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
ACTIFED				
	GLAXOSMITHKLINE	120MG;5MG	N018996 001	Jun 17, 1985
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
	KV PHARM	120MG;5MG	A071798 001	Mar 16, 1989
SYRUP;ORAL				
ACTAHIST				
	CENCI	30MG/5ML;1.25MG/5ML	A088344 001	Feb 09, 1984
HISTAFED				
	CENCI	30MG/5ML;1.25MG/5ML	A088283 001	Apr 20, 1984
MYFED				
	USL PHARMA	30MG/5ML;1.25MG/5ML	A088116 001	Mar 04, 1983
TRILITRON				
	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	A088474 001	Feb 12, 1985
TABLET;ORAL				
ALLERFED				
	PVT FORM	60MG;2.5MG	A088860 001	Jan 31, 1985
CORPHED				
	SANDOZ	60MG;2.5MG	A088602 001	Apr 11, 1985
PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE				
	SANDOZ	60MG;2.5MG	A088193 001	May 17, 1983
TRILITRON				
	NEWTRON PHARMS	60MG;2.5MG	A088515 001	Jan 09, 1985
TRIPHED				
	TEVA	60MG;2.5MG	A088630 001	May 17, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE				
	WATSON LABS	60MG;2.5MG	A088318 002	Jan 13, 1984
	WEST WARD	60MG;2.5MG	A088117 001	Apr 19, 1983
TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
	IVAX SUB TEVA PHARMS	60MG;2.5MG	A085273 001	Dec 12, 1984
	SUPERPHARM	60MG;2.5MG	A088578 001	Feb 21, 1985
TABLET, EXTENDED RELEASE;ORAL				
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES				
	KV PHARM	120MG;5MG	A072758 001	Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL				
PSEUDO-12				
	UCB INC	EQ 60MG HCL/5ML	N019401 001	Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL				
PYRIDOSTIGMINE BROMIDE				
	ANI PHARMS INC	30MG	A040512 002	Jul 20, 2005
		60MG	A040512 001	Oct 08, 2003
	COREPHARMA	60MG	A040457 001	Dec 26, 2002
	SOLVAY	30MG	A089572 001	Nov 27, 1990
	US ARMY	30MG	N020414 001	Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION				
HEXA-BETALIN				
	LILLY	100MG/ML	A080854 001	
PYRIDOXINE HYDROCHLORIDE				
	AKORN	100MG/ML	A087967 001	Oct 01, 1982
	BEL MAR	100MG/ML	A080761 001	
	DELL LABS	50MG/ML	A083771 001	
		100MG/ML	A083772 001	
	ELKINS SINN	100MG/ML	A080581 001	
	LUITPOLD	100MG/ML	A080669 001	
	WATSON LABS	100MG/ML	A080572 001	
		100MG/ML	A083760 001	

PYRILAMINE MALEATE

TABLET;ORAL				
PYRILAMINE MALEATE				
	IMPAX LABS	25MG	A080808 001	
	WATSON LABS	25MG	A085231 001	

PYRIMETHAMINE; SULFADOXINE
TABLET;ORAL
FANSIDAR

ROCHE	25MG;500MG	N018557 001	

PYRITHIONE ZINC
LOTION;TOPICAL
HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT	0.3%	N019412 002	Mar 10, 1986

PYRVINIUM PAMOATE
SUSPENSION;ORAL
POVAN

PARKE DAVIS	EQ 50MG BASE/5ML	N011964 001	

TABLET;ORAL
POVAN

PARKE DAVIS	EQ 50MG BASE	N012485 002	

QUAZEPAM
TABLET;ORAL
DORAL

CUTIS HEALTH LLC	7.5MG	N018708 003	Feb 26, 1987

QUETIAPINE FUMARATE
TABLET;ORAL
QUETIAPINE FUMARATE

ACTAVIS GRP PTC	EQ 25MG BASE	A201762 001	Feb 27, 2013
	EQ 50MG BASE	A201762 002	Feb 27, 2013
	EQ 100MG BASE	A201762 003	Feb 27, 2013
	EQ 150MG BASE	A201762 004	Feb 27, 2013
	EQ 200MG BASE	A201762 005	Feb 27, 2013
	EQ 300MG BASE	A201762 006	Feb 27, 2013
	EQ 400MG BASE	A201762 007	Feb 27, 2013

SEROQUEL

ASTRAZENECA PHARMS	EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020639 004	Dec 20, 1998

QUINAPRIL HYDROCHLORIDE
TABLET;ORAL
QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 5MG BASE	A076459 001	Dec 22, 2004
	EQ 10MG BASE	A076459 002	Dec 22, 2004
	EQ 20MG BASE	A076459 003	Dec 22, 2004
	EQ 40MG BASE	A076459 004	Dec 22, 2004
ACTAVIS LABS FL INC	EQ 5MG BASE	A076049 001	Jan 14, 2005
	EQ 10MG BASE	A076049 002	Jan 14, 2005
	EQ 20MG BASE	A076049 003	Jan 14, 2005
	EQ 40MG BASE	A076049 004	Jan 14, 2005
APOTEX INC	EQ 5MG BASE	A076240 001	Jan 26, 2006
	EQ 10MG BASE	A076240 002	Jan 26, 2006
	EQ 20MG BASE	A076240 003	Jan 26, 2006
	EQ 40MG BASE	A076240 004	Jan 26, 2006
MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005
	EQ 10MG BASE	A076036 002	Jan 28, 2005
	EQ 20MG BASE	A076036 003	Jan 28, 2005
	EQ 40MG BASE	A076036 004	Jan 28, 2005
SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005
	EQ 10MG BASE	A076803 002	Mar 02, 2005
	EQ 20MG BASE	A076803 003	Mar 02, 2005
	EQ 40MG BASE	A076803 004	Mar 02, 2005

QUINESTROL
TABLET;ORAL
ESTROVIS

PARKE DAVIS	0.1MG	N016768 002	
	0.2MG	N016768 003	

QUINETHAZONE
TABLET;ORAL
HYDROMOX

LEDERLE	50MG	N013264 001	

FDA data supplied by DrugPatentWatch.com

QUINETHAZONE; RESERPINE
TABLET;ORAL
HYDROMOX R

LEDERLE	50MG;0.125MG	N013927 001	

QUINIDINE GLUCONATE
TABLET;ORAL
QUINACT

BAYER HLTHCARE	266MG	A085978 001	
	400MG	A086099 001	

TABLET, EXTENDED RELEASE;ORAL
DURAQUIN

WARNER CHILCOTT	330MG	N017917 001	

QUINAGLUTE

BAYER HLTHCARE	324MG	N016647 001	

QUINALAN

LANNETT	324MG	A088081 001	Feb 10, 1986

QUINATIME

WATSON LABS	324MG	A087448 001	

QUINIDINE GLUCONATE

ASCOT	324MG	A088582 001	Jun 17, 1985
AUROLIFE PHARMA LLC	324MG	A089894 001	Dec 15, 1988
CYCLE PHARMS LTD	324MG	A088431 001	Jan 06, 1984
HALSEY	324MG	A089476 001	Apr 10, 1987
SUPERPHARM	324MG	A089164 001	Nov 21, 1985
WATSON LABS	324MG	A087785 001	Jan 24, 1983
	324MG	A087810 001	Sep 29, 1982

QUINIDINE POLYGALACTURONATE
TABLET;ORAL
CARDIOQUIN

PHARM RES ASSOC	275MG	N011642 002	

QUINIDINE SULFATE
CAPSULE;ORAL
CIN-QUIN

SOLVAY	200MG	A085296 001	
	300MG	A085297 001	

QUINIDINE SULFATE

LILLY	200MG	A085103 001	

TABLET;ORAL
CIN-QUIN

SOLVAY	100MG	A085299 001	
	200MG	A084932 001	
	300MG	A085298 001	

QUINIDINE SULFATE

BARR	200MG	A084177 001	
CONTRACT PHARMACAL	200MG	A083808 001	
CYCLE PHARMS LTD	200MG	A083640 001	
	300MG	A085632 001	
DAVA PHARMS INC	200MG	A087011 001	
ELKINS SINN	200MG	A083622 001	
EVERYLIFE	200MG	A083439 001	
HALSEY	200MG	A083583 001	
HIKMA PHARMS LLC	200MG	A083862 001	
IMPAX LABS	200MG	A083347 001	
IVAX SUB TEVA PHARMS	200MG	A084549 001	
KING PHARMS	200MG	A085175 001	
KV PHARM	200MG	A085276 001	
LANNETT	200MG	A083743 001	
LEDERLE	200MG	A086176 001	
LILLY	200MG	A085038 001	
PERRIGO	200MG	A085322 001	
PHARMAVITE	200MG	A084627 001	
PUREPAC PHARM	200MG	A084003 001	
SANDOZ	200MG	A084631 001	
	200MG	A084914 001	
	300MG	A089839 001	Sep 29, 1988
SCHERER LABS	200MG	A085068 001	
SUN PHARM INDS	100MG	A081029 001	Apr 14, 1989
SUPERPHARM	200MG	A088973 001	Apr 10, 1985
USL PHARMA	200MG	A087837 001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393 001	
VANGARD	200MG	A087909 001	Jul 13, 1982

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

VINTAGE PHARMS	200MG	A083963 001	
WARNER CHILCOTT	200MG	A083879 001	
WATSON LABS	100MG	A085584 001	
	200MG	A085140 002	
WHITEWORTH TOWN PLSN	200MG	A085444 001	

QUINORA

KEY PHARMS	200MG	A083576 001	
SCHERING	300MG	A085222 001	

TABLET, EXTENDED RELEASE;ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796 002	

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

EISAI INC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020973 001	May 29, 2002

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513 001	Jun 18, 2008
	2.5MG	A077513 002	Jun 18, 2008
	5MG	A077513 003	Jun 18, 2008
	10MG	A077513 004	Jun 18, 2008
CIPLA	1.25MG	A077004 001	Aug 07, 2008
	2.5MG	A077004 002	Aug 07, 2008
	5MG	A077004 003	Aug 07, 2008
	10MG	A077004 004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009
	10MG	A078849 002	Mar 06, 2009
SANDOZ	1.25MG	A077514 001	Jun 18, 2008
	2.5MG	A077514 002	Jun 18, 2008
	5MG	A077514 003	Jun 18, 2008
	10MG	A077514 004	Jun 18, 2008

TABLET;ORAL

ALTACE

KING PFIZER	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021 001	Feb 27, 2007
	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021 002	Feb 27, 2007
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021 003	Feb 27, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021 004	Feb 27, 2007

RAMIPRIL

MYLAN PHARMS INC	1.25MG	A090650 001	Jun 30, 2011
	2.5MG	A090650 002	Jun 30, 2011
	5MG	A090650 003	Jun 30, 2011
	10MG	A090650 004	Jun 30, 2011
ZYDUS PHARMS USA INC	1.25MG	A090697 001	Sep 24, 2009
	2.5MG	A090697 002	Sep 24, 2009
	5MG	A090697 003	Sep 24, 2009
	10MG	A090697 004	Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET;ORAL

TRITEC

GLAXOSMITHKLINE	400MG	N020559 001	Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL				
RANITIDINE HYDROCHLORIDE				
	MYLAN	EQ 150MG BASE	A075564	001 Oct 27, 2000
		EQ 300MG BASE	A075564	002 Oct 27, 2000
	TEVA	EQ 150MG BASE	A075557	001 Oct 31, 2003
		EQ 300MG BASE	A075557	002 Oct 31, 2003
ZANTAC 150				
	GLAXOSMITHKLINE	EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020095	001 Mar 08, 1994
ZANTAC 300				
	GLAXOSMITHKLINE	EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020095	002 Mar 08, 1994
GRANULE, EFFERVESCENT;ORAL				
ZANTAC 150				
	GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002 Mar 31, 1994
INJECTABLE;INJECTION				
RANITIDINE HYDROCHLORIDE				
	BEDFORD	EQ 25MG BASE/ML	A074764	001 Nov 19, 2004
ZANTAC IN PLASTIC CONTAINER				
	IGI LABS INC	EQ 1MG BASE/ML	N019593	002 Sep 27, 1991
		EQ 50MG BASE/100ML	N019593	001 Dec 17, 1986
SYRUP;ORAL				
RANITIDINE HYDROCHLORIDE				
	APOTEX INC	EQ 15MG BASE/ML	A077602	001 Sep 17, 2007
	RANBAXY	EQ 15MG BASE/ML	A078448	001 Dec 13, 2007
	WOCKHARDT	EQ 15MG BASE/ML	A079211	001 May 26, 2009
		EQ 15MG BASE/ML	A079212	001 Feb 23, 2009
TABLET;ORAL				
RANITIDINE HYDROCHLORIDE				
	BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662	001 Aug 29, 1997
		EQ 300MG BASE	A074662	002 Aug 29, 1997
	MYLAN	EQ 150MG BASE	A074023	001 Aug 22, 1997
		EQ 150MG BASE	A074552	001 Jul 30, 1998
		EQ 300MG BASE	A074023	002 Aug 22, 1997
		EQ 300MG BASE	A074552	002 Jul 30, 1998
	RANBAXY	EQ 75MG BASE	A075254	001 Jan 14, 2000
		EQ 150MG BASE	A075000	001 Jan 30, 1998
		EQ 300MG BASE	A075000	002 Jan 30, 1998
	SANDOZ	EQ 75MG BASE	A075519	001 Sep 26, 2002
	SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001 Jan 14, 2000
		EQ 150MG BASE	A075439	001 Apr 19, 2000
		EQ 300MG BASE	A075439	002 Apr 19, 2000
	WATSON LABS	EQ 75MG BASE	A075212	001 Jan 14, 2000
		EQ 150MG BASE	A074864	001 Oct 20, 1997
		EQ 300MG BASE	A074864	002 Oct 20, 1997
	WATSON LABS INC	EQ 150MG BASE	A077426	001 Dec 19, 2005
		EQ 300MG BASE	A077426	002 Dec 19, 2005
	WOCKHARDT	EQ 75MG BASE	A078884	001 Jul 31, 2008
		EQ 150MG BASE	A078653	001 Nov 26, 2007
		EQ 150MG BASE	A078701	001 Nov 12, 2009
		EQ 300MG BASE	A078701	002 Dec 11, 2009
TABLET, EFFERVESCENT;ORAL				
ZANTAC 150				
	GLAXO GRP LTD	EQ 150MG BASE	N020251	001 Mar 31, 1994
ZANTAC 25				
	GLAXO GRP LTD	EQ 25MG BASE	N020251	003 Apr 01, 2004
ZANTAC 75				
	BOEHRINGER INGELHEIM	EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020745	001 Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE;INJECTION				
RAPLON				
	ORGANON USA INC	100MG/VIAL	N020984	001 Aug 18, 1999
		200MG/VIAL	N020984	002 Aug 18, 1999

FDA data supplied by DrugPatentWatch.com

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL		
HIWOLFIA		
BOWMAN PHARMS	50MG	N009276 003
	50MG	N009276 005
	100MG	N009276 004
HYSERPIN		
PHYS PRODS VA	50MG	N010581 001
KOGLUCOID		
PANRAY	50MG	N009278 001
	100MG	N009278 002
RAUDIXIN		
APOTHECON	50MG	N008842 001
	100MG	N008842 002
RAUSERPIN		
FERNDALE LABS	50MG	N009926 002
	100MG	N009926 004
RAUVAL		
PAL PAK	50MG	N009108 002
	100MG	N009108 004
RAUWOLFIA SERPENTINA		
BUNDY	50MG	N009477 001
	100MG	N009477 002
HALSEY	50MG	A080498 001
	100MG	A080498 002
IMPAX LABS	50MG	N009273 001
	100MG	N009273 002
IVAX SUB TEVA PHARMS	50MG	N011521 001
	100MG	N011521 002
PUREPAC PHARM	50MG	A080842 001
	100MG	A080842 002
PVT FORM	50MG	A080583 001
	100MG	A080583 002
SOLVAY	50MG	A080500 001
	100MG	A080500 002
TABLICAPS	50MG	A083867 001
	100MG	A083444 001
VALEANT PHARM INTL	50MG	N009668 001
	100MG	N009668 002
WATSON LABS	50MG	A080907 001
	100MG	A080914 001
WOLFINA		
FOREST PHARMS	50MG	N009255 008
	100MG	N009255 006

RESCINNAMINE

CAPSULE;ORAL		
CINNASIL		
PANRAY	0.5MG	A084736 001
TABLET;ORAL		
MODERIL		
PFIZER	0.25MG	N010686 003
	0.5MG	N010686 006

RESERPINE

ELIXIR;ORAL		
SERPASIL		
NOVARTIS	0.2MG/4ML	N009115 005
INJECTABLE;INJECTION		
SANDRIL		
LILLY	2.5MG/ML	N010012 001
SERPASIL		
NOVARTIS	2.5MG/ML	N009434 002
TABLET;ORAL		
HISERPIA		
BOWMAN PHARMS	0.1MG	N009631 002
	0.25MG	N009631 004
RAU-SED		
BRISTOL MYERS SQUIBB	0.1MG	N009357 001
	0.25MG	N009357 004
	0.5MG	N009357 006
	1MG	N009357 008

FDA data supplied by DrugPatentWatch.com

RESERPINE
TABLET;ORAL

RESERPINE			
BARR	0.25MG	A080721 002	
BELL PHARMA	0.1MG	A083058 001	
	0.25MG	A083058 002	
BUNDY	0.1MG	N009663 001	
	0.25MG	N009663 003	
CYCLE PHARMS LTD	0.1MG	N009859 001	
	0.25MG	N009859 002	
ELKINS SINN	0.1MG	A083145 001	
	0.25MG	A083145 002	
EVERYLIFE	0.1MG	N010441 001	
	0.25MG	N010441 002	
	0.5MG	N010441 003	
	1MG	N010441 004	
HALSEY	0.1MG	A080457 002	
	0.25MG	A080457 001	
	1MG	A080457 003	
HIKMA INTL PHARMS	0.1MG	A080975 001	
	0.25MG	A080975 002	
	1MG	A080975 003	
IMPAX LABS	0.1MG	N009627 001	
	0.25MG	N009627 002	
IVAX SUB TEVA PHARMS	0.1MG	N011185 001	
	0.25MG	N011185 002	
MARSHALL PHARMA	0.1MG	A080492 001	
	0.25MG	A080492 002	
MK LABS	0.1MG	A080525 002	
	0.25MG	A080525 001	
MYLAN	1MG	A084974 001	
PHARMAVITE	0.25MG	A084663 001	
PUREPAC PHARM	0.1MG	A080753 002	
	0.25MG	A080753 001	
PVT FORM	0.1MG	A086117 001	
	0.25MG	A080582 001	
	0.25MG	A085775 001	
	1MG	A080582 002	
REXALL	0.25MG	A080637 001	
SOLVAY	0.25MG	A080446 001	
TABLICAPS	0.25MG	A085207 001	
TEVA	0.1MG	A089020 001	Mar 07, 1985
	0.25MG	A089019 001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667 001	
	0.25MG	N009667 002	
WATSON LABS	0.1MG	A080679 001	
	0.25MG	A080393 001	
	0.25MG	A085401 001	
	1MG	A080749 001	
WHITEWORTH TOWN PLSN	0.1MG	A080723 001	
	0.25MG	A080723 002	
	1MG	A080723 003	
SANDRIL			
LILLY	0.1MG	N009376 004	
	0.25MG	N009376 001	
SERPALAN			
LANNETT	0.1MG	N010124 001	
	0.25MG	N010124 002	
SERPANRAY			
PANRAY	0.1MG	N009391 001	
	0.25MG	N009391 002	
	1MG	N009391 004	
SERPASIL			
NOVARTIS	0.1MG	N009115 001	
	0.25MG	N009115 003	
	1MG	N009115 004	
SERPATE			
VALE	0.1MG	N009453 001	
	0.25MG	N009453 002	
SERPIVITE			
VITARINE	0.25MG	N009645 002	

RESERPINE; TRICHLORMETHIAZIDE

TABLET;ORAL			
METATENSIN #2			
SANOFI AVENTIS US	0.1MG;2MG	N012972 001	
METATENSIN #4			
SANOFI AVENTIS US	0.1MG;4MG	N012972 002	
NAQUIVAL			
SCHERING	0.1MG;4MG	N012265 003	
TRICHLORMETHIAZIDE W/ RESERPINE			
WATSON LABS	0.1MG;4MG	A085248 001	

RIBAVIRIN

CAPSULE;ORAL			
REBETOL			
MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**	N020903 001	Jun 03, 1998
TABLET;ORAL			
COPEGUS			
ROCHE	400MG	N021511 002	Jun 21, 2005

RIMANTADINE HYDROCHLORIDE

SYRUP;ORAL			
FLUMADINE			
FOREST LABS	50MG/5ML	N019650 001	Sep 17, 1993
TABLET;ORAL			
RIMANTADINE HYDROCHLORIDE			
ACTAVIS ELIZABETH	100MG	A076375 001	Jan 14, 2003
COREPHARMA	100MG	A075916 001	Nov 02, 2001

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC			
VEXOL			
ALCON	1%	N020474 001	Dec 30, 1994

RISEDRONATE SODIUM

TABLET;ORAL			
ACTONEL			
APIL	75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020835 004	Apr 16, 2007

RISPERIDONE

SOLUTION;ORAL			
RISPERIDONE			
SILARX PHARMS INC	1MG/ML	A202386 001	Jan 12, 2015
WOCKHARDT	1MG/ML	A078744 001	Oct 08, 2009
TABLET;ORAL			
RISPERDAL			
JANSSEN PHARMS	5MG	N020272 005	Dec 29, 1993
RISPERIDONE			
CADISTA PHARMS	0.25MG	A078828 001	Mar 23, 2009
	0.5MG	A078828 002	Mar 23, 2009
	1MG	A078828 003	Mar 23, 2009
	2MG	A078828 004	Mar 23, 2009
	3MG	A078828 005	Mar 23, 2009
	4MG	A078828 006	Mar 23, 2009
RATIOPHARM	0.25MG	A077784 001	Jun 08, 2010
	0.5MG	A077784 002	Jun 08, 2010
	1MG	A077784 003	Jun 08, 2010
	2MG	A077784 004	Jun 08, 2010
	3MG	A077784 005	Jun 08, 2010
	4MG	A077784 006	Jun 08, 2010
SYNTHON PHARMS	0.25MG	A078187 001	Oct 22, 2009
	0.5MG	A078187 002	Oct 22, 2009
	1MG	A078187 003	Oct 22, 2009
	2MG	A078187 004	Oct 22, 2009
	3MG	A078187 005	Oct 22, 2009
	4MG	A078187 006	Oct 22, 2009
WATSON LABS	0.25MG	A077860 001	Dec 05, 2008
	0.5MG	A077860 002	Dec 05, 2008
	1MG	A077860 003	Dec 05, 2008
	2MG	A077860 004	Dec 05, 2008
	3MG	A077860 005	Dec 05, 2008

RISPERIDONE
TABLET;ORAL
RISPERIDONE

	4MG	A077860	006	Dec 05, 2008
WEST WARD PHARMS	0.25MG	A078740	001	May 29, 2009
	0.5MG	A078740	002	May 29, 2009
	1MG	A078740	003	May 29, 2009
	2MG	A078740	004	May 29, 2009
	3MG	A078740	005	May 29, 2009
	4MG	A078740	006	May 29, 2009

RITODRINE HYDROCHLORIDE
INJECTABLE;INJECTION
RITODRINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A071188	001	Jul 23, 1987
	15MG/ML	A071189	001	Jul 23, 1987
HOSPIRA	10MG/ML	A071618	001	Feb 28, 1991
	15MG/ML	A071619	001	Feb 28, 1991

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML	A071438	001	Jan 22, 1991

YUTOPAR

ASTRAZENECA	10MG/ML	N018580	001	
	15MG/ML	N018580	002	

TABLET;ORAL
YUTOPAR

ASTRAZENECA	10MG	N018555	001	

RITONAVIR
CAPSULE;ORAL
NORVIR

ABBOTT	100MG	N020680	001	Mar 01, 1996

RIVASTIGMINE TARTRATE
SOLUTION;ORAL
EXELON

NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000

ROCURONIUM BROMIDE
INJECTABLE;INJECTION
ZEMURON

ORGANON USA INC	50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214	001	Mar 17, 1994
	10MG/ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214	002	Mar 17, 1994
	100MG/10ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214	003	Mar 17, 1994

ROFECOXIB
SUSPENSION;ORAL
VIOXX

MERCK	12.5MG/5ML	N021052	001	May 20, 1999
	25MG/5ML	N021052	002	May 20, 1999

TABLET;ORAL
VIOXX

MERCK	12.5MG	N021042	001	May 20, 1999
	25MG	N021042	002	May 20, 1999
	50MG	N021042	003	Feb 25, 2000

ROPINIROLE HYDROCHLORIDE
TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

COREPHARMA	EQ 0.25MG BASE	A078230	001	May 20, 2008
	EQ 0.5MG BASE	A078230	002	May 20, 2008
	EQ 1MG BASE	A078230	003	May 20, 2008
	EQ 2MG BASE	A078230	004	May 20, 2008
	EQ 3MG BASE	A078230	005	May 20, 2008
	EQ 4MG BASE	A078230	006	May 20, 2008
	EQ 5MG BASE	A078230	007	May 20, 2008

FDA data supplied by DrugPatentWatch.com

ROPINIROLE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
REQUIP XL

GLAXOSMITHKLINE LLC	EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022008 002	Jun 13, 2008

ROPIVACAINE HYDROCHLORIDE
SOLUTION;INJECTION
NAROPIN

FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533 013	May 01, 1998
	75MG/10ML (7.5MG/ML)	N020533 012	Sep 24, 1996

ROSE BENGAL SODIUM I-131
INJECTABLE;INJECTION
ROBENGATOPE

BRACCO	0.5mCi/VIAL	N016224 001	
	1mCi/VIAL	N016224 002	
	2mCi/VIAL	N016224 003	

SODIUM ROSE BENGAL I 131

SORIN	0.5mCi/ML	N017318 001	

RUFINAMIDE
TABLET;ORAL
BANZEL

EISAI INC	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021911 001	Nov 14, 2008

SAFFLOWER OIL
INJECTABLE;INJECTION
LIPOSYN 10%

ABBOTT	10% (10GM/100ML)	N018203 001	

LIPOSYN 20%

ABBOTT	20% (20GM/100ML)	N018614 001	

SAFFLOWER OIL; SOYBEAN OIL
INJECTABLE;INJECTION
LIPOSYN II 10%

HOSPIRA	5%;5% (5GM/100ML)	N018997 001	Aug 27, 1984

LIPOSYN II 20%

HOSPIRA	10%;10% (10GM/100ML)	N018991 001	Aug 27, 1984

SALMETEROL XINAFOATE
AEROSOL, METERED;INHALATION
SEREVENT

GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236 001	Feb 04, 1994

SAQUINAVIR
CAPSULE;ORAL
FORTOVASE

HOFFMANN LA ROCHE	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020828 001	Nov 07, 1997

SARALASIN ACETATE
INJECTABLE;INJECTION
SARENIN

PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009 001	

SECOBARBITAL SODIUM
CAPSULE;ORAL
SECOBARBITAL SODIUM

ANABOLIC	100MG	A084422 001	
BARR	100MG	A084225 001	
EVERYLIFE	100MG	A085895 001	
HALSEY	100MG	A084676 001	
IVAX PHARMS	100MG	A085869 001	
KV PHARM	100MG	A085285 001	
LANNETT	50MG	A085909 001	
	100MG	A085903 001	
PARKE DAVIS	100MG	A084762 001	
PERRIGO	100MG	A084561 001	
PUREPAC PHARM	100MG	A085867 001	
VALEANT PHARM INTL	100MG	A085477 001	

FDA data supplied by DrugPatentWatch.com

SECOBARBITAL SODIUM

CAPSULE;ORAL			
SECOBARBITAL SODIUM			
VITARINE	100MG	A085898 001	
	100MG	A086273 001	
WATSON LABS	100MG	A085792 001	
WEST WARD	100MG	A084926 001	
WHITEWORTH TOWN PLSN	100MG	A085798 001	
WYETH AYERST	100MG	A086390 001	
INJECTABLE;INJECTION			
SECOBARBITAL SODIUM			
ELKINS SINN	100MG/VIAL	A083281 001	
WYETH AYERST	50MG/ML	A083262 001	
SECONAL SODIUM			
LILLY	50MG/ML	N007392 002	
SUPPOSITORY;RECTAL			
SECONAL SODIUM			
LILLY	30MG	A086530 001	
	60MG	A086530 002	
	120MG	A086530 003	
	200MG	A086530 004	

SECRETIN

INJECTABLE;INJECTION			
SECRETIN-FERRING			
FERRING	75CU/VIAL	N018290 001	

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION;INTRAVENOUS			
SECREFLO			
CHIRHOCLIN	16MCG/VIAL	N021136 001	Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL			
SELEGILINE HYDROCHLORIDE			
LANNETT HOLDINGS INC	5MG	A075145 001	Sep 15, 2003
TABLET;ORAL			
SELEGILINE HYDROCHLORIDE			
DAVA PHARMS INC	5MG	A074641 001	Aug 02, 1996
G AND W LABS INC	5MG	A074537 001	Aug 02, 1996
	5MG	A074744 001	Jan 27, 1997
	5MG	A074756 001	Nov 25, 1998
SIEGFRIED	5MG	A074672 001	Apr 01, 1997
SOMERSET	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019334 001	Jun 05, 1989
VINTAGE PHARMS LLC	5MG	A074565 001	Aug 02, 1996

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL			
EXSEL			
ALLERGAN HERBERT	2.5%	A083892 001	
SELENIUM SULFIDE			
ACTAVIS MID ATLANTIC	2.5%	A084394 001	
G AND W LABS INC	2.5%	A086209 001	
IVAX PHARMS	2.5%	A085777 001	

SELENOMETHIONINE SE-75

INJECTABLE;INJECTION			
SELENOMETHIONINE SE 75			
GE HEALTHCARE	250uCi/ML	N017257 001	
MALLINCKRODT	100uCi/ML	N017098 001	
PHARMALUCENCE	500uCi/ML	N017322 001	
SETHOTOPE			
BRACCO	85-550uCi/ML	N017047 001	

SERACTIDE ACETATE

INJECTABLE;INJECTION			
ACTHAR GEL-SYNTHETIC			
ARMOUR PHARM	40 UNITS/ML	N017861 001	
	80 UNITS/ML	N017861 002	

SERMORELIN ACETATE
INJECTABLE;INJECTION
GEREF

EMD SERONO	EQ 0.05MG BASE/AMP **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019863 001	Dec 28, 1990
EMD SERONO INC	EQ 0.5MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020443 001	Sep 26, 1997
	EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020443 002	Sep 26, 1997

SERTRALINE HYDROCHLORIDE
CONCENTRATE;ORAL
SERTRALINE HYDROCHLORIDE

RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007
ROXANE	EQ 20MG BASE/ML	A076934 001	Jun 30, 2006

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 25MG BASE	A077345 001	Feb 06, 2007
	EQ 50MG BASE	A077345 002	Feb 06, 2007
	EQ 100MG BASE	A077345 003	Feb 06, 2007
CIPLA LTD	EQ 25MG BASE	A077162 001	Feb 06, 2007
	EQ 50MG BASE	A077162 002	Feb 06, 2007
	EQ 100MG BASE	A077162 003	Feb 06, 2007
DR REDDYS LABS LTD	EQ 25MG BASE	A076442 001	Apr 30, 2007
	EQ 50MG BASE	A076442 002	Apr 30, 2007
	EQ 100MG BASE	A076442 003	Apr 30, 2007
FRONTIDA BIOPHARM	EQ 25MG BASE	A077818 001	Feb 06, 2007
	EQ 50MG BASE	A077818 002	Feb 06, 2007
	EQ 100MG BASE	A077818 003	Feb 06, 2007
HIKMA PHARMS	EQ 25MG BASE	A077864 001	Aug 10, 2009
	EQ 50MG BASE	A077864 002	Aug 10, 2009
	EQ 100MG BASE	A077864 003	Aug 10, 2009
IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719 003	Jun 30, 2006
	EQ 50MG BASE	A075719 001	Jun 30, 2006
	EQ 100MG BASE	A075719 002	Jun 30, 2006
MYLAN PHARMS INC	EQ 25MG BASE	A076540 001	Mar 20, 2007
	EQ 50MG BASE	A076540 002	Mar 20, 2007
	EQ 100MG BASE	A076540 003	Mar 20, 2007
PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299 001	Feb 06, 2007
	EQ 50MG BASE	A077299 002	Feb 06, 2007
	EQ 100MG BASE	A077299 003	Feb 06, 2007
ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007
	EQ 50MG BASE	A076881 002	Feb 06, 2007
	EQ 100MG BASE	A076881 003	Feb 06, 2007
SANDOZ	EQ 25MG BASE	A077713 001	Feb 06, 2007
	EQ 50MG BASE	A077713 002	Feb 06, 2007
	EQ 100MG BASE	A077713 003	Feb 06, 2007
WATSON LABS	EQ 25MG BASE	A077663 001	Feb 06, 2007
	EQ 50MG BASE	A077663 002	Feb 06, 2007
	EQ 100MG BASE	A077663 003	Feb 06, 2007

ZOLOFT

PFIZER	EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019839 003	Dec 30, 1991
	EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019839 004	Dec 30, 1991

SEVELAMER HYDROCHLORIDE
CAPSULE;ORAL
RENAGEL

GENZYME	403MG	N020926 001	Oct 30, 1998

FDA data supplied by DrugPatentWatch.com

SIBUTRAMINE HYDROCHLORIDE
CAPSULE;ORAL
MERIDIA

ABBOTT	5MG	N020632 001	Nov 22, 1997
	10MG	N020632 002	Nov 22, 1997
	15MG	N020632 003	Nov 22, 1997

SILDENAFIL CITRATE
TABLET;ORAL
SILDENAFIL CITRATE

ACTAVIS GRP PTC	EQ 20MG BASE	A200149 001	Feb 25, 2013
TEVA	EQ 25MG BASE	A077342 001	Mar 09, 2016
	EQ 50MG BASE	A077342 002	Mar 09, 2016
	EQ 100MG BASE	A077342 003	Mar 09, 2016

SILVER SULFADIAZINE
DRESSING;TOPICAL
SILDAFLO

FRANKLIN PHARMS	1%	N019608 001	Nov 30, 1989

SIMETHICONE-CELLULOSE
SUSPENSION;ORAL
SONORX

BRACCO	7.5MG/ML	N020773 001	Oct 29, 1998

SIMVASTATIN
TABLET;ORAL
SIMVASTATIN

SANDOZ INC	5MG	A077766 001	Dec 20, 2006
	10MG	A077766 002	Dec 20, 2006
	20MG	A077766 003	Dec 20, 2006
	40MG	A077766 004	Dec 20, 2006
	80MG	A077766 005	Dec 20, 2006
SUN PHARM INDS LTD	5MG	A076285 001	Dec 20, 2006
	10MG	A076285 002	Dec 20, 2006
	20MG	A076285 003	Dec 20, 2006
	40MG	A076285 004	Dec 20, 2006
	80MG	A076285 005	Jun 23, 2006

TABLET, ORALLY DISINTEGRATING;ORAL
SIMVASTATIN

SYNTHON PHARMS	10MG	N021961 001	Oct 09, 2007
	20MG	N021961 002	Oct 09, 2007
	40MG	N021961 003	Oct 09, 2007
	80MG	N021961 004	Oct 09, 2007

SIMVASTATIN; SITAGLIPTIN PHOSPHATE
TABLET;ORAL
JUVISYNC

MERCK SHARP DOHME	10MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N202343 004	Sep 18, 2012
	10MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N202343 001	Oct 07, 2011
	20MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N202343 005	Sep 18, 2012
	20MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N202343 002	Oct 07, 2011
	40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N202343 006	Sep 18, 2012
	40MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N202343 003	Oct 07, 2011

FDA data supplied by DrugPatentWatch.com

SIROLIMUS
TABLET;ORAL
RAPAMUNE

PF PRISM CV	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021110 003	Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATE
SOLUTION;ORAL
UCEPHAN

B BRAUN	100MG/ML;100MG/ML	N019530 001	Dec 23, 1987

SODIUM BICARBONATE
INJECTABLE;INJECTION
SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT	0.9MEQ/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019443 001	Jun 03, 1986
	1MEQ/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019443 002	Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACID
GRANULE, EFFERVESCENT;ORAL
BAROS

MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985

SODIUM CHLORIDE
INJECTABLE;INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM	9MG/ML	A088909 001	Feb 07, 1985

SODIUM CHLORIDE

ABBOTT	20GM/100ML	N017013 001	
B BRAUN	20GM/100ML	N017038 001	

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	450MG/100ML	N018184 001	
MILES	450MG/100ML	N018503 001	

SODIUM CHLORIDE 0.9%

MEDEFIL INC	18MG/2ML (9MG/ML)	N202832 002	Jan 06, 2012
	22.5MG/2.5ML (9MG/ML)	N202832 003	Jan 06, 2012
	27MG/3ML (9MG/ML)	N202832 004	Jan 06, 2012
	45MG/5ML (9MG/ML)	N202832 005	Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	9MG/ML	N019218 001	Jul 13, 1984
MEDEFIL INC	9MG/ML (9MG/ML)	N202832 001	Jan 06, 2012
MILES	900MG/100ML	N018502 001	

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ABRAXIS PHARM	234MG/ML	N019329 001	Apr 22, 1987

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

B BRAUN	3GM/100ML	N019635 003	Mar 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML	N019635 004	Mar 09, 1988

SOLUTION;IRRIGATION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE	450MG/100ML	N017864 001	
	450MG/100ML	N018497 001	Feb 19, 1982
HOSPIRA	450MG/100ML	N017670 001	
	450MG/100ML	N018380 001	

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES	900MG/100ML	N018247 001	

SODIUM CHROMATE CR-51
INJECTABLE;INJECTION
CHROMITOPE SODIUM

BRACCO	2mCi/VIAL	N013993 002	
	200uCi/ML	N013993 001	

SODIUM CHROMATE CR 51

MALLINKRODT NUCLEAR	100uCi/ML	N016708 001	

FDA data supplied by DrugPatentWatch.com

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS			
FLUORINE F-18			
GE HEALTHCARE	2mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017042 001	
SODIUM FLUORIDE F 18			
NIH NCI DCTD	10-200mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022494 001	Jan 26, 2011

SODIUM IODIDE I-123

CAPSULE;ORAL			
SODIUM IODIDE I 123			
CARDINAL HEALTH 418	400uCi	N018671 003	May 27, 1982
GE HEALTHCARE	100uCi	N017630 001	
SOLUTION;ORAL			
SODIUM IODIDE I 123			
GE HEALTHCARE	2mCi/ML	N017630 002	

SODIUM IODIDE I-131

CAPSULE;ORAL			
IODOTOPE			
BRACCO	1-130mCi	N010929 001	
	1-150mCi	N010929 003	
SODIUM IODIDE I 131			
CIS	50uCi	N017316 001	
	100uCi	N017316 002	
JUBILANT DRAXIMAGE	2-200mCi	N021305 004	Nov 18, 2004
MALLINKRODT NUCLEAR	0.8-100mCi	N016515 002	
	15-100uCi	N016517 002	
SOLUTION;ORAL			
HICON			
JUBILANT DRAXIMAGE	1-250mCi/0.25ML	N021305 002	Jan 24, 2003
	1-500mCi/0.5ML	N021305 003	Jan 24, 2003
	1-1000mCi/ML	N021305 005	Apr 04, 2006
IODOTOPE			
BRACCO	7-106mCi/BOT	N010929 002	
SODIUM IODIDE I 131			
CIS	50mCi/ML	N017315 001	

SODIUM LACTATE

INJECTABLE;INJECTION			
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER			
B BRAUN	1.87GM/100ML	N018186 001	
BAXTER HLTHCARE	1.87GM/100ML	N016692 001	
HOSPIRA	1.87GM/100ML	N018249 001	
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER			
B BRAUN	1.87GM/100ML	N020004 001	Apr 21, 1992

SODIUM MONOFLUOROPHOSPHATE

GEL;DENTAL			
EXTRA-STRENGTH AIM			
CHESEBROUGH PONDS	1.2%	N019518 002	Aug 06, 1986
PASTE;DENTAL			
EXTRA-STRENGTH AIM			
CHESEBROUGH PONDS	1.2%	N019518 001	Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION			
NIPRIDE			
ROCHE	50MG/VIAL	N017546 001	
NITROPRESS			
ABBOTT	50MG/VIAL	A071555 001	Nov 16, 1987
ABBVIE	50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018450 001	
HOSPIRA	50MG/VIAL	A070566 001	Jun 09, 1986
SODIUM NITROPRUSSIDE			
ABRAXIS PHARM	50MG/VIAL	A070031 001	Jan 17, 1985
BAXTER HLTHCARE	50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or	N018581 001	Jul 28, 1982

SODIUM NITROPRUSSIDE
INJECTABLE;INJECTION
SODIUM NITROPRUSSIDE

	efficacy reasons**		
TEVA PARENTERAL	25MG/ML	A073465 001	Mar 30, 1992

SODIUM PHOSPHATE P-32
SOLUTION;INJECTION, ORAL
PHOSPHOTOPE

BRACCO	1-8mCi/VIAL	N010927 001	

SODIUM PHOSPHATE P 32

MALLINCKRODT	0.67mCi/ML	N011777 001	
	1.5mCi/VIAL	N011777 002	

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
TABLET;ORAL
VISICOL

SALIX PHARMS	0.398GM;1.102GM	N021097 001	Sep 21, 2000

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
TABLET;ORAL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC	0.398GM;1.102GM	A079247 001	Dec 30, 2011

SODIUM POLYSTYRENE SULFONATE
POWDER;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

CITRUSPHRMA	454GM/BOT	A040909 001	Dec 03, 2008
WOCKHARDT	453.6GM/BOT	A088786 001	Sep 11, 1984

SUSPENSION;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

MORTON GROVE	15GM/60ML	A088717 001	Sep 11, 1984
ROXANE	15GM/60ML	A088453 001	Nov 17, 1983

SODIUM SUCCINATE
INJECTABLE;INJECTION
SODIUM SUCCINATE

ELKINS SINN	30%	A080516 001	

SODIUM TETRADECYL SULFATE
INJECTABLE;INJECTION
SOTRADECOL

ELKINS SINN	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005970 004	
	3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005970 005	

SODIUM THIOSULFATE
INJECTABLE;INJECTION
SODIUM THIOSULFATE

US ARMY	250MG/ML	N020166 001	Feb 14, 1992

SOMATREM
INJECTABLE;INJECTION
PROTROPIN

GENENTECH	5MG/VIAL	N019107 001	Oct 17, 1985
	10MG/VIAL	N019107 002	Oct 24, 1989

SOMATROPIN
INJECTABLE;INJECTION
ASELLACRIN 10

SERONO	10 IU/VIAL	N017726 001	

ASELLACRIN 2

SERONO	2 IU/VIAL	N017726 002	Jul 21, 1983

CRESCORMON

GENENTECH	4 IU/VIAL	N017992 001	

SOMATROPIN RECOMBINANT
INJECTABLE;INJECTION
ACCRETROPIN

EMERGENT	5MG/ML (5MG/ML)	N021538 001	Jan 23, 2008

BIO-TROPIN

FERRING	4.8MG/VIAL	N019774 001	May 25, 1995

FDA data supplied by DrugPatentWatch.com

SOMATROPIN RECOMBINANT
INJECTABLE;INJECTION

HUMATROPE				
LILLY	2MG/VIAL	N019640	001	Jun 23, 1987
NORDITROPIN				
NOVO NORDISK INC	4MG/VIAL	N019721	001	May 08, 1995
	5MG/1.5ML	N021148	001	Jun 20, 2000
	8MG/VIAL	N019721	002	May 08, 1995
	10MG/1.5ML	N021148	002	Jun 20, 2000
	15MG/1.5ML	N021148	003	Jun 20, 2000
NORDITROPIN NORDIFLEX				
NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004
	10MG/1.5ML	N021148	005	Oct 01, 2004
	15MG/1.5ML	N021148	006	Oct 01, 2004
	30MG/3ML	N021148	007	Mar 10, 2009
NUTROPIN				
GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993
	10MG/VIAL	N020168	002	Nov 17, 1993
NUTROPIN AQ				
GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995
NUTROPIN DEPOT				
GENENTECH	13.5MG/VIAL	N021075	001	Dec 22, 1999
	18MG/VIAL	N021075	002	Dec 22, 1999
	22.5MG/VIAL	N021075	003	Dec 22, 1999
SAIZEN				
EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007
	6MG/VIAL	N019764	001	Oct 08, 1996
SEROSTIM				
EMD SERONO	8.8MG/VIAL	N020604	004	Sep 06, 2001
ZORBTIVE				
EMD SERONO	4MG/VIAL	N021597	001	Dec 01, 2003
	5MG/VIAL	N021597	002	Dec 01, 2003
	6MG/VIAL	N021597	003	Dec 01, 2003
INJECTABLE;SUBCUTANEOUS				
SEROSTIM LQ				
EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005

SORBITOL
SOLUTION;IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	3GM/100ML	N018512	001	May 27, 1982

SOTALOL HYDROCHLORIDE
TABLET;ORAL

BETAPACE				
COVIS PHARMA SARL	320MG	N019865	004	Oct 30, 1992
BETAPACE AF				
COVIS PHARMA SARL	40MG	N021151	006	Apr 02, 2003
	60MG	N021151	007	Apr 02, 2003
	100MG	N021151	005	Mar 14, 2003
SOTALOL HYDROCHLORIDE				
IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000
	120MG	A075663	002	Nov 07, 2000
	160MG	A075663	003	Nov 07, 2000
	240MG	A075663	004	Nov 07, 2000
SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001
	80MG	A076576	001	Apr 08, 2004
	120MG	A075515	004	Oct 15, 2001
	120MG	A076576	002	Apr 08, 2004
	160MG	A075515	002	Oct 15, 2001
	160MG	A076576	003	Apr 08, 2004
	240MG	A075515	003	Oct 15, 2001
WATSON LABS	80MG	A075238	001	Jul 13, 2000
	120MG	A075238	002	Jul 13, 2000
	160MG	A075238	003	Jul 13, 2000
	240MG	A075238	004	Jul 13, 2000

SOYBEAN OIL
INJECTABLE;INJECTION

LIPOSYN III 10%				
HOSPIRA	10%	N018969	001	Sep 24, 1984
LIPOSYN III 20%				
HOSPIRA	20%	N018970	001	Sep 25, 1984

FDA data supplied by DrugPatentWatch.com

SOYBEAN OIL
INJECTABLE;INJECTION
LIPOSYN III 30%

HOSPIRA	30%	N020181 001	Jan 13, 1998

SOYACAL 10%

ALPHA THERA	10%	N018465 001	Jun 29, 1983

SOYACAL 20%

ALPHA THERA	20%	N018786 001	Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE	10%	N018660 001	Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE	20%	N018758 001	Feb 15, 1983

SPARFLOXACIN
TABLET;ORAL
ZAGAM

MYLAN	200MG	N020677 001	Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE
INJECTABLE;INJECTION
TROBICIN

PFIZER	EQ 2GM BASE/VIAL	N050347 001	
	EQ 4GM BASE/VIAL	N050347 002	

SPIRAPRIL HYDROCHLORIDE
TABLET;ORAL
RENORMAX

SCHERING	3MG	N020240 001	Dec 29, 1994
	6MG	N020240 002	Dec 29, 1994
	12MG	N020240 003	Dec 29, 1994
	24MG	N020240 004	Dec 29, 1994

SPIRONOLACTONE
TABLET;ORAL
SPIRONOLACTONE

ASCOT	25MG	A087687 001	Oct 20, 1982
IVAX PHARMS	25MG	A087108 001	
LEDERLE	25MG	A087634 001	
MUTUAL PHARM	25MG	A087265 001	
MYLAN	25MG	A087086 001	
PUREPAC PHARM	25MG	A087998 001	Oct 14, 1983
	25MG	A088053 001	Aug 25, 1983
SUPERPHARM	25MG	A089364 001	Nov 07, 1986
UPSHER SMITH	25MG	A087554 001	
VANGARD	25MG	A087648 001	Feb 01, 1982
WARNER CHILCOTT	25MG	A087952 001	Nov 18, 1982
WATSON LABS	25MG	A086898 002	Mar 02, 1982
	25MG	A087078 001	

STANOZOLOL
TABLET;ORAL
WINSTROL

LUNDBECK INC	2MG	N012885 001	May 14, 1984

STAVUDINE
CAPSULE;ORAL
ZERIT

BRISTOL MYERS SQUIBB	5MG	N020412 001	Jun 24, 1994

CAPSULE, EXTENDED RELEASE;ORAL
ZERIT XR

BRISTOL MYERS SQUIBB	37.5MG	N021453 001	Dec 31, 2002
	50MG	N021453 002	Dec 31, 2002
	75MG	N021453 003	Dec 31, 2002
	100MG	N021453 004	Dec 31, 2002

STERILE WATER FOR INJECTION
LIQUID;N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%	A089099 001	Dec 29, 1987
	100%	A089100 001	Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN	100%	N019077 001	Mar 02, 1984

FDA data supplied by DrugPatentWatch.com

STERILE WATER FOR IRRIGATION
LIQUID;IRRIGATION
STERILE WATER IN PLASTIC CONTAINER

MILES	100%	N018246 001	

STREPTOMYCIN SULFATE
INJECTABLE;INJECTION
STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML	A060684 001	
LILLY	EQ 1GM BASE/VIAL	A060107 001	
	EQ 1GM BASE/2ML	A060404 001	
	EQ 5GM BASE/VIAL	A060107 002	
PFIZER	EQ 1GM BASE/VIAL	A060076 001	
	EQ 1GM BASE/2.5ML	A060111 001	
	EQ 5GM BASE/VIAL	A060076 002	

SUCCINYLCHOLINE CHLORIDE
INJECTABLE;INJECTION
ANECTINE

SANDOZ	50MG/ML	N008453 003	
	500MG/VIAL	N008453 001	
	1GM/VIAL	N008453 004	

QUELICIN PRESERVATIVE FREE

HOSPIRA	50MG/ML	N008845 002	
	100MG/ML	N008845 004	

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION	100MG/VIAL	A085400 001	Feb 04, 1982
ORGANON USA INC	20MG/ML	A080997 001	

SUCOSTRIN

APOTHECON	20MG/ML	N008847 001	
	100MG/ML	N008847 003	

SUFENTANIL CITRATE
INJECTABLE;INJECTION
SUFENTANIL CITRATE

WATSON LABS	EQ 0.05MG BASE/ML	A074406 001	Dec 15, 1995

SULFACETAMIDE SODIUM
OINTMENT;OPHTHALMIC
BLEPH-10

ALLERGAN	10%	A084015 001	

CETAMIDE

ALCON	10%	A080021 001	

SODIUM SULAMYD

SCHERING	10% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005963 002	

SULFAIR 10

PHARMAFAIR	10%	A088000 001	Dec 22, 1982

SOLUTION/DROPS;OPHTHALMIC
BLEPH-30

ALLERGAN	30%	A080028 002	

ISOPTO CETAMIDE

ALCON	15%	A080020 002	

OCUSULF-10

MIZA PHARMS USA	10%	A080660 001	

OCUSULF-30

MIZA PHARMS USA	30%	A080660 002	

SODIUM SULAMYD

SCHERING	10% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005963 001	
	30% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005963 003	

SODIUM SULFACETAMIDE

AKORN	10%	A083021 001	
	15%	A083021 002	
	30%	A083021 003	
SOLA BARNES HIND	10%	A084143 001	
	10%	A084145 001	
	30%	A084146 001	
	30%	A084147 001	

FDA data supplied by DrugPatentWatch.com

SULFACETAMIDE SODIUM
SOLUTION/DROPS;OPHTHALMIC

SULF-10			
NOVARTIS	10%	A080025 001	
SULF-15			
NOVARTIS	15%	A089047 001	Oct 31, 1995
SULFACEL-15			
OPTOPICS	15%	A080024 001	
SULFACETAMIDE SODIUM			
AKORN	30%	A040216 001	May 25, 1999
ALCON PHARMS LTD	30%	A089068 001	May 05, 1987
PHARMAFAIR	10%	A088947 001	May 17, 1985
SULFAIR 10			
PHARMAFAIR	10%	A087949 001	Dec 13, 1982
SULFAIR FORTE			
PHARMAFAIR	30%	A088385 001	Oct 13, 1983
SULFAIR-15			
PHARMAFAIR	15%	A088186 001	May 25, 1983
SULTEN-10			
BAUSCH AND LOMB	10%	A087818 001	Feb 03, 1983

SULFACYTINE
TABLET;ORAL

RENOQUID			
GLENWOOD	250MG	N017569 001	

SULFADIAZINE
TABLET;ORAL

SULFADIAZINE			
ABBVIE	300MG	N004125 005	
EVERYLIFE	500MG	A080088 001	
IMPAX LABS	500MG	A080081 001	
LANNETT	500MG	A080084 001	
LEDERLE	500MG	N004054 001	
LILLY	500MG	N004122 002	

SULFADIAZINE SODIUM
INJECTABLE;INJECTION

SULFADIAZINE SODIUM			
LEDERLE	250MG/ML	N004054 002	

SULFADIAZINE; SULFAMERAZINE
SUSPENSION;ORAL

SULFONAMIDES DUPLEX			
LILLY	250MG/5ML;250MG/5ML	N006317 007	

SULFAMETER
TABLET;ORAL

SULLA			
BAYER HLTHCARE	500MG	N016000 002	

SULFAMETHIZOLE
TABLET;ORAL

MICROSUL			
FOREST PHARMS	1GM	A086012 001	
PROKLAR			
FOREST PHARMS	500MG	A080273 001	
THIOSULFIL			
WYETH AYERST	250MG	N008565 001	
	500MG	N008565 004	

SULFAMETHOXAZOLE
SUSPENSION;ORAL

GANTANOL			
ROCHE	500MG/5ML	N013664 002	

TABLET;ORAL

GANTANOL			
ROCHE	500MG	N012715 002	
GANTANOL-DS			
ROCHE	1GM	N012715 003	
SULFAMETHOXAZOLE			
ASCOT	500MG	A087662 001	Oct 20, 1982
AUROLIFE PHARMA LLC	500MG	A085844 001	
BARR	500MG	A087189 001	Jul 25, 1983
HEATHER	500MG	A086163 001	
WATSON LABS	500MG	A085053 001	

SULFAMETHOXAZOLE
TABLET;ORAL
SULFAMETHOXAZOLE
1GM A086000 001
UROBAK
SHIONOGI 500MG A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM
INJECTABLE;INJECTION
BACTRIM
MUTUAL PHARM 80MG/ML;16MG/ML N018374 001
SEPTRA
MONARCH PHARMS 80MG/ML;16MG/ML N018452 001
SULFAMETHOXAZOLE AND TRIMETHOPRIM
ABRAXIS PHARM 80MG/ML;16MG/ML A070223 001 Dec 29, 1987
BEDFORD 80MG/ML;16MG/ML A072383 001 Apr 29, 1992
HOSPIRA 80MG/ML;16MG/ML A073199 001 Sep 11, 1992
WATSON LABS 80MG/ML;16MG/ML A071556 001 Dec 29, 1987
WEST-WARD PHARMS INT 80MG/ML;16MG/ML A070627 001 Dec 29, 1987
80MG/ML;16MG/ML A070628 001 Dec 29, 1987
SUSPENSION;ORAL
BACTRIM
SUN PHARM INDS 200MG/5ML;40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N017560 001
BACTRIM PEDIATRIC
SUN PHARM INDS 200MG/5ML;40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N017560 002
SEPTRA
MONARCH PHARMS 200MG/5ML;40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N017598 001
SEPTRA GRAPE
MONARCH PHARMS 200MG/5ML;40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N017598 002 Feb 12, 1986
SULFAMETHOXAZOLE AND TRIMETHOPRIM
ANI PHARMS INC 200MG/5ML;40MG/5ML A070028 001 Jun 02, 1987
200MG/5ML;40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** A077612 001 Nov 13, 2006
TEVA 200MG/5ML;40MG/5ML N018812 001 Jan 28, 1983
200MG/5ML;40MG/5ML N018812 002 Jun 10, 1983
SULFATRIM
STI PHARMA LLC 200MG/5ML;40MG/5ML N018615 002 Jan 07, 1983
SULMEPRIM
USL PHARMA 200MG/5ML;40MG/5ML A070063 001 Aug 01, 1986
SULMEPRIM PEDIATRIC
USL PHARMA 200MG/5ML;40MG/5ML A070064 001 Aug 01, 1986
TRIMETH/SULFA
ALPHARMA US PHARMS 200MG/5ML;40MG/5ML A072289 001 May 23, 1988
200MG/5ML;40MG/5ML A072398 001 May 23, 1988
NASKA 200MG/5ML;40MG/5ML A072399 001 May 23, 1988
TABLET;ORAL
COTRIM
TEVA 400MG;80MG A070034 001 May 16, 1985
COTRIM D.S.
TEVA 800MG;160MG A070048 001 Mar 18, 1985
SULFAMETHOPRIM
NOVEL LABS INC 400MG;80MG A070022 001 Feb 15, 1985
SULFAMETHOPRIM-DS
NOVEL LABS INC 800MG;160MG A070032 001 Feb 15, 1985
SULFAMETHOXAZOLE AND TRIMETHOPRIM
HEATHER 400MG;80MG N018946 001 Aug 10, 1984
800MG;160MG N018946 002 Aug 10, 1984
INTERPHARM 400MG;80MG A071299 001 Oct 27, 1987
800MG;160MG A071300 001 Oct 27, 1987
MARTEC USA LLC 400MG;80MG A072408 001 Dec 07, 1988
MUTUAL PHARM 400MG;80MG A070006 001 Nov 14, 1984

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL				
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
	400MG;80MG	A071016	001	Aug 25, 1986
PLIVA	400MG;80MG	A070215	001	Sep 10, 1985
	800MG;160MG	A070216	001	Sep 10, 1985
ROXANE	400MG;80MG	A072768	001	Aug 30, 1991
SANDOZ	400MG;80MG	A070889	001	Nov 13, 1986
	400MG;80MG	N018598	003	May 19, 1982
	800MG;160MG	A070890	001	Nov 13, 1986
TEVA	400MG;80MG	N018242	001	
	800MG;160MG	N018242	002	
USL PHARMA	400MG;80MG	A070203	001	Nov 08, 1985
	800MG;160MG	A070204	001	Nov 08, 1985
WATSON LABS	400MG;80MG	A070002	001	Nov 07, 1984
	400MG;80MG	N018852	001	May 09, 1983
	800MG;160MG	A070000	001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH				
MARTEC USA LLC	800MG;160MG	A072417	001	Dec 07, 1988
MUTUAL PHARM	800MG;160MG	A070007	001	Nov 14, 1984
ROXANE	800MG;160MG	A072769	001	Aug 30, 1991
SANDOZ	800MG;160MG	N018598	004	May 19, 1982
WATSON LABS	800MG;160MG	N018854	001	May 09, 1983
SULFATRIM-DS				
SUPERPHARM	800MG;160MG	A070066	001	Jun 24, 1985
SULFATRIM-SS				
SUPERPHARM	400MG;80MG	A070065	002	Jun 24, 1985
UROPLUS DS				
SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS				
SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987

SULFANILAMIDE

CREAM;VAGINAL				
SULFANILAMIDE				
G AND W LABS INC	15%	A088718	001	Sep 19, 1985
SUPPOSITORY;VAGINAL				
AVC				
MEDA PHARMS	1.05GM	N006530	004	Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION;ORAL				
SULFABID				
PHARM RES ASSOC	500MG/5ML	N013093	001	
TABLET;ORAL				
SULFABID				
PURDUE FREDERICK	500MG	N013092	002	

SULFAPYRIDINE

TABLET;ORAL				
SULFAPYRIDINE				
LILLY	500MG	N000159	001	

SULFASALAZINE

SUSPENSION;ORAL				
AZULFIDINE				
PHARMACIA AND UPJOHN	250MG/5ML	N018605	001	
TABLET;ORAL				
S.A.S.-500				
SOLVAY	500MG	A083450	001	
SULFASALAZINE				
HERITAGE PHARMS INC	500MG	A080197	001	
SANDOZ	500MG	A086184	001	
SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987
SUPERPHARM	500MG	A089339	001	Oct 26, 1987
WATSON LABS	500MG	A084964	001	
	500MG	A087197	001	
TABLET, DELAYED RELEASE;ORAL				
SULFASALAZINE				
WATSON LABS	500MG	A088052	001	May 24, 1983

FDA data supplied by DrugPatentWatch.com

SULFINPYRAZONE

CAPSULE;ORAL			
ANTURANE			
NOVARTIS	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011556 004	
SULFINPYRAZONE			
BARR	200MG	A087666 001	Sep 17, 1982
IVAX PHARMS	200MG	A087770 001	Nov 19, 1982
PAR PHARM	200MG	A088934 001	Sep 06, 1985
VANGARD	200MG	A088666 001	Feb 17, 1984
TABLET;ORAL			
ANTURANE			
NOVARTIS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011556 003	
SULFINPYRAZONE			
BARR	100MG	A087665 001	Sep 17, 1982
IVAX PHARMS	100MG	A087769 001	Jun 01, 1982
PAR PHARM	100MG	A088933 001	Sep 06, 1985
WATSON LABS	100MG	A087667 001	May 26, 1982

SULFISOXAZOLE

TABLET;ORAL		
GANTRISIN		
ROCHE	500MG	N006525 001
SOSOL		
MK LABS	500MG	A080036 001
SOXAZOLE		
ALRA	500MG	A080366 001
SULFALAR		
PARKE DAVIS	500MG	A084955 001
SULFISOXAZOLE		
ANI PHARMS INC	500MG	A080142 001
AUROLIFE PHARMA LLC	500MG	A085628 001
BARR	500MG	A084031 001
HEATHER	500MG	A080189 001
IMPAX LABS	500MG	A080109 001
LANNETT	500MG	A080085 001
LEDERLE	500MG	A087649 001
PHARMERAL	500MG	A084385 001
PUREPAC PHARM	500MG	A080087 001
ROXANE	500MG	A080082 001
VALEANT PHARM INTL	500MG	A080268 002
VITARINE	500MG	A087332 001
WATSON LABS	500MG	A085534 001
WEST WARD	500MG	A080379 001
SULSOXIN		
SOLVAY	500MG	A080040 001

SULFISOXAZOLE ACETYL

EMULSION;ORAL		
LIPO GANTRISIN		
ROCHE	EQ 1GM BASE/5ML	N009182 009
SUSPENSION;ORAL		
GANTRISIN PEDIATRIC		
ROCHE	EQ 500MG BASE/5ML	N009182 004
SYRUP;ORAL		
GANTRISIN		
ROCHE	EQ 500MG BASE/5ML	N009182 002

SULFISOXAZOLE DIOLAMINE

INJECTABLE;INJECTION		
GANTRISIN		
ROCHE	EQ 400MG BASE/ML	N006917 001
OINTMENT;OPHTHALMIC		
GANTRISIN		
ROCHE	EQ 4% BASE	N008414 002
SOLUTION/DROPS;OPHTHALMIC		
GANTRISIN		
ROCHE	EQ 4% BASE	N007757 002

SULFISOXAZOLE DIOLAMINE
SOLUTION/DROPS;OPHTHALMIC
SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND	EQ 4% BASE	A084148 001	

SULFOXONE SODIUM
TABLET, DELAYED RELEASE;ORAL
DIASONE SODIUM

ABBVIE	165MG	N006044 003	

SULFUR
POWDER;TOPICAL
BENSULFOID

POYTHRESS	33.32%	N002918 001	

SULINDAC
TABLET;ORAL
CLINORIL

MERCK	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017911 001	
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017911 002	

SULINDAC

ANI PHARMS INC	150MG	A072972 001	Feb 28, 1992
	200MG	A072973 001	Feb 28, 1992
SANDOZ	150MG	A072712 001	Aug 30, 1991
	200MG	A072713 001	Aug 30, 1991

SUMATRIPTAN
SPRAY;NASAL
IMITREX

GLAXOSMITHKLINE	10MG/SPRAY	N020626 002	Aug 26, 1997

SUMATRIPTAN SUCCINATE
INJECTABLE;SUBCUTANEOUS
ALSUMA

MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079240 002	Sep 18, 2009
	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A079240 001	Sep 18, 2009
SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067 002	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067 001	Feb 06, 2009
TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318 001	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318 002	Feb 06, 2009

TABLET;ORAL
SUMATRIPTAN SUCCINATE

HIKMA PHARMS	EQ 25MG BASE	A078298 001	May 21, 2013
	EQ 50MG BASE	A078298 002	May 21, 2013
	EQ 100MG BASE	A078298 003	May 21, 2013
MYLAN	EQ 25MG BASE	A077163 001	Nov 02, 2009
	EQ 50MG BASE	A077163 002	Nov 02, 2009
	EQ 100MG BASE	A077163 003	Nov 02, 2009
ROXANE	EQ 25MG BASE	A078241 001	Aug 10, 2009
	EQ 50MG BASE	A078241 002	Aug 10, 2009
	EQ 100MG BASE	A078241 003	Aug 10, 2009
SANDOZ	EQ 25MG BASE	A076976 001	Aug 10, 2009
	EQ 50MG BASE	A076976 002	Aug 10, 2009
	EQ 100MG BASE	A076976 003	Aug 10, 2009
TEVA	EQ 25MG BASE	A076840 001	Feb 09, 2009
	EQ 50MG BASE	A076840 002	Feb 09, 2009
	EQ 100MG BASE	A076840 003	Feb 09, 2009

SUPROFEN
SOLUTION/DROPS;OPHTHALMIC
PROFENAL

ALCON	1%	N019387 001	Dec 23, 1988

FDA data supplied by DrugPatentWatch.com

SUTILAINS
OINTMENT;TOPICAL
TRAVASE

ABBOTT	82,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012828 001	

TACRINE HYDROCHLORIDE
CAPSULE;ORAL
COGNEX

SHIONOGI INC	EQ 10MG BASE	N020070 001	Sep 09, 1993
	EQ 20MG BASE	N020070 002	Sep 09, 1993
	EQ 30MG BASE	N020070 003	Sep 09, 1993
	EQ 40MG BASE	N020070 004	Sep 09, 1993

TACROLIMUS
CAPSULE;ORAL
TACROLIMUS

WATSON LABS	EQ 5MG BASE	A090402 001	Jul 01, 2010

TALBUTAL
TABLET;ORAL
LOTUSATE

SANOFI AVENTIS US	120MG	N009410 005	

TAMOXIFEN CITRATE
TABLET;ORAL
NOLVADEX

ASTRAZENECA	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017970 001	
	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017970 002	Mar 21, 1994

TAMOXIFEN CITRATE

ACTAVIS LABS FL INC	EQ 10MG BASE	A076179 001	Feb 20, 2003
	EQ 20MG BASE	A076179 002	Feb 20, 2003
AEGIS PHARMS	EQ 10MG BASE	A076398 001	Mar 31, 2003
	EQ 20MG BASE	A076398 002	Mar 31, 2003
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075740 001	Feb 20, 2003
	EQ 20MG BASE	A075740 002	Feb 20, 2003
PHARMACHEMIE	EQ 10MG BASE	A074539 001	Mar 31, 2003
ROXANE	EQ 10MG BASE	A076027 001	Feb 20, 2003
	EQ 20MG BASE	A076027 002	Feb 20, 2003
TEVA	EQ 10MG BASE	A074504 001	Apr 28, 2003
	EQ 20MG BASE	A074504 002	Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED
INJECTABLE;INJECTION
TC 99M-LUNGAGGREGATE

GE HEALTHCARE	5mCi/ML	N017848 001	

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
INJECTABLE;INJECTION
A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS	N/A	N017916 001	

AN-MAA

PHARMALUCENCE	N/A	N017792 001	

LUNGAGGREGATE REAGENT

GE HEALTHCARE	N/A	N017838 001	

MACROTEC

BRACCO	N/A	N017833 001	

TECHNESCAN MAA

MALLINCKRODT	N/A	N017842 001	

TECHNETIUM TC 99M MAA

GE HEALTHCARE	N/A	N017773 001	

TECHNETIUM TC-99M ALBUMIN COLLOID KIT
INJECTABLE;INJECTION
MICROLITE

PHARMALUCENCE	N/A	N018263 001	Mar 25, 1983

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M ALBUMIN KIT
INJECTABLE;INJECTION
TECHNETIUM TC 99M HSA
GE HEALTHCARE N/A N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
INJECTABLE;INJECTION
INSTANT MICROSPHERES
3M N/A N017832 001

TECHNETIUM TC-99M APCITIDE
INJECTABLE;INJECTION
ACUTECT
CIS BIO INTL SA N/A N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE
INJECTABLE;INJECTION
NEO TECT KIT
CIS BIO INTL SA N/A N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KIT
INJECTABLE;INJECTION
CINTICHEM TECHNETIUM 99M HEDSPA
GE HEALTHCARE N/A N017653 001
MPI STANNOUS DIPHOSPHONATE
GE HEALTHCARE N/A N017667 001
OSTEOSCAN
MALLINCKRODT N/A N017454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
GE HEALTHCARE N/A N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT
INJECTABLE;INJECTION
RENOTEC
BRACCO N/A N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT
INJECTABLE;INJECTION
GLUCOSCAN
BRISTOL MYERS SQUIBB N/A N017907 001
TECHNESCAN GLUCEPTATE
DRAXIMAGE N/A N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT
INJECTABLE;INJECTION
TECHNESCAN HIDA
DRAXIMAGE N/A N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-10
JUBILANT DRAXIMAGE N/A N018035 001

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
AMERSCAN MDP KIT
GE HEALTHCARE N/A N018335 001 Aug 05, 1982
OSTEOLITE
PHARMALUCENCE N/A N017972 001
TECHNETIUM TC 99M MPI MDP
GE HEALTHCARE N/A N018141 001
N/A N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
MPI DTPA KIT - CHELATE
GE HEALTHCARE N/A N017255 001
TECHNETIUM TC-99M PENTETATE KIT
GE HEALTHCARE N/A N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT
INJECTABLE;INJECTION
SODIUM POLYPHOSPHATE-TIN KIT
GE HEALTHCARE N/A N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
INJECTABLE;INJECTION
PYROLITE

PHARMALUCENCE	N/A	N017684 001	

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
PHOSPHOTEC

BRACCO	N/A	N017680 001	

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
RBC-SCAN

CADEMA	N/A	N020063 001	Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
MIRALUMA

LANTHEUS MEDCL	N/A	N019785 003	May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE
SOLUTION;INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M

GE HEALTHCARE	2-100mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017471 001	
MALLINCKRODT	10-60mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017725 001	
PHARMALUCENCE	12mCi/ML	N017321 001	
	24mCi/ML	N017321 002	
	48mCi/ML	N017321 003	

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INJECTION, ORAL
MINITEC

BRACCO	0.22-2.22 CI/GENERATOR	N017339 001	

SOLUTION;INTRAVENOUS
TECHNELITE

LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771 001	

ULTRA-TECHNEKOW FM

MALLINKRODT NUCLEAR	0.25-3 CI/GENERATOR	N017243 002	

SOLUTION;INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE	830-16600mCi/GENERATOR	N017693 001	

TECHNETIUM TC-99M SUCCIMER KIT
INJECTABLE;INJECTION
MPI DMSA KIDNEY REAGENT

GE HEALTHCARE	N/A	N017944 001	May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID
SOLUTION;INJECTION, ORAL
TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE	4mCi/ML	N017456 001	

SOLUTION;ORAL
TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT	3mCi/ML	N017724 001	

TECHNETIUM TC-99M SULFUR COLLOID KIT
SOLUTION;INJECTION, ORAL
TECHNECOLL

MALLINCKRODT	N/A	N017059 001	

TECHNETIUM TC 99M TSC

GE HEALTHCARE	N/A	N017784 001	

TESULOID

BRACCO	N/A	N016923 001	

TECHNETIUM TC-99M TEBOROXIME KIT
INJECTABLE;INJECTION
CARDIOTEC

BRACCO	N/A	N019928 001	Dec 19, 1990

TEGASEROD MALEATE
TABLET;ORAL
ZELNORM

US WORLDMEDS LLC	EQ 2MG BASE	N021200 001	Jul 24, 2002
	EQ 6MG BASE	N021200 002	Jul 24, 2002

TELAPREVIR
TABLET;ORAL
INCIVEK

VERTEX PHARMS	375MG	N201917 001	May 23, 2011

TELBIVUDINE
SOLUTION;ORAL
TYZEKA

NOVARTIS	100MG/5ML	N022154 001	Apr 28, 2009

TELITHROMYCIN
TABLET;ORAL
KETEK

SANOFI AVENTIS US	300MG	N021144 002	Feb 09, 2005
	400MG	N021144 001	Apr 01, 2004

TEMAZEPAM
CAPSULE;ORAL
TEMAZ

QUANTUM PHARMICS	15MG	A070564 001	Oct 15, 1985
	30MG	A070547 001	Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR	15MG	A071708 001	Sep 29, 1988
	30MG	A071709 001	Sep 29, 1988
SUN PHARM INDS	15MG	A071174 001	Jul 10, 1986
	30MG	A071175 001	Jul 10, 1986
USL PHARMA	15MG	A070489 001	Jul 07, 1986
	30MG	A070490 001	Jul 07, 1986
WATSON LABS	15MG	A070383 001	Mar 23, 1987
	15MG	A071446 001	May 21, 1993
	30MG	A070384 001	Mar 23, 1987
	30MG	A071447 001	May 21, 1993

TERAZOSIN HYDROCHLORIDE
CAPSULE;ORAL
HYTRIN

ABBOTT	EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020347 001	Dec 14, 1994
	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020347 002	Dec 14, 1994
	EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020347 003	Dec 14, 1994
	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020347 004	Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES	EQ 1MG BASE	A075384 001	Dec 01, 2000
	EQ 2MG BASE	A075384 002	Dec 01, 2000
	EQ 5MG BASE	A075384 003	Dec 01, 2000
	EQ 10MG BASE	A075384 004	Dec 01, 2000
RANBAXY LABS LTD	EQ 1MG BASE	A076021 001	Aug 22, 2002
	EQ 2MG BASE	A076021 002	Aug 22, 2002
	EQ 5MG BASE	A076021 003	Aug 22, 2002
	EQ 10MG BASE	A076021 004	Aug 22, 2002
SANDOZ	EQ 1MG BASE	A075667 001	Jul 28, 2000
	EQ 2MG BASE	A075667 002	Jul 28, 2000
	EQ 5MG BASE	A075667 003	Jul 28, 2000
	EQ 10MG BASE	A075667 004	Jul 28, 2000

TABLET;ORAL
HYTRIN

ABBOTT	EQ 1MG BASE	N019057 001	Aug 07, 1987
	EQ 2MG BASE	N019057 002	Aug 07, 1987
	EQ 5MG BASE	N019057 003	Aug 07, 1987

TERAZOSIN HYDROCHLORIDE
TABLET;ORAL

HYTRIN				
	EQ 10MG BASE	N019057	004	Aug 07, 1987
TERAZOSIN HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530	001	Apr 21, 2000
	EQ 2MG BASE	A074530	002	Apr 21, 2000
	EQ 5MG BASE	A074530	003	Apr 21, 2000
	EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315	001	Dec 31, 1998
	EQ 1MG BASE	A074657	001	Apr 28, 2000
	EQ 2MG BASE	A074315	002	Dec 31, 1998
	EQ 2MG BASE	A074657	002	Apr 28, 2000
	EQ 5MG BASE	A074315	003	Dec 31, 1998
	EQ 5MG BASE	A074657	003	Apr 28, 2000
	EQ 10MG BASE	A074315	004	Dec 31, 1998
	EQ 10MG BASE	A074657	004	Apr 28, 2000
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000

TERBINAFINE
GEL;TOPICAL

LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998

TERBINAFINE HYDROCHLORIDE
CREAM;TOPICAL

LAMISIL				
NOVARTIS	1%	N020192	001	Dec 30, 1992

SOLUTION;TOPICAL

LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE				
GEDEON RICHTER USA	EQ 250MG BASE	A077065	001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007
WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007

TERBUTALINE SULFATE
AEROSOL, METERED;INHALATION

BRETHAIRE				
NOVARTIS	0.2MG/INH	N018762	001	Aug 17, 1984
BRICANYL				
SANOFI AVENTIS US	0.2MG/INH	N018000	001	Mar 19, 1985

INJECTABLE;INJECTION

BRETHINE				
PHARMACARE	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018571	001	
BRICANYL				
SANOFI AVENTIS US	1MG/ML	N017466	001	
TERBUTALINE SULFATE				
TEVA PHARMS USA	1MG/ML	A076853	001	Jul 20, 2004

TABLET;ORAL

BRETHINE				
PHARMACARE LTD	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017849	001	
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017849	002	
BRICANYL				
SANOFI AVENTIS US	2.5MG	N017618	001	
	5MG	N017618	002	
TERBUTALINE SULFATE				
IMPAX LABS	2.5MG	A075877	001	Jun 26, 2001
	5MG	A075877	002	Jun 26, 2001

FDA data supplied by DrugPatentWatch.com

TERCONAZOLE
SUPPOSITORY;VAGINAL
TERCONAZOLE

FOUGERA PHARMS	80MG	A076850 001	Jul 12, 2006

TERIPARATIDE ACETATE
INJECTABLE;INJECTION
PARATHAR

SANOFI AVENTIS US	200 UNITS/VIAL	N019498 001	Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN
INJECTABLE;SUBCUTANEOUS
FORTEO

LILLY	0.75MG/3ML (0.25MG/ML)	N021318 001	Nov 26, 2002

TESAMORELIN ACETATE
POWDER;SUBCUTANEOUS
EGRIFTA

THERATECHNOLOGIES	EQ 2MG BASE/VIAL	N022505 002	Nov 29, 2011

TESTOLACTONE
INJECTABLE;INJECTION
TESLAC

BRISTOL MYERS SQUIBB	100MG/ML	N016119 001	

TABLET;ORAL
TESLAC

BRISTOL MYERS SQUIBB	50MG	N016118 001	
	250MG	N016118 002	

TESTOSTERONE
FILM, EXTENDED RELEASE;TRANSDERMAL
ANDRODERM

ALLERGAN SALES LLC	2.5MG/24HR	N020489 001	Sep 29, 1995
	5MG/24HR	N020489 002	May 02, 1997

TESTODERM

ALZA	4MG/24HR	N019762 001	Oct 12, 1993
	6MG/24HR	N019762 002	Oct 12, 1993

TESTODERM TTS

ALZA	5MG/24HR	N020791 001	Dec 18, 1997

INJECTABLE;INJECTION
TESTOSTERONE

WATSON LABS	25MG/ML	A086420 001	May 10, 1983
	50MG/ML	A086419 001	Aug 23, 1983
	100MG/ML	A086417 001	Jul 07, 1983

TESTOSTERONE CYPIONATE
INJECTABLE;INJECTION
DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN	50MG/ML	A085635 001	

TESTOSTERONE CYPIONATE

WATSON LABS	100MG/ML	A084401 001	
	100MG/ML	A086029 001	
	200MG/ML	A084401 002	

TESTOSTERONE ENANTHATE
INJECTABLE;INJECTION
DELATESTRYL

ENDO PHARMS	200MG/ML	N009165 001	

TESTOSTERONE ENANTHATE

WATSON LABS	100MG/ML	A083667 001	
	100MG/ML	A085599 001	
	200MG/ML	A083667 002	

TESTOSTERONE PROPIONATE
INJECTABLE;INJECTION
TESTOSTERONE PROPIONATE

BEL MAR	25MG/ML	A080741 001	
	50MG/ML	A080742 001	
	100MG/ML	A080743 001	
ELKINS SINN	25MG/ML	A080276 001	
LILLY	50MG/ML	A080254 002	
WATSON LABS	25MG/ML	A080188 001	
	25MG/ML	A085490 001	
	50MG/ML	A080188 002	
	50MG/ML	A085490 002	
	100MG/ML	A080188 003	

FDA data supplied by DrugPatentWatch.com

TESTOSTERONE PROPIONATE
INJECTABLE;INJECTION
TESTOSTERONE PROPIONATE

	100MG/ML	A083595 003	

TETRACYCLINE HYDROCHLORIDE
CAPSULE;ORAL

BRISTACYCLINE			
BRISTOL	250MG	A061658 001	
	250MG	A061888 001	
	500MG	A061658 002	
	500MG	A061888 002	
CYCLOPAR			
WARNER CHILCOTT	250MG	A061725 001	
	250MG	A062175 001	
	250MG	A062332 001	
	500MG	A061725 002	
	500MG	A062332 002	
PANMYCIN			
PHARMACIA AND UPJOHN	250MG	A060347 001	
RETET			
SOLVAY	250MG	A061443 001	
	500MG	A061443 002	
ROBITET			
WYETH AYERST	250MG	A061734 001	
	500MG	A061734 002	
SUMYCIN			
APOTHECON	100MG	A060429 002	
	125MG	A060429 004	
	250MG	A060429 001	
	500MG	A060429 003	
TETRACHEL			
ANGUS	250MG	A060343 001	
	500MG	A060343 003	
TETRACYCLINE HYDROCHLORIDE			
ABBOTT	250MG	A061802 001	
	500MG	A061802 002	
ELKINS SINN	250MG	A060059 001	
FERRANTE	125MG	A060173 001	
	250MG	A060173 002	
HEATHER	250MG	A061148 001	
	500MG	A061148 002	
HIKMA PHARMS LLC	250MG	A060768 001	
	500MG	A060768 002	
IDT AUSTRALIA LTD	250MG	A061471 001	
IVAX SUB TEVA PHARMS	250MG	A060704 001	
	500MG	A060704 002	
MAST MM	250MG	A062085 001	
MYLAN	250MG	A060783 001	
	500MG	A060783 002	
PUREPAC PHARM	250MG	A060290 001	
	500MG	A060290 002	
PVT FORM	250MG	A062686 001	Jul 24, 1986
	500MG	A062686 002	Jul 24, 1986
ROXANE	500MG	A061214 002	
SUN PHARM INDS	250MG	A060736 001	
	500MG	A060736 002	
SUPERPHARM	250MG	A062540 001	Mar 21, 1985
	500MG	A062540 002	Mar 21, 1985
VALEANT PHARM INTL	250MG	A060471 001	
	500MG	A060471 002	
WARNER CHILCOTT	250MG	A062300 001	
	500MG	A062300 002	
WATSON LABS	250MG	A062103 001	
	250MG	A062343 001	
	500MG	A062103 002	
	500MG	A062343 002	
WYETH AYERST	250MG	A061685 001	
	500MG	A061685 002	
TETRACYN			
PFIPHARMECS	250MG	A060082 003	
	500MG	A060082 004	

FDA data supplied by DrugPatentWatch.com

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE;PERIODONTAL			
ACTISITE			
SCHIFF AND CO	12.7MG/FIBER	N050653 001	Mar 25, 1994
FOR SOLUTION;TOPICAL			
TOPICYCLINE			
SHIRE	2.2MG/ML	N050493 001	
INJECTABLE;INJECTION			
ACHROMYCIN			
LEDERLE	250MG/VIAL	N050273 002	
	500MG/VIAL	N050273 003	
TETRACYN			
PFIZER	250MG/VIAL	A060096 001	
	500MG/VIAL	A060096 002	
OINTMENT;OPHTHALMIC			
ACHROMYCIN			
STORZ	10MG/GM	N050266 001	
SUSPENSION;ORAL			
ACHROMYCIN V			
LEDERLE	125MG/5ML	N050263 002	
SUMYCIN			
PAR PHARM	125MG/5ML	A060400 001	
TETRACYCLINE HYDROCHLORIDE			
ALPHARMA US PHARMS	125MG/5ML	A060633 001	
FERRANTE	125MG/5ML	A060174 001	
PROTER	125MG/5ML	A060446 001	
PUREPAC PHARM	125MG/5ML	A060291 001	
TETRACYN			
PFIPHARMECS	125MG/5ML	A060095 001	
TETRAMED			
IVAX SUB TEVA PHARMS	125MG/5ML	A061468 001	
SUSPENSION/DROPS;OPHTHALMIC			
ACHROMYCIN			
STORZ	1%	N050268 001	
TABLET;ORAL			
PANMYCIN			
PHARMACIA AND UPJOHN	250MG	A061705 001	
	500MG	A061705 002	
SUMYCIN			
PAR PHARM	50MG	A061147 003	
	100MG	A061147 002	
	250MG	A061147 001	
	500MG	A061147 004	

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE;ORAL			
TETREX			
BRISTOL	EQ 100MG HCL	A061653 001	
	EQ 250MG HCL	A061653 002	
	EQ 250MG HCL	A061889 002	
	EQ 250MG HCL	N050212 002	
	EQ 500MG HCL	A061653 003	
	EQ 500MG HCL	A061889 001	
	EQ 500MG HCL	N050212 003	

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION			
THALLOUS CHLORIDE TL 201			
BRACCO	1mCi/ML	N018548 001	Dec 30, 1982
TRACE LIFE	1mCi/ML	A075569 001	Nov 21, 2001
INJECTABLE;INTRAVENOUS			
THALLOUS CHLORIDE TL 201			
MALLINKRODT NUCLEAR	2mCi/ML	A077698 001	Nov 09, 2006

THEOPHYLLINE

CAPSULE;ORAL			
BRONKODYL			
SANOFI AVENTIS US	100MG	A085264 001	
	200MG	A085264 002	
ELIXOPHYLLIN			
FOREST LABS	100MG	A085545 001	Jul 31, 1984
	200MG	A083921 001	Jul 31, 1984

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

CAPSULE;ORAL

SOMOPHYLLIN-T				
FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985
THEOPHYLLINE				
KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986

CAPSULE, EXTENDED RELEASE;ORAL

AEROLATE III				
FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
AEROLATE JR				
FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
AEROLATE SR				
FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
ELIXOPHYLLIN SR				
FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985
SLO-BID				
SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985
SLO-PHYLLIN				
SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982
SOMOPHYLLIN-CRT				
GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985
THEO-DUR				
SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985
THEOBID				
WHITBY	260MG	A085983	001	Mar 20, 1985
THEOBID JR.				
WHITBY	130MG	A087854	001	Mar 20, 1985
THEOCLEAR L.A.-130				
SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982
THEOCLEAR L.A.-260				
SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982
THEOPHYL-SR				
ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985
THEOPHYLLINE				
CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985
HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995
INWOOD LABS	100MG	A040052	001	Feb 14, 1994
	125MG	A040052	002	Feb 14, 1994
	200MG	A040052	003	Feb 14, 1994
	300MG	A040052	004	Feb 14, 1994
SANDOZ	260MG	A087462	001	May 11, 1982
THEOPHYLLINE-SR				
SCHERER RP	300MG	A088255	001	Jun 12, 1986
THEOVENT				
SCHERING	125MG	A087010	001	Jan 31, 1985
	250MG	A087910	001	Jan 31, 1985

THEOPHYLLINE

ELIXIR;ORAL			
ELIXOMIN			
CENCI	80MG/15ML	A088303 001	Jan 25, 1984
LANOPHYLLIN			
LANNETT	80MG/15ML	A084578 001	
THEOLIXIR			
PANRAY	80MG/15ML	A084559 001	
THEOPHYL-225			
ORTHO MCNEIL PHARM	112.5MG/15ML	A086485 001	
THEOPHYLLINE			
ALPHARMA US PHARMS	80MG/15ML	A089223 001	May 27, 1988
CENCI	80MG/15ML	A087679 001	Apr 15, 1982
HALSEY	80MG/15ML	A085169 001	
PERRIGO	80MG/15ML	A085952 001	
PHARM ASSOC	80MG/15ML	A086720 001	
PRECISION DOSE	80MG/15ML	A085863 001	
ROXANE	80MG/15ML	A084739 001	
TARO	80MG/15ML	A089626 001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748 001	
INJECTABLE;INJECTION			
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	40MG/100ML	N019083 001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	80MG/100ML	N019083 002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	160MG/100ML	N019083 003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	200MG/100ML	N019212 001	Nov 07, 1984
	200MG/100ML	N019826 004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	4MG/ML	N019212 003	Nov 07, 1984
	400MG/100ML	N019212 002	Nov 07, 1984
	400MG/100ML	N019826 005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982
	40MG/100ML	N018649 001	Jul 26, 1982
	80MG/100ML	N018649 002	Jul 26, 1982
	160MG/100ML	N018649 003	Jul 26, 1982
	200MG/100ML	N018649 004	Jul 26, 1982
	320MG/100ML	N018649 006	Nov 13, 1985
	400MG/100ML	N018649 005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA INC	80MG/100ML	N019211 002	Dec 14, 1984
	200MG/100ML	N019211 004	Dec 14, 1984
	400MG/100ML	N019211 005	Dec 14, 1984
SOLUTION;ORAL			
AEROLATE			
FLEMING PHARMS	150MG/15ML	A089141 001	Dec 03, 1986
THEOLAIR			
3M	80MG/15ML	A086107 001	
THEOPHYLLINE			
ROXANE	80MG/15ML	A087449 001	Sep 15, 1983
SUSPENSION;ORAL			
ELIXICON			
FOREST LABS	100MG/5ML	A085502 001	
SYRUP;ORAL			
ACCURBRON			
SANOFI AVENTIS US	150MG/15ML	A088746 001	Nov 22, 1985
AQUAPHYLLIN			
FERNDALE LABS	80MG/15ML	A087917 001	Jan 18, 1983
SLO-PHYLLIN			
SANOFI AVENTIS US	80MG/15ML	A085187 001	
THEOCLEAR-80			
CENT PHARMS	80MG/15ML	A087095 001	Mar 01, 1982
THEOPHYLLINE			
ALPHARMA US PHARMS	80MG/15ML	A086001 001	
	150MG/15ML	A086545 001	
TABLET;ORAL			
QUIBRON-T			
MONARCH PHARMS	300MG	A088656 001	Aug 22, 1985

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

TABLET;ORAL

SLO-PHYLLIN

SANOFI AVENTIS US	100MG	A085202 001	
	200MG	A085204 001	

THEOCLEAR-100

CENT PHARMS	100MG	A085353 002	

THEOCLEAR-200

CENT PHARMS	200MG	A085353 001	

THEOLAIR

MEDICIS	125MG	A086399 001	
	250MG	A086399 002	

THEOPHYL-225

ORTHO MCNEIL PHARM	225MG	A084726 001	

TABLET, CHEWABLE;ORAL

THEOPHYL

ORTHO MCNEIL PHARM	100MG	A086506 001	Sep 12, 1985

TABLET, EXTENDED RELEASE;ORAL

DURAPHYL

FOREST LABS	100MG	A088503 001	Apr 03, 1985
	200MG	A088504 001	Apr 03, 1985
	300MG	A088505 001	Apr 03, 1985

LABID

WARNER CHILCOTT	250MG	A087225 001	

QUIBRON-T/SR

MONARCH PHARMS	300MG	A087563 001	Jun 21, 1983

SUSTAIRE

ROERIG	100MG	A085665 001	
	300MG	A085665 002	

T-PHYL

PHARM RES ASSOC	200MG	A088253 001	Aug 17, 1983

THEO-DUR

SCHERING	100MG	A085328 001	
	200MG	A086998 001	
	300MG	A085328 002	
	450MG	A089131 001	Jun 25, 1986

THEOCHRON

NOSTRUM LABS INC	300MG	A087400 002	Jan 11, 1983

THEOLAIR-SR

3M	200MG	A088369 001	Jul 16, 1987
	250MG	A086363 002	Jul 16, 1987
	300MG	A088364 001	Jul 16, 1987
	500MG	A089132 001	Jul 16, 1987

THEOPHYLLINE

ABLE	300MG	A040548 001	Apr 30, 2004
	400MG	A040543 001	Apr 27, 2004
	450MG	A040546 001	Apr 30, 2004
	600MG	A040539 001	Apr 27, 2004
INWOOD LABS	450MG	A040034 001	Apr 28, 1995
TEVA PHARMS	450MG	A081236 001	Nov 09, 1992

UNI-DUR

SCHERING	400MG	A089822 001	Jan 04, 1995
	600MG	A089823 001	Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR;ORAL

SYNOPHYLATE

CENT PHARMS	EQ 165MG BASE/15ML	N006333 008

TABLET;ORAL

ASBRON

NOVARTIS	EQ 150MG BASE	A085148 001

THIABENDAZOLE

SUSPENSION;ORAL

MINTEZOL

MERCK SHARP DOHME	500MG/5ML	N016097 001

TABLET, CHEWABLE;ORAL

MINTEZOL

MERCK SHARP DOHME	500MG	N016096 001

FDA data supplied by DrugPatentWatch.com

THIAMINE HYDROCHLORIDE
INJECTABLE;INJECTION

BETALIN S			
LILLY	100MG/ML	A080853 001	
THIAMINE HYDROCHLORIDE			
ABRAXIS PHARM	100MG/ML	A080509 001	
AKORN	100MG/ML	A087968 001	Oct 01, 1982
BEL MAR	100MG/ML	A080718 001	
	200MG/ML	A080712 001	
DELL LABS	100MG/ML	A083775 001	
EUROHLTH INTL SARL	100MG/ML	A080575 001	
HOSPIRA	100MG/ML	A040079 001	May 03, 1996
LUITPOLD	100MG/ML	A080667 001	
PARKE DAVIS	100MG/ML	A080770 001	
WATSON LABS	100MG/ML	A080571 001	
	100MG/ML	A083534 001	
	200MG/ML	A080571 002	
	200MG/ML	A083534 002	
WYETH AYERST	100MG/ML	A080553 001	

THIAMYLAL SODIUM
INJECTABLE;INJECTION

SURITAL			
PARKEDALE	1GM/VIAL	N007600 003	
	5GM/VIAL	N007600 005	
	10GM/VIAL	N007600 009	

THIETHYLPERAZINE MALATE
INJECTABLE;INJECTION

TORECAN			
NOVARTIS	5MG/ML	N012754 002	

THIETHYLPERAZINE MALEATE
SUPPOSITORY;RECTAL

TORECAN			
NOVARTIS	10MG	N013247 001	

TABLET;ORAL

TORECAN			
NOVARTIS	10MG	N012753 001	

THIOPENTAL SODIUM
SUSPENSION;RECTAL

PENTOTHAL			
ABBOTT	400MG/GM	N011679 001	

THIORIDAZINE
SUSPENSION;ORAL

MELLARIL-S			
NOVARTIS	EQ 25MG HCL/5ML	N017923 001	
	EQ 100MG HCL/5ML	N017923 002	

THIORIDAZINE HYDROCHLORIDE
CONCENTRATE;ORAL

MELLARIL			
NOVARTIS	30MG/ML	N011808 012	
	100MG/ML	N011808 018	
THIORIDAZINE HYDROCHLORIDE			
ACTAVIS MID ATLANTIC	100MG/ML	A088229 001	Aug 23, 1983
ALPHARMA US PHARMS	30MG/ML	A087766 001	Apr 26, 1983
ANI PHARMS INC	100MG/ML	A089603 001	Nov 09, 1987
HI TECH PHARMA	30MG/ML	A040125 001	Aug 16, 1996
	100MG/ML	A040126 001	Aug 16, 1996
PHARM ASSOC	30MG/ML	A040187 001	Aug 28, 1997
	100MG/ML	A040213 001	May 29, 1998
SANDOZ	30MG/ML	A088307 001	Nov 23, 1983
	100MG/ML	A088308 001	Nov 23, 1983
TEVA PHARMS	30MG/ML	A089602 001	Nov 09, 1987
WOCKHARDT	30MG/ML	A088258 001	Jul 25, 1983
	100MG/ML	A088227 001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE INTENSOL			
ROXANE	30MG/ML	A088941 001	Dec 16, 1985
	100MG/ML	A088942 001	Dec 16, 1985

TABLET;ORAL

MELLARIL			
NOVARTIS	10MG **Federal Register determination	N011808 003	

THIORIDAZINE HYDROCHLORIDE
TABLET;ORAL
MELLARIL

	that product was not discontinued or withdrawn for safety or efficacy reasons**		
	15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011808 016	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011808 006	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011808 011	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011808 009	
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011808 017	
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011808 015	

THIORIDAZINE HYDROCHLORIDE

ANI PHARMS INC	10MG	A088270 001	Apr 14, 1983
	10MG	A088493 001	May 17, 1985
	15MG	A088271 001	Apr 14, 1983
	25MG	A088272 001	Apr 14, 1983
	50MG	A088194 001	Apr 14, 1983
	100MG	A088273 001	Oct 03, 1983
	100MG	A088456 001	May 17, 1985
MUTUAL PHARM	10MG	A088375 001	Nov 18, 1983
	25MG	A087264 001	Nov 18, 1983
	50MG	A088370 001	Nov 18, 1983
	100MG	A088379 001	Nov 16, 1983
MYLAN	10MG	A088332 001	Jun 27, 1983
	25MG	A088333 001	Jun 27, 1983
	50MG	A088334 001	Jun 27, 1983
	100MG	A088335 001	Nov 18, 1983
PAR PHARM	10MG	A088351 001	Dec 05, 1983
	15MG	A088352 001	Dec 05, 1983
	25MG	A088336 001	Dec 05, 1983
	50MG	A088322 001	Dec 05, 1983
	100MG	A088480 001	Dec 29, 1983
	150MG	A089764 001	Feb 09, 1988
	200MG	A089765 001	Feb 09, 1988
ROXANE	10MG	A088663 001	Mar 15, 1984
	25MG	A088664 001	Mar 15, 1984
	50MG	A088665 001	Mar 15, 1984
	100MG	A089048 001	Feb 26, 1985
SANDOZ	10MG	A088131 001	Aug 30, 1983
	15MG	A088132 001	Aug 30, 1983
	25MG	A088133 001	Aug 30, 1983
	50MG	A088134 001	Aug 30, 1983
	100MG	A088135 001	Nov 20, 1984
	150MG	A088136 001	Sep 17, 1986
	200MG	A088137 001	Sep 17, 1986
SUN PHARM INDS	15MG	A088461 001	Nov 18, 1983
	150MG	A088737 001	Sep 26, 1984
	200MG	A088738 001	Oct 16, 1984
SUPERPHARM	10MG	A089103 001	Jul 02, 1985
	25MG	A089104 001	Jul 02, 1985
	50MG	A089105 001	Jul 02, 1985
WATSON LABS	10MG	A088412 001	Sep 12, 1983
	10MG	A088476 001	Nov 08, 1983
	10MG	A088561 001	May 11, 1984
	15MG	A088345 001	Jul 28, 1983
	15MG	A088477 001	Nov 08, 1983

THIORIDAZINE HYDROCHLORIDE
TABLET;ORAL
THIORIDAZINE HYDROCHLORIDE

	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088478	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088479	001	Nov 08, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	100MG	A088736	001	Jul 24, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA
INJECTABLE;INJECTION
THIOPLEX

IMMUNEX	15MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020058	001	Dec 22, 1994

THIOTEPA

FRESENIUS KABI USA	15MG/VIAL	A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL	N011683	001	
TEVA PARENTERAL	15MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075730	001	Apr 20, 2001
	30MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075730	002	Apr 20, 2001

THIOTHIXENE
CAPSULE;ORAL
NAVANE

PFIZER	1MG	N016584	001	
	2MG	N016584	002	
	5MG	N016584	003	
	10MG	N016584	004	
	20MG	N016584	005	

THIOTHIXENE

AM THERAP	1MG	A071884	001	Aug 12, 1987
	2MG	A071885	001	Aug 12, 1987
	5MG	A071886	001	Aug 12, 1987
	10MG	A071887	001	Aug 12, 1987
	20MG	A072200	001	Dec 17, 1987
SANDOZ	1MG	A071529	002	Jun 24, 1987
	2MG	A071529	003	Jun 24, 1987
	5MG	A071529	001	Jun 24, 1987
	10MG	A071529	004	Jun 24, 1987
WATSON LABS	1MG	A070600	001	Jun 05, 1987
	2MG	A070601	001	Jun 05, 1987
	2MG	A071626	001	Jun 25, 1987
	5MG	A070602	001	Jun 05, 1987
	5MG	A071627	001	Jun 25, 1987
	10MG	A070603	001	Jun 05, 1987
	10MG	A071628	001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE
CONCENTRATE;ORAL
NAVANE

PFIZER	EQ 5MG BASE/ML	N016758	001	

THIOTHIXENE HYDROCHLORIDE

ALPHARMA US PHARMS	EQ 5MG BASE/ML	A070969	001	Oct 16, 1987
PACO	EQ 1MG BASE/ML	A071917	001	Sep 20, 1989

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE;ORAL			
THIOTHIXENE HYDROCHLORIDE			
	EQ 5MG BASE/ML	A071939 001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184 001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554 001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL			
CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494 001	Jun 30, 1992
INJECTABLE;INJECTION			
NAVANE			
PFIZER	EQ 2MG BASE/ML	N016904 001	
	EQ 10MG BASE/VIAL	N016904 002	

THYROGLOBULIN

TABLET;ORAL			
PROLOID			
PARKE DAVIS	16MG	N002245 009	
	32MG	N002245 005	
	65MG	N002245 002	
	100MG	N002245 008	
	130MG	N002245 010	
	200MG	N002245 007	
	325MG	N002245 004	
THYROGLOBULIN			
IMPAX LABS	64.8MG	A080151 001	

THYROTROPIN

INJECTABLE;INJECTION			
THYTROPAR			
SANOFI AVENTIS US	10 IU/VIAL	N008682 001	

TIAGABINE HYDROCHLORIDE

TABLET;ORAL			
GABITRIL			
CEPHALON	6MG	N020646 006	Nov 29, 2005
	8MG	N020646 007	Nov 29, 2005
	10MG	N020646 008	Nov 29, 2005
	20MG	N020646 004	Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE;INJECTION			
TICAR			
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497 001	
	EQ 3GM BASE/VIAL	A062690 001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497 002	
	EQ 6GM BASE/VIAL	N050497 003	
	EQ 20GM BASE/VIAL	N050497 004	
	EQ 30GM BASE/VIAL	N050497 005	Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL			
TICLID			
ROCHE PALO	125MG	N019979 001	Mar 24, 1993
	250MG	N019979 002	Oct 31, 1991
TICLOPIDINE HYDROCHLORIDE			
ACTAVIS ELIZABETH	250MG	A075253 001	Aug 20, 1999
MYLAN	250MG	A075161 001	Sep 13, 1999
	250MG	A075316 001	Nov 02, 1999
SANDOZ	250MG	A075318 001	Aug 20, 1999
	250MG	A075326 001	Aug 20, 1999
WATSON LABS	250MG	A075309 001	Apr 26, 2000

TILUDRONATE DISODIUM

TABLET;ORAL			
SKELID			
SANOFI AVENTIS US	EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020707 001	Mar 07, 1997

TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

AKORN	EQ 0.25% BASE	A074465 001	Mar 25, 1997
	EQ 0.25% BASE	A074515 001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000
	EQ 0.5% BASE	A075412 001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667 001	Mar 25, 1997
	EQ 0.5% BASE	A074668 001	Mar 25, 1997

TABLET;ORAL
BLOCADREN

MERCK	5MG	N018017 001	
	10MG	N018017 002	
	20MG	N018017 004	

TIMOLOL MALEATE

QUANTUM PHARMICS	5MG	A072466 001	May 19, 1989
	10MG	A072467 001	May 19, 1989
	20MG	A072468 001	May 19, 1989
SANDOZ	5MG	A072550 001	Apr 13, 1989
	10MG	A072551 001	Apr 13, 1989
	20MG	A072552 001	Apr 13, 1989
TEVA	5MG	A072648 001	Jun 16, 1993
	10MG	A072649 001	Jun 16, 1993
	20MG	A072650 001	Jun 16, 1993
USL PHARMA	5MG	A072001 001	Apr 11, 1989
	10MG	A072002 001	Apr 11, 1989
	20MG	A072003 001	Apr 11, 1989
WATSON LABS	5MG	A072269 001	Apr 11, 1989
	5MG	A072917 001	Jul 31, 1991
	10MG	A072270 001	Apr 11, 1989
	10MG	A072918 001	Jul 31, 1991
	20MG	A072271 001	Apr 11, 1989
	20MG	A072919 001	Jul 31, 1991

TINZAPARIN SODIUM
INJECTABLE;INJECTION
INNOHEP

LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000

TIOCONAZOLE
CREAM;TOPICAL
TZ-3

PFIZER	1%	N018682 001	Feb 18, 1983

TIROFIBAN HYDROCHLORIDE
INJECTABLE;INJECTION
AGGRASTAT

MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912 001	May 14, 1998
	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913 001	May 14, 1998

TIZANIDINE HYDROCHLORIDE
TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 2MG BASE	A076283 001	Jul 12, 2002
	EQ 4MG BASE	A076283 002	Jul 12, 2002
BARR	EQ 2MG BASE	A076371 001	Apr 09, 2003
	EQ 4MG BASE	A076371 002	Apr 09, 2003
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076321 001	Sep 30, 2004
	EQ 4MG BASE	A076321 002	Sep 30, 2004
MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003
	EQ 4MG BASE	A076282 002	Dec 16, 2003

ZANAFLEX

ACORDA	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020397 002	Feb 04, 2000

TOBRAMYCIN
SOLUTION/DROPS;OPHTHALMIC
TOBRAMYCIN

ALCON PHARMS LTD	0.3%	A063176 001	May 25, 1994
APOTEX INC	0.3%	A065087 001	Feb 25, 2002

TOBRAMYCIN SULFATE
INJECTABLE;INJECTION
NEBCIN

LILLY	EQ 10MG BASE/ML	A062008 004	
	EQ 10MG BASE/ML	A062707 001	Apr 29, 1987
	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050477 005	
	EQ 40MG BASE/ML	A062008 001	
	EQ 1.2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050519 001	

TOBRAMYCIN SULFATE

APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994
	EQ 40MG BASE/ML	A064021 002	May 31, 1994
	EQ 40MG BASE/ML	A064026 001	May 31, 1994
HOSPIRA	EQ 10MG BASE/ML	A063080 001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161 001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121 001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122 001	Oct 31, 1994
WATSON LABS INC	EQ 10MG BASE/ML	A062945 001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945 002	Aug 09, 1989
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128 001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118 001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127 001	Nov 27, 1991

TOBRAMYCIN SULFATE (PHARMACY BULK)

HOSPIRA	EQ 40MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A063116 001	May 18, 1992

TOCAINIDE HYDROCHLORIDE
TABLET;ORAL
TONOCARD

ASTRAZENECA	400MG	N018257 001	Nov 09, 1984
	600MG	N018257 002	Nov 09, 1984

TOLAZAMIDE
TABLET;ORAL
TOLAZAMIDE

BARR	100MG	A070162 001	Jan 14, 1986
	250MG	A070163 001	Jan 14, 1986
	500MG	A070164 001	Jan 14, 1986
DURAMED PHARMS BARR	100MG	A070165 001	Jan 10, 1986
	250MG	A070166 001	Jan 10, 1986
	500MG	A070167 001	Jan 10, 1986
G AND W LABS INC	100MG	N018894 001	Nov 02, 1984
	250MG	N018894 002	Nov 02, 1984
	500MG	N018894 003	Nov 02, 1984
INTERPHARM	250MG	A071270 001	Sep 23, 1986
	500MG	A071271 001	Sep 23, 1986
PAR PHARM	100MG	A070159 001	Jan 06, 1986
	250MG	A070160 001	Jan 06, 1986
	500MG	A070161 001	Jan 06, 1986
SANDOZ	100MG	A071633 001	Dec 09, 1987
	250MG	A070289 001	Mar 13, 1986
	500MG	A070290 001	Mar 13, 1986
SUN PHARM INDS	100MG	A071357 001	Jul 16, 1987
	250MG	A071358 001	Jul 16, 1987
	500MG	A071359 001	Jul 16, 1987
SUPERPHARM	250MG	A070763 001	Jun 16, 1986
	500MG	A070764 001	Jun 16, 1986
USL PHARMA	100MG	A071355 001	Jan 11, 1988
	250MG	A070168 001	Apr 02, 1986
	500MG	A070169 001	Apr 02, 1986
WATSON LABS	100MG	A070242 001	Aug 01, 1986
	100MG	A070513 001	Jan 09, 1986
	250MG	A070243 001	Aug 01, 1986
	250MG	A070514 001	Jan 09, 1986
	500MG	A070244 001	Aug 01, 1986

TOLAZAMIDE
TABLET;ORAL
TOLAZAMIDE

	500MG	A070515 001	Jan 09, 1986

TOLINASE

PHARMACIA AND UPJOHN	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015500 002	
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015500 004	
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015500 005	

TOLAZOLINE HYDROCHLORIDE
INJECTABLE;INJECTION
PRISCOLINE

NOVARTIS	25MG/ML	N006403 005	Feb 22, 1985

TOLBUTAMIDE
TABLET;ORAL
ORINASE

PHARMACIA AND UPJOHN	250MG	N010670 002	
	500MG	N010670 001	

TOLBUTAMIDE

ALRA	500MG	A086141 001	
ASCOT	500MG	A087541 001	Mar 01, 1983
BARR	500MG	A087121 001	
DAVA PHARMS INC	500MG	A086926 001	
IVAX PHARMS	500MG	A087093 001	
PARKE DAVIS	500MG	A086047 001	
PUREPAC PHARM	500MG	A088950 001	Jun 17, 1985
SANDOZ	500MG	A086574 001	
	500MG	N012678 001	
SUPERPHARM	500MG	A088893 001	Nov 19, 1984
VANGARD	500MG	A087876 001	Apr 20, 1982
WATSON LABS	250MG	A089110 001	May 29, 1987
	500MG	A086109 001	
	500MG	A087318 001	
	500MG	A089111 001	May 29, 1987

TOLBUTAMIDE SODIUM
INJECTABLE;INJECTION
ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095 001	

TOLCAPONE
TABLET;ORAL
TASMAR

VALEANT PHARMS LLC	200MG	N020697 002	Jan 29, 1998

TOLMETIN SODIUM
CAPSULE;ORAL
TOLECTIN DS

ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084 001	

TOLMETIN SODIUM

ACTAVIS ELIZABETH	EQ 400MG BASE	A073308 001	Jan 24, 1992
IVAX SUB TEVA PHARMS	EQ 400MG BASE	A073392 001	Jan 24, 1992
SANDOZ	EQ 400MG BASE	A073462 001	Apr 30, 1992
SUN PHARM INDS	EQ 400MG BASE	A073311 001	Nov 27, 1991
TEVA	EQ 400MG BASE	A073519 001	May 29, 1992

TABLET;ORAL
TOLECTIN

ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628 001	

TOLECTIN 600

ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628 002	Mar 08, 1989

TOLMETIN SODIUM

ACTAVIS ELIZABETH	EQ 600MG BASE	A073527 001	Jun 30, 1992
G AND W LABS INC	EQ 600MG BASE	A074399 001	Mar 28, 1996
	EQ 600MG BASE	A074729 001	Feb 27, 1997
SANDOZ	EQ 200MG BASE	A073588 001	Jul 31, 1992
	EQ 600MG BASE	A074002 001	Sep 27, 1993

TOLVAPTAN
TABLET;ORAL
SAMSCA

OTSUKA AMERICA PHARM	60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022275 003	May 19, 2009

TOPIRAMATE
CAPSULE;ORAL
TOPAMAX SPRINKLE

JANSSEN PHARMS	50MG	N020844 003	Oct 26, 1998

TOPIRAMATE

BARR	15MG	A076448 001	Apr 15, 2009
	25MG	A076448 002	Apr 15, 2009
SANDOZ	15MG	A079206 001	Oct 14, 2009
	25MG	A079206 002	Oct 14, 2009

TABLET;ORAL
TOPAMAX

JANSSEN PHARMS	300MG	N020505 003	Dec 24, 1996
	400MG	N020505 006	Dec 24, 1996

TOPIRAMATE

ACTAVIS TOTOWA	25MG	A078637 001	Feb 27, 2013
	50MG	A078637 002	Feb 27, 2013
	100MG	A078637 003	Feb 27, 2013
	200MG	A078637 004	Feb 27, 2013
BARR	25MG	A076315 001	Mar 27, 2009
	100MG	A076315 002	Mar 27, 2009
	200MG	A076315 003	Mar 27, 2009
PLIVA HRVATSKA DOO	25MG	A077905 001	Mar 30, 2009
	50MG	A077905 002	Mar 30, 2009
	100MG	A077905 003	Mar 30, 2009
	200MG	A077905 004	Mar 30, 2009
ROXANE	25MG	A076306 001	Mar 27, 2009
	50MG	A076306 002	Mar 27, 2009
	100MG	A076306 003	Mar 27, 2009
	200MG	A076306 004	Mar 27, 2009
WATSON LABS	25MG	A077643 001	Mar 27, 2009
	50MG	A077643 002	Mar 27, 2009
	100MG	A077643 003	Mar 27, 2009
	200MG	A077643 004	Mar 27, 2009
WOCKHARDT USA	25MG	A090353 001	Sep 01, 2010
	50MG	A090353 002	Sep 01, 2010
	100MG	A090353 003	Sep 01, 2010
	200MG	A090353 004	Sep 01, 2010

TOPIRAMATE

HIKMA PHARMS	25MG	A091185 001	Nov 25, 2013
	50MG	A091185 002	Nov 25, 2013
	100MG	A091185 003	Nov 25, 2013
	200MG	A091185 004	Nov 25, 2013

TOPOTECAN HYDROCHLORIDE
INJECTABLE;INJECTION
TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 4MG BASE/VIAL	A091376 001	Nov 29, 2010

SOLUTION;INTRAVENOUS
TOPOTECAN

SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200199 001	Feb 25, 2011
	EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200199 002	Feb 25, 2011
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200199 003	Feb 25, 2011

FDA data supplied by DrugPatentWatch.com

TORSEMIDE

INJECTABLE;INJECTION			
DEMADEX			
ROCHE	50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020137 002	Aug 23, 1993
	20MG/2ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020137 001	Aug 23, 1993
TORSEMIDE			
LUITPOLD	20MG/2ML (10MG/ML)	A090656 001	Apr 21, 2010
	50MG/5ML (10MG/ML)	A090656 002	Apr 21, 2010
WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007 001	Jun 11, 2008
	50MG/5ML (10MG/ML)	A078007 002	Jun 11, 2008

TRAMADOL HYDROCHLORIDE

TABLET;ORAL			
TRAMADOL HYDROCHLORIDE			
ACTAVIS ELIZABETH	50MG	A075960 001	Jun 19, 2002
ASTA	50MG	A075974 001	Jul 12, 2002
IVAX SUB TEVA PHARMS	50MG	A075963 001	Jul 03, 2002
SANDOZ	50MG	A075968 001	Jun 25, 2002
WATSON LABS	50MG	A075962 001	Jun 24, 2002
ULTRAM			
JANSSEN PHARMS	100MG	N020281 001	Mar 03, 1995
TABLET, EXTENDED RELEASE;ORAL			
RYZOLT			
PURDUE PHARMA	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021745 001	Dec 30, 2008
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021745 002	Dec 30, 2008
	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021745 003	Dec 30, 2008
ULTRAM ER			
VALEANT PHARMS	100MG	N021692 001	Sep 08, 2005
	200MG	N021692 002	Sep 08, 2005
	300MG	N021692 003	Sep 08, 2005
TABLET, ORALLY DISINTEGRATING;ORAL			
RYBIX ODT			
SHIONOGI INC	50MG	N021693 001	May 05, 2005

TRANDOLAPRIL

TABLET;ORAL			
TRANDOLAPRIL			
CIPLA	1MG	A077307 002	Jun 12, 2007
	2MG	A077307 001	Jun 12, 2007
	4MG	A077307 003	Jun 12, 2007
COREPHARMA	1MG	A077256 001	Jun 12, 2007
	2MG	A077256 002	Jun 12, 2007
	4MG	A077256 003	Jun 12, 2007
DR REDDYS LABS LTD	1MG	A078493 001	Aug 25, 2008
	2MG	A078493 002	Aug 25, 2008
	4MG	A078493 003	Aug 25, 2008

TRANEXAMIC ACID

TABLET;ORAL			
CYKLOKAPRON			
PHARMACIA AND UPJOHN	500MG	N019280 001	Dec 30, 1986
TRANEXAMIC ACID			
AMERIGEN PHARMS LTD	650MG	A203256 001	Jul 25, 2016

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC			
IZBA			
NOVARTIS PHARMS CORP	0.003% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N204822 001	May 15, 2014

FDA data supplied by DrugPatentWatch.com

TRAVOPROST
SOLUTION/DROPS;OPHTHALMIC
TRAVATAN

ALCON PHARMS LTD	0.004% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021257 001	Mar 16, 2001

TRAZODONE HYDROCHLORIDE
TABLET;ORAL
DESYREL

PRAGMA PHARMS LLC	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018207 001	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018207 002	
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018207 003	Mar 25, 1985
	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018207 004	Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP	50MG	A071139 001	Oct 29, 1986
	100MG	A071140 001	Oct 29, 1986
AUROLIFE PHARMA LLC	50MG	A072484 001	Apr 30, 1990
MYLAN	50MG	A071405 001	Feb 27, 1991
	100MG	A071406 001	Feb 27, 1991
QUANTUM PHARMICS	100MG	A070921 001	Dec 01, 1986
SANDOZ	100MG	A072483 001	Apr 30, 1990
TEVA	150MG	A074357 001	Apr 30, 1997
USL PHARMA	50MG	A070491 001	Apr 29, 1987
	100MG	A070492 001	Apr 29, 1987
WATSON LABS	50MG	A070857 001	Oct 10, 1986
	50MG	A071112 001	Nov 17, 1986
	100MG	A070858 001	Oct 10, 1986
	100MG	A071113 001	Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS	50MG	A070942 001	Dec 01, 1986

TABLET, EXTENDED RELEASE;ORAL
OLEPTRO

ANGELINI PHARMA	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022411 001	Feb 02, 2010
	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022411 002	Feb 02, 2010

TRETINOIN
CAPSULE;ORAL
VESANOID

ROCHE	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020438 001	Nov 22, 1995

SOLUTION;TOPICAL
TRETINOIN

TEVA PHARMS	0.05%	A074873 001	Jun 19, 1998
WOCKHARDT	0.05%	A075260 001	Jan 25, 1999

SWAB;TOPICAL
RETIN-A

VALEANT INTL	0.05%	N016921 002	

TRIAMCINOLONE
TABLET;ORAL
ARISTOCORT

ASTELLAS	1MG	N011161 009	
	2MG	N011161 004	
	4MG	N011161 007	
	8MG	N011161 011	

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE

TABLET;ORAL

ARISTOCORT			
	16MG	N011161 010	
KENACORT			
DELCOR ASSET CORP	1MG	N011283 003	
	2MG	N011283 008	
	4MG	N011283 006	
	8MG	N011283 010	
TRIAMCINOLONE			
BARR	2MG	A084286 001	
	2MG	A084318 001	
	4MG	A084267 001	
	4MG	A084319 001	
	8MG	A084268 001	
	8MG	A084320 001	
IMPAX LABS	4MG	A084340 001	
IVAX SUB TEVA PHARMS	4MG	A083750 001	
MYLAN	2MG	A084406 001	
PUREPAC PHARM	2MG	A084020 002	
	4MG	A084020 003	
ROXANE	2MG	A084708 001	
	4MG	A084709 001	
	8MG	A084707 001	
SANDOZ	4MG	A085601 001	
TEVA	4MG	A084775 001	
WATSON LABS	4MG	A084270 001	
	4MG	A085834 001	

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED;INHALATION

AZMACORT			
ABBVIE	0.1MG/INH	N018117 001	Apr 23, 1982

AEROSOL, METERED;NASAL

NASACORT			
SANOFI AVENTIS US	0.055MG/INH	N019798 001	Jul 11, 1991

CREAM;TOPICAL

ARISTOCORT			
ASTELLAS	0.025%	A083017 003	
	0.1%	A083016 004	
	0.5%	A083015 002	
ARISTOCORT A			
ASTELLAS	0.025%	A083017 004	
	0.025%	A088818 001	Oct 16, 1984
	0.1%	A083016 005	
	0.1%	A088819 001	Oct 16, 1984
	0.5%	A083015 003	
	0.5%	A088820 001	Oct 16, 1984
FLUTEX			
IVAX PHARMS	0.025%	A085539 001	
	0.1%	A085539 002	
	0.5%	A085539 003	
KENALOG			
DELCOR ASSET CORP	0.5%	A083943 001	
KENALOG-H			
DELCOR ASSET CORP	0.1%	A086240 001	
TRIACET			
TEVA	0.025%	A084908 001	
	0.1%	A084908 002	
	0.5%	A084908 003	
TRIACORT			
SOLVAY	0.1%	A087113 001	
TRIAMCINOLONE ACETONIDE			
ACTAVIS MID ATLANTIC	0.1%	A087798 001	Jun 04, 1982
ALPHARMA US PHARMS	0.025%	A087797 001	Jun 07, 1982
AMBIX	0.025%	A087932 001	May 09, 1983
MORTON GROVE	0.025%	A088094 001	Sep 01, 1983
	0.1%	A088095 001	Sep 01, 1983
	0.5%	A088096 001	Sep 01, 1983
PHARMADERM	0.025%	A087990 001	Jul 07, 1983
	0.1%	A087991 001	Jul 07, 1983
	0.5%	A087992 001	Jul 07, 1983
PHARMAFAIR	0.025%	A087921 001	Aug 10, 1982

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
TRIAMCINOLONE ACETONIDE				
		0.1%	A087912 001	Aug 10, 1982
		0.5%	A087922 001	Aug 10, 1982
	TARO	0.025%	A040038 001	Oct 26, 1994
		0.025%	A086277 001	
		0.1%	A086276 001	
		0.5%	A086275 001	
	TOPIDERM	0.025%	A089274 001	Feb 21, 1989
		0.1%	A089275 001	Feb 21, 1989
		0.5%	A089276 001	Feb 21, 1989
TRIATEX				
	IVAX PHARMS	0.025%	A087430 001	Nov 01, 1988
		0.1%	A087429 001	Nov 01, 1988
		0.5%	A087428 001	Nov 01, 1988
TRYMEX				
	SAVAGE LABS	0.025%	A088196 001	Mar 25, 1983
		0.1%	A088197 001	Mar 25, 1983
		0.5%	A088198 001	Mar 25, 1983
GEL;TOPICAL				
ARISTOGEL				
	ASTELLAS	0.1%	A083380 001	
INJECTABLE;INJECTION				
TRIAMCINOLONE ACETONIDE				
	PARNELL	3MG/ML	N019503 001	Oct 16, 1987
	SANDOZ	10MG/ML	A090166 001	May 27, 2009
	SANDOZ CANADA INC	40MG/ML	A090164 001	Jun 01, 2009
	WATSON LABS	40MG/ML	A085825 001	
INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL				
TRIVARIS				
	ALLERGAN	8MG/0.1ML (8MG/0.1ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022220 001	Jun 16, 2008
LOTION;TOPICAL				
KENALOG				
	DELCOR ASSET CORP	0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A084343 001	
		0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011602 003	
		0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A084343 002	
		0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011602 001	
TRIAMCINOLONE ACETONIDE				
	ALPHARMA US PHARMS	0.025%	A087191 001	Sep 08, 1982
		0.1%	A087192 001	Sep 08, 1982
OINTMENT;TOPICAL				
ARISTOCORT				
	ASTELLAS	0.1%	A080750 004	
		0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080745 002	
ARISTOCORT A				
	ASTELLAS	0.1%	A080750 003	
		0.1%	A088780 001	Oct 01, 1984
		0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080745 003	
		0.5%	A088781 001	Oct 05, 1984
FLUTEX				
	IVAX PHARMS	0.025%	A087375 001	Nov 01, 1988
		0.1%	A087377 001	Nov 01, 1988
		0.5%	A087376 001	Nov 01, 1988

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL			
KENALOG			
DELCOR ASSET CORP	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083944 001	
TRIAMCINOLONE ACETONIDE			
ACTAVIS MID ATLANTIC	0.1%	A087799 001	Jun 07, 1982
ALPHARMA US PHARMS	0.5%	A089913 001	Dec 23, 1988
MORTON GROVE	0.025%	A088090 001	Sep 01, 1983
	0.1%	A088091 001	Sep 01, 1983
	0.5%	A088092 001	Sep 01, 1983
PHARMADERM	0.025%	A088692 001	Aug 02, 1984
	0.1%	A088690 001	Aug 02, 1984
TARO	0.025%	A040040 001	Sep 30, 1994
	0.025%	A040374 001	Jun 05, 2001
	0.1%	A087902 001	Dec 27, 1982
	0.5%	A040386 001	Jun 05, 2001
TRYMEX			
SAVAGE LABS	0.025%	A088693 001	Aug 02, 1984
	0.1%	A088691 001	Aug 02, 1984
PASTE;DENTAL			
KENALOG IN ORABASE			
DELCOR ASSET CORP	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012097 001	
ORALONE			
TARO	0.1%	A071383 001	Jul 06, 1987
SPRAY, METERED;NASAL			
ALLERNAZE			
LUPIN ATLANTIS	0.05MG/SPRAY	N020120 001	Feb 04, 2000
NASACORT HFA			
SANOFI AVENTIS US	0.055MG/SPRAY	N020784 001	Apr 07, 2004
TRIAMCINOLONE ACETONIDE			
TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009

TRIAMCINOLONE DIACETATE

INJECTABLE;INJECTION			
ARISTOCORT			
SANDOZ	25MG/ML	N011685 003	
	40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012802 001	
TRIAMCINOLONE DIACETATE			
AKORN	25MG/ML	A085122 001	
	40MG/ML	A086394 001	
WATSON LABS	40MG/ML	A084072 001	
	40MG/ML	A085529 001	
SYRUP;ORAL			
ARISTOCORT			
ASTELLAS	2MG/5ML	N011960 004	
KENACORT			
DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515 001	

TRIAZOLAM

TABLET;ORAL			
HALCION			
PHARMACIA AND UPJOHN	0.5MG	N017892 002	Nov 15, 1982
TRIAZOLAM			
WATSON LABS	0.125MG	A074445 001	Oct 20, 1995
	0.25MG	A074445 002	Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET;ORAL			
METAHYDRIN			
SANOFI AVENTIS US	2MG	N012594 001	Jun 16, 1988
	4MG	N012594 002	Jun 16, 1988
NAQUA			
SCHERING	2MG	N012265 001	
	4MG	N012265 002	
TRICHLOREX			
LANNETT	4MG	A083436 001	

FDA data supplied by DrugPatentWatch.com

TRICHLORMETHIAZIDE
TABLET;ORAL
TRICHLOREX

	4MG	A085630	001

TRICHLORMAS

MAST MM	4MG	A086259	001

TRICHLORMETHIAZIDE

IMPAX LABS	4MG	A083967	001
PAR PHARM	2MG	A087007	001
	4MG	A087005	001
SANDOZ	4MG	A086171	001
TG UNITED LABS	4MG	A085568	001
WATSON LABS	2MG	A083847	001
	2MG	A086458	001
	4MG	A083462	001
	4MG	A083855	001
	4MG	A085962	001

TRICLOFOS SODIUM
SOLUTION;ORAL
TRICLOS

SANOFI AVENTIS US	1.5GM/15ML	N016830	001

TABLET;ORAL
TRICLOS

SANOFI AVENTIS US	750MG	N016809	002

TRIDIHEXETHYL CHLORIDE
INJECTABLE;INJECTION
PATHILON

LEDERLE	10MG/ML	N009729	001

TABLET;ORAL
PATHILON

LEDERLE	25MG	N009489	005

TRIFLUOPERAZINE HYDROCHLORIDE
CONCENTRATE;ORAL
STELAZINE

GLAXOSMITHKLINE	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011552	006

TRIFLUOPERAZINE HYDROCHLORIDE

SANDOZ	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982
WOCKHARDT	EQ 10MG BASE/ML	A088143	001	Jul 26, 1983

INJECTABLE;INJECTION
STELAZINE

GLAXOSMITHKLINE	EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011552	005

TABLET;ORAL
STELAZINE

GLAXOSMITHKLINE	EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011552	001
	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011552	002
	EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011552	003
	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011552	004

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR	EQ 1MG BASE	A088967	001	Apr 23, 1985
	EQ 2MG BASE	A088968	001	Apr 23, 1985
	EQ 5MG BASE	A088969	001	Apr 23, 1985
	EQ 10MG BASE	A088970	001	Apr 23, 1985
IVAX PHARMS	EQ 1MG BASE	A087612	001	Nov 19, 1982
	EQ 2MG BASE	A087613	001	Nov 19, 1982
	EQ 5MG BASE	A087328	001	Nov 19, 1982

TRIFLUOPERAZINE HYDROCHLORIDE
TABLET;ORAL
TRIFLUOPERAZINE HYDROCHLORIDE

	EQ 10MG BASE	A087614 001	Nov 19, 1982
SANDOZ	EQ 1MG BASE	A040153 001	Oct 25, 1996
	EQ 2MG BASE	A040153 002	Oct 25, 1996
	EQ 5MG BASE	A040153 003	Oct 25, 1996
	EQ 10MG BASE	A040153 004	Oct 25, 1996
WATSON LABS	EQ 1MG BASE	A085975 001	Jun 23, 1988
	EQ 2MG BASE	A085976 001	Jun 23, 1988
	EQ 5MG BASE	A085973 001	Jun 23, 1988
	EQ 10MG BASE	A088710 001	Jun 23, 1988

TRIFLUPROMAZINE
SUSPENSION;ORAL
VESPRIN

APOTHECON	EQ 50MG HCL/5ML	N011491 004	

TRIFLUPROMAZINE HYDROCHLORIDE
INJECTABLE;INJECTION
VESPRIN

APOTHECON	3MG/ML	N011325 005	
	10MG/ML	N011325 004	
	20MG/ML	N011325 001	

TABLET;ORAL
VESPRIN

BRISTOL MYERS SQUIBB	10MG	N011123 001	
	25MG	N011123 002	
	50MG	N011123 003	

TRIHEXYPHENIDYL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
ARTANE

LEDERLE	5MG	N006773 010	
	5MG	N012947 001	

ELIXIR;ORAL
ARTANE

LEDERLE	2MG/5ML	N006773 009	

TRIHEXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES	2MG/5ML	A089514 001	Apr 07, 1989

TABLET;ORAL
ARTANE

LEDERLE	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006773 005	
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006773 003	

TREMIN

SCHERING	2MG	A080381 001	
	5MG	A080381 003	

TRIHEXYPHENIDYL HYDROCHLORIDE

HIKMA PHARMS LLC	2MG	A040337 002	Feb 16, 2000
	5MG	A040337 001	Feb 16, 2000
NYLOS	5MG	A085622 001	
VANGARD	2MG	A088035 001	Jul 30, 1982
WATSON LABS	2MG	A040184 001	Feb 06, 1998
	2MG	A085117 001	
	5MG	A040184 002	Feb 06, 1998
	5MG	A085105 001	

TRILOSTANE
CAPSULE;ORAL
MODRASTANE

BIOENVISION	30MG	N018719 002	Dec 31, 1984
	60MG	N018719 001	Dec 31, 1984

TRIMEPRAZINE TARTRATE
CAPSULE, EXTENDED RELEASE;ORAL
TEMARIL

ALLERGAN HERBERT	EQ 5MG BASE	N011316 004	

FDA data supplied by DrugPatentWatch.com

TRIMEPRAZINE TARTRATE

SYRUP;ORAL			
TEMARIL			
ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316 003	
TRIMEPRAZINE TARTRATE			
ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015 001	Feb 18, 1982
MORTON GROVE	EQ 2.5MG BASE/5ML	A088285 001	Apr 11, 1985
TABLET;ORAL			
TEMARIL			
ALLERGAN HERBERT	EQ 2.5MG BASE	N011316 001	

TRIMETHADIONE

CAPSULE;ORAL			
TRIDIONE			
ABBVIE	300MG	N005856 005	
SOLUTION;ORAL			
TRIDIONE			
ABBVIE	200MG/5ML	N005856 002	

TRIMETHAPHAN CAMSYLATE

INJECTABLE;INJECTION			
ARFONAD			
ROCHE	50MG/ML	N008983 001	

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION			
TRIMETHOBENZAMIDE HYDROCHLORIDE			
HOSPIRA	100MG/ML	A088804 001	Apr 03, 1987
SMITH AND NEPHEW	100MG/ML	A088960 001	Apr 04, 1986
	100MG/ML	A089043 001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094 001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577 001	Oct 19, 1982
	100MG/ML	A087939 001	Dec 28, 1982

TRIMETHOPRIM

TABLET;ORAL			
PROLOPRIM			
MONARCH PHARMS	100MG	N017943 001	
	200MG	N017943 003	Jul 14, 1982
TRIMETHOPRIM			
SUN PHARM INDS	100MG	A070494 001	Jan 22, 1986
	200MG	A070495 001	Sep 24, 1986
TEVA	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A071259 001	Jun 18, 1987
TRIMPEX			
ROCHE	100MG	N017952 001	
TRIMPEX 200			
ROCHE	200MG	N017952 002	Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL			
PRIMSOL			
AYTU PHARMS	EQ 25MG BASE/5ML	N074374 001	Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE;INJECTION			
NEUTREXIN			
MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N020326 001	Dec 17, 1993
	EQ 200MG BASE/VIAL	N020326 002	Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE;ORAL			
TRIMIPRAMINE MALEATE			
USL PHARMA	EQ 25MG BASE	A071283 001	Dec 08, 1987
	EQ 50MG BASE	A071284 001	Dec 08, 1987
	EQ 100MG BASE	A071285 001	Dec 08, 1987

TRIOXSALEN

TABLET;ORAL			
TRISORALEN			
VALEANT PHARM INTL	5MG	N012697 001	

FDA data supplied by DrugPatentWatch.com

TRIPELENNAMINE CITRATE

ELIXIR;ORAL			
PBZ			
NOVARTIS	EQ 25MG HCL/5ML	N005914 004	

TRIPELENNAMINE HYDROCHLORIDE

TABLET;ORAL			
PBZ			
NOVARTIS	25MG	A083149 001	
	50MG	N005914 002	
TRIPELENNAMINE HYDROCHLORIDE			
ANABOLIC	50MG	A083037 001	
BARR	50MG	A080744 001	
HEATHER	50MG	A083989 001	
IMPAX LABS	50MG	A080785 001	
LANNETT	50MG	A083557 001	
NYLOS	50MG	A085412 001	
PARKE DAVIS	25MG	A083625 001	
	50MG	A083626 001	
WATSON LABS	50MG	A080713 001	
	50MG	A080790 001	
	50MG	A085188 001	
TABLET, EXTENDED RELEASE;ORAL			
PBZ-SR			
NOVARTIS	50MG	N010533 002	
	100MG	N010533 001	

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL			
GYNE-SULF			
G AND W LABS	3.7%;2.86%;3.42%	A088607 001	Jun 09, 1986
SULTRIN			
ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%	N005794 001	
TRIPLE SULFA			
ALPHARMA US PHARMS	3.7%;2.86%;3.42%	A087864 001	Sep 01, 1982
FOUGERA	3.7%;2.86%;3.42%	A086424 001	
PERRIGO NEW YORK	3.7%;2.86%;3.42%	A087285 001	Nov 15, 1982
TRYSUL			
SAVAGE LABS	3.7%;2.86%;3.42%	A087887 001	Jul 23, 1982
VAGILIA			
G AND W LABS INC	3.7%;2.86%;3.42%	A088821 001	Nov 09, 1987
TABLET;VAGINAL			
SULTRIN			
ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG	N005794 002	
TRIPLE SULFA			
FOUGERA	184MG;143.75MG;172.5MG	A088463 001	Jan 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG	A088462 001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL			
ACTIDIL			
GLAXOSMITHKLINE	1.25MG/5ML	N011496 002	Jul 01, 1983
MYIDYL			
USL PHARMA	1.25MG/5ML	A087963 001	Jan 18, 1983
TRIPROLIDINE HYDROCHLORIDE			
ALPHARMA US PHARMS	1.25MG/5ML	A085940 001	
HALSEY	1.25MG/5ML	A088735 001	Jan 17, 1985
PHARM ASSOC	1.25MG/5ML	A087514 001	Feb 10, 1982
TABLET;ORAL			
ACTIDIL			
GLAXOSMITHKLINE	2.5MG	N011110 002	Jul 01, 1983
TRIPROLIDINE HYDROCHLORIDE			
VITARINE	2.5MG	A085610 001	
WATSON LABS	2.5MG	A085094 001	

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL			
LANTRISUL			
LANNETT	167MG/5ML;167MG/5ML;167MG/5ML	A080123 002	
NEOTRIZINE			
LILLY	167MG/5ML;167MG/5ML;167MG/5ML	N006317 012	
SULFALOID			
FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080100 001	

FDA data supplied by DrugPatentWatch.com

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL			
SULFOSE			
WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	A080013 002	
TERFONYL			
BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML	N006904 002	
TRIPLE SULFA			
ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080280 001	
TRIPLE SULFAS			
LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML	N006920 003	
TABLET;ORAL			
NEOTRIZINE			
LILLY	167MG;167MG;167MG	N006317 011	
SULFA-TRIPLE #2			
IMPAX LABS	167MG;167MG;167MG	A080079 001	
SULFALOID			
FOREST PHARMS	167MG;167MG;167MG	A080099 001	
SULFOSE			
WYETH AYERST	167MG;167MG;167MG	A080013 001	
TERFONYL			
BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904 001	
TRIPLE SULFA			
PUREPAC PHARM	167MG;167MG;167MG	A080086 001	
TRIPLE SULFAS			
LEDERLE	167MG;167MG;167MG	N006920 002	
TRIPLE SULFOID			
PAL PAK	167MG;167MG;167MG	A080094 001	

TROGLITAZONE

TABLET;ORAL			
PRELAY			
SANKYO	200MG	N020719 001	Jan 29, 1997
	300MG	N020719 003	Aug 04, 1997
	400MG	N020719 002	Jan 29, 1997
REZULIN			
PFIZER PHARMS	200MG	N020720 001	Jan 29, 1997
	300MG	N020720 003	Aug 04, 1997
	400MG	N020720 002	Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS;OTIC			
CERUMENEX			
PHARM RES ASSOC	10%	N011340 002	

TROLEANDOMYCIN

CAPSULE;ORAL			
TAO			
PFIZER	EQ 250MG BASE	N050336 002	
SUSPENSION;ORAL			
TAO			
PFIZER	EQ 125MG BASE/5ML	N050332 001	

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC			
MYDRIACYL			
ALCON	0.5%	N012111 002	
	1%	N012111 004	
MYDRIAFAIR			
PHARMAFAIR	0.5%	A088274 001	Sep 16, 1983
	1%	A088230 001	Sep 16, 1983
TROPICAMIDE			
AKORN	1%	A088447 001	Aug 28, 1985
ALCON PHARMS LTD	1%	A089172 001	Dec 28, 1990
MIZA PHARMS USA	0.5%	A087636 001	Jul 30, 1982
	1%	A087637 001	Aug 09, 1982
WATSON LABS	0.5%	A089171 001	Dec 28, 1990

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL			
SANCTURA XR			
ALLERGAN	60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022103 001	Aug 03, 2007

FDA data supplied by DrugPatentWatch.com

TROSPIUM CHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
TROSPIUM CHLORIDE

UPSHER-SMITH LABS	60MG	A091635 001	Apr 29, 2015

TABLET;ORAL
SANCTURA

ALLERGAN	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021595 001	May 28, 2004

TROVAFLOXACIN MESYLATE
TABLET;ORAL
TROVAN

PFIZER	EQ 100MG BASE	N020759 001	Dec 18, 1997
	EQ 200MG BASE	N020759 002	Dec 18, 1997

TUBOCURARINE CHLORIDE
INJECTABLE;INJECTION
TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB	3MG/ML	N005657 001	
HOSPIRA	3MG/ML	N006095 001	
LILLY	3MG/ML	N006325 001	

TYROPANOATE SODIUM
CAPSULE;ORAL
BILOPAQUE

GE HEALTHCARE	750MG	N013731 001	

UNOPROSTONE ISOPROPYL
SOLUTION/DROPS;OPHTHALMIC
RESCULA

SUCAMPO PHARMA LLC	0.15% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021214 001	Aug 03, 2000

URACIL MUSTARD
CAPSULE;ORAL
URACIL MUSTARD

SHIRE	1MG	N012892 001	

UREA
INJECTABLE;INJECTION
STERILE UREA

HOSPIRA	40GM/VIAL	N017698 001	

UREAPHIL

HOSPIRA	40GM/VIAL	N012154 001	

UREA C-13
FOR SOLUTION;ORAL
BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA	EQ 75MG/POUCH	N020586 002	May 10, 2001

HELICOSOL

METABOLIC SOLUTIONS	125MG/VIAL	N021092 001	Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA	125MG/VIAL	N020586 001	Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES	100MG/VIAL	N020900 001	Feb 04, 1999

UROFOLLITROPIN
INJECTABLE;INTRAMUSCULAR
METRODIN

SERONO	75 IU/AMP	N019415 002	Sep 18, 1986
	150 IU/AMP	N019415 003	Sep 18, 1986

INJECTABLE;SUBCUTANEOUS
FERTINEX

SERONO	75 IU/AMP	N019415 005	Aug 23, 1996
	150 IU/AMP	N019415 004	Aug 23, 1996

UROKINASE
INJECTABLE;INJECTION
KINLYTIC

MICROBIX BIOSYSTEMS	5,000 IU/VIAL	N021846 003	
	9,000 IU/VIAL	N021846 002	
	250,000 IU/VIAL	N021846 001	

URSODIOL
CAPSULE;ORAL
ACTIGALL

ALLERGAN SALES LLC	150MG	N019594 001	Dec 31, 1987

TABLET;ORAL
URSODIOL

TEVA PHARMS USA	250MG	A079184 001	May 13, 2009
	500MG	A079184 002	May 13, 2009

VALDECOXIB
TABLET;ORAL
BEXTRA

GD SEARLE	10MG	N021341 002	Nov 16, 2001
	20MG	N021341 003	Nov 16, 2001

VALPROIC ACID
CAPSULE;ORAL
VALPROIC ACID

PAR PHARM	250MG	A070431 001	Feb 28, 1986
SCHERER RP	250MG	A070195 001	Jul 02, 1987
USL PHARMA	250MG	A070631 001	Jun 11, 1987

CAPSULE, DELAYED RELEASE;ORAL
STAVZOR

BIONPHARMA INC	125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022152 001	Jul 29, 2008
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022152 002	Jul 29, 2008
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022152 003	Jul 29, 2008

SYRUP;ORAL
VALPROIC ACID

APOTEX INC	250MG/5ML	A077105 001	Jul 29, 2005

VALSARTAN
CAPSULE;ORAL
DIOVAN

NOVARTIS	80MG	N020665 001	Dec 23, 1996
	160MG	N020665 002	Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE
FOR SOLUTION;ORAL
VANCOCIN HYDROCHLORIDE

ANI PHARMS INC	EQ 250MG BASE/5ML	A061667 002	Jul 13, 1983
	EQ 500MG BASE/6ML	A061667 001	

VANCOLED

LEDERLE	EQ 250MG BASE/5ML	A063321 002	Oct 15, 1993
	EQ 500MG BASE/6ML	A063321 003	Oct 15, 1993

INJECTABLE;INJECTION
VANCOCIN HYDROCHLORIDE

ANI PHARMS INC	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060180 001	
	EQ 500MG BASE/VIAL	A062476 001	Mar 15, 1984
	EQ 500MG BASE/VIAL	A062716 001	Mar 13, 1987
	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062812 001	Nov 17, 1987
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060180 002	Mar 21, 1986
	EQ 1GM BASE/VIAL	A062476 002	Mar 21, 1986
	EQ 1GM BASE/VIAL	A062716 002	Mar 13, 1987
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A062812 002	Nov 17, 1987
	EQ 10GM BASE/VIAL **Federal Register determination that product was not	A062812 003	Nov 17, 1987

VANCOMYCIN HYDROCHLORIDE
INJECTABLE;INJECTION
VANCOCIN HYDROCHLORIDE
discontinued or withdrawn for safety or efficacy reasons**
VANCOLED
WEST-WARD PHARMS INT — EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — A062682 001 Jul 22, 1986
EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — A062682 002 Mar 30, 1988
EQ 2GM BASE/VIAL **Federal Register determination that product was discontinued or withdrawn for safety or efficacy reasons** — A062682 003 May 11, 1988
EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — A062682 004 May 11, 1988
EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — A062682 005 May 11, 1988
VANCOMYCIN HYDROCHLORIDE
WEST-WARD PHARMS INT — EQ 500MG BASE/VIAL — A062879 001 Aug 02, 1988
EQ 1GM BASE/VIAL — A062879 002 Aug 02, 1988
VANCOR
PHARMACIA AND UPJOHN — EQ 500MG BASE/VIAL — A062956 001 Aug 01, 1988
EQ 1GM BASE/VIAL — A062956 002 Aug 01, 1988

VASOPRESSIN TANNATE
INJECTABLE;INJECTION
PITRESSIN TANNATE
PARKE DAVIS — 5PRESSOR UNITS/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — N003402 001

VECURONIUM BROMIDE
INJECTABLE;INJECTION
NORCURON
ORGANON USA INC — 10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — N018776 002 Apr 30, 1984
20MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — N018776 003 Jan 03, 1992
VECURONIUM BROMIDE
EUROHLTH INTL SARL — 10MG/VIAL — A075218 001 Aug 23, 1999
20MG/VIAL — A075218 002 Aug 23, 1999
HOSPIRA — 4MG/VIAL — A075558 001 Sep 11, 2001
WATSON LABS — 10MG/VIAL — A074334 001 Aug 31, 1995
20MG/VIAL — A074334 002 Aug 31, 1995

VELAGLUCERASE ALFA
POWDER;IV (INFUSION)
VPRIV
SHIRE HUMAN GENETIC — 200 UNITS/VIAL — N022575 002 Feb 26, 2010

VENLAFAXINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
EFFEXOR XR
WYETH PHARMS INC — EQ 100MG BASE — N020699 003 Oct 20, 1997
TABLET;ORAL
EFFEXOR
WYETH PHARMS INC — EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — N020151 001 Dec 28, 1993
EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** — N020151 002 Dec 28, 1993
EQ 37.5MG BASE **Federal Register — N020151 006 Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

EFFEXOR

	determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 003	Dec 28, 1993
	EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 004	Dec 28, 1993
	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020151 005	Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517 001	Jun 13, 2008
	EQ 37.5MG BASE	A078517 002	Jun 13, 2008
	EQ 50MG BASE	A078517 003	Jun 13, 2008
	EQ 75MG BASE	A078517 004	Jun 13, 2008
	EQ 100MG BASE	A078517 005	Jun 13, 2008
SANDOZ	EQ 25MG BASE	A077515 001	Jun 13, 2008
	EQ 37.5MG BASE	A077515 002	Jun 13, 2008
	EQ 50MG BASE	A077515 003	Jun 13, 2008
	EQ 75MG BASE	A077515 004	Jun 13, 2008
	EQ 100MG BASE	A077515 005	Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE;INJECTION

CALAN

GD SEARLE LLC	2.5MG/ML	N019038 001	Mar 30, 1984

ISOPTIN

MT ADAMS	2.5MG/ML	N018485 001	

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM	2.5MG/ML	A070348 001	May 01, 1986
BEDFORD	2.5MG/ML	A072888 001	Jul 28, 1995
HOSPIRA	2.5MG/ML	A070577 001	Feb 02, 1987
	2.5MG/ML	A070739 001	May 06, 1987
	2.5MG/ML	A070740 001	May 06, 1987
INTL MEDICATION	2.5MG/ML	A070451 001	Dec 16, 1985
LUITPOLD	2.5MG/ML	A070225 001	Nov 12, 1985
	2.5MG/ML	A070617 001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233 001	Feb 26, 1993
	2.5MG/ML	A073485 001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696 001	Jul 31, 1987
	2.5MG/ML	A070697 001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695 001	Jul 31, 1987

TABLET;ORAL

CALAN

GD SEARLE LLC	40MG	N018817 003	Feb 23, 1988
	160MG	N018817 004	Feb 23, 1988

ISOPTIN

MT ADAMS	40MG	N018593 003	Nov 23, 1987
	80MG	N018593 001	Mar 08, 1982
	120MG	N018593 002	Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986
	120MG	A070468 001	Sep 24, 1986
MUTUAL PHARM	80MG	A070482 001	Sep 24, 1986
	120MG	A070483 001	Sep 24, 1986
PLIVA	40MG	A072751 001	Feb 23, 1996
	80MG	A072124 001	Jan 26, 1989
	120MG	A072125 001	Jan 26, 1989
SANDOZ	40MG	A073168 001	Jul 31, 1992
	80MG	A071423 001	May 24, 1988
	120MG	A071424 001	May 25, 1988
SUN PHARM INDS	80MG	A071489 002	Jan 13, 1988
	120MG	A071489 001	Jan 13, 1988
WARNER CHILCOTT	80MG	A070340 001	Sep 24, 1986
	120MG	A070341 001	Sep 24, 1986
WATSON LABS	40MG	A072799 001	Apr 28, 1989

VERAPAMIL HYDROCHLORIDE
TABLET;ORAL
VERAPAMIL HYDROCHLORIDE

	40MG	A072923 001	Jun 29, 1993
	80MG	A070855 001	Sep 24, 1986
	80MG	A071366 001	Oct 01, 1986
	120MG	A070856 001	Sep 24, 1986
	120MG	A071367 001	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL
CALAN SR

PFIZER	180MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019152 002	Dec 15, 1989

VERAPAMIL HYDROCHLORIDE

PLIVA	240MG	A072922 001	Mar 01, 1996

VERATRUM VIRIDE ROOT
TABLET;ORAL
VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691 002	

VIDARABINE
INJECTABLE;INJECTION
VIRA-A

PARKEDALE	EQ 187.4MG BASE/ML	N050523 001	

OINTMENT;OPHTHALMIC
VIRA-A

PARKEDALE	3%	N050486 001	

VINBLASTINE SULFATE
INJECTABLE;INJECTION
VELBAN

LILLY	10MG/VIAL	N012665 001	

VINBLASTINE SULFATE

ABRAXIS PHARM	10MG/VIAL	A089011 001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565 001	Aug 18, 1987

VINCRISTINE SULFATE
INJECTABLE;INJECTION
ONCOVIN

LILLY	1MG/VIAL	N014103 001	
	1MG/ML	N014103 003	Mar 07, 1984
	5MG/VIAL	N014103 002	

VINCASAR PFS

TEVA PARENTERAL	1MG/ML	A071426 001	Jul 17, 1987

VINCREX

BRISTOL MYERS SQUIBB	5MG/VIAL	A070867 001	Jul 12, 1988

VINCRISTINE SULFATE

ABIC	1MG/ML	A070873 001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411 001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296 001	Dec 20, 2002
	1MG/ML	A076401 001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559 001	Apr 11, 1988
	2MG/VIAL	A071560 001	Apr 11, 1988
	5MG/VIAL	A071561 001	Apr 11, 1988

VINORELBINE TARTRATE
INJECTABLE;INJECTION
VINORELBINE TARTRATE

EBEWE PHARMA	EQ 10MG BASE/ML	A078408 001	Feb 13, 2008

VIOMYCIN SULFATE
INJECTABLE;INJECTION
VIOCIN SULFATE

PFIZER	EQ 1GM BASE/VIAL	A061086 001	
	EQ 5GM BASE/VIAL	A061086 002	

VITAMIN A
CAPSULE;ORAL
AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080 002	
	50,000USP UNITS	A083080 001	

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973 001	
CHASE CHEM	50,000 IU	A083351 001	

FDA data supplied by DrugPatentWatch.com

VITAMIN A
CAPSULE;ORAL
VITAMIN A

EVERYLIFE	50,000 IU	A083134 001	
IMPAX LABS	50,000USP UNITS	A080952 001	
WEST WARD	50,000USP UNITS	A080985 001	

VITAMIN A PALMITATE
CAPSULE;ORAL

AFAXIN			
STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187 001	
ALPHALIN			
LILLY	EQ 50,000 UNITS BASE	A080883 001	
DEL-VI-A			
DEL RAY LABS	EQ 50,000 UNITS BASE	A080830 001	
VI-DOM-A			
BAYER PHARMS	EQ 50,000 UNITS BASE	A080972 001	
VITAMIN A			
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001	
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001	
CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001	
	EQ 50,000 UNITS BASE	A083207 001	
ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001	
EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001	
	EQ 50,000 UNITS BASE	A083114 001	
IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001	
	EQ 50,000 UNITS BASE	A080955 001	
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001	
	EQ 50,000 UNITS BASE	A083190 001	
MK LABS	EQ 25,000 UNITS BASE	A083457 002	
	EQ 50,000 UNITS BASE	A083457 001	
WEST WARD	EQ 50,000 UNITS BASE	A080967 001	
WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001	
VITAMIN A PALMITATE			
ARCUM	EQ 50,000 UNITS BASE	A083311 001	
	EQ 50,000 UNITS BASE	A083321 001	
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001	
	EQ 50,000 UNITS BASE	A083981 001	
VITAMIN A SOLUBILIZED			
TEVA	EQ 50,000 UNITS BASE	A080921 001	

INJECTABLE;INJECTION
VITAMIN A PALMITATE

BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001	

WARFARIN POTASSIUM
TABLET;ORAL
ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771 007	
	5MG	N011771 004	
	10MG	N011771 005	
	25MG	N011771 006	

WARFARIN SODIUM
INJECTABLE;INJECTION
COUMADIN

BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995
	50MG/VIAL	N009218 020	
	75MG/VIAL	N009218 012	

TABLET;ORAL
ATHROMBIN

PHARM RES ASSOC	5MG	N011771 003	
	10MG	N011771 002	
	25MG	N011771 001	
PANWARFIN			
ABBOTT	2MG	N017020 001	
	2.5MG	N017020 002	
	5MG	N017020 003	
	7.5MG	N017020 004	
	10MG	N017020 005	
WARFARIN SODIUM			
SANDOZ	1MG	A040196 001	Sep 30, 1997
	2MG	A040196 002	Sep 30, 1997
	2.5MG	A040196 003	Sep 30, 1997
	3MG	A040196 008	Jul 26, 2000

WARFARIN SODIUM
TABLET;ORAL
WARFARIN SODIUM

	4MG	A040196 004	Sep 30, 1997
	5MG	A040196 005	Sep 30, 1997
	6MG	A040196 009	Jul 26, 2000
	7.5MG	A040196 006	Sep 30, 1997
	10MG	A040196 007	Sep 30, 1997
USL PHARMA	2MG	A088719 001	Jun 27, 1985
	2.5MG	A088720 001	Aug 06, 1985
	5MG	A088721 001	Jul 02, 1985
WATSON LABS	2MG	A086123 001	Aug 17, 1982
	2.5MG	A086120 001	Aug 17, 1982
	5MG	A086119 001	Aug 17, 1982
	7.5MG	A086118 001	Aug 17, 1982
	10MG	A086122 001	Aug 17, 1982

XENON XE-127
GAS;INHALATION
XENON XE 127

MALLINCKRODT	5mCi/VIAL	N018536 001	Oct 01, 1982
	10mCi/VIAL	N018536 002	Oct 01, 1982

XENON XE-133
GAS;INHALATION
XENON XE 133

GE HEALTHCARE	1 CI/AMP	N017256 002	
	10mCi/VIAL	N017687 002	
	20mCi/VIAL	N017687 003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550 001	
	0.25-5 CI/AMP	N017550 003	

XENON XE 133-V.S.S.

GE HEALTHCARE	10mCi/VIAL	N017687 001	

INJECTABLE;INJECTION
XENON XE 133

GE HEALTHCARE	1.3-1.7 CI/AMP	N017256 001	
LANTHEUS MEDCL	6.3mCi/ML	N017283 001	

SOLUTION;INHALATION, INJECTION
XENEISOL

MALLINCKRODT	18-25mCi/AMP	N017262 002	

XYLOSE
POWDER;ORAL
XYLO-PFAN

SAVAGE LABS	25GM/BOT	N017605 001	

XYLOSE

LYNE	25GM/BOT	N018856 001	Mar 26, 1987

ZALCITABINE
TABLET;ORAL
HIVID

ROCHE	0.375MG	N020199 001	Jun 19, 1992
	0.75MG	N020199 002	Jun 19, 1992

ZALEPLON
CAPSULE;ORAL
ZALEPLON

UPSHER SMITH	5MG	A078706 001	Jun 06, 2008
	10MG	A078706 002	Jun 06, 2008
UPSHER-SMITH LABS	5MG	A078095 001	Jun 06, 2008
	10MG	A078095 002	Jun 06, 2008

ZICONOTIDE ACETATE
INJECTABLE;INTRATHECAL
PRIALT

JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004

ZIDOVUDINE
INJECTABLE;INJECTION
ZIDOVUDINE

LIAONING CHENGDA	10MG/ML	A204538 001	Nov 26, 2013

TABLET;ORAL
RETROVIR

VIIV HLTHCARE	200MG	N020518 001	Dec 19, 1995
	300MG **Federal Register determination that product was not discontinued or	N020518 002	Oct 04, 1996

ZIDOVUDINE
TABLET;ORAL
RETROVIR
withdrawn for safety or efficacy reasons**
ZIDOVUDINE

AUROBINDO PHARMA	60MG	N022294 001	Jul 23, 2009
MATRIX LABS LTD	100MG	N200732 001	Feb 23, 2011
RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005
SUNSHINE LAKE	300MG	A202058 001	Oct 07, 2011

ZILEUTON
TABLET;ORAL
ZYFLO

CHIESI USA INC	300MG	N020471 001	Dec 09, 1996

ZINC SULFATE
INJECTABLE;INJECTION
ZINC SULFATE

ABRAXIS PHARM	EQ 1MG ZINC/ML	N019229 002	May 05, 1987

ZIPRASIDONE HYDROCHLORIDE
SUSPENSION;ORAL
GEODON

PFIZER INC	EQ 10MG BASE/ML	N021483 001	Mar 29, 2006

ZOLEDRONIC ACID
INJECTABLE;IV (INFUSION)
ZOMETA

NOVARTIS	EQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021223 001	Aug 20, 2001

ZOLPIDEM TARTRATE
TABLET;ORAL
ZOLPIDEM TARTRATE

DR REDDYS LABS LTD	5MG	A077985 001	Apr 23, 2007
	10MG	A077985 002	Apr 23, 2007
HIKMA	5MG	A078129 001	Apr 30, 2008
	10MG	A078129 002	Apr 30, 2008
MYLAN PHARMS INC	5MG	A078016 001	Apr 23, 2007
	10MG	A078016 002	Apr 23, 2007
SUN PHARM INDS	5MG	A077288 001	Apr 23, 2007
	10MG	A077288 002	Apr 23, 2007
SYNTHON PHARMS	5MG	A077540 001	Apr 23, 2007
	10MG	A077540 002	Apr 23, 2007
VIVIMED LABS	5MG	A076062 001	Apr 23, 2007
	10MG	A076062 002	Apr 23, 2007
WATSON LABS	5MG	A077773 001	Apr 23, 2007
	10MG	A077773 002	Apr 23, 2007

TABLET, ORALLY DISINTEGRATING;ORAL
TOVALT ODT

BIOVAIL LABS INTL	5MG	N021412 001	Apr 25, 2007
	10MG	N021412 002	Apr 25, 2007

ZONISAMIDE
CAPSULE;ORAL
ZONISAMIDE

ANI PHARMS INC	25MG	A077639 001	Dec 22, 2005
	25MG	A077641 003	Dec 22, 2005
	50MG	A077639 002	Dec 22, 2005
	50MG	A077641 002	Dec 22, 2005
	100MG	A077639 003	Dec 22, 2005
	100MG	A077641 001	Dec 22, 2005
COREPHARMA	25MG	A077876 001	Feb 21, 2007
	50MG	A077876 002	Feb 21, 2007
	100MG	A077876 003	Feb 21, 2007
DR REDDYS LABS LTD	25MG	A077645 002	Sep 29, 2006
	50MG	A077645 003	Sep 29, 2006
	100MG	A077645 001	Dec 22, 2005
ROXANE	25MG	A077648 001	Dec 22, 2005
	50MG	A077648 002	Dec 22, 2005
	100MG	A077648 003	Dec 22, 2005
SUN PHARM INDS	25MG	A077635 001	Dec 22, 2005
	50MG	A077635 002	Dec 22, 2005

FDA data supplied by DrugPatentWatch.com

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

	100MG	A077635	003	Dec 22, 2005
UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005
	50MG	A077644	002	Dec 22, 2005
	100MG	A077644	003	Dec 22, 2005
WATSON LABS	25MG	A077650	001	Apr 20, 2006
	50MG	A077650	002	Apr 20, 2006
	100MG	A077650	003	Apr 20, 2006

FDA data supplied by DrugPatentWatch.com

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:
http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** 8 **

8-MOP, METHOXSALEN

** A **

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSTRAL, FENTANYL CITRATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE SODIUM , ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICLATE, DOXYCYCLINE HYCLATE
ACTICLATE CAP, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIGUAT
ADENOCARD, ADENOSINE
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADLYXIN, LIXISENATIDE
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS XR-ODT, AMPHETAMINE
AEROSPAN HFA, FLUNISOLIDE
AFEDITAB CR, NIFEDIPINE
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AFREZZA, INSULIN RECOMBINANT HUMAN
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKNE-MYCIN, ERYTHROMYCIN
AKOVAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTIPAK, BENZOYL PEROXIDE
AKTOB, TOBRAMYCIN
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLZITAL, ACETAMINOPHEN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
AMABELZ, ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMCINONIDE, AMCINONIDE
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMYVID, FLORBETAPIR F-18
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX, NAPROXEN SODIUM
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIZOL, FOMEPIZOLE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE
APIDRA, INSULIN GLULISINE RECOMBINANT
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARALEN, CHLOROQUINE PHOSPHATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARCAPTA NEOHALER, INDACATEROL MALEATE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARIMIDEX, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARISTADA, ARIPIPRAZOLE LAUROXIL
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARTHROTEC, DICLOFENAC SODIUM
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN, ASPIRIN (OTC)
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** A **

ATROPEN, ATROPINE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROVENT, IPRATROPIUM BROMIDE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AURYXIA, FERRIC CITRATE
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVEED, TESTOSTERONE UNDECANOATE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AVYCAZ, AVIBACTAM SODIUM
AXERT, ALMOTRIPTAN MALATE
AXID AR, NIZATIDINE (OTC)
AXIRON, TESTOSTERONE
AXUMIN, FLUCICLOVINE F-18
AYGESTIN, NORETHINDRONE ACETATE
AYUNA, ETHINYL ESTRADIOL
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

** B **

BACIIM, BACITRACIN
BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** B **

BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BARACLUDE, ENTECAVIR
BASAGLAR, INSULIN GLARGINE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELSOMRA, SUVOREXANT
BELVIQ, LORCASERIN HYDROCHLORIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BIAXIN, CLARITHROMYCIN
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLISOVI 24 FE, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** B **

BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BONIVA, IBANDRONATE SODIUM
BONJESTA, DOXYLAMINE SUCCINATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BOSULIF, BOSUTINIB MONOHYDRATE
BRAVELLE, UROFOLLITROPIN
BREO ELLIPTA, FLUTICASONE FUROATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRIDION, SUGAMMADEX SODIUM
BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRISDELLE, PAROXETINE MESYLATE
BRIVIACT, BRIVARACETAM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BROMSITE, BROMFENAC SODIUM
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON, EXENATIDE SYNTHETIC
BYDUREON PEN, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
BYVALSON, NEBIVOLOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN, VERAPAMIL HYDROCHLORIDE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALDOLOR, IBUPROFEN
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANTIL, MEPENZOLATE BROMIDE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARNEXIV, CARBAMAZEPINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** C **

CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTIN, CEFUROXIME AXETIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CETYLEV, ACETYLCYSTEINE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLBAM, CHOLIC ACID
CHOLEDYL SA, OXTRIPHYLLINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRODEX, CIPROFLOXACIN

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLAFORAN, CEFOTAXIME SODIUM
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** C **

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOLAR, CLOFARABINE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE , CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCRYS, COLCHICINE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLPREP KIT, MAGNESIUM SULFATE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMMIT, NICOTINE POLACRILEX (OTC)
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY, IOTHALAMATE MEGLUMINE
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** C **

COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CREON, PANCRELIPASE (AMYLASE
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUBICIN RF, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTARABINE, CYTARABINE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** C **

CYTOMEL, LIOTHYRONINE SODIUM
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE, GANCICLOVIR SODIUM

** D **

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
DALIRESP, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DAPTOMYCIN, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DASATINIB, DASATINIB
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE
DDAVP, DESMOPRESSIN ACETATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DEFITELIO, DEFIBROTIDE SODIUM
DELATESTRYL, TESTOSTERONE ENANTHATE
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMADEX, TORSEMIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENAVIR, PENCICLOVIR
DENDRID, IDOXURIDINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DEPOCYT, CYTARABINE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** D **

DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMATOP, PREDNICARBATE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESCOVY, EMTRICITABINE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONATE, DESONIDE
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE (OTC)
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXILANT, DEXLANSOPRAZOLE
DEXILANT SOLUTAB, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** D **

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50% , DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIAMOX, ACETAZOLAMIDE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM , DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** D **

DIDANOSINE, DIDANOSINE
DIDRONEL, ETIDRONATE DISODIUM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DISULFIRAM , DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCEFREZ, DOCETAXEL
DOCETAXEL, DOCETAXEL
DOFETILIDE, DOFETILIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIBAX, DORIPENEM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** D **

DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUAC, BENZOYL PEROXIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURLAZA, ASPIRIN
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DUVOID, BETHANECHOL CHLORIDE
DYANAVEL XR, AMPHETAMINE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYLOJECT, DICLOFENAC SODIUM
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

** E **

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGRIFTA, TESAMORELIN ACETATE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELELYSO, TALIGLUCERASE ALFA
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELIDEL, PIMECROLIMUS
ELIFEMME, ETHINYL ESTRADIOL
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIPHOS, CALCIUM ACETATE
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBEDA, MORPHINE SULFATE
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDOMETRIN, PROGESTERONE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENULOSE, LACTULOSE
ENVARSUS XR, TACROLIMUS
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPANED KIT, ENALAPRIL MALEATE
EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
EPCLUSA, SOFOSBUVIR
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL VALERATE AND DIENOGEST, DIENOGEST
ESTRASORB, ESTRADIOL HEMIHYDRATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** E **

ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOMELA, MELPHALAN HYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVZIO, NALOXONE HYDROCHLORIDE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXONDYS 51, ETEPLIRSEN
EXPAREL, BUPIVACAINE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODEXTRIN
EZETIMIBE, EZETIMIBE

** F **

FABIOR, TAZAROTENE
FACTIVE, GEMIFLOXACIN MESYLATE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FAMVIR, FAMCICLOVIR
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FARXIGA, DAPAGLIFLOZIN PROPANEDIOL
FARYDAK, PANOBINOSTAT LACTATE
FASLODEX, FULVESTRANT
FAYOSIM, ETHINYL ESTRADIOL
FAZACLO ODT, CLOZAPINE
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMTRACE, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE, FENTANYL CITRATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** F **

FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERRIPROX, DEFERIPRONE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINACEA , AZELAIC ACID
FINASTERIDE, FINASTERIDE
FIORICET, ACETAMINOPHEN
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL, ASPIRIN
FIORINAL W/CODEINE, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRMAGON, DEGARELIX ACETATE
FLAGYL, METRONIDAZOLE
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLOLAN, EPOPROSTENOL SODIUM
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOWTUSS, GUAIFENESIN
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCITE, FLUORESCEIN SODIUM
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** F **

FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORADIL, FORMOTEROL FUMARATE
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTESTA, TESTOSTERONE
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FULYZAQ, CROFELEMER
FURADANTIN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE
FYAVOLV, ETHINYL ESTRADIOL
FYCOMPA, PERAMPANEL

** G **

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALZIN, ZINC ACETATE
GANCICLOVIR, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** G **

GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GELNIQUE 3%, OXYBUTYNIN
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN, SOMATROPIN RECOMBINANT
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAZO, BALSALAZIDE DISODIUM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD
GILOTRIF, AFATINIB DIMALEATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
GLUCOTROL, GLIPIZIDE
GLUCOTROL XL, GLIPIZIDE
GLUCOVANCE, GLYBURIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
GLYXAMBI, EMPAGLIFLOZIN
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONITRO, NITROGLYCERIN

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** G **

GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUAIFENESIN, GUAIFENESIN (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)

** H **

H.P. ACTHAR GEL, CORTICOTROPIN
HABITROL, NICOTINE (OTC)
HALAVEN, ERIBULIN MESYLATE
HALCION, TRIAZOLAM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HALOG, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HARVONI, LEDIPASVIR
HEATHER, NORETHINDRONE
HECTOROL, DOXERCALCIFEROL
HEMABATE, CARBOPROST TROMETHAMINE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
HEPSERA, ADEFOVIR DIPIVOXIL
HER STYLE, LEVONORGESTREL (OTC)
HETLIOZ, TASIMELTEON
HEXALEN, ALTRETAMINE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HICON, SODIUM IODIDE I-131
HIPREX, METHENAMINE HIPPURATE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HORIZANT, GABAPENTIN ENACARBIL
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** H **

HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R KWIKPEN, INSULIN HUMAN
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCOFENIX, GUAIFENESIN
HYDERGINE, ERGOLOID MESYLATES
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE ,
HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
HYSINGLA, HYDROCODONE BITARTRATE
HYZAAR, HYDROCHLOROTHIAZIDE

** I **

IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBRANCE, PALBOCICLIB
IBU-TAB, IBUPROFEN
IBU-TAB 200, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN LYSINE, IBUPROFEN LYSINE
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
IBUPROHM, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICLUSIG, PONATINIB HYDROCHLORIDE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** I ****

IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
ILEVRO, NEPAFENAC
ILOPERIDONE, ILOPERIDONE
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMURAN, AZATHIOPRINE
INAPSINE, DROPERIDOL
INCASSIA, NORETHINDRONE
INCRELEX, MECASERMIN RECOMBINANT
INCRUSE ELLIPTA , UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INSPRA, EPLERENONE
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTERMEZZO, ZOLPIDEM TARTRATE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVIRASE, SAQUINAVIR MESYLATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** I ****

IONSYS, FENTANYL HYDROCHLORIDE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRIVASK, DESIRUDIN RECOMBINANT
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISIBLOOM, DESOGESTREL
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVERMECTIN, IVERMECTIN
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE

**** J ****

JADENU, DEFERASIROX
JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JUBLIA, EFINACONAZOLE
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE

**** K ****

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** K **

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KADIAN, MORPHINE SULFATE
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALYDECO, IVACAFTOR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KEFZOL, CEFAZOLIN SODIUM
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHEDEZLA, DESVENLAFAXINE
KIMIDESS, DESOGESTREL
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KORLYM, MIFEPRISTONE
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYBELLA, DEOXYCHOLIC ACID
KYLEENA, LEVONORGESTREL
KYNAMRO, MIPOMERSEN SODIUM
KYPROLIS, CARFILZOMIB

** L **

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** L **

LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LAMPRENE, CLOFAZIMINE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE , LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANTUS, INSULIN GLARGINE RECOMBINANT
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACAFT, ALCAFTADINE
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LAZANDA, FENTANYL CITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LENVIMA, LENVATINIB MESYLATE
LERIBANE, ETHINYL ESTRADIOL
LESCOL, FLUVASTATIN SODIUM
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVAQUIN, LEVOFLOXACIN
LEVEMIR, INSULIN DETEMIR RECOMBINANT
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** L **

LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LILETTA, LEVONORGESTREL
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LINEZOLID, LINEZOLID
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPIODOL, ETHIODIZED OIL
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO MINASTRIN FE, ETHINYL ESTRADIOL
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOMAIRA, PHENTERMINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
LONSURF, TIPIRACIL HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** L **

LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPANETA PACK, LEUPROLIDE ACETATE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUVOX CR, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LUZU, LULICONAZOLE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNPARZA, OLAPARIB
LYRICA, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID

** M **

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M.V.I. ADULT, ASCORBIC ACID
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACUGEN, PEGAPTANIB SODIUM
MAFENIDE ACETATE, MAFENIDE ACETATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MAKENA, HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** M **

MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE, MEGESTROL ACETATE
MEGACE ES, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPURINE, MERCAPTOPURINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** M **

METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRO-K, POTASSIUM CHLORIDE
MICRO-K 10, POTASSIUM CHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** M **

MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICRONOR, NORETHINDRONE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILNACIPRAN HYDROCHLORIDE, MILNACIPRAN HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINITRAN, NITROGLYCERIN
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MODICON 28, ETHINYL ESTRADIOL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHOLROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** M **

MORPHABOND, MORPHINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXATAG, AMOXICILLIN
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON
MYSOLINE, PRIMIDONE
MYZILRA, ETHINYL ESTRADIOL

** N **

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALOXONE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE
NATACYN, NATAMYCIN
NATAZIA, DIENOGEST
NATEGLINIDE, NATEGLINIDE
NATESTO, TESTOSTERONE
NATRECOR, NESIRITIDE RECOMBINANT
NATROBA, SPINOSAD
NAVELBINE, VINORELBINE TARTRATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-FRADIN, NEOMYCIN SULFATE
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NEPHRAMINE 5.4%, AMINO ACIDS
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXPLANON, ETONOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILUTAMIDE, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NISOLDIPINE, NISOLDIPINE
NITHIODOTE, SODIUM NITRITE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL, KETOCONAZOLE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORDITROPIN FLEXPRO, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE,
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 28-DAY, MESTRANOL
NORITATE, METRONIDAZOLE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORTHERA, DROXIDOPA
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOXAFIL, POSACONAZOLE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUPLAZID, PIMAVANSERIN TARTRATE
NUTRESTORE, GLUTAMINE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUVARING, ETHINYL ESTRADIOL
NUVESSA, METRONIDAZOLE
NUVIGIL, ARMODAFINIL
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
NYMALIZE, NIMODIPINE
NYSTATIN, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTOP, NYSTATIN

**** O ****

OBREDON, GUAIFENESIN
OCALIVA, OBETICHOLIC ACID
OCTOCAINE, EPINEPHRINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
OCUPRESS, CARTEOLOL HYDROCHLORIDE
ODEFSEY, EMTRICITABINE
ODOMZO, SONIDEGIB PHOSPHATE
OFEV, NINTEDANIB ESYLATE
OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OLYSIO, SIMEPREVIR SODIUM
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** O **

OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN RECOMBINANT
OMTRYG, OMEGA-3-ACID ETHYL ESTERS TYPE A
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONMEL, ITRACONAZOLE
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPANA, OXYMORPHONE HYDROCHLORIDE
OPANA ER, OXYMORPHONE HYDROCHLORIDE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIMARK, GADOVERSETAMIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPTIVAR, AZELASTINE HYDROCHLORIDE
ORABLOC, ARTICAINE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORALTAG, IOHEXOL
ORAP, PIMOZIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORKAMBI, IVACAFTOR
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORSYTHIA, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORVATEN, MIDODRINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OSENI, ALOGLIPTIN BENZOATE
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
OSPHENA, OSPEMIFENE
OTEZLA, APREMILAST
OTICAIR, HYDROCORTISONE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OTIPRIO, CIPROFLOXACIN
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
OTREXUP, METHOTREXATE
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXANDRIN, OXANDROLONE
OXANDROLONE, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAYDO, OXYCODONE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
OXCARBAZEPINE, OXCARBAZEPINE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
OXISTAT, OXICONAZOLE NITRATE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
OXTELLAR XR, OXCARBAZEPINE
OXYBUTYNIN, OXYBUTYNIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
OXYTROL, OXYBUTYNIN
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
PACITAXEL, PACLITAXEL
PACLITAXEL, PACLITAXEL
PALIPERIDONE, PALIPERIDONE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCREAZE, PANCRELIPASE (AMYLASE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAGARD T 380A, COPPER
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROEX, CHLORHEXIDINE GLUCONATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PASER, AMINOSALICYLIC ACID
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** P **

PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL, BISACODYL
PEGANONE, ETHOTOIN
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID, FAMOTIDINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID AC , FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERTZYE, PANCRELIPASE (AMYLASE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHILITH, ETHINYL ESTRADIOL
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PICATO, INGENOL MEBUTATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** P **

PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIMOZIDE, PIMOZIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLIAGLIS, LIDOCAINE
PODOFILOX, PODOFILOX
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYTRIM, POLYMYXIN B SULFATE
POMALYST, POMALIDOMIDE
PONSTEL, MEFENAMIC ACID
PORTIA-28, ETHINYL ESTRADIOL
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** P ****

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** P **

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POTIGA, EZOGABINE
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIMET, METFORMIN HYDROCHLORIDE
PRANDIN, REPAGLINIDE
PRAVACHOL, PRAVASTATIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PREDNISONE INTENSOL, PREDNISONE
PREGNYL, GONADOTROPIN, CHORIONIC
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PREPOPIK, CITRIC ACID
PRESTALIA, AMLODIPINE BESYLATE
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR ETHANOLATE
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINIVIL, LISINOPRIL
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** P **

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROFEN, IBUPROFEN (OTC)
PROFERDEX, IRON DEXTRAN
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** P **

PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVAYBLUE, METHYLENE BLUE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PUR-WASH, PURIFIED WATER (OTC)
PURINETHOL, MERCAPTOPURINE
PURIXAN, MERCAPTOPURINE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYTEST, UREA, C-14
PYTEST KIT, UREA, C-14

** Q **

QBRELIS, LISINOPRIL
QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUARTETTE, ETHINYL ESTRADIOL
QUASENSE, ETHINYL ESTRADIOL
QUDEXY XR, TOPIRAMATE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QUTENZA, CAPSAICIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

** R **

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** R **

RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYALDEE, CALCIFEDIOL
RAYOS, PREDNISONE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIES, BARIUM SULFATE
REBETOL, RIBAVIRIN
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
REQUIP, ROPINIROLE HYDROCHLORIDE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESERPINE, RESERPINE
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REZIRA, HYDROCODONE BITARTRATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RIBASPHERE, RIBAVIRIN
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** R **

RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE, GLIMEPIRIDE
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
RUBRACA, RUCAPARIB CAMSYLATE
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RYANODEX, DANTROLENE SODIUM
RYTARY, CARBIDOPA
RYTHMOL, PROPAFENONE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYZODEG 70/30, INSULIN ASPART

** S **

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SALURON, HYDROFLUMETHIAZIDE
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL
SCLEROSOL, TALC
SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECONAL SODIUM, SECOBARBITAL SODIUM
SECTRAL, ACEBUTOLOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** S **

SEEBRI, GLYCOPYRROLATE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELFEMRA, FLUOXETINE HYDROCHLORIDE
SELSUN, SELENIUM SULFIDE
SELZENTRY, MARAVIROC
SEMPREX-D, ACRIVASTINE
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SERNIVO, BETAMETHASONE DIPROPIONATE
SEROMYCIN, CYCLOSERINE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SETLAKIN, ETHINYL ESTRADIOL
SEVOFLURANE, SEVOFLURANE
SFROWASA, MESALAMINE
SHADE UVAGUARD, AVOBENZONE (OTC)
SIGNIFOR, PASIREOTIDE DIASPARTATE
SIGNIFOR LAR, PASIREOTIDE PAMOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINEMET CR, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN
SKYLA, LEVONORGESTREL
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** S **

SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLIQUA 100/33, INSULIN GLARGINE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SSD, SILVER SULFADIAZINE
SSD AF, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STARLIX, NATEGLINIDE
STAVUDINE, STAVUDINE
STAXYN, VARDENAFIL HYDROCHLORIDE
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCRAID, SACROSIDASE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUSTIVA, EFAVIRENZ
SUSTOL, GRANISETRON
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYMBICORT, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMLIN, PRAMLINTIDE ACETATE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNAREL, NAFARELIN ACETATE
SYNERA, LIDOCAINE
SYNERCID, DALFOPRISTIN
SYNJARDY, EMPAGLIFLOZIN
SYNJARDY XR, EMPAGLIFLOZIN
SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TAFINLAR, DABRAFENIB MESYLATE
TAGAMET HB, CIMETIDINE (OTC)
TAGRISSO, OSIMERTINIB MESYLATE
TALC, TALC
TALWIN, PENTAZOCINE LACTATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAPAZOLE, METHIMAZOLE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TASMAR, TOLCAPONE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAXOL, PACLITAXEL

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TAXOTERE, DOCETAXEL
TAYTULLA, ETHINYL ESTRADIOL
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNIVIE, OMBITASVIR
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKTURNA, ALISKIREN HEMIFUMARATE
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TENEX, GUANFACINE HYDROCHLORIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIL, CARBAMAZEPINE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTRED, METHYLTESTOSTERONE
TETRABENAZINE, TETRABENAZINE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEVETEN, EPROSARTAN MESYLATE
TEXACORT, HYDROCORTISONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THEO-24, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** T ****

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOLA, TIOPRONIN
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE
THRIVE, NICOTINE POLACRILEX (OTC)
THYROGEN, THYROTROPIN ALFA
THYROLAR-0.25, LIOTRIX (T4
THYROLAR-0.5, LIOTRIX (T4
THYROLAR-1, LIOTRIX (T4
THYROLAR-2, LIOTRIX (T4
THYROLAR-3, LIOTRIX (T4
THYROSAFE, POTASSIUM IODIDE (OTC)
THYROSHIELD, POTASSIUM IODIDE (OTC)
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIKOSYN, DOFETILIDE
TIMOLOL, TIMOLOL
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM
TIS-U-SOL, MAGNESIUM SULFATE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIVICAY, DOLUTEGRAVIR SODIUM
TIVORBEX, INDOMETHACIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOLAK, FLUOROURACIL
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLCAPONE, TOLCAPONE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOTECT, DEXRAZOXANE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** T **

TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELSTAR, TRIPTORELIN PAMOATE
TRESIBA, INSULIN DEGLUDEC
TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TREXIMET, NAPROXEN SODIUM
TREZIX, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDIONE, TRIMETHADIONE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
TRIFERIC , FERRIC PYROPHOSPHATE CITRATE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRILYTE, POLYETHYLENE GLYCOL 3350
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRINTELLIX, VORTIOXETINE HYDROBROMIDE
TRIOSTAT, LIOTHYRONINE SODIUM
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROKENDI XR, TOPIRAMATE
TROPHAMINE, AMINO ACIDS
TROPHAMINE 10%, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
TROXYCA ER, NALTREXONE HYDROCHLORIDE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
TWYNSTA, AMLODIPINE BESYLATE
TYBOST, COBICISTAT
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL , ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYVASO, TREPROSTINIL
TYZEKA, TELBIVUDINE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

U-CORT, HYDROCORTISONE ACETATE
UCERIS, BUDESONIDE
ULESFIA, BENZYL ALCOHOL
ULORIC, FEBUXOSTAT
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
ULTRESA, PANCRELIPASE (AMYLASE
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UPTRAVI, SELEXIPAG
URECHOLINE, BETHANECHOL CHLORIDE
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UTIBRON, GLYCOPYRROLATE
UVADEX, METHOXSALEN

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** V **

VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VALTROPIN, SOMATROPIN RECOMBINANT
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARIBAR, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITEX CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERMOX, MEBENDAZOLE
VERSACLOZ, CLOZAPINE
VESICARE, SOLIFENACIN SUCCINATE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICOPROFEN, HYDROCODONE BITARTRATE
VICTOZA, LIRAGLUTIDE RECOMBINANT

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** V **

VIDAZA, AZACITIDINE
VIDEX, DIDANOSINE
VIDEX EC, DIDANOSINE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIEKIRA XR, DASABUVIR SODIUM
VIENVA, ETHINYL ESTRADIOL
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIOKACE, PANCRELIPASE (AMYLASE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTOGARD, URIDINE TRIACETATE
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITEKTA, ELVITEGRAVIR
VITRASE, HYALURONIDASE
VITUZ, CHLORPHENIRAMINE MALEATE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VIVITROL, NALTREXONE
VIVLODEX, MELOXICAM
VIZAMYL, FLUTEMETAMOL F-18
VOGELXO, TESTOSTERONE
VOLNEA, DESOGESTREL
VOLTAREN, DICLOFENAC SODIUM
VORICONAZOLE, VORICONAZOLE
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOSPIRE ER, ALBUTEROL SULFATE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VPRIV, VELAGLUCERASE ALFA
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VUMON, TENIPOSIDE
VUSION, MICONAZOLE NITRATE
VYFEMLA, ETHINYL ESTRADIOL
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

** W **

WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WOMEN'S ROGAINE, MINOXIDIL (OTC)

** X **

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

** X **

XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARELTO, RIVAROXABAN
XARTEMIS XR, ACETAMINOPHEN
XELJANZ, TOFACITINIB CITRATE
XELJANZ XR, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENON XE 133, XENON XE-133
XERESE, ACYCLOVIR
XIFAXAN, RIFAXIMIN
XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL
XIIDRA, LIFITEGRAST
XOFIGO, RADIUM RA-223 DICHLORIDE
XOLEGEL, KETOCONAZOLE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
XTAMPZA ER, OXYCODONE
XTANDI, ENZALUTAMIDE
XTORO, FINAFLOXACIN
XULANE, ETHINYL ESTRADIOL
XULTOPHY 100/3.6, INSULIN DEGLUDEC
XURIDEN, URIDINE TRIACETATE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYREM, SODIUM OXYBATE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

** Y **

YAELA, DROSPIRENONE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE
YONDELIS, TRABECTEDIN
YOSPRALA, ASPIRIN

** Z **

ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC, RANITIDINE HYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZECUITY, SUMATRIPTAN SUCCINATE
ZEGERID, OMEPRAZOLE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZENPEP, PANCRELIPASE (AMYLASE
ZEPATIER, ELBASVIR
ZERBAXA, CEFTOLOZANE SULFATE
ZERIT, STAVUDINE

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZINACEF, CEFUROXIME SODIUM
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMACTON, SOMATROPIN RECOMBINANT
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZUPLENZ, ONDANSETRON
ZURAMPIC, LESINURAD
ZUTRIPRO, CHLORPHENIRAMINE MALEATE
ZYBAN, BUPROPION HYDROCHLORIDE
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYFREL, ACETAMINOPHEN
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

FDA data supplied by DrugPatentWatch.com

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** 3 **

3D IMAGING DRUG
* 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M
* 3M CO
  PERIDEX, CHLORHEXIDINE GLUCONATE
* 3M HEALTH CARE INC
  AVAGARD, ALCOHOL (OTC)
  DURAPREP, IODINE POVACRYLEX (OTC)
* 3M PHARMACEUTICALS INC
  PROVENTIL-HFA, ALBUTEROL SULFATE

3M DRUG DELIVERY
* 3M DRUG DELIVERY SYSTEMS DIVISION
  FENTANYL-100, FENTANYL
  FENTANYL-12, FENTANYL
  FENTANYL-25, FENTANYL
  FENTANYL-50, FENTANYL
  FENTANYL-75, FENTANYL

** A **

AAA USA INC
* ADVANCED ACCELERATOR APPLICATIONS USA INC
  NETSPOT, GALLIUM DOTATATE GA-68

AAIPHARMA LLC
* AAIPHARMA LLC
  AZASAN, AZATHIOPRINE

ABBVIE
* ABBVIE INC
  ANDROGEL, TESTOSTERONE
  BIAXIN, CLARITHROMYCIN
  CREON, PANCRELIPASE (AMYLASE
  CYCLOSPORINE, CYCLOSPORINE
  DEPACON, VALPROATE SODIUM
  DEPAKENE, VALPROIC ACID
  DEPAKOTE ER, DIVALPROEX SODIUM
  DEPAKOTE, DIVALPROEX SODIUM
  GENGRAF, CYCLOSPORINE
  K-TAB, POTASSIUM CHLORIDE
  KALETRA, LOPINAVIR
  MARINOL, DRONABINOL
  MAVIK, TRANDOLAPRIL
  MIVACRON, MIVACURIUM CHLORIDE
  NIASPAN, NIACIN
  NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
  NIMBEX, CISATRACURIUM BESYLATE
  NORVIR, RITONAVIR
  SURVANTA, BERACTANT
  SYNTHROID, LEVOTHYROXINE SODIUM **
  TARKA, TRANDOLAPRIL
  TEVETEN, EPROSARTAN MESYLATE
  TRICOR, FENOFIBRATE
  TRIDIONE, TRIMETHADIONE
  TRILIPIX, CHOLINE FENOFIBRATE
  ULTANE, SEVOFLURANE
  VICOPROFEN, HYDROCODONE BITARTRATE
  ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE
* ABBVIE ENDOCRINE INC
  LUPANETA PACK, LEUPROLIDE ACETATE

ABBVIE ENDOCRINE INC
* ABBVIE ENDOCRINE INC
  LUPRON DEPOT, LEUPROLIDE ACETATE
  LUPRON DEPOT-PED, LEUPROLIDE ACETATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

ABBVIE INC
* ABBVIE INC
DUOPA, CARBIDOPA
TECHNIVIE, OMBITASVIR
VENCLEXTA, VENETOCLAX
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIEKIRA XR, DASABUVIR SODIUM

ABHAI
* ABHAI LLC
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI INC
* ABHAI INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

ABRAXIS BIOSCIENCE
* ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

ABRAXIS PHARM
* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADIA PHARMS INC
* ACADIA PHARMACEUTICALS INC
NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS
* ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE
* ACCORD HEALTHCARE INC
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CISPLATIN, CISPLATIN
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
DOCETAXEL, DOCETAXEL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOPOSIDE, ETOPOSIDE
FINASTERIDE, FINASTERIDE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL, LISINOPRIL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ACCORD HEALTHCARE INC
  NORETHINDRONE, NORETHINDRONE
  ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
  PARICALCITOL, PARICALCITOL
  PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
  PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
  SIMVASTATIN, SIMVASTATIN
  TACROLIMUS, TACROLIMUS
  TOPIRAMATE, TOPIRAMATE
  TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA
  DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
  FINASTERIDE, FINASTERIDE
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  RAMIPRIL, RAMIPRIL
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
  SPIRONOLACTONE, SPIRONOLACTONE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
  BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
  GABAPENTIN, GABAPENTIN

ACI HEALTHCARE LTD

* ACI HEALTHCARE LTD
  GABAPENTIN, GABAPENTIN
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC FINE CHEMS

* ACIC FINE CHEMICALS INC
  TRANEXAMIC ACID, TRANEXAMIC ACID

ACORDA

* ACORDA THERAPEUTICS INC
  AMPYRA, DALFAMPRIDINE
  QUTENZA, CAPSAICIN
  ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ACS DOBFAR

* ACS DOBFAR SPA
  AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
  CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
  CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
  CEFOXITIN, CEFOXITIN SODIUM
  CEFTAZIDIME, CEFTAZIDIME
  CEFTRIAXONE, CEFTRIAXONE SODIUM
  IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
  KEFZOL, CEFAZOLIN SODIUM
  MEROPENEM, MEROPENEM

ACS DOBFAR INFO SA

* ACS DOBFAR INFO SA
  CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
  FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
  LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACS DOBFAR SPA

* ACS DOBFAR SPA
  AMPICILLIN SODIUM, AMPICILLIN SODIUM
  CEFOXITIN, CEFOXITIN SODIUM

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
  ALPRAZOLAM, ALPRAZOLAM
  BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS ELIZABETH LLC
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MORPHINE SULFATE, MORPHINE SULFATE
NIFEDIPINE, NIFEDIPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TEMAZEPAM, TEMAZEPAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS GRP PTC

* ACTAVIS GROUP PTC EHF
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
METHOXSALEN, METHOXSALEN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACTAVIS LABS FL INC

* ACTAVIS LABORATORIES FL INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CABERGOLINE, CABERGOLINE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ACTAVIS LABORATORIES FL INC
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
  DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
  DUTASTERIDE, DUTASTERIDE
  FLUTAMIDE, FLUTAMIDE
  GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
  GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
  GUAIFENESIN, GUAIFENESIN (OTC)
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
  HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
  KETOPROFEN, KETOPROFEN
  LACOSAMIDE, LACOSAMIDE
  LEVETIRACETAM, LEVETIRACETAM
  LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
  LORATADINE, LORATADINE (OTC)
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
  MIRTAZAPINE, MIRTAZAPINE
  NAPROXEN SODIUM, NAPROXEN SODIUM
  NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
  OMEPRAZOLE, OMEPRAZOLE
  OXYCODONE AND ASPIRIN, ASPIRIN
  PALIPERIDONE, PALIPERIDONE
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  RAMELTEON, RAMELTEON
  RISPERIDONE, RISPERIDONE
  TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
  TAZTIA XT, DILTIAZEM HYDROCHLORIDE
  TRANEXAMIC ACID, TRANEXAMIC ACID
  TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
  VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS NY INC

* ACTAVIS LABORATORIES NY INC
  NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
  CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
  CLONIDINE, CLONIDINE
  EMLA, LIDOCAINE
  FENTANYL-100, FENTANYL
  FENTANYL-25, FENTANYL
  FENTANYL-50, FENTANYL
  FENTANYL-75, FENTANYL
  FIORICET W/ CODEINE, ACETAMINOPHEN
  FIORICET, ACETAMINOPHEN
  FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
  LIDOCAINE, LIDOCAINE
  NORINYL 1+50 28-DAY, MESTRANOL
  TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
  TENUATE, DIETHYLPROPION HYDROCHLORIDE
  TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

* ACTAVIS LLC
  AZACITIDINE, AZACITIDINE
  LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
  MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
  ACETASOL HC, ACETIC ACID, GLACIAL
  ACYCLOVIR, ACYCLOVIR
  ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS MID ATLANTIC LLC
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ENULOSE, LACTULOSE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
VALNAC, BETAMETHASONE VALERATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
BICALUTAMIDE, BICALUTAMIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
REPAGLINIDE, REPAGLINIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION PHARMS LTD

* ACTELION PHARMACEUTICALS LTD
OPSUMIT, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

* ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE

ADAPT

* ADAPT PHARMA OPERATIONS LTD
NARCAN, NALOXONE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

ADARE PHARMS INC
* ADARE PHARMACEUTICALS INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

AEGERION
* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

AGOURON
* AGOURON PHARMACEUTICALS INC
VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS PVT LTD
* AILEX PHARMACEUTICALS PVT LTD
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AIPING PHARM INC
* AIPING PHARMACEUTICAL INC
FOLIC ACID, FOLIC ACID
IBUPROFEN, IBUPROFEN

AJANTA PHARMA
* AJANTA PHARMA LTD
LEVETIRACETAM, LEVETIRACETAM

AJANTA PHARMA LTD
* AJANTA PHARMA LTD
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
LANSOPRAZOLE, LANSOPRAZOLE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
RISPERIDONE, RISPERIDONE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

AKORN
* AKORN INC
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ENDOSOL EXTRA, CALCIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC
ERYTHROMYCIN, ERYTHROMYCIN
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IC-GREEN, INDOCYANINE GREEN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LATANOPROST, LATANOPROST
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PYRAZINAMIDE, PYRAZINAMIDE
RIFAMPIN, RIFAMPIN
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOLOL, TIMOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROPICACYL, TROPICAMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

AKORN INC

* AKORN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DRONABINOL, DRONABINOL
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
INAPSINE, DROPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* AKORN INC
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALARA PHARM

* ALARA PHARMACEUTICAL CORPORATION
  LEVO-T, LEVOTHYROXINE SODIUM **

ALCON

* ALCON LABORATORIES INC
  BETOPTIC, BETAXOLOL HYDROCHLORIDE
  BSS PLUS, CALCIUM CHLORIDE
  BSS, CALCIUM CHLORIDE
  CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
  CROMOLYN SODIUM, CROMOLYN SODIUM
  DENDRID, IDOXURIDINE
  MAXITROL, DEXAMETHASONE
  MIOSTAT, CARBACHOL
  MYDRIACYL, TROPICAMIDE
  NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
  NATACYN, NATAMYCIN
  TOBREX, TOBRAMYCIN

ALCON LABS INC

* ALCON LABORATORIES INC
  LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE

ALCON PHARMA

* ALCON RESEARCH LTD
  AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
  BETADINE, POVIDONE-IODINE
  BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
  DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
  KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
  NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
  OFLOXACIN, OFLOXACIN
  QOLIANA, BRIMONIDINE TARTRATE
  SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
  TRIFLURIDINE, TRIFLURIDINE

ALCON RES

* ALCON RESEARCH LTD
  DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  LATANOPROST, LATANOPROST

ALCON RES LTD

* ALCON RESEARCH LTD
  BIMATOPROST, BIMATOPROST
  EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
  GATIFLOXACIN, GATIFLOXACIN
  GENTAMICIN SULFATE, GENTAMICIN SULFATE
  LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
  METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
  TIMOLOL MALEATE, TIMOLOL MALEATE
  TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

ALEMBIC LTD

* ALEMBIC LTD
  LITHIUM CARBONATE, LITHIUM CARBONATE
  METRONIDAZOLE, METRONIDAZOLE
  MODAFINIL, MODAFINIL
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  THEOPHYLLINE, THEOPHYLLINE
  VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ALEMBIC PHARMACEUTICALS LTD
  AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
  ARIPIPRAZOLE, ARIPIPRAZOLE
  CELECOXIB, CELECOXIB
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
  DESVENLAFAXINE, DESVENLAFAXINE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  FAMOTIDINE, FAMOTIDINE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  IRBESARTAN, IRBESARTAN
  ITRACONAZOLE, ITRACONAZOLE
  LACOSAMIDE, LACOSAMIDE
  LAMOTRIGINE, LAMOTRIGINE
  LEFLUNOMIDE, LEFLUNOMIDE
  LINEZOLID, LINEZOLID
  LITHIUM CARBONATE, LITHIUM CARBONATE
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  MEPROBAMATE, MEPROBAMATE
  METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  METRONIDAZOLE, METRONIDAZOLE
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
  TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
  TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  TELMISARTAN, TELMISARTAN
  VALSARTAN, VALSARTAN
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  ZOLMITRIPTAN, ZOLMITRIPTAN

ALEXZA PHARMS

* ALEXZA PHARMACEUTICALS INC
  ADASUVE, LOXAPINE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
  ILUVIEN, FLUOCINOLONE ACETONIDE

ALKEM

* ALKEM LABORATORIES LTD
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  GABAPENTIN, GABAPENTIN
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
  CEFUROXIME AXETIL, CEFUROXIME AXETIL
  CEPHALEXIN, CEPHALEXIN
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  FINASTERIDE, FINASTERIDE
  GABAPENTIN, GABAPENTIN
  HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  LAMOTRIGINE, LAMOTRIGINE
  LINEZOLID, LINEZOLID
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
  MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
  OLANZAPINE, OLANZAPINE
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  RILUZOLE, RILUZOLE
  RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

ALKERMES

* ALKERMES INC
  VIVITROL, NALTREXONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

ALKERMES INC
* ALKERMES INC
ARISTADA, ARIPIPRAZOLE LAUROXIL

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN
* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
ZYMAXID, GATIFLOXACIN
* ALLERGAN INC
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
LASTACAFT, ALCAFTADINE
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTASIS, CYCLOSPORINE
TAZORAC, TAZAROTENE
ZYMAR, GATIFLOXACIN
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
OCUFEN, FLURBIPROFEN SODIUM
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE

ALLERGAN HOLDINGS
* ALLERGAN HOLDINGS UNLTD CO
VIBERZI, ELUXADOLINE

ALLERGAN INC
* ALLERGAN INC
ACZONE, DAPSONE

ALLERGAN SALES LLC
* ALLERGAN SALES LLC
ACTIGALL, URSODIOL
ALORA, ESTRADIOL
ANDRODERM, TESTOSTERONE
BREVICON 28-DAY, ETHINYL ESTRADIOL
CONDYLOX, PODOFILOX
CORDRAN, FLURANDRENOLIDE
CRINONE, PROGESTERONE
ESTRACE, ESTRADIOL
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
GELNIQUE 3%, OXYBUTYNIN
GELNIQUE, OXYBUTYNIN CHLORIDE
INFED, IRON DEXTRAN
KADIAN, MORPHINE SULFATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ALLERGAN SALES LLC
  MICROZIDE, HYDROCHLOROTHIAZIDE
  NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
  NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
  NUVESSA, METRONIDAZOLE
  OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
  OXYTROL, OXYBUTYNIN
  PROGESTERONE, PROGESTERONE
  RAPAFLO, SILODOSIN
  TRELSTAR, TRIPTORELIN PAMOATE
  TRETINOIN, TRETINOIN

ALLERQUEST
* ALLERQUEST LLC
  PRE-PEN, BENZYLPENICILLOYL POLYLYSINE

ALLIED PHARMA INC
* ALLIED PHARMA INC
  CLARITHROMYCIN, CLARITHROMYCIN
  LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
  METRONIDAZOLE, METRONIDAZOLE

ALLOS
* ALLOS THERAPEUTICS INC
  FOLOTYN, PRALATREXATE

ALPHARMA
* ALPHARMA USPD INC
  PREDNISOLONE, PREDNISOLONE
  VALPROIC ACID, VALPROIC ACID

ALPHARMA PHARMS
* ALPHARMA PHARMACEUTICALS LLC
  EMBEDA, MORPHINE SULFATE

ALRA
* ALRA LABORATORIES INC
  CHOLAC, LACTULOSE
  CONSTILAC, LACTULOSE
  GEN-XENE, CLORAZEPATE DIPOTASSIUM
  IBU-TAB 200, IBUPROFEN (OTC)
  IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC
* ALTAIRE PHARMACEUTICALS INC
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
  OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC
* ALTATHERA PHARMACEUTICALS LLC
  SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN
* ALVOGEN GROUP HOLDINGS 2 LLC
  DAPSONE, DAPSONE
  OFLOXACIN, OFLOXACIN
* ALVOGEN GROUP HOLDINGS LLC
  ADALAT CC, NIFEDIPINE
* ALVOGEN INC
  TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

ALVOGEN INC
* ALVOGEN INC
  ACETYLCYSTEINE, ACETYLCYSTEINE
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
  PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
  VORICONAZOLE, VORICONAZOLE

ALVOGEN MALTA
* ALVOGEN MALTA OPERATIONS LTD
  ATENOLOL AND CHLORTHALIDONE, ATENOLOL
  ATENOLOL, ATENOLOL
  BUDESONIDE, BUDESONIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ALVOGEN MALTA OPERATIONS LTD
  CARBIDOPA, CARBIDOPA
  DISULFIRAM , DISULFIRAM
  EXEMESTANE, EXEMESTANE
  FELBAMATE, FELBAMATE
  MACROBID, NITROFURANTOIN
  MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
  NAPRELAN, NAPROXEN SODIUM
  NATEGLINIDE, NATEGLINIDE
  NEVIRAPINE, NEVIRAPINE
  OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
  RIVASTIGMINE, RIVASTIGMINE
  TENORETIC 100, ATENOLOL
  TENORETIC 50, ATENOLOL
  TENORMIN, ATENOLOL
  ZESTORETIC, HYDROCHLOROTHIAZIDE
  ZESTRIL, LISINOPRIL

AM ANTIBIOTICS

* AMERICAN ANTIBIOTICS INC
  AMOXICILLIN, AMOXICILLIN

AMAG PHARMA USA

* AMAG PHARMA USA INC
  MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
  MAKENA, HYDROXYPROGESTERONE CAPROATE

AMAG PHARMS INC

* AMAG PHARMACEUTICALS INC
  FERAHEME, FERUMOXYTOL

AMARIN PHARMS

* AMARIN PHARMACEUTICALS IRELAND LTD
  VASCEPA, ICOSAPENT ETHYL

AMEDRA PHARMS

* AMEDRA PHARMACEUTICALS LLC
  ADRENACLICK, EPINEPHRINE
  DEXEDRINE, DEXTROAMPHETAMINE SULFATE

AMEDRA PHARMS LLC

* AMEDRA PHARMACEUTICALS LLC
  ALBENZA, ALBENDAZOLE
  EMVERM, MEBENDAZOLE

AMERIGEN PHARMS LTD

* AMERIGEN PHARMACEUTICALS LTD
  CARBIDOPA, CARBIDOPA
  INDAPAMIDE, INDAPAMIDE
  TEMOZOLOMIDE, TEMOZOLOMIDE

AMGEN

* AMGEN INC
  SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC

* AMGEN INC
  CORLANOR, IVABRADINE HYDROCHLORIDE

AMHERST PHARMS LLC

* AMHERST PHARMACEUTICALS LLC
  ZOLPIMIST, ZOLPIDEM TARTRATE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
  ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
  BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
  DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
  FLECAINIDE ACETATE, FLECAINIDE ACETATE
  FOLIC ACID, FOLIC ACID
  GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
  HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  PRIMIDONE, PRIMIDONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
  ACYCLOVIR, ACYCLOVIR
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
  ARIPIPRAZOLE, ARIPIPRAZOLE
  ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
  ATOVAQUONE, ATOVAQUONE
  BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
  BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  CALCIUM ACETATE, CALCIUM ACETATE
  CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
  CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  DUTASTERIDE, DUTASTERIDE
  ENTECAVIR, ENTECAVIR
  EPTIFIBATIDE, EPTIFIBATIDE
  ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  ESTRADIOL, ESTRADIOL
  FELBAMATE, FELBAMATE
  GABAPENTIN, GABAPENTIN
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  IBUPROFEN, IBUPROFEN (OTC)
  INDOMETHACIN, INDOMETHACIN
  ITRACONAZOLE, ITRACONAZOLE
  LACOSAMIDE, LACOSAMIDE
  LEVETIRACETAM, LEVETIRACETAM
  LIDOCAINE, LIDOCAINE
  LINEZOLID, LINEZOLID
  LORAZEPAM, LORAZEPAM
  MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  MEROPENEM, MEROPENEM
  METAXALONE, METAXALONE
  MILNACIPRAN HYDROCHLORIDE, MILNACIPRAN HYDROCHLORIDE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  NIACIN, NIACIN
  NITROFURANTOIN, NITROFURANTOIN
  NIZATIDINE, NIZATIDINE
  NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
  OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  OXCARBAZEPINE, OXCARBAZEPINE
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  PARICALCITOL, PARICALCITOL
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
  PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
  QUININE SULFATE, QUININE SULFATE
  RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
  RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  RISPERIDONE, RISPERIDONE
  SILDENAFIL CITRATE, SILDENAFIL CITRATE
  SPIRONOLACTONE, SPIRONOLACTONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TEMOZOLOMIDE, TEMOZOLOMIDE
TOBRAMYCIN, TOBRAMYCIN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
WARFARIN SODIUM, WARFARIN SODIUM
* AMNEAL PHARMACEUTICALS HOLDINGS GMBH
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
* AMNEAL PHARMACEUTICALS LLC
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

AMNEAL PHARMS CO
* AMNEAL PHARMACEUTICALS CO GMBH
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

AMNEAL PHARMS LLC
* AMNEAL PHARMACEUTICALS LLC
ACTIVELLA, ESTRADIOL
AZATHIOPRINE, AZATHIOPRINE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE

AMNEAL PHARMS NY
* AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

AMPHASTAR PHARM
* AMPHASTAR PHARMACEUTICAL INC
AMPHADASE, HYALURONIDASE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

AMPHASTAR PHARMS INC
* AMPHASTAR PHARMACEUTICALS INC
BUMETANIDE, BUMETANIDE
CORTROSYN, COSYNTROPIN
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* AMPHASTAR PHARMACEUTICALS INC
  DIPYRIDAMOLE, DIPYRIDAMOLE
  DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
  ENALAPRILAT, ENALAPRILAT
  FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
  FAMOTIDINE, FAMOTIDINE
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
  TERBUTALINE SULFATE, TERBUTALINE SULFATE
  VALPROATE SODIUM, VALPROATE SODIUM

ANACOR PHARMS INC

* ANACOR PHARMACEUTICALS INC
  EUCRISA, CRISABOROLE
  KERYDIN, TAVABOROLE

ANBEX

* ANBEX INC
  IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB CO LTD

* ANBISON LABORATORY CO LTD
  MONTELUKAST SODIUM, MONTELUKAST SODIUM

ANCHEN PHARMS

* ANCHEN PHARMACEUTICALS INC
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CLONIDINE HYDROCHLORIDE , CLONIDINE HYDROCHLORIDE
  DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
  FENOFIBRIC ACID, CHOLINE FENOFIBRATE
  FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
  LAMOTRIGINE, LAMOTRIGINE
  LEVETIRACETAM, LEVETIRACETAM
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  TRETINOIN, TRETINOIN
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ANCHEN PHARMACEUTICALS TAIWAN INC
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
* ANCHEN PHARMACEUTICALS, INC
  ALPRAZOLAM, ALPRAZOLAM
  CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ANDRX LABS LLC

* ANDRX LABS LLC
  FORTAMET, METFORMIN HYDROCHLORIDE

ANI PHARMS

* ANI PHARMACEUTICALS INC
  CORTENEMA, HYDROCORTISONE
  LACTULOSE, LACTULOSE
  LUVOX, FLUVOXAMINE MALEATE
  METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
  REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANI PHARMS INC

* ANI PHARMACEUTICALS INC
  ALPRAZOLAM, ALPRAZOLAM
  CEFUROXIME AXETIL, CEFUROXIME AXETIL
  CHLORPROPAMIDE, CHLORPROPAMIDE
  CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
  DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
  ETODOLAC, ETODOLAC
  FLECAINIDE ACETATE, FLECAINIDE ACETATE
  FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
  GLIPIZIDE, GLIPIZIDE
  GUANABENZ ACETATE, GUANABENZ ACETATE
  INDAPAMIDE, INDAPAMIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ANI PHARMACEUTICALS INC
  INDERAL LA, PROPRANOLOL HYDROCHLORIDE
  ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
  LITHOBID, LITHIUM CARBONATE
  LORAZEPAM, LORAZEPAM
  METHAZOLAMIDE, METHAZOLAMIDE
  NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
  NILUTAMIDE, NILUTAMIDE
  NIZATIDINE, NIZATIDINE
  OXCARBAZEPINE, OXCARBAZEPINE
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
  POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
  PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
  PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  RISPERIDONE, RISPERIDONE
  TESTOSTERONE, TESTOSTERONE
  TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  VALPROIC ACID, VALPROIC ACID
  VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ANTARES PHARMA INC

* ANTARES PHARMA INC
  OTREXUP, METHOTREXATE
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

ANTIBIOTICE

* ANTIBIOTICE SA
  AMPICILLIN SODIUM, AMPICILLIN SODIUM
  NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANTIBIOTICS SA

* ANTIBIOTICS SA
  AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

ANTRIM PHARMS LLC

* ANTRIM PHARMACEUTICALS LLC
  ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

APEX PHARMS INC

* APEX PHARMACEUTICALS INC
  CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APGDI

* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
  MYRBETRIQ, MIRABEGRON

APIL

* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
  ACTONEL, RISEDRONATE SODIUM
  ASACOL HD, MESALAMINE
  ATELVIA, RISEDRONATE SODIUM
  DELZICOL, MESALAMINE
  DIDRONEL, ETIDRONATE DISODIUM
  ENABLEX, DARIFENACIN HYDROBROMIDE
  ESTROSTEP FE, ETHINYL ESTRADIOL
  FEMCON FE, ETHINYL ESTRADIOL
  FEMHRT, ETHINYL ESTRADIOL
  FEMRING, ESTRADIOL ACETATE
  FEMTRACE, ESTRADIOL ACETATE
  LO LOESTRIN FE, ETHINYL ESTRADIOL
  LO MINASTRIN FE, ETHINYL ESTRADIOL
  LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
  LOESTRIN 21 1/20, ETHINYL ESTRADIOL
  LOESTRIN 24 FE, ETHINYL ESTRADIOL
  LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
  LOESTRIN FE 1/20, ETHINYL ESTRADIOL
  MINASTRIN 24 FE, ETHINYL ESTRADIOL
  NOR-QD, NORETHINDRONE
  NORCO, ACETAMINOPHEN
  NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
  SARAFEM, FLUOXETINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
  TAYTULLA, ETHINYL ESTRADIOL

APOPHARMA INC

* APOPHARMA INC
  FERRIPROX, DEFERIPRONE

APOTEX

* APOTEX CORP
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
* APOTEX INC
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  CARBIDOPA AND LEVODOPA, CARBIDOPA
  CEFUROXIME AXETIL, CEFUROXIME AXETIL
  CIMETIDINE, CIMETIDINE
  CIMETIDINE, CIMETIDINE (OTC)
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CYCLOSPORINE, CYCLOSPORINE
  DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
  DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
  ENALAPRIL MALEATE, ENALAPRIL MALEATE
  EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
  EPLERENONE, EPLERENONE
  ETODOLAC, ETODOLAC
  FAMCICLOVIR, FAMCICLOVIR
  FAMOTIDINE, FAMOTIDINE
  FLUCONAZOLE, FLUCONAZOLE
  FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
  GEMFIBROZIL, GEMFIBROZIL
  GLIPIZIDE, GLIPIZIDE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LAMIVUDINE, LAMIVUDINE
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
  OMEPRAZOLE, OMEPRAZOLE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
  PENTOXIFYLLINE, PENTOXIFYLLINE
  PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
  RAMIPRIL, RAMIPRIL
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
  SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
  TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
  TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
  TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
  TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
  TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

APOTEX CORP

* APOTEX CORP
  AZITHROMYCIN, AZITHROMYCIN
  CABERGOLINE, CABERGOLINE
  CLARITHROMYCIN, CLARITHROMYCIN
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
  NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
  QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  RILUZOLE, RILUZOLE
  SILDENAFIL CITRATE, SILDENAFIL CITRATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX CORP
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

APOTEX INC

* APOTEX INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
BUDESONIDE, BUDESONIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITONIN-SALMON, CALCITONIN SALMON
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DASATINIB, DASATINIB
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
IMIQUIMOD, IMIQUIMOD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LOVASTATIN, LOVASTATIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NEVIRAPINE, NEVIRAPINE
OFLOXACIN, OFLOXACIN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTZAC, DILTIAZEM HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
LEFLUNOMIDE, LEFLUNOMIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
OXAPROZIN, OXAPROZIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
ZONISAMIDE, ZONISAMIDE

* APOTEX INC RICHMOND HILL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
FLUNISOLIDE, FLUNISOLIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APOTEX INC RICHMOND HILL
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
  RISPERIDONE, RISPERIDONE
* APOTEX INC.
  DILTZAC, DILTIAZEM HYDROCHLORIDE
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTEX TECHNOLOGIES

* APOTEX TECHNOLOGIES INC
  PAXIL CR, PAROXETINE HYDROCHLORIDE
  PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
  KENALOG-10, TRIAMCINOLONE ACETONIDE
  KENALOG-40, TRIAMCINOLONE ACETONIDE

APP PHARMS

* APP PHARMACEUTICALS LLC
  DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO PHARMA LLC

* APPCO PHARMA LLC
  CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
  GLYCOPYRROLATE, GLYCOPYRROLATE
  LAMIVUDINE, LAMIVUDINE
  METRONIDAZOLE, METRONIDAZOLE
  VORICONAZOLE, VORICONAZOLE

APRECIA PHARMS CO

* APRECIA PHARMACEUTICALS CO
  SPRITAM, LEVETIRACETAM

AQUA PHARMS

* AQUA PHARMACEUTICALS
  ACTICLATE CAP, DOXYCYCLINE HYCLATE
  CORDRAN SP, FLURANDRENOLIDE
  CORDRAN, FLURANDRENOLIDE
  MONODOX, DOXYCYCLINE
  VERDESO, DESONIDE
* AQUA PHARMACEUTICALS LLC
  FLUOROPLEX, FLUOROURACIL
  XOLEGEL, KETOCONAZOLE

AQUA PHARMS LLC

* AQUA PHARMACEUTICALS LLC
  ACTICLATE, DOXYCYCLINE HYCLATE
  ALTABAX, RETAPAMULIN
  VELTIN, CLINDAMYCIN PHOSPHATE

ARALEZ PHARMS

* ARALEZ PHARMACEUTICALS TRADING DAC
  YOSPRALA, ASPIRIN
  ZONTIVITY, VORAPAXAR SULFATE

ARALEZ PHARMS INC

* ARALEZ PHARMACEUTICALS INC
  FIBRICOR, FENOFIBRIC ACID

ARBOR PHARMS LLC

* ARBOR PHARMACEUTICALS LLC
  BIDIL, HYDRALAZINE HYDROCHLORIDE
  CETYLEV, ACETYLCYSTEINE
  E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
  E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
  EDARBI, AZILSARTAN KAMEDOXOMIL
  EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
  ERY-TAB, ERYTHROMYCIN
  ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
  ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
  ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
  ERYTHROMYCIN, ERYTHROMYCIN
  EVEKEO, AMPHETAMINE SULFATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ARBOR PHARMACEUTICALS LLC
  GLIADEL, CARMUSTINE
  HORIZANT, GABAPENTIN ENACARBIL
  NYMALIZE, NIMODIPINE
  PCE, ERYTHROMYCIN
  SKLICE, IVERMECTIN
  SOTYLIZE, SOTALOL HYDROCHLORIDE

ARCO PHARMS LLC
* ARCO PHARMACEUTICALS LLC
  THYROSHIELD, POTASSIUM IODIDE (OTC)

AREVA PHARMS
* AREVA PHARMACEUTICALS INC
  PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD
* ARIAD PHARMACEUTICALS INC
  ICLUSIG, PONATINIB HYDROCHLORIDE

ASCEND THERAPS US
* ASCEND THERAPEUTICS US LLC
  ESTROGEL, ESTRADIOL

ASCENT PHARMS INC
* ASCENT PHARMACEUTICALS INC
  DUTASTERIDE, DUTASTERIDE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ASPEN GLOBAL
* ASPEN GLOBAL INC
  MYLERAN, BUSULFAN

ASPEN GLOBAL INC
* ASPEN GLOBAL INC
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  CYCLESSA, DESOGESTREL
  HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
  LEUKERAN, CHLORAMBUCIL
  THIOGUANINE, THIOGUANINE

ASTELLAS
* ASTELLAS PHARMA US INC
  ADENOCARD, ADENOSINE
  AMBISOME, AMPHOTERICIN B
  ASTAGRAF XL, TACROLIMUS
  CRESEMBA, ISAVUCONAZONIUM SULFATE
  LEXISCAN, REGADENOSON
  MYCAMINE, MICAFUNGIN SODIUM
  PROGRAF, TACROLIMUS
  VESICARE, SOLIFENACIN SUCCINATE
  XTANDI, ENZALUTAMIDE

ASTRAZENECA
* ASTRAZENECA LP
  PULMICORT FLEXHALER, BUDESONIDE
  SYMBICORT, BUDESONIDE
* ASTRAZENECA PHARMACEUTICALS LP
  ATACAND HCT, CANDESARTAN CILEXETIL
  ATACAND, CANDESARTAN CILEXETIL
  FASLODEX, FULVESTRANT
  SEROQUEL XR, QUETIAPINE FUMARATE
  ZOMIG, ZOLMITRIPTAN
  ZOMIG-ZMT, ZOLMITRIPTAN
* ASTRAZENECA UK LTD
  ARIMIDEX, ANASTROZOLE
  CASODEX, BICALUTAMIDE
  MERREM, MEROPENEM
  ZOLADEX, GOSERELIN ACETATE

ASTRAZENECA AB
* ASTRAZENECA AB
  BYDUREON PEN, EXENATIDE SYNTHETIC
  BYDUREON, EXENATIDE SYNTHETIC

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* ASTRAZENECA AB
  BYETTA, EXENATIDE SYNTHETIC
  FARXIGA, DAPAGLIFLOZIN PROPANEDIOL
  KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
  ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
  SYMLIN, PRAMLINTIDE ACETATE
  XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL

ASTRAZENECA LP

* ASTRAZENECA LP
  BRILINTA, TICAGRELOR
  NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ASTRAZENECA PHARMS

* ASTRAZENECA PHARMACEUTICALS LP
  DALIRESP, ROFLUMILAST
  EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
  IRESSA, GEFITINIB
  LYNPARZA, OLAPARIB
  MOVANTIK, NALOXEGOL OXALATE
  NEXIUM IV, ESOMEPRAZOLE SODIUM
  NEXIUM, ESOMEPRAZOLE MAGNESIUM
  PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
  PRILOSEC, OMEPRAZOLE MAGNESIUM
  PULMICORT RESPULES, BUDESONIDE
  RHINOCORT ALLERGY, BUDESONIDE (OTC)
  SEROQUEL, QUETIAPINE FUMARATE
  TAGRISSO, OSIMERTINIB MESYLATE
  TOPROL-XL, METOPROLOL SUCCINATE
  TUDORZA PRESSAIR, ACLIDINIUM BROMIDE

ATLAS PHARMS LLC

* ATLAS PHARMACEUTICALS LLC
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

ATNAHS PHARMA US

* ATNAHS PHARMA US LTD
  ANAPROX DS, NAPROXEN SODIUM
  ANAPROX, NAPROXEN SODIUM
  EC-NAPROSYN, NAPROXEN
  NAPROSYN, NAPROXEN

ATON

* ATON PHARMA INC
  CUPRIMINE, PENICILLAMINE
  EDECRIN, ETHACRYNATE SODIUM
  EDECRIN, ETHACRYNIC ACID
  LACRISERT, HYDROXYPROPYL CELLULOSE
  LODOSYN, CARBIDOPA
  SYPRINE, TRIENTINE HYDROCHLORIDE
  TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
  TIMOPTIC, TIMOLOL MALEATE

ATON PHARMA VPNA

* ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC
  DEMSER, METYROSINE

AUROBINDO

* AUROBINDO PHARMA LTD
  AMOXICILLIN, AMOXICILLIN
  CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  CLARITHROMYCIN, CLARITHROMYCIN
  DIDANOSINE, DIDANOSINE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LISINOPRIL, LISINOPRIL
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  MIRTAZAPINE, MIRTAZAPINE
  NEVIRAPINE, NEVIRAPINE
  ZIDOVUDINE, ZIDOVUDINE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

AUROBINDO PHARM

* AUROBINDO PHARMA USA INC
  FLUCONAZOLE, FLUCONAZOLE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  GABAPENTIN, GABAPENTIN
  LEVETIRACETAM, LEVETIRACETAM
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

AUROBINDO PHARMA

* AUROBINDO PHARMA
  AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
* AUROBINDO PHARMA LTD
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  AMPICILLIN SODIUM, AMPICILLIN SODIUM
  ATENOLOL, ATENOLOL
  BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
  BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
  CARISOPRODOL, CARISOPRODOL
  CARVEDILOL, CARVEDILOL
  CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
  CEFDINIR, CEFDINIR
  CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
  CEFPROZIL, CEFPROZIL
  CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
  DIDANOSINE, DIDANOSINE
  FINASTERIDE, FINASTERIDE
  FLUCONAZOLE, FLUCONAZOLE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
  GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
  GLYBURIDE, GLYBURIDE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LAMOTRIGINE, LAMOTRIGINE
  LEVETIRACETAM, LEVETIRACETAM
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  MELOXICAM, MELOXICAM
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON, ONDANSETRON
  PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
  PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
  PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
  QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  RIBAVARIN, RIBAVIRIN
  RIBAVIRIN, RIBAVIRIN
  RISPERIDONE, RISPERIDONE
  SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
  SIMVASTATIN, SIMVASTATIN
  STAVUDINE, STAVUDINE
  SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
  TOPIRAMATE, TOPIRAMATE
  TORSEMIDE, TORSEMIDE
  TRANDOLAPRIL, TRANDOLAPRIL
  VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  ZALEPLON, ZALEPLON
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  LEVOFLOXACIN, LEVOFLOXACIN
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
* AUROBINDO PHARMA LTD
  ABACAVIR SULFATE, ABACAVIR SULFATE
  ACETAMINOPHEN, ACETAMINOPHEN (OTC)
  ACETYLCYSTEINE, ACETYLCYSTEINE
  ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
  AFIRMELLE, ETHINYL ESTRADIOL
  ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
  ALPRAZOLAM, ALPRAZOLAM
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
  AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
  AMOXICILLIN, AMOXICILLIN
  ARIPIPRAZOLE, ARIPIPRAZOLE
  ATHENTIA NEXT, LEVONORGESTREL (OTC)
  ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
  ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
  AYUNA, ETHINYL ESTRADIOL
  AZITHROMYCIN, AZITHROMYCIN
  BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
  BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
  CAFFEINE CITRATE, CAFFEINE CITRATE
  CEFIXIME, CEFIXIME
  CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
  CELECOXIB, CELECOXIB
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  CLOZAPINE, CLOZAPINE
  CYONANZ, ETHINYL ESTRADIOL
  DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
  DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  ENTACAPONE, ENTACAPONE
  ENTECAVIR, ENTECAVIR
  EPTIFIBATIDE, EPTIFIBATIDE
  ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
  ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
  ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
  ESZOPICLONE, ESZOPICLONE
  FAMCICLOVIR, FAMCICLOVIR
  FAMOTIDINE, FAMOTIDINE
  FAMOTIDINE, FAMOTIDINE (OTC)
  FELODIPINE, FELODIPINE
  FENOFIBRATE, FENOFIBRATE
  FINASTERIDE, FINASTERIDE
  FLECAINIDE ACETATE, FLECAINIDE ACETATE
  GABAPENTIN, GABAPENTIN
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  GEMFIBROZIL, GEMFIBROZIL
  GLIMEPIRIDE, GLIMEPIRIDE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  IBANDRONATE SODIUM, IBANDRONATE SODIUM
  INCASSIA, NORETHINDRONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISOSULFAN BLUE, ISOSULFAN BLUE
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
MILI, ETHINYL ESTRADIOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NEVIRAPINE, NEVIRAPINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
TRANEXAMIC ACID, TRANEXAMIC ACID
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-MILI, ETHINYL ESTRADIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLMITRIPTAN, ZOLMITRIPTAN
* AUROBINDO PHARMA LTD INC
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
MIRTAZAPINE, MIRTAZAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA

* AUROBINDO PHARMA USA INC
ALPRAZOLAM, ALPRAZOLAM
NAPROXEN, NAPROXEN
OMEPRAZOLE, OMEPRAZOLE

AUROLIFE PHARMA LLC

* AUROLIFE PHARMA LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DUTASTERIDE, DUTASTERIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA LLC

* AUSTARPHARMA LLC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
METHOCARBAMOL, METHOCARBAMOL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS

* AUXILIUM PHARMACEUTICALS INC
TESTIM, TESTOSTERONE

AUXILIUM PHARMS INC

* AUXILIUM PHARMACEUTICALS INC
EDEX, ALPROSTADIL
SEMPREX-D, ACRIVASTINE
STRIANT, TESTOSTERONE
TESTOPEL, TESTOSTERONE
THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC

* AUXILIUM PHARMACEUTICALS LLC
DILATRATE-SR, ISOSORBIDE DINITRATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
THEO-24, THEOPHYLLINE

AVACOR PRODS

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* AVACOR PRODUCTS LLC
  MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVANIR PHARMS

* AVANIR PHARMACEUTICALS
  ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
* AVANIR PHARMACEUTICALS INC
  NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
  CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
  DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE
  DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
  DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
  INDOMETHACIN, INDOMETHACIN
  LOMAIRA, PHENTERMINE HYDROCHLORIDE
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEDRO INC

* AVEDRO INC
  PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
  PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

AVEMA PHARMA

* AVEMA PHARMA SOLUTIONS
  IBUPROFEN, IBUPROFEN (OTC)

AVENT

* AVENT INC
  PYTEST KIT, UREA, C-14
  PYTEST, UREA, C-14

AVEVA

* AVEVA DRUG DELIVERY SYSTEMS INC
  CLONIDINE, CLONIDINE
  FENTANYL-100, FENTANYL
  FENTANYL-12, FENTANYL
  FENTANYL-25, FENTANYL
  FENTANYL-50, FENTANYL
  FENTANYL-75, FENTANYL
  NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC

* AVID RADIOPHARMACEUTICALS INC
  AMYVID, FLORBETAPIR F-18

AYTU BIOSCIENCE INC

* AYTU BIOSCIENCE INC
  NATESTO, TESTOSTERONE
  PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

** B **

B BRAUN

* B BRAUN MEDICAL INC
  ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
  AMINO ACIDS, AMINO ACIDS
  BALANCED SALT, CALCIUM CHLORIDE
  CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
  CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
  CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
  CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
  CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
  CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
  CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
  DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
  DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
  DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
  DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
  DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
  DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
  DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC

* B BRAUN MEDICAL INC
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ MEDICAL LLC

* BAJAJ MECICAL LLC
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)

BARR

* BARR LABORATORIES INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARANELLE, ETHINYL ESTRADIOL
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BARR LABORATORIES INC
  BALZIVA-28, ETHINYL ESTRADIOL
  BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
  CHLORZOXAZONE, CHLORZOXAZONE
  CLONAZEPAM, CLONAZEPAM
  DANAZOL, DANAZOL
  DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
  DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
  DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
  DIAZEPAM, DIAZEPAM
  DIDANOSINE, DIDANOSINE
  DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
  DIPYRIDAMOLE, DIPYRIDAMOLE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
  DUTASTERIDE, DUTASTERIDE
  ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
  ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
  ESTRADIOL AND NORGESTIMATE, ESTRADIOL
  ESTROPIPATE, ESTROPIPATE
  ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
  FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
  FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
  HYDROXYUREA, HYDROXYUREA
  HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
  ISONIAZID, ISONIAZID
  JUNEL 1.5/30, ETHINYL ESTRADIOL
  JUNEL 1/20, ETHINYL ESTRADIOL
  JUNEL FE 1.5/30, ETHINYL ESTRADIOL
  JUNEL FE 1/20, ETHINYL ESTRADIOL
  KARIVA, DESOGESTREL
  KELNOR, ETHINYL ESTRADIOL
  LEFLUNOMIDE, LEFLUNOMIDE
  LESSINA-28, ETHINYL ESTRADIOL
  MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
  MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
  MEGESTROL ACETATE, MEGESTROL ACETATE
  MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  METHOTREXATE SODIUM, METHOTREXATE SODIUM
  NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
  NIACIN, NIACIN
  NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
  NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
  NORTREL 0.5/35-28, ETHINYL ESTRADIOL
  NORTREL 1/35-21, ETHINYL ESTRADIOL
  NORTREL 1/35-28, ETHINYL ESTRADIOL
  NORTREL 7/7/7, ETHINYL ESTRADIOL
  ONDANSETRON, ONDANSETRON
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
  PORTIA-28, ETHINYL ESTRADIOL
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  SPRINTEC, ETHINYL ESTRADIOL
  TEMOZOLOMIDE, TEMOZOLOMIDE
  TREXALL, METHOTREXATE SODIUM
  TRI-LEGEST 21, ETHINYL ESTRADIOL
  TRI-LEGEST FE, ETHINYL ESTRADIOL
  TRI-SPRINTEC, ETHINYL ESTRADIOL
  WARFARIN SODIUM, WARFARIN SODIUM
* BARR PHARMACEUTICALS
  LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

BARR LABS DIV TEVA

* BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
  ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
  BUDESONIDE, BUDESONIDE
  OXYBUTYNIN, OXYBUTYNIN

BARR LABS INC

* BARR LABORATORIES INC
  ACITRETIN, ACITRETIN
  CLOZAPINE, CLOZAPINE
  DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
  ESTRADIOL, ESTRADIOL
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
  NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  OLANZAPINE, OLANZAPINE
  OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
  OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
  TRETINOIN, TRETINOIN
  TRI LO SPRINTEC, ETHINYL ESTRADIOL

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
  ALAWAY, KETOTIFEN FUMARATE (OTC)
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  ALREX, LOTEPREDNOL ETABONATE
  BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
  CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
  IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
  ISTALOL, TIMOLOL MALEATE
  LATANOPROST, LATANOPROST
  LOTEMAX, LOTEPREDNOL ETABONATE
  MIOCHOL-E, ACETYLCHOLINE CHLORIDE
  OFLOXACIN, OFLOXACIN
  OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
  PROLENSA, BROMFENAC SODIUM
  RETISERT, FLUOCINOLONE ACETONIDE
  TIMOLOL MALEATE, TIMOLOL MALEATE
  VITRASE, HYALURONIDASE
  ZIRGAN, GANCICLOVIR
  ZYLET, LOTEPREDNOL ETABONATE
* BAUSCH AND LOMB PHARMACEUTICALS INC
  ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
  BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
  BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
  CROLOM, CROMOLYN SODIUM
  CROMOLYN SODIUM, CROMOLYN SODIUM
  CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
  DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
  DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  DEXASPORIN, DEXAMETHASONE
  ERYTHROMYCIN, ERYTHROMYCIN
  FLUNISOLIDE, FLUNISOLIDE
  GENTAMICIN SULFATE, GENTAMICIN SULFATE
  IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
  LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
  NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
  NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
  NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
  NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
  NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
  OFLOXACIN, OFLOXACIN
  OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH AND LOMB PHARMACEUTICALS INC
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
BEPREVE, BEPOTASTINE BESILATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LOTEMAX, LOTEPREDNOL ETABONATE
PODOFILOX, PODOFILOX

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
EXTRANEAL, ICODEXTRIN
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FORANE, ISOFLURANE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
IFEX, IFOSFAMIDE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NEXTERONE, AMIODARONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION
SUPRANE, DESFLURANE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP
  TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
  TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
  TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
  VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
* BAXTER HEALTHCARE INTERNATI0NAL SPECIALTY THERAPIES DIV
  PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
  PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
* BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

BAYER

* BAYER HEALTHCARE LLC
  ALEVE, NAPROXEN SODIUM (OTC)
  ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
  FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)

BAYER HEALTHCARE LLC

* BAYER HEALTHCARE LLC
  CHILDREN'S CLARITIN, LORATADINE (OTC)
  CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
  CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
  CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
  CLARITIN HIVES RELIEF, LORATADINE (OTC)
  CLARITIN REDITABS, LORATADINE (OTC)
  CLARITIN, LORATADINE (OTC)
  CLARITIN-D 24 HOUR, LORATADINE (OTC)
  CLARITIN-D, LORATADINE (OTC)
  GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
  GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
  GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
  GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
  LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
  MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
  MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
  MYCELEX-7, CLOTRIMAZOLE (OTC)
  OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
  SHADE UVAGUARD, AVOBENZONE (OTC)
  ZEGERID OTC, OMEPRAZOLE (OTC)

BAYER HLTHCARE

* BAYER HEALTHCARE CONSUMER CARE
  ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
* BAYER HEALTHCARE PHARMACEUTICALS INC
  ADEMPAS, RIOCIGUAT
  ANGELIQ, DROSPIRENONE
  AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
  AVELOX, MOXIFLOXACIN HYDROCHLORIDE
  BEYAZ, DROSPIRENONE
  BILTRICIDE, PRAZIQUANTEL
  CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
  CIPRO, CIPROFLOXACIN
  CIPRO, CIPROFLOXACIN HYDROCHLORIDE
  CLIMARA PRO, ESTRADIOL
  CLIMARA, ESTRADIOL
  DESONATE, DESONIDE
  DTIC-DOME, DACARBAZINE
  EOVIST, GADOXETATE DISODIUM
  FINACEA , AZELAIC ACID
  FINACEA, AZELAIC ACID
  GADAVIST, GADOBUTROL
  KYLEENA, LEVONORGESTREL
  LEVITRA, VARDENAFIL HYDROCHLORIDE
  MAGNEVIST, GADOPENTETATE DIMEGLUMINE
  MENOSTAR, ESTRADIOL
  MIRENA, LEVONORGESTREL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAYER HEALTHCARE PHARMACEUTICALS INC
  NATAZIA, DIENOGEST
  NEXAVAR, SORAFENIB TOSYLATE
  PRECOSE, ACARBOSE
  SAFYRAL, DROSPIRENONE
  SKYLA, LEVONORGESTREL
  STAXYN, VARDENAFIL HYDROCHLORIDE
  STIVARGA, REGORAFENIB
  ULTRAVIST (PHARMACY BULK), IOPROMIDE
  ULTRAVIST 150, IOPROMIDE
  ULTRAVIST 240, IOPROMIDE
  ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
  ULTRAVIST 300, IOPROMIDE
  ULTRAVIST 370, IOPROMIDE
  XOFIGO, RADIUM RA-223 DICHLORIDE
  YASMIN, DROSPIRENONE
  YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

* BAYSHORE PHARMACEUTICALS LLC
  METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
  PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BECTON DICKINSON

* BECTON DICKINSON AND CO
  CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
  E-Z SCRUB 201, POVIDONE-IODINE (OTC)
  E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO

* BECTON DICKINSON AND CO
  CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
  CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
  CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
  CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
  CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
  CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEDFORD

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
  CEFTRIAXONE, CEFTRIAXONE SODIUM

BEDFORD LABS

* BEDFORD LABORATORIES
  LORAZEPAM PRESERVATIVE FREE, LORAZEPAM

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC
  CEPHALEXIN, CEPHALEXIN
  DESLORATADINE, DESLORATADINE

BELCHER PHARMS LLC

* BELCHER PHARMACEUTICALS LLC
  EPINEPHRINE, EPINEPHRINE
  SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

BEXIMCO PHARMS USA

* BEXIMCO PHARMACEUTICALS USA INC
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC
  CARVEDILOL, CARVEDILOL

BI-COASTAL PHARMA

* BI-COASTAL PHARMA INTERNATIONAL LLC
  DUVOID, BETHANECHOL CHLORIDE

BIO NUCLEONICS

* BIO NUCLEONICS INC
  STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

BIO PHARM INC

* BIO PHARM INC
  CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BIO PHARM INC
  CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  RISPERIDONE, RISPERIDONE

BIO-PHARM INC
* BIO-PHARM INC
  LACTULOSE, LACTULOSE
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

BIOCON LIMITED
* BIOCON LIMITED
  SIMVASTATIN, SIMVASTATIN

BIOCON LTD
* BIOCON LTD
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

BIOCRYST
* BIOCRYST PHARMACEUTICALS INC
  RAPIVAB, PERAMIVIR

BIODELIVERY SCI INTL
* BIODELIVERY SCIENCES INTERNATIONAL INC
  BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE

BIOFRONTERA
* BIOFRONTERA BIOSCIENCE GMBH
  AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN IDEC
* BIOGEN IDEC INC
  SPINRAZA, NUSINERSEN SODIUM

BIOGEN IDEC INC
* BIOGEN IDEC INC
  TECFIDERA, DIMETHYL FUMARATE

BIOKEY
* BIOKEY INC
  CILOSTAZOL, CILOSTAZOL

BIOMARIN PHARM
* BIOMARIN PHARMACEUTICAL INC
  KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIOMEDCL RES FDN
* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISANA
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC
* BIONPHARMA INC
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
  BENZONATATE, BENZONATATE
  BEXAROTENE, BEXAROTENE
  CALCITRIOL, CALCITRIOL
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
  DUTASTERIDE, DUTASTERIDE
  ETHOSUXIMIDE, ETHOSUXIMIDE
  GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
  IBUPROFEN, IBUPROFEN (OTC)
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
  MIDOL LIQUID GELS, IBUPROFEN (OTC)
  NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
  NIMODIPINE, NIMODIPINE
  PARICALCITOL, PARICALCITOL
  PROGESTERONE, PROGESTERONE
  VALPROIC ACID, VALPROIC ACID
  VITAMIN D, ERGOCALCIFEROL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BIONPHARMA INC
  ZONISAMIDE, ZONISAMIDE

BLAIREX

* BLAIREX LABORATORIES INC
  BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLU CARIBE

* BLU CARIBE INC
  GEMFIBROZIL, GEMFIBROZIL

BLU CARIBE INC

* BLU CARIBE INC
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

BLUE EARTH

* BLUE EARTH DIAGNOSTICS LTD
  AXUMIN, FLUCICLOVINE F-18

BOEHRINGER INGELHEIM

* BOEHRINGER INGELHEIM
  CATAPRES, CLONIDINE HYDROCHLORIDE
  CATAPRES-TTS-1, CLONIDINE
  CATAPRES-TTS-2, CLONIDINE
  CATAPRES-TTS-3, CLONIDINE
  GILOTRIF, AFATINIB DIMALEATE
  GLYXAMBI, EMPAGLIFLOZIN
  MICARDIS HCT, HYDROCHLOROTHIAZIDE
  MICARDIS, TELMISARTAN
  MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
  ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
  ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
  AGGRENOX, ASPIRIN
  APTIVUS, TIPRANAVIR
  ATROVENT HFA, IPRATROPIUM BROMIDE
  ATROVENT, IPRATROPIUM BROMIDE
  COMBIVENT RESPIMAT, ALBUTEROL SULFATE
  FLOMAX, TAMSULOSIN HYDROCHLORIDE
  JARDIANCE, EMPAGLIFLOZIN
  JENTADUETO XR, LINAGLIPTIN
  JENTADUETO, LINAGLIPTIN
  MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
  MOBIC, MELOXICAM
  OFEV, NINTEDANIB ESYLATE
  PERSANTINE, DIPYRIDAMOLE
  PRADAXA, DABIGATRAN ETEXILATE MESYLATE
  SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
  SPIRIVA, TIOTROPIUM BROMIDE
  STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
  STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
  SYNJARDY XR, EMPAGLIFLOZIN
  SYNJARDY, EMPAGLIFLOZIN
  TRADJENTA, LINAGLIPTIN
  TWYNSTA, AMLODIPINE BESYLATE
  VIRAMUNE XR, NEVIRAPINE
  VIRAMUNE, NEVIRAPINE

BRACCO

* BRACCO DIAGNOSTICS INC
  CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
  CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
  CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
  CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
  CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
  E-Z-HD, BARIUM SULFATE
  GASTROGRAFIN, DIATRIZOATE MEGLUMINE
  ISOVUE-200, IOPAMIDOL
  ISOVUE-250, IOPAMIDOL
  ISOVUE-300, IOPAMIDOL
  ISOVUE-370, IOPAMIDOL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BRACCO DIAGNOSTICS INC
  ISOVUE-M 200, IOPAMIDOL
  ISOVUE-M 300, IOPAMIDOL
  KINEVAC, SINCALIDE
  LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
  MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
  MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
  MULTIHANCE, GADOBENATE DIMEGLUMINE
  PROHANCE MULTIPACK, GADOTERIDOL
  PROHANCE, GADOTERIDOL
  READI-CAT 2 SMOOTHIES, BARIUM SULFATE
  READI-CAT 2, BARIUM SULFATE
  RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
  SINOGRAFIN, DIATRIZOATE MEGLUMINE
  VARIBAR, BARIUM SULFATE

BRAEBURN PHARMS INC

* BRAEBURN PHARMACEUTICALS INC
  PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE

BRAINTREE

* BRAINTREE LABORATORIES INC
  GOLYTELY, POLYETHYLENE GLYCOL 3350
  NULYTELY, POLYETHYLENE GLYCOL 3350
  NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
  SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
  BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
  CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
  CILOSTAZOL, CILOSTAZOL
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  DUTASTERIDE, DUTASTERIDE
  EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
  ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
  LEVETIRACETAM, LEVETIRACETAM
  MEFENAMIC ACID, MEFENAMIC ACID
  MELOXICAM, MELOXICAM
  METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
  OXCARBAZEPINE, OXCARBAZEPINE
  PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
  POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRECKENRIDGE PHARMS

* BRECKENRIDGE PHARMACEUTICALS INC
  AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
  AMMONIA N 13, AMMONIA N-13

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
  AZACTAM, AZTREONAM
  BARACLUDE, ENTECAVIR
  GLUCOVANCE, GLYBURIDE
  LYSODREN, MITOTANE
  MEGACE, MEGESTROL ACETATE
  PRAVACHOL, PRAVASTATIN SODIUM
* BRISTOL MYERS SQUIBB CO
  AZACTAM IN PLASTIC CONTAINER, AZTREONAM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BRISTOL MYERS SQUIBB CO
  DROXIA, HYDROXYUREA
  GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
  HYDREA, HYDROXYUREA
  REYATAZ, ATAZANAVIR SULFATE
  SPRYCEL, DASATINIB
  SUSTIVA, EFAVIRENZ
  VIDEX EC, DIDANOSINE
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
  ELIQUIS, APIXABAN
  ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
  GLUCOPHAGE, METFORMIN HYDROCHLORIDE
  VIDEX, DIDANOSINE
  ZERIT, STAVUDINE
* BRISTOL MYERS SQUIBB PHARMA CO
  COUMADIN, WARFARIN SODIUM

BRISTOL-MYERS SQUIBB

* BRISTOL-MYERS SQUIBB CO
  DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
  EVOTAZ, ATAZANAVIR SULFATE

** C **

CADILA PHARMS LTD

* CADILA PHARMACEUTICALS LTD
  ACYCLOVIR, ACYCLOVIR
  FOLIC ACID, FOLIC ACID
  GEMFIBROZIL, GEMFIBROZIL
  HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  OFLOXACIN, OFLOXACIN
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CADISTA PHARMS

* CADISTA PHARMACEUTICALS INC
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  OXCARBAZEPINE, OXCARBAZEPINE

CALL INC

* CALL INC DBA ROCHESTER PHARMACEUTICALS
  ADAPALENE, ADAPALENE

CARACO

* CARACO PHARMACEUTICAL LABORATORIES LTD
  BACLOFEN, BACLOFEN
  FLUMADINE, RIMANTADINE HYDROCHLORIDE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC
  TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

CARDINAL HEALTH 418

* CARDINAL HEALTH 418 INC
  SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARLSBAD

* CARLSBAD TECHNOLOGY INC
  ACYCLOVIR, ACYCLOVIR
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  FAMOTIDINE, FAMOTIDINE
  GLIMEPIRIDE, GLIMEPIRIDE
  LOVASTATIN, LOVASTATIN

CAROLINA MEDCL

* CAROLINA MEDICAL PRODUCTS CO
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* CAROLINA MEDICAL PRODUCTS CO
  HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
  ISONIAZID, ISONIAZID
  SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
  SPS, SODIUM POLYSTYRENE SULFONATE
  TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CASPER PHARMA LLC
* CASPER PHARMA LLC
  CORTISPORIN, HYDROCORTISONE
  FURADANTIN, NITROFURANTOIN
  ROBINUL FORTE, GLYCOPYRROLATE
  ROBINUL, GLYCOPYRROLATE

CATALENT
* CATALENT PHARMA SOLUTIONS LLC
  VALPROIC ACID, VALPROIC ACID

CEDAR PHARMS
* CEDAR PHARMACEUTICALS LLC
  SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

CELGENE
* CELGENE CORP
  ISTODAX, ROMIDEPSIN
  POMALYST, POMALIDOMIDE
  REVLIMID, LENALIDOMIDE
  THALOMID, THALIDOMIDE
  VIDAZA, AZACITIDINE

CELGENE CORP
* CELGENE CORP
  OTEZLA, APREMILAST

CENTAUR PHARMS PVT
* CENTAUR PHARMACEUTICALS PVT LTD
  LAMIVUDINE, LAMIVUDINE

CEPHALON
* CEPHALON INC
  ACTIQ, FENTANYL CITRATE
  FENTORA, FENTANYL CITRATE
  GABITRIL, TIAGABINE HYDROCHLORIDE
  NUVIGIL, ARMODAFINIL
  PROVIGIL, MODAFINIL
  TREANDA, BENDAMUSTINE HYDROCHLORIDE
  TRISENOX, ARSENIC TRIOXIDE

CEREXA
* CEREXA INC
  TEFLARO, CEFTAROLINE FOSAMIL

CEREXA INC
* CEREXA INC
  AVYCAZ, AVIBACTAM SODIUM

CEROVENE INC
* CEROVENE INC
  OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

CFT PHARMS LLC
* CFT PHARMACEUTICALS LLC
  VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

CHANGZHOU PHARM
* CHANGZHOU PHARMACEUTICAL FACTORY
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL CIENCA
* CHARTWELL CIENCA DA VIDA LLC
  TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHARTWELL LIFE SCI
* CHARTWELL LIFE SCIENCE LLC
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  DOXYCYCLINE, DOXYCYCLINE
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHARTWELL MOLECULES

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* CHARTWELL MOLECULES LLC
  GEMFIBROZIL, GEMFIBROZIL
  NABUMETONE, NABUMETONE

CHATTEM

* CHATTEM INC
  SELSUN, SELENIUM SULFIDE
  UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEM WERTH INC

* CHEM WERTH INC
  TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

CHEMI SPA

* CHEMI SPA
  TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR

* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
  ASCLERA, POLIDOCANOL

CHIESI USA INC

* CHIESI USA INC
  BETHKIS, TOBRAMYCIN
  CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
  CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
  CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
  CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
  CARDENE, NICARDIPINE HYDROCHLORIDE
  CLEVIPREX, CLEVIDIPINE
  CUROSURF, PORACTANT ALFA
  KENGREAL, CANGRELOR
  ZYFLO CR, ZILEUTON
  ZYFLO, ZILEUTON

CHILDRENS HOSP MI

* CHILDRENS HOSP MICHIGAN
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES

* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN

* CHIRHOCLIN INC
  CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
  CONZIP, TRAMADOL HYDROCHLORIDE
  LIPOFEN, FENOFIBRATE

CIPHER PHARMS US

* CIPHER PHARMACEUTICALS US LLC
  SITAVIG, ACYCLOVIR

CIPLA

* CIPLA LTD
  NEVIRAPINE, NEVIRAPINE
  RISPERIDONE, RISPERIDONE
  ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD

* CIPLA LTD
  ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  ANASTROZOLE, ANASTROZOLE
  CARBOPLATIN, CARBOPLATIN
  CARVEDILOL, CARVEDILOL
  CELECOXIB, CELECOXIB
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CICLOPIROX, CICLOPIROX
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* CIPLA LTD
  ENTECAVIR, ENTECAVIR
  EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
  FAMCICLOVIR, FAMCICLOVIR
  FENOFIBRATE, FENOFIBRATE
  FINASTERIDE, FINASTERIDE
  FLUTAMIDE, FLUTAMIDE
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
  IRBESARTAN, IRBESARTAN
  IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
  LAMOTRIGINE, LAMOTRIGINE
  LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
  LEVOFLOXACIN, LEVOFLOXACIN
  MELOXICAM, MELOXICAM
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  NEVIRAPINE, NEVIRAPINE
  PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  STAVUDINE, STAVUDINE
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
  TOPIRAMATE, TOPIRAMATE
  TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
  VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  ZALEPLON, ZALEPLON
  ZIDOVUDINE, ZIDOVUDINE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CLARIS

* CLARIS PHARMASERVICES
  BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
  CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
  CIPROFLOXACIN, CIPROFLOXACIN
  FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
  FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
  FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
  FUROSEMIDE, FUROSEMIDE
  LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
  LEVOFLOXACIN, LEVOFLOXACIN
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
  MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
  NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
  ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

CLINIGEN HLTHCARE

* CLINIGEN HEALTHCARE LTD
  ETHYOL, AMIFOSTINE
  FOSCAVIR, FOSCARNET SODIUM
  TOTECT, DEXRAZOXANE HYDROCHLORIDE

CLOVER PHARMS

* CLOVER PHARMACEUTICALS CORP
  AMICAR, AMINOCAPROIC ACID

CLOVIS ONCOLOGY INC

* CLOVIS ONCOLOGY INC
  RUBRACA, RUCAPARIB CAMSYLATE

CNTY LINE PHARMS

* COUNTY LINE PHARMACEUTICALS LLC
  BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
  BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
  DYNACIN, MINOCYCLINE HYDROCHLORIDE
  LIDEX, FLUOCINONIDE
  LOPROX, CICLOPIROX
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* COUNTY LINE PHARMACEUTICALS LLC
  TAMBOCOR, FLECAINIDE ACETATE
  TRANDATE, LABETALOL HYDROCHLORIDE
  UREX, METHENAMINE HIPPURATE

COASTAL PHARMS

* COASTAL PHARMACEUTICALS
  BROMFENAC SODIUM, BROMFENAC SODIUM
  HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE

COLGATE

* COLGATE ORAL PHARMACEUTICALS INC
  PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE

* COLGATE PALMOLIVE
  COLGATE TOTAL, SODIUM FLUORIDE (OTC)

COLGATE-PALMOLIVE CO

* COLGATE-PALMOLIVE CO
  PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC

* COLLEGIUM PHARMACEUTICAL INC
  XTAMPZA ER, OXYCODONE

CONCORDIA LABS INC

* CONCORDIA LABORATORIES INC
  PHOTOFRIN, PORFIMER SODIUM

CONCORDIA PHARMS INC

* CONCORDIA PHARMACEUTICALS INC
  DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
  DUTOPROL, HYDROCHLOROTHIAZIDE
  DYRENIUM, TRIAMTERENE
  KAPVAY, CLONIDINE HYDROCHLORIDE
  KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
  LANOXIN, DIGOXIN
  NILANDRON, NILUTAMIDE
  ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
  PARNATE, TRANYLCYPROMINE SULFATE
  PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
  UROXATRAL, ALFUZOSIN HYDROCHLORIDE

CONTRACT PHARMACAL

* CONTRACT PHARMACAL CORP
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CIMETIDINE, CIMETIDINE (OTC)
  FOLIC ACID, FOLIC ACID
  IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
  IBUPROFEN, IBUPROFEN
  IBUPROFEN, IBUPROFEN (OTC)
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
  NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
  PREDNISONE, PREDNISONE
  PROFEN, IBUPROFEN (OTC)
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

CORCEPT THERAP

* CORCEPT THERAPEUTICS INC
  KORLYM, MIFEPRISTONE

CORDEN PHARMA

* CORDEN PHARMA LATINA SPA
  GLEOSTINE, LOMUSTINE

COREPHARMA

* COREPHARMA LLC
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
  DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
  DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
  FELBAMATE, FELBAMATE
  GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* COREPHARMA LLC
  GLYBURIDE, GLYBURIDE
  LEVOCARNITINE, LEVOCARNITINE
  METAXALONE, METAXALONE
  METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
  METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
  PHENYTOIN, PHENYTOIN
  POTASSIUM CITRATE, POTASSIUM CITRATE
  TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
  URSODIOL, URSODIOL

COVIS PHARMA SARL

* COVIS PHARMA SARL
  ALTOPREV, LOVASTATIN
  BETAPACE AF, SOTALOL HYDROCHLORIDE
  BETAPACE, SOTALOL HYDROCHLORIDE
  LANOXIN PEDIATRIC, DIGOXIN
  LANOXIN, DIGOXIN
  RILUTEK, RILUZOLE
  SULAR, NISOLDIPINE

CPDC

* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV
  SUTENT, SUNITINIB MALATE

CRANE PHARMS LLC

* CRANE PHARMACEUTICALS LLC
  DAPTOMYCIN, DAPTOMYCIN

CROSSMEDIKA SA

* CROSSMEDIKA SA
  MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
  TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

CROWN LABS

* CROWN LABORATORIES INC
  ALA-CORT, HYDROCORTISONE
  ALA-SCALP, HYDROCORTISONE
  TRIDERM, TRIAMCINOLONE ACETONIDE

CSL BEHRING

* CSL BEHRING LLC
  STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

CSPC NBP PHARM CO

* CSPC NBP PHARMACEUTICAL CO LTD
  BENZONATATE, BENZONATATE

CSPC OUYI PHARM CO

* CSPC OUYI PHARMACEUTICAL CO LTD
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CUBIST PHARMS

* CUBIST PHARMACEUTICALS INC
  ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC

* CUBIST PHARMACEUTICALS LLC
  CUBICIN RF, DAPTOMYCIN
  CUBICIN, DAPTOMYCIN
  DIFICID, FIDAXOMICIN
  SIVEXTRO, TEDIZOLID PHOSPHATE
  ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* CUMBERLAND PHARMACEUTICALS INC
  ACETADOTE, ACETYLCYSTEINE
  CALDOLOR, IBUPROFEN
  LACTULOSE, LACTULOSE
  VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE

CUTANEA
* CUTANEA LIFE SCIENCES INC
  AKTIPAK, BENZOYL PEROXIDE

CUTIS HEALTH LLC
* CUTIS HEALTH LLC
  DORAL, QUAZEPAM

CYPRESS BIOSCIENCE
* CYPRESS BIOSCIENCE INC
  SAVELLA, MILNACIPRAN HYDROCHLORIDE

CYPRESS PHARM
* CYPRESS PHARMACEUTICAL INC
  CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
  ELIPHOS, CALCIUM ACETATE
  REZIRA, HYDROCODONE BITARTRATE
  VITUZ, CHLORPHENIRAMINE MALEATE
  ZUTRIPRO, CHLORPHENIRAMINE MALEATE

CYPRESS PHARM INC
* CYPRESS PHARMACEUTICAL INC
  ZYFREL, ACETAMINOPHEN

** D **

DAEWOONG PHARM CO
* DAEWOONG PHARMACEUTICAL CO LTD
  MEROPENEM, MEROPENEM

DAIICHI SANKYO
* DAIICHI SANKYO INC
  AZOR, AMLODIPINE BESYLATE
  BENICAR HCT, HYDROCHLOROTHIAZIDE
  BENICAR, OLMESARTAN MEDOXOMIL
  TRIBENZOR, AMLODIPINE BESYLATE
  WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO INC
* DAIICHI SANKYO INC
  EVOXAC, CEVIMELINE HYDROCHLORIDE
  MORPHABOND, MORPHINE SULFATE
  SAVAYSA, EDOXABAN TOSYLATE

DANCO LABS LLC
* DANCO LABORATORIES LLC
  MIFEPREX, MIFEPRISTONE

DAVA INTL INC
* DAVA INTERNATIONAL INC
  ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC
* DAVA PHARMACEUTICALS INC
  ACYCLOVIR, ACYCLOVIR
  AMOXICILLIN, AMOXICILLIN
  AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
  ATENOLOL, ATENOLOL
  CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
  DIAZEPAM, DIAZEPAM
  DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
  GLYBURIDE (MICRONIZED), GLYBURIDE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  METHOTREXATE SODIUM, METHOTREXATE SODIUM
  MORPHINE SULFATE, MORPHINE SULFATE
  PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
  PROPYLTHIOURACIL, PROPYLTHIOURACIL
  PYRAZINAMIDE, PYRAZINAMIDE
  SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DAVA PHARMACEUTICALS INC
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DELCOR ASSET

* DELCOR ASSET CORP
OLUX E, CLOBETASOL PROPIONATE
ZOVIRAX, ACYCLOVIR

DELCOR ASSET CORP

* DELCOR ASSET CORP
ERYGEL, ERYTHROMYCIN
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXTINA, KETOCONAZOLE
KENALOG, TRIAMCINOLONE ACETONIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LUXIQ, BETAMETHASONE VALERATE
OLUX, CLOBETASOL PROPIONATE
PREDNISONE, PREDNISONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VUSION, MICONAZOLE NITRATE
ZONALON, DOXEPIN HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR

DENCO ASSET

* DENCO ASSET LLC
DENAVIR, PENCICLOVIR

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPOMED INC

* DEPOMED INC
CAMBIA, DICLOFENAC POTASSIUM
GRALISE, GABAPENTIN
LAZANDA, FENTANYL CITRATE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM

DEPROCO

* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DEXCEL LTD

* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
OMEPRAZOLE, OMEPRAZOLE (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DIAGNOSTIC GREEN

* DIAGNOSTIC GREEN GMBH
INDOCYANINE GREEN, INDOCYANINE GREEN

DIALYSIS SUPS

* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

DIGESTIVE CARE INC
* DIGESTIVE CARE INC
  PERTZYE, PANCRELIPASE (AMYLASE

DORADO PHARMA
* DORADO PHARMA LLC
  KETOPROFEN, KETOPROFEN

DORC
* DORC INTERNATIONAL BV
  MEMBRANEBLUE, TRYPAN BLUE
  VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS
* DOUGLAS PHARMACEUTICALS AMERICA LTD
  MYORISAN, ISOTRETINOIN

DOW PHARM
* DOW PHARMACEUTICAL SCIENCES
  ACANYA, BENZOYL PEROXIDE
  AKNE-MYCIN, ERYTHROMYCIN
  ATRALIN, TRETINOIN
  JUBLIA, EFINACONAZOLE
  ONEXTON, BENZOYL PEROXIDE
  OXSORALEN-ULTRA, METHOXSALEN

DR REDDYS LA
* DR REDDYS LABORATORIES LOUISIANA LLC
  IBUPROFEN, IBUPROFEN
  IBUPROFEN, IBUPROFEN (OTC)
  LOPURIN, ALLOPURINOL
  SSD AF, SILVER SULFADIAZINE
  SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC
* DR REDDYS LABORATORIES INC
  AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  AMOXIL, AMOXICILLIN
  AUGMENTIN '125', AMOXICILLIN
  AUGMENTIN '200', AMOXICILLIN
  AUGMENTIN '250', AMOXICILLIN
  AUGMENTIN '400', AMOXICILLIN
  AUGMENTIN '500', AMOXICILLIN
  AUGMENTIN '875', AMOXICILLIN
  AUGMENTIN ES-600, AMOXICILLIN
  AUGMENTIN XR, AMOXICILLIN
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  FINASTERIDE, FINASTERIDE
  FLUCONAZOLE, FLUCONAZOLE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  HABITROL, NICOTINE (OTC)
  IBUPROFEN, IBUPROFEN
  IBUPROFEN, IBUPROFEN (OTC)
  LAROTID, AMOXICILLIN
  LEVOFLOXACIN, LEVOFLOXACIN
  MELOXICAM, MELOXICAM
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
  NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
  NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
  NITROGLYCERIN, NITROGLYCERIN
  PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
  SIMVASTATIN, SIMVASTATIN
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
  TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
  ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

DR REDDYS LABS INTL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

* DR REDDYS LABORATORIES INTERNATIONAL SA
  MERCAPTOPURINE, MERCAPTOPURINE
  RAMELTEON, RAMELTEON

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
* DR REDDYS LABORATORIES LTD
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  ANASTROZOLE, ANASTROZOLE
  ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
  AZACITIDINE, AZACITIDINE
  BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
  CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
  CARVEDILOL, CARVEDILOL
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
  CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
  CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  DECITABINE, DECITABINE
  DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
  DESLORATADINE, DESLORATADINE
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  DOCETAXEL, DOCETAXEL
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
  ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
  ESZOPICLONE, ESZOPICLONE
  FAMOTIDINE, FAMOTIDINE
  FAMOTIDINE, FAMOTIDINE (OTC)
  FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
  FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
  FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
  FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
  FINASTERIDE, FINASTERIDE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  GLIMEPIRIDE, GLIMEPIRIDE
  GLYCOPYRROLATE, GLYCOPYRROLATE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  IBANDRONATE SODIUM, IBANDRONATE SODIUM
  IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
  IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
  IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  IRBESARTAN, IRBESARTAN
  IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
  LAMOTRIGINE, LAMOTRIGINE
  LANSOPRAZOLE, LANSOPRAZOLE
  LANSOPRAZOLE, LANSOPRAZOLE (OTC)
  LATANOPROST, LATANOPROST
  LETROZOLE, LETROZOLE
  LEVETIRACETAM, LEVETIRACETAM
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZAFIRLUKAST, ZAFIRLUKAST
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZENATANE, ISOTRETINOIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA
* DR REDDYS LABORATORIES SA
FENOFIBRATE (MICRONIZED), FENOFIBRATE

DRAXIMAGE
* DRAXIMAGE INC
DTPA, TECHNETIUM TC-99M PENTETATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

DUCHESNAY
* DUCHESNAY INC
BONJESTA, DOXYLAMINE SUCCINATE
DICLEGIS, DOXYLAMINE SUCCINATE

DURAMED PHARMS BARR
* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ENPRESSE-28, ETHINYL ESTRADIOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VELIVET, DESOGESTREL

DURAMED RES
* DURAMED RESEARCH INC
AYGESTIN, NORETHINDRONE ACETATE

DURATA THERAPS INTL
* DURATA THERAPEUTICS INTERNATIONAL BV
DALVANCE, DALBAVANCIN HYDROCHLORIDE

DUSA

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

* DUSA PHARMACEUTICALS INC
  LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
  DESLORATADINE, DESLORATADINE
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

** E **

EAGLE PHARMS

* EAGLE PHARMACEUTICALS INC
  ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
  BENDEKA, BENDAMUSTINE HYDROCHLORIDE
  DOCETAXEL, DOCETAXEL
  RYANODEX, DANTROLENE SODIUM

EASTMAN KODAK

* EASTMAN KODAK CO
  LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

ECI PHARMS LLC

* ECI PHARMACEUTICALS LLC
  CALCIUM ACETATE, CALCIUM ACETATE
  HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  METHIMAZOLE, METHIMAZOLE
  PARICALCITOL, PARICALCITOL

ECLAT PHARMS LLC

* ECLAT PHARMACEUTICALS LLC
  BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
  VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

ECOLAB

* ECOLAB INC
  CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
  CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

* ECR PHARMACEUTICALS
  DEXAMETHASONE, DEXAMETHASONE

ECR PHARMA

* ECR PHARMA
  TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS

* EDENBRIDGE PHARMACEUTICALS LLC
  CARBIDOPA, CARBIDOPA
  ETHACRYNIC ACID, ETHACRYNIC ACID
  IVERMECTIN, IVERMECTIN
  PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  TINIDAZOLE, TINIDAZOLE

EDGEMONT PHARMS LLC

* EDGEMONT PHARMACEUTICALS LLC
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  FORFIVO XL, BUPROPION HYDROCHLORIDE

EDISON THERAPS LLC

* EDISON THERAPEUTICS LLC
  METHERGINE, METHYLERGONOVINE MALEATE

EGALET US INC

* EGALET US INC
  OXAYDO, OXYCODONE HYDROCHLORIDE
  SPRIX, KETOROLAC TROMETHAMINE

EI INC

* EI INC
  THEROXIDIL, MINOXIDIL (OTC)

EISAI INC

* EISAI INC
  ACIPHEX, RABEPRAZOLE SODIUM
  ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
  ARICEPT, DONEPEZIL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EISAI INC
BANZEL, RUFINAMIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BELVIQ, LORCASERIN HYDROCHLORIDE
FYCOMPA, PERAMPANEL
HALAVEN, ERIBULIN MESYLATE
HEXALEN, ALTRETAMINE
LENVIMA, LENVATINIB MESYLATE
PANRETIN, ALITRETINOIN
SALAGEN, PILOCARPINE HYDROCHLORIDE

ELAN PHARMA INTL LTD

* ELAN PHARMA INTERNATIONAL LTD
EVAMIST, ESTRADIOL
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

ELI LILLY AND CO

* ELI LILLY AND CO
AXIRON, TESTOSTERONE
BASAGLAR, INSULIN GLARGINE
EFFIENT, PRASUGREL HYDROCHLORIDE
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
PROZAC, FLUOXETINE HYDROCHLORIDE

ELI LILLY CO

* ELI LILLY CO
ADCIRCA, TADALAFIL
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS

* ELITE LABORATORIES INC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC

* ELITE LABORATORIES INC
DANTROLENE SODIUM, DANTROLENE SODIUM
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
ISRADIPINE, ISRADIPINE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

EMCURE PHARMS

* EMCURE PHARMACEUTICALS LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS INDIA

* EMCURE PHARMACEUTICALS LTD INDIA
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM

EMCURE PHARMS LTD

* EMCURE PHARMACEUTICALS LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM , ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BICNU, CARMUSTINE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
ETOMIDATE, ETOMIDATE
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RIFAMPIN, RIFAMPIN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRANEXAMIC ACID, TRANEXAMIC ACID

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EMCURE PHARMACEUTICALS LTD
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMD SERONO

* EMD SERONO INC
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F, FOLLITROPIN ALFA/BETA
OVIDREL, CHORIOGONADOTROPIN ALFA
SAIZEN, SOMATROPIN RECOMBINANT
SEROSTIM, SOMATROPIN RECOMBINANT
ZORBTIVE, SOMATROPIN RECOMBINANT

EMD SERONO INC

* EMD SERONO INC
CETROTIDE, CETRORELIX

EMMAUS MEDCL

* EMMAUS MEDICAL INC
NUTRESTORE, GLUTAMINE

ENDO PHARM

* ENDO PHARMACEUTICAL SOLUTIONS INC
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VANTAS, HISTRELIN ACETATE

ENDO PHARMS

* ENDO PHARMACEUTICALS INC
DELATESTRYL, TESTOSTERONE ENANTHATE
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
OPANA ER, OXYMORPHONE HYDROCHLORIDE
OPANA, OXYMORPHONE HYDROCHLORIDE
PERCODAN, ASPIRIN

ENDO PHARMS INC

* ENDO PHARMACEUTICALS INC
AVEED, TESTOSTERONE UNDECANOATE
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
COLY-MYCIN S, COLISTIN SULFATE
MEGACE ES, MEGESTROL ACETATE
NASCOBAL, CYANOCOBALAMIN
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

ENDO VENTURES LTD

* ENDO VENTURES LTD IRELAND
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

ENDOCEUTICS INC

* ENDOCEUTICS INC
INTRAROSA, PRASTERONE

EPIC PHARMA

* EPIC PHARMA INC
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

* EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC
ESTRADIOL, ESTRADIOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EPIC PHARMA LLC
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

ERGOJECT
* ERGOJECT LLC
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

ESSENTIAL ISOTOPES
* ESSENTIAL ISOTOPES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM
* ETHYPHARM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETHYPHARM USA CORP
* ETHYPHARM USA CORP
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

EUROHLTH INTL SARL
* EUROHEALTH INTERNATIONAL SARL
ADENOSINE, ADENOSINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
BUMETANIDE, BUMETANIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFOXITIN, CEFOXITIN SODIUM
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MORPHINE SULFATE, MORPHINE SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EUROHEALTH INTERNATIONAL SARL
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
IDKIT:HP, CITRIC ACID

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE
IBUPROFEN LYSINE, IBUPROFEN LYSINE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

EXELA PHARMA SCS LLC

* EXELA PHARMA SCIENCES LLC
CAFFEINE CITRATE, CAFFEINE CITRATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
MAGNESIUM SULFATE, MAGNESIUM SULFATE
POTASSIUM ACETATE, POTASSIUM ACETATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EXELIXIS

* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

* EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS SUISSE

* EXELTIS SUISSE SA
ECOZA, ECONAZOLE NITRATE

EXELTIS USA INC

* EXELTIS USA INC
ESTRASORB, ESTRADIOL HEMIHYDRATE

FOUGERA

* E FOUGERA DIV ALTANA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** E **

* ELI LILLY AND CO
  HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
  HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
  HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
  HUMULIN R KWIKPEN, INSULIN HUMAN
  HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
  HUMULIN R, INSULIN HUMAN
  HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
  PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
  QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
  STRATTERA, ATOMOXETINE HYDROCHLORIDE
  SYMBYAX, FLUOXETINE HYDROCHLORIDE
  ZYPREXA ZYDIS, OLANZAPINE
  ZYPREXA, OLANZAPINE

** F **

FACTA FARMA
* FACTA FARMACEUTICI SPA
  CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
  CEFTRIAXONE, CEFTRIAXONE SODIUM
  CEFUROXIME SODIUM, CEFUROXIME SODIUM

FDC LTD
* FDC LTD
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  LATANOPROST, LATANOPROST
  OFLOXACIN, OFLOXACIN
  TIMOLOL MALEATE, TIMOLOL MALEATE

FEINSTEIN
* FEINSTEIN INSTITUTE MEDICAL RESEARCH
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS
* FERA PHARMACEUTICALS LLC
  TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC
* FERA PHARMACEUTICALS LLC
  LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
  SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

FERNDALE LABS
* FERNDALE LABORATORIES INC
  HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE

FERRING
* FERRING PHARMACEUTICALS INC
  ACTHREL, CORTICORELIN OVINE TRIFLUTATE
  BRAVELLE, UROFOLLITROPIN
  CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
  ENDOMETRIN, PROGESTERONE
  FIRMAGON, DEGARELIX ACETATE
  MENOPUR, MENOTROPINS (FSH
  MINIRIN, DESMOPRESSIN ACETATE
  ZOMACTON, SOMATROPIN RECOMBINANT

FERRING PHARMS AS
* FERRING PHARMACEUTICALS AS
  LYSTEDA, TRANEXAMIC ACID
  PREPOPIK, CITRIC ACID

FERRING PHARMS INC
* FERRING PHARMACEUTICALS INC
  CERVIDIL, DINOPROSTONE
  DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
  DDAVP, DESMOPRESSIN ACETATE

FLAMEL IRELAND LTD
* FLAMEL IRELAND LIMITED
  AKOVAZ, EPHEDRINE SULFATE

FLAMINGO PHARMS

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FLAMINGO PHARMACEUTICALS LTD
  METRONIDAZOLE, METRONIDAZOLE
  PIROXICAM, PIROXICAM

FOREST LABS

* FOREST LABORATORIES INC
  BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
  CELEXA, CITALOPRAM HYDROBROMIDE
  LEXAPRO, ESCITALOPRAM OXALATE
  THYROLAR-0.25, LIOTRIX (T4
  THYROLAR-0.5, LIOTRIX (T4
  THYROLAR-1, LIOTRIX (T4
  THYROLAR-2, LIOTRIX (T4
  THYROLAR-3, LIOTRIX (T4

FOREST LABS INC

* FOREST LABORATORIES INC
  BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
  BENTYL, DICYCLOMINE HYDROCHLORIDE
  CARAFATE, SUCRALFATE
  FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
  RECTIV, NITROGLYCERIN
  ULTRESA, PANCRELIPASE (AMYLASE
  URSO 250, URSODIOL
  URSO FORTE, URSODIOL
  VIOKACE, PANCRELIPASE (AMYLASE
  ZENPEP, PANCRELIPASE (AMYLASE

FOREST LABS LLC

* FOREST LABORATORIES LLC
  BYVALSON, NEBIVOLOL HYDROCHLORIDE
  CANASA, MESALAMINE
  LINZESS, LINACLOTIDE
  NAMENDA XR, MEMANTINE HYDROCHLORIDE
  NAMENDA, MEMANTINE HYDROCHLORIDE
  NAMZARIC, DONEPEZIL HYDROCHLORIDE
  PYLERA, BISMUTH SUBCITRATE POTASSIUM
  SAPHRIS, ASENAPINE MALEATE
  VIIBRYD, VILAZODONE HYDROCHLORIDE

FOREST RES INST INC

* FOREST RESEARCH INSTITUTE INC
  VRAYLAR, CARIPRAZINE HYDROCHLORIDE

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
  ADAPALENE, ADAPALENE
  ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
  AMCINONIDE, AMCINONIDE
  BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CALCIPOTRIENE, CALCIPOTRIENE
  CICLOPIROX, CICLOPIROX
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CLOTRIMAZOLE, CLOTRIMAZOLE
  CUTIVATE, FLUTICASONE PROPIONATE
  DESONIDE, DESONIDE
  DESOXIMETASONE, DESOXIMETASONE
  DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
  ECONAZOLE NITRATE, ECONAZOLE NITRATE
  ERYTHROMYCIN, ERYTHROMYCIN
  FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
  FLUOCINONIDE, FLUOCINONIDE
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
  HYDROCORTISONE, HYDROCORTISONE
  IMIQUIMOD, IMIQUIMOD
  KETOCONAZOLE, KETOCONAZOLE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FOUGERA PHARMACEUTICALS INC
  LIDOCAINE AND PRILOCAINE, LIDOCAINE
  METRONIDAZOLE, METRONIDAZOLE
  MOMETASONE FUROATE, MOMETASONE FUROATE
  MUPIROCIN, MUPIROCIN
  NYSTATIN, NYSTATIN
  OXISTAT, OXICONAZOLE NITRATE
  PANDEL, HYDROCORTISONE PROBUTATE
  PREDNICARBATE, PREDNICARBATE
  SOLARAZE, DICLOFENAC SODIUM
  SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
  TERCONAZOLE, TERCONAZOLE
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
  TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
  ACYCLOVIR, ACYCLOVIR
  FLUOCINONIDE, FLUOCINONIDE
  TACROLIMUS, TACROLIMUS

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
  INTRALIPID 10%, SOYBEAN OIL
  INTRALIPID 20%, SOYBEAN OIL
  INTRALIPID 30%, SOYBEAN OIL

FRESENIUS KABI

* FRESENIUS KABI AUSTRIA GMBH
  LACTULOSE, LACTULOSE

FRESENIUS KABI ONCOL

* FRESENIUS KABI ONCOLOGY PLC
  ANASTROZOLE, ANASTROZOLE
  BICALUTAMIDE, BICALUTAMIDE
  CARBOPLATIN, CARBOPLATIN
  EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
  LETROZOLE, LETROZOLE
  OXALIPLATIN, OXALIPLATIN
  PACLITAXEL, PACLITAXEL

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
  ACETAMINOPHEN, ACETAMINOPHEN
  ACETYLCYSTEINE, ACETYLCYSTEINE
  ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
  ADENOSINE, ADENOSINE
  AMIKACIN SULFATE, AMIKACIN SULFATE
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  ARGATROBAN, ARGATROBAN
  ASTRAMORPH PF, MORPHINE SULFATE
  AZITHROMYCIN, AZITHROMYCIN
  AZTREONAM, AZTREONAM
  BACITRACIN, BACITRACIN
  BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  BIVALIRUDIN, BIVALIRUDIN
  BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
  CAFFEINE CITRATE, CAFFEINE CITRATE
  CARBOPLATIN, CARBOPLATIN
  CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
  CEFOTETAN, CEFOTETAN DISODIUM
  CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
  CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
  CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
  CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
  CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
  CISPLATIN, CISPLATIN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MESNA, MESNA
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SMOFLIPID 20%, FISH OIL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS MEDICAL CARE NORTH AMERICA
  DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
  DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
  DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
  DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
  PHOSLO GELCAPS, CALCIUM ACETATE
  PHOSLYRA, CALCIUM ACETATE
  SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FRONTIDA BIOPHARM

* FRONTIDA BIOPHARM INC
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
  PRIMIDONE, PRIMIDONE

FSC THERAP

* FSC THERAPEUTICS LLC
  ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM

** G **

G AND W LABS

* G AND W LABORATORIES INC
  ACEPHEN, ACETAMINOPHEN (OTC)
  CICLOPIROX, CICLOPIROX
  FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
  INDOMETHACIN, INDOMETHACIN
  METRONIDAZOLE, METRONIDAZOLE
  MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
  MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
  MOMETASONE FUROATE, MOMETASONE FUROATE
  PROCHLORPERAZINE, PROCHLORPERAZINE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

G AND W LABS INC

* G AND W LABORATORIES INC
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  BETA-VAL, BETAMETHASONE VALERATE
  BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CALCIPOTRIENE, CALCIPOTRIENE
  CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
  CICLOPIROX, CICLOPIROX
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  DESONIDE, DESONIDE
  DESOXIMETASONE, DESOXIMETASONE
  DOXYCYCLINE, DOXYCYCLINE
  ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
  FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
  FLUOCINONIDE, FLUOCINONIDE
  GENTAMICIN SULFATE, GENTAMICIN SULFATE
  IMIQUIMOD, IMIQUIMOD
  MESALAMINE, MESALAMINE
  METRONIDAZOLE, METRONIDAZOLE
  MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
  MYKACET, NYSTATIN
  NYSTATIN, NYSTATIN
  PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* G AND W LABORATORIES INC
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GALDERMA LABS
* GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP
* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE
* GALDERMA LABORATORIES LP
CAPEX, FLUOCINOLONE ACETONIDE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
DIFFERIN, ADAPALENE (OTC)
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
PLIAGLIS, LIDOCAINE
SOOLANTRA, IVERMECTIN
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

GALEN SPECIALTY
* GALEN SPECIALTY PHARMA US LLC
SYNERA, LIDOCAINE

GASTROENTERO
* GASTROENTERO LOGIC LLC
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

GATE PHARMS
* GATE PHARMACEUTICALS
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
LINEZOLID, LINEZOLID

GATOR PHARMS
* GATOR PHARMACEUTICALS INC
COLPREP KIT, MAGNESIUM SULFATE

GAVIS PHARMS
* GAVIS PHARMACEUTICALS LLC
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINARETIC, HYDROCHLOROTHIAZIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

GAVIS PHARMS LLC
* GAVIS PHARMACEUTICALS LLC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

GD SEARLE
* GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

GD SEARLE LLC
* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CALAN, VERAPAMIL HYDROCHLORIDE
COVERA-HS, VERAPAMIL HYDROCHLORIDE
CYTOTEC, MISOPROSTOL
FLAGYL ER, METRONIDAZOLE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GD SEARLE LLC
FLAGYL, METRONIDAZOLE
INSPRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE

* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
METASTRON, STRONTIUM CHLORIDE SR-89
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC

* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GEDEON RICHTER USA

* GEDEON RICHTER USA INC
FINASTERIDE, FINASTERIDE

GEMINI LABS LLC

* GEMINI LABORATORIES LLC
OXANDRIN, OXANDROLONE

GENENTECH

* GENENTECH INC
ERIVEDGE, VISMODEGIB
NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT

GENENTECH INC

* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
ESBRIET, PIRFENIDONE

GENZYME

* GENZYME CORP
CEREZYME, IMIGLUCERASE
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
RENVELA, SEVELAMER CARBONATE
THYROGEN, THYROTROPIN ALFA

GENZYME CORP

* GENZYME CORP
CAPRELSA, VANDETANIB
CERDELGA, ELIGLUSTAT TARTRATE
HECTOROL, DOXERCALCIFEROL

GILEAD

* GILEAD SCIENCES INC
ATRIPLA, EFAVIRENZ
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GILEAD SCIENCES INC
HEPSERA, ADEFOVIR DIPIVOXIL
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
COMPLERA, EMTRICITABINE
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
TYBOST, COBICISTAT
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VITEKTA, ELVITEGRAVIR
ZYDELIG, IDELALISIB

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MEROPENEM, MEROPENEM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACITAXEL, PACLITAXEL
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

GLAXO GRP ENGLAND

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA , UMECLIDINIUM BROMIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
FLOVENT HFA, FLUTICASONE PROPIONATE

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREO ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
AVODART, DUTASTERIDE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GLAXOSMITHKLINE
  CEFTIN, CEFUROXIME AXETIL
  EPIVIR-HBV, LAMIVUDINE
  FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
  IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
  IMITREX, SUMATRIPTAN
  IMITREX, SUMATRIPTAN SUCCINATE
  JALYN, DUTASTERIDE
  MALARONE PEDIATRIC, ATOVAQUONE
  MALARONE, ATOVAQUONE
  NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
  NICORETTE, NICOTINE POLACRILEX (OTC)
  POTIGA, EZOGABINE
  RELENZA, ZANAMIVIR
  VALTREX, VALACYCLOVIR HYDROCHLORIDE
  WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
  ZYBAN, BUPROPION HYDROCHLORIDE
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
  ANORO ELLIPTA, UMECLIDINIUM BROMIDE
  ARNUITY ELLIPTA, FLUTICASONE FUROATE
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
  SEREVENT, SALMETEROL XINAFOATE
  VENTOLIN HFA, ALBUTEROL SULFATE

GLAXOSMITHKLINE CON

* GLAXOSMITHKLINE CONSUMER HEALTH
  TRANSDERM SCOP, SCOPOLAMINE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
  ALLI, ORLISTAT (OTC)
  COMMIT, NICOTINE POLACRILEX (OTC)
  EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
  FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
  NICORETTE, NICOTINE POLACRILEX (OTC)
  PREVACID 24 HR, LANSOPRAZOLE (OTC)
  VOLTAREN, DICLOFENAC SODIUM

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
  AMERGE, NARATRIPTAN HYDROCHLORIDE
  DYAZIDE, HYDROCHLOROTHIAZIDE
  FLOLAN, EPOPROSTENOL SODIUM
  INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
  LAMICTAL CD, LAMOTRIGINE
  LAMICTAL ODT, LAMOTRIGINE
  LAMICTAL XR, LAMOTRIGINE
  LAMICTAL, LAMOTRIGINE
  MEPRON, ATOVAQUONE
  REQUIP XL, ROPINIROLE HYDROCHLORIDE
  REQUIP, ROPINIROLE HYDROCHLORIDE
  RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
  RYTHMOL, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
  ADAPALENE, ADAPALENE
  BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CALCIPOTRIENE, CALCIPOTRIENE
  IMIQUIMOD, IMIQUIMOD
  MOMETASONE FUROATE, MOMETASONE FUROATE
  MUPIROCIN, MUPIROCIN CALCIUM
  NIZATIDINE, NIZATIDINE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  ZONISAMIDE, ZONISAMIDE
* GLENMARK GENERICS LIMITED
  BRIELLYN, ETHINYL ESTRADIOL
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GLENMARK GENERICS LTD
  ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
  ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
  ALYACEN 1/35, ETHINYL ESTRADIOL
  ALYACEN 7/7/7, ETHINYL ESTRADIOL
  ASHLYNA, ETHINYL ESTRADIOL
  ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
  CARVEDILOL, CARVEDILOL
  CICLOPIROX, CICLOPIROX
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  DESOXIMETASONE, DESOXIMETASONE
  ESZOPICLONE, ESZOPICLONE
  FELODIPINE, FELODIPINE
  FLUCONAZOLE, FLUCONAZOLE
  FLUOCINONIDE, FLUOCINONIDE
  GABAPENTIN, GABAPENTIN
  HEATHER, NORETHINDRONE
  HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
  LAMOTRIGINE, LAMOTRIGINE
  LEVOFLOXACIN, LEVOFLOXACIN
  LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  LITHIUM CARBONATE, LITHIUM CARBONATE
  MARLISSA, ETHINYL ESTRADIOL
  MELOXICAM, MELOXICAM
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
  MOMETASONE FUROATE, MOMETASONE FUROATE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  NAPROXEN SODIUM, NAPROXEN SODIUM
  NAPROXEN, NAPROXEN
  NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  NORETHINDRONE, NORETHINDRONE
  NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  OMEPRAZOLE, OMEPRAZOLE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON, ONDANSETRON
  OXCARBAZEPINE, OXCARBAZEPINE
  PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  RILUZOLE, RILUZOLE
  RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
  TELMISARTAN, TELMISARTAN
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
  THEOPHYLLINE, THEOPHYLLINE
  TOPIRAMATE, TOPIRAMATE
  TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
  TRETINOIN, TRETINOIN
  TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
  URSODIOL, URSODIOL
  VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
  VIORELE, DESOGESTREL
  ZOLMITRIPTAN, ZOLMITRIPTAN
* GLENMARK GENERICS LTD INDIA
  INDOMETHACIN, INDOMETHACIN
  NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

* GLENMARK PHARMACEUTICALS INC USA
  CICLOPIROX, CICLOPIROX
  CLOTRIMAZOLE, CLOTRIMAZOLE
  MUPIROCIN, MUPIROCIN
* GLENMARK PHARMACEUTICALS LTD
  MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
* GLENMARK PHARMACEUTICALS SA

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

* GLENMARK PHARMACEUTICALS SA
  CALCIPOTRIENE, CALCIPOTRIENE
  CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  LINEZOLID, LINEZOLID
  NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

GLENMARK PHARMS INC

* GLENMARK PHARMACEUTICALS INC USA
  LITHIUM CARBONATE, LITHIUM CARBONATE

GLENMARK PHARMS LTD

* GLENMARK PHARMACEUTICALS LTD
  BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
  DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
  EZETIMIBE, EZETIMIBE
  FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
  HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  LEVONORGESTREL, LEVONORGESTREL (OTC)
  LIDOCAINE, LIDOCAINE
  NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
  RUFINAMIDE, RUFINAMIDE
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
  VORICONAZOLE, VORICONAZOLE

GLOBAL ISOTOPES LLC

* GLOBAL ISOTOPES LLC DBA ZEVACOR MOLECULAR
  AMMONIA N 13, AMMONIA N-13
  CHOLINE C-11, CHOLINE C-11
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

GRANULES INDIA

* GRANULES INDIA LTD
  IBUPROFEN, IBUPROFEN (OTC)
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRANULES INDIA LTD

* GRANULES INDIA LTD
  IBUPROFEN, IBUPROFEN
  IBUPROFEN, IBUPROFEN (OTC)

GROUPE PARIMA INC

* GROUPE PARIMA INC
  DESOXIMETASONE, DESOXIMETASONE

GUARDIAN DRUG

* GUARDIAN DRUG CO INC
  FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUERBET

* GUERBET LLC
  DOTAREM, GADOTERATE MEGLUMINE
  LIPIODOL, ETHIODIZED OIL

HANFORD GC

* GC HANFORD MANUFACTURING CO
  AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
  AMPICILLIN SODIUM, AMPICILLIN SODIUM
  PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

POHL BOSKAMP

* G POHL BOSKAMP GMBH AND CO KG
  GONITRO, NITROGLYCERIN

** H **

HAEMONETICS

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HAEMONETICS CORP
  SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HALOCARBON PRODS

* HALOCARBON PRODUCTS CORP
  ISOFLURANE, ISOFLURANE
  SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP

* HALOZYME THERAPEUTICS INC
  HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN PHARMA PLUS

* HAMELN PHARMA PLUS GMBH
  PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
  PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM

HAMELN RDS GMBH

* HAMELN RDS GMBH
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

HARRIS PHARM

* HARRIS PHARMACEUTICAL INC
  FLUCONAZOLE, FLUCONAZOLE
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HAUPT PHARMA

* HAUPT PHARMA INC
  NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

HEC PHARM USA INC

* HEC PHARM USA INC
  CLARITHROMYCIN, CLARITHROMYCIN

HELSINN HLTHCARE

* HELSINN HEALTHCARE SA
  AKYNZEO, NETUPITANT
  ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
  NITROGLYCERIN, NITROGLYCERIN

HERITAGE LIFE

* HERITAGE LIFE SCIENCES BARBADOS INC
  CLOZARIL, CLOZAPINE

HERITAGE PHARMA

* HERITAGE PHARMA LABS INC
  ACETAZOLAMIDE, ACETAZOLAMIDE
  BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
  DIFLUNISAL, DIFLUNISAL
  HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
  LITHIUM CARBONATE, LITHIUM CARBONATE
  METHIMAZOLE, METHIMAZOLE
  NIFEDIPINE, NIFEDIPINE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
  ACETAZOLAMIDE, ACETAZOLAMIDE
  ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
  ALPRAZOLAM, ALPRAZOLAM
  CALCIUM ACETATE, CALCIUM ACETATE
  CARISOPRODOL AND ASPIRIN, ASPIRIN
  DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  DOXYCYCLINE, DOXYCYCLINE
  ETHOSUXIMIDE, ETHOSUXIMIDE
  FELODIPINE, FELODIPINE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
  GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HERITAGE PHARMACEUTICALS INC
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
LEFLUNOMIDE, LEFLUNOMIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHOLROTHIAZIDE, HYDROCHLOROTHIAZIDE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NYSTATIN, NYSTATIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
SULINDAC, SULINDAC
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERON THERAPS INC

* HERON THERAPEUTICS INC
SUSTOL, GRANISETRON

HETERO LABS LTD III

* HETERO LABS LTD UNIT III
ABACAVIR SULFATE, ABACAVIR SULFATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHOCARBAMOL, METHOCARBAMOL
NEVIRAPINE, NEVIRAPINE
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
TORSEMIDE, TORSEMIDE
ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
FAMCICLOVIR, FAMCICLOVIR
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TETRABENAZINE, TETRABENAZINE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN

HEYL CHEMISCH

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
  RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA

* HI TECH PHARMACAL CO INC
  ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
  ACYCLOVIR, ACYCLOVIR
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
  CALCIPOTRIENE, CALCIPOTRIENE
  CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
  CICLOPIROX, CICLOPIROX
  CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
  CORMAX, CLOBETASOL PROPIONATE
  DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  EMBELINE E, CLOBETASOL PROPIONATE
  EMBELINE, CLOBETASOL PROPIONATE
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  GABAPENTIN, GABAPENTIN
  HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
  HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  LACTULOSE, LACTULOSE
  LEVOCARNITINE, LEVOCARNITINE
  LEVOFLOXACIN, LEVOFLOXACIN
  LIDOCAINE AND PRILOCAINE, LIDOCAINE
  LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
  MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
  MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
  MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
  NYSTATIN, NYSTATIN
  OFLOXACIN, OFLOXACIN
  PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
  PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
  TIMOLOL MALEATE, TIMOLOL MALEATE
  VOSOL HC, ACETIC ACID, GLACIAL
  VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO

* HI TECH PHARMACAL CO INC
  FLUNISOLIDE, FLUNISOLIDE
  PREDNISOLONE, PREDNISOLONE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
  FAMOTIDINE, FAMOTIDINE
  GATIFLOXACIN, GATIFLOXACIN
  LORAZEPAM, LORAZEPAM
  PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
  BROMFENAC SODIUM, BROMFENAC SODIUM
  IBUPROFEN, IBUPROFEN
  LEVETIRACETAM, LEVETIRACETAM
  PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
  VALPROIC ACID, VALPROIC ACID

HIKMA

* HIKMA FARMACEUTICA LDA
  CEFOTAXIME, CEFOTAXIME SODIUM
* HIKMA PHARMACEUTICALS
  AMOXICILLIN, AMOXICILLIN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIKMA PHARMACEUTICALS
  CEFACLOR, CEFACLOR
  CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
  CEPHALEXIN, CEPHALEXIN
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  GLYBURIDE (MICRONIZED), GLYBURIDE

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
  CEFOXITIN, CEFOXITIN SODIUM
  CEFTRIAXONE, CEFTRIAXONE SODIUM
  CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
  CIPROFLOXACIN, CIPROFLOXACIN
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  ENALAPRILAT, ENALAPRILAT
  FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
  FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
  FLUMAZENIL, FLUMAZENIL
  FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
  GLYCOPYRROLATE, GLYCOPYRROLATE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
  LEVETIRACETAM, LEVETIRACETAM
  LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
  MILRINONE LACTATE, MILRINONE LACTATE
  ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  PROGESTERONE, PROGESTERONE
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
  TERBUTALINE SULFATE, TERBUTALINE SULFATE
  TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
  VALPROATE SODIUM, VALPROATE SODIUM
* HIKMA FARMACEUTICA PORTUGAL LDA
  CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
  CEFUROXIME SODIUM, CEFUROXIME SODIUM
  FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
* HIKMA FARMACEUTICA PORTUGAL SA
  CEFOTETAN, CEFOTETAN DISODIUM
  DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
  ETOMIDATE, ETOMIDATE
  METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
  OXYTOCIN, OXYTOCIN
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
* HIKMA FARMACEUTICA SA
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
  BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
  BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
  CAPTOPRIL, CAPTOPRIL
  CORTISONE ACETATE, CORTISONE ACETATE
  DIGOXIN, DIGOXIN
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  HYDROCORTISONE, HYDROCORTISONE
  ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
  LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LISINOPRIL, LISINOPRIL
  METHOCARBAMOL, METHOCARBAMOL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
  MITIGARE, COLCHICINE
  NAPROXEN, NAPROXEN
  PRIMIDONE, PRIMIDONE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
  ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
  AMOXICILLIN, AMOXICILLIN
  CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
  ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
  GEMFIBROZIL, GEMFIBROZIL
  ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
  LETROZOLE, LETROZOLE
  MODAFINIL, MODAFINIL
  PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
  RIFAMPIN, RIFAMPIN
* HIKMA PHARMACEUTICALS CO LTD
  PARICALCITOL, PARICALCITOL
* HIKMA PHARMACEUTICALS LLC
  PREDNISONE, PREDNISONE

HIKMA PHARMS LLC

* HIKMA PHARMACEUTICALS LLC
  ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
  BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
  CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
  DOXERCALCIFEROL, DOXERCALCIFEROL
  FOLIC ACID, FOLIC ACID
  HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
  ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
  ZALEPLON, ZALEPLON

HILL DERMAC

* HILL DERMACEUTICALS INC
  DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
  DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

* HILL DERMACEUTICALS INC
  TOLAK, FLUOROURACIL

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
  SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
  EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
  IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
* HISUN PHARMACEUTICAL HANGZHOU CO LTD
  IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  IRBESARTAN, IRBESARTAN

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
  BONIVA, IBANDRONATE SODIUM
  INVIRASE, SAQUINAVIR MESYLATE
  VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
  XELODA, CAPECITABINE
  XENICAL, ORLISTAT
  ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

* HOFFMANN-LA ROCHE INC
  ALECENSA, ALECTINIB HYDROCHLORIDE
  INVIRASE, SAQUINAVIR MESYLATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

HOPE PHARMS
* HOPE PHARMACEUTICALS
  NITHIODOTE, SODIUM NITRITE
  SODIUM NITRITE, SODIUM NITRITE
  SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON PHARMA
* HORIZON PHARMA INC
  DUEXIS, FAMOTIDINE
  RAYOS, PREDNISONE
* HORIZON PHARMA IRELAND LTD
  PENNSAID, DICLOFENAC SODIUM
* HORIZON PHARMA RHEUMATOLOGY LLC
  MIGERGOT, CAFFEINE

HORIZON PHARMA INC
* HORIZON PHARMA INC
  BUPHENYL, SODIUM PHENYLBUTYRATE

HORIZON PHARMA USA
* HORIZON PHARMA USA INC
  VIMOVO, ESOMEPRAZOLE MAGNESIUM

HORIZON THERAPS INC
* HORIZON THERAPEUTICS INC
  RAVICTI, GLYCEROL PHENYLBUTYRATE

HOSPIRA
* HOSPIRA INC
  A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
  A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
  ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
  ACETYLCYSTEINE, ACETYLCYSTEINE
  ALFENTANIL, ALFENTANIL HYDROCHLORIDE
  AMIDATE, ETOMIDATE
  AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
  AMINOPHYLLINE, AMINOPHYLLINE
  AMINOSYN 10% (PH6), AMINO ACIDS
  AMINOSYN 10%, AMINO ACIDS
  AMINOSYN 3.5% M, AMINO ACIDS
  AMINOSYN 3.5%, AMINO ACIDS
  AMINOSYN 5%, AMINO ACIDS
  AMINOSYN 7% (PH6), AMINO ACIDS
  AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
  AMINOSYN 7%, AMINO ACIDS
  AMINOSYN 8.5% (PH6), AMINO ACIDS
  AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
  AMINOSYN 8.5%, AMINO ACIDS
  AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
  AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
  AMINOSYN II 10%, AMINO ACIDS
  AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
  AMINOSYN II 7%, AMINO ACIDS
  AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
  AMINOSYN II 8.5%, AMINO ACIDS
  AMINOSYN-HBC 7%, AMINO ACIDS
  AMINOSYN-HF 8%, AMINO ACIDS
  AMINOSYN-PF 10%, AMINO ACIDS
  AMINOSYN-PF 7%, AMINO ACIDS
  AMINOSYN-RF 5.2%, AMINO ACIDS
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
  AQUASOL A, VITAMIN A PALMITATE
  ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
  ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
  AZITHROMYCIN, AZITHROMYCIN
  BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
  BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
  BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
  BUMETANIDE, BUMETANIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% , DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LTA II KIT, LIDOCAINE HYDROCHLORIDE
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. ADULT, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROPOFOL, PROPOFOL
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TALWIN, PENTAZOCINE LACTATE
TAZICEF, CEFTAZIDIME
THAM, TROMETHAMINE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VITAMIN K1, PHYTONADIONE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
* HOSPIRA WORLDWIDE, INC
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NITROPRESS, SODIUM NITROPRUSSIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

* HOSPIRA INC
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ARGATROBAN, ARGATROBAN
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BIVALIRUDIN, BIVALIRUDIN
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
DAPTOMYCIN, DAPTOMYCIN
DOCETAXEL, DOCETAXEL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
MILRINONE LACTATE, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NIPENT, PENTOSTATIN
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SODIUM BICARBONATE, SODIUM BICARBONATE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

* HOT SHOTS NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HOUSTON CYCLOTRON

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOUSTON CYCLOTRON PARTNERS LP
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

* HQ SPECIALTY PHARMA CORP
  CISPLATIN, CISPLATIN
  DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
  ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
  ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
  MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
  METHOTREXATE SODIUM, METHOTREXATE SODIUM
  TAXOL, PACLITAXEL

HQ SPECIALITY PHARMA

* HQ SPECIALITY PHARMA LLC
  LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HQ SPECLT PHARMA

* HQ SPECIALTY PHARMA
  VUMON, TENIPOSIDE

HRA PHARMA

* HRA PHARMA LLC
  METOPIRONE, METYRAPONE

HUMANWELL PURACAP

* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
  IBUPROFEN, IBUPROFEN (OTC)

ROCHE

* HOFFMANN LA ROCHE INC
  BONIVA, IBANDRONATE SODIUM
  COPEGUS, RIBAVIRIN
  FUZEON, ENFUVIRTIDE
  KLONOPIN, CLONAZEPAM
  TAMIFLU, OSELTAMIVIR PHOSPHATE
  VALIUM, DIAZEPAM

** I **

IBA MOLECULAR N AM

* IBA MOLECULAR NORTH AMERICA INC
  AMMONIA N 13, AMMONIA N-13

IBSA INST BIO

* IBSA INSTITUT BIOCHIMIQUE SA
  TIROSINT-SOL, LEVOTHYROXINE SODIUM

IDENTI PHARMS INC

* IDENTI PHARMACEUTICALS INC
  FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

IDT AUSTRALIA LTD

* IDT AUSTRALIA LTD
  TEMOZOLOMIDE, TEMOZOLOMIDE

IGI LABS INC

* IGI LABORATORIES INC
  FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
  FORTAZ, CEFTAZIDIME
  ZANTAC, RANITIDINE HYDROCHLORIDE
  ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
  ZINACEF, CEFUROXIME SODIUM

IMPAX LABS

* IMPAX LABORATORIES INC
  ACARBOSE, ACARBOSE
  ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
  BACLOFEN, BACLOFEN
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CARBIDOPA AND LEVODOPA, CARBIDOPA
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
  DANTROLENE SODIUM, DANTROLENE SODIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* IMPAX LABORATORIES INC
  DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
  DIGOXIN, DIGOXIN
  DIPYRIDAMOLE, DIPYRIDAMOLE
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  FENOFIBRATE (MICRONIZED), FENOFIBRATE
  FENOFIBRATE, FENOFIBRATE
  FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
  METHYLTESTOSTERONE, METHYLTESTOSTERONE
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
  NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
  OMEPRAZOLE, OMEPRAZOLE
  OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
  PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
  PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
  RILUZOLE, RILUZOLE
  RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

IMPAX LABS INC

* IMPAX LABORATORIES INC
  ACITRETIN, ACITRETIN
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  BUDESONIDE, BUDESONIDE
  BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
  DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
  DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
  DOXYCYCLINE, DOXYCYCLINE
  EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
  FENOFIBRIC ACID, CHOLINE FENOFIBRATE
  GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
  HYDROCORTISONE, HYDROCORTISONE
  HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
  LAMOTRIGINE, LAMOTRIGINE
  LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
  METHYLTESTOSTERONE, METHYLTESTOSTERONE
  METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
  MIRTAZAPINE, MIRTAZAPINE
  MORPHINE SULFATE, MORPHINE SULFATE
  NABUMETONE, NABUMETONE
  NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
  PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
  RYTARY, CARBIDOPA
  URSODIOL, URSODIOL

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
  GEMFIBROZIL, GEMFIBROZIL
  MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
  ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

INCYTE CORP

* INCYTE CORP
  JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA

* INDICUS PHARMA LLC
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  LETROZOLE, LETROZOLE
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDIVIOR INC

* INDIVIOR INC
  BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
  SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO REMEDIES

* INDOCO REMEDIES LTD

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INDOCO REMEDIES LTD
ALLOPURINOL, ALLOPURINOL
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
GLIMEPIRIDE, GLIMEPIRIDE

INGENUS PHARMS LLC
* INGENUS PHARMACEUTICALS LLC
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

INGENUS PHARMS NJ
* INGENUS PHARMACEUTICALS NJ LLC
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PROBENECID AND COLCHICINE, COLCHICINE

INJECTALIA
* INJECTALIA SRL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

INNOPHARMA LICENSING
* INNOPHARMA LICENSING LLC
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE

INST BIOCHEM
* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INST BIOCHIMIQUE
* INSTITUTE BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM

INSTITUT BIOCHIMIQUE
* INSTITUT BIOCHIMIQUE SA IBSA
TIROSINT, LEVOTHYROXINE SODIUM

INSYS THERAP
* INSYS THERAPEUTICS INC
SUBSYS, FENTANYL

INTELLIPHARMACEUTICS
* INTELLIPHARMACEUTICS CORP
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM

INTERCEPT PHARMS INC
* INTERCEPT PHARMACEUTICALS INC
OCALIVA, OBETICHOLIC ACID

INTERGEL PHARM
* INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

INTERGEL PHARMS INC
* INTERGEL PHARMACEUTICALS INC
DUTASTERIDE, DUTASTERIDE

INTERPHARMA PRAHA AS
* INTERPHARMA PRAHA AS
ORALTAG, IOHEXOL

INTL MEDICATED
* INTERNATIONAL MEDICATED SYSTEMS LTD
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

INTL MEDICATION SYS
* INTERNATIONAL MEDICATION SYSTEMS LTD
LORAZEPAM, LORAZEPAM

INTL SPECLT CHEMS
* INTERNATIONAL SPECIALTY CHEMICALS AND PHARMACEUTICALS INC
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

INVAGEN PHARMS
* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOLIC ACID, FOLIC ACID
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL, LISINOPRIL
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
OLANZAPINE, OLANZAPINE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

INVATECH PHARMA
* INVATECH PHARMA SOLUTIONS LLC
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

INVENTIA HLTHCARE
* INVENTIA HEALTHCARE PRIVATE LTD
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ILOPERIDONE, ILOPERIDONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN

IPCA LABS LTD
* IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* IPCA LABORATORIES LTD
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

IPR
* IPR PHARMACEUTICALS INC
CRESTOR, ROSUVASTATIN CALCIUM
ZOMIG, ZOLMITRIPTAN

IPSEN INC
* IPSEN BIOPHARMACEUTICALS INC
INCRELEX, MECASERMIN RECOMBINANT

IPSEN PHARMA
* IPSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

IROKO PHARMS
* IROKO PHARMACEUTICALS LLC
INDOCIN, INDOMETHACIN

IROKO PHARMS LLC
* IROKO PHARMACEUTICALS LLC
TIVORBEX, INDOMETHACIN
VIVLODEX, MELOXICAM
ZORVOLEX, DICLOFENAC

IRONWOOD PHARMS INC
* IRONWOOD PHARMACEUTICALS INC
ZURAMPIC, LESINURAD

ISO TEX
* ISO TEX DIAGNOSTICS INC
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX
* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA
* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

IVAX INTL
* IVAX INTERNATIONAL GMBH
SYNRIBO, OMACETAXINE MEPESUCCINATE

IVAX PHARMS
* IVAX PHARMACEUTICALS INC
VALSARTAN, VALSARTAN

IVAX PHARMS INC
* IVAX PHARMACEUTICALS INC
OLANZAPINE, OLANZAPINE

IVAX SUB TEVA PHARMS
* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUMETANIDE, BUMETANIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METHYLDOPA, METHYLDOPA
MISOPROSTOL, MISOPROSTOL
NADOLOL, NADOLOL
OXAPROZIN, OXAPROZIN
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
SIMVASTATIN, SIMVASTATIN
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ****

J AND J CONSUMER INC

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MOTRIN IB, IBUPROFEN (OTC)
PEPCID AC , FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
SINE-AID IB, IBUPROFEN (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TYLENOL , ACETAMINOPHEN (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JACOBUS

* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JAI PHARMA LTD

* JAI PHARMA LTD
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JAI PHARMA LTD
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE,
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
AXERT, ALMOTRIPTAN MALATE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVOKAMET XR, CANAGLIFLOZIN
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
LEVAQUIN, LEVOFLOXACIN
MICRONOR, NORETHINDRONE
MODICON 28, ETHINYL ESTRADIOL
NIZORAL, KETOCONAZOLE
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
PANCREAZE, PANCRELIPASE (AMYLASE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TOPAMAX, TOPIRAMATE
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
VERMOX, MEBENDAZOLE
XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
EDURANT, RILPIVIRINE HYDROCHLORIDE
OLYSIO, SIMEPREVIR SODIUM
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR ETHANOLATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JANSSEN PRODUCTS LP
YONDELIS, TRABECTEDIN

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

JANSSEN RES AND DEV

* JANSSEN RESEARCH AND DEVELOPMENT LLC
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAVELIN PHARMS INC

* JAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUDSIDIARY OF HOSPIRA INC
DYLOJECT, DICLOFENAC SODIUM

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
LUVOX CR, FLUVOXAMINE MALEATE
XYREM, SODIUM OXYBATE

JAZZ PHARMS III

* JAZZ PHARMACEUTICALS III INTERNATIONAL LTD
FAZACLO ODT, CLOZAPINE
* JAZZ PHARMACEUTICALS INTERNATIONAL III
VERSACLOZ, CLOZAPINE

JAZZ PHARMS INC

* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

JAZZ PHARMS INTL

* JAZZ PHARMACEUTICALS INTERNATIONAL LTD
PRIALT, ZICONOTIDE ACETATE

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU HENGRUI MED

* JIANGSU HENGRUI MEDICINE CO LTD
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

* JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)
* JOHNSON AND JOHNSON HEALTHCARE PRODUCTS DIV MCNEIL-PPC INC
NIZORAL A-D, KETOCONAZOLE (OTC)

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
PREDNISONE, PREDNISONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JUBILANT CADISTA PHARMACEUTICALS INC
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

* JUBILANT DRAXIMAGE INC
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
SODIUM IODIDE I 131, SODIUM IODIDE I-131

JUBILANT GENERICS

* JUBILANT GENERICS LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SPIRONOLACTONE, SPIRONOLACTONE
TELMISARTAN, TELMISARTAN
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

JUBILANT HOLLISTRSTR

* JUBILANT HOLLISTERSTIER LLC
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

JUBILANT LIFE

* JUBILANT LIFE SCIENCES LTD
LEVETIRACETAM, LEVETIRACETAM

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ****

GRIFFEN

* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KALEO INC

* KALEO INC
AUVI-Q, EPINEPHRINE
EVZIO, NALOXONE HYDROCHLORIDE

KASTLE THERAPS LLC

* KASTLE THERAPEUTICS LLC
KYNAMRO, MIPOMERSEN SODIUM

KEN LIFESCIENCE

* KEN LIFESCIENCE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** K **

* KEN LIFESCIENCE
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
  AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KING PHARMS

* KING PHARMACEUTICALS INC
  ALTACE, RAMIPRIL
  BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
  BICILLIN C-R, PENICILLIN G BENZATHINE
  BICILLIN L-A, PENICILLIN G BENZATHINE
  CORZIDE, BENDROFLUMETHIAZIDE
  PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
  SILVADENE, SILVER SULFADIAZINE
  SKELAXIN, METAXALONE
  SYNERCID, DALFOPRISTIN
  TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC
  TAPAZOLE, METHIMAZOLE
  TUSSIGON, HOMATROPINE METHYLBROMIDE

KING PHARMS R AND D

* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC
  CYTOMEL, LIOTHYRONINE SODIUM
  LEVOXYL, LEVOTHYROXINE SODIUM **

KNIGHT THERAPS

* KNIGHT THERAPEUTICS USA INC
  IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
  LIVALO, PITAVASTATIN CALCIUM

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KREMERS URBAN DEV

* KREMERS URBAN DEVELOPMENT CO
  RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM

KREMERS URBAN PHARMS

* KREMERS URBAN PHARMACEUTICALS INC
  ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
  BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  GLYCOLAX, POLYETHYLENE GLYCOL 3350
  GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
  ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
  LETROZOLE, LETROZOLE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  MONOKET, ISOSORBIDE MONONITRATE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  OMEPRAZOLE, OMEPRAZOLE
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  TEMOZOLOMIDE, TEMOZOLOMIDE

KRKA TOVARNA ZDRAVIL

* KRKA TOVARNA ZDRAVIL DD NOVO MESTO
  LANSOPRAZOLE , LANSOPRAZOLE

KVK TECH

* KVK TECH INC
  BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** K **

* KVK TECH INC
  BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
  CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
  HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  KALEXATE, SODIUM POLYSTYRENE SULFONATE
  PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
  SANCUSO, GRANISETRON

KYTHERA BIOPHARMS

* KYTHERA BIOPHARMACEUTICALS INC
  KYBELLA, DEOXYCHOLIC ACID

** L **

L PERRIGO CO

* L PERRIGO CO
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
  ELLA, ULIPRISTAL ACETATE

LABORATORIOS SALVAT

* LABORATORIOS SALVAT SA
  OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LABS LICONSA

* LABORATORIOUS LICONSA SA
  LANSOPRAZOLE, LANSOPRAZOLE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
  ACETAZOLAMIDE, ACETAZOLAMIDE
  DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
  DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
  LANIAZID, ISONIAZID
  LANORINAL, ASPIRIN
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
  PRIMIDONE, PRIMIDONE
  PROBALAN, PROBENECID
  SUMATRIPTAN, SUMATRIPTAN
* LANNETT HOLDINGS INC
  BACLOFEN, BACLOFEN
  BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
  CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  DANAZOL, DANAZOL
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  DOXYCYCLINE, DOXYCYCLINE
  FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
  HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
  PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
  RIFAMPIN, RIFAMPIN
  TERBUTALINE SULFATE, TERBUTALINE SULFATE
  URSODIOL, URSODIOL

LANNETT HOLDINGS INC

* LANNETT HOLDINGS INC
  BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
  BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
  CODEINE SULFATE, CODEINE SULFATE
  DIAZEPAM, DIAZEPAM
  DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
  LETROZOLE, LETROZOLE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LANNETT HOLDINGS INC
  LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
  METAXALONE, METAXALONE
  MORPHINE SULFATE, MORPHINE SULFATE
  NEOMYCIN SULFATE, NEOMYCIN SULFATE
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
  TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
  CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
  DEFINITY, PERFLUTREN
  GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
  NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
  TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
  THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
  XENON XE 133, XENON XE-133

LANTHEUS MEDICAL

* LANTHEUS MEDICAL IMAGING INC
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS

* LARKEN LABORATORIES INC
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  OFLOXACIN, OFLOXACIN

LARKEN LABS INC

* LARKEN LABORATORIES INC
  ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
  ALLZITAL, ACETAMINOPHEN
  BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

LAVIPHARM LABS

* LAVIPHARM LABORATORIES INC
  FENTANYL-100, FENTANYL
  FENTANYL-25, FENTANYL
  FENTANYL-50, FENTANYL
  FENTANYL-75, FENTANYL

LEADING PHARMA LLC

* LEADING PHARMA LLC
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  FOLIC ACID, FOLIC ACID
  FUROSEMIDE, FUROSEMIDE
  GLYCOPYRROLATE, GLYCOPYRROLATE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
  LORAZEPAM, LORAZEPAM

LEHIGH VALLEY

* LEHIGH VALLEY TECHNOLOGIES INC
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

LEO LABS

* LEO LABORATORIES LTD
  PICATO, INGENOL MEBUTATE

LEO PHARMA AS

* LEO PHARMA AS
  DOVONEX, CALCIPOTRIENE
  ENSTILAR, BETAMETHASONE DIPROPIONATE
  PROTOPIC, TACROLIMUS
  TACLONEX, BETAMETHASONE DIPROPIONATE

LG LIFE

* LG LIFE SCIENCES LTD
  VALTROPIN, SOMATROPIN RECOMBINANT

LG LIFE SCIENCES

* LG LIFE SCIENCES LTD

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LG LIFE SCIENCES LTD
  FACTIVE, GEMIFLOXACIN MESYLATE

LIEBEL-FLARSHEIM

* LIEBEL-FLARSHEIM CO LLC
  CONRAY 30, IOTHALAMATE MEGLUMINE
  CONRAY 43, IOTHALAMATE MEGLUMINE
  CONRAY, IOTHALAMATE MEGLUMINE
  CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
  MD-76R, DIATRIZOATE MEGLUMINE
  MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
  OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
  OPTIMARK, GADOVERSETAMIDE
  OPTIRAY 240, IOVERSOL
  OPTIRAY 300, IOVERSOL
  OPTIRAY 320, IOVERSOL
  OPTIRAY 350, IOVERSOL
  SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFESTAR PHARMA

* LIFESTAR PHARMA LLC
  RISPERIDONE, RISPERIDONE

LNK

* LNK INTERNATIONAL INC
  DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
  IBUPROFEN, IBUPROFEN (OTC)
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
  ANTHELIOS 20, AVOBENZONE (OTC)
  ANTHELIOS 40, AVOBENZONE (OTC)
  ANTHELIOS SX, AVOBENZONE (OTC)
  CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
  LEVETIRACETAM, LEVETIRACETAM
  LEVONORGESTREL, LEVONORGESTREL
  LEVONORGESTREL, LEVONORGESTREL (OTC)

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
  ACETYLCYSTEINE, ACETYLCYSTEINE
  ADENOSINE, ADENOSINE
  AMINOCAPROIC ACID, AMINOCAPROIC ACID
  AMINOPHYLLINE, AMINOPHYLLINE
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
  BROMFENAC SODIUM, BROMFENAC SODIUM
  BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  CAFFEINE CITRATE, CAFFEINE CITRATE
  CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  CYANOCOBALAMIN, CYANOCOBALAMIN
  CYCLOSPORINE, CYCLOSPORINE
  DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  DEXFERRUM, IRON DEXTRAN
  DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
  DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  DROPERIDOL, DROPERIDOL
  ESTRADIOL VALERATE, ESTRADIOL VALERATE
  ETOMIDATE, ETOMIDATE
  FOMEPIZOLE, FOMEPIZOLE
  FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
  GLYCOPYRROLATE, GLYCOPYRROLATE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  IBUTILIDE FUMARATE, IBUTILIDE FUMARATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LUITPOLD PHARMACEUTICALS INC
  LATANOPROST, LATANOPROST
  LEVETIRACETAM, LEVETIRACETAM
  LEVOCARNITINE, LEVOCARNITINE
  LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
  MANNITOL 25%, MANNITOL
  METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
  METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
  NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
  NITROGLYCERIN, NITROGLYCERIN
  OLANZAPINE, OLANZAPINE
  ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
  PHENYTOIN SODIUM, PHENYTOIN SODIUM
  PROGESTERONE, PROGESTERONE
  TRANEXAMIC ACID, TRANEXAMIC ACID
  TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
  TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
  VENOFER, IRON SUCROSE
  ZIDOVUDINE, ZIDOVUDINE

LUITPOLD PHARMS INC

* LUITPOLD PHARMACEUTICALS INC
  BUSULFAN, BUSULFAN
  DACTINOMYCIN, DACTINOMYCIN
  ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
  GANCICLOVIR, GANCICLOVIR SODIUM
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  INJECTAFER, FERRIC CARBOXYMALTOSE
  LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
  NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC
  ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK LLC

* LUNDBECK LLC
  CARNEXIV, CARBAMAZEPINE
  ONFI, CLOBAZAM
  SABRIL, VIGABATRIN

LUNDBECK NA LTD

* LUNDBECK NA LTD
  NORTHERA, DROXIDOPA

LUPIN

* LUPIN LTD
  AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  CARVEDILOL, CARVEDILOL
  CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
  CEFDINIR, CEFDINIR
  CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
  CEFPROZIL, CEFPROZIL
  CEFTRIAXONE, CEFTRIAXONE SODIUM
  CEFUROXIME AXETIL, CEFUROXIME AXETIL
  CEPHALEXIN, CEPHALEXIN
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
  LEVETIRACETAM, LEVETIRACETAM
  LEVOFLOXACIN, LEVOFLOXACIN
  LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LISINOPRIL, LISINOPRIL
  LOVASTATIN, LOVASTATIN
  QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
  RAMIPRIL, RAMIPRIL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LUPIN LTD
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
ANTARA (MICRONIZED), FENOFIBRATE
DESOXIMETASONE, DESOXIMETASONE
MIBELAS 24 FE, ETHINYL ESTRADIOL

LUPIN LTD

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
* LUPIN LTD
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
AMABELZ, ESTRADIOL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARMODAFINIL, ARMODAFINIL
AZITHROMYCIN, AZITHROMYCIN
BEKYREE, DESOGESTREL
BIMATOPROST, BIMATOPROST
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
CALCIUM ACETATE, CALCIUM ACETATE
CELECOXIB, CELECOXIB
CIPROFLOXACIN, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
DAYSEE, ETHINYL ESTRADIOL
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENSKYCE, DESOGESTREL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FAMOTIDINE, FAMOTIDINE
FAYOSIM, ETHINYL ESTRADIOL
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FYAVOLV, ETHINYL ESTRADIOL
GATIFLOXACIN, GATIFLOXACIN
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
JENCYCLA, NORETHINDRONE
KAITLIB FE, ETHINYL ESTRADIOL
KURVELO, ETHINYL ESTRADIOL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LUPIN LTD
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NIACIN, NIACIN
NIKKI, DROSPIRENONE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
RIFABUTIN, RIFABUTIN
SUPRAX, CEFIXIME
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VYFEMLA, ETHINYL ESTRADIOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS

* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLORATADINE, DESLORATADINE
MELOXICAM, MELOXICAM
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIFAMPIN, RIFAMPIN
SUPRAX, CEFIXIME
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYMOL MEDCL

* LYMOL MEDICAL CORP
SCLEROSOL, TALC
TALC, TALC

LYNE

* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOCARNITINE, LEVOCARNITINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO

* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* L PERRIGO CO
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TAB-PROFEN, IBUPROFEN (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

** M **

MA GENERAL HOSP
* MASSACHUSETTS GENERAL HOSP
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD
* MACLEODS PHARMACEUTICALS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CELECOXIB, CELECOXIB
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

MALLINCKRODT
* MALLINCKRODT CHEMICAL INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
* MALLINCKRODT INC
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MALLINCKRODT INC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

MALLINCKRODT ARD

* MALLINCKRODT ARD INC
H.P. ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP

* MALLINCKRODT HOSPITAL PRODUCTS IP LTD
INOMAX, NITRIC OXIDE
UVADEX, METHOXSALEN

MALLINCKRODT INC

* MALLINCKRODT INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
GABLOFEN, BACLOFEN
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
ROXICODONE, OXYCODONE HYDROCHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
XARTEMIS XR, ACETAMINOPHEN

MALLINCKRODT IP

* MALLINCKRODT IP
OFIRMEV, ACETAMINOPHEN

MALLINCKRODT LLC

* MALLINCKRODT LLC
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

MALLINKRODT NUCLEAR

* MALLINCKRODT NUCLEAR MEDICINE LLC
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

MANNKIND

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MANNKIND CORP
  AFREZZA, INSULIN RECOMBINANT HUMAN

MARKSANS PHARMA

* MARKSANS PHARMA LTD
  GABAPENTIN, GABAPENTIN
  IBUPROFEN, IBUPROFEN
  IBUPROFEN, IBUPROFEN (OTC)
  LORATADINE, LORATADINE (OTC)
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
  NAPROXEN, NAPROXEN
  PARICALCITOL, PARICALCITOL

MARNEL PHARMS

* MARNEL PHARMACEUTICALS LLC
  CROTAN, CROTAMITON

MATRIX LABS LTD

* MATRIX LABORATORIES LTD
  NIFEDIPINE, NIFEDIPINE
  STAVUDINE, STAVUDINE

MAYER LABS INC

* MAYER LABORATORIES INC
  TODAY, NONOXYNOL-9 (OTC)

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
  DORYX MPC, DOXYCYCLINE HYCLATE
  DORYX, DOXYCYCLINE HYCLATE
  ERYC, ERYTHROMYCIN
* MAYNE PHARMA LLC
  BUDESONIDE, BUDESONIDE
  CAMILA, NORETHINDRONE
  CARBIDOPA AND LEVODOPA, CARBIDOPA
  CLARITHROMYCIN, CLARITHROMYCIN
  CLONIDINE, CLONIDINE
  CLOZAPINE, CLOZAPINE
  CYCLOSPORINE, CYCLOSPORINE
  DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
  DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
  DIAZEPAM, DIAZEPAM
  DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
  DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
  ERRIN, NORETHINDRONE
  ESTAZOLAM, ESTAZOLAM
  ESTRADIOL, ESTRADIOL
  LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  LEVORA 0.15/30-28, ETHINYL ESTRADIOL
  LOW-OGESTREL-28, ETHINYL ESTRADIOL
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
  MICROGESTIN 1/20, ETHINYL ESTRADIOL
  MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
  MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
  NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
  TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
  TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
  TRIMETHOPRIM, TRIMETHOPRIM
  TRIVORA-28, ETHINYL ESTRADIOL
  ZOVIA 1/35E-28, ETHINYL ESTRADIOL

MAYNE PHARMA INC

* MAYNE PHARMA INC
  BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
  BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN
  HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MAYNE PHARMA INC
  LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
  METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  NYSTATIN, NYSTATIN
  OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
  OXYCODONE AND ASPIRIN, ASPIRIN
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

MCNEIL

* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
  IBUPROFEN, IBUPROFEN (OTC)

MCNEIL CONS

* MCNEIL CONSUMER HEALTHCARE
  SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

MCPRF

* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
  AMMONIA N 13, AMMONIA N-13
  CHOLINE C-11, CHOLINE C-11
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MEDA PHARMS

* MEDA PHARMACEUTICALS
  AEROSPAN HFA, FLUNISOLIDE
  DYMISTA, AZELASTINE HYDROCHLORIDE
  EDLUAR, ZOLPIDEM TARTRATE
* MEDA PHARMACEUTICALS INC
  ANADROL-50, OXYMETHOLONE
  ASTELIN, AZELASTINE HYDROCHLORIDE
  AVC, SULFANILAMIDE
  BUTISOL SODIUM, BUTABARBITAL SODIUM
  CESAMET, NABILONE
  COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
  CORTIFOAM, HYDROCORTISONE ACETATE
  DEMADEX, TORSEMIDE
  DEPEN, PENICILLAMINE
  DIPENTUM, OLSALAZINE SODIUM
  ELESTRIN, ESTRADIOL
  EPIFOAM, HYDROCORTISONE ACETATE
  FELBATOL, FELBAMATE
  GASTROCROM, CROMOLYN SODIUM
  MUSE, ALPROSTADIL
  OPTIVAR, AZELASTINE HYDROCHLORIDE
  PROCTOFOAM HC, HYDROCORTISONE ACETATE
  ROWASA, MESALAMINE
  SFROWASA, MESALAMINE
  TRILYTE, POLYETHYLENE GLYCOL 3350
* MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC
  ASTEPRO, AZELASTINE HYDROCHLORIDE
  SOMA, CARISOPRODOL

MEDAC PHARMA INC

* MEDAC PHARMA INC
  RASUVO, METHOTREXATE

MEDEFIL INC

* MEDEFIL INC
  SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

MEDICINES360

* MEDICINES360
  LILETTA, LEVONORGESTREL

MEDICIS

* MEDICIS PHARMACEUTICAL CORP
  ALDARA, IMIQUIMOD
  AMMONUL, SODIUM BENZOATE
  CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  LOPROX, CICLOPIROX

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MEDICIS PHARMACEUTICAL CORP
  LUZU, LULICONAZOLE
  METROGEL-VAGINAL, METRONIDAZOLE
  MINITRAN, NITROGLYCERIN
  SOLODYN, MINOCYCLINE HYDROCHLORIDE
  SYNACORT, HYDROCORTISONE
  VANOS, FLUOCINONIDE
  ZIANA, CLINDAMYCIN PHOSPHATE
  ZYCLARA, IMIQUIMOD

MEDICURE

* MEDICURE INTERNATIONAL INC
  AGGRASTAT, TIROFIBAN HYDROCHLORIDE

MEDIGENE AG

* MEDIGENE AG
  VEREGEN, SINECATECHINS

MEDIMETRIKS PHARMS

* MEDIMETRIKS PHARMACEUTICALS INC
  LOPROX, CICLOPIROX
  NEO-SYNALAR, FLUOCINOLONE ACETONIDE
  SYNALAR, FLUOCINOLONE ACETONIDE

MEDTECH PRODUCTS

* MEDTECH PRODUCTS INC
  MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
  MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
  MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
  MONISTAT 3, MICONAZOLE NITRATE
  MONISTAT 3, MICONAZOLE NITRATE (OTC)
  MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
  MONISTAT 7, MICONAZOLE NITRATE (OTC)
  NIX, PERMETHRIN (OTC)
  TAGAMET HB, CIMETIDINE (OTC)

MEM SLOAN-KETTERING

* MEMORIAL SLOAN-KETTERING CANCER CENTER
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK

* MERCK AND CO INC
  CANCIDAS, CASPOFUNGIN ACETATE
  EMEND, APREPITANT
  FOSAMAX PLUS D, ALENDRONATE SODIUM
  MAXALT, RIZATRIPTAN BENZOATE
  MAXALT-MLT, RIZATRIPTAN BENZOATE
  PRIMAXIN, CILASTATIN SODIUM
  PROSCAR, FINASTERIDE
  SINGULAIR, MONTELUKAST SODIUM
  ZOLINZA, VORINOSTAT
* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
  PRINIVIL, LISINOPRIL
  PROPECIA, FINASTERIDE
  SINGULAIR, MONTELUKAST SODIUM
  TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
  ZOCOR, SIMVASTATIN

MERCK AND CO INC

* MERCK AND CO INC
  EMEND, FOSAPREPITANT DIMEGLUMINE
  FOSAMAX, ALENDRONATE SODIUM

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
  ASMANEX HFA, MOMETASONE FUROATE
  ASMANEX TWISTHALER, MOMETASONE FUROATE
  BELSOMRA, SUVOREXANT
  CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
  CLARINEX D 24 HOUR, DESLORATADINE
  CLARINEX, DESLORATADINE
  CLARINEX-D 12 HOUR, DESLORATADINE
  COZAAR, LOSARTAN POTASSIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MERCK SHARP AND DOHME CORP
  CRIXIVAN, INDINAVIR SULFATE
  DIPROLENE AF, BETAMETHASONE DIPROPIONATE
  DIPROLENE, BETAMETHASONE DIPROPIONATE
  DULERA, FORMOTEROL FUMARATE
  ELOCON, MOMETASONE FUROATE
  GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
  HYZAAR, HYDROCHLOROTHIAZIDE
  INVANZ, ERTAPENEM SODIUM
  ISENTRESS, RALTEGRAVIR POTASSIUM
  JANUMET XR, METFORMIN HYDROCHLORIDE
  JANUMET, METFORMIN HYDROCHLORIDE
  JANUVIA, SITAGLIPTIN PHOSPHATE
  LOTRISONE, BETAMETHASONE DIPROPIONATE
  NASONEX, MOMETASONE FUROATE
  NITRO-DUR, NITROGLYCERIN
  NOXAFIL, POSACONAZOLE
  REBETOL, RIBAVIRIN
  SINEMET CR, CARBIDOPA
  SINEMET, CARBIDOPA
  STROMECTOL, IVERMECTIN
  TEMODAR, TEMOZOLOMIDE
  ZEPATIER, ELBASVIR

MERIDIAN MEDCL
* MERIDIAN MEDICAL TECHNOLOGIES INC
  DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN
* MERIDIAN MEDICAL TECHNOLOGIES INC
  ATROPEN, ATROPINE
  MORPHINE SULFATE, MORPHINE SULFATE
  PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

MERRIMACK PHARMS
* MERRIMACK PHARMACEUTICALS INC
  ONIVYDE, IRINOTECAN HYDROCHLORIDE

MERRO PHARM
* MERRO PHARMACEUTICAL CO LTD
  IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS
* MERZ PHARMACEUTICALS LLC
  CUVPOSA, GLYCOPYRROLATE

METHAPHARM
* METHAPHARM INC
  LEVETIRACETAM, LEVETIRACETAM
  PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS
* METUCHEN PHARMACEUTICALS LLC
  STENDRA, AVANAFIL

MICRO LABS LTD
* MICRO LABS LTD
  MEFENAMIC ACID, MEFENAMIC ACID
  NEVIRAPINE, NEVIRAPINE
  SIMVASTATIN, SIMVASTATIN

MICRO LABS LTD INDIA
* MICRO LABS LTD INDIA
  AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
  CROMOLYN SODIUM, CROMOLYN SODIUM
  GLIMEPIRIDE, GLIMEPIRIDE
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDATECH PHARMA US
* MIDATECH PHARMA US INC
  ORAVIG, MICONAZOLE
  SOLTAMOX, TAMOXIFEN CITRATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MIDATECH PHARMA US INC
  ZUPLENZ, ONDANSETRON

MIDWEST MEDCL

* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKAH PHARMA

* MIKAH PHARMA LLC
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
  TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

MIKAH PHARMA LLC

* MIKAH PHARMA LLC
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

MIKART

* MIKART INC
  ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
  BENZONATATE, BENZONATATE
  BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
  BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
  BUTAPAP, ACETAMINOPHEN
  CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
  CHLORZOXAZONE, CHLORZOXAZONE
  DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
  DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
  ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
  ETHOSUXIMIDE, ETHOSUXIMIDE
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  ISONIAZID, ISONIAZID
  MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
  METHAZOLAMIDE, METHAZOLAMIDE
  OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
  PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
  TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MIKART INC

* MIKART INC
  BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
  CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
  CHLORZOXAZONE, CHLORZOXAZONE

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC
  NINLARO, IXAZOMIB CITRATE
  VELCADE, BORTEZOMIB

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MISSION PHARMA

* MISSION PHARMACAL CO
  BINOSTO, ALENDRONATE SODIUM
  LITHOSTAT, ACETOHYDROXAMIC ACID
  PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  TEXACORT, HYDROCORTISONE
  THIOLA, TIOPRONIN
  TINDAMAX, TINIDAZOLE
  UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

* MISSION PHARMACAL CO
  CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
  FLOWTUSS, GUAIFENESIN
  HYCOFENIX, GUAIFENESIN
  POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MIST PHARMS LLC
* MIST PHARMACEUTICALS LLC
NITROMIST, NITROGLYCERIN

MOBERG PHARMA NORTH
* MOBERG PHARMA NORTH AMERICA LLC
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

MOBIUS THERAP
* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH
* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS
* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTISPORIN, HYDROCORTISONE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC
* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MORTON GROVE
* MORTON GROVE PHARMACEUTICALS INC
LACTULOSE, LACTULOSE

MORTON GROVE PHARMS
* MORTON GROVE PHARMACEUTICALS INC
GENERLAC, LACTULOSE

MSD INTL
* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH
* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MSD MERCK CO
* MERCK SHARP AND DOHME CORP A SUBSIDIARY OF MERCK AND CO INC
EMEND, APREPITANT

MSN LABS PVT LTD
* MSN LABORATORIES PRIVATE LTD
LACOSAMIDE, LACOSAMIDE

MURTY PHARMS
* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVZAT ILAC
* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

MUTUAL PHARM
* MUTUAL PHARMACEUTICAL CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOXIDIL, MINOXIDIL
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

MYLAN

* MYLAN LABORATORIES INC
  ACYCLOVIR, ACYCLOVIR
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
  CAPTOPRIL, CAPTOPRIL
  ETODOLAC, ETODOLAC
  OLANZAPINE, OLANZAPINE
  TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
* MYLAN PHARMACEUTICALS
  FENOFIBRATE, FENOFIBRATE
  METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  TRANEXAMIC ACID, TRANEXAMIC ACID
* MYLAN PHARMACEUTICALS INC
  ACARBOSE, ACARBOSE
  ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
  ACYCLOVIR, ACYCLOVIR
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
  ALLOPURINOL, ALLOPURINOL
  ALPRAZOLAM, ALPRAZOLAM
  AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
  AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  ANASTROZOLE, ANASTROZOLE
  ATENOLOL AND CHLORTHALIDONE, ATENOLOL
  ATENOLOL, ATENOLOL
  AVITA, TRETINOIN
  AZATHIOPRINE, AZATHIOPRINE
  AZITHROMYCIN, AZITHROMYCIN
  BACLOFEN, BACLOFEN
  BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
  BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
  BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
  BICALUTAMIDE, BICALUTAMIDE
  BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
  BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
  BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
  BUDESONIDE, BUDESONIDE
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
  BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
  CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
  CARBIDOPA AND LEVODOPA, CARBIDOPA
  CARVEDILOL, CARVEDILOL
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
  CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
  CHLOROTHIAZIDE, CHLOROTHIAZIDE
  CHLORPROPAMIDE, CHLORPROPAMIDE
  CHLORTHALIDONE, CHLORTHALIDONE
  CILOSTAZOL, CILOSTAZOL
  CIMETIDINE, CIMETIDINE
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  CLARITHROMYCIN, CLARITHROMYCIN
  CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
  CLONAZEPAM, CLONAZEPAM
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
  CLORPRES, CHLORTHALIDONE
  CLOZAPINE, CLOZAPINE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETOPOSIDE, ETOPOSIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MELOXICAM, MELOXICAM
MENTAX, BUTENAFINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NISOLDIPINE, NISOLDIPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIROXICAM, PIROXICAM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
STAVUDINE, STAVUDINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TACROLIMUS, TACROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
  THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
  THIOTHIXENE, THIOTHIXENE
  TIMOLOL MALEATE, TIMOLOL MALEATE
  TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
  TOLMETIN SODIUM, TOLMETIN SODIUM
  TOPIRAMATE, TOPIRAMATE
  TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  TRANDOLAPRIL, TRANDOLAPRIL
  TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
  URSODIOL, URSODIOL
  VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
  WARFARIN SODIUM, WARFARIN SODIUM
  ZALEPLON, ZALEPLON
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
  ZONISAMIDE, ZONISAMIDE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
  SULFAMYLON, MAFENIDE ACETATE
* MYLAN INSTITUTIONAL LLC
  ACETYLCYSTEINE, ACETYLCYSTEINE
  ALOPRIM, ALLOPURINOL SODIUM
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  ARGATROBAN, ARGATROBAN
  AZACITIDINE, AZACITIDINE
  CARBOPLATIN, CARBOPLATIN
  CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
  CIDOFOVIR, CIDOFOVIR
  COSYNTROPIN, COSYNTROPIN
  DANTROLENE SODIUM, DANTROLENE SODIUM
  DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
  DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
  DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
  DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
  DURACLON, CLONIDINE HYDROCHLORIDE
  ENLON, EDROPHONIUM CHLORIDE
  ENLON-PLUS, ATROPINE SULFATE
  ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
  ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
  FOMEPIZOLE, FOMEPIZOLE
  HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
  ISOSULFAN BLUE, ISOSULFAN BLUE
  KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
  MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
  MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
  MESNA, MESNA
  METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
  METHOCARBAMOL, METHOCARBAMOL
  MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
  NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
  NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
  OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
  PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
  PENTOSTATIN, PENTOSTATIN
  PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
  RIMSO-50, DIMETHYL SULFOXIDE
  ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
  SCANLUX-300, IOPAMIDOL
  SCANLUX-370, IOPAMIDOL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN INSTITUTIONAL LLC
SOTRADECOL, SODIUM TETRADECYL SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM
CARBAMAZEPINE, CARBAMAZEPINE
MIACALCIN, CALCITONIN SALMON
PIROXICAM, PIROXICAM
SUCRALFATE, SUCRALFATE
THEOPHYLLINE, THEOPHYLLINE

MYLAN LABS

* MYLAN LABORATORIES LTD
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
NEVIRAPINE, NEVIRAPINE

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
ADENOSINE, ADENOSINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CYTARABINE, CYTARABINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MESNA, MESNA
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN LABORATORIES LTD
  VALSARTAN, VALSARTAN
  VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
  VECURONIUM BROMIDE, VECURONIUM BROMIDE
  VINORELBINE TARTRATE, VINORELBINE TARTRATE
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC
  ABACAVIR SULFATE, ABACAVIR SULFATE
  ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
  ACITRETIN, ACITRETIN
  ACYCLOVIR, ACYCLOVIR
  ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
  ALPRAZOLAM, ALPRAZOLAM
  AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  AMNESTEEM, ISOTRETINOIN
  ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
  ARMODAFINIL, ARMODAFINIL
  ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
  ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
  AVITA, TRETINOIN
  BACLOFEN, BACLOFEN
  BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  CABERGOLINE, CABERGOLINE
  CAPECITABINE, CAPECITABINE
  CELECOXIB, CELECOXIB
  CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
  CILOSTAZOL, CILOSTAZOL
  CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
  CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
  CLONAZEPAM, CLONAZEPAM
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  CLOZAPINE, CLOZAPINE
  CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
  CYTARABINE, CYTARABINE
  DESLORATADINE, DESLORATADINE
  DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
  DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
  DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
  DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
  DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DIDANOSINE, DIDANOSINE
  DIGOXIN, DIGOXIN
  DISULFIRAM, DISULFIRAM
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  DOXYCYCLINE, DOXYCYCLINE
  DUTASTERIDE, DUTASTERIDE
  EFAVIRENZ, EFAVIRENZ
  ENTACAPONE, ENTACAPONE
  EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
  ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
  ESZOPICLONE, ESZOPICLONE
  FENOFIBRATE (MICRONIZED), FENOFIBRATE
  FENOFIBRATE, FENOFIBRATE
  FENOFIBRIC ACID, CHOLINE FENOFIBRATE
  FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISRADIPINE, ISRADIPINE
ITRACONAZOLE, ITRACONAZOLE
LACOSAMIDE, LACOSAMIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
REPAGLINIDE, REPAGLINIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
  RILUZOLE, RILUZOLE
  RISEDRONATE SODIUM, RISEDRONATE SODIUM
  RISPERIDONE, RISPERIDONE
  RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
  RUFINAMIDE, RUFINAMIDE
  SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
  SILDENAFIL CITRATE, SILDENAFIL CITRATE
  SIMVASTATIN, SIMVASTATIN
  TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
  TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  TELMISARTAN, TELMISARTAN
  TEMOZOLOMIDE, TEMOZOLOMIDE
  TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
  TOLAZAMIDE, TOLAZAMIDE
  TOLBUTAMIDE, TOLBUTAMIDE
  TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
  TRIAZOLAM, TRIAZOLAM
  VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  VORICONAZOLE, VORICONAZOLE
  ZIDOVUDINE, ZIDOVUDINE
  ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
  ZOLMITRIPTAN, ZOLMITRIPTAN
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
  ZONISAMIDE, ZONISAMIDE
* MYLAN PHARMACEUTICALS INC.
  FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
  NIZATIDINE, NIZATIDINE
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECLT

* MYLAN SPECIALTY LP
  ACCUNEB, ALBUTEROL SULFATE
  CROMOLYN SODIUM, CROMOLYN SODIUM
  EPIPEN JR., EPINEPHRINE
  EPIPEN, EPINEPHRINE
  IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
  LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
  PERFOROMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES
  XULANE, ETHINYL ESTRADIOL
* MYLAN TECHNOLOGIES INC
  CLONIDINE, CLONIDINE
  ESTRADIOL, ESTRADIOL
  FENTANYL-100, FENTANYL
  FENTANYL-12, FENTANYL
  FENTANYL-25, FENTANYL
  FENTANYL-37, FENTANYL
  FENTANYL-50, FENTANYL
  FENTANYL-62, FENTANYL
  FENTANYL-75, FENTANYL
  FENTANYL-87, FENTANYL
  LIDOCAINE, LIDOCAINE
  NITROGLYCERIN, NITROGLYCERIN

MYLAN TEORANTA

* MYLAN TEORANTA
  LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM

** N **

NAMIGEN LLC

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NAMIGEN LLC
  SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

NANG KUANG PHARM CO

* NANG KUANG PHARMACEUTICAL CO LTD
  LINEZOLID, LINEZOLID

NANJING KING-FRIEND

* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
  ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
  ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
  CARBOPLATIN, CARBOPLATIN

NAPO PHARMS INC

* NAPO PHARMACEUTICALS INC
  FULYZAQ, CROFELEMER

NATCO PHARMA

* NATCO PHARMA LTD
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
  CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
  ALPRAZOLAM, ALPRAZOLAM
  ANASTROZOLE, ANASTROZOLE
  ARMODAFINIL, ARMODAFINIL
  CARISOPRODOL, CARISOPRODOL
  CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
  GLYCOPYRROLATE, GLYCOPYRROLATE
  LANSOPRAZOLE, LANSOPRAZOLE
  LANSOPRAZOLE, LANSOPRAZOLE (OTC)
  LETROZOLE, LETROZOLE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
  RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAVIDEA BIOPHARMS

* NAVIDEA BIOPHARMACEUTICALS INC
  LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT

NAVINTA LLC

* NAVINTA LLC
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  FAMOTIDINE, FAMOTIDINE
  FOMEPIZOLE, FOMEPIZOLE
  HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
  RIBAVIRIN, RIBAVIRIN
  ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
  SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

NCM USA BRONX LLC

* NCM USA BRONX LLC
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOS THERAP INC

* NEOS THERAPEUTICS INC
  HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS

* NEOS THERAPEUTICS
  ADZENYS XR-ODT, AMPHETAMINE

NEPHRON

* NEPHRON CORP
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
  ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
  ALBUTEROL SULFATE, ALBUTEROL SULFATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

NESHER PHARMS
* NESHER PHARMACEUTICALS USA LLC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

NEW HAVEN PHARMS
* NEW HAVEN PHARMACEUTICALS INC
DURLAZA, ASPIRIN

NEW RIVER
* NEW RIVER PHARMACEUTICALS INC
PROFERDEX, IRON DEXTRAN

NEWGEN PHARMS LLC
* NEWGEN PHARMACEUTICALS LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

NEXGEN PHARMA
* NEXGEN PHARMA INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC
* NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

NEXTWAVE PHARMS
* NEXTWAVE PHARMACEUTICALS INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NIAGARA PHARMS
* NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NODEN PHARMA
* NODEN PHARMA DAC
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TEKTURNA, ALISKIREN HEMIFUMARATE

NORTEC DEV ASSOC
* NORTEC DEVELOPMENT ASSOC INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTH CREEK PHARMS
* NORTH CREEK PHARMACEUTICALS LLC
DAPSONE, DAPSONE
TRANEXAMIC ACID, TRANEXAMIC ACID

NORTHSTAR HLTHCARE
* NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

NOSTRUM LABS INC
* NOSTRUM LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
CALCIUM ACETATE, CALCIUM ACETATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
DAPSONE, DAPSONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NOSTRUM LABORATORIES INC
  ELIXOPHYLLIN, THEOPHYLLINE
  LEVETIRACETAM, LEVETIRACETAM
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  NITROFURANTOIN, NITROFURANTOIN
  PINDOLOL, PINDOLOL
  PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  THEOCHRON, THEOPHYLLINE
  VALPROIC ACID, VALPROIC ACID

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NOVA LABS LTD

* NOVA LABORATORIES LTD
  PURIXAN, MERCAPTOPURINE

NOVARTIS

* NOVARTIS CONSUMER HEALTH INC
  LAMISIL AT, TERBINAFINE (OTC)
  LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
  LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
  THRIVE, NICOTINE POLACRILEX (OTC)
  VAGISTAT-1, TIOCONAZOLE (OTC)
* NOVARTIS PHARMACEUTICALS CORP
  AFINITOR, EVEROLIMUS
  ARCAPTA NEOHALER, INDACATEROL MALEATE
  COARTEM, ARTEMETHER
  DESFERAL, DEFEROXAMINE MESYLATE
  DIOVAN HCT, HYDROCHLOROTHIAZIDE
  DIOVAN, VALSARTAN
  ESTRADERM, ESTRADIOL
  EXELON, RIVASTIGMINE
  EXELON, RIVASTIGMINE TARTRATE
  EXFORGE HCT, AMLODIPINE BESYLATE
  EXFORGE, AMLODIPINE BESYLATE
  EXJADE, DEFERASIROX
  FAMVIR, FAMCICLOVIR
  FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
  FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
  FORADIL, FORMOTEROL FUMARATE
  GILENYA, FINGOLIMOD
  GLEEVEC, IMATINIB MESYLATE
  HYDERGINE, ERGOLOID MESYLATES
  LAMISIL, TERBINAFINE HYDROCHLORIDE
  LAMPRENE, CLOFAZIMINE
  LESCOL XL, FLUVASTATIN SODIUM
  LESCOL, FLUVASTATIN SODIUM
  LOPRESSOR, METOPROLOL TARTRATE
  LOTREL, AMLODIPINE BESYLATE
  MYFORTIC, MYCOPHENOLIC ACID
  NEORAL, CYCLOSPORINE
  OCUPRESS, CARTEOLOL HYDROCHLORIDE
  RECLAST, ZOLEDRONIC ACID
  REGITINE, PHENTOLAMINE MESYLATE
  RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
  RITALIN, METHYLPHENIDATE HYDROCHLORIDE
  RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
  SANDIMMUNE, CYCLOSPORINE
  SANDOSTATIN LAR, OCTREOTIDE ACETATE
  SANDOSTATIN, OCTREOTIDE ACETATE
  SIGNIFOR, PASIREOTIDE DIASPARTATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
STARLIX, NATEGLINIDE
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TOBI PODHALER, TOBRAMYCIN
TRILEPTAL, OXCARBAZEPINE
TYZEKA, TELBIVUDINE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
ZOMETA, ZOLEDRONIC ACID
ZORTRESS, EVEROLIMUS

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE
TOBI, TOBRAMYCIN

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
ARRANON, NELARABINE
AZOPT, BRINZOLAMIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DUREZOL, DIFLUPREDNATE
EMADINE, EMEDASTINE DIFUMARATE
ENTRESTO, SACUBITRIL
FARYDAK, PANOBINOSTAT LACTATE
FLAREX, FLUOROMETHOLONE ACETATE
FLUORESCITE, FLUORESCEIN SODIUM
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
ILEVRO, NEPAFENAC
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
JADENU, DEFERASIROX
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MYDRIACYL, TROPICAMIDE
NEVANAC, NEPAFENAC
ODOMZO, SONIDEGIB PHOSPHATE
OMNIPRED, PREDNISOLONE ACETATE
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PROMACTA, ELTROMBOPAG OLAMINE
SEEBRI, GLYCOPYRROLATE
SIGNIFOR LAR, PASIREOTIDE PAMOATE
SIMBRINZA, BRIMONIDINE TARTRATE
TAFINLAR, DABRAFENIB MESYLATE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TOBRADEX ST, DEXAMETHASONE
TOBRADEX, DEXAMETHASONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NOVARTIS PHARMACEUTICALS CORP
  TOBREX, TOBRAMYCIN
  TRAVATAN Z, TRAVOPROST
  TRIESENCE, TRIAMCINOLONE ACETONIDE
  TYKERB, LAPATINIB DITOSYLATE
  UTIBRON, GLYCOPYRROLATE
  VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
  VOTRIENT, PAZOPANIB HYDROCHLORIDE
  XTORO, FINAFLOXACIN
  ZOFRAN ODT, ONDANSETRON
  ZOFRAN, ONDANSETRON HYDROCHLORIDE
  ZYKADIA, CERITINIB

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
  NORETHINDRONE, NORETHINDRONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
  ACETAZOLAMIDE, ACETAZOLAMIDE
  DASETTA 1/35, ETHINYL ESTRADIOL
  DASETTA 7/7/7, ETHINYL ESTRADIOL
  DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
  ELINEST, ETHINYL ESTRADIOL
  FALMINA, ETHINYL ESTRADIOL
  HER STYLE, LEVONORGESTREL (OTC)
  LARIN 1.5/30, ETHINYL ESTRADIOL
  LARIN 1/20, ETHINYL ESTRADIOL
  LARIN 24 FE, ETHINYL ESTRADIOL
  LARIN FE 1.5/30, ETHINYL ESTRADIOL
  LARIN FE 1/20, ETHINYL ESTRADIOL
  LERIBANE, ETHINYL ESTRADIOL
  LEVONEST, ETHINYL ESTRADIOL
  MELAMISA, DROSPIRENONE
  MONO-LINYAH, ETHINYL ESTRADIOL
  NIFEDIPINE, NIFEDIPINE
  NORETHINDRONE, NORETHINDRONE
  PHILITH, ETHINYL ESTRADIOL
  PIMTREA, DESOGESTREL
  SETLAKIN, ETHINYL ESTRADIOL
  TRI-LINYAH, ETHINYL ESTRADIOL
  WERA, ETHINYL ESTRADIOL
  YAELA, DROSPIRENONE

NOVEL LABS INC

* NOVEL LABORATORIES INC
  AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
  CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
  CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  DESOXIMETASONE, DESOXIMETASONE
  DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
  DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  FAMOTIDINE, FAMOTIDINE
  HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  LEVONORGESTREL, LEVONORGESTREL (OTC)
  LINEZOLID, LINEZOLID
  METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
  MISOPROSTOL, MISOPROSTOL
  MORPHINE SULFATE, MORPHINE SULFATE
  NITROFURANTOIN, NITROFURANTOIN
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
  PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

* NOVEL LABORATORIES INC
  PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL,
  PHENELZINE SULFATE, PHENELZINE SULFATE
  POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  TEMAZEPAM, TEMAZEPAM
  TINIDAZOLE, TINIDAZOLE
  TRIMETHOPRIM, TRIMETHOPRIM
  VORICONAZOLE, VORICONAZOLE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVEN

* NOVEN PHARMACEUTICALS INC
  MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
  COMBIPATCH, ESTRADIOL
  DAYTRANA, METHYLPHENIDATE

NOVO NORDISK

* NOVO NORDISK PHARMACEUTICALS INC
  GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

NOVO NORDISK INC

* NOVO NORDISK INC
  LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
  LEVEMIR, INSULIN DETEMIR RECOMBINANT
  NORDITROPIN FLEXPRO, SOMATROPIN RECOMBINANT
  NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
  NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
  NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
  NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
  NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
  NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
  NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
  NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
  NOVOLOG, INSULIN ASPART RECOMBINANT
  PRANDIMET, METFORMIN HYDROCHLORIDE
  PRANDIN, REPAGLINIDE
  RYZODEG 70/30, INSULIN ASPART
  SAXENDA, LIRAGLUTIDE RECOMBINANT
  TRESIBA, INSULIN DEGLUDEC
  VAGIFEM, ESTRADIOL
  VICTOZA, LIRAGLUTIDE RECOMBINANT
  XULTOPHY 100/3.6, INSULIN DEGLUDEC

NOVOCOL

* NOVOCOL PHARMACEUTICAL INC
  ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE

NPS PHARMS INC

* NPS PHARMACEUTICALS INC
  GATTEX KIT, TEDUGLUTIDE RECOMBINANT

NU PHARM

* NU PHARM INC
  DIVALPROEX SODIUM, DIVALPROEX SODIUM

NUVO PHARM INC

* NUVO PHARMACEUTICAL INC
  BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
  FOLIC ACID, FOLIC ACID
  POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
  SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

NUVO RES INC

* NUVO RESEARCH INC
  PENNSAID, DICLOFENAC SODIUM

NYCOMED US

* NYCOMED US INC
  TERCONAZOLE, TERCONAZOLE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

OAK PHARMS
* OAK PHARMACEUTICALS INC
  NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
  XYLOCAINE, LIDOCAINE HYDROCHLORIDE

OAK PHARMS AKORN
* OAK PHARMACEUTICALS INC SUB AKORN INC
  COGENTIN, BENZTROPINE MESYLATE
  DIURIL, CHLOROTHIAZIDE SODIUM

OAK PHARMS INC
* OAK PHARMACEUTICALS INC
  ZIOPTAN, TAFLUPROST
* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
  AZASITE, AZITHROMYCIN
  BETIMOL, TIMOLOL
  COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
  COSOPT, DORZOLAMIDE HYDROCHLORIDE
  XOPENEX, LEVALBUTEROL HYDROCHLORIDE

OC PHARMA
* OC PHARMA LLC
  LEVONORGESTREL, LEVONORGESTREL (OTC)
  NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

ODYSSEY PHARMS
* ODYSSEY PHARMACEUTICALS INC
  ANTABUSE, DISULFIRAM
  NYSTATIN, NYSTATIN
  SURMONTIL, TRIMIPRAMINE MALEATE
  URECHOLINE, BETHANECHOL CHLORIDE
  VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM
* OHM CORP
  IBUPROFEN, IBUPROFEN (OTC)

OHM LABS
* OHM LABORATORIES INC
  ACETAMINOPHEN, ACETAMINOPHEN (OTC)
  IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
  IBUPROHM, IBUPROFEN (OTC)
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC
* OHM LABORATORIES INC
  VALSARTAN, VALSARTAN

OLTA PHARMS
* OLTA PHARMACEUTICALS CORP
  LINDANE, LINDANE

OMAN PHARM PRODUCTS
* OMAN PHARMACEUTICAL PRODUCTS CO LLC
  NEOMYCIN SULFATE, NEOMYCIN SULFATE

OMEROS
* OMEROS CORP
  OMIDRIA, KETOROLAC TROMETHAMINE

ONY
* ONY INC
  INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX THERAP
* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
  KYPROLIS, CARFILZOMIB

OPKO IRELAND GLOBAL
* OPKO IRELAND GLOBAL HOLDINGS LTD
  RAYALDEE, CALCIFEDIOL

ORAPHARMA
* ORAPHARMA INC
  ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE
* ORCHID HEALTHCARE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORCHID HEALTHCARE
  CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
  CEFDINIR, CEFDINIR
  CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
  CEFPROZIL, CEFPROZIL
  CEFUROXIME AXETIL, CEFUROXIME AXETIL
  CEPHALEXIN, CEPHALEXIN
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
  DESLORATADINE, DESLORATADINE
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  ESZOPICLONE, ESZOPICLONE
  FELODIPINE, FELODIPINE
  GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  IBANDRONATE SODIUM, IBANDRONATE SODIUM
  LEVETIRACETAM, LEVETIRACETAM
  LEVOFLOXACIN, LEVOFLOXACIN
  MODAFINIL, MODAFINIL
  NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
  OLANZAPINE, OLANZAPINE
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  RASAGILINE MESYLATE, RASAGILINE MESYLATE
  RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  ZALEPLON, ZALEPLON

OREXIGEN

* OREXIGEN THERAPEUTICS INC
  CONTRAVE, BUPROPION HYDROCHLORIDE

OREXO US INC

* OREXO US INC
  ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON SUB MERCK

* ORGANON USA INC A SUBSIDIARY OF MERCK AND CO INC
  BRIDION, SUGAMMADEX SODIUM

ORGANON USA INC

* ORGANON USA INC
  DESOGEN, DESOGESTREL
  FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
  GANIRELIX ACETATE, GANIRELIX ACETATE
  NEXPLANON, ETONOGESTREL
  NUVARING, ETHINYL ESTRADIOL
  PREGNYL, GONADOTROPIN, CHORIONIC
  REMERON SOLTAB, MIRTAZAPINE
  REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
  CARISOPRODOL, CARISOPRODOL
  MIGLITOL, MIGLITOL

ORION CORP ORION

* ORION CORP ORION PHARMA
  BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
  NADOLOL, NADOLOL
  PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
  SPIRONOLACTONE, SPIRONOLACTONE

ORION PHARMA

* ORION PHARMA
  COMTAN, ENTACAPONE
  STALEVO 100, CARBIDOPA
  STALEVO 125, CARBIDOPA
  STALEVO 150, CARBIDOPA
  STALEVO 200, CARBIDOPA

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* ORION PHARMA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

ORIT LABS LLC

* ORIT LABORATORIES LLC
BENZONATATE, BENZONATATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
LEVETIRACETAM, LEVETIRACETAM

ORPHAN EUROPE

* ORPHAN EUROPE
CARBAGLU, CARGLUMIC ACID

OSI PHARMS

* OSI PHARMACEUTICALS INC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA

* OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE

OSMOTICA PHARM

* OSMOTICA PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM CORP

* OSMOTICA PHARMACEUTICAL CORP
KHEDEZLA, DESVENLAFAXINE

OSMOTICA PHARM US

* OSMOTICA PHARMACEUTICAL US LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

OTONOMY INC

* OTONOMY INC
OTIPRIO, CIPROFLOXACIN

OTSUKA

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA PHARM

* OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
DACOGEN, DECITABINE
REXULTI, BREXPIPRAZOLE

OUTLOOK PHARMS

* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OXFORD PHARMS

* OXFORD PHARMACEUTICALS LLC
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

**** P ****

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

P AND L DEV LLC
* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
  IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA
* PACIFIC PHARMA
  TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
  TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC
* PACIRA PHARMACEUTICALS INC
  DEPOCYT, CYTARABINE
  EXPAREL, BUPIVACAINE

PACK PHARMS LLC
* PACK PHARMACEUTICALS LLC
  CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
  CROMOLYN SODIUM, CROMOLYN SODIUM

PADDOCK
* PADDOCK LABORATORIES INC
  BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

PADDOCK LABS
* PADDOCK LABORATORIES INC
  CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

PADDOCK LLC
* PADDOCK LABORATORIES LLC
  ACETAMINOPHEN, ACETAMINOPHEN
  BROMFENAC SODIUM, BROMFENAC SODIUM
  BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
  BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
  CALCIUM ACETATE, CALCIUM ACETATE
  CICLOPIROX, CICLOPIROX
  CLINDA-DERM, CLINDAMYCIN PHOSPHATE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  CLOTRIMAZOLE, CLOTRIMAZOLE
  COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
  COLOCORT, HYDROCORTISONE
  COMPRO, PROCHLORPERAZINE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
  FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
  HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
  HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE ,
  HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
  INDOMETHACIN, INDOMETHACIN
  KIONEX, SODIUM POLYSTYRENE SULFONATE
  LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
  LORAZEPAM, LORAZEPAM
  MIDAMOR, AMILORIDE HYDROCHLORIDE
  MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
  MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
  NYSTOP, NYSTATIN
  PODOFILOX, PODOFILOX
  POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  REPAGLINIDE, REPAGLINIDE
  SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
  TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
  TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
  TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

PANACEA BIOTEC LTD
* PANACEA BIOTEC LTD
  TACROLIMUS, TACROLIMUS

PAR FORM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PAR FORMULATIONS PRIVATE LTD
  DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
  MAFENIDE ACETATE, MAFENIDE ACETATE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

* PAR PHARMACEUTICAL
  OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
  PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
  TESTOSTERONE, TESTOSTERONE
* PAR PHARMACEUTICAL INC
  ALPRAZOLAM, ALPRAZOLAM
  AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
  AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
  CABERGOLINE, CABERGOLINE
  CALCITONIN-SALMON, CALCITONIN SALMON
  CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
  CHOLESTYRAMINE, CHOLESTYRAMINE
  CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
  CLONAZEPAM, CLONAZEPAM
  CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
  DEXAMETHASONE, DEXAMETHASONE
  DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
  DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
  DOXYCYCLINE, DOXYCYCLINE
  ESTAZOLAM, ESTAZOLAM
  FENTANYL CITRATE, FENTANYL CITRATE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  FLUTAMIDE, FLUTAMIDE
  GLIPIZIDE, GLIPIZIDE
  GLYCOPYRROLATE, GLYCOPYRROLATE
  HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
  HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  HYDROXYUREA, HYDROXYUREA
  IBUPROFEN, IBUPROFEN (OTC)
  IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
  ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
  LAMOTRIGINE, LAMOTRIGINE
  LEVETIRACETAM, LEVETIRACETAM
  MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
  MEGESTROL ACETATE, MEGESTROL ACETATE
  METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
  METRONIDAZOLE, METRONIDAZOLE
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
  MINOXIDIL, MINOXIDIL
  NATEGLINIDE, NATEGLINIDE
  NIFEDIPINE, NIFEDIPINE
  OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  OLANZAPINE, OLANZAPINE
  OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
  OXANDROLONE, OXANDROLONE
  OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
  PIMOZIDE, PIMOZIDE
  POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  RISPERIDONE, RISPERIDONE
  SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TORSEMIDE, TORSEMIDE
  TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PAR PHARMACEUTICAL INC
  TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
  TRAVOPROST, TRAVOPROST
  URSODIOL, URSODIOL
  VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
  ACCOLATE, ZAFIRLUKAST
  AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
  ANTIZOL, FOMEPIZOLE
  BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  DAPSONE, DAPSONE
  DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
  ENTECAVIR, ENTECAVIR
  FENTANYL-100, FENTANYL
  FENTANYL-25, FENTANYL
  FENTANYL-50, FENTANYL
  FENTANYL-75, FENTANYL
  ITRACONAZOLE, ITRACONAZOLE
  METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
  OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
  TOLCAPONE, TOLCAPONE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
  ADRENALIN, EPINEPHRINE
  ARGATROBAN, ARGATROBAN
  BREVITAL SODIUM, METHOHEXITAL SODIUM
  BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  COLY-MYCIN M, COLISTIMETHATE SODIUM
  DANTRIUM, DANTROLENE SODIUM
  DELESTROGEN, ESTRADIOL VALERATE
  DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
  ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
  ETOMIDATE, ETOMIDATE
  FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
  GANCICLOVIR, GANCICLOVIR SODIUM
  KETALAR, KETAMINE HYDROCHLORIDE
  LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
  MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
  MEROPENEM, MEROPENEM
  MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
  PITOCIN, OXYTOCIN
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
  TRIOSTAT, LIOTHYRONINE SODIUM
  VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK

* PARAGON BIOTECK INC
  PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC

* PARAPRO LLC
  NATROBA, SPINOSAD

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
  CELONTIN, METHSUXIMIDE
  CEREBYX, FOSPHENYTOIN SODIUM
  DILANTIN, PHENYTOIN SODIUM
  DILANTIN-125, PHENYTOIN
  NARDIL, PHENELZINE SULFATE
  NEURONTIN, GABAPENTIN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PARKE DAVIS DIV WARNER LAMBERT CO
  ZARONTIN, ETHOSUXIMIDE
* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
  ZARONTIN, ETHOSUXIMIDE

PATRIN PHARMA INC

* PATRIN PHARMA INC
  CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

PEARL THERAPS INC

* PEARL THERAPEUTICS INC
  BEVESPI AEROSPHERE, FORMOTEROL FUMARATE

PERNIX IRELAND LTD

* PERNIX IRELAND LTD
  TREXIMET, NAPROXEN SODIUM

PERNIX IRELAND PAIN

* PERNIX IRELAND PAIN LIMITED
  ZOHYDRO ER, HYDROCODONE BITARTRATE

PERNIX THERAPS LLC

* PERNIX THERAPEUTICS LLC
  SILENOR, DOXEPIN HYDROCHLORIDE

PERRIGO

* PERRIGO CO
  BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
  CICLOPIROX, CICLOPIROX
  CIMETIDINE, CIMETIDINE (OTC)
  CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
  CLINDETS, CLINDAMYCIN PHOSPHATE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  ERYTHROMYCIN, ERYTHROMYCIN
  FAMOTIDINE, FAMOTIDINE
  FAMOTIDINE, FAMOTIDINE (OTC)
  HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
  IBUPROFEN, IBUPROFEN (OTC)
  JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
  MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
  MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
  MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
  MOMETASONE FUROATE, MOMETASONE FUROATE
  NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
  PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
  STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

* PERRIGO CO TENNESSEE INC
  BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
  BACITRACIN, BACITRACIN
  BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
  ERYTHROMYCIN, ERYTHROMYCIN
  GENTAMICIN SULFATE, GENTAMICIN SULFATE
  GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
  NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
  NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
  SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

* PERRIGO ISRAEL PHARMACEUTICALS
  FLUOCINONIDE, FLUOCINONIDE
* PERRIGO ISRAEL PHARMACEUTICALS LTD
  AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
  CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  DESOXIMETASONE, DESOXIMETASONE
  FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  GYNAZOLE-1, BUTOCONAZOLE NITRATE
  HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PERRIGO ISRAEL PHARMACEUTICALS LTD
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
MINOXIDIL, MINOXIDIL (OTC)
NITROGLYCERIN, NITROGLYCERIN
TESTOSTERONE, TESTOSTERONE

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CENTANY, MUPIROCIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
KETOCONAZOLE, KETOCONAZOLE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
CLINDESSE, CLINDAMYCIN PHOSPHATE
ENTOCORT EC, BUDESONIDE
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
TRETINOIN, TRETINOIN

PERRIGO PHARMS CO

* PERRIGO PHARMACEUTICALS CO
SCOPOLAMINE, SCOPOLAMINE

PERRIGO R AND D

* PERRIGO R AND D CO
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAPROXEN, NAPROXEN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PERRIGO R AND D CO
  NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
  OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
  OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  FLURANDRENOLIDE, FLURANDRENOLIDE
  NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PETNET

* PETNET SOLUTIONS INC
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
  BOSULIF, BOSUTINIB MONOHYDRATE
  INLYTA, AXITINIB
  LYRICA, PREGABALIN
  RAPAMUNE, SIROLIMUS
  TORISEL, TEMSIROLIMUS
  TYGACIL, TIGECYCLINE
  VFEND, VORICONAZOLE
  XALKORI, CRIZOTINIB
  XELJANZ, TOFACITINIB CITRATE
  ZMAX, AZITHROMYCIN

PFIZER

* PFIZER CENTRAL RESEARCH
  DIFLUCAN, FLUCONAZOLE
  ZITHROMAX, AZITHROMYCIN
* PFIZER CHEMICALS DIV PFIZER INC
  DIFLUCAN, FLUCONAZOLE
  ZITHROMAX, AZITHROMYCIN
* PFIZER INC
  ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
  ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
  ADVIL COLD AND SINUS, IBUPROFEN (OTC)
  ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
  ADVIL LIQUI-GELS, IBUPROFEN (OTC)
  ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
  ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
  ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
  ADVIL, IBUPROFEN (OTC)
  ALAVERT, LORATADINE (OTC)
  ARGATROBAN, ARGATROBAN
  AXID AR, NIZATIDINE (OTC)
  CADUET, AMLODIPINE BESYLATE
  CALAN SR, VERAPAMIL HYDROCHLORIDE
  CARDURA XL, DOXAZOSIN MESYLATE
  CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
  CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
  CHILDREN'S ADVIL, IBUPROFEN (OTC)
  CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
  DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
  DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
  DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
  ELELYSO, TALIGLUCERASE ALFA
  GEODON, ZIPRASIDONE HYDROCHLORIDE
  GEODON, ZIPRASIDONE MESYLATE
  GLUCOTROL XL, GLIPIZIDE
  GLUCOTROL, GLIPIZIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PFIZER INC
  HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
  HEPARIN SODIUM, HEPARIN SODIUM
  JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
  LIPITOR, ATORVASTATIN CALCIUM
  LORATADINE, LORATADINE (OTC)
  NORVASC, AMLODIPINE BESYLATE
  PEDIATRIC ADVIL, IBUPROFEN (OTC)
  PROCARDIA, NIFEDIPINE
  REVATIO, SILDENAFIL CITRATE
  SONATA, ZALEPLON
  TESSALON, BENZONATATE
  TOVIAZ, FESOTERODINE FUMARATE
  UNASYN, AMPICILLIN SODIUM
  ZITHROMAX, AZITHROMYCIN
* PFIZER LABORATORIES DIV PFIZER INC
  CARDURA, DOXAZOSIN MESYLATE
  DIABINESE, CHLORPROPAMIDE
  FELDENE, PIROXICAM
  MINIPRESS, PRAZOSIN HYDROCHLORIDE
  PERMAPEN, PENICILLIN G BENZATHINE
  PFIZERPEN, PENICILLIN G POTASSIUM
  PROCARDIA XL, NIFEDIPINE
  TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
  UNASYN, AMPICILLIN SODIUM
  VIBRAMYCIN, DOXYCYCLINE
  VIBRAMYCIN, DOXYCYCLINE CALCIUM
  VIBRAMYCIN, DOXYCYCLINE HYCLATE
  VISTARIL, HYDROXYZINE PAMOATE
* PFIZER PHARMACEUTICALS INC
  ZOLOFT, SERTRALINE HYDROCHLORIDE
* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
  TIKOSYN, DOFETILIDE

PFIZER CONS HLTHCARE

* PFIZER CONSUMER HEALTHCARE
  ADVIL, IBUPROFEN SODIUM (OTC)

PFIZER INC

* PFIZER INC
  CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
  CHANTIX, VARENICLINE TARTRATE
  ELLENCE, EPIRUBICIN HYDROCHLORIDE
  FRAGMIN, DALTEPARIN SODIUM
  IBRANCE, PALBOCICLIB
  NICOTROL, NICOTINE
  QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
  TROXYCA ER, NALTREXONE HYDROCHLORIDE
  XELJANZ XR, TOFACITINIB CITRATE

PFIZER IRELAND

* PFIZER IRELAND PHARMACEUTICALS
  RELPAX, ELETRIPTAN HYDROBROMIDE
  VIAGRA, SILDENAFIL CITRATE

PFIZER LABS

* PFIZER LABS
  DOCETAXEL, DOCETAXEL

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
  ACCUPRIL, QUINAPRIL HYDROCHLORIDE
  ACCURETIC, HYDROCHLOROTHIAZIDE
  DILANTIN, PHENYTOIN
  LOPID, GEMFIBROZIL
  NEURONTIN, GABAPENTIN
  NITROSTAT, NITROGLYCERIN

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
  CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PHARMACEUTICAL ASSOC INC
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  LORAZEPAM, LORAZEPAM
  NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
  PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
  CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
  DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
  ETHOSUXIMIDE, ETHOSUXIMIDE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
  HALOPERIDOL, HALOPERIDOL LACTATE
  LACTULOSE, LACTULOSE
  METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
  NYSTATIN, NYSTATIN
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
  PREDNISOLONE, PREDNISOLONE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
  VALPROIC ACID, VALPROIC ACID
* PHARMACEUTICAL ASSOCIATES INC
  ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  LEVETIRACETAM, LEVETIRACETAM
  MORPHINE SULFATE, MORPHINE SULFATE
  THEOPHYLLINE, THEOPHYLLINE

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACEUTICS

* PHARMACEUTICS INTERNATIONAL INC
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

PHARMACEUTICS INTL

* PHARMACEUTICS INTERNATIONAL INC
  BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
  HYDROCORTISONE, HYDROCORTISONE
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
  CARBOPLATIN, CARBOPLATIN
  CISPLATIN, CISPLATIN
  DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
  METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
  METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN
  XANAX XR, ALPRAZOLAM
* PHARMACIA AND UPJOHN CO
  AROMASIN, EXEMESTANE
  AZULFIDINE EN-TABS, SULFASALAZINE
  AZULFIDINE, SULFASALAZINE
  BACITRACIN, BACITRACIN
  CAVERJECT IMPULSE, ALPROSTADIL
  CAVERJECT, ALPROSTADIL
  CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
  CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  CLEOCIN T, CLINDAMYCIN PHOSPHATE
  CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
  CLEOCIN, CLINDAMYCIN PHOSPHATE
  COLESTID, COLESTIPOL HYDROCHLORIDE
  CORTEF, HYDROCORTISONE
  CORVERT, IBUTILIDE FUMARATE
  CYKLOKAPRON, TRANEXAMIC ACID

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PHARMACIA AND UPJOHN CO
  DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
  DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
  DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
  DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
  DETROL LA, TOLTERODINE TARTRATE
  DETROL, TOLTERODINE TARTRATE
  DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
  EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
  ESTRING, ESTRADIOL
  FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
  GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
  GENOTROPIN, SOMATROPIN RECOMBINANT
  GLYNASE, GLYBURIDE
  GLYSET, MIGLITOL
  HALCION, TRIAZOLAM
  HEMABATE, CARBOPROST TROMETHAMINE
  IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
  LINCOCIN, LINCOMYCIN HYDROCHLORIDE
  MEDROL, METHYLPREDNISOLONE
  MYCOBUTIN, RIFABUTIN
  NICOTROL, NICOTINE
  OGEN .625, ESTROPIPATE
  OGEN 1.25, ESTROPIPATE
  OGEN 2.5, ESTROPIPATE
  OGEN 5, ESTROPIPATE
  PREPIDIL, DINOPROSTONE
  PROSTIN E2, DINOPROSTONE
  PROSTIN VR PEDIATRIC, ALPROSTADIL
  PROVERA, MEDROXYPROGESTERONE ACETATE
  R-GENE 10, ARGININE HYDROCHLORIDE
  SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
  SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
  SOMAVERT, PEGVISOMANT
  XALATAN, LATANOPROST
  XANAX, ALPRAZOLAM
  ZINECARD, DEXRAZOXANE HYDROCHLORIDE
  ZYVOX, LINEZOLID
* PHARMACIA AND UPJOHN SUB PFIZER INC
  DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMACYCLICS INC

* PHARMACYCLICS INC
  IMBRUVICA, IBRUTINIB

PHARMADAX INC

* PHARMADAX INC
  GLYBURIDE, GLYBURIDE
  LEVETIRACETAM, LEVETIRACETAM

PHARMAFORCE

* PHARMAFORCE INC
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  NANDROLONE DECANOATE, NANDROLONE DECANOATE

PHARMALUCENCE

* PHARMALUCENCE INC
  AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
  CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
  CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
  HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
  TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
  TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT

PHARMAX

* PHARMAX GROUP INC
  BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

PHARMS

* PHARMACEUTICALS INTERNATIONAL
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

PHOTOCURE ASA
* PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE
* PIERRE FABRE MEDICAMENT
NAVELBINE, VINORELBINE TARTRATE

PIERRE FABRE DERMA
* PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL
* PIERREL S.P.A.
ORABLOC, ARTICAINE HYDROCHLORIDE

PIRAMAL CRITICAL
* PIRAMAL CRITICAL CARE INC
ISOFLURANE, ISOFLURANE
SOJOURN, SEVOFLURANE

PIRAMAL ENT
* PIRAMAL ENTERPRISES LTD
ISOFLURANE, ISOFLURANE

PIRAMAL IMAGING
* PIRAMAL IMAGING SA
NEURACEQ, FLORBETABEN F-18

PLIVA
* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO
* PLIVA HRVATSKA DOO
ADAPALENE, ADAPALENE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

PLIVA LACHEMA
* PLIVA LACHEMA AS
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PLIVA PHARM IND
* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA
* PLX PHARMA INC
ASPIRIN, ASPIRIN (OTC)

POHL BOSKAMP
* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS
* POLYGEN PHARMACEUTICALS INC

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* POLYGEN PHARMACEUTICALS INC
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

POLYMEDICA

* POLYMEDICA INDUSTRIES INC
  NEOPAP, ACETAMINOPHEN (OTC)

POWDER PHARMS

* POWDER PHARMACEUTICALS INC
  ZINGO, LIDOCAINE HYDROCHLORIDE

PRAGMA PHARMS LLC

* PRAGMA PHARMACEUTICALS LLC
  KEFLEX, CEPHALEXIN

PRECISION DERMAT

* PRECISION DERMATOLOGY INC
  CLINDAGEL, CLINDAMYCIN PHOSPHATE
  LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
  LOCOID, HYDROCORTISONE BUTYRATE
  MINOCIN, MINOCYCLINE HYDROCHLORIDE

PRECISION DOSE

* PRECISION DOSE INC
  RISPERIDONE, RISPERIDONE

PRECISION NUCLEAR

* PRECISION NUCLEAR LLC
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
  BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CAPTOPRIL, CAPTOPRIL
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
  ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
  IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  IRBESARTAN, IRBESARTAN
  LEVETIRACETAM, LEVETIRACETAM
  LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LISINOPRIL, LISINOPRIL
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  METHOCARBAMOL, METHOCARBAMOL
  NEVIRAPINE, NEVIRAPINE
  PAROXETINE, PAROXETINE HYDROCHLORIDE
  QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
  RISPERIDONE, RISPERIDONE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  VALSARTAN, VALSARTAN
  VORICONAZOLE, VORICONAZOLE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
  PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
  PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
  PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROMIUS PHARMA

* PROMIUS PHARMA LLC
  SECTRAL, ACEBUTOLOL HYDROCHLORIDE
  TENEX, GUANFACINE HYDROCHLORIDE

PROMIUS PHARMA LLC

* PROMIUS PHARMA LLC
  CLODERM, CLOCORTOLONE PIVALATE
  SERNIVO, BETAMETHASONE DIPROPIONATE

PROSTRAKAN INC

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PROSTRAKAN INC
  FARESTON, TOREMIFENE CITRATE

PROVENSIS
* PROVENSIS LTD
  VARITHENA, POLIDOCANOL

PROVEPHARM SAS
* PROVEPHARM SAS
  PROVAYBLUE, METHYLENE BLUE

PROVIDENT PHARM
* PROVIDENT PHARMACEUTICAL INC
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

PULMOFLOW INC
* PULMOFLOW INC
  KITABIS PAK, TOBRAMYCIN

PURACAP PHARM
* PURACAP PHARMACEUTICAL LLC
  MELOXICAM, MELOXICAM

PURACAP PHARM LLC
* PURACAP PHARMACEUTICAL LLC
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

PURDUE GMP
* PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
  SEROMYCIN, CYCLOSERINE

PURDUE PHARM PRODS
* PURDUE PHARMACEUTICAL PRODUCTS LP
  DILAUDID, HYDROMORPHONE HYDROCHLORIDE
  DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

PURDUE PHARMA
* PURDUE PHARMA PRODUCTS LP
  INTERMEZZO, ZOLPIDEM TARTRATE

PURDUE PHARMA LP
* PURDUE PHARMA LP
  BUTRANS, BUPRENORPHINE
  HYSINGLA, HYDROCODONE BITARTRATE
  MS CONTIN, MORPHINE SULFATE
  OXYCONTIN, OXYCODONE HYDROCHLORIDE

** Q **

QILU PHARM CO LTD
* QILU PHARMACEUTICAL CO LTD
  CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
  CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
  CEFTRIAXONE, CEFTRIAXONE SODIUM
  IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
  OLANZAPINE, OLANZAPINE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  OXALIPLATIN, OXALIPLATIN

QOL MEDCL
* QOL MEDICAL LLC
  ETHAMOLIN, ETHANOLAMINE OLEATE
  SUCRAID, SACROSIDASE

QUEEN HAMAMATSU PET
* QUEEN HAMAMATSU PET IMAGING CENTER
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

** R **

R-PHARM US LLC
* R-PHARM US LLC
  IXEMPRA KIT, IXABEPILONE

R2 PHARMA LLC
* R2 PHARMA LLC
  ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

RANBAXY
* RANBAXY LABORATORIES INC

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RANBAXY LABORATORIES INC
  ABSORICA, ISOTRETINOIN
  EURAX, CROTAMITON
  EXELDERM, SULCONAZOLE NITRATE
  HALOG, HALCINONIDE
  ULTRAVATE, HALOBETASOL PROPIONATE

RANBAXY LABS LTD

* RANBAXY LABORATORIES LTD
  KENALOG, TRIAMCINOLONE ACETONIDE

RAPTOR INC

* RAPTOR PHARMACEUTICALS INC
  PROCYSBI, CYSTEAMINE BITARTRATE

RARE DIS THERAP

* RARE DISEASE THERAPEUTICS INC
  CYSTADANE, BETAINE HYDROCHLORIDE

RARITAN PHARMS INC

* RARITAN PHARMACEUTICALS INC
  POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

RECIP

* RECIP AB
  THYROSAFE, POTASSIUM IODIDE (OTC)

RECKITT BENCKISER

* RECKITT BENCKISER LLC
  DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
  MUCINEX D, GUAIFENESIN (OTC)
  MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
  MUCINEX, GUAIFENESIN (OTC)

RECORDATI RARE

* RECORDATI RARE DISEASES INC
  CHEMET, SUCCIMER
  COSMEGEN, DACTINOMYCIN
  DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
  INDOCIN, INDOMETHACIN SODIUM
  MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
  NEOPROFEN, IBUPROFEN LYSINE
  PEGANONE, ETHOTOIN
  TRANXENE, CLORAZEPATE DIPOTASSIUM

RECRO GAINESVILLE

* RECRO GAINESVILLE LLC
  VERELAN PM, VERAPAMIL HYDROCHLORIDE
  VERELAN, VERAPAMIL HYDROCHLORIDE

RELYPSA INC

* RELYPSA INC
  VELTASSA, PATIROMER SORBITEX CALCIUM

REMPEX PHARMS INC

* REMPEX PHARMACEUTICALS INC
  MINOCIN, MINOCYCLINE HYDROCHLORIDE

RENAISSANCE PHARMA

* RENAISSANCE PHARMA US HOLDINGS INC
  ELIMITE, PERMETHRIN

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
  APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
  FENOFIBRATE (MICRONIZED), FENOFIBRATE
  FENOFIBRATE, FENOFIBRATE
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  MORPHINE SULFATE, MORPHINE SULFATE
  OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  THEOPHYLLINE, THEOPHYLLINE

RICONPHARMA LLC

* RICONPHARMA LLC
  GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
  NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RICONPHARMA LLC
  QUININE SULFATE, QUININE SULFATE

RISING PHARMS INC

* RISING PHARMACEUTICALS INC
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DOXERCALCIFEROL, DOXERCALCIFEROL
  DUTASTERIDE, DUTASTERIDE
  GLYCOPYRROLATE, GLYCOPYRROLATE
  HYDROCORTISONE, HYDROCORTISONE
  LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
  LEVOFLOXACIN, LEVOFLOXACIN
  METHIMAZOLE, METHIMAZOLE
  PARICALCITOL, PARICALCITOL
  TEMOZOLOMIDE, TEMOZOLOMIDE

ROCHE PALO

* ROCHE PALO ALTO LLC
  CELLCEPT, MYCOPHENOLATE MOFETIL
  CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
  CYTOVENE, GANCICLOVIR SODIUM

ROCKWELL MEDICAL INC

* ROCKWELL MEDICAL INC
  TRIFERIC , FERRIC PYROPHOSPHATE CITRATE
  TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

ROMARK

* ROMARK LABORATORIES
  ALINIA, NITAZOXANIDE

ROSEMONT PHARMS LTD

* ROSEMONT PHARMACEUTICALS LTD
  SIMVASTATIN, SIMVASTATIN

ROUSES POINT PHARMS

* ROUSES POINT PHARMACEUTICALS LLC
  LEVETIRACETAM, LEVETIRACETAM

ROXANE

* ROXANE LABORATORIES INC
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  CODEINE SULFATE, CODEINE SULFATE
  CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
  DIGOXIN, DIGOXIN
  DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  FUROSEMIDE, FUROSEMIDE
  LEVETIRACETAM, LEVETIRACETAM
  LITHIUM CARBONATE, LITHIUM CARBONATE
  LITHIUM CITRATE, LITHIUM CITRATE
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
  METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

RP SCHERER

* RP SCHERER TECHNOLOGIES LLC
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

RTRX

* RETROPHIN INC
  CHOLBAM, CHOLIC ACID

RUBICON RES PVT LTD

* RUBICON RESEARCH PVT LTD
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  SILDENAFIL CITRATE, SILDENAFIL CITRATE

** S **

SAGE PRODS

* SAGE PRODUCTS INC

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SAGE PRODUCTS INC
  CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT AGILA

* SAGENT AGILA LLC
  ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
  BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
  BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SAGENT PHARMS

* SAGENT PHARMACEUTICALS INC
  AMIKACIN SULFATE, AMIKACIN SULFATE
  AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
  AMPICILLIN SODIUM, AMPICILLIN SODIUM
  CAFFEINE CITRATE, CAFFEINE CITRATE
  CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
  CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
  DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
  FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
  FLUMAZENIL, FLUMAZENIL
  FLUOROURACIL, FLUOROURACIL
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  GLYDO, LIDOCAINE HYDROCHLORIDE
  HALOPERIDOL, HALOPERIDOL LACTATE
  HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
  HEPARIN SODIUM, HEPARIN SODIUM
  IBANDRONATE SODIUM, IBANDRONATE SODIUM
  KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
  LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
  LEVETIRACETAM, LEVETIRACETAM
  LEVOFLOXACIN, LEVOFLOXACIN
  MESNA, MESNA
  METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
  NAFCILLIN SODIUM, NAFCILLIN SODIUM
  OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
  OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
  ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
  OXACILLIN SODIUM, OXACILLIN SODIUM
  PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
  PROPOFOL, PROPOFOL
  ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
  TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
  VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
  VECURONIUM BROMIDE, VECURONIUM BROMIDE
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

SAGENT STRIDES

* SAGENT STRIDES LLC
  ADENOSINE, ADENOSINE
  AZITHROMYCIN, AZITHROMYCIN
  BACITRACIN, BACITRACIN
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
  MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
  POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
  ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC
  ANUSOL HC, HYDROCORTISONE
  DIURIL, CHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SALIX PHARMACEUTICALS INC
  METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
  MOVIPREP, ASCORBIC ACID
  OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
  PEPCID, FAMOTIDINE
  RELISTOR, METHYLNALTREXONE BROMIDE
  XIFAXAN, RIFAXIMIN

SALIX PHARMS INC

* SALIX PHARMACEUTICALS INC
  RELISTOR, METHYLNALTREXONE BROMIDE

SAMSON MEDCL

* SAMSON MEDICAL TECHNOLOGIES LLC
  CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
  CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
  CEFTRIAXONE, CEFTRIAXONE SODIUM
  VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ

* SANDOZ
  DOCETAXEL, DOCETAXEL
* SANDOZ CANADA INC
  ANECTINE, SUCCINYLCHOLINE CHLORIDE
  ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
  BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
  DIGOXIN, DIGOXIN
  DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
  FLUMAZENIL, FLUMAZENIL
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
  INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
  INFUVITE PEDIATRIC, ASCORBIC ACID
  ISONIAZID, ISONIAZID
  KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
  MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
  METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  REGONOL, PYRIDOSTIGMINE BROMIDE
  ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
  TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
* SANDOZ INC
  ALPRAZOLAM, ALPRAZOLAM
  ALTAVERA, ETHINYL ESTRADIOL
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
  AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
  AMOXICILLIN, AMOXICILLIN
  AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
  AMPICILLIN SODIUM, AMPICILLIN SODIUM
  AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
  APREPITANT, APREPITANT
  ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
  ATENOLOL, ATENOLOL
  AZITHROMYCIN, AZITHROMYCIN
  BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
  BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
  BICALUTAMIDE, BICALUTAMIDE
  BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
  BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
  BUMETANIDE, BUMETANIDE
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CAFERGOT, CAFFEINE
  CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CILOSTAZOL, CILOSTAZOL
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPLERENONE, EPLERENONE
ESTARYLLA, ETHINYL ESTRADIOL
ETODOLAC, ETODOLAC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
INTROVALE, ETHINYL ESTRADIOL
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORATADINE, LORATADINE (OTC)

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
  LORAZEPAM, LORAZEPAM
  LORYNA, DROSPIRENONE
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  LOVASTATIN, LOVASTATIN
  MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
  MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
  MEROPENEM, MEROPENEM
  METAXALONE, METAXALONE
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
  METHAZOLAMIDE, METHAZOLAMIDE
  METHIMAZOLE, METHIMAZOLE
  METHYLPREDNISOLONE, METHYLPREDNISOLONE
  METOLAZONE, METOLAZONE
  MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
  MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
  NABUMETONE, NABUMETONE
  NADOLOL, NADOLOL
  NAFCILLIN SODIUM, NAFCILLIN SODIUM
  NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
  NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
  NIZATIDINE, NIZATIDINE
  OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  OMEPRAZOLE, OMEPRAZOLE
  OMNITROPE, SOMATROPIN RECOMBINANT
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON, ONDANSETRON
  ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
  ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
  OXACILLIN SODIUM, OXACILLIN SODIUM
  OXALIPLATIN, OXALIPLATIN
  OXAPROZIN, OXAPROZIN
  OXAZEPAM, OXAZEPAM
  PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
  PENICILLIN G SODIUM, PENICILLIN G SODIUM
  PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
  PERPHENAZINE, PERPHENAZINE
  PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
  PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
  PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
  PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  QUINIDINE SULFATE, QUINIDINE SULFATE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  RESERPINE, RESERPINE
  RIBAVIRIN, RIBAVIRIN
  RIFAMPIN, RIFAMPIN
  RISPERIDONE, RISPERIDONE
  RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  SPIRONOLACTONE, SPIRONOLACTONE
  SULFADIAZINE, SULFADIAZINE
  SYEDA, DROSPIRENONE
  TACROLIMUS, TACROLIMUS
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  TEMAZEPAM, TEMAZEPAM
  TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC

* SANDOZ CANADA INC
PARICALCITOL, PARICALCITOL

SANDOZ INC

* SANDOZ INC
ACETAMINOPHEN, ACETAMINOPHEN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BIMATOPROST, BIMATOPROST
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CEFTRIAXONE, CEFTRIAXONE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
DECITABINE, DECITABINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
ELIFEMME, ETHINYL ESTRADIOL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
GLATOPA, GLATIRAMER ACETATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISIBLOOM, DESOGESTREL
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
OLANZAPINE, OLANZAPINE
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
RIBAVIRIN, RIBAVIRIN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TELMISARTAN, TELMISARTAN
TIGECYCLINE, TIGECYCLINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VIENVA, ETHINYL ESTRADIOL
VOLNEA, DESOGESTREL
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANJA PHARMS CO

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANJA PHARMACEUTICALS CO
  CARBOPLATIN, CARBOPLATIN

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
  JEVTANA KIT, CABAZITAXEL
* SANOFI AVENTIS US LLC
  ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
  ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
  ALLEGRA, FEXOFENADINE HYDROCHLORIDE
  ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
  ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
  AMARYL, GLIMEPIRIDE
  AMBIEN CR, ZOLPIDEM TARTRATE
  AMBIEN, ZOLPIDEM TARTRATE
  APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
  APIDRA, INSULIN GLULISINE RECOMBINANT
  ARALEN, CHLOROQUINE PHOSPHATE
  ARAVA, LEFLUNOMIDE
  AUBAGIO, TERIFLUNOMIDE
  AVALIDE, HYDROCHLOROTHIAZIDE
  AVAPRO, IRBESARTAN
  CANTIL, MEPENZOLATE BROMIDE
  CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
  CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
  CLAFORAN, CEFOTAXIME SODIUM
  CLOMID, CLOMIPHENE CITRATE
  DIABETA, GLYBURIDE
  ELOXATIN, OXALIPLATIN
  FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
  GAVISCON, ALUMINUM HYDROXIDE (OTC)
  LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
  LANTUS, INSULIN GLARGINE RECOMBINANT
  LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
  LOVENOX, ENOXAPARIN SODIUM
  MULTAQ, DRONEDARONE HYDROCHLORIDE
  NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
  NICODERM CQ, NICOTINE (OTC)
  PLAVIX, CLOPIDOGREL BISULFATE
  PRIFTIN, RIFAPENTINE
  PRIMAQUINE, PRIMAQUINE PHOSPHATE
  RIFADIN, RIFAMPIN
  RIFAMATE, ISONIAZID
  RIFATER, ISONIAZID
  TAXOTERE, DOCETAXEL

SANOFI US SERVICES

* SANOFI US SERVICES INC
  TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT

SANOFI-AVENTIS US

* SANOFI-AVENTIS US LLC
  ADLYXIN, LIXISENATIDE
  SOLIQUA 100/33, INSULIN GLARGINE

SANTARUS INC

* SANTARUS INC
  FENOGLIDE, FENOFIBRATE
  GLUMETZA, METFORMIN HYDROCHLORIDE
  ZEGERID, OMEPRAZOLE

SANTOS BIOTECH

* SANTOS BIOTECH INDUSTRIES INC
  ANASTROZOLE, ANASTROZOLE

SAOL THERAPS RES LTD

* SAOL THERAPEUTICS RESEARCH LTD
  LIORESAL, BACLOFEN

SAREPTA THERAPS INC

* SAREPTA THERAPEUTICS INC
  EXONDYS 51, ETEPLIRSEN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SAVIOR LIFETEC CORP
* SAVIOR LIFETEC CORP
MEROPENEM, MEROPENEM

SB PHARMCO
* SB PHARMCO PUERTO RICO INC
AVANDIA, ROSIGLITAZONE MALEATE

SCHERING
* SCHERING CORP
INTEGRILIN, EPTIFIBATIDE
NOXAFIL, POSACONAZOLE
REBETOL, RIBAVIRIN

SCHERING PLOUGH
* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)

SCIEGEN PHARMS INC
* SCIEGEN PHARMACEUTICALS INC
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE

SCIOS LLC
* SCIOS LLC
NATRECOR, NESIRITIDE RECOMBINANT

SEBELA IRELAND LTD
* SEBELA IRELAND LTD
BRISDELLE, PAROXETINE MESYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
ONMEL, ITRACONAZOLE
PEXEVA, PAROXETINE MESYLATE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN
ZYLOPRIM, ALLOPURINOL

SECAN PHARMS
* SECAN PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM

SENTYNL THERAPS INC
* SENTYNL THERAPEUTICS INC
ABSTRAL, FENTANYL CITRATE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

SEPTODONT
* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
OCTOCAINE, EPINEPHRINE

SEPTODONT HOLDING
* SEPTODONT HOLDING SAS

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SEPTODONT HOLDING SAS
  ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

* SEPTODONT INC
  LIDOCAINE, LIDOCAINE
  PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
  PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERB SA

* SERB SA
  CYANOKIT, HYDROXOCOBALAMIN

SETON PHARM

* SETON PHARMACEUTICAL LLC
  PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SHANGHAI HENGRUI

* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
  SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW

* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
  HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
  HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

* SHERTECH LABORATORIES LLC
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHILPA MEDICARE

* SHILPA MEDICARE LTD
  AZACITIDINE, AZACITIDINE

SHILPA MEDICARE LTD

* SHILPA MEDICARE LTD
  CAPECITABINE, CAPECITABINE

SHIONOGI INC

* SHIONOGI INC
  DORIBAX, DORIPENEM
  OSPHENA, OSPEMIFENE
  PONSTEL, MEFENAMIC ACID
  ULESFIA, BENZYL ALCOHOL

SHIRE

* SHIRE DEVELOPMENT INC
  ADDERALL XR 10, AMPHETAMINE ASPARTATE
  ADDERALL XR 15, AMPHETAMINE ASPARTATE
  ADDERALL XR 20, AMPHETAMINE ASPARTATE
  ADDERALL XR 25, AMPHETAMINE ASPARTATE
  ADDERALL XR 30, AMPHETAMINE ASPARTATE
  ADDERALL XR 5, AMPHETAMINE ASPARTATE
  CARBATROL, CARBAMAZEPINE
  INTUNIV, GUANFACINE HYDROCHLORIDE
  LIALDA, MESALAMINE
  PENTASA, MESALAMINE

SHIRE DEV LLC

* SHIRE DEVELOPMENT LLC
  FOSRENOL, LANTHANUM CARBONATE
  XIIDRA, LIFITEGRAST

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC
  VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

* SHIRE HUMAN GENETIC THERAPIES INC
  VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

* SHIRE DEVELOPMENT LLC
  AGRYLIN, ANAGRELIDE HYDROCHLORIDE
  FOSRENOL, LANTHANUM CARBONATE
  SALURON, HYDROFLUMETHIAZIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SHIRE ORPHAN THERAP
* SHIRE ORPHAN THERAPIES INC
FIRAZYR, ICATIBANT ACETATE

SIDMAK LABS INDIA
* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGMA TAU
* SIGMA TAU PHARMACEUTICALS INC
ABELCET, AMPHOTERICIN B
ADAGEN, PEGADEMASE BOVINE
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SIGMAPHARM LABS LLC
* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
ERGOCALCIFEROL, ERGOCALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SILARX
* SILARX PHARMACEUTICALS INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

SILARX PHARMS INC
* SILARX PHARMACEUTICALS INC
ARIPIPRAZOLE, ARIPIPRAZOLE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LAMIVUDINE, LAMIVUDINE
LOPINAVIR AND RITONAVIR, LOPINAVIR
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

SILVERGATE PHARMS
* SILVERGATE PHARMACEUTICALS INC
EPANED KIT, ENALAPRIL MALEATE
EPANED, ENALAPRIL MALEATE
QBRELIS, LISINOPRIL

SINTETICA SA
* SINTETICA SA
BACLOFEN, BACLOFEN

SKINMEDICA
* SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SKYEPHARMA AG
  TRIGLIDE, FENOFIBRATE

SMITHKLINE BEECHAM

* SMITHKLINE BEECHAM
  LOVAZA, OMEGA-3-ACID ETHYL ESTERS
* SMITHKLINE BEECHAM (CORK) LTD IRELAND
  COREG CR, CARVEDILOL PHOSPHATE
  COREG, CARVEDILOL

SOAPCO

* SOAPCO INC
  BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS
  NIMODIPINE, NIMODIPINE
* SOFGEN PHARMACEUTICALS LLC
  IBUPROFEN, IBUPROFEN (OTC)
  PROGESTERONE, PROGESTERONE

SOMERSET

* SOMERSET PHARMACEUTICALS INC
  ELDEPRYL, SELEGILINE HYDROCHLORIDE
  EMSAM, SELEGILINE

SOMERSET THERAPS LLC

* SOMERSET THERAPEUTICS LLC
  CYANOCOBALAMIN, CYANOCOBALAMIN
  EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
  OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE

SOVEREIGN PHARMS

* SOVEREIGN PHARMACEUTICALS LLC
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  OBREDON, GUAIFENESIN

SPEAR PHARMS

* SPEAR PHARMACEUTICALS INC
  FLUOROURACIL, FLUOROURACIL

SPEAR PHARMS INC

* SPEAR PHARMACEUTICALS INC
  FLUOROURACIL, FLUOROURACIL
  TRETINOIN, TRETINOIN

SPECTRON MRC LLC

* SPECTRON MRC LLC
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SPECTRUM PHARMS

* SPECTRUM PHARMACEUTICALS INC
  BELEODAQ, BELINOSTAT
  EVOMELA, MELPHALAN HYDROCHLORIDE
  FLUOROURACIL, FLUOROURACIL
  FUSILEV, LEVOLEUCOVORIN CALCIUM

SPROUT PHARMS

* SPROUT PHARMACEUTICALS INC
  ADDYI, FLIBANSERIN

ST RENATUS

* ST RENATUS LLC
  KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH

* STANDARD HOMEOPATHIC CO
  IVY BLOCK, BENTOQUATAM (OTC)

STANDARD CHEM PHARM

* STANDARD CHEM AND PHARM CO LTD
  REPAGLINIDE, REPAGLINIDE

STASON

* STASON INDUSTRIAL CORP
  ACYCLOVIR, ACYCLOVIR
  SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

STASON PHARMS
* STASON PHARMACEUTICALS INC
ARIPIPRAZOLE, ARIPIPRAZOLE
BICALUTAMIDE, BICALUTAMIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
PURINETHOL, MERCAPTOPURINE

STI PHARMA LLC
* STI PHARMA LLC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
DEXAMETHASONE, DEXAMETHASONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
TRIACIN-C, CODEINE PHOSPHATE

STIEFEL
* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

STIEFEL LABS INC
* STIEFEL LABORATORIES INC
FABIOR, TAZAROTENE
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE

STRIDES ARCOLAB LTD
* STRIDES ARCOLAB LTD
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL

STRIDES PHARMA
* STRIDES PHARMA GLOBAL PTE LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ACARBOSE, ACARBOSE
BENZONATATE, BENZONATATE
CALCITRIOL, CALCITRIOL
CARISOPRODOL, CARISOPRODOL
DUTASTERIDE, DUTASTERIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIQUIMOD, IMIQUIMOD
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
MELOXICAM, MELOXICAM
METHOXSALEN, METHOXSALEN
METRONIDAZOLE, METRONIDAZOLE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NEVIRAPINE, NEVIRAPINE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TACROLIMUS, TACROLIMUS
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

STRONGBRIDGE US
* STRONGBRIDGE US INC
KEVEYIS, DICHLORPHENAMIDE

SUCAMPO PHARMA LLC
* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUN PHARM INDS
* SUN PHARMACEUTICAL INDUSTRIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARISOPRODOL, CARISOPRODOL
CHLORTHALIDONE, CHLORTHALIDONE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FELODIPINE, FELODIPINE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUALAQUIN, QUININE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SYNALGOS-DC, ASPIRIN
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE
* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TORSEMIDE, TORSEMIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BENZONATATE, BENZONATATE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
ERGOCALCIFEROL, ERGOCALCIFEROL
FLURBIPROFEN, FLURBIPROFEN
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LITHIUM CARBONATE, LITHIUM CARBONATE
MELOXICAM, MELOXICAM
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NIMODIPINE, NIMODIPINE
OXAPROZIN, OXAPROZIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
RISPERIDONE, RISPERIDONE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMACEUTICAL INDUSTRIES LTD
  ACETAMINOPHEN, ACETAMINOPHEN (OTC)
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
  AZITHROMYCIN, AZITHROMYCIN
  BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
  BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
  BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
  CARISOPRODOL, CARISOPRODOL
  CARVEDILOL, CARVEDILOL
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
  CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CLARITHROMYCIN, CLARITHROMYCIN
  CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
  CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
  DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  DOXYCYCLINE, DOXYCYCLINE
  EXELDERM, SULCONAZOLE NITRATE
  FAMOTIDINE, FAMOTIDINE (OTC)
  FELODIPINE, FELODIPINE
  FENOFIBRATE, FENOFIBRATE
  FLECAINIDE ACETATE, FLECAINIDE ACETATE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  GABAPENTIN, GABAPENTIN
  GLYCOPYRROLATE, GLYCOPYRROLATE
  IBANDRONATE SODIUM, IBANDRONATE SODIUM
  LANSOPRAZOLE, LANSOPRAZOLE
  LETROZOLE, LETROZOLE
  LEVETIRACETAM, LEVETIRACETAM
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
  LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
  LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LISINOPRIL, LISINOPRIL
  LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
  LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
  LORATADINE REDIDOSE, LORATADINE (OTC)
  LORATADINE, LORATADINE (OTC)
  LORAZEPAM, LORAZEPAM
  MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
  NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
  NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON, ONDANSETRON
  OPCICON ONE-STEP, LEVONORGESTREL (OTC)
  OXCARBAZEPINE, OXCARBAZEPINE
  OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
  QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
  RILUZOLE, RILUZOLE
  RIOMET, METFORMIN HYDROCHLORIDE
  RISPERIDONE, RISPERIDONE
  SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMACEUTICAL INDUSTRIES LTD
  TOPIRAMATE, TOPIRAMATE
  TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
  VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  VALPROIC ACID, VALPROIC ACID
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* SUN PHARMACEUTICAL INDUSTRIES LTD.
  ANASTROZOLE, ANASTROZOLE

SUN PHARMA GLOBAL

* SUN PHARMA GLOBAL FZE
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
  BROMSITE, BROMFENAC SODIUM
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CAFFEINE CITRATE, CAFFEINE CITRATE
  CARBIDOPA AND LEVODOPA, CARBIDOPA
  CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
  CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  DECITABINE, DECITABINE
  DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
  DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
  DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
  DOCEFREZ, DOCETAXEL
  DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  ENTACAPONE, ENTACAPONE
  ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
  ESZOPICLONE, ESZOPICLONE
  FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
  FINASTERIDE, FINASTERIDE
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  IMATINIB MESYLATE, IMATINIB MESYLATE
  IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
  LACOSAMIDE, LACOSAMIDE
  LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
  LEVETIRACETAM, LEVETIRACETAM
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
  NIACIN, NIACIN
  NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
  OXALIPLATIN, OXALIPLATIN
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  RISEDRONATE SODIUM, RISEDRONATE SODIUM
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TEMOZOLOMIDE, TEMOZOLOMIDE
  TETRABENAZINE, TETRABENAZINE
  TOPIRAMATE, TOPIRAMATE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  VECURONIUM BROMIDE, VECURONIUM BROMIDE
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  ZOLEDRONIC ACID, ZOLEDRONIC ACID
  ZOLMITRIPTAN, ZOLMITRIPTAN
* SUN PHARMA GLOBAL INC
  ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
  ALPRAZOLAM, ALPRAZOLAM
  AMIFOSTINE, AMIFOSTINE
  AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
  BICALUTAMIDE, BICALUTAMIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMA GLOBAL INC
  CARBOPLATIN, CARBOPLATIN
  FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
  KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
  PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

SUNEVA MEDCL
* SUNEVA MEDICAL INC
  TRETINOIN, TRETINOIN

SUNOVION
* SUNOVION PHARMACEUTICALS INC
  BROVANA, ARFORMOTEROL TARTRATE
  XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC
* SUNOVION PHARMACEUTICALS INC
  APTIOM, ESLICARBAZEPINE ACETATE
  LATUDA, LURASIDONE HYDROCHLORIDE
  LUNESTA, ESZOPICLONE
  ZONEGRAN, ZONISAMIDE

SUNSTAR AMERICAS
* SUNSTAR AMERICAS INC
  PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS
* SUPERNUS PHARMACEUTICALS INC
  OXTELLAR XR, OXCARBAZEPINE
  TROKENDI XR, TOPIRAMATE

SUVEN LIFE
* SUVEN LIFE SCIENCES LTD
  MALATHION, MALATHION

SVADS HOLDINGS SA
* SVADS HOLDINGS SA
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

SVC PHARMA
* SVC PHARMA LP
  DRONABINOL, DRONABINOL

SWAN PHARMS LLC
* SWAN PHARMACEUTICALS LLC
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

SWEDISH ORPHAN
* SWEDISH ORPHAN BIOVITRUM AB PUBL
  ORFADIN, NITISINONE

SYMPLMED PHARMS LLC
* SYMPLMED PHARMACEUTICALS LLC
  ACEON, PERINDOPRIL ERBUMINE
  PRESTALIA, AMLODIPINE BESYLATE

SYNTHON PHARMS
* SYNTHON PHARMACEUTICALS INC
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

** T **

METHODIST HOSP RES
* THE METHODIST HOSP RESEARCH INSTITUTE
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP
* THE RITEDOSE CORP
  ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
  LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAIHO ONCOLOGY
* TAIHO ONCOLOGY INC

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TAIHO ONCOLOGY INC
  LONSURF, TIPIRACIL HYDROCHLORIDE

TAKEDA GMBH

* TAKEDA GMBH
  ALVESCO, CICLESONIDE
  OMNARIS, CICLESONIDE
  ZETONNA, CICLESONIDE

TAKEDA PHARMS USA

* TAKEDA PHARMACEUTICALS USA INC
  ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
  ACTOPLUS MET, METFORMIN HYDROCHLORIDE
  ACTOS, PIOGLITAZONE HYDROCHLORIDE
  COLCRYS, COLCHICINE
  DEXILANT SOLUTAB, DEXLANSOPRAZOLE
  DEXILANT, DEXLANSOPRAZOLE
  DUETACT, GLIMEPIRIDE
  KAZANO, ALOGLIPTIN BENZOATE
  NESINA, ALOGLIPTIN BENZOATE
  OSENI, ALOGLIPTIN BENZOATE
  PREVACID, LANSOPRAZOLE
  PREVPAC, AMOXICILLIN
  ROZEREM, RAMELTEON
  TRINTELLIX, VORTIOXETINE HYDROBROMIDE
  ULORIC, FEBUXOSTAT

TALON THERAP

* TALON THERAPEUTICS INC
  MARQIBO KIT, VINCRISTINE SULFATE

TAMARANG

* TAMARANG SA
  ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
  ACETAZOLAMIDE, ACETAZOLAMIDE
  CARBAMAZEPINE, CARBAMAZEPINE
  CARVEDILOL, CARVEDILOL
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
  CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
  DESLORATADINE, DESLORATADINE
  DESONIDE, DESONIDE
  ENALAPRIL MALEATE, ENALAPRIL MALEATE
  ETODOLAC, ETODOLAC
  EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
  FLUCONAZOLE, FLUCONAZOLE
  FLUOROURACIL, FLUOROURACIL
  GABAPENTIN, GABAPENTIN
  HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
  IMIQUIMOD, IMIQUIMOD
  KETOCONAZOLE, KETOCONAZOLE
  LAMOTRIGINE, LAMOTRIGINE
  LEVETIRACETAM, LEVETIRACETAM
  LORATADINE, LORATADINE (OTC)
  MELOXICAM, MELOXICAM
  METRONIDAZOLE, METRONIDAZOLE
  NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  OXCARBAZEPINE, OXCARBAZEPINE
  PHENYTOIN, PHENYTOIN
* TARO PHARMACEUTICALS INC
  BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  CLOTRIMAZOLE, CLOTRIMAZOLE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TARO PHARMACEUTICALS INC
  CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
  DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
  FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
  FLUOCINONIDE, FLUOCINONIDE
  HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
  MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
  NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
  TOPICORT, DESOXIMETASONE
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
  WARFARIN SODIUM, WARFARIN SODIUM
* TARO PHARMACEUTICALS USA INC
  ACETIC ACID, ACETIC ACID, GLACIAL
  ACYCLOVIR, ACYCLOVIR
  ADAPALENE, ADAPALENE
  ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  AMMONIUM LACTATE, AMMONIUM LACTATE
  BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CICLOPIROX, CICLOPIROX
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
  CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CLOTRIMAZOLE, CLOTRIMAZOLE
  DERMABET, BETAMETHASONE VALERATE
  DESONIDE, DESONIDE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
  ECONAZOLE NITRATE, ECONAZOLE NITRATE
  ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
  FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
  FLUOCINONIDE, FLUOCINONIDE
  FLUOROURACIL, FLUOROURACIL
  GENTAMICIN SULFATE, GENTAMICIN SULFATE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
  HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
  HYDROCORTISONE, HYDROCORTISONE
  KETOZOLE, KETOCONAZOLE
  LIDOCAINE, LIDOCAINE
  LORATADINE, LORATADINE (OTC)
  MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
  MOMETASONE FUROATE, MOMETASONE FUROATE
  MUPIROCIN, MUPIROCIN
  NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
  NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
  NYSTATIN, NYSTATIN
  OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
  PHENYTOIN, PHENYTOIN
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  RISPERIDONE, RISPERIDONE
  SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
  TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
  TERCONAZOLE, TERCONAZOLE
  TERIL, CARBAMAZEPINE
  TOPICORT, DESOXIMETASONE
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
  TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
  U-CORT, HYDROCORTISONE ACETATE
* TARO PHARMACEUTICALS, INC.
  HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TARO PHARMACEUTICALS, INC.
  TOPICORT, DESOXIMETASONE

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
  AMCINONIDE, AMCINONIDE
  CARBAMAZEPINE, CARBAMAZEPINE
  CICLOPIROX, CICLOPIROX
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  DESLORATADINE, DESLORATADINE
  ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
  ETODOLAC, ETODOLAC
  HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
  LAMOTRIGINE, LAMOTRIGINE
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

TARO PHARMS IRELAND

* TARO PHARMACEUTICALS IRELAND LTD
  SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
  STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

TARO PHARMS NORTH

* TARO PHARMACEUTICALS NORTH AMERICA INC
  ACETAMINOPHEN, ACETAMINOPHEN (OTC)
  INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
  OVIDE, MALATHION
  TOPICORT, DESOXIMETASONE

TEDOR PHARM

* TEDOR PHARMA INC
  BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

TEDOR PHARMA INC

* TEDOR PHARMA INC
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
  LIDODERM, LIDOCAINE

TELIGENT PHARMA INC

* TELIGENT PHARMA INC
  BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
  CEFOTAN, CEFOTETAN DISODIUM
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  DESOXIMETASONE, DESOXIMETASONE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  ECONAZOLE NITRATE, ECONAZOLE NITRATE
  FLURANDRENOLIDE, FLURANDRENOLIDE
  LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
  LIDOCAINE, LIDOCAINE
  NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TERSERA THERAP

* TERSERA THERAPEUTICS LLC
  ERGOMAR, ERGOTAMINE TARTRATE

TESARO INC

* TESARO INC
  VARUBI, ROLAPITANT HYDROCHLORIDE

TEVA

* TEVA NEUROSCIENCE INC
  AZILECT, RASAGILINE MESYLATE
* TEVA PHARMACEUTICALS USA INC
  ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
  ACYCLOVIR, ACYCLOVIR
  ADIPEX-P, PHENTERMINE HYDROCHLORIDE
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CAPTOPRIL, CAPTOPRIL
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOR
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPITOL, CARBAMAZEPINE
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORAP, PIMOZIDE
OXAPROZIN, OXAPROZIN
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN-VK, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRELONE, PREDNISOLONE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
DIAMOX, ACETAZOLAMIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROGLYCEM, DIAZOXIDE
QNASL, BECLOMETHASONE DIPROPIONATE
QUARTETTE, ETHINYL ESTRADIOL
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE
SEASONALE, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
  SEASONIQUE, ETHINYL ESTRADIOL
  ZECUITY, SUMATRIPTAN SUCCINATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
  DAPTOMYCIN, DAPTOMYCIN
  LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
  ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
  ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
  ANASTROZOLE, ANASTROZOLE
  AZITHROMYCIN, AZITHROMYCIN
  BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
  BUDESONIDE, BUDESONIDE
  CARBAMAZEPINE, CARBAMAZEPINE
  CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
  CEFDINIR, CEFDINIR
  CEFPROZIL, CEFPROZIL
  CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  CROMOLYN SODIUM, CROMOLYN SODIUM
  DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
  DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
  ETHOSUXIMIDE, ETHOSUXIMIDE
  FAMCICLOVIR, FAMCICLOVIR
  FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
  GABAPENTIN, GABAPENTIN
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
  GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
  HALOPERIDOL, HALOPERIDOL LACTATE
  HYDROCORTISONE, HYDROCORTISONE
  HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
  IRBESARTAN, IRBESARTAN
  LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
  LANSOPRAZOLE, LANSOPRAZOLE
  LEFLUNOMIDE, LEFLUNOMIDE
  LETROZOLE, LETROZOLE
  LEVETIRACETAM, LEVETIRACETAM
  LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
  LINEZOLID, LINEZOLID
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  MEGESTROL ACETATE, MEGESTROL ACETATE
  MELOXICAM, MELOXICAM
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
  NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
  OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  OLANZAPINE, OLANZAPINE
  OXALIPLATIN, OXALIPLATIN
  PACLITAXEL, PACLITAXEL
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
  PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
  PROGESTERONE, PROGESTERONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZALEPLON, ZALEPLON

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ACITRETIN, ACITRETIN
ADENOSINE, ADENOSINE
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARIPIPRAZOLE, ARIPIPRAZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CLARAVIS, ISOTRETINOIN
CLOZAPINE, CLOZAPINE
COPAXONE, GLATIRAMER ACETATE
CYTOSAR-U, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
ENTECAVIR, ENTECAVIR
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETOPOSIDE, ETOPOSIDE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LINEZOLID, LINEZOLID
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MESNA, MESNA
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE, GLIMEPIRIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZANOSAR, STREPTOZOCIN
ZOLMITRIPTAN, ZOLMITRIPTAN
* TEVA PHARMACEUTICALS USA INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CAPECITABINE, CAPECITABINE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
METRONIDAZOLE, METRONIDAZOLE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SELFEMRA, FLUOXETINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TEVA WOMENS

* TEVA WOMENS HEALTH INC
ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
PARAGARD T 380A, COPPER
ZIAC, BISOPROLOL FUMARATE

THE FEINSTEIN INST

* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THE MEDICINES CO

* THE MEDICINES CO
ANGIOMAX, BIVALIRUDIN
IONSYS, FENTANYL HYDROCHLORIDE
ORBACTIV, ORITAVANCIN DIPHOSPHATE

THE PHARMA NETWORK

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* THE PHARMA NETWORK LLC
  BENZONATATE, BENZONATATE

THE PHARMANETWORK

* THE PHARMANETWORK LLC
  METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
  BENZONATATE, BENZONATATE
  ISONIAZID, ISONIAZID
  NIMODIPINE, NIMODIPINE
  THERMAZENE, SILVER SULFADIAZINE

THERATECHNOLOGIES

* THERATECHNOLOGIES INC
  EGRIFTA, TESAMORELIN ACETATE

THERAVANCE BIOPHARMA

* THERAVANCE BIOPHARMA ANTIBIOTICS INC
  VIBATIV, TELAVANCIN HYDROCHLORIDE

THREE RIVERS PHARMS

* THREE RIVERS PHARMACEUTICALS LLC
  RIBASPHERE, RIBAVIRIN
  RIBAVIRIN, RIBAVIRIN

TIGER PHARMS LLC

* TIGER PHARMACEUTICALS LLC
  DOFETILIDE, DOFETILIDE

TOLMAR

* TOLMAR INC
  ADAPALENE, ADAPALENE
  ATRIDOX, DOXYCYCLINE HYCLATE
  BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
  CALCIPOTRIENE, CALCIPOTRIENE
  CICLOPIROX, CICLOPIROX
  CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  DICLOFENAC SODIUM , DICLOFENAC SODIUM
  ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  IMIQUIMOD, IMIQUIMOD
  KETOCONAZOLE, KETOCONAZOLE
  LEVETIRACETAM, LEVETIRACETAM
  LIDOCAINE AND PRILOCAINE, LIDOCAINE
  METRONIDAZOLE, METRONIDAZOLE
  MOMETASONE FUROATE, MOMETASONE FUROATE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
  ELIGARD, LEUPROLIDE ACETATE

TORPHARM

* TORPHARM INC
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT PHARM

* TORRENT PHARMA INC
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

TORRENT PHARMA INC

* TORRENT PHARMA INC
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LIMITED
  LEVOFLOXACIN, LEVOFLOXACIN
* TORRENT PHARMACEUTICALS LTD
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  CARBAMAZEPINE, CARBAMAZEPINE
  CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TORRENT PHARMACEUTICALS LTD
  ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
  LAMOTRIGINE, LAMOTRIGINE
  LEVETIRACETAM, LEVETIRACETAM
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  RISPERIDONE, RISPERIDONE
  SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
  TOPIRAMATE, TOPIRAMATE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* TORRENT PHARMACEUTICALS LTD.
  ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

TORRENT PHARMS LLC

* TORRENT PHARMACEUTICALS LLC
  AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  OLANZAPINE, OLANZAPINE
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
  AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
  ARIPIPRAZOLE, ARIPIPRAZOLE
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CELECOXIB, CELECOXIB
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
  DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
  ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
  ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
  FELODIPINE, FELODIPINE
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
  LAMOTRIGINE, LAMOTRIGINE
  LEVETIRACETAM, LEVETIRACETAM
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
  OLANZAPINE, OLANZAPINE
  OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
  PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
  SILDENAFIL CITRATE, SILDENAFIL CITRATE
  TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
  TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  TELMISARTAN, TELMISARTAN
  TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
  TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
  VALSARTAN, VALSARTAN

TRIAD ISOTOPES INC

* TRIAD ISOTOPES INC
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

TRIS PHARMA INC

* TRIS PHARMA INC
  CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
  DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TRIS PHARMA INC
  DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
  DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
  DYANAVEL XR, AMPHETAMINE
  GABAPENTIN, GABAPENTIN
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
  HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
  HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
  HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
  IBUPROFEN, IBUPROFEN (OTC)
  KARBINAL ER, CARBINOXAMINE MALEATE
  LEVETIRACETAM, LEVETIRACETAM
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
  PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  RISPERIDONE, RISPERIDONE
  THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA

* TRUSTEES OF THE UNIV OF PENNSYLVANIA
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TRYGG

* TRYGG PHARMA INC
  OMTRYG, OMEGA-3-ACID ETHYL ESTERS TYPE A

TURING PHARMS AG

* TURING PHARMACEUTICALS AG
  DARAPRIM, PYRIMETHAMINE

TWI PHARMS INC

* TWI PHARMACEUTICALS INC
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
  MEGESTROL ACETATE, MEGESTROL ACETATE
  NIFEDIPINE, NIFEDIPINE

** U **

UCB INC

* UCB INC
  BRIVIACT, BRIVARACETAM
  KEPPRA XR, LEVETIRACETAM
  KEPPRA, LEVETIRACETAM
  METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
  METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  NEUPRO, ROTIGOTINE
  TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
  VIMPAT, LACOSAMIDE
  XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
  ZAROXOLYN, METOLAZONE

UCLA BIOMEDICAL

* UCLA BIOMEDICAL CYCLOTRON
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RODIOPHARM

* UCSF RADIOPHARMACEUTICAL FACILITY
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UIHC PET IMAGING

* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNICHEM

* UNICHEM LABORATORIES LTD

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** U **

* UNICHEM LABORATORIES LTD
  BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  MELOXICAM, MELOXICAM
  ZALEPLON, ZALEPLON

UNICHEM LABS LTD

* UNICHEM LABORATORIES LIMITED
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
* UNICHEM LABORATORIES LTD
  ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  IRBESARTAN, IRBESARTAN
  LAMOTRIGINE, LAMOTRIGINE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  METRONIDAZOLE, METRONIDAZOLE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
  TOPIRAMATE, TOPIRAMATE

UNICHEM PHARMS (USA)

* UNICHEM PHARMACEUTICALS (USA) INC
  BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIMARK REMEDIES LTD

* UNIMARK REMEDIES LTD
  MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE PHARM LABS

* UNIQUE PHARMACEUTICAL LABORATORIES
  ATENOLOL, ATENOLOL
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  FLUCONAZOLE, FLUCONAZOLE
  GLIPIZIDE, GLIPIZIDE
  LITHIUM CARBONATE, LITHIUM CARBONATE
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
  TINIDAZOLE, TINIDAZOLE

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC
  TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
  RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
  ORENITRAM, TREPROSTINIL DIOLAMINE
  REMODULIN, TREPROSTINIL
  TYVASO, TREPROSTINIL

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV NORTH DAKOTA

* UNIV NORTH DAKOTA
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
  AMMONIA N 13, AMMONIA N-13
  CHOLINE C-11, CHOLINE C-11
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UNIV TEXAS MD ANDERSON CANCER CENTER
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UPSHER SMITH

* UPSHER SMITH LABORATORIES INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MORPHINE SULFATE, MORPHINE SULFATE
NIACOR, NIACIN
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREVALITE, CHOLESTYRAMINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
SORINE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES INC
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE

UPSHER-SMITH LABS

* UPSHER-SMITH LABORATORIES INC
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
KLOR-CON, POTASSIUM CHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
QUDEXY XR, TOPIRAMATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
VOGELXO, TESTOSTERONE

US PHARM HOLDINGS

* US PHARMACEUTICAL HOLDINGS II LLC
ANZEMET, DOLASETRON MESYLATE
CLAFORAN, CEFOTAXIME SODIUM
DEMEROL, MEPERIDINE HYDROCHLORIDE
DRISDOL, ERGOCALCIFEROL
HIPREX, METHENAMINE HIPPURATE
LASIX, FUROSEMIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

US PHARMS HOLDINGS I

* US PHARMACEUTICALS HOLDINGS I LLC
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS

* US WORLDMEDS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

US WORLDMEDS LLC

* US WORLDMEDS LLC
CORGARD, NADOLOL

USL PHARMA

* USL PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BACLOFEN, BACLOFEN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** U **

* USL PHARMA INC
  BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
  CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
  CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
  FLUOXYMESTERONE, FLUOXYMESTERONE
  JANTOVEN, WARFARIN SODIUM
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

USV NORTH AMERICA

* USV NORTH AMERICA INC
  OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
  ZOLEDRONIC ACID, ZOLEDRONIC ACID

** V **

VALEANT

* VALEANT PHARMACEUTICALS INTERNATIONAL
  ANCOBON, FLUCYTOSINE
  BONTRIL PDM, PHENDIMETRAZINE TARTRATE
  D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
  MIGRANAL, DIHYDROERGOTAMINE MESYLATE
  MYSOLINE, PRIMIDONE

VALEANT BERMUDA

* VALEANT INTERNATIONAL BERMUDA
  BENZACLIN, BENZOYL PEROXIDE
  DERMATOP E EMOLLIENT, PREDNICARBATE
  ELIDEL, PIMECROLIMUS
  PENLAC, CICLOPIROX
  RETIN-A, TRETINOIN
  XERESE, ACYCLOVIR
  ZOVIRAX, ACYCLOVIR

VALEANT INTL

* VALEANT INTERNATIONAL BARBADOS SRL
  ATIVAN, LORAZEPAM
  CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
  CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
  CARDIZEM, DILTIAZEM HYDROCHLORIDE
  RETIN-A MICRO, TRETINOIN
  RETIN-A, TRETINOIN
  RETIN-A-MICRO, TRETINOIN
  VASERETIC, ENALAPRIL MALEATE
  WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
* VALEANT INTERNATIONAL SRL
  BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

* VALEANT PHARMACEUTICALS LUXEMBOURG SARL
  ERTACZO, SERTACONAZOLE NITRATE
  TARGRETIN, BEXAROTENE
  VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
  8-MOP, METHOXSALEN
  ANDROID 25, METHYLTESTOSTERONE
  EFUDEX, FLUOROURACIL
  LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
  MESTINON, PYRIDOSTIGMINE BROMIDE
  OXSORALEN, METHOXSALEN
  TESTRED, METHYLTESTOSTERONE
  VIRAZOLE, RIBAVIRIN
  ZELAPAR, SELEGILINE HYDROCHLORIDE

VALEANT PHARMS

* VALEANT PHARMACEUTICALS NORTH AMERICA
  MEPHYTON, PHYTONADIONE
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
  LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
  MESTINON, PYRIDOSTIGMINE BROMIDE
  MINITRAN, NITROGLYCERIN

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
  PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INC

* VALEANT PHARMACEUTICALS INTERNATIONAL INC
  GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

VALEANT PHARMS INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
  APRISO, MESALAMINE
  COLAZAL, BALSALAZIDE DISODIUM
  GIAZO, BALSALAZIDE DISODIUM
  UCERIS, BUDESONIDE

VALEANT PHARMS LLC

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
  CAPITAL AND CODEINE, ACETAMINOPHEN
  MACUGEN, PEGAPTANIB SODIUM
  MESTINON, PYRIDOSTIGMINE BROMIDE
  TASMAR, TOLCAPONE
  TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
  APLENZIN, BUPROPION HYDROBROMIDE
  CARAC, FLUOROURACIL
  DERMATOP, PREDNICARBATE
  DIASTAT ACUDIAL, DIAZEPAM
  DIASTAT, DIAZEPAM
  DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
  FENOFIBRATE, FENOFIBRATE
  IPRIVASK, DESIRUDIN RECOMBINANT
  ISORDIL, ISOSORBIDE DINITRATE
  KLARON, SULFACETAMIDE SODIUM
  MINITRAN, NITROGLYCERIN
  NIFEDIPINE, NIFEDIPINE
  NORITATE, METRONIDAZOLE
  PEPCID, FAMOTIDINE
  RENOVA, TRETINOIN
  RETIN-A, TRETINOIN
  SECONAL SODIUM, SECOBARBITAL SODIUM
  TIAZAC, DILTIAZEM HYDROCHLORIDE
  VASOTEC, ENALAPRIL MALEATE
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  XENAZINE, TETRABENAZINE

VALIDUS PHARMS

* VALIDUS PHARMACEUTICALS LLC
  NIFEDIPINE, NIFEDIPINE
  ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC

* VALIDUS PHARMACEUTICALS INC
  BUMEX, BUMETANIDE
  EQUETRO, CARBAMAZEPINE
  MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC

* VANDA PHARMACEUTICALS INC
  FANAPT, ILOPERIDONE
  HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC

* VELOXIS PHARMACEUTICALS INC
  ENVARSUS XR, TACROLIMUS

VERNALIS R AND D LTD

* VERNALIS R AND D LTD
  MOXATAG, AMOXICILLIN
  TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX

VEROSCIENCE

* VEROSCIENCE LLC
  CYCLOSET, BROMOCRIPTINE MESYLATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VERTEX PHARMS
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC
* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR

VERTICAL PHARMS LLC
* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VIB
* VALEANT INTERNATIONAL BERMUDA
ZOVIRAX, ACYCLOVIR

VICURON
* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS
* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIV HLTHCARE
* VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE
* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOLIC ACID, FOLIC ACID
GLIMEPIRIDE, GLIMEPIRIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VINTAGE PHARMACEUTICALS LLC
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
  ALPRAZOLAM, ALPRAZOLAM
  BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
  CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
  DISULFIRAM, DISULFIRAM
  GILDAGIA, ETHINYL ESTRADIOL
  GILDESS 24 FE, ETHINYL ESTRADIOL
  GLYCOPYRROLATE, GLYCOPYRROLATE
  GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  KIMIDESS, DESOGESTREL
  LEVETIRACETAM, LEVETIRACETAM
  METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
  METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
  OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
* VINTAGE PHARMACEUTICALS INC
  ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
  ALLOPURINOL, ALLOPURINOL
  AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
  BACLOFEN, BACLOFEN
  BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
  BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
  CARISOPRODOL, CARISOPRODOL
  CLONAZEPAM, CLONAZEPAM
  CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
  DEXAMETHASONE, DEXAMETHASONE
  DIAZEPAM, DIAZEPAM
  FUROSEMIDE, FUROSEMIDE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
  HYDROCORTISONE, HYDROCORTISONE
  HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  IBUPROFEN, IBUPROFEN
  IBUPROFEN, IBUPROFEN (OTC)
  ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
  LACTULOSE, LACTULOSE
  LEVETIRACETAM, LEVETIRACETAM
  LORAZEPAM, LORAZEPAM
  MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
  METHOCARBAMOL, METHOCARBAMOL
  METHYLPREDNISOLONE, METHYLPREDNISOLONE
  METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
  NYSTATIN, NYSTATIN
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
  OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  PERPHENAZINE, PERPHENAZINE
  PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
  PREDNISONE, PREDNISONE
  PRIMIDONE, PRIMIDONE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
  SULFASALAZINE, SULFASALAZINE
  TEMAZEPAM, TEMAZEPAM
  TORSEMIDE, TORSEMIDE
  TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VINTAGE PHARMS LLC
* VINTAGE PHARMACEUTICALS LLC
  CYCLAFEM 1/35, ETHINYL ESTRADIOL
  CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
  DUTASTERIDE, DUTASTERIDE
  EMOQUETTE, DESOGESTREL
  FELODIPINE, FELODIPINE
  GILDESS 1.5/30, ETHINYL ESTRADIOL
  GILDESS 1/20, ETHINYL ESTRADIOL
  GILDESS FE 1.5/30, ETHINYL ESTRADIOL
  GILDESS FE 1/20, ETHINYL ESTRADIOL
  LETROZOLE, LETROZOLE
  LEVETIRACETAM, LEVETIRACETAM
  MEFENAMIC ACID, MEFENAMIC ACID
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  MORPHINE SULFATE, MORPHINE SULFATE
  MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
  MYZILRA, ETHINYL ESTRADIOL
  ORSYTHIA, ETHINYL ESTRADIOL
  PERCOCET, ACETAMINOPHEN
  PREVIFEM, ETHINYL ESTRADIOL
  TRI-PREVIFEM, ETHINYL ESTRADIOL

VIRTUS PHARM
* VIRTUS PHARMACEUTICAL INC
  ACARBOSE, ACARBOSE

VIRTUS PHARMS
* VIRTUS PHARMACEUTICALS LLC
  PROMETRIUM, PROGESTERONE

VISTA PHARMS
* VISTA PHARMACEUTICALS INC
  SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM
* VISTAPHARM INC
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
  LACTULOSE, LACTULOSE
  METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
  METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
  MORPHINE SULFATE, MORPHINE SULFATE
  NYSTATIN, NYSTATIN
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
  PHENYTOIN, PHENYTOIN

VIVIMED LABS
* VIVIMED LABS ALATHUR PRIVATE LTD
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  METRONIDAZOLE, METRONIDAZOLE

VIVUS
* VIVUS INC
  QSYMIA, PHENTERMINE HYDROCHLORIDE

VPNA
* VALEANT PHARMACEUTICALS NORTH AMERICA
  DICLOFENAC SODIUM, DICLOFENAC SODIUM

** W **

WA UNIV SCH MED
* WASHINGTON UNIV SCHOOL MEDICINE
  AMMONIA N 13, AMMONIA N-13
  CHOLINE C-11, CHOLINE C-11

WARNER CHILCOTT LLC
* WARNER CHILCOTT CO LLC
  CHOLEDYL SA, OXTRIPHYLLINE

WATSON LABS

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WATSON LABORATORIES
  FOLIC ACID, FOLIC ACID
  PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
  PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
* WATSON LABORATORIES INC
  ACARBOSE, ACARBOSE
  AFEDITAB CR, NIFEDIPINE
  ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
  ALBUTEROL SULFATE, ALBUTEROL SULFATE
  ALENDRONATE SODIUM, ALENDRONATE SODIUM
  ALLOPURINOL, ALLOPURINOL
  AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  AMOXAPINE, AMOXAPINE
  ATENOLOL AND CHLORTHALIDONE, ATENOLOL
  CAPTOPRIL, CAPTOPRIL
  CARISOPRODOL, CARISOPRODOL
  CHLORZOXAZONE, CHLORZOXAZONE
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
  CLONAZEPAM, CLONAZEPAM
  COL-PROBENECID, COLCHICINE
  DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
  DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
  DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
  ESTAZOLAM, ESTAZOLAM
  ESTROPIPATE, ESTROPIPATE
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  GLIPIZIDE, GLIPIZIDE
  GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
  HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
  HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
  IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
  ISRADIPINE, ISRADIPINE
  LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
  LAMOTRIGINE, LAMOTRIGINE
  LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  LISINOPRIL, LISINOPRIL
  LORAZEPAM, LORAZEPAM
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
  MEPROBAMATE, MEPROBAMATE
  METHOCARBAMOL, METHOCARBAMOL
  METHYLDOPA, METHYLDOPA
  METHYLPREDNISOLONE, METHYLPREDNISOLONE
  METOPROLOL TARTRATE, METOPROLOL TARTRATE
  METRONIDAZOLE, METRONIDAZOLE
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
  MINOXIDIL, MINOXIDIL
  MIRTAZAPINE, MIRTAZAPINE
  NABUMETONE, NABUMETONE
  NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
  NATEGLINIDE, NATEGLINIDE
  NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
  NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
  NIZATIDINE, NIZATIDINE
  NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
  NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
  OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
  ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
  OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
  OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
  PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
  PREDNISOLONE, PREDNISOLONE
  PREDNISONE, PREDNISONE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WATSON LABORATORIES INC
  PRIMIDONE, PRIMIDONE
  PROBENECID, PROBENECID
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
  QUASENSE, ETHINYL ESTRADIOL
  QUINIDINE SULFATE, QUINIDINE SULFATE
  RAMIPRIL, RAMIPRIL
  RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
  SIMVASTATIN, SIMVASTATIN
  SULFASALAZINE, SULFASALAZINE
  SULINDAC, SULINDAC
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TELMISARTAN, TELMISARTAN
  TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
  TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
  TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
  TOPIRAMATE, TOPIRAMATE
  TRANDOLAPRIL, TRANDOLAPRIL
  TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
  TRIMETHOPRIM, TRIMETHOPRIM
  VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
  VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
  ZOVIA 1/50E-28, ETHINYL ESTRADIOL
* WATSON LABS INC
  LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS FLORIDA

* WATSON LABORATORIES INC FLORIDA
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

WATSON LABS INC

* WATSON LABORATORIES INC
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
  AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
  AMMONIUM LACTATE, AMMONIUM LACTATE
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CELECOXIB, CELECOXIB
  CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
  DICLOFENAC SODIUM, DICLOFENAC SODIUM
  DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
  DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
  ESTRADIOL VALERATE AND DIENOGEST, DIENOGEST
  IBANDRONATE SODIUM, IBANDRONATE SODIUM
  INDOMETHACIN, INDOMETHACIN
  LEVOFLOXACIN, LEVOFLOXACIN
  LEVONORGESTREL, LEVONORGESTREL (OTC)
  LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
  METRONIDAZOLE, METRONIDAZOLE
  MODAFINIL, MODAFINIL
  MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
  NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
  PERPHENAZINE, PERPHENAZINE
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
  PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
  PROPOFOL, PROPOFOL
  RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
  RASAGILINE MESYLATE, RASAGILINE MESYLATE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
  SILDENAFIL CITRATE, SILDENAFIL CITRATE
  VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  VALSARTAN, VALSARTAN
  VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

WATSON PHARMS INC
* WATSON PHARMACEUTICALS INC
RIFAMPIN, RIFAMPIN

WELLSTAT THERAP
* WELLSTAT THERAPEUTICS CORP
VISTOGARD, URIDINE TRIACETATE
XURIDEN, URIDINE TRIACETATE

WES PHARMA INC
* WES PHARMA INC
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

WEST WARD PHARM CORP
* WEST WARD PHARMACEUTICAL CORP
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

WEST-WARD PHARM CORP
* WEST-WARD PHARMACEUTICAL CORP
CEFOTETAN, CEFOTETAN DISODIUM

WEST-WARD PHARMS INT
* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMRINONE LACTATE, INAMRINONE LACTATE
ANASTROZOLE, ANASTROZOLE
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAFCIT, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLADRIBINE, CLADRIBINE
CLARITHROMYCIN, CLARITHROMYCIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIAZEPAM INTENSOL, DIAZEPAM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISULFIRAM, DISULFIRAM
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DURAMORPH PF, MORPHINE SULFATE
DUTASTERIDE, DUTASTERIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESZOPICLONE, ESZOPICLONE
ETOPOSIDE, ETOPOSIDE
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFUMORPH, MORPHINE SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACTULOSE, LACTULOSE
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LORAZEPAM INTENSOL, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
MESNA, MESNA
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALOXONE, NALOXONE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOSTATIN, PENTOSTATIN
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
ROBAXIN, METHOCARBAMOL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROXICET, ACETAMINOPHEN
RUFINAMIDE, RUFINAMIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
THIOTEPA, THIOTEPA
TINIDAZOLE, TINIDAZOLE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TORSEMIDE, TORSEMIDE
TRIAZOLAM, TRIAZOLAM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE

WI MEDCL CYCLOTRON

* WISCONSIN MEDICAL CYCLOTRON LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL
LAMOTRIGINE, LAMOTRIGINE
PERPHENAZINE, PERPHENAZINE

WOCKHARDT

* WOCKHARDT AMERICAS INC
CAPTOPRIL, CAPTOPRIL
FAMOTIDINE, FAMOTIDINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WOCKHARDT EU OPERATIONS (SWISS) AG
  ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
  ACETIC ACID, ACETIC ACID, GLACIAL
  AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
  AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
  AMOXICILLIN, AMOXICILLIN
  BROMFED-DM, BROMPHENIRAMINE MALEATE
  CARBAMAZEPINE, CARBAMAZEPINE
  CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
  CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
  CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
  CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
  CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
  CROMOLYN SODIUM, CROMOLYN SODIUM
  CYCLOSPORINE, CYCLOSPORINE
  DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
  DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
  ERYTHROMYCIN, ERYTHROMYCIN
  FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
  FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
  FUROSEMIDE, FUROSEMIDE
  HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
  HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
  LEVETIRACETAM, LEVETIRACETAM
  LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
  LINDANE, LINDANE
  LITHIUM CITRATE, LITHIUM CITRATE
  LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
  LORATADINE, LORATADINE (OTC)
  MEGESTROL ACETATE, MEGESTROL ACETATE
  METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
  MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
  MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
  NYSTATIN, NYSTATIN
  OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
  PHENYTOIN, PHENYTOIN
  PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
  PREDNISOLONE, PREDNISOLONE
  PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
  PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
  PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
  SELENIUM SULFIDE, SELENIUM SULFIDE
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
  VALPROIC ACID, VALPROIC ACID
* WOCKHARDT LTD
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  AZITHROMYCIN, AZITHROMYCIN
  BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
  BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
  CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
  CEFOTAXIME, CEFOTAXIME SODIUM
  CEFPROZIL, CEFPROZIL
  CEFTAZIDIME, CEFTAZIDIME
  CEFTRIAXONE, CEFTRIAXONE SODIUM
  CEFUROXIME AXETIL, CEFUROXIME AXETIL
  CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
  CLARITHROMYCIN, CLARITHROMYCIN
  DIVALPROEX SODIUM, DIVALPROEX SODIUM
  DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
  FAMOTIDINE, FAMOTIDINE (OTC)
  FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
  FUROSEMIDE, FUROSEMIDE
  KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
  LEVETIRACETAM, LEVETIRACETAM

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WOCKHARDT LTD
  LEVOFLOXACIN, LEVOFLOXACIN
  LISINOPRIL, LISINOPRIL
  METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
  NIACIN, NIACIN
  NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
  ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
  PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
  RISPERIDONE, RISPERIDONE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
  SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  TIMOLOL MALEATE, TIMOLOL MALEATE
  VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
  ZONISAMIDE, ZONISAMIDE

WOCKHARDT BIO AG

* WOCKHARDT BIO AG
  OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

WOCKHARDT EU OPERATN

* WOCKHARDT EU OPERATIONS SWISS AG
  AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
  DEXAMETHASONE, DEXAMETHASONE
  TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

WOCKHARDT LTD

* WOCKHARDT LTD
  BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
  CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
  CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
  CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
  CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
  ENTACAPONE, ENTACAPONE
  FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
  FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
  LAMOTRIGINE, LAMOTRIGINE
  LANSOPRAZOLE, LANSOPRAZOLE (OTC)
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA

* WOCKHARDT USA INC
  GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
* WOCKHARDT USA LLC
  ENALAPRIL MALEATE, ENALAPRIL MALEATE
  LANSOPRAZOLE, LANSOPRAZOLE

WRASER PHARMS

* WRASER PHARMACEUTICALS LLC
  CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC

* WRASER PHARMACEUTICALS LLC
  TREZIX, ACETAMINOPHEN

WUSM CYCLOTRON

* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS INC

* WYETH PHARMACEUTICALS INC
  CORDARONE, AMIODARONE HYDROCHLORIDE
  EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
  PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
  PREMARIN, ESTROGENS, CONJUGATED
  PREMPHASE 14/14, ESTROGENS, CONJUGATED

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WYETH PHARMACEUTICALS INC
  PREMPRO, ESTROGENS, CONJUGATED
  PRISTIQ, DESVENLAFAXINE SUCCINATE
  PROTONIX IV, PANTOPRAZOLE SODIUM
  PROTONIX, PANTOPRAZOLE SODIUM
  TRECATOR, ETHIONAMIDE
  ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
  ZOSYN, PIPERACILLIN SODIUM

WYETH PHARMS PFIZER

* WYETH PHARMACEUTICALS INC WHOLLY OWNED SUB PFIZER INC
  DUAVEE, BAZEDOXIFENE ACETATE

** X **

X GEN PHARMS

* X GEN PHARMACEUTICALS INC
  ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
  AMPHOTERICIN B, AMPHOTERICIN B
  BACIIM, BACITRACIN
  COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
  LEVETIRACETAM, LEVETIRACETAM
  LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
  NEO-FRADIN, NEOMYCIN SULFATE
  NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
  NEOMYCIN SULFATE, NEOMYCIN SULFATE
  NYSTATIN, NYSTATIN
  POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
  STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
  TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS

* X-GEN PHARMACEUTICALS INC
  PHENYTOIN SODIUM, PHENYTOIN SODIUM
  PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

X-GEN PHARMS INC

* X-GEN PHARMACEUTICALS INC
  HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
  LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
  TRANEXAMIC ACID, TRANEXAMIC ACID

XELLIA PHARMS APS

* XELLIA PHARMACEUTICALS APS
  BACITRACIN, BACITRACIN
  COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
  POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
  TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
  VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

XSPIRE

* XSPIRE LLC
  NALFON, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
  CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
  EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

** Y **

YAOPHARMA CO LTD

* YAOPHARMA CO LTD
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YUNG SHIN PHARM

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
  CEFACLOR, CEFACLOR
  CEPHALEXIN, CEPHALEXIN
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  MELOXICAM, MELOXICAM
  ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

** Z **

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** Z **

ZACH SYSTEM SPA
* ZACH SYSTEM SPA
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE

ZACH SYSTEMS
* ZACH SYSTEMS SPA
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE

ZAMBON SPA
* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZEVACOR PHARMA INC
* ZEVACOR PHARMA INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ZYDUS HLTHCARE
* ZYDUS HEALTHCARE USA LLC
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS PHARMS USA
* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC
* ZYDUS PHARMACEUTICALS USA INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE

FDA data supplied by DrugPatentWatch.com

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** Z **

* ZYDUS PHARMACEUTICALS USA INC
  FINASTERIDE, FINASTERIDE
  GABAPENTIN, GABAPENTIN
  GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
  GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
  GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
  GLYBURIDE, GLYBURIDE
  HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
  INDOMETHACIN, INDOMETHACIN
  IRBESARTAN, IRBESARTAN
  LAMOTRIGINE, LAMOTRIGINE
  LEVETIRACETAM, LEVETIRACETAM
  LEVOFLOXACIN, LEVOFLOXACIN
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  METRONIDAZOLE, METRONIDAZOLE
  NATEGLINIDE, NATEGLINIDE
  OMEPRAZOLE, OMEPRAZOLE
  PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
  POTASSIUM CITRATE, POTASSIUM CITRATE
  PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
  PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
  PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
  RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
  RISPERIDONE, RISPERIDONE
  ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
  SIROLIMUS, SIROLIMUS
  TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
  TELMISARTAN, TELMISARTAN
  TOPIRAMATE, TOPIRAMATE
  TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
  VORICONAZOLE, VORICONAZOLE
  ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS WORLDWIDE

* ZYDUS WORLDWIDE DMCC
  MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL, FOAM
AEROSOL, METERED
CAPSULE
CAPSULE, DELAYED REL PELLETS
CAPSULE, DELAYED RELEASE
CAPSULE, EXTENDED RELEASE
CLOTH
CONCENTRATE
CREAM
CREAM, AUGMENTED
ELIXIR
EMULSION
ENEMA
FILM
FILM, EXTENDED RELEASE
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, DELAYED RELEASE
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
OIL
OIL/DROPS
OINTMENT
OINTMENT, AUGMENTED
PASTE
PATCH
PELLET
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION, GEL FORMING/DROPS
SOLUTION, METERED
SOLUTION/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION, EXTENDED RELEASE
SUSPENSION/DROPS
SWAB
SYRUP
SYSTEM
SYSTEM, EXTENDED RELEASE
TABLET
TABLET, CHEWABLE
TABLET, COATED PARTICLES
TABLET, DELAYED RELEASE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, EXTENDED RELEASE, CHEWABLE
TABLET, FOR SUSPENSION
TABLET, ORALLY DISINTEGRATING
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
TAPE
TROCHE/LOZENGE

Note: Terms comprise currently marketed products

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
DENTAL
ENDOCERVICAL
ENTERAL
FOR RX COMPOUNDING
IMPLANTATION
INHALATION
INJECTION
INTRA-ANAL
INTRACRANIAL
INTRAMUSCULAR
INTRAOCULAR
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVENOUS
INTRAVESICAL
INTRAVITREAL
IONTOPHORESIS
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION, CARDIAC
PERIODONTAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TRANSDERMAL
TRANSMUCOSAL
URETHRAL
VAGINAL

Note: Terms comprise currently marketed products

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

ABBREVIATIONS

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for periods of exclusivity and provides patent information concerning the listed drug products. During exclusivity periods, certain abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (505(b)(2) applications) for those drug products in some instances may not be submitted or approved as described below. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act, those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act, and those drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed by the trade name. Active ingredient headings for multiple ingredient fixed-combination drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity. These exclusivities do not prevent the submission or approval of an application submitted pursuant to Section 505(b)(1) of the FD&C Act that would otherwise be blocked if it had been submitted pursuant to Section 505(b)(2) or 505(j), except in the case of Orphan Drug Exclusivity. Drugs that may qualify for periods of exclusivity include:

(1) A new chemical entity, submitted in a new drug application under section 505(b) of the FD&C Act and approved after September 24, 1984. A new chemical entity is an active ingredient that contains “no active ingredient (including any ester or salt of the active ingredient)” that has been approved by FDA in any other application submitted under section 505(b) of the FD&C Act. No subsequent ANDA or 505(b)(2) application for a drug that contains the same “active ingredient (including any ester or salt of the active ingredient)” may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought. See sections 505(j)(5)(F)(ii) and 505(c)(3)(E)(ii) of the FD&C Act.

(2) A new drug application approved after September 24, 1984, for a drug product containing ”an active ingredient (including any ester or salt of the active ingredient)” that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, a subsequent ANDA or a 505(b)(2) application may not be approved for the exclusivity-protected “conditions of approval of such drug” before the expiration of *three years* from the date of approval of the original application. If a NDA or 505(b)(2) applicant has exclusivity only for a new indication or use, this exclusivity generally does not preclude the approval of an ANDA or 505(b)(2) application for indications and uses not covered by the exclusivity, assuming the

FDA data supplied by DrugPatentWatch.com

proposed drug product will be safe and effective as labeled. See sections 505(j)(5)(F)(iii) and 505(c)(3)(E)(iii) of the FD&C Act.

(3) A supplement to a new drug application for a drug containing a previously approved "active ingredient (including any ester or salt of the active ingredient)" approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. A subsequent ANDA or 505(b)(2) application may not be approved for an exclusivity-protected change approved in the supplement for *three years* from the date of approval of the original supplement. See sections 505(j)(5)(F)(iv) and 505(c)(3)(E)(iv) of the FD&C Act.

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using Form FDA 3542a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the Agency within 30 days of the date of approval on Form FDA 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement." Please note that the date of approval for an NDA for which FDA recommends controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see section 505(x)(1) and (2) of the FD&C Act). Patent information on unapproved applications or on patents beyond the scope of the FD&C Act (i.e., process or manufacturing patents) will not be published. Form FDA 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents, which include formulation/composition patents; method-of-use patents that claim one or more approved methods of using the approved drug product; and certain other patents as detailed on Form FDA 3542. This information, as provided by the sponsor on Form FDA 3542, will be published as described above. As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the QI Program Supplemental Funding Act (Public Law 110-379) (QI Act).

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published daily in the Electronic Orange Book. The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic

Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE - ZIAGEN						
N 020977 001	6294540	May 14, 2018	DS DP U-65		D-147	Mar 23, 2018
ABACAVIR SULFATE - ZIAGEN						
N 020978 001	6294540	May 14, 2018	DS DP U-65		D-147	Mar 23, 2018
	6641843	Feb 04, 2019	DP			
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ						
N 205551 001	5905082*PED	Nov 18, 2016			NCE	Aug 12, 2018
	6294540	May 14, 2018	DS DP U-1572			
	6294540*PED	Nov 14, 2018				
	6417191*PED	Sep 28, 2016				
	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
ABACAVIR SULFATE; LAMIVUDINE - ABACAVIR SULFATE AND LAMIVUDINE						
A 079246 001					PC	Mar 28, 2017
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM						
N 021652 001	6294540	May 14, 2018	DS DP U-257			
	6417191*PED	Sep 28, 2016				
ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR						
N 021205 001	6294540	May 14, 2018	DS DP U-65			
ABARELIX - PLENAXIS						
N 021320 001	5968895	Dec 11, 2016	DP			
	6180608	Dec 11, 2016	DP U-549			
	6699833	Dec 11, 2016	DP			
ABIRATERONE ACETATE - ZYTIGA						
N 202379 001	5604213	Dec 13, 2016	DS DP U-1126			
	5604213	Dec 13, 2016	DS DP U-1314			
	8822438	Aug 24, 2027	U-1579			
	8822438	Aug 24, 2027	U-1580			
ACETAMINOPHEN - OFIRMEV						
N 022450 001	6028222	Aug 05, 2017	DP			
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	9399012	Sep 11, 2031	U-1882			
	9399012*PED	Mar 11, 2032				
ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)						
N 020802 001	5972916	Jul 14, 2017	U-296			
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			
	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
	9468636	May 16, 2032	U-1499			
ACETYLCYSTEINE - ACETADOTE						
N 021539 001	8148356	May 21, 2026	DP			
	8399445	Aug 24, 2025	U-1373			
	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
	9327028	Jul 21, 2031	U-1839			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETYLCYSTEINE - CETYLEV						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
ACETYLCYSTEINE - CETYLEV						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR						
N 202450 001	6681768	Aug 07, 2022	DP		NCE	Jul 23, 2017
	6750226	Sep 05, 2020	DS DP U-1264			
	7078412	Jul 16, 2020	DS DP U-1263			
	8051851	Apr 22, 2027	DP			
	9056100	Jul 07, 2020	DP U-1263			
	9333195	Jul 07, 2020	DP U-1263			
ACYCLOVIR - SITAVIG						
N 203791 001	8592434	Jun 16, 2030	DP U-1460			
	8747896	Jun 03, 2027	DP U-1460			
	8791127	Mar 23, 2027	DP U-1460			
ACYCLOVIR; HYDROCORTISONE - XERESE						
N 022436 001	6514980	Jul 24, 2018	DP U-1006		NPP	Jan 22, 2017
	6514980	Jul 24, 2018	DP U-1484			
	7223387	Nov 13, 2022	DP U-1006			
	7223387	Nov 13, 2022	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
ADAPALENE - DIFFERIN						
N 020380 002					RTO	Jul 08, 2019
ADAPALENE - DIFFERIN						
N 021753 001	7579377	Feb 23, 2025	U-818			
	7737181	Aug 29, 2024	DP			
	7834060	Mar 12, 2023	U-1078			
	7838558	Mar 12, 2023	DP			
	7868044	Mar 12, 2023	U-1078			
	8703820	Mar 12, 2023	U-1078			
ADAPALENE - DIFFERIN						
N 022502 001	7998467	May 31, 2028	DP U-1078			
	8435502	Sep 15, 2026	DP U-1078			
	8709392	Sep 15, 2026	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO						
N 022320 001	7820186	Nov 23, 2025	DP			
	7964202	Sep 01, 2024	DP U-1078			
	8071644	Jul 18, 2027	DP U-1078			
	8080537	Jul 18, 2027	U-1078			
	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8241649	Dec 23, 2022	DP			
	8445543	Jul 12, 2027	U-1078			
	8809305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE						
N 207917 001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8809305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
ADEFOVIR DIPIVOXIL - HEPSERA						
N 021449 001	6451340	Jul 23, 2018	DS DP U-470			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AFATINIB DIMALEATE - GILOTRIF						
N 201292 001	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
AFATINIB DIMALEATE - GILOTRIF						
N 201292 002	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
AFATINIB DIMALEATE - GILOTRIF						
N 201292 003	6251912	Jul 29, 2018	DS DP U-1067		I-730	Apr 15, 2019
	8426586	Oct 10, 2029	DS		NCE	Jul 12, 2018
	8545884	Dec 19, 2029	DP		ODE	Jul 12, 2020
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
ALBUMIN HUMAN - OPTISON						
N 020899 001	6723303	Apr 20, 2021	DP			
ALBUTEROL SULFATE - PROVENTIL-HFA						
N 020503 001	6006745	Dec 28, 2016	DP			
ALBUTEROL SULFATE - ACCUNEB						
N 020949 001	6702997	Dec 28, 2021	U-558			
ALBUTEROL SULFATE - ACCUNEB						
N 020949 002	6702997	Dec 28, 2021	U-558			
ALBUTEROL SULFATE - VENTOLIN HFA						
N 020983 001	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6558651	Dec 19, 2016	DP U-716			
	6743413	Jun 01, 2021	U-716			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
ALBUTEROL SULFATE - PROAIR HFA						
N 021457 001	6446627	Dec 18, 2017	DP			
	7105152	Sep 12, 2023	DP			
	7566445	Jun 04, 2017	DP			
	8132712	Sep 07, 2028	DP			
	8834849	Jun 04, 2017	DP			
	9463289	May 18, 2031	DP			
ALBUTEROL SULFATE - PROAIR RESPICLICK						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP		NPP	Apr 28, 2019
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB							
N 020950	001	6632842	Dec 28, 2021	U-532			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT							
N 021747	001	5964416	Oct 04, 2016	DP			
		6149054	Dec 19, 2016	DP			
		6176442	Oct 04, 2016	DP			
		6453795	Dec 05, 2016	DP			
		6726124	Oct 04, 2016	DP			
		6846413	Aug 28, 2018	DP			
		6977042	Aug 28, 2018	DP			
		6988496	Feb 23, 2020	DP			
		7104470	Oct 04, 2016	DP			
		7284474	Aug 26, 2024	DP			
		7396341	Oct 10, 2026	DP			
		7802568	Feb 26, 2019	DP			
		7837235	Mar 13, 2028	DP			
		7896264	May 26, 2025	DP			
		7988001	Aug 04, 2021	DP			
		8733341	Dec 16, 2029	DP			
		9027967	Mar 31, 2027	DP			
ALCAFTADINE - LASTACAFT							
N 022134	001	8664215	Dec 23, 2027	U-1493			
ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD							
N 021074	001	7081246	Aug 03, 2016	DP			
ALECTINIB HYDROCHLORIDE - ALECENSA							
N 208434	001	9126931	May 29, 2031	DS		NCE	Dec 11, 2020
		9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
		9440922	Jun 09, 2030	DP			
ALENDRONATE SODIUM - FOSAMAX							
N 021575	001	5994329	Jul 17, 2018		Y		
		6015801	Jul 17, 2018		Y		
		6225294	Jul 17, 2018		Y		
ALENDRONATE SODIUM - BINOSTO							
N 202344	001	7488496	Aug 11, 2023	DS DP			
		7964212	Mar 06, 2023	DS DP			
ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D							
N 021762	001	5994329	Jul 17, 2018	U-647	Y		
ALFUZOSIN HYDROCHLORIDE - UROXATRAL							
N 021287	001	6149940	Aug 22, 2017				
ALISKIREN HEMIFUMARATE - TEKTURNA							
N 021985	001	5559111	Jul 21, 2018	DS DP U-3			
		8617595	Feb 19, 2026	DP			
ALISKIREN HEMIFUMARATE - TEKTURNA							
N 021985	002	5559111	Jul 21, 2018	DS DP U-3			
		8617595	Feb 19, 2026	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	001	5559111	Jul 21, 2018	DS DP U-3			
		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	002	5559111	Jul 21, 2018	DS DP U-3			
		8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	003	5559111	Jul 21, 2018	DS DP U-3			
		8613949	Dec 21, 2029	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N 022545 004	5559111	Jul 21, 2018	DS DP U-3			
	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N 200045 001	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N 200045 002	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N 200045 003	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N 200045 004	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N 200045 005	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA						
N 022217 001	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA						
N 022217 002	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
ALITRETINOIN - PANRETIN						
N 020886 001	5932622	Aug 03, 2016	U-562			
ALOGLIPTIN BENZOATE - NESINA						
N 022271 001	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA						
N 022271 002	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE - NESINA						
N 022271 002	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
ALOGLIPTIN BENZOATE - NESINA						
N 022271 003	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO						
N 203414 001	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO						
N 203414 002	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 001	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 002	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 003	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 003	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 004	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 005	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 006	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
ALPRAZOLAM - NIRAVAM						
N 021726 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
ALPRAZOLAM - NIRAVAM						
N 021726 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
ALPRAZOLAM - NIRAVAM						
N 021726 003	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
ALPRAZOLAM - NIRAVAM						
N 021726 004	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
ALVIMOPAN - ENTEREG						
N 021775 001	6469030	Nov 29, 2020	U-879		M-128	Oct 18, 2016
	8112290	Jul 31, 2030	U-1443			
	8645160	Jun 18, 2029	U-1485			
	8946262	Feb 12, 2030	U-1655			
AMBRISENTAN - LETAIRIS						
N 022081 001	8377933	Dec 11, 2027	U-1754		I-716	Oct 02, 2018
	9474752	Dec 11, 2027	U-1754			
	RE42462	Jul 29, 2018	DS			
AMBRISENTAN - LETAIRIS						
N 022081 002	8377933	Dec 11, 2027	U-1754		I-716	Oct 02, 2018
	9474752	Dec 11, 2027	U-1754			
	RE42462	Jul 29, 2018	DS			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMIFOSTINE - ETHYOL						
N 020221 001	5994409	Dec 08, 2017	U-305			
AMIFOSTINE - ETHYOL						
N 020221 002	5994409	Dec 08, 2017	U-305			
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN						
N 020965 001	5954703	Oct 31, 2017	U-289			
	6709446	May 01, 2018	U-289			
	7723910	Jun 17, 2019	U-289			
	8216289	May 01, 2018	U-289			
	8758418	May 01, 2018	U-289			
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ						
N 208081 001	6559183	Nov 12, 2019	DP U-804		NP	May 10, 2019
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 001	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 002	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE						
N 022325 003	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE						
N 022026 001	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE						
N 022026 002	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE						
N 022026 003	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
N 021540 001	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
N 021540 002	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
N 021540 003	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
N 021540 004	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
N 021540 005	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
N 021540 006	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
N 021540 007	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
N 021540 008	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET							
N 021540	009	5969156	Jul 08, 2016	DS			
		6455574	Aug 11, 2018			U-552	
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET							
N 021540	010	5969156	Jul 08, 2016	DS			
		6455574	Aug 11, 2018			U-552	
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET							
N 021540	011	5969156	Jul 08, 2016	DS			
		6455574	Aug 11, 2018			U-552	
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL							
N 020364	002	6162802	Dec 19, 2017			U-367	
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL							
N 020364	003	6162802	Dec 19, 2017			U-367	
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL							
N 020364	004	6162802	Dec 19, 2017			U-367	
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL							
N 020364	005	6162802	Dec 19, 2017			U-367	
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL							
N 020364	006	6162802	Dec 19, 2017	DS DP		U-185	
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL							
N 020364	007	6162802	Dec 19, 2017	DS DP		U-185	
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	001	6294197	Jun 18, 2017	DP		U-3	
		8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	002	6294197	Jun 18, 2017	DP		U-3	
		8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	003	6294197	Jun 18, 2017	DP		U-3	
		8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	004	6294197	Jun 18, 2017	DP		U-3	
		8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	005	6294197	Jun 18, 2017	DP		U-3	
		8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	001	6696481	Apr 15, 2023	DS DP		U-3	
		7846961	Oct 05, 2029	DS DP		U-3	
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	002	6696481	Apr 15, 2023	DS DP		U-3	
		7846961	Oct 05, 2029	DS DP		U-3	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA						
N 205003 003	6696481	Apr 15, 2023	DS DP U-3			
	7846961	Oct 05, 2029	DS DP U-3			
AMLODIPINE BESYLATE; VALSARTAN - EXFORGE						
N 021990 002	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
AMLODIPINE BESYLATE; VALSARTAN - EXFORGE						
N 021990 003	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
AMLODIPINE BESYLATE; VALSARTAN - EXFORGE						
N 021990 004	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
AMLODIPINE BESYLATE; VALSARTAN - EXFORGE						
N 021990 005	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
AMOXICILLIN - MOXATAG						
N 050813 001	6544555	Oct 13, 2020	DS DP U-897			
	6669948	Oct 13, 2020	DS DP U-897			
	6723341	Oct 13, 2020	DS DP U-897			
	8299052	May 07, 2027	U-1304			
	8357394	Dec 08, 2026	DP			
	8778924	Dec 08, 2026	DS DP U-897			
AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR						
N 050785 001	6746692	Apr 04, 2020	DP			
	6783773	Apr 04, 2020	DP			
	6878386	Apr 04, 2020	U-926			
	7217430	Apr 04, 2020	DP U-926			
	7250176	Apr 04, 2020	U-926			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE - DYANAVEL XR						
N 208147 001	8062667	Mar 29, 2029	DP		NP	Oct 19, 2018
	8597684	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	8883217	Mar 15, 2027	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10						
N 011522 007	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20						
N 011522 008	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5						
N 011522 009	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30						
N 011522 010	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5						
N 011522 011	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5						
N 011522 012	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15						
N 011522 013	6384020	Jul 06, 2020				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10						
N 021303 001	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20						
N 021303 002	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30						
N 021303 003	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25						
N 021303 004	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5						
N 021303 005	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15						
N 021303 006	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15						
N 021303 006	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
AMPHOTERICIN B - ABELCET						
N 050724 001	6406713	Jun 18, 2019	DS			
AMPHOTERICIN B - AMBISOME						
N 050740 001	5965156	Oct 12, 2016	DP U-922			
AMPRENAVIR - AGENERASE						
N 021007 001	6730679	Nov 11, 2017	DP			
AMPRENAVIR - AGENERASE						
N 021007 002	6730679	Nov 11, 2017	DP			
ANIDULAFUNGIN - ERAXIS						
N 021632 001	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
ANIDULAFUNGIN - ERAXIS						
N 021632 002	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
APIXABAN - ELIQUIS						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1501		I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1167		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
	6967208	Feb 03, 2023	DS DP U-1729			
	6967208	Feb 03, 2023	DS DP U-1730			
	9326945	Feb 24, 2031	DP			
APIXABAN - ELIQUIS						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1200		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	9326945	Feb 24, 2031	DP			
APREMILAST - OTEZLA						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
APREMILAST - OTEZLA						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA						
N 205437 002	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
APREMILAST - OTEZLA						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
APREPITANT - EMEND						
N 021549 001	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
APREPITANT - EMEND						
N 021549 002	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
APREPITANT - EMEND						
N 021549 003	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
APREPITANT - EMEND						
N 207865 001	6096742	Jul 01, 2018	DS DP U-1916		NPP	Aug 28, 2018
	8258132	Sep 26, 2027	DP U-1916			
ARFORMOTEROL TARTRATE - BROVANA						
N 021912 001	6040344	Nov 12, 2016	DS			
	6472563	Nov 09, 2021	DS			
	6667344	Jun 22, 2021	DP			
	6720453	Nov 09, 2021	DS			
	6814953	Jun 22, 2021	U-793			
	7145036	Nov 09, 2021	DS			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE						
N 022434 001	7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 001	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 002	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 003	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 004	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 005	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 005	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 006	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021713 001	6977257	Apr 24, 2022	DP		I-700	Dec 12, 2017
	6977257*PED	Oct 24, 2022			M-137	Jun 09, 2017
	7053092	Jan 28, 2022	U-839		ODE	Dec 12, 2021
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 002	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 003	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 004	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 005	7053092	Jan 28, 2022	U-839		I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021866 001	7115587	Jul 21, 2024	DP U-764		I-700	Dec 12, 2017
	7115587*PED	Jan 21, 2025			M-137	Jun 09, 2017
	7550445	Jul 21, 2024	DP		ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-543			
ARMODAFINIL - ARMODAFINIL						
A 200043 001					PC	Nov 28, 2016
ARMODAFINIL - ARMODAFINIL						
A 200043 002					PC	Nov 28, 2016
ARMODAFINIL - ARMODAFINIL						
A 200043 003					PC	Nov 28, 2016
ARMODAFINIL - ARMODAFINIL						
A 200156 004					PC	Nov 28, 2016
ARMODAFINIL - NUVIGIL						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARMODAFINIL - NUVIGIL						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARSENIC TRIOXIDE - TRISENOX						
N 021248 001	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP						
N 021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
ASENAPINE MALEATE - SAPHRIS						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS						
N 022117 003	5763476	Jun 09, 2020	DP U-1893			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASPIRIN - ASPIRIN						
N 203697 001	8865187	Mar 23, 2022	DP			
	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
	9351984	Dec 19, 2021	DP			
ASPIRIN; DIPYRIDAMOLE - AGGRENOX						
N 020884 001	6015577	Jan 18, 2017	U-302			
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 001	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 001	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 002	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
ATAZANAVIR SULFATE - REYATAZ						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			NPP	Sep 24, 2018
	6087383	Dec 21, 2018	DS DP		PED	Dec 02, 2017
	6087383*PED	Jun 21, 2019			PED	Mar 24, 2019
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
N 021411 001	5658590	Nov 26, 2016	U-494			
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
N 021411 002	5658590	Nov 26, 2016	U-494			
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
N 021411 003	5658590	Nov 26, 2016	U-494			
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
N 021411 004	5658590	Nov 26, 2016	U-494			
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
N 021411 005	5658590	Nov 26, 2016	U-494			
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
N 021411 006	5658590	Nov 26, 2016	U-494			
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
N 021411 007	5658590	Nov 26, 2016	U-494			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ATOMOXETINE HYDROCHLORIDE - STRATTERA						
N 021411 008	5658590	Nov 26, 2016	U-494			
ATORVASTATIN CALCIUM - LIPITOR						
N 020702 001	5969156	Jul 08, 2016	DS			
ATORVASTATIN CALCIUM - LIPITOR						
N 020702 002	5969156	Jul 08, 2016	DS			
ATORVASTATIN CALCIUM - LIPITOR						
N 020702 003	5969156	Jul 08, 2016	DS			
ATORVASTATIN CALCIUM - LIPITOR						
N 020702 004	5969156	Jul 08, 2016	DS			
ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET						
N 200153 001	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET						
N 200153 002	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET						
N 200153 003	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET						
N 200153 004	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
ATOVAQUONE - MEPRON						
N 020500 001	6649659	Jul 10, 2016	DS DP U-69			
AVANAFIL - STENDRA						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
AVANAFIL - STENDRA						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
AVANAFIL - STENDRA						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
AXITINIB - INLYTA						
N 202324 001	6534524	Apr 29, 2025	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
	8791140	Aug 05, 2030	DS			
AXITINIB - INLYTA						
N 202324 002	6534524	Apr 29, 2025	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
	8791140	Aug 05, 2030	DS			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AXITINIB - INLYTA						
N 202324 002	6534524	Apr 29, 2025	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
	8791140	Aug 05, 2030	DS			
AZELAIC ACID - FINACEA						
N 021470 001	6534070	Nov 18, 2018				
AZELAIC ACID - FINACEA						
N 207071 001	6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
	7700076	Sep 18, 2027	DP			
	8435498	Mar 01, 2024	U-1727			
	8722021	Oct 24, 2023	DP			
	8900554	Oct 24, 2023	DP			
	9211259	Jan 26, 2029	U-1796			
	9265725	Dec 08, 2027	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO						
N 022203 001	8071073	Jun 04, 2028	DP		M-129	Aug 30, 2016
	8518919	Nov 22, 2025	U-1430		NPP	Aug 30, 2016
					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
AZELASTINE HYDROCHLORIDE - ASTEPRO						
N 022203 002	8071073	Jun 04, 2028	DP		M-129	Aug 30, 2016
	8518919	Nov 22, 2025	U-1430		NPP	Aug 30, 2016
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81		PED	Aug 20, 2018
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
	8163723*PED	Feb 29, 2024				
	8168620	Feb 24, 2026	DP			
	9259428	Jun 13, 2023	U-644			
	9259428*PED	Dec 13, 2023				
AZILSARTAN KAMEDOXOMIL - EDARBI						
N 200796 001	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI						
N 200796 002	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR						
N 202331 001	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
	9169238	Feb 04, 2030	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR						
N 202331 002	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
	9169238	Feb 04, 2030	DP			
AZITHROMYCIN - ZITHROMAX						
N 050693 001	6268489	Jul 31, 2018	DS			
AZITHROMYCIN - ZITHROMAX						
N 050710 001	6268489	Jul 31, 2018	DS			
AZITHROMYCIN - ZITHROMAX						
N 050710 002	6268489	Jul 31, 2018	DS			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZITHROMYCIN - ZITHROMAX						
N 050711 001	6268489	Jul 31, 2018	DS			
AZITHROMYCIN - ZITHROMAX						
N 050730 001	6268489	Jul 31, 2018	DS			
AZITHROMYCIN - ZITHROMAX						
N 050733 001	6268489	Jul 31, 2018	DS			
AZITHROMYCIN - ZITHROMAX						
N 050784 001	6268489	Jul 31, 2018	DS			
AZITHROMYCIN - ZMAX						
N 050797 001	6068859	May 30, 2017	DP			
	6268489	Jul 31, 2018	DS			
	6984403	Feb 14, 2024	DP U-282			
	7887844	Feb 14, 2024	DP			
AZITHROMYCIN - AZASITE						
N 050810 001	6159458	Nov 04, 2017	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
AZTREONAM - CAYSTON						
N 050814 001	7208141	Dec 20, 2021	DP U-1031		ODE	Feb 22, 2017
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
	8399496	Dec 20, 2021	DP U-1377			
BACLOFEN - KEMSTRO						
N 021589 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
BACLOFEN - KEMSTRO						
N 021589 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
BALSALAZIDE DISODIUM - COLAZAL						
N 020610 001	7452872	Aug 24, 2026	U-141			
	7625884	Aug 24, 2026	U-141			
BALSALAZIDE DISODIUM - GIAZO						
N 022205 001	6197341	Mar 13, 2018	DP U-1229			
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
	8497256	Jun 23, 2031	U-1229			
	9192616	Aug 02, 2026	U-1229			
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE						
N 022247 001	5998402	Apr 04, 2017	DS DP U-594		NP	Oct 03, 2016
	6479535	May 06, 2019	DP U-594			
	6479535	May 06, 2019	DP U-904			
	7138392	Apr 04, 2017	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			
	8815934	May 06, 2019	DP			
BECLOMETHASONE DIPROPIONATE - QVAR 80						
N 020911 001	6446627	Dec 18, 2017	DP			
	9463289	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR 40						
N 020911 002	6446627	Dec 18, 2017	DP			
	9463289	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QNASL						
N 202813 001	7780038	Jan 24, 2027	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BECLOMETHASONE DIPROPIONATE - QNASL						
N 202813 002	7780038	Jan 24, 2027	DP		NS	Dec 17, 2017
BEDAQUILINE FUMARATE - SIRTURO						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		NCE	Dec 28, 2017
	8546428	Mar 19, 2029	DS DP U-1321		ODE	Dec 28, 2019
BELINOSTAT - BELEODAQ						
N 206256 001	6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
	8835501	Oct 27, 2027	DP		ODE	Jul 03, 2021
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 003	8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 004	8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - BENDEKA						
N 208194 001	8609707	Aug 11, 2031	DP U-1542			
	8791270	Jan 12, 2026	DP U-1790			
	8791270*PED	Jul 12, 2026				
	9000021	Mar 15, 2033	U-1542			
	9034908	Mar 15, 2033	U-1542			
	9144568	Mar 15, 2033	U-1542			
	9265831	Jan 28, 2031	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA						
N 050819 001	8288434	Aug 05, 2029	DP U-124			
	8663699	Jun 03, 2029	U-124			
	8895070	Jun 03, 2029	U-124			
	9078870	Jun 03, 2029	DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON						
N 050819 002	8288434	Aug 05, 2029	DP U-124			
	8288434	Aug 05, 2029	DP U-134			
	8288434	Aug 05, 2029	DP U-818			
	8288434	Aug 05, 2029	DP U-916			
	8288434	Aug 05, 2029	DP U-921			
	8288434	Aug 05, 2029	DP U-1033			
	9504704	Jun 03, 2029	DP U-124			
	9504704	Jun 03, 2029	DP U-134			
	9504704	Jun 03, 2029	DP U-818			
	9504704	Jun 03, 2029	DP U-916			
BENZYL ALCOHOL - ULESFIA						
N 022129 001	5858383	Aug 11, 2017	U-970			
	6139859	Aug 11, 2017	U-970			
	6793931	Jul 11, 2022	DP U-970			
	7294342	May 19, 2024	U-970			
BEPOTASTINE BESILATE - BEPREVE						
N 022288 001	6780877	Sep 19, 2019	DS DP			
	8784789	Sep 05, 2024	DP			
	8877168	Jul 30, 2023	DP			
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE						
N 022308 001	6685958	Jun 29, 2021	DP U-80			
	6699492	Mar 31, 2019	DP U-80			
	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
	8937062	Nov 13, 2029	U-80			
BETAMETHASONE DIPROPIONATE - SERNIVO						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
	9433630	Aug 31, 2030	DP U-1858			
	9439911	Aug 31, 2030	DP U-1858			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR						
N 207589 001	6753013	Jan 27, 2020	DP U-1761		NP	Oct 16, 2018
	9119781	Jun 10, 2031	DP U-1761			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX						
N 021852 001	6753013	Jan 27, 2020	DP U-88		NPP	Dec 23, 2017
	6753013	Jan 27, 2020	DP U-193			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX						
N 022185 001	6753013	Jan 27, 2020	DP U-88		NPP	Aug 29, 2017
	6753013	Jan 27, 2020	DP U-193			
	6753013	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-1761			
BETAMETHASONE VALERATE - LUXIQ						
N 020934 001	7078058	May 24, 2017	DP			
BEXAROTENE - TARGRETIN						
N 021055 001	5962731	Oct 05, 2016	U-475		M-164	Jul 29, 2018
BEXAROTENE - TARGRETIN						
N 021056 001	5962731	Oct 05, 2016				
BIMATOPROST - LUMIGAN						
N 022184 001	7851504	Jun 13, 2027	DS DP			
	8278353	Mar 16, 2025	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BIMATOPROST - LUMIGAN							
N 022184	001	8299118	Mar 16, 2025	U-1295			
		8309605	Mar 16, 2025	U-1293			
		8309605	Mar 16, 2025	U-1294			
		8338479	Mar 16, 2025	DP U-1295			
		8524777	Mar 16, 2025	U-1235			
		8586630	Mar 16, 2025	U-1458			
		8772338	Mar 16, 2025	DP U-1528			
		8933120	Mar 16, 2025	DP			
		8933127	Mar 16, 2025	DP			
		9155716	Mar 16, 2025	DP U-1528			
		9241918	Mar 16, 2025	DP U-1814			
BIMATOPROST - LATISSE							
N 022369	001	7351404	May 25, 2024	U-939	Y	M-140	Sep 04, 2017
		7388029	Jan 21, 2022	U-938	Y		
		8038988	Aug 25, 2023	DS DP U-1208			
		8101161	May 25, 2024	U-1217			
		8101161	May 25, 2024	U-1218			
		8263054	Jan 15, 2023	U-1277			
		8541466	Jan 31, 2021	U-1217			
		8632760	Jan 15, 2023	U-1487			
		8758733	Jan 15, 2023	U-1487			
		8906962	Jan 31, 2021	U-1217			
		8926953	Jan 15, 2023	U-1217			
		8986715	Jan 15, 2023	U-1217			
		9216183	Jan 15, 2023	U-1487			
		9226931	Jan 15, 2023	U-1799			
BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY							
N 021551	003	7291324	Oct 22, 2022	U-837			
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA							
N 050786	001	6350468	Dec 14, 2018	U-932			
		6350468	Dec 14, 2018	U-956			
BIVALIRUDIN - ANGIOMAX							
N 020873	001	7582727	Jul 27, 2028	DP			
		7598343	Jul 27, 2028	DP			
BOCEPREVIR - VICTRELIS							
N 202258	001	7772178	Nov 11, 2027	DP U-1128			
		8119602	Mar 17, 2027	U-1233			
		RE43298	Dec 22, 2024	DS DP U-1128			
BORTEZOMIB - VELCADE							
N 021602	001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
		5780454*PED	Nov 03, 2017			D-142	Oct 08, 2017
		6713446	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
		6713446*PED	Jul 25, 2022			M-139	Aug 08, 2017
		6958319	Jan 25, 2022	DS DP		M-165	Sep 14, 2018
		6958319*PED	Jul 25, 2022			ODE	Oct 08, 2021
						PED	Feb 08, 2018
						PED	Apr 08, 2018
						PED	Apr 08, 2018
						PED	Apr 08, 2018
						PED	Mar 14, 2019
						PED	Apr 08, 2022
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	001	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
		7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
		7767678	Nov 23, 2026	DS DP			
		7919625	Dec 11, 2025	DP			
		RE42376	Apr 13, 2024	DS			
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	002	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
		7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
		7767678	Nov 23, 2026	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BOSUTINIB MONOHYDRATE - BOSULIF						
N 203341 002	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
BREXPIPRAZOLE - REXULTI						
N 205422 001	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 002	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 003	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 004	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 005	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 006	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP U-1529		NCE	Jul 10, 2020
	8618109	Apr 12, 2026	U-543			
BRIMONIDINE TARTRATE - ALPHAGAN P						
N 021262 001	6562873	Jul 10, 2021				
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
BRIMONIDINE TARTRATE - QOLIANA						
N 021764 001	7265117	Aug 19, 2025	DP			
BRIMONIDINE TARTRATE - ALPHAGAN P						
N 021770 001	6562873	Jul 10, 2021	DP			
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
	8858961	Sep 02, 2023	DP			
	8858961*PED	Mar 02, 2024				
	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
BRIMONIDINE TARTRATE - MIRVASO						
N 204708 001	7439241	Aug 25, 2025	U-1428		NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
	8859551	May 25, 2024	U-1428			
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA						
N 204251 001	6316441	Dec 07, 2019	U-778			
	9044484	Oct 30, 2030	DP			
	9421265	Jun 17, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN						
N 021398 001	7030149	Apr 19, 2022	U-849			
	7320976	Apr 19, 2022	U-849			
	7323463	Jan 19, 2023	DP	Y		
	7642258	Apr 19, 2022	DS DP U-1024			
	8133890	Apr 19, 2022	U-1235			
	8354409	Apr 19, 2022	DP U-1371			
	8748425	Apr 19, 2022	DP U-1524			
	9474751	Apr 19, 2022	DP U-1524			
BRIVARACETAM - BRIVIACT						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
BRIVARACETAM - BRIVIACT						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
BROMFENAC SODIUM - PROLENSA						
N 203168 001	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-810			
	8927606	Jan 16, 2024	U-1095			
	9144609	Jan 16, 2024	DP			
BROMFENAC SODIUM - BROMSITE						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE - PULMICORT RESPULES						
N 020929 001	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
BUDESONIDE - PULMICORT RESPULES						
N 020929 002	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
BUDESONIDE - PULMICORT RESPULES						
N 020929 003	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
BUDESONIDE - ENTOCORT EC						
N 021324 001					M-178	Apr 29, 2019
					NPP	Apr 29, 2019
BUDESONIDE - PULMICORT FLEXHALER						
N 021949 001	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
BUDESONIDE - PULMICORT FLEXHALER						
N 021949 002	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
BUDESONIDE - UCERIS						
N 203634 001	7410651	Jun 09, 2020	DP U-1325			
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	8784888	Jun 09, 2020	DP			
	8895064	Sep 07, 2031	DP			
	9132093	Sep 07, 2031	DP			
	9192581	Sep 07, 2031	DP U-1325			
	9320716	Jun 09, 2020	DP U-1325			
	RE43799	Jun 09, 2020	DP U-1325			
BUDESONIDE - UCERIS						
N 205613 001					NP	Oct 07, 2017
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 001	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
	8387615	Nov 10, 2024	DP			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
	8616196	Apr 07, 2029	DP			
	8875699	Nov 10, 2024	DP			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 002	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 002	8616196	Apr 07, 2029	DP			
	8875699	Nov 10, 2024	DP			
BUPIVACAINE - EXPAREL						
N 022496 001	8182835	Sep 18, 2018	DP U-1246			
	8834921	Sep 18, 2018	DP U-1587			
BUPIVACAINE - EXPAREL						
N 022496 002	8182835	Sep 18, 2018	DP U-1246			
	8834921	Sep 18, 2018	DP U-1587			
	9205052	Sep 18, 2018	U-1246			
BUPRENORPHINE - BUTRANS						
N 021306 001	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
BUPRENORPHINE - BUTRANS						
N 021306 002	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
BUPRENORPHINE - BUTRANS						
N 021306 003	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
BUPRENORPHINE - BUTRANS						
N 021306 004	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
BUPRENORPHINE - BUTRANS						
N 021306 005	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE						
N 204442 001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 001	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 002	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 003	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 004	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 005	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 006	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 007	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 001	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 002	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 003	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE						
N 022410 004	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 001	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 002	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 003	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 004	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 004	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 006	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP	Y		
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE - WELLBUTRIN XL							
N 021515	001	6096341	Oct 30, 2018				
BUPROPION HYDROCHLORIDE - WELLBUTRIN XL							
N 021515	002	6096341	Oct 30, 2018				
BUPROPION HYDROCHLORIDE - FORFIVO XL							
N 022497	001	7674479	Jun 25, 2027	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE							
N 200063	001	7375111	Mar 26, 2025	DP		NC	Sep 10, 2017
		7462626	Jul 20, 2024	U-1583			
		8088786	Feb 03, 2029	DP			
		8318788	Nov 08, 2027	U-1584			
		8722085	Nov 08, 2027	U-1585			
		8815889	Jul 20, 2024	U-1586			
		8916195	Feb 02, 2030	U-1639			
		9107837	Jun 04, 2027	U-1639			
		9125868	Nov 08, 2027	U-1585			
		9248123	Jan 13, 2032	U-1808			
BUTOCONAZOLE NITRATE - BUTOCONAZOLE NITRATE							
N 019881	001	5993856	Nov 17, 2017	DP U-457			
CABAZITAXEL - JEVTANA KIT							
N 201023	001	5847170	Mar 26, 2021	DS DP			
		7241907	Dec 10, 2025	DS			
		8927592	Oct 27, 2030	U-1630			
CABOZANTINIB S-MALATE - COMETRIQ							
N 203756	001	7579473	Aug 14, 2026	DS DP		NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP U-1617		ODE	Nov 29, 2019
CABOZANTINIB S-MALATE - COMETRIQ							
N 203756	002	7579473	Aug 14, 2026	DS DP		NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP U-1617		ODE	Nov 29, 2019
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692	001	7579473	Aug 14, 2026	DS DP		NCE	Nov 29, 2017
		8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
		8877776	Oct 08, 2030	DS DP			
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692	002	7579473	Aug 14, 2026	DS DP		NCE	Nov 29, 2017
		8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
		8877776	Oct 08, 2030	DS DP			
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692	003	7579473	Aug 14, 2026	DS DP		NCE	Nov 29, 2017
		8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
		8877776	Oct 08, 2030	DS DP			
CALCIFEDIOL - RAYALDEE							
N 208010	001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
		8207149	Apr 25, 2028	U-1871			
		8361488	Jul 19, 2028	DP			
		8426391	Aug 27, 2028	DP U-1872			
		8778373	Apr 25, 2028	U-1873			
		8906410	Feb 02, 2027	DP			
		9408858	Apr 25, 2028	U-1888			
		9498486	Apr 25, 2028	U-1920			
CALCIPOTRIENE - SORILUX							
N 022563	001	8263580	Sep 27, 2028	DP U-1280			
		8629128	May 26, 2026	DP U-1280			
		8629128	May 26, 2026	DP U-1767			
CALCITONIN SALMON RECOMBINANT - FORTICAL							
N 021406	001	6440392	Feb 02, 2021	DP U-227			
		RE40812	Feb 02, 2021	DP			
		RE43580	Feb 02, 2021	DP U-227			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCITONIN SALMON RECOMBINANT - FORTICAL							
N 021406	001	6440392	Feb 02, 2021	DP U-227			
		RE40812	Feb 02, 2021	DP			
		RE43580	Feb 02, 2021	DP U-227			
CALCITRIOL - CALCIJEX							
N 018874	001	6051567	Aug 02, 2019				
		6265392	Aug 02, 2019				
		6274169	Aug 02, 2019				
CALCITRIOL - CALCIJEX							
N 018874	002	6051567	Aug 02, 2019				
		6265392	Aug 02, 2019				
		6274169	Aug 02, 2019				
CALCIUM ACETATE - PHOSLO							
N 021160	002	6576665	Apr 03, 2021				
CALCIUM ACETATE - PHOSLO GELCAPS							
N 021160	003	6576665	Apr 03, 2021				
		6875445	Jul 30, 2021	DP			
CALCIUM ACETATE - PHOSLYRA							
N 022581	001	8591938	Feb 23, 2030	DP U-1469			
		8592480	Jul 20, 2027	U-1469			
		9089528	Jul 20, 2027	U-1469			
CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE							
N 020958	001	5989588	Sep 30, 2017	DP U-349			
		5989588*PED	Mar 30, 2018				
		6814978	Aug 26, 2021	DP			
CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)							
N 021823	001	5994329	Jul 17, 2018	U-353			
		6015801	Jul 17, 2018	U-353			
		6165513	Jun 10, 2018	DP			
		6432932	Jul 17, 2018	U-595			
		6465443	Aug 14, 2018	DP			
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL							
N 022193	001	7084130	Nov 29, 2021	DP U-891			
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
N 207026	001					ODE	Jan 13, 2022
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
N 207026	002					ODE	Jan 13, 2022
CANAGLIFLOZIN - INVOKANA							
N 204042	001	7943582	Feb 26, 2029	DS DP U-493		I-733	May 20, 2019
		7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493			
		8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN - INVOKANA							
N 204042	002	7943582	Feb 26, 2029	DS DP U-493		I-733	May 20, 2019
		7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493			
		8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET							
N 204353	001	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
		7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
		8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
		8513202	Dec 03, 2027	DS DP U-493			
		8785403	Jul 30, 2024	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 003	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 001	6723340	Oct 25, 2021	DP		I-735	May 20, 2019
	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 002	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 003	6723340	Oct 25, 2021	DP		I-735	May 20, 2019
	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 004	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANGRELOR - KENGREAL						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
	9295687	Jul 10, 2035	DP			
	9427448	Nov 10, 2030	U-1926			
	9439921	Jul 10, 2035	DP			
CAPECITABINE - XELODA						
N 020896 001					M-131	Dec 10, 2016
					PED	Jun 10, 2017
CAPECITABINE - XELODA						
N 020896 002					M-131	Dec 10, 2016
					PED	Jun 10, 2017

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CAPSAICIN - QUTENZA						
N 022395 001	6239180	Nov 06, 2017	DP		ODE	Nov 16, 2016
CARBAMAZEPINE - EQUETRO						
N 021710 001	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO						
N 021710 002	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO						
N 021710 003	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - CARNEXIV						
N 206030 001	7635773	Mar 13, 2029	DP		ODE	Oct 07, 2023
	8410077	Mar 13, 2029	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50						
N 021485 001	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100						
N 021485 002	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150						
N 021485 003	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200						
N 021485 004	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75						
N 021485 005	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125						
N 021485 006	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	9463246	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - DUOPA						
N 203952 001					NP	Jan 09, 2018
					ODE	Jan 09, 2022
CARBINOXAMINE MALEATE - KARBINAL ER						
N 022556 001	8062667	Mar 29, 2029	DP			
	9522191	Mar 15, 2027	DP			
CARFILZOMIB - KYPROLIS						
N 202714 001	7232818	Apr 14, 2025	DS DP		I-712	Jul 24, 2018
	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	7491704	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
	7737112	Dec 07, 2027	DP		NCE	Jul 20, 2017
	8129346	Apr 14, 2025	U-1260		ODE	Jul 20, 2019
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
	9511109	Oct 21, 2029	U-1924			
CARFILZOMIB - KYPROLIS						
N 202714 002	7232818	Apr 14, 2025	DS DP		I-712	Jul 24, 2018
	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	7491704	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
	7737112	Dec 07, 2027	DP		NCE	Jul 20, 2017
	8129346	Apr 14, 2025	U-1260		ODE	Jul 20, 2019
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
	9511109	Oct 21, 2029	U-1924			
CARGLUMIC ACID - CARBAGLU						
N 022562 001					ODE	Mar 18, 2017

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 001	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 002	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 003	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR						
N 022012 004	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
CASPOFUNGIN ACETATE - CANCIDAS						
N 021227 001	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
CASPOFUNGIN ACETATE - CANCIDAS						
N 021227 002	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
CEFDITOREN PIVOXIL - SPECTRACEF						
N 021222 001	5958915	Oct 14, 2016				
CEFDITOREN PIVOXIL - SPECTRACEF						
N 021222 002	5958915	Oct 14, 2016	DP			
CEFIXIME - SUPRAX						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676		NPP	May 27, 2019
	6906055	Dec 15, 2021	DS DP		NPP	May 27, 2019
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676		NPP	May 27, 2019
	6906055	Dec 15, 2021	DS DP		NPP	May 27, 2019
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	7129232	Oct 21, 2024	DS DP U-36		NCE	Dec 19, 2019
	8476425	Sep 27, 2032	DS		GAIN	Dec 19, 2024
	8685957	Sep 27, 2032	DS U-36			
	8906898	May 28, 2034	DS DP			
	8968753	Mar 14, 2034	U-1672			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA							
N 206829	001	8968753	Mar 14, 2034	U-1673			
		9320740	Mar 14, 2034	DP			
CERITINIB - ZYKADIA							
N 205755	001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
		7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
		7964592	Jan 13, 2027	DS DP			
		8039479	Jun 29, 2030	DS DP			
		8377921	Nov 20, 2027	U-1179			
		8703787	Feb 02, 2032	U-1179			
		9309229	Jan 18, 2032	DS DP			
CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY							
N 021621	003	6455533	Jul 02, 2018	DP U-295			
CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY							
N 021621	004	6455533	Jul 02, 2018	DP U-295			
CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF							
N 021621	005	6455533	Jul 02, 2018	DP U-295			
CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF							
N 021621	006	6455533	Jul 02, 2018	DP U-295			
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR							
N 021150	002	6469009	Jul 13, 2019	DP U-295			
		7014867	Jun 10, 2022	DP			
		7226614	Jun 10, 2022	U-295			
CETRORELIX - CETROTIDE							
N 021197	001	6319192	Apr 23, 2019	U-426			
CETRORELIX - CETROTIDE							
N 021197	002	6319192	Apr 23, 2019	U-426			
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE							
N 021669	001	7066916	Feb 17, 2024	U-737			
		7427574	Apr 25, 2026	DP			
		7595021	May 12, 2023	DP U-1022			
		7717889	Feb 27, 2025	DP U-1022			
		7935093	Oct 02, 2027	DP U-1022			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP							
N 020832	001	5690958	Sep 30, 2016	DP			
		6536975	Nov 10, 2020	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT							
N 020832	002	5690958	Sep 30, 2016	DP			
		6729786	Mar 14, 2023	DP			
		6991394	Jan 31, 2024	DP			
		7182536	Dec 30, 2023	DP			
		7241065	Mar 14, 2023	DP			
		7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP							
N 020832	003	5690958	Sep 30, 2016	DP			
		5772346	Apr 22, 2017	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP							
N 020832	004	5690958	Sep 30, 2016	DP			
		6536975	Nov 10, 2020	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT							
N 020832	005	5690958	Sep 30, 2016	DP			
		6536975	Nov 10, 2020	DP			
		6729786	Mar 14, 2023	DP			
		7241065	Mar 14, 2023	DP			
		7422388	Apr 25, 2027	DP U-1397			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP						
N 020832 006	5690958	Sep 30, 2016	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT						
N 020832 007	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK						
N 021524 003	D468424	Jan 07, 2017				
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP						
N 021555 001	5690958	Sep 30, 2016	DP			
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE						
N 206323 001	6248363	Nov 23, 2019	DP U-1716			
	6383471	Apr 06, 2019	DP U-1716			
	9066942	Jan 03, 2032	U-1716			
	9107921	Jan 03, 2032	DP			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS						
N 021441 001	7863287	Feb 28, 2027	DP			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
CHOLIC ACID - CHOLBAM						
N 205750 001					NCE	Mar 17, 2020
					ODE	Mar 17, 2022
CHOLIC ACID - CHOLBAM						
N 205750 002					NCE	Mar 17, 2020
					ODE	Mar 17, 2022
CHOLINE C-11 - CHOLINE C-11						
N 203155 001					NCE	Sep 12, 2017
					W	Sep 12, 2017
CHOLINE FENOFIBRATE - TRILIPIX						
N 022224 001	7259186	Jan 07, 2025	DS			
CHOLINE FENOFIBRATE - TRILIPIX						
N 022224 002	7259186	Jan 07, 2025	DS			
CHORIOGONADOTROPIN ALFA - OVIDREL						
N 021149 002	6706681	Mar 16, 2021	DP			
CICLESONIDE - ALVESCO						
N 021658 002	5482934	Oct 24, 2017	DS DP U-1002			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - ALVESCO						
N 021658 003	5482934	Oct 24, 2017	DS DP U-1002			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - OMNARIS						
N 022004 001	5482934	Oct 24, 2017	DS DP U-557			
	6767901	Oct 21, 2020	DP			
	6939559	Apr 21, 2019	DP			
	7235247	Apr 21, 2019	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CICLESONIDE - OMNARIS						
N 022004 001	8371292	Feb 01, 2028	U-1356			
	8383611	Oct 20, 2020	DP			
CICLESONIDE - ZETONNA						
N 202129 001	5482934	Oct 24, 2017	DS DP U-1002			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Feb 01, 2028	U-1357			
CICLOPIROX - LOPROX						
N 020519 001	7018656	Sep 05, 2018	DP			
	7026337	Nov 21, 2016	U-714			
CICLOPIROX - LOPROX						
N 021159 001	7981909	Sep 16, 2017	U-1162			
	8227490	Sep 16, 2017	U-1256			
CINACALCET HYDROCHLORIDE - SENSIPAR						
N 021688 001	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016	U-559		ODE	Nov 21, 2021
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
	9375405	Sep 22, 2026	DP			
CINACALCET HYDROCHLORIDE - SENSIPAR						
N 021688 002	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016			ODE	Nov 21, 2021
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
	9375405	Sep 22, 2026	DP			
CINACALCET HYDROCHLORIDE - SENSIPAR						
N 021688 003	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016	U-559		ODE	Nov 21, 2021
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
	9375405	Sep 22, 2026	DP			
CIPROFLOXACIN - OTIPRIO						
N 207986 001	8318817	Apr 27, 2030	U-1792		NP	Dec 10, 2018
	9205048	Apr 21, 2029	U-1793			
	9220796	Jul 01, 2035	DP			
	9233068	Dec 11, 2029	DP			
CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR						
N 021744 001	5972389	Sep 19, 2016	DP U-663			
	6340475	Sep 19, 2016	DP U-663			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP U-663			
CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR						
N 021473 001	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR						
N 021473 002	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX						
N 021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
	8846650	Jun 04, 2025	DP U-1578			
	9149486	Sep 13, 2022	DP U-1578			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1679			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
CLARITHROMYCIN - BIAXIN XL						
N 050775 001	6010718	Apr 11, 2017	DP U-924			
	6551616	Jun 15, 2017	U-924			
CLEVIDIPINE - CLEVIPREX						
N 022156 001	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 002	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 003	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
CLINDAMYCIN PHOSPHATE - CLEOCIN						
N 050767 001	6495157	Jul 20, 2020	DP			
CLINDAMYCIN PHOSPHATE - CLINDAGEL						
N 050782 001	6387383	Aug 03, 2020	DP U-818			
CLINDAMYCIN PHOSPHATE - CLINDESSE						
N 050793 001	5993856	Nov 17, 2017	DP U-137			
	6899890	Apr 27, 2023	DP U-137			
CLINDAMYCIN PHOSPHATE - EVOCLIN						
N 050801 001	7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA						
N 050802 001	6387383	Aug 03, 2020	DP U-916			
CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN						
N 050803 001	9492384	Aug 31, 2025	DP U-1412			
CLOBAZAM - ONFI						
N 202067 001					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
CLOBAZAM - ONFI						
N 202067 002					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
CLOBAZAM - ONFI						
N 202067 003					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
CLOBAZAM - ONFI						
N 203993 001					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
CLOBETASOL PROPIONATE - CLOBEX						
N 021535 001	6106848	Sep 22, 2017				
CLOBETASOL PROPIONATE - CLOBEX						
N 021644 001	7316810	Jun 17, 2019	DP			
	7700081	Jan 03, 2022	U-1044			
	8066975	Jun 17, 2019	DP			
	8066976	Jun 17, 2019	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLOBETASOL PROPIONATE - CLOBEX						
N 021835 001	5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
CLOBETASOL PROPIONATE - OLUX E						
N 022013 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1410			
	8962000	Aug 31, 2025	DP U-1410			
CLOFARABINE - CLOLAR						
N 021673 001	5661136	Jan 14, 2018	U-626			
CLONIDINE HYDROCHLORIDE - KAPVAY						
N 022331 003					M-149	Nov 20, 2017
CLONIDINE HYDROCHLORIDE - KAPVAY						
N 022331 004					M-149	Nov 20, 2017
CLOPIDOGREL BISULFATE - PLAVIX						
N 020839 001	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
CLOPIDOGREL BISULFATE - PLAVIX						
N 020839 002	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
CLOZAPINE - FAZACLO ODT						
N 021590 001	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
CLOZAPINE - FAZACLO ODT						
N 021590 002	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
CLOZAPINE - FAZACLO ODT						
N 021590 003	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
CLOZAPINE - FAZACLO ODT						
N 021590 004	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
CLOZAPINE - FAZACLO ODT						
N 021590 005	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
CLOZAPINE - FAZACLO ODT						
N 021590 006	6024981	Apr 09, 2018	DP			
	6106861	Dec 05, 2017	DP			
	6221392	Apr 09, 2018	DP			
COBICISTAT - TYBOST						
N 203094 001	8148374	Sep 03, 2029	DS DP U-1279		NP	Sep 24, 2017
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 001	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX							
N 205395	001	RE42889*PED	Apr 19, 2017				
		RE43596	May 09, 2017	DS DP			
		RE43596*PED	Nov 09, 2017				
		RE43802	Oct 19, 2016	U-1660			
		RE43802*PED	Apr 19, 2017				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA							
N 207561	001	5914331	Jul 02, 2017	DS		NCE	Nov 05, 2020
		5914331*PED	Jan 02, 2018				
		6642245	Nov 04, 2020	U-257			
		6642245*PED	May 04, 2021				
		6703396	Mar 09, 2021	DS DP			
		6703396*PED	Sep 09, 2021				
		7176220	Nov 20, 2023	DS DP U-257			
		7390791	May 07, 2022	DS DP			
		7635704	Oct 26, 2026	DS DP U-257			
		7803788	Feb 02, 2022	U-257			
		8148374	Sep 03, 2029	DS DP U-1279			
		8633219	Apr 24, 2030	DP U-257			
		8754065	Aug 15, 2032	DS DP U-257			
		8981103	Oct 26, 2026	DS DP			
		9296769	Aug 15, 2032	DS DP U-257			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD							
N 203100	001	5914331	Jul 02, 2017	DS		I-704	Dec 17, 2017
		5922695	Jul 25, 2017	DS U-257			
		5935946	Jul 25, 2017	DS DP U-257			
		5977089	Jul 25, 2017	DS DP U-257			
		6043230	Jul 25, 2017	U-257			
		6642245	Nov 04, 2020	U-257			
		6703396	Mar 09, 2021	DS DP			
		7176220	Nov 20, 2023	DS DP U-257			
		7635704	Oct 26, 2026	DS DP U-257			
		8148374	Sep 03, 2029	DS DP U-1279			
		8592397	Jan 13, 2024	DP U-257			
		8633219	Apr 24, 2030	DP U-257			
		8716264	Jan 13, 2024	DP U-257			
		8981103	Oct 26, 2026	DS DP			
		9457036	Jan 13, 2024	DP U-257			
COBIMETINIB FUMARATE - COTELLIC							
N 206192	001	7803839	Feb 01, 2027	DS DP		NCE	Nov 10, 2020
		8362002	Oct 05, 2026	U-1776		ODE	Nov 10, 2022
COLCHICINE - COLCRYS							
N 022352	001	7601758	Feb 10, 2029	U-1007		ODE	Jul 29, 2016
		7619004	Dec 03, 2028	U-1020			
		7820681	Feb 17, 2029	U-1020			
		7906519	Feb 17, 2029	U-1116			
		7915269	Feb 17, 2029	U-1007			
		7935731	Dec 03, 2028	U-1116			
		7964647	Oct 06, 2028	U-1007			
		7964648	Oct 06, 2028	U-1161			
		7981938	Oct 06, 2028	U-1166			
		8093296	Oct 06, 2028	U-1007			
		8093297	Oct 06, 2028	U-1161			
		8093298	Oct 06, 2028	U-1116			
		8097655	Oct 06, 2028	U-1020			
		8415395	Oct 06, 2028	U-1007			
		8415396	Oct 06, 2028	U-1007			
		8440721	Feb 17, 2029	U-1007			
		8440722	Feb 17, 2029	U-1020			
COLCHICINE - MITIGARE							
N 204820	001	8927607	Aug 22, 2033	U-1020			
		9399036	Aug 22, 2033	U-1020			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLESEVELAM HYDROCHLORIDE - WELCHOL						
N 021176 001	7229613	Apr 17, 2022	U-851			
COLESEVELAM HYDROCHLORIDE - WELCHOL						
N 022362 001	7229613	Apr 17, 2022	U-493			
COLESEVELAM HYDROCHLORIDE - WELCHOL						
N 022362 002	7229613	Apr 17, 2022	U-493			
CONIVAPTAN HYDROCHLORIDE - VAPRISOL						
N 021697 001	5723606	Dec 15, 2019	DS DP U-698			
	5723606	Dec 15, 2019	DS DP U-868			
CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER						
N 021697 002	5723606	Dec 15, 2019	DS DP U-698			
	5723606	Dec 15, 2019	DS DP U-868			
CORTICOTROPIN - H.P. ACTHAR GEL						
N 008372 008					ODE	Oct 15, 2017
CRIZOTINIB - XALKORI						
N 202570 001	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
	7825137	May 12, 2027	U-1179		NCE	Aug 26, 2016
	7858643	Oct 08, 2029	DS DP		ODE	Aug 26, 2018
	8217057	Nov 06, 2029	DS DP		ODE	Mar 11, 2023
	8785632	Mar 01, 2025	DS			
CRIZOTINIB - XALKORI						
N 202570 002	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
	7825137	May 12, 2027	U-1179		NCE	Aug 26, 2016
	7858643	Oct 08, 2029	DS DP		ODE	Aug 26, 2018
	8217057	Nov 06, 2029	DS DP		ODE	Mar 11, 2023
	8785632	Mar 01, 2025	DS			
CROFELEMER - FULYZAQ						
N 202292 001	7323195	Jun 07, 2018	DP		NCE	Dec 31, 2017
	7341744	Jun 16, 2018	U-1319			
	8574634	Jan 11, 2018	U-1319			
	8962680	Oct 31, 2031	U-1319			
CYANOCOBALAMIN - NASCOBAL						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7404489	Mar 12, 2024	DP			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
	9415007	Jul 28, 2024	U-1896			
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX						
N 021777 001	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023	U-979			
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023	U-1088			
	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX						
N 021777 002	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023	U-979			
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023	U-1088			
	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
CYCLOSPORINE - RESTASIS						
N 050790 001	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYCLOSPORINE - RESTASIS						
N 050790 001	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
CYCLOSPORINE - RESTASIS MULTIDOSE						
N 050790 002	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001	8026284	Sep 22, 2027	U-1399		NPP	Aug 14, 2018
	9173851	Jun 17, 2034	DP		ODE	Apr 30, 2020
	9192590	Jan 26, 2027	U-1399		ODE	Aug 14, 2022
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 002	8026284	Sep 22, 2027	U-1399		NPP	Aug 14, 2018
	9173851	Jun 17, 2034	DP		ODE	Apr 30, 2020
	9192590	Jan 26, 2027	U-1399		ODE	Aug 14, 2022
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
CYSTEAMINE HYDROCHLORIDE - CYSTARAN						
N 200740 001					ODE	Oct 02, 2019
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 001	6087380	Feb 18, 2018	DS DP U-1089		I-682	Apr 04, 2017
	7866474	Aug 31, 2027	DP		I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		M-168	Nov 20, 2018
	9034822	Jan 20, 2031	U-1759			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 002	6087380	Feb 18, 2018	DS DP U-1089		I-682	Apr 04, 2017
	7866474	Aug 31, 2027	DP		I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		M-168	Nov 20, 2018
	9034822	Jan 20, 2031	U-1759			
DABIGATRAN ETEXILATE MESYLATE - PRADAXA						
N 022512 003	6087380	Feb 18, 2018	DS DP U-1089		NS	Nov 20, 2018
	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
	9034822	Jan 20, 2031	U-1759			
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP U-1406		M-170	Nov 20, 2018
	8703781	Oct 15, 2030	DS DP U-1713		NCE	May 29, 2018
	9233956	May 04, 2029	U-1811		ODE	May 29, 2020
					ODE	Jan 09, 2021
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP U-1406		M-170	Nov 20, 2018
	8703781	Oct 15, 2030	DS DP U-1713		NCE	May 29, 2018
	9233956	May 04, 2029	U-1811		ODE	May 29, 2020
					ODE	Jan 09, 2021
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 001	8329159	Apr 13, 2028	DS		D-161	Feb 05, 2019
	8629171	Jun 13, 2031	DS DP U-1724		D-162	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP U-1724		I-726	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP U-1725		I-727	Feb 05, 2019
	8900566	Aug 08, 2027	U-1724		NCE	Jul 24, 2020
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 001	9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 002	8329159	Apr 13, 2028	DS		D-161	Feb 05, 2019
	8629171	Jun 13, 2031	DS DP U-1724		D-162	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP U-1724		I-726	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP U-1725		I-727	Feb 05, 2019
	8900566	Aug 08, 2027	U-1724		NCE	Jul 24, 2020
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DALBAVANCIN HYDROCHLORIDE - DALVANCE						
N 021883 001	6900175	Dec 25, 2023	U-1517		D-154	Jan 20, 2019
	7115564	Nov 14, 2023	DP		NCE	May 23, 2019
	7119061	Nov 14, 2023	DP		GAIN	May 23, 2024
	8143212	Nov 14, 2023	U-1517			
DALFAMPRIDINE - AMPYRA						
N 022250 001	5540938	Jul 30, 2018	U-1030		ODE	Jan 22, 2017
	8007826	May 26, 2027	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
	8663685	Jan 18, 2025	U-1030			
DANTROLENE SODIUM - RYANODEX						
N 205579 001	7758890	Jul 01, 2025	DP		ODE	Jul 22, 2021
	8110225	Dec 24, 2022	DP			
	8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		M-157	Mar 11, 2018
	6515117	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		M-157	Mar 11, 2018
	6515117	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 003	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 004	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
DAPSONE - ACZONE						
N 021794 001	5863560	Sep 11, 2016	DP			
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
DAPSONE - ACZONE						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
	9517219	Nov 18, 2033	U-1033			
DAPTOMYCIN - CUBICIN						
N 021572 001	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8058238	Nov 28, 2020	DS DP			
DAPTOMYCIN - CUBICIN						
N 021572 002	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8003673	Sep 04, 2028	U-1180			
	8058238	Nov 28, 2020	DS DP			
	8129342	Nov 28, 2020	DS DP			
DAPTOMYCIN - CUBICIN RF						
N 021572 003	9138456	Nov 23, 2030	DP			
DARIFENACIN HYDROBROMIDE - ENABLEX						
N 021513 001	6106864	Aug 21, 2016	DP U-630			
DARIFENACIN HYDROBROMIDE - ENABLEX						
N 021513 002	6106864	Aug 21, 2016	DP U-630			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 001	7470506	Jun 23, 2019	U-935		PED	Aug 01, 2016
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 002	7470506	Jun 23, 2019	U-935		PED	Aug 01, 2016
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 003	7470506	Jun 23, 2019	U-935		PED	Aug 01, 2016
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 004	7470506	Jun 23, 2019	U-935		PED	Aug 01, 2016
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 005	7470506	Jun 23, 2019	U-935		PED	Aug 01, 2016
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 006	7470506	Jun 23, 2019	U-935		PED	Aug 01, 2016
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N 021976 006	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
DARUNAVIR ETHANOLATE - PREZISTA						
N 202895 001	7470506	Jun 23, 2019	U-1209		PED	Aug 01, 2016
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	7148359	Jul 19, 2019	DP		D-163	Apr 22, 2019
	7364752	Nov 10, 2020	DP		NCE	Dec 19, 2019
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR						
N 208624 001	7148359	Jul 19, 2019	DP		NCE	Dec 19, 2019
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
DASATINIB - SPRYCEL						
N 021986 001	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - SPRYCEL						
N 021986 002	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL						
N 021986 003	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL						
N 021986 004	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL						
N 021986 005	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
DASATINIB - SPRYCEL						
N 021986 006	6596746	Jun 28, 2020	DS DP U-748			
	6596746	Jun 28, 2020	DS DP U-780			
	7125875	Apr 13, 2020	U-779			
	7125875	Apr 13, 2020	U-780			
	7153856	Apr 28, 2020	U-780			
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			
DEFERASIROX - EXJADE						
N 021882 001	6465504	Apr 05, 2019	DS DP		ODE	Jan 23, 2020
	6596750	Jun 24, 2017	DS U-735			
DEFERASIROX - EXJADE						
N 021882 002	6465504	Apr 05, 2019	DS DP		ODE	Jan 23, 2020
	6596750	Jun 24, 2017	DS U-735			
DEFERASIROX - EXJADE						
N 021882 003	6465504	Apr 05, 2019	DS DP		ODE	Jan 23, 2020
	6596750	Jun 24, 2017	DS U-735			
DEFERASIROX - JADENU						
N 206910 001	6465504	Apr 05, 2019	DS DP		ODE	Jan 23, 2020
	6596750	Jun 24, 2017	DS U-735			
	9283209	Nov 21, 2034	DS DP			
DEFERASIROX - JADENU						
N 206910 002	6465504	Apr 05, 2019	DS DP		ODE	Jan 23, 2020
	6596750	Jun 24, 2017	DS U-735			
	9283209	Nov 21, 2034	DS DP			
DEFERASIROX - JADENU						
N 206910 003	6465504	Apr 05, 2019	DS DP		ODE	Jan 23, 2020
	6596750	Jun 24, 2017	DS U-735			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFERASIROX - JADENU						
N 206910 003	9283209	Nov 21, 2034	DS DP			
DEFERIPRONE - FERRIPROX						
N 021825 001	7049328	Jun 28, 2021	U-735		NCE	Oct 14, 2016
					ODE	Oct 14, 2018
DEFERIPRONE - FERRIPROX						
N 208030 001	7049328	Jun 28, 2021	U-735		NCE	Oct 14, 2016
	8703156	Oct 29, 2029	DP U-735		ODE	Oct 14, 2018
DEFIBROTIDE SODIUM - DEFITELIO						
N 208114 001					NCE	Mar 30, 2021
					ODE	Mar 30, 2023
DEGARELIX ACETATE - FIRMAGON						
N 022201 001	5925730	May 18, 2021	DS DP U-943			
	9415085	Apr 27, 2032	U-1895			
DEGARELIX ACETATE - FIRMAGON						
N 022201 002	5925730	May 18, 2021	DS DP U-943			
	9415085	Apr 27, 2032	U-1895			
DELAVIRDINE MESYLATE - RESCRIPTOR						
N 020705 002	6177101	Jun 07, 2019				
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
DESLORATADINE - CLARINEX						
N 021165 001	6100274	Jul 07, 2019				
	7405223	Jul 07, 2019	U-886			
DESLORATADINE - CLARINEX						
N 021300 001	6514520	Jun 01, 2018	DP			
DESLORATADINE - CLARINEX						
N 021312 001	6100274	Jul 07, 2019	DP			
	7618649	Dec 19, 2020	DP U-1017			
DESLORATADINE - CLARINEX						
N 021312 002	6100274	Jul 07, 2019	DP			
	7618649	Dec 19, 2020	DP U-1017			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR						
N 021313 001	6100274	Jul 07, 2019	DP			
	6709676	Feb 18, 2021	DP U-707			
	7618649	Dec 19, 2020	DP U-1017			
	8187630	Dec 19, 2020	DP U-1017			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR						
N 021605 001	6100274	Jul 07, 2019	DP			
	6979463	Mar 28, 2022	DP			
	7618649	Dec 19, 2020	DP U-1017			
	7820199	Mar 28, 2022	DP			
DESONIDE - DESONATE						
N 021844 001	6387383	Aug 03, 2020	DS DP U-783			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESONIDE - VERDESO						
N 021978 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1412			
	8962000	Aug 31, 2025	DP U-1412			
	9492384	Aug 31, 2025	DP U-1412			
DESOXIMETASONE - TOPICORT						
N 204141 001	5990100	Mar 24, 2018	DP U-1408			
	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 001	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 002	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
DEXAMETHASONE - OZURDEX						
N 022315 001	6726918	Oct 20, 2020	DP U-1204		I-686	Jun 29, 2017
	6726918	Oct 20, 2020	DP U-1205		ODE	Sep 24, 2017
	6899717	Nov 01, 2023	U-1206			
	7033605	Oct 20, 2020	DP			
	7767223	Nov 28, 2021	DP			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8043628	Oct 20, 2020	U-1205			
	8063031	Oct 20, 2020	DP			
	8088407	Oct 20, 2020	U-1205			
	8506987	Jan 09, 2023	U-1204			
	8506987	Jan 09, 2023	U-1205			
	9012437	Oct 20, 2020	U-1205			
	9192511	Jan 09, 2023	DP			
	9283178	Oct 20, 2020	U-1205			
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			
	8450287	Dec 19, 2027	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	6462058	Jun 15, 2020	DS DP U-949		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-950		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-951		NPP	Jul 08, 2019
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-950		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-951		NPP	Jul 08, 2019
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT SOLUTAB						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXLANSOPRAZOLE - DEXILANT SOLUTAB						
N 208056 001	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 001	6716867	Mar 31, 2019			U-1472	
	6716867*PED	Oct 01, 2019				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 002	6716867	Mar 31, 2019			U-1472	
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 003	6716867	Mar 31, 2019			U-1472	
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 004	6716867	Mar 31, 2019			U-1472	
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE						
A 202842 005					PC	Jul 04, 2017
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE						
A 202842 007					PC	Jul 04, 2017
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N 021802 001	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N 021802 002	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N 021802 003	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N 021802 004	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N 021802 005	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N 021802 006	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N 021802 007	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N 021802 008	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
DEXRAZOXANE HYDROCHLORIDE - TOTECT						
N 022025 001	6727253	Mar 13, 2020	U-829			
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM						
N 021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM						
N 021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA						
N 021879 001	7659282	Aug 13, 2026	U-1093			
	8227484	Jul 17, 2023	U-1093			
DEXTROMETHORPHAN POLISTIREX - DELSYM						
N 018658 001	5980882	Apr 16, 2017	DP			
DICHLORPHENAMIDE - KEVEYIS						
N 011366 002					ODE	Aug 07, 2022
DICLOFENAC - ZORVOLEX						
N 204592 001	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
	8999387	Apr 23, 2030	U-55		NP	Oct 18, 2016
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
DICLOFENAC - ZORVOLEX						
N 204592 002	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
	8999387	Apr 23, 2030	U-55		NP	Oct 18, 2016
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
DICLOFENAC EPOLAMINE - FLECTOR						
N 021234 001	5607690	Apr 13, 2019	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC POTASSIUM - CAMBIA						
N 022165 001	6974595	May 15, 2017	U-436			
	7482377	May 15, 2017	DS DP U-436			
	7759394	Jun 16, 2026	DS DP U-436			
	8097651	Jun 16, 2026	DS DP U-436			
	8927604	Jun 16, 2026	U-436			
DICLOFENAC POTASSIUM - ZIPSOR						
N 022202 001	6287594	Jan 15, 2019	DP			
	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
	8110606	Feb 24, 2029	U-980			
	8623920	Feb 24, 2029	U-1482			
DICLOFENAC SODIUM - PENNSAID						
N 020947 001	8217078	Jul 10, 2029	U-1248			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
DICLOFENAC SODIUM - DYLOJECT						
N 022396 001	6407079	Jun 18, 2019	DP		NP	Dec 23, 2017
	8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
	8871809	Oct 17, 2027	U-1614			
	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA						
N 022252 001	6133251	Oct 25, 2016	DP U-1	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-828	Y		
	6884793	Oct 25, 2016	DP	Y		
	8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
DIFLUPREDNATE - DUREZOL						
N 022212 001	6114319	May 18, 2019	DP		ODE	Jun 13, 2019
	6114319*PED	Nov 18, 2019			PED	Sep 22, 2016
					PED	Dec 13, 2019
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA						
N 021392 001	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA						
N 021392 002	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA						
N 021392 003	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA						
N 021392 004	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA						
N 021392 005	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
DILTIAZEM HYDROCHLORIDE - CARDIZEM LA						
N 021392 006	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
	8759393	Oct 29, 2019	DP			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
	8759393	Oct 29, 2019	DP			
DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM						
N 021394 001	8263647	May 30, 2022	DP			
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM						
N 021393 001	8883849	Jan 17, 2022	U-1618			
	9155718	Jan 17, 2022	DP			
DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM						
N 205352 001					NC	Jan 17, 2017
DIVALPROEX SODIUM - DEPAKOTE ER						
N 021168 001	6419953	Dec 18, 2018				
	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6528091	Dec 18, 2018	U-106			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
DIVALPROEX SODIUM - DEPAKOTE ER						
N 021168 002	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
DOCETAXEL - DOCETAXEL						
N 205934 001	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
DOCETAXEL - DOCETAXEL						
N 205934 002	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
DOCETAXEL - DOCETAXEL						
N 205934 003	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOFETILIDE - DOFETILIDE						
A 207058 001					PC	Dec 04, 2016
DOFETILIDE - DOFETILIDE						
A 207058 002					PC	Dec 04, 2016
DOFETILIDE - DOFETILIDE						
A 207058 003					PC	Dec 04, 2016
DOFETILIDE - TIKOSYN						
N 020931 001	6124363	Oct 09, 2018				
DOFETILIDE - TIKOSYN						
N 020931 002	6124363	Oct 09, 2018				
DOFETILIDE - TIKOSYN						
N 020931 003	6124363	Oct 09, 2018				
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 001	8129385	Oct 05, 2027	DS DP		M-166	Jul 30, 2018
	9242986	Dec 08, 2029	DS DP		NCE	Aug 12, 2018
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 002	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 003	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
DONEPEZIL HYDROCHLORIDE - ARICEPT						
N 022568 001	8481565	Oct 04, 2026	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 001	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 002	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 002	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025			U-1641	
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 003	8039009	Mar 24, 2029			U-1641	
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029			U-1641	
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025			U-1641	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025			U-1641	
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025			U-1641	
	8362085	Nov 22, 2025			U-1641	
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025			U-1641	
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 004	8039009	Mar 24, 2029			U-1641	
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029			U-1641	
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025			U-1641	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025			U-1641	
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025			U-1641	
	8362085	Nov 22, 2025			U-1641	
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025			U-1641	
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DORIPENEM - DORIBAX						
N 022106 001	8247402	Mar 30, 2021	DS DP			
DORIPENEM - DORIBAX						
N 022106 002	8247402	Mar 30, 2021	DS DP			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 001	6211229	Feb 17, 2020			U-620	
	7915307	Aug 24, 2027			U-620	
	8513299	Sep 07, 2030			U-620	
	9107898	May 01, 2028			U-620	
	9486437	May 18, 2027			U-620	
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 002	6211229	Feb 17, 2020			U-620	
	7915307	Aug 24, 2027			U-620	
	8513299	Sep 07, 2030			U-620	
	9107898	May 01, 2028			U-620	
	9486437	May 18, 2027			U-620	

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOXYCYCLINE - ORACEA						
N 050805 001	5789395	Aug 30, 2016	U-925	Y		
	5919775	Aug 30, 2016	U-925	Y		
	7211267	Apr 05, 2022	U-925			
	7232572	Apr 05, 2022	U-925			
	7749532	Dec 19, 2027	DP U-1063			
	8206740	Dec 24, 2025	DP U-925			
	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
	8603506	Apr 05, 2022	U-1063			
	8709478	Apr 07, 2024	U-1063			
	9241946	Apr 05, 2022	U-1063			
DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE						
A 090431 003					PC	Nov 19, 2016
DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE						
A 090431 005					PC	Nov 15, 2016
DOXYCYCLINE HYCLATE - DORYX						
N 050795 001	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 002	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 003	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 005	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX MPC						
N 050795 007	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	9511031	Oct 23, 2034	DP			
DOXYCYCLINE HYCLATE - DORYX MPC						
N 050795 008	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	9511031	Oct 23, 2034	DP			
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS						
N 021876 001	6340695	Jun 21, 2021	DP U-1382			
	7560122	Jan 25, 2019	DP			
DRONEDARONE HYDROCHLORIDE - MULTAQ						
N 022425 001	5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	7323493	Jun 19, 2018	DP			
	8318800	Jun 19, 2018	DP			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
	8602215	Jun 30, 2031	U-1473			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DRONEDARONE HYDROCHLORIDE - MULTAQ						
N 022425 001	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
DROSPIRENONE; ESTRADIOL - ANGELIQ						
N 021355 001	8906890	Oct 22, 2031	DP			
DROSPIRENONE; ESTRADIOL - ANGELIQ						
N 021355 002	6933395	Aug 11, 2017	DS			
DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN						
N 021098 001	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DS			
DROSPIRENONE; ETHINYL ESTRADIOL - YAZ						
N 021676 001	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DP			
	6958326	Dec 20, 2021	DP			
	6987101	Dec 22, 2017	U-758			
	7163931	Dec 20, 2021	U-1			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM						
A 203593 001					PC	Apr 09, 2017
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ						
N 022532 001	6441168	Jul 30, 2022	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
	8617597	Feb 08, 2030	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL						
N 022574 001	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
	8617597	Feb 08, 2030	DP			
DROXIDOPA - NORTHERA						
N 203202 001					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
DROXIDOPA - NORTHERA						
N 203202 002					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
DROXIDOPA - NORTHERA						
N 203202 003					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
DULOXETINE HYDROCHLORIDE - CYMBALTA						
N 021427 001	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
DULOXETINE HYDROCHLORIDE - CYMBALTA						
N 021427 002	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
DULOXETINE HYDROCHLORIDE - CYMBALTA						
N 021427 004	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
ECONAZOLE NITRATE - ECOZA						
N 205175 001	5993830	Jan 16, 2018	DP U-1449		NDF	Oct 24, 2016
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
	9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
	9149532	Mar 28, 2028	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
	9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
	9149532	Mar 28, 2028	DP			
EFAVIRENZ - SUSTIVA						
N 020972 001	6238695	Apr 06, 2019	DP		PED	Nov 02, 2016
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
EFAVIRENZ - SUSTIVA						
N 020972 002	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
EFAVIRENZ - SUSTIVA						
N 020972 003	6238695	Apr 06, 2019	DP		PED	Nov 02, 2016
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
EFAVIRENZ - SUSTIVA						
N 021360 001	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
EFAVIRENZ - SUSTIVA						
N 021360 002	6639071	Feb 14, 2018	DS		PED	Nov 02, 2016
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N 021937 001	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
	8592397	Jan 13, 2024	DP U-750			
	8592397	Jan 13, 2024	DP U-1170			
	8598185	May 01, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N 021937 001	8716264	Jan 13, 2024	DP U-257			
	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
	9457036	Jan 13, 2024	DP U-257			
EFINACONAZOLE - JUBLIA						
N 203567 001	7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
	9302009	Oct 24, 2030	DP			
ELBASVIR; GRAZOPREVIR - ZEPATIER						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
ELETRIPTAN HYDROBROMIDE - RELPAX						
N 021016 001	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
ELETRIPTAN HYDROBROMIDE - RELPAX						
N 021016 002	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
ELIGLUSTAT TARTRATE - CERDELGA						
N 205494 001	6916802	Apr 29, 2022	U-1571		NCE	Aug 19, 2019
	7196205	Apr 29, 2022	DS		ODE	Aug 19, 2021
	7615573	Apr 29, 2022	U-1571			
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 005	7790704	May 24, 2021	U-1575			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
	7332481	May 24, 2021	U-1736		PED	Dec 11, 2018
	7452874	May 24, 2021	DS DP		PED	Dec 11, 2018
	7473686	May 24, 2021	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-1736			
	7790704	May 24, 2021	U-1736			
	7795293	May 24, 2023	U-1736			
ELUXADOLINE - VIBERZI						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
ELUXADOLINE - VIBERZI						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
ELVITEGRAVIR - VITEKTA						
N 203093 001	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
ELVITEGRAVIR - VITEKTA						
N 203093 002	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-160	Jun 26, 2018
	8551957	Oct 14, 2029	U-1651		M-161	Jun 26, 2018
					M-174	Mar 18, 2019
					NCE	Aug 01, 2019
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-160	Jun 26, 2018
	8551957	Oct 14, 2029	U-1651		M-161	Jun 26, 2018
					M-174	Mar 18, 2019
					NCE	Aug 01, 2019
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	6303661	Apr 24, 2017	U-1651		I-739	Dec 02, 2019
	6890898	Feb 02, 2019	U-1652		NC	Jan 30, 2018
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	May 02, 2025	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	6303661	Apr 24, 2017	U-1651		I-739	Dec 02, 2019
	6890898	Feb 02, 2019	U-1652		NC	Jan 30, 2018
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 001	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 003	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 004	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 001	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 002	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 003	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 004	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
EMTRICITABINE - EMTRIVA						
N 021500 001	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020	U-257			
	6642245	Nov 04, 2020	U-541			
	6703396	Mar 09, 2021	DS DP			
EMTRICITABINE - EMTRIVA						
N 021896 001	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY						
N 208351 001	5914331	Jul 02, 2017	DS		NCE	Nov 05, 2020
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA						
N 202123 001	5914331	Jul 02, 2017	DS		NPP	Dec 13, 2016
	5922695	Jul 25, 2017	DS U-257			
	5935946	Jul 25, 2017	DS DP U-257			
	5977089	Jul 25, 2017	DS DP U-257			
	6043230	Jul 25, 2017	U-257			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8592397	Jan 13, 2024	DP U-257			
	8716264	Jan 13, 2024	DP U-257			
	8841310	Dec 09, 2025	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY						
N 208215 001	5914331	Jul 02, 2017	DS		NCE	Nov 05, 2020
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N 021752 001	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	8592397	Jan 13, 2024	DP U-248			
	8592397	Jan 13, 2024	DP U-541			
	8592397	Jan 13, 2024	DP U-1170			
	8716264	Jan 13, 2024	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N 021752 002	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N 021752 003	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N 021752 003	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA						
N 021752 004	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
ENALAPRIL MALEATE - EPANED KIT						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-1892			
ENTACAPONE - COMTAN						
N 020796 001	6599530	Sep 14, 2018	DP U-219			
ENTECAVIR - BARACLUDE						
N 021797 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
ENTECAVIR - BARACLUDE						
N 021797 002					NPP	Mar 20, 2017
					PED	Sep 20, 2017
ENTECAVIR - BARACLUDE						
N 021798 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENZALUTAMIDE - XTANDI						
N 203415 001	7709517	Aug 13, 2027	DS DP		I-693	Sep 10, 2017
	8183274	May 15, 2026	U-1281		NCE	Aug 31, 2017
	8183274	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-1588			
EPINEPHRINE - EPIPEN						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
EPINEPHRINE - EPIPEN JR.						
N 019430 002	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
EPINEPHRINE - TWINJECT 0.3						
N 020800 001	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
EPINEPHRINE - TWINJECT 0.15						
N 020800 002	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
EPINEPHRINE - AUVI-Q						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
EPINEPHRINE - AUVI-Q						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q						
N 201739 002	9278182	Feb 01, 2026	DP			
EPINEPHRINE - ADRENALIN						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
EPINEPHRINE - ADRENALIN						
N 204640 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
EPINEPHRINE - EPINEPHRINE						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT						
N 021504 001	6629968	Jun 30, 2020	DS DP			
	6635045	Jun 29, 2021	DS DP			
EPLERENONE - INSPRA						
N 021437 001	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
EPLERENONE - INSPRA						
N 021437 002	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
EPLERENONE - INSPRA						
N 021437 003	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
EPOPROSTENOL SODIUM - VELETRI						
N 022260 001	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
EPOPROSTENOL SODIUM - VELETRI						
N 022260 002	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
ERIBULIN MESYLATE - HALAVEN						
N 201532 001	6214865	Jul 20, 2023	DS		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1096		ODE	Jan 28, 2023
	6469182	Jun 16, 2019	U-1812			
	7470720	Jun 16, 2019	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERIBULIN MESYLATE - HALAVEN						
N 201532 001	8097648	Jan 22, 2021	U-1096			
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		D-164	May 20, 2019
	5747498*PED	May 08, 2019			M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-659		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		D-164	May 20, 2019
	5747498*PED	May 08, 2019			M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-659		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		D-164	May 20, 2019
	5747498*PED	May 08, 2019			M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-659		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
ERTAPENEM SODIUM - INVANZ						
N 021337 001	5952323	May 15, 2017	DP			
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1746		I-715	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1842		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1746		I-715	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1842		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1746		I-715	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1842		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1746		I-715	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1842		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
ESMOLOL HYDROCHLORIDE - BREVIBLOC						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
ESMOLOL HYDROCHLORIDE - BREVIBLOC						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N 021153 001	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N 021153 002	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N 021153 002	6428810	Nov 03, 2019	DP U-770			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N 021957 001	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N 021957 002	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N 021957 003	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N 021957 004	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N 022101 001	6369085	May 25, 2018	DS DP U-858			
	6428810	Nov 03, 2019	DP U-858			
	7411070	May 25, 2018	DS			
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR						
N 204655 001	5900424*PED	Nov 04, 2016			RTO	Mar 28, 2017
	6369085	May 25, 2018	DS DP U-1509			
	6369085	May 25, 2018	DS DP U-1875			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810	Nov 03, 2019	DP U-1874			
	6428810*PED	May 03, 2020				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR						
N 207920 01	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1784			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1785			
	6428810*PED	May 03, 2020				
	7411070	May 18, 2018	DS			
	7411070*PED	Nov 18, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N 022511 001	6369085	May 25, 2018	DS DP U-1053			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
	8852636	May 31, 2022	DP U-1052			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N 022511 001	8858996	May 31, 2022	DP U-1052			
	8945621	Oct 17, 2031	U-1661			
	9161920	May 31, 2022	U-1760			
	9198888	May 31, 2022	U-1781			
	9220698	Mar 10, 2031	U-1781			
	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029	U-1781			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N 022511 002	6369085	May 25, 2018	DS DP U-1053			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
	8945621	Oct 17, 2031	U-1661			
	9161920	May 31, 2022	U-1760			
	9198888	May 31, 2022	U-1781			
	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029	U-1781			
ESOMEPRAZOLE SODIUM - NEXIUM IV						
N 021689 001					D-138	Mar 04, 2017
					I-679	Mar 04, 2017
ESOMEPRAZOLE SODIUM - NEXIUM IV						
N 021689 002					D-138	Mar 04, 2017
					I-679	Mar 04, 2017
ESTRADIOL - VAGIFEM						
N 020908 002	5860946	Jul 01, 2017	DP			
	7018992	Sep 17, 2022	U-1023			
ESTRADIOL - MENOSTAR						
N 021674 001	5891868	Nov 21, 2017	DP U-594			
	6692763	Nov 21, 2017	DP U-594			
ESTRADIOL - ELESTRIN						
N 021813 001	7198801	Jun 25, 2022	DP			
	7470433	Aug 03, 2021	DP			
ESTRADIOL - EVAMIST						
N 022014 001	6299900	Feb 19, 2017	DP U-888			
	6299900	Feb 19, 2017	DP U-889			
	6818226	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-888			
	6923983	Feb 19, 2017	DP U-889			
	6978945	Jul 31, 2022	DP			
ESTRADIOL - MINIVELLE						
N 203752 001	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
ESTRADIOL - MINIVELLE						
N 203752 002	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
ESTRADIOL - MINIVELLE						
N 203752 003	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
ESTRADIOL - MINIVELLE						
N 203752 004	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - MINIVELLE						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 001	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 002	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 003	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025	U-904			
	7799771	Dec 21, 2021	DP			
ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST						
N 021040 001	6747019	Mar 20, 2020	U-311			
	7320970	Mar 30, 2020	DP U-844			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA						
N 021443 001	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA						
N 021443 002	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA						
N 021443 003	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA						
N 021443 004	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA						
N 021443 005	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
ETEPLIRSEN - EXONDYS 51						
N 206488 001	8486907	Jun 28, 2025	U-1904		NCE	Sep 19, 2021
	9018368	Jun 28, 2025	DS DP		ODE	Sep 19, 2023
	9416361	May 04, 2021	DS			
	9506058	Mar 14, 2034	U-1918			
	9506058	Mar 14, 2034	U-1919			
ETEPLIRSEN - EXONDYS 51						
N 206488 002	8486907	Jun 28, 2025	U-1904		NCE	Sep 19, 2021
	9018368	Jun 28, 2025	DS DP		ODE	Sep 19, 2023
	9416361	May 04, 2021	DS			
	9506058	Mar 14, 2034	U-1918			
	9506058	Mar 14, 2034	U-1919			
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO						
N 021241 001	6214815	Jun 09, 2019	U-112			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE							
N 021840	001	7320969	Jan 30, 2024		U-828		
		7615545	Jun 15, 2023		U-1		
		7855190	Dec 05, 2028		U-1		
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE							
N 022262	001	7615545	Jun 15, 2023		U-1		
		7855190	Dec 05, 2028		U-1		
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING							
N 021187	001	5989581	Apr 08, 2018				
ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT							
N 020946	001	6156742	Dec 05, 2020		U-374		
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE							
N 021544	001	5898032	Jun 23, 2017		U-1		
		RE39861	Jun 23, 2017		U-828		
ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL							
N 021864	001	6500814	Sep 03, 2018		U-1		
ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE							
N 204061	001	8415332	Mar 11, 2029	DP			
		8450299	Oct 07, 2025		U-1		
ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE							
N 021490	001	6667050	Apr 06, 2019	DP	U-1		
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
N 022573	001	6667050	Apr 06, 2019	DP	U-828		
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE							
N 022501	001	7704984	Feb 02, 2029		U-1090		
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE							
N 203667	001	6667050	Apr 06, 2019	DP	U-1		
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - TAYTULLA							
N 204426	001	6652880	Mar 29, 2020	DP			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE							
N 204654	001	6667050	Apr 06, 2019	DP	U-1		
		7704984	Feb 02, 2029		U-1		
ETHIODIZED OIL - LIPIODOL							
N 009190	001					ODE	Apr 04, 2021
ETONOGESTREL - NEXPLANON							
N 021529	002	8722037	Sep 28, 2027	DP			
		8888745	Aug 28, 2026	DP			
ETRAVIRINE - INTELENCE							
N 022187	001	6878717	Nov 05, 2019		U-256		
		6878717	Nov 05, 2019		U-1016		
		6878717	Nov 05, 2019		U-1237		
		7037917	Dec 13, 2020	DS DP	U-256		
		7037917	Dec 13, 2020	DS DP	U-1016		
		7037917	Dec 13, 2020	DS DP	U-1237		
		7887845	Mar 25, 2019	DP			
		8003789	Nov 01, 2019	DS DP			
ETRAVIRINE - INTELENCE							
N 022187	002	6878717	Nov 05, 2019		U-256		
		6878717	Nov 05, 2019		U-1016		
		6878717	Nov 05, 2019		U-1237		
		7037917	Dec 13, 2020	DS DP	U-256		
		7037917	Dec 13, 2020	DS DP	U-1016		
		7037917	Dec 13, 2020	DS DP	U-1237		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETRAVIRINE - INTELENCE						
N 022187 002	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
ETRAVIRINE - INTELENCE						
N 022187 003	6878717	Nov 05, 2019	U-256			
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
EVEROLIMUS - ZORTRESS						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049			
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
EVEROLIMUS - ZORTRESS						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049			
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
EVEROLIMUS - ZORTRESS						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049			
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
EVEROLIMUS - AFINITOR						
N 022334 001	5665772	Sep 09, 2019	DS DP		I-724	Feb 26, 2019
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	7297703	Dec 06, 2019	DP		ODE	May 05, 2018
	7741338	Dec 06, 2019	DP		ODE	Apr 26, 2019
	8410131	Nov 01, 2025	U-1368		PED	Apr 29, 2018
	8410131*PED	May 01, 2026			PED	Nov 05, 2018
	8436010	Feb 22, 2022	U-1396		PED	Oct 26, 2019
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 002	5665772	Sep 09, 2019	DS DP		I-724	Feb 26, 2019
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	7297703	Dec 06, 2019	DP		ODE	May 05, 2018
	7741338	Dec 06, 2019	DP		ODE	Apr 26, 2019
	8410131	Nov 01, 2025	U-1368		PED	Apr 29, 2018
	8410131*PED	May 01, 2026			PED	Nov 05, 2018
	8436010	Feb 22, 2022	U-1396		PED	Oct 26, 2019
	8436010*PED	Aug 22, 2022				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR						
N 022334 002	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 003	5665772	Sep 09, 2019	DS DP		I-724	Feb 26, 2019
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	7297703	Dec 06, 2019	DP		ODE	May 05, 2018
	7741338	Dec 06, 2019	DP		ODE	Apr 26, 2019
	8410131	Nov 01, 2025	U-1368		PED	Apr 29, 2018
	8410131*PED	May 01, 2026			PED	Nov 05, 2018
	8436010	Feb 22, 2022	U-1396		PED	Oct 26, 2019
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 004	5665772	Sep 09, 2019	DS DP		I-724	Feb 26, 2019
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	7297703	Dec 06, 2019	DP		ODE	May 05, 2018
	7741338	Dec 06, 2019	DP		ODE	Apr 26, 2019
	8410131	Nov 01, 2025	U-1368		PED	Apr 29, 2018
	8410131*PED	May 01, 2026			PED	Nov 05, 2018
	8436010	Feb 22, 2022	U-1396		PED	Oct 26, 2019
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 001	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP			
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 002	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP			
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 003	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP			
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
EXENATIDE SYNTHETIC - BYETTA						
N 021773 001	5424286	Dec 01, 2016	U-653		M-148	Nov 24, 2017
	5424286	Dec 01, 2016	U-1108			
	6858576	Jan 06, 2017	U-656			
	6858576	Jan 06, 2017	U-1108			
	6872700	Jan 14, 2020	U-654			
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018	U-687			
	6956026	Jan 07, 2018	U-1074			
	6956026	Jan 07, 2018	U-1623			
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYETTA						
N 021773 001	7741269	Jan 07, 2018	U-653			
	7741269	Jan 07, 2018	U-1074			
	7741269	Jan 07, 2018	U-1108			
EXENATIDE SYNTHETIC - BYETTA						
N 021773 002	5424286	Dec 01, 2016	U-653		M-148	Nov 24, 2017
	5424286	Dec 01, 2016	U-1108			
	6858576	Jan 06, 2017	U-656			
	6858576	Jan 06, 2017	U-1108			
	6872700	Jan 14, 2020	U-654			
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018	U-687			
	6956026	Jan 07, 2018	U-1074			
	6956026	Jan 07, 2018	U-1623			
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018	U-653			
	7741269	Jan 07, 2018	U-1074			
	7741269	Jan 07, 2018	U-1108			
EXENATIDE SYNTHETIC - BYDUREON						
N 022200 001	5424286	Dec 01, 2016	U-1108		M-162	Sep 24, 2018
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
EZETIMIBE - EZETIMIBE						
A 078560 001					PC	Jun 10, 2017
EZETIMIBE - ZETIA						
N 021445 001	7030106	Jan 25, 2022	DP			
	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EZETIMIBE - ZETIA						
N 021445 001	7612058*PED	Apr 30, 2026				
	RE37721	Oct 25, 2016	DS DP		U-473	
	RE42461	Oct 25, 2016	DS DP		U-473	
	RE42461	Oct 25, 2016	DS DP		U-1173	
EZETIMIBE; SIMVASTATIN - VYTORIN						
N 021687 001	RE37721	Oct 25, 2016	DS DP		U-473	
	RE42461	Oct 25, 2016	DS DP		U-473	
EZETIMIBE; SIMVASTATIN - VYTORIN						
N 021687 002	RE37721	Oct 25, 2016	DS DP		U-473	
	RE42461	Oct 25, 2016	DS DP		U-473	
EZETIMIBE; SIMVASTATIN - VYTORIN						
N 021687 003	RE37721	Oct 25, 2016	DS DP		U-473	
	RE42461	Oct 25, 2016	DS DP		U-473	
EZETIMIBE; SIMVASTATIN - VYTORIN						
N 021687 004	RE37721	Oct 25, 2016	DS DP		U-473	
	RE42461	Oct 25, 2016	DS DP		U-473	
FAMOTIDINE - PEPCID AC						
N 020801 002	6814978	Aug 26, 2021	DP			
FAMOTIDINE - FLUXID						
N 021712 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
FAMOTIDINE - FLUXID						
N 021712 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
FAMOTIDINE; IBUPROFEN - DUEXIS						
N 022519 001	8067033	Jul 18, 2026	DP			
	8067451	Jul 18, 2026	DP		U-1196	
	8309127	Jul 18, 2026	DP			
	8318202	Jul 18, 2026	DP			
	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026			U-1196	
FEBUXOSTAT - ULORIC						
N 021856 001	5614520	Mar 25, 2019	DS DP		U-954	
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031			U-1346	
	9107912	Sep 08, 2031			U-1346	
FEBUXOSTAT - ULORIC						
N 021856 002	5614520	Mar 25, 2019	DS DP		U-954	
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031			U-1346	
	9107912	Sep 08, 2031			U-1346	
FENOFIBRATE - TRICOR						
N 021203 001	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
FENOFIBRATE - TRICOR						
N 021203 003	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRATE - TRIGLIDE						
N 021350 001	6696084	Sep 11, 2021	DS DP U-680			
FENOFIBRATE - TRIGLIDE						
N 021350 002	6696084	Sep 11, 2021	DS DP U-680			
FENOFIBRATE - TRICOR						
N 021656 001	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
FENOFIBRATE - TRICOR						
N 021656 002	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 001	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 003	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 004	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
FENOFIBRATE - ANTARA (MICRONIZED)						
N 021695 005	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
FENOFIBRATE - FENOGLIDE						
N 022118 001	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
FENOFIBRATE - FENOGLIDE						
N 022118 002	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
FENOFIBRIC ACID - FIBRICOR						
N 022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
FENOFIBRIC ACID - FIBRICOR						
N 022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRIC ACID - FIBRICOR						
N 022418 002	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
FENTANYL - SUBSYS						
N 202788 001	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 002	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 004	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 005	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
FENTANYL - SUBSYS						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
FENTANYL CITRATE - FENTORA						
N 021947 001	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 002	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - FENTORA						
N 021947 002	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 003	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 004	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 005	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
FENTANYL CITRATE - FENTORA						
N 021947 006	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 001	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 002	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 003	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 004	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ONSOLIS						
N 022266 005	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
FENTANYL CITRATE - ABSTRAL						
N 022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N 022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - ABSTRAL						
N 022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N 022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N 022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N 022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - LAZANDA						
N 022569 001	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA						
N 022569 002	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
FENTANYL HYDROCHLORIDE - IONSYS						
N 021338 001	5697896	Dec 16, 2016	DP			
	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP U-736			
	6881208	Apr 19, 2022	U-736			
	6975902	Apr 01, 2024	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
	9364656	Sep 30, 2031	U-736			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP U-1432			
	8895612	Jan 08, 2027	DP U-1620			
	9376505	Oct 20, 2023	DS DP			
FERRIC CITRATE - AURYXIA						
N 205874 001	5753706	Feb 03, 2017	DP U-1577			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
	9328133	Feb 18, 2024	DS DP U-1577			
	9387191	Jul 21, 2030	DP			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 206317 001	7816404	Apr 17, 2029	DP		U-1656	
FERUMOXYTOL - FERAHEME						
N 022180 001	6599498	Jun 30, 2023	DS DP			
	7553479	Mar 08, 2020	DS DP			
	7871597	Mar 08, 2020	DS DP			
	8501158	Mar 08, 2020			U-1422	
	8591864	Mar 08, 2020	DP			
	8926947	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ						
N 022030 001	6858650	Jul 03, 2022	DS		U-913	
	7384980	May 11, 2019	DS DP		U-913	
	7807715	Jun 07, 2027	DP		U-913	
	7855230	May 11, 2019			U-913	
	7985772	May 11, 2019	DS DP		U-913	
	8088398	Jun 07, 2027	DP		U-913	
	8338478	May 11, 2019	DS DP		U-913	
	8501723	Jun 07, 2027	DP			
FESOTERODINE FUMARATE - TOVIAZ						
N 022030 002	6858650	Jul 03, 2022	DS		U-913	
	7384980	May 11, 2019	DS DP		U-913	
	7807715	Jun 07, 2027	DP		U-913	
	7855230	May 11, 2019			U-913	
	7985772	May 11, 2019	DS DP		U-913	
	8088398	Jun 07, 2027	DP		U-913	
	8338478	May 11, 2019	DS DP		U-913	
	8501723	Jun 07, 2027	DP			
FEXOFENADINE HYDROCHLORIDE - ALLEGRA						
N 020625 001	6037353	Mar 14, 2017			U-138	
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N 020872 005	6037353	Mar 14, 2017			U-1160	
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N 020872 006	6037353	Mar 14, 2017			U-1160	
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY						
N 020872 007	6037353	Mar 14, 2017			U-1160	
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES						
N 020872 008	6037353	Mar 14, 2017			U-1160	
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES						
N 020872 009	6037353	Mar 14, 2017			U-1160	
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY						
N 020872 010	6037353	Mar 14, 2017			U-1160	
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N 021909 002	6037353	Mar 14, 2017			U-1158	
	6037353	Mar 14, 2017			U-1466	
	6723348	Nov 26, 2021	DP		U-1466	
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N 021909 003	6037353	Mar 14, 2017				
	6723348	Nov 26, 2021	DP			
FEXOFENADINE HYDROCHLORIDE - ALLEGRA						
N 021963 001	6037353	Mar 14, 2017			U-772	
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N 201373 001	6037353	Mar 14, 2017			U-1157	
	8933097	Aug 16, 2032	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES							
N 201373	002	6037353	Mar 14, 2017	U-1157			
		8933097	Aug 16, 2032	DP			
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION							
N 020786	002	6037353	Mar 14, 2017	U-1159			
		6039974	Jul 31, 2018	DP			
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION							
N 021704	002	6037353	Mar 14, 2017	U-1159			
		6613357	Dec 25, 2020	DP U-1159			
		RE39069	May 29, 2018	DP			
FIDAXOMICIN - DIFICID							
N 201699	001	7378508	Jul 31, 2027	DS DP			
		7863249	Jul 31, 2027	DS DP			
		7906489	Mar 04, 2027	U-319			
		8586551	Jul 15, 2023	DS DP			
		8859510	Jul 31, 2027	U-319			
FINAFLOXACIN - XTORO							
N 206307	001	6133260	Apr 12, 2017	DS DP		NCE	Dec 17, 2019
		6432948	Apr 12, 2017	DS DP		PED	Jun 17, 2020
		8536167	Aug 08, 2031	U-1679			
		9119859	Jul 02, 2030	U-1679			
		9504691	Nov 21, 2033	DP U-1679			
FINASTERIDE - PROSCAR							
N 020180	001	5942519	Oct 23, 2018	U-280			
FINGOLIMOD - GILENYA							
N 022527	001	5604229	Feb 18, 2019	DS U-1086			
		6004565	Sep 23, 2017	U-1086			
		8324283	Mar 29, 2026				
		9187405	Jun 25, 2027	U-1086			
FLIBANSERIN - ADDYI							
N 022526	001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
		7420057	Aug 01, 2022	DS DP			
		8227471	May 09, 2023	U-1734			
		9468639	Oct 16, 2022	U-1734			
FLORBETABEN F-18 - NEURACEQ							
N 204677	001	7807135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
FLORBETAPIR F-18 - AMYVID							
N 202008	001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
		8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID							
N 202008	002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
		8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID							
N 202008	003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
		8506929	Apr 30, 2027	DS DP U-1423			
FLUCICLOVINE F-18 - AXUMIN							
N 208054	001	5808146	Nov 09, 2017	DS		NCE	May 27, 2021
		9387266	Nov 28, 2026	U-1879			
FLUDARABINE PHOSPHATE - OFORTA							
N 022273	001	7148207	Dec 20, 2022	DP U-944			
		7547776	Dec 10, 2018	DS			
FLUNISOLIDE - AEROSPAN HFA							
N 021247	001					M-128	Aug 28, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUOCINOLONE ACETONIDE - RETISERT						
N 021737 001	6217895	Mar 22, 2019	DP U-708			
	6548078	Mar 22, 2019	DP U-708			
FLUOCINOLONE ACETONIDE - ILUVIEN						
N 201923 001	6217895	Mar 22, 2019	DP U-1597		NP	Sep 26, 2017
	6375972	Apr 26, 2020	DP U-1597			
	6548078	Mar 22, 2019	DP U-1597			
	8252307	Jun 27, 2019	DP			
	8871241	Aug 12, 2027	DP			
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA						
N 021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
	8247395	Oct 22, 2022	DP			
	8653053	Oct 25, 2022	DP			
FLUOCINONIDE - VANOS						
N 021758 001	6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023	U-861			
	7794738	Sep 11, 2022	U-1084			
	8232264	Mar 09, 2023	DP			
FLUOROURACIL - CARAC						
N 020985 001	6670335	Jun 02, 2021	DP U-68			
FLUOROURACIL - TOLAK						
N 022259 001	7169401	Jul 18, 2023	DP		NP	Sep 18, 2018
FLUOXETINE HYDROCHLORIDE - PROZAC						
N 018936 001	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
FLUOXETINE HYDROCHLORIDE - PROZAC						
N 018936 003	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
FLUOXETINE HYDROCHLORIDE - PROZAC						
N 018936 004					NPP	Jul 26, 2016
FLUOXETINE HYDROCHLORIDE - PROZAC						
N 018936 006	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY						
N 021235 001	5910319	May 29, 2017	U-396			
	5985322	May 29, 2017	U-397			
	RE39030	May 29, 2017	DP U-396			
	RE39030	May 29, 2017	DP U-397			
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
N 021520 001	6960577	Nov 01, 2017	U-962		M-142	Oct 10, 2017
					NPP	Jul 26, 2016
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
N 021520 002	5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
N 021520 003	5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
N 021520 004	5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
N 021520 005	5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 001	7270800	Sep 03, 2025	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8236282	May 21, 2024	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTEMETAMOL F-18 - VIZAMYL							
N 203137	001	8691185	Jan 24, 2023	U-336			
		8916131	Sep 16, 2028	DP			
FLUTEMETAMOL F-18 - VIZAMYL							
N 203137	002	7270800	Sep 03, 2025	DS DP U-336		NCE	Oct 25, 2018
		7351401	Jan 24, 2023	DS DP U-336			
		8236282	May 21, 2024	DS DP			
		8691185	Jan 24, 2023	U-336			
		8916131	Sep 16, 2028	DP			
FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF							
N 022051	002	6858596	Aug 03, 2021	DP U-1890			
		7101866	Aug 03, 2021	DS DP U-1890			
		7541350	Aug 03, 2021	DP U-1890			
		8062264	Apr 05, 2026	DP			
		8147461	Oct 15, 2028	DP			
		8347879	Jul 15, 2028	DP			
		8752543	Apr 05, 2026	DP			
		9320862	Nov 06, 2024	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA							
N 205625	001	7101866	Aug 03, 2021	DS DP U-1559		NP	Aug 20, 2017
		7629335	Aug 03, 2021	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8201556	Feb 05, 2029	DP			
		8534281	Aug 10, 2029	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA							
N 205625	002	7101866	Aug 03, 2021	DS DP U-1559		NP	Aug 20, 2017
		7629335	Aug 03, 2021	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8201556	Feb 05, 2029	DP			
		8534281	Aug 10, 2029	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275	001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
		6537983	Aug 03, 2021	DP U-1691			
		6759398	Aug 03, 2021	DP U-1401			
		6759398	Aug 03, 2021	DP U-1691			
		6878698	Aug 03, 2021	U-1401			
		7101866	Aug 03, 2021	DS DP U-1401			
		7101866	Aug 03, 2021	DS DP U-1691			
		7439393	Sep 11, 2022	DS DP U-1401			
		7439393	Sep 11, 2022	DS DP U-1691			
		7629335	Aug 03, 2021	DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8511304	Jun 14, 2027	DP U-1424			
		8511304	Jun 14, 2027	DP U-1691			
		8534281	Aug 10, 2029	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		RE44874	Mar 23, 2023	DS DP U-1548			
		RE44874	Mar 23, 2023	DS DP U-1691			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275	002	6537983	Aug 03, 2021	DP U-1691		NP	Apr 30, 2018
		6759398	Aug 03, 2021	DP U-1691			
		7101866	Aug 03, 2021	DS DP U-1691			
		7439393	Sep 11, 2022	DS DP U-1691			
		7629335	Aug 03, 2021	DP			
		7776895	Sep 11, 2022	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 002	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
FLUTICASONE PROPIONATE - CUTIVATE						
N 021152 001	7300669	Oct 20, 2019	DP U-835		NPP	Jan 16, 2018
FLUTICASONE PROPIONATE - FLOVENT HFA						
N 021433 001	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE - FLOVENT HFA						
N 021433 002	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE - FLOVENT HFA						
N 021433 003	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF						
N 205434 001					M-147	Jul 23, 2017
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
N 021254 001	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017				
	6743413	Jun 01, 2021			U-1591	
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
N 021254 002	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6743413	Jun 01, 2021			U-1591	
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
N 021254 003	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6743413	Jun 01, 2021			U-1591	
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
FLUVASTATIN SODIUM - LESCOL XL						
N 021192 001	6242003	Apr 13, 2020				
FLUVOXAMINE MALEATE - LUVOX CR						
N 022033 001	7465462	May 10, 2020	DP		U-929	
FLUVOXAMINE MALEATE - LUVOX CR						
N 022033 002	7465462	May 10, 2020	DP		U-929	

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOLLITROPIN ALFA/BETA - GONAL-F						
N 020378 004	7563763	Aug 23, 2019	DP			
FOLLITROPIN ALFA/BETA - GONAL-F						
N 020378 005	7563763	Aug 23, 2019	DP			
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N 021211 001	5929028	Jan 14, 2018	DP		U-567	
	5929028	Jan 14, 2018	DP		U-1366	
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019			U-993	
	7563763	Aug 23, 2019			U-1183	
	7563763	Aug 23, 2019			U-1367	
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N 021211 002	5929028	Jan 14, 2018	DP		U-567	
	5929028	Jan 14, 2018	DP		U-1366	
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019			U-993	
	7563763	Aug 23, 2019			U-1183	
	7563763	Aug 23, 2019			U-1367	
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N 021211 003	5929028	Jan 14, 2018	DP		U-567	
	5929028	Jan 14, 2018	DP		U-1366	
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019			U-993	
	7563763	Aug 23, 2019			U-1183	
	7563763	Aug 23, 2019			U-1367	
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N 021211 004	5929028	Jan 14, 2018	DP		U-567	
	5929028	Jan 14, 2018	DP		U-1366	
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019			U-993	
	7563763	Aug 23, 2019			U-1183	
	7563763	Aug 23, 2019			U-1367	
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N 021273 001	5929028	Jan 14, 2018	DP		U-1366	
FOLLITROPIN ALFA/BETA - FOLLISTIM AQ						
N 021273 002	5929028	Jan 14, 2018	DP		U-1366	
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT						
N 021684 001	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT						
N 021684 002	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT						
N 021684 003	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
FOMEPIZOLE - ANTIZOL						
N 020696 001	7553863	Jun 30, 2027	DS DP			
FORMOTEROL FUMARATE - FORADIL						
N 020831 001	6488027	Mar 08, 2019				
	6887459	Nov 28, 2020			U-762	
FORMOTEROL FUMARATE - PERFOROMIST						
N 022007 001	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	DP		U-813	
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP		U-813	
	8623922	Jun 22, 2021	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
	9415009	May 28, 2030	U-1841			
	9463161	May 28, 2030	DP U-1841			
FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA						
N 022518 001	6068832	Aug 27, 2017	DP U-1068			
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA						
N 022518 002	6068832	Aug 27, 2017	DP U-1068			
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
FOSAMPRENAVIR CALCIUM - LEXIVA						
N 021548 001	6436989	Dec 24, 2017	DS DP U-257			
	6514953	Jul 15, 2019	DS DP U-257			
FOSAMPRENAVIR CALCIUM - LEXIVA						
N 022116 001	6436989	Dec 24, 2017	DS DP U-257			
FOSAPREPITANT DIMEGLUMINE - EMEND						
N 022023 001	5691336	Mar 04, 2019	DS DP			
FOSAPREPITANT DIMEGLUMINE - EMEND						
N 022023 002	5691336	Mar 04, 2019	DS DP		D-155	Feb 01, 2019
FOSPROPOFOL DISODIUM - LUSEDRA						
N 022244 001	6204257	Jul 01, 2022	DS DP U-945			
	6872838	Aug 07, 2018	DS			
FULVESTRANT - FASLODEX						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
GABAPENTIN - NEURONTIN						
N 020235 001	6054482	Apr 25, 2017				
GABAPENTIN - NEURONTIN						
N 020235 002	6054482	Apr 25, 2017				
GABAPENTIN - NEURONTIN						
N 020235 003	6054482	Apr 25, 2017				
GABAPENTIN - NEURONTIN						
N 020882 001	6054482	Apr 25, 2017				
GABAPENTIN - NEURONTIN						
N 020882 002	6054482	Apr 25, 2017				
GABAPENTIN - NEURONTIN						
N 021129 001	6054482	Apr 25, 2017				
	7256216	May 28, 2022	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN - GRALISE						
N 022544 001	6340475	Sep 19, 2016	DP		ODE	Jan 28, 2018
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
GABAPENTIN - GRALISE						
N 022544 002	6340475	Sep 19, 2016	DP		ODE	Jan 28, 2018
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 001	6818787	Nov 06, 2022	DS DP		ODE	Jun 06, 2019
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 002	6818787	Nov 06, 2022	DS DP		ODE	Jun 06, 2019
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
GADOBUTROL - GADAVIST						
N 201277 001	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
GADOBUTROL - GADAVIST						
N 201277 002	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
					I-731	Apr 27, 2019
GADOBUTROL - GADAVIST						
N 201277 003	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
GADOBUTROL - GADAVIST						
N 201277 004	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
GADOBUTROL - GADAVIST						
N 201277 005	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
GADOBUTROL - GADAVIST						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119		I-688	Jun 11, 2017
GADOFOSVESET TRISODIUM - ABLAVAR						
N 021711 001	6676929	May 04, 2020	DP			
GADOFOSVESET TRISODIUM - ABLAVAR						
N 021711 002	6676929	May 04, 2020	DP			
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 001					NCE	Mar 20, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 002					NCE	Mar 20, 2018
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 003					NCE	Mar 20, 2018
GADOTERATE MEGLUMINE - DOTAREM						
N 204781 004					NCE	Mar 20, 2018
GADOXETATE DISODIUM - EOVIST						
N 022090 001	6039931	Nov 13, 2021	U-1239		M-155	Mar 27, 2018
GADOXETATE DISODIUM - EOVIST						
N 022090 002					M-155	Mar 27, 2018
GALANTAMINE HYDROBROMIDE - RAZADYNE						
N 021169 001	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP U-322			
GALANTAMINE HYDROBROMIDE - RAZADYNE						
N 021169 002	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP U-322			
GALANTAMINE HYDROBROMIDE - RAZADYNE						
N 021169 003	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP U-322			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER						
N 021615 001	7160559	Dec 20, 2019	DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER						
N 021615 002	7160559	Dec 20, 2019	DP			
GALANTAMINE HYDROBROMIDE - RAZADYNE ER						
N 021615 003	7160559	Dec 20, 2019	DP			
GALLIUM DOTATATE GA-68 - NETSPOT						
N 208547 001					NCE	Jun 01, 2021
					ODE	Jun 01, 2023
GANCICLOVIR - ZIRGAN						
N 022211 001					ODE	Sep 15, 2016
GANIRELIX ACETATE - GANIRELIX ACETATE						
N 021057 001	6653286	Jun 16, 2018	U-1354			
GATIFLOXACIN - ZYMAR						
N 021493 001	6333045	Aug 20, 2019	DP	Y		
	6333045*PED	Feb 20, 2020				
GEFITINIB - IRESSA						
N 021399 001	5770599	May 05, 2017	DS DP U-881			
GEFITINIB - IRESSA						
N 206995 001	5770599	May 05, 2017	DS DP U-1755		NP	Jul 13, 2018
					ODE	Jul 13, 2022
GEMIFLOXACIN MESYLATE - FACTIVE						
N 021158 001	5776944	Apr 04, 2017	DS DP			
	6262071	Sep 21, 2019	U-513			
	6331550	Sep 21, 2019	U-511			
	6340689	Sep 14, 2019	U-512			
	6455540	Sep 21, 2019	U-511			
	6723734	Mar 20, 2018	DS DP			
	6803376	Sep 21, 2019	DS DP U-608			
	6803376	Sep 21, 2019	DS DP U-609			
GLATIRAMER ACETATE - COPAXONE						
N 020622 003	8232250	Aug 19, 2030	U-441		NP	Jan 28, 2017
	8399413	Aug 19, 2030	U-441			
	8969302	Aug 19, 2030	U-441			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLATIRAMER ACETATE - COPAXONE						
N 020622 003	9155776	Aug 19, 2030	U-441			
	9402874	Aug 19, 2030	U-441			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT						
N 021925 001	6303640	Aug 09, 2016	U-753			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT						
N 021925 002	6303640	Aug 09, 2016	U-753			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL						
N 021700 001	7358366	Apr 19, 2020	DS			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL						
N 021700 002	7358366	Apr 19, 2020	DS			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL						
N 021700 003	7358366	Apr 19, 2020	DS			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL						
N 021700 004	7358366	Apr 19, 2020	DS			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL						
N 021700 005	7358366	Apr 19, 2020	DS			
GLIPIZIDE - GLIPIZIDE						
A 202298 001					PC	Jul 27, 2016
GLIPIZIDE - GLUCOTROL XL						
N 020329 001	RE44459	Mar 26, 2019	U-1431			
GLIPIZIDE - GLUCOTROL XL						
N 020329 002	RE44459	Mar 26, 2019	U-1431			
GLIPIZIDE - GLUCOTROL XL						
N 020329 003	RE44459	Mar 26, 2019	U-1431			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE						
N 021178 001	6303146	Jul 14, 2019	U-412			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE						
N 021178 002	6303146	Jul 14, 2019	U-412			
GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE						
N 021178 003	6303146	Jul 14, 2019	U-412			
GLYCEROL PHENYLBUTYRATE - RAVICTI						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378		ODE	Feb 01, 2020
	8404215	Mar 09, 2032	U-1383			
	8642012	Sep 22, 2030	U-1383			
	9095559	Mar 09, 2032	U-1383			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
GLYCOPYRROLATE - CUVPOSA						
N 022571 001	7638552	Aug 20, 2023	U-1076		ODE	Jul 28, 2017
	7816396	Aug 20, 2023	U-1076			
GLYCOPYRROLATE - SEEBRI						
N 207923 001	6582678	Apr 24, 2018	DP		NP	Oct 29, 2018
	7229607	Apr 09, 2021	U-1773			
	7736670	Jun 27, 2021	DP			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8182838	Oct 20, 2028	DP			
	8303991	Jun 27, 2021	DP			
	8435567	Jun 27, 2021	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLYCOPYRROLATE - SEEBRI						
N 207923 001	8479730	Oct 11, 2028	DP			
	8580306	Jun 27, 2021	DP			
	8956661	Jun 27, 2021	DP			
GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON						
N 207930 001	6582678	Apr 24, 2018	DP		NCE	Jul 01, 2016
	6878721	Feb 25, 2025	DS DP U-1773		NP	Oct 29, 2018
	7229607	Apr 09, 2021	U-1773			
	7736670	Jun 27, 2021	DP			
	7820694	Jun 02, 2020	DP U-1773			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8067437	Jun 02, 2020	U-1773			
	8182838	Oct 20, 2028	DP			
	8283362	Jun 02, 2020	DP U-1773			
	8303991	Jun 27, 2021	DP			
	8435567	Jun 27, 2021	DP			
	8479730	Oct 11, 2028	DP			
	8580306	Jun 27, 2021	DP			
	8658673	Jun 02, 2020	DP U-1773			
	8796307	Jun 02, 2020	DP			
	8956661	Jun 27, 2021	DP			
GOSERELIN ACETATE - ZOLADEX						
N 019726 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
GOSERELIN ACETATE - ZOLADEX						
N 020578 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
GRANISETRON - SANCUSO						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
GRANISETRON - SUSTOL						
N 022445 001	6613355	Jun 28, 2021	DP		NDF	Aug 09, 2019
	6790458	May 11, 2021	DP			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			
GRANISETRON HYDROCHLORIDE - KYTRIL						
N 020239 001	5952340	Sep 14, 2016	U-519			
GRANISETRON HYDROCHLORIDE - KYTRIL						
N 020239 002	5952340	Sep 14, 2016	U-519			
GRANISETRON HYDROCHLORIDE - KYTRIL						
N 020239 004	5952340	Sep 14, 2016	U-519			
GUAIFENESIN - MUCINEX						
N 021282 001	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
GUAIFENESIN - MUCINEX						
N 021282 002	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D						
N 021585 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
	7838032	Apr 28, 2020	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D							
N 021585	002	6372252	Apr 28, 2020	DP			
		6955821	Apr 28, 2020	DP U-686			
		7838032	Apr 28, 2020	DP			
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	001	6287599	Dec 20, 2020	DP		D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021			M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP U-494		PED	May 19, 2018
		6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	002	6287599	Dec 20, 2020	DP		D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021			M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP U-494		PED	May 19, 2018
		6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	003	6287599	Dec 20, 2020	DP		D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021			M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP U-494		PED	May 19, 2018
		6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	004	6287599	Dec 20, 2020	DP		D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021			M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP U-494		PED	May 19, 2018
		6811794*PED	Jan 04, 2023				
HALOBETASOL PROPIONATE - ULTRAVATE							
N 208183	001	8962028	Jun 19, 2033	DP U-1775		NP	Nov 06, 2018
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT							
N 022555	001	7348361	Nov 06, 2020	DP U-1087			
		7530461	Jan 11, 2017	DP U-1087			
HISTRELIN ACETATE - SUPPRELIN LA							
N 022058	001	8062652	Jun 16, 2026	U-1197			
HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT							
N 021859	001	7767429	Sep 23, 2027	DS DP			
HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL							
N 020727	001	6465463	Sep 08, 2020	U-71			
		6784177	Sep 08, 2020	U-71			
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE							
A 078827	001					PC	Apr 24, 2017
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE							
A 078827	002					PC	Apr 24, 2017
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE							
A 078827	003					PC	Apr 24, 2017
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT							
N 021532	002	6878703	Nov 19, 2021	U-3	Y		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT							
N 021532	003	6878703	Nov 19, 2021	U-3	Y		
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT							
N 021532	005	6878703	Nov 19, 2021	U-3	Y		
HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT							
N 021162	001	6358986	Jan 10, 2020				
HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT							
N 021162	002	6358986	Jan 10, 2020				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT						
N 020818 001	6294197	Jun 18, 2017	U-3			
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT						
N 020818 002	6294197	Jun 18, 2017	U-3			
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT						
N 020818 003	6294197	Jun 18, 2017	U-3			
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT						
N 020818 004	6294197	Jun 18, 2017	U-3			
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT						
N 020818 005	6294197	Jun 18, 2017	U-3			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 001	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 002	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 003	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 004	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 005	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 005	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER						
N 202880 006	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 001	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 002	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 003	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 003	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP		U-1556	
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 004	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP		U-1556	
	8309060	Nov 20, 2023	DP		U-1556	
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP		U-1556	
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 005	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP		U-1556	
	8309060	Nov 20, 2023	DP		U-1556	
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP		U-1556	
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 006	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 007	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP U-1556			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN						
N 020716 001	6348216	Jun 10, 2017				
	6599531	Jun 10, 2017				
HYDROCORTISONE BUTYRATE - LOCOID						
N 022076 001	7378405	Dec 19, 2026	DP			
	7981877	Jan 23, 2025	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP						
N 019034 001	6589960	Nov 09, 2020	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP						
N 019034 002	6589960	Nov 09, 2020	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 003	6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 004	6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 005	6589960	Nov 09, 2020	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019891 001	6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019892 001	6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019892 002	6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019892 003	6589960	Nov 09, 2020	DS DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE						
N 021044 001	6589960	Nov 09, 2020	DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE						
N 021044 002	6589960	Nov 09, 2020	DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE						
N 021044 003	6589960	Nov 09, 2020	DP			
HYDROMORPHONE HYDROCHLORIDE - PALLADONE						
N 021044 004	6589960	Nov 09, 2020	DP			
HYDROXOCOBALAMIN - CYANOKIT						
N 022041 001	5834448	Nov 14, 2016	DP			
HYDROXOCOBALAMIN - CYANOKIT						
N 022041 002	5834448	Nov 14, 2016	DP U-789			
HYDROXYPROGESTERONE CAPROATE - MAKENA						
N 021945 001					ODE	Feb 03, 2018
IBANDRONATE SODIUM - BONIVA						
N 021455 001	6143326	Apr 21, 2017	U-642			
	6294196	Oct 07, 2019	DP			
IBANDRONATE SODIUM - BONIVA						
N 021455 002	6294196	Oct 07, 2019	DP			
	7192938	May 06, 2023	U-798			
	7410957	May 06, 2023	U-887			
	7718634	May 06, 2023	U-642			
IBRUTINIB - IMBRUVICA						
N 205552 001	7514444	Dec 28, 2026	DS DP		D-165	May 06, 2019
	8008309	Dec 28, 2026	DS DP		I-680	Feb 12, 2017
	8476284	Dec 28, 2026	U-1456		I-689	Jul 28, 2017
	8476284	Dec 28, 2026	U-1491		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1456		I-729	Mar 04, 2019
	8497277	Dec 28, 2026	U-1491		I-736	May 06, 2019
	8497277	Dec 28, 2026	U-1650		I-737	May 06, 2019
	8697711	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8703780	Dec 28, 2026	U-1491		ODE	Nov 13, 2020
	8735403	Dec 28, 2026	DS DP		ODE	Feb 12, 2021
	8754090	Jun 03, 2031	U-1456		ODE	Jul 28, 2021
	8754091	Dec 28, 2026	DP		ODE	Jan 29, 2022
	8957079	Dec 28, 2026	DS DP		ODE	Mar 04, 2023
	8999999	Jun 03, 2031	U-1683		ODE	May 06, 2023
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
	9181257	Dec 28, 2026	DS DP			
	9296753	Oct 30, 2033	DS DP			
IBUPROFEN - MIDOL LIQUID GELS						
N 021472 001	6251426	Jun 25, 2018				
IBUPROFEN - CALDOLOR						
N 022348 001	6727286	Nov 27, 2021	DP U-981			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBUPROFEN - CALDOLOR						
N 022348 002	6727286	Nov 27, 2021	DP U-981		D-152	Nov 20, 2018
	8735452	Sep 30, 2029	U-981		NPP	Nov 20, 2018
	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
	9114068	Sep 30, 2029	U-1735			
	9138404	Sep 30, 2029	U-1756			
	9295639	Sep 30, 2029	U-1756			
IBUPROFEN LYSINE - NEOPROFEN						
N 021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
	8415337	Mar 02, 2032	DS DP			
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD						
N 021128 001	6211246	Jun 10, 2019				
ICATIBANT ACETATE - FIRAZYR						
N 022150 001	5648333	Jul 15, 2019	DS DP U-1187		NCE	Aug 25, 2016
					ODE	Aug 25, 2018
ICODEXTRIN - EXTRANEAL						
N 021321 001	6077836	Jun 20, 2017	U-495			
	6248726	Jun 19, 2018	U-495			
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1478			
IDELALISIB - ZYDELIG						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560		ODE	Jul 23, 2021
	8138195	Apr 24, 2021	DS DP U-1549		ODE	Jul 23, 2021
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IDELALISIB - ZYDELIG						
N 205858 002	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560		ODE	Jul 23, 2021
	8138195	Apr 24, 2021	DS DP U-1549		ODE	Jul 23, 2021
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			
ILOPERIDONE - FANAPT						
N 022192 001	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N 022192 002	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N 022192 003	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N 022192 004	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N 022192 005	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 005	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N 022192 006	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
ILOPERIDONE - FANAPT						
N 022192 007	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
IMATINIB MESYLATE - IMATINIB MESYLATE						
A 078340 001					PC	Jul 30, 2016
IMATINIB MESYLATE - IMATINIB MESYLATE						
A 078340 002					PC	Jul 30, 2016
IMATINIB MESYLATE - GLEEVEC						
N 021335 001	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC						
N 021335 002	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC						
N 021588 001	6894051	May 23, 2019	DS DP U-649		ODE	Jan 25, 2020
	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
IMATINIB MESYLATE - GLEEVEC						
N 021588 002	6894051	May 23, 2019	DS DP U-649		ODE	Jan 25, 2020
	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IMIQUIMOD - ALDARA						
N 020723 001	7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
IMIQUIMOD - ZYCLARA						
N 022483 001	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-172			
	8598196	Aug 18, 2029	U-1455			
IMIQUIMOD - ZYCLARA						
N 022483 002	8222270	Dec 11, 2029	U-68			
INDACATEROL MALEATE - ARCAPTA NEOHALER						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168		NCE	Jul 01, 2016
	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
	8658673	Jun 02, 2020	DS DP U-1168			
	8796307	Jun 02, 2020	DS DP			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 001	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 003	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 005	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
INDINAVIR SULFATE - CRIXIVAN						
N 020685 006	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN						
N 020314 001	6123916	Sep 26, 2017	U-1125			
INDOMETHACIN - TIVORBEX						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
INGENOL MEBUTATE - PICATO						
N 202833 001	6432452	Aug 19, 2018	U-68		M-169	Nov 19, 2018
	6787161	Aug 19, 2018	U-68		NCE	Jan 23, 2017
	6844013	Dec 13, 2018	U-1221			
	7410656	Oct 10, 2020	U-1222			
	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
INGENOL MEBUTATE - PICATO						
N 202833 002	6432452	Aug 19, 2018	U-68		NCE	Jan 23, 2017
	6787161	Aug 19, 2018	U-68			
	6844013	Dec 13, 2018	U-1221			
	7410656	Oct 10, 2020	U-1222			
	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INGENOL MEBUTATE - PICATO						
N 202833 002	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30						
N 021172 001	5866538	Jun 20, 2017	DP			
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL						
N 021172 002	5866538	Jun 19, 2017	DP			
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL						
N 021172 003	5866538	Jun 19, 2017	DP			
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN						
N 021172 004	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50						
N 021810 001	5866538	Jun 20, 2017	DP			
INSULIN ASPART RECOMBINANT - NOVOLOG						
N 020986 001	5866538	Jun 20, 2017	DP			
INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL						
N 020986 002	5866538	Jun 20, 2017	DP			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN						
N 020986 003	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET						
N 020986 004	5866538	Jun 20, 2017	DP			
	RE41956	Jan 21, 2021	DP			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH						
N 020986 005	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30						
N 203313 001	5866538	Jun 20, 2017	DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP		NPP	Dec 16, 2019
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN DEGLUDEC - TRESIBA						
N 203314 001	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP		NPP	Dec 16, 2019
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
INSULIN DEGLUDEC - TRESIBA						
N 203314 002	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP		NPP	Dec 16, 2019
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6						
N 208583 001	6268343	Aug 22, 2022	DS DP		NC	Nov 21, 2019
	6458924	Aug 22, 2017	DS DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP			
	7235627	Aug 22, 2017	DS			
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR						
N 021536 001	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN						
N 021536 002	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET						
N 021536 003	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL						
N 021536 004	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH						
N 021536 005	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH						
N 021536 005	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
INSULIN GLARGINE - BASAGLAR						
N 205692 001					NP	Dec 16, 2018
INSULIN GLARGINE RECOMBINANT - LANTUS						
N 021081 001	7476652	Jul 23, 2023	DP			
	7713930	Jun 13, 2023	DP			
	7918833	Sep 23, 2027	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33						
N 208673 001	7918833	Sep 23, 2027	DP		NC	Nov 21, 2019
	8512297	Sep 15, 2024	DP		NCE	Jul 27, 2021
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	U-1923			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	RE45313	Jul 12, 2020	DS DP			
INSULIN GLULISINE RECOMBINANT - APIDRA						
N 021629 001	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
INSULIN GLULISINE RECOMBINANT - APIDRA						
N 021629 002	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
N 021629 003	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
N 021629 003	7696162	Mar 22, 2022	DP U-471			
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
INSULIN HUMAN - HUMULIN R						
N 018780 004	7291132	Aug 09, 2024	DP			
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN						
N 021017 002	7291132	Aug 09, 2024	DP			
INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN						
N 021018 002	7291132	Aug 09, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN						
N 020563 003	7291132	Aug 09, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
INSULIN RECOMBINANT HUMAN - EXUBERA						
N 021868 001	6257233	May 14, 2019	U-704			
	6546929	May 14, 2019	U-704			
	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			
INSULIN RECOMBINANT HUMAN - EXUBERA						
N 021868 002	6257233	May 14, 2019	U-704			
	6546929	May 14, 2019	U-704			
	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 001	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 001	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP U-1788			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	9511198	Feb 16, 2030	U-1929			
	9511198	Feb 16, 2030	U-1930			
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 002	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP U-1788			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	9511198	Feb 16, 2030	U-1929			
	9511198	Feb 16, 2030	U-1930			
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 003	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP U-1788			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	9511198	Feb 16, 2030	U-1929			
	9511198	Feb 16, 2030	U-1930			
INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30						
N 019717 001	7291132	Aug 09, 2024	DP			
INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN						
N 019717 002	7291132	Aug 09, 2024	DP			
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N						
N 018781 001	7291132	Aug 09, 2024	DP			
IPRATROPIUM BROMIDE - ATROVENT HFA						
N 021527 001	6739333	May 26, 2020	DP			
	6983743	May 26, 2020	DP			
	8474447	Jan 17, 2030	DP			
IRINOTECAN HYDROCHLORIDE - CAMPTOSAR						
N 020571 001	6403569	Apr 28, 2020	U-449			
	6794370	May 01, 2020	U-606			
IRINOTECAN HYDROCHLORIDE - CAMPTOSAR						
N 020571 002	6403569	Apr 28, 2020	U-449			
	6794370	May 01, 2020	U-606			
IRINOTECAN HYDROCHLORIDE - ONIVYDE						
N 207793 001	8147867	Aug 29, 2028	DS DP		NP	Oct 22, 2018
	8329213	May 02, 2025	DS DP		ODE	Oct 22, 2022
	8703181	May 02, 2025	U-1434			
	8992970	May 02, 2025	DS DP			
	9339497	Jun 12, 2033	U-1848			
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1848			
	9492442	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1917			
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISOTRETINOIN - ABSORICA						
N 021951 001	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 002	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISOTRETINOIN - ABSORICA						
N 021951 002	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 003	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 004	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
ITRACONAZOLE - SPORANOX						
N 020657 001	6407079	Jun 18, 2019				
ITRACONAZOLE - SPORANOX						
N 020966 001	6407079	Jun 18, 2019				
ITRACONAZOLE - ONMEL						
N 022484 001	6509038	May 12, 2017	DP U-1054			
	7081255	May 12, 2017	DP U-1054			
	8486456	Oct 03, 2028	DP U-1054			
	8591948	May 12, 2017	DP U-1054			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVACAFTOR - KALYDECO						
N 203188 001	7495103	May 20, 2027	DS DP		I-705	Dec 30, 2017
	8324242	Aug 05, 2027	U-1311		I-740	Feb 21, 2017
	8324242	Aug 05, 2027	U-1906		NCE	Jan 31, 2017
	8354427	Jul 06, 2026	U-1311		ODE	Jan 31, 2019
	8354427	Jul 06, 2026	U-1905			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
IVACAFTOR - KALYDECO						
N 207925 001	7495103	May 20, 2027	DS DP		I-740	Feb 21, 2017
	8324242	Aug 05, 2027	U-1311		NCE	Jan 31, 2017
	8324242	Aug 05, 2027	U-1906		ODE	Jan 31, 2019
	8354427	Jul 06, 2026	U-1311			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 001	8354427	Jul 06, 2026	U-1905			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
IVACAFTOR - KALYDECO						
N 207925 002	7495103	May 20, 2027	DS DP		I-740	Feb 21, 2017
	8324242	Aug 05, 2027	U-1311		NCE	Jan 31, 2017
	8324242	Aug 05, 2027	U-1906		ODE	Jan 31, 2019
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Aug 05, 2027	U-1311		ODE	Jul 02, 2022
	8324242	Aug 05, 2027	U-1911		ODE	Sep 28, 2023
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1717			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 002	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Aug 05, 2027	U-1911		NPP	Sep 28, 2019
	8410274	Dec 28, 2026	DP		ODE	Jul 02, 2022
	8507534	Sep 20, 2030	DS DP		ODE	Sep 28, 2023
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DP			
IVERMECTIN - SKLICE						
N 202736 001	6103248	May 22, 2018	DP			
	8791153	Oct 12, 2027	DP			
	8927595	Oct 12, 2027	U-1782			
IVERMECTIN - SOOLANTRA						
N 206255 001	5952372	Sep 18, 2018	U-1631		NP	Dec 19, 2017
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT						
N 022065 001	6670384	Jan 23, 2022	DP U-959			
	6670384	Jan 23, 2022	DP U-960			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	Sep 28, 2020	DS DP U-961			
IXABEPILONE - IXEMPRA KIT						
N 022065 002	6670384	Jan 23, 2022	DP U-959			
	6670384	Jan 23, 2022	DP U-960			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	Sep 28, 2020	DS DP U-961			
IXAZOMIB CITRATE - NINLARO						
N 208462 001	7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
	7687662	Aug 06, 2027	DS DP		ODE	Nov 20, 2022
	8003819	Aug 06, 2027	DS DP U-1780			
	8530694	Aug 06, 2027	DS DP U-1780			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-1779			
	9175017	Jun 16, 2029	U-1778			
	9233115	Aug 12, 2024	U-1778			
IXAZOMIB CITRATE - NINLARO						
N 208462 002	7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
	7687662	Aug 06, 2027	DS DP		ODE	Nov 20, 2022
	8003819	Aug 06, 2027	DS DP U-1780			
	8530694	Aug 06, 2027	DS DP U-1780			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-1779			
	9175017	Jun 16, 2029	U-1778			
	9233115	Aug 12, 2024	U-1778			
IXAZOMIB CITRATE - NINLARO						
N 208462 003	7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
	7687662	Aug 06, 2027	DS DP		ODE	Nov 20, 2022
	8003819	Aug 06, 2027	DS DP U-1780			
	8530694	Aug 06, 2027	DS DP U-1780			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-1779			
	9175017	Jun 16, 2029	U-1778			
	9233115	Aug 12, 2024	U-1778			
KETOCONAZOLE - EXTINA						
N 021738 001	7553835	Oct 19, 2018	DP U-245			
	8026238	Oct 19, 2018	DP U-1213			
KETOCONAZOLE - XOLEGEL						
N 021946 001	7179475	Dec 04, 2018	DP U-792			
	8232276	Nov 24, 2020	DP			
	8735393	Dec 04, 2018	DP			
KETOROLAC TROMETHAMINE - ACULAR LS						
N 021528 001	8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024	U-1251			
	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
	8648107	May 28, 2024	DP			
	8906950	May 28, 2024	U-1626			
	8946281	May 28, 2024	U-1662			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
KETOROLAC TROMETHAMINE - ACULAR LS						
N 021528 001	9216167	May 28, 2024	U-1800			
KETOROLAC TROMETHAMINE - SPRIX						
N 022382 001	6333044	Dec 25, 2018	DP U-1057			
KETOROLAC TROMETHAMINE - ACUVAIL						
N 022427 001	7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
	8992952	Aug 05, 2024	DP			
	9192571	Mar 07, 2028	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA						
N 205388 001	8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			
	9066856	Oct 23, 2033	DP			
	9278101	Jul 30, 2023	U-1518			
	9399040	Jul 30, 2023	DP			
	9486406	Oct 23, 2033	DP			
LACOSAMIDE - VIMPAT						
N 022253 001	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
LACOSAMIDE - VIMPAT						
N 022253 002	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
LACOSAMIDE - VIMPAT						
N 022253 003	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
LACOSAMIDE - VIMPAT						
N 022253 004	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
LACOSAMIDE - VIMPAT						
N 022254 001	RE38551	Mar 17, 2022	DS DP U-1565		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1568		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
LACOSAMIDE - VIMPAT						
N 022255 001	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
LAMIVUDINE - EPIVIR						
N 020564 001	5905082*PED	Nov 18, 2016			D-147	Mar 23, 2018
LAMIVUDINE - EPIVIR						
N 020564 003	5905082*PED	Nov 18, 2016			D-147	Mar 23, 2018
LAMIVUDINE - EPIVIR						
N 020596 001	5905082*PED	Nov 18, 2016			D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
LAMIVUDINE - EPIVIR-HBV						
N 021004 001	6004968	Mar 20, 2018				
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-1663			
	7435734	Oct 21, 2022	U-1663			
	7754731	Mar 11, 2029	DS DP U-1663			
	7820660	Apr 25, 2023	DS			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL						
N 020241 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 005					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 006					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL XR						
N 022115 001	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 002	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 003	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 004	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 005	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 006	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL ODT						
N 022251 001	7919115	Jan 04, 2029	DS DP		M-159	May 18, 2018
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			
LAMOTRIGINE - LAMICTAL ODT						
N 022251 002	7919115	Jan 04, 2029	DS DP		M-159	May 18, 2018
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			
LAMOTRIGINE - LAMICTAL ODT						
N 022251 003	7919115	Jan 04, 2029	DS DP		M-159	May 18, 2018
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL ODT						
N 022251 004	7919115	Jan 04, 2029	DS DP		M-159	May 18, 2018
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 001	5595760	Mar 08, 2020	DP U-831		I-701	Dec 19, 2017
					ODE	Dec 16, 2021
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 002	5595760	Mar 08, 2020	DP U-831		I-701	Dec 19, 2017
					ODE	Dec 16, 2021
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 003	5595760	Mar 08, 2020	DP U-831		I-701	Dec 19, 2017
					ODE	Dec 16, 2021
LANSOPRAZOLE - PREVACID						
N 021428 001	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
LANSOPRAZOLE - PREVACID						
N 021428 002	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
LANSOPRAZOLE - PREVACID IV						
N 021566 001	7396841	Aug 17, 2021	DP U-947			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 001	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 002	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 003	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 004	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 001	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001	6828320	Jul 11, 2017	U-800			
	6828320	Jul 11, 2017	U-1429			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
	8821927	Sep 18, 2029	DS DP			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001	7964580	Mar 26, 2029	DS DP U-1470		D-153	Nov 12, 2018
	8088368	May 12, 2030	DS DP		D-158	Feb 12, 2019
	8273341	May 12, 2030	U-1470		D-159	Feb 12, 2019
	8334270	Mar 21, 2028	DS DP U-1470		D-160	Feb 12, 2019
	8580765	Mar 21, 2028	DS DP U-1470		I-718	Nov 12, 2018
	8618076	Dec 11, 2030	DS DP U-1470		I-719	Nov 12, 2018
	8633309	Mar 26, 2029	DS DP U-1470		I-720	Nov 12, 2018
	8735372	Mar 21, 2028	U-1470		NCE	Oct 10, 2019
	8822430	May 12, 2030	DS DP U-1470		NPP	Nov 12, 2018
	8841278	May 12, 2030	DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
	9393256	Sep 14, 2032	U-1470			
	9511056	May 12, 2030	DP U-1470			
LENALIDOMIDE - REVLIMID						
N 021880 001	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 002	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 002	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 003	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 004	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 004	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 005	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 006	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	7253286	Oct 19, 2021	DS DP		I-734	May 13, 2019
	7612208	Sep 19, 2026	DS DP		NCE	Feb 13, 2020
	9006256	Jul 27, 2027	U-1695		ODE	Feb 13, 2022
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	7253286	Oct 19, 2021	DS DP		I-734	May 13, 2019
	7612208	Sep 19, 2026	DS DP		NCE	Feb 13, 2020
	9006256	Jul 27, 2027	U-1695		ODE	Feb 13, 2022
LESINURAD - ZURAMPIC						
N 207988 001	8003681	Aug 25, 2025	DS		NCE	Dec 22, 2020
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 019732 001	6036976	Dec 13, 2016				
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N 020263 002	6036976	Dec 13, 2016				
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N 020263 005	6036976	Dec 13, 2016				
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N 020263 006	6036976	Dec 13, 2016				
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N 020263 007	6036976	Dec 13, 2016	DP			
LEUPROLIDE ACETATE - LUPRON DEPOT-PED						
N 020263 008	6036976	Dec 13, 2016	DP			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020517 001	6036976	Dec 13, 2016				
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020517 002	6036976	Dec 13, 2016				
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020517 003	6036976	Dec 13, 2016	DP			
	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020708 001	6036976	Dec 13, 2016				
LEUPROLIDE ACETATE - VIADUR						
N 021088 001	5728396	Jan 30, 2017	U-316			
	5932547	Jun 13, 2017				
	5985305	Jan 30, 2017				
	6113938	Jul 24, 2018				
	6124261	Jun 13, 2017				
	6132420	Jan 30, 2017				
	6156331	Jan 30, 2017				
	6235712	Jun 13, 2017				
	6375978	Dec 17, 2018				
	6395292	Jan 30, 2017				
LEUPROLIDE ACETATE - ELIGARD						
N 021343 001	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEUPROLIDE ACETATE - ELIGARD						
N 021343 001	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
LEUPROLIDE ACETATE - ELIGARD						
N 021379 001	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
	9283282	Oct 28, 2018	DS DP			
LEUPROLIDE ACETATE - ELIGARD						
N 021488 001	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
	9283282	Oct 28, 2018	DS DP			
LEUPROLIDE ACETATE - ELIGARD						
N 021731 001	6565874	Oct 28, 2018	DP U-621			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	U-621			
	9283282	Oct 28, 2018	DS DP			
LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK						
N 203696 001	6036976	Dec 13, 2016	DP			
LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK						
N 203696 002	6036976	Dec 13, 2016	DP			
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 001	6451289	Mar 21, 2021			M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 002	6451289	Mar 21, 2021			M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 003	6451289	Mar 21, 2021			M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 004	6451289	Mar 21, 2021	DP		M-151	Jan 22, 2018
LEVALBUTEROL TARTRATE - XOPENEX HFA						
N 021730 001	7256310	Oct 08, 2024	DS DP U-636		M-156	Mar 12, 2018
	8765153	Dec 08, 2023	DP			
LEVETIRACETAM - KEPPRA						
N 021035 001	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA						
N 021035 002	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA						
N 021035 003	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA						
N 021035 004	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA XR						
N 022285 001	7858122	Sep 17, 2028	DP			
LEVETIRACETAM - KEPPRA XR						
N 022285 002	7858122	Sep 17, 2028	DP			
LEVETIRACETAM - SPRITAM						
N 207958 001	6471992	Feb 20, 2018	DP			
	9463160	Feb 20, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVETIRACETAM - SPRITAM						
N 207958 002	6471992	Feb 20, 2018	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
LEVETIRACETAM - SPRITAM						
N 207958 003	6471992	Feb 20, 2018	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
LEVETIRACETAM - SPRITAM						
N 207958 004	6471992	Feb 20, 2018	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
LEVOCARNITINE - CARNITOR						
N 020182 001	6335369	Jan 18, 2021	U-433			
	6429230	Jan 18, 2021	U-433			
	6696493	Jan 18, 2021	U-433			
LEVOFLOXACIN - LEVAQUIN						
N 021721 001	6806256	Feb 26, 2022	DP			
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM						
A 206263 001					PC	Feb 11, 2017
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N 020140 001	6500829	Mar 07, 2022	DS DP		ODE	Apr 29, 2018
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N 020140 002	6500829	Mar 07, 2022	DS DP		ODE	Apr 29, 2018
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N 020140 003	6500829	Mar 07, 2022	DS DP		ODE	Apr 29, 2018
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 001	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 002	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 003	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 004	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023	U-839			
LEVONORGESTREL - SKYLA						
N 203159 001	7252839	Nov 13, 2023	DP			
LEVONORGESTREL - LILETTA						
N 206229 001					NP	Feb 26, 2018
LEVONORGESTREL - KYLEENA						
N 208224 001	7252839	Nov 13, 2023	DP		NP	Sep 16, 2019
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 001	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 002	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023	U-759			
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 001	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 002	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 003	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 004	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 005	6399101	Mar 30, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 006	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 007	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 008	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 009	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 010	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - LEVO-T						
N 021342 011	6399101	Mar 30, 2020				
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 003	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 004	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 005	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 006	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 007	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 008	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 009	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 010	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 022121 001	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LIDOCAINE HYDROCHLORIDE - ZINGO						
N 022114 001	6004286	Mar 17, 2017	DP			
	8540665	Oct 22, 2029	U-1438			
	9358338	Apr 27, 2035	U-1870			
	9370622	Sep 28, 2035	U-1870			
LIDOCAINE HYDROCHLORIDE - AKTEN						
N 022221 001	8759401	Jul 24, 2026	DP U-1523			
LIDOCAINE; PRILOCAINE - ORAQIX						
N 021451 001	6031007	Apr 01, 2017	DP U-553			
LIDOCAINE; TETRACAINE - SYNERA						
N 021623 001	6465709	Jul 07, 2020	DP			
LIDOCAINE; TETRACAINE - PLIAGLIS						
N 021717 001	6528086	Sep 28, 2019	DP			
LIFITEGRAST - XIIDRA						
N 208073 001	7314938	Mar 10, 2025	DS DP		NCE	Jul 11, 2021
	7745460	Nov 05, 2024	DS DP U-1880			
	7790743	Nov 05, 2024	U-1880			
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029	U-1880			
	8367701	Apr 15, 2029	DP U-1880			
	8592450	May 17, 2026	U-1880			
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
	9447077	Apr 15, 2029	U-1900			
LINACLOTIDE - LINZESS						
N 202811 001	7304036	Aug 30, 2026	DS DP U-1278		NCE	Aug 30, 2017
	7304036	Aug 30, 2026	DS DP U-1516			
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8802628	Nov 17, 2031	DP			
	8933030	Feb 17, 2031	DP			
LINACLOTIDE - LINZESS						
N 202811 002	7304036	Aug 30, 2026	DS DP U-1278		NCE	Aug 30, 2017
	7304036	Aug 30, 2026	DS DP U-1516			
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8802628	Nov 17, 2031	DP			
	8933030	Feb 17, 2031	DP			
LINAGLIPTIN - TRADJENTA						
N 201280 001	6303661	Apr 24, 2017	U-774			
	6303661	Apr 24, 2017	U-1270			
	6890898	Feb 02, 2019	U-493			
	6890898	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN - TRADJENTA						
N 201280 001	7078381	Feb 02, 2019	U-1270			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-493			
	7459428	Feb 02, 2019	U-1270			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1244			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1270			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8853156	Mar 05, 2031	U-1642			
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1503			
	9173859	May 04, 2027	DP U-1768			
	9486526	Aug 05, 2029	U-1915			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	6303661	Apr 24, 2017	U-802		M-146	Jul 30, 2017
	6890898	Feb 02, 2019	U-1039			
	7078381	Feb 02, 2019	U-1039			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	6303661	Apr 24, 2017	U-802		M-146	Jul 30, 2017
	6890898	Feb 02, 2019	U-1039			
	7078381	Feb 02, 2019	U-1039			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	6303661	Apr 24, 2017	U-802		M-146	Jul 30, 2017
	6890898	Feb 02, 2019	U-1039			
	7078381	Feb 02, 2019	U-1039			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
LINEZOLID - ZYVOX						
N 021130 001	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
LINEZOLID - ZYVOX						
N 021130 002	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
LINEZOLID - ZYVOX						
N 021131 001	6559305	Jan 29, 2021	DS			
LINEZOLID - ZYVOX						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
LINEZOLID - ZYVOX						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
LINEZOLID - ZYVOX						
N 021132 001	6559305	Jan 29, 2021	DS			
LIRAGLUTIDE RECOMBINANT - VICTOZA						
N 022341 001	6004297	Jan 28, 2019	DP		M-176	Apr 22, 2019
	6268343	Aug 22, 2022	DS DP U-968			
	6458924	Aug 22, 2017	DS DP U-968			
	7235627	Aug 22, 2017	DS DP			
	8114833	Aug 13, 2025	DP			
	8846618	Jun 27, 2022	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255		NP	Jan 25, 2017
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 26, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 005	7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 007	7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	7655630	Feb 24, 2023	DS		M-188	Oct 14, 2019
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
LISINOPRIL - QBRELIS						
N 208401 001	9463183	Nov 06, 2035	DP			
LIXISENATIDE - ADLYXIN						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9511193	Jan 19, 2032	DP			
	RE45313	Jul 12, 2020	DS DP			
LIXISENATIDE - ADLYXIN						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9511193	Jan 19, 2032	DP			
	RE45313	Jul 12, 2020	DS DP			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 002	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS						
N 020448 001	6814978	Aug 26, 2021	DP			
LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF						
N 021140 001	6103260	Jul 17, 2017	DP			
LOPINAVIR; RITONAVIR - KALETRA						
N 021226 001	6232333	Nov 07, 2017				
	6458818	Nov 07, 2017				
	6521651	Nov 07, 2017	DP			
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
LOPINAVIR; RITONAVIR - KALETRA						
N 021251 001	6911214	Nov 28, 2021	DP U-895			
	8501219	Nov 28, 2021	DP			
LOPINAVIR; RITONAVIR - KALETRA						
N 021906 001	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOPINAVIR; RITONAVIR - KALETRA						
N 021906 001	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
LOPINAVIR; RITONAVIR - KALETRA						
N 021906 002	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
LORATADINE - CLARITIN						
N 020641 002	6132758	Jun 01, 2018	DP			
LORCASERIN HYDROCHLORIDE - BELVIQ						
N 022529 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1762			
	9169213	Dec 06, 2032	U-1763			
	9169213	Dec 06, 2032	U-1764			
	9169213	Dec 06, 2032	U-1765			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LORCASERIN HYDROCHLORIDE - BELVIQ XR						
N 208524 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1884			
	9169213	Dec 06, 2032	U-1885			
	9169213	Dec 06, 2032	U-1886			
	9169213	Dec 06, 2032	U-1887			
LOTEPREDNOL ETABONATE - LOTEMAX						
N 202872 001	5800807	Jan 29, 2017	DP			
LOVASTATIN - ALTOPREV						
N 021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
LOVASTATIN - ALTOPREV						
N 021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
LOVASTATIN - ALTOPREV						
N 021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
LOVASTATIN - ALTOPREV						
N 021316 004	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
LOXAPINE - ADASUVE						
N 022549 001	6716416	May 20, 2022	DP			
	7052679	Oct 26, 2021	DP			
	7078020	Oct 26, 2021	DP U-1375			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOXAPINE - ADASUVE						
N 022549 001	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 28, 2024	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Jul 25, 2022	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			
	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
	9370629	May 20, 2024	DP			
	9439907	Oct 26, 2021	DP			
	9440034	Oct 26, 2021	DP			
LUBIPROSTONE - AMITIZA						
N 021908 001	6414016	Sep 05, 2020	U-717			
	6414016	Sep 05, 2020	U-1392			
	6583174	Oct 16, 2020	DP			
	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	7417067	Oct 16, 2020	DP			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1203			
	8071613	Sep 05, 2020	U-1393			
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
	8748481	Sep 01, 2025	U-1520			
	8779187	Jul 23, 2027	DP			
LUBIPROSTONE - AMITIZA						
N 021908 002	6414016	Sep 05, 2020	U-874			
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-873			
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024	U-1085			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1202			
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
LULICONAZOLE - LUZU						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540		NCE	Nov 14, 2018
	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Jun 25, 2026	U-1770			
	9174975*PED	Dec 25, 2026				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 002	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Jun 25, 2026	U-1770			
	9174975*PED	Dec 25, 2026				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Jun 25, 2026	U-1770			
	9174975*PED	Dec 25, 2026				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 004	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Jun 25, 2026	U-1770			
	9174975*PED	Dec 25, 2026				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 005	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Jun 25, 2026	U-1770			
	9174975*PED	Dec 25, 2026				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
MACITENTAN - OPSUMIT						
N 204410 001	7094781	Oct 12, 2022	DS DP		NCE	Oct 18, 2018
	8268847	Apr 18, 2029	U-1446		ODE	Oct 18, 2020
	8367685	Oct 04, 2028	DP U-1445			
	9265762	May 29, 2027	DP U-1820			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25							
N 021910	001	5945449	Oct 31, 2017	DP U-785			
		7300674	Mar 04, 2023	DP U-785			
MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35							
N 021910	002	5945449	Oct 31, 2017	DP U-785			
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
N 021850	001	6489346	Jul 16, 2016	DS DP U-588			
		6645988	Jul 16, 2016	DS DP U-588			
		6699885	Jul 16, 2016	U-588			
		7399772	Jul 16, 2016	U-588			
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID							
N 021850	002	6489346	Jul 16, 2016	DS DP U-623			
		6645988	Jul 16, 2016	DS DP U-623			
		6699885	Jul 16, 2016	U-623			
		7399772	Jul 16, 2016	U-623			
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE							
N 022456	001	6489346	Jul 16, 2016	DP U-588			
		6489346	Jul 16, 2016	DP U-1021			
		6645988	Jul 16, 2016	DP			
		6699885	Jul 16, 2016	DP U-588			
		6699885	Jul 16, 2016	DP U-1021			
		7399772	Jul 16, 2016	DP U-588			
		7399772	Jul 16, 2016	DP U-1021			
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE							
N 022456	002	6489346	Jul 16, 2016	DP U-588			
		6489346	Jul 16, 2016	DP U-1021			
		6645988	Jul 16, 2016	DP			
		6699885	Jul 16, 2016	DP U-588			
		6699885	Jul 16, 2016	DP U-1021			
		7399772	Jul 16, 2016	DP U-588			
		7399772	Jul 16, 2016	DP U-1021			
MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT							
N 022372	001	6946149	Mar 07, 2023	DP U-837			
MALATHION - OVIDE							
N 018613	001	7560445	Feb 01, 2027	DS DP U-986			
		7977324	Aug 14, 2026	DP			
MARAVIROC - SELZENTRY							
N 022128	001	6586430	Dec 01, 2019	DS DP U-824			
		6667314	Aug 06, 2021	DS DP U-824			
		7368460	Nov 25, 2022	U-824			
		7576097	May 25, 2021	DS			
MARAVIROC - SELZENTRY							
N 022128	002	6586430	Dec 01, 2019	DS DP U-824			
		6667314	Aug 06, 2021	DS DP U-824			
		7368460	Nov 25, 2022	U-824			
		7576097	May 25, 2021	DS			
MARAVIROC - SELZENTRY							
N 208984	001	6586430	Dec 01, 2019	DS DP U-824			
		6667314	Aug 06, 2021	DS DP U-824			
		7368460	Nov 25, 2022	U-824			
		7576097	May 25, 2021	DS			
MEBENDAZOLE - VERMOX							
N 208398	001					NS	Oct 19, 2019
MECASERMIN RECOMBINANT - INCRELEX							
N 021839	001	5681814	Sep 18, 2017	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR						
N 202317 001	7838564	Mar 07, 2026	DP		NDF	Aug 23, 2016
	7872050	Jul 08, 2029	U-1427		ODE	Aug 23, 2020
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
	9382191	Mar 07, 2026	DP			
MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104						
N 021583 001	6495534	May 15, 2020	DP			
MEGESTROL ACETATE - MEGACE ES						
N 021778 001	6592903	Sep 21, 2020	DP			
	7101576	Apr 22, 2024	U-755			
	9040088	Apr 22, 2024	U-755			
	9101540	Apr 22, 2024	DP U-755			
	9101549	Apr 22, 2024	U-755			
	9107827	Apr 22, 2024	U-755			
MELOXICAM - MOBIC						
N 021530 001	6184220	Mar 25, 2019	DP			
MELOXICAM - VIVLODEX						
N 207233 001	9526734	Mar 31, 2033	DP		NP	Oct 22, 2018
MELOXICAM - VIVLODEX						
N 207233 002	9526734	Mar 31, 2033	DP		NP	Oct 22, 2018
MELPHALAN HYDROCHLORIDE - EVOMELA						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 001	8039009	Mar 24, 2029	U-539		M-138	Jul 03, 2017
	8039009*PED	Sep 24, 2029			PED	Jan 03, 2018
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 002	8039009	Mar 24, 2029	U-539		M-138	Jul 03, 2017
	8039009*PED	Sep 24, 2029			PED	Jan 03, 2018
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 003	8039009	Mar 24, 2029	U-539		M-138	Jul 03, 2017
	8039009*PED	Sep 24, 2029			PED	Jan 03, 2018
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MEMANTINE HYDROCHLORIDE - NAMENDA XR							
N 022525	003	8329752*PED	May 22, 2026				
		8362085	Nov 22, 2025	U-539			
		8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR							
N 022525	004	8039009	Mar 24, 2029	U-539		M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029			PED	Jan 03, 2018
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-539			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-539			
		8283379*PED	May 22, 2026				
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8362085	Nov 22, 2025	U-539			
		8362085*PED	May 22, 2026				
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
MENOTROPINS (FSH;LH); MENOTROPINS (FSH;LH) - MENOPUR							
N 021663	001					D-139	Feb 19, 2017
MENTHOL; METHYL SALICYLATE - SALONPAS							
N 022029	001	8809615	Jan 03, 2030	DP			
		9233184	Aug 01, 2027	DP			
MENTHOL; METHYL SALICYLATE - SALONPAS							
N 022029	002	8809615	Jan 03, 2030	DP			
		9233184	Aug 01, 2027	DP			
MEQUINOL; TRETINOIN - SOLAGE							
N 020922	001	6353029	Aug 24, 2020				
MERCAPTOPURINE - PURIXAN							
N 205919	001					ODE	Apr 28, 2021
MESALAMINE - SFROWASA							
N 019618	002	7645801	Jul 24, 2027	DS DP			
MESALAMINE - CANASA							
N 021252	001					M-187	Sep 02, 2019
MESALAMINE - CANASA							
N 021252	002	8217083	Jun 06, 2028	DP			
		8436051	Jun 06, 2028	DP			
MESALAMINE - ASACOL HD							
N 021830	001	6893662	Nov 15, 2021	DP U-141			
		8580302	Nov 15, 2021	DP			
		9089492	Nov 15, 2021	DP			
MESALAMINE - LIALDA							
N 022000	001	6773720	Jun 08, 2020	DP			
MESALAMINE - APRISO							
N 022301	001	6551620	Apr 20, 2018	DS DP U-907			
		8337886	Apr 20, 2018	DP U-1310			
		8496965	Apr 20, 2018	DP			
		8865688	May 01, 2030	U-1310			
		8911778	Apr 20, 2018	DP U-1310			
		8940328	Apr 20, 2018	DP			
		8956647	Apr 20, 2018	DP			
MESALAMINE - DELZICOL							
N 204412	001	6649180	Apr 13, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METAXALONE - SKELAXIN						
N 013217 003	7122566	Feb 06, 2026	U-915			
	7714006	Dec 03, 2021	U-1050			
METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE						
A 091664 001					PC	Jul 30, 2016
METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE						
A 091664 002					PC	Jul 30, 2016
METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR						
N 021202 001	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR						
N 021202 004	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
METFORMIN HYDROCHLORIDE - FORTAMET						
N 021574 001	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
METFORMIN HYDROCHLORIDE - FORTAMET						
N 021574 002	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
METFORMIN HYDROCHLORIDE - RIOMET						
N 021591 001	6890957	Sep 14, 2023	DP			
METFORMIN HYDROCHLORIDE - GLUMETZA						
N 021748 001	6340475	Sep 19, 2016	DS DP U-669			
	6488962	Jun 20, 2020	DS DP			
	6635280	Sep 19, 2016	DS DP			
	6723340	Oct 25, 2021	DS DP			
METFORMIN HYDROCHLORIDE - GLUMETZA						
N 021748 002	6488962	Jun 20, 2020	DS DP			
	7780987	Mar 23, 2025	DS DP			
	8323692	Mar 23, 2025	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET						
N 021842 001	9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET						
N 021842 002	9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N 022024 001	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			
	9060941	Sep 19, 2023	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024	002	6099859	Mar 20, 2018	DP			
		6495162	Mar 20, 2018	DP			
		6790459	Mar 17, 2021	U-974			
		6866866	Mar 17, 2021	DP			
		7785627	Jul 31, 2026	DP			
		7919116	Mar 20, 2018	U-973			
		7919116	Mar 20, 2018	U-1120			
		7959946	Jul 31, 2026	DP			
		8470368	Sep 19, 2023	DP			
		8475841	Mar 20, 2018	U-973			
		8668931	Sep 19, 2023	DP			
		9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	001	6288095	Feb 11, 2017	U-493	Y		
		7358366	Apr 19, 2020	DS			
		8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	002	6288095	Feb 11, 2017	U-493	Y		
		7358366	Apr 19, 2020	DS			
		8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	003	6288095	Feb 11, 2017	U-493	Y		
		7358366	Apr 19, 2020	DS			
		8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	004	7358366	Apr 19, 2020	DS			
		8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	005	7358366	Apr 19, 2020	DS			
		8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	001	8628799	Jul 13, 2025	DP		M-175	Apr 05, 2019
		9339472	Jul 13, 2025	DP			
		RE44186	Jul 31, 2023	DS DP U-1097			
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET							
N 022044	001	6699871	Jul 26, 2022	DS DP U-802			
		7125873	Jul 26, 2022	DP U-803			
		7125873	Jul 26, 2022	DP U-1036			
		7125873	Jul 26, 2022	DP U-1038			
		7326708	Nov 24, 2026	DS DP U-802			
		8414921	Jul 21, 2028	DP U-1036			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET							
N 022044	002	6699871	Jul 26, 2022	DS DP U-802			
		7125873	Jul 26, 2022	DP U-803			
		7125873	Jul 26, 2022	DP U-1036			
		7125873	Jul 26, 2022	DP U-1038			
		7326708	Nov 24, 2026	DS DP U-802			
		8414921	Jul 21, 2028	DP U-1036			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR							
N 202270	001	6340475	Sep 19, 2016	DP			
		6635280	Sep 19, 2016	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 001	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Nov 24, 2026	DS DP U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 002	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Nov 24, 2026	DS DP U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 003	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Nov 24, 2026	DS DP U-1227			
METHOTREXATE - OTREXUP						
N 204824 001	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 002	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 003	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 005	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - OTREXUP						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
METHOTREXATE - RASUVO						
N 205776 001	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 002	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 003	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 004	8664231	Jun 01, 2029	U-1442			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - RASUVO						
N 205776 005	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 006	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 007	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 008	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 009	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 010	8664231	Jun 01, 2029	U-1442			
METHYLENE BLUE - PROVAYBLUE						
N 204630 001					ODE	Apr 08, 2023
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 001	6559158	Nov 03, 2017	U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 002	6559158	Nov 03, 2017	U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 003	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 208271 001	6559158	Nov 03, 2017	U-1185		NP	Jul 19, 2019
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
	9314461	Mar 10, 2031	DP			
METHYLPHENIDATE - DAYTRANA						
N 021514 001	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA						
N 021514 002	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA						
N 021514 003	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE - DAYTRANA						
N 021514 004	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 001	6919373	Jul 31, 2017	U-666			
	6930129	Jul 31, 2017	U-666			
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 002	6919373	Jul 31, 2017	U-666			
	6930129	Jul 31, 2017	U-666			
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 003	6919373	Jul 31, 2017	U-666			
	6930129	Jul 31, 2017	U-666			
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA						
N 021121 004	6919373	Jul 31, 2017	U-666			
	6930129	Jul 31, 2017	U-666			
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD						
N 021259 001	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD						
N 021259 002	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD						
N 021259 003	6344215	Oct 27, 2020	DP			
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD						
N 021259 004	6344215	Oct 27, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA						
N 021284 001	6228398	Nov 01, 2019	DP U-472			
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA						
N 021284 002	6228398	Nov 01, 2019	DP U-472			
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA						
N 021284 003	6228398	Nov 01, 2019	DP U-472			
METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA						
N 021284 004	6228398	Nov 01, 2019	DP U-472			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN						
N 021419 001	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN						
N 021419 002	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
	8563033	Feb 15, 2031	DP U-1415			
	8778390	Feb 15, 2031	DP U-1543			
	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 006	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 001	8202537	Mar 15, 2027	DP		NP	Dec 04, 2018
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 002	8202537	Mar 15, 2027	DP		NP	Dec 04, 2018
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 003	8202537	Mar 15, 2027	DP		NP	Dec 04, 2018
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT						
N 021793 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT						
N 021793 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT						
N 022246 001	6413549	Jul 11, 2017	DP			
METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT						
N 022246 002	6413549	Jul 11, 2017	DP			
METRONIDAZOLE - METROGEL						
N 021789 001	6881726	Feb 21, 2022	DP U-743			
	7348317	Feb 21, 2022	DP U-743			
METRONIDAZOLE - VANDAZOLE						
N 021806 001	7456207	Sep 22, 2024	DP			
METRONIDAZOLE - NUVESSA						
N 205223 001	7893097	Feb 19, 2028	DP		NP	Mar 24, 2017
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
	9198858	Jun 28, 2032	U-1664			
MICAFUNGIN SODIUM - MYCAMINE						
N 021506 002	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
MICAFUNGIN SODIUM - MYCAMINE						
N 021506 003	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MICAFUNGIN SODIUM - MYCAMINE						
N 021506 003	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
MICONAZOLE - ORAVIG						
N 022404 001	6916485	Sep 11, 2022	DP U-1051			
	7651698	Sep 11, 2022	U-1051			
	8518442	Sep 11, 2022	DP			
MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK						
N 021308 001	6153635	Nov 28, 2020		Y		
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION						
N 021026 001	8147852	Mar 30, 2028	U-1426			
MIFEPRISTONE - KORLYM						
N 202107 001	8921348	Aug 27, 2028	U-1643		ODE	Feb 17, 2019
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 001	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 002	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 003	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N 022256 004	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
MILTEFOSINE - IMPAVIDO						
N 204684 001					NCE	Mar 19, 2019
					ODE	Mar 19, 2021
MINOCYCLINE HYDROCHLORIDE - MINOCIN						
N 050444 001	9084802	May 12, 2031	U-282			
	9278105	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - ARESTIN						
N 050781 001	6682348	Mar 29, 2022	DP			
	7699609	Mar 29, 2022	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 001	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 002	5908838	Feb 19, 2018	U-917			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 002	5908838	Feb 19, 2018	U-917			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 003	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 004	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 005	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 006	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 007	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N 050808 008	5908838	Feb 19, 2018	U-917			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 003	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
MINOXIDIL - MEN'S ROGAINE						
N 021812 001	6946120	Apr 20, 2019	DP U-702			
MINOXIDIL - WOMEN'S ROGAINE						
N 021812 002	6946120	Apr 20, 2019	DP U-702		NP	Feb 28, 2017
MIPOMERSEN SODIUM - KYNAMRO						
N 203568 001	6166197	Dec 26, 2017	DS		NCE	Jan 29, 2018
	6451991	Feb 11, 2017	DS		ODE	Jan 29, 2020
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Jan 29, 2027	DS			
MIRABEGRON - MYRBETRIQ						
N 202611 001	6346532	Mar 27, 2022	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023	U-1527			
	RE44872	Nov 04, 2023	U-1527			
MIRABEGRON - MYRBETRIQ						
N 202611 002	6346532	Mar 27, 2022	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023	U-1527			
	RE44872	Nov 04, 2023	U-1527			
MITOMYCIN - MITOSOL						
N 022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
	9205075	Jul 19, 2026	DP			
MODAFINIL - PROVIGIL						
N 020717 001	7297346	Nov 29, 2023	DP			
MODAFINIL - PROVIGIL						
N 020717 002	7297346	Nov 29, 2023	DP			
MOMETASONE FUROATE - NASONEX						
N 020762 001	6127353	Oct 03, 2017	DS DP			
MOMETASONE FUROATE - ASMANEX TWISTHALER						
N 021067 001	6240918	Feb 20, 2017	DP			
	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
MOMETASONE FUROATE - ASMANEX TWISTHALER						
N 021067 002	6240918	Feb 20, 2017	DP			
	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MOMETASONE FUROATE - ASMANEX HFA						
N 205641 001	6068832	Aug 27, 2017	DP U-645			
MOMETASONE FUROATE - ASMANEX HFA						
N 205641 002	6068832	Aug 27, 2017	DP U-645			
MONTELUKAST SODIUM - SINGULAIR						
N 021409 001	8007830	Oct 24, 2022	DP			
MORPHINE SULFATE - AVINZA						
N 021260 001	6066339	Nov 25, 2017	DP			
MORPHINE SULFATE - AVINZA						
N 021260 002	6066339	Nov 25, 2017	DP			
MORPHINE SULFATE - AVINZA						
N 021260 003	6066339	Nov 25, 2017	DP			
MORPHINE SULFATE - AVINZA						
N 021260 004	6066339	Nov 25, 2017	DP			
MORPHINE SULFATE - AVINZA						
N 021260 005	6066339	Nov 25, 2017	DP			
MORPHINE SULFATE - AVINZA						
N 021260 006	6066339	Nov 25, 2017	DP			
MORPHINE SULFATE - DEPODUR						
N 021671 001	5891467	Jan 31, 2017	DP			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
MORPHINE SULFATE - DEPODUR						
N 021671 002	5891467	Jan 31, 2017	DP			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
MORPHINE SULFATE - DEPODUR						
N 021671 003	5891467	Jan 31, 2017	DP			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 001	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 002	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 003	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 004	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 005	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHABOND						
N 206544 001	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
MORPHINE SULFATE - MORPHABOND						
N 206544 002	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
MORPHINE SULFATE - MORPHABOND						
N 206544 003	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
MORPHINE SULFATE - MORPHABOND						
N 206544 004	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 001	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 002	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MOXIFLOXACIN HYDROCHLORIDE - AVELOX						
N 021085 001	5849752	Dec 05, 2016	U-298		M-185	Sep 27, 2019
	6610327	Oct 29, 2019	DP U-298			
MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER						
N 021277 001	5849752	Dec 05, 2016	U-298		M-185	Sep 27, 2019
	6548079	Jul 25, 2020	DP U-298			
MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX						
N 021598 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	U-709			
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N 022428 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	DP U-709			
	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
MUPIROCIN - CENTANY						
N 050788 001	6013657	Jul 08, 2018	DP			
MYCOPHENOLIC ACID - MYFORTIC						
N 050791 001	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
MYCOPHENOLIC ACID - MYFORTIC						
N 050791 002	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
NAFTIFINE HYDROCHLORIDE - NAFTIN						
N 019599 002					M-191	Nov 10, 2019
NAFTIFINE HYDROCHLORIDE - NAFTIN						
N 204286 001	8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033	U-540			
NALOXEGOL OXALATE - MOVANTIK						
N 204760 001	7056500	Jun 29, 2024	DP U-1185		NCE	Sep 16, 2019
	7662365	Oct 18, 2022	DS DP			
	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
	9012469	Apr 02, 2032	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXEGOL OXALATE - MOVANTIK						
N 204760 002	7056500	Jun 29, 2024	DP U-1185		NCE	Sep 16, 2019
	7662365	Oct 18, 2022	DS DP			
	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
	9012469	Apr 02, 2032	DS DP			
NALOXONE HYDROCHLORIDE - EVZIO						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9517307	Jul 18, 2034	DP U-1925			
NALOXONE HYDROCHLORIDE - NARCAN						
N 208411 001	9211253	Mar 16, 2035	DP			
	9468747	Mar 16, 2035	DP U-1903			
NALOXONE HYDROCHLORIDE - EVZIO						
N 209862 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9517307	Jul 18, 2034	DP U-1925			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 001	6277384	Dec 22, 2018	DP		NC	Jul 23, 2017
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 001	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
	9511066	May 10, 2022	U-1921			
	9522919	Mar 30, 2025	DS DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 002	6277384	Dec 22, 2018	DP		NC	Jul 23, 2017
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
	9511066	May 10, 2022	U-1921			
	9522919	Mar 30, 2025	DS DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 003	6277384	Dec 22, 2018	DP		NC	Jul 23, 2017
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
	9511066	May 10, 2022	U-1921			
	9522919	Mar 30, 2025	DS DP			
NALTREXONE - VIVITROL						
N 021897 001	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6264987	May 19, 2020	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALTREXONE - VIVITROL							
N 021897	001	6331317	Nov 12, 2019	DP			
		6379703	Dec 30, 2018	DP			
		6379704	May 19, 2020	DP			
		6395304	Nov 12, 2019	DP			
		6403114	May 02, 2017	DP			
		6495164	May 25, 2020	DP			
		6495166	Nov 12, 2019	DP			
		6534092	May 19, 2020	DP			
		6537586	Nov 12, 2019	DP			
		6596316	Dec 30, 2018	DP			
		6667061	May 25, 2020	DP			
		6713090	Nov 12, 2019	DP			
		6939033	Nov 12, 2019	DP			
		7799345	May 25, 2020	DP			
		7919499	Oct 15, 2029	U-1123			
		7919499	Oct 15, 2029	U-1124			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	001	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	002	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	003	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	004	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	005	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER							
N 207621	006	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET							
N 021926	001	6060499	Aug 14, 2017	DP U-867			
		6060499*PED	Feb 14, 2018				
		6586458	Aug 14, 2017	DP U-867			
		6586458*PED	Feb 14, 2018				
		7332183	Oct 02, 2025	DP U-867			
		7332183*PED	Apr 02, 2026				
		8022095	Aug 14, 2017	DP U-867			
		8022095*PED	Feb 14, 2018				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET							
N 021926	002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
		5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
		6060499	Aug 14, 2017	DP U-1719			
		6060499*PED	Feb 14, 2018				
		6586458	Aug 14, 2017	DP U-1719			
		6586458*PED	Feb 14, 2018				
		7332183	Oct 02, 2025	DP U-1719			
		7332183*PED	Apr 02, 2026				
NATEGLINIDE - STARLIX							
N 021204	001	6559188	Sep 15, 2020	DP U-827			
		6641841	Nov 14, 2017	DP U-214			
		6844008	Nov 14, 2017	DP U-214			
		6878749	Sep 15, 2020	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NATEGLINIDE - STARLIX						
N 021204 002	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
N 021742 002	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
N 021742 003	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
N 021742 004	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
N 021742 005	6545040	Dec 17, 2021	DP U-3			
NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
NELARABINE - ARRANON						
N 021877 001	5424295	Jun 13, 2017	DS DP			
NEPAFENAC - NEVANAC						
N 021862 001	7834059	Jan 31, 2027	U-1095			
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
NEPAFENAC - ILEVRO						
N 203491 001	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			
	8921337	Mar 31, 2032	DP			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 205718 001	6297375	Feb 22, 2020	DS		NCE	Oct 10, 2019
	8623826	Nov 18, 2030	U-528			
	8951969	Nov 18, 2030	DP			
	9186357	Nov 18, 2030	U-528			
	9271975	Sep 09, 2031	U-528			
NEVIRAPINE - VIRAMUNE XR						
N 201152 001	8460704	Mar 12, 2029	U-1409			
NIACIN - NIASPAN						
N 020381 001	6080428	May 27, 2017	U-331			
NIACIN - NIASPAN						
N 020381 002	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
NIACIN - NIASPAN						
N 020381 003	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN - NIASPAN						
N 020381 003	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
NIACIN - NIASPAN						
N 020381 004	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
NIACIN - NIASPAN TITRATION STARTER PACK						
N 020381 005	6080428	May 27, 2017	U-331			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER						
N 019734 002	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 003	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER						
N 019734 004	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICOTINE - NICODERM CQ						
N 020165 004	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			
NICOTINE - NICODERM CQ						
N 020165 005	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			
NICOTINE - NICODERM CQ						
N 020165 006	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICOTINE POLACRILEX - NICORETTE						
N 018612 002	8323683	Apr 30, 2028				
NICOTINE POLACRILEX - NICORETTE						
N 020066 002	8323683	Apr 30, 2028	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 001	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 002	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836			
	8163904	Aug 23, 2028	DS DP			
	8293756	Sep 25, 2027	DP			
	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
	9061029	Apr 07, 2032	DP U-1374			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836			
	8163904	Aug 23, 2028	DS DP			
	8293756	Sep 25, 2027	DP			
	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
	9061029	Apr 07, 2032	DP U-1374			
NIMODIPINE - NYMALIZE						
N 203340 001					ODE	May 10, 2020
NINTEDANIB ESYLATE - OFEV						
N 205832 001	6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
	7989474	Apr 06, 2024	U-1677			
NINTEDANIB ESYLATE - OFEV						
N 205832 002	6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
	7989474	Apr 06, 2024	U-1677			
NITAZOXANIDE - ALINIA						
N 021497 001	5968961	May 07, 2017	DP			
NITAZOXANIDE - ALINIA						
N 021498 001	5965590	Jul 03, 2017	U-523			
	5968961	May 07, 2017				
	6117894	May 07, 2017				
NITISINONE - ORFADIN						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
NITRIC OXIDE - INOMAX						
N 020845 002	5732693	Dec 13, 2016	DP U-1230			
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	6125846*PED	Nov 16, 2017				
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITRIC OXIDE - INOMAX						
N 020845 002	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
NITRIC OXIDE - INOMAX						
N 020845 003	5732693	Dec 13, 2016	DP U-1230		M-167	Oct 09, 2018
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	6125846*PED	Nov 16, 2017				
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY						
N 018705 002	7872049	Mar 14, 2028	DP U-39			
NITROGLYCERIN - NITROSTAT						
N 021134 001	6500456	Sep 16, 2018				
NITROGLYCERIN - NITROSTAT						
N 021134 002	6500456	Sep 16, 2018				
NITROGLYCERIN - NITROSTAT						
N 021134 003	6500456	Sep 16, 2018				
NITROGLYCERIN - GONITRO						
N 208424 001	9101592	Mar 11, 2032	DP			
NIZATIDINE - AXID						
N 021494 001	6930119	Jul 17, 2022	DP			
NUSINERSEN SODIUM - SPINRAZA						
N 209531 001					NCE	Dec 23, 2021
OBETICHOLIC ACID - OCALIVA						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OBETICHOLIC ACID - OCALIVA						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
N 021008 001	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
N 021008 002	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
N 021008 003	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
OLANZAPINE - ZYPREXA						
N 020592 001	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA						
N 020592 002	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA						
N 020592 003	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA						
N 020592 004	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA						
N 020592 005	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA						
N 020592 006	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA ZYDIS						
N 021086 001	6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA ZYDIS						
N 021086 002	6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA ZYDIS						
N 021086 003	6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
OLANZAPINE - ZYPREXA ZYDIS						
N 021086 004	6960577	Nov 01, 2017	U-964		NPP	Jul 26, 2016
OLANZAPINE PAMOATE - ZYPREXA RELPREVV						
N 022173 001	6169084	Sep 30, 2018	DS DP U-1026			
OLANZAPINE PAMOATE - ZYPREXA RELPREVV						
N 022173 002	6169084	Sep 30, 2018	DS DP U-1026			
OLANZAPINE PAMOATE - ZYPREXA RELPREVV						
N 022173 003	6169084	Sep 30, 2018	DS DP U-1026			
OLAPARIB - LYNPARZA						
N 206162 001	7151102	Apr 29, 2022	DS DP		NCE	Dec 19, 2019
	7449464	Oct 11, 2024	DS DP		ODE	Dec 19, 2021
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%						
N 204508 001					NP	Oct 03, 2016

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL						
A 078276 001					PC	Apr 24, 2017
OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL						
A 078276 002					PC	Apr 24, 2017
OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL						
A 078276 003					PC	Apr 24, 2017
OLMESARTAN MEDOXOMIL - BENICAR						
N 021286 001	6878703	Nov 19, 2021	U-3	Y		
OLMESARTAN MEDOXOMIL - BENICAR						
N 021286 003	6878703	Nov 19, 2021	U-3	Y		
OLMESARTAN MEDOXOMIL - BENICAR						
N 021286 004	6878703	Nov 19, 2021	U-3	Y		
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT						
N 203108 001	5964416	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP U-1547			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1547			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1547			
	8044046	Nov 10, 2023	U-1547			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT						
N 206756 001	5964416	Oct 04, 2016	DP		M-173	Mar 18, 2019
	6149054	Dec 19, 2016	DP		NC	May 21, 2018
	6176442	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1703			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT						
N 206756 001	5964416	Oct 04, 2016	DP		M-173	Mar 18, 2019
	6149054	Dec 19, 2016	DP		NC	May 21, 2018
	6176442	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1703			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			
OLOPATADINE HYDROCHLORIDE - PATADAY						
N 021545 001	6995186	Nov 12, 2023	DP U-765			
	7402609	Jun 19, 2022	DP			
OLOPATADINE HYDROCHLORIDE - PATANASE						
N 021861 001	7977376	Feb 02, 2023	DP			
	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
OLOPATADINE HYDROCHLORIDE - PAZEO						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP	Jan 30, 2018
					PED	Jul 30, 2018
OMACETAXINE MEPESUCCINATE - SYNRIBO						
N 203585 001	6987103	Jun 28, 2023	U-1300		NCE	Oct 26, 2017
	RE45128	Mar 16, 2019	DS DP U-1576		ODE	Oct 26, 2019
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE						
N 207931 001	6037157*PED	Dec 26, 2016			NCE	Dec 19, 2019
	6703403*PED	Dec 26, 2016			NP	Jul 24, 2018
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG						
N 204977 001					NCE	Apr 23, 2019
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
	7960370	Feb 07, 2025	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA						
N 205060 001	8383678	Feb 07, 2025	DP U-1511			
	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP U-1511			
OMEPRAZOLE - PRILOSEC						
N 019810 001	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
OMEPRAZOLE - PRILOSEC						
N 019810 002	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
OMEPRAZOLE - PRILOSEC						
N 019810 003	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
OMEPRAZOLE - OMEPRAZOLE						
N 022032 001	9023391	Aug 16, 2025	DP			
OMEPRAZOLE MAGNESIUM - PRILOSEC OTC						
N 021229 001	6403616	Nov 15, 2019				
	6428810	Nov 03, 2019				
OMEPRAZOLE MAGNESIUM - PRILOSEC						
N 022056 001	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
OMEPRAZOLE MAGNESIUM - PRILOSEC						
N 022056 002	6428810	Nov 03, 2019	DP U-864			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-588		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623		Y	
	6489346	Jul 15, 2016	DP U-624		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-623		Y	
	6699885	Jul 15, 2016	U-624		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID						
N 021849 001	7399772	Jul 15, 2016	U-588			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC						
N 022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
	7399772	Jul 15, 2016	U-1025			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC						
N 022283 001	5840737	Jul 15, 2016	U-1025			
	6780882	Jul 15, 2016	DP			
	7399772	Jul 15, 2016	U-1025			
ONDANSETRON - ZUPLENZ						
N 022524 001	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
ONDANSETRON - ZUPLENZ						
N 022524 002	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
ORITAVANCIN DIPHOSPHATE - ORBACTIV						
N 206334 001	5840684	Nov 24, 2017	DS DP U-1569		NCE	Aug 06, 2019
	5998581	Nov 12, 2017	DS		GAIN	Aug 06, 2024
	8420592	Aug 29, 2029	U-1570			
ORLISTAT - XENICAL						
N 020766 001	6004996	Jan 06, 2018				
ORLISTAT - ALLI						
N 021887 001	6004996	Jan 06, 2018	DP			
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 001	5763483	Aug 23, 2016	DS DP U-1113			
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 002	5763483	Aug 23, 2016	DS DP U-1113			
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 003	5763483	Aug 23, 2016	DS DP U-1113			
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021246 001	5763483	Dec 27, 2016	DS U-376			
	5763483	Dec 27, 2016	DS U-1113			
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021246 002	5763483	Aug 23, 2016	DS DP U-1113			
	5763483*PED	Feb 23, 2017				
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 001	8946235	Aug 08, 2032	DS DP U-1777		NCE	Nov 13, 2020
					ODE	Nov 13, 2022
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 002	8946235	Aug 08, 2032	DS DP U-1777		NCE	Nov 13, 2020
					ODE	Nov 13, 2022
OSPEMIFENE - OSPHENA						
N 203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8642079	Jul 09, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
OXALIPLATIN - ELOXATIN						
N 021492 001	5420319	Aug 09, 2016	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXALIPLATIN - ELOXATIN						
N 021492 002	5420319	Aug 09, 2016	DS			
OXALIPLATIN - ELOXATIN						
N 021759 001	5420319	Aug 09, 2016	DS			
OXALIPLATIN - ELOXATIN						
N 021759 002	5420319	Aug 09, 2016	DS			
OXALIPLATIN - ELOXATIN						
N 021759 003	5420319	Aug 09, 2016	DS			
OXANDROLONE - OXANDRIN						
N 013718 001	5872147	Dec 05, 2017			U-585	
	6090799	Jul 18, 2017			U-585	
	6576659	Dec 05, 2017			U-585	
	6828313	Dec 05, 2017			U-585	
OXANDROLONE - OXANDRIN						
N 013718 002	5872147	Dec 05, 2017			U-585	
	6090799	Jul 18, 2017			U-585	
	6576659	Dec 05, 2017			U-585	
	6828313	Dec 05, 2017			U-585	
OXCARBAZEPINE - TRILEPTAL						
N 021014 001	7037525	Feb 12, 2018			U-724	
OXCARBAZEPINE - TRILEPTAL						
N 021014 002	7037525	Feb 12, 2018			U-724	
OXCARBAZEPINE - TRILEPTAL						
N 021014 003	7037525	Feb 12, 2018			U-724	
OXCARBAZEPINE - TRILEPTAL						
N 021285 001	7037525	Feb 12, 2018			U-724	
	8119148	Dec 19, 2020	DP		U-724	
OXCARBAZEPINE - OXTELLAR XR						
N 202810 001	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027			U-1298	
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027			U-1298	
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 002	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027			U-1298	
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027			U-1298	
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 003	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027			U-1298	
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027			U-1298	
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
OXYBUTYNIN - OXYTROL						
N 021351 002	6743441	Apr 26, 2020	DP		U-318	
	7081249	Apr 26, 2020	DP		U-318	
	7081250	Apr 26, 2020	DP		U-318	
	7081251	Apr 26, 2020	DP		U-318	
	7081252	Apr 26, 2020	DP		U-318	
	7179483	Apr 26, 2020	DS DP		U-318	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYBUTYNIN - OXYTROL						
N 021351 002	6743441	Apr 26, 2020	DP U-318			
	7081249	Apr 26, 2020	DP U-318			
	7081250	Apr 26, 2020	DP U-318			
	7081251	Apr 26, 2020	DP U-318			
	7081252	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	DS DP U-318			
OXYBUTYNIN - OXYTROL FOR WOMEN						
N 202211 001	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
OXYBUTYNIN - GELNIQUE 3%						
N 202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
OXYBUTYNIN CHLORIDE - GELNIQUE						
N 022204 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	8241662	Apr 26, 2020	U-318			
	8920392	Mar 26, 2031	U-1644			
	9259388	Nov 06, 2029	U-1644			
OXYCODONE - XTAMPZA ER						
N 208090 001	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
OXYCODONE - XTAMPZA ER						
N 208090 002	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
OXYCODONE - XTAMPZA ER						
N 208090 003	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
OXYCODONE - XTAMPZA ER						
N 208090 004	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE - XTAMPZA ER						
N 208090 005	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 005	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 006	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
OXYCODONE HYDROCHLORIDE - OXAYDO						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DS DP			
OXYCODONE HYDROCHLORIDE - OXAYDO						
N 202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DS DP			
OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE						
N 208032 001	6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 001	7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 002	7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 003	7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 004	7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 005	7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 006	7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 021610 007	7276250	Feb 04, 2023	DP U-826			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 001	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 002	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 003	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
PACLITAXEL - ABRAXANE						
N 021660 001	7758891	Feb 21, 2026	U-1434		I-676	Sep 06, 2016
	7820788	Oct 27, 2024	DP U-1092		ODE	Sep 06, 2020
	7820788	Oct 27, 2024	DP U-1290			
	7820788	Oct 27, 2024	DP U-1434			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	8034375	Aug 13, 2026	U-1290			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8268348	Feb 21, 2026	U-1290			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PACLITAXEL - ABRAXANE						
N 021660 001	8853260	Oct 10, 2020	DP U-1092			
	8853260	Oct 10, 2020	DP U-1290			
	8853260	Oct 10, 2020	DP U-1434			
	9101543	Feb 21, 2026	U-1434			
	9393318	Aug 03, 2032	U-1290			
	9511046	Oct 17, 2033	U-1434			
	RE41884	Aug 14, 2016	U-1117			
	RE41884	Aug 14, 2016	U-1290			
	RE41884	Aug 14, 2016	U-1434			
PALBOCICLIB - IBRANCE						
N 207103 001	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-1658			
	7456168	Jan 16, 2023	U-1818			
PALBOCICLIB - IBRANCE						
N 207103 002	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-1658			
	7456168	Jan 16, 2023	U-1818			
PALBOCICLIB - IBRANCE						
N 207103 003	6936612	Jan 22, 2023	DS DP		I-725	Feb 19, 2019
	7208489	Jan 16, 2023	DS DP		NCE	Feb 03, 2020
	7456168	Jan 16, 2023	U-1658			
	7456168	Jan 16, 2023	U-1818			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 001	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543			
	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 002	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543			
	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 003	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543			
	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 004	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543			
	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA						
N 022264 005	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543			
	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 001	7947724	Jan 30, 2024	DP		I-684	May 27, 2017
	7947724*PED	Jul 30, 2024			M-136	May 27, 2017
	7947725	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947725*PED	Jul 30, 2024			PED	Nov 27, 2017
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457021	Jan 30, 2024	DP			
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 002	7947724	Jan 30, 2024	DP		I-684	May 27, 2017
	7947724*PED	Jul 30, 2024			M-136	May 27, 2017
	7947725	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947725*PED	Jul 30, 2024			PED	Nov 27, 2017
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE						
N 022175 001					NCE	May 17, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE						
N 022175 002					NCE	May 17, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 007	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 001	9198871	Feb 07, 2030	DP U-1787			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 002	9198871	Feb 07, 2030	DP U-1787			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 003	9198871	Feb 07, 2030	DP U-1787			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 004	9198871	Feb 07, 2030	DP U-1787		M-93	Jul 29, 2019
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON						
N 020725 005	9198871	Feb 07, 2030	DP U-1787		M-93	Jul 29, 2019
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 001	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028	U-1274			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 002	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028	U-1274			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 003	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028	U-1274			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028				
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 004	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028	U-1274			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP						
N 022210 006	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N 022222 001					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N 022222 002					NCE	Mar 01, 2017

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA						
N 022222 003					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE						
N 022542 001					NCE	Mar 01, 2017
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE						
N 022542 002					NCE	Mar 01, 2017
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021		U-1669		
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028		U-1669		
PANTOPRAZOLE SODIUM - PROTONIX						
N 020987 001	5997903	Dec 07, 2016				
PANTOPRAZOLE SODIUM - PROTONIX						
N 020987 002	5997903	Dec 07, 2016				
PANTOPRAZOLE SODIUM - PROTONIX IV						
N 020988 001	6780881	Nov 17, 2021	DP			
	7351723	Nov 17, 2021	DP			
	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
PANTOPRAZOLE SODIUM - PROTONIX						
N 022020 001	7544370	Jun 07, 2026	DP			
	7550153	Sep 30, 2024		U-859		
	7553498	Sep 30, 2024		U-859		
	7838027	Sep 30, 2024	DP	U-859		
PARICALCITOL - ZEMPLAR						
N 020819 001	6136799	Apr 08, 2018				
	6361758	Apr 08, 2018	DP			
PARICALCITOL - ZEMPLAR						
N 020819 002	6136799	Apr 08, 2018				
	6361758	Apr 08, 2018	DP			
PARICALCITOL - ZEMPLAR						
N 020819 003	6136799	Apr 08, 2018				
	6136799*PED	Oct 08, 2018				
	6361758	Apr 08, 2018	DP			
	6361758*PED	Oct 08, 2018				
PARICALCITOL - ZEMPLAR						
N 021606 001					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PARICALCITOL - ZEMPLAR						
N 021606 002					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023
PARICALCITOL - ZEMPLAR						
N 021606 003					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020031 001	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020031 002	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020031 003	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020031 004	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020031 005	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020710 001	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020885 001	6063927	Apr 23, 2019				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6172233	Jan 15, 2018				
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020885 002	6063927	Apr 23, 2019				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6172233	Jan 15, 2018				
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020885 003	6063927	Apr 23, 2019				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6172233	Jan 15, 2018				
PAROXETINE HYDROCHLORIDE - PAXIL						
N 020885 004	6063927	Apr 23, 2019				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6172233	Jan 15, 2018				
PAROXETINE HYDROCHLORIDE - PAXIL CR						
N 020936 001	6121291	Mar 17, 2017	U-286			
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP U-816			
PAROXETINE HYDROCHLORIDE - PAXIL CR						
N 020936 002	6121291	Mar 17, 2017	U-286			
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP U-816			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PAROXETINE HYDROCHLORIDE - PAXIL CR						
N 020936 003	6121291	Mar 17, 2017	U-286			
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP U-816			
PAROXETINE MESYLATE - PEXEVA						
N 021299 001	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-518			
	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 002	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-518			
	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 003	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-518			
	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 004	5874447	Jun 10, 2017	U-46			
	5874447	Jun 10, 2017	U-286			
	5874447	Jun 10, 2017	U-518			
	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - BRISDELLE						
N 204516 001	5874447	Jun 10, 2017	DS			
	7598271	May 04, 2025	DS			
	8658663	Apr 06, 2029	DS DP U-904			
	8946251	Aug 04, 2026	DS DP U-904			
	9393237	Aug 04, 2026	U-904			
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 001	7473761	Jul 29, 2025	DS DP		NCE	Dec 14, 2017
	8299209	Dec 27, 2025	DS DP		ODE	Dec 14, 2019
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 002	7473761	Jul 29, 2025	DS DP		NCE	Dec 14, 2017
	8299209	Dec 27, 2025	DS DP		ODE	Dec 14, 2019
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 003	7473761	Jul 29, 2025	DS DP		NCE	Dec 14, 2017
	8299209	Dec 27, 2025	DS DP		ODE	Dec 14, 2019
PASIREOTIDE PAMOATE - SIGNIFOR LAR						
N 203255 001	7473761	Jul 29, 2025	DS DP		NCE	Dec 14, 2017
	7759308	Oct 25, 2026	DP		NP	Dec 15, 2017
	8822637	Aug 06, 2023	U-1629		ODE	Dec 15, 2021
PASIREOTIDE PAMOATE - SIGNIFOR LAR						
N 203255 002	7473761	Jul 29, 2025	DS DP		NCE	Dec 14, 2017
	7759308	Oct 25, 2026	DP		NP	Dec 15, 2017
	8822637	Aug 06, 2023	U-1629		ODE	Dec 15, 2021
PASIREOTIDE PAMOATE - SIGNIFOR LAR						
N 203255 003	7473761	Jul 29, 2025	DS DP		NCE	Dec 14, 2017
	7759308	Oct 25, 2026	DP		NP	Dec 15, 2017
	8822637	Aug 06, 2023	U-1629		ODE	Dec 15, 2021
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 001	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	8147873	Mar 11, 2026	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	Mar 11, 2026	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 001	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 002	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	8147873	Mar 11, 2026	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	Mar 11, 2026	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 003	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	8147873	Mar 11, 2026	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	Mar 11, 2026	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
PAZOPANIB HYDROCHLORIDE - VOTRIENT						
N 022465 001	7105530	Oct 19, 2023	DS DP		ODE	Apr 26, 2019
	7262203	Dec 19, 2021	DS DP			
	8114885	Dec 19, 2021	DS DP			
PAZOPANIB HYDROCHLORIDE - VOTRIENT						
N 022465 002	7105530	Oct 19, 2023	DS DP		ODE	Apr 26, 2019
	7262203	Dec 19, 2021	DS DP			
	8114885	Dec 19, 2021	DS DP			
PEGAPTANIB SODIUM - MACUGEN						
N 021756 001	5932462	Aug 03, 2016	DS			
	6011020	Jan 04, 2017	DS			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS						
N 202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGINESATIDE ACETATE - OMONTYS						
N 202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
PEGVISOMANT - SOMAVERT						
N 021106 001	5849535	Mar 25, 2017	DS			
PEGVISOMANT - SOMAVERT						
N 021106 002	5849535	Mar 25, 2017	DS			
PEGVISOMANT - SOMAVERT						
N 021106 003	5849535	Mar 25, 2017	DS			
PEGVISOMANT - SOMAVERT						
N 021106 004	5849535	Mar 25, 2017	DS			
PEGVISOMANT - SOMAVERT						
N 021106 005	5849535	Mar 25, 2017	DS			
PEMETREXED DISODIUM - ALIMTA						
N 021462 001	5344932	Jul 24, 2016	DS DP			
	7772209	Nov 24, 2021	U-1077			
	7772209	Nov 24, 2021	U-1296			
PEMETREXED DISODIUM - ALIMTA						
N 021462 002	5344932	Jul 24, 2016	DS DP			
	7772209	Nov 24, 2021	U-1296			
PENCICLOVIR - DENAVIR						
N 020629 001	6469015	Oct 22, 2019	U-501			
	6579981	Jun 17, 2020	U-501			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMIVIR - RAPIVAB						
N 206426 001	6503745	Nov 05, 2019	DS		NCE	Dec 19, 2019
	6562861	Dec 17, 2018	DS			
	8778997	May 07, 2027	U-1627			
PERAMPANEL - FYCOMPA						
N 202834 001	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
PERAMPANEL - FYCOMPA						
N 202834 002	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
PERAMPANEL - FYCOMPA						
N 202834 003	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
PERAMPANEL - FYCOMPA						
N 202834 004	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
PERAMPANEL - FYCOMPA						
N 202834 005	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
PERAMPANEL - FYCOMPA						
N 202834 006	6949571	Jun 08, 2021	DS DP U-106		I-710	Jun 19, 2018
	8772497	May 16, 2026	DS		NCE	Oct 22, 2017
PERAMPANEL - FYCOMPA						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
PERFLUTREN - DEFINITY						
N 021064 001	8658205	Jun 18, 2019	DP			
	8685441	Jan 13, 2019	U-665			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 001	6149938	Jul 23, 2018	DP			
	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 002	6149938	Jul 23, 2018	DP			
	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA						
N 202088 003	6149938	Jul 23, 2018	DP U-1243			
	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	6071537	Jun 23, 2017	U-1262			
	7056890	Jun 14, 2020	DP U-1262			
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
	8895057	Jun 09, 2028	U-1262			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	6071537	Jun 23, 2017	U-1262			
	7056890	Jun 14, 2020	DP U-1262			
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
	8895057	Jun 09, 2028	U-1262			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	6071537	Jun 23, 2017	U-1262			
	7056890	Jun 14, 2020	DP U-1262			
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
	8895057	Jun 09, 2028	U-1262			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 004	6071537	Jun 23, 2017	U-1262			
	7056890	Jun 14, 2020	DP U-1262			
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029	U-1262			
	8895057	Jun 09, 2028	U-1262			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTOLAMINE MESYLATE - ORAVERSE						
N 022159 001	6764678	May 11, 2021	U-967		NPP	Mar 18, 2019
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023	U-967			
	7575757	Apr 21, 2025	DP			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE						
N 203510 001	8859623	Nov 14, 2033	U-1594			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE						
N 203510 002	8859623	Nov 14, 2033	U-1594			
PIMAVANSERIN TARTRATE - NUPLAZID						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9296694	Mar 06, 2021	DS DP			
PIMECROLIMUS - ELIDEL						
N 021302 001	6423722	Jun 26, 2018				
PIOGLITAZONE HYDROCHLORIDE - ACTOS						
N 021073 001	6303640	Aug 09, 2016	U-425			
PIOGLITAZONE HYDROCHLORIDE - ACTOS						
N 021073 002	6303640	Aug 09, 2016	U-425			
PIOGLITAZONE HYDROCHLORIDE - ACTOS						
N 021073 003	6303640	Aug 09, 2016	U-425			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N 050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N 050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N 050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N 050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N 050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N 050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N 050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
PIRFENIDONE - ESBRIET						
N 022535 001	7566729	Apr 22, 2029	U-1600		NCE	Oct 16, 2019
	7635707	Apr 22, 2029	U-1609		ODE	Oct 15, 2021
	7696236	Dec 18, 2027	U-1601			
	7767225	Sep 22, 2026	DP U-1602			
	7767700	Dec 18, 2027	U-1601			
	7816383	Jan 08, 2030	U-1603			
	7910610	Jan 08, 2030	U-1604			
	7988994	Sep 22, 2026	DP U-1602			
	8013002	Jan 08, 2030	U-1603			
	8084475	Jan 08, 2030	U-1605			
	8318780	Jan 08, 2030	U-1606			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2027	DP U-1608			
	8592462	Apr 22, 2029	U-1609			
	8609701	Apr 22, 2029	U-1610			
	8648098	Jan 08, 2030	U-1611			
	8753679	Sep 22, 2026	DP U-1602			
	8754109	Jan 08, 2030	U-1612			
	8778947	Aug 30, 2033	U-1613			
PITAVASTATIN CALCIUM - LIVALO						
N 022363 001	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DP			
PITAVASTATIN CALCIUM - LIVALO						
N 022363 002	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PITAVASTATIN CALCIUM - LIVALO						
N 022363 002	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DP			
PITAVASTATIN CALCIUM - LIVALO						
N 022363 003	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DS DP			
PLERIXAFOR - MOZOBIL						
N 022311 001	6987102	Jul 22, 2023	U-936			
	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2018	DP			
POLIDOCANOL - VARITHENA						
N 205098 001	6572873	May 26, 2020	U-1461			
	6846412	Jul 19, 2022	DP			
	6942165	May 26, 2020	DP			
	7025290	May 26, 2020	DP U-1461			
	7357336	May 26, 2020	U-1461			
	7604185	May 26, 2020	DS DP U-1462			
	7731986	Nov 17, 2024	DS DP U-1463			
	7814943	Nov 19, 2027	DP U-1461			
	7842282	May 26, 2020	U-1461			
	7842283	May 26, 2020	DP			
	8122917	Sep 09, 2024	DP			
	8323677	May 26, 2020	DS			
	8734833	May 26, 2020	DS DP			
	9480652	May 12, 2032	DP			
	RE40640	Oct 14, 2016	DS DP U-1462			
POMALIDOMIDE - POMALYST						
N 204026 001	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
POMALIDOMIDE - POMALYST						
N 204026 002	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POMALIDOMIDE - POMALYST						
N 204026 002	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
POMALIDOMIDE - POMALYST						
N 204026 003	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
POMALIDOMIDE - POMALYST						
N 204026 004	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-836		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9493470	Dec 12, 2033	DS DP U-1700			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-836		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9493470	Dec 12, 2033	DS DP U-1700			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	9029533	Dec 22, 2026	U-836		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-1283		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9493470	Dec 12, 2033	DS DP U-1700			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	9029533	Dec 22, 2026	U-836		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-1283		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9493470	Dec 12, 2033	DS DP U-1700			
POSACONAZOLE - NOXAFIL						
N 022003 001	5661151	Jul 19, 2019	DS DP U-760			
	6958337	Oct 05, 2018	DS DP U-760			
	8263600	Apr 01, 2022	DP			
POSACONAZOLE - NOXAFIL						
N 205053 001	5661151	Jul 19, 2019	DS DP U-1454			
POSACONAZOLE - NOXAFIL						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
	9023790	Jul 04, 2031	DP U-1698			
	9358297	Jun 24, 2031	DP U-1454			
	9493582	Feb 27, 2033	DP			
PRALATREXATE - FOLOTYN						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004		ODE	Sep 24, 2016
	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
PRALATREXATE - FOLOTYN						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004		ODE	Sep 24, 2016
	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE						
A 202206 006					PC	Jan 01, 2017
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N 020667 001	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N 020667 002	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N 020667 003	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N 020667 005	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N 020667 006	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
N 020667 007	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 001	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 002	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 003	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 004	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 005	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 006	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 007	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMLINTIDE ACETATE - SYMLIN						
N 021332 001	5686411	Mar 16, 2019	DS DP U-638			
	6114304	Sep 05, 2017	U-640			
PRAMLINTIDE ACETATE - SYMLIN						
N 021332 002	5686411	Mar 16, 2019	DS DP U-638			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
PRAMLINTIDE ACETATE - SYMLIN						
N 021332 003	5686411	Mar 16, 2019	DS DP U-638			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
PRASTERONE - INTRAROSA						
N 208470 001	8268806	Mar 19, 2031	DP		NCE	Nov 16, 2021
	8629129	Aug 07, 2028	DP			
	8957054	Aug 07, 2028	U-1922			
PRASUGREL HYDROCHLORIDE - EFFIENT						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
PRASUGREL HYDROCHLORIDE - EFFIENT						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
PREDNISOLONE ACETATE - FLO-PRED						
N 022067 001	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
PREDNISOLONE ACETATE - FLO-PRED						
N 022067 002	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT						
N 021959 001	6740341	Nov 24, 2019	DP			
PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT						
N 021959 002	6740341	Nov 24, 2019	DP			
PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT						
N 021959 003	6740341	Nov 24, 2019	DP			
PREDNISONE - RAYOS						
N 202020 001	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREDNISONE - RAYOS						
N 202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREDNISONE - RAYOS						
N 202020 003	8168218	Jan 07, 2028	DP U-1269			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREGABALIN - LYRICA						
N 021446 001	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N 021446 002	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N 021446 003	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N 021446 004	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N 021446 005	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N 021446 006	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREGABALIN - LYRICA						
N 021446 007	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N 021446 008	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
PREGABALIN - LYRICA						
N 022488 001	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
PROGESTERONE - ENDOMETRIN						
N 022057 001	7300664	Nov 17, 2019	U-856			
	7320800	Nov 17, 2019	U-856			
	7393543	Nov 17, 2019	DP U-880			
PROPOFOL - DIPRIVAN						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL						
N 021438 001	6500454	Oct 04, 2021	DP			
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL						
N 021438 002	6500454	Oct 04, 2021	DP			
PROPRANOLOL HYDROCHLORIDE - HEMANGEOL						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP	Mar 14, 2017
					ODE	Mar 14, 2021
QUAZEPAM - DORAL						
N 018708 001	7608616	Jun 03, 2028	U-1012			
QUAZEPAM - DORAL						
N 018708 003	7608616	Jun 03, 2028	U-1012			
QUETIAPINE FUMARATE - QUETIAPINE FUMARATE						
A 090681 004					PC	Apr 30, 2017
QUETIAPINE FUMARATE - SEROQUEL XR						
N 022047 001	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
QUETIAPINE FUMARATE - SEROQUEL XR						
N 022047 002	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
QUETIAPINE FUMARATE - SEROQUEL XR						
N 022047 003	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
QUETIAPINE FUMARATE - SEROQUEL XR						
N 022047 004	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
QUETIAPINE FUMARATE - SEROQUEL XR						
N 022047 005	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE						
N 204736 001					PED	Sep 26, 2016
RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE						
N 204736 002					PED	Sep 26, 2016
RADIUM RA-223 DICHLORIDE - XOFIGO						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
RALOXIFENE HYDROCHLORIDE - EVISTA						
N 020815 001	6458811	Mar 10, 2017	DS DP U-825			
	6797719	Mar 10, 2017	DP			
	6894064	Mar 10, 2017	DP U-657			
	8030330	Mar 10, 2017	DP			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 022145 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7754731	Mar 11, 2029	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 203045 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 203045 002	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 205786 001	7169780	Oct 03, 2023	DS DP		NDF	Dec 20, 2016
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
RAMELTEON - ROZEREM						
N 021782 001	6034239	Jul 22, 2019	DS DP U-674			
RAMIPRIL - ALTACE						
N 019901 001	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE						
N 019901 002	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE						
N 019901 003	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE						
N 019901 004	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE						
N 022021 001	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE						
N 022021 002	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE						
N 022021 003	7368469	Aug 30, 2020	U-871			
RAMIPRIL - ALTACE						
N 022021 004	7368469	Aug 30, 2020	U-871			
RANOLAZINE - RANEXA						
N 021526 001	6303607	May 27, 2019	U-705			
	6369062	May 27, 2019	DP	Y		
	6479496	May 27, 2019	U-705			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RANOLAZINE - RANEXA						
N 021526 001	6503911	May 27, 2019	DP			
	6525057	May 27, 2019	U-705			
	6562826	May 27, 2019	U-705			
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019	U-705			
	6852724	May 27, 2019	U-705			
	6864258	May 27, 2019	U-705			
RANOLAZINE - RANEXA						
N 021526 002	6303607	May 27, 2019	U-705			
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019	U-705			
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019	U-705			
	6562826	May 27, 2019	U-705			
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019	U-705			
	6852724	May 27, 2019	U-705			
	6864258	May 27, 2019	U-705			
RASAGILINE MESYLATE - AZILECT						
N 021641 001	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
RASAGILINE MESYLATE - AZILECT						
N 021641 002	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
REGADENOSON - LEXISCAN						
N 022161 001	6403567	Apr 10, 2022	DS DP U-869			
	6642210	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-116			
	7144872	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-870			
	7183264	Jun 22, 2019	DP U-116			
	7183264	Jun 22, 2019	DP U-869			
	7183264	Jun 22, 2019	DP U-870			
	7582617	Jun 22, 2019	U-1003			
	7655636	Jun 22, 2019	U-869			
	7655637	Jun 22, 2019	DS DP U-869			
	7683037	Jun 22, 2019	U-1042			
	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
	8470801	Jun 22, 2019	U-116			
	8536150	Jun 22, 2019	U-116			
	9045519	Jun 22, 2019	DP			
	9085601	Feb 02, 2027	DP			
	9289446	Jun 22, 2019	DP U-116			
REGORAFENIB - STIVARGA						
N 203085 001	7351834	Jan 12, 2020	DS		NCE	Sep 27, 2017
	8637553	Feb 16, 2031	DS DP		ODE	Feb 25, 2020
	8680124	Jun 02, 2030	U-1506			
	9458107	Apr 08, 2031	DP			
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
N 020630 001	5866591	Sep 10, 2017	DP			
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
N 020630 002	5866591	Sep 10, 2017	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
N 020630 003	5866591	Sep 10, 2017	DP			
RETAPAMULIN - ALTABAX						
N 022055 001	7875630	Feb 14, 2027	DS			
	8207191	Aug 30, 2024	U-805			
	RE39128	Apr 12, 2021	DS DP U-805			
	RE43390	Apr 12, 2021	DS DP U-805			
RIBAVIRIN - VIRAZOLE						
N 018859 001	6150337	Nov 21, 2017	U-400			
RIBAVIRIN - REBETOL						
N 020903 001	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
RIBAVIRIN - REBETOL						
N 020903 002	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
RIBAVIRIN - REBETOL						
N 021546 001	6172046	Sep 21, 2017	U-521			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-521			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-521			
	6524570	Nov 01, 2016	U-1013			
	6790837	Apr 05, 2023	DP			
RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA						
N 203324 001					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%						
N 203324 002					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
RIFAXIMIN - XIFAXAN						
N 021361 001	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS U-1526			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	9271968	Feb 27, 2026	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIFAXIMIN - XIFAXAN							
N 021361	001	7045620	Jun 19, 2024	DS DP			
		7612199	Jun 19, 2024	DS DP			
		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
		7928115	Jul 24, 2029	U-1121			
		8158644	Jun 19, 2024	DP			
		8158781	Jun 19, 2024	DS			
		8193196	Sep 02, 2027	DS DP			
		8518949	Feb 27, 2026	DP			
		8741904	Feb 27, 2026	DS U-1526			
		8835452	Jun 19, 2024	DS DP			
		8853231	Jun 19, 2024	DP			
		9271968	Feb 27, 2026	DP			
RIFAXIMIN - XIFAXAN							
N 022554	001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
		6861053	Aug 11, 2019	U-1708		ODE	Mar 24, 2017
		7045620	Jun 19, 2024	DS			
		7452857	Aug 11, 2019	U-1707			
		7452857	Aug 11, 2019	U-1708			
		7605240	Aug 11, 2019	U-1707			
		7605240	Aug 11, 2019	U-1708			
		7612199	Jun 19, 2024	DS DP			
		7718608	Aug 11, 2019	U-1707			
		7718608	Aug 11, 2019	U-1708			
		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
		7915275	Feb 23, 2025	U-1707			
		7915275	Feb 23, 2025	U-1708			
		7935799	Aug 11, 2019	U-1707			
		7935799	Aug 11, 2019	U-1708			
		8158644	Jun 19, 2024	DP			
		8158781	Jun 19, 2024	DS			
		8193196	Sep 02, 2027	DS DP U-1707			
		8193196	Sep 02, 2027	DS DP U-1708			
		8309569	Jul 18, 2029	U-1707			
		8309569	Jul 18, 2029	U-1708			
		8518949	Feb 27, 2026	DP			
		8642573	Oct 02, 2029	U-1481			
		8741904	Feb 27, 2026	DS U-1526			
		8741904	Feb 27, 2026	DS U-1707			
		8741904	Feb 27, 2026	DS U-1708			
		8829017	Jul 24, 2029	U-1562			
		8835452	Jun 19, 2024	DS DP			
		8853231	Jun 19, 2024	DP			
		8946252	Jul 24, 2029	U-1481			
		8969398	Oct 02, 2029	U-1481			
		9271968	Feb 27, 2026	DP			
		9421195	Mar 10, 2030	U-1481			
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N 202022	001	6838464	Feb 26, 2021	DS DP		NPP	Aug 26, 2018
		7067522	Dec 20, 2019	DS DP			
		7125879	Apr 21, 2025	DS DP U-1153			
		7125879	Apr 21, 2025	DS DP U-1307			
		7125879	Apr 21, 2025	DS DP U-1740			
		7638522	Apr 14, 2023	DP			
		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			
RIOCIGUAT - ADEMPAS							
N 204819	001	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
		7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
RIOCIGUAT - ADEMPAS							
N 204819	002	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
		7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIOCIGUAT - ADEMPAS						
N 204819 003	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
RIOCIGUAT - ADEMPAS						
N 204819 004	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
RIOCIGUAT - ADEMPAS						
N 204819 005	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
RISEDRONATE SODIUM - ACTONEL						
N 020835 001	6165513	Jun 10, 2018				
RISEDRONATE SODIUM - ACTONEL						
N 020835 002	6165513	Jun 10, 2018				
RISEDRONATE SODIUM - ACTONEL						
N 020835 003	5994329	Jul 17, 2018	U-353			
	6015801	Jul 17, 2018	U-353			
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018	U-595			
	6465443	Aug 14, 2018	DP			
RISEDRONATE SODIUM - ACTONEL						
N 020835 004	6165513	Jun 10, 2018	DP			
RISEDRONATE SODIUM - ACTONEL						
N 020835 005	6165513	Jun 10, 2018	DP			
	7192938	May 06, 2023	U-353			
	7718634	May 06, 2023	U-662			
RISEDRONATE SODIUM - ATELVIA						
N 022560 001	7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
	8246989	Jan 16, 2026	DP			
RISPERIDONE - RISPERDAL CONSTA						
N 021346 001	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
RISPERIDONE - RISPERDAL CONSTA						
N 021346 002	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
RISPERIDONE - RISPERDAL CONSTA						
N 021346 003	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
RISPERIDONE - RISPERDAL CONSTA						
N 021346 004	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - RISPERDAL CONSTA						
N 021346 004	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
RISPERIDONE - RISPERDAL						
N 021444 001	6224905	Jun 10, 2017	DP			
RISPERIDONE - RISPERDAL						
N 021444 002	6224905	Jun 10, 2017	DP			
RISPERIDONE - RISPERDAL						
N 021444 003	6224905	Jun 10, 2017	DP			
RISPERIDONE - RISPERDAL						
N 021444 004	6224905	Jun 10, 2017	DP			
RISPERIDONE - RISPERDAL						
N 021444 005	6224905	Jun 10, 2017	DP			
RITONAVIR - NORVIR						
N 020945 001	6232333	Nov 07, 2017				
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
RITONAVIR - NORVIR						
N 022417 001	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-688			
	8691878*PED	Feb 25, 2025				
RIVAROXABAN - XARELTO						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301		NCE	Jul 01, 2016
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
RIVAROXABAN - XARELTO						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301		NCE	Jul 01, 2016
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
RIVAROXABAN - XARELTO						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301		NCE	Jul 01, 2016
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020	U-1167			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO						
N 022406 003	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
RIVASTIGMINE - EXELON						
N 022083 001	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
RIVASTIGMINE - EXELON						
N 022083 002	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
RIVASTIGMINE - EXELON						
N 022083 005	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
ROFECOXIB - VIOXX						
N 021042 001	6063811	May 06, 2017	U-602			
ROFECOXIB - VIOXX						
N 021042 002	6063811	May 06, 2017	U-602			
ROFECOXIB - VIOXX						
N 021042 003	6063811	May 06, 2017	U-602			
ROFECOXIB - VIOXX						
N 021052 001	6063811	May 06, 2017	U-266			
ROFECOXIB - VIOXX						
N 021052 002	6063811	May 06, 2017	U-266			
ROFLUMILAST - DALIRESP						
N 022522 001	5712298	Jan 27, 2020	DS DP U-1115			
	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
ROLAPITANT HYDROCHLORIDE - VARUBI						
N 206500 001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
	7563801	Apr 04, 2027	DP			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Oct 09, 2029	U-1741			
	8470842	Jan 18, 2029	U-1741			
	8796299	Dec 17, 2022	U-1741			
ROMIDEPSIN - ISTODAX						
N 022393 001	7608280	Aug 22, 2021	DS		ODE	Nov 05, 2016
	7611724	Aug 22, 2021	DS		ODE	Jun 16, 2018
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N 022008 001	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N 022008 002	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N 022008 003	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N 022008 004	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N 022008 005	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N 022008 006	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
ROSIGLITAZONE MALEATE - AVANDIA						
N 021071 002	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
ROSIGLITAZONE MALEATE - AVANDIA						
N 021071 003	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
ROSIGLITAZONE MALEATE - AVANDIA						
N 021071 004	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM						
A 079168 001					PC	Oct 29, 2016
ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM						
A 079168 002					PC	Oct 29, 2016
ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM						
A 079168 003					PC	Oct 29, 2016
ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM						
A 079168 004					PC	Oct 29, 2016
ROSUVASTATIN CALCIUM - CRESTOR						
N 021366 002	6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
ROSUVASTATIN CALCIUM - CRESTOR						
N 021366 003	6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROSUVASTATIN CALCIUM - CRESTOR						
N 021366 004	6316460	Aug 04, 2020	DP		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-618		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
ROSUVASTATIN CALCIUM - CRESTOR						
N 021366 005	6316460	Aug 04, 2020	DP		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
ROTIGOTINE - NEUPRO						
N 021829 001	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
ROTIGOTINE - NEUPRO						
N 021829 002	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
ROTIGOTINE - NEUPRO						
N 021829 003	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
ROTIGOTINE - NEUPRO						
N 021829 004	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
ROTIGOTINE - NEUPRO						
N 021829 005	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
ROTIGOTINE - NEUPRO						
N 021829 006	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001	6495541	Jan 10, 2020	DS DP		NCE	Dec 19, 2021
	7351701	Jul 23, 2024	U-1927			
	7531530	Jul 23, 2024	U-1927			
	8071579	Aug 12, 2027	U-1927			
	8143241	Aug 12, 2027	U-1927			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-1927			
	9045487	Feb 10, 2031	DS DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	6495541	Jan 10, 2020	DS DP		NCE	Dec 19, 2021
	7351701	Jul 23, 2024	U-1927			
	7531530	Jul 23, 2024	U-1927			
	8071579	Aug 12, 2027	U-1927			
	8143241	Aug 12, 2027	U-1927			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-1927			
	9045487	Feb 10, 2031	DS DP			
RUFINAMIDE - BANZEL						
N 021911 001	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
RUFINAMIDE - BANZEL						
N 021911 002	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
RUFINAMIDE - BANZEL						
N 021911 003	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
RUFINAMIDE - BANZEL						
N 201367 001	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002	9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			PED	Oct 23, 2017
	7566714	Nov 17, 2024	U-989			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156	Y		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 022181 001	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 16, 2026				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 205065 001	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 205065 002	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
SAQUINAVIR - FORTOVASE						
N 020828 001	6352717	Nov 16, 2019				
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 001	7951400	Nov 30, 2028	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-995			
	RE44186	Jul 31, 2023	DS DP U-1837			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N 022350 002	7951400	Nov 30, 2028	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-995			
	RE44186	Jul 31, 2023	DS DP U-1837			
SELEGILINE - EMSAM						
N 021336 001	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
SELEGILINE - EMSAM						
N 021336 002	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
SELEGILINE - EMSAM						
N 021336 003	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
SELEXIPAG - UPTRAVI						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEXIPAG - UPTRAVI						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SERTRALINE HYDROCHLORIDE - ZOLOFT						
N 020990 001	6727283	Oct 11, 2019	DP U-580			
	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
SEVELAMER CARBONATE - RENVELA						
N 022127 001	7985418	Oct 27, 2025	DP		NPP	Nov 25, 2019
SEVELAMER CARBONATE - RENVELA						
N 022318 001	9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
SEVELAMER CARBONATE - RENVELA						
N 022318 002	9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
SEVELAMER HYDROCHLORIDE - RENAGEL						
N 021179 001	6733780	Oct 18, 2020	DP			
SEVELAMER HYDROCHLORIDE - RENAGEL						
N 021179 002	6733780	Oct 18, 2020	DP			
SEVOFLURANE - ULTANE						
N 020478 001	5990176	Jan 27, 2017				
	6074668	Jan 09, 2018				
	6288127	Jan 27, 2017				
	6444859	Jan 27, 2017				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SILDENAFIL CITRATE - VIAGRA						
N 020895 001	6469012	Oct 22, 2019	U-155			
SILDENAFIL CITRATE - VIAGRA						
N 020895 002	6469012	Oct 22, 2019	U-155			
SILDENAFIL CITRATE - VIAGRA						
N 020895 003	6469012	Oct 22, 2019	U-155			
SILDENAFIL CITRATE - REVATIO						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
SILDENAFIL CITRATE - REVATIO						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
SILDENAFIL CITRATE - REVATIO						
N 203109 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
SILODOSIN - RAPAFLO						
N 022206 001	5387603	Dec 01, 2018	DS DP			
SILODOSIN - RAPAFLO						
N 022206 002	5387603	Dec 01, 2018	DS DP			
SIMEPREVIR SODIUM - OLYSIO						
N 205123 001	7671032	May 19, 2025	DS DP		D-151	Oct 05, 2018
	8148399	Sep 05, 2029	DS DP U-1467		I-697	Nov 05, 2017
	8349869	Jul 28, 2026	DS DP U-1467		I-717	Oct 05, 2018
	8741926	Jul 28, 2026	DS U-1467		M-171	Feb 26, 2019
	8754106	Jul 28, 2026	DS U-1467		M-179	May 20, 2019
	9040562	Jul 28, 2026	DS DP U-1467		NCE	Nov 22, 2018
	9353103	Jul 28, 2026	U-1467			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 001	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 002	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 003	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 003	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 004	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 005	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 006	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
SINCALIDE - KINEVAC						
N 017697 001	6803046	Aug 16, 2022	DP			
SINECATECHINS - VEREGEN						
N 021902 001	5795911	Oct 31, 2020	U-172			
	5968973	Apr 10, 2017	U-172			
	7858662	Oct 02, 2026	DP U-172			
SIROLIMUS - RAPAMUNE						
N 021083 001					ODE	May 28, 2022

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIROLIMUS - RAPAMUNE						
N 021110 001	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 002	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 003	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 004	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 001	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7326708	Nov 24, 2026	DS DP U-802			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 002	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7326708	Nov 24, 2026	DS DP U-802			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 003	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022	U-775			
	7125873	Jul 26, 2022	U-1036			
	7125873	Jul 26, 2022	U-1037			
	7125873	Jul 26, 2022	U-1038			
	7326708	Nov 24, 2026	DS DP U-802			
SODIUM NITRITE - SODIUM NITRITE						
N 203922 001	8568793	Dec 24, 2031	DS DP		ODE	Jan 14, 2018
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419		ODE	Jan 14, 2018
	8568793	Dec 24, 2031	DS DP			
SODIUM OXYBATE - XYREM						
N 021196 001	6780889	Jul 04, 2020	DP			
	7262219	Jul 04, 2020	DP			
	7668730	Jun 16, 2024	U-1110			
	7765106	Jun 16, 2024	U-1069			
	7765107	Jun 16, 2024	U-1070			
	7851506	Dec 22, 2019	U-1101			
	7851506	Dec 22, 2019	U-1102			
	7895059	Dec 17, 2022	U-1110			
	8263650	Dec 22, 2019	DP U-1101			
	8263650	Dec 22, 2019	DP U-1102			
	8324275	Dec 22, 2019	U-1101			
	8324275	Dec 22, 2019	U-1102			
	8457988	Dec 17, 2022	U-1110			
	8589182	Dec 17, 2022	U-1110			
	8731963	Dec 17, 2022	U-1110			
	8772306	Mar 15, 2033	U-1532			
	8859619	Dec 22, 2019	DP			
	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
	9486426	Mar 15, 2033	U-1532			
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP						
N 021892 001	7687075	Jun 22, 2028	DS DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419		ODE	Jan 14, 2018
SOFOSBUVIR - SOVALDI						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Dec 06, 2018
	8334270	Mar 21, 2028	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
SOLIFENACIN SUCCINATE - VESICARE						
N 021518 001	6017927	Nov 19, 2018	DS DP			
SOLIFENACIN SUCCINATE - VESICARE						
N 021518 002	6017927	Nov 19, 2018	DS DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE						
N 020280 001	6152897	Nov 20, 2018	DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE						
N 020280 002	6152897	Nov 20, 2018	DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE						
N 020280 003	6152897	Nov 20, 2018	DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE						
N 020280 005	6152897	Nov 20, 2018	DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE						
N 020280 008	6152897	Nov 20, 2018	DP			
SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE						
N 020280 009	6152897	Nov 20, 2018	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
N 021148 004	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
N 021148 005	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
N 021148 006	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
N 021148 007	6004297	Jan 28, 2019	DP			
	8841252	Dec 26, 2017	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
N 021148 007	6004297	Jan 28, 2019	DP			
	8841252	Dec 26, 2017	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N 021148 008	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N 021148 009	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N 021148 010	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N 021148 011	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
SONIDEGIB PHOSPHATE - ODOMZO						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
SORAFENIB TOSYLATE - NEXAVAR						
N 021923 001	7235576	Jan 12, 2020	DS DP		I-677	Nov 22, 2016
	7351834	Jan 12, 2020	DS		ODE	Nov 22, 2020
	7897623	Jan 12, 2020	DP			
	8124630	Jan 12, 2020	U-1459			
	8618141	Feb 11, 2023	U-1480			
	8841330	Jan 12, 2020	U-1696			
	8877933	Dec 24, 2027	DS DP U-1624			
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE						
N 022306 001					ODE	Jul 02, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SPINOSAD - NATROBA						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
STAVUDINE - ZERIT XR						
N 021453 001	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR						
N 021453 002	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR						
N 021453 003	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR						
N 021453 004	7135465	Feb 18, 2023	DP U-167			
SUCROFERRIC OXYHYDROXIDE - VELPHORO						
N 205109 001	6174442	Dec 19, 2017	DS U-1468		NP	Nov 27, 2016
SUGAMMADEX SODIUM - BRIDION						
N 022225 001	6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
SUGAMMADEX SODIUM - BRIDION						
N 022225 002	6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON						
N 203684 001	5686060	Nov 11, 2017	DS DP		I-728	Mar 31, 2019
					NCE	Oct 10, 2019
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO						
N 022239 001	6135979	Mar 21, 2017	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
	8343130	Oct 18, 2022	DP			
	8491524	Nov 21, 2022	DP			
SUMATRIPTAN SUCCINATE - ALSUMA						
N 022377 001	7811254	Aug 26, 2027	DP U-1083			
SUMATRIPTAN SUCCINATE - ZECUITY						
N 202278 001	6745071	Feb 21, 2023	DP			
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
	8983594	Nov 19, 2030	DP U-1328			
	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL						
N 206099 001	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
SUNITINIB MALATE - SUTENT						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
SUNITINIB MALATE - SUTENT						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
SUNITINIB MALATE - SUTENT						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
SUNITINIB MALATE - SUTENT						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
SUVOREXANT - BELSOMRA						
N 204569 001	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
SUVOREXANT - BELSOMRA						
N 204569 002	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
SUVOREXANT - BELSOMRA						
N 204569 003	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
SUVOREXANT - BELSOMRA						
N 204569 004	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
TACROLIMUS - ASTAGRAF XL						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
TACROLIMUS - ASTAGRAF XL						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
TACROLIMUS - ASTAGRAF XL						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 001	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - ENVARSUS XR						
N 206406 001	9161907	Aug 30, 2024	DP U-1752			
TACROLIMUS - ENVARSUS XR						
N 206406 002	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
TACROLIMUS - ENVARSUS XR						
N 206406 003	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
TADALAFIL - CIALIS						
N 021368 001	5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6140329	Jul 11, 2016	DP U-1184			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-1184			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-1184			
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
TADALAFIL - CIALIS						
N 021368 002	5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
TADALAFIL - CIALIS						
N 021368 003	5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
TADALAFIL - CIALIS						
N 021368 004	5859006	Nov 21, 2017	DS DP			
	6140329	Jul 11, 2016	DP U-155			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TADALAFIL - ADCIRCA						
N 022332 001	5859006	Nov 21, 2017	DS DP U-975			
	6821975	Nov 19, 2020	DS DP			
	7182958	Apr 26, 2020	DP			
TAFLUPROST - ZIOPTAN						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778		NCE	Feb 10, 2017
TALIGLUCERASE ALFA - ELELYSO						
N 022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
	8741620	Feb 24, 2024	DS DP		NPP	Aug 27, 2017
	8790641	Oct 18, 2025	U-1564			
	8790641	Oct 18, 2025	U-1574			
TAMOXIFEN CITRATE - SOLTAMOX						
N 021807 001	6127425	Jun 26, 2018	DP			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 001	6071970	Jun 06, 2017	U-931			
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 002	6071970	Jun 06, 2017	U-931			
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 003	6071970	Jun 06, 2017	U-931			
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 001	6071970	Jun 06, 2017	U-1178			
	6071970	Jun 06, 2017	U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 002	6071970	Jun 06, 2017	U-1178			
	6071970	Jun 06, 2017	U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 003	6071970	Jun 06, 2017	U-1178			
	6071970	Jun 06, 2017	U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 003	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 004	6071970	Jun 06, 2017	U-1178			
	6071970	Jun 06, 2017	U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 005	6071970	Jun 06, 2017	U-1178			
	6071970	Jun 06, 2017	U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 203794 001	6071970	Jun 06, 2017	U-1289			
	7994364	Jun 27, 2025	DS DP U-1289			
	RE39593	Aug 05, 2022	DS DP U-1289			
TASIMELTEON - HETLIOZ						
N 205677 001	5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
	8785492	Jan 25, 2033	U-1486		ODE	Jan 31, 2021
	9060995	Jan 25, 2033	U-1710			
TAVABOROLE - KERYDIN						
N 204427 001	7582621	May 26, 2027	U-718		NCE	Jul 07, 2019
	7767657	May 22, 2027	DP			
TAZAROTENE - FABIOR						
N 202428 001	8808716	Feb 24, 2030	DP			
TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID						
N 017858 001					ODE	Aug 13, 2019
TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC						
N 019928 001	6056941	Jul 28, 2019	DP			
TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT						
N 202207 001	6409990	May 12, 2020	DS		I-687	Jun 13, 2017
	9439985	Sep 27, 2033	DS DP		NCE	Mar 13, 2018
					ODE	Jun 13, 2021
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205435 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205436 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TEDUGLUTIDE RECOMBINANT - GATTEX KIT						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		NCE	Dec 21, 2017
	7056886	Sep 18, 2022	DP U-1320		ODE	Dec 21, 2019
	7847061	Nov 01, 2025	U-1320			
	9060992	Nov 01, 2025	U-1320			
TELAPREVIR - INCIVEK						
N 201917 001	7820671	Feb 25, 2025	DS DP			
	8431615	May 30, 2028	U-1398			
	8529882	Aug 31, 2021	U-1398			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728			
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021	U-1005			
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021	U-282			
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728			
	6858584	Aug 24, 2022	DP			
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021	U-1005			
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021	U-282			
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
TELBIVUDINE - TYZEKA						
N 022011 001	6395716	Aug 10, 2019	U-782			
	6444652	Aug 10, 2019	U-782			
	6566344	Aug 10, 2019	U-782			
	6569837	Oct 25, 2020	U-782			
	6569837	Oct 25, 2020	U-999			
	7589079	Sep 11, 2023	DS DP U-999			
	7795238	Aug 10, 2019	U-999			
	7858594	Sep 11, 2023	DS DP U-999			
TELBIVUDINE - TYZEKA						
N 022154 001	6395716	Aug 10, 2019	U-999			
	6444652	Aug 10, 2019	U-999			
	6566344	Aug 10, 2019	U-999			
	6569837	Oct 25, 2020	U-999			
	7795238	Aug 10, 2019	U-999			
	7858594	Sep 11, 2023	DS DP U-999			
TELITHROMYCIN - KETEK						
N 021144 001	5635485	Apr 01, 2018	DS DP U-578			
TELITHROMYCIN - KETEK						
N 021144 002	5635485	Apr 01, 2018	DS DP U-578			
TELMISARTAN - MICARDIS						
N 020850 001	6358986	Jan 10, 2020				
TELMISARTAN - MICARDIS						
N 020850 002	6358986	Jan 10, 2020				
	7998953	Jun 06, 2020	U-1177			
	8003679	Oct 06, 2022	U-1176			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TELMISARTAN - MICARDIS						
N 020850 003	6358986	Jan 10, 2020				
TEMOZOLOMIDE - TEMODAR						
N 022277 001	6987108	Sep 08, 2023	DP			
	7786118	Feb 21, 2023	DP			
	8623868	Feb 21, 2023	DP			
TEMSIROLIMUS - TORISEL						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y		
	5362718*PED	Aug 15, 2019				
	8026276	Jan 20, 2026	DP			
	8299116	Jul 25, 2023	DP			
	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	8791097	May 10, 2032	U-1550			
	8791097	May 10, 2032	U-1551			
	8791097*PED	Nov 10, 2032				
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY						
N 208464 001	7390791	May 07, 2022	DS DP		NCE	Nov 05, 2020
	7803788	Feb 02, 2022	U-999		NP	Nov 11, 2019
	8754065	Aug 15, 2032	DS DP U-999			
	9296769	Aug 15, 2032	DS DP U-999			
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N 021356 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-256		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N 021356 002	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-256		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N 021356 002	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N 021356 003	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-256		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N 021356 004	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-256		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
TENOFOVIR DISOPROXIL FUMARATE - VIREAD						
N 022577 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-256		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TERIFLUNOMIDE - AUBAGIO						
N 202992 001	6794410	Sep 12, 2026	U-1285		NCE	Sep 12, 2017
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034	U-1786			
TERIFLUNOMIDE - AUBAGIO						
N 202992 002	6794410	Sep 12, 2026	U-1285		NCE	Sep 12, 2017
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034	U-1786			
TERIPARATIDE RECOMBINANT HUMAN - FORTEO						
N 021318 001	6770623	Dec 08, 2018	DP U-597			
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
TERIPARATIDE RECOMBINANT HUMAN - FORTEO						
N 021318 002	6770623	Dec 08, 2018	DP U-982			
	6977077	Aug 19, 2019	U-982			
	6977077	Aug 19, 2019	U-994			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7351414	Aug 19, 2019	U-994			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
TESAMORELIN ACETATE - EGRIFTA						
N 022505 001	5861379	May 26, 2020	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
TESAMORELIN ACETATE - EGRIFTA						
N 022505 002	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
TESTOSTERONE - TESTODERM						
N 019762 001	5840327	Aug 15, 2016				
TESTOSTERONE - TESTODERM						
N 019762 002	5840327	Aug 15, 2016				
TESTOSTERONE - TESTODERM TTS						
N 020791 001	6348210	Nov 10, 2019	U-440			
TESTOSTERONE - ANDROGEL						
N 021015 001	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL						
N 021015 002	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL						
N 021015 003	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - TESTIM						
N 021454 001	7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
	7935690	Apr 21, 2023	U-1009			
	8063029	Apr 21, 2023	U-843			
	8178518	Apr 21, 2023	DP			
TESTOSTERONE - FORTESTA						
N 021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
TESTOSTERONE - STRIANT						
N 021543 001	6248358	Aug 23, 2019	U-527			
TESTOSTERONE - ANDROGEL						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
TESTOSTERONE - ANDROGEL						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - AXIRON						
N 022504 001	6299900	Feb 19, 2017	DP U-1103			
	6818226	Feb 19, 2017	DP U-1103			
	6923983	Feb 19, 2017	DP U-1103			
	8071075	Feb 19, 2017	DP U-1103			
	8419307	Feb 26, 2027	U-1386			
	8435944	Sep 27, 2027	U-1390			
	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
	9289586	Feb 26, 2027	U-1390			
TESTOSTERONE - VOGELXO						
N 204399 002	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
	9295675	Feb 11, 2034	DP U-1531			
TESTOSTERONE - VOGELXO						
N 204399 003	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
	9295675	Feb 11, 2034	DP U-1531			
TESTOSTERONE - NATESTO						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
TESTOSTERONE UNDECANOATE - AVEED						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026	U-1500			
THALIDOMIDE - THALOMID						
N 020785 001	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID						
N 020785 002	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N 020785 002	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID						
N 020785 003	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
THALIDOMIDE - THALOMID						
N 020785 004	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N 020785 004	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-731			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
TIAGABINE HYDROCHLORIDE - GABITRIL						
N 020646 001	5958951	Jun 10, 2017				
TIAGABINE HYDROCHLORIDE - GABITRIL						
N 020646 002	5958951	Jun 10, 2017				
TIAGABINE HYDROCHLORIDE - GABITRIL						
N 020646 003	5958951	Jun 10, 2017				
TIAGABINE HYDROCHLORIDE - GABITRIL						
N 020646 004	5958951	Jun 10, 2017				
TIAGABINE HYDROCHLORIDE - GABITRIL						
N 020646 005	5958951	Jun 10, 2017				
TICAGRELOR - BRILINTA						
N 022433 001	6251910	Jul 15, 2018	DS		I-714	Sep 03, 2018
	6525060	Dec 02, 2019	DS DP U-1171		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
	8425934	Apr 17, 2030	DP			
TICAGRELOR - BRILINTA						
N 022433 002	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171		NS	Sep 03, 2018
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
	8425934	Apr 17, 2030	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIGECYCLINE - TYGACIL						
N 021821 001	7879828	Feb 05, 2029	DP			
	8372995	Oct 08, 2030	DP			
	8975242	Oct 24, 2028	DP			
	9254328	Mar 13, 2026	DP			
TIMOLOL MALEATE - TIMOLOL MALEATE						
N 020963 001	6174524	Mar 26, 2019	DP			
TIMOLOL MALEATE - TIMOLOL MALEATE						
N 020963 002	6174524	Mar 26, 2019	DP			
TIMOLOL MALEATE - ISTALOL						
N 021516 001	6335335	Nov 02, 2018	DP			
	6645963	Nov 16, 2018	DP			
TIOTROPIUM BROMIDE - SPIRIVA						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	7070800	Jan 22, 2022	DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7642268	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
	8022082	Jan 19, 2026	DP U-1186			
	RE38912	Oct 11, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-566			
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT						
N 021936 001	5964416	Oct 04, 2016	DP		NP	Sep 24, 2017
	6149054	Dec 16, 2016	DP		PED	Mar 24, 2018
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1593			
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT						
N 021936 002	5964416	Oct 04, 2016	DP		NP	Sep 15, 2018
	6149054	Dec 16, 2016	DP		PED	Mar 15, 2019
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF						
N 207981 001	6479500	Mar 16, 2020	U-1751		NCE	Sep 22, 2020
	7799783	Dec 16, 2026	U-1751			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	002	6479500	Mar 16, 2020	U-1751		NCE	Sep 22, 2020
		7799783	Dec 16, 2026	U-1751			
TIPRANAVIR - APTIVUS							
N 021814	001	5852195	Jun 22, 2019	DS			
		6147095	Oct 29, 2019	U-670			
		6231887	Jul 27, 2018	DP			
TIPRANAVIR - APTIVUS							
N 022292	001	5852195	Jun 22, 2019	DS			
		6147095	Oct 29, 2019	U-670			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020912	001	5733919	Oct 23, 2016				
		5965581	Oct 23, 2016				
		5972967	Oct 23, 2016				
		5978698	Oct 08, 2017				
		6136794	Jan 29, 2019				
		6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020912	002	5733919	Oct 23, 2016	DS			
		5965581	Oct 23, 2016	DP			
		5972967	Oct 23, 2016	DP			
		5978698	Oct 08, 2017	U-1897			
		6136794	Jan 29, 2019	U-1898			
		6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	001	5733919	Oct 23, 2016				
		5965581	Oct 23, 2016				
		5972967	Oct 23, 2016				
		5978698	Oct 08, 2017				
		6136794	Jan 29, 2019				
		6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	002	5733919	Oct 23, 2016				
		5965581	Oct 23, 2016				
		5972967	Oct 23, 2016				
		5978698	Oct 08, 2017				
		6136794	Jan 29, 2019				
		6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	003	5733919	Oct 23, 2016				
		5965581	Oct 23, 2016				
		5972967	Oct 23, 2016				
		5978698	Oct 08, 2017				
		6136794	Jan 29, 2019				
		6770660	May 01, 2023	U-1444			
TOBRAMYCIN - TOBI PODHALER							
N 201688	001	7368102	Dec 19, 2022	DP U-909			
		7442388	May 10, 2020	DP			
		7516741	Jan 11, 2024	DP			
		7559325	Oct 27, 2025	DP			
		8069851	Sep 24, 2024	DP			
		8349294	May 10, 2020	DP			
		8715623	Dec 19, 2022	DP U-909			
TOBRAMYCIN - BETHKIS							
N 201820	001	6987094	Sep 22, 2022	DP			
		7696178	Mar 17, 2023	DP			
		7939502	Jun 14, 2022	U-1324			
TOFACITINIB CITRATE - XELJANZ							
N 203214	001	6956041	Dec 08, 2020	DP		M-135	Feb 21, 2017
		6965027	Mar 25, 2023	DS		NCE	Nov 06, 2017

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOFACITINIB CITRATE - XELJANZ						
N 203214 001	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 001	6956041	Dec 08, 2020	DP		NCE	Nov 06, 2017
	6965027	Mar 25, 2023	DS			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
TOLTERODINE TARTRATE - DETROL LA						
N 021228 001	6630162	Nov 11, 2019	DP U-544			
	6770295	Aug 26, 2019	DP U-544			
	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
TOLTERODINE TARTRATE - DETROL LA						
N 021228 002	6630162	Nov 11, 2019	DP U-544			
	6770295	Aug 26, 2019	DP U-544			
	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
TOLVAPTAN - SAMSCA						
N 022275 001	5753677	May 19, 2020	U-978			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA						
N 022275 002	5753677	May 19, 2020	U-978			
	8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA						
N 022275 003	5753677	May 19, 2020	U-978			
	8501730	Sep 01, 2026	DS			
TOPIRAMATE - TOPAMAX						
N 020505 001					NPP	Mar 28, 2017
TOPIRAMATE - TOPAMAX						
N 020505 002					NPP	Mar 28, 2017
TOPIRAMATE - TOPAMAX						
N 020505 003					NPP	Mar 28, 2017
TOPIRAMATE - TOPAMAX						
N 020505 004					NPP	Mar 28, 2017
TOPIRAMATE - TOPAMAX						
N 020505 005					NPP	Mar 28, 2017
TOPIRAMATE - TOPAMAX						
N 020505 006					NPP	Mar 28, 2017
TOPIRAMATE - TOPAMAX						
N 020844 001	7125560	Mar 01, 2019	U-766		NPP	Mar 28, 2017
TOPIRAMATE - TOPAMAX						
N 020844 002	7125560	Mar 01, 2019	U-766		NPP	Mar 28, 2017
TOPIRAMATE - TOPAMAX SPRINKLE						
N 020844 003	7125560	Mar 01, 2019	U-766		NPP	Mar 28, 2017
TOPIRAMATE - TROKENDI XR						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 001	8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
	8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
	8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
	8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - QUDEXY XR						
N 205122 001	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 002	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 003	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 004	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 005	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N 020981 001	8158645	Dec 10, 2024	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N 020981 002	8158645	Dec 10, 2024	DP			
TRABECTEDIN - YONDELIS						
N 207953 001	8895557	Jan 07, 2028	DP		NCE	Oct 23, 2020
					ODE	Oct 23, 2022
TRAMADOL HYDROCHLORIDE - ULTRAM						
N 020281 001	6339105	Oct 12, 2019	U-435			
TRAMADOL HYDROCHLORIDE - ULTRAM						
N 020281 002	6339105	Oct 12, 2019	U-435			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMADOL HYDROCHLORIDE - RYBIX ODT						
N 021693 001	6106861	Dec 05, 2017	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 001	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 002	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 003	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - CONZIP						
N 022370 001	7858118	Apr 11, 2022	DP U-1104			
TRAMADOL HYDROCHLORIDE - CONZIP						
N 022370 002	7858118	Apr 11, 2022	DP U-1104			
TRAMADOL HYDROCHLORIDE - CONZIP						
N 022370 003	7858118	Apr 11, 2022	DP U-1104			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		M-170	Nov 20, 2018
	8703781	Oct 15, 2030	DS DP U-1712		NCE	May 29, 2018
	8835443	Sep 13, 2025	U-1581		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8703781	Oct 15, 2030	DS DP U-1712		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1581		ODE	Jan 08, 2021
	8835443	Sep 13, 2025	U-1582			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		M-170	Nov 20, 2018
	8703781	Oct 15, 2030	DS DP U-1712		NCE	May 29, 2018
	8835443	Sep 13, 2025	U-1581		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
TRANEXAMIC ACID - LYSTEDA						
N 022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
	8273795	Mar 04, 2025	U-1182			
	8487005	Mar 04, 2025	DP U-1182			
	8791160	Mar 04, 2025	DP U-1182			
	8809394	Mar 04, 2025	DP U-1182			
	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
TRAVOPROST - TRAVATAN Z						
N 021994 001	8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
	8388941	Sep 20, 2027	DP			
TRAVOPROST - IZBA						
N 204822 001	8178582	Oct 10, 2029	DP		NP	May 15, 2017
	8722735	Oct 10, 2029	DP			
	8754123	May 19, 2029	DP			
	9144561	Mar 13, 2029	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 001	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 002	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 003	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL						
N 018207 004	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N 022411 001	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - OLEPTRO						
N 022411 002	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
TREPROSTINIL - REMODULIN						
N 021272 001	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
TREPROSTINIL - REMODULIN						
N 021272 002	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
TREPROSTINIL - REMODULIN						
N 021272 003	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
TREPROSTINIL - REMODULIN						
N 021272 004	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
TREPROSTINIL - TYVASO						
N 022387 001	6521212	Nov 13, 2018	U-1018		M-145	May 20, 2017
	6756033	Nov 13, 2018	U-1018		ODE	Jul 30, 2016
	6765117	Oct 24, 2017	DS			
	8497393	Dec 15, 2028	DS			
	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 001	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024	U-1475		NDF	Dec 20, 2016
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 001	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 002	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024	U-1475		NDF	Dec 20, 2016
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 003	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024	U-1475		NDF	Dec 20, 2016
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 004	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024	U-1475		NDF	Dec 20, 2016
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
TRETINOIN - RETIN-A MICRO						
N 020475 001	5955109	Sep 21, 2016	DP U-134			
TRETINOIN - RETIN-A MICRO						
N 020475 002	5955109	Sep 21, 2016	U-134			
TRETINOIN - RETIN-A-MICRO						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
TRETINOIN - RENOVA						
N 021108 001	6531141	Mar 07, 2020				
TRIAMCINOLONE ACETONIDE - NASACORT ALLERGY 24 HOUR						
N 020468 002	5976573	Jul 03, 2016	DP			
	6143329	Jul 03, 2016	DP			
	7977045	Jul 03, 2016	DP			
TRIAMCINOLONE ACETONIDE - TRIESENCE						
N 022048 001	6395294	Jan 13, 2020	DP U-846			
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1257			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRIAMCINOLONE ACETONIDE - TRIESENCE						
N 022048 001	8211880	Mar 10, 2029	U-1258			
TRIMETHOPRIM HYDROCHLORIDE - PRIMSOL						
N 074973 001	5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				
TRIMETREXATE GLUCURONATE - NEUTREXIN						
N 020326 001	6017922	May 18, 2018				
TRIMETREXATE GLUCURONATE - NEUTREXIN						
N 020326 002	6017922	May 18, 2018				
TROGLITAZONE - PRELAY						
N 020719 001	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
TROGLITAZONE - PRELAY						
N 020719 002	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
TROGLITAZONE - PRELAY						
N 020719 003	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
TROSPIUM CHLORIDE - SANCTURA XR						
N 022103 001	7410978	Feb 01, 2025	DP			
	7759359	Nov 04, 2024	U-1071			
	7763635	Nov 04, 2024	U-1071			
	7781448	Nov 04, 2024	U-1071			
	7781449	Nov 04, 2024	U-1071			
ULIPRISTAL ACETATE - ELLA						
N 022474 001	8426392	Jun 12, 2030	U-1389			
	8512745	Jun 02, 2030	DP			
	8735380	Feb 20, 2029	DP			
	8962603	Jun 12, 2030	U-1657			
	9283233	Apr 13, 2030	U-1821			
UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA						
N 205382 001	7488827	Apr 27, 2025	DS DP		M-172	Feb 24, 2019
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001	7439393	Sep 11, 2022	DS DP U-1476		NP	Dec 18, 2016
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8309572	Apr 27, 2025	U-1476			
	8511304	Jun 14, 2027	DP U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	RE44874	Mar 23, 2023	DS DP U-1476			
UNOPROSTONE ISOPROPYL - RESCULA						
N 021214 001	6458836	Jul 09, 2021	U-333			
	6458836	Jul 09, 2021	U-1315			
	6770675	Nov 24, 2018	DP U-1322			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
URIDINE TRIACETATE - VISTOGARD						
N 208159 001	5968914	Oct 19, 2016	U-1791		NCE	Sep 04, 2020
	6258795	Jul 10, 2018	DP		NP	Dec 11, 2018
	7776838	Aug 17, 2027	U-1791		ODE	Dec 11, 2022
URIDINE TRIACETATE - XURIDEN						
N 208169 001	6258795	Jul 10, 2018	DP		NCE	Sep 04, 2020
					ODE	Sep 04, 2022
UROFOLLITROPIN - BRAVELLE						
N 021289 001					D-139	Feb 19, 2017
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 021304 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 022257 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VALSARTAN - DIOVAN						
N 021283 001	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
VALSARTAN - DIOVAN						
N 021283 002	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
VALSARTAN - DIOVAN						
N 021283 003	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
VALSARTAN - DIOVAN						
N 021283 004	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
VANDETANIB - CAPRELSA						
N 022405 001	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Jun 27, 2022	DS DP			
VANDETANIB - CAPRELSA						
N 022405 002	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Jun 27, 2022	DS DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N 021400 001	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N 021400 002	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N 021400 003	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA						
N 021400 004	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VARDENAFIL HYDROCHLORIDE - STAXYN						
N 200179 001	6362178	Oct 31, 2018	U-155			
	7696206	Oct 31, 2018	U-155			
	8613950	Dec 23, 2028	DP			
VARENICLINE TARTRATE - CHANTIX						
N 021928 001	6410550	May 10, 2020	DS DP U-56		M-143	Oct 15, 2017
	6890927	May 06, 2022	DS DP U-56		M-144	Oct 15, 2017
	7265119	Aug 03, 2022	DS DP U-56		M-183	Aug 12, 2019
					M-192	Dec 16, 2019
VARENICLINE TARTRATE - CHANTIX						
N 021928 002	6410550	May 10, 2020	DS DP U-56		M-143	Oct 15, 2017
	6890927	May 06, 2022	DS DP U-56		M-144	Oct 15, 2017
	7265119	Aug 03, 2022	DS DP U-56		M-183	Aug 12, 2019
					M-192	Dec 16, 2019
VASOPRESSIN - VASOSTRICT						
N 204485 001	9375478	Jan 30, 2035	U-1857			
VELAGLUCERASE ALFA - VPRIV						
N 022575 001					M-130	Nov 21, 2016
VELAGLUCERASE ALFA - VPRIV						
N 022575 002					M-130	Nov 21, 2016
VEMURAFENIB - ZELBORAF						
N 202429 001	7504509	Oct 22, 2026	DS DP		M-184	Aug 31, 2019
	7863288	Jun 20, 2029	DS DP		NCE	Aug 17, 2016
	8143271	Jun 21, 2026	DS DP		ODE	Aug 17, 2018
	8470818	Aug 02, 2026	U-1418			
	8741920	Jul 27, 2030	DS DP			
	9447089	Jun 06, 2032	DP			
VENETOCLAX - VENCLEXTA						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
VENETOCLAX - VENCLEXTA						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
VENETOCLAX - VENCLEXTA						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR						
N 020699 001	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017	U-451			
	6403120	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR						
N 020699 002	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017	U-451			
	6403120	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR						
N 020699 003	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017	U-451			
	6403120	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR						
N 020699 004	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017	U-451			
	6403120	Mar 20, 2017	U-535			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR						
N 020699 004	6419958	Mar 20, 2017	U-459			
	6419958	Mar 20, 2017	U-535			
VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE						
N 022104 001	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE						
N 022104 002	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE						
N 022104 003	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE						
N 022104 004	6403120	Mar 20, 2017	U-535			
	6403120	Mar 20, 2017	U-839			
	6419958	Mar 20, 2017	U-535			
	6419958	Mar 20, 2017	U-839			
VERAPAMIL HYDROCHLORIDE - COVERA-HS						
N 020552 001	6096339	Apr 04, 2017	U-365			
VERAPAMIL HYDROCHLORIDE - COVERA-HS						
N 020552 002	6096339	Apr 04, 2017	U-365			
VIGABATRIN - SABRIL						
N 020427 001					NPP	Oct 26, 2016
					PED	Apr 26, 2017
VIGABATRIN - SABRIL						
N 022006 001					NPP	Oct 26, 2016
					ODE	Aug 21, 2016
					PED	Feb 21, 2017
					PED	Apr 26, 2017
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 001	5532241	Sep 29, 2019	DS DP		D-146	Mar 16, 2018
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
	8673921	Jun 05, 2022	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 002	5532241	Sep 29, 2019	DS DP		D-146	Mar 16, 2018
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
	8673921	Jun 05, 2022	DS DP			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 003	5532241	Sep 29, 2019	DS DP		D-146	Mar 16, 2018
	7834020	Jun 05, 2022	DS DP U-839			
	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
	8673921	Jun 05, 2022	DS DP			
VINCRISTINE SULFATE - MARQIBO KIT						
N 202497 001	6723338	Mar 31, 2020	U-1271		ODE	Aug 09, 2019
	7247316	Sep 25, 2020	DP			
	7887836	Mar 31, 2020	U-1271			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VISMODEGIB - ERIVEDGE						
N 203388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
	9278961	Dec 15, 2028	U-1825			
VORAPAXAR SULFATE - ZONTIVITY						
N 204886 001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
	7304078	Apr 06, 2024	DS DP U-1512			
VORICONAZOLE - VFEND						
N 021267 001	6632803	Jun 02, 2018	DP			
VORINOSTAT - ZOLINZA						
N 021991 001	7399787	Feb 09, 2025	U-892			
	7456219	Mar 11, 2027	DS			
	7652069	Mar 04, 2023	DP			
	7732490	Mar 04, 2023	U-892			
	7851509	Feb 21, 2024	DP U-892			
	8067472	Mar 04, 2023	U-892			
	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
	8450372	Mar 18, 2028	U-892			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 001	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9227946	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 002	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9227946	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 003	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9227946	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 004	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9227946	Jun 15, 2027	U-1668			
ZICONOTIDE ACETATE - PRIALT						
N 021060 001	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
ZICONOTIDE ACETATE - PRIALT						
N 021060 002	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
ZICONOTIDE ACETATE - PRIALT						
N 021060 003	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	8653033	Oct 01, 2024	U-48			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZICONOTIDE ACETATE - PRIALT						
N 021060 003	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
ZICONOTIDE ACETATE - PRIALT						
N 021060 004	5364842	Dec 30, 2016	U-48			
	5364842	Dec 30, 2016	U-55			
	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 001	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 002	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 003	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 004	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 021483 001	6150366	May 27, 2019	DP U-719			
	6245766	Dec 18, 2018	U-601			
	7175855	May 18, 2020	DP			
ZIPRASIDONE MESYLATE - GEODON						
N 020919 001	6110918	Mar 26, 2017				
	6232304	Apr 01, 2017				
	6399777	Apr 01, 2017				
ZOLEDRONIC ACID - ZOMETA						
N 021223 002	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
ZOLEDRONIC ACID - ZOMETA						
N 021223 003	7932241	Feb 05, 2028	DP			
	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
ZOLEDRONIC ACID - RECLAST						
N 021817 001	7932241	Feb 05, 2028	DP			
	8052987	Oct 27, 2023	U-1199			
ZOLMITRIPTAN - ZOMIG						
N 021450 003	6750237	Nov 28, 2020	DP		NPP	Jun 12, 2018
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				
ZOLMITRIPTAN - ZOMIG						
N 021450 004	6750237	Nov 28, 2020	DP		NPP	Jun 12, 2018
	7220767	Nov 28, 2020	DP			
ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE						
A 204299 001					PC	Sep 18, 2016
ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE						
A 204299 002					PC	Sep 18, 2016

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZOLPIDEM TARTRATE - AMBIEN CR						
N 021774 001	6514531	Dec 01, 2019	DP			
ZOLPIDEM TARTRATE - AMBIEN CR						
N 021774 002	6514531	Dec 01, 2019	DP			
ZOLPIDEM TARTRATE - EDLUAR						
N 021997 001	6761910	Sep 24, 2019	DP		U-674	
	8512747	Sep 24, 2019			U-674	
	9265720	May 13, 2030			U-674	
ZOLPIDEM TARTRATE - EDLUAR						
N 021997 002	6761910	Sep 24, 2019	DP		U-674	
	8512747	Sep 24, 2019			U-674	
	9265720	May 13, 2030			U-674	
ZOLPIDEM TARTRATE - ZOLPIMIST						
N 022196 001	7632517	Oct 01, 2017			U-70	
	8236285	Aug 07, 2032	DS DP		U-70	
ZOLPIDEM TARTRATE - INTERMEZZO						
N 022328 001	7658945	Apr 15, 2027	DP		U-1194	
	7682628	Feb 16, 2025			U-1194	
	8242131	Aug 20, 2029			U-1266	
	8252809	Feb 16, 2025	DP			
ZOLPIDEM TARTRATE - INTERMEZZO						
N 022328 002	7658945	Apr 15, 2027	DP		U-1194	
	7682628	Feb 16, 2025			U-1194	
	8242131	Aug 20, 2029			U-1266	
	8252809	Feb 16, 2025	DP			

Footnote:

1. Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).

2. Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.

3. As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT & EXCLUSIVITY ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY DOSING SCHEDULE

D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING
D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED

EXCLUSIVITY DOSING SCHEDULE

	ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
D-90	ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
D-91	ALTERNATE INTERMITTENT DOSING REGIMEN
D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY

EXCLUSIVITY DOSING SCHEDULE

	INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.
D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION

EXCLUSIVITY DOSING SCHEDULE

	WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
D-150	1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
D-151	DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
D-152	DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
D-153	IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
D-154	ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
D-155	SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-156	DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
D-157	UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
D-158	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
D-159	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
D-160	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
D-161	DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
D-162	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
D-163	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
D-164	UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
D-165	DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

	PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

I-202	SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

EXCLUSIVITY INDICATION

I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
I-250	PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
I-251	TREATMENT OF GENERALIZED ANXIETY DISORDER
I-252	NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
I-253	COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
I-254	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
I-255	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
I-256	USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
I-257	TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION
I-258	FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
I-259	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-260	EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH

EXCLUSIVITY INDICATION

	TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

	SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
I-387	ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
I-388	TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-389	SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
I-390	USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
I-391	ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
I-392	TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRANCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL

EXCLUSIVITY INDICATION

I-393	CHRONIC BACTERIAL PROSTATITIS
I-394	USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
I-395	TO IMPROVE PHYSICAL FUNCTION
I-396	EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
I-397	EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
I-398	IDIOPATHIC SHORT STATURE
I-399	TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
I-400	USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-401	LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402	DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403	USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405	TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406	PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407	IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
I-408	STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS

EXCLUSIVITY INDICATION

	WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
I-432	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
I-433	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
I-434	PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
I-435	CHRONIC IDIOPATHIC CONSTIPATION
I-436	FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
I-437	TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-438	EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
I-439	USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
I-440	FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
I-441	USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
I-442	USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
I-443	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
I-444	USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS
I-445	TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
I-446	EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
I-447	USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
I-448	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
I-449	TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
I-450	TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
I-451	MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
I-452	EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
I-453	USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
I-454	MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
I-455	MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%
I-456	TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
I-457	TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
I-458	USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

I-459	NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
I-460	TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
I-461	USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
I-462	LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
I-463	TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
I-464	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
I-465	PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
I-466	FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
I-467	USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
I-468	USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION
I-469	RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
I-470	DIABETIC PERIPHERAL NEUROPATHIC PAIN
I-471	INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
I-472	USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
I-473	USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
I-474	TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN
I-475	PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
I-476	TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
I-477	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
I-478	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
I-479	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
I-480	PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
I-481	INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-482	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
I-483	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-484	FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
I-485	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-486	ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
I-487	INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
I-488	MAINTENANCE THERAPY IN BIPOLAR I DISORDER
I-489	FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
I-490	FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
I-491	INFLUENZA PROPHYLAXIS
I-492	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
I-493	ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
I-494	CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
I-495	ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST

EXCLUSIVITY INDICATION

	CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
I-496	LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
I-497	PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
I-498	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-499	USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
I-500	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
I-502	FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
I-503	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-504	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
I-505	TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
I-506	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-507	ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-508	PREMENSTRUAL DYSPHONIC DISORDER
I-509	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
I-510	ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)
I-511	ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
I-512	ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
I-513	ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
I-514	ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
I-515	PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
I-516	PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-517	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
I-518	TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
I-519	USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-520	USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
I-521	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
I-522	TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
I-523	USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
I-524	GENERALIZED ANXIETY DISORDER (GAD)
I-525	USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
I-526	TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
I-527	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-528	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-529	TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
I-530	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND

EXCLUSIVITY INDICATION

	OLDER
I-531	MAINTENANCE TREATMENT OF SCHIZOPHRENIA
I-532	TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
I-533	ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
I-534	EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
I-535	MANAGEMENT OF FIBROMYALGIA
I-536	FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
I-537	LONG TERM TREATMENT OF PANIC DISORDER
I-538	SHORT TERM TREATMENT OF PANIC DISORDER
I-539	REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
I-540	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
I-541	TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
I-542	EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
I-543	USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-544	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-545	ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
I-546	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
I-547	ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
I-548	SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
I-549	USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-550	TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
I-551	TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
I-552	ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
I-553	FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-554	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
I-555	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
I-556	PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
I-557	USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
I-558	MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-559	ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
I-560	MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR

EXCLUSIVITY INDICATION

I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
I-605	ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
I-606	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
I-607	INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
I-608	REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
I-610	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-611	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND

EXCLUSIVITY INDICATION

	POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
I-612	MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
I-613	MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
I-614	SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
I-615	MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-616	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
I-617	MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
I-618	ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
I-619	INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
I-620	FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
I-621	PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
I-622	ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
I-623	TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
I-624	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
I-625	PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
I-626	RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER
I-627	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
I-628	MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
I-629	ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-630	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
I-631	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
I-632	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
I-633	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-634	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
I-635	ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
I-636	TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
I-637	USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
I-638	FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
I-639	TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
I-640	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-641	TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-642	TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-643	REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
I-644	MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
I-645	MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
I-646	SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
I-647	SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
I-648	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
I-649	TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

	PRIOR CHEMOTHERAPY
I-650	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
I-651	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
I-652	MANAGEMENT OF POSTHERPETIC NEURALGIA
I-653	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
I-654	MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
I-655	TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
I-656	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
I-657	PLAQUE PSORIASIS OF THE SCALP
I-658	FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
I-659	PLAQUE PSORIASIS OF THE BODY
I-660	TREATMENT OF DEEP VEIN THROMBOSIS
I-661	TREATMENT OF PULMONARY EMBOLISM
I-662	REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
I-663	IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
I-664	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
I-665	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
I-666	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
I-667	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
I-668	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
I-669	SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
I-670	TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
I-671	FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-672	USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
I-673	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
I-674	TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
I-675	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-676	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARACINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
I-677	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOCACTIVE IODINE TREATMENT
I-678	TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-679	RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
I-680	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-681	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

(PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-REISISTANT PROSTATE CANCER (CRPC)
I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION AND FREE SURVIVAL.
I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)
I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN
I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.
I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE
I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFRACTION
I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.
I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY INDICATION

	HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY
I-717	EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4
I-718	EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY
I-719	EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.
I-720	EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.
I-721	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.
I-722	REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
I-723	AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
I-724	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
I-725	TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.
I-726	EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION
I-727	EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL
I-728	EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS
I-729	PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
I-730	NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
I-731	FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
I-732	TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
I-733	USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
I-734	EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.
I-735	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
I-736	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
I-737	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
I-738	REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
I-739	TO REDUCE THE RISK OF CARDIOVASCULAR DEALTH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-740	EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY MISCELLANEOUS

M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
M-30	CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
M-31	INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
M-32	ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
M-33	INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
M-34	EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-35	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
M-36	ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
M-37	INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
M-38	SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
M-39	FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
M-40	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS

EXCLUSIVITY MISCELLANEOUS

M-41	REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
M-42	ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
M-43	INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
M-44	CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
M-45	INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
M-46	PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
M-47	PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
M-48	CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
M-49	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
M-50	NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
M-51	INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
M-52	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
M-53	FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
M-54	INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
M-55	INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
M-56	INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
M-57	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
M-58	CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
M-59	RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
M-60	CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
M-61	REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-62	CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
M-63	DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
M-64	CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
M-65	ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
M-66	USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
M-67	INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
M-68	DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
M-69	RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
M-70	PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
M-71	REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
M-72	INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
M-73	NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY MISCELLANEOUS

M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
M-75 PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98 NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
M-102 INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC

EXCLUSIVITY MISCELLANEOUS

	SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
M-103	SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
M-104	INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
M-105	NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
M-106	ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
M-107	INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
M-108	CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
M-109	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-110	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-111	LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
M-112	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
M-113	LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
M-114	CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
M-115	REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
M-116	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
M-117	ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
M-118	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
M-119	LABELING CHANGES REGARDING MISSED DOSES
M-120	CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
M-121	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
M-122	LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
M-123	UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
M-124	LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
M-125	LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
M-126	UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
M-127	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
M-128	CLINICAL TRIAL STUDY RESULTS
M-129	RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
M-130	ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
M-131	INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
M-132	REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
M-133	INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
M-134	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
M-135	ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
M-136	ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

EXCLUSIVITY MISCELLANEOUS

M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY
M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER
M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM
M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLITFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC

EXCLUSIVITY MISCELLANEOUS

	LYMPHOMA (LL)"
M-166	UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS
M-167	APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".
M-168	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)
M-169	UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.
M-170	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
M-171	UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL
M-172	UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS
M-173	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS
M-174	INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN
M-175	INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES
M-176	INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT
M-177	INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE
M-178	INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS
M-179	UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS
M-180	INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
M-181	UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
M-182	UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"
M-183	CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM
M-184	UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES
M-185	UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
M-186	UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232
M-187	ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
M-188	PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)
M-189	LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY EXTENDED-RELEASE MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES
M-190	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS
M-191	ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2
M-192	PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF

FDA data supplied by DrugPatentWatch.com

EXCLUSIVITY MISCELLANEOUS

	PSYCHIATRIC DISORDERS
M-193	INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
U-109	ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121	METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122	A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123	METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124	TREATMENT OF ACNE
U-125	TREATMENT NEUROGENERATIVE DISEASES
U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHOD FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE

PATENT USE

	DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER

PATENT USE

	PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS

PATENT USE

U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

PATENT USE

U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH

PATENT USE

	METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN

PATENT USE

	SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION
U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	TREATMENT OF MIGRAINE
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES

PATENT USE

	RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY
U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI
U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION
U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT
U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516	METHOD OF TREATING A PSYCHOTIC DISEASE
U-517	STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518	OBSESSIVE COMPULSIVE DISORDER
U-519	POST OPERATIVE NAUSEA AND VOMITING
U-520	PREMENOPAUSAL OSTEOPOROSIS
U-521	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522	TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523	METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524	METHOD OF TREATING DIARRHEA
U-525	METHOD OF TREATING PARASITIC INFECTIONS
U-526	METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527	METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528	PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529	ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530	TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531	TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN

PATENT USE

	WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532	TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533	ERECTILE DYSFUNCTION
U-534	HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS
U-541	METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542	METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543	TREATMENT OF SCHIZOPHRENIA
U-544	TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545	METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546	USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547	MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
U-548	A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549	USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551	METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552	TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553	MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
U-554	TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
U-555	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556	USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-558	INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
U-559	METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
U-560	METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
U-561	COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
U-562	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-563	MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
U-564	TREATMENT OF HIV IN CONCOMITANT THERAPY
U-565	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
U-566	FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-567	METHOD OF TREATING INFERTILITY
U-568	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
U-569	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
U-570	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
U-571	TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

PATENT USE

U-572	INTENSIVE CARE UNIT SEDATION
U-573	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574	PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-575	LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
U-576	ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
U-577	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
U-578	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
U-579	TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580	TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
U-581	METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
U-582	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
U-583	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
U-584	SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
U-585	TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586	AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
U-587	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
U-588	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-589	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
U-590	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
U-591	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
U-592	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-593	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-594	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595	35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-596	TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-597	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
U-598	PROPHYLACTIC TREATMENT OF MIGRAINE
U-599	METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
U-600	A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
U-601	TREATMENT OF BIPOLAR DISORDER
U-602	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
U-603	METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
U-604	METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION

PATENT USE

U-605	TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
U-606	USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
U-607	CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
U-608	USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
U-609	USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
U-610	ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
U-611	METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
U-612	TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-613	REDUCTION OF SERUM PHOSPHATE
U-614	TREATMENT OF SEXUAL DYSFUNCTION
U-615	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-616	MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
U-617	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-618	USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
U-619	TREATMENT OF MALIGNANT NEOPLASM
U-620	TREATMENT OF INSOMNIA
U-621	METHOD OF TREATING CANCER
U-622	TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
U-623	SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
U-624	REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
U-625	ALLERGIC RHINITIS OR NASAL POLYPS
U-626	CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
U-627	TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
U-628	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-629	METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
U-630	TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
U-631	TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
U-632	METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
U-633	METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
U-634	METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
U-635	TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
U-636	TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
U-637	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
U-638	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
U-639	TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
U-640	USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA
U-641	USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC

PATENT USE

	MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
U-642	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-643	THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
U-644	TREATMENT OF SEASONAL ALLERGIC RHINITIS
U-645	TREATMENT OF ASTHMA
U-646	METHOD OF TREATING OTITIS
U-647	TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-648	THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
U-649	A METHOD FOR TREATING A TUMOR DISEASE
U-650	TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
U-651	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
U-652	TREATMENT OF CARDIAC ARRHYTHMIA
U-653	STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
U-654	LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
U-655	TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
U-656	REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-657	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-658	TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
U-659	TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
U-660	TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
U-661	TREATMENT OF SEIZURE DISORDER
U-662	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-663	THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
U-664	TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
U-665	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
U-666	METHOD OF TREATING ADHD
U-667	MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
U-668	LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
U-669	INDICATION OF TYPE II DIABETES
U-670	TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
U-671	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
U-672	TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
U-673	METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
U-674	METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
U-675	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
U-676	METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
U-677	A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
U-678	METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-679	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-680	A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
U-681	TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-682	NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-683	PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
U-684	TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-685	EXPECTORANT AND COUGH SUPPRESSANT
U-686	EXPECTORANT AND NASAL DECONGESTANT
U-687	REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-688	TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-689	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-690	TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-691	USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-692	USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
U-693	THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
U-694	LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
U-695	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-696	TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-697	A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY
U-698	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
U-699	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-700	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-701	TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
U-702	TOPICAL AEROSOL HAIR REGROWTH TREATMENT
U-703	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
U-704	METHOD OF ADMINISTERING INSULIN VIA INHALATION
U-705	TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
U-706	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
U-707	ALLERGIC RHINITIS
U-708	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-709	METHOD OF COMBATING BACTERIA IN A PATIENT
U-710	A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
U-711	ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-712	A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
U-713	TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
U-714	TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
U-715	FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
U-716	THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
U-717	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-718	TREATMENT OF FUNGAL INFECTIONS
U-719	TREATENT OF PSYCHOSIS
U-720	TREATMENT OF NEUROLEPTIC DISEASES
U-721	TREATMENT OF INFLUENZA
U-722	PROPHYLAXIS OF INFLUENZA
U-723	PROPHYLACTIC TREATMENT OF MIGRAINE
U-724	METHOD OF TREATING SEIZURES

PATENT USE

U-725	ALLERGIC RHINITIS AND URTICARIA
U-726	ALLERGIC RHINITIS
U-727	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-728	METHOD FOR TREATING BACTERIAL INFECTION
U-729	TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-730	USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
U-731	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-732	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
U-733	MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
U-734	FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
U-735	METHOD OF TREATING CHRONIC IRON OVERLOAD
U-736	METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
U-737	DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
U-738	INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
U-739	METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
U-740	FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
U-741	COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
U-742	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
U-743	ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
U-744	TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
U-745	TREATMENT OR PREVENTION OF EMESIS
U-746	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-747	PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-748	A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
U-749	METHOD OF CONTRACEPTION
U-750	TREATMENT OF HIV-1 INFECTION IN ADULTS
U-751	ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
U-752	SUNSCREEN
U-753	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
U-754	USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
U-755	TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
U-756	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-757	USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
U-758	TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
U-759	METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
U-760	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS
U-761	TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
U-762	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-763	ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
U-764	TREATMENT OF SCHIZOPHRENIA
U-765	METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
U-766	TREATMENT OF SEIZURES
U-767	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
U-768	A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
U-769	REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-770	LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-771	METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-772	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
U-773	PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-774	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
U-775	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
U-776	TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
U-777	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-778	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-779	A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
U-780	A METHOD FOR THE TREATMENT OF CANCER
U-781	FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
U-782	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
U-783	DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
U-784	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
U-785	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
U-786	PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
U-787	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
U-788	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
U-789	TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
U-790	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
U-791	GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
U-792	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-793	FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-794	CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
U-795	METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
U-796	METHOD OF TREATING DEPRESSION
U-797	METHOD OF TREATING ANXIETY
U-798	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
U-799	METHOD FOR INHIBITING SEROTONIN UPTAKE
U-800	TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
U-801	METHOD OF TREATING CANCER
U-802	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-803	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
U-804	TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
U-805	TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
U-806	INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
U-807	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
U-808	THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-809	TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
U-810	METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
U-811	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
U-812	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-813	MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-814	TREATMENT OF SCHIZOPHRENIA
U-815	TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
U-816	DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
U-817	NASAL ADMINISTRATION OF CYANOCOBALAMIN
U-818	TOPICAL TREATMENT OF ACNE VULGARIS
U-819	MANAGEMENT OF FIBROMYALGIA
U-820	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
U-821	METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
U-822	USE IN LIPID MANAGEMENT
U-823	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
U-824	METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
U-825	USE FOR PREVENTION OF BREAST CANCER
U-826	RELIEF OF MODERATE TO SEVERE PAIN
U-827	USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
U-828	PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-829	TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
U-830	TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
U-831	METHOD OF ADMINISTERING LANREOTIDE ACETATE
U-832	ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
U-833	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
U-834	INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
U-835	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
U-836	A METHOD FOR THE TREATMENT OF LEUKEMIAS
U-837	GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
U-838	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
U-839	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-840	TREATMENT FOR TYPE 2 DIABETES MELLITUS
U-841	INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
U-842	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
U-843	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-844	PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
U-845	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
U-846	USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
U-847	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-848	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-849	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

PATENT USE

U-850	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-851	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-852	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-853	TREATMENT OR PREVENTION OF EMESIS
U-854	PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
U-855	METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
U-856	SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-857	INHIBITION OF TRANSPLANT REJECTION
U-858	PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-859	EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
U-860	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
U-861	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-862	ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
U-863	TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
U-864	PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-865	TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
U-866	THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
U-867	TREATMENT OF MIGRAINE
U-868	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
U-869	METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-870	METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
U-871	METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
U-872	TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-873	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
U-874	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-875	FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
U-876	TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-877	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
U-878	A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
U-879	A METHOD OF TREATING OR PREVENTING ILEUS
U-880	ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-881	TREATMENT OF NON-SMALL CELL LUNG CANCER
U-882	MANAGEMENT OF FIBROMYALGIA (FM)
U-883	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
U-884	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
U-885	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
U-886	ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
U-887	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-888	FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
U-889	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
U-890	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-891	USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE

PATENT USE

U-892	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
U-893	CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
U-894	TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
U-895	TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-896	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
U-897	METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
U-898	USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
U-899	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-900	INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
U-901	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
U-902	USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
U-903	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
U-904	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
U-905	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
U-906	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
U-907	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
U-908	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
U-909	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-910	TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
U-911	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
U-912	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-913	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
U-914	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-915	TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-916	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
U-917	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-918	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
U-919	FOR THE TREATMENT OF DERMATITIS
U-920	STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
U-921	TREATMENT OF ACNE VULGARIS
U-922	FOR THE TREATMENT OF FUNGAL INFECTIONS
U-923	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-924	TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
U-925	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA
U-926	MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
U-927	METHOD FOR INCREASING TEAR PRODUCTION
U-928	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-929	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
U-930	TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
U-931	RELIEF OF MODERATE TO SEVERE ACUTE PAIN
U-932	PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
U-933	FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL

PATENT USE

	ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-934	IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
U-935	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
U-936	USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
U-937	TREATMENT OF PROSTATE CANCER
U-938	TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-939	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-940	METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
U-941	METHOD TO TREAT OVARIAN CANCER
U-942	METHOD TO TREAT MULTIPLE MYELOMA
U-943	GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
U-944	TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-945	SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
U-946	TREATMENT OF BREAST CANCER
U-947	WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS
U-948	TREATMENT OF DIABETES MELLITUS
U-949	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
U-950	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
U-951	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
U-952	USE AS AN ANALGESIC
U-953	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-954	CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
U-955	PROPHYLACTIC TREATMENT OF MIGRAINE
U-956	TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
U-957	A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
U-958	METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
U-959	METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
U-960	METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
U-961	METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
U-962	SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-963	PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-964	ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-965	USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
U-966	TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
U-967	A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
U-968	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-969	TREATMENT OF MIGRAINE
U-970	TOPICAL TREATMENT OF LICE INFESTATIONS

PATENT USE

U-971	INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
U-972	MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
U-973	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
U-974	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-975	TREATMENT OF PULMONARY HYPERTENSION
U-976	IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
U-977	TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
U-978	METHOD OF TREATING HYPONATREMIA
U-979	RELIEF OF MUSCLE SPASM
U-980	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-981	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-982	A METHOD OF TREATING OSTEOPOROSIS
U-983	METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
U-984	METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
U-985	TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-986	TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
U-987	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
U-988	TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
U-989	FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-990	TREATMENT OF PROTOZOAL INFECTION
U-991	TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
U-992	REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
U-993	METHOD OF TREATING INFERTILITY
U-994	METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
U-995	METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
U-996	AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA
U-997	TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
U-998	ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
U-999	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
U-1000	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
U-1001	METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
U-1002	METHOD OF TREATING INFLAMMATORY CONDITIONS
U-1003	A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
U-1004	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1005	METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
U-1006	NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
U-1007	METHOD OF TREATING GOUT FLARES
U-1008	APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
U-1009	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-1010	TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
U-1011	USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA

PATENT USE

	AND VOMITING
U-1012	METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
U-1013	METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1014	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1015	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1016	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
U-1017	A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-1018	TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
U-1019	TREATMENT OF PULMONARY HYPERTENSION
U-1020	METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
U-1021	SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
U-1022	FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
U-1023	TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
U-1024	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
U-1025	TREATING FREQUENT HEARTBURN
U-1026	A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
U-1027	REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
U-1028	A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
U-1029	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
U-1030	IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
U-1031	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1032	USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
U-1033	TOPICAL TREATMENT OF ACNE VULGARIS
U-1034	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
U-1035	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1036	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
U-1037	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
U-1038	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
U-1039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
U-1040	INHIBITION OF THROMBIN IN A PATIENT
U-1041	TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
U-1042	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-1043	MANAGEMENT OF MODERATE TO SEVERE PAIN
U-1044	TOPICAL TREATMENT OF SCALP PSORIASIS
U-1045	MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY
U-1046	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
U-1047	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
U-1048	WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
U-1049	PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT
U-1050	USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-1051	TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-1052	RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1053	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1054	ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON

PATENT USE

	MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
U-1055	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
U-1056	TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1057	TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1058	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-1059	ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
U-1060	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS
U-1061	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
U-1062	ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
U-1063	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-1064	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-1065	METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-1066	METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
U-1067	TREATMENT OF CANCER
U-1068	TREATMENT OF ASTHMA
U-1069	A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1070	A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE
U-1071	METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
U-1072	THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
U-1073	USE FOR THE TREATMENT OF ASTHMA AND COPD
U-1074	USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
U-1075	USE FOR THE TREATMENT OF ASTHMA
U-1076	REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
U-1077	PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION
U-1078	TREATMENT OF ACNE
U-1079	REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1080	METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
U-1081	LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1082	USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
U-1083	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES
U-1084	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-1085	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
U-1086	TREATMENT OF AUTOIMMUNE DISEASE
U-1087	DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-1088	RELIEF OF MUSCLE SPASM
U-1089	INHIBITION OF THROMBIN
U-1090	LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOF OF CONTRACEPTION
U-1091	ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
U-1092	TREATMENT OF BREAST CANCER
U-1093	TREATMENT OF PSEUDOBULBAR AFFECT
U-1094	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
U-1095	METHOD OF TREATING OCULAR INFLAMMATION
U-1096	TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1097	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
U-1098	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
U-1099	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1100	REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
U-1101	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1102	METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
U-1103	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1104	USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
U-1105	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
U-1106	TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
U-1107	TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
U-1108	TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
U-1109	TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-1110	METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1111	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1112	METHOD OF MR IMAGING OF A MAMMAL
U-1113	TREATMENT AND PROPHYLAXIS OF INFLUENZA
U-1114	TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
U-1115	TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
U-1116	METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
U-1117	TREATMENT OF BREAST CANCER
U-1118	USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-1119	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-1120	TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
U-1121	METHOD OF TREATING TRAVELERS' DIARRHEA
U-1122	TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
U-1123	TREATMENT OF ALCOHOL DEPENDENCE
U-1124	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
U-1125	METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
U-1126	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
U-1127	TREATMENT OF PATENT DUCTUS ARTERIOSUS
U-1128	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
U-1129	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
U-1130	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1131	TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
U-1132	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1133	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1134	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1135	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
U-1136	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

PATENT USE

U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
U-1151 TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA)
U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
U-1163 METHOD OF TREATING THROMBOSIS
U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN

PATENT USE

U-1170	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1171	REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
U-1172	TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
U-1173	TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
U-1174	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERIILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176	TREATMENT OR PREVENTION OF STROKE
U-1177	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178	RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179	TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
U-1180	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183	A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184	TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
U-1185	TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186	ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187	TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191	METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)
U-1192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193	METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194	METHOD FOR TREATING INSOMNIA
U-1195	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196	RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198	RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
U-1199	TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200	REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204	TREATMENT OF UVEITIS
U-1205	TREATMENT OF MACULAR EDEMA
U-1206	DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207	INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS

PATENT USE

U-1208	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-1209	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER
U-1210	USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
U-1211	USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1212	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1213	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
U-1214	METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1215	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1216	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1217	METHOD OF INCREASING HAIR GROWTH
U-1218	METHOD OF STIMULATING HAIR GROWTH
U-1219	METHOD OF INCREASING THE NUMBER OF HAIRS
U-1220	TREATMENT OF RENAL CELL CARCINOMA
U-1221	TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
U-1222	TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
U-1223	METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
U-1224	REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
U-1225	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
U-1226	A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
U-1227	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
U-1228	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
U-1229	TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
U-1230	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
U-1231	TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
U-1232	USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN
U-1233	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL

PATENT USE

	ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
U-1274	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
U-1275	TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1277	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
U-1278	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
U-1279	TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-1280	USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
U-1281	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
U-1282	PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
U-1283	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
U-1284	A METHOD OF TREATING A NEOPLASM
U-1285	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
U-1286	A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
U-1287	METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1288	TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
U-1289	MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1290	TREATMENT OF LUNG CANCER
U-1291	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-1292	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
U-1293	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1294	METHOD OF TREATING GLAUCOMA IN A PATIENT
U-1295	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1296	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
U-1297	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
U-1298	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
U-1299	TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1300	TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1301	TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
U-1302	TREATMENT OF PULMONARY EMBOLISM (PE)
U-1303	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
U-1304	USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
U-1305	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
U-1306	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
U-1307	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1308	MULTIPLE MYELOMA
U-1309	BONE METASTASES
U-1310	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
U-1311	METHOD OF TREATING CYSTIC FIBROSIS
U-1312	USE FOR THE TREATMENT OF HYPERGLYCEMIA
U-1313	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1314	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1315	THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-1316	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1317	TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1318	TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1319	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
U-1320	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-1321	TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
U-1322	METHOD OF REDUCING OCULAR HYPERTENSION
U-1323	REDUCING THE RISK OF STROKE
U-1324	MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
U-1325	INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
U-1326	METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
U-1327	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
U-1328	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
U-1347 TREATMENT OF A SKIN DISORDER
U-1348 TREATMENT OF OSTEOARTHRITIS
U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS
U-1351 TREATMENT OF ACUTE PAIN
U-1352 TREATMENT OF PRIMARY DYSMENORRHEA
U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

PATENT USE

U-1360 USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1361 USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
U-1362 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
U-1363 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
U-1364 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1365 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
U-1366 TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
U-1367 METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
U-1368 TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
U-1369 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
U-1370 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
U-1371 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
U-1373 METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
U-1374 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
U-1375 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
U-1376 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-1377 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1378 TREATMENT OF A NITROGEN METABOLISM DISORDER
U-1379 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1380 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
U-1381 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1382 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
U-1383 DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
U-1384 METHOD OF TREATING MULTIPLE SCLEROSIS
U-1385 METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
U-1386 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS
U-1388 TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1389 ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
U-1391 METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1393 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1394 METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/-10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396 TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN

PATENT USE

	COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
U-1397	USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
U-1398	METHOD OF TREATING CHRONIC HEPATITIS C
U-1399	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
U-1400	FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1401	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
U-1402	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
U-1403	FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
U-1404	METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
U-1405	THERAPEUTIC TREATMENT OF BONE METASTASES
U-1406	TREATMENT OF MELANOMA
U-1407	TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
U-1408	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-1409	TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
U-1410	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
U-1411	THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1412	TREATMENT OF ATOPIC DERMATITIS
U-1413	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
U-1414	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
U-1415	TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
U-1416	USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
U-1417	USE FOR TREATMENT OF HELICOBACTER INFECTIONS
U-1418	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
U-1419	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
U-1420	METHOD OF ONCE A DAY ADMINISTRATION
U-1421	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
U-1422	METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
U-1423	AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1424	LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1425	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1426	USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
U-1427	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
U-1428	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
U-1429	TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
U-1430	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-1431	METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
U-1432	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
U-1433	IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1434	TREATMENT OF PANCREATIC CANCER

PATENT USE

U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE
U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION
U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA
U-1449 METHOD OF ALLEVIATING A SKIN CONDITION
U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT
U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1455 TREATMENT OF PERIANAL WARTS
U-1456 TREATMENT OF MANTLE CELL LYMPHOMA
U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1459 TREATMENT OF CARCINOMA OF THE THYROID
U-1460 TREATMENT OF HERPES LABIALIS
U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1467 METHOD OF TREATING HEPATITIS C
U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
U-1469 USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
U-1470 FOR THE TREATMENT OF HEPATITIS C
U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE
U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
U-1481 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1482 DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1483 INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1484 COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
U-1485 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1486 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
U-1487 METHOD OF INCREASING EYELASH GROWTH
U-1488 USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
U-1489 USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
U-1490 FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
U-1491 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1492 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1493 METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1494 SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1495 RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
U-1496 METHOD TO TREAT HEMANGIOMA.
U-1497 NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1498 METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
U-1499 MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-1500 TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
U-1501 PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
U-1502 PROPHYLAXIS OF PULMONARY EMBOLISM
U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1504 USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
U-1505 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1506 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
U-1507 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1508 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
U-1509 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
U-1510 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOD TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA
U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.
U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE
U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1530 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
U-1544 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
U-1545 A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
U-1546 FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
U-1547 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
U-1548 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1549 FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
U-1550 METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
U-1551 METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.
U-1552 FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
U-1553 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1554 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
U-1555 MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1556 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM

PATENT USE

	OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1557	A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
U-1558	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
U-1559	INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
U-1560	A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
U-1561	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1562	TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
U-1563	A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
U-1564	A METHOD OF TREATING GAUCHER'S DISEASE
U-1565	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1566	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-1567	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
U-1568	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1569	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
U-1570	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
U-1571	TREATMENT OF GAUCHER DISEASE TYPE 1
U-1572	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
U-1573	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
U-1574	A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
U-1575	PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
U-1576	TREATMENT OF LEUKEMIA
U-1577	CONTROL OF SERUM PHOSPHOROUS LEVELS
U-1578	TREATMENT OF ACUTE OTITIS MEDIA
U-1579	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1580	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY
U-1581	IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
U-1582	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
U-1583	FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1584	USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
U-1585	USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
U-1586	FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
U-1587	SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
U-1588	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
U-1589	METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-1590	KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
U-1591	TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
U-1592	TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-1593	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
U-1594	DILATION OF THE PUPIL
U-1595	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
U-1596	LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
U-1597	TREATMENT OF DIABETIC MACULAR EDEMA

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1598	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
U-1599	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADNUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-1600	DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1601	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1602	METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
U-1603	METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-1604	METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
U-1605	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1606	METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
U-1607	METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
U-1608	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
U-1609	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1610	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE
U-1611	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
U-1612	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1613	DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN
U-1614	USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN
U-1615	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1616	NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1617	METHOD OF TREATING MEDULLARY THYROID CANCER
U-1618	A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FONNULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT
U-1619	TREATMENT OF IMMUNE (IDIOPATIC) THROMBOCYTOPENIA (ITP)
U-1620	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.
U-1621	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.
U-1622	FOR THE TREATMENT OF POLYCYTHEMIA VERA
U-1623	USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.
U-1624	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
U-1625	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
U-1626	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
U-1627	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
U-1628	METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
U-1629	METHOD OF TREATING ACROMEGALY
U-1630	TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED IWTH DOCETAXEL
U-1631	TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
U-1632	TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1633	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1634	TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
U-1635	USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
U-1636	USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
U-1637	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

PATENT USE

U-1638 TREATMENT OF HCV INFECTION USING PARITAPREVIR
U-1639 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1640 TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1641 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-1642 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
U-1643 TREATING CUSHING'S SYNDROME
U-1644 TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
U-1645 TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1646 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1647 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1648 TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1649 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
U-1650 TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
U-1651 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
U-1653 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
U-1654 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
U-1655 A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
U-1656 METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
U-1657 METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99
U-1658 TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN
U-1659 MANAGEMENT OF PAIN
U-1660 TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-1661 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
U-1662 A METHOD OF TREATING OCULAR PAIN
U-1663 TREATMENT OF HIV-1 INFECTION
U-1664 TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
U-1665 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1
U-1666 PALLIATIVE TREATMENT OF PROSTATE CANCER
U-1667 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS
U-1668 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
U-1669 TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
U-1670 NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.
U-1671 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS
U-1672 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
U-1673 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
U-1674 DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1675 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
U-1676 METHODS FOR TREATING BACTERIAL INFECTIONS
U-1677 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
U-1678 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1679 TREATMENT OF ACUTE OTITIS EXTERNA

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1680 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1681 TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
U-1682 TREATMENT OF BACTERIAL VAGINOSIS
U-1683 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-1684 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1685 DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1686 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
U-1687 TREATMENT OF HCV INFECTION USING OMBITASVIR
U-1688 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1689 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1690 METHOD FOR REDUCTION OF SUBMENTAL FAT
U-1691 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
U-1692 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1693 METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1694 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
U-1695 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
U-1696 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
U-1697 PULMONARY ADMINISTRATION OF A COMPISITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.
U-1698 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1699 A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
U-1700 A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
U-1701 A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
U-1702 TREATMENT OF COPD
U-1703 TREATMENT OF RESPIRATORY COMPLAINTS
U-1704 USE FOR TREATMENT IN PATIENTS WITH DIABETES
U-1705 USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA
U-1706 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE
U-1707 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
U-1708 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
U-1709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
U-1710 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
U-1711 FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL
U-1712 MEKENIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1713 TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1714 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1715 P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
U-1716 TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
U-1717 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
U-1718 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
U-1719 ACUTE TREATMENT OF MIGRAINE
U-1720 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA

PATENT USE

U-1721	USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
U-1722	TREATMENT OF BASAL CELL CARCINOMA
U-1723	TREATMENT OF HEART FAILURE
U-1724	METHOD OF INHIBITING HEPATITIS C VIRUS
U-1725	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
U-1726	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1727	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1728	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1729	REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
U-1730	REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
U-1731	TEMPORARY RELIEF OF MINOR ACHES AND PAINS
U-1732	TEMPORARY REDUCTION OF FEVER
U-1733	TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
U-1734	USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-1735	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL
U-1736	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1737	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
U-1738	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-1739	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1740	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY
U-1741	PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1742	ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1743	FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
U-1744	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
U-1746	MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY
U-1747	FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD
U-1748	FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1749	ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-1750	TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-1751	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-1752	PROPHYLAXIS OF ORGAN REJECTION
U-1753	TREATMENT OF HCV INFECTION USING DASABUVIR
U-1754	FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
U-1755	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
U-1756	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-1757	INHIBITION ON PI3K KINASE
U-1758	METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
U-1759	METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB
U-1760	RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT
U-1761	PLAQUE PSORIASIS

PATENT USE

U-1762	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1763	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1764	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1765	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1766	TREATMENT OF HYPERKALEMIA
U-1767	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
U-1768	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
U-1769	TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE
U-1770	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA
U-1771	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION
U-1772	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1773	LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1774	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE
U-1775	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
U-1776	METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA
U-1777	TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTORE RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
U-1778	METHOD FOR TREATING MULTIPLE MYELOMA
U-1779	METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS
U-1780	METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
U-1781	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
U-1782	FOR HEAD LICE INFESTATIONS
U-1783	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED
U-1784	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED
U-1785	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED
U-1786	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE
U-1787	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY
U-1788	TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN
U-1789	METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
U-1790	FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA
U-1791	EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS
U-1792	TREATMENT OF OTIC INFECTION OR INFLAMMATION
U-1793	TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1794	REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK
U-1795	REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
U-1796	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

PATENT USE

U-1797 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
U-1798 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN
U-1799 METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
U-1800 A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
U-1801 REDUCTION OF SERUM URIC ACID LEVELS
U-1802 TREATMENT OF GOUT
U-1803 TREATMENT OF HYPERURICEMIA
U-1804 ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
U-1805 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
U-1806 COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
U-1807 TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
U-1808 USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
U-1809 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
U-1810 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
U-1811 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
U-1812 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
U-1813 TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
U-1814 METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
U-1815 TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-1816 TREATMENT OF A UREA CYCLE DISORDER
U-1817 PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-1818 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1819 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1820 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1821 METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-1822 TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
U-1823 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
U-1824 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1825 METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
U-1826 TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCOCLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1827 A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWBLE TABLET ACCORDING TO CLAIM 1
U-1828 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-1829 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
U-1830 INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
U-1831 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
U-1832 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1833 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1834 TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1835	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-1836	TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANIE
U-1837	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
U-1838	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
U-1839	COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
U-1840	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
U-1841	USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1842	METHOD OF TREATING EPILEPSY
U-1843	TREATMENT OF PSYCHOSIS
U-1844	TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
U-1845	TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
U-1846	TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
U-1847	METHOD OF TREATING A BACTERIAL INFECTION
U-1848	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1849	METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-1850	METHOD OF ADMINISTERING LEVETIRACETAM
U-1851	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1852	METHOD OF TREATING TYPE 2 DIABETES
U-1853	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
U-1854	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
U-1855	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
U-1856	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-1857	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
U-1858	TREATMENT OF PLAQUE PSORIASIS
U-1859	TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1860	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1861	USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
U-1862	TREATMENT OF POST-MYOCARDIAL INFARCTION
U-1863	TREATMENT OF STROKE
U-1864	TREATMENT OF MYOCARDIAL INFARCTION
U-1865	TREATMENT OF THROMBOTIC STROKE
U-1866	TREATMENT OF STABLE AND UNSTABLE ANGINA
U-1867	METHOD OF INHIBITING PLATELET AGGREGATION
U-1868	TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
U-1869	TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
U-1870	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1871	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D
U-1872	USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY
U-1873	ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE
U-1874	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8

PATENT USE

U-1875	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3
U-1876	METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH
U-1877	METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL
U-1878	FOR OPIOID DEPENDENCE
U-1879	METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
U-1880	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1881	IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
U-1882	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY
U-1883	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
U-1884	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1885	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1886	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1887	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1888	USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE
U-1889	TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
U-1890	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
U-1891	TREATMENT OR PREVENTION OF NAUSEA AND VOMITING
U-1892	METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
U-1893	METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
U-1894	COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-1895	METHOD OF TREATING PROSTATE CANCER
U-1896	SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
U-1897	METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1898	METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1899	TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1900	TREATMENT OF THE SIGNS SYMPTOMS OF DRY EYE DISEASE (DED)
U-1901	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
U-1902	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-1903	USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
U-1904	(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1905	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1906	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1907	USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
U-1908	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
U-1909	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR

FDA data supplied by DrugPatentWatch.com

PATENT USE

U-1910	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
U-1911	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
U-1912	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606
U-1913	TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1914	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1915	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
U-1916	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)
U-1917	TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1918	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1919	RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1920	USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
U-1921	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT
U-1922	INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
U-1923	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1924	KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-1925	USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCI
U-1926	METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS IN FUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
U-1927	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUBRACA, WHEREIN THE CANCER IS ASSOCIATED WITH A GENETIC DEFECT IN AT LEAST ONE OF THE BRCA1 AND BRCA2 GENES.
U-1928	RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
U-1929	TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
U-1930	METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
U-1931	PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE